<SEC-DOCUMENT>0001193125-26-092546.txt : 20260305
<SEC-HEADER>0001193125-26-092546.hdr.sgml : 20260305
<ACCEPTANCE-DATETIME>20260305072054
ACCESSION NUMBER:		0001193125-26-092546
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		96
CONFORMED PERIOD OF REPORT:	20251231
FILED AS OF DATE:		20260305
DATE AS OF CHANGE:		20260305

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Climb Bio, Inc.
		CENTRAL INDEX KEY:			0001768446
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				832273741
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40708
		FILM NUMBER:		26724188

	BUSINESS ADDRESS:	
		STREET 1:		20 WILLIAM STREET
		STREET 2:		SUITE 145
		CITY:			WELLESLEY HILLS
		STATE:			MA
		ZIP:			02481
		BUSINESS PHONE:		1-866-857-2596

	MAIL ADDRESS:	
		STREET 1:		20 WILLIAM STREET
		STREET 2:		SUITE 145
		CITY:			WELLESLEY HILLS
		STATE:			MA
		ZIP:			02481

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Eliem Therapeutics, Inc.
		DATE OF NAME CHANGE:	20190219
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>clym-20251231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2026-03-04T20:15:57.8215+00:00 -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:clym="http://climbbio.com/20251231" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_16527e97-dc93-4ed0-ad7e-7b7abd3cd558" name="dei:EntityCentralIndexKey" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6">0001768446</ix:nonNumeric><ix:nonNumeric id="F_9ec1bf85-71d7-40e2-a04b-50f075db7fba" name="dei:AmendmentFlag" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric id="F_800d4fd8-ba6d-4002-9a2a-dc9451e31b51" name="dei:DocumentFiscalPeriodFocus" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6">FY</ix:nonNumeric><ix:nonFraction id="F_6e9c1843-16ca-4b62-af29-4ec50ad49bc2" name="us-gaap:CommitmentsAndContingencies" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_1a7d6320-c589-4343-9bdf-6398fa567414" name="us-gaap:CommitmentsAndContingencies" contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_2a7e8018-774a-4c44-8376-7e8c696ec434" name="us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" contextRef="C_4e50e1e3-bd9c-40de-bb68-3128ec238afe">http://fasb.org/us-gaap/2025#PropertyPlantAndEquipmentUsefulLife</ix:nonNumeric><ix:nonNumeric id="F_0ecb2fd9-391a-4200-85ea-df3460e76587" name="us-gaap:LeaseExpirationDate1" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" format="ixt:date-day-month-year">31-12-2026</ix:nonNumeric><ix:nonNumeric id="F_1ed21085-1747-4238-9882-f67da405f9c3" name="us-gaap:OpenTaxYear" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6">2018 2019 2020 2121 2022 2323 2024 2025</ix:nonNumeric><ix:nonNumeric id="F_486ead36-778f-4db7-a0cb-c45b1a00e08c" name="us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6">http://fasb.org/srt/2025#ChiefExecutiveOfficerMember</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="clym-20251231.xsd"/></ix:references><ix:resources><xbrli:context id="C_80658773-af42-4dbf-91d7-91c7e6c647c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_80b88047-d92c-4121-9779-7cec8fdafae6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_80f05462-1973-4d3e-8520-b5a9f59b1778"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">clym:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_816130b0-f672-44b1-b634-9034b70a760f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-02-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_81960adb-5d4d-4573-bc54-80d5eb37fb9c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">clym:StockBasedCompensationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_81a10eed-87b5-4e58-b248-df503d6194b9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">clym:TwoThousandTwentyFiveInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_826ab126-2f0f-4ee0-80a3-17e4f28432a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">clym:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_84f00985-ac68-4cfe-8454-b7dc6d4cc926"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">clym:SeveranceAndBenefitsCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8579d8f5-3430-4159-88d1-ebaf49448cd2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">clym:CrhAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">clym:DevelopmentRegulatoryCommercialAndSalesMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_871db5fb-78d1-4c8c-9435-954b2bb1e0b9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">clym:LongTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_892c3e10-a60b-4010-9024-013505fca3fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_89c728ad-be3d-454b-8a42-c4b78f7c05f2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_89e402ec-8a69-4241-9a74-d42ab514978d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">clym:ManufacturingServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">clym:ProbiogenAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8b239563-a96d-46e3-ad49-e8ca68499571"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8c7ebad7-98a1-4e64-b935-7123699f4e44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8d01d41c-acfb-4b36-86b4-52db5162e53b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">clym:AcelyrinAssetPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">clym:DevelopmentRegulatoryAndCommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8df34eff-0fa0-4471-a95a-aa6f2075612e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_90041a5e-41bb-41f0-9714-a6b1a0938dd1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">clym:AcquisitionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clym:BlackbirdClinicalAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9044897e-bda8-464c-bcb1-ec1f0a7b9592"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_905153fa-065a-4b24-a22c-0410b7b3bfda"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">clym:ProbiogenAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">clym:MilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_95114177-d276-4bf7-acfa-a07347587ae6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_98215062-e0fc-42fc-b9b2-81c479845247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">clym:DirectExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">clym:CLYM116Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_98544ab6-691e-467e-be62-d270667fdc07"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9919181b-3aee-4458-b7d9-1a4a0eaa9fb2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9b4e2e25-766b-4195-902e-5d8cc2e9e3df"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">clym:StockBasedCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9d3703f0-77df-42a1-9ca1-0e2e95db2565"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9e183b21-7abc-4bbb-a514-9fac970fc0da"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a1639fe2-538e-4c2e-8eb6-781b99e56320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">clym:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a2afa2c5-af46-4829-87c9-63140a0edb2a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a81d855c-f7c2-4536-8f9e-51e73b2054d6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a8e8a23d-3bb9-47c3-9f60-1878b2e54d8c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a9351123-b279-44ed-b948-3c21858af6ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">clym:ManufacturingServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">clym:ProbiogenAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a9d1e150-d582-4292-80b0-a0a5033ea1b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aa482204-5cdf-42f9-b194-151104d06794"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_aad0ea95-775d-4c74-b575-deb8723088ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_adc4015d-fb3a-4ffb-9ada-76a96f681121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_afdf6eb5-5976-48c1-824a-42df181b79c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">clym:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b0c73b5f-de7f-4ef4-87ec-0e261c6ff876"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b2c1de80-7339-46dc-9101-dff3552ca399"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b2cb9c72-8c63-4b1f-9bfe-c20a91b5c47f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">clym:RouAssetImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b2cd3b34-df50-4fcb-a36c-6d0072bb1fba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">clym:FourZeroOneKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b4452408-22d4-4ee5-aebd-bdfbc907dccc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b4634d19-4dbe-4167-828d-3b0dea46ce12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">clym:MabworksAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">clym:UpfrontPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b4947833-f3f8-4c09-9229-596d3c11ebb0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b551ae63-1f55-4c33-bec6-c98569fc1002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b6de63ae-c1ba-465a-83f3-ca5197585acd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">clym:CrhAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">clym:MilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b8dc21c9-0746-48db-ae13-fe4513f56fc2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">clym:AcquisitionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-10</xbrli:startDate><xbrli:endDate>2024-04-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ba58008a-9a99-409a-9227-d0761c6dddab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ba5d6e15-a48f-47c7-9a81-6786f5b4f65b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">clym:SeveranceAndBenefitsCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bb651521-2c6d-4fbd-b7ad-6cfc21cd0b6a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">clym:FirstDayOfOfferingPeriodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bd13e69e-5c42-4043-b717-21b094f74c19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">clym:DirectExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">clym:BudoprutugServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bde3f747-62a1-4f1f-a73d-375dcd93e40c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bed1b934-9767-4736-8d75-5898620908e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c03b49f0-805e-4685-86c8-e850f4d0a421"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c04dc289-c837-42ec-90ed-96b37ca44352"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">clym:LastDayOfOfferingPeriodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c2a2497b-98c5-4d07-ac31-0ab57e9c6f6a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c4117672-57e4-4a80-95aa-824a99550138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c6853a23-c64f-400c-a86c-924a3bb8491a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c6ae4ef4-19bf-455d-8977-04567e0168e2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c6e42dca-dd21-461f-8178-f4beb56519dc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c751770e-5639-4fb1-ae0f-ff557e717b97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ca2a5c36-84bf-4318-8dcb-1ce0dfebe519"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">clym:AcquisitionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cb8006fb-9972-4de5-8228-dd0f468981f6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">clym:CrhAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">clym:DevelopmentRegulatoryCommercialAndSalesMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ce134265-fb84-4e8d-9157-57ff9ef7e7ff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">clym:AfterFirstAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d015dd5d-fe12-4337-9262-398335ac7a9b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d4c5c2ea-4149-489e-bc3b-000c9f96aa69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d868bdfb-8cf1-4ee9-b1bf-c44bf7490d1f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">clym:LongTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dacb7ce4-e0c8-40f2-abc8-8ae1a39abc75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dcc85fc3-485a-42b9-b4a7-8f1dd16319b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">clym:AcquisitionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-27</xbrli:startDate><xbrli:endDate>2024-06-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dd8c59f4-3742-43b0-84bb-363445fa8ccb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">clym:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ddbb4b04-852b-4f3b-aeb7-aa35ab1cf616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_deced632-72c6-45c5-a3ca-d77bd56f0dad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e08c8f3c-6d20-45a5-9fa5-1cb8ef652339"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e158c5d9-1a89-4e43-8ef0-1635b5f8acb7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clym:ExchangeAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">clym:PreFundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e15c6a9d-687e-42af-b12a-cad341bda1e1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">clym:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e1c23734-80c9-41dd-8d11-0134db853cac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e2570053-78b9-4413-a875-a4e14bf5d7a4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e3e5dc09-b6d0-4ff0-b26f-a809c7b2d2a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e56178b2-2c10-48d7-b80d-784d82a747b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e5a79ba0-ff7c-4c63-a7dc-6397a5945808"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">clym:AdditionalOfficeSpaceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2026-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e5b62da0-95aa-41be-88d8-378341822749"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e8ccac22-cccd-4604-a52d-f88a9f26a088"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">clym:AcelyrinAssetPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eae9b56b-e6e5-40e9-bbd0-fcdfa9342978"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">clym:TwoThousandTwentyFiveInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eb135969-7a37-4398-8643-db443b9da969"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">clym:AcquisitionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-27</xbrli:startDate><xbrli:endDate>2024-06-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ecee46ed-d146-4031-b499-6e0840c72f93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ef6867d1-f320-430c-a6a8-a7cce3a87985"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">clym:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f19e76bb-81d4-4bcc-92ba-46dff13be9f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f2839107-9d2e-4b8c-98bb-fb38fcdc5134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">clym:PensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f3c7c70c-8584-4bd4-8cb7-4ec3bb217286"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">clym:FourZeroOneKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f497deb3-4bfb-4c8f-9883-3d0724584857"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">clym:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f4a412c4-4532-42cb-8fef-51e2df6f0cd9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f71c8195-caff-4e2d-b7a5-aa6363cff720"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f88dd6f3-ebdc-4647-b965-79b931a0dc44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fab74366-ad6b-4993-b418-2c772c8de0bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">clym:MabworksAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">clym:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fad7a1ea-38aa-452c-960d-f95e7b53f110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fe9354d0-7134-4802-ac6f-dbcfc70b829d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">clym:StephenThomasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ffe66a6a-2737-4df5-8bd7-75a6156fd39c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">clym:DirectExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">clym:BudoprutugServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_015297a3-3968-4419-a989-c89674259ced"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">clym:PersonnelRelatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">clym:UnallocatedExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0427b5f4-a659-4e63-a2a5-bbd14bc3d153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">clym:StephenThomasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_04dcce48-ee98-4468-a92e-30daf88a02ee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_06ef22a7-6f48-4029-8a4d-33c077e1cac9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">clym:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_077a91d2-792f-4523-9b7a-5cb3ca9f9427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_08d2f2e1-0339-4338-abfa-e32c391b4121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_09c5db3e-d09d-4b4f-b0d8-2f7673550209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0b3af095-e13b-4823-afed-c09031e8be17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">clym:MabworksAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">clym:CommercialMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0d0169f6-b7e0-49bb-b22e-a0097bdb8aef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0d43faf6-11a6-437b-94d9-14ad3457ce60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0f8a9914-3000-454c-ab10-75100dc7832f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">clym:ProbiogenAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">clym:SalesMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0fbedef7-74ba-4411-abad-f702157bda82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_116ecf73-7a8a-49b3-bad1-9ebacd1a92f4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_11bb4c97-86dc-433d-8f9f-b1671660f359"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1209e286-0944-4ac4-896b-e702d0d7ea37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_122e88aa-833d-49ea-931c-cdd318154ed2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_12593a5c-196b-480a-886e-b17facf60df2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">clym:ProbiogenAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">clym:DevelopmentManufacturingAndCommercialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_12786af0-d6f4-4fe0-aebb-f1db256fd20d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_12d2135a-b5b7-4af6-8957-a06f4411e554"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_130e2c73-2289-4af1-866f-b3e95291e78a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_132b3bc1-f201-4b4f-9cc1-62f73c6af233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">clym:LongTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_143ed184-c01f-49b6-be44-844b0eccbf0d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">clym:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1469ea52-2e42-41aa-be6d-28e711fcb465"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">clym:SharesConvertedUponAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_16927a58-af3a-42b4-98d5-64f89907d927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">clym:RouAssetImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_16c70f60-6525-47ed-a134-8055357fb60d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">clym:FourZeroOneKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_17e50103-a558-453b-9429-8e636ff6a3b8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1898b0b8-f16b-4f56-9289-bef317318637"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clym:Pre-FundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1b535855-abfa-4f1d-9fb5-d30b12645dea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">clym:StockBasedCompensationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1bcd3bb5-c5b5-4602-ab79-6c587ad285a1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">clym:UnallocatedExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1c1140e8-fbcf-4f4b-b119-b4e0831d7ee2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">clym:RouAssetImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1cd90362-0202-4f43-82f2-856942e3293d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">clym:SharesConvertedUponAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">clym:AcquisitionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-27</xbrli:startDate><xbrli:endDate>2024-06-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1f63916b-0391-41c4-8463-6860486b9487"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_20e4b68b-286f-4226-a52b-f50692b883e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_21205dde-2f21-4a5b-878c-9c16723dcb5f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_229c18f8-1124-4b2d-9a29-665a8a728b8d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">clym:AcquisitionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_239f2b84-9e87-4d24-8ef6-ec35e511039c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">clym:ProbiogenAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">clym:SalesMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_24b9841c-7af8-45b7-a8fd-326e3878b0f2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_259b8ff0-14b6-480a-93a7-28890d7655ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">clym:OptionToExtendMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">clym:AdditionalOfficeSpaceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2027-01-01</xbrli:startDate><xbrli:endDate>2027-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_26331409-5c32-4037-8326-ec8e383f9fff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2691b0a1-6374-46d9-a04c-367ba1059083"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">clym:UnallocatedExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_28105de5-c93d-4001-a309-95d3ba3b4731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">clym:LongTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2829c600-2470-432e-befb-c0c057ac53de"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">clym:MabworksAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">clym:MilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_29397fb4-e48e-4a21-bd44-1d67c539182e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">clym:AcquisitionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2a071569-fdc7-4495-8732-ea28c8ae9688"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2d40f93a-6e30-47ec-9b7b-b71b689a098a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_304c3dfd-55bb-45b2-a8b2-e1afe73e55f4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clym:ExchangeAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-12-11</xbrli:startDate><xbrli:endDate>2025-12-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3208a51a-315a-4c57-94b7-9a59ba63f36c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3238fdb8-36cf-4c49-90ac-67c04b90e3fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_34d8c2a2-a75c-4398-b4d8-8fa4f3948fad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3657c5eb-d257-42f6-9ce8-e538450d6c16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3764c6b2-4005-4af7-aa82-8f2372cb37f7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">clym:CompanyStockOwnedByRACapitalImmediatelyPriorToAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">clym:AcquisitionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_380311ae-d23a-413a-a7a8-c787758e7d24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3831b4d7-2630-4d1c-a211-547ef8149bc9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3883179f-cde0-439b-9eb8-f31242d68421"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3893b746-214f-47a9-ab19-782719fe3a18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">clym:AcquisitionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_389487f4-111c-4263-b8a6-56fb2d222f6d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">clym:MabworksAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-08</xbrli:startDate><xbrli:endDate>2025-01-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3a31c020-0ff0-49fa-b2ef-a1848d998afe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3a734757-e1ee-40b3-8578-67d0507ee846"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">clym:AcquisitionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clym:SeraServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3c01e103-0ded-4d1e-be15-85317f4afcac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">clym:DirectExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">clym:CLYM116Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3cb182f5-fa8c-4e88-b58e-b8e49cc15ab2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">clym:FirstAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3cce3a91-16bf-4fd1-a028-5515dbbca5c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3d75d312-973d-41a8-a6dc-96c192554cdc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3e184d6d-add2-4b8e-bb9b-90a0e05d219a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clym:ExchangeAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-12-11</xbrli:startDate><xbrli:endDate>2025-12-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3f3384f6-f21d-457a-af6e-c427fa15b93a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_41711020-7e54-4cd4-9a26-fdac1e897d3f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">clym:SeveranceAndBenefitsCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_428a9132-cc2d-4fef-8e17-79b45da3689d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_43590eda-3065-4d1d-82a7-d6a196b38e75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4886ee1e-e6b0-4ffe-a68d-f50c26f75b4c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_48b9f054-2754-412a-9e64-8ac7cd01dbef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">clym:ProbiogenAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">clym:DevelopmentManufacturingAndCommercialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_48e4ad5a-7bc4-467d-b65f-6be30cf02804"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">clym:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4a576f93-6b66-4d5d-b1c0-bff422cdc503"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4b99e9a3-7e4b-4844-b231-419f9b1fc292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4e50e1e3-bd9c-40de-bb68-3128ec238afe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5003f42b-a928-4d3a-9175-c224ea1b673a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_50f9f95a-751c-4f2f-91d3-e149f6c84a6f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">clym:PerformanceBasedVestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_51534b8e-0ca9-48c3-97a9-d9df1a0b13ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">clym:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_52e5d444-52de-4a17-998f-18fdef06290a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_54357343-07e1-4dfa-b18d-381a152a7bcd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_54db0f01-b239-4cf6-8fdb-eb4625a650a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_550b780f-159a-4ee0-bc82-3f2210b1684b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5544a4ea-f6c3-43ec-b41e-4209eb125966"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">clym:TwoThousandTwentyFiveInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-09-30</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_55e0a766-eff7-448c-af18-1396354e6f58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">clym:DirectExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">clym:LegacyProgramExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5917f89f-b247-498e-9e76-b710f5430033"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_59a3bf61-d6f4-4d70-be41-c0021e29d89c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5aa3c816-c0b5-4d5f-9461-9b02539bee4b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">clym:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5b33bfda-7940-4aa2-a368-a61504f508d9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5ba093f0-d16e-4ef7-8562-6da6013de54a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">clym:DirectExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">clym:LegacyProgramExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5c3cedbc-3847-4e15-a7c4-4fe16652631d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5e29120a-ab8d-4722-9dfa-39d97775d181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">clym:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-03-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5ebc4489-2c5c-40db-bf3d-8aa0443a01d9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_63169a3f-785d-4de2-b401-eff12e91f2ac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">clym:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_633a4534-233a-47cb-9dd5-77bb31081fad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_63ae5d9d-6a3f-4dea-8e44-bc65e7b9ac46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_64d950f8-dcf6-4e8a-9c63-e1b34b08c3d9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6566157b-2549-4f25-ab16-6ff8b45c4d64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_66f073f4-73ec-4e49-b873-cf1990ed99bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_67a4d641-d6ae-4d5f-aded-eba6a55bcaed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_67fbe650-9798-4fbe-bbe0-3a6d9e4fd743"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">clym:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_691140a1-fa6d-479a-bd61-6df4cc2c5e1a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_692bb88f-3f78-4543-9ceb-82120ad5dcf9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_69a98cdd-d277-4823-8526-1135dd15782f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">clym:PersonnelRelatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">clym:UnallocatedExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6a0b2fc4-e53f-4894-a5d0-249ab8cdaaa8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6bb7bc11-3822-497f-a5fa-c0b7de9605dc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6cab0607-2860-4e20-a77b-ee3751551c8f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6fd1e7a7-23cc-4225-bfaa-c65b03df60f2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_745ac205-619f-4d46-a569-a29ce2487e40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_746a74d7-c8f6-4d27-bf0b-6d5329bfce92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_748a9a3a-36eb-4467-86a9-2986b4bca451"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_75ea6436-b4b6-4e75-8aec-a8b8c3cc4fd8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clym:Pre-FundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_760e2bea-9b82-40c0-9ace-1bb642dcf176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_79c45355-4ab4-4e2a-a1e5-2f20b0546a60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7a1a17c3-5482-4393-8497-495abe0d0025"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7c0e8a73-22f5-429f-9ff0-a34f09540718"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001768446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="U_EUR"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:unit id="U_USDollarShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segments"><xbrli:measure>clym:Segments</xbrli:measure></xbrli:unit><xbrli:unit id="U_GBP"><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_12707c51-ddf2-4b1d-9b50-539eb84344b9" fromRefs="F_94a611c6-fe60-4f7e-aa05-ab8af00ceabb F_24849bd4-af46-419c-b5d3-444ee75bc1f2"/><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_c66c06d3-a16d-45aa-bd91-9bfdc6bbe5d7" fromRefs="F_f1bda04b-4315-43f6-8d54-43a89d4c656b F_ee2ef0ab-8059-46e1-9500-b4698a700b23"/></ix:resources></ix:header></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.32in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="border-top:1.5pt double;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Washington, D.C. 20549</span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_10eece64-cd1c-4013-94b1-b41a014e5b84" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10-K</span></ix:nonNumeric></span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Mark One)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:4%;box-sizing:content-box;"/>
     <td style="width:96%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_7dbd6f5c-86bb-4ca8-8995-3f893f61a049" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_44e2b039-0d26-4057-be86-32b02b4b3f79" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fb224c3b-778d-4671-a9de-f25bd79778fc" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_435dfeb5-072c-448a-89a7-b98d3b8113a4" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2025</span></ix:nonNumeric></span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:4%;box-sizing:content-box;"/>
     <td style="width:96%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_56a8a397-d861-49e8-826e-3dde9bcea97f" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM                      TO</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">                     </span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commission File Number </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3d40ffa5-0a1d-43d3-983f-b261c2d41f75" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">001-40708</span></ix:nonNumeric></span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_35d405fb-18bf-421c-9ad7-0eb5428d70a0" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CLIMB BIO, INC.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact name of Registrant as specified in its Charter)</span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:50%;box-sizing:content-box;"/>
     <td style="width:50%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_ad6f40f2-5ad8-48b4-ba30-5783a5ba1ce2" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_7032b58e-f697-4c8c-84c0-b4957f4e527d" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">83-2273741</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">incorporation or organization)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(I.R.S. Employer</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Identification No.)</span></p></td>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_07a96dfb-c7d2-446f-b9b4-d344de31dc53" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">20 William Street</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_824b0ea3-14ff-4e35-b445-d6b1d95c8aa0" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Suite 145</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_87f6c35b-eebe-4123-9150-ff88bc08b9d7" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Wellesley Hills</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:9pt;"><ix:nonNumeric id="F_4c52b4dd-044e-4056-a1c4-fc89893e4a78" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="dei:EntityAddressStateOrProvince"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">MA</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_456101b3-5d43-42f6-b8f3-03e18ff3e06c" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">02481</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Zip Code)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registrant&#8217;s telephone number, including area code:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (</span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7ea26bec-b6bb-442b-b651-3b6fed528085" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">866)</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3b38503e-6dc1-4050-a8f4-102fd4d0bec4" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">857-2596</span></ix:nonNumeric></span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:38.088%;box-sizing:content-box;"/>
     <td style="width:1.06%;box-sizing:content-box;"/>
     <td style="width:14.943%;box-sizing:content-box;"/>
     <td style="width:1.06%;box-sizing:content-box;"/>
     <td style="width:44.849%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8.65pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9.35pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;text-indent:80pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid;padding-right:0in;"><p style="margin-left:14.813%;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title of each class</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid;padding-right:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Symbol(s)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid;padding-right:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
    </tr>
    <tr style="height:12.25pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_a7d31672-a742-4821-b788-b236a2f6c3e9" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:11.5pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;text-indent:1pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="margin-left:0.187%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_d617300a-9ef1-4383-9508-6f661084e0d3" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common Stock, par value $0.0001 per share</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_dff5db90-0489-4a10-ba7d-3aa624313a1d" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">CLYM</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(The Nasdaq Global Market)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act: </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YES &#9744;     </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8ede689b-bfb0-490e-b41e-7d795490dee4" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="dei:EntityWellKnownSeasonedIssuer"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#9746;</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.  YES &#9744;     </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9be300bc-01d8-478c-b549-dcfc08947069" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="dei:EntityVoluntaryFilers"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#9746;</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_efa9cf6c-d5fb-496c-8050-b6ed7d8bef3e" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="dei:EntityCurrentReportingStatus"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#9746;     NO &#9744;</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3c35842e-8eef-435d-a99d-e37b70abed86" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="dei:EntityInteractiveDataCurrent"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#9746;     NO &#9744;</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:18.832%;box-sizing:content-box;"/>
     <td style="width:1.001%;box-sizing:content-box;"/>
     <td style="width:1.001%;box-sizing:content-box;"/>
     <td style="width:55.104%;box-sizing:content-box;"/>
     <td style="width:1.001%;box-sizing:content-box;"/>
     <td style="width:16.082%;box-sizing:content-box;"/>
     <td style="width:1.157%;box-sizing:content-box;"/>
     <td style="width:5.822%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Large accelerated filer</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accelerated filer</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
    </tr>
    <tr style="height:2.15pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_b094bc2d-7e6f-4a16-9837-a80854e878c9" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Smaller reporting company</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_eabbb2ac-aaae-4edc-88cc-dffa2f259abf" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:2.15pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Emerging growth company</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_11181031-2fc0-445a-8d38-e4accda33059" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b5e7d694-e27d-41fa-a7a7-29a5c6024f1a" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_50a20db0-e5d4-417e-a41d-695d2766e91a" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_068c9a18-bb7f-4180-bde2-d78fdcfe3ce9" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dc6465c3-4a78-42ca-90d8-298a9e8284f0" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">     No &#9746;</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of June 30, 2025, the market value of voting stock held by non-affiliates of the registrant was $</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f0d4d97c-2268-4171-9e90-be164e2f1e39" contextRef="C_f71c8195-caff-4e2d-b7a5-aa6363cff720" name="dei:EntityPublicFloat" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">44.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The calculation of the aggregate market value of voting and non-voting stock excludes certain shares of the registrant&#8217;s common stock held by current executive officers, directors and stockholders that the registrant has concluded are affiliates of the registrant. Exclusion of such shares should not be construed to indicate that any such person possesses the power, direct or indirect, to direct or cause the direction of the management or policies of the registrant or that such person is controlled by or under common control with the registrant.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.32in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of February 27, 2026, the registrant ha</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">d </span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32e58395-7170-457e-826e-746460a32441" contextRef="C_816130b0-f672-44b1-b634-9034b70a760f" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">47,767,980</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock, $0.0001 par value per share, outstanding.</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_74bf168e-b18e-4320-895a-005ff5453989" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Portions of the registrant&#8217;s definitive proxy statement for its 2026 Annual Meeting of Stockholders, which the registrant intends to file pursuant to Regulation 14A with the Securities and Exchange Commission not later than 120 days after the registrant&#8217;s fiscal year ended December 31, 2025, are incorporated by reference into Part III of this Annual Report on Form 10-K.</span></p></ix:nonNumeric></div><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1.5pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:10.704%;box-sizing:content-box;"/>
     <td style="width:81.597%;box-sizing:content-box;"/>
     <td style="width:7.698%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Page</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PART I</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_business"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Business</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1A.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a_risk_factors"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Risk Factors</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1B.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1C.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1c_cybersecurity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Cybersecurity</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 2.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_properties"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Properties</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 3.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_legal_proceedings"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Legal Proceedings</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 4.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PART II</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 5.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5_market_for_registrants_common"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 6.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_6_reserved"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">[Reserved]</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 7.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7_managements_discussion"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">103</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 7A.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7a_quantitative_and_qualitative"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">110</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 8.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_8_financial_statements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">111</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9_changes_in_and_disagreements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">137</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9A.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9a_controls_and_procedures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Controls and Procedures</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">137</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9B.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9b_other_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Other Information</span></a></p></td>
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">138</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9C.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#disclosure_regarding_foreign"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">138</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PART III</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 10.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_10_directors_executive_officers"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">139</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 11.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_11_executive_compensation"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Executive Compensation</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">139</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 12.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_12_security_ownership"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">139</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 13.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_13_certain_relationships"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">139</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 14.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_14_principal_accounting_fees"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Principal Accounting Fees and Services</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">139</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PART IV</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 15.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_15_exhibits_financial_statement"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Exhibits, Financial Statement Schedules</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">140</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 16.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_16_form_10_k_summary"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form 10-K Summary</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">143</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Annual Report on Form 10-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve substantial risk and uncertainties. All statements, other than statements of historical fact, contained in this Annual Report on Form 10-K, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The forward-looking statements in this Annual Report on Form 10-K include, among other things, statements about:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the initiation, timing, progress and results of our research and development programs, nonclinical studies and clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the anticipated timing of the submission and clearance of investigational new drug applications (IND) and comparable foreign applications for budoprutug and CLYM116; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our estimates regarding the potential patient populations for our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our estimates regarding expenses, future revenue, capital requirements, need for additional financing and the period over which we believe our cash, cash equivalents and marketable securities will be sufficient to fund our operating expenses and capital expenditure requirements;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our plans to develop and, if approved, subsequently commercialize our product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing of and our ability to submit applications for, and obtain and maintain regulatory approvals for our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our intellectual property position and our expectations regarding our ability to obtain, maintain and enforce intellectual property protection for our product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our estimates regarding the size of the potential markets for our product candidates and our ability to serve those markets; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our commercialization, marketing and manufacturing capabilities and strategy;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our competitive position and expectations regarding developments and projections relating to our competitors and any competing products that are or might become available;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the impact of government laws and regulations;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the benefits of, and our ability to satisfy our obligations under, our license agreements, including the technology transfer and exclusive license agreement (the Mabworks Agreement) with Beijing Mabworks Biotech Co., Ltd. (Mabworks);</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to enter into future collaborations, strategic alliances, or option and license arrangements; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectations regarding the time during which we will be an emerging growth company under the Jumpstart Our Business Startups Act (JOBS Act).</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in this Annual Report on Form 10-K particularly in the &#8220;Risk Factor Summary&#8221; below and in Part I, Item 1A, &#8220;Risk Factors,&#8221; that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You should read this Annual Report on Form 10-K and the documents that we reference herein and have filed or incorporated by reference hereto completely and with the understanding that our actual future results may be materially different from what we expect. The forward-looking statements contained in this Annual Report on Form 10-K are made as of the date of this Annual Report on Form 10-K, and we do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risk Factor Summary</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business is subject to numerous risks and uncertainties, including, among others, the following:</span></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have incurred significant losses since our inception and expect to continue incurring substantial losses for the foreseeable future. </span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to access capital when needed and on acceptable terms, we may be forced to delay, reduce, or discontinue our product candidate development programs, commercialization efforts, or other operations.</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently have no source of product revenue and may never become profitable. </span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our future success is dependent on the regulatory approval and commercialization of our product candidates, and if we are unable to successfully develop and commercialize our product candidates, or experience any delay in doing so, our business could be materially harmed.</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Preliminary, initial, or interim results from clinical trials that we announce, present, or publish from time to time may change as more data and information become available (or are updated based upon audit, validation and verification procedures of the data/information commonly performed for clinical trials) that could result in material changes in the final trial results. </span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nonclinical and clinical development involves a lengthy, complex, and expensive process, which is uncertain and may not predict final outcomes, and our product candidates may not demonstrate safety or efficacy in later-stage trials or satisfy regulatory requirements. Further, clinical development in immunology and autoimmune diseases presents inherent challenges, such as disease heterogeneity, variable clinical course, and evolving regulatory expectations for clinically meaningful endpoints, any of which may delay or impair our ability to obtain regulatory approval.</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we encounter difficulties enrolling or retaining patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We face significant competition in an environment of rapid technological change, and our competitors may develop or obtain regulatory approval for products before us or develop products that are safer, less expensive, or more effective than our product candidates, which could impair our commercial prospects.</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our estimates of market opportunity and forecasts of market growth for our product candidates may prove to be inaccurate, and even if the markets in which we compete achieve the forecasted growth, our business may not grow at similar rates, or at all.</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are, have been, and may in the future become, involved in litigation that could result in significant costs, divert the attention of management and harm our business.</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval and commercialize our product candidates, if and when approved, and may affect the prices we may charge for such product candidates, if and when approved.</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disruptions in our supply chain or manufacturing, including reliance on single-source suppliers and the complexities of biologics manufacturing, could delay, prevent, or impair our development or commercialization efforts.</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to obtain, maintain, or enforce adequate intellectual property protection, our competitive position could be harmed, and we rely heavily on certain in-licensed patents and other intellectual property rights in connection with our development of our product candidates and may be required to acquire or license additional patents or other intellectual property rights to continue to develop and commercialize our product candidates.</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With respect to budoprutug, we own six pending U.S. provisional applications, nine pending U.S. nonprovisional patent applications, three pending Patent Cooperation Treaty international patent applications (each, a PCT application), and six pending ex-U.S. patent applications, and we have also exclusively licensed four issued U.S. patents and at least 45 ex-U.S. patents or patent applications under our license agreement with Cancer Research Technology Limited (CRH). With respect to CLYM116, we have one exclusively in-licensed PCT application under the Mabworks Agreement and three co-owned U.S. provisional patent applications with Mabworks. We can provide no assurance that any of our current or future patent applications will result in issued patents. If we are unable to obtain, maintain and protect sufficient patent and other intellectual property rights for our product candidates and technology, or if the scope of patent and other intellectual property rights obtained is not sufficiently broad, we may not be able to compete effectively in our market.</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our information technology systems or data, or those of third parties upon which we rely, such as contract research organizations (CROs), are or were compromised or interrupted, we could experience adverse consequences resulting from such compromise or interruption, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse consequences.</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not be able to attract or retain key personnel necessary to execute our business strategy.</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The trading price of our common stock has been and may continue to be volatile, and purchasers of our common stock could incur substantial losses.</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have identified material weaknesses in our internal control over financial reporting; if we are unable to remediate these material weaknesses, or if we identify additional material weaknesses in the future, or otherwise fail to maintain effective internal control over financial reporting, we may not be able to accurately or timely report our financial condition or results of operations, which may adversely affect our business.</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART I</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1_business"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1. Business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company Overview</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a clinical-stage biotechnology company committed to developing potential best-in-class therapeutics that address significant unmet need for patients living with immune-mediated diseases. We have built our pipeline by strategically acquiring or in-licensing product candidates that we believe have clear biological rationale, well-defined development pathways, and the potential to address multiple indications.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are developing our product candidates for multiple immune-mediated diseases, as summarized in the pipeline figure below.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img22994243_0.jpg" alt="img22994243_0.jpg" style="width:672px;height:317px;"/></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We acquired the rights to our product candidates through license and asset purchase agreements. We have worldwide rights to develop and commercialize budoprutug for all indications, except for oncology. We have rights to develop and commercialize CLYM116 for all indications worldwide outside of mainland China, Hong Kong, Macau, and Taiwan, which we refer to as Greater China.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Budoprutug</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our lead product candidate, budoprutug, is a clinical-stage anti-CD19 monoclonal antibody (mAb) designed to deplete CD19-positive B cells. CD19 plays a mechanistic role across all stages of B-cell development, and emerging clinical evidence continues to support the importance of CD19 in immune-mediated diseases. By targeting CD19, budoprutug has the potential to provide rapid, profound, and durable reductions in B cells and pathogenic autoantibodies, which may allow for a disease-modifying therapeutic approach. We have focused our initial development strategy for budoprutug on primary membranous nephropathy (pMN), immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE), which we believe each offer a strong mechanistic rationale for CD19-directed therapy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In pMN, a rare, immune-mediated renal disease, autoantibodies acting against proteins in the glomerular basement membrane of the kidney drive proteinuria, nephrotic syndrome, and progressive loss of renal function. These autoantibodies are primarily secreted by plasmablasts that express CD19 but largely lack CD20, which help inform our rationale for targeting CD19-selective depletion. Early clinical data support this biological hypothesis and given the absence of approved therapies for pMN, we believe budoprutug may offer a meaningful and potentially durable treatment for patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITP is a rare autoimmune disorder characterized by antibody-mediated platelet destruction, which results in bruising, bleeding episodes, hemorrhage, and fatigue. Current therapies, such as thrombopoietin receptor agonists (TPO-RAs) and rituximab, either do not address the underlying autoimmune driver or do not provide a durable response. By depleting CD19-expressing plasmablasts and some plasma cells, and their precursors, budoprutug may offer the potential for more sustained clinical responses or disease remission.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SLE is an additional development opportunity for budoprutug. SLE is a chronic, inflammatory autoimmune disorder characterized by the formation of autoantibodies and immune complexes that can lead to damage across multiple organs, including the skin, joints, and kidneys. CD19 is broadly expressed across multiple autoreactive B-cell subsets implicated in SLE pathogenesis, including na&#239;ve, memory, and plasmablast populations. Notably, recent third-party clinical data with CD19-directed modalities, including chimeric antigen receptor T-cell therapy (CAR-T), have demonstrated meaningful clinical activity and durable responses in patients with highly refractory SLE. Budoprutug may offer the potential for broad B-cell targeting with the safety and convenience of a mAb.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2025, we received U.S. Food and Drug Administration (FDA) clearance for a Phase 2, dose range finding clinical trial of budoprutug in pMN, known as PrisMN. We dosed our first patient in the Phase 2 PrisMN clinical trial in November 2025 and are actively enrolling patients. Budoprutug was previously evaluated in a Phase 1b clinical trial in pMN, the results of which suggest that budoprutug may have the potential to induce remission of pMN in patients with moderate to severe disease. In that clinical trial, three out of five patients (60%) who received budoprutug and completed at least 48-weeks of follow-up achieved a complete remission of proteinuria, an important clinical endpoint in pMN. In addition, all five patients achieved complete peripheral B-cell depletion and, among the three patients with baseline anti-PLA2R (Phospholipase A2 Receptor) antibodies, serologic remission. Long-term follow-up data demonstrated durable reductions in proteinuria for up to three years after initial dosing in the four patients who received up to four doses of budoprutug. Additionally, three of these patients required no further immunosuppressive therapy. Notably, the FDA has granted budoprutug orphan-drug designation for the treatment of pMN.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Separately, in March 2025, we received FDA clearance for a Phase 1b/2a clinical trial of budoprutug in ITP. We are actively enrolling patients in the Phase 1b portion of this clinical trial to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical efficacy, including B-cell depletion and platelet counts, of budoprutug in ITP.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2024, we received FDA clearance for a Phase 1b clinical trial of budoprutug in SLE. We are actively enrolling patients in this global, open-label, dose-escalation Phase 1b trial. In this trial, a single dose of budoprutug will be administered in moderate to severe SLE patients to evaluate safety, tolerability, PK, PD, and preliminary efficacy, including B-cell depletion, autoantibody levels, and clinical activity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2025, we received clearance of our IND to initiate a separate, parallel Phase 1b clinical trial in SLE patients in China, which will complement our ongoing global Phase 1b clinical trial and also seek to enroll SLE patients who have lupus nephritis (LN).</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each of our clinical trials of budoprutug in pMN, ITP and SLE utilizes an intravenous (IV) formulation of budoprutug. In parallel, we are advancing a high-concentration subcutaneous (SC) formulation of budoprutug, which may offer a differentiated convenience profile and potential commercial advantage. We have generated nonclinical data using a proprietary SC formulation of budoprutug, which demonstrated high bioavailability, B-cell depletion, and favorable tolerability. In September 2025, we initiated a Phase 1 clinical trial of the SC formulation of budoprutug in healthy volunteers in Australia. We have completed dosing, and we anticipate sharing these data in the first half of 2026.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">CLYM116</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to budoprutug, we are developing CLYM116, a next-generation anti-APRIL (A PRoliferation-Inducing Ligand) mAb for the treatment of IgA Nephropathy (IgAN) and other B-cell mediated diseases. CLYM116 is a highly potent, Fc-engineered antibody that prevents APRIL signaling by potently blocking the binding of APRIL to its receptors and promoting lysosomal APRIL degradation through a pH-dependent bind-and-release &#8216;sweeper&#8217; mechanism. Through this unique binding profile and half-life-extending Fc engineering, CLYM116 has the potential to enable deep and durable inhibition of APRIL signaling and IgA production. In October 2025, we received clearance for our CTA in Australia to initiate a Phase 1 clinical trial of CLYM116 in healthy volunteers. We initiated the Phase 1 clinical trial in healthy volunteers in November 2025 and are actively enrolling subjects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Separately, our partner, Mabworks, received clearance for their IND in December 2025 and initiated a Phase 1/2 clinical trial of CLYM116 in China designed to evaluate the safety, tolerability, PK, and PD in healthy volunteers and IgAN patients.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Portfolio Approach</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Budoprutug and CLYM116 represent a portfolio that we believe has the potential to address a broad spectrum of B-cell mediated diseases, including but not limited to the diseases identified in the image below. CD19 and APRIL are important and complementary targets in immune-mediated diseases, representing distinct leverage points along the B-cell lineage. We estimate that there are more than 500,000 patients in the U.S. across pMN, ITP, SLE, and IgAN, and approximately 2.0 million people in the U.S. living with immune-mediated diseases that budoprutug and CLYM116 have the potential to benefit. Given the prevalence of immune-mediated disease and the unmet need, we believe there is a meaningful market opportunity for differentiated therapies targeting immune-mediated diseases.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><img src="img22994243_1.jpg" alt="img22994243_1.jpg" style="width:672px;height:289px;"/></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Strategy</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our strategy is to develop best-in-class treatments for patients with immune-mediated diseases, especially where we believe the mechanistic rationale is clear or clinically validated, patient populations are well-defined with high unmet need, development in multiple indications is feasible, and therapeutic differentiation can support meaningful value creation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The key elements of our strategy include:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Advance budoprutug into late-stage development in pMN. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on encouraging Phase 1b data and the biologic rationale for CD19 in pMN, we are further evaluating budoprutug in a Phase 2 clinical trial in pMN. In November 2025, we achieved first-patient-in (FPI) in the PrisMN Phase 2 trial. The trial is designed to evaluate PD, including B cells, anti-PLA2R, and total immunoglobulin, and preliminary efficacy, including complete and partial remission, in pMN patients with persistent proteinuria despite optimized Renin-Angiotensin-Aldosterone System (RAAS) inhibition, and to identify a dose for Phase 3 clinical development.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluate budoprutug in ITP and SLE</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Dosing is ongoing in our open-label, dose-escalation Phase 1b/2a clinical trial of budoprutug in previously treated patients with ITP. The trial is designed to evaluate safety, tolerability, PK, PD, and preliminary efficacy, including B-cell depletion and platelet counts. In addition, dosing is ongoing in our global, open-label, dose-escalation Phase 1b clinical trial of budoprutug in moderate to severe SLE patients. In this trial, we are administering a single dose of budoprutug to evaluate safety, tolerability, PK, PD, and preliminary efficacy, including B-cell depletion, autoantibody levels, and clinical activity. In December 2025, we received clearance of our IND to initiate a separate, parallel Phase 1b clinical trial in SLE patients in China, which will complement our ongoing global Phase 1b clinical trial and also seek to enroll SLE patients who have LN.</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Advance the SC formulation of budoprutug. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Given the chronic nature of many autoimmune diseases, we believe an SC formulation represents an important strategic and commercial differentiator. We are currently advancing a SC formulation of budoprutug, and nonclinical data of this formulation demonstrated high bioavailability and favorable tolerability at high concentration. In September 2025, we initiated a Phase 1 clinical trial of our SC formulation of budoprutug in healthy volunteers in Australia. We have completed dosing, and we anticipate sharing these data in the first half of 2026.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expand budoprutug into additional B-cell mediated diseases. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on the breadth of CD19 biology and clinical precedent from anti-CD20 mAbs, we believe budoprutug may have pipeline-in-a-product potential across additional immune-mediated diseases. We expect data from our ongoing pMN, ITP, and SLE clinical trials, together with external data from CD20- and CD19-directed agents, to inform our future indication selection and development strategy in additional B-cell mediated diseases.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accelerate development of CLYM116. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe CLYM116&#8217;s</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">differentiated &#8216;sweeper&#8217; mechanism and potential for favorable PK and potent APRIL and IgA suppression position it for meaningful differentiation from other anti-APRIL and B-cell activating factor (BAFF)/APRIL programs. In preclinical studies, CLYM116 achieved deeper, more durable IgA reductions and demonstrated a longer half-life relative to a first-generation anti-APRIL antibody. In December 2025, we dosed the first subject in our Phase 1 clinical trial of CLYM116 in healthy volunteers, which is designed to evaluate safety, tolerability, PK, PD, including IgA reductions, and immunogenicity. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Explore opportunities to expand our pipeline through business development.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Business development is a core element of our corporate strategy, as demonstrated by our acquisition of Tenet Medicines, Inc. (Tenet) and the Mabworks Agreement. While focusing on the development of our existing product candidates, we plan to continue to evaluate external opportunities to expand our pipeline that are aligned with our strategy. We intend to prioritize opportunities that leverage our expertise in immune-mediated diseases and nephrology, supported by strong human biology and translational data, have well-defined development pathways, and have the potential for efficient, capital-disciplined development in clearly defined patient populations. </span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Immune-Mediated Disease Background</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are over one hundred known immune-mediated diseases, with a collective healthcare cost in the U.S. of over $100 billion each year. This places immune-mediated disease among the costliest categories of disease to diagnose and treat in the U.S. Immune-mediated diseases are complex conditions characterized by an immune system that mistakenly attacks the body&#8217;s own cells and tissues, with clinical manifestations ranging from localized, organ-specific conditions like pMN and ITP, to systemic diseases such as SLE. A hallmark of many immune-mediated diseases is the presence of autoantibodies, produced by autoreactive B cells. In addition, B cells also contribute to disease pathogenesis through interactions with T cells and cytokine production.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the early 2000s, anecdotal observations revealed that anti-CD20 B-cell depletion therapy, via treatment with rituximab, an anti-CD20 mAb, led to significant improvements in rheumatoid arthritis (RA) and other autoimmune conditions. This discovery transformed the understanding of autoimmune pathophysiology, highlighting the critical role of B cells and leading to rituximab&#8217;s marketing authorization and inclusion in guidelines for treatment of multiple immune-mediated diseases.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Despite rituximab&#8217;s success, limitations remain. For example, not all patients respond to treatment with rituximab, with certain B-cell subsets, such as tissue-resident B cells or CD20-low-expressing cells, often evading depletion. Further, rituximab does not directly deplete autoantibody-producing plasmablasts, delaying impact on circulating autoantibody levels. This has led to the development of newer therapeutic approaches aimed at achieving more rapid, deeper, and more sustained depletion of pathogenic B-lineage cells. Targeting B cells through the next generation of approaches and targets offers a promising strategy to mitigate the production of disease-causing autoantibodies and disrupt the cycle of autoimmunity. Recent advancements targeting B cells include effector-function-enhanced monoclonal antibodies, CAR T-cell treatments, and bispecific T-cell engagers (TCEs). In addition, therapies targeting various alternative B-cell surface antigens, as well as signaling cytokines, are being investigated. Among these, CD19 and APRIL have emerged as promising targets. We believe that CD19-directed B-cell depletion and APRIL-targeted modulation of IgA production represent complementary approaches with the potential to address a broad range of antibody-mediated diseases.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Budoprutug</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our lead product candidate, budoprutug, is a highly potent anti-CD19 mAb with the potential to address a broad range of B-cell mediated diseases. We seek to position budoprutug as a potential best-in-class approach capable of delivering on efficacy, safety, and convenience.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Rationale for CD19 in Treating Immune-Mediated Diseases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:7.2pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Budoprutug is designed to target and deplete CD19-expressing B cells. We believe there is a significant advantage to targeting CD19 relative to other B-cell antigens for the treatment of immune-mediated diseases because of CD19&#8217;s broad expression profile across many B-cell sub-types.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:4.8pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CD19 antigen is found on pro-B cells and maintains surface expression throughout maturation to tissue-resident plasma cells. While CD19 expression tends to wane on bone marrow-resident plasma cells, we view this as an attractive benefit given those cells are a key component of humoral immune memory, which is responsible for actions such as conferring long-term protection post-vaccination and against infection. Most importantly, the ability to target both autoantibody-secreting cells and their progenitors provides a unique opportunity for rapid onset of action and durability of self-reactive B-cell depletion, which could potentially improve clinical benefit for patients with B-cell driven diseases.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The broad expression of CD19 across B lineage cells as compared to other B-cell targets is illustrated by the graphic below.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:7.2pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><img src="img22994243_2.gif" alt="img22994243_2.gif" style="width:501px;height:229px;"/></p><p style="font-size:10pt;margin-top:4.8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notably, CD19-targeted therapies in development have demonstrated robust efficacy in controlled trials and case reports of patients with immune-mediated diseases. Meaningful clinical activity has been observed even in patients who have failed or relapsed on other B-cell targeted therapies, including agents targeting depletion through CD20, a finding that may reflect CD19&#8217;s broader expression across the B-cell lineage and the ability to directly target plasmablasts and certain plasma cells. In this context, B-cell depletion with an anti-CD19 therapy can be viewed as acting upstream of other approaches to antibody-mediated diseases, including activation inhibitors and accelerators of antibody degradation, such as neonatal Fc receptor (FcRn)-targeted therapies. Additionally, a CD19-directed mAb, Uplinza (inebilizumab), has been approved by the FDA for the treatment of neuromyelitis optica spectrum disorder (NMOSD), immunoglobulin G4-related disease (IgG4-RD), and generalized myasthenia gravis (gMG), further supporting the clinical relevance of CD19 targeting in autoantibody-driven disease.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Rationale for a mAb-Based Approach to Targeting CD19</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the evolving landscape of B-cell targeted therapies, there are CD19-targeted approaches across multiple construct classes, including mAbs, CAR T-cell therapies, CAR-natural killer cell therapies, and TCEs. We believe a mAb-based approach to targeting CD19 is ideal for four key reasons:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturability</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. mAbs traditionally have well-established manufacturing and supply chains, favorable cost-of-goods, and scalability. The ability to readily scale manufacturing and drug supply is critical to realizing the full potential of a product candidate. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Targeting</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. mAbs generally have preferential targeting, and the core of their functionality is the ability to recognize and bind antigens with high specificity. One perceived limitation of the mAb-based approach to CD19-targeted B-cell depletion is that mAbs are unable to reach tissues, the desired site of action, and, even if they do, they lack the potency and functionality to deplete B cells within those tissues. However, in a transgenic mouse model, we observed dose dependent B-cell depletion in tissues (namely, bone marrow, lymph node and spleen) following budoprutug administration, supporting our view that mAbs can penetrate tissues and induce deep B-cell depletion. While patient-level data with anti-CD19 antibodies that directly demonstrate B-cell depletion at the tissue level are currently limited, there is clinical evidence from the widespread use of rituximab showing that </span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">mAbs can induce dose-dependent reductions of target antigen-expressing B cells in tissues. More specifically, rituximab has been shown to deplete the CD20-positive B-cell populations resident within many different tissue types, including lymph node and spleen. These data suggest that CD19-targeted mAbs may be able to penetrate tissues and deplete antigen-expressing cells within those tissues.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Safety and Tolerability</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe the safety profile of mono-specific monoclonal antibodies compares favorably to other approaches to CD19 B-cell depletion. Specifically, TCEs and CAR T-cell therapies are projected to have higher risk for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Both CRS and ICANS can be life-threatening and present poor equipoise for many patients with autoantibody driven diseases. Additionally, unlike with CAR T-cell therapies, there is no requirement for a lymphodepleting chemotherapy pretreatment regimen with mAbs. We also believe that the ability to titrate dose and redose over time provides additional flexibility to balance efficacy and tolerability in chronic autoimmune settings.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patient-Tailoring and Access</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Targeting CD19 with a mAb presents the opportunity for optimized dosing and administration. Opportunity exists to formulate mAbs for both IV and SC administration. In addition, the potential for self-administration subcutaneously through autoinjectors or pens may offer optionality for development and facilitate patient-tailored treatment strategies. Such optionality in formulation and administration does not exist for cell-based approaches targeting CD19, which require in-hospital administration. In addition, mAb approaches provide dosing flexibility and can be administered in single or multiple doses as required to achieve the desired amount of drug delivery. Given physician familiarity with mAbs, we believe these therapies can be administered outside of tertiary referral centers in community hospitals that do not require special units, enabling broader patient access. </span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our CD19 Approach: Budoprutug</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:7.2pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Budoprutug, our lead product candidate, targets CD19, which is expressed across a wider repertoire of B-cell lineages than CD20, potentially enabling broader and more durable depletion of pathogenic B cells. While CD19-targeted CAR-T therapies have shown encouraging efficacy, both CAR T-cell and TCEs are associated with significant drawbacks, including high rates of CRS and ICANS. In addition, CAR T-cell therapies require lymphodepleting chemotherapy, which is associated with significant toxicities as well as an FDA-recognized risk of secondary malignancies. These therapies are also associated with a complex and costly manufacturing process and, for autologous cells, delay of treatment</span><span style="color:#242424;white-space:pre-wrap;font-size:10.5pt;font-family:'Segoe UI',sans-serif;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">due to the time required for cell collection, modification, and re-infusion.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:4.8pt;font-family:Times New Roman;margin-bottom:18pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Budoprutug is a highly potent anti-CD19 mAb designed with a low-fucosylated Fc region, resulting in enhanced effector function and pronounced antibody dependent cellular cytotoxicity (ADCC). We believe there are several unique attributes of budoprutug that have the potential to differentiate it from other anti-CD19 treatment approaches for immune-mediated diseases. In the diagram below, we highlight budoprutug&#8217;s key features, including its low picomolar activity, enhanced ADCC, and high concentration formulation. Taken together, we believe these key features of budoprutug create a compelling opportunity for broad utility across a number of immune-mediated diseases where unmet need remains high.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:18pt;text-align:center;"><img src="img22994243_3.jpg" alt="img22994243_3.jpg" style="width:672px;height:209px;"/></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Picomolar Affinity</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:7.2pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Budoprutug&#8217;s high affinity for CD19 has the potential to overcome lower antigen density of CD19 on some B-cell sub-types, such as plasma cells, and enables direct targeting of those pathogenic B cells, which are upstream as a source of inflammation.</span></p><p style="font-size:10pt;margin-top:4.8pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Functionally Enhanced ADCC</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The glycoengineered, low-fucosylated Fc region of budoprutug increases affinity for Fc gamma receptors, thereby functionally enhancing ADCC. We believe that budoprutug&#8217;s enhanced effector function coupled with potent antigen binding will drive deep and durable B-cell depletion. In the figure below, we show that budoprutug&#8217;s glycoengineering demonstrated 100-fold improved potency relative to a budoprutug construct containing a wild type IgG1 backbone and that budoprutug demonstrated improved cell-killing potency against Daudi lymphoma cells relative to rituximab.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><img src="img22994243_4.jpg" alt="img22994243_4.jpg" style="width:645px;height:258px;"/></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In an initial clinical trial of budoprutug in pMN, subjects receiving as low as 100 mg induction doses achieved undetectable levels of circulating B cells for at least 6 months. In patients with B-cell malignancies, repeated doses as high as 1,000 mg once weekly for four weeks were generally well-tolerated. These early data are encouraging, and we believe this feature of budoprutug will potentially lead to deep and durable depletion of both peripheral and tissue-resident B cells in patients with immune-mediated diseases, providing potentially significant opportunity for clinical benefit. We believe this profile, together with the convenience of a mAb-based approach, may offer an attractive balance of efficacy, safety, and practicality relative to other CD19-directed treatment modalities, including cell-based therapies.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">High Concentration</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have been able to successfully formulate budoprutug to concentrations exceeding 175 milligrams per milliliter while maintaining low viscosity, creating an opportunity to pursue a SC dose form that potentially features a low volume injection. We believe there is an opportunity to optimize both the dosing regimen and dose form for specific patient populations, potentially enabling a patient-tailored approach to disease management.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our Budoprutug Development Strategy</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CD19 plays a mechanistic role across all stages of B-cell development, and emerging evidence from CD19-directed mAb, bispecific antibody, and CAR-T cell therapy studies demonstrates its importance in immune-mediated diseases. By targeting CD19-expressing cells, including plasmablasts and subsets of plasma cells, budoprutug has the potential to offer rapid, profound, and durable reductions in pathogenic autoantibodies, which may allow for a disease-modifying therapeutic approach. We have focused our initial development strategy for budoprutug on pMN, ITP, and SLE, which we believe each offer a strong mechanistic rationale for CD19-directed therapy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Primary Membranous Nephropathy</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Background on pMN</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pMN is a rare immune-mediated disease characterized by proteinuria, nephrotic syndrome, and progressive loss of renal function. We estimate there are approximately 70,000 people in the U.S. with pMN. There are currently no therapies approved by the FDA for the treatment of pMN.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In pMN, B-lineage cells produce autoantibodies that target antigens present on glomerular podocytes, usually including antibodies to PLA2R. Immune complexes of antigen and autoantibody are deposited in the glomerular basement membrane where they mediate inflammation and injury to podocytes that eventually leads to proteinuria which, if left untreated, can lead to kidney failure. Clinically, pMN often presents with nephrotic syndrome, characterized by significant proteinuria, hypoalbuminemia, and edema. Diagnosis typically involves blood tests to measure cholesterol and protein levels, urine tests for proteinuria, glomerular filtration rate tests, and kidney biopsies to detect specific antibodies. The management of pMN is focused on achieving complete remission of proteinuria, as this has been definitively correlated to improved long term maintenance of renal function.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Without an approved treatment in the U.S., the standard of care in pMN includes supportive treatments to manage symptoms like hypertension and edema and, when necessary, immunosuppressive therapy, which may include corticosteroids, calcineurin inhibitors, or other agents. These treatments have undesirable side effects, including, among others, hypertension, neurotoxicity, metabolic abnormalities, a heightened risk of life-threatening bacterial, viral, and fungal infections, malignancies, hypoglycemia and gastrointestinal disturbances. Newer therapies, including rituximab, have been used with some success, however, the response to this treatment is delayed and the majority of treated patients do not achieve complete remission of the disease.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disease flares following initial responses are common, and complications of treatment add to the overall disease burden. There remains an unmet medical need for more effective therapies for refractory cases and strategies to prevent long-term kidney damage and improve patient outcomes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Budoprutug for pMN</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pMN is caused by the destruction of podocytes mediated by autoantibodies to podocyte antigens, predominantly PLA2R autoantibodies. There is evidence that a majority of the autoantibody secretion come from plasmablasts, which are B-lineage cells that express CD19 but have largely lost CD20 expression. Given budoprutug&#8217;s mechanism of targeting and depleting CD19-expressing cells from the pre-B-cells stage through the plasmablast stage, we believe that budoprutug administration may lead to a rapid decline in autoantibodies, permit healing of podocytes, and resolution of proteinuria.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A Phase 1b clinical trial of budoprutug demonstrated proof-of-concept for budoprutug in pMN. In this pilot study, budoprutug was administered in two IV infusions 14 days apart at Week 0 and Week 24. Three patients received 100 milligrams at each dose and two patients received 200 milligrams at each dose. Data from the five patients who received all four doses of budoprutug in the Phase 1b clinical trial is presented in the figure below.</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Three of five (60%) patients achieved complete remission of proteinuria at week 48 (right chart).</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rapid and significant reductions in anti-PLA2R autoantibodies, a key driver of pMN, with serological remission occurred in the three patients that were PLA2R-positive at baseline (middle chart).</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Complete and sustained B-cell depletion was observed in all patients (5/5), with undetectable levels of B cells occurring after just two doses of study drug at doses as low as 100 mg (left chart).</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><img src="img22994243_5.jpg" alt="img22994243_5.jpg" style="width:648px;height:170px;"/></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Budoprutug was generally well-tolerated at doses up to 200 mg administered as two doses separated by 14 days, the highest dose tested in the study, with no reported drug-related serious adverse events. Among the eight patients who received at least one injection of budoprutug in the clinical trial, there were no deaths, there were three serious adverse events (grade 3 bacterial pneumonia, grade 4 rhabdomyolysis, and grade 3 chronic obstructive pulmonary disease), none of which were considered to be related to budoprutug by the investigator, and all of which resolved with treatment or observation. There were no discontinuations due to adverse events and there were no dose limiting toxicities observed. Four patients reported infections during the trial of which three were cases of COVID-19 and one was bacterial pneumonia.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Long-term follow-up data from the previously conducted Phase 1b trial demonstrated control of proteinuria for up to three years after initial dosing in four patients who received four doses of budoprutug. Additionally, in three of these four patients, no further immunosuppressive treatment was required.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe the Phase 1b data in pMN, together with the broader clinical experience with CD19-directed therapy in IgG4-mediated disease, support the potential of budoprutug to offer deep and durable remissions in pMN.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Development of Budoprutug for pMN</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2025, we received FDA clearance for a Phase 2 clinical trial, PrisMN, to further evaluate budoprutug in pMN. We have obtained regulatory clearances to open sites in Argentina, Brazil, Georgia, Taiwan, and Ukraine, and we continue to pursue regulatory clearance to open additional trial sites outside the U.S. The PrisMN trial is expected to enroll approximately 45 pMN patients who have persistent evidence of disease activity despite optimized RAAS inhibition. The trial is designed to evaluate safety, PD, including B cells, anti-PLA2R, and total immunoglobulin, and preliminary efficacy, including complete and partial remission, and to identify a dose for Phase 3 clinical development. In November 2025, we achieved FPI in the PrisMN study, and we anticipate reporting initial data from the first, low dose cohort, including B cells and anti-PLA2R, in the second half of 2026.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Immune Thrombocytopenia</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Background on ITP</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITP is a rare autoimmune disorder characterized by autoantibody-mediated destruction of platelets, leading to low levels of circulating platelets and risk of bleeding. ITP is classified as acute (short term, remitting) or chronic (persistent). Acute cases are more common in children and chronic cases are more prevalent in adults. We estimate there are approximately 85,000 patients with chronic ITP in the U.S. Of these, there are approximately 24,000 adults with chronic ITP that is refractory to treatment.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In ITP, autoantibodies attach themselves to antigens on the surface of platelets, marking them for destruction in the spleen. Megakaryocytes in the bone marrow attempt to compensate by increasing platelet cell production but may themselves become targeted for destruction. Low platelet counts result in bruising or petechiae and purpura, hemorrhagic episodes or extensive bleeding, and chronic fatigue, which are all characteristic symptoms of ITP and commonly reported. Mortality is higher than is observed in aged-matched controls.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Current treatment recommendations of the American Society of Hematology exemplify the significant unmet need for ITP patients. Even if a patient is fortunate enough to stabilize on a first line therapy with corticosteroids or IV immunoglobulin, upwards of 80% relapse and move to second line treatments, which may include rituximab or TPO-RAs. Many of those necessitate a third line treatment with additional doses of rituximab and TPO-RAs, or a trial of fostamatinib or other immunosuppressive therapy. If unsuccessful, combination therapy or splenectomy are considered.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Budoprutug for ITP</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Few current treatments target upstream disease pathogenesis. We believe the limitations of rituximab, including non-targeting of plasma cells, leaves opportunity for budoprutug in ITP. Because CD19 is expressed on antibody-producing plasmablasts and plasma cell subsets as well as their progenitors, we believe budoprutug has the potential to reduce production of pathogenic autoantibodies more durably than CD20-directed approaches.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Development of Budoprutug for ITP</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2025, we received FDA clearance to initiate a Phase 1b/2a open-label clinical trial in ITP to evaluate the safety, tolerability, PK, PD, and preliminary clinical activity of budoprutug. We have obtained regulatory clearances to open sites in Bulgaria, Greece, Serbia, Spain and Ukraine, and we are actively enrolling patients in these five countries. The trial consists of a dose-escalation and expansion design in previously treated patients with ITP, defined as a platelet count of less than 30,000/&#181;L despite an adequate trial of at least one prior therapy. The Phase 1b dose-escalation portion of the trial includes three sequential cohorts of up to six patients each. Initial data from the Phase 1b portion of the trial, including B-cell depletion and platelet counts are anticipated in the second half of 2026.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Systemic Lupus Erythematosus</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Background on SLE</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SLE is a chronic, inflammatory autoimmune disorder characterized by the formation of autoantibodies and immune complexes that can lead to damage across multiple organs, including, but not limited to, the skin, joints, and kidneys. SLE has a prevalence of approximately 240,000 patients in the U.S., disproportionately affects women (9:1 female to male ratio) and has a higher prevalence among African American, Asian, African Caribbean and Hispanic individuals. Approximately one third of SLE patients in the U.S. will experience clinically significant renal involvement, most commonly manifesting as LN, a serious and potentially life-threatening complication driven by immune-complex deposition and inflammation within the kidney. LN is a major contributor to morbidity and long-term outcomes in SLE, with patients experiencing higher rates of hospitalization, accelerated organ damage, and progression to chronic kidney disease and end-stage renal failure.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The autoantibody targets and the mechanisms by which the antibodies that arise in SLE cause injury to vary across patients, which accounts for some of the differences in clinical presentation. Some antibodies that arise in SLE bind directly to cells that are then destroyed through phagocytosis or cytotoxicity, which is the case with thrombocytopenia and anemia in SLE. Some antibodies form immune complexes that deposit in blood vessels causing inflammation that injure tissue, as is the case with nephritis, synovitis, rash and vasculitis. Some antibodies bind mediators or receptors and very directly interfere with important functions, including antiphospholipid antibodies that trigger the clotting system causing strokes and miscarriages, or antibodies to elements in the nervous system that are thought cause fatigue, cognitive impairment, depression and even psychosis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Current treatment of SLE aims to control symptoms, prevent flares, and minimize organ damage. Treatment typically begins with corticosteroids to rapidly reduce inflammation, then hydroxychloroquine to reduce the risk of another flare. When this is inadequate, or when patients cannot reduce steroids, treatments include broad spectrum oral immune suppressants, such as azathioprine or mycophenolate. Targeted inhibitors of the type I interferon receptor (anifrolumab) and of B-cell activating factor (belimumab) may also be utilized. However, despite these approaches, up to 20% of SLE patients progress to end stage renal failure, and the mortality from complications of these treatments, notably steroid therapy, is high in both renal and non-renal patients. In addition to preventing progression to renal failure, there is a need for therapeutic regimens that can reduce the use of steroids and their complications, address antiphospholipid syndrome, address fatigue and cognitive impairment and fetal risk, and prevent the accumulation of damage from repeated flares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Budoprutug for SLE</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe recent case reports and early clinical data from trials administering CD19 CAR T-cell therapies in SLE patients who were refractory to multiple lines of therapy are promising, with most patients achieving complete responses. While these data support the biological rationale for targeting CD19, several patients developed serious adverse events, including CRS and ICANS. In addition, the logistics and likely costly production of the CAR-T therapies could limit broad utility. This provides potential opportunity for a mAb approach to targeting CD19 such as budoprutug. We believe that a CD19-directed monoclonal antibody could capture many of the benefits of deep B-cell depletion, while offering a more predictable and potentially more manageable safety, logistics, and cost profile.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Development of Budoprutug for SLE</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2024, we received FDA clearance for our IND to evaluate budoprutug in a Phase 1b clinical trial in SLE. We have obtained regulatory clearances to open sites in Bulgaria, Georgia, Greece, Romania, Spain and Ukraine. We are currently enrolling patients in a global, open-label, dose-escalation Phase 1b trial, in which we will administer a single dose of budoprutug to patients with moderate to severe SLE to evaluate safety, tolerability, PK, PD, and preliminary efficacy, including augmented B cell and antibody analysis to assess whether budoprutug may have a long-term impact on autoreactive B memory cells as well as rapid depletion of antibody-producing plasmablasts. The trial includes four sequential cohorts of up to six patients each. We are initially dosing patients with a low dose of budoprutug to assess safety and tolerability prior to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">advancing to a clinically relevant dose, and we expect the safety, PK, PD, and preliminary efficacy data generated from this trial to inform subsequent development in SLE and potentially other complex systemic autoimmune diseases. Initial data are anticipated in the second half of 2026.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2025, we received clearance of our IND to initiate a separate, parallel Phase 1b clinical trial in SLE patients in China, which will complement our ongoing global Phase 1b clinical trial and also seek to enroll SLE patients who have LN. We anticipate achieving FPI in the first half of 2026.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Subcutaneous Formulation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are developing a SC formulation of budoprutug above 175 mg/ml while maintaining low viscosity, to help create an opportunity to pursue an SC dosing form that potentially features a low volume injection. We believe there is an opportunity to optimize both the dosing regimen and dose form for specific patient populations, potentially enabling a patient-tailored approach to disease management. An SC formulation could have advantages in many disease and patient settings where home-based dosing may be preferred. We have generated nonclinical data, including nonhuman primates (NHPs) data, supporting high bioavailability and favorable local tolerability of the SC formulation of budoprutug. In September 2025, we initiated a Phase 1 clinical trial of the SC formulation of budoprutug in healthy volunteers in Australia. We have completed dosing, and we anticipate sharing these data in the first half of 2026.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CLYM116</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2025, we entered into the Mabworks Agreement for rights to develop and commercialize CLYM116, an anti-APRIL mAb, in the territory outside of Greater China. We believe CLYM116 has the potential to deliver meaningful differentiation from first-generation APRIL and APRIL/BAFF inhibitors for patients with IgAN and other B-cell mediated diseases and represents a mechanistically complementary approach to our budoprutug program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Rationale for APRIL in Treating Immune-Mediated Diseases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CLYM116 is engineered to prevent APRIL signaling through a differentiated, next-generation mechanism of action. APRIL was identified in a genome-wide association study as a susceptibility locus for IgAN, and has been implicated in several other autoimmune conditions, including SLE, RA, alopecia areata, MG, Sjogren&#8217;s syndrome, and bullous pemphigoid. APRIL and its receptors play defined and non-redundant roles in the process of B-cell maturation and survival. Additionally, APRIL is involved in immunoglobulin class switching in B cells, thus contributing to the pathogenesis of diseases with aberrant Ig production. APRIL exerts its effects through binding to its two receptors: B-cell maturation antigen and transmembrane activator and CAML interactor. These two receptors also bind to a related ligand from the tumor necrosis factor family, called BAFF. While structurally related to BAFF, APRIL engages its receptors with distinct affinities and contributes to biologic functions not addressed by BAFF-directed agents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While broad B-cell depletion with agents such as rituximab has been shown to be ineffective in IgAN, more targeted plasma cell modulation through APRIL or APRIL/BAFF inhibition has demonstrated clinically validated proteinuria reductions and the potential for disease-modifying benefit. There are currently two monoclonal antibodies targeting APRIL and three fusion proteins targeting both APRIL and BAFF under late-stage clinical investigation for IgAN. In November 2025, Otsuka Pharmaceutical Co., Ltd received accelerated approval from the FDA for sibreprenlimab, a mAb targeting APRIL, and Vera Therapeutics, Inc. submitted a BLA for FDA approval of atacicept, a mAb targeting APRIL/BAFF. In early clinical studies, these agents demonstrated reductions in free APRIL, serum immunoglobulin levels, proteinuria, and stabilization of the decline in kidney function, establishing proof-of-concept for APRIL signaling inhibition. However, available data indicate that current agents may provide incomplete suppression of APRIL biology, require frequent dosing, and may introduce BAFF-related immunosuppressive liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our APRIL Approach: CLYM116</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CLYM116 is designed to address key limitations observed with first-generation APRIL and APRIL/BAFF inhibitors. As illustrated in the graphic below, CLYM116 incorporates three core differentiating features: (1) a &#8216;sweeper&#8217; mechanism of action that is designed to facilitate recycling of CLYM116 and the elimination of APRIL, (2) high-affinity, pH-dependent binding to APRIL, and (3) Fc engineering to extend serum half-life and minimize effector function. Collectively, these attributes support the potential for deeper and more durable APRIL and IgA suppression, a favorable tolerability profile without BAFF-related immunosuppression, and convenient SC administration with the potential for less frequent dosing. These characteristics may be particularly valuable in IgAN, a chronic disease affecting younger patients who require life-long therapy that minimizes treatment burden.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><img src="img22994243_6.jpg" alt="img22994243_6.jpg" style="width:672px;height:254px;"/><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#8216;Sweeper&#8217; mechanism</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CLYM116 is the only known &#8216;sweeper&#8217; anti-APRIL mAb in development. CLYM116&#8217;s &#8216;sweeper&#8217; mechanism of action employs a pH-dependent bind-and-release design coupled with Fc engineering to optimize APRIL elimination, antibody recycling, and long-duration pharmacology. As illustrated in the graphic below, (1) at physiologic pH (7.4), CLYM116 exhibits high-affinity binding to APRIL to promote efficient target engagement and potent blocking to APRIL, binding to its receptors; and (2) at endosomal pH (5.8), CLYM116 releases APRIL to promote APRIL degradation in the lysosome, while (3) maintaining high-affinity binding to FcRn to support efficient CLYM116 antibody recycling. This mechanism is intended to drive deep and durable suppression of APRIL signaling and downstream IgA production, providing the potential for improved activity and less frequent dosing vs. first generation anti-APRIL approaches or half-life extension alone.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img22994243_7.jpg" alt="img22994243_7.jpg" style="width:507px;height:316px;"/></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe early in vitro and in vivo data for CLYM116 support the mechanistic and pharmacologic profile described above. In preclinical studies, CLYM116 demonstrated pH-dependent binding, deep, and sustained clearance of APRIL, and enhanced antibody recycling, as compared to benchmark first-generation anti-APRIL mAbs, including sibeprenlimab (a third-party anti-APRIL mAb granted accelerated approval by the FDA for the treatment of IgAN) and zigakibart (a third-party anti-APRIL mAb in late-stage clinical trials). The left panel illustrates data from a pH-dependent enzyme-linked immunosorbent (ELISA) assay that demonstrated differential binding for CLYM116 at varying pH, whereas sibeprenlimab and zigakibart did not exhibit a comparable pH-dependent binding profile. In the APRIL degradation assay study depicted in the middle panel, wild-type C57BL/6 mice were administered either CLYM116, sibeprenlimab, or zigakibart (single dose, 10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">mg/kg) and human APRIL (single dose, 15 mg/kg) 36 hours later. APRIL concentration was assessed every 2 hours thereafter. CLYM116 reduced circulating APRIL and demonstrated enhanced APRIL clearance kinetics as compared to sibeprenlimab and zigakibart. In the APRIL antibody exposure assay depicted in the right panel, humanized FcRn transgenic mice were administered either CLYM116, sibeprenlimab, or zigakibart (single dose, 10 mg/kg) and 48 hours later, administered either human APRIL (single dose, 15 mg/kg) or saline. Serum antibody concentration were measured over time. In the sibeprenlimab and zigakibart treated animals, antibody exposure decreased after the addition of APRIL compared to those injected with saline. In contrast, the exposure of CLYM116 continued to be maintained, even after the addition of APRIL, supporting the efficient recycling mechanism of CLYM116.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img22994243_8.jpg" alt="img22994243_8.jpg" style="width:672px;height:164px;"/></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In subsequent head-to-head studies in NHPs, CLYM116 demonstrated approximately 85% bioavailability and an approximately 2-3 fold longer half-life compared to sibeprenlimab, supporting the potential for improved exposure and less frequent dosing in humans. Further, after a single SC administration of equivalent doses (6 mg/kg), CLYM116 demonstrated robust and durable free APRIL suppression and deeper and more prolonged IgA reduction compared to sibeprenlimab, as depicted in the figure below. CLYM116 demonstrated over 70% maximal reduction in IgA, with over 50% reduction in IgA maintained out to three months, supporting the potential for a differentiated activity profile relative to sibeprenlimab.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><img src="img22994243_9.jpg" alt="img22994243_9.jpg" style="width:423px;height:255px;"/></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A 28-day repeat-dose toxicity study in NHPs showed a similar magnitude of IgA suppression. After three SC doses of CLYM116 on days 1, 15, and 29, an over 70% reduction of IgA was observed through the eight-week recovery period, as depicted in the figure below. In the subset of animals in the 100 mg/kg cohort that were observed through an extended six-month recovery period, sustained IgA suppression (over 70% from baseline) was observed through day 183. A favorable tolerability profile was observed in this study, as well as the prior NHP studies with no local tolerance issues identified on histopathology and no CLYM116 related toxicity findings.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><img src="img22994243_10.gif" alt="img22994243_10.gif" style="width:442px;height:261px;"/></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, on a high performance liquid chromatography analysis, CLYM116 formed fewer high molecular weight complexes vs. sibeprenlimab, reflective of binding to distinct epitopes on APRIL. Notably, formation of high molecular weight complexes has been associated with potentially higher risk of immunogenicity in humans.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our CLYM116 Development Strategy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inhibition of APRIL signaling has potential application in the treatment of IgAN and other B-cell mediated diseases. CLYM116, with its unique anti-APRIL &#8216;sweeper&#8217; mechanism, has the potential to demonstrate a differentiated, disease-modifying activity profile in IgAN.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IgA Nephropathy</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Background on IgAN</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IgAN, also known as Berger's disease, is an autoantibody-mediated disease caused by deposition of immune complexes containing IgA and IgG in the glomeruli. We estimate there are approximately 200,000 cases of IgAN in the U.S. with a higher prevalence in Europe and Asia. Diagnosis is made by kidney biopsy, and symptoms include hematuria, proteinuria, high blood pressure, and edema. If left untreated, 30% to 40% of patients will develop kidney failure within 10 years of diagnosis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The standard of care for IgAN includes optimized supportive care, which focuses on controlling blood pressure, reducing proteinuria, and managing cardiovascular risk factors. This often involves the use of angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs), along with lifestyle modifications such as a low-salt diet and smoking cessation. Despite these treatments, there is a need for more effective therapies to prevent disease progression, better biomarkers for early diagnosis and monitoring, and strategies to reduce the risk of kidney failure. Additionally, there is a need for personalized treatment approaches to address the variability in disease progression and response to therapy.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The KDIGO (Kidney Disease Improving Global Outcomes) Guideline for the treatment of IgAN was updated in September 2025, recommending important changes, including a more liberal kidney biopsy policy to enable earlier diagnosis and revised treatment goals, supporting stricter disease control. Additionally, KDIGO recommends initiation of treatment with therapies that prevent or reduce pathogenic IgA and immune complex formation along with therapies that manage the disease-induced nephron loss, which may result in the use of multiple treatment strategies simultaneously as treatment for IgAN continues to evolve.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2025, sibeprenlimab (brand name VOYXACT) received FDA accelerated approval for adults with IgAN at risk for progression, marking a significant advancement as the first therapy targeting the APRIL pathway. Long-term kidney function data from the ongoing Phase 3 trial of sibeprenlimab is being generated to support full FDA approval. We believe that, while sibeprenlimab has demonstrated the validity of targeting the APRIL pathway for IgAN and represents an important step forward, a significant opportunity continues to exist for additional safe, effective treatment options with improved convenience.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Development of CLYM116 for IgAN</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2025, we received clearance for our CTA in Australia to initiate a Phase 1 single-ascending dose and multiple ascending dose clinical trial of CLYM116 in healthy volunteers. We achieved first-subject-in in December 2025 and are actively enrolling subjects to evaluate safety, tolerability, PK, PD (including IgA reductions) and immunogenicity. We anticipate reporting initial data from the Phase 1 study in mid-2026. Positive results from the Phase 1 trial would provide potential for advancement of CLYM116 into patients with IgAN.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2025, our partner, Mabworks, received IND clearance to initiate a parallel Phase 1 clinical trial of CLYM116 (known as MIL116 in Greater China), in SLE patients in China, which is intended to complement our global Phase 1 trial and may support accelerated progression into later-stage clinical development, if warranted.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Legacy Programs</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Previously, we focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems, and our lead program was ETX-123, a Kv7.2/3 potassium channel opener. In July 2023, we decided to pause further development of our Kv7 program, and we intend to seek a potential partner for this program.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">License Agreements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Agreements Related to Budoprutug</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 27, 2024, we completed our acquisition of Tenet, a private development stage biotechnology company. As a result of the acquisition, the following agreements effectively became our agreements.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Acelyrin Asset Purchase Agreement</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 11, 2024, Tenet entered into an asset purchase agreement (the Asset Purchase Agreement) with Acelyrin, Inc. (Acelyrin) and WH2, LLC, providing for the acquisition of certain assets of Acelyrin related to budoprutug (the Transferred Assets), including certain assigned contracts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under these assigned contracts, we (i) received worldwide licenses (with the right to sublicense) to certain patents, know-how and other intellectual property rights to develop, manufacture, use and commercialize budoprutug for any non-oncology indication, and (ii) assumed certain liabilities of Acelyrin arising from (1) governmental authority action or notification relating to budoprutug, (2) contracts assigned to us pursuant to the Asset Purchase Agreement and (3) our ownership, lease or operation of the Transferred Assets. The Asset Purchase Agreement includes customary representations, warranties and covenants, as well as standard mutual indemnities, including those covering losses arising from any material breach of the Asset Purchase Agreement.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Asset Purchase Agreement, we also acquired the rights and obligations, including financial obligations, under a license agreement with CRH, which Tenet subsequently amended and restated in the CRH Agreement (as defined below) and a cell line development, manufacturing services and license agreement with ProBioGen AG (ProBioGen).</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Asset Purchase Agreement, with respect to any &#8220;Product&#8221; (as such term is defined in the Asset Purchase Agreement), we are obligated to (i) make total payments of up to $157.5 million to Acelyrin upon the achievement of various development, regulatory and commercial milestones, (ii) pay royalties in the single-digit percentages, subject to specified reductions, to Acelyrin on worldwide net sales in a given calendar year, and (iii) make non-refundable and non-creditable payments to Acelyrin on sublicense income with rates ranging from the low single digit to mid teen percent depending on the stage of development of the most advanced Product at the time of such sublicense.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The royalty term continues for each Product on a country-by-country and Product-by-Product basis beginning on the first commercial sale of such Product and ending on the latest of (a) the date when such Product is no longer covered by a valid claim of a royalty-bearing patent (as such term is defined in the Asset Purchase Agreement) in such country, (b) the expiration of any regulatory exclusivity period for such Product in such country, and (c) the twelfth anniversary of the first commercial sale of such Product in such country.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are obligated to use commercially reasonable efforts to commercialize at least one Product in the U.S., to the extent a Product exists under the Asset Purchase Agreement, and to achieve specified development, regulatory and commercial milestones for such Product set forth in the Asset Purchase Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent a Product exists under the Asset Purchase Agreement, if Acelyrin asserts that we have failed to meet a specified diligence obligation under the Asset Purchase Agreement within specified time periods, and such failure is finally determined through a dispute resolution process, Acelyrin may elect, in lieu of a claim for damages, to repurchase the Transferred Assets at the then-fair market value of such Transferred Assets, as Acelyrin&#8217;s sole and exclusive remedy for such breach.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If, within a specified period following the top line data readout from the first Phase 2 clinical trial of a Product, we receive a bona fide offer or proposal from a third party to sell, transfer or otherwise divest all or substantially all of the rights to the Transferred Assets or Products, or grant an exclusive license or exclusive sublicense to such third party to develop and commercialize Products under specified terms, then prior to entering into any discussions or negotiations with any third party in relation to such a transaction, we shall provide written notice to Acelyrin of such intent or receipt of proposal. Acelyrin shall have the right to negotiate with us the terms for a definitive agreement with respect to such sale, transfer or grant of the rights to Products for a specified period of time. If Acelyrin does not exercise its right to negotiate or the parties are unable to agree on the terms of a definitive agreement, we shall have the right to negotiate or enter into an agreement with a third party with respect to such transaction, subject to specified conditions.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not sell, assign or transfer all or substantially all of the rights to develop or commercialize a Product unless, as a condition to such sale, assignment or transfer, the purchaser, assignee or transferee (as applicable) assumes in writing all of our obligations as set forth in the Asset Purchase Agreement with respect to the applicable Products.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 31, 2025, we filed a complaint in Delaware Superior Court against Alumis Inc. and its wholly owned subsidiary, Acelyrin, relating to a dispute concerning the Asset Purchase Agreement seeking a declaratory judgment that budoprutug is not a Product under the Asset Purchase Agreement, and that we do not owe a milestone payment sought by Alumis in connection with our development of budoprutug. This matter is currently pending. We are unable to predict the timeline for resolution or the outcome of this matter. Irrespective of the outcome of this matter, our financial guidance includes the full potential milestone burden.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">CRH Agreement</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Asset Purchase Agreement, in January 2024 Tenet was assigned a license agreement with CRH and, in connection with such assignment, Tenet entered into an amended and restated license agreement with CRH (the CRH Agreement). The CRH Agreement granted us a worldwide exclusive license (other than specified patent rights and materials, which are licensed to us on a non-exclusive basis) under certain know-how, patents and materials, or the licensed rights, to research, develop, test, manufacture or sell certain licensed products related to budoprutug, for all therapeutic uses except for oncology indications. We are permitted to grant a sublicense under these licenses with CRH&#8217;s prior written consent.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CRH retains, on behalf of itself and the charitable company Cancer Research U.K., a worldwide, fully paid-up, perpetual and irrevocable right in the licensed rights and in certain intellectual property owned or controlled by us that is necessary to exploit the licensed products and used, conceived or generated in the course of exercising the license or exploiting any licensed product, or product-specific foreground intellectual property, for the purpose of non-commercial, non-clinical scientific research.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are obligated to use commercially reasonable efforts to perform all activities set forth in a mutually agreed-upon development plan within the timelines set forth therein. We are also obligated to develop at least one licensed product in an autoimmune indication and to pursue worldwide regulatory authorization for licensed products. We must use commercially reasonable efforts to commercialize each licensed product throughout each of the specified major markets as soon as practicable following receipt of regulatory authorization for such product in such market.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, we must use commercially reasonable efforts to make the licensed product available through the United Kingdom (U.K.) and negotiate with relevant regulatory authorities to make each licensed product available through the National Health Service in England and Wales within a specified time of the licensed product being made available elsewhere in the territory. If we fail to meet one or more of these diligence obligations, and such failure is not remedied within the specified cure period, CRH shall have the right to terminate the CRH Agreement with respect to the relevant licensed product.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are obligated to pay CRH a mid-five figure digit fee on each anniversary of the effective date. We are obligated pay up to an aggregate of &#163;106.8 million ($143.6 million as of December 31, 2025) upon the achievement of specified development, regulatory, commercial and sales milestone events, including: (i) payments of up to mid-six figure digits in pounds sterling for certain development milestones, (ii) payments of up to low-eight figures in pounds sterling per indication (for up to three indications) for certain regulatory and commercial milestones and (iii) payments up to mid-eight figures in pounds sterling</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for certain sales milestones. We are also obligated to pay tiered royalties ranging from a rate in the mid-single digit to high-single digit percentage on net sales. The royalty term continues for each licensed product on a country-by-country basis beginning on the first commercial sale of such licensed product and ending on the latest of (a) the date when such licensed product is no longer covered by a valid claim of a licensed patent in such country, (b) the expiration of the exclusivity period for such licensed product in such country, and (c) the tenth anniversary of the first commercial sale of such licensed product in such country. We are also responsible for a sublicensing revenue payment ranging from a rate in the mid-single digit to mid-double digits for any sublicense revenue.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CRH Agreement shall remain in effect in each country in the territory until the expiry of our obligation to pay royalties in such country. Either party may terminate the CRH Agreement if the other party is in material breach that has not been remedied within the specified cure period or if the other party becomes insolvent.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CRH also has the right to terminate the CRH Agreement if we or one of our sublicensees or affiliates challenges a licensed patent, or if we are acquired by a tobacco company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ProBioGen Agreement</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Asset Purchase Agreement, Tenet was assigned a cell line development, manufacturing services and license agreement (the ProBioGen Agreement) originally entered into by ValenzaBio, Inc. and ProBioGen in February 2021.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ProBioGen Agreement granted us a non-exclusive license under certain know-how, patents and materials, to use cell lines in which ProBioGen&#8217;s proprietary technology is applied, to research, develop, manufacture, use, sell, offer to sell, import or export budoprutug. This license includes a non-exclusive sublicense by ProBioGen of certain third-party patent rights, limited to the use of budoprutug.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are obligated to (i) make payments of up to &#8364;10.0 million ($11.7 million as of December 31, 2025) upon the achievement of certain development, manufacturing and commercial milestones, including the start of a Phase 2 clinical trial for budoprutug, and (ii) make milestone payments of up to &#8364;7.0 million ($8.2 million as of December 31, 2025) upon the achievement of certain sales milestones.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we elect to contract ProBioGen to perform certain manufacturing services for budoprutug, the milestone payments would be reduced by &#8364;1.1 million ($1.2 million as of December 31, 2025).</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ProBioGen Agreement will remain in effect until the services are completed for the service-related component and until the payment obligations expire in connection with the commercial license component. Both parties have the right to terminate the ProBioGen Agreement if the other party becomes insolvent, or materially breaches the ProBioGen Agreement and fails to remedy such default within the specified cure period.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Agreements Related to CLYM116</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Mabworks Agreement</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 8, 2025, we entered into the Mabworks Agreement with Mabworks, pursuant to which Mabworks granted to us: (1) an exclusive (even as to Mabworks and its affiliates), sublicensable right and license under certain patent rights and related know-how (the Licensed Intellectual Property) to develop, manufacture and commercialize Mabworks&#8217; proprietary antibodies associated with Mabworks&#8217; proprietary antibody program identified as MIL116 (the Licensed Compounds or CLYM116) and products containing the Licensed Compounds (Licensed Products) outside of Greater China (the Licensed Territory), (2) a non-exclusive, sublicensable right and license under the Licensed Intellectual Property to manufacture the Licensed Compounds and Licensed Products in Greater China and (3) a non-exclusive, sublicensable right and license under the Licensed Intellectual Property to develop the Licensed Compounds and Licensed Products in the Greater China in connection with certain global clinical studies (as described below).</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the Mabworks Agreement, we paid to Mabworks a $9.0 million upfront payment, and we are obligated to pay a total of up to $30.0 million upon the achievement of certain development and regulatory milestones pertaining to the first indication for a Licensed Product, additional lower amounts upon the achievement of certain development and regulatory milestones pertaining to up to two additional indications for a Licensed Product and a total of up to $832.0 million upon the achievement of certain commercial milestones for all Licensed Products. In addition, we are obligated to pay Mabworks tiered royalties in the low-to mid-single-digit percentages on aggregate annual net sales of all Licensed Products in the Licensed Territory.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are obligated to pay royalties on a Licensed Product-by-Licensed Product and country-by-country basis from the date of the first commercial sale in such country until the latest of: (i) the expiration of the last valid claim on the Licensed Intellectual Property covering the composition of matter of the Licensed Compound in such Licensed Product in such country; and (ii) ten years following the first commercial sale of such Licensed Product in such country (each, a Royalty Term). The royalty rate is subject to reduction on a Licensed Product-by-Licensed Product and country-by-country basis under certain circumstances. In the event that we grant sublicenses under the Licensed Intellectual Property, we will be obligated to pay Mabworks a percentage, in the mid-single-digits to low-double-digits, of certain consideration that we receive under such sublicenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We agreed to use commercially reasonable efforts to develop, obtain regulatory approval for and commercialize a Licensed Product in the U.S. We have also granted Mabworks a right of first refusal to develop and commercialize in Greater China any product we control that contains an antibody directed to tumor necrosis factor ligand superfamily member 13 (APRIL). Mabworks has agreed not to exploit in the Licensed Territory any product that is directed to APRIL during the term of the Mabworks Agreement. The Mabworks Agreement also contains a mechanism for the parties to collaborate on global clinical studies in the future, where we have a right to perform clinical studies in Greater China with Mabworks&#8217; approval in the event that Mabworks elects not to participate in such global clinical studies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless earlier terminated, the Mabworks Agreement will expire on the expiration of the last to expire Royalty Term. Either party may terminate the Mabworks Agreement for the other party&#8217;s material breach, following a customary notice and cure period, or insolvency. Additionally, we may terminate the Mabworks Agreement for any reason upon 60 days written notice to Mabworks.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intellectual Property</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We strive to protect the proprietary technology, inventions and improvements that are commercially important to our business, including seeking, maintaining, and defending patent rights, whether developed internally or licensed from third parties. We also rely on know-how relating to our proprietary technology, product candidates and continuing innovation to develop, strengthen and maintain our proprietary position. In addition, we plan to rely on data exclusivity, market exclusivity and patent term extensions or adjustments when available.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our commercial success will depend in part on our ability to obtain and maintain patent and other proprietary protection for our technology, inventions and improvements; to defend and enforce our proprietary rights, including any patents that we may own or in-license in the future; and to operate without infringing the valid and enforceable patents and other proprietary rights of third parties. Intellectual property rights may not address all potential threats to our competitive advantage.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We intend, or understand that our licensors intend, to pursue patent protection covering, when possible, compositions, methods of use, methods of manufacture, dosing and formulations of budoprutug, CLYM116, and other intellectual property rights. We or our licensors also may pursue patent protection with respect to manufacturing and drug development processes and technologies. Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental patent agencies. We or our licensors may not be able to obtain patent protections for our compositions, methods of use, dosing and formulations, manufacturing and drug development processes and technologies throughout the world. Issued patents can provide protection for varying periods of time, depending upon the date of filing of the patent application, the date of patent issuance and the legal term of patents in the countries in which they are obtained.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In general, patents issued for applications filed in the U.S. can provide exclusionary rights for 20 years from the earliest nonprovisional application or PCT application filing date. In addition, in certain instances, the term of an issued U.S. patent that is directed to or claims an FDA-approved product can be extended to recapture a portion of the term effectively lost as a result of the FDA regulatory review period, which is called &#8220;patent term extension&#8221; (PTE). Further, the term of an issued U.S. patent may be adjusted if the issue of an original patent is delayed due to the failure of the U.S. Patent and Trademark Office (USPTO) to meet certain timelines during the prosecution of such patent, which is called &#8220;patent term adjustment&#8221; (PTA).</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The restoration period for patents extended under PTE cannot be longer than five years and the total patent term, including the restoration period, must not exceed 14 years following FDA approval. The term of patents outside of the U.S. varies in accordance with the laws of the jurisdiction, but typically is also 20 years from its earliest filing date (as determined by the patent laws of that country) or PCT application filing date plus any extensions of term that may be available under national law. The actual protection afforded by a patent varies on a product-by-product basis, from country-to-country, and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability of legal remedies in a particular country, and the validity and enforceability of the patent. Patent term may be inadequate to protect our competitive position on our products for an adequate amount of time.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The patent positions of companies like ours are generally uncertain and involve complex legal and factual questions. No consistent policy regarding the scope of claims allowable in patents in the field of biopharmaceuticals has emerged in the U.S. The relevant patent laws and their interpretation outside of the U.S. are also uncertain. Changes in either the patent laws or their interpretation in the U.S. and other countries may diminish our ability to protect our technology or product candidates and could affect the value of such intellectual property. In particular, our ability to stop third parties from making, using, selling, offering to sell or importing products that infringe our intellectual property will depend in part on our success in obtaining and enforcing patent claims that cover our technology, inventions, and improvements. We cannot guarantee that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications we or our licensors may file in the future, nor can we be sure that any patents that may be granted to us or our licensors in the future will be commercially useful in protecting our products, the methods of use, or the methods of manufacture of those products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, even our issued patents do not guarantee us the right to practice our technology in relation to the commercialization of our products. Patent and other intellectual property rights in the pharmaceutical and biotechnology space are evolving and involve many risks and uncertainties. For example, third parties may have blocking patents that could be used to prevent us from commercializing our product candidates and practicing our proprietary technology, and our issued patents may be challenged, invalidated, deemed unenforceable or circumvented, which could limit our ability to stop competitors from marketing related products or could limit the term of patent protection that otherwise may exist for our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the scope of the rights granted under any issued patents may not provide us with protection or competitive advantages against competitors with similar technology. Our competitors may independently develop similar technologies that are outside the scope of the rights granted under any issued patents. For these reasons, we may face competition with respect to budoprutug and CLYM116. Moreover, because of the extensive time required for development, testing and regulatory review of a potential product, it is possible that, before any particular product candidate can be commercialized, any patent directed to such product may expire or remain in force for only a short period following commercialization, thereby reducing the commercial advantage the patent provides.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success depends in significant part on our ability and the ability of our licensors, or future licensors, licensees, or collaborators to obtain, maintain, enforce and defend patents and other intellectual property rights with respect to budoprutug, CLYM116, or any product candidates we may develop and our technology and to operate our business without infringing, misappropriating or otherwise violating the intellectual property rights of others.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With respect to budoprutug, we own six pending U.S. provisional applications, nine pending U.S. nonprovisional patent applications, three pending PCT applications and six pending ex-U.S. patent applications. These applications relate to new uses of budoprutug, new formulations for budoprutug, and new methods of manufacturing budoprutug. With respect to manufacturing, at least four of these nine U.S. patent applications cover various aspects of a manufacturing process for budoprutug that we believe allows for more efficient and robust production of budoprutug. We co-own three pending U.S. provisional applications with Mabworks with respect to CLYM116, relating to new uses of CLYM116. We can provide no assurance that any of these current patent applications or future patent applications will result in issued patents or that any issued patents will provide us with any competitive advantage. Failure to obtain issued patents could have a material adverse effect on our ability to develop and commercialize budoprutug, CLYM116, or any product candidates we may develop. Furthermore, other parties may successfully challenge, invalidate or circumvent our issued patents so that our patent rights do not create an effective competitive barrier or revenue source.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">In-licensed Patents and Patent Applications</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We exclusively in-license from CRH four issued U.S. patents and at least 45 ex-U.S. patents or patent applications under the CRH Agreement related to budoprutug. Each of the exclusively in-licensed patents and applications from CRH relate to budoprutug, including its composition-of-matter, uses, dosage forms, methods of making, or its derivatives and uses thereof.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The issued patents, or patents that may be issued from the pending patent applications that we exclusively in-license from CRH are expected to expire beginning in December 2026, excluding any PTA that might be available following the grant of the patent, and any PTE that might be available following the grant of marketing authorizations. For example, the term of one of the U.S. patents exclusively in-licensed from CRH is adjusted by 1703 days and is expected to expire in August 2031.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the budoprutug patents we in-license, we have filed additional patents providing protection that relate to new uses of budoprutug, new formulations for budoprutug, and new methods of manufacturing budoprutug. The patents that may be issued from these pending patent applications that we filed in 2025 are expected to expire in 2045, excluding any PTA that might be available following the grant of the patent and any PTE that might be available following the grant of marketing authorizations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2025, we exclusively in-licensed from Mabworks one PCT application. The application relates to CLYM116, including composition-of-matter, uses, and methods of making. The patents that may be issued from this pending patent application that we exclusively in-license from Mabworks are expected to expire in 2044, excluding any PTA that might be available following the grant of the patent and any PTE that might be available following the grant of marketing authorizations.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">However, there can be no assurance that any of the pending patent applications will issue. Furthermore, there can be no assurance that we will benefit from any PTE or favorable adjustments to the term of any of the issued patents or patents that may issue from any pending patent applications in the future. The applicable authorities, including the FDA and the USPTO, may not agree with our assessment of whether such PTE should be granted or PTA is warranted, and if applicable, the extension or adjustment may be more limited than we request.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Trade Secrets and Other Protections</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the protections afforded by patents and other regulatory protections, we may rely, in some circumstances, on trade secrets to protect our technology. Trade secrets may be useful to protect proprietary know-how that is not patentable or which we elect not to patent. Trade secrets may also be useful for processes or improvements for which patents are difficult to enforce. We also protect our products and proprietary technology through confidentiality agreements with employees, consultants, advisors, contractors and collaborators. These agreements are designed to protect our proprietary information and, in the case of the invention assignment agreements, to grant us ownership of technologies that are developed through a relationship with a third party. These agreements may be breached, and we may not have adequate remedies for any such breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our commercial partners, collaborators, employees and consultants use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Infringement of Third-Party Proprietary Rights</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our commercial success will depend in part on not infringing upon or otherwise violating the intellectual property and proprietary rights of third parties. If we are found to infringe a third party&#8217;s intellectual property rights, we could be required to obtain a license from such third party to continue any future development and marketing of our products and technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. We could also be forced, including by court order, to cease commercializing the infringing product or technology. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees, if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our products or force us to cease some of our business operations. For more information regarding these risks, see the section titled &#8220;Risk Factors&#8212;Risks Related to Intellectual Property.&#8221;</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales and Marketing</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have not yet defined our sales, marketing or product distribution strategy for budoprutug or CLYM116 because both programs are still in development. Our commercial strategy may include the use of strategic partners, distributors, a contract sales force, or establishing our own commercial sales force. We plan to further evaluate these alternatives as we approach potential approval for budoprutug and CLYM116.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competition</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The development and commercialization of new drug products is highly competitive. Moreover, the field of immune-mediated diseases is characterized by rapidly evolving science, significant competition, and a strong emphasis on intellectual property. We will face competition from major pharmaceutical companies, specialty pharmaceutical companies, and biotechnology companies worldwide. Potential competitors also include academic institutions, government agencies, and other public and private research organizations that conduct research, seek patent protection, and establish collaborative arrangements for development, manufacturing, and commercialization.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are a number of large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of products the disease indications we are targeting with budoprutug or CLYM116. Some competitive products and therapies are based on similar scientific approaches, while others are based on entirely different approaches.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The competitive landscape for budoprutug includes multiple companies developing biologics and other modalities targeting CD19 for immune-mediated diseases. We are aware of several companies developing naked monoclonal antibodies, including Amgen Inc., which has an approved treatment, UPLIZNA (inebilizumab), for NMOSD, IgG4-RD, and gMG, and IASO Biotherapeutics, Inc. (RD129/IASO782 in Phase 1 development for autoimmune disease). AbbVie Inc. is developing a CD19-targeting glucocorticoid receptor modulator antibody-drug conjugate (ABBV-319). Companies developing bispecific TCEs or CD19 bifunctional monoclonal antibodies include but are not limited to, Cullinan Therapeutics, Inc. (CLN-978), Zenas BioPharma, Inc. (obexelimab), L. Hoffmann-La Roche Ltd. (RG6382) and Merck &amp; Co., Inc. (CN201). Companies developing CD19 CAR-T and chimeric antigen receptor-natural killer (CAR-NK) therapies include but are not limited to Novartis AG, Bristol Myers Squibb Company, Cabaletta Bio, Inc., Kyverna Therapeutics, Inc. and Nkarta, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The competitive landscape for CLYM116 includes, but is not limited to, companies developing biologics targeting APRIL or BAFF/APRIL for IgAN, such as Otsuka Pharmaceutical Co., Ltd, which has an approved treatment for IgAN, VOYXACT (sibeprenlimab), Novartis AG (zigakibart), Jade Biosciences, Inc. (JADE-101), Vertex Pharmaceuticals Incorporated (povetacicept) and Vera Therapeutics, Inc, which has submitted a BLA for FDA approval of atacicept for the treatment of IgAN. In addition, companies targeting CD38, such as Biogen Inc. (felzartamab) and Takeda Pharmaceutical Company Limited (mezagitamab), companies developing degraders for IgAN such as Biohaven, Ltd. (BHV-1400), and companies developing IgA sweeper antibodies such as argenx (ARGX-121) are also potential competitors for CLYM116.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of our current or potential competitors, either alone or with their collaboration partners, may have significantly greater financial resources and expertise in research and development, manufacturing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products. Mergers and acquisitions in the pharmaceutical, biotechnology, and gene therapy industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management consultants and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize product candidates that are safer, more effective, have fewer or less severe side effects, are more convenient, or are less expensive than budoprutug or CLYM116, or that would render budoprutug or CLYM116 obsolete or non-competitive. Our competitors also may obtain FDA or other regulatory approval for their product candidates more rapidly than we may obtain approval for budoprutug and CLYM116, which could result in our competitors establishing a strong market position before we are able to enter the market. Additionally, technologies developed by our competitors may render budoprutug or CLYM116 uneconomical or obsolete, and we may not be successful in marketing budoprutug or CLYM116 against competitors. In addition, as a result of the expiration or successful challenge of our patent rights, we could face more litigation with respect to the validity and scope of patents relating to our competitors&#8217; products. The availability of our competitors&#8217; products could limit the demand, and the price we are able to charge, for budoprutug or CLYM116.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we successfully obtain approval for budoprutug or CLYM116, we believe that the key competitive factors that will affect the success of these candidates will be efficacy, safety, tolerability, convenience, price and the availability of reimbursement from government and other third-party payors relative to such competing products. Our commercial opportunity could be reduced or eliminated if our competitors have products that are superior in one or more of these categories.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturing</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not own or operate, and do not currently plan to establish any manufacturing facilities. We source all of our nonclinical and clinical supply through third-party contract development and manufacturing organizations (CDMOs).</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For clinical supply, we utilize CDMOs who are obligated to comply with the FDA&#8217;s current Good Manufacturing Practices (cGMPs) for the manufacture of drug substance and drug product. In connection with the development of our product candidates, we rely and expect to continue to rely on third parties for our manufacturing processes and for producing all clinical drug substance and drug product, and we anticipate continuing this model for commercial supply if our product candidates are approved. We have also used additional contract manufacturers for fill, finish, labeling, packaging, storage and distribution of investigational drug products, and we expect this outsourcing model to remain in place for commercial supplies of budoprutug, CLYM116, or any future product candidates. It is our intent to identify and qualify additional manufacturers to provide active pharmaceutical ingredients and fill-and-finish services prior to submission of a Biologics License Application (BLA) to the FDA for any product candidate.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ProBioGen Agreement provides us with a non-exclusive license under certain know-how, patents and materials, to use cell lines incorporating ProBioGen&#8217;s proprietary technology to research, develop, manufacture, use, sell, offer to sell, import or export budoprutug. In the first quarter of 2025, we completed a cell line switch from the original budoprutug manufacturing line to a new cell line and manufacturing process with approximately ten-fold higher productivity and better scalability. The characterization of material from both processes demonstrated comparability, and material from the new process has been cleared by regulatory authorities where we are conducting clinical trials for use in our ongoing and planned clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have filed multiple patent applications that protect our new manufacturing process using this new cell line. The patents that may be issued from these pending patent applications are expected to expire in 2045, excluding any applicable PTA. We can provide no assurance that any current or future patent applications will result in issued patents or that any issued patents will provide us with any competitive advantage.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Government Regulation</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">U.S. FDA Regulation Overview</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA and other regulatory authorities at federal, state, and local levels, as well as in foreign jurisdictions, including the European Union (EU), extensively regulate, among other things, the research, development, testing, manufacture, quality, safety, potency, purity, approval, labeling, packaging, storage, record keeping, advertising, promotion, sale, distribution, marketing, and post-marketing surveillance of pharmaceutical products such as the monoclonal antibodies that we are developing, budoprutug and CLYM116. We, along with third-party contractors, will be required to navigate the various nonclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure of budoprutug and CLYM116. The regulatory requirements applicable to product development, approval and marketing require the expenditure of substantial time and financial resources. They also may be revised or reinterpreted by government agencies in ways that may have a significant impact on our business.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Licensure and Regulation of Biologics in the U.S.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the U.S., the FDA regulates biologics under both the Federal Food, Drug and Cosmetic Act (FDCA) and the Public Health Services Act (PHSA) and their implementing regulations. A company, institution, or organization which takes responsibility for the initiation and management of a clinical development program for such products, and for their regulatory approval, is typically referred to as a sponsor. The failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject a sponsor to a variety of administrative or judicial sanctions, such as the FDA&#8217;s refusal to approve a pending BLA, withdrawal of an approval, imposition of a clinical hold, issuance of untitled or warning letters, product recalls or withdrawals from the market, product seizures, total or partial suspension of production or distribution, injunctions, debarment, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The process required by the FDA before a biologic product may be marketed in the U.S. generally involves:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">completion of nonclinical studies, including laboratory evaluations, which must be conducted in accordance with the FDA&#8217;s current good laboratory practice (GLPs); </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">preparation of and submission to the FDA of an IND;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">approval by an institutional review board (IRB) or ethics committee for each clinical site before the trial may commence at that particular site;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">performance of adequate and well-controlled clinical trials, conducted under good clinical practice (GCP) requirements to establish the safety, purity and potency of the biologic for its intended indication;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">preparation of and submission to the FDA of a BLA that includes substantial evidence of potency, safety, and purity of the product from results of nonclinical testing and clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a determination by the FDA within 60 days of its receipt of a BLA that the application is sufficiently complete to file for review;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">satisfactory completion of an FDA Advisory Committee review, if applicable;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the proposed product is produced to assess compliance with cGMPs and to assure that the facilities, methods and controls are adequate to preserve the biological product&#8217;s continued safety, purity and potency, and of selected clinical investigation sites to assess compliance with GCPs; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">payment of application and program fees pursuant to the Prescription Drug User Fee Act (PDUFA);</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FDA approval of the BLA and licensure of the proposed product to permit commercial marketing of the product for particular indications for use in the U.S.; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">compliance with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy (REMS), and any post-approval studies or other post-marketing commitments required by the FDA. </span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FDA Regulation of the Clinical Development Program</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to beginning a clinical trial in the U.S., we must submit an IND to the FDA. An IND is a request for authorization from the FDA to administer an investigational product to humans within a specific defined clinical study or studies. The central focus of an IND submission is on the general investigational plan and the protocol(s) for clinical studies. The IND also includes results of animal and in vitro studies assessing the toxicology, PK, pharmacology, and PD characteristics of the product candidate; chemistry, manufacturing, and controls (CMC) information; and any available human data or literature to support the use of the investigational product. An IND must be cleared before human clinical trials may begin in the U.S. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises safety concerns or questions about the proposed clinical trial, including any CMC issues. In such a case, the IND may be placed on clinical hold until the IND sponsor and the FDA resolve the outstanding concerns or questions. The FDA also may impose a partial clinical hold that would limit a trial, for example, to certain doses or for a certain length of time or to a certain number of subjects. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial.</span></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With the passage of the FDA&#8217;s Modernization Act 2.0 in December 2022, Congress eliminated provisions in both the FDCA and the PHSA that required animal testing in support of an NDA or BLA. While animal testing may still be conducted, the FDA was authorized to rely on alternative non-clinical tests, including cell-based assays, microphysiological systems, or bioprinted or computer models. In April 2025, the FDA released a roadmap to replace animal testing in nonclinical safety studies with scientifically validated new approach methodologies, such as organ-on-a-chip systems and computational modeling, which are referred to as in silica models, as well as advanced in vitro assays.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical study.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. For new indications, a separate new IND may be required.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial, its informed consent form and other communications to study subjects before the clinical trial begins at that site. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB must monitor the study until completed, including any changes to the study plans while it is being conducted.</span></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk, the clinical trial is not being conducted in accordance with the FDA&#8217;s or IRB&#8217;s requirements, if the investigational product has been associated with unexpected serious harm to subjects or that the trial is unlikely to meet its stated objectives.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data monitoring committee, which provides advice to the sponsor on whether or not a study should move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information about some clinical trials, including a description of the trial and trial results, must be submitted within specific timeframes to the National Institutes of Health for public dissemination on their ClinicalTrials.gov website. The failure to submit clinical trial information to clinicaltrials.gov is a prohibited act under the FDCA with violations subject to potential civil monetary penalties of up to $10,000 for each day the violation continues. Violations may also result in injunctions and criminal prosecution or disqualification from federal grants.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A development safety and update report detailing the results of the clinical trials must be submitted at least annually to the FDA. In addition, IND safety reports must be submitted to the FDA for any of the following: serious and unexpected suspected adverse reactions; findings from other trials or animal or in vitro testing that suggest a significant risk in humans exposed to the product; and any clinically important increase in the occurrence of a serious suspected adverse reaction over that listed in the protocol or investigator brochure.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Trials</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical trials are typically conducted in three sequential phases that may overlap or be combined.</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trials evaluate safety, tolerability, PK, and sometimes PD endpoints in healthy volunteers or patients. Safety findings may limit dosing or progression.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trials assess preliminary efficacy, appropriate dosing, and additional safety data in a larger patient population. These trials help determine suitable dose regimens for Phase 3.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trials are adequate and well-controlled studies designed to confirm safety and efficacy for the intended indication. Successful completion of Phase 3 trials is typically required for full BLA approval.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These post-approval or post-marketing studies may be made a condition to approval of the BLA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2022, with the passage of Food and Drug Omnibus Reform Act of 2022 (FDORA), Congress began requiring sponsors to develop and submit a diversity action plan (DAP), for each Phase 3 clinical trial or any other &#8220;pivotal study&#8221; of a new drug or biological product. These plans are meant to encourage the enrollment of more diverse patient populations in late-stage clinical trials of FDA-regulated products. In June 2024, as mandated by FDORA, the FDA issued draft guidance outlining the general requirements for DAPs. On January 27, 2025, in response to an Executive Order issued by President Trump on January 21, 2025, on Diversity, Equity and Inclusion programs, the FDA removed this DAP draft guidance from its website. Subsequently, in July 2025, pursuant to a court order, the FDA restored the draft DAP guidance to its website with a statement that &#8220;information on this page may be modified and/or removed in the future subject to the terms of the court&#8217;s order and implemented consistent with applicable law.&#8221;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2025, the FDA issued final guidance with updated recommendations for GCPs aimed at modernizing the design and conduct of clinical trials. The updates are intended to help pave the way for more efficient clinical trials to facilitate the development of medical products. The final guidance is adopted from the International Council for Harmonisation&#8217;s recently updated E6(R3) final guideline that was developed to enable the incorporation of rapidly developing technological and methodological innovations into the clinical trial enterprise. In addition, the FDA issued draft guidance outlining recommendations for the implementation of decentralized clinical trials.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2025, the FDA issued final guidance that focuses on patient-focused drug development. The guidance outlines how stakeholders, such as patients, caregivers, researchers and medical product developers, can submit patient experience data in support of the development and approval of drug products. To that end, the guidance provides an overview of clinical outcome assessments (COAs) in clinical trials, and the role that COAs may play in evaluating the clinical benefit of a medical product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Concurrent with clinical trials, companies may complete additional animal studies and develop additional information about the biological characteristics of the product candidate and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate. In addition, the sponsor must develop and validate analytical methods for testing the identity, strength, quality and purity of the final product, or for biologics, the safety, purity and potency. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, under the Pediatric Research Equity Act (PREA), a BLA or supplement to a BLA must contain data to assess the safety, potency and purity of the investigational product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe, potent and pure. The FDA may grant deferrals for submission of data or full or partial waivers from the pediatric data requirements. A deferral may be granted for several reasons, including a finding that the investigational biologic is ready for approval for use in adults before pediatric trials are completed. The FDA is required to send a PREA Non-Compliance letter to sponsors who have failed to submit their pediatric assessments under PREA, have failed to seek or obtain a deferral or deferral extension or have failed to request approval for a required pediatric formulation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless otherwise required by regulation, PREA does not apply to any investigational product for an indication for which orphan designation has been granted, although the FDA has taken steps to limit what it considers abuse of this statutory exemption in PREA by announcing that it does not intend to grant any additional orphan drug designations for rare pediatric subpopulations of what is otherwise a common disease. In May 2023, the FDA issued new draft guidance that further describes the pediatric study requirements under PREA. The FDA also maintains a list of diseases that are exempt from PREA requirements due to low prevalence of disease in the pediatric population.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with our clinical development programs, we may conduct trials at sites outside the U.S. When a foreign clinical study is conducted under an IND, all IND requirements must be met unless waived. When a foreign clinical study is not conducted under an IND, the sponsor must ensure that the study complies with certain regulatory requirements of the FDA in order to use the study as support for an IND or application for marketing approval. Specifically, the studies must be conducted in accordance with GCP, including undergoing review and receiving approval by an independent ethics committee, and seeking and receiving informed consent from subjects. GCP requirements encompass both ethical and data integrity standards for clinical studies. The FDA&#8217;s regulations are intended to help ensure the protection of human subjects enrolled in non-IND foreign clinical studies, as well as the quality and integrity of the resulting data. They further help ensure that non-IND foreign studies are conducted in a manner comparable to that required for IND studies.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">BLA Submission, Review and Approval</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, nonclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. The BLA must include all relevant data available from pertinent nonclinical and clinical studies, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#8217;s CMC and proposed labeling, among other things. The submission of a BLA requires payment of a substantial application user fee to FDA, unless a waiver or exemption applies.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Once the FDA receives an application, it has 60 days to review the BLA to determine if it is substantially complete to permit a substantive review, before it accepts the BLA for filing. If the FDA determines that a BLA does not satisfy this standard, the FDA will issue a Refuse to File (RTF) determination to the sponsor. The FDA may request additional information and studies, and the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. In October 2025, the FDA issued internal guidance clarifying that &#8220;materially incomplete or inadequately organized&#8221; applications that would not permit timely, efficient and complete review will be subject to RTFs. Once the submission is accepted for filing, the FDA begins an in-depth review of the BLA. Under the goals and policies agreed to by the FDA under the PDUFA, the FDA has 10 months from acceptance of filing in which to complete its initial review of a standard BLA and respond to the sponsor, and six months from acceptance of filing for a priority BLA. The FDA does not always meet its PDUFA goal dates. The review process and the PDUFA goal date may be extended by three months or longer if the FDA requests that the BLA sponsor provides additional information or clarification regarding information already provided in the submission before the PDUFA goal date.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA seeks to meet these timelines for review of an application but its ability to do so may be affected by a variety of factors, including government budget and funding levels, the ability to hire and retain key personnel and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent years as a result. For example, during the past decade, the U.S. government has shut down several times and certain regulatory agencies, including the FDA, have had to furlough critical employees and stop critical activities, including potentially the review of INDs and BLAs.</span></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After the BLA is accepted for filing, the FDA reviews a BLA to determine, among other things, whether a product is safe, potent and pure, and whether the facility in which it is manufactured, processed, packed, or held meets standards designed to assure the product&#8217;s continued quality standards. The FDA may convene an advisory committee to provide clinical insight on application review questions.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, the FDA will review a sponsor&#8217;s financial relationship with the principal investigators who conducted the clinical trials in support of the BLA. Depending on the level of that compensation and any other financial interest a principal investigator may have in a sponsor, the sponsor may be required to report these relationships to the FDA. The FDA will then evaluate that financial relationship and determine whether it creates a conflict of interest or otherwise affects the interpretation of the trial or the integrity of the data generated at the principal investigator&#8217;s clinical trial site. If so, the FDA may exclude data from the clinical trial site in connection with its determination of safety and efficacy of the investigational product.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the PHSA, the FDA may approve a BLA if it determines that the product is safe, pure and potent and the facility where the product will be manufactured meets standards designed to ensure that it continues to be safe, pure and potent. To reach this determination, the FDA must determine that the investigational product is effective and that its expected benefits outweigh its potential risks to patients. This &#8220;benefit-risk&#8221; assessment is informed by the extensive body of evidence about the product&#8217;s safety, purity and potency in the BLA. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</span></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After the FDA evaluates a BLA and conducts any necessary inspections, the FDA may issue an approval letter or a Complete Response Letter (CRL). An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A CRL, which indicates that the review cycle is complete, will describe all of the deficiencies that the FDA has identified in the BLA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the CRL without first conducting required inspections, testing submitted product lots, or reviewing proposed labeling. In issuing the CRL, the FDA may recommend actions that the sponsor might take to place the BLA in condition for approval, including requests for additional information or clarification. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information or require post-marketing testing and surveillance to monitor safety, potency or purity of a product. While CRLs were previously treated by the FDA as confidential and were only disclosed in action packages for approved products, the FDA announced in September 2025 that it will now release CRLs promptly after they are issued to sponsors.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">31</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the BLA with a REMS, to ensure the benefits of the product outweigh its risks.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A REMS is a safety strategy to manage a known or potential serious risk associated with a product and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre-and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more post-market studies and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization and may limit further marketing of the product based on the results of these post-marketing studies.</span></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expedited Review Programs</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA is authorized to expedite the review of applications in several ways. While none of these expedited programs change the standards for approval, each may help expedite the development or approval process governing product candidates. A product is eligible for priority review if the FDA determines that it has the potential to provide safe and effective therapy where no satisfactory alternative therapy exists or to provide a significant improvement in the treatment, diagnosis or prevention of a serious disease or condition compared to marketed products. For products containing new molecular entities, Priority Review designation means the FDA&#8217;s goal is to take action on the marketing application within six months of the 60-day filing date (compared with ten months under standard review).</span></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To be eligible for a fast track designation, the FDA must determine, based on the request of a sponsor, that a product is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address an unmet medical need by providing a therapy where none exists or a therapy that may be potentially superior to existing therapy based on efficacy or safety factors. Fast track designation provides additional opportunities for frequent interactions with the FDA review team to expedite development and review of the product. The FDA may also review sections of the BLA for a fast track product on a rolling basis before the complete application is submitted, if the sponsor and FDA agree on a schedule for the submission of the application sections, and the sponsor pays any required user fees upon submission of the first section of the BLA. The review clock does not begin until the final section of the BLA is submitted. The FDA may decide to rescind the fast track designation if it determines that the qualifying criteria no longer apply.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, a sponsor can request designation of a product candidate as a &#8220;breakthrough therapy.&#8221; A breakthrough therapy is defined as a drug or biologic that is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug or biologic may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Products designated as breakthrough therapies are eligible for intensive guidance from the FDA on an efficient development program, organizational commitment to the development and review of the product including involvement of senior managers, and, like fast track products, are also eligible for rolling review of the BLA. Both fast track and breakthrough therapy products may also be eligible for accelerated approval and priority review if relevant criteria are met.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accelerated Approval</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, products studied for their safety, potency and purity in treating serious or life-threatening diseases or conditions may receive accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of accelerated approval, the FDA will generally require the sponsor to perform adequate and well-controlled post-marketing clinical studies to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">32</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With the passage of FDORA, Congress modified certain provisions governing accelerated approval of drug and biologic products. Specifically, the new legislation authorized the FDA to require a sponsor to have its confirmatory clinical trial underway before accelerated approval is awarded and to submit progress reports on its post-approval studies to the FDA every six months until the study is completed. Moreover, FDORA established expedited procedures authorizing the FDA to withdraw an accelerated approval if certain conditions are met, including where a required confirmatory study fails to verify and describe the predicted clinical benefit or where evidence demonstrates the product is not shown to be safe or effective under the conditions of use. The FDA may also use such procedures to withdraw an accelerated approval if a sponsor fails to conduct any required post-approval study of the product with due diligence, including with respect to &#8220;conditions specified by the Secretary.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2023, the FDA issued draft guidance that outlines its current thinking and approach to accelerated approval. Although single-arm trials have been commonly used to support accelerated approval, a randomized controlled trial is the preferred approach as it provides a more robust assessment and allows for direct comparisons to an available therapy. Subsequently, in December 2024 and January 2025, the FDA issued additional draft guidances relating to accelerated approval. These guidances describe FDA&#8217;s views on what it means to conduct a confirmatory trial with due diligence and how the agency plans to interpret whether such a study needs to be underway at the time of approval. While these guidances are currently only in draft form and will ultimately not be legally binding even when finalized, sponsors typically observe the FDA&#8217;s guidance closely to ensure that their investigational products qualify for accelerated approval.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. Furthermore, priority review, fast track designation, breakthrough therapy designation, and accelerated approval do not change the standards for approval and may not ultimately expedite the development or approval process.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Post-approval regulation</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If regulatory approval for marketing of a product or new indication for an existing product is obtained, the sponsor will be required to comply with all regular post-approval regulatory requirements as well as any post-approval requirements that the FDA has imposed as part of the approval process. The sponsor will be required to report certain adverse reactions and production problems to the FDA, provide updated safety and efficacy information and comply with requirements concerning advertising and promotional labeling requirements. Manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with ongoing regulatory requirements, including cGMP regulations, which impose certain procedural and documentation requirements upon manufacturers. Accordingly, the sponsor and its third-party manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain compliance with cGMP regulations and other regulatory requirements.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A product may also be subject to official lot release, meaning that the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Once an approval is granted, the FDA may withdraw its approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about a product;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">mandated modification of promotional materials and labeling and issuance of corrective information;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fines, warning letters or holds on post-approval clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product license approvals;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product recall, seizure or detention, or refusal to permit the import or export of products; </span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">33</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">consent decrees, corporate integrity agreements, debarment, or exclusion from federal health care programs.</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA strictly regulates the marketing, labeling, advertising and promotion of prescription drug products placed on the market. This regulation includes, among other things, standards and regulations for direct-to-consumer advertising, communications regarding unapproved uses, industry-sponsored scientific and educational activities and promotional activities involving the Internet and social media. Promotional claims about a drug&#8217;s safety or effectiveness are prohibited before the drug is approved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After approval, a drug product generally may not be promoted for uses that are not approved by the FDA, as reflected in the product&#8217;s prescribing information. In September 2021, the FDA published final regulations that describe the types of evidence that the agency will consider in determining the intended use of a drug or biologic.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It may be permissible, under very specific, narrow conditions, for a manufacturer to engage in nonpromotional, non-misleading communication regarding off-label information, such as distributing scientific or medical journal information. Moreover, with passage of the Pre-Approval Information Exchange Act in December 2022, sponsors of products that have not been approved may proactively communicate to payors certain information about products and product candidates in development to help expedite patient access upon product approval. Previously, such communications were permitted under FDA guidance but the new legislation explicitly provides protection to sponsors who convey certain information about products and product candidates in development to payors, including unapproved uses of approved products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, in January 2025, the FDA published final guidance outlining its policies governing the distribution of scientific information to healthcare providers about unapproved uses of approved products. The final guidance calls for such communications to be truthful, non-misleading and scientifically sound and to include all information necessary for healthcare providers to interpret the strengths and weaknesses and validity and utility of the information about the unapproved use of the approved product. If a company engages in such communications consistent with the guidance&#8217;s recommendations, the FDA indicated that it will not treat such communications as evidence of unlawful promotion of a new intended use for the approved product.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a company is found to have promoted off-label uses, it may become subject to adverse public relations and administrative and judicial enforcement by the FDA, the Department of Justice, or the Office of the Inspector General of the U.S. Department of Health and Human Services (HHS), as well as state authorities. This could subject a company to a range of penalties that could have a significant commercial impact, including civil and criminal fines and agreements that materially restrict the manner in which a company promotes or distributes drug products. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Finally, if there are any modifications to the product, including changes in indications, labeling or manufacturing processes or facilities, the sponsor may be required to submit and obtain FDA approval of a new BLA or a BLA supplement, which may require the sponsor to develop additional data or conduct additional nonclinical studies and clinical trials. Securing FDA approval for new indications is similar to the process for approval of the original indication and requires, among other things, submitting data from adequate and well-controlled clinical trials to demonstrate the product&#8217;s safety, purity and potency in the new indication.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Biosimilars and Reference Product Exclusivity</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When a biological product is licensed for marketing by the FDA with approval of a BLA, the product may be entitled to certain types of market and data exclusivity barring the FDA from approving competing products for certain periods of time. In March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the ACA), was enacted in the U.S. and included the Biologics Price Competition and Innovation Act of 2009 (BPCIA). The BPCIA amended the PHSA to create an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with a FDA-licensed reference biological product. To date, the FDA has approved both biosimilar and interchangeable biosimilar products.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">34</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the BPCIA, a manufacturer may submit an application for licensure of a biologic product that is &#8220;biosimilar to&#8221; or &#8220;interchangeable with&#8221; a previously approved biological product or &#8220;reference product.&#8221; In order for the FDA to approve a biosimilar product, it must find that there are no clinically meaningful differences between the reference product and proposed biosimilar product in terms of safety, purity, and potency. For the FDA to approve a biosimilar product as interchangeable with a reference product, the FDA must find that the biosimilar product can be expected to produce the same clinical results as the reference product, and (for products administered multiple times) that the biologic and the reference biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. In December 2022, Congress clarified through the FDORA that the FDA may approve multiple first interchangeable biosimilar biological products so long as the products are all approved on the first day on which such a product is approved as interchangeable with the reference product.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reference biologic is granted twelve years of exclusivity from the time of first licensure of the reference product. Approval of a 351(k) application may not be made effective until twelve years after the date of first licensure of the reference product, which under the statute excludes the date of licensure of supplements and certain other applications.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, a 351(k) application for a biosimilar or interchangeable biological product cannot be submitted for review until four years after the date on which the reference product was first licensed under Section 351(a) of the PHSA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if a product is considered to be a reference product eligible for exclusivity, however, another company could market a competing version of that product if the FDA approves a full BLA for such product containing the sponsor&#8217;s own nonclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity, and potency of its product.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There have been recent government proposals to reduce the twelve-year reference product exclusivity period, but none has been enacted to date. At the same time, since passage of the BPCIA, many states have passed laws or amendments to laws, which address pharmacy practices involving biosimilar products. The BPCIA is complex and continues to be interpreted and implemented by the FDA. In addition, government proposals have sought to reduce the 12-year reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate impact, implementation, and impact of the BPCIA is subject to significant uncertainty. In October 2025, the FDA issued draft guidance which proposes to eliminate the need for sponsors of biosimilar products to conduct comparative human clinical efficacy studies, allowing them to rely instead on analytical testing to demonstrate product differences from a reference product.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Orphan Drug Designation and Exclusivity</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat rare diseases affecting fewer than 200,000 individuals in the U.S. Orphan designation must be requested before submitting a BLA. After the FDA grants orphan designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. The orphan drug designation does not convey any advantage in, or automatically shorten the duration of, the regulatory review or approval process.</span></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a product that has orphan designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan exclusivity, which means that the FDA may not approve any other applications, including a full BLA, to market the same product for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. Orphan exclusivity does not prevent the FDA from approving a different drug or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for clinical testing and waiver of BLA application fees, and seven years of market exclusivity upon approval. Orphan exclusivity applies only to the specific approved indication. It may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA and Congress may further reevaluate and revise the Orphan Drug Act and its regulations and policies. For example, in September 2021, the Court of Appeals for the 11th Circuit held that, for the purpose of determining the scope of orphan drug exclusivity, the term &#8220;same disease or condition&#8221; means the designated &#8220;rare disease or condition&#8221; and not the &#8220;indication or use&#8221; for which the product is approved. Subsequently, in another case, a federal district court in Washington, D.C. followed the reasoning of the 11th Circuit decision and that decision was appealed to the U.S. Court of Appeals for the D.C. Circuit. On February 3, 2026, the Consolidated Appropriations Act of 2026 was enacted into law. It overruled these court decisions and codified the FDA&#8217;s longstanding interpretation of the scope of orphan drug exclusivity to apply to &#8220;the same drug for the same approved use or indication within such designated rare disease or condition.&#8221; This change, which applies retroactively, expressly authorizes the FDA to approve multiple versions of the same orphan drug for different</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">35</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sub-indications and subpopulations, such as adult and pediatric patients or multiple variations of the same disease that are caused by different genetic variants.</span></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pediatric Exclusivity</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:18pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pediatric exclusivity is another type of non-patent exclusivity in the U.S. and for biologics, if granted, provides for the attachment of an additional six months of regulatory exclusivity to the term of any existing regulatory exclusivity, including orphan exclusivity. This six-month exclusivity may be granted if a BLA sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA&#8217;s request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity that cover the product are extended by six months.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent Term Restoration and Extension</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the U.S., a patent claiming a new biologic product, its method of use or its method of manufacture may be eligible for a limited PTE under the Drug Price Competition and Patent Term Restoration Act of 1984, which permits a patent extension of up to five years for patent term lost during product development and FDA regulatory review. Assuming grant of the patent for which the extension is sought, the restoration period for a patent covering a product is typically one-half the time between the effective date of the IND clearing clinical studies and the submission date of the BLA, plus the time between the submission date of the BLA and the ultimate approval date. Patent term restoration cannot be used to extend the remaining term of a patent past a total of 14 years from the product&#8217;s approval date in the U.S. Only one patent applicable to an approved product is eligible for the extension, and the application for the extension must be submitted prior to the expiration of the patent for which extension is sought. A patent that covers multiple products for which approval is sought can only be extended in connection with one of the approvals. The USPTO reviews and approves the application for any PTE in consultation with the FDA.</span></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">EU/Rest of World Regulation</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to regulations in the U.S., there are a variety of laws and regulations in other jurisdictions governing, among other things, clinical trials, commercial sales and distribution of medicinal products. Even if FDA approval of a particular product is obtained, a sponsor must still obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries and jurisdictions outside of the U.S., including the EU, have a similar process that requires the submission of a clinical trial application much like the IND prior to the commencement of human clinical trials.</span></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Trials in the EU</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EU, clinical trials are governed by the Clinical Trials Regulation (EU) No 536/2014 (CTR), which entered into application on January 31, 2022 repealing and replacing the former Clinical Trials Directive 2001/20.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CTR is intended to harmonize and streamline clinical trial authorizations, simplify adverse-event reporting procedures, improve the supervision of clinical trials and increase transparency. Specifically, the CTR, which is directly applicable in all member states of the EU (EU Member States), introduces a streamlined application procedure through a single-entry point, the &#8220;EU portal&#8221;, the Clinical Trials Information System; a single set of documents to be prepared and submitted for the application; as well as simplified reporting procedures for clinical trial sponsors. A harmonized procedure for the assessment of applications for clinical trials has been introduced and is divided into two parts. Part I assessment is led by the competent authorities of a reference EU Member State selected by the trial sponsor and relates to clinical trial aspects that are considered to be scientifically harmonized across EU Member States. This assessment is then submitted to the competent authorities of all concerned EU Member States in which the trial is to be conducted for their review.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Part II is assessed separately by the competent authorities and Ethics Committees in each concerned EU Member State. Individual EU Member States retain the power to authorize the conduct of clinical trials on their territory.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Parties conducting certain clinical studies must, as in the U.S., post clinical trial information in the EU at the EudraCT website: https://eudract.ema.europa.eu.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In all cases, clinical trials must be conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. Medicines used in clinical trials must be manufactured in accordance with the guidelines on cGMP and in a GMP licensed facility, which can be subject to GMP inspections.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The EU pharmaceutical legislation is currently undergoing a complete review process, in the context of the Pharmaceutical Strategy for Europe initiative, launched by the European Commission in November 2020. The European Commission&#8217;s proposal for revision of several legislative instruments related to medicinal products was published in April 2023. The European Parliament requested several amendments in April 2024. On December 11, 2025, the European Parliament and Council reached a provisional political agreement on the legislation which is expected to be adopted by mid-2026. Key changes include updating regulatory data exclusivity to a new system, with 8 years of data exclusivity and a reduced market exclusivity period to 1 year, which can be extended if specific conditions are fulfilled, adding launch/supply obligations, incentivizing antibiotic innovation with transferable vouchers, and streamlining approval procedures in the EU. If the legislation is finalized in line with the provisional political agreement it will have a profound impact on the pharmaceutical industry.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Brexit and the regulatory framework in the United Kingdom</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of January 1, 2025, the Medicines and Healthcare Products Regulatory Agency (MHRA) is responsible for approving all medicinal products destined for the U.K. market (Great Britain and Northern Ireland), and the European Medicines Agency (EMA) will no longer have any role in approving medicinal products destined for Northern Ireland. The MHRA relies on the Human Medicines Regulations 2012 (SI 2012/1916), as amended (HMR) as the basis for regulating medicines. The HMR has incorporated into domestic law the body of EU law instruments governing medicinal products that pre-existed prior to the U.K.&#8217;s withdrawal from the EU. On April 28, 2025, the U.K. Parliament adopted amendments to improve and strengthen the U.K.&#8217;s clinical trials regulatory regime, which will take effect on April 28, 2026. These changes were needed since the current U.K. requirements are based upon the now-repealed EU Clinical Trials Directive (2001/20/EC), which has been replaced by the CTR.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following January 1, 2024, a new international recognition procedure (IRP) applies which intends to facilitate approval of pharmaceutical products in the U.K. The IRP is open to applicants that have already received an authorization for the same product from one of the MHRA&#8217;s specified Reference Regulators (RRs). The RRs notably include EMA and regulators in the European Economic Area (EEA) member states for approvals in the EU centralized procedure and mutual recognition procedure as well as the FDA (for product approvals granted in the U.S.). The RR assessment must have undergone a full and standalone review. RR assessments based on reliance or recognition cannot be used to support an IRP application. A Committee for Medicinal Products for Human Use (CHMP) positive opinion or a Mutual Recognition Decentralised Procedure positive end of procedure outcome is an RR authorization for the purposes of IRP.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other laws and regulations</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Healthcare providers, including physicians and third-party payors in the U.S. and elsewhere will play a primary role in the recommendation and prescription of any drug products for which we obtain marketing approval. Our current and future arrangements with third-party payors, customers, healthcare providers, physicians and others, in connection with the clinical research, sales, marketing and promotion of products, once approved, and related activities, may expose a pharmaceutical manufacturer to broadly applicable fraud and abuse and other healthcare laws and regulations. In particular, the research of our product candidates, as well as the promotion, sales and marketing of healthcare items and services and certain business arrangements in the healthcare industry, are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, structuring and commission(s), certain customer incentive programs and other business or financial arrangements. The applicable federal, state and foreign healthcare laws and regulations that may affect our ability to operate include, but are not limited to:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the U.S. federal Anti-Kickback Statute, which makes it illegal for any person or entity, including a prescription drug manufacturer, or a party acting on its behalf, to knowingly and willfully solicit, receive, offer or pay any remuneration, including any kickback, bribe, or rebate, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual, or the purchase, lease, order, arrangement, or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it to have committed a violation; </span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">37</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the U.S. federal civil and criminal false claims laws, including the False Claims Act (FCA), which can be enforced through &#8220;qui tam&#8221; or &#8220;whistleblower&#8221; actions, and civil monetary penalty laws, which impose criminal and civil penalties against individuals or entities for, among other things, knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid, or other federal health care programs that are false, fictitious or fraudulent; knowingly making, using, or causing to be made or used, a false record or statement material to a false, fictitious or fraudulent claim or an obligation to pay or transmit money or property to the federal government; or knowingly concealing or knowingly and improperly avoiding or decreasing or concealing such an obligation. to pay money to the federal government. In addition, a claim that includes items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the U.S. federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), which created additional federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">e.g.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false, fictitious or fraudulent statement or representation, or making or using any false writing or document knowing the same to contain any materially false fictitious or fraudulent statement or entry in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity can be found guilty of violating HIPAA fraud provisions without actual knowledge of the statute or specific intent to violate it;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the U.S. federal Physician Payments Sunshine Act and its implementing regulations, which require certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program to report annually to the Centers for Medicare and Medicaid Services (CMS), an agency within the HHS, under the Open Payments Program, information related to direct or indirect payments and other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals, (such as physician assistants and nurse practitioners), and teaching hospitals, as well as ownership and investment interests held by the physicians and their immediate family members.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (HITECH) and their implementing regulations, also imposes obligations, including mandatory contractual terms, on &#8220;covered entities,&#8221; including certain healthcare providers, health plans, healthcare clearinghouses, and their respective &#8220;business associates&#8221; that create, receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity as well as their covered subcontractors, with respect to safeguarding the privacy, security and transmission of individually identifiable health information, as well as analogous state and foreign laws that govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">U.S. federal and state consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">analogous U.S. state laws and regulations, including state anti-kickback and false claims and laws that may apply to items or services reimbursed by any third-party payor, including commercial insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and other relevant compliance guidance promulgated by the federal government that otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to file reports with states regarding pricing and marketing information, such as the tracking and reporting of gifts, compensations and other remuneration and items of value provided to healthcare professionals and entities; state and local laws requiring the registration of pharmaceutical sales representatives; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">European and other foreign law equivalents of each of the laws, including reporting requirements detailing interactions with and payments to healthcare providers.</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">38</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. Efforts to ensure that business arrangements comply with applicable healthcare laws involve substantial costs. It is possible that governmental and enforcement authorities will conclude that our business practices do not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against us and we are not successful in defending ourselves or asserting its rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, damages, disgorgement, imprisonment, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, reporting obligations and oversight if we become subject to integrity and oversight agreements to resolve allegations of non-compliance, contractual damages, reputational harm, diminished profits and future earnings and curtailment of operations, any of which could adversely affect our ability to operate our business and the results of operations. In addition, commercialization of any drug product outside the U.S. will also likely be subject to foreign equivalents of the healthcare laws mentioned above, among other foreign laws. Further, if any of the physicians or other healthcare providers or entities with whom we expect to do business with are found to be not in compliance with applicable laws, they may be subject to similar penalties.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Data privacy and security laws</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the U.S., federal, state and local governments have enacted numerous data privacy and security laws, including data breach notification laws, personal data privacy laws, and consumer protection laws. These privacy laws include, without limitation, the following laws and regulations: Section 5 of the Federal Trade Commission Act, HIPAA, as amended by HITECH (which imposes specific requirements relating to the privacy, security and transmission of individually identifiable health information), and the California Consumer Privacy Act of 2018 (CCPA).</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CCPA applies to personal information of consumers, business representatives, and employees, and requires businesses to provide specific disclosures in privacy notices and honor requests of California residents to exercise certain privacy rights. The CCPA provides for civil penalties of up to $7,500 per violation and allows private litigants affected by certain data breaches to recover significant statutory damages. Although the CCPA exempts some data processed in the context of clinical trials, the CCPA increases compliance costs and potential liability with respect to other personal data we maintain about California residents. In addition, the California Privacy Rights Act (CPRA) amended the CCPA and expanded the CCPA&#8217;s requirements, including by adding a new right for individuals to correct their personal information and establishing a new regulatory agency to implement and enforce the law.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to California, at least 18 other states have passed comprehensive privacy laws similar to the CCPA and CPRA. These laws are either in effect or will go into effect sometime before the end of 2026. Like the CCPA and CPRA, these laws create obligations related to the processing of personal information, as well as special obligations for the processing of &#8220;sensitive&#8221; data (which includes health data in some cases). Some of the provisions of these laws may apply to our business activities. There are also states that are considering or have already passed comprehensive privacy laws during the 2023 legislative sessions that will go into effect in 2024 and beyond. There are also states that are specifically regulating health information that may affect our business. For example, Washington state recently passed a health privacy law that will regulate the collection and sharing of health information, and the law also has a private right of action, which further increases the relevant compliance risk. These laws may impact our business activities, including our identification of research subjects, relationships with business partners and ultimately the marketing and distribution of our products.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Plaintiffs&#8217; lawyers are also increasingly using privacy-related statutes at both the state and federal level to bring lawsuits against companies for their data-related practices. In particular, there have been a significant number of cases filed against companies for their use of pixels and other web trackers. These cases often allege violations of the California Invasion of Privacy Act and other state laws regulating wiretapping, as well as the federal Video Privacy Protection Act. The rise in these types of lawsuits creates potential risk for our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outside the U.S., an increasing number of laws, regulations, and industry standards apply to data privacy and security. For example, the EU&#8217;s General Data Protection Regulation (EU GDPR) and the equivalent law in the U.K. (U.K. GDPR) and, together with EU GDPR, the GDPR, impose strict requirements for processing the personal data of individuals, including sensitive data that we may process such as health data. For example, under the GDPR, companies may face temporary or definitive bans on data processing and other corrective actions, as well as fines of up to 20 million euros under the EU GDPR, 17.5 million pounds sterling under the U.K. GDPR, or, in each case, 4% of annual global revenue, whichever is greater. Further, individuals may initiate litigation related to our processing of their personal data. Additionally, under various privacy laws and other obligations, we may be required to obtain certain consents to process personal data. Our inability or failure to do so could result in adverse consequences.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">39</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the ordinary course of business, we may transfer personal data from Europe and other jurisdictions to the U.S. or other countries. The EEA, the U.K. and certain jurisdictions have enacted data localization laws and cross-border personal data transfer laws. In particular, the EEA and the U.K. have significantly restricted the transfer of personal data to the U.S. and other countries whose privacy laws it believes are inadequate. Other jurisdictions may adopt similarly stringent interpretations of their data localization and cross-border data transfer laws. Although there are currently various mechanisms that may be used to transfer personal data from the EEA and U.K. to the U.S. in compliance with law, such as the EEA standard contractual clauses, the U.K. International Data Transfer Agreement and the EU-U.S. Data Privacy Framework (which allows for transfers for relevant U.S.-based organizations who self-certify compliance and participate in the Framework), these mechanisms are subject to legal challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal data to the U.S.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If there is no lawful manner for us to transfer personal data from the EEA, the U.K. or other jurisdictions to the U.S., or if the requirements for a legally-compliant transfer are too onerous, we could face significant adverse consequences, including the interruption or degradation of our operations, the need to relocate part of or all of our business or data processing activities to other jurisdictions at significant expense, increased exposure to regulatory actions, substantial fines and penalties, the inability to transfer data and work with partners, vendors and other third parties, and injunctions against our processing or transferring of personal data necessary to operate our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, companies that transfer personal data out of the EEA and U.K. to other jurisdictions, particularly to the U.S., are subject to increased scrutiny from regulators, individual litigants, and activist groups. Some European regulators have ordered certain companies to suspend or permanently cease certain transfers out of Europe for allegedly violating the EU GDPR&#8217;s cross-border data transfer limitations.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are also bound by contractual obligations related to data privacy and security, and our efforts to comply with such obligations may not be successful. For example, certain privacy laws, such as the GDPR and the CCPA, require our customers to impose specific contractual restrictions on their service providers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Current and future healthcare reform legislation</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The U.S. and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system. In March 2010 the ACA was enacted, which includes measures that have significantly changed the way health care is financed by both governmental and private insurers.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There have been executive, judicial, and congressional challenges to certain aspects of the ACA. For example, on June 17, 2021, the U.S. Supreme Court dismissed a judicial challenge to the ACA without specifically ruling on its constitutionality. Changes in presidential administrations have also resulted in shifts in policy priorities relating to ACA implementation and enforcement, contributing to continued uncertainty regarding the future of the law.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (IRA) into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025 and eliminates the Medicare Part D coverage gap beginning in 2025 through a newly established manufacturer discount program. It remains unclear how future legislative, regulatory, or administrative actions may affect the ACA or related coverage and payment provisions.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The IRA includes several provisions specifically affecting drug manufacturers. Among other things, the IRA:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">requires manufacturers of certain products to engage in price negotiations with Medicare beginning in 2026,</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">imposes inflation-based rebates under Medicare Parts B and D, and</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">replaces the Part D coverage gap discount program with a new manufacturer discount program beginning in 2025.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the IRA, CMS may negotiate prices for certain high-cost, single-source drugs and biologics reimbursed under Medicare Parts B and D. This provision applies to drug products that have been approved for at least 9 years and biologics that have been licensed for 13 years. Drugs and biologics that have been approved for a single rare disease or condition were originally categorically excluded from price negotiation. With passage of the One Big Beautiful Bill Act on July 3, 2025, which was signed into law on July 4, 2025, Congress extended this exemption to drugs and biologics with multiple orphan drug designations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CMS began the first negotiation cycle in 2023 and published negotiated prices for ten selected Part D drugs on August 15, 2024, which took effect on January 1, 2026. CMS announced fifteen additional drugs selected for negotiation on January 17,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">40</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2025, with negotiated prices for these drugs scheduled to take effect January 1, 2027. The agency has indicated its intent to continue implementing the program and pursue additional transparency measures.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The IRA subjects manufacturers to civil monetary penalties and potential excise taxes for noncompliance with negotiation or inflation-rebate requirements. The law also caps Medicare beneficiary annual out-of-pocket drug costs at approximately $4,000 in 2024 and $2,000 beginning in 2025. CMS finalized rules governing inflation rebate programs under Medicare Parts B and D in December 2024.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Several pharmaceutical manufacturers and industry groups, including Merck &amp; Co., the U.S. Chamber of Commerce, Bristol Myers Squibb, PhRMA, and others, have filed lawsuits challenging the IRA&#8217;s drug price negotiation provisions on constitutional and statutory grounds. HHS has generally won the substantive disputes in these cases or succeeded in getting claims dismissed for lack of standing. For example, on May 8, 2025, the U.S. Court of Appeals for the Third Circuit rejected AstraZeneca L.P.&#8217;s challenge to the Medicare price negotiation program, finding that the program did not violate the company&#8217;s due process rights under the Constitution since there is no protected property interest in selling goods to Medicare beneficiaries at a price higher than what the government is willing to pay in reimbursement. Litigation involving these and other provisions of the IRA will continue with unpredictable and uncertain results.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. For example, the Budget Control Act of 2011 included aggregate reductions to Medicare payments to providers of, on average, 2% per fiscal year beginning April 1, 2013. Due to subsequent legislative amendments, including the Infrastructure Investment and Jobs Act and the Consolidated Appropriations Act of 2023, these reductions will remain in effect until 2032, unless Congress takes additional action.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Trump Administration has also taken a number of actions to reduce the costs of pharmaceutical products. For example, on April 15, 2025, President Trump issued an Executive Order which directs HHS to take steps to reduce the prices of pharmaceutical products. Such measures include streamlining the state drug importation program and modifying provisions of the 340B program. Further, on May 12, 2025, President Trump issued an additional Executive Order calling on pharmaceutical manufacturers to voluntarily reduce the prices of medicines in the U.S. The Order provides that if such actions do not lower the costs of pharmaceuticals, the Secretary of HHS would pursue other actions, including proposing a rulemaking that imposes most favored nation (MFN) pricing in the U.S. Thereafter, on July 31, 2025, the President issued letters to 17 pharmaceutical companies reiterating the requirements of the May 12, 2025, Executive Order and demanding that such companies extend MFN pricing to Medicaid patients, guarantee MFN pricing for newly-launched drug products, return increased revenues abroad to American patients and provide for direct purchasing at MFN pricing. Since that time, virtually all of these pharmaceutical companies have entered into agreements with the Trump Administration to provide for lower prices on certain pharmaceuticals.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the state level, individual states have enacted legislation intended to control pharmaceutical pricing, including pricing or reimbursement caps, transparency measures, restrictions on certain product access, and, in some cases, policies designed to encourage importation or bulk purchasing. Regional health systems and hospital networks are also increasingly using competitive bidding and formulary management to determine which products will be covered. Additional state or federal reform measures may further limit the amounts payors are willing to reimburse, reducing demand or increasing pricing pressure on our products if approved. This may be particularly true for products approved under the FDA&#8217;s accelerated approval pathway; some state Medicaid programs and other payors have adopted significant coverage restrictions for such products, citing evidentiary concerns.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accordingly, while it is unclear how the IRA and other such regulations and legislative actions will ultimately be implemented, we cannot predict with certainty what impact federal or state healthcare reforms will have on us. Such changes could impose new or more stringent regulatory requirements or result in reduced reimbursement for budoprutug or CLYM116, if approved, or any future products we may develop, any of which could adversely affect our business, results of operations, and financial condition.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">41</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EU, similar political, economic, and regulatory developments may affect our ability to profitably commercialize budoprutug or CLYM116, if approved. In addition to ongoing pricing and cost-containment pressures, legislative changes at the EU or Member State level may impose additional requirements or obstacles that increase operating costs. In many markets outside the U.S. and EU, reimbursement and healthcare payment systems vary significantly, and many countries have instituted price ceilings or other governmental controls. In such jurisdictions, pricing negotiations with governmental authorities may take considerable time after marketing approval is received. To obtain reimbursement or pricing approval in certain countries, we or our collaborators may be required to conduct cost-effectiveness or health technology assessment studies comparing our product to available therapies.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If reimbursement for our products is unavailable, limited, or set at a level insufficient to support commercial viability, our business could be materially harmed. We expect that future healthcare reform measures may result in more rigorous coverage standards and additional downward pressure on the prices we may receive for any approved products. Any reduction in reimbursement from government programs or private payors may adversely affect our future revenues and our ability to achieve or sustain profitability.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Foreign regulation</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For other countries outside of the EU and the U.S., such as countries in Eastern Europe, Latin America or Asia, the requirements governing product development, the conduct of clinical trials, manufacturing, distribution, marketing approval, advertising and promotion, product licensing, pricing and reimbursement vary from country to country. Additionally, clinical trials must be conducted in accordance with GCP requirements and the applicable regulatory requirements and the ethical principles originating in the Declaration of Helsinki.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we fail to comply with applicable foreign regulatory requirements, we may be subject to fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, to the extent that any of our product candidates, once approved, are sold in a foreign country, we may be subject to applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws, corporate compliance obligations, and reporting of payments or other transfers of value to healthcare professionals.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Additional laws and regulations governing international operations</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we further expand our operations outside of the U.S., we will be required to dedicate additional resources to comply with numerous laws and regulations in each jurisdiction in which we plan to operate. The Foreign Corrupt Practices Act (FCPA) prohibits any U.S. individual or business from paying, offering, authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or to obtain or retain business. The FCPA also obligates companies whose securities are listed in the U.S. to comply with certain accounting provisions requiring us to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered by U.S. authorities that enforce the FCPA, including the Department of Justice, to be foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed improper payments to government officials and have led to FCPA enforcement actions.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Various laws, regulations and executive orders also restrict the use and dissemination outside of the U.S., or the sharing with certain non-U.S. nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. If we expand our presence outside of the U.S., it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and product candidates outside of the U.S., which could limit our growth potential and increase our development costs.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The failure to comply with laws governing international business practices may result in substantial civil and criminal penalties and suspension or debarment from government contracting. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#8217;s accounting provisions.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">42</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 10, 2025, President Trump issued an Executive Order directing the Attorney General to review the guidelines and policies governing FCPA investigations and enforcement actions. Per the Executive Order, this review will result in new Department of Justice FCPA guidelines intended to enhance American economic competitiveness and to safeguard national security interests. During the 180-day review period, any new FCPA investigations and enforcement actions are to be suspended absent authorization from the Attorney General, and all existing FCPA investigations and enforcement actions are required to be reviewed.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Coverage, pricing and reimbursement</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Significant uncertainty exists as to the coverage, pricing and reimbursement status of any products that may receive regulatory approval. Successful commercialization of new drug products depends in part on the extent to which coverage and reimbursement will be available from government health administration authorities, private health insurers and other organizations. The availability of coverage and extent of reimbursement depend substantially, both domestically and abroad, on the extent to which the costs of drug products are paid for by third-party payors, such as government health care programs (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">e.g.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, Medicare, Medicaid), health maintenance organizations, managed care providers, pharmacy benefit and similar healthcare management organizations, private health coverage insurers and other third-party payors. These third-party payors decide which medications they will pay for and establish reimbursement levels.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the U.S., no uniform policy of coverage and reimbursement for drug products exists among third-party payors and coverage and reimbursement levels for drug products can differ significantly from payor to payor. Third-party payors often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates, but also have their own methods and approval process apart from Medicare determinations. Factors payors consider in determining reimbursement include assessing whether the product is:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a covered benefit under its health plan;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">safe, effective and medically necessary;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">appropriate for the specific patient;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cost-effective; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">neither experimental nor investigational.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, the process for determining whether a payor will provide coverage for a product may be separate from the process for setting the reimbursement rate that the payor will pay for the product. One payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage and reimbursement for the product. Third-party payors may also limit coverage to specific products on an approved list, or formulary, which might not include all FDA-approved products for a particular indication.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Increasing efforts by third-party payors in the U.S. and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our product candidates. In order to secure coverage and reimbursement for any product that may be approved for sale, we may need to conduct expensive pharmacoeconomic studies to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain FDA or comparable regulatory approvals. Additionally, we may also need to provide discounts to purchasers, private health plans or government healthcare programs. Our product candidates, if approved, may nonetheless not be considered medically necessary or cost-effective. If third-party payors do not consider a product to be cost-effective compared to other available therapies, they may not cover the product after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow us to sell our products at a profit. We expect to experience pricing pressures from third-party payors in connection with the potential sale of any of our product candidates.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outside of the U.S., the pricing of pharmaceutical products is subject to governmental control in many countries. For example, in the EU, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare a particular therapy's cost effectiveness to currently available therapies or so-called health technology assessments, to obtain reimbursement or pricing approval. Other countries may allow companies to fix their own prices for products but monitor and control product volumes and issue guidance to physicians to limit prescriptions. Efforts to control prices and utilization of pharmaceutical products will likely continue as countries attempt to manage healthcare expenditures. Historically, products launched in the EU do not follow U.S. price structures, and prices tend to be significantly lower.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">43</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employees and Human Capital</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, we had 28 full-time employees, and one part-time employee, including a total of six employees with M.D., Ph.D. or equivalent degrees. Of these employees, 15 were engaged in research and development. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are committed to a work environment that is welcoming, inclusive and encouraging. To achieve our plans and goals, it is imperative that we attract and retain top talent. In order to do so, we aim to have a safe and encouraging workplace, with opportunities for our employees to grow and develop professionally, supported by strong compensation, benefits, and other incentives. In addition to competitive base salaries, we offer our employees discretionary cash-based performance bonuses and, in addition, may utilize our equity incentive plan to attract, retain and motivate selected employees, consultants and directors through the granting of stock-based compensation awards.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporate Information</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We were incorporated under the laws of the state of Delaware in October 2018. Our principal mailing address is 20 William Street, Suite 145, Wellesley Hills, MA 02481. Our telephone number is (866) 857-2596. Our website is climbbio.com. Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and all amendments to those reports are available free of charge on our website as soon as reasonably practicable after such material is electronically filed with, or furnished to, the Securities and Exchange Commission.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">44</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1a_risk_factors"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1A. Risk Factors</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The following information sets forth risk factors that could cause our actual results to differ materially from those contained in forward-looking statements we have made in this Annual Report on Form 10-K and those we may make from time to time. You should carefully consider the risks described below, in addition to the other information contained in this Annual Report on Form 10-K and our other public filings. Our business, financial condition or results of operations could be harmed by any of these risks. The risks and uncertainties described below are not the only ones we face. Additional risks not presently known to us or other factors not perceived by us to present significant risks to our business at this time also may impair our business operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to our Financial Position and Need for Additional Capital</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have incurred significant losses since our inception, expect to continue to incur substantial losses for the foreseeable future and may never achieve or sustain profitability.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a clinical-stage biotechnology company with a limited operating history. Our efforts are focused primarily on the treatment of unmet needs in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">immune-mediated diseases. We are initially developing our lead product candidate budoprutug in pMN, ITP and SLE. In addition, in January 2025, we expanded our pipeline of B-cell targeted therapeutics by entering into the Mabworks Agreement, pursuant to which Mabworks granted us licenses to develop, manufacture and commercialize CLYM116, an anti-APRIL mAb, and products containing CLYM116.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, we have not received regulatory approvals for any of our product candidates or generated any revenue from product sales. We do not expect to generate revenue from product sales for the foreseeable future. Budoprutug and CLYM116 are both in early stages of research and development. </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result, we are not profitable, and we </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">have incurred significant operating losses since inception and expect to continue to incur substantial losses, including expenses incurred to advance the development of budoprutug and CLYM116, conduct clinical trials, pursue regulatory approvals, maintain, expand, and protect our intellectual property portfolio, operate as a public company, potentially acquire or in-license other technologies, and build the capabilities necessary for potential commercialization of our product candidates, if approved. Our net loss was $59.9 million for the year ended December 31, 2025, and as of December 31, 2025, we had an accumulated deficit of $289.7 million. We may never achieve or sustain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to access capital when needed, it could force us to delay, reduce or terminate our product candidate development programs, commercialization efforts, or other operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Conducting nonclinical studies and clinical trials, obtaining regulatory approvals, and preparing for potential commercialization are costly, time-consuming, and subject to significant uncertainty. As of December 31, 2025, we had cash, cash equivalents and marketable securities of $160.7 million. Based on our current operating plan and assumptions, we believe our existing capital resources will be sufficient to fund our operations into 2028. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. In addition, our operating plan may change, and we may require additional capital sooner than anticipated. Our future need for additional funding depends on many factors, including:</span></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number and scope of development, nonclinical and clinical programs we decide to pursue, and the timing, cost and progress of activities related to such programs; </span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the progress, costs and results of our clinical trials of budoprutug in pMN, ITP, and SLE, our Phase 1 clinical trial of the SC formulation of budoprutug, our Phase 1 clinical trial of CLYM116, and any future clinical trials of our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of manufacturing our product candidates by third parties;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the terms of any collaborations, license or research and development agreements we may enter into;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of regulatory requirements, regulatory submissions and timing of regulatory approvals;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs involved in prosecuting and enforcing patent and other intellectual property claims;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the potential delays in our development programs and clinical trial activities due to the effects of global events, including macroeconomic conditions and supply chain disruptions;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the impact of inflationary pressures on salaries and wages, and costs of goods and transportation expenses, including the impact of tariffs and other trade restrictions;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">45</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of commercialization activities if any of our product candidates are approved for sale, including marketing, sales and distribution costs; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our efforts to enhance operational systems and hire personnel to support the development of our product candidates.</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot be certain that additional funding will be available on acceptable terms, or at all. Our ability to raise additional capital may be adversely impacted by disruptions to, or continuing volatility in, the credit and financial markets in the U.S. and worldwide, including increased volatility in the trading prices for shares of public companies in the biopharmaceutical sector, actual and perceived changes in interest rates and inflation, macroeconomic uncertainties, or otherwise. We have no committed source of additional capital, and if we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of our product candidates or other research and development initiatives.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or our product candidates.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Until such time, if ever, as we can generate substantial revenues from product sales, we may need or may seek to finance our operations through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans. To the extent that we raise additional capital through the sale of common stock, convertible securities or other equity securities, our stockholders&#8217; ownership interest may be diluted, and the terms of these securities could include liquidation or other preferences and anti-dilution protections that could adversely affect the rights of a common stockholder. In addition, debt financing, if available, may result in fixed payment obligations and may involve agreements that include restrictive covenants that limit our ability to take specific actions, such as incurring additional debt, making capital expenditures, creating liens, redeeming stock or declaring dividends, that could adversely impact our ability to conduct our business. Further, securing financing could require a substantial amount of time and attention from our management and may divert a disproportionate amount of their attention away from day-to-day activities, which may adversely affect our management&#8217;s ability to oversee the development of our product candidates. Additional capital may not be available to us, or even if it is, the cost of such capital may be high.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, we have issued, and may in the future issue additional, equity securities as consideration for business development transactions, which may also dilute our existing stockholders&#8217; ownership interests. For example, we issued additional shares of our common stock in connection with the Acquisition, as well as in the concurrent private placement of shares of our common stock to certain institutional investors (Private Placement).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market our product candidates that we would otherwise prefer to develop and market ourselves.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We currently have no source of product revenue and may never become profitable.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have never commercialized a product or generated any revenues from commercial product sales, or otherwise, and we may never become profitable. Our ability to generate revenue from product sales or achieve profitability will depend upon our ability, alone or with any future collaborators, to successfully commercialize our product candidates or any products that we may develop, in-license or acquire in the future. Even if we are able to successfully achieve regulatory approval for our product candidates, we do not know when our product candidates will generate revenue from product sales for us, if at all. Our ability to generate revenue also depends on a number of additional factors, including our or any current or future collaborators&#8217; ability to:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">complete and submit INDs to the FDA that allow commencement of clinical trials for our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">complete development activities, including the necessary clinical trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">complete and submit BLAs to the FDA and obtain regulatory approval for indications for which there is a commercial market; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">complete and submit applications to, and obtain regulatory approval from, foreign regulatory authorities; </span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">46</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">set a commercially viable price for any products; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establish and maintain supply and manufacturing relationships with third parties, and ensure adequate and legally compliant manufacturing of bulk drug substances and drug products to maintain that supply; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">develop a commercial organization capable of sales, marketing and distribution for any products for which we obtain marketing approval and intend to sell ourselves in the markets in which we choose to commercialize on our own; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">find suitable distribution partners to help us market, sell and distribute our approved products in other markets; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain coverage and adequate reimbursement from third-party payors, including government and private payors; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">achieve market acceptance for any products; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establish, maintain and protect our intellectual property rights; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">attract, hire and retain qualified personnel. </span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, because of the numerous risks and uncertainties associated with pharmaceutical product development, our product candidates may not advance through development or achieve the endpoints of applicable clinical trials. We are unable to predict the timing or amount of increased expenses, or when or if we will be able to achieve or maintain profitability. In addition, our expenses could increase beyond expectations if we decide or are required by the FDA or foreign regulatory authorities, to perform studies or trials in addition to those that we currently anticipate. Even if we can complete the development and regulatory process for our product candidates, we anticipate incurring significant costs associated with commercializing any such products. Even if we can generate revenue from the sale of any of our product candidates that may be approved, we may not become profitable.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be required to make significant payments in connection with our license agreements, which could strain our capital resources.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may be required to make significant payments under our license and asset purchase agreements, including development, regulatory, commercial and sales&#8209;based milestone, and royalty payments. These obligations may be substantial and strain our capital resources, and we may not have sufficient funds when payments become due. If we fail to meet payment or diligence obligations, licensors may terminate the agreements, resulting in the loss of rights to budoprutug, CLYM116 or any other product candidate we may license.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result of the Acquisition, certain legacy Tenet agreements effectively became agreements of ours, including the Asset Purchase Agreement, the CRH Agreement, and the ProBioGen Agreement. In addition, in January 2025, we entered into the Mabworks Agreement, pursuant to which we obtained licenses to develop, manufacture and commercialize CLYM116, and products containing CLYM116, in certain territories.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may be obligated to make significant future payments under these agreements, including obligations to pay certain contingent development, commercial, sales and regulatory milestones and royalties, as well as other obligations, as applicable. Certain of these agreements set forth specific development, regulatory and commercial events, the occurrence of which would result in related payments that we would be obligated to make. These potential obligations represent significant cash amounts that we may ultimately be obligated to pay. We cannot guarantee that we will have sufficient funds available to meet these obligations if and when these payments become due. The obligation to pay some or all of these milestone and royalty amounts may materially harm our development efforts, as well as our overall financial condition.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to our Business and the Development of our Product Candidates</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our future success is dependent on the regulatory approval and commercialization of our product candidates, and if we are unable to successfully develop and commercialize our product candidates, or experience any delay in doing so, our business could be materially harmed.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our future success depends on developing our product candidates, obtaining regulatory approval and successfully commercializing our product candidates. Delays or failures in clinical development, regulatory review, or commercialization could prevent or delay us from generating revenue or achieving profitability. Regulatory approval processes are lengthy, complex, and inherently uncertain, and regulatory expectations may evolve during development.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">47</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not have any product candidates that have gained regulatory approval, and we are substantially dependent on the success of budoprutug and CLYM116. As a result, our prospects, including our ability to finance our operations and generate revenue, are dependent on our ability to obtain regulatory approval for budoprutug and CLYM116, and, if approved, to successfully commercialize budoprutug and CLYM116. We cannot commercialize our product candidates or any product candidates we may develop in the U.S. without first obtaining regulatory approval for the product from the FDA; similarly, we cannot commercialize our product candidates or any product candidates we may develop outside of the U.S. without obtaining regulatory approval from comparable foreign regulatory authorities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the PDUFA, the FDA&#8217;s standard review process for a BLA is meant to take 10 months from the date a BLA is accepted for filing, but that process may take longer to complete, and FDA approval is never guaranteed. Before obtaining regulatory approvals for the commercial sale of our product candidates for a target indication, we must demonstrate with substantial evidence gathered in nonclinical and well-controlled clinical trials, and, with respect to approval in the U.S., to the satisfaction of the FDA, that the product candidate is potent, safe and pure for use for that target indication and that the manufacturing facilities, processes and controls are adequate. If our product candidates encounter undesirable safety signals, insufficient efficacy results, development delays, regulatory issues or other problems, our development plans and business would be significantly harmed. Additionally, pediatric studies may be required pursuant to PREA or comparable foreign requirements.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if approved, our products may be subject to post&#8209;approval requirements, limitations on use, labeling changes, safety monitoring, or withdrawal or changes in law, guidance, or waiver from the FDA. A deferral of the requirement to conduct pediatric studies may be granted for several reasons, including a finding that the product or therapeutic candidate is ready for approval for use in adults before pediatric trials are complete or that additional safety, potency and purity data need to be collected before the pediatric trials begin.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The law requires the FDA to send a PREA Non-Compliance letter to sponsors who have failed to submit their pediatric assessments required under PREA, have failed to seek or obtain a deferral or deferral extension or have failed to request approval for a required pediatric formulation. It further requires the FDA to publicly post the PREA Non-Compliance letter and sponsor&#8217;s response.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The applicable legislation in the EU also requires sponsors to either conduct clinical trials in a pediatric population in accordance with a Pediatric Investigation Plan approved by the Pediatric Committee of the EMA or to obtain a waiver or deferral from the conduct of these studies by this Committee. For any product candidates for which we seek regulatory approval in the U.S. or the EU, we cannot guarantee that we will be able to obtain a waiver or alternatively complete any required studies and other requirements in a timely manner, or at all, which could result in associated reputational harm and subject us to enforcement action.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For any of our product candidates for which we seek regulatory approval in the U.S. or the EU, we cannot guarantee that we will be able to obtain a waiver or alternatively complete any required studies and other requirements in a timely manner, or at all, which could result in an issuance and publication of a PREA Non-Compliance letter and associated reputational harm, our product candidate being considered misbranded and subject to relevant enforcement action, invalidation of the marketing application, and financial penalties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or a comparable foreign regulatory authority may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA or comparable foreign regulatory authority may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory authority, as the case may be, and may ultimately lead to the denial of marketing approval of one or more of our product candidates.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Obtaining regulatory approval for marketing of our product candidates in one country does not ensure we will be able to obtain regulatory approval in other countries, but a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory process in other countries.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">48</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if our product candidates were to successfully obtain approval from the FDA and comparable foreign regulatory authorities, any approval might contain significant limitations related to use restrictions for specified age groups, gender or subpopulation of target indication, warnings, precautions or contraindications, or may be subject to burdensome post-approval study or risk management requirements, obligations, or review timelines. If we are unable to obtain regulatory approval for one or more jurisdictions, or an approval contains significant limitations, we may not be able to obtain sufficient funding or generate sufficient revenue to continue the development of budoprutug, CLYM116 or any product candidate that we may discover, in-license, develop or acquire. Also, any regulatory approval of our product candidates, once obtained, may be withdrawn.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, even if we obtain regulatory approval for any of our product candidates, such product&#8217;s commercial success will depend on a number of factors, including the following:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">development of a commercial organization or establishment of a commercial collaboration with a commercial infrastructure; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establishment of commercially viable pricing and adequate reimbursement from third-party and government payors; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability of our third-party manufacturers to manufacture quantities of such product in commercially sufficient processes and at a scale sufficient to meet anticipated demand and enable us to reduce our cost of manufacturing; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our success in educating physicians and patients about the benefits, administration and use of such products; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability, perceived advantages, relative cost, relative safety and relative efficacy of alternative and competing treatments; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the effectiveness of our own or our potential strategic collaborators&#8217; marketing, sales and distribution strategy and operations; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acceptance of such product as potent, safe and pure by patients and the medical community; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a continued acceptable safety profile of such product following approval.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Many of these factors are beyond our control. If we, or our potential commercialization collaborators, are unable to successfully commercialize our product candidates, we may not be able to earn sufficient revenue to continue our business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if our product candidates receive regulatory approval, they may still face future development and regulatory difficulties.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we obtain regulatory approval for any of our product candidates, it would be subject to ongoing requirements by the FDA and comparable foreign regulatory authorities governing the manufacture, quality control, further development, labeling, packaging, storage, distribution, safety surveillance, import, export, advertising, promotion, recordkeeping and reporting of safety and other post-market information. The safety profile of any product will continue to be closely monitored by the FDA and comparable foreign regulatory authorities after approval. If the FDA or comparable foreign regulatory authorities become aware of new safety information after approval of such product candidate, they may require labeling changes or establishment of a REMS or similar strategy, impose significant restrictions on a product&#8217;s indicated uses or marketing, or impose ongoing requirements for potentially costly post-approval studies or post-market surveillance.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, manufacturers of drug products and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with cGMPs and other regulations. If we or a regulatory agency discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing. If we, our product candidates or the manufacturing facilities for such product candidates, fail to comply with applicable regulatory requirements, a regulatory agency may:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">issue warning letters or untitled letters; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">impose restrictions on the marketing or manufacturing of such product candidate; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">mandate modifications to promotional materials or require us to provide corrective information to healthcare practitioners; </span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">49</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">require us or any future collaborator to enter into a consent decree, which can include imposition of various fines, reimbursements for inspection costs, required due dates for specific remediation actions and penalties for noncompliance; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seek an injunction or impose civil or criminal penalties or monetary fines; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">suspend or withdraw regulatory approval; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">suspend any ongoing clinical trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refuse to approve pending applications or supplements to applications filed by us; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">suspend or impose restrictions on operations, including costly new manufacturing requirements; or</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seize or detain products, refuse to permit the import or export of products, or require us to initiate a product recall. </span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates, if approved, and generate revenue. The FDA strictly regulates the advertising and promotion of drug products, and drug products may only be marketed or promoted for their FDA approved uses, consistent with the product&#8217;s approved labeling. Violations may lead to civil, criminal and administrative sanctions by the FDA or other enforcement authorities.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Advertising and promotion of any product candidate that obtains approval in the U.S. will be heavily scrutinized by the FDA, the Department of Justice, the Office of Inspector General of the HHS, state attorneys general, members of Congress and the public. For example, there has been increased scrutiny by the current government administration on advertising practices, and recently, the FDA issued a generic &#8220;notice letter&#8221; to a substantial number of companies directing such companies to &#8220;remove any noncompliant advertising and bring all promotional communications into compliance.&#8221;</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, advertising and promotion of any product candidate that obtains approval outside of the U.S. will be heavily scrutinized by relevant foreign regulatory authorities.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Existing government regulations may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained or be subject to fines or enhanced government oversight and reporting obligations, which would adversely affect our business, prospects and ability to achieve or sustain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to develop and market new product candidates may also be impacted by litigation challenging the FDA&#8217;s approval of another company&#8217;s drug product. In April 2023, the U.S. District Court for the Northern District of Texas invalidated the approval by the FDA of mifepristone, a drug product which was originally approved in 2000 and whose distribution is governed by various measures adopted under a REMS. The Court of Appeals for the Fifth Circuit declined to order the removal of mifepristone from the market but did hold that plaintiffs were likely to prevail in their claim that changes allowing for expanded access of mifepristone, which the FDA authorized in 2016 and 2021, were arbitrary and capricious. In June 2024, the U.S. Supreme Court reversed that decision after unanimously finding that the plaintiffs (anti-abortion doctors and organizations) did not have standing to bring this legal action against the FDA. On October 11, 2024, the Attorneys General of three states filed an amended complaint in the district court in Texas challenging the FDA&#8217;s actions. On January 16, 2025, the district court in Texas agreed to allow these states to file an amended complaint and continue to pursue this challenge. Thereafter, on September 30, 2025, the district court declined to dismiss the case and, instead, transferred it to federal district court in the Eastern District of Missouri. Depending on the outcome of this litigation, our ability to develop new product candidates and to maintain approval of any product candidates, if and when approved, could be delayed, undermined or subject to protracted litigation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">50</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Preliminary, initial, or interim results from clinical trials that we announce, present, or publish from time to time may change as more data and information become available (or are updated based upon audit, validation and verification procedures of the data/information commonly performed for clinical trials) that could result in material changes in the final trial results.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may announce, present or publish preliminary, initial, or interim data or other information from our clinical trials, such as the preliminary data we announced from the Phase 1b clinical trial of budoprutug for the treatment of pMN. Any such data and other results from our clinical trials may materially change as more patient data and information become available. Such data and information may also undergo significant change following subsequent auditing, validation and verification procedures that are commonly conducted in clinical trials. Thus, any preliminary, initial, or interim data or other information may not be predictive of final results from the clinical trial and should be viewed with caution until the final data are available. We may also arrive at different conclusions, or other determinations that may qualify such results, once we have received and fully evaluated the additional data.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Differences between preliminary, initial or interim results and final results could lead to significantly different interpretations or conclusions of the trial outcomes. Further, others, including regulatory authorities and collaboration or regional partners, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of our product candidates, the approvability or commercialization of our product candidates, and our business, in general. In addition, the information we choose to publicly disclose regarding a particular clinical trial is based on what is typically extensive information, and investors may not agree with what we determine is material or otherwise appropriate information to publicly disclose.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the preliminary, initial or interim data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize our product candidates may be harmed, which could significantly harm our reputation, business, results of operations, financial condition and prospects.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Nonclinical and clinical development involves a lengthy, complex and expensive process with an uncertain outcome. The outcome of nonclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and the results of our clinical trials may not satisfy the requirements of the FDA or comparable foreign regulatory authorities. Further, clinical development in immunology and autoimmune diseases presents inherent challenges, which may delay or impair our ability to demonstrate clinical benefit and obtain regulatory approval for our product candidates.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To obtain the requisite regulatory approvals to commercialize our product candidates, we must demonstrate through extensive nonclinical studies and clinical trials that such product candidates are potent, safe and pure in humans to the satisfaction of the FDA. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A product candidate can fail at any stage of testing, even after observing promising signs of activity in earlier nonclinical studies or clinical trials, as demonstrated by the failure of our legacy program, ETX-810, which failed to achieve statistically significant separation from placebo on the primary endpoint in either of our Phase 2a clinical trials in diabetic peripheral neuropathic pain or</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">lumbosacral radicular pain. The results of nonclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. Initial success in clinical trials may not be indicative of results obtained when such trials are completed. There is typically an extremely high rate of attrition from the failure of product candidates proceeding through clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy profile despite having progressed through nonclinical studies and initial clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, clinical development in immunology and autoimmune diseases, including pMN, ITP, SLE, and IgAN, presents inherent challenges, such as heterogeneous disease courses, variable endpoints, competition to enroll patients in trials, background therapy effects, and long-duration studies, which may delay or impair our ability to demonstrate clinical benefit and obtain regulatory approval for our product candidates. Regulators may require additional studies, protocol modifications, or changes to endpoints, and guidance from regulators can evolve, which could affect our development plans and timing. Manufacturing scale&#8209;up, assay validation, and process comparability for biologics can also delay trials or approvals. Any delays could increase our costs, shorten any effective exclusivity periods we may obtain for a product candidate, and enable competitors to reach the market earlier than us, reducing commercial viability for our product candidates.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A number of companies in the biotechnology industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or emergence of unacceptable safety issues, notwithstanding promising results in earlier trials. Most product candidates that commence clinical trials are never approved and there can be no assurance that any of our future clinical trials will ultimately be successful or support further nonclinical or clinical development of our product candidates. Our success is</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">51</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">dependent on the progress and outcomes of our development efforts, including our Phase 2 clinical trial of budoprutug for pMN, our Phase 1b/2a clinical trial of budoprutug for ITP, our Phase 1b clinical trial of budoprutug for SLE, our Phase 1 clinical trial of the SC formulation of budoprutug in healthy volunteers, and our Phase 1 clinical trial of CLYM116</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In addition, the commencement and rate of completion of nonclinical studies and clinical trials may be delayed by many factors, including:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inability to generate sufficient nonclinical or other in vivo or in vitro data to support the initiation of clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nonclinical studies or clinical trials may show a product candidate to be less effective than expected (e.g., a clinical trial could fail to meet its primary endpoint(s)) or have unacceptable side effects or toxicities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to establish clinical endpoints that applicable regulatory authorities would consider clinically meaningful;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in identifying, recruiting and training suitable clinical investigators;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">differences in trial design between early-stage clinical trials and later-stage clinical trials make it difficult to extrapolate the results of earlier clinical trials to later clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in reaching a consensus with regulatory authorities on trial design and any nonclinical studies required in support of our product candidates and the potential for a delay in site initiations; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in recruiting suitable patients to participate in our clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in manufacturing, testing, releasing, validating or importing/exporting sufficient stable quantities of our product candidates we may develop for use in nonclinical studies or clinical trials or the inability to do any of the foregoing;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">insufficient or inadequate supply or quality of our product candidates or other materials necessary for use in nonclinical studies or clinical trials, or delays in sufficiently developing, characterizing or controlling a manufacturing process suitable for such studies or trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">imposition of a temporary or permanent clinical hold by regulatory authorities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developments on trials conducted by competitors for related technology that raise FDA or foreign regulatory authority concerns about risk to patients of the technology broadly, or if the FDA or a foreign regulatory authority finds that the investigational protocol or plan is clearly deficient to meet its stated objectives;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in recruiting, screening and enrolling patients and delays caused by patients withdrawing from clinical trials or failing to return for post-treatment follow-up;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">difficulty collaborating with patient groups and investigators;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure by our CROs, other third parties or us to adhere to clinical trial protocols;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to perform in accordance with the FDA&#8217;s or any other regulatory authority&#8217;s GCPs or applicable regulatory guidelines in other countries;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">occurrence of adverse events associated with any of our product candidates that are viewed to outweigh such product candidate&#8217;s potential benefits, or occurrence of adverse events in trial of the same class of agents conducted by other companies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of nonclinical studies and clinical trials of our product candidates being greater than we anticipate;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical trials of our product candidates producing negative or inconclusive results, which may result in our deciding, or regulators requiring us, to conduct additional clinical trials or abandon development of such product candidate;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">imposition of a clinical hold by regulatory authorities as a result of a serious adverse event, or after an inspection of trial sites or manufacturing facilities or otherwise; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols; </span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">52</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">transfer of manufacturing processes to larger-scale facilities operated by a third-party CDMO and delays or failure by our CDMOs or us to make any necessary changes to such manufacturing process; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">third parties being unwilling or unable to satisfy their contractual obligations to us.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any inability to successfully initiate or complete nonclinical studies or clinical trials could result in additional costs to us or impair our ability to generate revenue from product sales. Clinical trial delays could also shorten any periods during which our products have patent protection and may allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our product candidates and may seriously harm our business. In addition, changes in marketing approval policies during the development period, changes in or the enactment or promulgation of additional statutes, regulations or guidance or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, in December 2022, with the passage of FDORA, Congress required sponsors to develop and submit a DAP for each Phase 3 clinical trial or any other &#8220;pivotal study&#8221; of a new drug or biological product. These plans are meant to encourage the enrollment of more diverse patient populations in late-stage clinical trials of FDA-regulated products. In June 2024, as mandated by FDORA, the FDA issued draft guidance outlining the general requirements for DAPs. On January 27, 2025, in response to an Executive Order issued by President Trump on January 21, 2025, on Diversity, Equity and Inclusion programs, the FDA removed the draft DAP guidance from its website. Thereafter, following litigation, the FDA restored the draft DAP guidance to the FDA website but stated that &#8220;information on this page may be modified and/or removed in the future subject to the terms of the court&#8217;s order and implemented consistent with applicable law.&#8221; In light of these ongoing actions, there is considerable uncertainty surrounding the draft DAP guidance and how the FDA will consider DAPs in connection with its review of clinical studies.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we seek to conduct clinical trials in foreign countries or pursue marketing approvals in foreign jurisdictions, we must comply with numerous foreign regulatory requirements governing, among other things, the conduct of clinical trials, manufacturing and marketing authorization, pricing and third-party reimbursement. The foreign regulatory approval process varies among countries and jurisdictions and may include all of the risks associated with FDA approval described above and risks attributable to the satisfaction of local regulations in foreign jurisdictions. Moreover, the time required to obtain approval may differ jurisdiction-to-jurisdiction from that required to obtain FDA approval. Approval by foreign regulatory authorities does not ensure approval by the FDA and, similarly, approval by the FDA does not ensure approval by regulatory authorities outside the U.S. Successful completion of clinical trials is a prerequisite to submitting a marketing application to foreign regulatory authorities or the FDA for each product candidate and, consequently, the ultimate approval and commercial marketing of any product candidate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may experience negative or inconclusive results, or regulators may be unwilling to accept nonclinical or clinical data obtained in foreign jurisdictions, which may result in our deciding, or our being required by regulators, to conduct additional clinical studies or trials or abandon some or all of our product development programs, which could harm our business.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the FDA and other regulatory authorities&#8217; policies with respect to clinical trials may change and additional government regulations may be enacted. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies governing clinical trials, our development plans may be impacted, and our product development costs may increase if we experience delays in testing or marketing approvals. In addition, if we make manufacturing or other changes to our product candidates, we may need to conduct additional studies to bridge such new formulations to earlier versions. We do not know whether any of our clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. We may also decide to change the design or protocol of one or more of our clinical trials, which could result in delays.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our product candidates may cause adverse events or undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following any marketing approval.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain adverse events and undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or pause clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign regulatory authorities. If undesirable side effects do occur in our future clinical trials they could cause delay or even discontinuance of further development of our product candidates, which would impair our ability to generate revenue and would have a material adverse effect on our business, results of operations, financial condition and cash flows and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">53</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result of undesirable side effects or further safety issues that we may experience in our clinical trials in the future, we may not receive approval to market our product candidates, which could prevent us from ever generating revenue or achieving profitability. Results of our trials could reveal an unacceptably high severity and prevalence of side effects.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In such an event, our trials could be suspended or terminated and the FDA or comparable foreign regulatory authorities could order us to cease further development of, or deny approval of, our product candidates for any or all targeted indications. The drug-related side effects could affect patient recruitment or the ability of enrolled subjects to complete the trial or result in potential product liability claims. Safety signals within APRIL/CD19 classes, including with respect to any products that may compete with our product candidates, could affect regulatory approval, labeling, or market uptake, if approved. Any of these occurrences may have a material adverse effect on our business, results of operations, financial condition and cash flows and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, if any of our product candidates receive marketing approval, and we, or others, later identify undesirable side effects caused by such product, a number of potentially significant negative consequences could result, including:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be forced to suspend marketing of such product; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory authorities may withdraw their approvals of such product; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory authorities may require additional warnings on the label that could diminish the usage or otherwise limit the commercial success of such product; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA or other regulatory bodies may issue safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings about such product; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA may require the establishment or modification of a REMS or a comparable foreign regulatory authority may require the establishment or modification of a similar strategy that may, for instance, restrict distribution of our products and impose burdensome implementation requirements on us; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be required to change the way the product is administered or conduct additional clinical trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we could be sued and held liable for harm caused to subjects or patients; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be subject to litigation or product liability claims; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our reputation may suffer. </span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we encounter difficulties enrolling or retaining patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not be able to continue our ongoing clinical trials or initiate new clinical trials on a timely basis or at all if we are unable to recruit and enroll a sufficient number of eligible patients to participate in these trials through completion of such trials as required by the FDA or other comparable foreign regulatory authorities. Patient enrollment is a significant factor in the timing of clinical trials. Our ability to enroll eligible patients may be limited or may result in slower enrollment than we anticipate. There may be limited patient pools from which to draw for clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The eligibility criteria of our clinical trials will further limit the pool of available study participants as we will require that patients have specific characteristics that we can measure or to assure their disease is either severe enough or not too advanced to include them in a study. Patient enrollment for our clinical trials may be affected by other factors, including:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the patient eligibility criteria defined in the protocol;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the size of the patient population required for analysis of the trial&#8217;s primary endpoints;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the proximity of patients to trial sites;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the design of the trial;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability and efficacy of approved drugs for the disease under investigation, including the potential availability of drug candidates currently in development;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">54</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">perceived risks and benefits of the product candidate under study;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">competing clinical trials and clinicians&#8217; and patients&#8217; perceptions as to the potential advantages and risks of the product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications that we are investigating;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinicians&#8217; willingness to screen their patients for biomarkers to indicate which patients may be eligible for enrollment in our clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain and maintain patient consents;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">patient referral practices of physicians;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability to monitor patients adequately during and after treatment; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the risk that patients enrolled in clinical trials will drop out of the trials before completion.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, our clinical trials may compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition would reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials in such clinical trial site.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our inability to enroll enough patients for our clinical trials would result in significant delays or might require us to abandon one or more clinical trials. Delays in patient enrollment may result in increased costs, affect the timing or outcome of our clinical trials, product candidate development and approval process and jeopardize our ability to seek and obtain the regulatory approval required to commence product sales and generate revenue, which could prevent completion of these trials, adversely affect our ability to advance the development of our product candidates, cause the value of our company to decline and limit our ability to obtain additional financing if needed. Furthermore, even if we can enroll enough patients for our clinical trials, we may have difficulty maintaining participation in our clinical trials through the treatment and any follow-up periods.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are also required to register certain clinical trials and post the results of completed clinical trials on a government-sponsored database, such as www.ClinicalTrials.gov in the U.S., within certain time frames. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We could be subject to product liability lawsuits based on the use of our product candidates in clinical testing or, if obtained, following any such product&#8217;s marketing approval and commercialization. Product liability lawsuits brought against us or any of our future collaborators could divert our resources and attention, require us to cease clinical testing, cause us to incur substantial liabilities or limit commercialization of our product candidates.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are exposed to potential product liability and professional indemnity risks that are inherent in the research, development, manufacturing, marketing and use of biotechnology products. Currently, we have no products that have been approved for commercial sale; however, the use of our product candidates by us and any collaborators in clinical trials may expose us to liability claims. We will face an even greater risk if a product candidate is approved by regulatory authorities and introduced commercially.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Product liability claims may be brought against us or our partners if any product candidate we develop allegedly causes injury or is found to be otherwise unsuitable for human use during product testing, manufacturing, marketing or sale. Any such product liability claim may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability and a breach of warranties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Claims could also be asserted under state consumer protection acts. Such claims could be made by participants enrolled in our clinical trials, patients, health care providers, biotechnology companies, our collaborators or others using, administering or selling any of our future approved products. If we cannot successfully defend ourselves against any such claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates, if approved. Even successful defense would require significant financial and management resources.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">55</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regardless of the merits or eventual outcome, product liability claims may result in:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">decreased demand for any of our future approved products;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">injury to our reputation;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">withdrawal of clinical trial participants;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">termination of clinical trial sites or entire trial programs;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant litigation costs;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">substantial monetary awards to, or costly settlements with, patients or other claimants;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product recalls or a change in the indications for which any approved drug products may be used;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">loss of revenue;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">diversion of management and scientific resources from our business operations; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the inability to commercialize our product candidates.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although the clinical trial process is designed to identify and assess potential side effects, clinical development does not always fully characterize the safety and efficacy profile of a new medicine, and it is always possible that a drug, even after regulatory approval, may exhibit unforeseen side effects. If any of our product candidates were to cause adverse side effects during clinical trials or after approval, we may be exposed to substantial liabilities. Physicians and patients may not comply with any warnings that identify known potential adverse effects and patients who should not use such product candidate. If any of our product candidates are approved for commercial sale, we will be highly dependent upon consumer perceptions of us and the safety and quality of such product. We could be adversely affected if we are subject to negative publicity associated with illness or other adverse effects resulting from physicians&#8217; or patients&#8217; use or misuse of any approved products or any similar products distributed by other companies.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we maintain product liability insurance coverage, including clinical trial liability, this insurance may not fully cover potential liabilities that we may incur. The cost of any product liability litigation or other proceeding, even if resolved in our favor, could be substantial. We will need to increase our insurance coverage if we commercialize any product that receives regulatory approval. In addition, insurance coverage is becoming increasingly expensive. If we are unable to maintain sufficient insurance coverage at an acceptable cost or to otherwise protect against potential product liability claims, it could prevent or inhibit the development and commercial production and sale of our product candidates, which could harm our business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We face significant competition in an environment of rapid technological change, and there is a possibility that our competitors may achieve regulatory approval before us or develop therapies that are safer, less expensive or more advanced or effective than us, which may harm our financial condition and our ability to successfully market or commercialize our product candidates.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The development and commercialization of new drug products is highly competitive. Moreover, the immunology and inflammation field is characterized by rapidly changing technologies, significant competition, and a strong emphasis on intellectual property. We will face competition with respect to our product candidates from major pharmaceutical companies, specialty pharmaceutical companies, and biotechnology companies. Potential competitors also include academic institutions, government agencies, and other public and private research organizations that conduct research, seek patent protection, and establish collaborative arrangements for development, manufacturing, and commercialization.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are a number of large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of products for the treatment of the disease indications for which we are developing budoprutug or CLYM116. Some of these competitive products and therapies are based on scientific approaches that are similar to our approach, and others are based on entirely different approaches.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The competitive landscape for budoprutug includes multiple companies developing biologics and other modalities targeting CD19 for immune-mediated diseases. We are aware of several companies developing naked monoclonal antibodies, including Amgen Inc., which has an approved treatment, UPLIZNA (inebilizumab), for NMOSD, IgG4-RD, and gMG, and IASO Biotherapeutics, Inc. (RD129/IASO782) in Phase 1 development for autoimmune disease. AbbVie Inc. is developing a CD19-targeting glucocorticoid receptor modulator antibody-drug conjugate (ABBV-319). Companies developing bispecific T-cell engagers or CD19 bifunctional monoclonal antibodies include but are not limited to, Cullinan Therapeutics, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">56</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(CLN-978), Zenas BioPharma, Inc. (obexelimab), L. Hoffmann-La Roche Ltd. (RG6382) and Merck &amp; Co., Inc. (CN201). Companies developing CD19 CAR-T and CAR-NK therapies include but are not limited to Novartis AG, Bristol Myers Squibb Company, Cabaletta Bio, Inc., Kyverna Therapeutics, Inc. and Nkarta, Inc.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The competitive landscape for CLYM116 includes, but is not limited to, companies developing biologics targeting APRIL or BAFF/APRIL for IgAN, such as Otsuka Pharmaceutical Co., Ltd, which has an approved treatment for IgAN, VOYXACT (sibeprenlimab), Novartis AG (zigakibart), Jade Biosciences, Inc. (JADE-101), Vertex Pharmaceuticals Incorporated (povetacicept) and Vera Therapeutics, Inc, which has submitted a BLA for FDA approval of atacicept for the treatment of IgAN. In addition, companies targeting CD38, such as Biogen Inc. (felzartamab) and Takeda Pharmaceutical Company Limited (mezagitamab), companies developing degraders for IgAN such as Biohaven, Ltd. (BHV-1400), and companies developing IgA sweeper antibodies such as argenx (ARGX-121) are also potential competitors for CLYM116. Many of our current or potential competitors, either alone or with their collaboration partners, may have significantly greater financial resources and expertise in research and development, manufacturing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products. Mergers and acquisitions in the pharmaceutical, biotechnology, and gene therapy industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management consultants and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize product candidates that are safer, more effective, have fewer or less severe side effects, are more convenient, or are less expensive than budoprutug or CLYM116, or that would render budoprutug or CLYM116 obsolete or non-competitive. Our competitors also may obtain FDA or other regulatory approval for their product candidates more rapidly than we may obtain approval for budoprutug and CLYM116, which could result in our competitors establishing a strong market position before we are able to enter the market. Additionally, technologies developed by our competitors may render budoprutug or CLYM116 uneconomical or obsolete, and we may not be successful in marketing budoprutug or CLYM116 against competitors.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, as a result of the expiration or successful challenge of our patent rights, we could face more litigation with respect to the validity or scope of patents relating to our competitors&#8217; products. The availability of our competitors&#8217; products could limit the demand, and the price we are able to charge, for budoprutug or CLYM116.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we successfully obtain approval for budoprutug or CLYM116, we believe that the key competitive factors that will affect the success of these candidates will be efficacy, safety, tolerability, convenience, price and the availability of reimbursement from government and other third-party payors relative to such competing products. Our commercial opportunity could be reduced or eliminated if our competitors have products that are superior in one or more of these categories.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Drug development is highly uncertain, and if we are unable to successfully develop and commercialize our product candidates, or experience significant delays in doing so, our business may be harmed.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Drug development is a highly uncertain undertaking and involves a substantial degree of risk. For example, previously we paused or discontinued the development of all of our legacy product candidates for the treatment of neuronal excitability disorders, including ETX-155 and ETX-123, which were still in drug discovery stages, and we may not ever obtain regulatory approval for our product candidates. In addition, as a company, we have </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">no prior experience developing biological product candidates. As such, we may encounter delays or difficulties in our efforts to develop and commercialize budoprutug and CLYM116.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, we have not initiated or completed a pivotal clinical trial, obtained marketing approval for any product candidate, manufactured a commercial scale product or arranged for a third party to do so on our behalf, or conducted the sales and marketing activities necessary for successful product commercialization. Our short operating history as a company makes any assessment of our future success and viability subject to significant uncertainty.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will encounter risks and difficulties frequently experienced by early-stage biotechnology companies in rapidly evolving fields, and we have not yet demonstrated an ability to successfully overcome such risks and difficulties. If we do not address these risks and difficulties successfully, our business may be harmed.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">57</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our estimates of market opportunity and forecasts of market growth for our product candidates may prove to be inaccurate, and even if the markets in which we compete achieve the forecasted growth, our business may not grow at similar rates, or at all.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our market opportunity estimates and growth forecasts are subject to significant uncertainty and are based on assumptions and estimates which may not prove to be accurate. We currently focus our research and product development on budoprutug for the treatment of pMN, ITP, and SLE and on CLYM116 for the treatment of IgAN. Our understanding of the patient populations with these diseases is based on estimates in published literature.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These estimates, and our estimates and forecasts relating to size and expected growth based on these estimates, may prove to be incorrect and new studies may reduce the estimated incidence or prevalence of these diseases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The number of patients in the U.S. and elsewhere may turn out to be lower than expected, patients may not be otherwise amenable to treatment with budoprutug or CLYM116, or patients may become increasingly difficult to identify and access. Even if the patient populations meet our size estimates and growth forecasts, our business may not grow at similar rates, or at all. Our growth is subject to many factors, including our success in implementing our business strategy, which is subject to many risks and uncertainties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our revenue will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval, the accepted price for our product candidates, the ability to obtain coverage and reimbursement, the ability to gain market share and whether we own the commercial rights for that territory. If the number of addressable patients is not as significant as we estimate, the indication approved by regulatory authorities is narrower than we expect or the treatment population is narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenue from sales of our product candidates, even if approved. Further, there are several factors that could contribute to making the actual number of patients who receive our product candidates less than the potentially addressable market. These include the lack of widespread availability of, and limited reimbursement for, new therapies in many underdeveloped markets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have no experience in sales, marketing and distribution and may have to enter into agreements with third parties to perform these functions, which could prevent us from successfully commercializing our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We currently have no sales, marketing or distribution capabilities. To commercialize our product candidates, we must either develop our own sales, marketing and distribution capabilities or make arrangements with third parties to perform these services for us. If we decide to market or distribute our product candidates on our own, we will have to commit significant resources to developing a marketing and sales force and supporting distribution capabilities. If we decide to enter into arrangements with third parties for performance of these services, we may find that they are not available on terms acceptable to us, or at all. If we are not able to establish and maintain successful arrangements with third parties or build our own sales and marketing infrastructure, we may not be able to commercialize our product candidates, which would adversely affect our business, results of operations, financial condition and cash flows and prospects.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Disruptions at the FDA and other government agencies from funding cuts, personnel losses, regulatory reform, government shutdowns and other developments could hinder our ability to obtain guidance from the FDA regarding our clinical development program and develop and secure approval of our product candidates in a timely manner, which would negatively impact our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disruptions at the FDA and other agencies, including workforce changes, budget constraints, regulatory reform, government shutdowns, or public health emergencies could delay inspections, guidance from the FDA, and application review, which could hinder our ability to secure approval of our product candidates in a timely manner. Even with the user&#8209;fee program established under the PDUFA, resource constraints could delay PDUFA dates, and changes in government policy or enforcement priorities may alter review practices and post&#8209;approval obligations with respect to the FDA or other comparable regulatory agencies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA and comparable regulatory agencies in foreign jurisdictions, such as the EMA and CHMP, play an important role in the development of our product candidates by providing guidance on our clinical development programs and reviewing our regulatory submissions, including INDs, requests for special designations and marketing applications. If these oversight and review activities are disrupted, then correspondingly our ability to develop and secure timely approval of our product candidates could be impacted in a negative manner.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, the recent loss and retirement of FDA leadership and personnel could lead to disruptions and delays in FDA guidance, review and approval of our product candidates. In July 2025, the Trump Administration began to carry out layoffs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">58</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">at the FDA and, in November 2025, Congress agreed to provide full-year funding for the FDA through September 30, 2026, at a slight decrease compared to previous spending levels. There were several reports in 2025 of the FDA failing to meet its PDUFA goal dates for approval of an NDA or BLA due to heavy workload and limited resources.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is also substantial uncertainty as to how regulatory reform measures being implemented by the Trump Administration across the government will impact the FDA and other federal agencies with jurisdiction over our activities. For example, since taking office, the President has issued a number of executive orders that could have a significant impact on the manner in which the FDA conducts its operations and engages in regulatory and oversight activities. If these or other orders or executive actions impose constraints on the FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable. Over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions and could impact our ability to access the public markets and obtain necessary capital in order to continue our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the same time, disruptions at the FDA and other government agencies may result from public health events similar to the COVID-19 pandemic. For example, during the pandemic, a number of companies announced receipt of CRLs due to the FDA&#8217;s inability to complete required inspections for their applications. In the event of a similar public health emergency in the future, the FDA may not be able to continue its current pace and review timelines could be extended. Regulatory authorities outside the U.S. facing similar circumstances may adopt similar restrictions or other policy measures in response to a similar public health emergency and may also experience delays in their regulatory activities.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accordingly, if any of the foregoing developments and others impact the ability of the FDA to provide us with guidance regarding our clinical development programs or delay the FDA&#8217;s review and processing of our regulatory submissions, including INDs, NDAs, and BLAs, our business would be negatively impacted. Further, the current and any future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Legal and Regulatory Compliance</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval and commercialize our product candidates, if and when approved, and may affect the prices we may charge for such product candidates, if and when approved.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The U.S. and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product for which we obtain marketing approval.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2010, the ACA was enacted, which includes measures that have significantly changed the way health care is financed by both governmental and private insurers. There have been executive, judicial and congressional challenges to certain aspects of the ACA. For example, on June 17, 2021, the U.S. Supreme Court dismissed a judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. For example, in August 2011, the Budget Control Act of 2011 was signed into law, which, among other things, included aggregate reductions to Medicare payments to providers of, on average, 2% per fiscal year, effective April 1, 2013, which, due to subsequent legislative amendments including the Infrastructure Investment and Jobs Act and the Consolidated Appropriations Act of 2023, will stay in effect until 2032 unless Congress takes additional action.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recently, there has been increasing legislative and enforcement interest in the U.S. with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. presidential executive orders, congressional inquiries and legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drugs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">59</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On August 16, 2022, the IRA was signed into law by President Biden. The new legislation has implications for Medicare Part D, which is a program available to individuals who are entitled to Medicare Part A or enrolled in Medicare Part B to give them the option of paying a monthly premium for outpatient prescription drug coverage.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (that began in 2025). The IRA permits the Secretary of the HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Specifically, with respect to price negotiations, Congress authorized Medicare to negotiate lower prices for certain costly single-source drug and biologic products that do not have competing generics or biosimilars and are reimbursed under Medicare Part B and Part D. CMS may negotiate prices for ten high-cost drugs paid for by Medicare Part D starting in 2026, followed by 15 Part D drugs in 2027, 15 Part B or Part D drugs in 2028, and 20 Part B or Part D drugs in 2029 and beyond. This provision applies to drug products that have been approved for at least nine years and biologics that have been licensed for 13 years. Drugs and biologics that have been approved for a single rare disease or condition were originally categorically excluded from price negotiation. With passage of the One Big Beautiful Bill Act on July 3, 2025, which was signed into law on July 4, 2025, Congress extended this exemption to drugs and biologics with multiple orphan drug designations.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since CMS may establish a maximum price for these products in price negotiations, we would be fully at risk of government action if any of our product candidates are the subject of Medicare price negotiations. Given this risk, these provisions of the IRA may also further heighten the risk that we would not be able to achieve the expected return on any product candidate, if approved, or the full value of our patents protecting any such approved drug products if prices are set after any such approved products have been on the market for nine years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The first cycle of negotiations for the Medicare Drug Price Negotiation Program commenced in the summer of 2023 and the prices of the ten drugs that were the subject of these negotiations became effective January 1, 2026. The second cycle of negotiations with participating drug companies occurred during 2025, and any negotiated prices for this second set of drugs will be effective starting January 1, 2027.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, the legislation subjects drug manufacturers to civil monetary penalties and a potential excise tax for failing to comply with the legislation by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; under the law or for taking price increases that exceed inflation. In addition to the drug price negotiation program, the IRA established inflation rebate programs under Medicare Part B and Part D. These programs require manufacturers to pay rebates to Medicare if they raise their prices for certain Part B and Part D drugs faster than the rate of inflation. On December 9, 2024, with issuance of its 2025 Physician Fee Schedule final regulation, CMS finalized its rules governing the IRA inflation rebate programs. The new law also caps Medicare out-of-pocket drug costs at an estimated $2,000 a year.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 6, 2023, Merck &amp; Co. filed a lawsuit against the HHS and CMS asserting that, among other things, the IRA&#8217;s Drug Price Negotiation Program for Medicare constitutes an uncompensated taking in violation of the Fifth Amendment of the Constitution. Subsequently, a number of other parties with similar constitutional claims against the HHS and CMS. HHS has generally won the substantive disputes in these cases or succeeded in getting claims dismissed for lack of standing. On May 8, 2025, the U.S. Court of Appeals for the Third Circuit rejected AstraZeneca L.P.&#8217;s challenge to the Medicare price negotiation program, finding that the program did not violate the company&#8217;s due process rights under the Constitution since there is no protected property interest in selling goods to Medicare beneficiaries at a price higher than what the government is willing to pay in reimbursement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect that litigation involving these and other provisions of the IRA will continue, with unpredictable and uncertain results. Accordingly, while it is currently unclear how the IRA will be effectuated, we cannot predict with certainty what impact any federal or state health reforms will have on us, but such changes could impose new or more stringent regulatory requirements on our activities or result in reduced reimbursement for our products, any of which could adversely affect our business, results of operations and financial condition.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the Trump Administration has taken a number of actions to reduce the costs of pharmaceutical products. For example, on April 15, 2025, President Trump issued an Executive Order which directs HHS to take steps to reduce the prices of pharmaceutical products. Such measures include streamlining the state drug importation program and modifying provisions of the 340B program. Further, on May 12, 2025, President Trump issued an additional Executive Order calling on pharmaceutical manufacturers to voluntarily reduce the prices of medicines in the U.S. The Order provides that if such actions do not lower the costs of pharmaceuticals, the Secretary of HHS would pursue other actions, including proposing a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">60</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rulemaking that imposes MFN pricing in the U.S. Thereafter, on July 31, 2025, the President issued letters to 17 pharmaceutical companies reiterating the requirements of the May 12, 2025, Executive Order and demanding that such companies extend MFN pricing to Medicaid patients, guarantee MFN pricing for newly-launched drug products, return increased revenues abroad to American patients and provide for direct purchasing at MFN pricing. Since that time, virtually all of these pharmaceutical companies have entered into agreements with the administration to provide for lower prices on certain pharmaceuticals.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare organizations and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These measures could reduce the ultimate demand for our product candidates, if and when approved, and any other products we may develop, or put pressure on our product pricing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This may be especially true with respect to products approved pursuant to the accelerated approval pathway. State Medicaid programs and other payers are developing strategies and implementing significant coverage barriers, or refusing to cover these products outright, arguing that accelerated approval drugs have insufficient or limited evidence despite meeting the FDA&#8217;s standards for accelerated approval. In the EU, similar political, economic and regulatory developments may affect our ability to profitably commercialize our product candidates, if and when approved, and any other products we may develop.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In markets outside of the U.S. and the EU, reimbursement and healthcare payment systems vary significantly by country and many countries have instituted price ceilings on specific products and therapies. In many countries, including those of the EU, the pricing of prescription pharmaceuticals is subject to governmental control and access. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To obtain reimbursement or pricing approval in some countries, we or our collaborators may be required to conduct a clinical trial that compares the cost-effectiveness of our product to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount or if pricing is set at unsatisfactory levels, our business could be materially harmed.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect that the healthcare reform measures that have been adopted and may be adopted in the future may result in more rigorous coverage criteria and additional downward pressure on the price that we receive for any approved product and could seriously harm our future revenues. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business operations and current and future relationships with investigators, health care professionals, consultants, third-party payors and customers will be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Healthcare providers and others play a primary role in the recommendation and prescription of any products for which we obtain marketing approval. Although we do not currently have any products on the market, our operations may be, directly or indirectly through our prescribers, customers and third-party payors, subject to various U.S. federal and state healthcare laws and regulations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These laws may impact, among other things, our current business operations, including our clinical research activities and proposed sales, marketing and education programs and constrain the business of financial arrangements and relationships with healthcare providers and other parties through which we may market, sell and distribute our products for which we obtain marketing approval. In addition, we may be subject to additional healthcare, statutory and regulatory requirements and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">61</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">enforcement by foreign regulatory authorities in jurisdictions in which we conduct our business. The laws that may affect our ability to operate include:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the U.S. federal Anti-Kickback Statute, which makes it illegal for any person or entity, including a prescription drug manufacturer (or a party acting on its behalf), to knowingly and willfully solicit, receive, offer or pay any remuneration, including any kickback, bribe, or rebate, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual, or the purchase, lease, order, arrangement, or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the U.S. federal civil and criminal false claims laws, including the FCA, which can be enforced through &#8220;qui tam&#8221; or &#8220;whistleblower&#8221; actions, and civil monetary penalty law, which impose criminal and civil penalties against individuals or entities for, among other things, knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid, or other federal health care programs that are false, fictitious or fraudulent; knowingly making, using, or causing to be made or used, a false record or statement material to a false, fictitious or fraudulent claim or an obligation to pay or transmit money or property to the federal government; or knowingly concealing or knowingly and improperly avoiding or decreasing or concealing such an obligation to pay money to the federal government. In addition, a claim that includes items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim under the FCA;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">HIPAA, which created additional federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false, fictitious or fraudulent statement or representation, or making or using any false writing or document knowing the same to contain any materially false fictitious or fraudulent statement or entry in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity can be found guilty of violating HIPAA fraud provisions without actual knowledge of the statute or specific intent to violate it;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">HIPAA, as amended by HITECH and their implementing regulations, also imposes obligations, including mandatory contractual terms, on &#8220;covered entities,&#8221; including certain healthcare providers, health plans, healthcare clearinghouses, and their respective &#8220;business associates&#8221; that create, receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity as well as their covered subcontractors, with respect to safeguarding the privacy, security and transmission of individually identifiable health information, as well as analogous state and foreign laws that govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the U.S. federal Physician Payments Sunshine Act and its implementing regulations, which require certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program to report annually to the CMS, an agency within the HHS under the Open Payments Program, information related to direct or indirect payments and other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other health care professionals (such as physician assistants and nurse practitioners), and teaching hospitals, as well as information regarding ownership and investment interests held by physicians and their immediate family members;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">U.S. federal and state consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">analogous U.S. state laws and regulations, including state anti-kickback and false claims laws that may apply to items or services reimbursed by any third-party payor, including commercial insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and other relevant compliance guidance promulgated by the federal government that otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to file reports with states regarding pricing and marketing information, such as the tracking and </span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">62</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reporting of gifts, compensations and other remuneration and items of value provided to healthcare professionals and entities; and state and local laws requiring the registration of pharmaceutical sales representatives; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">European and other foreign law equivalents of each of the laws, including reporting requirements detailing interactions with and payments to healthcare providers.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from U.S. government funded healthcare programs, such as Medicare and Medicaid, or similar programs in other countries or jurisdictions, disgorgement, imprisonment, contractual damages, reputational harm, diminished profits, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws and the delay, reduction, termination or restructuring of our operations. Further, defending against any such actions can be costly and time-consuming, and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any of the physicians or other providers or entities with whom we expect to do business is found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment. If any of the above occur, it could adversely affect our ability to operate our business and our results of operations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Actual or alleged non&#8209;compliance by us could result in investigations, significant civil or criminal penalties, exclusion of our company from government programs, reputational harm, and operational restrictions. Non-compliance could adversely affect our ability to operate our business and our results of operations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are subject to stringent and evolving U.S. and foreign laws, regulations, rules, contractual obligations, policies and other obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation, including class claims, and mass arbitration demands; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse business consequences.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We process personal data and other sensitive data, including health data we collect about participants in connection with our clinical trials, proprietary and confidential business data, trade secrets, intellectual property, and sensitive third-party data. Our data processing activities subject us to numerous data privacy and security obligations, such as various laws, regulations, guidance, industry standards, external and internal privacy and security policies, contracts, and other obligations that govern the processing of personal data by us and on our behalf.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the U.S., federal, state, and local governments have enacted numerous data privacy and security laws, including data breach notification laws, personal data privacy laws, and consumer protection laws. These privacy laws include, without limitation, the following laws and regulations:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5 of the Federal Trade Commission Act, HIPAA, as amended by the HITECH (which imposes specific requirements relating to the privacy, security and transmission of individually identifiable health information for covered entities and their business associates); and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CCPA applies to personal information of consumers, business representatives, and employees, and requires businesses to provide specific disclosures in privacy notices and honor requests of California residents to exercise certain privacy rights. In addition, the CPRA amended the CCPA and expanded the CCPA&#8217;s requirements, including by adding a new right for individuals to correct their personal information and establishing a new regulatory agency to implement and enforce the law.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to California, many other states have passed comprehensive privacy laws similar to the CCPA and CPRA. These laws are either in effect or will go into effect sometime before the end of 2026. Like the CCPA and CPRA, these laws create obligations related to the processing of personal information, as well as special obligations for the processing of &#8220;sensitive&#8221; data (which includes health data in some cases). Some of the provisions of these laws may apply to our business activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">63</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect other states will be considering similar laws in the future, and Congress has also been debating passing a federal privacy law. These laws may impact our business activities, including our identification of research subjects, relationships with business partners and ultimately the marketing and distribution of our products.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outside the U.S., an increasing number of laws, regulations, and industry standards apply to data privacy and security. For example, the GDPR impose strict requirements for processing the personal data of individuals, including sensitive data that we may process such as health data.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are also bound by contractual obligations related to data privacy and security, and our efforts to comply with such obligations may not be successful. For example, certain privacy laws, such as the GDPR and the CCPA, require our customers to impose specific contractual restrictions on their service providers. We publish privacy policies, marketing materials and other statements, such as compliance with certain certifications or self-regulatory principles, regarding data privacy and security. If these policies, materials or statements are found to be deficient, lacking in transparency, deceptive, unfair, or misrepresentative of our practices, we may be subject to investigation, enforcement actions by regulators or other adverse consequences. Our obligations related to data privacy and security are quickly changing in an increasingly stringent fashion, creating some uncertainty as to the effective future legal framework. Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent or in conflict among jurisdictions. Preparation for and compliance with these obligations requires us to devote significant resources. These obligations may necessitate changes to our information technologies, systems, and practices and to those of any third parties that process personal data on our behalf. Although we try to comply with all applicable data privacy and security obligations, we may at times fail (or be perceived as having failed). Despite our efforts, our personnel or third parties upon whom we rely may fail to comply with such obligations, which could negatively impact our business operations and compliance posture. Moreover, clinical trial subjects about whom we or our potential collaborators obtain information, as well as the third-party providers (such as research institutions) who share this information with us, may contractually limit our ability to use and disclose the information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we or the third parties on which we rely fail, or are perceived to have failed, to address or comply with data privacy and security obligations, we could face significant consequences. These consequences may include, but are not limited to, government enforcement actions (e.g., investigations, fines, penalties, audits, inspections, and similar); litigation, including class-related claims, and mass arbitration demands; additional reporting requirements and oversight; bans on processing personal data; and orders to destroy or not use personal data.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of these events could have a material adverse effect on our reputation, business, or financial condition, including but not limited to: loss of customers; interruptions or stoppages in our business operations, including our clinical trials; inability to process personal data or to operate in certain jurisdictions; limited ability to develop or commercialize our product candidates; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or revision or restructuring of our operations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may seek certain designations for our product candidates, including Breakthrough Therapy, Fast Track and Priority Review designations in the U.S., and PRIority MEdicines (PRIME) Designation in the EU, but we might not receive such designations, and even if we do, such designations may not lead to a faster development or regulatory review or approval process.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may seek certain designations for our product candidates that could expedite review and approval by the FDA. A Breakthrough Therapy product is defined as a product that is intended, alone or in combination with one or more other products, to treat a serious condition, and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For products that have been designated as Breakthrough Therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA may also designate a product for Fast Track review if it is intended, whether alone or in combination with one or more other products, for the treatment of a serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such a disease or condition. For Fast Track review products, sponsors may have greater interactions with the FDA and the FDA may initiate review of sections of a Fast Track product&#8217;s application before the application is complete. This rolling review may be available if the FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a Fast Track review product may be effective.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">64</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may also seek a Priority Review designation for our product candidates. If the FDA determines that a product candidate offers major advances in treatment or provides a treatment where no adequate therapy exists, the FDA may designate the product candidate for priority review. A Priority Review designation means that the goal is for the FDA to review an application for marketing approval in six months, rather than the standard review period of 10 months. On June 17, 2025, the FDA announced the creation of a new voucher program to expedite the development and approval of new drug products. Vouchers issued under the new program, which is known as the Commissioner&#8217;s National Priority Voucher (CNPV) Program, may reportedly be redeemed by sponsors to shorten the review time of an NDA from approximately 10 to 12 months to one to two months. The FDA has indicated that the CNPV Program will convene experts from the FDA&#8217;s offices for a team-based review rather than using the standard review system of a drug application being sent to numerous FDA offices. Clinical information will be reviewed by a multidisciplinary team of physicians and scientists who will pre-review the submitted information and convene for a one-day meeting. Vouchers under the CNPV Program will reportedly be given to companies aligned with U.S. national priorities.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These designations are within the discretion of the FDA. Accordingly, even if we believe that our product candidates meet the criteria for these designations, the FDA may disagree and instead determine not to make such designation. Further, even if we receive a designation, the receipt of such designation for a product candidate may not result in a faster development or regulatory review or approval process compared to product candidates considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if our product candidates qualify for these designations, the FDA may later decide that such product candidate no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EU, we may seek PRIME designation for our product candidates. The PRIME program focuses on product candidates that target conditions for which there exists no satisfactory method of treatment in the EU, or even if such a method exists, the product candidate may offer a major therapeutic advantage over existing treatments. To be accepted for PRIME designation, a product candidate must meet the eligibility criteria in respect of its major public health interest and therapeutic innovation based on information that is capable of substantiating the claims. The benefits of a PRIME designation include the appointment of a rapporteur of the CHMP to provide continued support and help to build knowledge ahead of a marketing authorization application, early dialogue and scientific advice at key development milestones, and the potential to qualify products for accelerated review, meaning reduction in the review time for an opinion on approvability to be issued earlier in the application process. PRIME designation enables an applicant to request parallel EMA scientific advice and health technology assessment advice to facilitate timely market access. Even if we receive PRIME designation for our product candidates, the designation may not result in a materially faster development process, review or approval compared to conventional EMA procedures. Further, obtaining PRIME designation does not assure or increase the likelihood of EMA&#8217;s grant of a marketing authorization.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accelerated approval by the FDA, even if granted for our product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may pursue accelerated approval (U.S.) or conditional authorization (EU) of our product candidates based on surrogate endpoints or limited datasets, but regulators can require pre&#8209;approval readiness (e.g., confirmatory trials underway), extensive post&#8209;approval commitments, labeling controls, and can withdraw approvals if benefit is not verified or safety/efficacy concerns arise. Accelerated/conditional pathways do not guarantee faster overall timelines or ultimate full approval. A product may be eligible for accelerated approval if it treats a serious or life-threatening condition, generally provides a meaningful advantage over available therapies, and demonstrates an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. The FDA or other applicable regulatory agency makes the determination regarding whether a surrogate endpoint is reasonably likely to predict long-term clinical benefit. Prior to seeking such accelerated approval, we will seek feedback from the FDA and otherwise evaluate our ability to seek and receive such accelerated approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a condition of approval, the FDA requires that a sponsor of a product receiving accelerated approval perform an adequate and well-controlled post-marketing confirmatory clinical trial or trials. These confirmatory trials must be completed with due diligence, and we may be required to evaluate different or additional endpoints in these post-marketing confirmatory trials. These confirmatory trials may require enrollment of more patients than we currently anticipate and will result in additional costs, which may be greater than the estimated costs we currently anticipate. In addition, the FDA currently requires as a condition for accelerated approval preapproval of promotional materials, which could adversely impact the timing of the commercial launch of the product.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There can be no assurance that the FDA will agree with any proposed surrogate endpoints or that we will decide to pursue or submit a BLA for accelerated approval or any other form of expedited development, review or approval for our product</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">65</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">candidates. Similarly, there can be no assurance that, after feedback from FDA, we will continue to pursue or apply for accelerated approval or any other form of expedited development, review or approval, even if we initially decide to do so. Furthermore, if we decide to submit an application for accelerated approval or under another expedited regulatory designation, there can be no assurance that such submission or application will be accepted or that any expedited review or approval will be granted on a timely basis, or at all.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA may withdraw approval of a product candidate approved under the accelerated approval pathway if, for example, the trial required to verify the predicted clinical benefit of our product candidate fails to verify such benefit or does not demonstrate sufficient clinical benefit to justify the risks associated with the drug. The FDA may also withdraw approval if other evidence demonstrates that our product candidate is not shown to be safe or effective under the conditions of use, we fail to conduct any required post approval trial of our product candidate with due diligence or we disseminate false or misleading promotional materials relating to our product candidate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A failure to obtain accelerated approval or any other form of expedited development, review or approval for our product candidates, or withdrawal of a product candidate, would result in a longer time period for commercialization of such product candidate, could increase the cost of development of such product candidate and could harm our competitive position in the marketplace.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There can be no assurance that we will satisfy all FDA requirements, including new provisions, that govern accelerated approval. For example, with passage of the FDORA, Congress modified certain provisions governing accelerated approval of drug and biologic products. Specifically, the new legislation authorized the FDA to require a sponsor to have its confirmatory clinical trial underway before accelerated approval is awarded and to submit progress reports on its post-approval studies to the FDA every six months until the study is completed. Moreover, FDORA established expedited procedures authorizing the FDA to withdraw an accelerated approval if certain conditions are met, including where a required confirmatory study fails to verify and describe the predicted clinical benefit or where evidence demonstrates the product is not shown to be safe or effective under the conditions of use. The FDA may also use such procedures to withdraw an accelerated approval if a sponsor fails to conduct any required post-approval study of the product with due diligence, including with respect to &#8220;conditions specified by the Secretary.&#8221; The new procedures include the provision of due notice and an explanation for a proposed withdrawal, and opportunities for a meeting with the Commissioner of the FDA or the Commissioner&#8217;s designee and a written appeal, among other things. We will need to fully comply with these and other requirements in connection with the development and approval of any product candidate that qualifies for accelerated approval. The FDA may also use such procedures to withdraw an accelerated approval if a sponsor fails to conduct any required post-approval study of the product with due diligence. The new procedures include the provision of due notice and an explanation for a proposed withdrawal, and opportunities for a meeting with the FDA and a written appeal, among other things. We will need to fully comply with these and other requirements in connection with the development and approval of any of our product candidates that qualify for accelerated approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">More recently, in March 2023, the FDA issued draft guidance that outlines its current thinking and approach to accelerated approval. The FDA indicated that the accelerated approval pathway is commonly used for approval of oncology drugs due to the serious and life-threatening nature of cancer. Although single-arm trials have been commonly used to support accelerated approval, a randomized controlled trial is the preferred approach as it provides a more robust efficacy and safety assessment and allows for direct comparisons to an available therapy. To that end, the FDA outlined considerations for designing, conducting, and analyzing data for trials intended to support accelerated approvals of oncology therapeutics. Subsequently, in December 2024 and January 2025, the FDA issued additional draft guidances relating to accelerated approval. These guidances describe FDA&#8217;s latest thinking on what it means to conduct a confirmatory trial with due diligence and how the agency plans to interpret whether such a study needs to be underway at the time of approval. While these guidances are currently only in draft form and will ultimately not be legally binding even when finalized, we will need to observe the FDA&#8217;s guidance closely if we seek accelerated approval for any of our product candidates. Accordingly, even if we do receive accelerated approval, we may not experience a faster development or regulatory review or approval process, and receiving accelerated approval does not provide assurance of ultimate full FDA approval.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EU, a &#8220;conditional&#8221; marketing authorization may be granted in cases where all the required safety and efficacy data are not yet available. A conditional marketing authorization is subject to conditions to be fulfilled for generating missing data or ensuring increased safety measures. A conditional marketing authorization is valid for one year and has to be renewed annually until fulfillment of all relevant conditions. Once the applicable pending studies are provided, a conditional marketing authorization can become a &#8220;standard&#8221; marketing authorization. However, if the conditions are not fulfilled within the timeframe set by the EMA, the marketing authorization will cease to be renewed.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">66</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have received orphan drug designation for budoprutug for the treatment of pMN, but we may be unable to realize the benefits associated with orphan drug designation, including market exclusivity.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, defined as a disease or condition with a patient population of fewer than 200,000 in the U.S., or a patient population greater than 200,000 in the U.S. when there is no reasonable expectation that the cost of developing and making available the drug or biologic in the U.S. will be recovered from sales in the U.S. for that drug or biologic. In order to obtain orphan drug designation, the request must be made before submitting a BLA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the U.S., orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages, and user-fee waivers. After the FDA grants orphan drug designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a product that has orphan drug designation subsequently receives the first FDA approval of that particular product for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a BLA, to market the same biologic (meaning, a product with the same principal molecular structural features) for the same indication for seven years, except in limited circumstances such as a showing of clinical superiority to the product with orphan drug exclusivity or if the FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. As a result, even if budoprutug receives orphan exclusivity, the FDA can still approve other biologics that do not have the same principal molecular structural features for use in treating the same indication or disease or the same biologic for a different indication or disease during the exclusivity period. Furthermore, the FDA can waive orphan exclusivity if we are unable to manufacture a sufficient supply of budoprutug or if a subsequent sponsor demonstrates clinical superiority over budoprutug.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA granted orphan drug designation to budoprutug for the treatment of pMN. We may seek orphan drug designation for budoprutug in other specific orphan indications in which there is a medically plausible basis for the use of budoprutug and we may also seek orphan drug designation for CLYM116 or any future product candidates. We may never receive such designations. In addition, even with orphan drug designation, exclusive marketing rights in the U.S. may be limited if we seek approval for an indication broader than the orphan designated indication and may be lost if the FDA later determines that the request for designation was materially defective or if we are unable to assure sufficient quantities of our product candidates to meet the needs of patients with the rare disease or condition, or if a subsequent sponsor demonstrates clinical superiority over our product candidates, if approved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA and Congress may further reevaluate and revise the Orphan Drug Act and its regulations and policies. For example, in September 2021, the Court of Appeals for the 11th Circuit held that, for the purpose of determining the scope of orphan drug exclusivity, the term &#8220;same disease or condition&#8221; means the designated &#8220;rare disease or condition&#8221; and not the &#8220;indication or use&#8221; for which the product is approved. Subsequently, in another case, a federal district court in Washington, D.C. followed the reasoning of the 11th Circuit decision and that decision was appealed to the U.S. Court of Appeals for the D.C. Circuit. On February 3, 2026, the Consolidated Appropriations Act of 2026 was enacted into law. It overruled these court decisions and codified the FDA&#8217;s longstanding interpretation of the scope of orphan drug exclusivity to apply to &#8220;the same drug for the same approved use or indication within such designated rare disease or condition.&#8221; This change, which applies retroactively, expressly authorizes the FDA to approve multiple versions of the same orphan drug for different sub-indications and subpopulations, such as adult and pediatric patients or multiple variations of the same disease that are caused by different genetic variants.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not know if, when, or how the FDA may change the orphan drug regulations and policies in the future or whether Congress will take legislative action, and it is uncertain how any changes might affect our business. Depending on what changes the FDA or Congress may make to orphan drug regulations and policies, our business could be adversely impacted.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If approved, our product candidates regulated as biologics may face competition from biosimilars approved through an abbreviated regulatory pathway.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our product candidates regulated as biologics are approved, they may face biosimilar competition, which could reduce our pricing power with respect to such product candidate and market share. Future legislative or regulatory changes in the U.S. or EU could shorten data exclusivity periods and affect our commercial prospects. Substitution dynamics, payer policies, and evolving guidance from the FDA or EMA could introduce uncertainty that may increase competitive pressure and compress net pricing.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">67</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The BPCIA created an abbreviated approval pathway for biologic products that are biosimilar to or interchangeable with an FDA-licensed reference biologic product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During this 12-year period of regulatory exclusivity, another company may still market a competing version of the reference product if the FDA approves a BLA for the competing product containing the sponsor&#8217;s own nonclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity, and potency of the other company&#8217;s product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2022, Congress clarified through the FDORA, that the FDA may approve multiple first interchangeable biosimilar biological products so long as the products are all approved on the same first day on which such a product is approved as interchangeable with the reference product and the exclusivity period may be shared amongst multiple first interchangeable products. More recently, in October 2023, the FDA issued its first interchangeable exclusivity determination under the BPCIA.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that any of our product candidates, if approved as a biologic product under a BLA, should qualify for the 12-year period of exclusivity. Nonetheless, the approval of biosimilar products referencing our product candidates would have a material adverse impact on our business due to increased competition and pricing pressures. Moreover, there is a risk that any exclusivity we do receive could be shortened due to congressional action or otherwise, or that the FDA will not consider our products to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The extent to which a biosimilar, once licensed, will be substituted for any of our product candidates in a way that is similar to traditional generic substitution for non-biologic products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. If competitors are able to obtain regulatory approval for biosimilars referencing any of our product candidates, such product may become subject to competition from such biosimilars, with the attendant competitive pressure and consequences. The ultimate impact, implementation, and meaning of the BPCIA are subject to uncertainty, and any new regulations, guidance, policies or processes adopted by the FDA to implement the law could have a material adverse effect on the future commercial prospects for our product candidates.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, foreign regulatory authorities may change their approval policies and new regulations may be enacted relating to non-patent exclusivity. For example, the European Commission launched a review of EU pharmaceutical legislation in November 2020. On December 11, 2025, the European Parliament and Council reached a provisional political agreement on the legislation, which is expected to be adopted by mid-2026. Key changes include updating regulatory data exclusivity to a new system with 8 years data exclusivity and a reduced market exclusivity period to 1 year, which can be extended if specific conditions are fulfilled. These provisions are expected to be adopted in the second quarter of 2026 and to take effect in mid-2028. If the legislation is finalized in line with the provisional political agreement, it will have a profound impact on the pharmaceutical industry in the EU.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We conduct clinical trials at sites outside the U.S. The FDA may not accept data from trials conducted in such locations, and the conduct of trials outside the U.S. could subject us to additional delays and expense.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We conduct clinical trials with trial sites that are located outside the U.S. The acceptance by the FDA or other regulatory authorities of trial data from clinical trials conducted outside their jurisdiction may be subject to certain conditions or may not be accepted at all. Trials outside the U.S. also present operational risks, including complying with local regulations, foreign exchange rate risk, potentially more limited IP protection, and geopolitical risks that can add cost and delay to conducting clinical trials. In cases where data from foreign clinical trials are intended to serve as the sole basis for marketing approval in the U.S., the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the U.S. population and U.S. medical practice; (ii) the trials were performed by clinical investigators of recognized competence and pursuant to GCP regulations; and (iii) the data may be considered valid without the need for an on-site inspection by the FDA, or if the FDA considers such inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, even where the foreign trial data are not intended to serve as the sole basis for approval, the FDA will not accept the data as support for an application for marketing approval unless the trial is well-designed and well-conducted in accordance with GCP requirements and the FDA is able to validate the data from the trial through an onsite inspection if deemed necessary.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">68</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many foreign regulatory authorities have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any comparable foreign regulatory authority will accept data from trials conducted outside of the U.S. or the applicable jurisdiction.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the FDA or any comparable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which could be costly and time-consuming, and which may result in our product candidates not receiving approval for commercialization in the applicable jurisdiction. Conducting clinical trials outside the U.S. will also expose us to additional risks, including risks associated with:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">additional foreign regulatory requirements; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">foreign exchange fluctuations; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">compliance with foreign manufacturing, customs, shipment and storage requirements; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cultural differences in medical practice and clinical research; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">diminished protection of intellectual property in some countries; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">interruptions or delays in our trials resulting from geopolitical events, such as war or terrorism. </span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our failure to obtain regulatory approval in foreign jurisdictions would prevent us from marketing our product candidates outside the U.S.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we succeed in developing our product candidates, we intend to market them in foreign jurisdictions in addition to the U.S. In order to market and sell products in other jurisdictions, we must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the U.S. generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the U.S., we must secure product pricing and reimbursement approvals before regulatory authorities will approve the product for sale in that country. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our product candidates in certain countries.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries and regulatory approval in one country does not ensure approval in any other country, while a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory approval process in others. If we fail to obtain approval of any of our product candidates by regulatory authorities in another country, we will be unable to commercialize any such product in that country, and the commercial prospects of that product candidate and our business prospects could decline. In addition, failure to obtain regulatory approval in one country or region could adversely affect future regulatory approvals in other countries.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, in many countries outside the U.S., a product candidate must also be approved for reimbursement before it can be sold in that country. In some cases, the price that we intend to charge for our products, if approved, is also subject to approval. Obtaining non-U.S. regulatory approvals and compliance with non-U.S. regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of any of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, if we fail to obtain the non-U.S. approvals required to market any of our product candidates outside the U.S. or if we fail to comply with applicable non-U.S. regulatory requirements, our target markets will be reduced and our ability to realize the full market potential of such product candidate will be harmed and our business, financial condition, results of operations and prospects may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, we could face heightened risks with respect to obtaining marketing authorization in the U.K. as a result of the withdrawal of the U.K. from the EU, commonly referred to as Brexit. As of January 1, 2025, the MHRA, is responsible for approving all medicinal products destined for the U.K. market (i.e., Great Britain and Northern Ireland), and the EMA will no longer have any role in approving medicinal products destined for Northern Ireland. The MHRA relies on the HMR as the basis for regulating medicines. The HMR has incorporated into domestic law the body of EU law instruments governing medicinal products that pre-existed prior to Brexit. On April 28, 2025, the U.K. Parliament adopted amendments to improve</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">69</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and strengthen the U.K.&#8217;s clinical trials regulatory regime, which will take effect on April 28, 2026. These changes were needed since the current U.K. requirements are based upon the now-repealed EU Clinical Trials Directive (2001/20/EC), which has been replaced by the European CTR (Regulation EU No 536/2014). Since the U.K. left the EU prior to the date on which the EU CTR took effect, the U.K. legal framework did not benefit from the same revisions as occurred at EU level.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of January 1, 2024, a new IRP applies which intends to facilitate approval of pharmaceutical products in the U.K. The IRP is open to applicants that have already received an authorization for the same product from one of the MHRA&#8217;s specified RRs. The RRs notably include the EMA and regulators in the EEA member states for approvals in the EU centralized procedure and mutual recognition procedure as well as the FDA (for product approvals granted in the U.S.). The RR assessment must have undergone a full and standalone review, and RR assessments based on reliance or recognition cannot be used to support an IRP application. A CHMP positive opinion or an Mutual Recognition/Decentralised Reliance Procedure positive end of procedure outcome is an RR authorization for the purposes of IRP.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to our Dependence on Third Parties</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We rely, and expect to continue to rely, on third parties to conduct, supervise, and monitor our nonclinical studies and clinical trials. If these third parties do not properly and successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our product candidates.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely, and expect to continue to rely, on third-party CROs to conduct, supervise, and monitor our future nonclinical studies and clinical trials for our product candidates, and we do not currently plan to independently conduct nonclinical studies or future clinical trials of any other potential product candidates. While we have agreements governing their activities, we have limited influence over their actual performance and control only certain aspects of their activities. The failure of these third parties to successfully carry out their contractual duties or meet expected deadlines could substantially harm our business because we may not obtain marketing approval for or commercialize our product candidates in a timely manner or at all. Moreover, these agreements might terminate for various reasons, including a failure to perform by the third parties. If we need to enter into alternative arrangements, product development activities may be delayed and such delays may harm our business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Delays, errors, or non-performance from our CROs, CDMOs, and other third parties could delay the development, regulatory review, or commercialization of our product candidates. Our reliance on third parties for development activities will reduce our control over these activities. Nevertheless, we are responsible for ensuring that each of our studies and clinical trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on CROs does not relieve us of our regulatory responsibilities. Moreover, the FDA and comparable foreign regulatory authorities require us to comply with GCPs for conducting, monitoring, recording, and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity, and confidentiality of trial participants are protected. As a clinical trial sponsor, we will also have regulatory requirements that directly apply to us. Regulatory authorities enforce these requirements through periodic inspections of trial sponsors, clinical investigators, and trial sites. If we or any of our CROs fail to comply with applicable GCPs, we or our CROs may be subject to enforcement or other legal actions, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, if and when we have an approved product, we will be required to report certain financial interests of our third-party investigators if these relationships exceed certain financial thresholds or meet other criteria. The FDA and comparable foreign regulatory authorities may question the integrity of the data from those clinical trials conducted by investigators who previously served or currently serve as scientific advisors or consultants to us from time to time and receive cash compensation in connection with such services or otherwise receive compensation from us that could be deemed to impact study outcome, proprietary interests in a product candidate, certain company equity interests or significant payments of other sorts.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials complies with GCP regulations. In addition, our clinical trials must be conducted with product candidates that were produced under cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. We also are required to register certain clinical trials and post the results of certain completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within specified time frames. Failure to do so can result in enforcement actions and adverse publicity.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our CROs may also have relationships with other entities, some of which may be our competitors, for whom they may also be conducting clinical trials or other drug development activities that could harm our competitive position. In addition, our</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">70</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CROs are not our employees, and except for remedies available to us under our agreements with such CROs, we cannot control whether or not they devote sufficient time and resources to any of our development programs.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct any of our nonclinical studies or clinical trials in accordance with regulatory requirements or our stated protocols, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates, and we will not be able to, or may be delayed in our efforts to, successfully commercialize such product candidate, or we or they may be subject to regulatory enforcement actions. As a result, our results of operations and the commercial prospects for such product candidate would be harmed, our costs could increase and our ability to generate revenue could be delayed. To the extent we are unable to successfully identify and manage the performance of third-party service providers in the future, our business may be harmed.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or to do so on commercially reasonable terms. Switching or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays could occur, which could compromise our ability to meet our desired development timelines. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not harm our business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We contract with third parties, including single-source manufacturers, for the manufacture of materials and expect to continue to do so for the development and, if approved, commercialization of our product candidates. This reliance on third parties increases the risk that we will not have sufficient quantities of such materials or that such supply will not be available to us at an acceptable cost or timelines, which could delay, prevent, or impair our development or commercialization efforts.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not have any manufacturing facilities. We contract with third parties, including single-source manufacturers, for the manufacture of materials for our product candidates, and we expect to continue to rely on such third parties for the manufacture of clinical and commercial supply of our product candidates. Reliance on these third parties introduces risks such as loss of control over quality and timing, regulatory compliance, supply interruptions, and potential misappropriation of proprietary information. If a third-party manufacturer fails to meet our requirements or terminates the relationship, we may not be able to secure an alternative in a timely or cost-effective manner, which could delay or prevent the development or commercialization of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may be unable to establish future agreements or maintain existing agreements with third-party manufacturers or to do so on acceptable terms for one or more of our material needs. Even if we are able to establish and maintain agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the possible failure of the third party to manufacture our product candidates according to our schedule, or at all, including if the third party gives greater priority to the supply of other products over our product candidates or otherwise do not satisfactorily perform according to the terms of the agreements between us and them;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the possible breach of the manufacturing agreement by the third party;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the possible misappropriation of our proprietary information, including our trade secrets and know-how;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reliance on the third party for regulatory compliance, quality assurance, safety, and pharmacovigilance and related reporting.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any performance failure on the part of our existing or future manufacturers could delay any potential clinical development or marketing approval of our product candidates. We do not currently have arrangements in place for redundant supply for bulk drug substances.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any one of our current contract manufacturers cannot perform as agreed, we may be required to replace that manufacturer, or we may be forced to manufacture the materials ourselves, for which we may not have the capabilities or resources, or enter into an agreement with a different third-party manufacturer, which we may not be able to do on reasonable terms, if at all. In</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">71</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">either scenario, our clinical trial supply could be delayed significantly as we establish alternative supply sources. These materials must meet stringent regulatory standards, making it difficult to quickly qualify alternative sources.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In some cases, the technical skills required to manufacture our product candidates may be unique or proprietary to the original third-party manufacturer and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such skills to a back-up or alternate supplier, or we may be unable to transfer such skills at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, if we are required to change third-party manufacturers for any reason, we will be required to verify that the new third-party manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations. We will also need to verify, such as through a manufacturing comparability study, that any new manufacturing process will produce our product candidates according to the specifications previously submitted to the FDA or another regulatory authority.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The delays associated with the verification of a new third-party manufacturer could negatively affect our ability to develop or commercialize our drug product candidates in a timely manner or within budget.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, a third-party manufacturer may possess technology related to the manufacture of our product candidates that such third-party manufacturer owns independently. This would increase our reliance on such third-party manufacturer or require us to obtain a license from such third-party manufacturer in order to have another third-party manufacturer our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, changes in manufacturers often involve changes in manufacturing procedures and processes, which could require that we conduct bridging studies between its prior clinical supply used in its clinical trials and that of any new manufacturer. We may be unsuccessful in demonstrating the comparability of clinical supplies which could require the conduct of additional clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our current and anticipated future dependence upon others for the manufacture of our product candidates may adversely affect our future expenses and our ability to commercialize our product candidates, if we receive marketing approval, on a timely and competitive basis. Our reliance on single-source manufacturers also exposes us to pricing volatility and limits our ability to mitigate supply chain risks. If we are unable to secure adequate supply of materials to meet our operational needs, our ability to advance our pipeline, meet contractual obligations, or generate revenue could be materially and adversely affected.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we or any contract manufacturers and suppliers we engage fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We and any contract manufacturers and suppliers we engage are subject to numerous federal, state, and local environmental, health, and safety laws, regulations, and permitting requirements, including those governing laboratory procedures; the generation, handling, use, storage, treatment, and disposal of hazardous and regulated materials and wastes; the emission and discharge of hazardous materials into the ground, air, and water; and workplace health and safety. Under certain environmental laws, we could be held responsible for costs relating to any contamination at third-party facilities. We also could incur significant costs associated with civil or criminal fines and penalties. Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our research and product development efforts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty, and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended, which could have a material adverse effect on our business, results of operations, financial condition, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we may incur substantial costs in order to comply with current or future environmental, health, and safety laws, regulations, and permitting requirements. These current or future laws, regulations, and permitting requirements may impair our development, or production efforts. Failure to comply with these laws, regulations, and permitting requirements also may result in substantial fines, penalties, or other sanctions or business disruption, which could have a material adverse effect on our business, results of operations, financial condition, and prospects.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">72</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any third-party contract manufacturers and suppliers we engage will also be subject to these and other environmental, health, and safety laws and regulations. Liabilities they incur pursuant to these laws and regulations could result in significant costs or an interruption in operations, which could have a material adverse effect on our business, results of operations, financial condition, and prospects.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not have access to the raw materials and other components necessary for the manufacturing of our product candidates.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are dependent on third parties, including single-source suppliers, for the supply of various materials that are necessary to produce our product candidates for our clinical trials. Even with supply agreements, it is possible that the supply may be reduced or interrupted at any time. In such case, we may not be able to find other suppliers of acceptable materials in appropriate quantities at an acceptable cost. If we lose key suppliers or the supply of materials is diminished or discontinued, we may not be able to continue to develop, manufacture and market our product candidates in a timely and competitive manner. In addition, these materials are subject to stringent manufacturing processes and rigorous testing. Delays in the completion and validation of facilities and manufacturing processes of these materials could adversely affect our ability to complete trials and commercialize our products in a cost-effective and timely manner. Any disruption in the supply of these raw materials and other components due to quality issues, regulatory enforcement actions, manufacturing delays, geopolitical instability, or financial difficulties of the third parties could significantly delay our development efforts. In some cases, we may not be able to obtain suitable alternatives on commercially reasonable terms, or at all, without incurring substantial time and cost to validate new suppliers and obtain necessary regulatory approvals. If we encounter difficulties in the supply of these materials, or if we are not able to maintain our supply agreements or establish new supply agreements in the future or incur increased production costs as a result of any of the foregoing, our product development and business prospects could be significantly compromised.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are not able to establish future collaborations, we may have to alter some of our future development and commercialization plans.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product development programs and the potential commercialization of our product candidates will require substantial additional capital to fund expenses. We may decide to collaborate for the future development and potential commercialization of our product candidates. Furthermore, we may find that our programs require the use of proprietary rights held by third parties, and the growth of our business may depend in part on our ability to acquire, in-license or use these proprietary rights. For example, in January 2025, we entered into the Mabworks Agreement, pursuant to which we obtained licenses to develop, manufacture and commercialize CLYM116, and products containing CLYM116, in certain territories.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will likely have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of any product candidates we may seek to develop with them. We cannot predict the success of any collaboration that we have entered into or will enter into.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We face significant competition in seeking appropriate collaborators, and many more established companies may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, financial resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA, EMA, the MHRA, or similar foreign regulatory authorities, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge, and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. We may also be restricted under future license agreements from entering into agreements on certain terms with potential collaborators. Collaborations are complex and time consuming to negotiate and document.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. We may not be able to negotiate further collaborations on a timely basis, on acceptable terms, or at all. Even if we are able to obtain a license to intellectual property of interest, we may not be able to secure exclusive rights, in which case others could use the same rights and compete with us. Collaboration partners may not prioritize our product candidates or otherwise not effectively pursue the development of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">73</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">such product candidates which may delay, reduce or terminate the development of such product candidate, reduce or delay its development program or delay its potential commercialization. Further, if we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to delay, reduce or terminate the development of such product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. Doing so will likely harm our ability to execute our business plans. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue.</span><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in and uncertainty surrounding U.S. and international trade policies, particularly with respect to China, may adversely impact our business and operating results.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are exposed to evolving U.S. and international trade policies, particularly those targeting China, which can directly impact our supply chain, costs, and ability to collaborate with Chinese partners. Recent and proposed U.S. legislation, including the BIOSECURE Act and Section 1260H of the National Defense Authorization Act, may restrict or prohibit federal funding for contracts with certain Chinese biotechnology companies and could limit our ability to work with key suppliers and collaborators such as Mabworks.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our collaboration with Mabworks is central to our pipeline, and any restrictions, tariffs, or sanctions affecting Chinese biotech firms could require us to identify and qualify alternative suppliers or partners, which may not be feasible on a timely or cost-effective basis. In addition, tariffs on pharmaceutical products and ingredients imported from China, as well as potential retaliatory actions by the Chinese government, could increase our manufacturing costs, disrupt supply of raw materials, and delay development timelines.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The regulatory environment remains fluid, and future trade agreements, export controls, or sanctions could further impact our operations, costs, and competitive position. We may need to invest significant resources to adapt our supply chain, ensure compliance, and mitigate risks associated with geopolitical tensions and regulatory changes.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Some of our manufacturers and suppliers are located in China. Prior to the recent imposing of tariffs on China, trade tensions and conflicts between the U.S. and China had been escalating in recent years and, as such, we are exposed to the possibility of product supply disruption and increased costs and expenses in the event of changes to the laws, rules, regulations and policies of the governments of the U.S. or China, or due to geopolitical unrest and unstable economic conditions. Certain Chinese biotechnology companies may become subject to trade restrictions, sanctions, other regulatory requirements or proposed legislation by the U.S. government, which could restrict or even prohibit our ability to work with such entities, thereby potentially disrupting their supply of material to us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, in February 2024, U.S. lawmakers called for investigations into and the imposition of possible economic sanctions against Chinese biotechnology companies WuXi AppTec and WuXi Biologics (together, Wuxi) over alleged ties to the Chinese military. Subsequently, in December 2025, as part of the Fiscal Year 2026 National Defense Authorization Act, President Trump signed into law the BIOSECURE Act. Under the BIOSECURE Act, U.S. government agencies cannot (1) buy or obtain biotechnology equipment or services provided by biotechnology companies of concern (BCCs), (2) enter into, extend, or renew a contract with any entity using biotechnology equipment or services provided by a BCC to perform a government contract, or (3) expend, loan or grant funds for biotechnology equipment or services provided by a BCC, whether directly or through a loan or grant recipient. The BIOSECURE Act does not name specific companies as BCCs but treats any company on the Department of Defense 1260H list of &#8220;Chinese military companies&#8221; as a BCC. On December 18, 2025, the Chairs of multiple Senate and House committees, including the House Select Committee on China, sent a letter to the Department of Defense recommending that Wuxi be added to the 1260H list, which would make it a BCC. The 1260H list was updated by the Department of Defense in January 2024 and January 2025. On February 13, 2026, the Department published an updated list, which included WuXi AppTec, but then abruptly withdrew the list. The implications of this action remain unclear.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently rely on certain foreign or foreign-owned third-party vendors, including WuXi and its affiliates, to manufacture certain materials used in the development of our product candidates or to provide services in connection with such development activities. In addition, we rely on Mabworks, a Chinese corporation, pursuant to the Mabworks Agreement, to conduct nonclinical studies of CLYM116 and to provide clinical supply of CLYM116 for these studies. If these bills become law, or similar laws are passed, they would have the potential to severely restrict the ability of companies to contract with certain Chinese BCCs without losing the ability to contract with, or otherwise received funding from, the U.S.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">74</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">government. Such disruptions could have adverse effects on the development of our product candidates and our business operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any unfavorable government policies on international trade, such as export controls, capital controls or tariffs, may increase the cost of manufacturing our product candidates and platform materials, affect the demand for our product candidates (if and once approved), the competitive position of our product candidates, and import or export of raw materials and finished product candidates used in our nonclinical studies and clinical trials, particularly with respect to any product candidates and materials that we import from China. On September 25, 2025, via a post on Truth Social, President Trump announced that, beginning October 1, 2025, all branded or patented drugs imported in the U.S. would face a 100% tariff. At the same time, President Trump indicated that these tariffs could be avoided by building pharmaceutical manufacturing facilities in the U.S. Thereafter, President Trump delayed the October 1st effective date of the tariffs on branded or patented pharmaceutical products announcing that the Trump Administration had now &#8220;begun preparing&#8221; tariffs on manufacturers that do not build in the U.S. or enter into a most-favored-nation drug pricing agreement with the Trump Administration. As a result of changes in tariffs that have been announced or implemented, and the underlying uncertainty currently surrounding international trade, we could experience a negative impact to our costs of materials and production processes, and supply chain disruptions and delays as a result of any new tariff policies or trade restrictions. We cannot yet predict the effect of the recently imposed U.S. tariffs on imports, or the extent to which other countries, in particular, China, will impose and maintain quotas, duties, tariffs, taxes or other similar restrictions upon imports or exports in the future, nor can we predict future trade policy or the terms of any renegotiated trade agreements and their impact on our business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We rely heavily on certain in-licensed patents and other intellectual property rights in connection with our development of our product candidates and may be required to acquire or license additional patents or other intellectual property rights to continue to develop and commercialize our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely heavily on patents, know-how and other intellectual property licensed from others. We are party to license agreements with each of CRH and Mabworks pursuant to each of which we are granted rights to intellectual property that are important to budoprutug and CLYM116, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, we may need to acquire or license intellectual property rights from additional third parties in the future in order to continue to develop or commercialize our product candidates. Any future license agreements where we in-license intellectual property may impose on us various development, regulatory or commercial diligence obligations, payment of milestones and royalties, and other obligations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to obtain, maintain, or enforce sufficient patent and other intellectual property rights, or if those rights are limited in scope, we may not be able to compete effectively or to develop, manufacture, or commercialize our product candidates. Licenses and collaborations may include diligence, milestone, royalty, field-of-use, or territorial restrictions; failure to comply can lead to termination and loss of rights. Complex license terms and disputes (scope, sublicensing, ownership, payments) can impact our freedom to operate, timelines, and costs.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we fail to comply with any of the obligations under such license agreements, including payment terms and diligence terms, the licensors may have the right to terminate these agreements, in which case we may lose important intellectual property rights and we may not be able to develop, manufacture, market or sell our product candidates or may face other penalties under such agreements or be subject to litigation for breach of these agreements. In addition, such a termination could result in the licensor reacquiring the intellectual property rights and subsequently enabling a competitor to access the technology. Any such occurrence could materially adversely affect the value of any of our product candidates. Termination of license agreements or reduction or elimination of our rights under them may result in us having to negotiate a new or reinstated agreement, which may not be available on equally favorable terms, or at all, which may mean we are unable to develop or commercialize our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For instance, these licenses may not provide exclusive rights to use the subject intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology and our product candidates in the future, such as provisions under the license agreement with CRH prohibiting us from developing our product candidates for oncology indications, or provisions under the Mabworks Agreement prohibiting us from undertaking certain activities in Greater China. In that event, we may be required to expend significant time and resources to redesign our technology or the methods for manufacturing or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">75</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, the agreements under which we currently license, and may license in the future, intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. Accordingly, material disputes may arise between us and our licensors, regarding intellectual property subject to such license agreement, including those relating to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope of rights, if any, granted under the license agreement and other interpretation-related issues; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope and practice of any rights reserved by our licensors; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether a licensor had the right to grant the license agreement; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether third parties are entitled to compensation or equitable relief, such as an injunction, for our use of the intellectual property without their authorization; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">its right to sublicense patent and other rights to third parties under collaborative development relationships; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether we are complying with our obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our involvement in the prosecution of the licensed patents and our licensors&#8217; overall patent enforcement strategy; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the allocation of ownership of inventions and know-how resulting from the creation or use of intellectual property by our licensors and by us and our partners, including jointly developed intellectual property; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the amounts of royalties, milestones or other payments due under the license agreement. </span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, increase what we believe to be our financial or other obligations under the relevant agreement, or decrease the financial or other benefits it might otherwise receive under the relevant agreement. If material disputes over intellectual property that we have licensed prevent or impair our ability to maintain licensing arrangements on acceptable terms or are insufficient to provide us the necessary rights to use the intellectual property, we may be unable to successfully develop and commercialize our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we or any such licensors fail to adequately protect the relevant in-licensed intellectual property, our ability to commercialize our product candidates could suffer. Any material disputes with licensors or any termination of the licenses on which we depend would have a material adverse effect on our business, results of operations, financial condition and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">With respect to budoprutug, we own six pending U.S. provisional applications, nine pending U.S. nonprovisional patent applications, three pending PCT applications and six pending ex-U.S. patent applications, and we have also exclusively licensed four issued U.S. patents and at least 45 ex-U.S. patents or patent applications under our license agreement with CRH. With respect to CLYM116, we have one exclusively in-licensed PCT application under the Mabworks Agreement and three co-owned U.S. provisional patent applications with Mabworks. We can provide no assurance that any of our current or future patent applications will result in issued patents for budoprutug or CLYM116. If we are unable to obtain, maintain and protect sufficient patent and other intellectual property rights for our product candidates and technology, or if the scope of patent and other intellectual property rights obtained is not sufficiently broad, we may not be able to compete effectively in our market.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success depends in significant part on our ability and the ability of our licensors, or future licensors, licensees or collaborators to obtain, maintain, enforce and defend patents and other intellectual property rights with respect to budoprutug, CLYM116, or any other product candidates we may develop and to operate our business without infringing, misappropriating or otherwise violating the intellectual property rights of others.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our patent applications may not issue or may issue with limited scope, and issued patents can be challenged or circumvented, reducing our ability to prevent competitors from developing similar therapies. Oppositions, post-grant reviews, inter partes reviews, or litigation can narrow, invalidate, or render patents unenforceable, increasing costs and impacting collaborations and financing. Prosecution, maintenance, or enforcement errors, or lack of alignment with licensors, may compromise protection or priority.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With respect to budoprutug, we own six pending U.S. provisional applications, nine pending U.S. nonprovisional patent applications, three pending PCT applications and six pending ex-U.S. patent applications. We also have exclusively licensed four issued U.S. patents and at least 45 ex-U.S. patents or patent applications under our license agreement with CRH. With</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">76</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">respect to CLYM116, we have one exclusively in-licensed PCT application under the Mabworks Agreement and three co-owned U.S. provisional patent applications with Mabworks. We can provide no assurance that any of these current patent applications or future patent applications will result in issued patents or that any issued patents will provide us with any competitive advantage. Failure to obtain issued patents could have a material adverse effect on our ability to develop and commercialize budoprutug, CLYM116 or any other product candidates we may develop.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, other parties may successfully challenge, invalidate or circumvent our issued patents so that our patent rights do not create an effective competitive barrier or revenue source.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A U.S. provisional patent application is not eligible to become an issued patent until, among other things, we file nonprovisional patent application within 12 months of filing of the provisional patent application. With regard to such U.S. provisional patent applications, if we do not timely file any nonprovisional patent applications, we may lose our priority dates with respect to our provisional patent applications and any patent protection on the inventions disclosed in our provisional patent applications. While we intend to timely file nonprovisional patent applications relating to our provisional patent applications, we cannot predict whether any such patent applications will result in the issuance of patents that provide us with any competitive advantage. If our licensors are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If there are material defects in the form, preparation, prosecution, or enforcement of our or our licensors&#8217; patents or patent applications, such patents may be invalid and unenforceable, and such applications may never result in valid, enforceable patents. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices in the U.S. and abroad.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may be subject to a third-party pre-issuance submission of prior art to the USPTO or become involved in opposition, derivation, revocation, reexamination, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">inter partes </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others, or other proceedings in the USPTO or applicable foreign offices that challenge priority of invention or other features of patentability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An adverse determination in any such submission, proceeding or litigation could result in loss of exclusivity or freedom to operate, patent claims being narrowed, invalidated or held unenforceable, in whole or in part, limit the scope or duration of the patent protection of budoprutug, CLYM116 or any other product candidates, all of which could limit our ability to stop others from using or commercializing similar or identical product candidates or technology to compete directly with us, without payment to us, or result in our inability to manufacture or commercialize product candidates or approved products (if any) without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize budoprutug, CLYM116 or any other product candidates, or could have a material adverse effect on our ability to raise funds necessary to continue our research programs or clinical trials. Such proceedings also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot be certain that the USPTO and courts in the U.S. or the patent offices and courts in foreign countries will consider the claims in our patents and applications covering budoprutug, CLYM116 and any other product candidates as patentable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Method-of-use patents protect the use of a product for the specified method. This type of patent does not prevent a competitor from making and marketing a product that is identical to our product for an indication that is outside the scope of the patented method. Moreover, even if competitors do not actively promote their product for our targeted indications, physicians may prescribe these products off-label. Although off-label prescriptions may infringe or contribute to the infringement of method-of-use patents, the practice is common and such infringement is difficult to prevent, including through legal action.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we cannot obtain or lose patent protection for budoprutug, CLYM116 or any other product candidates, it could have a material adverse impact on our business. Additionally, as a licensee, we rely on third parties to file and prosecute patent applications and maintain patents and otherwise protect the licensed intellectual property under some of our license agreements. For example, under the license agreement with CRH, CRH is responsible for prosecuting and maintaining intellectual property protection for budoprutug in consultation with us. We have not had and do not have primary control over these activities for certain of our in-licensed patents or patent applications and other intellectual property rights. For example,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">77</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we cannot be certain that such activities by CRH or other licensors will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents and other intellectual property rights.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have limited control over the manner in which CRH or our other licensors may initiate an infringement proceeding against a third-party infringer of such intellectual property rights, or defend certain intellectual property that may be licensed to us. It is possible that CRH or our other licensors infringement proceeding or defense activities may be less vigorous than if we conduct them ourselves. We cannot be certain that such activities by third parties have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents or other intellectual property rights.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, under the Mabworks Agreement, Mabworks is responsible for prosecuting and maintaining intellectual property protection for CLYM116 in Greater China in consultation with us. We have not had and do not have primary control over these activities in Greater China for CLYM116.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot be certain that such activities by Mabworks will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents and other intellectual property rights in Greater China. Pursuant to the terms of the license agreements with some of our licensors, the licensors may have the right to control enforcement of our licensed patents or defense of any claims asserting the invalidity of these patents and even if we are permitted to pursue such enforcement or defense, we will require the cooperation of our licensors. We cannot be certain that our licensors will allocate sufficient resources or prioritize their or our enforcement of such patents or defense of such claims to protect its interests in the licensed patents. Even if we are not a party to these legal actions, an adverse outcome could harm our business because it might prevent us from continuing to license intellectual property that we may need to operate our business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any of our licensors or any of our future licensors or future collaborators fail to appropriately prosecute and maintain patent protection for patents covering our product candidates, our ability to develop and commercialize our product candidates may be adversely affected and we may not be able to prevent competitors from making, using and selling competing products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, even where we have the right to control prosecution of patent applications we have acquired or licensed from third parties, we may still be adversely affected or prejudiced by actions or inactions of our licensors and their counsel that took place prior to our assuming control over patent prosecution. The patent prosecution process is expensive and time-consuming. We and our licensors, and any future licensors, licensees or collaborators, may not be able to prepare, file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is also possible that we or our licensors will fail to identify patentable aspects of our research and development output in time to obtain patent protection or fail to file patent applications covering inventions made in the course of development and commercialization activities before a competitor or another third party files a patent application covering, or publishes information disclosing, a similar, independently-developed invention. Such competitor&#8217;s or other third party&#8217;s patent application may pose obstacles to our ability to obtain patent protection or limit the scope of the patent protection we may obtain.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, collaborators, CROs, CDMOs, consultants, advisors and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. In addition, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the U.S. and other jurisdictions are typically not published until 18 months after the initial filing date, or in some cases not at all. Therefore, we cannot be certain that we or our future licensors were the first to make the inventions claimed in our owned or any future licensed patents or pending patent applications, or were the first to file for patent protection of such inventions.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, our technology acquired or licensed from various third parties, including our licensors, may be subject to retained rights. Our licensors often retain certain rights under their agreements with us, including the right to use the underlying technology for use in fields other than the fields licensed to us or for use in noncommercial academic and research use, to publish general scientific findings from research related to the technology, and to make customary scientific and scholarly disclosures of information relating to the technology.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is difficult to monitor whether our licensors limit their use of the technology to these uses, and we could incur substantial expenses to enforce our rights to its licensed technology in the event of misuse by the licensor.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">78</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The patent position of biotechnology and pharmaceutical companies generally is uncertain, involves complex legal and factual questions and is the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our and our current or future licensors&#8217; patent rights are uncertain.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our and our future licensors&#8217; pending, and future patent applications may not result in patents being issued that protect our technology or product candidates, in whole or in part, or which effectively exclude others from commercializing competitive technologies and product candidates. The patent examination process may require us or our future licensors to narrow the scope of the claims of our pending and future patent applications, and therefore, even if such patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us or otherwise provide us with any competitive advantage.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our and our licensors&#8217; patent applications cannot be enforced against third parties practicing the technology claimed in pending applications unless and until a patent issues from such applications, and then only to the extent the issued claims cover such technology. Any patents that we hold or license, or may in-license in the future may be challenged, narrowed, circumvented or invalidated by third parties. Consequently, we do not know whether budoprutug, CLYM116 or any other product candidates will be protectable or remain protected by valid and enforceable patents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our competitors or other third parties may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner. Any of the foregoing could impair our competitive position and harm our business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The patent protection we obtain for budoprutug, CLYM116 or any other product candidates and technologies may be challenged and rendered invalid or unenforceable.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patent challenges, including oppositions, post-grant reviews, inter partes reviews, derivations, and litigation, can narrow, invalidate, or render our patents unenforceable, reducing exclusivity and enabling competitors to commercialize similar technologies. Adverse outcomes may limit our ability to prevent competition, shorten patent duration, or require costly and time-consuming legal proceedings.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if our owned or co-owned patent applications issue as patents, the issuance of any such patents is not conclusive as to their inventorship, scope, validity or enforceability, and such patents or patents we license from third parties, may be challenged, invalidated, narrowed or held to be unenforceable, including in the courts or patent offices in the U.S. and abroad, or circumvented.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We or our licensors may be subject to a third-party preissuance submission of prior art to the USPTO or equivalent foreign bodies, or become involved in opposition, derivation, revocation, re-examination, post-grant and inter partes review or interference proceedings challenging our or our licensors&#8217; patent rights or the patent rights of others.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our or our licensors&#8217; patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. Moreover, we may have to participate in interference or derivation proceedings declared by the USPTO to determine priority or ownership of invention or in post-grant challenge proceedings, such as oppositions in a foreign patent office, that challenge priority of invention or other features of patentability. Such proceedings and any other patent challenges may result in loss of patent rights, loss of exclusivity, loss of priority or in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products or limit the duration of the patent protection of our technology and product candidates. Such proceedings also may result in substantial costs and require significant time from our scientists and management, even if the eventual outcome is favorable to us. Moreover, there could be public announcements of the results of hearings, motions or other developments related to any of the foregoing proceedings. If securities analysts or investors perceive those results to be negative, it could cause the price of shares of our common stock to decline. Any of the foregoing could harm our business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our reliance on third parties for development, manufacturing, and other services requires us to share trade secrets and confidential information, increasing the risk of misappropriation, inadvertent disclosure, or incorporation into others&#8217; technology. While we use confidentiality and related agreements, these may not provide adequate protection or remedies, and monitoring compliance is challenging. If competitors lawfully obtain or independently develop our trade secrets, or if unauthorized disclosure occurs, our competitive position could be impaired.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">79</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, collaborative research agreements, consulting agreements or other similar agreements with our collaborators, advisors, employees and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, such as trade secrets. Despite these contractual agreements with third parties, sharing trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others or are disclosed or used in violation of these agreements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#8217;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may become involved in lawsuits to protect or enforce our patents, the patents of our licensors or other intellectual property, which could be expensive, time-consuming and unsuccessful, and issued patents covering our technology and product candidates could be found invalid or unenforceable if challenged.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intellectual property litigation can be costly and time-consuming; adverse outcomes (invalidity, unenforceability, narrow claim construction) can limit our ability to prevent competition and harm our business. Litigation may also result in disclosure of confidential information and distract management, and enforcement can be especially challenging in some jurisdictions.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competitors and other third parties may infringe, misappropriate or otherwise violate our owned, co-owned and licensed patents or other intellectual property. In addition, our owned, co-owned and licensed patents may become involved in inventorship or priority disputes. Our pending patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent is issued from such applications. To counter infringement or other unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents or that our patents are invalid or unenforceable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In a patent infringement proceeding, a court may decide that an owned, co-owned or licensed patent of ours is invalid or unenforceable, in whole or in part, construe the patent&#8217;s claims narrowly or refuse to stop the other party from using the technology at issue on the grounds that our owned, co-owned and licensed patents do not cover the technology. An adverse result in any litigation proceeding could put one or more of our owned, co-owned or licensed patents at risk of being invalidated, held unenforceable or interpreted narrowly. We may find it impractical or undesirable to enforce our intellectual property against some third parties.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In patent litigation in the U.S., defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, non-enablement or insufficient written description. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third parties may also raise similar claims before the USPTO or an equivalent foreign body, even outside the context of litigation. Potential proceedings include re-examination, post-grant review, inter partes review, interference proceedings, derivation proceedings and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in the revocation of, cancellation of, or amendment to our patents in such a way that they no longer cover our technology or any product candidates that we may develop.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on the applicable product candidates or technology covered by the patent rendered invalid or unenforceable. Such a loss of patent protection would harm our business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interference or derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the ownership or priority of inventions with respect to our patents or patent applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Such licenses may not be available on commercially reasonable terms, or at all, or may be non-exclusive.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">80</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to obtain and maintain such licenses, we may need to cease the development, manufacture and commercialization of one or more of the product candidates we may develop. In addition, if we, our existing licensors or any future licensors are unsuccessful in any inventorship disputes to which we or they are subject, we may lose valuable intellectual property rights, such as exclusive ownership of, or the exclusive right to use, our owned, licensed or any future in-licensed patents. The loss of exclusivity or the narrowing of such patent claims could limit our ability to stop others from using or commercializing similar or identical technology and products. Any of the foregoing could harm our business. Even if we are successful in any of the foregoing disputes, it could result in substantial costs and be a distraction to management and other employees. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or proceeding.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Most of our competitors are larger than we are and have substantially greater resources. They are, therefore, likely to be able to sustain the costs of complex patent litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing, misappropriating or otherwise violating our intellectual property. Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims could result in substantial costs and diversion of management resources, which could harm our business. In addition, the uncertainties associated with litigation could compromise our ability to raise the funds necessary to initiate anticipated clinical trials, continue our internal research programs or in-license needed technology or other product candidates. There could also be public announcements of the results of the hearing, motions or other interim proceedings or developments. If securities analysts or investors perceive those results to be negative, it could cause the price of shares of our common stock to decline. Any of the foregoing events could harm our business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be able to protect our intellectual property rights throughout the world.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Legal protections for proprietary intellectual property vary in jurisdictions throughout the world. The enforcement of intellectual property rights can be difficult and costly, and some jurisdictions provide weaker protection than the U.S.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competitors may use our technology in countries where we lack protection or where enforcement is limited and may export infringing products into protected markets. Efforts to enforce rights abroad can be expensive, time-consuming, and may not yield meaningful remedies, limiting our ability to secure a commercial advantage. Filing, prosecuting, maintaining, defending and enforcing patents and other intellectual property rights on budoprutug, CLYM116 or any other product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the U.S. can be less extensive than those in the U.S. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the U.S. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the U.S., or from selling or importing products made using our inventions in and into the U.S. or other jurisdictions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competitors may use our technologies in jurisdictions where we have not obtained patent protection or other intellectual property rights to develop their own products and may export otherwise infringing, misappropriating or violating products to territories where we have patent or other intellectual property protection, but enforcement rights are not as strong as those in the U.S. These products may compete with budoprutug, CLYM116 or any other product candidates, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of some countries do not favor the enforcement of patents and other intellectual property rights, which could make it difficult for us to stop the infringement, misappropriation or other violation of our intellectual property rights generally. Proceedings to enforce our intellectual property rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many countries, including EU countries, India, Japan and China, have compulsory licensing laws under which a patent owner may be compelled under specified circumstances to grant licenses to third parties. In addition, many countries limit the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">81</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">enforceability of patents against government agencies or government contractors. In those countries, we may have limited remedies if patents are infringed or if we are compelled to grant a license to a third party, which could materially diminish the value of those patents. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license, which could harm our business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent which might adversely affect our ability to develop and market our product candidates.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending patent application in the U.S. and abroad that is relevant to or necessary for the commercialization of budoprutug, CLYM116 or any other product candidates in any jurisdiction. For example, freedom-to-operate analyses may miss relevant third-party rights or misinterpret scope or expiration, leading to infringement risk, redesigns, licensing costs, or delays. If we fail to identify or correctly interpret relevant patents, we may face costly litigation, delays, or be forced to obtain licenses on unfavorable terms, which could adversely affect the development and commercialization of our product candidates.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patent applications in the U.S. and elsewhere are published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering budoprutug, CLYM116 or any other product candidates could have been filed by third parties without our knowledge. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover budoprutug, CLYM116 or any other product candidates or their use.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market such product candidates. If we fail to identify and correctly interpret relevant patents or if we are unable to obtain licenses to relevant patents, we may be subject to infringement claims. We cannot guarantee that we will be able to successfully settle or otherwise resolve such infringement claims. If we fail in any such dispute, in addition to being forced to pay damages, which may be significant, we may be temporarily or permanently prohibited from commercializing any of our product candidates that are held to be infringing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We might, if possible, also be forced to redesign product candidates so that we no longer infringe the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business and could harm our business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to comply with our obligations in the agreements under which we license intellectual property rights from our licensors, otherwise experience disruption to our business relationships with our licensors, or we are unable to obtain licenses from other third parties on commercially reasonable terms or fail to comply with our obligations under such agreements, we could lose license rights that our important to our business and our business could be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a party to a number of license agreements under which we are granted rights to intellectual property that are important to our business, and we may enter into additional license agreements in the future for budoprutug, CLYM116 or any other product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our existing license agreements impose on us, and we expect that any future license agreements where we in-license intellectual property will impose on us, various development, regulatory and commercial diligence obligations, payment of milestones and royalties and other obligations. If we fail to comply with our obligations under these agreements, or we are subject to bankruptcy-related proceedings, our licensors may have the right to terminate our licenses, in which case, we would not be able to market products covered by the licenses. Additionally, non-compliance with license terms (e.g., payment, diligence, reporting, or other obligations) can lead to termination or re-purchase of assets, loss of rights, or restrictions that delay development and commercialization of our product candidates.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We acquired our right to a number of licenses pursuant to the Asset Purchase Agreement, as well as from license agreements that Tenet entered into in connection with the Asset Purchase Agreement. Those license agreements impose on us various development, regulatory and commercial diligence obligations, payment of milestones and royalties and other obligations. To the extent a Product (as such term is defined in the Asset Purchased Agreement) exists under the Asset Purchase Agreement, Climb may also have diligence and payment obligations to Acelyrin, and Acelyrin may have certain related rights if we fail to comply with diligence obligations, including the right to re-purchase the Transferred Assets (as defined in the Asset</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">82</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Purchase Agreement), including our rights to the licenses subject to the Asset Purchase Agreement, in which case, we may not be able to market or develop such Product.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With respect to CLYM116, we have an existing license agreement with Mabworks, which imposes on us various development, regulatory and commercial diligence obligations, payment of milestones and royalties and other obligations. If we fail to comply with our obligations under the license agreement, Mabworks may have the right to terminate the license agreement, in which case, we may not be able to market or develop CLYM116.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Loss of licensed rights may require renegotiation on less favorable terms, or may enable competitors to access the technology, materially harming our business. We may need to obtain additional licenses from third parties to advance our research or commercialize budoprutug, CLYM116 or any other product candidates, and we cannot provide any assurances that third-party patents do not exist that might be enforced against budoprutug, CLYM116 or such other product candidates in the absence of such a license. The licensing or acquisition of third-party intellectual property rights is a competitive area, and several more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We may fail to obtain any of these licenses on commercially reasonable terms, if at all. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology. If we are unable to do so, we may be unable to develop or commercialize budoprutug, CLYM116 or any other product candidates, which could materially harm our business and the third parties owning such intellectual property rights could seek either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties and other forms of compensation. Licensing of intellectual property is of critical importance to our business and involves complex legal, business and scientific issues. Disputes may arise between us and our licensors regarding intellectual property subject to a license agreement, including:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope of rights granted, or payment obligations, under the license agreement and other interpretation-related issues; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether and the extent to which our technology and processes infringe intellectual property of the licensor that is not subject to the licensing agreement;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our right to sublicense patent rights and other rights to third parties;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our right to transfer or assign licenses; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and our affiliates and sublicensees and by us and our partners and sublicensees. </span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may not be able to successfully develop and commercialize our product candidates, which would have a material adverse effect on our business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, some of our patents and patent applications in the future may be co-owned with third parties. If we are unable to obtain an exclusive license to any such co-owners&#8217; interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, who could market competing products and technology. In addition, we may need the cooperation of any such co-owners to enforce such patents against third parties, and such cooperation may not be provided to us.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent terms may be inadequate to protect our competitive position on budoprutug, CLYM116 or any other product candidates for an adequate amount of time.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patents have a limited lifespan. Even with possible extensions, patent protection may expire before or shortly after commercialization, enabling earlier competition and potentially reducing the amount of revenue we are able to generate from sale of any of our product candidates that receive approval. If we do not have sufficient patent life to protect our product candidates, our business and competitive position may be adversely affected. In the U.S., if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. nonprovisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">83</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">budoprutug, CLYM116 or any other product candidates are obtained, once the patent life has expired for a product candidate, we may be open to competition from competitive medications, including generic medications.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized. As a result, our owned, co-owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing product candidates similar or identical to ours.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we intend, or understand that our licensors intend, to pursue additional patent protection covering, when possible, compositions, methods of use, methods of manufacture, and dosing and formulations of budoprutug and CLYM116.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any patent that may be issued from our owned pending patent applications relating to budoprutug is expected to expire in 2045, excluding any PTA that might be available following the grant of any such patent and any PTE that might be available following the grant of marketing authorizations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With respect to budoprutug, the issued patents, or patents that may be issued from the pending patent applications that we exclusively in-license from CRH are expected to expire beginning in December 2026, excluding any PTA that might be available following the grant of any such patent and any PTE that might be available following the grant of marketing authorizations. In the case of one of the U.S. patents exclusively in-licensed from CRH, the patent term is adjusted by 1703 days and is expected to expire in August 2031. In each instance of the above, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to budoprutug.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any patent that may be issued from our co-owned pending patent applications relating to CLYM116 is expected to expire in 2046, excluding any PTA that might be available following the grant of any such patent and any PTE that might be available following the grant of marketing authorizations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With respect to CLYM116, the patents that may be issued from the pending patent application that we exclusively in-license from Mabworks are expected to expire in 2044, excluding any PTA that might be available following the grant of any such patent and any PTE that might be available following the grant of marketing authorizations. In each instance of the above, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to CLYM116.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depending upon the timing, duration and conditions of any FDA marketing approval of budoprutug, CLYM116 or any other product candidates, one or more of our U.S. owned, co-owned or licensed patents may be eligible for limited PTE under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments, and one or more of our foreign owned, co-owned or licensed patents may be eligible for PTE under similar legislation, for example, in the EU. In the U.S., the Hatch-Waxman Amendments permit a PTE of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. However, there are no assurances that the FDA or any comparable foreign regulatory authority or national patent office will grant such extensions, in whole or in part. For example, we may not receive an extension if we fail to exercise due diligence during the testing phase or regulatory review process, fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. Only one patent per approved product can be extended, the extension cannot extend the total patent term beyond 14 years from approval, and only those claims covering the approved drug, a method for using it or a method for manufacturing it may be extended.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to obtain PTE or the term of any such extension is less than we request, the period during which we can enforce our patent rights for the applicable product candidate will be shortened, and our competitors may obtain approval to market competing products sooner. As a result, our revenue from applicable products could be reduced.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, if this occurs, our competitors may take advantage of our investment in development and trials by referencing our clinical and nonclinical data and launch their product earlier than might otherwise be the case, and our competitive position and business could be harmed.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in patent law could diminish the value of our patents, thereby impairing our ability to protect our intellectual property for budoprutug, CLYM116 or any other product candidates.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the pharmaceutical industry is inherently uncertain, due in part to ongoing changes in the patent laws. Legal and policy changes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">84</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">can alter patentability, validity standards, and challenge mechanisms, affecting our ability to obtain, maintain, and enforce intellectual property protections. Court decisions, legislative reforms, and evolving international standards may narrow patent scope, increase uncertainty, and raise costs for intellectual property prosecution, enforcement, and defense. Depending on decisions by Congress, the federal courts, and the USPTO and equivalent institutions in other jurisdictions, the laws and regulations governing patents, and interpretation thereof, could change in unpredictable ways that could weaken our ability to obtain new patents or to enforce existing or future patents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Therefore, there is increased uncertainty with regard to our ability to obtain patents in the future, as well as uncertainty with respect to the value of patents once obtained.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued and licensed patents. Assuming that other requirements for patentability are met, prior to March 2013, in the U.S., the first to invent the claimed invention was entitled to the patent, while outside the U.S., the first to file a patent application was entitled to the patent.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After March 2013, under the Leahy-Smith America Invents Act (Leahy-Smith Act) enacted in September 2011, the U.S. transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. The Leahy-Smith Act also includes a number of significant changes that affect the way patent applications are prosecuted and may also affect patent litigation. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO-administered post-grant proceedings, including post-grant review, inter partes review and derivation proceedings. The USPTO recently developed new regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, particularly the first inventor-to-file provisions. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued or licensed patents, all of which could harm our business.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated if we fail to comply with these requirements.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Periodic maintenance fees, renewal fees, annuity fees and various other government fees on any patents and patent applications are required to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of a patent. In certain circumstances, we may rely on our licensors to pay these fees. The USPTO and various foreign patent agencies also require compliance with a number of procedural, documentary, fee payment and other similar requirements during the patent application and prosecution process.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Administrative errors or missed deadlines (by us or licensors) can lead to abandonment or loss of rights. Failure to pay fees, respond to official actions, or submit required documents can result in loss of patent protection in relevant jurisdictions. If we or our licensors, or any future licensors or collaborators, fail to maintain the patents and patent applications covering budoprutug, CLYM116 or any other product candidates, our competitors might be able to enter the market with similar or identical products or technology, which would harm our business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could negatively impact the success of our business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our commercial success depends upon our ability and the ability of any of our collaborators to develop, manufacture, market and sell budoprutug, CLYM116 and any other product candidates and use our proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property and other proprietary rights of third parties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is considerable intellectual property litigation in the biotechnology and pharmaceutical industries. We may become party to, or be threatened with, future adversarial proceedings or litigation regarding intellectual property rights with respect</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">85</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to budoprutug, CLYM116 or any other product candidates and technology, including re-examination, interference, post-grant review, inter partes review or derivation proceedings before the USPTO or an equivalent foreign body. Numerous U.S. and foreign issued patents and pending patent applications owned by third parties exist in the fields in which we are developing our product candidates. In the event that any of these patents were asserted against us, we believe that we would have defenses against any such action, including that such patents are not valid or that we would be able to replace such technology with alternative, non-infringing technology.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">However, if any such patents were to be asserted against us and our defenses to such assertion were unsuccessful and such alternative technology was not available or technologically or commercially practical, unless we obtain a license to such patents, we could be liable for damages, which could be significant and include treble damages and attorneys&#8217; fees if we are found to willfully infringe such patents, and we could be precluded from commercializing any product candidates that were ultimately held to infringe such patents. Any potential future legal proceedings relating to these patents could cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. If we are unsuccessful in our challenges to these patents and become subject to litigation or are unable to obtain a license on commercially reasonable terms with respect to these patents, it could harm our business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third parties may allege that we are infringing, misappropriating, or otherwise violating their intellectual property rights. Defending such claims can be costly, time-consuming, and distracting. If we are found to infringe, we may be required to obtain licenses (which may not be available on reasonable terms), pay damages, or cease development or commercialization of affected products.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may also be required to indemnify collaborators or licensors, further increasing costs. Any of these outcomes could materially harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/>  </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be subject to claims by third parties asserting that we or our employees have infringed upon, misappropriated or otherwise violated their intellectual property rights, or claiming ownership of what we regard as our own intellectual property.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of our employees were previously employed at other biotechnology or pharmaceutical companies. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these individuals have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s former employer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employee or consultant background intellectual property claims can lead to disputes, costs, delays, or loss of rights. We may face allegations that our personnel used or disclosed proprietary information from prior employers, or that we do not own inventions developed by our team. Litigation or disputes over intellectual property ownership can be costly, distract management, and may result in loss of rights or personnel. Litigation may be necessary to defend against these claims.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs, delay development of our product candidates and be a distraction to management. Any of the foregoing events would harm our business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intellectual property litigation can be expensive, time-consuming, and may divert management and technical personnel from core business activities. Even successful outcomes can result in significant costs and operational disruption. Public proceedings may also impact our reputation or stock price.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">86</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace, including compromising our ability to raise the funds necessary to initiate anticipated clinical trials, continue our research programs, license necessary technology from third parties or enter into development collaborations that would help us commercialize budoprutug, CLYM116 or any other product candidates, if approved. Any of the foregoing events would harm our business.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on trade secrets and know-how to protect proprietary technology, especially where patent protection is unavailable or inappropriate. Trade secrets can be difficult to protect, and confidentiality agreements and security measures may be breached, and remedies may be inadequate. If our trade secrets are disclosed, misappropriated, or independently developed by competitors, our competitive position could be harmed.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trade secrets and know-how can be difficult to protect. We seek to protect these trade secrets and other proprietary technology, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, licensors, collaborators, CROs, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. We cannot guarantee that we have entered into such agreements with each party that may have or has had access to our trade secrets or proprietary technology and processes. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the U.S. are less willing or unwilling to protect trade secrets.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third party, our competitive position would be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As is common in the biotechnology industry, we engage the services of consultants to assist us in the development of our product candidates. Many of these consultants were previously employed at, or may have previously provided or may be currently providing consulting services to, other biotechnology companies including our competitors or potential competitors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may become subject to claims that we or our consultants inadvertently or otherwise used or disclosed trade secrets or other information proprietary to our consultants&#8217; former employers or their former or current clients. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely affect our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to our management team.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be able to protect and enforce our trademarks and trade names or build name recognition in our markets of interest thereby harming our competitive position.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We intend to rely on both registered and common law rights for our trademarks. We plan to apply to register these trademarks with the USPTO and may in the future seek to register additional trademarks in the U.S. and other countries.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trademark protection may be limited or unavailable in some jurisdictions, and third parties may oppose, cancel, or infringe our marks. Failure to secure or enforce trademarks can diminish brand value, create confusion, and harm our competitive position. Building name recognition in our markets of interest may be challenging, and litigation or administrative proceedings to protect trademarks can be costly and uncertain.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intellectual property rights do not necessarily address all potential threats.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. Even robust intellectual property may not prevent all competition; alternative technologies, off-label use, safe-harbor R&amp;D, and missed filings can erode intellectual property exclusivity.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">87</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competitors may independently develop similar or alternative technologies, design around our patents, or benefit from aspects of our inventions that are not patentable or not protected. Intellectual property rights may not cover all threats, and the patents of others may adversely affect our business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others may be able to make products that are similar to any product candidates we may develop or utilize similar technology but that are not covered by the claims of the patents that we own, co-own or license now or own, co-own or license in the future;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we, or our current or future licensors, might not have been the first to make the inventions covered by the issued patent or pending patent application that we own, co-own or license now or own, co-own or license in the future;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we, or our current or future licensors, might not have been the first to file patent applications covering certain of our or their inventions;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">it is possible that our pending owned, co-owned or licensed patent applications or those that we may own, co-own or license in the future will not lead to issued patents; issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our competitors might conduct research and development activities in the U.S. under FDA-related safe harbor patent infringement exemptions or in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may not develop additional proprietary technologies that are patentable;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the patents of others may harm our business; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Should any of these events occur, they could harm our business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to our Business Operations and Employee Matters</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If our information technology systems or data, or those of third parties upon which we rely, such as CROs, are or were compromised or interrupted, we could experience adverse consequences resulting from such compromise or interruption, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse consequences.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the ordinary course of our business, we may collect, store, use, transmit, disclose, or otherwise process proprietary, confidential, and sensitive data, including personal data (such as health-related data), intellectual property, and trade secrets using information technology networks and systems, including the Internet and artificial intelligence-based software.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cyberattacks, malicious internet-based activity, online and offline fraud, and other similar activities threaten the confidentiality, integrity and availability of our data and information technology systems, and those of the third parties upon which we rely. Such threats are prevalent and continue to increase and are becoming increasingly difficult to detect. These threats come from a variety of sources.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to traditional computer &#8220;hackers,&#8221; threat actors, &#8220;hacktivists&#8221;, organized criminal threat actors, personnel (such as through theft or misuse), sophisticated nation-states, and nation-state-supported actors now engage in attacks. Some actors now engage and are expected to continue to engage in cyber-attacks, including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, we, and the third parties upon which we rely, may be vulnerable to a heightened risk of these attacks, including retaliatory cyber-attacks, that could materially disrupt our systems and operations, supply chain, and harm our business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We and the third parties upon which we rely, such as CROs, may be subject to a variety of evolving threats, including but not limited to social-engineering attacks, including through the use of artificial intelligence and deep fakes, which may become increasingly more difficult to identify as fake, and phishing attacks, malicious code, such as viruses and worms, malware,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">88</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">including as a result of advanced persistent threat intrusions, denial-of-service attacks, such as credential stuffing, credential harvesting, personnel misconduct or error, ransomware attacks, supply-chain attacks, software bugs, server malfunctions, software or hardware failures, loss of data or other information technology assets, adware, telecommunications failures, geopolitical developments, earthquakes, fires, floods, and other similar threats. Ransomware attacks are becoming increasingly prevalent and severe and can lead to significant interruptions in our operations, loss of data and income, reputational harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments. We also rely upon third-party service providers and technologies to operate critical business systems to process confidential information and personal data in a variety of contexts, including, without limitation, third-party providers of cloud-based infrastructure, encryption and authentication technology, employee email and other functions. Our ability to monitor these third parties&#8217; cybersecurity practices is limited, and these third parties may not have adequate information security measures in place. We may share or receive sensitive data with or from third parties, and if they experience a security incident or other interruption, we could experience adverse consequences.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Similarly, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties and infrastructure in our supply chain or our third-party partners&#8217; supply chains have not been affected. While we may be entitled to damages if our third-party service providers fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our damages, or we may be unable to recover such award.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Some of our personnel work from home, which poses increased risks to our information technology systems and data as they utilize network connections outside our premises. Future business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies. Furthermore, we may discover security issues that were not found during due diligence of such acquired or integrated entities, and it may be difficult to integrate companies into our information technology environment and security program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of the previously identified or similar threats could cause a security incident or other interruption. A security incident or other interruption could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access to our data or our information technology systems, or those of the third parties upon whom we rely. Additionally, sensitive data could be leaked, disclosed, or revealed as a result of or in connection with our employee&#8217;s, personnel&#8217;s, or vendor&#8217;s use of generative artificial intelligence technologies. If such an event were to occur, it could result in a material disruption of our development programs and our business operations. For example, the loss of clinical trial data from completed, ongoing or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on third parties for the manufacture of our product candidates and to conduct clinical trials, and similar events relating to their computer systems could also harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may expend significant resources or modify our business activities, including future clinical trial activities, to protect against security incidents. Certain data privacy and security obligations may require us to implement and maintain specific security measures, industry-standard or reasonable security measures to protect our information technology systems and data. While we have implemented security measures designed to protect against security incidents, there can be no assurance that these measures will be effective.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We take steps to detect and remediate vulnerabilities, but we may be unable in the future to detect and remediate vulnerabilities because such threats and techniques change frequently, are often sophisticated in nature, and therefore may not be detected until after a security incident has occurred. These vulnerabilities therefore may pose material risks to our business. Further, we may experience delays in developing and deploying remedial measures designed to address any such identified vulnerabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Applicable data privacy and security obligations may require us to notify relevant stakeholders of security incidents. Such disclosures are costly, and the disclosures or the failure to comply with such requirements could lead to adverse consequences. If we (or a third party upon whom we rely) experience a security incident or are perceived to have experienced a security incident, we may experience adverse consequences.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These consequences may include: government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and oversight; restrictions on processing data, including personal data; litigation, including class claims; indemnification obligations; negative publicity; reputational harm; monetary expenditures; interruptions in our operations, including availability of data; financial loss; and other similar harms.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">89</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Security incidents and attendant consequences may cause delays in the development of our product candidates and negatively impact our ability to grow and operate our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations. We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims. In addition to experiencing a security incident, third parties may gather, collect, or infer sensitive information about us from public sources, data brokers, or other means that reveals competitively sensitive details about our organization and could be used to undermine our competitive advantage or market position.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to attract and retain management and other key personnel, we may be unable to continue to successfully develop or commercialize our product candidates or otherwise implement our business plan.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to compete effectively in the pharmaceuticals industry depends on our ability to attract and retain highly qualified managerial, scientific, medical, legal, sales and marketing and other personnel. We are highly dependent on recruiting and retaining our management and scientific personnel. The loss of the services of any of these key personnel or the inability to recruit suitable replacements could impede or delay the successful development of our product candidates, completion of our clinical trials, and negatively impact our ability to implement our business plan. We also rely on the services of consultants and advisors who may have other commitments, which could limit their availability and impact our ability to execute our business strategy.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs and vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are exposed to the risk that our employees, independent contractors, consultants, licensors, commercial collaborators, principal investigators, CROs and vendors may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless or negligent conduct or unauthorized activities that violate (1) the laws and regulations of the FDA, the EMA, the MHRA and other similar regulatory authorities, including those laws requiring the reporting of true, complete and accurate information to such authorities, (2) manufacturing standards, (3) federal and state data privacy, security, fraud and abuse and other healthcare laws and regulations in the U.S. and abroad and (4) laws that require the true, complete and accurate reporting of financial information or data. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Misconduct by these parties could also involve the improper use of individually identifiable information, including information obtained in the course of clinical trials, creating fraudulent data in our nonclinical studies or clinical trials or illegal misappropriation of product candidates, which could result in regulatory sanctions and harm our reputation.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have adopted a code of business conduct and ethics, but it is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, including damages, fines, disgorgement, imprisonment, exclusion from participation in government healthcare programs, such as Medicare and Medicaid, contractual damages, reputational harm and the delay, reduction, termination or restructuring of our operations.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our international operations may expose us to business, regulatory, political, operational, financial, pricing and reimbursement risks associated with doing business outside of the U.S.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating internationally adds regulatory complexity, pricing and reimbursement variability, foreign exchange and logistics risks, and exposure to geopolitical and anti-corruption issues that can delay or limit market access. We may face different regulatory requirements, reduced intellectual property protection, trade restrictions, currency fluctuations, tax consequences,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">90</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and challenges in staffing and managing foreign operations. Political instability, public health emergencies, and other disruptions can further impact our ability to operate and grow outside the U.S.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business strategy incorporates potential international expansion as we seek to conduct clinical trials, obtain regulatory approval for, and commercialize, our product candidates in patient populations outside the U.S. For example, we are actively conducting clinical trials in multiple countries outside of the U.S, including in Australia and Europe. If budoprutug, CLYM116 or any of our future product candidates are approved in international jurisdictions, we may hire sales representatives and conduct physician and patient association outreach activities outside of the U.S. Doing business internationally involves a number of risks, including but not limited to:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">multiple, conflicting and changing laws and regulations;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure by us to obtain and maintain regulatory approvals for the use of our products in various countries; rejection or qualification of foreign clinical trial data by the competent authorities of other countries;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays or interruptions in the supply of clinical trial materials resulting from any events affecting raw material supply or manufacturing capabilities abroad;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">additional potentially relevant third-party patent and other intellectual property rights;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">complexities and difficulties in obtaining, maintaining, protecting and enforcing our intellectual property;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">difficulties in staffing and managing foreign operations;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">complexities associated with managing multiple payor reimbursement regimes, government payors or patient self-pay systems;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">limits in our ability to penetrate international markets;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for our product candidates and exposure to foreign currency exchange rate fluctuations;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">currency exchange rate fluctuations and the resulting effect on our revenue and expenses and the cost and risk of entering into hedging transactions if we chose to do so in the future;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak of disease, including related public health guidance measures, boycotts, curtailment of trade and other business restrictions;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">certain expenses including, among others, expenses for travel and insurance; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory and compliance risks that relate to anti-corruption compliance and record-keeping that may fall within the purview of the FCPA, its accounting provisions or its anti- bribery provisions or provisions of anti-corruption or anti-bribery laws in other countries.</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of these factors could harm our future international expansion and operations and, consequently, our results of operations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be able to utilize a significant portion of our net operating loss carryforwards.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, we had net operating loss (NOL) carryforwards of approximately $55.8 million for federal income tax purposes, $63.2 million for foreign income tax purposes and $9.5 million for state income tax purposes. The federal NOLs may be used to offset up to 80% of future taxable income each year while the state and foreign losses may be used to offset up to 100% of future taxable income. The federal and foreign NOL carryforwards can be carried forward indefinitely while the state NOL carryforwards will begin to expire in varying amounts in 2038. The NOL carryforwards subject to expiration could expire unused and be unavailable to offset future income tax liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not be able to utilize a significant portion of our NOL carryforwards or tax credits due to limitations under U.S. tax law, including Section 382 and 383 ownership change rules, changes in tax law, or insufficient future taxable income. If we are unable to use these tax attributes, our future cash flows and financial condition could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">91</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have and may continue to seek to grow our business through acquisitions or investments in new or complementary businesses, products or technologies, through the licensing of products or technologies from third parties or through other strategic alliances, and the failure to manage acquisitions, investments, licenses or other strategic alliances, or the failure to integrate them with our existing business, could have a material adverse effect on our operating results, dilute our stockholders&#8217; ownership, increase our debt or cause us to incur significant expense.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success depends on our ability to continually enhance and broaden our product offerings in response to changing clinician and patients&#8217; needs, competitive technologies and market pressures. Accordingly, we have and may continue to consider opportunities to acquire, make investments in or license other technologies, products and businesses that may enhance our capabilities, complement our existing products and technologies or expand the breadth of our markets or customer base. For example, we entered into the Mabworks Agreement where we acquired licenses for the development, manufacture and commercialization of CLYM116 and products containing CLYM116 in certain territories.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Potential and completed acquisitions, strategic investments, licenses and other alliances, including our acquisition of Tenet and the Mabworks Agreement, involve numerous risks, including:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">difficulty assimilating or integrating acquired or licensed technologies, products, employees or business operations; issues maintaining uniform standards, procedures, controls and policies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unanticipated costs associated with acquisitions or strategic alliances, including the assumption of unknown or contingent liabilities and the incurrence of debt or future write-offs of intangible assets or goodwill;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">diversion of management&#8217;s attention from our core business and disruption of ongoing operations;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adverse effects on existing business relationships with suppliers, sales agents, health care facilities, surgeons and other health care providers;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">risks associated with entering new markets in which we have limited or no experience; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential losses related to investments in other companies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential loss of key employees of acquired businesses; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">increased legal and accounting compliance costs. </span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To finance any acquisitions, investments or strategic alliances, we may choose to issue shares of our common stock as consideration, which could dilute the ownership of our stockholders. For example, in June 2024 we issued 5,560,047 shares of our common stock as consideration in connection with the closing of the Acquisition, and we issued 31,238,282 shares of our common stock in connection with the closing of the related P</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rivate Placement, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">resulting in the issuance of a total of an additional 36,798,329 shares of our common stock.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the price of our common stock is low or volatile, we may be unable to consummate any acquisitions, investments or strategic alliances using our common stock as consideration. Additional funds may not be available on terms favorable to us, or at all.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to our Common Stock</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The trading price of our common stock has been and may continue to be volatile, and purchasers of our common stock could incur substantial losses.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our stock price has been volatile. Through December 31, 2025, our stock price has fluctuated from a high trading price of $29.69 per share in August 2021 to a low trading price of $1.05 in April 2025. The stock market in general and the market for biotechnology companies in particular have also experienced extreme volatility that has often been unrelated to the operating performance of particular companies. The market price for our common stock may continue to be volatile in the future and may be influenced by many factors, including:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any delay in our regulatory filings for our product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#8217;s review of such filings, including without limitation the FDA&#8217;s issuance of a &#8220;refusal to file&#8221; letter or a request for additional information;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the commencement, enrollment or results of any clinical trials or nonclinical development activities we may conduct, or changes in the development status of our product candidates;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">92</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adverse results from, delays in or termination of our clinical trials or those of our competitors;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unanticipated serious safety concerns related to the use of any of our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adverse regulatory decisions, including results of regulatory interactions and review for any of our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">lower than expected market acceptance of our product candidates following approval for commercialization;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in financial estimates by us or by any securities analysts who might cover our stock;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">conditions or trends in our industry;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in the market valuations of similar companies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">stock market price and volume fluctuations of comparable companies and, in particular, those that operate in the pharmaceutical industry;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">publication of research reports about us or our industry or positive or negative recommendations or withdrawal of research coverage by securities analysts;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcements by us or our competitors of strategic transactions, significant acquisitions, strategic partnerships or divestitures;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcements of investigations or regulatory scrutiny of our operations or lawsuits filed against us;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">investors&#8217; general perception of our company and our business;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">actions by institutional or activist investors;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes to our business, including pipeline reprioritizations and restructurings;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">recruitment or departure of key personnel;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">overall performance of the equity markets;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">trading volume of our common stock;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disputes or other developments relating to intellectual property rights, including patents, litigation matters and our ability to obtain, maintain, defend, protect and enforce patent and other intellectual property rights for our technologies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">threats of or actual significant lawsuits, including patent or stockholder litigation;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">proposed changes to healthcare laws in the U.S. or foreign jurisdictions, or speculation regarding such changes;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">general political and economic conditions; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">other events or factors, including the other factors described in this &#8220;Risk Factors&#8221; section, many of which are beyond our control.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the past, stockholders have initiated class action lawsuits against pharmaceutical and biotechnology companies following periods of volatility in the market prices of these companies&#8217; stock, in particular following significant drops in stock price. Such litigation, if instituted against us, could cause us to incur substantial costs and divert management&#8217;s attention and resources from our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, in the current volatile market for biotechnology stocks, in particular where shares are trading below cash balances, certain biotechnology investors have advocated for increases in short-term stockholder value through proposed corporate actions such as financial restructurings, special dividends, stock repurchases, mergers, other business combinations or sales of assets. Any such proposals directed at us could cause us to incur substantial costs and divert management&#8217;s attention and resources from our business.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">93</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be our stockholders&#8217; sole source of gain.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. As a result, capital appreciation, if any, of our common stock will be our stockholders&#8217; sole source of gain for the foreseeable future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have broad discretion in the use of our cash, cash equivalents and marketable securities and may not use them effectively.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management has broad discretion in the application of our cash, cash equivalents and marketable securities and could use such funds in ways that do not improve our results of operations or enhance the value of our common stock or in ways that our stockholders may not agree with. The failure by our management to apply these funds effectively could result in financial losses that could cause the price of our common stock to decline and delay the development of our product candidates. Pending their use, we may invest these funds in a manner that does not produce income or that loses value.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">A significant portion of our common stock may be sold into the market, which could cause the market price of our common stock to drop significantly.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales of a substantial number of shares of our common stock in the public market could occur at any time. If our stockholders sell, or the market perceives that our stockholders intend to sell, substantial amounts of our common stock in the public market, the market price of our common stock could decline significantly. Sales of substantial amounts of our common stock, or the perception that such sales could occur, could cause the market price of our common stock to decline and impair our ability to raise capital.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have registered and intend to continue to register all shares of common stock that we may issue under our equity compensation plans. These shares can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, the holders of an aggregate of 7.0 million shares of our common stock, or their transferees, have rights, subject to some conditions, to require us to file one or more registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. If we were to register the resale of these shares, they could be freely sold in the public market without limitation. If these additional shares are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Private Placement related to the Acquisition, we entered into a registration rights agreement, pursuant to which we are required to register for resale the shares to be purchased in the Private Placement and the consideration issued in the Acquisition. Pursuant to this agreement, in July 2024, we filed a registration statement covering the resale of the shares purchased by the purchasers in the Private Placement and the consideration issued in connection with the Acquisition.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we agreed to use commercially reasonable efforts to cause such registration statement to become effective as soon as practicable after it was filed with the SEC and to keep such registration statement effective until the date the shares covered by the registration statement have been sold or can be resold without restriction under Rule 144 of the Securities Act.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of our company more difficult, limit attempts by our stockholders to replace or remove our current management and limit the market price of our common stock.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Provisions in our amended and restated certificate of incorporation and amended and restated bylaws and Delaware law could make an acquisition of our company more difficult and may prevent attempts by stockholders to replace or remove current management. Such provisions may discourage proxy contests, delay or prevent mergers or acquisitions, and limit the ability of stockholders to influence corporate actions. Our amended and restated certificate of incorporation and amended and restated bylaws include provisions that:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provide for a classified board of directors whose members serve staggered terms;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">94</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">authorize our board of directors to issue, without further action by the stockholders, shares of undesignated preferred stock with terms, rights and preferences determined by our board of directors that may be senior to our common stock;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">require that any action to be taken by our stockholders be effected at a duly called annual or special meeting and not by written consent;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">specify that special meetings of our stockholders can be called only by our board of directors, the chairperson of our board of directors or our chief executive officer;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establish an advance notice procedure for stockholder proposals to be brought before an annual meeting, including proposed nominations of persons for election to our board of directors;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">prohibit cumulative voting in the election of directors;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provide that our directors may be removed for cause only upon the vote of the holders of at least 66 2/3% of our outstanding shares of common stock;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">require the approval of our board of directors or the holders of at least 66 2/3% of our outstanding shares of common stock to amend our bylaws and certain provisions of our certificate of incorporation.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law (DGCL) which generally, subject to certain exceptions, prohibits a Delaware corporation from engaging in any of a broad range of business combinations with any &#8220;interested&#8221; stockholder for a period of three years following the date on which the stockholder became an &#8220;interested&#8221; stockholder. Any delay or prevention of a change of control transaction or changes in our management could cause the market price of our common stock to decline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our amended and restated certificate of incorporation and amended and restated bylaws provide that we will indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, as permitted by Section 145 of the DGCL, our amended and restated bylaws and our indemnification agreements that we have entered into with our directors and officers provide that:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will indemnify our directors and officers for serving us in those capacities or for serving other business enterprises at our request, to the fullest extent permitted by Delaware law. Delaware law provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the registrant and, with respect to any criminal proceeding, had no reasonable cause to believe such person&#8217;s conduct was unlawful.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will not be obligated pursuant to our amended and restated bylaws to indemnify a person with respect to proceedings initiated by that person against us or our other indemnitees, except with respect to proceedings authorized by our board of directors or brought to enforce a right to indemnification.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The rights conferred in our amended and restated bylaws are not exclusive, and we are authorized to enter into indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify such persons.</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">95</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not retroactively amend our amended and restated bylaw provisions to reduce our indemnification obligations to directors, officers, employees and agents. Claims for indemnification may reduce our available funds to satisfy third-party claims or to invest in our business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Concentration of ownership of our common stock among our existing executive officers, directors and principal stockholders, including affiliates of RA Capital Management L.P., may limit or prevent new investors from influencing significant corporate decisions and also reduces the public float for our common stock, which could make our common stock less attractive to some investors or otherwise harm our stock price.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based upon our common stock outstanding as of December 31, 2025, our executive officers, directors and current beneficial owners of 5% or more of our common stock, in the aggregate, beneficially own approximately 36% of our outstanding common stock. In particular, affiliates of RA Capital Management, L.P., own approximately 24% of our outstanding common stock and, in addition, they have the right to exercise pre-funded warrants to purchase up to 33.0% of our common stock (as described below). These stockholders, acting together, are able to significantly influence all matters requiring stockholder approval, including the election of directors and any merger or other significant corporate transaction. The interests of this group of stockholders may not coincide with the interests of other stockholders.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, as a result of this concentration of ownership, there is a limited number of shares of our common stock that are not held by officers, directors and principal stockholders (which is referred to as our public float), thereby adversely impacting the liquidity of our common stock and potentially depressing the price at which our stockholders&#8217; may be able to sell shares of common stock. This concentration may limit our stockholders&#8217; ability to influence corporate matters and could delay or prevent a change in control.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2025, we entered into an exchange agreement (the Exchange Agreement) with RA Capital Management L.P., (RA Capital) and an entity affiliated with RA Capital (the Exchanging Holder) pursuant to which the Exchanging Holder exchanged an aggregate of 20,440,000 shares of our common stock beneficially owned by the Exchanging Holder for a pre-funded warrant to purchase the same number of shares of our common stock. The shares of our common stock exchanged by the Exchanging Holder were retired, and we had 47.7 million shares of common stock outstanding immediately after the transaction. The pre-funded warrant is exercisable at any time, however, the Exchanging Holder will not be entitled to exercise any portion of the pre-funded warrant if, upon giving effect or immediately prior to such exercise, such exercise would result in the aggregate number of shares of our common stock beneficially owned by RA Capital, the Exchanging Holder and their respective affiliates, collectively, to exceed 33.0% of the number of shares of our common stock issued and outstanding immediately after giving effect to such exercise, as such percentage ownership is determined in accordance with the terms of the pre-funded warrant. The Exchanging Holder may increase or decrease such percentage to any other percentage not in excess of 33.0%; provided that any such increase will not be effective until the 61st day after notice from the Exchanging Holder is delivered to us. In addition, in accordance with the terms of the Exchange Agreement, RA Capital and the Exchanging Holder have agreed to, and to cause each other account or fund managed by or affiliated with RA Capital to, vote all securities beneficially owned by them or their respective affiliates in excess of 33.0% of the total voting power of our outstanding capital stock, in proportion to and in accordance with the vote of all of our stockholders (excluding RA Capital and the Exchanging Holder and their respective affiliates).</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have identified material weaknesses in our internal control over financial reporting. If we are unable to remediate these material weaknesses, or if we identify additional material weaknesses in the future or otherwise fail to maintain effective internal control over financial reporting, we may not be able to accurately or timely report our financial condition or results of operations, which may adversely affect our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to the completion of our initial public offering (IPO), we were a private company with limited accounting personnel to adequately execute our accounting processes and other supervisory resources with which to address our internal control over financial reporting. In connection with the preparation of our consolidated financial statements for the year ended December 31, 2020, we identified material weaknesses in our internal control over financial reporting, two of which remain unremediated as of December 31, 2025. The unremediated material weaknesses, and our remediation plan, are disclosed in Item 9A, &#8220;Controls and Procedures,&#8221; of this Annual Report on Form 10-K.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe we have made substantial progress toward achieving the effectiveness of our internal control over financial reporting and disclosure controls and procedures. The actions that have been taken are subject to continued review and testing by management as well as oversight by the audit committee of our board of directors. We will not be able to conclude whether the steps we have taken will fully remediate these material weaknesses in our internal control over financial reporting until we have completed our remediation efforts and subsequent evaluation of their effectiveness.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">96</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to remediate these weaknesses, or if additional weaknesses are identified, we may not be able to accurately or timely report our financial condition or results of operations, which could adversely affect our business and reputation. Failure to maintain effective internal controls could also result in regulatory investigations, actions, or negative impacts on our stock price.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended (Exchange Act), the Sarbanes-Oxley Act, and the rules and regulations of the Nasdaq Stock Market. Section 302 of the Sarbanes-Oxley Act requires, among other things, that we report on the effectiveness of our disclosure controls and procedures in our quarterly and annual reports and Section 404 of the Sarbanes-Oxley Act requires that we perform system and process evaluation and testing of our internal control over financial reporting to allow management to report on the effectiveness of our internal control over financial reporting in our Form 10-K filings.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot assure you that the measures we have taken to date, and are continuing to implement, or any measures we may take in the future, will be sufficient to identify or prevent future material weaknesses. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected. In addition, our independent registered public accounting firm will be required to attest to the effectiveness of our internal control over financial reporting in our first annual report required to be filed with the SEC following the date we are no longer an emerging growth company or a smaller reporting company with less than $100 million in revenue.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are not able to comply with the requirements of Section 404 of the Sarbanes-Oxley Act in a timely manner, or if we are unable to maintain proper and effective internal controls, we may not be able to produce timely and accurate financial statements. If that were to happen, the market price of our stock could decline and we could be subject to sanctions or investigations by the Nasdaq Stock Market, the SEC or other regulatory authorities. In addition, our common stock may not be able to remain listed on the Nasdaq Stock Market or any other securities exchange.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our amended and restated certificate of incorporation designates the Court of Chancery of the State of Delaware and, to the extent enforceable, the federal district courts of the United States of America as the exclusive forums for substantially all disputes between us and our stockholders, which restricts our stockholders&#8217; ability to choose the judicial forum for disputes with us or our directors, officers, or employees.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our amended and restated certificate of incorporation designates the Court of Chancery of the State of Delaware and, to the extent enforceable, the federal district courts of the United States of America as the exclusive forums for substantially all disputes between us and our stockholders. These provisions may restrict our stockholders&#8217; ability to choose the judicial forum for disputes with us or our directors, officers, or employees, and may discourage lawsuits or increase costs if a court finds such provisions unenforceable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, our amended and restated certificate of incorporation provides that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. These choice of forum provisions will not apply to suits brought to enforce a duty or liability created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Such provisions are intended to benefit and may be enforced by us, our officers and directors, employees and agents, including the underwriters for any offering giving rise to such complaint and any other professional or entity who has prepared or certified any part of the document underlying the offering and may result in increased costs for stockholders to bring a claim.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe these provisions may benefit us by providing increased consistency in the application of Delaware law and federal securities laws by chancellors and judges, as applicable, particularly experienced in resolving corporate disputes, efficient administration of cases on a more expedited schedule relative to other forums and protection against the burdens of multi-forum litigation. These choice of forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage lawsuits with respect to such claims or make such lawsuits more costly for stockholders, although our stockholders will not be deemed to have waived our compliance with federal securities laws and the rules and regulations thereunder. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">97</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in a venue other than those designated in the exclusive forum provisions, and there can be no assurance that such provisions will be enforced by a court in those other jurisdictions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a court were to find either choice of forum provision contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General Risk Factors</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are, have been, and may in the future become, involved in litigation that could result in significant costs, divert the attention of management and harm our business.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may be involved in litigation arising in the ordinary course of business or from specific events. These matters may relate to a wide range of issues, including contracts, intellectual property, employment matters, data protection and privacy, product liability, securities laws, stockholder allegations, or other business practices.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we believe we have strong defenses, we may decide to settle claims for business or strategic reasons, particularly when the risks, costs, and burdens of litigation outweigh the potential benefits of continuing to defend a matter.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Litigation outcomes are unpredictable and the number and complexity of claims may increase as our business grows. Any current or future legal proceedings could materially adversely affect our business, financial condition, cash flows, and operating results.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If equity research analysts publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our stock price and trading volume may be influenced by equity research analysts&#8217; reports published about us or our business, which we do not control. Unfavorable opinions or reports by an equity research analyst or downgrade by one or more equity research analysts could cause our stock price to decline.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Unfavorable global economic conditions could adversely affect our business, financial condition, stock price, and results of operations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unfavorable global economic conditions, including volatility, inflation, recession, banking instability, military conflicts, sanctions, tariffs, and trade policy changes, could adversely affect our business, financial condition, stock price, and results of operations. These factors may impact our ability to raise capital, conduct clinical trials, and achieve operating goals.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The global credit and financial markets have experienced extreme volatility and disruptions, including as a result of actual or perceived changes in interest rates, inflation, and macroeconomic uncertainties, which has included severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, high inflation, uncertainty about economic stability, and increases in unemployment rates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The financial markets and the global economy may also be adversely affected by the current or anticipated impact of military conflicts or other geopolitical events. Sanctions, tariffs and general trade policy changes imposed by the U.S. and other countries may also continue to adversely impact the financial markets and the global economy, and any economic countermeasures by the affected countries or others could exacerbate market and economic instability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. A severe or prolonged economic downturn could result in a variety of risks to our business, including a decrease in the demand for our product candidates and in our ability to raise additional capital when needed on acceptable terms, if at all. In addition, current inflationary trends in the global economy may impact salaries and wages, costs of goods and transportation expenses, among other things, and recent and potential future disruptions in access to bank deposits or lending commitments due to bank failures may create market and economic instability. We cannot anticipate all of the ways in which the foregoing, and the current economic climate and financial market conditions generally, could adversely impact our business.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">98</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company,&#8221; and as a result of the reduced reporting requirements applicable to &#8220;emerging growth companies&#8221; and &#8220;smaller reporting companies,&#8221; our common stock may be less attractive to investors.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are an &#8220;emerging growth company,&#8221; as defined in the JOBS Act. For as long as we continue to be an &#8220;emerging growth company,&#8221; we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not &#8220;emerging growth companies,&#8221; including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. We may take advantage of these exemptions until we are no longer an &#8220;emerging growth company.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will be an &#8220;emerging growth company&#8221; until December 31, 2026. We are also a &#8220;smaller reporting company,&#8221; as defined in the Exchange Act. Even after we no longer qualify as an &#8220;emerging growth company,&#8221; we may still qualify as a &#8220;smaller reporting company,&#8221; which would allow us to continue to take advantage of many of the same exemptions from disclosure requirements. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and the price of our common stock may be more volatile.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be unable to maintain adequate insurance coverage.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We presently have general liability, workers&#8217; compensation, directors&#8217; and officers&#8217;, cybersecurity, and product liability insurance coverage. Although we believe we will be able to maintain such coverage for a reasonable cost and obtain any additional coverages that our business may require, no assurances can be made that we will be able to do so.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in tax laws or regulations that are applied adversely to us may seriously harm our business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in tax laws or regulations, including the OECD Pillar Two rules and U.S. legislation such as the One Big Beautiful Bill Act or other tax related legislation, could adversely affect our business, financial performance, and tax treatment of future earnings. Existing tax laws may also be interpreted or applied adversely to us.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">99</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1b_unresolved_staff_comments"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">em 1B. Unresolved Staff Comments.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_951b4037-c06b-4a9a-a925-8c36e31f23da" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1c_cybersecurity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1C. Cybersecurity.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risk Management and Strategy</span></p><div><ix:nonNumeric id="F_1d4c5332-e080-4f03-82ee-ef7a55195958" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have implemented and maintain various information security </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4db55927-ea6d-45ba-8ac9-173614ed438e" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">processes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> designed to identify, assess and manage material risks from cybersecurity threats to our critical computer networks, third-party hosted services, communications systems, and our critical data, including intellectual property, confidential information that is proprietary, strategic or competitive in nature, and data related to nonclinical studies and clinical trials involving certain of our product candidates (Information Systems and Data).</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We manage, identify and assess risks from cybersecurity threats by monitoring and evaluating our threat environment and risk profile using various methods including, for example: through the use of automated tools, including but not limited to tools for monitoring, remote wiping, threat detection, intrusion detection and prevention; conducting (</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_10259f2b-74a8-4d83-8a0e-12d5058acb59" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">through third parties</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) regular audits and threat assessments for internal and external threats; subscribing to reports and services that identify cybersecurity threats; analyzing reports of threats and actors; conducting vulnerability assessments to identify vulnerabilities; evaluating our and our industry&#8217;s risk profile; and evaluating threats reported to us.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depending on the environment, we implement and maintain various processes, standards and policies designed to manage and mitigate material risks from cybersecurity threats to our Information Systems and Data, including, for example: risk assessments, implementation of security standards and certifications, encryption of data in transit and at rest, network security controls, data segregation, access controls, systems monitoring, vendor risk management program, employee training and penetration testing.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of our cybersecurity risk management program, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_af33229d-16c8-4f04-8fbd-6af584727b87" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we maintain processes to assess and review the cybersecurity practices of third-party vendors and suppliers</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Prior to engaging key third-party vendors and suppliers, we conduct a security assessment and, as appropriate, include security requirements in contracts.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We, like other companies in our industry, face cybersecurity risks in connection with our business. However, to date, risks from cybersecurity threats have not </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_929f0df5-5f3b-4a90-b246-46c4d25defc3" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">materially affected</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and are not reasonably likely to materially affect our business strategy, results of operations, and financial condition. For more information on our cybersecurity related risks, see &#8220;Risk Factors&#8221; under Part I, Item 1A of this Annual Report on Form 10-K.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_33f2f5fb-abce-4537-bec6-2e62cc277008" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governance</span></p><div><ix:nonNumeric id="F_0153025c-0570-41c1-98c6-13b070a9f6fb" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors considers cybersecurity risk management as part of its general oversight function. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cf4867e2-2a87-47a2-8a8a-8414a0f929b8" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The audit committee of our board of directors is responsible for overseeing our cybersecurity risk management processes, including oversight and mitigation of risks from cybersecurity threats.</span></ix:nonNumeric></span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_311f4785-0030-48b6-bb99-b3346b578755" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4e26fa3e-d3ea-4955-b768-2be1407400fb" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management team provides periodic updates to the audit committee regarding our cybersecurity program, including information about cyber risk management governance and status updates on various projects intended to enhance the overall cybersecurity posture of the Company. </span></ix:nonNumeric></span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f6890bce-59fd-4ab6-b81c-ab47d955175d" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_289d3463-95dc-42fc-8c90-55300a8ab3e9" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">chief financial officer</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, with the assistance of third-party technical advisors, leads the operational oversight of company-wide cybersecurity strategy, policy, standards and processes and works across relevant departments to assess and help the Company and our employees to address cybersecurity risks.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bd9b83e7-73b8-4e8a-b463-6880c426f868" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our third-party technical advisors include consultants with over 20 years of experience in IT leadership as well as subject matter experts in cybersecurity that have extensive experience managing cybersecurity programs.</span></ix:nonNumeric></span></p></ix:nonNumeric></div></ix:nonNumeric></div></ix:nonNumeric></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_2_properties"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">em 2. Properties.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We lease approximately 5,728 square feet of office space for our company headquarters in Wellesley Hills, Massachusetts under a non-cancelable operating lease, as amended, that expires in December 2026, with an option to extend for an additional 12 months. We believe that our facility arrangement is sufficient for our current needs.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">100</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_3_legal_proceedings"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">m 3. Legal Proceedings.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information with respect to legal proceedings is included in Note 8 of the Notes to Consolidated Financial Statements contained in Part II, Item 8 of this Annual Report on Form 10-K, which is incorporated herein by reference.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_4_mine_safety_disclosures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">em 4. Mine Safety Disclosures.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">101</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART II</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_5_market_for_registrants_common"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">em 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Market Information</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our common stock has been listed on the Nasdaq Global Market under the symbol &#8220;ELYM&#8221; since August 10, 2021 and &#8220;CLYM&#8221; since October 2024. Prior to our IPO on August 10, 2021, there was no public market for our common stock.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Holders of Common Stock</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of February 27, 2026, there were 47,767,980 shares of our common stock issued and held by approximately 13 stockholders of record. The actual number of stockholders is greater than this number of record holders and includes stockholders who are beneficial owners but whose shares are held in street name by brokers and other nominees.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dividend Policy</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have never declared or paid any cash dividends on our capital stock. We currently intend to retain all available funds and any future earnings to support our operations and finance the growth and development of our business. We do not intend to pay cash dividends on our common stock for the foreseeable future. Any future determination related to our dividend policy will be made at the discretion of our board of directors and will depend upon, among other factors, our results of operations, financial condition, capital requirements, contractual restrictions, business prospects and other factors our board of directors may deem relevant.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Sales of Unregistered Securities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the fourth quarter of the year ended December 31, 2025, the Company did not sell any equity securities that were not registered under the Securities Act of 1933, as amended, and not previously reported on a Current Report on Form 8-K.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Issuer Purchases of Equity Securities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_6_reserved"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 6. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[Reserved]</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">102</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7_managements_discussion"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">em 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and related notes included in &#8220;Item 8. Financial Statements and Supplementary Data.&#8221; in this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10-K, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve substantial risks and uncertainties. As a result of many factors, including those factors set forth in Part I, Item 1A. &#8220;Risk Factors&#8221; of this Annual Report on Form 10-K, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. For further information regarding our forward-looking statements, see &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221; in this Annual Report on Form 10-K.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a clinical-stage biotechnology company committed to developing potential best-in-class therapeutics that address significant unmet need for patients living with immune-mediated diseases. We have built our pipeline by strategically acquiring or in-licensing product candidates that we believe have clear biological rationale, well-defined development pathways, and the potential to address multiple indications.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are developing our product candidates for multiple immune-mediated diseases, as summarized in the pipeline figure below.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img22994243_0.jpg" alt="img22994243_0.jpg" style="width:672px;height:317px;"/><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We acquired the rights to our product candidates through license and asset purchase agreements. We have worldwide rights to develop and commercialize budoprutug for all indications, except for oncology. We have rights to develop and commercialize CLYM116 for all indications worldwide outside of Greater China.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since our inception, we have primarily funded our operations with proceeds from the sale and issuance of shares of our redeemable convertible preferred stock, our IPO, and the sale and issuance of shares in a Private Placement in connection with the Acquisition. We do not have any products approved for sale and have not generated any revenue from product sales since our inception. Our ability to generate product revenue will depend on the successful development, regulatory approval and eventual commercialization of one or more of our product candidates, if approved. We cannot assure you that we will ever be profitable or generate positive cash flow from operating activities. We expect to continue to incur operating losses for the foreseeable future and will need to raise substantial additional capital in the future. Until such time, if ever, as we can generate significant revenue from product sales, we may finance our operations through equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. Adequate funding may not be available when needed or on terms acceptable to us, or at all.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">103</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we fail to obtain necessary capital when needed on acceptable terms, or at all, it could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations. Insufficient liquidity may also require us to relinquish rights to product candidates at an earlier stage of development or on less favorable terms than we would otherwise choose. Our ability to raise additional funds may be adversely impacted by the potential worsening of global economic conditions and the recent disruptions to, and volatility in, worldwide credit and financial markets, resulting from increased volatility in the trading prices for shares in the biopharmaceutical industry, or otherwise. Further, imposition of tariffs and other trade restrictions by the U.S., as well as reciprocal trade restrictions imposed by other countries, could adversely affect global economies, financial markets and the overall environment in which we do business, as further described in Part I, Item 1A, &#8220;Risk Factors&#8221; of this Annual Report on Form 10-K.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on our current operating plan, we estimate that our cash, cash equivalents and marketable securities will be sufficient to fund our planned operations into 2028. We have based this estimate on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently anticipate, in which case we would be required to obtain additional financing, which may not be available to us on acceptable terms, or at all. See &#8220;&#8212;Liquidity and Capital Resources&#8221;.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Components of Operating Results</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating Expenses</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our operating expenses consist of (i) research and development expenses, (ii) acquired in-process research and development (IPR&amp;D) expense, related party, and (iii) general and administrative expenses.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses consist of costs incurred for our research and development activities, including development of our product candidates, budoprutug and CLYM116, and our previous product candidates, ETX-123 and ETX-155, consisting primarily of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">employee-related expenses, such as salaries, bonuses, benefits, stock-based compensation, and termination benefits, for employees engaged in research and development functions; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expenses incurred in connection with the nonclinical and clinical development of our product candidates, including under agreements with CROs and consultants; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of third-party suppliers and manufacturers for material used in our development activities, including under agreements with CDMOs; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">facilities and other expenses, which include direct and allocated expenses including rent; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">payments made under third-party licensing agreements. </span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expense research and development costs to operations as incurred. Advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our direct research and development expenses are tracked on a program-by-program basis and consist primarily of external costs, such as fees paid to CDMOs, CROs, consultants and contractors, in connection with our nonclinical and clinical development activities. We do not allocate employee costs, costs associated with facility expenses, or other indirect costs, to specific programs because these costs are deployed across multiple product development programs and, as such, are not separately classified.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect our research and development expenses to increase substantially for the foreseeable future as we conduct our ongoing research and development activities. The process of conducting nonclinical studies, acquiring drug product supply, and conducting clinical trials necessary to obtain regulatory approval is costly and time consuming. We may never succeed in achieving marketing approval for budoprutug, CLYM116, or any product candidate we may develop.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">104</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The timelines and costs associated with research and development activities are uncertain and can vary significantly among product candidates and development programs due to the inherently unpredictable nature of nonclinical and clinical development. We anticipate that we will make determinations as to which indications to pursue in connection with our clinical development of budoprutug, CLYM116, or any product candidates we may develop and how much funding to direct to each such indication on an ongoing basis in response to nonclinical and clinical results, regulatory developments, and ongoing assessments as to each such indication&#8217;s commercial potential. Our future research and development costs may vary significantly and differ materially from expectations, and a change in the outcome of variables with respect to the development of budoprutug, CLYM116, or any product candidates we may develop could significantly change the costs and timing associated with such development. See the section titled &#8220;Risk Factors&#8212;Risks Related to our Financial Position and Need for Additional Capital.&#8221;</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Acquired In-Process Research and Development, Related Party</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our acquired IPR&amp;D expense consists of the fair value of consideration transferred in the Acquisition allocated to assets acquired that were in the research and development phase and determined to not have any alternative future use.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our general and administrative expenses consist primarily of personnel-related expenses such as salaries, bonuses, benefits, stock-based compensation, and termination benefits, for our personnel in executive, finance and accounting, legal, human resources, business development, information technology and other administrative functions. Other significant general and administrative expenses include legal fees relating to corporate matters and intellectual property, professional fees for accounting, audit, regulatory, tax and consulting services, insurance costs, as well as investor and public relations costs.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect that our general and administrative expenses will increase for the foreseeable future, including increases in headcount as we continue to support our growth strategy and, if any product candidates receive marketing approval, commercialization activities, as well as to support our operations generally.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Income (Expense)</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest Income</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our interest income consists of interest earned on our cash, cash equivalents and marketable securities, including amortization of purchase premiums and accretion of discounts of marketable securities.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Foreign Currency Loss</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our foreign currency loss consists of foreign exchange losses resulting from remeasurement of foreign currency transactions to the U.S. Dollar.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Results of Operations</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth our results of operations (in thousands):</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:53.809%;box-sizing:content-box;"/>
     <td style="width:2.799%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.598%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:2.799%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.598%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:2.799%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.598%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,713</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,336</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,377</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Acquired in-process research and development, related party</span></p></td>
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">51,659</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(51,659</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,170</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,025</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,145</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67,883</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82,020</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(14,137</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(67,883</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(82,020</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,137</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income (expense):</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,323</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,132</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">191</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign currency loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(291</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(9</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(282</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other income, net</span></p></td>
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,032</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,123</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(91</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(59,851</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(73,897</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,046</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">105</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comparison of the Years Ended December 31, 2025 and 2024</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating Expenses</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth our research and development expenses (in thousands):</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:53.809%;box-sizing:content-box;"/>
     <td style="width:2.799%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.598%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:2.799%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.598%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:2.799%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.598%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Direct research and development expenses:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Budoprutug</span></p></td>
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,045</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,982</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,063</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">CLYM116</span></p></td>
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,964</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,964</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Legacy programs</span></p></td>
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">201</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(94</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unallocated research and development expenses:</span></p></td>
     <td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel-related (including stock-based compensation)</span></p></td>
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,232</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,990</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">242</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other research and development expenses</span></p></td>
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,365</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">163</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,202</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total research and development expenses</span></p></td>
     <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,713</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,336</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,377</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses increased from $14.3 million for the year ended December 31, 2024 to $46.7 million for the year ended December 31, 2025. The increase was due primarily to an increase of $19.1 million for our budoprutug program, which we acquired as part of the Acquisition on June 27, 2024. Costs incurred for our budoprutug program increased primarily due to costs related to the advancement of our clinical trials of budoprutug in pMN, ITP and SLE, and increased manufacturing costs, and milestone payments under our license agreements. Costs related to our CLYM116 program, which we licensed in January 2025, were $12.0 million, consisting of an upfront payment of $9.0 million under the Mabworks Agreement, milestone payments under our license agreements, and nonclinical, clinical, and manufacturing costs. Personnel-related expenses increased by $0.2 million due primarily to increased headcount and stock-based compensation expense, partially offset by a decrease due to prior year restructuring costs. Research and development expenses for the years ended December 31, 2025 and 2024 included stock-based compensation expense of $3.5 million and $3.0 million, respectively. Other research and development expenses increased by $1.2 million primarily due to an increase in consulting expenses to support our programs.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Acquired In-Process Research and Development, Related Party</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Acquired IPR&amp;D expense, related party was $51.7 million for the year ended December 31, 2024. This amount represents the recognition of IPR&amp;D expense from the Acquisition completed on June 27, 2024.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses increased from $16.0 million for the year ended December 31, 2024 to $21.2 million for the year ended December 31, 2025. The increase was primarily due to an increase in personnel-related expenses of $3.3 million from increased headcount and stock-based compensation expense. General and administrative expenses for the years ended December 31, 2025 and 2024 included stock-based compensation expense of $4.6 million and $2.5 million, respectively. Legal expenses also increased by $1.0 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Income (Expense)</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest Income</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest income increased from $8.1 million for the year ended December 31, 2024 to $8.3 million for the year ended December 31, 2025 due to higher invested balances, partially offset by lower yields during 2025 as compared to 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Foreign Currency Loss</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Foreign currency loss for the year ended December 31, 2025 consisted of the remeasurement of transactions denominated in a foreign currency. Foreign currency loss was not material for the year ended December 31, 2024.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">106</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liquidity and Capital Resources</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sources of Liquidity</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since our inception, we have primarily funded our operations with proceeds from the sale and issuance of shares of our redeemable convertible preferred stock, our IPO, and the sale and issuance of shares of our common stock in the Private Placement in connection with the Acquisition. We have not generated any revenue from product sales or otherwise. We have incurred net losses from operations since our inception and anticipate we will continue to incur net losses for the foreseeable future. As of December 31, 2025, we had cash, cash equivalents and marketable securities of $160.7 million.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2025, we entered into an Equity Distribution Agreement (the Distribution Agreement) with Oppenheimer &amp; Co. Inc., as agent (Oppenheimer), pursuant to which we may offer and sell shares of our common stock from time to time through Oppenheimer having an aggregate offering price of up to $22.4 million in an at the market offering. During the year ended December 31, 2025, we did not issue and sell any shares of our common stock pursuant to the Distribution Agreement.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash Flows</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth our cash flows (in thousands):</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:63.625%;box-sizing:content-box;"/>
     <td style="width:3.301%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.885%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:3.301%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.885%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in operating activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(54,356</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(15,562</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by (used in) investing activities</span></p></td>
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,833</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(121,092</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by (used in) financing activities</span></p></td>
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(21</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">130,729</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating activities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2025, net cash used in operating activities was $54.4 million, resulting from our net loss of $59.9 million and cash used by changes in our operating assets and liabilities of $0.6 million, partially offset by $6.1 million in non-cash charges. Cash used by changes in our operating assets and liabilities primarily consisted of an increase in other long-term assets of $1.5 million and an increase in prepaid expenses and other current assets of $0.8 million, partially offset by an increase in accounts payable and accrued expenses and other current liabilities of $1.9 million.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2024, net cash used in operating activities was $15.6 million, resulting from our net loss of $73.9 million, partially offset by $56.6 million in non-cash charges, which consisted primarily of our IPR&amp;D charge of $51.7 million, and cash provided by changes in our operating assets and liabilities of $1.7 million. Cash provided by changes in our operating assets and liabilities primarily consisted of a decrease in prepaid expenses and other current assets of $1.9 million.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in prepaid expenses and other current assets, other assets, accounts payable, and accrued expenses and other current liabilities were generally due to the advancement of our research and development programs and the timing of vendor invoicing and payments.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investing activities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2025, net cash provided by investing activities was $2.8 million consisting primarily of $111.1 million in proceeds received from maturities of marketable securities, partially offset by purchases of $108.1 million of marketable securities.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2024, net cash used by investing activities was $121.1 million, consisting primarily of purchases of $132.2 million of marketable securities, the issuance of a promissory loan of $5.0 million and cash paid of $4.6 million in connection with the Acquisition, partially offset by $20.8 million in proceeds received from maturities of marketable securities.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">107</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Financing activities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2025, net cash used by financing activities was less than $0.1 million, consisting of pre-funded warrant issuance costs, partially offset by $0.1 million in proceeds from exercises of stock options. On December 11, 2025, we entered into the Exchange Agreement, pursuant to which the Exchanging Holder exchanged an aggregate of 20,440,000 shares of our common stock beneficially owned by the Exchanging Holder for a pre-funded warrant to purchase the same number of shares of common stock at an exercise price of $0.0001 per share. The exchange of common stock for the pre-funded warrant did not impact cash (See Note 6 to our consolidated financial statements included in this Annual Report on Form 10-K for a discussion of the Exchange Agreement).</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2024, net cash provided by financing activities was $130.7 million, consisting of $119.7 million in proceeds received from the issuance of our common stock in the Private Placement in connection with the Acquisition and $11.0 million in proceeds from exercises of stock options.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Funding Requirements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe our existing cash, cash equivalents and marketable securities of $160.7 million as of December 31, 2025 will be sufficient to fund our operations into 2028. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. We anticipate that our expenses will increase for the foreseeable future as we continue to advance our current product candidates </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and any product candidates we may develop</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, expand our corporate infrastructure, and incur costs associated with potential commercialization.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to all of the risks typically related to the development of biopharmaceutical candidates, and we may encounter unforeseen expenses, difficulties, complications, delays, and other unknown factors that may adversely affect our business. Our future funding requirements will depend on many factors, including the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number and scope of development, nonclinical and clinical programs we decide to pursue, and the timing, cost and progress of activities related to such programs; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the progress, costs and results of our clinical trials of budoprutug in pMN, ITP, and SLE, our Phase 1 clinical trial of the SC formulation of budoprutug, our Phase 1 clinical trial of CLYM116, and any future clinical trials of our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of manufacturing our product candidates by third parties;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the terms of any collaborations, license or research and development agreements we may enter into;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of regulatory requirements, regulatory submissions and timing of regulatory approvals;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs involved in prosecuting and enforcing patent and other intellectual property claims;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the potential delays in our development programs and clinical trial activities due to the effects of global events, including macroeconomic conditions and supply chain disruptions;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the impact of inflationary pressures on salaries and wages, and costs of goods and transportation expenses, including the impact of tariffs and other trade restrictions;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of commercialization activities if any of our product candidates are approved for sale, including marketing, sales and distribution costs; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our efforts to enhance operational systems and hire personnel to support development of budoprutug, CLYM116, or any product candidates we may develop. </span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, our operating plans may change, and we may need additional funds to meet operational needs and capital requirements for clinical trials and other research and development expenditures. Until such time, if ever, as we can generate substantial revenue from product sales, we may finance our operations through equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed or on favorable terms or at all. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">108</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. If we raise funds through collaborations, or other similar arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or our product candidates or grant licenses on terms that may not be favorable to us and may reduce the value of our common stock. Our failure to raise capital or enter into such other arrangements when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts, or grant rights to develop and market budoprutug, CLYM116, or </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any product candidates we may develop </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">even if we would otherwise prefer to develop and market such</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> product candidates </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ourselves.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Contractual Commitments and Obligations</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the normal course of business, we enter into contracts with CROs, CDMOs, and other third parties for nonclinical studies and clinical trials, supply of materials and manufacturing services. These contracts do not contain material minimum purchase commitments and generally provide us with the option to cancel, reschedule and adjust our requirements based on our business needs, prior to the delivery of goods or performance of services. However, it is not possible to predict the maximum potential amount of future payments under these agreements due to the conditional nature of our obligations and the unique facts and circumstances involved in each agreement.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have a lease agreement, as amended, for office space in Wellesley Hills, Massachusetts with remaining fixed payments of $0.3 million through December 2026, with an option to extend the lease through December 2027 for additional fixed payments of $0.3 million.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have obligations under the Asset Purchase Agreement with Acelyrin with respect to Products (as defined in the Asset Purchase Agreement) and certain license agreements that may obligate us to make specified milestone and royalty payments. The payment obligations under these agreements are contingent upon future events, such as our achievement of specified development, regulatory and commercial milestones, or generating product sales. We are unable to estimate the timing or likelihood of achieving these milestones or generating future product sales. See Note 8 to our consolidated financial statements included in this Annual Report on Form 10-K for a discussion of these milestone and royalty obligations.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Critical Accounting Policies and Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our consolidated financial statements are prepared in accordance with GAAP. The preparation of our consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue, costs and expenses, and the disclosure of contingent assets and liabilities in our consolidated financial statements. We base our estimates on historical experience, known trends and events, and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While our significant accounting policies are described in more detail in Note 2 to our audited consolidated financial statements, appearing in Part II of Item 8 of this Annual Report on Form 10-K, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of the process of preparing our consolidated financial statements, we are required to estimate certain research and development expenses. This process involves estimating the level of services performed and the associated cost incurred for services when we have not yet been invoiced or otherwise notified of actual costs, or when payments for such activities differ from the pattern of costs incurred. We make estimates of our accrued expenses or prepaid expenses as of each balance sheet date in our consolidated financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of certain estimates with the service providers. Examples of estimated accrued research and development expenses include those related to fees paid to:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">vendors in connection with nonclinical and clinical development activities, including CROs; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of third-party suppliers and manufacturers for material used in our development activities, including CDMOs;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">109</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We base the expense recorded on our estimates of the services received and efforts expended pursuant to quotes and contracts with our vendors, CROs and CDMOs that conduct services and supply materials. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. In recording service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. Certain of our service providers invoice us in arrears for services performed, on a pre-determined schedule or when contractual milestones are met; while others require advance payments. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. We record these as prepaid expenses on our consolidated balance sheet. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, there have been no material differences between our estimates of such expenses and the amounts actually incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-Based Compensation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We measure our stock options with service-based vesting or performance-based vesting granted to employees, non-employee directors, consultants and independent advisors based on the estimated fair value on the date of grant using the Black-Scholes option-pricing model. We measure compensation expense for restricted common stock units based on the fair value on the date of grant using the market value of our common stock. Compensation expense for the awards is recognized over the requisite service period for employees and directors and as services are delivered for consultants and independent advisors, both of which are generally the vesting period of the respective award. We use the straight-line method to record the expense of awards with only service-based vesting conditions. We use the graded-vesting method to record the expense of awards with both service-based and performance-based vesting conditions, commencing once achievement of the performance condition becomes probable. The Black-Scholes option-pricing model uses as inputs assumptions we make for the volatility of our common stock, the expected term of our stock options, the risk-free interest rate for a period that approximates the expected term of our stock options and our expected dividend yield. We do not estimate and apply a forfeiture rate as we have elected to account for forfeitures of share-based awards as they occur.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Pronouncements Not Yet Adopted</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See Note 2 to our audited consolidated financial statements, appearing in Part II of Item 8 of this Annual Report on Form 10-K.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Internal Controls over Financial Reporting</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the preparation of our consolidated financial statements for the year ended December 31, 2020, we identified material weaknesses in our internal control over financial reporting, two of which remain unremediated as of December 31, 2025. The material weaknesses, and our remediation plan, are disclosed in Part II of Item 9A of this Annual Report on Form 10-K.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Emerging Growth Company Status</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are an emerging growth company, as defined in the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued after the enactment of the JOBS Act until those standards apply to private companies. Other exemptions and reduced reporting requirements under the JOBS Act for emerging growth companies include presentation of only two years audited consolidated financial statements in a registration statement for an IPO, an exemption from the requirement to provide an auditor&#8217;s report on internal controls over financial reporting pursuant to the Sarbanes-Oxley Act, an exemption from any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation, and less extensive disclosure about our executive compensation arrangements. We have elected to use the extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that (i) we are no longer an emerging growth company or (ii) we affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. We will cease to be an emerging growth company on December 31, 2026.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7a_quantitative_and_qualitative"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">m 7A. Quantitative and Qualitative Disclosures About Market Risk.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a smaller reporting company, we are not required to provide the information requested by this item pursuant to Item 305(e) of Regulation S-K.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">110</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;" id="item_8_financial_statements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">m 8. Financial Statements and Supplementary Data.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:93%;box-sizing:content-box;"/>
     <td style="width:7%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Page</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#opinion"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Report of Independent Registered Public Accounting Firm (PCAOB ID </span><span><ix:nonNumeric id="F_1d565ce3-0d42-42d7-8d72-793d791c4792" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="dei:AuditorFirmId"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">238</span></ix:nonNumeric></span><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">)</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">112</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Balance Sheets</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">113</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_state_of_oper_and_comp_loss"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Operations and Comprehensive Loss</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">114</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consoli_state_of_prefe_stock_and_deficit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Stockholders&#8217; Equity</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">115</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_of_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Cash Flows</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">116</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_to_consolidated_financial_statemen"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">117</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">111</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="opinion"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the Board of Directors and Stockholders of Climb Bio, Inc.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a235792f-7105-4432-b178-af69a11e4bc0" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="dei:AuditorOpinionTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Opinion on the Financial Statements</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Climb Bio, Inc. and its subsidiaries (the &#8220;Company&#8221;) as of December 31, 2025 and 2024, and the related consolidated statements of operations and comprehensive loss, of stockholders&#8217; equity and of cash flows for the years then ended, including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis for Opinion</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_71a08637-cc59-4a86-b6e7-cba74f21b893" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="dei:AuditorName"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PricewaterhouseCoopers LLP</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9d311eb9-2d22-4a7f-9ece-531cb4e982f9" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="dei:AuditorLocation"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Seattle, Washington</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 5, 2026</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have served as the Company&#8217;s auditor since 2021.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">112</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Climb Bio, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_balance_sheets"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated B</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">alance Sheets</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(In thousands, except share and per share amounts)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:69.714%;box-sizing:content-box;"/>
     <td style="width:2.3%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.842%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:2.3%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.842%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current assets:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_51f2263d-068d-48e7-bcca-c81905f8fa6d" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,685</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b82cc5d1-c500-4400-b7c5-fb4ff384e920" contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">87,229</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term marketable securities</span></p></td>
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6dadc4b3-c8f1-4b28-ab1c-96e8c5755083" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">65,395</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c7e69392-5df4-461b-bfd5-1f93feecbca3" contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,690</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4b4b88a-d7d3-493c-870e-6ec3b8a65faf" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,769</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_faf020b4-0623-4776-8a38-60fa47fe8a5b" contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,953</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current assets</span></p></td>
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca5a3b2a-90a7-4232-88d9-aa3eb8ec21df" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">105,849</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_149401bb-7dff-4cab-b836-be11b8643cbf" contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">154,872</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Long-term marketable securities</span></p></td>
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f344c39f-4ef1-4012-b4a7-addad690ff41" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:MarketableSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59,572</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c49727a-5a78-4d5b-8d19-fd0654124eb1" contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e" name="us-gaap:MarketableSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,610</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_59fc71ae-2184-4b4d-b7e7-b38c12005a84" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">505</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fff33242-a012-4b9f-b45b-3cbc19d1647b" contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">490</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f65553d1-e98e-44a6-a83e-a2adfe7ecbaa" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">288</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a1c1c717-4f9e-4473-8c89-2eb9197776f6" contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">199</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other long-term assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f80d363f-f811-4717-b65d-bcd41c292897" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,530</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eedf356f-745d-48d8-ba92-3177cfff2da3" contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ab70e26-218d-44d7-a120-4297113220cf" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">167,744</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a6e20038-4f3d-4866-aa1d-634de421bb92" contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">217,187</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Liabilities and Stockholders&#8217; Equity</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current liabilities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cdd9f1ee-2ea9-4094-b780-c71930734fb2" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,269</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4787c469-7be2-4dbf-beaf-375329eef263" contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">705</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e53613a2-9eda-4a1b-8bae-fc61f583b9dc" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,459</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a39a805a-bb9d-44c5-800e-e4acf6e513ad" contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,069</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities</span></p></td>
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ab88fea-7bdf-4a51-a40d-1d225f54ffe2" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">256</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a68a18db-1d17-40bb-9deb-beb392cc79ea" contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">157</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current liabilities</span></p></td>
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_14efe678-d23e-40ad-b73a-9aeb683b8cf4" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,984</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_21855285-dfd2-4e98-a450-76886af681ee" contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,931</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities, net of current portion</span></p></td>
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_941e5c41-dd6f-4647-9459-b2a8cd91c92d" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">285</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5461f45f-4c4a-4895-8c14-c48a1538c712" contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">375</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:5.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities</span></p></td>
     <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:5.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a3d80ea4-61eb-4c91-a626-a580a071cdc9" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,269</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34ed4006-8a82-46a3-b58c-03f37ae3c474" contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,306</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_6e9c1843-16ca-4b62-af29-4ec50ad49bc2;"><span style="-sec-ix-hidden:F_1a7d6320-c589-4343-9bdf-6398fa567414;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commitments and contingencies (Note 8</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stockholders&#8217; equity:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock, $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c28957af-8b14-41e9-8d53-5c97b990ce36" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_USDollarShare" scale="0" decimals="4"><ix:nonFraction id="F_bb1e8afc-ec3d-4915-89c4-5f5755528622" contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_USDollarShare" scale="0" decimals="4">0.0001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;par value; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f450f74-d0a0-46c6-b7d5-c8ec560e0f38" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_c55a433f-5c6b-47b4-bd51-633bd1165c40" contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">250,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares authorized; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ac3c955-ae2f-4554-a18c-c8ee78b13f31" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_b43527f0-6ae1-4631-bc7e-7abd3f427299" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">47,766,338</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br/>&#160;&#160;and </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ec880b2-7ee1-4550-802d-9faab7edbffe" contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_0d2e4576-8861-4b1e-b74f-83f591a24203" contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">67,255,434</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares issued and outstanding at December 31, 2025 and<br/>&#160;&#160;2024, respectively</span></p></td>
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_68216a99-5ceb-4cb0-a790-a06d1e2924ee" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_522e8012-f1e5-45e6-b87e-664c69e0ec07" contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additional paid-in capital</span></p></td>
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7e10db51-295c-45f2-b1eb-ba13638e2663" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">449,762</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6717ea91-d192-4fd6-b8d0-c249dd4f4ae6" contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">441,727</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated other comprehensive income</span></p></td>
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_06a20337-f033-4ad0-a6c3-b76664ec9dde" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">435</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95eddd25-81bc-4d46-8fb8-2d37692a20b8" contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated deficit</span></p></td>
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e4402734-63e5-4388-9955-bbf4d6c754b4" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">289,727</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7388c61-2f24-4f41-9dbc-3e34352c8ceb" contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">229,876</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stockholders&#8217; equity</span></p></td>
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aef6ba98-cf8e-42a3-af6f-ef28240fa22d" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">160,475</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a3295770-ad66-4e40-b00d-815508ca8170" contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">211,881</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities and stockholders&#8217; equity</span></p></td>
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_676cdfb9-bf88-4c6d-8e20-5e9575835576" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">167,744</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c5c7378b-7fdf-4cd3-9fa0-cb78ba5d0100" contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">217,187</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">113</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Climb Bio, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_state_of_oper_and_comp_loss"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Statements of Ope</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rations and Comprehensive Loss</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(In thousands, except share and per share amounts)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:64.72%;box-sizing:content-box;"/>
     <td style="width:1.84%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:13.8%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.84%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:13.8%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_04a6f76a-888c-449b-8e6c-670011026f45" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,713</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_77069f6f-fff7-49e0-9623-102080a3e3ea" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,336</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Acquired in-process research and development, related party</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_30c66287-2250-43bf-8e2e-e07d2f820faf" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="clym:AcquiredInProcessResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41668d27-f9d0-42bf-b234-530457929a53" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="clym:AcquiredInProcessResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">51,659</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_82a679f8-81ed-4a70-a2cf-b10ad3d08496" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,170</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_26b64c1c-ac60-4bde-921b-2d2d2db2e09b" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,025</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce0d849e-161b-448d-975c-2a109ae26cb9" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">67,883</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1ccf37d-6a1c-45d1-83c1-6c3efd687553" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,020</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_28818bfd-69d5-4e45-b830-3f6a4fb1f232" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">67,883</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b631ed8e-e7d2-41cf-bbfc-33b92bba7b6a" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">82,020</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income (expense):</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_436b5892-9ced-4d44-ae00-a4b5fd372a28" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,323</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a7ccf149-7e5a-4ee7-aa60-c112c8c244e2" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,132</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign currency loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_81a15814-e08e-4474-9413-1fc45dba8c43" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">291</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_49cff15f-7bc4-4e69-9a54-176e0862a708" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other income, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de6c206e-9f8a-4d70-bbee-26f95fd7d62f" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,032</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ff7b890-cd4d-40b0-8918-63eef085ad10" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,123</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_53acd088-5b29-4892-a229-8c406fd773b5" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">59,851</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6cc374f0-dacc-40cf-9327-0a9d06260f71" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">73,897</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c51c63e-e2f9-414a-bc66-d9bf6e70bd39" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_d3b6721b-2748-4f0b-9978-0c86fc7a4558" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.88</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af596a67-92fa-4276-a6d1-da7333f408fb" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_944c0e0b-f9a5-4388-b8c2-01b7502d775c" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.53</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average common shares outstanding, basic and diluted</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1afddb10-4895-4c07-976b-771c453b0ea8" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_4c3d007f-69e7-420a-891a-44a849d62f57" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">67,812,145</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e6747fd-74dd-406a-9f7e-fe3b5854428a" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_312707ad-8c98-455a-89f7-b529f84f99be" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">48,163,301</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Comprehensive loss:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9caee71a-e34a-4afa-9066-1d01961fa4eb" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">59,851</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_836a3b72-c09c-41fb-812b-03896b6f3464" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">73,897</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive income:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized gain on marketable securities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ada2c2c-7411-4bfc-a0cb-035e208090e7" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">412</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95d3837a-d13b-406d-bbf2-dcdd6203dded" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Comprehensive loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2a6be381-5d0e-41f8-abfa-cb26166799f5" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">59,439</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7abd867c-04fc-4ee9-84c2-80d5423867d3" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">73,872</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">114</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Climb Bio, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consoli_state_of_prefe_stock_and_deficit"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Statements of</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Stockholders&#8217; Equity</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(In thousands, except share amounts)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:33.933%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8.238%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.18%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6.339%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.18%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.758%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.18%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8.878%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.18%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.758%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.18%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8.198%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Additional</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Other</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common Stock</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Paid-in</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Comprehensive</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Stockholders&#8217;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Capital</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Income (Loss)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deficit</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equity</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balances at December 31, 2023</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34bc079a-c41d-4d01-84b0-4fa74ae91ed7" contextRef="C_6566157b-2549-4f25-ab16-6ff8b45c4d64" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">27,626,435</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_385701dc-7b26-4002-b494-175aaa229bb9" contextRef="C_6566157b-2549-4f25-ab16-6ff8b45c4d64" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ccd06060-2e82-41ef-8d9f-3df4da16f2a4" contextRef="C_7c0e8a73-22f5-429f-9ff0-a34f09540718" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">263,577</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b0e44a6-7b27-444c-a908-4a827592204b" contextRef="C_98544ab6-691e-467e-be62-d270667fdc07" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_58ae6ed4-83b1-41fa-a346-a0b21c5fa01b" contextRef="C_550b780f-159a-4ee0-bc82-3f2210b1684b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">155,979</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_589b134e-b133-4429-8076-1bf227512c0a" contextRef="C_c2a2497b-98c5-4d07-ac31-0ab57e9c6f6a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">107,599</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vesting of restricted stock awards and units</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c659bc0c-885b-4cad-8ee7-9b21bb070815" contextRef="C_11bb4c97-86dc-433d-8f9f-b1671660f359" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">154,599</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock upon exercise of <br/>&#160;&#160;&#160;stock options</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a4451480-a335-4cd7-80f6-77c603379c99" contextRef="C_11bb4c97-86dc-433d-8f9f-b1671660f359" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,676,071</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae30ad78-f876-4a04-87df-d26c5ac56c7d" contextRef="C_a9d1e150-d582-4292-80b0-a0a5033ea1b3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,979</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_08875668-1a8a-4d31-a522-4a0e2377e35b" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,979</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">Issuance of common stock in private placement, net of <br/>&#160;&#160;&#160;issuance cost of $</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_474e390d-53c0-491e-b3cf-b30f6dce632a" contextRef="C_e2570053-78b9-4413-a875-a4e14bf5d7a4" name="us-gaap:NoninterestExpenseOfferingCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">250</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dbd5febb-eced-4eec-8749-80547f054fe5" contextRef="C_deced632-72c6-45c5-a3ca-d77bd56f0dad" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">31,238,282</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9fb42b38-49b4-4a60-aa7d-ef8751a9910e" contextRef="C_deced632-72c6-45c5-a3ca-d77bd56f0dad" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_beb767ef-07aa-419a-bac9-b9281f993086" contextRef="C_79c45355-4ab4-4e2a-a1e5-2f20b0546a60" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">119,747</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d701a922-8624-4137-8d82-0c68f6dda858" contextRef="C_b0c73b5f-de7f-4ef4-87ec-0e261c6ff876" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">119,750</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock for the acquisition of <br/>&#160;&#160;&#160;in-process research and development from a <br/>&#160;&#160;&#160;related party</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e754d34a-1bac-45de-a879-01c4ae7421e0" contextRef="C_ddbb4b04-852b-4f3b-aeb7-aa35ab1cf616" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">5,560,047</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9706074c-731e-438f-805e-136d4b1bc972" contextRef="C_ddbb4b04-852b-4f3b-aeb7-aa35ab1cf616" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_21557e2d-07fd-45b4-bc8b-03618b13b13d" contextRef="C_892c3e10-a60b-4010-9024-013505fca3fd" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,867</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee59fb94-0b5c-4646-9bd8-2debf66f8b2a" contextRef="C_21205dde-2f21-4a5b-878c-9c16723dcb5f" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,868</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3cb96f4c-4572-4faf-afba-17d49cc49811" contextRef="C_a9d1e150-d582-4292-80b0-a0a5033ea1b3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,557</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c7386794-6ae3-4e99-b985-9ac5c71bc6da" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,557</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized gain on marketable securities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b49b6ed-53ff-4f96-8dbd-6dcfb77ca244" contextRef="C_b551ae63-1f55-4c33-bec6-c98569fc1002" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c084f807-2a67-4c7c-b1b3-6b9320995a81" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e976280-a5a9-43be-907b-78343ade0401" contextRef="C_a8e8a23d-3bb9-47c3-9f60-1878b2e54d8c" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">73,897</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c2db32f-5d95-46c8-8c40-e342cb1df4b7" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">73,897</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balances at December 31, 2024</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_430173ca-57da-4a57-8097-94a5792cd8a4" contextRef="C_3657c5eb-d257-42f6-9ce8-e538450d6c16" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">67,255,434</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dbde915a-364f-4541-87c0-d974a0b61469" contextRef="C_3657c5eb-d257-42f6-9ce8-e538450d6c16" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_110ffec6-f986-4ca1-ac29-f591e9a9af59" contextRef="C_0d0169f6-b7e0-49bb-b22e-a0097bdb8aef" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">441,727</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_031afdb8-1a1d-4d5f-a7aa-6f7b1f280229" contextRef="C_746a74d7-c8f6-4d27-bf0b-6d5329bfce92" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f99220d-3539-4bde-bf25-74e6ffcc939a" contextRef="C_9d3703f0-77df-42a1-9ca1-0e2e95db2565" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">229,876</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b6edee4a-94e4-4673-b0e5-837801536d6a" contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">211,881</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vesting of restricted stock units</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e85dde4-b13b-454b-812e-8e0f000a6bf2" contextRef="C_e56178b2-2c10-48d7-b80d-784d82a747b6" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">929,563</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock upon exercise of <br/>&#160;&#160;&#160;stock options</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0938392c-3e27-4a68-84dc-90153457b6c0" contextRef="C_e56178b2-2c10-48d7-b80d-784d82a747b6" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">21,341</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_12cf910d-31cb-44ae-b465-d48249c31c75" contextRef="C_122e88aa-833d-49ea-931c-cdd318154ed2" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">65</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7ba0db2-ca86-47de-98b5-4190b2698722" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">65</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">Exchange of common stock for pre-funded warrant,<br/>&#160;&#160;&#160;net of issuance costs of $</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_782f017a-f24d-4c71-93fc-fa8016154ff0" contextRef="C_1f63916b-0391-41c4-8463-6860486b9487" name="us-gaap:NoninterestExpenseOfferingCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">86</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0880d4b6-9286-4332-8c48-b4274dcd755b" contextRef="C_e56178b2-2c10-48d7-b80d-784d82a747b6" name="clym:SharesExchangedForPreFundedWarrants" unitRef="U_shares" decimals="0" sign="-" format="ixt:num-dot-decimal">20,440,000</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_27110df4-d4d3-4170-8bd7-1049000a00bd" contextRef="C_e56178b2-2c10-48d7-b80d-784d82a747b6" name="clym:SharesExchangedForPreFundedWarrantsValue" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f6dcf7d4-7059-4543-be89-77af2b0bba86" contextRef="C_122e88aa-833d-49ea-931c-cdd318154ed2" name="clym:SharesExchangedForPreFundedWarrantsValue" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">84</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eca749e9-e0b1-4b0c-a283-4968b97813f3" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="clym:SharesExchangedForPreFundedWarrantsValue" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">86</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_560fc9ce-f323-42ac-9a3b-282664a376dc" contextRef="C_122e88aa-833d-49ea-931c-cdd318154ed2" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,054</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d84d89bc-ec64-4b89-94d1-982dfa1852f9" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,054</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized gain on marketable securities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b5a2f52f-d215-4cc4-b35c-375a4b96071f" contextRef="C_3d75d312-973d-41a8-a6dc-96c192554cdc" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">412</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_320c3172-c65b-45ea-b27f-c3077a20193b" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">412</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34128aa9-ff30-49c5-ae10-af39f62da0bc" contextRef="C_26331409-5c32-4037-8326-ec8e383f9fff" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">59,851</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fdee6bb1-3d7b-472b-bba4-417d7e08c1e6" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">59,851</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balances at December 31, 2025</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ccace5e8-0bf9-4ef1-8034-f1c435a5f70d" contextRef="C_d015dd5d-fe12-4337-9262-398335ac7a9b" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">47,766,338</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_96903683-3697-487e-899b-1da630425b48" contextRef="C_d015dd5d-fe12-4337-9262-398335ac7a9b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_82f7bcc2-df97-4244-b978-b2e487af0c2f" contextRef="C_4b99e9a3-7e4b-4844-b231-419f9b1fc292" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">449,762</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a85c465-2f24-4561-a9da-bb89e1064e1c" contextRef="C_3a31c020-0ff0-49fa-b2ef-a1848d998afe" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">435</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_80b150ed-c8fc-446c-b35e-390887806c10" contextRef="C_691140a1-fa6d-479a-bd61-6df4cc2c5e1a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">289,727</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ca4912e-76ec-49a7-a12e-94d57f6ed8c7" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">160,475</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">115</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Climb Bio, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_of_cash_flows"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated State</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ments of Cash Flows</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(In thousands)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:67.4%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.98%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.64%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.98%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from operating activities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ae1fb87-4b35-42ff-b9ca-23f98a819dff" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">59,851</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4aa1c278-a85e-4922-8291-ded715540642" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">73,897</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb954c51-5daa-45a9-864f-08391282ad0b" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,054</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1e5b052-3da8-44a7-af64-07504ba6f8bf" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,557</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-cash operating lease expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_566598ea-05e0-4a36-a615-5f84201aac0e" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">201</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f693eef-e315-4b08-bf3f-e46717c2b3f6" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">220</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accretion of discounts on marketable securities, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_42c1a929-e90a-4de3-aadb-649eabf724c1" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,274</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba9307a5-e819-4c37-a02d-25b7056442c9" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">757</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation and amortization expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d597f09-531d-42ef-90e0-e1abbedeecfb" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">97</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e42efcc2-e504-4237-989f-9c4f0f53d80f" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">In-process research and development, related party</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_58084c58-9735-48bf-b4a7-314cc88ee120" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="clym:AcquiredInProcessResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_59a153bc-d1e7-4059-b8ad-7416650c7f88" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="clym:AcquiredInProcessResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">51,659</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized foreign currency transaction (gain) loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34d634eb-6162-43e1-b63b-be3b64af6711" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">18</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87f49326-b4e5-42a3-affe-fc3618c1708f" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:15pt;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b7679b56-e5bc-44f3-ae78-cfca01697f25" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">816</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_28298fd0-9aff-4576-9d96-936305f282f6" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,942</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other long-term assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a690678-3789-478f-8b35-22a4dbd5dc4b" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,514</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_21b7e3e5-8d41-495b-94ff-24e2f2f6f34d" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">200</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_94f54e1e-93dd-4d28-bdfa-c97b7e100d94" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,564</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d89dcff-fa63-47f5-b03d-3e50fa742d3c" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">963</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable and accrued liabilities, related party</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2742d40f-1774-4618-8f4b-ee00418bac54" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="clym:IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedparties" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d97f86a-4734-4aaf-a1b0-730d37494845" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="clym:IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedparties" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">177</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a9c186e-0fcd-49d8-ac8e-e89121af1987" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">372</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f677223-6bee-4216-bb1b-90f4550364c9" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,445</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_130251c1-235a-45da-abda-710e85d7aafa" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">207</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b3fdea2-4e81-4131-989c-16dbfc3881bd" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">327</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Long-term liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa4afab6-8f2f-43ec-94a5-2e709628580a" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3bc10223-b848-473e-bbae-2f2853b73551" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">22</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:25pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:4.627%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in operating activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3049cf3c-369d-43bc-a7cf-dbbb8d64191a" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">54,356</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_63e4fbeb-771c-4354-82b4-f103369b6a46" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">15,562</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from investing activities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of property and equipment</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f869c928-7fd4-4b17-b0b2-d64824ecc8e0" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">186</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cee6a6ad-608c-4c7f-ada0-92cfc47a9871" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of marketable securities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd84721d-bcfc-4c9d-8416-655a633c348d" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">108,078</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_209196d7-ba22-4fdb-b637-dabd65ebc78b" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">132,197</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Maturities of marketable securities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8828a1e7-ab55-461e-aa53-b37ffaaf9575" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">111,097</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92c4a8aa-c797-4b1b-a6e1-5f3e6b49d74b" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,750</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of promissory loan in connection with asset acquisition</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_71bac7ee-a6cc-4e81-aad7-337637390aa6" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="clym:IssuanceOfPromissoryLoanInConnectionWithAssetsAcquisition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_344f69a6-28b0-4b6c-b06d-78b7276ca9c3" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="clym:IssuanceOfPromissoryLoanInConnectionWithAssetsAcquisition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,000</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid in connection with asset acquisition, net of cash received</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bc951d62-e62a-4085-903a-e878953dfaca" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_833810a5-e3d7-4be4-a882-e8510f5118cb" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,645</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:25pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:4.627%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by (used in) investing activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a369325-c2d8-473b-b73a-7f1f624c44ab" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,833</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0752913a-4a64-4b20-a07d-c9495987ade3" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">121,092</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from financing activities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from exercise of stock options</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b5504c4c-5aaf-4784-9477-a7eaf30a3f63" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">65</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_51cd9221-7860-44db-8667-dcac668e46ff" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,979</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pre-funded warrant issuance costs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4218354e-7794-4b5a-b025-054fc0ee70c2" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">86</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_53fea17c-df60-4785-9143-78cf7a5214f0" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from issuance of common stock in private placement, net of issuance costs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eed0b69e-24af-4632-bb10-6e965c97a33b" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a80e4ee1-4df5-4d29-9b14-d9b5dbe8801a" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">119,750</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:25pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:4.627%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by (used in) financing activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_43114343-2706-4f7d-b859-656ba953a8bd" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">21</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_be40e8c8-abb2-4cfb-903c-261da82b124c" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">130,729</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effect of exchange rate changes on cash and cash equivalents</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f50cbe4a-4cfc-4a8a-9c80-b8dd8148ee62" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_37089460-1e15-4f65-82bd-37a3cb4597c0" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net change in cash and cash equivalents</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0582bcee-764f-4ba5-8626-798339e6e0e5" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">51,544</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6aaf865d-5315-400c-a97d-99feb7b7255a" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,883</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents at beginning of period</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85618ce4-3db9-4330-ab69-b71efe09dbd5" contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">87,229</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0bdd4570-6efb-4b2f-99da-685101f98976" contextRef="C_c2a2497b-98c5-4d07-ac31-0ab57e9c6f6a" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">93,112</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents at end of period</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ba056aa-7675-4bb5-b4af-fd7b4b634dba" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,685</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd91ca69-2050-457a-ad9b-04db031da80f" contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">87,229</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Supplemental disclosure of noncash investing and financing activities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock in exchange for in-process research and development</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c7c031dc-7ab3-457a-bb09-5959eed1b506" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="clym:CommonStockIssuedInExchangeForIn-ProcessResearchAndDevelopmentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d1f31b8c-8de8-40ab-b6a9-1b21ec30128a" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="clym:CommonStockIssuedInExchangeForIn-ProcessResearchAndDevelopmentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,867</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Settlement of promissory loan in connection with asset acquisition</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f062108-5619-4dc0-9da2-08e06517f54d" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="clym:AmountOfPromissoryLoanSettledInConnectionWithAnAssetAcquisition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_754fb854-22d5-4e64-b8ff-8677067df23c" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="clym:AmountOfPromissoryLoanSettledInConnectionWithAnAssetAcquisition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,036</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">116</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CLIMB BIO, INC</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="notes_to_consolidated_financial_statemen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATE</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">D FINANCIAL STATEMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_b1b28963-ecc0-4130-928b-7f7960109f8d" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" escape="true" continuedAt="F_b1b28963-ecc0-4130-928b-7f7960109f8d_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 1. Nature of Operations and Basis of Presentation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Organization</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Climb Bio, Inc. (the Company), is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company&#8217;s pipeline includes budoprutug and CLYM116. Budoprutug is an anti-CD19 monoclonal antibody designed to treat a broad range of B-cell mediated diseases. The Company is currently developing budoprutug for the treatment of primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus. CLYM116 is an anti-APRIL (A Proliferation-Inducing Ligand) monoclonal antibody currently being developed for the treatment of immunoglobulin A nephropathy. The Company was incorporated on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9a0b9f1d-e148-4365-b54d-dd58fd2eaa26" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="dei:EntityIncorporationDateOfIncorporation" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 18, 2018</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in Delaware, and its corporate headquarters is in Massachusetts.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 27, 2024, the Company completed its acquisition of Tenet Medicines, Inc. (the Acquisition). In connection with the closing of the Acquisition, the Company issued and sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fcd6a570-80f8-4bad-9933-3a31a01a6c44" contextRef="C_dcc85fc3-485a-42b9-b4a7-8f1dd16319b6" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">31,238,282</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01453f02-8b66-42b3-84f6-ece155ec9a1e" contextRef="C_3893b746-214f-47a9-ab19-782719fe3a18" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.84</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share in a private placement to several accredited institutional investors (the Private Placement). The Company received aggregate gross proceeds from the Private Placement of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cf0eeff8-82d6-41d3-b567-961a7c9825bb" contextRef="C_dcc85fc3-485a-42b9-b4a7-8f1dd16319b6" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">120.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, before deducting offering costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8723a503-9252-401a-8769-f928a0c8bd87" contextRef="C_dcc85fc3-485a-42b9-b4a7-8f1dd16319b6" name="us-gaap:NoninterestExpenseOfferingCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (see Note 3). </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 8, 2025, the Company entered into a technology transfer and exclusive license agreement (the Mabworks Agreement) with Beijing Mabworks Biotech Co., Ltd. (Mabworks), for rights to develop and commercialize CLYM116 for all indications worldwide outside of mainland China, Hong Kong, Macau, and Taiwan (Greater China) (see Note 8).</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_7b6675d6-7c6f-4404-ae12-3f6f1341293d" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:RisksAndUncertaintiesInEntitysBusiness" continuedAt="F_7b6675d6-7c6f-4404-ae12-3f6f1341293d_1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risks and Uncertainties</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_7b6675d6-7c6f-4404-ae12-3f6f1341293d_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, reliance on single-source suppliers and manufacturers, availability of raw materials, patentability of the Company&#8217;s product candidates and processes and clinical efficacy and safety of the Company&#8217;s product candidates, compliance with government regulations and the need to obtain additional financing to fund operations. Budoprutug, CLYM116, or any product candidate the Company may develop will require significant additional research and development efforts, including extensive nonclinical studies, clinical trials, and regulatory approval, prior to commercialization. These efforts will require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance and reporting.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There can be no assurance that any future research and development will be successfully completed, that adequate protection for the Company&#8217;s intellectual property will be obtained or maintained, that any product candidate developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if any future product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales. The Company operates in an environment of rapid technological change and substantial competition from other pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and other third parties.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ebd27b73-a763-4d50-b08e-8cc1edc75823" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true"><ix:nonNumeric id="F_04df00cf-f147-4799-ab28-82c800221b1c" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:ConsolidationPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of Presentation and Principles of Consolidation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (U.S. GAAP). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Update (ASU) of the Financial Accounting Standards Board (FASB).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying consolidated financial statements reflect the operations of the Company and its wholly owned subsidiaries. Intercompany transactions and balances have been eliminated in consolidation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></ix:nonNumeric></div></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">117</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_b1b28963-ecc0-4130-928b-7f7960109f8d_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Liquidity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since inception, the Company has experienced recurring losses from operations and generated negative cash flows from operations. The Company has an accumulated deficit of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f29225b9-4d1a-4225-969e-0a02942e67be" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">289.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of December 31, 2025 and expects to incur additional losses from operations in the future. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2025, the Company entered into an Equity Distribution Agreement (the Distribution Agreement) with Oppenheimer &amp; Co. Inc., as agent (Oppenheimer), pursuant to which the Company may offer and sell shares of its common stock from time to time through Oppenheimer having an aggregate offering price of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_86646a05-e1a4-4c79-9a59-2c35de076108" contextRef="C_5e29120a-ab8d-4722-9dfa-39d97775d181" name="clym:AggregateGrossSalesProceedsUnderSalesAgreements" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">22.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in an at the market offering. During the year ended December 31</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, 2025, the Company did not issue and sell any shares of its common stock pursuant to the Distribution Agreement.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company believes its available cash, cash equivalents and marketable securities of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_183414dc-c0f1-43bd-aa0b-510df55911ac" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">160.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of December 31, 2025 will be sufficient to meet its projected operating requirements for at least the next twelve months from the filing date of these consolidated financial statements, and the Company anticipates that it will need to raise substantial financing in the future to fund its operations. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company may finance future cash needs through the sale of equity, debt financings or other capital sources, which could include income from collaborations, strategic partnerships or other strategic arrangements. There are no assurances that the Company will be able to raise sufficient amounts of funding in the future on acceptable terms, or at all.</span></p></ix:continuation></div><div><ix:nonNumeric id="F_61a5b8dc-7bad-4cda-9db2-df006e36f260" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true" continuedAt="F_61a5b8dc-7bad-4cda-9db2-df006e36f260_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 2. Summary of Significant Accounting Policies</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (JOBS Act). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued after the enactment of the JOBS Act until those standards apply to private companies. The Company has elected to avail itself of this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4767f4c7-8c5a-4435-b294-ec0dfb63869d" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:UseOfEstimates" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts and disclosures. Accordingly, actual results could differ from those estimates. Key management estimates include those related to the accrual of research and development expenses and the valuation of stock-based awards. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b29127bc-265e-46d6-af1f-1628f2c14c69" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Foreign Currency</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s reporting currency is the U.S. dollar. The functional currency of the Company and its subsidiaries is the U.S. dollar. Monetary assets and liabilities resulting from transactions denominated in currencies other than the functional currency are remeasured in the functional currency at exchange rates prevailing at the balance sheet date, and income items and expenses are translated into U.S. dollars at the average exchange rate in effect during the period. Exchange gains and losses resulting from remeasurement and foreign currency transactions are included in the determination of net loss.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a2997997-3826-402a-90e0-20098e5cb9e0" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Information</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. Significantly all of the Company&#8217;s tangible assets are held in the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_22b3023b-1ff8-4f4e-90c6-a4d7bbfe4ec1" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:ConcentrationRiskCreditRisk" escape="true" continuedAt="F_22b3023b-1ff8-4f4e-90c6-a4d7bbfe4ec1_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Concentration of Credit Risk </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">and Significant Suppliers and Manufacturers</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company maintains its cash and cash equivalents at accredited financial institutions that may, at times, exceed federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company&#8217;s investments in money market funds and marketable securities are held in segregated accounts at a third-party custodian. The Company has established guidelines relative to credit ratings and maturities intended to safeguard principal balances and maintain liquidity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">118</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_61a5b8dc-7bad-4cda-9db2-df006e36f260_1" continuedAt="F_61a5b8dc-7bad-4cda-9db2-df006e36f260_2"><div><ix:continuation id="F_22b3023b-1ff8-4f4e-90c6-a4d7bbfe4ec1_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is dependent on third-party suppliers and manufacturers for material used in its nonclinical and clinical development activities. In particular, the Company relies and expects to continue to rely on single-source suppliers and manufacturers to supply it with certain critical materials related to the Company&#8217;s product candidates. The Company&#8217;s development efforts could be adversely affected if a supplier or manufacturer is unable to successfully carry out its contractual obligations or meet expected deadlines. If a supplier or manufacturer needs to be replaced, the Company may not be able to complete its product development on its anticipated timelines and may incur additional expenses as a result.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c41b61e3-e05c-4918-b04e-a58f82e99a2c" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company considers all highly liquid investments with maturities of three months or less from the purchase date to be cash equivalents.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_79364581-83be-42a3-b4e4-833e40d8f5bf" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:MarketableSecuritiesPolicy" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Marketable Securities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company classifies its marketable securities as available-for-sale. Marketable securities with remaining maturities of less than one year from the balance sheet date are classified as short-term marketable securities. Marketable securities with remaining maturities of greater than one year from the balance sheet date are classified as long-term marketable securities. The Company reports available-for-sale investments at fair value as of each balance sheet date and records unrealized gains or losses as a component of stockholders&#8217; equity in accumulated other comprehensive income (loss). Realized gains and losses of securities sold are determined on a specific identification basis and included in other income (expense) within the consolidated statements of operations and comprehensive loss.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When the fair value is below the amortized cost of a marketable security, the Company estimates the portion of the unrealized loss that relates to credit</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The credit-related impairment amount is recorded in other income (expense) in the consolidated statements of operations and comprehensive loss. Credit losses are recognized through the use of an allowance for credit losses account in the consolidated balance sheet and subsequent improvements in expected credit losses are recorded as a reversal of an amount in the allowance account. If the Company intends to sell the security or it is more likely than not that the Company will be required to sell the security prior to recovery of its amortized cost basis, then the allowance for the credit loss, if any, is written-off and the excess of the amortized cost basis of the asset over its fair value is recognized in other income (expense) in the consolidated statements of operations and comprehensive loss. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4169682a-fd33-4098-a5b5-50e2033e49bd" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_ff6d0913-6a7f-49bc-ba47-010e9cb99563" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> credit losses recorded during the years ended December 31, 2025 and 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_867fde65-3b04-48de-b010-7b03b0f9da6b" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1&#8212;Quoted prices in active markets for identical assets or liabilities. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2&#8212;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. </span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s cash equivalents and marketable securities are carried at fair value, determined according to the fair value hierarchy (see Note 4). The carrying values of the Company&#8217;s accounts payable and accrued expenses approximate their fair values due to the short-term nature of these liabilities.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dbd03d7c-1015-48e6-86d2-d16820a44d4b" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comprehensive Loss</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprehensive loss includes net loss as well as other changes in stockholders&#8217; equity that result from transactions and economic events other than those with stockholders. The Company&#8217;s only element of other comprehensive income (loss) is unrealized gains and losses on available-for-sale marketable securities.</span></p></ix:nonNumeric></div></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">119</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_61a5b8dc-7bad-4cda-9db2-df006e36f260_2" continuedAt="F_61a5b8dc-7bad-4cda-9db2-df006e36f260_3"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1a621bb2-6c46-431b-be45-7e84ae7de60e" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:BusinessCombinationsPolicy" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Asset Acquisitions</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In determining whether an acquisition of assets and related liabilities should be accounted for as a business combination or asset acquisition, the Company first determines whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets. If this is the case, the single identifiable asset or the group of similar assets is not deemed to be a business and the acquisition is accounted for as an asset acquisition. If this is not the case, the Company then further evaluates whether the acquisition includes, at a minimum, an input and a substantive process that together significantly contribute to the ability to create outputs. If so, the Company concludes that the acquisition is a business and accounts for it as a business combination.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the asset or group of assets, which includes transaction costs, allocated on a relative fair value basis. Goodwill is not recognized in asset acquisitions. In an asset acquisition, the cost allocated to acquire in-process research and development (IPR&amp;D) with no alternative future use is charged to expense at the acquisition date.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4a6a3a84-9ecd-4b8c-81b4-65706a640219" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property and Equipment</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_125c0bb5-20da-499c-af55-d842b9505db5" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="clym:ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" escape="true"><p style="margin-left:0.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;margin-right:0.13%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful life of each asset.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
         <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
          <tr style="visibility:collapse;">
           <td style="width:59.18%;box-sizing:content-box;"/>
           <td style="width:2.88%;box-sizing:content-box;"/>
           <td style="width:37.94%;box-sizing:content-box;"/>
          </tr>
          <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated Useful Life</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
           <td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_b304f535-cc08-4941-ac41-e489df697109" contextRef="C_bed1b934-9767-4736-8d75-5898620908e6" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5 </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">years</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
           <td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="-sec-ix-hidden:F_2a7e8018-774a-4c44-8376-7e8c696ec434;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shorter of remaining life of lease or useful life</span></span></span></p></td>
          </tr>
         </table></ix:nonNumeric></div><p style="margin-left:0.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When an item is sold or retired, the costs and related accumulated depreciation are eliminated, and the resulting gain or loss, if any, is credited or charged to operating loss in the consolidated statements of operations and comprehensive loss. Repairs and maintenance costs are expensed as incurred.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ccf85e97-d2a4-44c9-9970-5ac6117c345c" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for leases under ASC Topic 842, Leases (&#8220;ASC 842&#8221;). In accordance with ASC 842, the Company accounts for a contract as a lease when it has the right to control the asset for a period of time while obtaining substantially all of the asset&#8217;s economic benefits. The Company determines if an arrangement is a lease or contains an embedded lease at inception. For arrangements that meet the definition of a lease, the Company determines the initial classification and measurement of its right-of-use asset and lease liability at the lease commencement date and thereafter if modified. The lease term includes any renewal options that the Company is reasonably assured to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its estimated secured incremental borrowing rate for that lease term. The Company&#8217;s policy is to not record leases with an original term of 12 months or less on its consolidated balance sheets and recognizes those lease payments in the income statement on a straight-line basis over the lease term. The Company&#8217;s existing lease is for office space.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to rent, leases may require the Company to pay additional costs, such as utilities, maintenance and other operating costs, which are generally referred to as non-lease components. The Company has elected to not separate lease and non-lease components. Only the fixed costs for lease components and their associated non-lease components are accounted for as a single lease component and recognized as part of a right-of-use asset and lease liability. Rent expense for operating leases is recognized on a straight-line basis over the reasonably assured lease term based on the total lease payments and is included in operating expense in the consolidated statements of operations and comprehensive loss.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4a4a957f-3324-479c-8031-2d00d53ac131" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Long-Lived Assets</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Long-lived assets consist of property and equipment and right-of-use assets.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company reviews the recoverability of its long-lived assets, including the related useful lives, whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset might not be recoverable, based on undiscounted cash flows. If such assets are considered to be impaired, an impairment loss is recognized and is measured as the amount by which the carrying amount of the assets exceed their estimated fair value, which is measured based on the projected discounted future net cash flows arising from the assets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">120</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_61a5b8dc-7bad-4cda-9db2-df006e36f260_3" continuedAt="F_61a5b8dc-7bad-4cda-9db2-df006e36f260_4"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_64974de4-11fe-41df-9473-697355ad1103" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses consist of costs incurred in performing research and development activities, including salaries and bonuses, stock-based compensation, employee benefits, termination benefits, facilities costs and depreciation, and external costs of vendors engaged to conduct research, nonclinical and clinical development activities as well as the cost of acquiring and licensing technology.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upfront payments and milestone payments made for the licensing of technology are expensed as research and development over the period to which they relate. Costs for research and development activities are expensed in the period in which they are incurred. Payments for such activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid expense or accrued research and development expense. Determining the prepaid and accrued balances at the end of any reporting period incorporate certain judgments and estimates by management that are based on information available to the Company including information provided by vendors regarding the progress to completion of specific tasks or costs incurred.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_931bce22-7936-4e94-ba53-95c61bc7ad25" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent costs</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All patent-related costs incurred in connection with filing and prosecuting patent applications are recorded as general and administrative expenses as incurred.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f679130f-2c86-40cc-95b2-55d114362bef" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-Based Compensation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company measures its stock options with service-based vesting or performance-based vesting granted to employees, non-employee directors, consultants and independent advisors based on the estimated fair value on the date of grant using the Black-Scholes option-pricing model. The Company measures compensation expense for restricted common stock units based on the fair value on the date of grant using the market value of the Company&#8217;s common stock. Compensation expense for the awards is recognized over the requisite service period for employees and directors and as services are delivered for consultants and independent advisors, both of which are generally the vesting period of the respective award. The Company uses the straight-line method to record the expense of awards with only service-based vesting conditions. The Company uses the graded-vesting method to record the expense of awards with both service-based and performance-based vesting conditions, commencing once achievement of the performance condition becomes probable. The Company accounts for forfeitures of share-based awards as they occur.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company classifies stock-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#8217;s payroll costs are classified or in which the award recipient&#8217;s service payments are classified.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3e4b7d0a-f826-42cd-b149-1d52c9f68147" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#8217;s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to the provision for income taxes. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. Any resulting unrecognized tax benefits are recorded within the provision for income taxes.</span></p></ix:nonNumeric></div></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">121</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_61a5b8dc-7bad-4cda-9db2-df006e36f260_4"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e63d0b4e-54b1-42e4-a0de-5a07ab6f3a6b" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Loss Per Share</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net loss per share attributable to common stockholders is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net loss per share attributable to common stockholders is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, adjusted for potential dilutive common shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In periods in which the Company reported a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company reported a net loss attributable to common stockholders for the years ended December 31, 2025 and 2024.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6c2c8aff-9e3a-49bd-80b6-287c4dbfc1d0" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Pronouncements Not Yet Adopted</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU No. 2023-09 (ASU 2023-09), </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which requires, among other things, the following for public business entities: (i) enhanced disclosures of specific categories of reconciling items included in the rate reconciliation, as well as additional information for any of these items meeting certain qualitative and quantitative thresholds; (ii) disclosure of the nature, effect and underlying causes of each individual reconciling item disclosed in the rate reconciliation and the judgment used in categorizing them if not otherwise evident; and (iii) enhanced disclosures for income taxes paid, which includes federal, state, and foreign taxes, as well as for individual jurisdictions over a certain quantitative threshold. The amendments in ASU 2023-09 eliminate the requirement to disclose the nature and estimate of the range of the reasonably possible change in unrecognized tax benefits for the 12 months after the balance sheet date. The effective date of this update for non-public companies is for fiscal years beginning after December 15, 2025; early adoption is permitted. The Company expects ASU 2023-09 to require additional disclosures in the notes to its consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03 (ASU 2024-03), </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Disaggregation of Income Statement Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which requires additional disclosures about specific types of expenses included in the expense captions presented on the face of the income statement, as well as disclosures about selling expenses. The provisions of ASU 2024-03 are effective for public business entities for fiscal years beginning after December 15, 2026, and interim periods beginning after December 15, 2027. Early adoption is permitted. The guidance is to be applied prospectively, with the option for retrospective application. The Company is currently evaluating the impact of ASU 2024-03 on its consolidated financial statements.</span></p></ix:nonNumeric></div></ix:continuation></div><div><ix:nonNumeric id="F_b860f17f-94d0-498d-9aa9-c04465d8d3ee" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:AssetAcquisitionTextBlock" escape="true" continuedAt="F_b860f17f-94d0-498d-9aa9-c04465d8d3ee_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 3. Asset Acquisition and Private Placement with a Related Party</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Background</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company entered into (i) an Agreement and Plan of Merger and Reorganization, dated as of April 10, 2024 (the Acquisition Agreement), by and among the Company, Tango Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (Transitory Subsidiary), Tenet Medicines, Inc. (Tenet), a Delaware corporation, and, solely in his capacity as Tenet equityholder representative, Stephen Thomas, providing for the acquisition of Tenet by the Company through the merger of Transitory Subsidiary into Tenet, with Tenet surviving as a wholly owned subsidiary of the Company, (ii) a Securities Purchase Agreement, dated as of April 10, 2024 (the Securities Purchase Agreement), by and among the Company and several accredited institutional investors (the PIPE Investors) including funds affiliated with RA Capital Management, L.P. (RA Capital Management), pursuant to which the Company agreed to issue and sell to the PIPE Investors in the Private Placement an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85fb5591-611c-407f-ae21-6a0670b98f08" contextRef="C_b8dc21c9-0746-48db-ae13-fe4513f56fc2" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">31,238,282</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shar</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">es (the PIPE Shares) of the Company&#8217;s common stock, and (iii) a registration rights agreement with the PIPE Investors, pursuant to which the Company agreed to register for resale the PIPE Shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 27, 2024, the Company completed its acquisition of Tenet in accordance with the terms of the Acquisition Agreement. Tenet was a private, development stage biotechnology company that was majority-owned by funds affiliated with RA Capital Management prior to the closing of the Acquisition. Immediately prior to the closing of the Acquisition and Private Placement, RA Capital Management beneficially owned approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_49355560-fb4a-4b8f-bd3a-1ccafbc1827e" contextRef="C_3764c6b2-4005-4af7-aa82-8f2372cb37f7" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">43.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the Company&#8217;s outstanding common stock. The Private Placement closed immediately following the closing of the Acquisition. The Company received aggregate gross proceeds from the Private Placement of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_807bab24-a6f3-4b8a-8cd5-d3be7d52fefa" contextRef="C_ca2a5c36-84bf-4318-8dcb-1ce0dfebe519" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">120.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, before deducting offering costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e72c7268-79aa-4a64-b538-2d9bce873984" contextRef="C_eb135969-7a37-4398-8643-db443b9da969" name="us-gaap:NoninterestExpenseOfferingCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The offering costs were recorded as a reduction of additional paid-in capital generated in connection with the Private Placement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">122</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_b860f17f-94d0-498d-9aa9-c04465d8d3ee_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the effective time of the Acquisition, by virtue of the Acquisition and without any action on the part of the holders of common stock of Tenet, (i) all issued and outstanding shares of the common stock of Tenet and (ii) all securities convertible into shares of common stock of Tenet were converted into the right to receive, in the aggregate, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a367c2f6-5902-4697-b5ee-2f76fb3754e9" contextRef="C_1cd90362-0202-4f43-82f2-856942e3293d" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,560,047</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Acquisition Accounting</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounted for the Acquisition as an asset acquisition and accordingly, total consideration of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e04a09ee-2f1e-4712-9786-68148451fb29" contextRef="C_1469ea52-2e42-41aa-be6d-28e711fcb465" name="us-gaap:BusinessCombinationConsiderationTransferred1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">52.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, comprised of the fair value of common stock issued of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae0c75ac-3ef0-4504-b464-ce708469db9f" contextRef="C_229c18f8-1124-4b2d-9a29-665a8a728b8d" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">41.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, settlement of pre-existing loan of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b49c576e-5ebd-4add-83c2-a778caf1d814" contextRef="C_29397fb4-e48e-4a21-bd44-1d67c539182e" name="clym:BusinessCombinationConsiderationTransferredSettlementOfPreExistingLoan" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and transaction costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c009d9e-f8fa-458a-89c3-4299f88b27c7" contextRef="C_29397fb4-e48e-4a21-bd44-1d67c539182e" name="us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, was allocated to the assets acquired and liabilities assumed on a relative fair value basis. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7d842f40-c630-4d6b-a67c-15a38cd3b450" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" escape="true" continuedAt="F_7d842f40-c630-4d6b-a67c-15a38cd3b450_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth the allocation of the purchase consideration (in thousands):</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_7d842f40-c630-4d6b-a67c-15a38cd3b450_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:86.24%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.76%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Assets acquired</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;In-process research and development</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c68e14bd-d73e-4d52-96bb-243964ae3bb8" contextRef="C_17e50103-a558-453b-9429-8e636ff6a3b8" name="clym:AmountOfIn-ProcessResearchAndDevelopmentAssetsAcquired" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">51,659</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Cash and cash equivalents</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ebf8de66-ba05-4190-8615-04a2fb2c46b6" contextRef="C_17e50103-a558-453b-9429-8e636ff6a3b8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,204</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Prepaid expenses and other current assets</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_481ca79c-eb2c-48f0-a490-de3cb756fb42" contextRef="C_17e50103-a558-453b-9429-8e636ff6a3b8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,861</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets acquired</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_75865d90-d224-4325-b0b1-81b6ac092b99" contextRef="C_17e50103-a558-453b-9429-8e636ff6a3b8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">54,724</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Liabilities assumed</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Accounts payable</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ddda152-0aa5-416a-af84-ebd6802a163a" contextRef="C_17e50103-a558-453b-9429-8e636ff6a3b8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,603</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Accounts payable, related party</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_181dfea8-b977-4ad5-818d-3257faf0f62c" contextRef="C_12786af0-d6f4-4fe0-aebb-f1db256fd20d" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">101</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Accrued expenses and other current liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a135e603-7a1a-4507-8ba3-480440230016" contextRef="C_17e50103-a558-453b-9429-8e636ff6a3b8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">192</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Accrued expenses, related party</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d4a2cb7b-1c66-4f83-bce5-e833efe6ad4d" contextRef="C_12786af0-d6f4-4fe0-aebb-f1db256fd20d" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities assumed</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_698f1613-87e8-42ea-a412-9cc7da8aadc0" contextRef="C_17e50103-a558-453b-9429-8e636ff6a3b8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,972</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net assets acquired</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_434cefe6-6388-4c53-a4db-dd77d1781c95" contextRef="C_17e50103-a558-453b-9429-8e636ff6a3b8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">52,752</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:continuation></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The value of the IPR&amp;D was expensed in the consolidated statements of operations and comprehensive loss, as the IPR&amp;D was determined to have no future alternative use.</span></p></ix:continuation></div><div><ix:nonNumeric id="F_d8455684-7e36-40a5-b00e-847ae5386931" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" escape="true" continuedAt="F_d8455684-7e36-40a5-b00e-847ae5386931_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 4. Marketable Securities and Fair Value Measurements</span></p><div><ix:nonNumeric id="F_732e261e-b827-4b77-82a7-c912e418aeb6" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" escape="true" continuedAt="F_732e261e-b827-4b77-82a7-c912e418aeb6_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketable securities consisted of available-for-sale securities as follows (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:52.899%;box-sizing:content-box;"/>
         <td style="width:1.879%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:7.897%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.879%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:7.897%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.879%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:7.897%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.879%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:7.897%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8197;&#8197;&#8197;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cost</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gain</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Loss</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term marketable securities:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9b1c7a43-1fa4-416b-8421-7ef3c836ddf7" contextRef="C_bde3f747-62a1-4f1f-a73d-375dcd93e40c" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,874</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_13a33ac4-c398-43c2-bf6b-37c270b5c296" contextRef="C_143ed184-c01f-49b6-be44-844b0eccbf0d" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">102</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a73e8dac-bc18-4580-8db2-05177ac03f3d" contextRef="C_143ed184-c01f-49b6-be44-844b0eccbf0d" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_905229e0-5041-4049-bf94-a73cbbad12a5" contextRef="C_bde3f747-62a1-4f1f-a73d-375dcd93e40c" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,976</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e0fc09a-0754-4b71-ac4c-bb6a9d614076" contextRef="C_5c3cedbc-3847-4e15-a7c4-4fe16652631d" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,296</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f2f6bfeb-84bd-4163-bcc0-1e165f1752b7" contextRef="C_5aa3c816-c0b5-4d5f-9461-9b02539bee4b" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">123</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bed62545-c9fa-4041-8234-cfd3b6de524d" contextRef="C_5aa3c816-c0b5-4d5f-9461-9b02539bee4b" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_790b7ca0-c9e3-4499-9c08-d7ffc9d0a56a" contextRef="C_5c3cedbc-3847-4e15-a7c4-4fe16652631d" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,419</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total short-term marketable securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_db8bc8ca-6d3c-4227-a6ed-198c4eddba3c" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">65,170</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed5d2a51-a457-42bc-9bd1-ef8439d589cc" contextRef="C_a1639fe2-538e-4c2e-8eb6-781b99e56320" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">225</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01f360a7-1886-416e-9b93-a06b712fcb34" contextRef="C_a1639fe2-538e-4c2e-8eb6-781b99e56320" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2fb7d47a-5a57-4d59-b5a8-18b3353ce602" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">65,395</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Long-term marketable securities:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe9fae4a-01e9-40a0-a27c-456590e41864" contextRef="C_bde3f747-62a1-4f1f-a73d-375dcd93e40c" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,341</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3353bc0b-3ae3-46bd-b056-4f0682e6de3b" contextRef="C_826ab126-2f0f-4ee0-80a3-17e4f28432a5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">177</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_47aa720e-aeb6-4306-94d3-b051f97ed80d" contextRef="C_826ab126-2f0f-4ee0-80a3-17e4f28432a5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa04a99a-dfaf-41ba-9894-210dedf7f68b" contextRef="C_bde3f747-62a1-4f1f-a73d-375dcd93e40c" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,518</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_041b7eb9-a6d2-448f-b545-2e8417d70fdc" contextRef="C_5c3cedbc-3847-4e15-a7c4-4fe16652631d" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,022</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_231b1f8c-15de-4ffe-a923-cf17c44645ee" contextRef="C_28105de5-c93d-4001-a309-95d3ba3b4731" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca09e2bc-1d54-40dd-85dd-f1dd84cb34e4" contextRef="C_28105de5-c93d-4001-a309-95d3ba3b4731" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef26cba2-3ca1-4fe2-b453-2b0098d27466" contextRef="C_5c3cedbc-3847-4e15-a7c4-4fe16652631d" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,054</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency debt securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c09dd7fd-b403-4fad-bc5f-3b6b5b22d839" contextRef="C_4886ee1e-e6b0-4ffe-a68d-f50c26f75b4c" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,999</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9fbdf008-f25e-4296-a50c-71b659658e9d" contextRef="C_e15c6a9d-687e-42af-b12a-cad341bda1e1" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_daa5959d-33f3-4832-b9e6-b4bf26db7bfa" contextRef="C_e15c6a9d-687e-42af-b12a-cad341bda1e1" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_671b18c0-fc8b-49c3-9baa-78969575d41b" contextRef="C_4886ee1e-e6b0-4ffe-a68d-f50c26f75b4c" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,000</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total long-term marketable securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_99e4e196-3c45-42ef-bd00-f0b57481091a" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59,362</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5dae0fd1-569d-40d1-9775-926334736489" contextRef="C_d868bdfb-8cf1-4ee9-b1bf-c44bf7490d1f" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">210</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2dae41c0-9ac5-415c-8327-68097dfbf72b" contextRef="C_d868bdfb-8cf1-4ee9-b1bf-c44bf7490d1f" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c48336b2-92f8-44a6-a3fe-3701ae968b9f" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59,572</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">123</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_d8455684-7e36-40a5-b00e-847ae5386931_1"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_732e261e-b827-4b77-82a7-c912e418aeb6_1">
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:52.899%;box-sizing:content-box;"/>
         <td style="width:1.879%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:7.897%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.879%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:7.897%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.879%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:7.897%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.879%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:7.897%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8197;&#8197;&#8197;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cost</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gain</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Loss</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term marketable securities:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_91332e08-b44f-429f-9b9c-ac9199a63f15" contextRef="C_0fbedef7-74ba-4411-abad-f702157bda82" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,519</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_515d984c-8ac1-4a29-a80a-5185cd3759ce" contextRef="C_06ef22a7-6f48-4029-8a4d-33c077e1cac9" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f40a54ef-2aa8-4bba-b6df-533a641fcd27" contextRef="C_06ef22a7-6f48-4029-8a4d-33c077e1cac9" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e219bddd-e3a4-4956-8284-d26d6c94c765" contextRef="C_0fbedef7-74ba-4411-abad-f702157bda82" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,537</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6155b72-6664-40c8-a006-77173f59cdfd" contextRef="C_748a9a3a-36eb-4467-86a9-2986b4bca451" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,130</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_621cd7d3-433c-4643-8bd0-6410dccffaca" contextRef="C_48e4ad5a-7bc4-467d-b65f-6be30cf02804" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b464bf80-8197-45b8-8e71-fbc969e4330c" contextRef="C_48e4ad5a-7bc4-467d-b65f-6be30cf02804" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b91956a4-4235-40f7-97ca-1726f4c09424" contextRef="C_748a9a3a-36eb-4467-86a9-2986b4bca451" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,153</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total short-term marketable securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b695f1a-0c2c-427a-9537-ca68c17b09fd" contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,649</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b661143f-1770-435b-839d-023181db6eba" contextRef="C_67fbe650-9798-4fbe-bbe0-3a6d9e4fd743" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d1d7c4d-359a-460d-b94d-93f82bc11f0d" contextRef="C_67fbe650-9798-4fbe-bbe0-3a6d9e4fd743" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1adc5fe-f1a9-4772-8cfc-dc4e092d69c4" contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,690</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Long-term marketable securities:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c30f6490-184a-4a4e-8edd-68c65dc56ee4" contextRef="C_0fbedef7-74ba-4411-abad-f702157bda82" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,982</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f2c8ed1-195f-42ac-936b-298ddba8ecd2" contextRef="C_ef6867d1-f320-430c-a6a8-a7cce3a87985" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a1b20950-7f63-40a0-8fe1-3f6a86c5555d" contextRef="C_ef6867d1-f320-430c-a6a8-a7cce3a87985" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a745896-b2bb-4dc7-9342-237b4a0ccaef" contextRef="C_0fbedef7-74ba-4411-abad-f702157bda82" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,955</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9249bd4b-add4-4c1a-82b3-4d9157e0f618" contextRef="C_748a9a3a-36eb-4467-86a9-2986b4bca451" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,146</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b29ffb6a-bf48-4613-9c79-3875a7daf89d" contextRef="C_871db5fb-78d1-4c8c-9435-954b2bb1e0b9" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a383c7f0-dd68-4af0-b27b-870c3c73a630" contextRef="C_871db5fb-78d1-4c8c-9435-954b2bb1e0b9" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_71abf1ca-805b-4f81-97c4-3f6842c5a4e5" contextRef="C_748a9a3a-36eb-4467-86a9-2986b4bca451" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,154</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency debt securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4034eb95-6c15-41fe-8261-ae475db315dc" contextRef="C_9919181b-3aee-4458-b7d9-1a4a0eaa9fb2" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,500</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_19f0c08d-3ce8-4a8e-96b5-5bac73ce7dcd" contextRef="C_f497deb3-4bfb-4c8f-9883-3d0724584857" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_08e5c6ab-81be-457b-8c5d-0b8274424c98" contextRef="C_f497deb3-4bfb-4c8f-9883-3d0724584857" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1533c39-c409-4b0c-8fc5-f640d74cd51e" contextRef="C_9919181b-3aee-4458-b7d9-1a4a0eaa9fb2" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,501</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total long-term marketable securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c4dc5eee-5aaa-4249-b2dd-2c8eabfaf2fd" contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,628</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85949dd1-b818-4f2c-867f-db7a6465729e" contextRef="C_132b3bc1-f201-4b4f-9cc1-62f73c6af233" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cbec59fd-fc8d-4400-8f8c-56710b103685" contextRef="C_132b3bc1-f201-4b4f-9cc1-62f73c6af233" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">58</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a1c1fe2-46cb-41c9-89bf-93de11abd87b" contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,610</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:continuation></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, the Company&#8217;s long-term marketable securities have contractual maturity dates between one and two years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4e580162-3b87-4332-9d56-8c12c97cd090" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables present information about the Company&#8217;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:54.489%;box-sizing:content-box;"/>
         <td style="width:1.94%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:7.439%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.94%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:7.439%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.94%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:7.439%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.94%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:7.439%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value Measurements at December 31, 2025 Using:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Assets:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_953499e4-e867-4b0c-9c80-44b46528abad" contextRef="C_130e2c73-2289-4af1-866f-b3e95291e78a" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,320</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e572db33-30d1-4f4c-b75a-f82c7eab5f2a" contextRef="C_3831b4d7-2630-4d1c-a211-547ef8149bc9" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba687cea-57c1-44d5-9cff-70c5c6cead33" contextRef="C_f88dd6f3-ebdc-4647-b965-79b931a0dc44" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ce1eb4f-4129-44a3-9257-edda83a588d4" contextRef="C_dacb7ce4-e0c8-40f2-abc8-8ae1a39abc75" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,320</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_29d95fb5-50c0-4c71-9840-41a2577a3f1e" contextRef="C_adc4015d-fb3a-4ffb-9ada-76a96f681121" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,473</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85286bf9-692d-4391-b17c-d7eacbce9cfa" contextRef="C_ecee46ed-d146-4031-b499-6e0840c72f93" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca33b190-5219-4877-b421-96fcc957212a" contextRef="C_ba58008a-9a99-409a-9227-d0761c6dddab" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e25f12e-ab24-4903-b9ba-8fdc55f2ca91" contextRef="C_d4c5c2ea-4149-489e-bc3b-000c9f96aa69" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,473</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fecdf1e1-0a08-4369-b876-3b6ce09b8de0" contextRef="C_8df34eff-0fa0-4471-a95a-aa6f2075612e" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_120106c0-6035-4942-8c0a-3c54ad4c37cc" contextRef="C_633a4534-233a-47cb-9dd5-77bb31081fad" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,494</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e37f14c-5b66-4018-8730-a74271402ee8" contextRef="C_aa482204-5cdf-42f9-b194-151104d06794" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95d40231-78ab-4b85-a544-905a3ea24aa6" contextRef="C_89c728ad-be3d-454b-8a42-c4b78f7c05f2" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,494</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency debt securities</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1a3904dd-2695-4586-9105-ec2f4dc39158" contextRef="C_95114177-d276-4bf7-acfa-a07347587ae6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c29c0415-3752-4c3a-87f9-2e49fb4cef59" contextRef="C_3883179f-cde0-439b-9eb8-f31242d68421" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,000</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd42f94c-01a1-4979-bfcc-4ac8e06b9bd0" contextRef="C_c6853a23-c64f-400c-a86c-924a3bb8491a" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d9d28c9d-3cb0-455d-98f0-55fc1020f692" contextRef="C_2a071569-fdc7-4495-8732-ea28c8ae9688" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,000</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:25pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:4.627%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total marketable securities</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_66ff2d25-380b-446d-90d7-7c050e64c2d5" contextRef="C_1209e286-0944-4ac4-896b-e702d0d7ea37" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,473</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_327dff62-0537-45be-8848-def9ce99e2ad" contextRef="C_12d2135a-b5b7-4af6-8957-a06f4411e554" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">85,494</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6dd68ce-522b-4dfe-a6ff-1b0e4d28670c" contextRef="C_692bb88f-3f78-4543-9ceb-82120ad5dcf9" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_619b1e9f-fd3e-4a59-94ea-03c8d87dc625" contextRef="C_428a9132-cc2d-4fef-8e17-79b45da3689d" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">124,967</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88310803-14b9-4aeb-98fb-e297f83b60a9" contextRef="C_1209e286-0944-4ac4-896b-e702d0d7ea37" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">74,793</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_21ddc7f3-cb50-4146-aed3-8d19b6c19317" contextRef="C_12d2135a-b5b7-4af6-8957-a06f4411e554" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">85,494</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_453814bd-698f-4527-8383-af09855b0db6" contextRef="C_692bb88f-3f78-4543-9ceb-82120ad5dcf9" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2fd2fb17-9ce3-46ef-9b14-a1fcbfb530e9" contextRef="C_428a9132-cc2d-4fef-8e17-79b45da3689d" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">160,287</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:54.489%;box-sizing:content-box;"/>
         <td style="width:1.94%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:7.439%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.94%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:7.439%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.94%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:7.439%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.94%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:7.439%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value Measurements at December 31, 2024 Using:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Assets:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d09ecc2-68a4-4785-a456-413d92a3cce2" contextRef="C_380311ae-d23a-413a-a7a8-c787758e7d24" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">85,612</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6e404996-be60-41ea-a814-9b68f56b6e9d" contextRef="C_e3e5dc09-b6d0-4ff0-b26f-a809c7b2d2a9" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_21762bec-2764-4ccb-ba3d-bce1b5e9df94" contextRef="C_52e5d444-52de-4a17-998f-18fdef06290a" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c08b220c-9a7a-4140-acd9-171d00e5180d" contextRef="C_64d950f8-dcf6-4e8a-9c63-e1b34b08c3d9" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">85,612</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_221989e7-2340-4a0e-b59b-da10567d3f9f" contextRef="C_8b239563-a96d-46e3-ad49-e8ca68499571" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">54,307</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee4dc145-ae69-46b4-b86b-00808409a190" contextRef="C_f19e76bb-81d4-4bcc-92ba-46dff13be9f8" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1eb16434-6870-4f2d-8182-537f8769803f" contextRef="C_54db0f01-b239-4cf6-8fdb-eb4625a650a6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3ab650b-cdf6-487b-abd4-6898189452c8" contextRef="C_077a91d2-792f-4523-9b7a-5cb3ca9f9427" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">54,307</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c92014c-fdda-4aea-9750-27ffd87b58f4" contextRef="C_63ae5d9d-6a3f-4dea-8e44-bc65e7b9ac46" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_277193a8-f234-4d3d-98e3-74a8e918b721" contextRef="C_3208a51a-315a-4c57-94b7-9a59ba63f36c" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">67,492</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5450693b-bf74-4704-bf73-7b2dd988ebd3" contextRef="C_0d43faf6-11a6-437b-94d9-14ad3457ce60" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7e8c26d0-248c-4071-b1d8-2e1bb7649877" contextRef="C_66f073f4-73ec-4e49-b873-cf1990ed99bd" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">67,492</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency debt securities</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_80058bfb-d630-4492-b738-f185a9e157db" contextRef="C_54357343-07e1-4dfa-b18d-381a152a7bcd" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d4eeb717-a649-4de0-bf42-0a2f44bb0f94" contextRef="C_a2afa2c5-af46-4829-87c9-63140a0edb2a" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,501</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c7dc2f1-845d-4d98-af77-a0422f24bb70" contextRef="C_b4947833-f3f8-4c09-9229-596d3c11ebb0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24d97697-2456-4ee9-8dd5-63bb2a5a8e27" contextRef="C_760e2bea-9b82-40c0-9ace-1bb642dcf176" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,501</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:25pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:4.627%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total marketable securities</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34d9aafd-8e49-416e-b86b-72c582aafe38" contextRef="C_43590eda-3065-4d1d-82a7-d6a196b38e75" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">54,307</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f07f0b6-bb4b-4dd4-b0a0-5762aaeb5f51" contextRef="C_6bb7bc11-3822-497f-a5fa-c0b7de9605dc" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">70,993</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ffcbe584-6bc2-482d-855c-6118d2246aca" contextRef="C_3cce3a91-16bf-4fd1-a028-5515dbbca5c5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_074c5659-a1a7-4ab7-8cc4-08458e045805" contextRef="C_9044897e-bda8-464c-bcb1-ec1f0a7b9592" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">125,300</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_23e64e80-0f4f-4ce7-9392-4028b11c584e" contextRef="C_43590eda-3065-4d1d-82a7-d6a196b38e75" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">139,919</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc6c61ad-68bc-4903-a799-4f8eed05a7a1" contextRef="C_6bb7bc11-3822-497f-a5fa-c0b7de9605dc" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">70,993</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a2dea16-0656-4e32-8471-7bf4cdf827bd" contextRef="C_3cce3a91-16bf-4fd1-a028-5515dbbca5c5" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e42fa104-5d94-41f4-a944-f45932345046" contextRef="C_9044897e-bda8-464c-bcb1-ec1f0a7b9592" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">210,912</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash equivalents and U.S. Treasury securities were valued by the Company based on quoted market prices for identical securities, which represent a Level 1 measurement within the fair value hierarchy. Corporate bonds and agency securities were valued by the Company using quoted prices in active markets for similar securities, which represent a Level 2 measurement within the fair value hierarchy. There were no transfers into or out of Level 3 for any of the periods presented.</span></p></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">124</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_07b873a9-ee82-4914-b1da-f1e37be1530e" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 5. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued Expenses and Other Current Liabilities</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_42eac4e7-9974-47f8-9ebe-dff8958ecf4d" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:72.446%;box-sizing:content-box;"/>
         <td style="width:2.18%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.598%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:2.18%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.598%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued payroll and related expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a38d8ad8-b4c8-44b1-9810-5ae2beaa1afa" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,891</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_04005647-47f0-4be8-a5eb-70ae9b320869" contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,997</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued external research and development expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_04498369-6d54-49c8-88fa-ea6f61ee9d1a" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="clym:AccruedExternalResearchAndDevelopmentsExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,816</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f2ebf08-27ef-4cc1-adb5-d2675dc4087e" contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e" name="clym:AccruedExternalResearchAndDevelopmentsExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,237</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued professional fees</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f82693fb-07de-4e18-98d2-7c0540cf14f0" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">693</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ec02959-0f2d-44c0-a391-f773f67f53e5" contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">746</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other accrued expenses and current liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f51c9a20-202b-430f-924b-c0438f7acbaa" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_83cd1de7-344e-4bc5-97f1-9399c1c96f4a" contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">89</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fce186d4-56ba-4395-85b5-0f701c8b573b" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,459</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7b76cb74-be08-4b8c-a382-07a8dc52d65a" contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,069</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_20e4391c-64a3-4c5d-a59c-bca6810e300a" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 6. Related Party Transactions</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equity</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 11, 2025, the Company entered into an exchange agreement (the Exchange Agreement) with RA Capital Management and an entity affiliated with RA Capital Management (the Exchanging Holder), pursuant to which the Exchanging Holder exchanged an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_107652de-a59f-40d0-86f9-8d6607dfc51e" contextRef="C_304c3dfd-55bb-45b2-a8b2-e1afe73e55f4" name="clym:SharesExchangedForPreFundedWarrants" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">20,440,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock, beneficially owned by the Exchanging Holder for a pre-funded warrant to purchase the same number of shares of the Company&#8217;s common stock (subject to adjustment in the event of stock splits, recapitalizations and other similar events affecting the Company&#8217;s common stock), with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d1769cf0-328b-4c31-ad76-f999b9087bd6" contextRef="C_e158c5d9-1a89-4e43-8ef0-1635b5f8acb7" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_USDollarShare" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. The pre-funded warrant is exercisable at any time and does not expire.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Exchanging Holder is not entitled to exercise any portion of the pre-funded warrant if, upon giving effect or immediately prior to such exercise, such exercise would result in the aggregate number of shares of common stock beneficially owned by RA Capital Management, the Exchanging Holder, and their respective affiliates, collectively, to exceed </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de6680c4-418f-4d0c-87c9-ec695919989f" contextRef="C_3e184d6d-add2-4b8e-bb9b-90a0e05d219a" name="clym:AggregateBeneficialOwnershipExchangingStockholders" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">33.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the number of shares of common stock issued and outstanding immediately after giving effect to such exercise, as such percentage ownership is determined in accordance with the terms of the pre-funded warrant. The Exchanging Holder may increase or decrease such percentage to any other percentage not in excess of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38abaeb3-d746-431f-914a-ed1649f06604" contextRef="C_3e184d6d-add2-4b8e-bb9b-90a0e05d219a" name="clym:AggregateBeneficialOwnershipExchangingStockholders" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">33.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%; provided that any such increase will not be effective until the 61st day after notice from the Exchanging Holder is delivered to the Company. In addition, following the date of the Exchange Agreement, RA Capital Management may exchange additional shares of common stock beneficially owned by it or its affiliates for pre-funded warrants, subject to certain terms and conditions, including the Company&#8217;s written consent.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company determined that the pre-funded warrant did not meet the classification of a liability under ASC 480, Distinguishing Liabilities from Equity. The Company concluded that the pre-funded warrant should be classified as equity based on an analysis performed under ASC 815-40, Contracts in an Entity's Own Equity. The Exchange Agreement did not have any cash impact, and the shares of common stock exchanged for the pre-funded warrant were retired.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2024, the Company issued shares to RA Capital Management and affiliates in connection with the Acquisition and Private Placement (see Note 3).</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Service Agreements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result of the Acquisition, the following legacy Tenet agreements effectively became agreements of the Company.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tenet was a party to a service agreement with Sera Services, Inc. (Sera Services), a wholly-owned subsidiary of Sera Medicines, LLC (Sera Medicines) to provide research and other services to the Company. Sera Medicines is an entity controlled by RA Capital Management, and Dr. Stephen Thomas, a current board member of the Company, owns a minority ownership in and is also a board member of Sera Medicines. No services were provided under the Sera Services Agreement for the year ended December 31, 2025 and, in March 2026, the Company terminated the agreement. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2dbe45d6-6e95-42a0-b2f2-9765c79bb616" contextRef="C_3a734757-e1ee-40b3-8578-67d0507ee846" name="us-gaap:OtherExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to Sera Services for services provided under the Sera Services Agreement for the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tenet was a party to a service agreement with Blackbird Clinical, Inc. (Blackbird), an entity controlled by RA Capital Management. Under the terms of the service agreement, Blackbird provided consulting services to Tenet in connection with its clinical trials. For the year ended December 31, 2024, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Company paid approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9eb5bed0-5293-41b7-a0b0-b7b21dd079c9" contextRef="C_90041a5e-41bb-41f0-9714-a6b1a0938dd1" name="us-gaap:OtherExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to Blackbird under the Blackbird Service Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In October 2024, the Company terminated the Blackbird Service Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">125</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:nonNumeric id="F_3a7d71d7-54f1-4375-92cb-a37a2d7bd28d" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:LesseeOperatingLeasesTextBlock" escape="true" continuedAt="F_3a7d71d7-54f1-4375-92cb-a37a2d7bd28d_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 7. Leases</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company leases office space under a non-cancelable operating lease in Wellesley, Massachusetts under a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b8f23b79-109a-475b-88f4-8837a8a1b530" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-month lease agreement that expires in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_0ecb2fd9-391a-4200-85ea-df3460e76587;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 2026</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The lease contains rent escalation clauses and an option to extend the term of the lease for an additional 12-month period at a market rate determined according to the lease. At the lease&#8217;s inception and as of December 31, 2025, the Company expects to exercise its </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_108e52b3-ce58-4d4c-bba6-49da2ab04414" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">option to extend</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the lease, and therefore the period covered by this option is included in the lease term.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2025, the Company amended the lease to add space to the existing lease for additional fixed payments totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3cfe4bb5-803a-42bd-b9bf-ad981cf9979f" contextRef="C_e5a79ba0-ff7c-4c63-a7dc-6397a5945808" name="us-gaap:LeaseCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million through 2026 with an option to extend the lease through 2027 for additional fixed payments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e940a34-bb26-4df9-9449-ba674cfc74e8" contextRef="C_259b8ff0-14b6-480a-93a7-28890d7655ca" name="us-gaap:LeaseCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. As the Company expects to exercise its option to extend the lease, the extension period is included in the lease term. Accordingly, the Company recorded an increase to operating lease right-of-use assets and operating lease liabilities of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa3e3926-e4b3-4204-b33a-8f8c86697328" contextRef="C_aad0ea95-775d-4c74-b575-deb8723088ed" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_9ac13657-5bb4-4402-b20f-b4e94cdb9e80" contextRef="C_aad0ea95-775d-4c74-b575-deb8723088ed" name="clym:IncreaseDecreaseInOperatingLeaseAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company previously leased office space in Bellevue, Washington, which expired in January 2025, and Cambridge, U.K., which expired in June 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_18c590ae-3b8f-4aa9-9aaf-70aedf942318" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:LeaseCostTableTextBlock" escape="true" continuedAt="F_18c590ae-3b8f-4aa9-9aaf-70aedf942318_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of lease expense were as follows (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:70.12%;box-sizing:content-box;"/>
         <td style="width:1.78%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.16%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.78%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.16%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease cost</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_79d2e938-caa6-4afc-9a37-b1ae9540ee35" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">250</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_45cde996-e02d-4f60-a536-ba0866080707" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">243</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term lease cost</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cbc0cea8-d500-4d85-942b-9552ac361a19" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:ShortTermLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_387abdae-9d3c-4c5a-9fa4-55027518ba3a" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:ShortTermLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Variable lease cost</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba4b57fc-b96d-41f3-89fa-0e7bfc7c21f7" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_53194cb0-eddb-486c-b548-dea1919a0cdb" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">86</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d9d96b9-2a82-4e45-9bfe-5e4479e2ad5c" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">259</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d30509f5-796a-4b4e-b80e-f8cbf9912777" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">329</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_db9b9a44-8db6-4de5-8ed1-b47b4672c0ee" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Supplemental disclosure of cash flow information related to leases was as follows (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:70.12%;box-sizing:content-box;"/>
         <td style="width:1.78%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.16%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.78%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.16%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for amounts included in the measurement of operating <br/>&#160;&#160;&#160;&#160;&#160;lease liabilities</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c720d6c4-57ba-47f1-a078-21455f160867" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">256</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_28c58b18-cd45-403e-b654-c6b3a7914718" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">350</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Operating lease liabilities arising from obtaining right-of-use<br/>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;asset</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d4de41d3-677b-4ed7-9429-d4fc8d765189" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">216</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0032c46b-1484-4be8-bf1c-15c52f84db2f" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">510</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_18c590ae-3b8f-4aa9-9aaf-70aedf942318_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted-average remaining lease term and discount rate were as follows:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:70.148%;box-sizing:content-box;"/>
         <td style="width:1.301%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.625%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.301%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.625%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average remaining lease term - operating lease (in years)</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_295dec30-1447-4651-bf8c-2bc2b0a540e7" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.0</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_e702d343-a929-46a4-99c1-d585ce60cf7b" contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.9</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average discount rate - operating lease</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7cba45b4-b9f5-421d-956a-e2ff136e5373" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">8.5</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4bbc8940-6ea1-477a-9a2f-217c0c5ee230" contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">8.5</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ec605b1b-dd0d-4953-861c-95536b1c5063" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, the annual future minimum lease payments due under the Company&#8217;s non-cancelable operating lease was as follows (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:82.44%;box-sizing:content-box;"/>
         <td style="width:2.08%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.48%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Year ending December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_28f5fe80-251f-4695-ab72-811695892ee7" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">293</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f34c2d68-534d-4756-b8a6-5b024ff3c0e0" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">298</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Total undiscounted lease payments</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_544b81e5-2e02-4847-8e7f-dd414e2fa157" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">591</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: imputed interest</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88348a85-4e74-4843-831c-22d2e44412f6" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Total operating lease liabilities</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4af9ecce-b9bd-45f6-9a6f-c430f6385247" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">541</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">126</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_3a7d71d7-54f1-4375-92cb-a37a2d7bd28d_1"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f0c1071f-b94b-4fcd-9eb5-dd7cbff507b3" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="clym:ScheduleOfBalanceSheetSupplementalDisclosuresTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Total operating lease liabilities in the table above are classified on the consolidated balance sheet as follows (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:82.44%;box-sizing:content-box;"/>
         <td style="width:2.08%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.48%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Included in the consolidated balance sheet (in thousands):</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current operating lease liability</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b99ab56-6ba6-4161-b9fd-051af272cd8c" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">256</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liability, net of current portion</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38ebd449-d9d8-44ad-9ac2-e8b920a03048" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">285</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Total operating lease liabilities</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64b80591-845a-40de-a9b6-3b1e0b58625a" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">541</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_c7967904-01ce-4c02-95c2-72f75d4c598e" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true" continuedAt="F_c7967904-01ce-4c02-95c2-72f75d4c598e_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 8. Commitments and Contingencies</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating Leases</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s commitments under its leases are described in Note 7.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License Agreements (Budoprutug)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result of the Acquisition, the following legacy Tenet agreements effectively became agreements of the Company.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Acelyrin Asset Purchase Agreement</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 11, 2024, Tenet entered into an asset purchase agreement (the Asset Purchase Agreement) with Acelyrin, Inc. (Acelyrin) and WH2, LLC, which was subsequently transferred to the Company by operation of law upon the closing of the Acquisition, providing for the acquisition of certain assets of Acelyrin related to budoprutug (the Transferred Assets), including certain assigned contracts. Under these assigned contracts, the Company (i) received worldwide licenses (with the right to sublicense) to certain patents, know-how and other intellectual property rights to develop, manufacture, use and commercialize budoprutug for any non-oncology indication, and (ii) assumed certain liabilities of Acelyrin arising from (1) governmental authority action or notification relating to budoprutug, (2) contracts assigned to the Company pursuant to the Asset Purchase Agreement and (3) the Company&#8217;s ownership, lease or operation of the Transferred Assets. The Asset Purchase Agreement includes customary representations, warranties and covenants, as well as standard mutual indemnities, including those covering losses arising from any material breach of the Asset Purchase Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Asset Purchase Agreement, the Company also acquired the rights and obligations, including financial obligations, under a license agreement with Cancer Research Technology Limited (CRH), which Tenet subsequently amended and restated in the CRH Agreement (as defined below) and a cell line development, manufacturing services and license agreement with ProBioGen AG (ProBioGen).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Asset Purchase Agreement with respect to any &#8220;Product&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (as such term is defined in the Asset Purchase Agreement), the Company is obligated to (i) make total payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_43dcb77c-83a2-4c31-b7bb-e77860e26816" contextRef="C_8d01d41c-acfb-4b36-86b4-52db5162e53b" name="clym:MilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">157.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to Acelyrin upon the achievement of various development, regulatory and commercial milestones, (ii) pay royalties in the single-digit percentages, subject to specified reductions, to Acelyrin on worldwide net sales in a given calendar year, and (iii) make non-refundable and non-creditable payments to Acelyrin on sublicense income with rates ranging from the low single digit to mid teen percent depending on the stage of development of the most advanced Product at the time of such sublicense.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The royalty term continues for each Product on a country-by-country and Product-by-Product basis beginning on the first commercial sale of such Product and ending on the latest of (a) the date when such Product is no longer covered by a valid claim of a royalty-bearing patent (as such term is defined in the Asset Purchase Agreement) in such country, (b) the expiration of any regulatory exclusivity period for such Product in such country, and (c) the twelfth anniversary of the first commercial sale of such Product in such country.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is obligated to use commercially reasonable efforts to commercialize at least one Product in the U.S., to the extent a Product exists under the Asset Purchase Agreement, and to achieve specified development, regulatory and commercial milestones for such Product set forth in the Asset Purchase Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent a Product exists under the Asset Purchase Agreement, if Acelyrin asserts that the Company has failed to meet a specified diligence obligation under the Asset Purchase Agreement within specified time periods, and such failure is finally determined through a dispute resolution process, Acelyrin may elect, in lieu of a claim for damages, to repurchase the Transferred Assets at the then-fair market value of such Transferred Assets, as Acelyrin&#8217;s sole and exclusive remedy for such breach.</span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">127</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_c7967904-01ce-4c02-95c2-72f75d4c598e_1" continuedAt="F_c7967904-01ce-4c02-95c2-72f75d4c598e_2"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If, within a specified period following the top line data readout from the first Phase 2 clinical trial of a Product, the Company receives a bona fide offer or proposal from a third party to sell, transfer or otherwise divest all or substantially all of the rights to the Transferred Assets or Products, or grant an exclusive license or exclusive sublicense to such third party to develop and commercialize Products under specified terms, then prior to entering into any discussions or negotiations with any third party in relation to such a transaction, the Company shall provide written notice to Acelyrin of such intent or receipt of proposal. Acelyrin shall have the right to negotiate with the Company the terms for a definitive agreement with respect to such sale, transfer or grant of the rights to Products for a specified period of time. If Acelyrin does not exercise its right to negotiate or the parties are unable to agree on the terms of a definitive agreement, the Company shall have the right to negotiate or enter into an agreement with a third party with respect to such transaction, subject to specified conditions.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company may not sell, assign or transfer all or substantially all of the rights to develop or commercialize a Product unless, as a condition to such sale, assignment or transfer, the purchaser, assignee or transferee (as applicable) assumes in writing all of our obligations as set forth in the Asset Purchase Agreement with respect to the applicable Products.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records expense related to milestone payments when achievement of the milestone is assessed as probable. As of December 31, 2025, the Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d147578-7c1d-42fd-a95d-97b6e8b26fe9" contextRef="C_e8ccac22-cccd-4604-a52d-f88a9f26a088" name="clym:MilestonePaymentsDue" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recorded expense related to milestone payments under the Asset Purchase Agreement. On December 31, 2025, the Company filed a complaint in Delaware Superior Court against Alumis Inc. and its wholly owned subsidiary, Acelyrin, relating to a dispute concerning the Asset Purchase Agreement as further described below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">CRH Agreement</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Asset Purchase Agreement, in January 2024 Tenet was assigned a license agreement with CRH and, in connection with such assignment, Tenet entered into an amended and restated license agreement with CRH (the CRH Agreement) which was subsequently transferred to the Company by operation of law upon the closing of the Acquisition. The CRH Agreement granted the Company a worldwide exclusive license (other than specified patent rights and materials, which are licensed to the Company on a non-exclusive basis) under certain know-how, patents and materials, or the licensed rights, to research, develop, test, manufacture or sell certain licensed products related to budoprutug, for all therapeutic uses except for oncology indications. The Company is permitted to grant a sublicense under these licenses with CRH&#8217;s prior written consent. CRH retains, on behalf of itself and the charitable company Cancer Research U.K., a worldwide, fully paid-up, perpetual and irrevocable right in the licensed rights and in certain intellectual property owned or controlled by the Company that is necessary to exploit the licensed products and used, conceived or generated in the course of exercising the license or exploiting any licensed product, or product-specific foreground intellectual property, for the purpose of non-commercial, non-clinical scientific research.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is obligated to use commercially reasonable efforts to perform all activities set forth in a mutually agreed-upon development plan within the timelines set forth therein. The Company is also obligated to develop at least one licensed product in an autoimmune indication and to pursue worldwide regulatory authorization for licensed products. The Company must use commercially reasonable efforts to commercialize each licensed product throughout each of the specified major markets as soon as practicable following receipt of regulatory authorization for such product in such market. Additionally, the Company must use commercially reasonable efforts to make the licensed product available through the U.K. and negotiate with relevant regulatory authorities to make each licensed product available through the National Health Service in England and Wales within a specified time of the licensed product being made available elsewhere in the territory. If the Company fails to meet one or more of these diligence obligations, and such failure is not remedied within the specified cure period, CRH shall have the right to terminate the CRH Agreement with respect to the relevant licensed product.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is obligated to pay CRH a mid-five figure digit fee on each anniversary of the effective date. The Company is obligated to pay up to an aggregate of &#163;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f12e4b05-0da9-4939-a4a6-0695e3beebf7" contextRef="C_8579d8f5-3430-4159-88d1-ebaf49448cd2" name="clym:MilestonePayments" unitRef="U_GBP" scale="6" decimals="-5" format="ixt:num-dot-decimal">106.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_970f43bd-b8ab-4d8d-8882-ee14a59af9d6" contextRef="C_cb8006fb-9972-4de5-8228-dd0f468981f6" name="clym:MilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">143.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of December 31, 2025) upon the achievement of specified development, regulatory, commercial and sales milestone events, including: (i) payments of up to mid-six figure digits in pounds sterling for certain development milestones, (ii) payments of up to low-eight figures in pounds sterling per indication (for up to three indications) for certain regulatory and commercial milestones and (iii) payments up to mid-eight figures in pounds sterling for certain sales milestones. The Company is also obligated to pay tiered royalties ranging from a rate in the mid-single digit to high-single digit percentage on net sales. The royalty term continues for each licensed product on a country-by-country basis beginning on the first commercial sale of such licensed product and ending on the latest of (a) the date when such licensed product is no longer covered by a valid claim of a licensed patent in such country, (b) the expiration of the exclusivity period for such licensed product in such country, and (c) the tenth anniversary of the first commercial sale of such licensed product in such country. The Company is also responsible for a sublicensing revenue payment ranging from a rate in the mid-single digit to mid-double digits for any sublicense revenue.</span></p></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">128</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_c7967904-01ce-4c02-95c2-72f75d4c598e_2" continuedAt="F_c7967904-01ce-4c02-95c2-72f75d4c598e_3"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CRH Agreement shall remain in effect in each country in the territory until the expiry of our obligation to pay royalties in such country. Either party may terminate the CRH Agreement if the other party is in material breach that has not been remedied within the specified cure period or if the other party becomes insolvent. CRH also has the right to terminate the CRH Agreement if the Company or one of its sublicensees or affiliates challenges a licensed patent, or if the Company is acquired by a tobacco company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records expense related to milestone payments when achievement of the milestone is assessed as probable. During the year ended December 31, 2025, the Company recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_906714ee-998e-4ab7-a07f-be8584893ab6" contextRef="C_b6de63ae-c1ba-465a-83f3-ca5197585acd" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of research and development expense related to the milestones.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ProBioGen Agreement</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Asset Purchase Agreement, Tenet was assigned a cell line development, manufacturing services and license agreement (the ProBioGen Agreement) originally entered into by ValenzaBio, Inc. and ProBioGen in February 2021, which was subsequently transferred to the Company by operation of law upon the closing of the Acquisition. The ProBioGen Agreement granted the Company a non-exclusive license under certain know-how, patents and materials, to use cell lines in which ProBioGen&#8217;s proprietary technology is applied, to research, develop, manufacture, use, sell, offer to sell, import or export budoprutug. This license includes a non-exclusive sublicense by ProBioGen of certain third-party patent rights, limited to the use of budoprutug.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is obligated to (i) make payments of up to &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6110c710-070a-4893-a4d7-7d1c9a0c6d44" contextRef="C_12593a5c-196b-480a-886e-b17facf60df2" name="clym:MilestonePayments" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dcba2d54-cdea-4cd5-a1c5-1045f1efa320" contextRef="C_48b9f054-2754-412a-9e64-8ac7cd01dbef" name="clym:MilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">11.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of December 31, 2025) upon the achievement of certain development, manufacturing and commercial milestones, including the start of a Phase 2 clinical trial for budoprutug, and (ii) make milestone payments of up to &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_02030359-058c-4734-9c82-fb5b2777ffbf" contextRef="C_0f8a9914-3000-454c-ab10-75100dc7832f" name="clym:MilestonePayments" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d0d0587a-126c-44b8-8a2b-b0d04d06e923" contextRef="C_239f2b84-9e87-4d24-8ef6-ec35e511039c" name="clym:MilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of December 31, 2025) upon the achievement of certain sales milestones. If the Company elects to contract ProBioGen to perform certain manufacturing services for budoprutug, the milestone payments would be reduced by &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a20fe0a2-5a34-44f1-9b3b-5a5f599185a1" contextRef="C_a9351123-b279-44ed-b948-3c21858af6ed" name="clym:MilestonePaymentAmountReduced" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_00f16c15-3b61-4e0d-8b76-6156771060b2" contextRef="C_89e402ec-8a69-4241-9a74-d42ab514978d" name="clym:MilestonePaymentAmountReduced" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of December 31, 2025).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ProBioGen Agreement will remain in effect until the services are completed for the service-related component and until the payment obligations expire in connection with the commercial license component. Both parties have the right to terminate the ProBioGen Agreement if the other party becomes insolvent, or materially breaches the ProBioGen Agreement and fails to remedy such default within the specified cure period.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records expense related to milestone payments when achievement of the milestone is assessed as probable. During the year ended December 31, 2025, the Company recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4415056f-318f-4a18-93ba-022aab48ff1b" contextRef="C_905153fa-065a-4b24-a22c-0410b7b3bfda" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of research and development expense related to the milestones.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License Agreement (CLYM116)</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 8, 2025, the Company entered into the Mabworks Agreement, pursuant to which Mabworks granted to the Company (i) an exclusive (even as to Mabworks and its affiliates), sublicensable right and license under certain patent rights and related know-how (the Licensed Intellectual Property) to develop, manufacture and commercialize Mabworks&#8217; proprietary antibodies associated with Mabworks&#8217; proprietary antibody program, identified as MIL116 (the Licensed Compounds or CLYM116) and products containing the Licensed Compounds (Licensed Products) outside of Greater China (the Licensed Territory), (ii) a non-exclusive, sublicensable right and license under the Licensed Intellectual Property to manufacture the Licensed Compounds and Licensed Products in Greater China and (iii) a non-exclusive, sublicensable right and license under the Licensed Intellectual Property to develop the Licensed Compounds and Licensed Products in the Greater China in connection with certain global clinical studies (as described below).</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the Mabworks Agreement, the Company paid to Mabworks a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b19fa417-f0f4-497f-9cab-f3601af7390d" contextRef="C_389487f4-111c-4263-b8a6-56fb2d222f6d" name="clym:UpfrontPaymentPaid" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upfront payment, and the Company is obligated to pay a total of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da9a3821-9cac-4feb-b59b-647a51432981" contextRef="C_fab74366-ad6b-4993-b418-2c772c8de0bd" name="clym:MilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">30.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon the achievement of certain development and regulatory milestones pertaining to the first indication for a Licensed Product, additional lower amounts upon the achievement of certain development and regulatory milestones pertaining to up to two additional indications for a Licensed Product and a total of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f42e340-e701-4d48-a3c7-4e003b4d8dcd" contextRef="C_0b3af095-e13b-4823-afed-c09031e8be17" name="clym:MilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">832.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">upon the achievement of certain commercial milestones for all Licensed Products. In addition, the Company is obligated to pay Mabworks tiered royalties in the low-to mid-single-digit percentages on aggregate annual net sales of all Licensed Products in the Licensed Territory. The Company is obligated to pay royalties on a Licensed Product-by-Licensed Product and country-by-country basis from the date of the first commercial sale in such country until the latest of: (i) the expiration of the last valid claim on the Licensed Intellectual Property covering the composition of matter of the Licensed Compound in such Licensed Product in such country; and (ii) ten years following the first commercial sale of such Licensed Product in such country (each, a Royalty Term). The royalty rate is subject to reduction on a Licensed Product-by-Licensed Product and country-by-country basis under certain circumstances. In the event that the Company grants sublicenses under the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">129</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_c7967904-01ce-4c02-95c2-72f75d4c598e_3"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licensed </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intellectual Property, the Company will be obligated to pay Mabworks a percentage, in the mid-single-digits to low-double-digits, of certain consideration received under such sublicenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company agreed to use commercially reasonable efforts to develop, obtain regulatory approval for and commercialize a Licensed Product in the U.S. The Company has also granted Mabworks a right of first refusal to develop and commercialize in Greater China any product the Company controls that contains an antibody directed to tumor necrosis factor ligand superfamily member 13 (APRIL). Mabworks has agreed not to exploit in the Licensed Territory any product that is directed to APRIL during the term of the Mabworks Agreement. The Mabworks Agreement also contains a mechanism for the parties to collaborate on global clinical studies in the future, where the Company has a right to perform clinical studies in Greater China with Mabworks&#8217; approval in the event that Mabworks elects not to participate in such global clinical studies. Unless earlier terminated, the Mabworks Agreement will expire on the expiration of the last to expire Royalty Term. Either party may terminate the Mabworks Agreement for the other party&#8217;s material breach, following a customary notice and cure period, or insolvency. Additionally, the Company may terminate the Mabworks Agreement for any reason upon 60 days written notice to Mabworks.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recorded the upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dbdc4004-67fd-430f-9771-8fed660bd907" contextRef="C_b4634d19-4dbe-4167-828d-3b0dea46ce12" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as research and development expenses in the first quarter of 2025 in the consolidated statements of operations and comprehensive loss. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records expense related to milestone payments when achievement of the milestone is assessed as probable. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2025, the Company recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_76d4eef5-4e07-428d-a19e-e0e1488632ad" contextRef="C_2829c600-2470-432e-befb-c0c057ac53de" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of research and development expense related to a milestone.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Legal Proceedings</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of its business activities. The Company records accruals for estimated losses when available information indicates a loss is probable and reasonably estimable. Significant judgment is required to determine both probability and the estimated amount. The Company expenses the costs related to its legal proceedings as they are incurred.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 31, 2025, the Company filed a complaint in Delaware Superior Court against Alumis Inc. and its wholly owned subsidiary, Acelyrin, relating to a dispute concerning the Asset Purchase Agreement seeking a declaratory judgment that the Company&#8217;s budoprutug drug candidate is not a Product under the Asset Purchase Agreement, and that the Company does not owe a milestone payment sought by Alumis in connection with its development of budoprutug. This matter is currently pending. The Company is unable to predict the timeline for resolution or the outcome of this matter.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of the date of these consolidated financial statements, the Company is not party to any other material legal matters or claims.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Indemnification</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless, and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third-party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the Company has entered into indemnification agreements with members of its board of directors and executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. To date, the Company has not incurred any material costs as a result of such indemnification provisions. The Company is not currently aware of any indemnification claims and has not accrued any liabilities related to such obligations in its consolidated financial statements as of December 31, 2025.</span></p></ix:continuation></div><div><ix:nonNumeric id="F_aa6cc44a-ed90-4167-91d0-4fca494c2e0f" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true" continuedAt="F_aa6cc44a-ed90-4167-91d0-4fca494c2e0f_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 9.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-Based Compensation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2019 and 2021 Equity Incentive Plans</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has outstanding awards under its 2019 Equity Incentive Plan (the 2019 Plan), but is no longer granting awards under this plan. The Company&#8217;s 2021 Equity Incentive Plan (the 2021 Plan and, together with the 2019 Plan, the Plans) provides for the grant of incentive stock options, non-statutory stock options, restricted stock awards, restricted stock units (RSUs), stock appreciation rights and other stock-based awards to the Company&#8217;s employees, officers, directors and consultants. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any shares that are returned under the 2019 Plan as a result of cancellation or forfeiture become available for grant under the 2021 Plan. Further, the number of shares of common stock reserved for issuance under the 2021 Plan automatically increases on January 1 of each year continuing through and including January 1, 2031, by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2521cad1-6b64-44e0-9997-00e9d41c75fa" contextRef="C_dd8c59f4-3742-43b0-84bb-363445fa8ccb" name="clym:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of the total number of shares of common stock outstanding on December 31 of the immediately preceding calendar year, or a lesser number of shares</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">130</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_aa6cc44a-ed90-4167-91d0-4fca494c2e0f_1" continuedAt="F_aa6cc44a-ed90-4167-91d0-4fca494c2e0f_2"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">determined </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">by the Company&#8217;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s board of directors. The number of authorized shares reserved for issuance under the 2021 Plan was increased by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_854da3b9-0ed8-4cce-8099-cbd8650aa061" contextRef="C_51534b8e-0ca9-48c3-97a9-d9df1a0b13ca" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,362,771</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares effective as of January 1, 2025 in accordance with the provisions of the 2021 Plan described above. As of December 31, 2025, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a3e51ca-1dee-4e35-b2bc-bfab1c0bb454" contextRef="C_63169a3f-785d-4de2-b401-eff12e91f2ac" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,124,834</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares remained available for future grant under the 2021 Plan. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The number of shares reserved for issuance under the 2021 Plan was increased by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ac8a538f-501c-4711-a776-8fa11d5cde1f" contextRef="C_afdf6eb5-5976-48c1-824a-42df181b79c2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,388,316</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares effective January 1, 2026.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f27c828b-f32a-4a56-9c6f-7a7183208868" contextRef="C_80f05462-1973-4d3e-8520-b5a9f59b1778" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the 2021 Plan, options are granted at an exercise price no less than fair value of the Company&#8217;s common stock on the grant date, except in certain cases related to significant corporate transactions. Options expire no later than </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1b870876-909a-4f68-b3a7-b47a7c512cca" contextRef="C_80f05462-1973-4d3e-8520-b5a9f59b1778" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the date of the grant.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2025 Inducement Plan</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2025, the Company&#8217;s board of directors adopted the 2025 Inducement Plan (the Inducement Plan), pursuant to which the Company may grant nonstatutory stock options, stock appreciation rights, restricted stock awards, RSUs and other stock-based awards with respect to an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a5e1e47-95fa-432d-aac0-334082b2b88f" contextRef="C_81a10eed-87b5-4e58-b248-df503d6194b9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,250,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock. Awards under the Inducement Plan may only be granted to new employees who were not previously an employee or director of the Company or are commencing employment with the Company following a bona fide period of non-employment, in either case, as an inducement material to the individual&#8217;s entering into employment with the Company in accordance with the requirements of Nasdaq Stock Market Rule 5635(c)(4). On September 30, 2025, the Company&#8217;s board of directors approved an amendment to the Inducement Plan to increase the number of shares of common stock authorized for issuance under the Inducement Plan by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d963852-80e4-4906-9c19-7eb711b5c517" contextRef="C_5544a4ea-f6c3-43ec-b41e-4209eb125966" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">750,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b6138a3d-4406-41f8-900c-7d8a858c8e17" contextRef="C_eae9b56b-e6e5-40e9-bbd0-fcdfa9342978" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares remained available for issuance under the Inducement Plan.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Employee Stock Purchase Plan</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d5e20941-5ac1-41e5-a3e3-edfe40fb77cd" contextRef="C_b4452408-22d4-4ee5-aebd-bdfbc907dccc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s 2021 Employee Stock Purchase Plan (the ESPP) allows employees, including executive officers, to contribute up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de762d4d-8b90-42b8-884e-477602c3c9d6" contextRef="C_b4452408-22d4-4ee5-aebd-bdfbc907dccc" name="clym:ShareBasedCompensationArrangementBySharebasedPaymentAwardContributionPercentMaximum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">15</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of their earnings, subject to certain limitations, for the purchase of the Company&#8217;s common stock at a price per share equal to the lower of (a) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d1776689-8dcb-4fbb-8e4c-5ffcfaf3cf0f" contextRef="C_bb651521-2c6d-4fbd-b7ad-6cfc21cd0b6a" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">85</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the fair market value of a share of common stock on the first day of the offering period, or (b) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4cf2f240-8631-4fce-b974-e13ec13aa19b" contextRef="C_c04dc289-c837-42ec-90ed-96b37ca44352" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">85</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the fair market value of a share of common stock on the last day of the offering period. The number of shares of common stock reserved for issuance under the ESPP automatically increases on January 1 of each calendar year through and including January 1, 2031, by the lesser of (1) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_039875fe-0117-4a52-8266-7ef5e60bac85" contextRef="C_e5b62da0-95aa-41be-88d8-378341822749" name="clym:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the total number of shares of the Company&#8217;s common stock outstanding on December 31 of the preceding calendar year or (2) a number of shares determined by the Company&#8217;s board of directors. Shares subject to purchase rights granted under the ESPP that terminate without having been exercised in full will not reduce the number of shares available for issuance under the ESPP. The number of authorized shares reserved for issuance under the ESPP was increased by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ec69507c-7427-4397-95c2-1ea63ee0a3aa" contextRef="C_2d40f93a-6e30-47ec-9b7b-b71b689a098a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">672,554</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares effective as of January 1, 2025 in accordance with the provisions of the ESPP described above. The first offering period began on December 16, 2025 and will end on June 15, 2026. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4833f7dd-4da9-4ca1-b887-2fd229db3377" contextRef="C_b4452408-22d4-4ee5-aebd-bdfbc907dccc" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares had been granted or purchased under the ESPP and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d4527ad-9288-4bcf-b5ac-717f058e8e3c" contextRef="C_9e183b21-7abc-4bbb-a514-9fac970fc0da" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,736,779</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares remained available for issuance under the ESPP. The number of shares reserved for issuance under the ESPP was increased by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_913ca7b3-c7d8-402f-96d9-61155e2f514e" contextRef="C_c4117672-57e4-4a80-95aa-824a99550138" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">477,663</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares effective January 1, 2026. </span></ix:nonNumeric></span><span style="font-size:10pt;font-family:Times New Roman;"></span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Option Valuation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of stock option grants is estimated on the date of grant using the Black Scholes option pricing model. Volatility is estimated based on the historical and implied volatilities of comparable publicly traded companies as the Company does not have sufficient history of trading in its common stock. The expected term of the Company&#8217;s stock options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8e3a3426-2e2a-40f8-91b9-59e42baa5264" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The relevant data used to determine the fair value of the stock option grants during the years ended December 31, 2025 and 2024 is as follows, presented on a weighted-average basis:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:62.72%;box-sizing:content-box;"/>
         <td style="width:1.6%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:15.04%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.6%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:15.04%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_64fe7ee2-9412-49eb-816d-c3a0fbdc1b98" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.0</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_dab6b8ec-093c-4ed5-9ba0-95b0a556637c" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.1</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d1654264-8855-484a-9e72-287fa6b44358" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">103.6</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc81edf7-c112-4170-acf1-00cfa8651b0b" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">104.0</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d0f4d85a-5fd0-4c9c-8bbe-874ac0e107ea" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.3</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aaec020d-0291-4dde-b399-cf02bc5a6906" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.0</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2a402cea-6dfb-481f-9152-8576899d4822" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01453d6b-54a3-4ba9-89cd-b9c7cb262a78" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">131</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_aa6cc44a-ed90-4167-91d0-4fca494c2e0f_2"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Option Activity</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outstanding stock options consist of option grants with service-based vesting conditions, typically </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_90bb676a-096d-4e7e-9453-3281ca521281" contextRef="C_3cb182f5-fa8c-4e88-b58e-b8e49cc15ab2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% on the first anniversary of the grant date with the remainder vesting monthly over the following </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_10b474f8-6e20-4faf-9aaa-6346163a17ca" contextRef="C_ce134265-fb84-4e8d-9157-57ff9ef7e7ff" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span><ix:nonNumeric id="F_58397267-7a57-4d34-ac33-4ab0dfa46aad" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true" continuedAt="F_58397267-7a57-4d34-ac33-4ab0dfa46aad_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The activity for stock options is as follows:</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_58397267-7a57-4d34-ac33-4ab0dfa46aad_1">
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:47.26%;box-sizing:content-box;"/>
         <td style="width:2.06%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.02%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:2.54%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:8.02%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:2.06%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:8.48%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:2.54%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:8.02%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Average</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Average</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">of</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exercise</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Contractual</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Intrinsic</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Price</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Term</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2f5099d2-650f-4896-9f0b-a1b9d78e49e5" contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,817,751</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ccccb1a8-7a9d-44f8-b33e-25a35b6c39f2" contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.49</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_df637f64-9fdc-4360-a654-1ad5c8a2cab4" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.87</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ede2223d-88bc-4823-94d0-6b8648c6f713" contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options granted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee3d5f18-b284-458f-b5ad-6be5bbb1feb7" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">5,766,696</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_325f785f-7b9b-45fd-add2-56379ffd4828" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.77</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b95ae85-6b74-461a-ae99-071f86646f58" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">21,341</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_56e02f30-099c-4aa8-9551-e1375c0e86e3" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.04</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options forfeited</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_712c54ca-9366-4d27-aa71-b9f0d47c31f2" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,135,329</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f8f4519e-b8c5-468b-bcbd-18537c77cae3" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.85</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0fb390d3-7212-41c3-af7c-52e2315cb553" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">6,427,777</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_efbc238b-d121-4def-ba9a-45e395bfae24" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.81</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_a0d249ff-be56-4802-8086-6dcf5b449963" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.05</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_56433c85-5f4d-432f-be26-9552191905df" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,727</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested and expected to vest as of December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98b4e16a-4cdf-4adf-9c44-844a63fd30a0" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">6,427,777</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f096ad19-9d08-4845-8957-ad0c935d9057" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.81</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_c29f5747-c497-470c-a9a1-030a6993a5ca" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.05</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bdade66e-d720-4b0f-9fc0-ff054d3836af" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,727</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercisable as of December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_46ac30a2-92a1-48be-80a1-81659df548d2" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">631,921</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bef84822-c428-405d-bd08-13ea2ed16d8f" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.24</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_e10c7de5-7aef-4142-94ff-8cb645bc799e" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.00</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_94631471-18dc-40e8-91e0-dd21486aec79" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">331</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:continuation></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate intrinsic value disclosed in the above table is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock for those stock options that had strike prices lower than the fair value of the Company&#8217;s common stock. The aggregate intrinsic value of options exercised during the years ended December 31, 2025 and 2024 was less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_771783ce-8f87-4740-9d37-226f18509995" contextRef="C_08d2f2e1-0339-4338-abfa-e32c391b4121" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_172332b9-9ab3-4508-8e62-b5152aa8aea9" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted-average grant date fair value of stock options granted duri</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ng the years ended December 31, 2025 and 2024 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_94a6cd6c-c10a-4f01-941c-b0fadd972aee" contextRef="C_3238fdb8-36cf-4c49-90ac-67c04b90e3fc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.45</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_33edeede-2c1f-41d4-aa53-0cbeb4e8a686" contextRef="C_5917f89f-b247-498e-9e76-b710f5430033" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.56</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, respectively.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Stock Units</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has outstanding RSUs with service-based vesting conditions and RSUs with performance-based vesting conditions. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_32d53db6-0f3f-497e-984f-c2e4c64d70c4" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" escape="true" continuedAt="F_32d53db6-0f3f-497e-984f-c2e4c64d70c4_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The activity for RSUs is as follows:</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Arial;"><ix:continuation id="F_32d53db6-0f3f-497e-984f-c2e4c64d70c4_1">
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:63.113%;box-sizing:content-box;"/>
         <td style="width:2.921%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:15.223%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:3.381%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.362%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average Grant Date Fair Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested at December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ceecbfd6-afe4-4d73-9598-81049673d7a7" contextRef="C_c751770e-5639-4fb1-ae0f-ff557e717b97" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,228,876</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e01f465-fc02-4ebb-b960-1fe8c2bb4a65" contextRef="C_c751770e-5639-4fb1-ae0f-ff557e717b97" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.17</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c746e17-f00a-4211-9ecc-3fecc35ec61c" contextRef="C_116ecf73-7a8a-49b3-bad1-9ebacd1a92f4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,084</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20d9ed9f-94a8-4cb4-87da-a4558c616172" contextRef="C_116ecf73-7a8a-49b3-bad1-9ebacd1a92f4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.62</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_35618a88-81cf-459e-9e3b-b27c83227de5" contextRef="C_116ecf73-7a8a-49b3-bad1-9ebacd1a92f4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">929,563</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf16fc93-22f2-4a35-9a1a-f8619f813d04" contextRef="C_116ecf73-7a8a-49b3-bad1-9ebacd1a92f4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.27</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_103706d0-0354-4510-9873-95c7c2d30ad7" contextRef="C_116ecf73-7a8a-49b3-bad1-9ebacd1a92f4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">92,500</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8dc9f114-5147-41cd-a22d-e6a7ceea47e7" contextRef="C_116ecf73-7a8a-49b3-bad1-9ebacd1a92f4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.44</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested at December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a76dea78-c527-4609-992e-119e645e3ee1" contextRef="C_6fd1e7a7-23cc-4225-bfaa-c65b03df60f2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">207,897</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_91d53013-ba7d-43d7-b312-c023d8e80ed4" contextRef="C_6fd1e7a7-23cc-4225-bfaa-c65b03df60f2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.50</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total fair value of restricted stock vested during the years ended December 31, 2025 and 2024 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_45d4b64d-5db6-4a7e-943a-8c26a508b1dc" contextRef="C_116ecf73-7a8a-49b3-bad1-9ebacd1a92f4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50df4759-e38b-4125-b738-f4a9cb47fa5d" contextRef="C_59a3bf61-d6f4-4d70-be41-c0021e29d89c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively</span></p></ix:continuation></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-Based Compensation</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6c535a04-879a-4cf0-af92-a204155ba1e7" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth stock-based compensation expense included in the Company&#8217;s consolidated statements of operations and comprehensive loss (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:62.695%;box-sizing:content-box;"/>
         <td style="width:2.079%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:14.574%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:2.079%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:14.574%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_15d21222-ca11-4a8b-9b2c-3880bd62574d" contextRef="C_c6ae4ef4-19bf-455d-8977-04567e0168e2" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,503</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0044e2bf-4a80-4fb2-9a37-27c2be963634" contextRef="C_09c5db3e-d09d-4b4f-b0d8-2f7673550209" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,032</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_61a09209-a220-48c9-abc0-73a1df09fe5b" contextRef="C_745ac205-619f-4d46-a569-a29ce2487e40" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,551</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb1f9da8-0654-4360-8049-92cd713dc7a5" contextRef="C_04dcce48-ee98-4468-a92e-30daf88a02ee" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,525</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9dd935c5-c6bc-44fa-ad29-d58c12f1c37a" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,054</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2279123b-6121-4010-8834-62cc8c403ddd" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,557</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense for the year ended December 31, 2025 included </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_594a4cc8-3a68-4ca0-9bdb-c46676308fd3" contextRef="C_50f9f95a-751c-4f2f-91d3-e149f6c84a6f" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million related to performance-based RSUs that vested in the third quarter of 2025 upon achievement of the performance conditions. As of December 31, 2025, ther</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">e was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ef82f55-ad6e-4ed3-9faf-0c8ee2e4f4e9" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">11.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million o</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">f total unrecognized compensation cost related to unvested awards expected to vest, which is expected to be recognized over a weighted average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0e3ba689-87d3-421c-b1ba-ee52f99a5947" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.9</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">132</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:nonNumeric id="F_719952dc-e5b0-427d-b94f-999a8cfe3fc4" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 10. Net Loss Per Share</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic and diluted net loss per share are computed using the weighted-average number of shares of common stock outstanding for the period. The Company issued a pre-funded warrant in December 2025 (see Note 6). The shares of common stock underlying the pre-funded warrant are included in the calculation of basic and diluted net loss per share because they are considered shares issuable for little or no consideration under ASC 260, Earnings Per Share. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a1b7f1b8-661b-4624-a008-3b8d47d21c67" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true" continuedAt="F_a1b7f1b8-661b-4624-a008-3b8d47d21c67_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table shows the computation of basic and diluted net loss per share (in thousands, except share and per share data):</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_a1b7f1b8-661b-4624-a008-3b8d47d21c67_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:64.307%;box-sizing:content-box;"/>
         <td style="width:2.1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.077%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:3.439%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.077%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1a295b97-616f-446d-acf7-04d0cdd60029" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">59,851</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b04f0d9c-ffdb-4533-81fe-a6fa645d7467" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">73,897</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Weighted-average common shares outstanding, basic <br/>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_774da70a-2bab-4b25-bc4e-02026f8a0788" contextRef="C_1f63916b-0391-41c4-8463-6860486b9487" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_0bfc3655-21f9-4e20-a75a-513fdb53daca" contextRef="C_1f63916b-0391-41c4-8463-6860486b9487" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">66,692,145</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b1f7462-d08f-4485-a94e-01ab75f8dea9" contextRef="C_5003f42b-a928-4d3a-9175-c224ea1b673a" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_00e62e53-78bc-4ee6-a0e0-74566d2b3a06" contextRef="C_5003f42b-a928-4d3a-9175-c224ea1b673a" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">48,163,301</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Weighted-average common shares outstanding under the <br/>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;pre-funded warrant, basic and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bef674c8-6f93-48ae-9130-d8428a6f9738" contextRef="C_75ea6436-b4b6-4e75-8aec-a8b8c3cc4fd8" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_e3feb66f-5faa-4b3b-96b8-44485f714c06" contextRef="C_75ea6436-b4b6-4e75-8aec-a8b8c3cc4fd8" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,120,000</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b0793b8-1ae0-4f31-a6e1-3c8c6161b7aa" contextRef="C_1898b0b8-f16b-4f56-9289-bef317318637" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:fixed-zero"><ix:nonFraction id="F_4f3023b9-c401-4766-8279-56071e80a0eb" contextRef="C_1898b0b8-f16b-4f56-9289-bef317318637" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Weighted-average common shares outstanding, basic <br/>&#160;&#160;&#160;&#160;&#160;&#160;&#160;and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ee73dfd-9c0e-4e04-86a3-a05e1a019781" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_e71305ab-a318-4988-b7c0-c0bb90016bf6" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">67,812,145</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e163f944-a653-45a4-ac31-0941248f6872" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_2722d890-30b9-4f14-8364-6da006b30b13" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">48,163,301</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Net loss per share, basic and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b822fa94-8185-477e-b7f0-bc49e0c97f37" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_9391023b-535a-4347-a5f1-e7ab6e8fc06a" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.88</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f66f1bad-a777-4985-ae60-8a872030bd8a" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_3fb49075-f4f1-4497-9fba-77727b7f28df" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.53</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0f6b4784-2a8d-45ce-a4fa-b06d473bd4a4" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share for the periods presented because their effect would have been anti-dilutive:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:64.32%;box-sizing:content-box;"/>
         <td style="width:1.64%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.54%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:2.96%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.54%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options to purchase common stock</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df18a44f-b260-498f-af00-36b69c360e5e" contextRef="C_6cab0607-2860-4e20-a77b-ee3751551c8f" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">6,427,777</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_67d2c71a-74eb-48aa-bf53-a0e2c9eab3e6" contextRef="C_20e4b68b-286f-4226-a52b-f50692b883e7" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,817,751</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested restricted stock units</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_44faf04f-8c93-465c-b59d-46f6c9db3418" contextRef="C_a81d855c-f7c2-4536-8f9e-51e73b2054d6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">207,897</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f287ae7a-8b1c-4df9-92f7-e357c1cc2c16" contextRef="C_fad7a1ea-38aa-452c-960d-f95e7b53f110" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,228,876</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares of common stock issuable under <br/>&#160;&#160;&#160;the ESPP</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_156499b4-b851-4045-a00a-9d7ee981eead" contextRef="C_24b9841c-7af8-45b7-a8fd-326e3878b0f2" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">23,944</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c799d860-ad07-4a31-b867-ef1f3fa9f09e" contextRef="C_5ebc4489-2c5c-40db-bf3d-8aa0443a01d9" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total potentially dilutive shares</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20c9a028-e50d-4f52-a73c-3e099cfe3418" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">6,659,618</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32236d6b-6c55-42cf-bda5-fb5796a78fef" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">4,046,627</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_22dfc61c-332b-47ef-86ab-538f3b803dfa" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true" continuedAt="F_22dfc61c-332b-47ef-86ab-538f3b803dfa_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 11. Income Taxes</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1e936b18-88db-4ecb-b6ea-5260408c8baf" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of net loss before tax provision from income taxes are as follows (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:64.387%;box-sizing:content-box;"/>
         <td style="width:2.1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.537%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:2.44%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.537%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">United States</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1f0d49f7-8bcf-45a7-9765-e95e9b87034b" contextRef="C_8c7ebad7-98a1-4e64-b935-7123699f4e44" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">59,579</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_43c800ee-9882-4504-80c7-b973b5938c44" contextRef="C_b2c1de80-7339-46dc-9101-dff3552ca399" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">67,137</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">United Kingdom</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5861d254-0a64-43ea-8c51-1a9c02bedfff" contextRef="C_f4a412c4-4532-42cb-8fef-51e2df6f0cd9" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">272</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b1e8d059-6846-4d08-87c3-1eb68ba42ff8" contextRef="C_e08c8f3c-6d20-45a5-9fa5-1cb8ef652339" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">6,760</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b8c6456-a7af-499b-a67f-94c6f6218f5f" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">59,851</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ebd5882-51e6-4b56-b3a3-a69738814e8a" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">73,897</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">133</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_22dfc61c-332b-47ef-86ab-538f3b803dfa_1" continuedAt="F_22dfc61c-332b-47ef-86ab-538f3b803dfa_2"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c38cf024-166b-40d7-baca-551d2f24dc18" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents a reconciliation of the Company&#8217;s expected tax computed at the U.S. statutory federal income tax rate to the total provision for income taxes (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:62.873%;box-sizing:content-box;"/>
         <td style="width:2.04%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.163%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:2.38%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.163%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:2.38%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. federal taxes at statutory rate</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6496c156-6d7f-4cac-acf8-492addc7ac6c" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">12,569</ix:nonFraction></span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3458ce1a-938a-4aa1-a12b-df321807b2f9" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">15,518</ix:nonFraction></span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;State taxes, net of federal benefit</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e921f07-b419-4783-827d-3e900ca98faf" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_61aaa363-cf07-4171-81a9-1bfab0314e80" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Acquired in-process research and development, related party</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fea8bf26-08bc-4339-8805-db388514be3b" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="clym:EffectiveIncomeTaxRateReconciliationAcquiredIn-ProcessResearchDevelopmentRelatedParty" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4eedbf5f-62df-4449-8782-6ef303f9f5ee" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="clym:EffectiveIncomeTaxRateReconciliationAcquiredIn-ProcessResearchDevelopmentRelatedParty" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,698</ix:nonFraction></span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Effect of cross-border transfers</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5f8edfe-b5fe-48a5-836b-da58d3ff3f59" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,303</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bddd55fc-8278-447c-823a-a06c1d9721e6" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Non-deductible officer compensation</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_84cf958d-cbe8-4428-9d03-e7d9aba23912" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="clym:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficerCompensationAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">293</ix:nonFraction></span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7b110d2-70a8-4179-ac19-32a993e97e30" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="clym:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficerCompensationAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">575</ix:nonFraction></span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Foreign rate differential</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3753548e-800b-4695-ad6f-d7f709713d62" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">237</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3a2034c8-740c-4553-a6c4-4200b0060a7c" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">211</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Stock-based compensation</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b0b8c6c-9ea9-477f-960a-5a35b027e37c" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">83</ix:nonFraction></span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3a312c08-519f-4dfa-a55e-f9ad03472682" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">588</ix:nonFraction></span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Tax credits</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ee8ceba-82af-49dd-b494-3c6a3f86aa45" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:IncomeTaxReconciliationTaxCredits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">403</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d0e049bf-8357-4ca4-b0a2-2f2b52eb95ef" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:IncomeTaxReconciliationTaxCredits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">86</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Other expenses, net</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_303b333b-f3e2-497e-b3e5-2e49723afded" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">228</ix:nonFraction></span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2fcac2c2-a189-4b8c-a941-afacfc0dc913" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">123</ix:nonFraction></span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Change in valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_082c70b4-9d4b-4256-8f60-993c77819468" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,284</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_efd91126-7155-4293-8969-0259954d70b9" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,076</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effective income tax rate</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7113d9c0-d909-42b2-afb2-af146035662c" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad7fa3f1-91c7-423b-b052-71469a7554ca" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4bd413ab-8b09-4ed8-a0df-3fe2f45d695f" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The significant components of the Company</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;s deferred tax assets and liabilities are presented below (in thousands):</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:64.387%;box-sizing:content-box;"/>
         <td style="width:2.1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.537%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:2.44%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.537%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Net operating losses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f546f73-4a5a-4e60-897a-6fc1e9ffbb39" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,202</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_05f6b5cb-c48e-474c-9bc4-0616cc40442b" contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,725</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Intangible assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2c3a9b55-7dbb-44ee-b250-07b47cecfa86" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,447</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3882855e-05c9-4405-b50d-cbd7133bcfd5" contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,946</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Research and development expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ab445d5b-477f-4977-8a7c-6ddc6bd47366" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="clym:DeferredTaxAssetsResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,824</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_624da2bd-cd0e-4112-bb0c-d705654a5d2c" contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e" name="clym:DeferredTaxAssetsResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,388</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Stock compensation expense, including 162m limitations</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_86e7f677-9c62-4901-a810-35bbcf74b480" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,400</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f18470e5-6c9a-4585-85b4-3c0e22b8c95e" contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">432</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Research credits</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4fe6cac6-593c-4f35-ac5a-a1780a905307" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,104</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f862819-842a-4799-a573-84c66471572e" contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">702</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Accrued compensation and benefits</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20269d61-1b1b-45f3-86ba-f3d5e7a16526" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">332</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eee8c3f2-1561-42d5-ab38-d44ef9675b89" contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">303</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Operating lease liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d35dfcd7-3928-4840-ae94-174ac6f1152a" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="clym:DefferedTaxAssetOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">113</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5feae16d-9b6b-4e65-aa4b-8f93a157c1bd" contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e" name="clym:DefferedTaxAssetOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">121</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Other expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c568f1c5-f9c2-4457-878d-740e18075747" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8eafc40-fba7-425a-b7ae-1f98327452da" contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total deferred tax assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_590bca23-6948-4344-b591-61cb9b9cc8f1" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,459</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1cf5e71f-379b-4b40-8a79-183d18188f56" contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,630</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_acfcf692-d544-4911-8c7f-8a96f248791a" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,368</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f41c214-26b6-4725-81e5-fd790b656ae6" contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,492</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Net deferred tax assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7584b400-86ac-468e-acbd-1b0339406d34" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">91</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4fa156de-ee7c-4530-ac49-3d423152695c" contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">138</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Operating lease, right-of-use asset</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e4c9ad75-79e5-4935-aa72-91af9f62dd07" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">106</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c37fff6-5745-4e55-b1d0-296dce81df38" contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">112</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Other assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ed4f26a-c708-41b6-8419-c4c86cafe40b" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:DeferredTaxLiabilitiesOther" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">15</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b42b515d-e5ed-43ec-b2d2-08001cfb812f" contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e" name="us-gaap:DeferredTaxLiabilitiesOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total deferred tax liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb45dcf6-93a0-41f8-915d-d217230f2dbe" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">91</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a7fb641-3033-43fb-8467-a158d38cb7ac" contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">138</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred tax assets and liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e9d0946-2899-4cd1-8a96-46fadb3cf962" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c9983bb0-7061-4d24-88a7-9e884fa71763" contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, the Company had federal net operating loss carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_320a0205-d790-4776-8fa5-20d14f084873" contextRef="C_7a1a17c3-5482-4393-8497-495abe0d0025" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">55.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which may be available to offset future taxable income and do not expire but are limited in their usage to an annual deduction equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_518ac01c-80ea-4052-b834-b179500d229a" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="clym:PercentageOfAnnualDeductionOfTaxableIncome" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">80</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of annual taxable income. As of December 31, 2025, the Company had state net operating loss carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c44ee1b4-44bd-4e65-93d6-d8d76d2cf503" contextRef="C_6a0b2fc4-e53f-4894-a5d0-249ab8cdaaa8" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which may be available to offset future taxable income and expire at various dates beginning in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_29698cea-5fba-4346-955f-9e8c8373199e" contextRef="C_5b33bfda-7940-4aa2-a368-a61504f508d9" name="clym:OperatingLossCarryforwardsExpirationStartYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2038</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As of December 31, 2025, the Company also had U.S. federal and state research and development tax credit carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5588120b-1bff-463e-9723-ee0340a6fd64" contextRef="C_7a1a17c3-5482-4393-8497-495abe0d0025" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88bfd315-1868-4870-85af-90d857a0f5e0" contextRef="C_6a0b2fc4-e53f-4894-a5d0-249ab8cdaaa8" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, which may be available to offset future tax liabilities and expire at various dates beginning in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e11a8fa3-ef34-484d-bdc9-02309cd431eb" contextRef="C_34d8c2a2-a75c-4398-b4d8-8fa4f3948fad" name="clym:TaxCreditCarryforwardExpirationYearStart"><ix:nonNumeric id="F_538dd92f-deee-4db8-a502-f02cb65bfdcf" contextRef="C_5b33bfda-7940-4aa2-a368-a61504f508d9" name="clym:TaxCreditCarryforwardExpirationYearStart"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2039</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As of December 31, 2025, the Company had foreign net operating loss carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4aa4cf05-37b7-40d7-bc79-3ab6dd892ca7" contextRef="C_67a4d641-d6ae-4d5f-aded-eba6a55bcaed" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">63.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which may be available to offset future taxable income and do not expire.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">134</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_22dfc61c-332b-47ef-86ab-538f3b803dfa_2"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Utilization of the U.S. federal and state net operating loss carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Sections 382 and 383 of the Internal Revenue Code of 1986, and corresponding provisions of state law, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income or tax liabilities. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50% over a three-year period. The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception due to the significant complexity and cost associated with such a study. If the Company has experienced a change of control, as defined by Section 382, at any time since inception, utilization of the net operating loss carryforwards or research and development tax credit carryforwards would be subject to an annual limitation under Section 382, which is determined by first multiplying the value of the Company&#8217;s stock at the time of the ownership change by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before utilization. Further, until a study is completed by the Company and any limitation is known, no amounts are being presented as an uncertain tax position.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As required by ASC 740, management of the Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets, which are comprised principally of net operating loss carryforwards. Management has determined that it is more likely than not that the Company will not recognize the benefits of its deferred tax assets and, as a result, a valuation allowance has been recorded.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_74c4e846-0db5-4911-9767-bacaca98a890" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:SummaryOfValuationAllowanceTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The changes in the valuation allowance were as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:64.387%;box-sizing:content-box;"/>
         <td style="width:2.1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.537%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:2.44%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.537%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance as of beginning of year</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ba55bcc-4e9f-410c-bd2e-0df5bdfd3cb0" contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,492</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f8ed12ee-7f82-4712-9da9-4d09f8cdf309" contextRef="C_c2a2497b-98c5-4d07-ac31-0ab57e9c6f6a" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,856</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Net increases recorded to income tax provision</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b75d969-6236-4999-a53e-45ffbe834e16" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,876</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_78f971fb-c1c2-4044-a0b8-daca9df11ad5" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,636</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance as of end of year</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_53e066a5-c197-4fb7-aaf5-68f81297b1f7" contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,368</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ae15b51-2d39-4e96-a947-82c149051c4d" contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,492</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The increase in the valuation allowance for deferred tax assets during the year ended December 31, 2025 related primarily to an increase in net operating losses. The increase in the valuation allowance for deferred tax assets during the year ended December 31, 2024 related primarily to increases in net operating losses and capitalized research and development costs.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company assesses the uncertainty in its income tax positions to determine whether a tax position of the Company is more likely than not to be sustained upon examination, including resolution of any related appeals of litigation processes, based on the technical merits of the position. For tax positions meeting the more-likely-than-not threshold, the tax amount recognized in the consolidated financial statements is reduced by the largest benefit that has a greater than fifty percent likelihood of being realized upon the ultimate settlement with the relevant taxing authority. No reserve for uncertain tax positions or related interest and penalties has been recorded at December 31, 2025 and 2024.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is subject to taxation in the U.S. (federal and various states) and the U.K. Currently, no historical years are under examination. The Company&#8217;s tax years starting in December 31, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_1ed21085-1747-4238-9882-f67da405f9c3;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2018</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> are open and subject to examination by the U.S. (federal and various states) and the U.K. taxing authorities due to the carryforward of utilized net operating losses and research and development credits.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_12070e85-cfef-4b9d-a6e0-c7c924bf0f57" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:DefinedBenefitPlanTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 12. Defined Contribution Plans</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.204%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has a 401(k) defined contribution plan. Participation in the plan is available to substantially all U.S.-based employees. Company contributions are discretionary but the Company has an employer matching program pursuant to which the Company makes matching contributions of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d82c937f-337c-4559-a179-871988d8efd9" contextRef="C_b2cd3b34-df50-4fcb-a36c-6d0072bb1fba" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of each participating employee&#8217;s eligible compensation. For the years ended December 31, 2025 and 2024, total expense recognized from the 401(k) matching contributions was approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_69598e2e-e790-4f53-b6b4-7d4d8b7aa678" contextRef="C_f3c7c70c-8584-4bd4-8cb7-4ec3bb217286" name="us-gaap:DefinedContributionPlanCostRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34acecd6-d161-4034-b8cf-8b78a95c61c9" contextRef="C_16c70f60-6525-47ed-a134-8055357fb60d" name="us-gaap:DefinedContributionPlanCostRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to the Company's restructuring in 2024 (see Note 13), the Company had a workplace pension contribution scheme for U.K.-based employees. For the year ended December 31, 2024, the Company made contributions to the pension scheme of approximatel</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">y $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_71690030-c5e7-4f34-8f15-44cc6eb40075" contextRef="C_f2839107-9d2e-4b8c-98bb-fb38fcdc5134" name="us-gaap:DefinedContributionPlanCostRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">135</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:nonNumeric id="F_003dd8b6-3364-4af2-8afd-e8fd1830f102" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 13. Restructuring Costs</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2024, the Company shifted its focus from developing therapeutics for neuronal excitability disorders to immune-mediated diseases. In connection with this shift, the Company ceased its operations in the U.K. and separated from seven U.K. employees in 2024. The costs associated with this headcount reduction were fully recognized and all of the related payments were made by December 31, 2024. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f9db8da0-0f52-43f9-9118-31fce5f59c89" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" escape="true" continuedAt="F_f9db8da0-0f52-43f9-9118-31fce5f59c89_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A summary of the restructuring costs recorded in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2024 were as follows (in thousands):</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_f9db8da0-0f52-43f9-9118-31fce5f59c89_1">
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:34.227%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.683%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.683%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:16.203%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:16.203%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="11" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">ROU Asset <br/>Impairment</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Severance and  <br/>Benefit Costs</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Stock-based<br/>Compensation</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total<br/>Restructuring<br/>Cost Recorded</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3a0c6461-51dc-4f2b-8bbb-70dfb084781c" contextRef="C_16927a58-af3a-42b4-98d5-64f89907d927" name="us-gaap:RestructuringCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_08fece21-4867-4a8e-8537-9d4d0aa073cd" contextRef="C_41711020-7e54-4cd4-9a26-fdac1e897d3f" name="us-gaap:RestructuringCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,778</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d4b60a36-955a-4ff0-afc8-4f6feec1a0b1" contextRef="C_81960adb-5d4d-4573-bc54-80d5eb37fb9c" name="us-gaap:RestructuringCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">944</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_158d404a-d690-476f-8a47-246051833651" contextRef="C_c6e42dca-dd21-461f-8178-f4beb56519dc" name="us-gaap:RestructuringCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,722</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7397d018-3da8-4e3c-a998-c8090ddcaf03" contextRef="C_b2cb9c72-8c63-4b1f-9bfe-c20a91b5c47f" name="us-gaap:RestructuringCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f6219282-9a75-4ecc-9710-8ba809a1e065" contextRef="C_84f00985-ac68-4cfe-8454-b7dc6d4cc926" name="us-gaap:RestructuringCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">475</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6eac4d9f-514d-4f56-8848-121b574cd20f" contextRef="C_1b535855-abfa-4f1d-9fb5-d30b12645dea" name="us-gaap:RestructuringCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">161</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e37745e-775c-4b6e-9676-abfd839d4cf6" contextRef="C_3f3384f6-f21d-457a-af6e-c427fa15b93a" name="us-gaap:RestructuringCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">636</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total restructuring costs</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_53bb6ebf-7b15-4de3-b446-23ece973f101" contextRef="C_1c1140e8-fbcf-4f4b-b119-b4e0831d7ee2" name="us-gaap:RestructuringCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a983f76-b3d9-4662-93f8-9dd0be53ff6d" contextRef="C_ba5d6e15-a48f-47c7-9a81-6786f5b4f65b" name="us-gaap:RestructuringCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,253</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f52bd53b-6975-401b-a506-abf44df3943d" contextRef="C_9b4e2e25-766b-4195-902e-5d8cc2e9e3df" name="us-gaap:RestructuringCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,105</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d6747052-7602-4ad0-8d92-3e06c497c58c" contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7" name="us-gaap:RestructuringCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,358</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:continuation></div></ix:nonNumeric></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6e40277a-e980-4a7c-9871-fa2610669eb8" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:SegmentReportingDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 14. Segments</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker (the CODM). The Company views its operations and manages its business as </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_58d19a22-2920-4eb0-8e07-88c1a4b0a3d4" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:NumberOfReportableSegments" unitRef="U_Segments" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_5d64bf2b-c07f-468a-86bf-88892f99d6aa" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:NumberOfOperatingSegments" unitRef="U_Segments" decimals="0" format="ixt-sec:numwordsen">one</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating and reportable segment, focused on developing therapeutics for patients with immune-mediated diseases. The Company&#8217;s CODM is its </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_486ead36-778f-4db7-a0cb-c45b1a00e08c;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">chief executive officer</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Segment profit or loss is measured as net loss presented in the consolidated statements of operations and comprehensive loss. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bfadf5b5-7780-4978-a038-1b86677710a6" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the purpose of evaluating segment performance and allocating resources, the CODM reviews the Company&#8217;s financial information on a consolidated basis together with certain operating metrics and evaluates net loss against comparable prior periods and the Company&#8217;s annual operating plan. The measure of segment assets is reported on the consolidated balance sheets as total consolidated assets.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:11pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fc9e4f23-fd4b-445d-b9d4-3ec9694a2841" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" escape="true"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the significant expense categories included within net loss presented on the consolidated statements of operations and comprehensive loss, the following table sets forth disaggregated research and development expenses (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:65.513%;box-sizing:content-box;"/>
         <td style="width:1.92%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.323%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.92%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.323%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Direct research and development expenses:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Budoprutug</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c74170fd-3bd4-4971-96df-7637f43ffde3" contextRef="C_bd13e69e-5c42-4043-b717-21b094f74c19" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,045</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4df717d8-b998-4bbd-a5f1-6baa25240a10" contextRef="C_ffe66a6a-2737-4df5-8bd7-75a6156fd39c" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,982</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">CLYM116</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">1</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_94a611c6-fe60-4f7e-aa05-ab8af00ceabb" contextRef="C_3c01e103-0ded-4d1e-be15-85317f4afcac" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,964</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24849bd4-af46-419c-b5d3-444ee75bc1f2" contextRef="C_98215062-e0fc-42fc-b9b2-81c479845247" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Legacy programs</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">2</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1bda04b-4315-43f6-8d54-43a89d4c656b" contextRef="C_5ba093f0-d16e-4ef7-8562-6da6013de54a" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">107</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee2ef0ab-8059-46e1-9500-b4698a700b23" contextRef="C_55e0a766-eff7-448c-af18-1396354e6f58" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">201</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unallocated research and development expenses:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel-related (including stock-based compensation)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c4676f52-fbe7-429e-b682-43cc4d33963c" contextRef="C_015297a3-3968-4419-a989-c89674259ced" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,232</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bdd3ae9b-f90b-4024-bb41-e0493a39459f" contextRef="C_69a98cdd-d277-4823-8526-1135dd15782f" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,990</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other research and development expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5d859c9-8cf4-4473-a17c-d70fb4cafa68" contextRef="C_2691b0a1-6374-46d9-a04c-367ba1059083" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,365</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c21b10f-0bbb-431b-87fa-e93d46147752" contextRef="C_1bcd3bb5-c5b5-4602-ab79-6c587ad285a1" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">163</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total research and development expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_007de669-c2ce-472c-a43f-a2b4964398e1" contextRef="C_4a576f93-6b66-4d5d-b1c0-bff422cdc503" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,713</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1eccdaa6-834b-43e2-ab9c-6f6ca189bdbc" contextRef="C_c03b49f0-805e-4685-86c8-e850f4d0a421" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,336</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3.35pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.695pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><ix:footnote id="FNT_12707c51-ddf2-4b1d-9b50-539eb84344b9" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes the upfront payment and the associated direct transaction costs incurred in connection with the Mabworks Agreement for the year ended December 31, 2025.</span></ix:footnote></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.695pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><ix:footnote id="FNT_c66c06d3-a16d-45aa-bd91-9bfdc6bbe5d7" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes direct expenses related to the Company's legacy product candidates ETX-123 and ETX-155.</span></ix:footnote></p></ix:nonNumeric></div></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">136</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9_changes_in_and_disagreements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">em 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9a_controls_and_procedures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">tem 9A. Controls and Procedures.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our chief executive officer (our principal executive officer) and chief financial officer (our principal financial officer) or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management, under the supervision and with the participation of our chief executive officer and chief financial officer (our principal executive officer and principal financial officer, respectively), evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2025. Based on our evaluation, our chief executive officer and chief financial officer have concluded that our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) were not effective as of December 31, 2025 because of the material weaknesses in our internal control over financial reporting described below.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding the material weaknesses, management believes the consolidated financial statements as included in Item 8 of this Annual Report on Form 10-K present fairly, in all material respects, the Company's financial condition, results of operations and cash flows as of and for the periods presented in accordance with generally accepted accounting principles in the United States.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Management&#8217;s Report on Internal Control Over Financial Reporting</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting. The Company&#8217;s internal control over financial reporting is a process designed under the supervision of our executive chair and our chief accounting officer to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the Company&#8217;s financial statements for external reporting purposes in accordance with generally accepted accounting principles.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, management conducted an assessment of the effectiveness of the Company&#8217;s internal control over financial reporting based on the framework established in &#8220;Internal Control&#8212;Integrated Framework&#8221; (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this assessment, management has determined that the Company&#8217;s internal control over financial reporting was not effective as of December 31, 2025, because of the unremediated material weaknesses in our internal control over financial reporting described below.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the annual or interim consolidated financial statements will not be prevented or detected on a timely basis. The material weaknesses are as follows:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We did not design or maintain an effective control environment. Specifically, we lacked a sufficient number of professionals with an appropriate level of accounting knowledge, training and experience to appropriately analyze, record and disclose accounting matters commensurate with accounting and reporting requirements. The lack of personnel contributed to the following material weakness.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We did not design and maintain formal accounting policies, procedures and controls to achieve complete, accurate and timely financial accounting, reporting and disclosures, including segregation of duties and controls over the preparation and review of journal entries, account reconciliations and consolidation.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These material weaknesses did not result in a misstatement to the consolidated financial statements. However, these material weaknesses could result in a misstatement of our account balances or disclosures that would result in a material misstatement of our annual or interim consolidated financial statements that would not be prevented or detected.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">137</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management&#8217;s report on internal control over financial reporting was not subject to attestation by the Company&#8217;s independent registered public accounting firm pursuant to the rules of the SEC that permit the Company to provide only management&#8217;s report.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Remediation Efforts to Address Material Weaknesses</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management has concluded that the material weaknesses in internal control over financial reporting were due to the fact that we were a private company with limited resources when the material weaknesses were identified and did not have the necessary business processes and related internal controls formally designed and implemented, coupled with the appropriate resources with the appropriate level of experience and technical expertise, to oversee our business processes and controls.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have implemented measures designed to improve internal control over financial reporting to remediate the control deficiencies that led to our material weaknesses. The remediation measures we have taken include:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Hired qualified personnel with appropriate expertise to perform specific functions and ensure adequate segregation of key duties and responsibilities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Continued to design and implement improved policies, processes, and internal controls, including senior management review and audit committee oversight, to achieve complete, accurate and timely financial accounting, reporting and disclosures;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Continued to implement and formalize policies, processes, and internal controls to identify and assess complex accounting transactions and other technical accounting and financial reporting matters; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Implemented financial systems to improve segregation of duties and controls and reliability of system generated data.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe we have made substantial progress toward achieving the effectiveness of our internal control over financial reporting and disclosure controls and procedures. The actions that have been taken are subject to continued review and testing by management as well as oversight by the audit committee of our board of directors. We will not be able to conclude whether the steps we have taken will fully remediate these material weaknesses in our internal control over financial reporting until we have completed our remediation efforts and subsequent evaluation of their effectiveness.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in Internal Control over Financial Reporting</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There have not been any changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended December 31, 2025 that have materially affected, or are reasonably likely to materially affect our internal control over financial reporting.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2388707b-e38e-4873-9c23-e668a6f44228" contextRef="C_e1c23734-80c9-41dd-8d11-0134db853cac" name="ecd:MtrlTermsOfTrdArrTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9b_other_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">em 9B. Other Information.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Director and Officer Trading Arrangements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The adoption or termination of contracts, instructions or written plans for the purchase or sale of our securities by our Section 16 officers and directors for the three months ended December 31, 2025, each of which is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act (&#8220;Rule 10b5-1 Plan&#8221;), were as follows:</span></p>
     <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
      <tr style="visibility:collapse;">
       <td style="width:17.163%;box-sizing:content-box;"/>
       <td style="width:15.743%;box-sizing:content-box;"/>
       <td style="width:22.545%;box-sizing:content-box;"/>
       <td style="width:11.262%;box-sizing:content-box;"/>
       <td style="width:18.044%;box-sizing:content-box;"/>
       <td style="width:1%;box-sizing:content-box;"/>
       <td style="width:13.243%;box-sizing:content-box;"/>
       <td style="width:1%;box-sizing:content-box;"/>
      </tr>
      <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
       <td style="border-top:0.5pt solid #000000;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name (Title)</span></p></td>
       <td style="border-top:0.5pt solid #000000;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Action taken<br/>(Date of Action)</span></p></td>
       <td style="border-top:0.5pt solid #000000;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Type of Trading Arrangement</span></p></td>
       <td style="border-top:0.5pt solid #000000;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Nature of Trading<br/>Arrangement</span></p></td>
       <td style="border-top:0.5pt solid #000000;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Duration of Trading<br/>Arrangement</span></p></td>
       <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate Number<br/>of Securities</span></p></td>
       <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      </tr>
      <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
       <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:pre-wrap;border-left:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_53cc9270-628c-4b53-a31b-fb446aa777b0" contextRef="C_0427b5f4-a659-4e63-a2a5-bbd14bc3d153" name="ecd:TrdArrIndName"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stephen Thomas</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"><br/>(</span><span style="font-size:9pt;"><ix:nonNumeric id="F_42b3774f-fdd1-45a5-9abf-4770f3abd48c" contextRef="C_0427b5f4-a659-4e63-a2a5-bbd14bc3d153" name="ecd:TrdArrIndTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">)</span></p></td>
       <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">Adoption<br/>(</span><span style="font-size:9pt;"><ix:nonNumeric id="F_e4eb3626-1974-415c-9eea-f2de931d15a7" contextRef="C_0427b5f4-a659-4e63-a2a5-bbd14bc3d153" name="ecd:TrdArrAdoptionDate"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">October 14, 2025</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">)</span></p></td>
       <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_cdbfcd16-675d-4137-a2cf-356edf3cdbaf" contextRef="C_0427b5f4-a659-4e63-a2a5-bbd14bc3d153" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rule 10b5-1</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;trading arrangement</span></p></td>
       <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sale</span></p></td>
       <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">Until </span><span style="font-size:9pt;"><ix:nonNumeric id="F_fde9c606-9a03-4338-88e7-de9ae92bc860" contextRef="C_0427b5f4-a659-4e63-a2a5-bbd14bc3d153" name="ecd:TrdArrExpirationDate"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">August 8, 2026</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">, or, if earlier, upon the completed sale of the maximum shares</span></p></td>
       <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca756d78-b9a9-4cbf-b784-56c42e01ae77" contextRef="C_fe9354d0-7134-4802-ac6f-dbcfc70b829d" name="ecd:TrdArrSecuritiesAggAvailAmt" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">150,000</ix:nonFraction></span></p></td>
       <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      </tr>
     </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="disclosure_regarding_foreign"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9C. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">138</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART III</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_10_directors_executive_officers"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">em 10. Directors, Executive Officers and Corporate Governance.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information required by this item and not set forth below will be set forth in the sections headed </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Election of Directors</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Executive</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Officers </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">contained in our definitive Proxy Statement to be filed with the Securities and Exchange Commission within 120 days after the conclusion of our fiscal year ended</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 (the Proxy Statement) pursuant to General Instructions G(3) of Form 10-K and is incorporated herein by reference.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b9765c03-962d-4edc-8847-a5ed7f0c57de" contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> a code of business conduct and ethics that applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. A current copy of our code of business conduct and ethics is available under the Corporate Governance section of our website at climbbio.com. If we make any substantive amendments to the code of business conduct and ethics or grant any waiver from a provision of the code of business conduct and ethics to any executive officer or director that are required to be disclosed pursuant to SEC rules, we will promptly disclose the nature of the amendment or waiver on our website or in a current report on Form 8-K.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_11_executive_compensation"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">em 11. Executive Compensation.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this item will be set forth in our Proxy Statement in the sections headed </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Executive and Director</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Compensation </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> Director Compensation </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">contained in our Proxy Statement and is incorporated herein by reference.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_12_security_ownership"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">em 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information required by this item will be set forth in the sections headed </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Management </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> Executive and Director Compensation </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">contained in our Proxy Statement and is incorporated herein by reference.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_13_certain_relationships"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">em 13. Certain Relationships and Related Transactions, and Director Independence.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information required by this item will be set forth in the sections headed </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Certain Related-Person Transactions</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Information</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Regarding the Board of Directors and Corporate Governance </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">contained in our Proxy Statement and is incorporated herein by reference.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_14_principal_accounting_fees"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">m 14. Principal Accounting Fees and Services.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information required by this item will be set forth in the sections headed </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Ratification of Selection of Independent Registered Public</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accounting Firm </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">contained in our Proxy Statement and is incorporated herein by reference.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">139</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART IV</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_15_exhibits_financial_statement"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">em 15. Exhibits, Financial Statement Schedules.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">(a) Documents filed as part of this report</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">(1) Financial Statements. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following consolidated financial statements of Climb Bio, Inc., together with the report of PricewaterhouseCoopers LLP, an independent registered public accounting firm, required to be filed pursuant to Part II, Item 8 of this Annual Report on Form 10-K are included on the following pages:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:94%;box-sizing:content-box;"/>
     <td style="width:6%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Page</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#opinion"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Report of Independent Registered Public Accounting Firm (PCAOB ID 238)</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">112</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Balance Sheets</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">113</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_state_of_oper_and_comp_loss"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Operations and Comprehensive Loss</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">114</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consoli_state_of_prefe_stock_and_deficit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Stockholders&#8217; Equity</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">115</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_of_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Cash Flows</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">116</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_to_consolidated_financial_statemen"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">117</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">(2) Financial Statement Schedules.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> None.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">(3) List of exhibits required by Item 601 of Regulation S-K</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. See part (b) below.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">(b) Exhibits.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">140</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit Index</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:91.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:10.593%;box-sizing:content-box;"/>
     <td style="width:1.099%;box-sizing:content-box;"/>
     <td style="width:40.527%;box-sizing:content-box;"/>
     <td style="width:1.099%;box-sizing:content-box;"/>
     <td style="width:6.571%;box-sizing:content-box;"/>
     <td style="width:1.099%;box-sizing:content-box;"/>
     <td style="width:12.044%;box-sizing:content-box;"/>
     <td style="width:1.099%;box-sizing:content-box;"/>
     <td style="width:6.571%;box-sizing:content-box;"/>
     <td style="width:1.099%;box-sizing:content-box;"/>
     <td style="width:17.099%;box-sizing:content-box;"/>
     <td style="width:1.099%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="7" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Incorporated by Reference</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit Number</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description of Exhibit</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Form</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">File No.</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Filing Date</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1768446/000119312524092520/d737147dex21.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Agreement and Plan of Merger and Reorganization, dated as of April 10, 2024, by and among the Company, Tango Merger Sub, Inc,. Tenet Medicines, Inc. and, solely in his capacity as the Company Equityholder Representative, Stephen Thomas</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-40708</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">April 11, 2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1768446/000095017024125294/clym-ex3_1.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Certificate of Incorporation of the Registrant as amended</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-40708</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 12, 2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1768446/000119312524231167/d888487dex32.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Bylaws of the Registrant</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;001-40708</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">October 2, 2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1768446/000095017025044350/clym-ex4_1.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of common stock certificate of the Registrant</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-40708</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 25, 2025</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1768446/000119312521217529/d105292dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Investors Rights Agreements, dated May 21, 2021, by and among the Registrant and the investors listed on Schedule A thereto</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-257980</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">August 2, 2021</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1768446/000095017025044350/clym-ex4_3.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Description of Securities</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-40708</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 25, 2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.4</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1768446/000119312525315108/d48098dex41.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Pre-Funded Warrant</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;001-40708</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 11, 2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1+</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1768446/000095017025044350/clym-ex10_1.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2021 Equity Incentive Plan</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-40708</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 25, 2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2+</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1768446/000095017025044350/clym-ex10_2.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Forms of Option Agreement, Stock Option Grant Notice and Notice of Exercise under the 2021 Equity Incentive Plan</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-40708</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 25, 2025</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3+</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1768446/000095017025044350/clym-ex10_3.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Forms of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the 2021 Equity Incentive Plan</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-40708</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 25, 2025</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4+</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1768446/000095017025044350/clym-ex10_4.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2021 Employee Stock Purchase Plan</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-40708</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 25, 2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.5+</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1768446/000119312521232117/d105292dex108.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Indemnification Agreement, by and between the Registrant and each of its directors and executive officers</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-257980</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.8</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">August 2, 2021</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.6</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1768446/000119312524092520/d737147dex105.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Registration Rights Agreement, dated April 10, 2024, by and among the Registrant and the persons party thereto</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-40708</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.5</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">April 11, 2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.7+</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1768446/000119312524159994/d839370dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Offer Letter, dated June 12, 2024, between the Registrant and Aoife Brennan</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-40708</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">June 12,2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.8&#134;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1768446/000119312524170599/d692630dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Asset Purchase Agreement, dated as of January 4, 2024, by and between Tenet Medicines, Inc., Acelyrin, Inc. and WH2, LLC</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-40708</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">June 27, 2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.9&#134;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1768446/000119312524170599/d692630dex102.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated License Agreement, dated as of January 11, 2024, by and between Tenet Medicines, Inc. and Cancer Research Technology Limited</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-40708</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">June 27, 2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.10&#134;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1768446/000119312524170599/d692630dex103.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Cell Line Development, Manufacturing Services and License Agreement, effective as</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-40708</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">June 27, 2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">141</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;">
   <table style="border-spacing:0;table-layout:auto;width:91.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:10.593%;box-sizing:content-box;"/>
     <td style="width:1.099%;box-sizing:content-box;"/>
     <td style="width:40.527%;box-sizing:content-box;"/>
     <td style="width:1.099%;box-sizing:content-box;"/>
     <td style="width:6.571%;box-sizing:content-box;"/>
     <td style="width:1.099%;box-sizing:content-box;"/>
     <td style="width:12.044%;box-sizing:content-box;"/>
     <td style="width:1.099%;box-sizing:content-box;"/>
     <td style="width:6.571%;box-sizing:content-box;"/>
     <td style="width:1.099%;box-sizing:content-box;"/>
     <td style="width:17.099%;box-sizing:content-box;"/>
     <td style="width:1.099%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1768446/000119312524170599/d692630dex103.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">of February 9, 2021 by and between Valenza Bio, Inc. and ProBioGen, Inc.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.11+</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1768446/000119312525227025/d33819dex101.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Offer Letter, dated September 30, 2025 between the Registrant and Susan Altschuller, Ph.D, MBA</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-40708</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">October 1, 2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.12</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1768446/000119312525125866/d854335dex101.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Separation and Release of Claims Agreement, dated as of May 23, 2025, by and between the Registrant and Brett Kaplan, M.D.</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-40708</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 23, 2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.13+</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1768446/000095017025106916/clym-ex10_1.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Offer Letter, dated February 1, 2025 between the Registrant and Perrin Wilson</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-40708</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">August 12, 2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.14+</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1768446/000095017024125294/clym-ex10_1.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consulting Agreement, dated June 27, 2024, between the Registrant and Stephen Thomas</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-40708</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 12, 2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.15+</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1768446/000095017024125294/clym-ex10_2.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment to Consulting Agreement, dated November 1, 2024, between the Registrant and Stephen Thomas</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-40708</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 12, 2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.16</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1768446/000095017025044350/clym-ex10_14.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Technology Transfer and Exclusive License Agreement, dated January 8, 2025, by and between the Registrant and Beijing Mabworks Biotech Co., Ltd.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-40708</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.14</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 25, 2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.17</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1768446/000119312525062629/d943630dex11.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Equity Distribution Agreement, dated as of March 25, 2025, by and between the Registrant and Oppenheimer &amp; Co. Inc.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-40708</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 25, 2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.18</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1768446/000119312525268086/clym-ex10_1.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2025 Inducement Plan, as amended</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-40708</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 6, 2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.19+</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1768446/000095017025070902/clym-ex10_4.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Stock Option Grant Notice under the 2025 Inducement Plan</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-40708</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 14, 2025</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.20+</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1768446/000095017025070902/clym-ex10_5.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Restricted Stock Unit Award Grant Notice under the 2025 Inducement Plan</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-40708</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.5</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 14, 2025</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.21+</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1768446/000095017025070902/clym-ex10_6.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Non-Employee Director Compensation Policy</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-40708</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.6</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 14, 2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.22</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1768446/000119312525315108/d48098dex101.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Exchange Agreement, dated December 11, 2025, between the Registrant and the holders of the common stock listed on Schedule I attached thereto</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-40708</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 11, 2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1768446/000095017025044350/clym-ex19_1.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Insider Trading Policy</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-40708</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 25, 2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.1*</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="clym-ex21_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">List of subsidiaries</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.1*</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="clym-ex23_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="background-color:#ffffff;padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.1*</span></p></td>
     <td style="background-color:#ffffff;padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#ffffff;padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="clym-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="background-color:#ffffff;padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#ffffff;padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#ffffff;padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="background-color:#ffffff;padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.2*</span></p></td>
     <td style="background-color:#ffffff;padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#ffffff;padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="clym-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="background-color:#ffffff;padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#ffffff;padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#ffffff;padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">142</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;">
   <table style="border-spacing:0;table-layout:auto;width:91.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:10.593%;box-sizing:content-box;"/>
     <td style="width:1.099%;box-sizing:content-box;"/>
     <td style="width:40.527%;box-sizing:content-box;"/>
     <td style="width:1.099%;box-sizing:content-box;"/>
     <td style="width:6.571%;box-sizing:content-box;"/>
     <td style="width:1.099%;box-sizing:content-box;"/>
     <td style="width:12.044%;box-sizing:content-box;"/>
     <td style="width:1.099%;box-sizing:content-box;"/>
     <td style="width:6.571%;box-sizing:content-box;"/>
     <td style="width:1.099%;box-sizing:content-box;"/>
     <td style="width:17.099%;box-sizing:content-box;"/>
     <td style="width:1.099%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="background-color:#ffffff;padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.1**</span></p></td>
     <td style="background-color:#ffffff;padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#ffffff;padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="clym-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="background-color:#ffffff;padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#ffffff;padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#ffffff;padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="background-color:#ffffff;padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.2**</span></p></td>
     <td style="background-color:#ffffff;padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#ffffff;padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="clym-ex32_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="background-color:#ffffff;padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#ffffff;padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#ffffff;padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="background-color:#ffffff;padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97.1</span></p></td>
     <td style="background-color:#ffffff;padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#ffffff;padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1768446/000095017024038023/elym-ex97_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Clawback Policy</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-40708</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 28, 2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="background-color:#ffffff;padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#ffffff;padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#ffffff;padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.INS*</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Instance Document</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.SCH*</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.CAL*</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.DEF*</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Extension Definition Linkbase Document</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.LAB*</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Label Linkbase Document</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.PRE*</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104*</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File (embedded within inline XBRL document)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:80%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* Filed herewith.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">** The certifications furnished in Exhibit 32.1 and 32.2 hereto are deemed to be furnished with this Annual Report on Form 10-K and will not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by reference.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">+ Indicates management contract or compensatory plan.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#134; Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_16_form_10_k_summary"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">em 16. Form 10-K Summary</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">143</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.8in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNATURES</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:49%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:3.62%;box-sizing:content-box;"/>
     <td style="width:46.38%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Climb Bio, Inc.</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 5, 2026</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Aoife Brennan</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aoife Brennan, M.B., Ch.B.</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">President and Chief Executive Officer</span></p></td>
    </tr>
   </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:2.3111111111111113in;box-sizing:content-box;"/>
     <td style="width:0.07013888888888889in;box-sizing:content-box;"/>
     <td style="width:3.03125in;box-sizing:content-box;"/>
     <td style="width:0.07291666666666667in;box-sizing:content-box;"/>
     <td style="width:1.5145833333333334in;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date</span></p></td>
    </tr>
    <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Aoife Brennan</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">President, Chief Executive Officer and Director</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 5, 2026</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aoife Brennan, M.B., Ch.B.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">&#160;(Principal Executive Officer)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Susan Altschuller</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 5, 2026</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Susan Altschuller, Ph.D., MBA</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(Principal Financial Officer)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Cindy J. Driscoll</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Senior Vice President, Finance</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 5, 2026</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cindy J. Driscoll, MBA</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(Principal Accounting Officer)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2.68pt;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Douglas E. Williams</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Director</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 5, 2026</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Douglas E. Williams, Ph.D.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(Chairman)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Alexander Cumbo</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Director</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 5, 2026</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Alexander Cumbo</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Kimberlee C. Drapkin</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Director</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 5, 2026</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Kimberlee C. Drapkin, CPA</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Judith Dunn</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Director</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 5, 2026</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Judith Dunn, Ph.D</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Andrew Levin</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Director</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 5, 2026</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Andrew Levin, M.D., Ph.D.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Stephen Thomas</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Director</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 5, 2026</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#160;Stephen Thomas, Ph.D.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">144</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>2
<FILENAME>clym-ex21_1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-03-04T20:15:56.9910+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-21.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="margin-left:73.333%;text-indent:25%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right; margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 21.1</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">List of Subsidiaries of Climb Bio, Inc.</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Eliem Therapeutics (UK) Ltd. (England and Wales)</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Climb Bio Operating Inc.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>clym-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-03-04T20:15:57.0442+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.39in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:24pt;font-family:Times New Roman;margin-bottom:24pt;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 23.1</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:24pt;font-family:Times New Roman;margin-bottom:24pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">													</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-286303, 333-278328, 333-270304, 333-263347 and 333-258771) and Form S-3 (Nos. 333-283166 and 333-280784) of Climb Bio, Inc. of our report dated March 5, 2026 relating to the financial statements, which appears in this Form 10-K.</font></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ PricewaterhouseCoopers LLP<br>Seattle, Washington</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 5, 2026</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:'Georgia',serif;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#ff0000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Georgia',serif;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#ff0000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Georgia',serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.39in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Georgia',serif;font-kerning:none;min-width:fit-content;">1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Georgia',serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Georgia',serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>clym-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-03-04T20:15:57.1161+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.1</font></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Aoife Brennan, certify that:</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. I have reviewed this Annual Report on Form 10-K of Climb Bio, Inc.;</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4. The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p><p style="margin-left:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p><p style="margin-left:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p><p style="margin-left:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p><p style="margin-left:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5. The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></p><p style="margin-left:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></p><p style="margin-left:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></p><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:43%;box-sizing:content-box;"></td>
     <td style="width:6%;box-sizing:content-box;"></td>
     <td style="width:3%;box-sizing:content-box;"></td>
     <td style="width:48%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 5, 2026</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Aoife Brennan</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aoife Brennan, M.B., Ch.B.</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">President and Chief Executive Officer</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>clym-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-03-04T20:15:57.0027+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.2</font></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Susan Altschuller, certify that:</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. I have reviewed this Annual Report on Form 10-K of Climb Bio, Inc.;</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4. The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p><p style="margin-left:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p><p style="margin-left:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p><p style="margin-left:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p><p style="margin-left:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5. The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></p><p style="margin-left:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></p><p style="margin-left:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></p><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:43%;box-sizing:content-box;"></td>
     <td style="width:6%;box-sizing:content-box;"></td>
     <td style="width:3%;box-sizing:content-box;"></td>
     <td style="width:48%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 5, 2026</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Susan Altschuller</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Susan Altschuller, Ph.D., MBA</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Chief Financial Officer</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(Principal Financial Officer)</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>clym-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-03-04T20:15:56.9985+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 32.1</font></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Annual Report on Form 10-K of Climb Bio, Inc. (the &#x201c;Company&#x201d;) for the period ended December 31, 2025, as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:45.46%;box-sizing:content-box;"></td>
     <td style="width:5.04%;box-sizing:content-box;"></td>
     <td style="width:3.04%;box-sizing:content-box;"></td>
     <td style="width:46.46%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 5, 2026</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Aoife Brennan</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aoife Brennan, M.B., Ch.B.</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">President and Chief Executive Officer</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. &#167; 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>clym-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-03-04T20:15:57.1070+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-32.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 32.2</font></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Annual Report on Form 10-K of Climb Bio, Inc. (the &#x201c;Company&#x201d;) for the period ended December 31, 2025, as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:45.451%;box-sizing:content-box;"></td>
     <td style="width:5.059%;box-sizing:content-box;"></td>
     <td style="width:3.039%;box-sizing:content-box;"></td>
     <td style="width:46.451%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 5, 2026</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Susan Altschuller</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Susan Altschuller, Ph.D., MBA</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Chief Financial Officer</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(Principal Financial Officer)</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. &#167; 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>img22994243_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img22994243_0.jpg
M_]C_X  02D9)1@ ! @$ > !X  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" ).!-\# 2(  A$! Q$!_\0
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M .V%_P"&_P#@[_\ /XK^ ^BC_4'A[_GWB_\ PJE_\C_5WY6/]>^(/^?F%_\
M":/_ ,D?WX?\14G_  3Z_P"B/_MA?^&_^#O_ ,_BC_B*D_X)]?\ 1'_VPO\
MPW_P=_\ G\5_ ?11_J#P]_S[Q?\ X52_^1_J[\K'^O?$'_/S"_\ A-'_ .2/
M]#CP=_P<H?L1^./ _P 8OB#H?P=_:S/A_P"!OAGP?XL\<FZ\$_!^"\32?''Q
M'\,_"W0SI5N/CG(+ZX/BGQ;I*W4326X@L#<70>1HA"_F_P#Q%2?\$^O^B/\
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M>T'@GX/RZBU[\(M1\*Z7XN&I69^.2+9Q+=>,-'_LYUFG^V1FY=EA\D!_-O\
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M !%2?\$^O^B/_MA?^&_^#O\ \_BOX#Z*/]0>'O\ GWB__"J7_P C_5WY6/\
M7OB#_GYA?_":/_R1_H<?#[_@Y0_8C^)>E?%C6/#7P=_:S:S^#/PJU+XQ^,S?
M>"?@_;2+X.TKQEX'\"W;::@^.<HO-2_MWX@^'UCLV:!7M6O)S.IMQ')YO_Q%
M2?\ !/K_ *(_^V%_X;_X._\ S^*_CM_8Y_Y$#_@H=_VCY\=?^M,?LIU\0UST
MN!<@G6Q4)4\5RT:E.,+8F6TJ%*H[^[J^:4OD[6TN;U>-\^A1PTU4PW-5A4E.
M^&A:\:TZ:MKHN6*OOK<_OP_XBI/^"?7_ $1_]L+_ ,-_\'?_ )_%'_$5)_P3
MZ_Z(_P#MA?\ AO\ X.__ #^*_@/HKH_U!X>_Y]XO_P *I?\ R/\ 5WY6P_U[
MX@_Y^87_ ,)H_P#R1_?A_P 14G_!/K_HC_[87_AO_@[_ //XH_XBI/\ @GU_
MT1_]L+_PW_P=_P#G\5_ ?11_J#P]_P ^\7_X52_^1_J[\K'^O?$'_/S"_P#A
M-'_Y(_OP_P"(J3_@GU_T1_\ ;"_\-_\ !W_Y_%'_ !%2?\$^O^B/_MA?^&_^
M#O\ \_BOX#Z*/]0>'O\ GWB__"J7_P C_5WY6/\ 7OB#_GYA?_":/_R1_?A_
MQ%2?\$^O^B/_ +87_AO_ (.__/XH_P"(J3_@GU_T1_\ ;"_\-_\ !W_Y_%?P
M'T4?Z@\/?\^\7_X52_\ D?ZN_*Q_KWQ!_P _,+_X31_^2/[\/^(J3_@GU_T1
M_P#;"_\ #?\ P=_^?Q1_Q%2?\$^O^B/_ +87_AO_ (.__/XK^ ^BC_4'A[_G
MWB__  JE_P#(_P!7?E8_U[X@_P"?F%_\)H__ "1_?A_Q%2?\$^O^B/\ [87_
M (;_ .#O_P _BC_B*D_X)]?]$?\ VPO_  W_ ,'?_G\5_ ?11_J#P]_S[Q?_
M (52_P#D?ZN_*Q_KWQ!_S\PO_A-'_P"2/]#WX,_\')?[$WQW^*/@[X0^!/@[
M^UD_B_QS>:E8:$NK>"O@_8:<T^EZ#JWB.Z%U>+\<KAH$&FZ+>F-A#)OF$4>!
MOW+Y;#_P=5?\$][B&&>/X/\ [89CFBCF3/P^^#H.R1 ZY'_"^>#M89'8U_(%
M_P $Q/\ D_K]FG_L9O&W_JHOB)7P%I7_ ""]-_Z\+/\ ])XZYH<#9 \77H.G
MBN2GAL)5C_M,K\U:KC(3N^75-4(66EGS=U;>7&^?+"T:RJ8;GJ8G%TI?[-&W
M+1I8*<+*^]\14N^JY=K:_P!__P#Q%2?\$^O^B/\ [87_ (;_ .#O_P _BC_B
M*D_X)]?]$?\ VPO_  W_ ,'?_G\5_ ?173_J#P]_S[Q?_A5+_P"1_J[\K8?Z
M]\0?\_,+_P"$T?\ Y(_OP_XBI/\ @GU_T1_]L+_PW_P=_P#G\4?\14G_  3Z
M_P"B/_MA?^&_^#O_ ,_BOX#Z*/\ 4'A[_GWB_P#PJE_\C_5WY6/]>^(/^?F%
M_P#":/\ \D?WX?\ $5)_P3Z_Z(_^V%_X;_X._P#S^*/^(J3_ ()]?]$?_;"_
M\-_\'?\ Y_%?P'T4?Z@\/?\ /O%_^%4O_D?ZN_*Q_KWQ!_S\PO\ X31_^2/[
M\/\ B*D_X)]?]$?_ &PO_#?_  =_^?Q1_P 14G_!/K_HC_[87_AO_@[_ //X
MK^ ^BC_4'A[_ )]XO_PJE_\ (_U=^5C_ %[X@_Y^87_PFC_\D?WX?\14G_!/
MK_HC_P"V%_X;_P"#O_S^*/\ B*D_X)]?]$?_ &PO_#?_  =_^?Q7\!]%'^H/
M#W_/O%_^%4O_ )'^KORL?Z]\0?\ /S"_^$T?_DC^_#_B*D_X)]?]$?\ VPO_
M  W_ ,'?_G\4?\14G_!/K_HC_P"V%_X;_P"#O_S^*_@/HH_U!X>_Y]XO_P *
MI?\ R/\ 5WY6/]>^(/\ GYA?_":/_P D?WX?\14G_!/K_HC_ .V%_P"&_P#@
M[_\ /XH_XBI/^"?7_1'_ -L+_P -_P#!W_Y_%?P'T4?Z@\/?\^\7_P"%4O\
MY'^KORL?Z]\0?\_,+_X31_\ DC^_#_B*D_X)]?\ 1'_VPO\ PW_P=_\ G\4?
M\14G_!/K_HC_ .V%_P"&_P#@[_\ /XK^ ^BC_4'A[_GWB_\ PJE_\C_5WY6/
M]>^(/^?F%_\ ":/_ ,D?WX?\14G_  3Z_P"B/_MA?^&_^#O_ ,_BC_B*D_X)
M]?\ 1'_VPO\ PW_P=_\ G\5_ ?11_J#P]_S[Q?\ X52_^1_J[\K'^O?$'_/S
M"_\ A-'_ .2/[\/^(J3_ ()]?]$?_;"_\-_\'?\ Y_%'_$5)_P $^O\ HC_[
M87_AO_@[_P#/XK^ ^BC_ %!X>_Y]XO\ \*I?_(_U=^5C_7OB#_GYA?\ PFC_
M /)']^'_ !%2?\$^O^B/_MA?^&_^#O\ \_BC_B*D_P""?7_1'_VPO_#?_!W_
M .?Q7\!]%'^H/#W_ #[Q?_A5+_Y'^KORL?Z]\0?\_,+_ .$T?_DC^_#_ (BI
M/^"?7_1'_P!L+_PW_P '?_G\4?\ $5)_P3Z_Z(_^V%_X;_X._P#S^*_@/HH_
MU!X>_P"?>+_\*I?_ "/]7?E8_P!>^(/^?F%_\)H__)']^'_$5)_P3Z_Z(_\
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MG:6L3SW-U=31V]M;P1*7DFGGE9(HHHU!9Y)&5$4%F( )K\'/V1_AY^T!KO\
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MJ<T^:TE'D7++FE%JQ^--%?I%\?O@5\*/!G_!-3]@KX\^&?"$.E?%KXQ_$?\
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MGQ=XXT?3+27Q#XB\;:7J7B&]^$-_X4\27D]U+'X:\)?"[P=JMO:1V$EEXHA
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M5;E4H.IA7)N[E&C*U)_*DZ<'O=Q;;U"BBBOECZ<**** "BBB@ HHHH ****
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M(591I5/XD$[*2;A)IO?E<J=.4HWY9.$&TW%6****V,3[N_X)B?\ )_7[-/\
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MJ,8Q3<I2;LHQ2NVVVDDE=O1']2G_  :G?!?5=6^.O[27Q^E@,.A^"OASX?\
MAA873IE=0U;QSKC>(-4M;:0$D/I=GX-TF:\4A1MU6RVEB6"_W%5^=G_!+?\
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M0WI?]#>I_P"$4?\ YJ]?Z6O^/C_PJ'XO_P#1(/BU_P"&Q\=?_*"C_A4/Q?\
M^B0?%K_PV/CK_P"4%?[!U%'_ !$NK_T)Z?\ X72_^9?7^EJ?\0WI?]#>I_X1
M1_\ FKU_I:_X^/\ PJ'XO_\ 1(/BU_X;'QU_\H*/^%0_%_\ Z)!\6O\ PV/C
MK_Y05_L'44?\1+J_]">G_P"%TO\ YE]?Z6I_Q#>E_P!#>I_X11_^:O7^EK_C
MX_\ "H?B_P#]$@^+7_AL?'7_ ,H*/^%0_%__ *)!\6O_  V/CK_Y05_L'44?
M\1+J_P#0GI_^%TO_ )E]?Z6I_P 0WI?]#>I_X11_^:O7^EK_ (^/_"H?B_\
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M_$2ZO_0GI_\ A=+_ .9?7^EJ?\0WI?\ 0WJ?^$4?_FKU_I:_X^/_  J'XO\
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M_"*/_P U>O\ 2U_Q\?\ A4/Q?_Z)!\6O_#8^.O\ Y04?\*A^+_\ T2#XM?\
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M!1_PJ'XO_P#1(/BU_P"&Q\=?_*"O]@ZBC_B)=7_H3T__  NE_P#,OK_2U/\
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MAO2_Z&]3_P (H_\ S5Z_TM?\?'_A4/Q?_P"B0?%K_P -CXZ_^4%'_"H?B_\
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M3_M6:]C"<;_4XOFYZDJC=OK.EN9JUWM>_0_Q\?\ A4/Q?_Z)!\6O_#8^.O\
MY04?\*A^+_\ T2#XM?\ AL?'7_R@K_8.HK;_ (B75_Z$]/\ \+I?_,OK_2UQ
M_P"(;TO^AO4_\(H__-7K_2U_Q\?^%0_%_P#Z)!\6O_#8^.O_ )04?\*A^+__
M $2#XM?^&Q\=?_*"O]@ZBC_B)=7_ *$]/_PNE_\ ,OK_ $M3_B&]+_H;U/\
MPBC_ /-7K_2U_P ?'_A4/Q?_ .B0?%K_ ,-CXZ_^4%'_  J'XO\ _1(/BU_X
M;'QU_P#*"O\ 8.HH_P"(EU?^A/3_ /"Z7_S+Z_TM3_B&]+_H;U/_  BC_P#-
M7K_2U_Q\?^%0_%__ *)!\6O_  V/CK_Y04?\*A^+_P#T2#XM?^&Q\=?_ "@K
M_8.HH_XB75_Z$]/_ ,+I?_,OK_2U/^(;TO\ H;U/_"*/_P U>O\ 2U_Q\?\
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M0WI?]#>I_P"$4?\ YJ]?Z6O^/C_PJ'XO_P#1(/BU_P"&Q\=?_*"C_A4/Q?\
M^B0?%K_PV/CK_P"4%?[!U%'_ !$NK_T)Z?\ X72_^9?7^EJ?\0WI?]#>I_X1
M1_\ FKU_I:_X^/\ PJ'XO_\ 1(/BU_X;'QU_\H*/^%0_%_\ Z)!\6O\ PV/C
MK_Y05_L'44?\1+J_]">G_P"%TO\ YE]?Z6I_Q#>E_P!#>I_X11_^:O7^EK_C
MX_\ "H?B_P#]$@^+7_AL?'7_ ,H*/^%0_%__ *)!\6O_  V/CK_Y05_L'44?
M\1+J_P#0GI_^%TO_ )E]?Z6I_P 0WI?]#>I_X11_^:O7^EK_ (^/_"H?B_\
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M_BY/=74J06\*_#+QNK2S2,%1 TFA(BEF(&7=5'=@*_V!J*7_ !$NK_T)Z?\
MX72_^9?7^EJ_^(;TO^AO4_\ "*/E_P!1/K^';7_,)_9@_P""*_\ P4-_:CU/
M1SH7P,UKX:>"M2FC,WQ$^+/_ !2?A^WL0W^EW5G9.)]9U2YMXPS16"V=H;J4
M) +J'S!(O]LW_!,7_@C)^SY_P3JTY?&4DL7Q@_:,U*T>UU?XP>(-+@MUT"TN
M$"76B?#C0W:X3PII5S@F]O3/=^(=35OL]_JTMG%!:Q?LA17S6<\89KG%.6'D
MX8/"2TG0PW,G55[I5JLFYSCWA'DIR^U!V5OH\GX1RO**D<1%3Q>*CK"OB.5^
MR=M71I12A"7:;YZD=HS6MRBBBOE#ZD**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "N ^+'_)+?B5_V('C+_U'=2KOZX#XL?\ )+?B
M5_V('C+_ -1W4JTH_P 6E_U\A_Z4B*G\.I_@E_Z2SPO]@8 ?L*_L6 # '[)G
M[.0 '0#_ (4]X-XKZSKY,_8'_P"3%?V+/^S3/V<O_5/>#:^LZUQO^^8O_L)K
M_P#IV9C@O]SPG_8-0_\ 34 HHHKF.D**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *X#XL?\DM^)7_8@>,O_4=U*N_K@/BQ_P DM^)7_8@>,O\ U'=2
MK2C_ !:7_7R'_I2(J?PZG^"7_I+/"_V!_P#DQ7]BS_LTS]G+_P!4]X-KZSKY
M,_8'_P"3%?V+/^S3/V<O_5/>#:^LZUQO^^8O_L)K_P#IV9C@O]SPG_8-0_\
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M_P"=OK_2U/\ B8OBW_H3<.?^"<S_ /GEZ_TM?[*O^'C'[$?_ $<5X%_+7/\
MY3T?\/&/V(_^CBO OY:Y_P#*>OXU:*/^);>$?^AWQ)_X-RS_ .=OK_2U/^)B
M^+?^A-PY_P""<S_^>7K_ $M?[*O^'C'[$?\ T<5X%_+7/_E/1_P\8_8C_P"C
MBO OY:Y_\IZ_C5HH_P");>$?^AWQ)_X-RS_YV^O]+4_XF+XM_P"A-PY_X)S/
M_P">7K_2U_LJ_P"'C'[$?_1Q7@7\M<_^4]'_  \8_8C_ .CBO OY:Y_\IZ_C
M5HH_XEMX1_Z'?$G_ (-RS_YV^O\ 2U/^)B^+?^A-PY_X)S/_ .>7K_2U_LJ_
MX>,?L1_]'%>!?RUS_P"4]'_#QC]B/_HXKP+^6N?_ "GK^-6BC_B6WA'_ *'?
M$G_@W+/_ )V^O]+4_P")B^+?^A-PY_X)S/\ ^>7K_2U_LJ_X>,?L1_\ 1Q7@
M7\M<_P#E/1_P\8_8C_Z.*\"_EKG_ ,IZ_C5HH_XEMX1_Z'?$G_@W+/\ YV^O
M]+4_XF+XM_Z$W#G_ ()S/_YY>O\ 2U_LJ_X>,?L1_P#1Q7@7\M<_^4]'_#QC
M]B/_ *.*\"_EKG_RGK^-6BC_ (EMX1_Z'?$G_@W+/_G;Z_TM3_B8OBW_ *$W
M#G_@G,__ )Y>O]+7^RK_ (>,?L1_]'%>!?RUS_Y3T?\ #QC]B/\ Z.*\"_EK
MG_RGK^-6BC_B6WA'_H=\2?\ @W+/_G;Z_P!+4_XF+XM_Z$W#G_@G,_\ YY>O
M]+7^RK_AXQ^Q'_T<5X%_+7/_ )3T?\/&/V(_^CBO OY:Y_\ *>OXU:*/^);>
M$?\ H=\2?^#<L_\ G;Z_TM3_ (F+XM_Z$W#G_@G,_P#YY>O]+7^RK_AXQ^Q'
M_P!'%>!?RUS_ .4]'_#QC]B/_HXKP+^6N?\ RGK^-6BC_B6WA'_H=\2?^#<L
M_P#G;Z_TM3_B8OBW_H3<.?\ @G,__GEZ_P!+7^RK_AXQ^Q'_ -'%>!?RUS_Y
M3T?\/&/V(_\ HXKP+^6N?_*>OXU:*/\ B6WA'_H=\2?^#<L_^=OK_2U/^)B^
M+?\ H3<.?^"<S_\ GEZ_TM?[*O\ AXQ^Q'_T<5X%_+7/_E/1_P /&/V(_P#H
MXKP+^6N?_*>OXU:*/^);>$?^AWQ)_P"#<L_^=OK_ $M3_B8OBW_H3<.?^"<S
M_P#GEZ_TM?[*O^'C'[$?_1Q7@7\M<_\ E/1_P\8_8C_Z.*\"_EKG_P IZ_C5
MHH_XEMX1_P"AWQ)_X-RS_P"=OK_2U/\ B8OBW_H3<.?^"<S_ /GEZ_TM?[*O
M^'C'[$?_ $<5X%_+7/\ Y3T?\/&/V(_^CBO OY:Y_P#*>OXU:*/^);>$?^AW
MQ)_X-RS_ .=OK_2U/^)B^+?^A-PY_P""<S_^>7K_ $M?[-K'_@H3^Q=J,XMK
M/]H;P)+,59]A?5X1M498[YM+C08'8MD]@:]Y\'_&WX1?$!"_@KXC^$/$K"3R
MO(TK6[*YO#)Q\JV(D%XV<C#+ 5)X!)K^$\@'@@$>A&:T]%UG6/#6H1:KX<U;
M4] U.!TDAU'1;^ZTN]C>-@Z$7-C+!-A7 8*7*DCE37!C_HU9).C+^S.),UP]
M?E]QX_#X3&47+HI+#QP,XQ?=.379G?@?I'9U"K'^T^'<KQ%#F7.L#B,7@ZJC
MU<7B)XZ$I+=)J*>UUN?WL?V[I(ZWT/\ X_\ _$4?V[I'_/\ 0_\ C_\ \37\
MZ/[%O_!3/7'UC2/A=^T=J*ZG9ZG<VVF^'?B<\<5O=Z?/+MAMK+Q=# D<-Q:/
M)MCBUBTBBEAW1QW5I,0UT_[MJRNJNCI)&ZJ\<D;K)')&ZADDCD0LDD;H0Z2(
MS(Z$,K%2"?YJXPX+SS@C,_[-SJA&/M(RJ8/&8>4JF"QU&+475PU6482O!M1J
MT:D*=:E)QYZ:C.G*?]&\(\99)QKEO]I9-6F_9RC3Q>#KJ-/&8&M).2IXBG&4
MXVDDW2JTYSHU4I<DW*,XQ]3_ +=TC_G^A_\ '_\ XFC^W=(_Y_H?_'__ (FO
M+:*^3/JSU+^W=(_Y_H?_ !__ .)H_MW2/^?Z'_Q__P")KRVB@#U+^W=(_P"?
MZ'_Q_P#^)H_MW2/^?Z'_ ,?_ /B:^"OC)\6=5T?7;?POX5U5M,GM4+ZIJ$"V
M[NMW*I%M:,;J":)(8V(>Z*HS@ ;2#Q7XO?MT?\%9/B%^R)XU^#WA?2]>?Q/K
M5_XNT7Q)\0]!O+73&C3X;6=XT6IZ7*8;:WFM[O7$,GD2QR++ ELDB@K*,_SC
MPK]);A7CSZ0$OHZ\"\,<7\6\68;&YA@\US_*</D;X1R7^QL%#&9YB<RS'$YY
M0Q]+"91.:R_$UJ665E5S5QR_!K$UYTXR^RSK@S&<-\"OC_/\RRS*LI=/#U,/
M@\3/%_VIBWC*_L<%3P^'IX2=*=7%*^(IPEB(\F&3KU73A&3C_4M_;ND?\_T/
M_C__ ,31_;ND?\_T/_C_ /\ $U\-:G^T1X6U_P"$'@CXH?#C4[?6-/\ B9HF
MD^(O"%TK*Z-I5Y'%<W+W"':PDM&\S2[J/;^ZO5N$SNAP?;O"'B:S\7>'=-UZ
MR92EW"HGC&<V]W& MQ P(!!5_F7(Y1E/-?IF#\4>"\?XG<0^$&'S:$N.^%\B
MR_B#-\HDE&5#!YA7JT/81FY7GCL%'ZEB,?A>12PV&S;+:MY^VJQH^//A_-*?
M#V XIEAV\ES+%UL'A,7%W52=*G":J62THUKU84*E[5*F&KQLN6+G[O\ V[I'
M_/\ 0_\ C_\ \31_;ND?\_T/_C__ ,37EM%?H1XIZE_;ND?\_P!#_P"/_P#Q
M-']NZ1_S_0_^/_\ Q->6T4 >I?V[I'_/]#_X_P#_ !-']NZ1_P _T/\ X_\
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M^W9X*^$$/[8'Q5_:8^$GQ>^ ?Q0\=WZ?%KQQ\ /&^M>$]=\+:)=ZSH+:59_
MKQQXW/P^OF*Q'4/#?CQM#\5P)F"ZT>)4W5_418?!SX2Z7JWQ"U[3?AGX#L-;
M^+4<,/Q2U>S\)Z';ZE\18K>SGTZ"+QO>Q6*W'BB.&PNKFRB36I+Q4M9YH% B
MD=3Y[\//V0OV4_A'J]EX@^%G[-OP,^'.NZ<NL)I^L^"/A9X*\+ZI9)X@M&L-
M=6UOM%T6SN8%UFQ=K/4UBD47ULQ@N1)&2M '\N'AOXW_ +?OA7]ES]GS]O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[LO++0.S>L^,+G_@B'\,?V:_A?\ MOWGP"TI_A5\1O'-MX>\*:_X9^&MW?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ME9S;D:PEN(9%N%,,GEN#C^>L'QWA<KX>X:RS TL/7QE/"9IEV<5\11Q<IX'
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P#1./"W_ARO!W_RPK^N.BC_ (F,X[_Z >&?_"#,?_GN'_$O/ __ $'<2_\
MA?E__P Z?ZN_*W\CG_#IW]N'_HG'A;_PY7@[_P"6%'_#IW]N'_HG'A;_ ,.5
MX._^6%?UQT4?\3&<=_\ 0#PS_P"$&8__ #W#_B7G@?\ Z#N)?_"_+_\ YT_U
M=^5OY'/^'3O[</\ T3CPM_X<KP=_\L*/^'3O[</_ $3CPM_X<KP=_P#+"OZX
MZ*/^)C.._P#H!X9_\(,Q_P#GN'_$O/ __0=Q+_X7Y?\ _.G^KORM_(Y_PZ=_
M;A_Z)QX6_P##E>#O_EA1_P .G?VX?^B<>%O_  Y7@[_Y85_7'11_Q,9QW_T
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M17WB243ZL+K5@XU#4K;SPKZ9;79,>DJL<5F%2-17V+11=WO=W[A96MT/C?\
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MGVF^;Y!3S?\ A"H-HG^PO")_+_M[[HOBE]Y._!C0V>_:_GJ>SA_S^I?=6_\
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M #,+.UA:;R_[>P%:]CNKP1!L+'=):;R+<32GLX?\_J2^5;]*+#F?\DOOA_\
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M:)X^*L%\>:<K%9 A/@R!@K-'JRQL1_;HW".2ZTB0KE=XTF=,K_:;-:'LX?\
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MB?R_[>^Z+XI?>3OP8T-GOVOYZS-HOCHR,R^.-/6,RNZQGP? Q6(W5_*D1?\
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M1/Y?]O?=%\4OO)WX,:&SW[7\]9FT7QT9&9?'&GK&97=8SX/@8K$;J_E2(O\
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M9PS64=U9"782LEREWL)MQ#+"-#^('E!3X^TTRB%4,O\ PA4 !F%G:PM-Y?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_14\.?\ A[RS_P":O-?>?:U%?%/_  \8_8C_ .CBO OY:Y_\IZ/^'C'[$?\
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M ,31_;ND?\_T/_C_ /\ $T :U%9/]NZ1_P _T/\ X_\ _$T?V[I'_/\ 0_\
MC_\ \30!K45D_P!NZ1_S_0_^/_\ Q-']NZ1_S_0_^/\ _P 30!K45D_V[I'_
M #_0_P#C_P#\31_;ND?\_P!#_P"/_P#Q- &M163_ &[I'_/]#_X__P#$T?V[
MI'_/]#_X_P#_ !- &M163_;ND?\ /]#_ ./_ /Q-']NZ1_S_ $/_ (__ /$T
M :U%9/\ ;ND?\_T/_C__ ,31_;ND?\_T/_C_ /\ $T :U%9/]NZ1_P _T/\
MX_\ _$T?V[I'_/\ 0_\ C_\ \30!K45D_P!NZ1_S_0_^/_\ Q-']NZ1_S_0_
M^/\ _P 30!K45D_V[I'_ #_0_P#C_P#\31_;ND?\_P!#_P"/_P#Q- &M163_
M &[I'_/]#_X__P#$T?V[I'_/]#_X_P#_ !- &M163_;ND?\ /]#_ ./_ /Q-
M']NZ1_S_ $/_ (__ /$T :U%9/\ ;ND?\_T/_C__ ,31_;ND?\_T/_C_ /\
M$T :U%9/]NZ1_P _T/\ X_\ _$T?V[I'_/\ 0_\ C_\ \30!K451CU/3Y2!'
M=PL3T^?'O_%C'XU=!# %2"#T(((/T(XH 6BBB@ HHHH **** "BBB@ HHHH
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MXN77(_ LMA&OB5[J3PWX:.FOJGVTLVD"WOEL_+ &IW6_*_C/\3?AUI_[<_\
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M7UVQO;;4K*SU&RD,UG?VMO>VDICDB,MM=1)/!(8IDCFC+Q2(WERQI(F=KHK
MJ/X5?B+\/_#7Q2_X(.^-_C5XBU[Q9KWB7X4_MA?$:[\ ZE%XSU>?0[RP\<_$
M?P5H5V^LV+W-S:^)=-_L2^>;04N9#;Z=/+#?V1#*H/Z2_MO? KX??L<_ /\
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M?0=-GN?-NHVV7>KV4>Q7/F[@JM\W>%/^"DOP*\5?'WX!_L[?\(W\4/#WB_\
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MHM/V8?VK[B!W0-MDA\.:E*F>A*[T7<H(##()YK\Y_!W_  4M_P""L>J?!?\
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M*** "BBB@ HHK"\4>(]+\'^&?$7BW6YC;Z-X6T+5_$>KS@*3!I>B:?<:G?S
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M\@*=117ZN?EH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ML@Q?"^?9GD&.:EB,MQ,J+J13C"O2E&-7#8B$6VXPQ&'J4J\8MMQ511;;3/\
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M_!$;_@F?-J'CG56_9PL5U#Q_K%IKVJ74?C3Q[%+HFIVFN6WB 3^!C'XE7_A
M$NK^U6/48/!W]BP:CIT]YI=['/IU[=6TOZ8> /&^@?$OP-X.^(GA6>6Y\->.
MO#&A>+M!FN(Q!<OI/B'3+;5; 7=N'D^S7B6UU''=VI=GMKE98'.^-JV-?UW2
M?"^A:UXEUZ\33M#\/:3J.N:SJ$B32QV&E:39S7^HWDD=O'-.\=K9V\T[I#%)
M*RH1'&[$*0#XE_:2_P"":'[%G[6WC3P9\0OCQ\&;#Q?XP\"V=KIND:U;:_XF
M\-W&H:78LK6FE>*D\-:OI47C'2[<*(XK#Q/'JMJD/[D1"+Y*V/"__!.O]C?P
M?\%/B7^SIHOP2\.K\%?BQXQUOQ[XM^'NH7&J:OH$?B?78K6&XOO#-OJ=]=MX
M-BT^&RM8M L?"SZ39>'HX4CT6"R3*GU[6/VBO ]A!\#-1T32/'7CK0/V@]7T
MK3?!'B;P/X0U'6M!TVQUK2H]9TSQ1XSNI38S^%O"UU8S1.NK7UJ=KRI&]NK'
MCU_Q+XET'P;X>UOQ9XIU6RT+PWX<TN]UK7-9U&806.F:7IUO)=7M[<RG[L5O
M!$\C!0SMC9&CNRJ0#X9_97_X)>?L1?L8^+K_ ,?? 'X,P>'?&U]82Z6OBOQ'
MXI\7^/\ 7],T^YP+NTT'5/'.N>(+O08;Y L=\FD2V8O(E$5QYD?RU^:G[*W_
M  0W^$.O6OQ6UG]NOX)>$?$WC>__ &@_&'Q!^'NL>%/B!XB@GO\ P3JM_/=Z
M7IWBZ?PG>^'DUFSS(C/X;\1)JUC!CRU39N#?JW\/?VU_#WQ(\0>#X-)^!/[2
M.E_#CXAZC%IW@/XZ:[X"\-6_PL\4?;[>ZN-!U&WAT[QUJGQ-T;1_$OV1X]'U
M7Q3\-]!L_P![:W&IRZ;97EM=2^8P_P#!2SP!)I?B'QK)^SS^U3#\&_"'C'5?
M!_B[XZ)X$^'NI?#CPT- UF/1/$7BC4K+1?BMJ?Q*E\)Z!<.USJFHZ9\/=0O(
MK""XN8=-G$+)0!] ^*?V./V>/%_Q*^!/Q8U3P$MMXP_9JL&TOX+MH6MZ]X<T
M#P;IAMA9QZ=!X5T/4K#PY?V5M:JEO:6NIZ9>0VD*)';I&J*!Y?\ M$_\$T?V
M*_VK?BMX6^-/QV^"NE^-OB%X2L[33;35'UGQ%I%CK6FV%Q+<V6F^,=#T75;#
M1?&NGVKSS)!9^*;'5;>."1[=8Q"Q0])\2/V]?V;OAK\5?@5\%[SQ7?\ BOQ_
M^T+JWA2Q\":;X$TI_$MA9:5XV-POACQ;XLUR&>WT?P]X8UA[:1=-N9[V;4M3
M&V33-*O829!W_P =/VE?"_P-U3P-X3/@SXB_%?XE_$F379/!?PI^$FD^']8\
M<ZSHWA2"PG\6>)V3Q9XH\%^&-,\-^&CJ^B0:KJ6K^)K _:=9T^"R@O'><6X!
MY[X:_P""?G[)GA+]F[QS^R/HOPJM8OV?OB+J^O:[XE^']WKOB+4;-M3\0WUA
MJ=U<:1J%_JMQJOA\6&H:7IMYH$.B7MC#X=N+"TET1+%[>(KQ>G_\$OOV)]._
M9<O?V-D^$<E[\ +WQ%>^+?\ A%M7\9^-M8UBQ\2W]\NI3ZWI/C74_$%UXQTC
M44NU#VMSIVN6TEHF8K9HHSLKZ9^ WQW\%?M#^!&\=>"K?Q!I*V&O:QX1\4^%
M/%^FPZ/XQ\#^,O#\D4>M^$O%FEVM[J=G9:YIHN;2::.QU/4K*6VO+6YM;VXA
MG1S[10!^7NB_\$H_V7/@AX<\6ZQ^R3\/M)^#'QJN_@=XS^#/A3X@3:MXK\10
MQV'BS[5/-J/C'3=5URZM_&>LM/<"U_X27Q%'J?B"VTZ.ULK>_6UL;6"/\!_@
M5_P0W_;4\+>-_A!;Q_"SX#?L\ZQ\.?&OA_7]>_:O\ ?M%?'+Q?\ $?Q3IGAW
M7$U"^@C^%M_XL/@/19O%-B@M&CTO1K2"Q,<2SI+%-?)<?V=44 >0?&7X'?#[
M]H+X0>*?@=\7].O?%?@'QOH<&@^+;&'6-6\/WVL6<4EM.[#5_#][INJV$TUS
M:QSO+87EO(&W('V,0<7Q'^S/\&O%O[.]U^RMXA\*R:G\$+SX>0?"VX\*3ZUK
M?VEO!EKID6D6U@OB)+]?$,=Y!901+'J\>IKJJ3(+D7@G_>5[S10!\[?LP?LI
M_ W]CCX7P?!W]GSPA)X,\!PZSJGB Z=<Z[KWB:_NM8UAXWOKZ^USQ-J6K:U?
M3.D-O;Q&[OIA;VEM;6D CMX(HU^B:** "N ^+'_)+?B5_P!B!XR_]1W4J[^N
M ^+'_)+?B5_V('C+_P!1W4JTH_Q:7_7R'_I2(J?PZG^"7_I+/"_V!_\ DQ7]
MBS_LTS]G+_U3W@VOK.ODS]@?_DQ7]BS_ +-,_9R_]4]X-KZSK7&_[YB_^PFO
M_P"G9F."_P!SPG_8-0_]-0/!/%_[,_P=\=?'3X<_M'^)?#E[>_%SX4>$?&7@
M;P/XAB\1>(;*STOPWX_M)K'Q193^'[/4X- U26^MIY$BO=3TZ[O+$L'L9[=P
M&'C>B_\ !.K]DWP]\)OA!\$=*^'^KP?#CX$_$FY^+?PST5_'_CRXN=$\=W>N
MZIXDGU6ZUF?Q%)K&MV[ZOK.H7 TK6KZ^TM$F6W2T%O#%$GS7_P %"O\ @I'\
M>/V$M0U#Q!9?L(>*OC/\"-)LO"XU+XZV7QQ\'^!M#L_$7BK4+;2+'PW)X5N_
M"GB7Q,UP-6O+6P6_BMY+)YIT:1H(B7'#>)?^"CO[5?AFY_9$_P"%K?LF:-^R
MC=?'G]IO4?@]XQ\(_%GQ_I7Q,U.W^'5CX3TS7T\>>'?%/@?5/"6A>';B6^O+
MVP>/Q)8ZM#;QZ=)-+;!904YCI/M[XC?L ?LM_%>Z_:/O/''@35=4N/VL?#_@
M;PO\<G@\<^-]+'BG1?AQ=QWWA*VL$TS7[1/"[Z?<Q(\USX872;G4 -E_+<H2
MI]'L?V5_@GIWQ>^'WQUM/#%]'\2_A=\,;GX/^"];/B;Q)):Z9X!NXK*"?29]
M%DU1M&U*X>/3[11JVHV-UJJ&,E+P&20MZ5I?Q5^%^M^&;_QKHOQ(\ ZOX-TJ
M8V^J>+=+\8>'M0\,Z;.KPQF"_P!>M-1ETJSF#W%NACN+N-P\\*E<RH&SY?C5
M\&X-'U/Q#-\6OAE#H&B:C;Z/K.N2^//"L>CZ1JUW$T]KI>IZF^JBRL-1N8%:
M:WL;N>*YFB5I(XF0$@ ^3/$7_!+[]B?Q9\ I_P!F;Q%\(Y-6^$<OC_7_ (H6
M^D7GC/QM)KNE>./%&J3ZOKNMZ%XR/B#_ (2W0Y+^\N)A+;Z7K-K:BV86:0K:
MJD*Y_P //^"5?[#?PH\%?&#X>?#[X/S>&?"?QY\!>&OAM\5--T_QQXZ5O$_A
MCPFU^^D"2\?Q$][8ZT9=3O9M2\1Z=/:Z[J\TWFZG?W4B(R_:T/Q0^&EQX8M?
M&T'Q$\#3^#+^ZAL;'Q=#XMT"7PQ>7US<"TM[.UU]-0;2KB[N+HBV@MX;MYI;
M@^3&C2?+6/+\<?@I!I^N:M-\8/A;#I7AC48]'\2:G+\0/"<>G^'M6E,JQ:7K
MEZ^KBVTG496MYQ'97\EO<N890L1,;[0#S.3]CKX 2^*OV:/&C^$M1/B']D31
M==\/_ >\'BWQ6L?A32O$GA>T\&ZO;ZA9C6!:>*GN?#]C;6:3^*8=7GMY$-W;
MR1W;O,WS#;?\$<_^">VG?'G2/VDM$^!TWAOXIZ#X]TKXF:1=^&/B!\1/#GA:
MP\8Z-JL.MV6IV_@+1_%%GX+2+^TX([JZT\:%_9]Z^];JVF21U;IOVH?VS-?^
M"?[1'[#'P[\,7'PSO/A7^TSXF^)EEX^\:^(I[F8:/X:\&> )?%^F:UX5\267
MB;2_#FGP3SH#?:CK%KK5A+IY)@%LY%P/MVR^*'PTU+PE=>/M.^(G@74/ MEY
MOVWQK9>+= NO"5IY$B13?:O$<&H2:/;^3+)'%+YMXGER2(CX9E! .YHKD?"/
MQ \!_$#39]8\!>-O"/C?2+6=[6ZU7PCXDT;Q+IMM=1H'>VGOM&O;VUAG1"'>
M&259%0ABH!!KG[3XV?!J_P!.U'5['XM_#&\TG1]6M- U?5+3Q[X5N-.TO7;^
M5[>PT74;V'57MK'5KV>.2&TTVYEBO+F5'CAA=U90 >G45\\_M(?M1_!G]E;X
M9^)OBA\6_%FFZ;IGASPSJWBJ#PW::OX=3QKXLT_18XI+VV\$^']:UO17\2ZB
M!/ D=I9W(W23PH9%:6,-O_#O]H+X0_$WX3:-\;/#OCOPO%\.]6T6PUJ?7M2\
M2^&X;+P]'?V\$_\ 9_B?4;76+W1]%U>R:XCM=2L+C4S)97@>UE/FH10![/17
MG.G?&'X2:QH#>*](^*7PYU3PNFIPZ*_B33O&_AF^T!-8N65;?26UBVU.73EU
M.=F58; W(NI690D3$C.MX8^(?@#QM=:S8^#/'/@_Q=>^';HV7B"S\,>)M%U^
MZT*]$DT)M-9M]*O;N;3+H36]Q$;>]2"4203)LW1.% .PHKA?#GQ1^&?C#6M4
M\-^$OB+X%\4^(M$$AUK0/#GB[P_K>M:0(95@E.J:5IFH75]IXBG=(9#=P0[)
M76-L.P!S8/C3\'+K4M'T:V^+/PSN-8\0S36^@:5!X\\+3:EKEQ;W+V<\&CV,
M>JM=:G-!=QO:S1644[QW*/ ZK*I4 'IE%?,GA'X_^(-9^/7[0/PJ\5_#K2?
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M>04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MFB>*.-;W1=.T^^-JOV)KDV9,! /H6BBB@ HHHH **** "BBB@ HHHH ****
M"ORQ_::UOXM?%O\ ;%^%?PG^!O@[X6?$)_V;O!EQ\;/B9HOQ>\>^*OA]X,_X
M2'XD-J?A'X:6L.N>#OAS\4M1D\5>'K#0_$6O-I%WX9BM)=&\3V5RVH)YJQ-^
MIU0K;VZ32W*00I<3JBS3K$BS3+$"(UEE"AY%C!(0.Q" D+@4 ?SP:5-XY/PQ
M\-?L6?%[Q%)X$\>?"K]OKPEX?UO3?@_\1M:_TCX%_&GP;\5?B1X3TS0?%FI>
M'?"GB/4O!E_+<>,/AW]IU'PGH]Q)9>%;ZSL8[.\TZSU&V]P\-?"3PQ:-_P %
M5?V4-"T_Q-K7P?\ "?PW^&?BKP)\-;CQ;XV\1W>C>*O'7PY^(VLZO!H6JW.N
M7GC$PZUK_A/P_=Q:*NKSP/<V[6L$#6UW-:O^U+:=I[SM=/8V;W+-"S7#6T#3
MLUL)5MV:8H9"T GG$)+9B$TH0J)'W3);6\<L\\=O"D]R(Q<S)%&LMP(0RQ">
M15#RB)7=8Q(S! S!<!CD _GK^!NI?!K0/@)_P2]M_P!G/QMI<NG:_P#'?X5V
M?Q;L_!'Q/UCQ3%_PGK^![(>(?#'C&%_%&M2Z+J,4ZLVH^![X6-MI\I<?V%;8
M"#[K_:M\(_M@?&#]FK]I3P'XI^&GP:LK.YT/3-0^'EM\)?BE\0/B#XS\:V?A
MKQSI/B/4M"U[PSXD^#'P\L=)O=:\*:-);PV.@^(?%4M[JUW)HL,=Q"\5U<_H
MW;:)HMDJI9Z1I=HB7'VM$MK"T@5+O&/M2K%$@6XP /. $F!C=6I0!\7?"/\
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M==^']!OX+6UOM$TB]MK)2EE;W>FV=Q!:(51"EK#-"\=NI6-%*Q*@*H@(PH
M/SL_X)C>'?'<7PR^-OQ0\>:K/KLWQX_:.\>_%+PSXAF\&W'P[3Q7X1NM'\*^
M&](\8VO@:[U/6+GPO8>))/#UY>:5I\VJ:F;G2$T[5X=1N[74[=U_2JF1QI$B
M11(D<4:+'''&H1(T0!41$4!515 554 *    *?0 4444 %%%% !1110 5P'Q
M8_Y);\2O^Q \9?\ J.ZE7?UP'Q8_Y);\2O\ L0/&7_J.ZE6E'^+2_P"OD/\
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M6]5E\)W&I0O<1P:\VJBWU62Y5(-3W.VFVOJ_[*7[&OP;_:&_9D_:'^"WP_\
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M4GA;5/BG\88+K5X=/O[Z/0=<UCQ-HNM:_I5OJDUMX6T^*QU G^K2B@ HHHH
M**** /Y9O^"G?[$VK_!7Q_JWQK\!Z1+<_"/QYJDM]JB:=;,\/@7Q+?/YES9W
MR01[++1=3N'9]*N9 EO%*WV%I#.R!_R8K^^W6M%TCQ'I.HZ%KVFV6L:-JUI/
M8:GI>HV\5W8WUG<QM%/;7-O,KQRQ2QL5964]<C! (_$K]H7_ ((R^$O$VHW?
MB']GSQA#X"ENFEGE\&>*([O4O#<4IS)MTB^MA)J-A'(Y,<-E(&LK2,1I&50'
M']:^&7CGEM/+L)D7&E:IA<1@Z<,-A,[=.I7P^)P].*A2ACXTHSK4L12@HP^L
M*%2G7BN>M*E43E5_E+Q*\$<QJ9ABL\X.HT\5A\95GB,5DJJ4Z-?#5ZCYJL\
MZLH4:N'J3<I_5W.G4H-N-)5*;C&E_./17Z7:I_P22_;4LKIH=/\ !WA#6;<%
M]M[!X_\ #5BCA9'12(+Z\CG7>BK*,K\HD"-AU8#._P"'3O[</_1./"W_ (<K
MP=_\L*_<8^(G <XJ2XQX;2DKI2SC 0E\X3KQG%^4HI^1^)R\/^.8R<7PAQ'=
M.SY<GQTXWTVE"A*,EKO&36^NC/SBHK]'?^'3O[</_1./"W_ARO!W_P L*/\
MAT[^W#_T3CPM_P"'*\'?_+"J_P"(A<"?]%CPS_X>\N_^:"?]0>./^B0XE_\
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M?G%17Z._\.G?VX?^B<>%O_#E>#O_ )84?\.G?VX?^B<>%O\ PY7@[_Y84?\
M$0N!/^BQX9_\/>7?_- ?Z@\<?]$AQ+_X9<P_^9_/\^S/SBHK]'?^'3O[</\
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M/^(A<"?]%CPS_P"'O+O_ )H#_4'CC_HD.)?_  RYA_\ ,_G^?9GYQ45^CO\
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M\(WJ_P#SPB_\"(_\:/\ A&]7_P">$7_@1'_C0!A45N_\(WJ__/"+_P "(_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %<!\6/^26_$K_L0/&7_ *CNI5W]<!\6/^26_$K_ +$#QE_ZCNI5
MI1_BTO\ KY#_ -*1%3^'4_P2_P#26>%_L#_\F*_L6?\ 9IG[.7_JGO!M?6=?
M)G[ _P#R8K^Q9_V:9^SE_P"J>\&U]9UKC?\ ?,7_ -A-?_T[,QP7^YX3_L&H
M?^FH!1117,=(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M ()H_P#RL.1=Y?\ @<__ )+^OFSA%T3QZ-F[QWIS8\O?CP; N_;_ &1YF/\
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M93:7\22E/[= 94NY]/NS'D!DL);;>!>M+!WM%'MI]J7_ ((H_P#RL.1=Y?\
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M(X=M%\=&1F7QQIZQF5W6,^#X&*Q&ZOY4B+_VV-Q2TGT^U,FT%GL)+G:#>M%
MQ=$\>C9N\=Z<V/+WX\&P+OV_V1YF/^)X=OF?9=8QR=G]KP?>_LM?M?=T4>UE
MVI?^":/_ ,K#D7>7_@<__DC@CH?C\QLH\>Z:)#$ZK)_PA4!"RFTOXDE*?VZ
MRI=SZ?=F/(#)82VV\"]:6";^QO'7F[O^$WT_RO/+^5_PA\.?(^W/,(?,_MO.
MX6+)8^=MYD0WGEAG\A>WHH=63Z4O_!-%?E3#D7>7_@<__DC@UT/Q^$4-X]TU
MG$<:L_\ PA<"AI%M],220+_;IVB2XMM4G"9;8NIPP!F&G+)<C:)X^*L%\>:<
MK%9 A/@R!@K-'JRQL1_;HW".2ZTB0KE=XTF=,K_:;-:=Y11[:?:E_P""*/\
M\K#D7>7_ ('/_P"2\OZNSAQHOCKS0Q\<:>8O.5S%_P (?"&, O;:9H1)_;9P
MS64=U9"782LEREWL)MQ#+"-#^('E!3X^TTRB%4,O_"%0 &86=K"TWE_V]@*U
M['=7@B#86.Z2TWD6XFE[ZBCVTUTI?^":+_.F'(N\O_ Y_P#R1PK:+X\)<KXZ
MTY06D* ^#8&V*TFK-&N?[<&XQQW6D1EB!O.DSR$+_:;+:*NB^.PZEO'.G,@D
M1F0>#H%+1K<:8[QAO[;.TO;VVJ6X?:=C:G#/M8Z<L=SW-%'M97O:E_X)HV^[
MV=@Y%WE_X'/_ .2.!_L/X@>45_X3[3?-\@IYO_"%0;1/]A>$3^7_ &]]T7Q2
M^\G?@QH;/?M?SUF;1?'1D9E\<:>L9E=UC/@^!BL1NK^5(B_]MC<4M)]/M3)M
M!9["2YV@WK10=Q11[67:E_X)H_\ RL.1=Y?^!S_^2_KYLX1=$\>C9N\=Z<V/
M+WX\&P+OV_V1YF/^)X=OF?9=8QR=G]KP?>_LM?M;3H?C\QLH\>Z:)#$ZK)_P
MA4!"RFTOXDE*?VZ RI=SZ?=F/(#)82VV\"]:6#O:*/;3[4O_  11_P#E8<B[
MR_\  Y__ "1Q']C>.O-W?\)OI_E>>7\K_A#X<^1]N>80^9_;>=PL62Q\[;S(
MAO/+#/Y"Q+H?C\(H;Q[IK.(XU9_^$+@4-(MOIB22!?[=.T27%MJDX3+;%U.&
M ,PTY9+GO**7M9=J?_@FC_\ (!R+O+_P.?\ \D<&VB>/BK!?'FG*Q60(3X,@
M8*S1ZLL;$?VZ-PCDNM(D*Y7>-)G3*_VFS6D@T7QUYH8^.-/,7G*YB_X0^$,8
M!>VTS0B3^VSAFLH[JR$NPE9+E+O83;B&7N**?M9=J7_@FC_\K#D7>7_@<_\
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MS_Y95_!M]BL_^?2V_P"_$7_Q%'V*S_Y]+;_OQ%_\11_Q+-E__17XS_PS4/\
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M_P"65'_"V?A7_P!%+^'_ /X67AS_ .65?P;?8K/_ )]+;_OQ%_\ $4?8K/\
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MQI.IQ-/INJ:=J$"X#36-];7<2DC(#26\LB#(Y&6&1R*M?:K;_GX@_P"_L?\
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MW^C_ /BJ/M5M_P _$'_?Z/\ ^*KQW ]!^0HP/0?D* /8OM5M_P _$'_?Z/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MX#XL?\DM^)7_ &('C+_U'=2KOZX#XL?\DM^)7_8@>,O_ %'=2K2C_%I?]?(?
M^E(BI_#J?X)?^DL\+_8'_P"3%?V+/^S3/V<O_5/>#:^LZ^3/V!_^3%?V+/\
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M7;F\72Y]0NK'P?H=Q/YL'AWPQ;SNFGZ=;JN(A(T:K-=S(H-S.YE?DU\Z4@&
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M52JISDVY!1117YB?I84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ;>A:@]E>(A8^1<,(Y
M5SP&)PDF/52<<<D'!Z5Z;7C .TAO[I#?0@Y!_#%>P6SF2VMW))+P1.2>I+1J
M23[\\T 3T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %<!\6/^26_$K_L0/&7_ *CNI5W]<!\6/^26_$K_
M +$#QE_ZCNI5I1_BTO\ KY#_ -*1%3^'4_P2_P#26>%_L#_\F*_L6?\ 9IG[
M.7_JGO!M?6=?)G[ _P#R8K^Q9_V:9^SE_P"J>\&U]9UKC?\ ?,7_ -A-?_T[
M,QP7^YX3_L&H?^FH'XY_\%&_VVOVIOV?/CW^SA\"/V9U_92TW4_C;X?\=ZSJ
M?BG]J_5/%_AOP1HS>#8&O!#_ ,)1X9\6:#'IKWMO&\-K;W.FZI-?WS0VUN8F
M<9^A/!W[9FF_ _\ 9Y^%OC[_ (*%?%[]FCX??$#X@7WBVWA\0?!'6?%^O?!#
M78=(U*^N]+_X1#7]8CUC4IY4\*MI4^K/?W:P2:P][#IS21+%&/A#_@KO^R!\
M;?V@_CY^RW\1_ G[%_A;]M[X:_#/PW\0=-\?_"7QE\6_!GPFT"_OO$,9AT*>
MZU?Q'KVFZD\NEW#)JMK_ &;IVI6[SVZ07@2-R#0\7?L@?'/XU?#3_@F7X?U'
M]A_P9\ _"G[/W[1>N:O\4OV=M/\ BK\/?B7X.^'/PIL5FM-!U#^VKG5;*R\8
MVFLK%!J<N@Z-;:SJ5E)<&VNK1O*8GF.D_6CX+_MG_LO_ +0^I7>D?!OXP^&_
M&VH67@32/B=<6]K;:YI97X?Z[?:GIFE^+8Y=?TG2H9]&GU#1M3LY+F"246<]
MI)'>K;EH]_P$/^"YW[#M]^U7X+_9T\._$OPCXA\+^*;74='OOC!::QXFAT[0
M?BJFOVOAW0/A9)X6E\ FXU'5?$M_<.+36[?78M)MA#B9G\Q2/E3_ (+2_#CQ
ME\$O&7[.OQN_96/A_P %?$SXV:=KG[ &LZ!IMG%IT&K>"_C-.;[P_?V6E:;Y
M420^"-37Q%>RW%KI[M8?VZ+LO'L5AU6I_P#!/SXP_LO_ +3?["/C3]F_]ECX
M:_'KX6_"WX)1?!#XK2ZYXR^'W@K5?"NL:MKV@7>K_&'6)?$VFG4?&NL:/G5]
M8TLZ/9:KX@N!:BP6YL9)8)) #T/X2?\ !4_X:?"7]IW]N'X;?MH?M.^%?!FA
M^%/VE8?AY^SSX9\3:38V=U9^&AH-O<7&G6#^$/"QU2_L8]0D(DUGQ7=7;K,Y
MA&H[49$_0#XP_P#!1_\ 89^ 7C#PCX ^+W[3/PR\&>+O'5AI&J>%]&N]2O=2
MDO\ 3=?B@N-%OY[K1+#4[#2;35+2ZM;ZRN-8NK"*?3KFWU%&-C/%<-^87BC_
M ()V_%3Q3H__  63U;7?@%X4\0>//VEM<\53?LPZUK&H_#;4-:\1Z=?>$'M]
M,.CZO?:[*_@,MXA<NC>([CPO=17 6ZE,<2I*/SNUW_@EM^WC\-+S7S:_LR^)
M/VEO"OQS_9Z_9W\)^.= \'_M3_ +X+:[X$UWX=?!SPKX%\6>!?%&K?$[X=?$
ME]9-KK6CWD&A:O\ #?6K/34T>.TD?6+Z69H+, _I>^-G_!0G]B[]G/59]$^-
MG[0_@+X?ZI!X+T#XAK::M-JMR]]X+\4ZE/I/A_7M(?2M,U"+6[75+ZUN([>+
M1Y+Z[\F)KR2WCL\7!Q?"_P#P4K_80\:_$WP#\'/"?[3_ ,,?$'Q*^)^G:=J?
M@7PMIFHW]S=:];ZO$TNF0I>II_\ 96GZG>A?+@T75;^QUA[EH[3[ +J6*%_S
M]\/?\$^O&=W^V5X,^('BOX!Z9J?P2\)?\$N]'^ ?AL>/O%?@'XBW/A7XUP:X
MDR^"9'NKV'4]8U71="OM2TM/'T/AJQ\.74 D>TU"U>>.!?FWP)_P2\^,_A#]
MD_\ 8&\-:9^SCX4T+XZ?"+]M7PC\8/C!>Z=KGPP@\2:-X$L/&-YJ&J:]=^+[
M7Q,8/$$,.DFTE70=%UC5;X;(TLM)^TQ;5 /V0UC_ (*7_L'^'_CO+^S+K7[3
M7PZTWXYV_B-?"-SX NI=92]M/$K2"+^Q;S5O[(/AZTODF/D317.KQ>1< V\Q
MCF4H/"-%_P""P'[*^I?MR>+?V*;_ ,5^&=&U+0+:ST31/'UWX@UG[-XG^+,-
MYJL7BKX4IX?D\%V\&CZIX0T_2WU74O$%_P")VT.>V=EAE5H27_(']L3]AK_@
MI]\??B=\5O#\G[.?A[5_!W_#1MK\4/ ?Q-\%?&#X >"O!NL^!-/\:)KEC8S_
M  VU+PO;_%6]\=2Z>[7&L>)/$/Q-T*RN=36Y*Z-<1M K_=7[1?[&_P"TI<_\
M% _BE\0_A'^SC\,/&7P=_:=_9H'P8U_XR7?BCP!X7U/]G_Q=+8^.(K_XA+X4
MU*QD\5>)_$=_<:CI=K<7?A:SDO9]/U$RSZRTEK/:1@'Z"^#O^"G/[ WQ ^,W
M_#/G@[]J3X8Z[\8#K$_A^+P?;7VIQ/=:W;RB!M+L=;NM,M_#=_>S7!6VLX++
M6)WU"Z>.UL1<7$D<;>CZ?^VQ^RQJWQSU#]FS2OC+X;U+XV:2-1&I>!["TUZ\
MFLYM(L9=1U2RGURWTB3PRNI:?9P337FE_P!M'4;?RVCEM5E'EU_/'\/O^">O
M[=?B[P=^R?\ L@^-?V+OV??@GX(_9B^-/@3XA:S^VWHOQ(\#Z]XG^(>C_#?Q
M#>Z\9M$\$>'HS\1-,U_Q<EV(P_B.]N+8WL$0OQI$1BOK/[(^$O[*G[5_@C_@
MH5XF\>_#+X 7'P!^ 'C?QU\0_$?QXU[Q-\8OA7\3OAU\7YM3TF]TO1_&/PP\
M&:9IQ^+WPX\5ZQ/-%J=Q!K$UIIR2%X=04Q[D8 _48?MU?LF'X&^&OVE!\:?#
MQ^!WC#QE;_#WPU\0_P"S/$_]E:KXRNO$E]X0M]!@L_[#_MF.YE\2:;?:4LMQ
MIL-H)[=Y&N! R3-IZE^VE^R[I/QYL/V8[WXQ^&Q\==2D@@MOA_;6VN:A>I=W
M-A<:K!I]]JVGZ3=>'=,U273;6:^72]2UBTU'[,JRFV"21%_YP9?V(_\ @J+9
M_LA^$_V %_94\ 7_ ,.?@Q^TSX=^*NC_ ![L?C]X$34_B1X=@^,6N^.KO^P/
MAU?R6=QHXLK3699IY/%.N:'?R6L5O%9Z3<WSS6\/WK??LP?M7Z)_P4QN/C-\
M"_V?IOA!\-_&'Q0TW7/V@/BKKWQA^%7C?X3?&KP9HG@8Z/I^JZ-\*9-,?XO^
M!OB3]INUTY;ZS-GIGGZ4))Y6TV6.:8 _>JBBB@ HHHH **** "OFS]L/P#>?
M$[]F#XW>#-.1IM2U'P%K%]IMND;2R7>I>'D3Q'I]C$B@L9KZ\TF&TAQRLLR-
MVKZ3H(!!!&0>"#T(]#79EV-JY;F&!S&A;V^7XS"XVC?;VN%KPKT[^7/35_(X
M\PP5+,L!C<OKW]CCL)B<'6MO[+$T9T9VU6O+-VU1_  RLC-&XVO&S1R+_==&
M*.I]U8$'W%)7ZB?\%+?V+=8_9^^)&J?%'PAI1F^#?Q"UB>^MI=/MI/LO@?7]
M0E:6?PYJ*JK+96-S.[-H=T[F"X#"S:5;UD@;\NZ_TPX<X@R[BC)L#G>5UHU<
M+C*,9N*:<\/627M\+7CO"OAZEZ=2+ZI2C>$HR?\ F[Q%D&8<,YQC<ES.C*EB
ML'5E#F<6H5Z+;='%46])T,13Y:E.2OH^65IQE%%%%%>X>*%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%==X#\">*_B9XMT3P/X)T:\U[Q+X@O([/3]/
MLHFD8EV42W5PX&RVLK5#YUW=SM'!!$"TC@E0<ZU:EAZ-7$8BK3HT*%.=6M6J
MSC3I4J5.+G4J5)R:C"$(IRE*32C%-MI(THT:N(JTJ%"G4K5ZU2%*C1I0E4JU
M:M22A3ITX13E.<Y-1A&*<I2:23;/UJ_X(Z^!+V[^(/Q4^)+Q&/3M!\+Z=X1M
MIV3Y;J]\0WK:C>PPR=-]E!HMC)<)U"WUNW.>/Z *^<_V5_V?](_9L^#GA[X=
M63V]YK(,FM>,-9@3:NL>*=12+[?/&S 2-:64,-MI5@7"&2SL(9WBBEFE0?1E
M?YT>)G$]'B[C/.,XPC;P#J4L'E\FG%U,'@J4</3K6:4HK$SA4Q2C)*4%64))
M.-E_H5X;<-5N$^#LHRC%I1QRA5QF/BFFJ>+QM25>=%M-Q;PT)4\-*46X2E1<
MHMJ5V4445\$?=!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!)$C2RQQJ,M)(J >NY@/T&
M3^%>P1)Y<4<?_/.-$XZ?*H7C\JXOPUI3,XU&=2J)G[,K#[['K+C^ZO1#W))'
M&">XH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "N ^+'_)+?B5_V('C+_U'=2KOZX#XL?\ )+?B5_V(
M'C+_ -1W4JTH_P 6E_U\A_Z4B*G\.I_@E_Z2SPO]@?\ Y,5_8L_[-,_9R_\
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M[</_ $3CPM_X<KP=_P#+"C_AT[^W#_T3CPM_X<KP=_\ +"OZXZ*/^)C.._\
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MC>K_ //"+_P(C_QH_P"$;U?_ )X1?^!$?^->ET4 >:?\(WJ__/"+_P "(_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX_8'_P"3%?V+/^S3/V<O_5/>#:^LZ^*/V)-/\2WW[&/[(=[X?\16GA[0;O\
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M\G^W@"B:I-8:F;?S &AL9-/\P+>-<P'LX?\ /ZDOE6_2BQ\S_DE]\/\ Y/\
MJWI?OZ*XEM&\<&=G7QMIZP&Y>18/^$1A++;'4[ZY2V,W]M99TTR>PTPW&P%I
M;&34#&&O&MH(4T3Q\%C#^/--=E2$2,/!<""1TA\/),X7^W6V"6:P\13*N6\I
M?$-K%EQH<;Z@N2/_ #^I_=6_^5!S/^27WP_^3.\HK@GT/X@&-U3Q[IJ2-#*B
M2'P5 P29[/78HIBG]NJ'6*\O=!O#$6 D30KFU+JNLO+8S_V-XX^T>9_PFVG_
M &?[4)?L_P#PB,.[[)_:D5R;7SO[:SO.E++I?VG9D32C4O*+1BU8]G'_ )_4
MW\JWZT@YG_))?.'Z39VU%<"NA?$$0HC>/M-:86\<;S#P5 JO<+I^D027 B_M
MXA%DU"UU?4!!O(CCU>"Q$C+IB3W;WT3QZ?,V>.].3=YWEY\&P/Y>_P#X2/R<
M_P#$\7S/)_M#PWN^[YO_  CEUG9_;TG]GOV</^?U+TM6_P#E-OQ%S/\ Y]S^
M^'_R?]6?E?NZ*XA=&\<B9';QOI[0BXCD>'_A$(59[==0TF>2W$HUHE&DTZUU
M?3Q/L)CEU:"^$;-IBV]W6&A?$+[.$/Q TTW'V41>?_PA$&TW8TN*V-UY']O8
MV'55EU3[-YF!#*NG>;MC%TY[./\ S^I+Y5OTI,.9_P#/N?WP_P#D_P"K>E_0
M**X=]%\=&1V3QQIZ1F65TC/@^%BD+7FNRQ1%SK8WM%9WN@V;2[5,KZ%<76Q&
MUF2*Q1-%\=JT9?QSISHKPF11X.A0R(DWAYYD##7#L,T%AXBA5@&\IO$-K* Y
MT.--07)'_G]3^ZM_\J'S/^27WP_^3.YHK@&T+XA&!D7Q_IHN#;/&LY\$P%5N
M3IE];)<^3_;P!1-4FL-3-OY@#0V,FG^8%O&N8++:-XX,[.OC;3U@-R\BP?\
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M$/Q TTW'V41>?_PA$&TW8TN*V-UY']O8V'55EU3[-YF!#*NG>;MC%TY[./\
MS^I+Y5OTI,.9_P#/N?WP_P#D_P"K>E_0**X=]%\=&1V3QQIZ1F65TC/@^%BD
M+7FNRQ1%SK8WM%9WN@V;2[5,KZ%<76Q&UF2*Q1-%\=JT9?QSISHKPF11X.A0
MR(DWAYYD##7#L,T%AXBA5@&\IO$-K* YT.--07)'_G]3^ZM_\J'S/^27WP_^
M3.YHK@&T+XA&!D7Q_IHN#;/&LY\$P%5N3IE];)<^3_;P!1-4FL-3-OY@#0V,
MFG^8%O&N8++:-XX,[.OC;3U@-R\BP?\ "(PEEMCJ=]<I;&;^VLLZ:9/8:8;C
M8"TMC)J!C#7C6T#=./\ S^I/Y5OUI(.9_P DOOA_\G_5O0[:BN#31/'P6,/X
M\TUV5(1(P\%P()'2'P\DSA?[=;8)9K#Q%,JY;RE\0VL67&AQOJ"/H?Q ,;JG
MCW34D:&5$D/@J!@DSV>NQ13%/[=4.L5Y>Z#>&(L!(FA7-J75=9>6Q/9P_P"?
MU+[JW_RD7,_^?<_OA_\ )G>T5Q/]C>./M'F?\)MI_P!G^U"7[/\ \(C#N^R?
MVI%<FU\[^VL[SI2RZ7]IV9$THU+RBT8M6KKH7Q!$*(WC[36F%O'&\P\%0*KW
M"Z?I$$EP(O[>(19-0M=7U 0;R(X]7@L1(RZ8D]VO9Q_Y_4U\JWZ4F/F?\DOO
MA_\ )G?45PCZ)X]/F;/'>G)N\[R\^#8'\O?_ ,)'Y.?^)XOF>3_:'AO=]WS?
M^$<NL[/[>D_L^1=&\<B9';QOI[0BXCD>'_A$(59[==0TF>2W$HUHE&DTZUU?
M3Q/L)CEU:"^$;-IBV]V>SC_S^I^MJW_RJ_X!S/\ DE]\/_DSMZ*\_&A?$+[.
M$/Q TTW'V41>?_PA$&TW8TN*V-UY']O8V'55EU3[-YF!#*NG>;MC%T]A]%\=
M&1V3QQIZ1F65TC/@^%BD+7FNRQ1%SK8WM%9WN@V;2[5,KZ%<76Q&UF2*Q?LX
M_P#/ZE]U;_Y4+F?_ #[G]\/_ ),[BBN&31?':M&7\<Z<Z*\)D4>#H4,B)-X>
M>9 PUP[#-!8>(H58!O*;Q#:R@.=#C34(6T+XA&!D7Q_IHN#;/&LY\$P%5N3I
ME];)<^3_ &\ 435)K#4S;^8 T-C)I_F!;QKF ]G#_G]27RK?I18^9_R2^^'_
M ,G_ %;TOW]%<2VC>.#.SKXVT]8#<O(L'_"(PEEMCJ=]<I;&;^VLLZ:9/8:8
M;C8"TMC)J!C#7C6T$*:)X^"QA_'FFNRI")&'@N!!(Z0^'DF<+_;K;!+-8>(I
ME7+>4OB&UBRXT.-]07)'_G]3^ZM_\J#F?\DOOA_\F=Y17!/H?Q ,;JGCW34D
M:&5$D/@J!@DSV>NQ13%/[=4.L5Y>Z#>&(L!(FA7-J75=9>6QG_L;QQ]H\S_A
M-M/^S_:A+]G_ .$1AW?9/[4BN3:^=_;6=YTI9=+^T[,B:4:EY1:,6K'LX_\
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M>-<P'LX?\_J2^5;]*+'S/^27WP_^3_JWI?OZ*XEM&\<&=G7QMIZP&Y>18/\
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MF/A'_H:?#G_@\TS_ .2J/J>+_P"@7$_^"*O_ ,CYK[P^MX3_ *"</_X.I_\
MR1T=%<Y_PF/A'_H:?#G_ (/-,_\ DJC_ (3'PC_T-/AS_P 'FF?_ "51]3Q?
M_0+B?_!%7_Y'S7WA];PG_03A_P#P=3_^2.CHKG/^$Q\(_P#0T^'/_!YIG_R5
M1_PF/A'_ *&GPY_X/-,_^2J/J>+_ .@7$_\ @BK_ /(^:^\/K>$_Z"</_P"#
MJ?\ \D='17.?\)CX1_Z&GPY_X/-,_P#DJC_A,?"/_0T^'/\ P>:9_P#)5'U/
M%_\ 0+B?_!%7_P"1\U]X?6\)_P!!.'_\'4__ )(Z.BN<_P"$Q\(_]#3X<_\
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M:9_\E4?4\7_T"XG_ ,$5?_D?-?>'UO"?]!.'_P#!U/\ ^2.CHKG/^$Q\(_\
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ML>'?'L5MJ=U>2:)9WMU=ZOKE@;5([" Z4\]O,UO'(L7P#X#^!?@_XR_LD?\
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MV%IIZ7L]Q;:@T<,]N)S; ']MGQY^._PO_9I^$_C'XU_&/Q+#X4^'O@?3UO\
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M%[PE;&Q^)7A>P\.Z-?66AV_CN+R/[0FDNI(8+.]O);>TAMH8HI=,N+^TCC+
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M4X4W%3A*IS2<MQ//>'-Y//=G.<W4TEP<C.#F9G.1N;!ZC)QU-5?(@_YXQ?\
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M=E]R(O(@_P">,7_?M/\ "CR(/^>,7_?M/\*EHHN^[^]A9=E]R(O(@_YXQ?\
M?M/\*/(@_P">,7_?M/\ "I:*+ON_O8679?<B+R(/^>,7_?M/\*/(@_YXQ?\
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M'0T^BB[>[?WA9+9+[CI=$\9>*_#=S'=Z'XBU?3YHRI7RKV9X?E.0&M9VEMG
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M9,\)?LW>.?V1]%^%5K%^S]\1=7U[7?$OP_N]=\1:C9MJ?B&^L-3NKC2-0O\
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MX0TFUT3PYX<T2TBLM,TK3;1=L4%M;PJJ LQ>:>5@TUS<RS7-P\D\TDC==10
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:2#5+[Q!>^"KKX;7=G_PAK>/S<V=I/X"?3?#[FT\9QGR]'LY H0-!7U5XO\
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M$C[IDMK>.6>>.WA2>Y$8N9DBC66X$(98A/(JAY1$KNL8D9@@9@N QR ?SU_
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M\,?%#2/$GA74/B[X ^$=LL_C6PDTNT+:SXQU.*Z9H89VNT.GZ-JD3O&(;AH
M^X?,'C']AC]N+]H;X<_\%#?VDOC?\-_!7A/]I']IW]GS3_@;\%?V:/!GCOP_
MKX\$>&_#]S!)';>)?B9?7VD>"M1U[7I8Q(;J'4H=*BMX5GFFM+JZ;3[3^D*B
MN8Z3^;7XP?L;?MBVWQ$_9.\6_L__ +-M]X5^-'@7X!?LR?"GQY^T.?C9\'+G
MX8IX=\%C3I_B#\/OBO\ !WQ-;:IXD\22^'9["]BT?Q#\.)[Y)EU:.73-0F>.
M4PY/[?G[!G[8VK?MG>./VC_A'\%=2_::\$_&GX&^%?A9XG\*^"_C_P#"#X&Z
M_P"#+[P^7_MB"YU'XW?#7Q]9WOA;54E==$@\*0V6N6;RO+>:I:_9UBN_Z8**
M /YEOC5^R-^WEX=^%?['OPZ^ 7[+(U?X8^%?V;(/A_XZ^&\G[07P#M_B[\(_
M'5ZTES)HFN?'#XD?#OQ7HOCOP1X?:X\E;;X?>#M.EU>:"22*[TZ.6.1/G/X8
M?\$Y/V]O@_\ #_\ 9AT_X>?LNWWA/]I;X<Z-K/@[6/VAM._: ^!^I?#>S\#:
MI^T'X_\ &MWX5^*?PK\21ZSJGBW31X=U.TUG1+[P(6U.WM=?AM)H[#6K2_TZ
MQ_KUHH _FP_X*"_L)_MD:]^V)-^TW\(O@_=_M*>'?B/^SKX<^#'C/P7X(^.O
MPF^!NM^#]7T6_O+S6IH-4^-_PX\?Z5=^#-92]<:/:>';.U\26MW+=3W6H:?'
M;PKJ'[)?L%?"*\^!7[(OP-^%VI?#W7OA-JGACP9:P:K\,_$GQ&TCXM:MX&U&
M>>>YN_#LWQ$\/Z;H^A^*$LI93Y6HZ3IEE8ND@2"!%2OKVB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HZ]:** /Q_\ VI/@9>_#CQ1=^+-%M#)X(\27LEQ"
M]M$WDZ#J-RY=]+N0 1!!+(2;"5F*2 B$L)R(S\GU_0_JVDZ9KNG7FD:Q8VVI
M:9?P26UY97D2S6]Q#(I5XY(W!!!!//!!Y!!&:^!?B+^PW:W=U/J'PUU^/2XI
M \G]A:[Y]Q C\MY5E?QAID5SD*MSF.(84,%&1_2O GBWE[P.'RKBFM+"8K"T
MX4:.:2A.IA\52@E&G]:]G&52CB(Q2C*JX2I5DO:3G3J-J7\W\=>$^8+'8C->
M&*,<5A<3.5:ME<9PIU\-5F^:H\+[24:=;#SDY2C24XU:+?)"-2%G'\VJ*^H[
MC]CGX[12LD.@:-=1CI,GB328E;D]$FG60<8/([_6H/\ ACWX]_\ 0L:3_P"%
M1HG_ ,DU^JKC7A"237$^0V:NN;-<%%ZVWC*LI)Z[-)K6^S/RQ\&<7)M/AG/;
MIV=LKQDE?RE&DXM>:;3W3L?,=%?3G_#'OQ[_ .A8TG_PJ-$_^2:/^&/?CW_T
M+&D_^%1HG_R33_USX1_Z*?(/_#M@?_E_G^?9B_U-XM_Z)G/O_#5C?_E/G^?9
MGS'17TY_PQ[\>_\ H6-)_P#"HT3_ .2:/^&/?CW_ -"QI/\ X5&B?_)-'^N?
M"/\ T4^0?^'; _\ R_S_ #[,/]3>+?\ HF<^_P##5C?_ )3Y_GV9\QT5].?\
M,>_'O_H6-)_\*C1/_DFC_ACWX]_]"QI/_A4:)_\ )-'^N?"/_13Y!_X=L#_\
MO\_S[,/]3>+?^B9S[_PU8W_Y3Y_GV9\QT5].?\,>_'O_ *%C2?\ PJ-$_P#D
MFC_ACWX]_P#0L:3_ .%1HG_R31_KGPC_ -%/D'_AVP/_ ,O\_P ^S#_4WBW_
M *)G/O\ PU8W_P"4^?Y]F?,=%?3G_#'OQ[_Z%C2?_"HT3_Y)H_X8]^/?_0L:
M3_X5&B?_ "31_KGPC_T4^0?^'; __+_/\^S#_4WBW_HF<^_\-6-_^4^?Y]F?
M,=%?3G_#'OQ[_P"A8TG_ ,*C1/\ Y)H_X8]^/?\ T+&D_P#A4:)_\DT?ZY\(
M_P#13Y!_X=L#_P#+_/\ /LP_U-XM_P"B9S[_ ,-6-_\ E/G^?9GS'17TY_PQ
M[\>_^A8TG_PJ-$_^2:/^&/?CW_T+&D_^%1HG_P DT?ZY\(_]%/D'_AVP/_R_
MS_/LP_U-XM_Z)G/O_#5C?_E/G^?9GS'17TY_PQ[\>_\ H6-)_P#"HT3_ .2:
M/^&/?CW_ -"QI/\ X5&B?_)-'^N?"/\ T4^0?^'; _\ R_S_ #[,/]3>+?\
MHF<^_P##5C?_ )3Y_GV9\QT5].?\,>_'O_H6-)_\*C1/_DFC_ACWX]_]"QI/
M_A4:)_\ )-'^N?"/_13Y!_X=L#_\O\_S[,/]3>+?^B9S[_PU8W_Y3Y_GV9\Q
MT5].?\,>_'O_ *%C2?\ PJ-$_P#DFC_ACWX]_P#0L:3_ .%1HG_R31_KGPC_
M -%/D'_AVP/_ ,O\_P ^S#_4WBW_ *)G/O\ PU8W_P"4^?Y]F?,=%?3G_#'O
MQ[_Z%C2?_"HT3_Y)H_X8]^/?_0L:3_X5&B?_ "31_KGPC_T4^0?^'; __+_/
M\^S#_4WBW_HF<^_\-6-_^4^?Y]F?,=%?3G_#'OQ[_P"A8TG_ ,*C1/\ Y)H_
MX8]^/?\ T+&D_P#A4:)_\DT?ZY\(_P#13Y!_X=L#_P#+_/\ /LP_U-XM_P"B
M9S[_ ,-6-_\ E/G^?9GS'17TY_PQ[\>_^A8TG_PJ-$_^2:/^&/?CW_T+&D_^
M%1HG_P DT?ZY\(_]%/D'_AVP/_R_S_/LP_U-XM_Z)G/O_#5C?_E/G^?9GS'1
M7TY_PQ[\>_\ H6-)_P#"HT3_ .2:/^&/?CW_ -"QI/\ X5&B?_)-'^N?"/\
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MO_ B/_&C_A&]7_YX1?\ @1'_ (T 85%;O_"-ZO\ \\(O_ B/_&C_ (1O5_\
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M9E8??8]9<?W5Z(>Y)(XP3W%(      !@ #  ] !P!2T %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
M?%C_ ));\2O^Q \9?^H[J5=_7 ?%C_DEOQ*_[$#QE_ZCNI5I1_BTO^OD/_2D
M14_AU/\ !+_TEGA?[ __ "8K^Q9_V:9^SE_ZI[P;7UG7R9^P/_R8K^Q9_P!F
MF?LY?^J>\&U]9UKC?]\Q?_837_\ 3LS'!?[GA/\ L&H?^FH!1117,=(4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+O\ YE#ZA0_Y^8W_ ,..8?\ S5Y?GW9\#?\ "C?^"@7_ $?S\-O_ !"G0_\
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M_P 0IT/_ .?Q1_PHW_@H%_T?S\-O_$*=#_\ G\5]\T5S_7Z__/O!?^&W+O\
MYE.CZA0_Y^8W_P ..8?_ #5Y?GW9\#?\*-_X*!?]'\_#;_Q"G0__ )_%'_"C
M?^"@7_1_/PV_\0IT/_Y_%??-%'U^O_S[P7_AMR[_ .90^H4/^?F-_P##CF'_
M ,U>7Y]V? W_  HW_@H%_P!'\_#;_P 0IT/_ .?Q1_PHW_@H%_T?S\-O_$*=
M#_\ G\5]\T4?7Z__ #[P7_AMR[_YE#ZA0_Y^8W_PXYA_\U>7Y]V? W_"C?\
M@H%_T?S\-O\ Q"G0_P#Y_%'_  HW_@H%_P!'\_#;_P 0IT/_ .?Q7WS11]?K
M_P#/O!?^&W+O_F4/J%#_ )^8W_PXYA_\U>7Y]V? W_"C?^"@7_1_/PV_\0IT
M/_Y_%'_"C?\ @H%_T?S\-O\ Q"G0_P#Y_%??-%'U^O\ \^\%_P"&W+O_ )E#
MZA0_Y^8W_P ..8?_ #5Y?GW9\#?\*-_X*!?]'\_#;_Q"G0__ )_%'_"C?^"@
M7_1_/PV_\0IT/_Y_%??-%'U^O_S[P7_AMR[_ .90^H4/^?F-_P##CF'_ ,U>
M7Y]V? W_  HW_@H%_P!'\_#;_P 0IT/_ .?Q1_PHW_@H%_T?S\-O_$*=#_\
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M7Z__ #[P7_AMR[_YE#ZA0_Y^8W_PXYA_\U>7Y]V? W_"C?\ @H%_T?S\-O\
MQ"G0_P#Y_%'_  HW_@H%_P!'\_#;_P 0IT/_ .?Q7WS11]?K_P#/O!?^&W+O
M_F4/J%#_ )^8W_PXYA_\U>7Y]V? W_"C?^"@7_1_/PV_\0IT/_Y_%'_"C?\
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MW_PXYA_\U>7Y]V? W_"C?^"@7_1_/PV_\0IT/_Y_%'_"C?\ @H%_T?S\-O\
MQ"G0_P#Y_%??-%'U^O\ \^\%_P"&W+O_ )E#ZA0_Y^8W_P ..8?_ #5Y?GW9
M\#?\*-_X*!?]'\_#;_Q"G0__ )_%'_"C?^"@7_1_/PV_\0IT/_Y_%??-%'U^
MO_S[P7_AMR[_ .90^H4/^?F-_P##CF'_ ,U>7Y]V? W_  HW_@H%_P!'\_#;
M_P 0IT/_ .?Q1_PHW_@H%_T?S\-O_$*=#_\ G\5]\T4?7Z__ #[P7_AMR[_Y
ME#ZA0_Y^8W_PXYA_\U>7Y]V? W_"C?\ @H%_T?S\-O\ Q"G0_P#Y_%'_  HW
M_@H%_P!'\_#;_P 0IT/_ .?Q7WS11]?K_P#/O!?^&W+O_F4/J%#_ )^8W_PX
MYA_\U>7Y]V? W_"C?^"@7_1_/PV_\0IT/_Y_%'_"C?\ @H%_T?S\-O\ Q"G0
M_P#Y_%??-%'U^O\ \^\%_P"&W+O_ )E#ZA0_Y^8W_P ..8?_ #5Y?GW9\#?\
M*-_X*!?]'\_#;_Q"G0__ )_%'_"C?^"@7_1_/PV_\0IT/_Y_%??-%'U^O_S[
MP7_AMR[_ .90^H4/^?F-_P##CF'_ ,U>7Y]V? W_  HW_@H%_P!'\_#;_P 0
MIT/_ .?Q1_PHW_@H%_T?S\-O_$*=#_\ G\5]\T4?7Z__ #[P7_AMR[_YE#ZA
M0_Y^8W_PXYA_\U>7Y]V? W_"C?\ @H%_T?S\-O\ Q"G0_P#Y_%'_  HW_@H%
M_P!'\_#;_P 0IT/_ .?Q7WS11]?K_P#/O!?^&W+O_F4/J%#_ )^8W_PXYA_\
MU>7Y]V? W_"C?^"@7_1_/PV_\0IT/_Y_%'_"C?\ @H%_T?S\-O\ Q"G0_P#Y
M_%??-%'U^O\ \^\%_P"&W+O_ )E#ZA0_Y^8W_P ..8?_ #5Y?GW9\#?\*-_X
M*!?]'\_#;_Q"G0__ )_%'_"C?^"@7_1_/PV_\0IT/_Y_%??-%'U^O_S[P7_A
MMR[_ .90^H4/^?F-_P##CF'_ ,U>7Y]V? W_  HW_@H%_P!'\_#;_P 0IT/_
M .?Q1_PHW_@H%_T?S\-O_$*=#_\ G\5]\T4?7Z__ #[P7_AMR[_YE#ZA0_Y^
M8W_PXYA_\U>7Y]V? W_"C?\ @H%_T?S\-O\ Q"G0_P#Y_%'_  HW_@H%_P!'
M\_#;_P 0IT/_ .?Q7WS11]?K_P#/O!?^&W+O_F4/J%#_ )^8W_PXYA_\U>7Y
M]V? W_"C?^"@7_1_/PV_\0IT/_Y_%'_"C?\ @H%_T?S\-O\ Q"G0_P#Y_%??
M-%'U^O\ \^\%_P"&W+O_ )E#ZA0_Y^8W_P ..8?_ #5Y?GW9\#?\*-_X*!?]
M'\_#;_Q"G0__ )_%'_"C?^"@7_1_/PV_\0IT/_Y_%??-%'U^O_S[P7_AMR[_
M .90^H4/^?F-_P##CF'_ ,U>7Y]V? W_  HW_@H%_P!'\_#;_P 0IT/_ .?Q
M1_PHW_@H%_T?S\-O_$*=#_\ G\5]\T4?7Z__ #[P7_AMR[_YE#ZA0_Y^8W_P
MXYA_\U>7Y]V? W_"C?\ @H%_T?S\-O\ Q"G0_P#Y_%'_  HW_@H%_P!'\_#;
M_P 0IT/_ .?Q7WS11]?K_P#/O!?^&W+O_F4/J%#_ )^8W_PXYA_\U>7Y]V?
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M?^"@7_1_/PV_\0IT/_Y_%'_"C?\ @H%_T?S\-O\ Q"G0_P#Y_%??-%'U^O\
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M#_\ G\5]\T4?7Z__ #[P7_AMR[_YE#ZA0_Y^8W_PXYA_\U>7Y]V? W_"C?\
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MC\1? FGRDLHCO?%WA^UD+(%+@)/J$;$J'0L,94,N<;AFE_PN3X0_]%5^&_\
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M_P !XO\ XBC[#9?\^=K_ . \7_Q%']FP_P"?TO\ P!>7][U_#S#_ (C[C?\
MHF,+_P"':KY?]2_U_#S/]#+_ (7)\(?^BJ_#?_PN?#'_ ,M*/^%R?"'_ **K
M\-__  N?#'_RTK_/-^PV7_/G:_\ @/%_\11]ALO^?.U_\!XO_B*/[-A_S^E_
MX O+^]Z_AYA_Q'W&_P#1,87_ ,.U7R_ZE_K^'F?Z&7_"Y/A#_P!%5^&__A<^
M&/\ Y:4?\+D^$/\ T57X;_\ A<^&/_EI7^>;]ALO^?.U_P# >+_XBC[#9?\
M/G:_^ \7_P 11_9L/^?TO_ %Y?WO7\/,/^(^XW_HF,+_ .':KY?]2_U_#S/]
M#+_A<GPA_P"BJ_#?_P +GPQ_\M*/^%R?"'_HJOPW_P#"Y\,?_+2O\\W[#9?\
M^=K_ . \7_Q%'V&R_P"?.U_\!XO_ (BC^S8?\_I?^ +R_O>OX>8?\1]QO_1,
M87_P[5?+_J7^OX>9_H9?\+D^$/\ T57X;_\ A<^&/_EI1_PN3X0_]%5^&_\
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M ( O+^]Z_AYA_P 1]QO_ $3&%_\ #M5\O^I?Z_AYG^AE_P +D^$/_15?AO\
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M $?_ ,57CN!Z#\A1@>@_(4 >Q?:K;_GX@_[_ $?_ ,51]JMO^?B#_O\ 1_\
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M@_[_ $?_ ,51]JMO^?B#_O\ 1_\ Q5>.X'H/R%&!Z#\A0![%]JMO^?B#_O\
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MJOA+3/#^FVL/]@F\&HZ-%;F*"UO[:VE\ME380#X!_P"",^@_$W]KWQA\5/\
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MOP<^%'B&VN)+G2]3\,^&K73[$O<:3/*\]M_:5Q>++=$75TL\XWU^T(
M   &  .  !P !T% "T444 %%%% !1110 5P'Q8_Y);\2O^Q \9?^H[J5=_7
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M)>/CX1U#Q!I'A<>)M$\):Q#;ZCK.BVFLZ[I5K?7MJ-EN+I9"&17*^A_L]_\
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M=RF\-*@JDY-RG44YR;<@HHHKF/T **** "BBB@ HHHH **** "BBB@ HHHH
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MZ38Z]I\&HV^G>*?"NI0:QX;U^RCG5A;ZKHFJ6T%]IUY%MFMKB-7C8'.7^"O
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M)_"OA>QTC58O[=6X76?*GM501C4A=W7VL(H$QGE+<N37U!110 4444 %%%%
M!1110 5P'Q8_Y);\2O\ L0/&7_J.ZE7?UP'Q8_Y);\2O^Q \9?\ J.ZE6E'^
M+2_Z^0_]*1%3^'4_P2_])9X7^P/_ ,F*_L6?]FF?LY?^J>\&U]9U\F?L#_\
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M\.=OV^O^B8>$?_#I^"?_ )8T?\.=OV^O^B8>$?\ PZ?@G_Y8U_9I11_:%?\
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MT?\ #G;]OK_HF'A'_P .GX)_^6-?V:44?VA7_EI?^ R_^3_J[\K'_$#.#_\
MH,X@_P#"S __ #L_J[\K?QE_\.=OV^O^B8>$?_#I^"?_ )8T?\.=OV^O^B8>
M$?\ PZ?@G_Y8U_9I11_:%?\ EI?^ R_^3_J[\K'_ ! S@_\ Z#.(/_"S _\
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M?\.=OV^O^B8>$?\ PZ?@G_Y8U_9I11_:%?\ EI?^ R_^3_J[\K'_ ! S@_\
MZ#.(/_"S _\ SL_J[\K?QE_\.=OV^O\ HF'A'_PZ?@G_ .6-'_#G;]OK_HF'
MA'_PZ?@G_P"6-?V:44?VA7_EI?\ @,O_ )/^KORL?\0,X/\ ^@SB#_PLP/\
M\[/ZN_*W\9?_  YV_;Z_Z)AX1_\ #I^"?_EC1_PYV_;Z_P"B8>$?_#I^"?\
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MD$1@$0@^X."XSV;BNIHH 0      #  & !Z #@"EHHH **** "BBB@ HHHH
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MOBO4"RR7R,4Z+]J+XU67BK]KWPEXG\*>$OAMX"^,WPW_ ."A?P3^'FMZC?\
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MT[0(-9U_4KAY+K5M9FTO2=/M[O4;IVGN?LZ-(<BO9J* "BBB@ HHHH ****
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M:T5_!!?2/&.O>$+[[;;_ !'^T)X*DL=6\,:[K6BS76O7%L]I:Z4+\:HMT]O
M]HKW, D /H"BO-_&/QA^%G@#1;KQ!XR^(7@OPUI-KJ=WH3WVN^)M&TFU;7[,
M-Y^@K<W][;P?VPCKY3:>9!<K(0C1@\5S'@G]HGX1>-G\':5!XY\*Z1XV\;>'
M].\1Z3\.=5\3Z!'XY-AJ5F+^W)\/PZC+>S9M3YWF6T<T+Q RQR-&"U 'M]%>
M7Z5\;?@YKNK:_H6B_%3X>ZMK7A2PN]4\3Z3IWC#0;S4?#VFV$JP7VH:S9V]_
M)<:;9V<[I%=7-Y'##!(P25U8@5<\.?%[X5>,--O=9\*?$CP/XDTC3;ZRTS4=
M3T/Q3HNJ6%CJ.IRK!IUA=W=E>306]Y?SLL-G;2NLUS(RI"CL0" >B45Y!X)^
M/_P6^(VIZIHG@KXG>#/$&MZ-J>O:3J6BV.O:>^KVUUX:G>#6';33.MX]G:[/
MM"W\<+6<]E)#>P3R6LT<K6=9^.WP4\.ZOX?T#7_BU\.-%USQ9;6-[X7T?5/&
M?A^QU+Q%9ZG=2V.G76B65SJ$=QJ=O?7L$]I:36<<T=Q<0RPQ,TB,H /5J*\/
ME^-<#?%74_AIIW@[Q!JMIX:M-(N/&GC.TO- 32_"$GB"WU.XT,:GH5QJL/BV
MXT^_&E72'7=/T.[T.T,<KW=_#%;7#Q1?#7XT:A\1]2@EA^%OCG0/ VN6ES?^
M"?B)JC:#<:+XLLX"[QW$FDZ5JU]XF\(I>VB-=6!\::/H/VO*6L.^\EB@< ]U
MHKR&#]H'X%W.J^)-"M_C%\,I]:\'QW\OBS28O&_AQ]1\-1:7<-::E)KMFNHF
MXTI+"Z5K>\:]CA%M,#%,4?BIQ\=_@HW@N3XCCXM_#<_#^'4SHLWC?_A-/#W_
M  BD6KC;G3)-?.H?V7'?C>I-HUT)P&4E,$&@#U>BO [;]H/PM?\ PCT[XN:9
MI6L:I8>(-0M-%\)>']..GW6L>*==UC7$\.>'-,TN:*\;2E77=4GM5AU.ZOX-
M+L+*<ZEJ=Y:6-O<SQ2:)\:[ZYUCP3X7\6?##QGX$\6^-=1\6Z=;Z%K5SX;U"
M.Q/A;P\?$JW1UW0=9U/P_J]IJ^G^7%;2Z%J6I&POV>PUA;"YAFC0 ]XHKY-\
M4?M;^%O#G@_5_%<'@OQEKTWACPUJ.O\ B[P[I4>CC6?#5WI_B^Y\#KX=OEN]
M3M[6?6;_ %_2]>@TZ.RN+B"[@T:6ZBF:"^TU[KL-6_:*\)Z9K_P1\.1:5K6H
M:C\<%N)]*2V%@A\,65KH[:G<7?B9+B[BDM_*N_+T1[:T2ZNUU-I8S#Y5I=20
M@'T%17C*_&G2_P#A8GBCX>R>%/&\4_A?P;J'C-]9/AR_>UUVUTO4K33+VQ\+
MZ7'$VO\ B*Y6>]B%K<:3I=U8:B^8=/NKF;:C<(G[3*ZEX7\-ZGX9^%7CWQ'X
MO\5^*/&OAG2?AW#+X:TK7(W^'^JW>E^)M2U;6=;UO3_"NAV5F;43QIJNM6MW
M<^<EK;V\EXDL$8!]0T5XG\0_B[JW@#PGX$UAOAGXE\0>+/'WB31_".F_#[3-
M<\%VVKV>O:KH>M:]):7NNZKXAL?"7EZ?;:#?13W-OK<UO<3B);*2X$BD\'\.
M_P!KSX3^-O$;>"M;U.R^&_C=GT>RL?"?C?Q'X6L]8UO7-4O-9L)]#\-Q6>LW
M:>([S2[G24CNYM&>\LY&U*Q6TN)V>0( ?5%%>1/\?_@8FN>)/#+_ !A^&:>(
MO!MKJM]XMT)O&WAU=7\,V6A1//K5UKNGG41=:5;Z3#%)+J4M[%"EE'&[W#1J
MI(KI^T7\ I;3PS?Q_&KX6/8^,[RYT_PC=IX\\,M;>)[ZSNC8W=GH,PU(QZM<
MVUZK6D\-BT\D5RI@=1("M 'LM%>4_%7XL6'PJL] O+[PWXH\01Z[X@T;0C)H
M.FM-8Z0NL:UI6@QZCK6KW+6^E:=!%>ZS9"*UN+Q-1U%/M+:9:7GV*[\FU\0?
MC+\+?A3>>%;#XC^.O#G@RX\:ZI-H_AO_ (2#4[;38M0U""SGO7B%Q<O'# AC
M@\F.:XDBAEO9[2QCD:[N[>&0 ],HKQ2X_:$^$21V>I67Q"\ :CX7^T>(K77O
M%EOX_P#!D6C>&9O#>C_VS?IJ37.MPW%Q)%:X>[BTZ&[DTN B^U1;2QS<57NO
MVBOA3)HGA/Q1X7\6^'_'GA;Q5X^MOA]_PDW@[Q%H.M:#HFIRZ-JVNW5WK&J6
MVHM9P6>FV&D227ZI+)<P)<02M!Y)=U /<Z*X/PA\4_AI\0- U#Q5X%\?^#?&
M/AG29;J#5/$'AGQ)I&MZ-ITUC;K=7L5[J6G7=Q9VTEI:NMQ<)-,C0P,LL@5"
M&KBQ^TU^SH;#3=4'QU^$9TW6=3N-%TF_'Q"\*_8]2UBT?R[K2[&X_M3RKJ_M
MY#LFM(7>>)_E= >* /<**\[O?B[\*M-\8VOP\U#XD>!['QY?8-GX,N_%.BV_
MBBZW0?:5^SZ'+>KJ4V;?$X$=LQ,)$@^0YKBO#G[2GP=\7>*?$7AWPSXZ\*:[
M8>%=*T6]UOQ9I/BCP]J/AFPU37-=U+P_;>&+O4+34IA:^($O;"$26%PL;M_:
M5A'$7FF,8 />:*X+Q3\5/AGX'TO4-;\9_$#P9X4T?2=4@T35-4\1>)-(T?3]
M.UBYB$]OI=[=W]W!!;:A/"RRQ6<SI/)&0ZQE2#7$^%_VFOV??&>A^+O$WAKX
MQ?#S4_#O@.XN(/%^MQ>*=(32M 2WF\C[?J%]+=);0Z3<N0;#5C(=-U",B2SN
M9T(:@#W.BOGWQI^U%\#?!OA/2_%C?$GP/KD/B6U-WX*TW1O&/AF?4?':)J0T
MJ5/!\<NJ11ZZ\-Z)H9OL$DPCDMYXV(>-E'I>H^.](TG6-$TS4I;'3[?6/"_B
M+Q7+J&H:[H.G_P!G:=X;?P^MY)+I=YJ,.KWEJB:_"]YJFGV-UI6C^5''J]Y9
M2ZEI:78!V]%<#X0^*GPX^(>GZQJGP]\<^$O'EGH$CV^KS^$/$.D^((M/NUBD
MF%G>2Z9=W,=K=21Q.4AG:-V"DXP"1YYX&_:A^!OCGP3=^.+;XE>!](L=#T:P
MUGQM8ZKXQ\,QWWP^COP MIXU$.J2P:#=0S$VTRWLL2"=6C5V(H ^@:*\?U;]
MH/X$Z!H7AKQ1KGQD^&.D>&_&?VK_ (1'7]2\<>&[+1_$_P!BF2WO/[!U&XU&
M.TU;[)/(D-S]AEG\B5U23:Q KDM*_:I^#%]X_P!3^&-_XPT;0?&<&O:AH>@:
M/J^K:7#-XR6PT#PGXA74/#;1W<D=U;ZA:>+[)-)MY7AOM3^Q:G/96TUK9RS*
M ?1M%>#_  P_:3^#GQ7M-.7P]X\\)Q^)KTB&\\#3^*?#T_C#1=0,\L TO5M&
ML=2N;FUU$O"2+5E,A!7 )->LCQ5X9-FFHCQ#HIT^35I-!CO?[2L_LCZW#>RZ
M=+I*7'G>4VHQ:A!/9268<W"74,D#1B5&4 &_17F.M?&OX/>&_$=EX/\ $/Q2
M^'VA^+-2U!=)T_PUJWB_0=/UV]U1DMI%TZUTNZOHKV:]9+RT=;:.%IBMS 0A
M$J97PM\5O#/B?5?$NBF4:+J.@?$/5_AM:VVKW=A!/XDUW1?#MAXGO&T"!+J2
M:\B72;V6Y,.Q;R.'3[ZXEMTMX?-(!Z;17EP^.'P:;Q'I/@]?BM\/#XKUZ2.+
M1/#8\8Z =<U>67/E1Z;I8O\ [;>O+@^6EO#(SX.T&N3L_P!JC]G"\TO5M:'Q
MM^&=GI>A>);SP?J]YJGB_1-)AL/$=E>SV+:9.VI7EKMFNI;=Y=.;!CU*T:&\
ML7GMIHI6 /?:*\YUOXP?"CPUJ7A;1O$/Q)\#:'J_CB*&?P;IFK>*=%L+_P 5
M0W/E"WE\/6EU>Q3ZO'/Y\/DO8).LGG1["=ZYPM1_:(^ FD:9>ZUJOQH^%VFZ
M1INN)X9U#5+[QUX:M;"R\1R075TFA75W-J200:N]M8WEPNG2NMV8;6XD$6R&
M0J >QT5#;W$%W!#=6LT5Q;7$4<]O/"ZRPS0RJ'CEBD0E)(Y$8,CJ2K*002#4
MU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MEXQ\*WFN:5!+=:IHMKXATFXU;3;: E9[F_TZ&[>\LX(2")9KB&..,@AV7!K
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M=%\3>$=0DU'4OB!/K:^*=%T'XA:1XMU*VUOP-;_ KPI"MW?6-A)';QZSX_\
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MGQ0\7&=D:2.U:4@U[-XR_9NUB*\U?4/AYX?^%\NF_P#"=^$O%^G?#;Q#)?\
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MU35_@I\:_!%IX-O/"^L^*O#\6C6WC/Q-I_CC1?[<O;_PI=Z'::9<V?C7X%?
MOQ-;V/A80V]P[V?@G7-./]N3"V\3:QJ"7]M9^E^$OVF/'OBKP)87FFZ;\,=:
M^(7BSQK8>"O#FD:-K>NII/@W6+K3QJ&KZ+\6=.U"VB\5>'?$7@H(UMXITBUL
M'N!=7%O!9QF1+A4^A+3XA7G@7P%/XG_:$U'P'\/9](OS8ZMKUGK[0^![I+AX
MCIU_IM]KIMK^RAN?M L&M-72"\^WVER\:-:36DL@!\W2_LJ^-Y=1U0R^*O#-
MSX=L+KX<:IX!T&6'4$_X1[6;/Q+X1UOXGWT]X+&3_D(6OA&#3?"4=K "MOJ>
MIQ:E):1W!->:>/\ ]C[XS>._&_CS7+O5_A]'I6MVWQ&M='/_  DLUK;ZG;>+
M+1[/1[76?"^D?!;3+_1S;1",ZK=2?$CQN9G,DD5M*YR?M*?]H#X4R?#^7XF^
M'/$\7Q \))K-MX=M[KX:VUSX^O-1UZ[OK33H](TK3?#$6HWNHZA'<7MN;BVM
M89)+>%FGF"1(S"32/CIX#UBPOKT?\)+I,FEZKX5T34]+\0^$_$&@ZUINJ^,[
M*TO]"LK_ $?4["VO[6::WOK<W0EA46+LT5V8GC<* ?.-S^S3\0]4T?7]=MK#
MX4?#CQ[>>-?#^NZ%X9\#:CK=W\/=.T>Q\/MX3\1QW>I'P5X8U*;4?%6C7MU+
MJ$5MX7MX#<Z5H4$EY,L<MY&EK^R=XGTKPAXK\.6VI>$M=M]*UGP+!\*O#NO7
M&L)X?E\">"M='BV;PMXYNUTK4;N >)_$=]J;ZL=/L->M$M=/\/-+;ZB+>>TK
MTGX>?M4^$/$TVJ:7XJT_7O"6J:9J_P 3K1=6O?"_B2T\!:M9?#KQ;K&@W0T#
MQQJ%A#X?US5X["PMKC4M+TZ^FNK747O;!(6>T<#L?#'[1?P^\4FX$-CX\T)H
M?"_B3QI OB_X>^+O";:GX6\*G2/[5US1UUS2K,ZK8$:YIKV,UEYRZBDS-9^:
M(I-H!XO\+?V8O$&A?$K7OB=XST?X8:9/K7A37=+TKP9X/EU'6?#O@/6[[7-+
MO[.\\*W>J^$_#04SVMG,^J:K!H>C7PO?)6WM'A>21>/M?V4_B1X:^$5Q\,]/
MC^'WQ!O'G\-ZU8>+/%_BW5/#7BG3-?L[.)-2BFUI?A-\0]/UW2M!O5F3P2NH
M^%TBM-">WT>YTVVELUU*;W>?]J3PC#XF\5>'(O 7QHU=?"VF>&]6?6?#7PE\
M;>)M*U2T\36[7%F=.GT72+MG>.-0[+*J&:$2W-OYL$$LBW;[]J3X86/A_P +
MZ\;7X@7DOB^^\3Z;I'AC3/AOXSU+QLM]X+GDM_%=OJ/@^STB;7],DT%XI#J0
MO;*$6T:F20A.: /'OB_^SC\0/B'X9^#-E>>'OA3XZU7P-X,\6^'/$NG:_P"-
M/'GPTT&WU/Q+;^$H[;5/#=SX#\(ZQ+J\6DC0;RTFL=6T?1--U>.=+S^S-,,W
MV"QL:E^S)XZGLM?DEU?P;XIOYO#_ .S_ &]CI7B.34;+0?%.H?!W6_$^K:AH
M7C$Z?H-Y]G\-:C!K5C8Z?=6FF:S,YL3<ZEHC+OM;GV?2_P!I?X6:UXAT+0-+
MN_$5[%XACTX67BF'PGX@/@:WU#5=#7Q'9Z#JGC,V(\/Z5XC;1WCO)="O[Z#4
MH$EB6:W1W53EZ=^U;\(=1U*+3A<>+K"._P!7L]$\/:SJ_@3Q7I7AWQA?7OB;
M3?"*CP9KU]I<.F>*+>VUK5K.*^N='N+J"RMC->W#QVL$LJ@'D'@C]FKQ[X=^
M(">/[CP[\%=(N/$^F>*-(\1:7X>N-4G3X9Q:I?->:5J7POU&?P!I4VM7Z#8F
MI1ZC:^"H2Y9[9RH6,^0^#OV+_B]X7ET_5-0;P'XQU/PHOA^&PT;QA\3M0U/P
M9\1;?2$U*"5O&>BZ7^SMX?DT"]W7G]IV%_<S_$VZM[JXN+2YENA!%J$_W%XI
M^/\ X$\*O';R6?C;Q%J,GB?5?"2Z/X*\!^*?&&L#5=$@>XU.1],T#3+V[33+
M6.-R^JO&+$L-BS,Q /M,4@FBCE"R()8TD"2QO%*@=0P62)PKQR+G#HX#(P*L
M 0: /CS7/V;;WQ7J_BGQ5K'A[X9Z9X@UCP7\&]"\.V^F_;=0M/!6I_#_ ,7:
M]XAU^/P_J4_AK2[FPTVZMM3LX-+O-.T[3[R\EMV34+*R@CB+>A>.O!/Q1T[Q
MWH_Q,^%$/@37=;/A&Z\$>)/#?Q"U_P 0>%M*N+&6_P!/U:SU[3?$/A[PKXTO
MEU&QNM.:R?29]"CM+^UU"6ZDU&WN;*&*?Z%HH ^%OA]^SS\5/#?BW0-1\06_
MPDN6\.^)_%/C:\^)^@7OB"P^(_C[6/$4UY>MH?B+2+CPA);:/H+7-XUK>31^
M-_$I>QA@%MI%N46%?J3PQXF\8ZEXFU'0/$'A*VTJTT7PIX6N]0\0Z?J.HW>C
MWGC;5?[0F\0>'/#[ZGHFBW.KZ+H=E'I%Q!XC%O +Z;4IK&?3["^TZ[MT]%HH
M ^ ],^!'QSM=%\$^&-5\(?L]>(M*^&/Q2\0^._#-_K7BSQ;J%WK^F>)M9\:S
M7EEJVF7OPDN;;PW?V6G^,1>VKZ9J&NPSZSH=@CO;1N+^UL0_L\_%G2/B)IWB
MK2-!^"E[%X3\>>,_B!H?BO4?$'B>Q\=^+)O$N@:KI-AX4\526GP[O8]&TG3;
MC4Q))J=GK?B59+:TMUM_#MM(B%/O2B@!J;RBF0*'VKO",60/@;@K,JEE!R%8
MJI(P2H/ =110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '-^,/#-MX
MR\,:UX5O;N[LK#7[*33-1EL?L_VB73;EE34+(?:H+F'R=1LC/I]UNA9_LMU-
MY31R[)4\!D_9%^$&GW^GW'@31+#X6:=;S^#[S5M!^'/ASPAX9TGQ1J/@?QSX
M6\=^']4\1):>'_M%]J5K?>%H],-[]HCN#I6K:O$'%Q<1W$/U%10!POBKX?Z+
MXPUKPSK&L/<2#PS#XGMH]-"VLFG:G;^*]%;0]0@U.&XMII)8X[5R\"PRPCSN
M9O-C_=UX)K7[)6C7_P#PB]WHWQ,^(/A?7O!>E> ='\+>(=/A\%:I>Z3:?#B^
M\?7'AP"T\2^$];TB]:*R^(&H:1.-0T^Z1['3=+=$2\2ZNKKZUHH \IUOX46O
MB[POH'AWQEXW^)NJWFAL99O$_AGQ_P")OA-KVN73))&T^LR?![4? 5E<Q^7(
M +!+.+34=$G2S6<>;6/\0_@7X?\ B!\*8?A)<Z[XCMM%MGT9H=4UNYL_B7JU
MTNBZC!J$47B+_A;-EXZT_P :0W;0""_3QE9:\+F)RSGSDBEC]NHH ^,=2_9<
MU#PS\*/AW\+?A5XNO/#A\,?%_3_B!=>+;/0?AWHVH:1;W&M:IK>MW6@^%;#P
M0GP[MY8[G4773M&A\'PZ5%$1&ELHC&?5O!_P"\/^%=5T37[GQ!XA\3:]I^G>
M/;/6]4UH:+#)XNO?B+?Z%>Z[J^MVFCZ3IEA;7<<?A[3["PM=#M=)TNVL5:(6
M+,$=/>** /D?_AD?1+N32;?7?B7\0/$'A_PEKFC:Y\/O#=_#X*M['P--H_C?
M0?&_V;3;_3/"5CKFLPWMQH2:--+XJU37;NVT:_OH=/N+2Y:&ZA[_ ,*_L^>$
MO"WB[QOXOAU37M1N/'D?C*'6-.OYK!;"&'QMXD'B;4X[,V5A:WD8@NLVMFTM
MU*Z6A(F::?$U>\T4 ?%'PT_8<^'/POUK1=6T/66$?AW7/#^M:-;:?\-O@EX1
MO8QX<CU&"QT_5O$_@?X9^&O%_B>VD@U!DO)_$VO:O?W,T"WDMV;V>\N+G4\1
M?L9> _%'Q8U;XL:KK^I2ZCJL^JW)L1X2^%YU"SDU?P5>^!KFWM?B%)X%?XIG
M2H],U"[NK;0I_&TVBP7T@D2P$,<<*?8=% 'RQ8?LN6%IINLK<_$_Q]J7BK4%
M^'+:3XYNK3P+%KGAF[^%DNH/X4O=,L++PA:^&KV6*+49;74(==T35;34[91%
M>V\RR3^;9\/?LN^'='F\<:IJ7C7QCXG\4?$?PI=^%_&7BC54\,6FH:O]JU:X
MU4:N++0_#VE:+8W]M]H^PVL&GZ9:Z7%9Q1K]@,H,I^GJ* /#KW]GCX72:MH7
MB'1_#&B^%?$>E^,O#OC;5_$?AGP_X=TG7?&NJ>&=)UO2--B\9:K;Z4+W6[98
M=?OYR9YA<QW#;[>XA629)>3UO]EOPOJWAKP9H-KXN\7Z+>_#Z]\0ZMX2\2:?
M_P (]-J^EZSX@\7VOC%M4\C4M"OM(NYK"]M386UM>:;/87&F7-S;ZC:7K2>8
M/IVB@#Y9A_9C-GI=C)IWQ@^(MCX]LO&^N^/C\3!I_P .[SQ!<:UXGTFZT/7X
MWT'4/!-WX%AL-0TR\GMUM;7PM EB7\[3C:S 2"Q8_LSPZ%'X?C\*?%/Q]X:%
MAX1L_!/BHVUGX$U4_$'1;".[CM3XB/B#PAJW]GWT:WDJM?\ A7_A'[F5%BCE
MD>.-5'T]10!\X0_LW>&].\+:KX=TW7O$)-[\+/AS\+K>>YN;.)XK#X72ZG=>
M'M2,UA96ES%J%_<ZDPUB:UE@_=1(VE+IEPHG'DW[)?P5^)OPB\1>-6\2^'/#
M/A?PWKELTEPFEI\+KO5/$OB"'59)-.UF;6/ 7PM^'OB*YM[73;C4TF7XA:SX
M[UR6;4H7CUF*2&_DO_NBB@#XR^(?[+L0T3XL:QX&N]1U[Q;\0-&\<:?)X?U_
M4-%LM#N8?'?C"/QCK5E%-/X>U"R5A<(UAI\?B33?$7AZ2T;R?$6A:[ TL4GF
M/A[]C'4?'OPM\/\ @SXK2Z3X+MO">O\ B:X\,^%=$\"?L[^+-)L]%\10V9O8
M[_1O^%(Z7\,8-7EU:/4=4L=>\)_#[PWK]I#J"P7NJZA>PR7LGZ-T4 ?+@_9.
M\ GX=WOPTEUGQ-+H-YXCTWQ,9?.TF&]M[W2? &F_#[3XK9[?2HH(;>UL=*M-
M5A"P>;'JT89)%L@MFKM!^"/CGP'>RZQX=^*?B7Q?XJ\3ZQ\/]-\3^*_&]CX)
MA;3/A[X*U$WESH>DZ%X9\(Z%H\MUJVD-?^&SJ#6::K$=7769=0FN],MS7U#1
M0!Y[>_#?1=0\>WOQ NKF^EO[_P"'S_#FXTMOLC:4VCOK<^N-=^6UL;HW[7$[
MP%FNC:_9PH^S>:#(<'X;?!?P[\,_AS+\-M-UCQ3J5A<R:K)?>(+S6[G3_%MV
MVISN4<^(- .CW]K<:98"TTG3+VQDMKZVL-/LU^T-/&TS>P44 ><_#_X7Z!\-
MEU--"UKXC:P-6^Q_:3X_^*WQ*^)S0?81<"+^S'^(GBKQ,^D>:+F3[8-+:T%\
M4MVO!.;:W,7EO@O]EWP=X(\-ZGX9T[Q#XIN[/5+KP)=S7%]+H[743^ -2DU+
M3%B-OI-O"$O99#'J(>%RT0'V8VSY:OIBB@#P#P[\ ;#P_P#$=_B!_P )SXOU
M.W@USQUX@T7P?>Q>&8] T&_^(K)-XF^PWECX?M/$MQ#<7@EO;>/4M=O1:S3R
M)#M@6.)/(K3]ACX=P>)O''BB?Q+K%SJ/C/3_ !78B[M_"'PIT77-)D\4>)-+
M\5KJ+^,- \ :7XS\5ZCX?UG1-)N- N?'6O\ B<V7V*-7$V^4O]N44 ?&?CW]
MB7X9^.M(^'NG27HL[OX=^'M1\-6.JZQX!^$7Q';4['6+ZVU;5KF]T?XJ?#_Q
MMX=L]5U'6+;^T[K5M$TC2[]Y;BYMO/%C/);'TS0_V=/!FBZ+I>@?;M5O=+TW
MQ9XM\6_9'AT6PMKFX\8VUW:ZEIC6FDZ586EII,$=Y)]AMM.@LVM]L:>8T:[3
M] 44 ?*=M^RKIDVBZQHOBCXF^/\ QE'-X3L?!'A&[UBW\$V5WX \.:9<I=V-
MKH;:!X2TB+5[F*6WL_/U+QA%XCU"^2SB6^N;D/-YG/:G^Q\WB"\M;[Q3\;_'
M_B>['B[3_&NI7FL>"O@9+J%YKFF6VEZ?:7>DZG%\*8M1\#7<>E:6FFKJ7@"Z
M\,:HD-U=SI>K>2BX7[-HH \>M_!'BCQ;X#\>>$/B1K+^3XQO?$=CI::0UG)>
M>&/!VHVT-AI>D+J<MCMUC4;...XNY-6U*VN+FXFN]ERTPA!.=XQ^!.A^+[3Q
MQ;OXC\2Z--XYU/PAJUW?:3)I(NM+NO!NG6FF:?\ V7]MTN\A"74%FC7HO(KI
MFDDD\AH$VJON5% 'R3J_[&'P;_L^"P^'^DVGP>)T%M!UB]^&OACP1HU[XI6"
M]T/4M'U+Q3-<^&;[^W=4T+4-%-YI]S?K-OFU75FO5NA=D*>)?V4T\6^#];\,
MZ_\ %GQ;K&I>+->MM<\8^*M<\#?!+Q'?^)/[,LA9Z!8RZ!X@^&&I^"]'C\.M
MNO=(OO#WAK2=7M]0D>\?4))B&'UM10!XMKOP)\*>(X/#T6I>*/C!:MX;T:UT
M6UD\,?''XO>!H[V"V5 +K6+/P3XT\/V&K:C(R9>^OK6>X",8(WCM\1#K_$/@
M'3/$>NZ#KUU>ZC!<^']'\3:+:PP20-#/;^*+"#3[R:Z:Y@GN)+BWB@5[9UF1
M3*S-<+." .ZHH ^>]4_9S\+ZGH5AHR^(/$UC<:-X&\%^"M#UFUDTDZCI+^ ]
M0N=2T+Q);K<:5/8S:RL]U*EW#>V=SHUU 6@DTLQ22*^/X<_9BT;2=7\4>*==
M\>>-/&?C/QIX)\5>!?$_BO6H/"6GWNIZ7XG.C!9QIWAKPSH>A6-UHD>CK'I2
M6&EVUF?MU[)?VMY*\4D7TY10!\S:A^S/I5YK9N+?Q_XTT[P=J4_AZ]\8?#FV
MM_",WASQIJ'AN.WCM;O5=2O?#-UXMTS[8MK%_:5KX:\1:+9WIW^;;_O'R^W_
M &;;6'4-.BF^)/C>\\$:#X_M_B)X9^'4]CX'70?#^K1WNO:A=6%KK$'A*+QC
M>Z1?7/B&]WVNK^)-0:T@CMK;39;.WB$1^EJ* /D>Y_9'T/4KC38-:^)7C_6/
M"_A?7U\1^ ?!]U!X*@TOP+?MXKTWQ9<?V7J5CX3M?$>KQ3W&GOIJ+XIUG76L
MM+OKNWTYK1S%+%K?%/\ 97\*?%.PO+'4?$.I627WCJ?QY<17WA;X;^.M(DO[
MC1IM&:QF\+?$GP7XP\*W-M%%-]JM+RYT6;6+*[CCDM-1A7<K?45% '@WPH_9
M]\*_"'0_$&@>'M6UVYLO$.A>$= G-T=+LVL;3P;X/L_!FG/IB:+INEP6<DUA
M91W4Z1Q?9X[MF%I#;6H2V3R3X7?L0^ /A=X@T_Q-IWB75;[5-.UCPQJZ26O@
MSX2^"X[Y_"MMXFM[!-<3X=_#[PE_;]U<GQ5J,VHZWK)OM?O)4MS+JA1'1_M2
MB@#YD\5_LR:/XDTFWTBR\?>-O#$7]E_%+0-4FTB+PG=3:WX=^+:J?$NBWJZY
MX:U6&"""X@LKO3+O3HK+4K>:RA$EY-#)<134?%'[*NA>+-2U>/4?'WC1? WB
MO2_!^C>//AJEIX+D\-^-].\%V2Z?IUKJVJ7/A6?Q?80W=LICU.+P_P")-(2[
M1WC95C=D/U310!\G0?LH:7-I%_I'B/XH?$+Q4D'ABT\(^!+S5(/!%G>_#71[
M"026/_".S:'X2TL:M?VXC@C;4_&*^);^ZC@5;R><O*7?<_LG>'=?T;4=-\>>
M/O'/CR_UWQS!X]\1:YK">$]+O-:U.U\ ZG\.;>QEL/#'AG0]#T_2H_#^HH7M
MM(TNP:>^LHKJXDE:YU 7?U=10!\6^$?V+?"_@;P3XU\$>&O%\.E6/C>WTK3M
M1N[#X(_LRV$C:)ICR[]$U33K'X+V^B>+[&_AD$%X_C;3/$5X AGMKF"ZFN)Y
M?4_A)\*_$_@;PMXC\ ZSXLU2_P#"$-K8>'_ QAGT_3?$&DZ7::4UEJ6K)J'A
MK3-!M=)N-8OW.I:=HVC65EI7A:-(M.T6VM;.-(5]_HH ^7(OV8TN+'6+KQ#\
M6OB)XF^(-YK/A[6]"^*-]:> ].\4>$[KPK9O9Z$FF:9H'@[2?!^IV]NEQ?27
M<7B7PWK8U9[Z0:I]LCM[-+;TJV^%377@:Y\&>,/B'\3/%UUJ-_\ VEJGC*#Q
M?J/P]\775POD)!%8ZC\*7\#1>';"&"U@A.F>&K?2-/N6%Q=7EM<7E]?7%QZS
M10!X7KOP*TS4?AAJGPLTCQGXVL-'UF[EFU/4O&&IVWQQU6_L[IXFOM&OV^/]
MG\4+._T6[CB$/]FWMI/;6B-(;".U=W=O,M _9!TOPU+H\&D_%GXDP>'[2\\'
MZMX@\,-;^ I-+\6:[X)M;2STC4;RX;P:=6\/VBP65O&/#?@W4?#GA6U@06NG
MZ+:6H6%?L&B@#Y;L/V6M$6^OH_$'Q \;>*_"+7?CK4M \"ZK;>#K+1?"NK_$
M'6+S6]<U33=3T'PMI/BC4+N&]O[HZ8/$&NZO#8))B&($ UFZA^RYK6I:=86M
MS^T)\5?[1T[P[XA\#0:ZFA?"!=2;X>>)8M'BU#P7(G_"M#8&V4Z%ITL'B$68
M\7I)&Y.OLLLBM];44 ?)WCW]D_1O',.H6+?$3Q?I&B:QH'@S1-:\.'0_AMXH
M\/:W/X$EA;0]6UC1_''@?Q-8ZG-Y,;VU[IE[#-H-Y%/(\VE-.L4L>[\.?V8O
M!WPUTSP1IFD:QJDD?@9OB/+8K;Z1X.\.6%W/\3IGN-<=]!\(^&M \/:7#:32
M.VE6.@:5I-A:J1&UM+&JH/I2B@#XH\.?L,_"_P +?$#3?'NF7L=Q+:3VMW?V
M&M_#GX,^(M0U:[M]!A\.R3'Q[KOPXU#XEZ(ES86]ONM?#7C'1K2VE69K&"U6
M\O5N-B\_9"TO48K:UU+XK_$:^L?#%T-1^%EE/:^ O+^%6K1^(=.\26^IZ!-'
MX-2Y\27%K=Z<EM#%\09O%UJ+"XN;5[=TDR/K^B@#Y"\0_LF)XH\&'P=K7Q>\
M9:HE]XNU#QMXAUC6O!/P2\0W^NZ]?2^>EZEIK_POU/1O#5SILX6;2;WPAIF@
M7VGRHDEM<HZ@CZSL;1+"RM+&*6ZGCLK6"TCFOKNXO[V9+>)(EEN[Z[DFN[RZ
MD5 \]U<RRW%Q*7EFD>1V8VJ* "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
-HHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>img22994243_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img22994243_1.jpg
M_]C_X  02D9)1@ ! @$ > !X  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" (W!24# 2(  A$! Q$!_\0
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M %8X@_Z%&._\$2\O\T'^LN0?]#; _P#@Z/\ 75?>?T845_.?_P 10G_!-/\
MZ!'[3G_AH-(_^;VC_B*$_P"":?\ T"/VG/\ PT&D?_-[1_JQQ!_T*,=_X(EY
M?YH/]9<@_P"AM@?_  ='^NJ^\_HPHK^<_P#XBA/^":?_ $"/VG/_  T&D?\
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M/_F]H_XBA/\ @FG_ - C]IS_ ,-!I'_S>T?ZL<0?]"C'?^")>7^:#_67(/\
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M$O+_ #0?ZRY!_P!#; _^#H_UU7WG]&%%?SG_ /$4)_P33_Z!'[3G_AH-(_\
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MH_U8X@_Z%&._\$2\O\T'^LN0?]#; _\ @Z/]=5]Y_1A17\Y__$4)_P $T_\
MH$?M.?\ AH-(_P#F]H_XBA/^":?_ $"/VG/_  T&D?\ S>T?ZL<0?]"C'?\
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M*Z:E%VM*+4HMQ:84445[9R!1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K^'S_@Z_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MXK$8=R;BVIP<Z,Z=27>[T_O+_P!]#_&C>G]Y?^^A_C7$T5_1!\.=MO3^\O\
MWT/\:-Z?WE_[Z'^-<310!VV]/[R_]]#_ !HWI_>7_OH?XUQ-% ';;T_O+_WT
M/\:-Z?WE_P"^A_C7$T4 =MO3^\O_ 'T/\:-Z?WE_[Z'^-<310!VV]/[R_P#?
M0_QHWI_>7_OH?XUQ-% ';;T_O+_WT/\ &C>G]Y?^^A_C7$T4 =MO3^\O_?0_
MQHWI_>7_ +Z'^-<310!VV]/[R_\ ?0_QHWI_>7_OH?XUQ-% ';;T_O+_ -]#
M_&C>G]Y?^^A_C7$T4 =MO3^\O_?0_P :-Z?WE_[Z'^-<310!VV]/[R_]]#_&
MC>G]Y?\ OH?XUQ-% ';;T_O+_P!]#_&C>G]Y?^^A_C7F>O6.HZGHNJ:?H^M3
M^'-5N[*XATW7;>TL]0ETF^9#]EO?L%_'+:7L4,P1I[254^T0>9#'/;2NEQ%Y
MU\-OB#J&MW6H^!?'-E;:!\4?"T"2:UI=NSG2_$6D[U@MO&GA*>8*]]X?U)FC
M\Z,@7>D7DHL[^*)GAWZQI2G3G4BU+V;7/!7YXP=DJEK:PYGRMIOEDX\R2E%O
M*56,*D*<DX^TNH3:7)*:NW3YKZ5.5<RC)+GBGR.3C-1^D=Z?WE_[Z'^-&]/[
MR_\ ?0_QKB:*R-3MMZ?WE_[Z'^-&]/[R_P#?0_QKB:* .VWI_>7_ +Z'^-&]
M/[R_]]#_ !KB:* .VWI_>7_OH?XT;T_O+_WT/\:XFB@#MMZ?WE_[Z'^-&]/[
MR_\ ?0_QKB:* .VWI_>7_OH?XT;T_O+_ -]#_&N)HH [;>G]Y?\ OH?XT;T_
MO+_WT/\ &N)HH [;>G]Y?^^A_C1O3^\O_?0_QKB:* .VWI_>7_OH?XT;T_O+
M_P!]#_&N)HH [;>G]Y?^^A_C1O3^\O\ WT/\:XFB@#MMZ?WE_P"^A_C1O3^\
MO_?0_P :XFB@#MMZ?WE_[Z'^-&]/[R_]]#_&N)HH [;>G]Y?^^A_C1O3^\O_
M 'T/\:XFB@#MMZ?WE_[Z'^-&]/[R_P#?0_QKB:* .VWI_>7_ +Z'^-&]/[R_
M]]#_ !KB:* .W!!Z$'Z$'^5+7(6MU):ON3E3]]#T8?T(['KVZ5U,$\=Q&)(S
MD'@@]5/<$?YS0!-1110 4444 %%%% !1110 4444 %%%% !7\'?_  =;_P#)
MYG[-/_9L=Y_ZM7Q77]XE?P=_\'6__)YG[-/_ &;'>?\ JU?%=?9<!_\ )1X?
M_L'Q?_IEGQ_'7_).XC_L(P?_ *D0/Y<Z***_=C\/"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** +$%I<7*7<D$32)8V
MWVRZ9<8AMOM%O:^:V2"5\^ZMX_E!.Z1>,9(KUU/AS_D'^-?^Q2;_ -2;PS7+
M4D[N7D[+_P !3_4;6B?>_P"#"BBBF(**** "BBB@ HHHH **** "BBB@ HHH
MH **/Z\#ZGH/QK[)T_\ X)V?M\:MX:L?&6E_L9_M)ZAX3U30;?Q3IOB.S^$O
MBR?2-0\-7=@FJ6NO6=XE@8[G2;G39$OX+V+=!+:.LZ,T9!K*K7H4.5UJU*BI
M-J/M:D*?,U:ZCSR7,U=72N]36E0KU^94:-6LXI.2I4YU'%-V3ER1E9-]79'Q
MM12LK*S*ZLC*2K(ZE75E)#*RL RLI!#*P!4@@@$4E:F044#D@>I 'U)P/UKW
M#XY_LZ?%C]G#4O 6D?%O1-,T2^^)?PS\(_%_P?%IGB'2/$27W@/QS8)J?AO4
MKJ72+BXCTV]N[-UDN-)O#'?V3DQW,2.,5#J4XSA3E.*J5%-TX.24IJFDYN,7
MK)04HN5KVNK[EJG4E"=2,).G3<5.:BW&#FVH*4DK1<FFHIM7L[;'A]%%%60%
M%%% !117<Z9\,?B/K7@#Q3\5]'\">*]4^&'@?6-$\/>,OB#8Z)>W/@_PMKWB
M5_+\/:-KVO11-8:9J>N.=FEV=U-'->MQ"K&E*48I.4HQ3E&*<FDG*348Q5[7
ME*348K=MI*[8XQE)M1BY-*4FHIMJ,4Y2D[;*,4W)[))MZ(X:BBBF(**** "B
MCIUKU7Q1\"OC5X(^'O@OXM^,OA/\0?"OPL^(\EU#\/\ XB:_X6U73/!OC66R
M:5+R/PSK]U;QZ?J[VSP3+,MI-(4,4G&%)J93A!Q4IPBYRY8*4HQ<Y6;Y8)M.
M4K)OEC=V3=K)E1A.2DXPE)0CS3<8MJ$;J/-)I-1CS2C&[LKM*]VCRJBBIK>W
MGN[BWM+6&2XNKJ>&VMK>%&DFN+FXD6&""&-06DEFE=(XT4%G=E50215$[[$-
M%>VV?[./QLF^.VC?LSZO\/\ 6O!/QQUOQ-I'A"'X?_$6-? FK:;K^NVD%_I5
MGX@_X2,V,6@)=V-U:WJ7&IM;P"UN8)RXCE0GF_C#\)?&_P !_BEXZ^#?Q*LM
M.TWQ]\.-?G\,^++#2-:TWQ%IEIJ]M#!/-#9:YH\]SI>J0+'<Q%;NQN)H')95
M<LK 91KT9SC3A5IRG.DJ\81G&4I46U%58I-MTW*44IKW6VDGJ:.C6C"525*I
M&$*OL9SE"48QK).3I2;24:BBFW!VDDF[:'FU%;/AWP[X@\7:[H_A?PIHFJ^)
M/$OB#4;/1]"T#0[&XU/5]8U74)TMK'3M.L+2.6XNKR[N)(X((8D9I)'50.:]
MU^+G['G[6'P"\/V?BSXX?LW_ !G^$OAC4-032;'Q!X_\ :]X;T>ZU215:/3X
MK_4+6*!KMU=2D)<,VX8!) IRK483A3G5I0J5/X=.52$9U+;\D&U*=NO*F$:-
M:<)U(4JDZ=/6I4C3G*$/\<TG&/\ V\T?.-%?9^F?\$X_V_\ 6M#TWQ-I'[%W
M[2VI>'=8T>U\0Z3K=G\)/%<VFZGH-]9)J5EK-C<K8%+G3;O3Y$O;:ZBW136S
MK*C,I!KXZOK&^TN]O--U.RN].U'3[JXL;^POK>6TO+*\M)GM[JUNK:=$EAGM
MYXY(I8I%5DD1E(R#4TL1AZ[DJ->C6<+<ZI585'&^W,H2ER[-:VU370=7#UZ*
MBZU"M24_@=6E.FIV2;Y7.*4K)INU]UW*M%>E:9\&?B[K7PS\1_&G2/ACXZU+
MX0>$-5T_0_%7Q/LO#6J3^!?#NLZM-!;:7I>K^)$MSIEE?:A<7-M!:6\LX>:6
MXAC4%I%!WO@W^SC^T#^T3?:WIOP$^"OQ-^,E_P"&[:TO?$-I\./"&K^*IM$M
M+^6:&QN-3&EV\PLXKN:WGBMVF*^:\,BH"5-.5>C&,YRK4HPI2Y*LY5(1C3E[
MONU)-I0E[T=)-/WH]U<C0K3E"$:-64ZBYJ<8TYN52.OO4XI7G'1ZQ36CUT9X
MO178>/OA[X\^%7B_6_A_\3?!OB7X?^.O#5Q%:>(?!_B_1[W0?$6BW4]K!>PP
M:EI5_%#=6LDMG=6UU&)$ >">*1258&N/K2,HRC&49*49)2C*+3C*+5U*+5TT
MTTTT[-:HSE&49.,HN,HMQE&2<91DG9QE%I---6::33T:N%%%%,045ZJGP*^-
M4OPFF^/4?PG^(+_!"WUX>%Y_BXGA;56^'D/B0B(C09/%0M_[*352)X<69N!*
M3*@QE@*Z;X9?LR_&+XP?"SXV_&?P%H.E:E\/OV>-&TK7_BKJE[XET;2+[1M+
MUJ]@T_3YM,T?4+F'4?$$DMW<1))!I,-Q)"K&24*JDUD\10C&4Y5J2A&I&C*3
MJ048U9SC"%*3O95)3G"*@[2<IQ25Y*^L:%>4HPC1JN4J<JT8J$KRI1C*<JL5
M:[IQA"<W->ZHQDV[)G@E%%%:F04444 %%%% !1110 4444 %%%% !2$ @@@$
M$8(/((/4$=P:6B@#]R_^"7'_  4QN_@YJ6C_ +/?Q[UZ:Z^$NJW,.G^!_&6I
MS--+\.-1NI0D.GZK=RN7/@^XD=4,K[CHS,)BPM4=:_JJCDCFCCFADCFAE1)8
MI8G62*6*10\<D<B%DDCD0AT=&*NI#*2"#7^<57]#G_!)W_@I/-HUSX=_98^/
M6N%]$N7CTOX1^/=5N.=(E8@6O@;Q!>3.6.GR,3'X>U"=BMD@73)G2WBM,_XA
M?M(?H"0SNCG?TA_!/)8PSK#T\1FOB=P1E>'45G.'IQ=;&<9Y!@Z,4O[7H0C4
MQ'$>6T(/^U:*J9OAH+,J6-AF?]P?1M\?G@)X+P[XVQK>!J2IX7AC/,54;>#J
M2:A1R7,*TWK@YMQIY=B9R_V6?+A*LGAIT)87^EROIGX#?&=_"%W#X3\37+OX
M8OI@EE>3.6&A74I"J2S9*Z;,Q"SC(6W)$XQ&C@_,Y!!((P0<$>])7^)GA-XJ
M\7^#/'&3\>\%8]X3-<LJ\M?#5'.67YQEE64?KN39K0A*/UG+\=3BH587C4HU
M(TL7A:E'%X?#UZ?]Q\2<.99Q5E&*R;-J/M<-B(WA4C95L+B(I^QQ6&FT_9UZ
M,G>+LXSBY4JD9TJDX2_9Y'21%>-E='4,CJ0RLK#*LK#(*D$$$$@CD4ZOBC]G
MGXS-$]IX \4W687Q!X<U.X<DQ.>(])N)&ZQ'[MF[GY,K"#M%?:]?],7@1XW\
M(^/O &7<<<*U?8SERX+B#(J]6$\PX<SRG2A/%Y7C%%1]I!<\:V!QL80I8_!5
M*.)A&G.56A1_@;C'A+,^#,ZKY1F,>>*O5P6,A%QHX["2DU3Q%*]^5Z.%:DY.
M5&K&4&Y)1G(HHHK]F/E0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *\U^(_P[B\<6VF:CIFIR>%_'?A6Y.I>"?&=I;BYNM%ONLUA
MJ%H98!K/A?68]UCXBT":XACU"PFF^RW-AJ M[^#TJBKIU)TIJ=.7+*.SLFFG
MHU*+3C*,DW&49)QE%N,DXMIQ4IPJPE":YHR6JNT]'=---2C*+2E&46I1DE*+
M4DFO#/"WQQT&72M0M?B,]CX"\>^%KU-&\9>%;BZDNA%J!C62WUCPS*($N_$'
MA#7;=X]2T+6H;.*065Q%;:S::3K$-YIEM[#I&L:7KVGV^JZ-?6VHZ==J6M[N
MUD66*0*Q5UR.5='#))&X5XW4HZJP('SG^T#\'M>\?W>C>(O"T%I=:MIMA)I5
MW9S306<US9"XFO87BN)BB2/'-,Z"%G+$;1&"3BM;]F.*QA^&TJ6NI&\NE\3Z
M[;ZSITT,UI?>&]9T^6'2K[0=0L;E4N+2YA>P6]59(T6YM[Z"^@WV]U$[?SME
M'B+XR9C](CBK@#'^$M3*_!S*^'L/C\G\2%]>E2QV:U<-E];V*S"I-Y7B5B,5
M7S#!4\EH4EFN7QP7UK&8FM2;YOMJ^1\+X;@?+,WAQ1#%<5XC&U:.)R+]S&I#
M"TZE6/M)8>*^L0E3I1P]6IBY-86O*M[.C2INR7N'B'7M)\*Z!KOBC7KO[!H7
MAK1M4\0:U?>1<7/V+2-&L9]2U*[^S6D4]W<?9K*VGF\BU@FN)MGEP122LJ-F
M>!/&_A?XE^"_"WQ"\$ZG_;7@_P ::)8^(_#6K_8[_3O[2T;4HA-97GV#5+6R
MU*S\Z,AOL]]9VUS'TEA1N*XO]H3_ )(#\<_^R.?$_P#]0C7*_"EOBKXLA\+_
M +"'P<NO$/[7FF_"9OV&(OB/JEK^Q9IOC^?X@K\1UU&'PWX7G\>ZI\,K*]\1
MVO@J2TN=NGV-XBZ))K/E7FHLL",Q_IK Y=]=I2E&;A.-5Q>G.O9QH5*LN6"2
ME*HW!1BN>,7>SULS\YQN8?4ZT82@I0E14EKROVLL12HQYIMN,::51N3Y&U:Z
MT33_ 'N^*WQ=^&OP.\%:A\0_BQXPTCP3X0TZ>TLI-5U:60R7NJ:C(8=+T+0]
M,M([G5O$7B/5YE:#1_#>@V.I:[J\ZM#INGW4JLH\X^$W[6'P6^-/BBZ\$>#[
M[XAZ+XPM]&F\10>%_BU\#_C;\!M>UK0K.YM;+4]6\+:5\;OA]\/KWQ?I^AW=
M_I=MXBNO"\.KQ>'9]8T2+7&T]]:TH7?Y4W6D^-?@=_PZ8US]L+Q3XN\1^&=%
MUCQX/C!X]^+_ (UF^('_  C?[0_C[0/#,GPUN/&7BF[DN-&L(;;45\1:7X99
MY_[(T*^-QIFES+ (B?K'Q7^UC^TK\-_CO\0OAKXL^%/P?^*W]G_L]?%GXW?!
MZU^ DOQ(\6_$K6[CPAXN\+^&_#'@/Q'HNKZ:8FU'Q))XBTZ[UJ/PM-<Q*-.N
MI8 \5NC)O+*X*"C2;Q-6<<3.G6AB*5'#N-#$U,/:,)TINK*U-5Y_OZ3C2K4O
M=VE/".9S=1RJJ.'I0EAX3HRH5:U=.OAZ5=.<X5(*DG*I*C!^QJ*52C5N^D?K
MRP_:9^!^J_M!ZW^RQIWCF&\^/'AOP1;?$77? T&B>))%TSPC=W<5C!J%QXG7
M1SX0%X;F>))=#77FUZ!)%FGTR.$^97N]?SK?LJ>--"\(?MZ?L^VVL?##]INW
M^*?Q'_9T^-6I_&+Q3XX_9?\ C!X#N_$'Q4\?_$WX6ZAJ'B341XE\-V4EMX \
M+VMA!X;O/&,Q'AK0S;60NKR"36(D?]#?VX[WXAZK\9_V%_A-X-^+WQ%^$7AO
MXP_%3XH>'/B7=_#36Y?#^O\ B7PII?PZ34AHL&L6\D=UHMX+EFFTOQ'ISC5?
M#]V3?Z:1< &EB<KA2Q>&PT*DX1JX2IB)U:\6US8>&)E7E"$(*2IS6&DZ,&I3
M2G%3F]6GALTE5PM?$3A"<J>+IT(4J$DFE7EAXTHSE.;C[2#Q"C5DFH-PDX1M
M9/\ 1RO&%^./A=OV@Y/V;QI?B >,X_A,_P 8CK1ATW_A%SX<C\36'A5M.%Q_
M:7]K_P!MF_U&&X$1T@6'V-)6-_YX2%_Q>^)&N?M6>+OC_P#M*?!_X<C]JOQ6
MO[-5C\,?"/P5OO!/[8WP\^#,437_ ,,-"\8:?XX^->D_$;Q5H7B3XZ3^*?&N
MHWUCKOB'5K/4M&N]$T:[\/VTK:G'>"WZ?XS_ !@\5_"C]H"Y^(OQIU;6OAY\
M3'_X)S^!M"\7S_"Z#0_$&L6_Q*\8_'KX:^$I-&\'7_F2>&=*;Q1XFUA-%T[Q
MA)<QZ-X)CUE/$SWD%OHGGII3R:[C%UZ-6I7PRJ4J5.I%U83K0H5*$ITH2G5L
MX5ES1E3B^=.,5.-IRSGG&DY*C5I4Z&(=.K5J0DJ4XTIU:=>,*LX0IW4Z3Y7&
M4KP]Z7(^:*_=34M2TW1M.O\ 6-8U"QTG2=+L[C4-3U34[NWL--TVPM(FGN[Z
M_OKN2*UL[.U@1YKFZN)8X((D:26144L&:3J^E:_I6FZ[H6J:=K>B:S8VNIZ1
MK.D7UMJ>DZKIM]"EQ9:CIFHV4L]G?V%Y;R1SVMY:S2V]Q"Z2PR/&RL?YX= \
M4?%3Q%JG[='[,/CK6_VE_!GAB#]BK4/C(GA[XD_M9Z#\=_BCH/B.*ZALK&YT
M'XC^ ?$?B*X\*>$?%NDW4\>L^"[F\C@UZ#=-#;"R8!+MWK?Q,^$_[,7_  36
M^$WP9\7_ +0/Q \,?M'>'].U#QU=:)^TGIOA+XC_ &K1?A5X4UC0/AM\.?C/
M\0M=T?2_ACX;NM0GGC@\):/JMGJ5S91)I6AQLZ.:;R2SC#ZU3]I.<7%_N_8^
MP>#EC)5'655TE-0A-1BIRA)I?O(IMI+.KWG]5J>SC3DIQ_>*LJZQ<,)&FJ3I
M*HX.=2#E)PC.*;M3;5G_ $0UXKX.^.GA;QM\:OC-\"],TKQ!:^*?@?HWPSUO
MQ/JM_#IJ>']4M?BI#XOFT*+0)K?4KC4II[!?!FI+JXU+3=-CB:YL?L4EZ'N#
M;_D9K7B[]KSP9\(_ 7PC^*WB+XJ? [P3\7?VU/!WPE\,_%K7?CQX-^*'[0/A
M7X'>(/A]K'CC4=(U[XQ^ ]:UE8O%&I_$CPYJOA;0?%%UJ']M6/@S5=,TMGS;
MQ+7M'[!^B:/X6_;A_P""BWA'0OB[XF^-%AX4TC]E+0AXD\:>*CXY\8:%/;:1
M\9KB;P7XD\8SW%UJ?B34]#-TMT=1UN>36%M-5M;.X8P6MJ3E/*X4<-C:TZ].
MLZ5!5*#HMU*;7U[!X=SE5IN=+FM6J0='G?+).7,[1YM89G.MB,%2A1G156LZ
M==5DJ=12^I8O$*$:511JN-Z5.:J\D;Q:CRKWU']6_$FN6OACP]KOB6^BN)[+
MP_I&H:S=P6BQM=36VFVLEW-';+-)#"T[QQ,L2RS11ER \B+EA\]_![]KSX,?
M&E/@E8:!JFK:)XS^/GP'T/\ :.\#^ /$6C7D?B"/X9:W:6]RM[K.I:2FJ^$+
M/4M.EN!8W^FQ>);B=KF*1[(7=J8[B3\^_P!H'7-8^)_QR_;GTWQ_^TY\2OV>
M?"'[+?P7\&7WPY\/^$/B%)X*\&ZC'XR\"S^*-;^)GQ'T W5MH_Q)TN+5A'H+
M>'O$HGTAM-EDT^>,>:&3E?V-?%OQ%$/_  3B^''A3QG<>'-*\0?\$HM+URWT
MZ\"W7ABW\;V?A30['P[XIUC2VC;[>VB2O"[(S8>VB>+:2U7'*J:P<JM2;E6Y
M*=5<O/3A3A4P-3&13FZ52-;W?92FJ:33YH<T=)RB>:5'BX4H04://.D[J%2I
M4G#'4L')J*J0E2O-U8P<[IJT^65G&/[F45_-[X^^.?[07[)7PT^*&D^/-6_:
M6E_:NU[X>-=^&?%FO_M)V/QK^ OC;2(?C%\//!?Q:^)_PT\))KVI>'O@'<Z+
MIGCO2-6\$VGQ%M_#8\,6&NM%;A].\,:O-!]+_![Q?^TC\"A\6OB1\1X?C]X&
M_9DTG]G'QCX\\6^-_CC^TA\+_P!LGQOX7\?^&K2TU;P_XS^%OASPIXH\4:N=
M"N/#;:_=ZQX0:&/P_K6IC0_)A6*&*-54R2I"FZL<30G&4W3P_OTU]:E%4N?V
M$8U9SJJ]6,*:I0J3E4C.G.%.<>5U#.H2J*G+#5XN,%/$/DJ-8:,O:<BKRE2A
M&DU[-RJ>UE3C&G*%2$ZL)77[5T5^"_[-GQ?^-FF?MD?"3X;S:E^T#X:\/?M!
M? ;XG^-C9_M%?M-^ OVC+34Y=!T:?6?"/C_P?X-\*>)_$+_"R&+5I5AU2P:'
M3K"YLD;P^(//M9E/EWCKXV?M$?LA?#_XIQ_$O6/VC-7_ &K=8^&7BW4/ ?C*
M_P#VB8/C'^S=\2;C1O'WA72/B+\0/A_\*[;6]0TWX$1:5HOBO2=<\%Z5\0]/
M\/6_AJUU?[!:,]KX>U+R6LCJRK*A#$T)5*D*,Z,%*FW4C5JU:,Y>[5<>2A.C
M-UG3E5G"G:<J<4JBIK^VZ:I.M+#UHTZ<ZT*TY1J*,'2ITJL8KFI1ESUHUH*C
M&I&E&I4O",W)PY_Z.:*_)/\ 8LLOVK=(^,.CW.N>'/CD/@'XN^%-YJ'C'5_V
MA/VM_A9^TGJ<WC^&Y\.7O@3Q-\,;?PEXN\1ZSX5T+7M'U+Q:/%&EVD=OX?NS
M/X6GMHT33(%3];*\S%X986M[)5J5=.*DITITYI7;3C/V<ZD8S3B[QYY/E<9.
MW-9>CA,2\52]JZ-6B^9QY*L)P;LDU**J0IRE!IJTG"*YE)*]KLHHHKE.H***
M* "BBB@ HHHH *L6US);2!T.1T9#]UU[@^A]&Z@^HR#7HH [*WGCN8Q)&>#P
MRGJK=U/]#T(Y%35R%K<O:R!UY4\.F>&7^A'8^M=7%*DT:R1G*L,CV/<'T(/!
M'K0!)1110 4444 %%%% !1110 4444 %?P=_\'6__)YG[-/_ &;'>?\ JU?%
M=?WB5_!W_P '6_\ R>9^S3_V;'>?^K5\5U]EP'_R4>'_ .P?%_\ IEGQ_'7_
M "3N(_[",'_ZD0/Y<Z***_=C\/"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** .I\.?\@_QI_P!BDW_J3>&:Y:NI\.?\
M@_QI_P!BDW_J3>&:Y:ICO/\ Q+_TB)3^&/\ V]^844451(4444 %%%% !111
M0 4444 %%%% !1110 Y/OK_O+_,5_6=\3_@MIVN?\%"O^"8'Q7OOVJ/V>_@H
MOA[]G;]D.63PUXB^*6I^&OCCJ":;\.M#(L_"WA2V\/?8[QO$95;'3'N?%=A!
M=+< 7 C1MI_DP4X93Z$$_0'FOVG_ &B/VB?^"=O[4WCO]G+XH^/OB=^UMX,O
M?@]\$?@=\,?%7PX\,_LT_#+Q#9^)-1^$OAO1M-OVT7XE7_[4&B3:39:WJ&E,
MMKJ-U\.M1GL;207#Z;<3?Z.OA9Q0JUJN%</;1I_5LQHU*M##2Q4H/$4J,(1=
M.,9?&U)*4DHIKWI13N>YE%>E2I8GG]C*HL1EU:G3KXA8:,OJ]:K.;51RC\-X
MWC%N34O=C)Z'H'@GX"> OVG/^"R7[67@#]H;X&ZOX*\/:C)^U%\1O^%37VH:
MMX+U30]5T;P[?^*O!6KW<_@W4M)G634TEL/%L]M!>26&HMJ[?;4NTEDW_(G[
M&?[._P (OBY\&O\ @HWXN\?^&)M;U_\ 9_\ @!-XZ^%%[%K_ (BTE?#?B=?B
MCX5\-+J$UKI&J6-GKJ#1]3O+7[%X@@U2Q)E^T&V^TQQ3)ZS9_P#!4Z#5/^"H
M-[^W?XH^&%U8?#KQ-I\_PV\2_"_1-;M]0\36_P ';SX:VOPLF@LO%%YIUA#J
MGC.WTFQL_$ O[ZPM8+W4H6TDO9V4D=W;['P^_:L_8#_9W^ _[<OPE^$5K^TG
M\2O&7[6/P\U'PWX:^*'C_P !^"/AW:^![=?'6C>)-'^'5WX$T7XI^/DO]*EM
M+>XOM<^)G_"4MJ,^HZ+H^FZ?\/["UU'4+V'C<<SI4J=+V.*A.I@\AA"GAZDJ
ME+#U:&)?]I0]K[3E@HT'%5).3EB*?NP=9QDEV1EEE6K4J2K86<(8O.YSJ5Z<
M:=6O2K8>'U"2I^S4IWK*;IQ4%&A4;E)45*+?/^)/A5^RE^QG^S1^QKXN^-?P
M!'[3WQ8_; \+'XY^([K7?B)\4OAMIOPH^"\URNDZ-X<^&EK\-_%_A;3M3\>W
MK31:M=^(/B#;^,=#6Z3R8/#\%@6M#^B?[6O[*GPI_:Z_X*"?L@_#!/%7CK0/
MV>O"?_!-;X7_ !>UC6[F+1_^%FZA\'_ACX$M]6BTN26/3TT#3O&.O:=-IUG?
MZE'HSZ;8W,MZ]KIL>;<P?F1JW[4'[)O[1_[-G[*/PQ_:FF^.W@7XB?L>Z)??
M#G0-3^#G@KPGX^T3XR?!YIQJFE^%M5U/Q9\1_!$_PE\3V=_'%8MXLL_#_P 3
M+$VA:]7PQO'V$_0OC3_@K3\*-._;5^ ?[2GPB^"WB>+X5>#OV0/#?[*7Q/\
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M]GCP%^Q/>_L3?LM_\+3\<V/Q+^+.F_&;XW_&WXO^#/#WPJUG5M5\+?\ $O\
M!?@7PC\,_"_C[XK6EEH.EZ3;VMQJGB#4_'UW=ZIJ<MS]FT32X@A;\SZ^HRV-
M94\1[3V_LGBZKPBQ,JDJZPO)3MSNLW62E65:5.-9^UC2<(R44HQ7S.8.BYX?
MV7L'4CA*2Q3PT:<:+Q/-4;Y%14:+:HNC&I*BO9RJQG).3;DRBBBO1//"BBB@
M HHHH **** "BBB@ HHHH *<CO&Z2Q.\4L3I+%+$[1RQ2QL'CEBD0AXY8W57
MCD0AT=592& (;10TFFFKIZ-/9KLPVV/ZP_\ @D]_P4,C^./ANQ_9X^,.LQCX
MO^$-,6+P;X@OYE23XB^%=/B2-+6XDD(\[Q7X?A5([AP2^KZ7Y-VZ&\L[ZXN_
MVUK_ #I?"OBGQ#X(\2Z#XQ\):M=Z#XG\,:K9ZWH.LV$K17>G:G8RB6WN(G4C
M<I(,5Q ^8;JVDFM;A)+>:6-O[</V ?VS- _;(^"]GXCE>UT[XG^$4M-$^)WA
MJ-PKVVJ^5MM]?L8R<R:-KRQ23P2KS!=+-!/' 6MUD_YN_P!IC]"BEX29Y6\=
MO##*O8^&W%>9\O&&1X&C;#<#<49A5_=XO"TJ<>7#<,\18F<EAZ:4</E.<U'E
MU/V.%Q^4X:G_ *2?1E\;9<78&GP'Q1B^?B7*<+?)\?7J7J9[E>'@DZ-6<M:N
M9Y=32]I)MU<9@TL3+GK8?%U9?=BLR,KHQ5D8,K*2&5E.592.000"".0>17Z)
M_ 3XN+XVTM?#FN7 _P"$JTB!0LLK?/K6GQ@(EVI))DO( !'>C[SGR[@DM*^/
MSJK4T36=1\/:M8:UI-R]KJ&G7"7%O,A(^9#\T<@!&^*5,QRH>&1CC# $?PQ]
M&/Z0W$'T=O$3"<2X+V^/X6S5X?+N-N'85+0S;)E5;^LX:$G[*&<Y2ZE3%Y5B
M))/G=?!5)QPF.Q2E_07B!P1@N.,CJ8"KR4<QPW/7RG'.-WAL5RV]G-I<SPN)
M2C3Q,%?10JQBZE&G;]C**X3X<>.].^(?A>SUZR*Q7&!;:K8A@7L=1C4>=$RY
M)$4O^NMVY5HWV!V>*3'=U_TS\,\29)QCP]DW%7#684,VR'B#+L+FN4YCAI<U
M+%8+%THU:-1)VE3J)-PK4*BC6P]:%2A6A"K3G"/\"YA@,7E>.Q678^A/#8S!
M5ZF'Q-"HK2IU:<G&2[2B[<T)Q;C.#C.#<9)LHHHKW#C"BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ KYU^).E:E\,_%,GQU\(V5Q>
MZ:]G;Z?\:_"E@A=_$/A:P1EL/'FG6B<2>+O T3/%=S1*L^M>$));343>CPSX
M>BL?HJ@@$$$*RD%65U5T96!#*Z,"KHP)5E8%64E6!!(K6C5=*=[*<))PJTVV
MHU*;:<H.VVJ4H2WIU(PJ1]Z$6L:]%5H*/,X3C)5*51).5.I&_+-7WT;C..TZ
M<ITY>[.2>)#+X=\:>&TFC_LSQ+X4\5Z*2%FB@U#2-=T'6;1HY8+FVF66WN[*
M^LYY+>[M+B-T>-YK:YCSYD8_./\ :5_8!NOBQ\1_!OC'P/I/[*/B+P/X1^&B
M?#G1_@1^U9\!M7^-'P5\"FWU*.\MO%?PG\!>'/&7@C1/!/B:>RB_L;4M22VN
MYY]+EFLK=K:VD:*OIS0R?@+X^M/!DS-'\'?B=K,X\!7$KDP?#WXB7YFO+GP)
M-*Y*P^&O&A6YO/"3S-&+#Q+!/H)FOKKQ3I4-I]-D$$@C!'!!Z@^AKKA6KY?5
MC5PM5^SJPE*C.44U*$KPDI0=U&K!J5.I;6,DW"3IRC*7-*E1S"C*EBJ252G.
M,:T%)IPJ1M.+C--.5*:<:E-O1Q:4XQJ1E&/RM^SI^RYX>^#7[-.C_LX>-[C1
M/BSX<,'B8>*-'UKPSIW_  KN>W\8>(M2\3ZCX$\+> [^._T[1OA+X7N-4;PY
M\/O!5^=27P_X,TK0]&N+J^DL6N9.]^%'[-/[.7P&N]7O_@;\ O@O\&K[Q!;V
MMIKUY\*_AAX*^']UK5K8O-)96VK7'A31=*EU&WM))YWM8;MYHX'FE:)4,CEO
M;**YJF*Q%65>4ZU3_::DJM>,9.%.K4E+G<ITXV@WS:KW;+I8Z*>%P]-45&C"
M^'IQI492BIU*=.,>51C4E>:]W1^]=ZWO<YZ;PCX4N?%-CXYN/#'A^?QKI>BW
MWAO3?&$VC:?+XHT_P[JEU:7VI:#9:\]NVJ6NC:A>Z?87E[ID%U'975U96D\\
M,DMM"R)K'A#PGXAU;PSK^O>&/#VMZ[X+O;W4O!VM:MHVGZCJOA/4=2M/L&HW
M_AO4+NWFN]#O+^Q_T*\NM-EMI[FT_P!'F=XODKHJ*RYYIIJ4DU%Q3YG=1::<
M5KI%J4DTM&FTUJS7ECJN6-G)2:LM9)IJ3TUDG%--ZII=D>'?%;]F+]FOX\:C
MIFL?'']GOX(_&35M%L'TO1]4^*GPL\$?$#4-)TR2>6ZDT[3;WQ5HFJW-C8O<
MSSW#VEM)% T\TLK1F21F/2:C\%?@WK%I<6&K?";X:ZI8W7@2/X6W5GJ'@;PS
M>VMQ\,H6MGB^'<]O<:9)%+X&B:SLVC\*2(VA(UI;%;$&"(IZ;15^WK\L(>VJ
M\E._LX^TGRPNTWR1O:-VDWRI7:3>J(]A0YIS]C2YJEO:2]G#FG9-+G=KRLFT
MN9NR;2W/&_AM^SK^S[\&HY8?A!\"_@_\*H9]/OM)GB^''PV\'>"8YM*U2\M]
M1U/3)4\-Z/IJR:?J.H6EK?7UFP-O=WEM;W,\;S0QNN/:?LI_LNV'P\UGX16/
M[-_P'L_A1XBU==?\0?#&U^$G@*W^'VNZ\A4KK>L>#HM!3P]J>K*40C4;S3YK
ML%5(F!48]\HI_6,1=R]O6YG*,G+VL^9RA=PDWS7<H-MQDW>+;LU=B^KX?E4?
M84>6,90C'V4.6,)I*<4N6RC))*44K222:=D>$Z)^RW^S+X:^''B3X.>'/V=O
M@;H'PB\8WQU/Q=\+-%^%'@;2_AUXIU(KIZ-J'B+P79:'#X<UJ]9-(TI6NM1T
MZYG*Z9IZE\6=N(^Q^'WP?^$OPEM#8?"KX7?#SX9V)TK2=!-GX \&>'?!]J=#
MT";5+C0M&-OX?T[3XCI6BW&N:U/I.G[/LFGS:OJ<MI%$]_=-+Z+12E7KS4HS
MK59J<N>:E4G)3G9+FFI2?-*T8KFE=^ZM=$.-"A!PE"C2C*G'D@XTX1<(:^Y!
MI)QCJ_=5EJ]-6>3^-O@+\#/B7XM\*>/_ (C_  9^%7C_ ,=^!&1O _C7QI\/
MO"GBCQ9X-:.Z6^1O"OB'6]*O=6\/LEZBW:G2KNU*W2K.,2J&&A#\'/A%;P:/
M:V_PL^'4%KX>\$S_  TT&VA\%>'(X-$^'-S MM<> -(A33ECTWP7/;(EO-X7
MLUAT62!5B>R,8"UZ112]M6Y8Q]K5Y8)J$?:3Y8)WNHJ]HI\TKI)*\F^KN_8T
MN:4O94^:;3G+DCS2:44G)VO)I1BDW=VC'LCP?X;?LL_LQ_!F+Q);_!_]G3X%
M_"J#QEI(T'Q?!\./A/X%\$Q>*M#$5S"-&\1Q^&]"TU-;TH0WEW%_9^I"YM/*
MNKF/RML\H>'X=?LH?LM_!_4M<UGX2_LV_ 7X7ZQXGT:[\.>)=5^'GPB\!>#-
M2\0^'K^>*ZOM"UN^\.Z#IUSJNCWEU!!<W6FWLL]G<3PQ32PO)&C#WZBK>)Q,
MN?FQ%>7M>55.:M4?M.6RC[2\GS\J2Y>:]K*Q"PV&CR*.'H)4N;V:5*FO9\SO
M+DM'W.9ZRY;7>YX!X&_9/_9:^%\MQ-\-/V;/@+\/9KO^U!=S>"/A%X!\*RW7
M]N::='UK[1)H>@6+3?VQI!.EZIYA;[?IQ-E=>;;_ +NI_AG^RQ^S%\%9M=N/
M@W^SG\"OA-<>*=*&A>)I_AK\)O G@>;Q%H@$ZC1]<E\-:%ICZKI86ZN0+"^:
M>U N)P(L2R;O>**)8G$RYU+$5Y*HHJHI5JC4U%WBIIRM+E;;CS7Y6VU:[".&
MPT7!QP]"+IN3IN-*FG!R24G!J/NN224N6UTDGHCP;X9_LK_LP_!7Q)?>,O@W
M^SE\"OA-XOU/3[O2-2\5?#7X3>!/ WB/4=*O[RUU"^TR^UKPSH6F:C=:?>7]
MC97UU9SW+V]Q=VEM<RQO-!$Z>\T45G4JU*TN>K4G5G9+FJ3E.5ELN:3;LNBO
M9&E.E3I1Y*5.%*%V^6G",(W>[Y8I*[ZNP4445!84444 %%%% !1110 4444
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MM(O8F&X0W42N]I=Q?ZRUO[*0M;7UE.J7%I<QO#/&DB,H[VOY4O\ @C9^VO\
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M'\6_AUHT]G\&?V4M4U73[[1[3X9:Q$WC6^.O:%-\;O#4]II[;]?L_$]H;($
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M1?#SQ-I\*DCSDLEOXR 2-X_LV6\?8?O!F1?E.Y@HSC]_Z<'8 @,0K AER=K
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MHU<17J1I4:,)5*M2;M&$(J\I/TZ)7;=DDVTB_P#"/X.^+OC'XC30_#=MY5G
MT<FM:]<HXTS1K1F ,MQ*%(>=UR+>TCW3SO@(C ,1^R_PA^!W@?X-:0MEX=LE
MN]8G1/[6\37L2-JNHRJI&%?YOL=HA9S#:POM3>Q+$L0.I^'7P\\,_"_PKI_A
M/PM9K;6-F@>YN753>:I?,H%QJ.H3 !I[J=LDDG;$FV&()$B(O<U^\\,<(X7(
MZ4,1B(PQ.:3BG.LTI0PUUK2PR>UM5.M;GJ:VY(/D/POB7BS%9U5GA\/*>'RR
M,K0HI\L\1RO2KB6OBNTI1HW<*>C?--<X4445]D?(!1110 4444 %%%% '->+
M?!_AKQUHEWX>\5Z1::SI5Y&T<D%U&K/$3]V:UF*F2VN(F >*6,@JZ@D-C%?D
M/^T/^RYKGPAEE\1^'6NO$'P_GD)^VE#)?^'G=CLM-85,DP 8$&I8\F88$C).
M)(U_9VJUY9VFHVES87]M!>V-[!);7=I<QK+!<6\JE)(98W!5T=2000?7K7SG
M$'#6 S^@U5C&CC(1:P^-A%>T@U?EA42M[6BV]82=U=NFXRU?T.0<1X[(JZ=*
M3K8.<D\1@YR?LYIV3G3O?V59+X:D59M)5%..A_-Q17UG^U%^SQ+\(=;7Q'X<
MBEG\ >(+N06>%9CX=U!\RMHURXS_ *,Z[Y-+F;AH$>W8E[8LWR97\_YCE^*R
MO&5L#C*?LZ]&5GUC.+UA4IRLN:G4C:4)6U3LTI)I?O67X_#9GA*.-PE3VE"M
M&Z>TH26DZ52.O+4IR]V<;O75-Q<9,HHHKB.T**** "BBI(89KF:&VMH9+BXN
M)8X+>"%2\L\\SB.**-%!+/([*J@#DD4)-NR5V]$ENWV#;5M)=6W9+S;>B7FR
MYI6E:EKFI66CZ/8W.IZIJ-Q':V-A9Q//<W5Q*<)'%$@+,3R6(&%4,[$*I(_6
M;]GO]D71/ ,=AXN^(4-MKWC4K'=6NDR*EQH_AJ4C>@ YCOM4B)!><@PV\@VQ
M-)AL=!^R]^SI9_"K1(?%7B:VBN?B#K=I&\GF(''AFPG4.-,M&8'9>SJ4;4IU
MPP(6U! 24-]=5^S<(\&4L)3I9GFU)5,9-1J8?"5(IPPB=I0G5B[J>(:UY9+E
MH[6=17A^.\6<8U<74JY;E55T\'%NG7Q5-M3Q;6DH4IJSAAT[Q;C[U:SU]D[3
M!@ *  J@*J@ *JC@*JC 50. H  '  %%%%?I1^<A1110 4444 %%%% $-S;6
MU[;S6EY;P7=I<QM%<6MS$DT$\3@J\<L4@*NK*2"",C/!!YK\UOVBOV.H[2'4
M/''PCM)&C0RWFL>"8@9&CCY>:\\/*/F=4&7FTQ1Y@&9+82YD"?I?17D9SDF
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M&4*N(I4Z\(\\9_N)PJ3E4;5OX+C2IU>7FC&IB*,5.2FI/]#Z***\T]$****
M"BBB@ K=TBXR&MV/3+Q@]<'[P'L#\WU8UA5-!*8)4E'56R1S@CH0<=B* .RH
MIJL'574Y5@&!]01D4Z@ HHHH **** "OX._^#K?_ )/,_9I_[-CO/_5J^*Z_
MO$K^#O\ X.M_^3S/V:?^S8[S_P!6KXKK[+@/_DH\/_V#XO\ ],L^/XZ_Y)W$
M?]A&#_\ 4B!_+G1117[L?AX4444 %%%% !1110 4444 %%%% !1110 4444
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M)G4L!F2RZK-_5<QDH13;M3Q>U&<5T=:RH2LO>;I-_ K?E71117X:?MH4444
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MM=5TYM<74=!UVUT[L_AO^V-^SO\ %K7_ !CX8\!^-M5U76_!'A27QYJ-G?\
MP\^)/AM=?\#0RW,#^-?AM=^)O".CV?Q;\(-/:M;P^)OA=<>+]$N+FXTZV@OI
M)]4TV.Z?U;,84?:_5\;&A.,)^T]E7C1E#DBJ<N?E4)1Y*D%"5VN2I'E=IJY]
M9R^=7V?M\'*O&4X*'M:#JQDY2=2*CS<ZESTYN:2OSTY<WO0=O2O%WP-^"/Q
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M)XAU6:*V\/Z!)\&?&G@S0?B[=:YXNO)H[#P-I%AX(NM0\<ZBW]G>$;?6KT-
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M<M4QWG_B7_I$2G\,?^WOS"BBBJ)"GQ1O-)'%&C222ND:(@+.[NP5551DEF)
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M]$9_[2D\P1PL$\I-N=S8^!O^"WO_ ".7P*_[%G7?_3A)7>?LN?\ *(WXW?\
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M0_I#(,7+&Y+EF)DVYU,)2C4;=W*I27L:DF^\ITY/YA1117C'L!1110 4444
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MQ-NUM\._"%[XF.DJ"9+*_N8&?RY0A/5?#O\ 9H_:NUOX0_LE_L:?$+X/^&_
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MOA?X9_!/QQ;>*[Z-/]$M)_'4FGZ;X>AN)"0/-N+G2;WR8UW-A&8A5^8^;_\
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MA'4KO4]72 R3Z393VNAW^KQI=I&;NR\/:C=0I)'83%/8_P#@O#X(U;2O@/\
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M6J8G$O#UJN(HT(4ZE6GB:F']8_8>_97^%'Q)M+3Q7^T!:ZK>Z1\1=8U3P/\
M!OPMI6N7_AZ_UW7-!TZYU+Q3XON9].N;2^G\/^&U2TT]4AE,%QJ,ERDR3K;&
M$^4^#_@[\,_!OP9^)?[1'Q1\-:IXUT6P^*US\'OA5\.HO$&J^&=*US78#>ZI
MJ^L^)_$>B7%KXB73M"T2VM;:QBTF[BDO=1O)&OO,BB4#[L^"'Q _9\^+'[7'
MP+3X9?$_X@:=X6^&G@VZ\%_"_P"$^I_!3[!::;IEEX:O&UJ]U/QE%\2[M;K6
M=9U.;4M>U'4W\-&:\N+H6C!$1'7Q/QIX<T+XB_L8?$#P%\%=:U_XFZY\)?VI
M-9\>^(]*_P"$2N?#_BJ3POXITA]$DU>R\$6FN>)[V_T_2_$,0TF6_M9[R11)
M#<O!81W9B/Q/]O9O5SW$4\=B\ZR[#YMB.%JF+PE:CFF74LBR_%9EG6&6%I8B
MK1P]/!5\7#"Y9A<=CL-63Q6+KXM8+$SC2A.C]F\CRFGDF'J8'"9-CZ^5X?B>
M&%Q=*ME>8U<[S#"Y=DF(>*JX>G5Q%3&4<+/%9IBL!@L31:PV%P^%>,PT)59P
MK>)^+O@[\+O$WP<^#O[2?PM\,77@W2=9^*=G\)_B9\,;S7-5\7:+I.OVY:^@
MUS1-:\1SWFO7.CZ]:QM:7%CJEU,+><(L"HDC@]#^TG^S%KGBW]J3]HS0_@UX
M1\)^$O 'PIC.OZ]<3W>E^!_ '@W0X;))2DNH7"PZ78SW3!A9V"XFNY2!&O.:
MZ"[%_P#"W]C/X(_"OQA:OH?CSXD_M'6OQ,LO".IQR6OB/3_ FFPR6-KKFJ:5
M*4O-)75-4N((+*WU.WM[F:))Y$@*KYB?9G[9-BW[12?M _ SX5F7PQ\5O@_X
MWF^)/B;X;Z,L=O#^T)H#6L3MXANII2=5UKQCX1@4_8M&NKRYT>""WA?2;+2D
M$8B)<09IE^<X)T\9.KESQ7%.74<UQ]6OCL)@LGAQ#D&&HYEC).O&MCX8:K4K
M99A\75K6I>VAB,9BUAZ6)J3%D&69AE&-Y\'"GF"PO"^85LJP-*A@<5C<VGD&
M>XBMEN#2H2I8">)I0HYG7PE*C>K[*=#!X5XBKAJ</P"(P2.#@XR.A^GM12LK
M(S(ZLCJ2KHZLCHRG#*Z, R,I!#*P#*000""*2OW$_%0HHJ"ZNX+"UNK^Z=8[
M:QMI[RX=F"*L-M$TTA+'A<JA )[D=>E)M)-MI))MM[)+5M^20TFVDE=MI)+=
MMZ)?,_(/]N?Q%'J_QDM]'ADW)X6\+Z9IMS'D$)J%Y/>ZM(PP3@O97]@"/]@>
MIKXRKM_B5XOD\>^/O%OC!SE->UN\N[3.=PTU'%MI2-GDO'ID%HCGC+J<*HPH
MXBOYCSK&K,,VS#&Q=X8C%UITGWHJ;C1?K[*,+^9_2F38-Y?E67X.2M.AA:,*
MB[5G%2K?+VLIV\@HHHKS#TPHHHH **** "BBB@ K^I'_ ((.?%1M<^#OQ>^$
M%W=&6Y\ ^--.\7:;%(WSPZ-XXTW[%]FMP3DP0:GX5U&Z<*,)+J#,Q_>#/\MU
M?L'_ ,$2?B&?"7[8=QX2N)S'I_Q)^''B'14@W;1/KNDWNEZMI+D;@K^38IKH
M"[6?]Z2A4!PW\3?M$/#^'B%]$7Q:PL*"JYCPMEF"X[RJ7)SRH5N$\PP^99C.
M"W4JO#\<YPO,FN58AR=XIQ?[;]';B"7#OB]PE5<^3#YKB:^0XI7Y5.&;X>IA
ML/&3VM#,'@JUG>[I)+6S7]>M.1VC=)%)#(ZNI!P0R,&&#VY%-HK_ )(8R<9*
M46U*+4HM:--.Z:?=/5'^N;5TT]GHS]>_!NMKXD\*>'==#;WU31]/NYSW6YEM
MHS=1GK\T=QYJ-[J:Z6O ?V:M7_M+X7V-HS[Y-$U+4M.<Y!8+)</?PHW<;(+N
M)%!_@"_4^_5_UA>"W&$N/_"/PUXTJ5/:XGB3@GAS-,=._,UF=;+,.LUIR=W>
M=',HXJC-W?OPEJS_ #>XKRM9+Q+GV4QCRPP&;8[#T5:W^SQKS>&DET4Z#IS2
MZ*205\U^+/V1_@7XW_:0^'G[67B+PYK-U\</A9X9U#PCX+\0P>*]>LM'T_0]
M4E>6\M[OPM;7::%J<SO(Y6ZO;26>,$!'4**^E**_5*&)Q&%E4GAJ]6A*K1JX
M>I*C4E3E.A7@Z=>C-P:<J56#<*D'[LXMQDFM#YNK0HUU"->E3K1IU:=:"J0C
M-0K4I*=*K%234:E.:4H35I1DKIIGFGQ>^#?PO^/G@#6_A=\8O!.@_$#P'XAC
M1=4\.^(;*&]LY)8=_P!FO;?S59K34;,R.]G?VY2YM79GAD4DU^?/PR_X(L?\
M$Y?A1XSTKQWX?^!^I:[K6A:C#JVC6?Q#^(?C3XB>&]-U&UE::RN[7PQXLU34
MM%BEL)RD]@R6B_8YH+>2#8T$>W]4:*[,'G6<9?AZV%P.:9A@\-B&W7P^%QF(
MH4:KE'DDZE.E4C"3E%*+;5W%)-V2.;$99EV+K4\1BL!@\37HV5*M7PU&K5II
M/F2A.<)2BE+5).R>JU/)/CA\#OAO^T5\)_%OP1^*NCWFK_#GQMIT.D^(-(TC
M6-1\-W<]A;RQ30PVFK:-/:ZAI_EO#'M:TFC;8NS.TXKP/XJ_\$\OV4/C7\!/
MA-^S3\1_ &JZ[\)?@A#X9M_AKID?C'Q)IVOZ#;^$K"STO2H7\665]%KVH1RZ
M?86MKJR7MY*NL1QXOQ-D@_:]%98;,\QP:HK"8[%X98?$RQE!4,15I*CBY4U1
MEB:2A./)7E22I2JQM-TUR-N.A=; X+$NI+$83#UW6H+#575HTZCJ8>,_:QH3
MYHOFI*I^\4'>*G[R5]3Y3^+W[%/[.OQSU']G_4_B)X0U6\N/V8-2AU7X+Q:)
MXKU_PU9>&;JWM- L;>.[LM&O+:VUVS@M?#&BP0V6JI<6\<=JZJ@\^7=ZA\<_
M@-\(?VEO .K?##XX^!-#^(?@G6)4NKC1];MDE^RZA%O^S:KI5T!]HTK5[,RR
M&SU*Q>*ZM6=C%(N:]<HJ?[0QZ>$:QN*3P$IRP+5>JI8.56L\14EAI*5Z,IUY
M2K3E3<7*JW-MR=ROJ6$?UB^%P[6+4(XI.C3:Q,:=-481KIQM54*25.*FFE!*
M*T5C\O\ X._\$;?^">7P.\;Z1\0_!_P3O]9\3^'[V+4]!E^)'C[QA\3-,T;4
MK=M]KJ.FZ-XRU/5=.L[ZRE"S65U! DMK,B2PLK*"/MK]H'X _##]J#X2^*_@
MA\9-'U'7OASXUMX+;Q#I6DZ[JOAF^NHK>430K!K.B7%KJ5F5D&2;:>,L/E)Q
M7LU%;XG.LXQF*H8[%YIF&)QF%E"6&Q5?%UZM?#RIR4X2HU9U)3I.,XJ2<'%J
M23W1C0RO+<-AZV$P^ P=##8A2C7P]+#TJ=*M&<>22JTXP4:BE!N+4D[Q;6Q\
ME_%[]A[]FOX[?L[>&?V5_B=X(U#7_@SX-MO"]MX6T:+Q3KVFZ_HA\'6$NEZ!
M=V/B^QO(?$,.HVVFW%S8SWZ7JW5W;75U%<2,L\@9/B?^Q#^SS\9;#]G_ $[X
MC:#XL\11?LQ^(O#WBKX0W,OQ \60:CI.M^%EACT2ZU[4(-12Z\6);1V\,<D&
MO27D5S'&J3*XKZUHJ*>;9I2]FJ>8XVG[&MB<32Y,36C[+$8RFJ6+K4[37)5Q
M--*%><;2JQ7+-R14\NP%1S<\%AINI3H4:CE1IOGI8:?M,/3G>/O0H3]^E%W5
M.6L4FSY6^.'[%W[/?[0_Q.^#GQF^)GAC7+CXG_ 34XM5^%_C+POXQ\1>#=7T
M.>"].I0V]U/X>O;)M7TZ/4&:[73M2,]H)V=_*RQ-9_[5'["G[+7[:-CHUK^T
M-\,;7Q9?^'1)'X?\4:3JFI>$O&NB6LTK3S6&E^+_  ]/9:[9:=/,[RS6,%XE
MO)([N4RS$_7-%%'-LTP\L'.AF.-HSR^-2&!G2Q5:G+!PJSE.K##2C-.C"I.<
MY3C3<8RE*3:;D[NIEV K1Q,*N"PM2.,E">+C4H4IQQ,Z<8PA.NI1:JRA&$8Q
ME--Q48I-61\-?LP?\$W?V-_V/-=O/%GP+^$L>D>,KVS?3F\;>+/$&M^/O&-I
MITS%[G3],\2^*[O4M6TVRO#L^V6UI<QQ7/DP"56$2X^EOC/\'/AY^T#\+_&7
MP<^*^AMXC^'WCW2)M$\2Z1%?76F7%S9388-::G8217VG7D$BI/:7MI+'<VLZ
M)-"ZR(K#T^BIQ&9YEBL9#,,3C\9B,?"=.I#&5L15JXF$Z,E*E*%:<W4C*G)*
M4&I)QDDXV8Z.!P6'PTL'0PF&HX249QEAJ=&G"A*-1<M12I1BH24XZ3NGS+1W
M1\E? []AS]FC]G3X%>*_V;OA5X$NM*^$7CA]=D\6:#K/B36_$NH:X_B. VVJ
M->Z]K5U=:M*S6VVWM2UR390Q01V^Q88PM?\ 9&_84_9H_8:T#Q7X:_9O\%ZK
MX3T[QMJ-AJGB677?%WB'QIJ>HW.EVK6>G1G5?$M[?7L-G:123M#9Q2K;I-<W
M,X3S;B5F^O:*NKF^:UX8VE6S+'5:>8UJ>(S"G4Q5:<,;7I/FI5L5&4VJ]6F[
M.$ZJE*+2::LB:>6Y?2EA9TL%A:<\#2G1P<X4*<986C-6G2H244Z4)+248-)I
MNZU84445YQVA1110 4C*'5D895U96'JK JP_$$BEHI-)III--6:>J:>Z:ZIA
MML?&FD>!O#_P_P#VG_"V@)!)+IOB_P "^+_&7A*2XD(DL/$'A/4["W\26$03
M;'+9VFE^(]!FL_-W7"O>W2D^4D0'V77S%^T2P\.>(OV?/B8OR1^$OB_9^&M=
MN>GV7P=\0]&O['6W+Y&!)K&A^%HMAPCEP6.42OI]E*,RMPRL5(]"IP?U%?*<
M&>&O ?AEDTLK\/\ A;*N%,KS;,<?G698+*J=2G1Q6=8FJJ>*QDU5JUIJ<\-2
MP5*%&$HX?#4:5*AA:-##PITH]F8\0YUQ#CJU7/,QQ.98C!PP^%PM7$RBYT\"
MJ$)TJ,>2,$XQQ$L4^=IU*DI2E4G.HY2?R#^U?\'/'/Q<U?\ 9<NO!=CIM]:_
M"S]ISX=_%#QM_:.JVFF&U\&>';DR:O=6,=USJEZD9/E:9;C[1<=(\FOACX??
ML$?';PIXE_:[L=7OO#6K?"RW\%_$_P"'W[#7A0:M8I-X7\/_ !CUW6_'OBJ#
M4Y6Q_P (U9Z/>^)1\-M$L[PB*W\+>%]-DMU6V:)1^T=%?>4,SQ.'H_5Z?L_9
MV2]Z#<DU6]MS)\WNR:<Z+DDKT:M2'VN9>'7RW#XBM[>HZOM&[^[-1BU[%4N5
MKEUBN6G52E>U:E3FOAL_Q<_;4\$?%?X$_L*_LL?$3X>GP[I?[57[+6E?!GP!
MX,L[^_%WI&N^(O''@G1_@OXQ\"I>V3*-3L+C5[O2_%,,]MN25O!%M>H/LZR&
MNB^(O[+/[27PX^'7[+OPW^"VG?$'Q7\+/ OA#Q0_QG\ _!G]HH?LO_%+6/B]
MXIEMO$"^,&^,*:EI&JZMX.L=:U'QA9:GX*CU18=4N[[P]JMQ%+_8%N4_6/7_
M  KX7\5Q:=;^*?#>@>)H-'U>S\0:1!X@T;3M:ATK7].6=-/US38M2MKE+'6+
M!+FY2RU.U6*]M5N)U@GC$T@;?))))))))))R23R22>22>IK:&;5:=.C%4J4Y
MTZ^)KS=2,N62K1:ITTX3A4BL/.KB:M*49QG"IB)2C+0QEE5*=2M)U:L(U*&&
MHP5.4>:/L90=2;YX2A)XB-'#4JL90E"=.A&+CJTOY^/ W[%G[1OPU^#_ (-\
M*:O^S=\0?%_QH\/>,?C=K^D?'?X)_MPZ?\(?'GAK0_B)XNGU;3?"NO\ C_5-
M;M?'_P 0="OEFAU[6]+UZ_U.PN]6M3/?02WSK(/LS]G+X3?M>?!_]INZ\=_%
MK0/#/QDL?C)\"_@1X5^+/QE\,>*_#/@Y?"/Q)^&.C7NF^++R;X=WRIJGB'3-
M?O&AU#39?#$:Q0)=202)NC++^G5%.OG.(Q$:T:M'#-5U551VKN7[VK&L^1RQ
M$G24:L8U%"ER4YRBG6A5L@H9/0P\J,Z5;$)T'2=-?[.E>E3=%.:CAX^UE*DW
M!SJ\]2,6U2G3N?DOXJ_9#^-VJ?LC>)?A!I^A^'#X\U7]M#0?C=:V;>)]*@L)
M? =A^TUX:^)MQJ,VKX^S1ZJO@S3+NX32W)O6NT33 1+(M>'?%3]A?XO6'Q1_
M:>MT^&7Q]^/7PB_:1\=>(/'=Q8?"3]O'6?V8O"D&D^-M%M]#\4^ O'7PNN/%
M6CZ+XAG:WM/+EUZRL)(M:T^]EM[]RT$:M^[-%%+.L72<W&-)JI4JU9+]]3?/
M5EAY-J=&M2JQY98:FX<M16O)2YDTD5<GPE504G53A3I4XO\ <SM"E&M%)PK4
M:E.7/&O-3YH/[+CRM7?P/HW[.7CC1?'?[7&J:?HMA;^&/BO\%OAQ\/\ X9?;
MO$UIJFK3WOA;X:6'A:\T_7KJ=GN[9+;4[=X/[4U"1H]053?!BL@->)_!/]E#
M]HOX=ZE^RWJZ1>%/#NO?"#_@FI;?LWZIK=QK.E^([+P]\=[+1]&@TZ/^R$5_
M^$E\-6>J6+37&J0H^G7<$)C9624BOUDHK%9GB%&<.6DU4A3A+FA*3:I8;ZK&
M]YM-NGK*Z?-/6UFXO:66X=RA.]6+A.<X\LHQLYXA8E[1NDJB2C9KECHM?>/P
MK^"'[)W[94_[1G[*?Q4^,'ASXEVR_!;Q+X_U#XO>)/B3^V/??&GPOXPU7Q9\
M./%OAJW\5?!KX0IK=YX=^&&@C6[N)9/#MOI=AJ>G:/K>D:7IB1Z?H>L?:-W]
MN8_%^^_;K^&%U^SMXG\6Z)\4/"'[,/C6UUZS\)W'P5\+BY\%^*_'/AM6NM7\
M4?M$Z9J?P^UB.&]2W@LM"\.P+XKL;N6+59)1I]I<*?VWKR/XH_L__ ;XXG2#
M\:_@A\'_ (Q'P^+A= /Q5^&?@KXAG0UNR&NQHY\7Z)K!TP73*IN!9>0)R 9=
MQ KJIYPY8RGB<10HN%/#5L-&E"FZE)0JRJS?-2KUFZD>:M-<BK4U&+BH.,8*
M+Y9Y0H82IA\-7JJ=3$T<3*K.I&G5<Z2I17+5HT4J<N6C!\[I5'*2DYW<W)?F
M?^SYX!M/C/HG_!.+X@_ SP;J?A_X6?LK>,/CWX'^(^F>._&&E:[XHT'6-"TZ
MU^&MY-8:] #9?$@7GB_PUK$L/BKPVTFF:M9/#K=A*UC>0,>)_;3_ &8/VX/C
MEXO_ &B?#.BV?C[Q?X*^(6A:9I7P,UWPA^UGJ'P'^$G@'0H_#EJNM^'/C!\%
M?#^M:1??%77M0\4V^N3CQ/J-IJ<5UI>M^'=&O3_9'A]TB_:KP]X>\/\ A'0=
M&\*^$]"T;POX7\.:79:)X=\-^'-+L=#\/Z!HNF6\=IINCZ)HVF06NFZ5I>GV
ML45M8Z?86UO:6EO''#;PQQHJC8J(YQ5I8KZQ1I4VJ:J1H*NZE2=.,\7/&*3J
MQJ0G*JJDW&4N9*=-NG4C-2ES:/*:57"_5ZU6HG-TI5G05.G3G*GA*>#<52E3
MG!4G3IJ48N+<)I3IR@XPY?QPO/V&_C._QO\ A;I$&G>'S^S-XZ@_9\^)/[3-
MD?$VG07^E?%_]F7PM=2^%].T#0X-MQXBL/'?CY/!5_XAU*VW6*Z;X"BAF#17
MJ ][^T3^S+X_\7_'3]H'XAW'P L_C[\./B1\%OA-X"\.>%-+^+7A7X6>+K7Q
M?X1\5:;JS^*]!\2Z]-;7'@O7? \MHOB#PSXET^XM=6M]3L;:71KB&\$4@_5*
MBL_[7Q7M*=2U*].C&C9>U@I*-2E4]I*5*K"HJSC0H4G5A.$O94H+XDYN_P"R
M<-[.=-2JI3JNK=NG-Q;IU*?LXQJTIP=*]:M5]G.$X^TK5'\+4%\5_L4^!OVB
M/ _A7Q];_'2^\76>AZGXS^W?"3P#\2_BQ%\?/BAX \)C2-.AU?3O&7QL6ZOY
M_'1UCQ;'KWB#0$O+^[N/#?AW4],\-F0)I:HOVI117#B*TL16G6E&$)3:;C33
M4%:*CIS2E)MVO*<Y2G.3E.<I3DY/MH48X>C"C&4YJ":4JC3D[MO7EC&,4KVC
M"$8PA%*$(QBDD4445B;!1110 4444 %%%% !1110 4444 =;82>9:0GT783[
MH=I_E5NLC2'S#(AZH^1]&']#G\Q6O0 4444 %?P=_P#!UO\ \GF?LT_]FQWG
M_JU?%=?WB5_!W_P=;_\ )YG[-/\ V;'>?^K5\5U]EP'_ ,E'A_\ L'Q?_IEG
MQ_'7_).XC_L(P?\ ZD0/Y<Z***_=C\/"BBB@ HHHH **** "BBB@ I0"S*J@
MLSLJ(J@LS.Q"JJJ,EF8D!5 ))( !)JU86%]JM[:Z;IEG<ZAJ%],EO9V-E!)<
MW=U/)]R&WMX5>6:1L'"1JS$ D#BOT5^%/P*T/P)IL.L:O'H'B'Q=>V\T4VJZ
MS)X7U?X9Z?;7>G>%]6CT7PCK\NKHR_M$^'Y]0FAM_!<\:36DI2"<"ZDN(H_:
MR7),5G>(E2H2A2I4TG7Q%2[A24K\J26LYRL^6%XII-RE&*;71A\-4Q$FHZ0C
M;GFU=1OLDNLGT2/A.R^'/CS4$U&2V\(Z^4T=;=]8>?3KBS32([N6W@M)=5>\
M2!=-ANI[NUAMIKXP13RW,$<3LTT8;.UOPAXE\.#=K.D75G'@DS@PW5LH'4O=
M6<MQ;I[;Y5)'(R*_7&\M&M73R-"\9Z]/%KVA>;X:M]%T,>/O%TB^/OAK-;Z/
M^UG9V.IW%SX9AU%E^Q> +>UAFFO+^YLXXXC;R7,L/]$0UGQW=6,=O-_P01TF
MZMIK6.-U?PMJ$D4\;PJK$K)X;<E9%Y^=F?!^=F;)/YSXS\0U?"S%<*_584\U
MPF=+-'CH5<%FTJ\%E_\ 9BB\+6RS"XVE1=1XVK)PQ=&3M&G%/FC5M_5O@-]'
MK(O&/)>-77S+,\LSO(O[)AE.*CQ5X:9+E3JYA3S&4O[0R[CCB'AC'YA!2P=-
M1GDN83C0BZGUEQE4PRJ?PD@@\@Y'J**_?'_@HE_P3_\ C#XM?6OCW\(?^";_
M ,4/V7/#WA_2KG5OB%X5T'1]=U3P0MC:()+KQ!IEG-I\#:*85WSWUK:Q-;;-
MTHV(A"_@:"& 92"K $$'(((R"#W!'(-='"W%65<7Y8LSRJ5=4XU'0Q%#%8;$
M83$X:O&,92IU*.*I4:KBU)2IU5#V=6+O%W4HQ_#_ !/\+N*O"3B1\,\5PRMX
MNIA:>/P>+R7/<BXBRW&X&M.I3IUJ68\/9GFV7*JITIT\1A/KDJ^%JQ<*L4G"
M<UHHHKZ0_.@HHHH **** "BBB@ HHHH ZGPY_P @_P :?]BDW_J3>&:Y:NI\
M.?\ (/\ &G_8I-_ZDWAFN6J8[S_Q+_TB)3^&/_;WYA1115$A1110!]Z?L,_%
M2+P]XJU/X::O=>5IOB]EOM",LF(H?$5O&(GM5W9PVI6R11PQH%4S1R2.=SDU
M^KE?S<V-]=Z9>V>I:?/):WUA<PW=G<Q,4D@N('$D4B,.00PYQU!([U^Z7[/_
M ,9M.^,W@>UU;S(XO$^DI!I_BS3MP$L.I+$ NHI'U^Q:LJ-=02*#&LWVFU#;
M[9U'[%X>9]"KAY9)B)I5L/SU<$Y/^+0DW.K1C?>=&3=2,5JZ<W9*-)L_(?$#
M(Y4L1'.L/!NCB.2GC5%:4J\4H4ZSMM&M%*$GLJL5=WJI'NE%%%?IQ^:A1110
M!=T_4M2TB]MM3TC4=0TG4[*5+BRU+2[VZT[4;.>,[HY[.^LI8+JUGC892:"6
M.1#RK U#=W=W?W5S?7]U=7U]>3R7-Y>WMQ-=WEY<S,7FN;NZN'DN+FXF<EY9
MYY'ED<EG=F)-045/+'FY^6//R\O/9<W+>_+S6ORW;=KVOK:Y7-+EY.:7)S.7
M)=\O,TDY<M[<S22;M>R2O8ZSP]X_\?>$;2ZL/"/CSQOX3L+V=KF]L?"WB_Q%
MX=LKRY>*.W:YN[31M2LK>YN&@BB@:>>-Y6ABCB+F.-%&/::YKE@NII8:WK%B
MFMQ2P:VEEJM_:+K4$\XNIX=86WN(QJD,]TJW4T5^+B.6Y47$BM, XRZ*CZO0
M4JDU0HJ=5Q=67LX<U5P=X.I+EO-P>L7)OE>JL6Z]=QA!UJKA24E2BZDW&FIJ
MTU"-[04UI)12YEH[FI_;NN'1U\.G6]9/AU+QM13P]_:NH?V"FH."KZ@NC?:/
M[,6_=20]XMJ+E@2&E(K+HHJXPA#FY(QCS2<Y<L5'FG+XI2LE>3ZR>KZLB4I2
MMS2E+EBHQYFWRQ6T5=NT5T2T71!1115$E+4M1L='TZ_U;4[J*RT[3+2XOKZ[
MG8)#;6MK$TLTTKGA41%)8]A7X#_%_P"(-S\4?B)XE\9S^8MOJ5\T>E6\A^:T
MT:S46FE6Y7)5)%LH86N-F%>X:63JQ-?<W[;/QSBCMW^#GAF[+7,S0W'C:\MW
MRL,"D20: )%.#+*P#Z@@SMC#VTVUSMK\SJ_%O$'/88W%T\IPTU*A@9N>)E%W
MC4QC3CR)K1K#0<H-_P#/R=2+5X7/V3@'(Y8/"SS;$P<:^-@H8:,E:4,'>,_:
M:ZKZQ-1DO^G<(2VF%%%%?G!^B!1110![G^SM\4'^%'Q0T/79Y2FA:DW]@^)4
M+;8_[(U&6)3=.2=JC3;R.TU&1]I<P6LT2_ZT@_NU%+%/%%/!(LL$\:302H0R
M2PRJ'CD1AP5=&# CL:_FR(!!!&0>"#T(]#7ZP?L8_'6+Q1H,/PK\2WO_ !4G
MAZVD;PW<7$GSZQH4"EVLU9SF2\TN,,Y0$O):K+,0%CK].\/,^CAZU3)<3/EI
MXF;JX*4GI'$-)5*";V]M%*5-:+VD9)7G55_S3Q R*5>E#.L-#FJ8>"I8V,5K
M+#IMTZ]EO[%MQJ/5^SE&3M&DS[PHHHK]B/R(**** #_$'\0<@_4$ CT/-=Q?
M?$_XG:IH[^'=3^)GQ%U/P]);164GA_4?'?BN^T*2RM]GD6<FCW6KRZ:]I (H
MQ#;/;&"(1QB.-=BXX>BLJE"C5<)5:-*K*E+FIRJ4X3=.5T^:#DFX2ND[QL[I
M:Z(TIUJU)3C2JU:<:L>6HJ=24%4CK[LU%I3CJ])76KTU.J\.>._'?@Z*Y@\'
M>.?&GA""]>.2]@\*>+/$'AN&\DA5EADNXM%U&QCN9(5=UB>=9&C5F5"H8@T6
M\4>)VUU_%+>)O$;>*99S=2>*&U[5CXDDNB,&Z?7S>?VN]R5^4W#7AF*_+OQQ
M6'12^K8?GJ5/84?:5H\E6?LH<]6#23C4ER\TXV27+)M62TT17UBOR4Z?MZWL
MZ4N>E#VD^2E.[?/3CS<L)7;?-%)W;=]38L_$7B'3EU5=.\0:[IZ:]#]GUY+#
M6=2LDUVW\UYOL^MI;742ZO!YTDDWDZ@+F/SG>7;O9F./TZ445HH0BY2C&,93
MMSM12<N6*C'F:5Y<L4HJ][122T5C-SG)14I2DHW44Y-J*DW)J*;LKR;D[6NV
MV]6%%%%42%?EK^W5\5AJNN:3\*M(NE>R\/,NL^)?)<%7UJ>)XK"PD*D%7T^T
MEN)KB%PRL]W9R##1\?<7QV^,&E_!GP->:_<,DVNWXET_PMIF09;S57BXN&3.
M1::<'2YN92/+#&"!V#7"!OPFU34[_6]3U#6-5N9+S4M4NY[Z^NI6+/-<W#F2
M1B3D[02$12?EC5$'"BOS/Q"SZ-##+),//]_B5&IC'%ZTL,FI0I2MM+$22DUN
MJ47=<M6+?Z1P!D4J^)>=8B#5##.5/!J4=*N):Y9U8WWCAXMQ4E=>UDK/FI2M
M0HHHK\;/V **** )8)YK6>"YMY&BN+::.>"5&9'CEA<21NK(0RE64'*D'WK]
M[/@7\3+7XK_#;0/%"S1OJJ6Z:7XD@5E,EMKUA&D5Z947B,7V$U.W09VVUY""
M=P('X'5]/?LM?&W_ (5#XX-KK,T@\%^*C!8:XH)*:==JQ2PUH)S@6YD:&[*C
M+0.CN0EMQ]CP7GL<FS3DQ$^7!8]0H5Y-VC2J*7[C$/M&#E*$WLJ=24G\*/D.
M,LCEG&6>TP\.;&X%RKT(I>]5IM+V]!=6YQC&<$M95*<(*W,V?ME14<,T-Q##
M<6\L=Q;W$4<]O/"ZR13P3(LD,T4BDJ\<L;*Z.I(96!!P:DK]_335T[IZIK9K
MN?@VVX4444 ='X?\8^,?"+W$GA+Q?XK\)R7?E_:W\+^)=;\.O=^26,/VI]&O
MK)KGR2S&(3%_++,4VECG1U[XD_$CQ78_V7XJ^(OQ \4Z7YJ3_P!F>)?&OB?7
M].\^,YCG^P:OJMY:>=&0&CE\GS(V *," :XNBL'A<+*JJ\L-0E734E6=&FZJ
ME%)1:J./.FDDD[W222V-XXK$QI.A'$5XT&FG1C5J*DU)WDG34N1J3;;5K-ZO
M4OZ9JNJZ+>Q:EHNJ:GHVI6X<6^HZ1J%YI>H0"12DGD7UA-;W4/F(2C^7*N]"
M5;*DBKNB>*/$_AG4Y-;\,^)O$?AK6I8IX)=9\.Z[JVAZO+!<RQS7,$NIZ5=V
ME])#<S1137$3SM'/+%'+*KO&C##HJYTJ51352G3FJD5":G",E.";:A--/FBF
MVU%W2;>FK,XU:D'!PJ3@Z<G.#C.47";LG.%FN6348WDK-\JUT1KZMXA\0^(-
M5?7O$'B#7=?UV00B37-<UG4M8UIQ;$FV#ZMJ5U<Z@PMBS&W#7!$!8F()DYLQ
M^+?%L6N-XHB\6>*(O$[B0/XFB\1:S'XCD$T?E3"37DO5U9Q-%^ZF#WA$L7[N
M3<GRUS]%+V%#E4/8TN2--THP]G#E5)V3IJ-K*FU&*<$N5V5UHA^VK<SG[6KS
MNHJKG[27,ZJ;:J.5[NHFVU-OF3;L]6.DDDE=Y97>661VDDDD=I)))')9WD=R
M6=W8EF=B69B2222:;116NVQF%?'/[9_Q4C\%?#=_!^G70C\1^/%>QV1R;9[3
MP_&Q74;M@I#QBY8&UMI5./.BE4\5]3^*?$VC>#?#VK^*/$%XECH^BV<M[>W#
MGG9$I*PPH,M+<3N!#;P(&DFF=(T5F8 _@W\7OB9JOQ:\>:SXQU(20PW4IM]'
MTYWWKI>CVY\NQLEP2GF+"JO<NAQ-<M)*>7-?#\<Y]'+,LE@J,_\ ;LQA*E%1
M?O4<,[QKUG;5<RO1I[-RE*46_9M'VO!.1SS/,H8VM!_4LOG&K*37NU<3%J5&
MBKZ/E=JM2U[1C&,K>TBSS+ITHHHK\'/W,**** "BBB@ HHHH **** "OIO\
M8O\ B"WPL_:O^ 'CD3&%-*^)6AV$S\[/(\3^?X4E$J@X:(+K>Y]^43:)6_U8
M(^9*N:=J<NB:CINMP;C/HNHV&L0!?O&;2[N&_B"G(PWF6Z[3D8.#D5\YQCP[
MA>,.$>*N$L=357!<4\-Y[PYC*4K-5<+GF5XK*\13?-[MIT<5..NFNNAZ.3YC
M5R?-\JS>A+DK95F6!S*C+7W:N!Q5+%4Y::Z3I1>FO8_T;GVAVVD,FX[&4@JR
MY^5E(X*LN"".""".#3:XGX::W'XE^&_P\\0Q2K.FN>!?".J^:K!@\E[H&GSS
M?,"02LSR(QR?G5AD]:[:O^'7'X*KEN.QN78A-5\!B\3@JZDG%JMA:TZ%5.+U
MBU.G)-/5/1G^Y.&KPQ.&P^)IN\,10I5X/O"K3C4B_NDC[1_9(U?Y?&.@L^ K
MZ?J\*'^-YU>SG*^Z1VD.X\<,O7M]GU^=?[+^H_9/B6;-FVQ:EH6HQD'HTUN8
M7MU^I\R3&?S'?]%*_P"B+]G=Q+/B#Z,/#&#JU/:5^%.(.*>&IMN\O90S.6=X
M2+714\)GE&A%+3EHKK<_B+QPP"P7B#F%6,>6&98++L>M$ES/#K!U'YN57!SF
M[]9!1117]QGY$%%%% !1110 445^:_\ P4:_;PL/V//!6BZ'X<BM]5^+WQ"C
MW>$M%^T6"ZF='@US0M$UNY\,:?J-Q;6WB3QS''KT4WA+P>)A<ZY<P3SA18Z?
M?W$'J9+DV8<09IA,HRNC[?&XVI[.E"ZC&*2<JE6K-Z0HT::E4JS>D(1;U=D\
M,5B:.#H5,37GR4J4>:3M=N[2C&*6LI2DU&*6[:1]U?$?XJ_#/X/^'Y_%7Q5\
M?^#_ (=^'K=%D?5O&7B'2_#]K)OD$,4=J=2N;=[V>>9E@M[:S2>XN)V2&&)Y
M65#\XVG_  4._8DO-7GT+_AI/X:V&JVZVCS6NNZA?>' L5_#'<V5PMQX@T_3
M+62UN[6:&ZMKN*9[::UEBN8Y6AD5S_$M\1OBI\1_CAXH'C'XK>*XO'6JRWNB
MES\1)?#J?"N%)=11XX_VE4EUTVW@SXE6AQ%H7A]$5);]88RW\0^KO^">USXA
MTV[^+T.C?\$^?&7[;_F6WPO-QKOQ5\+^7XK\$&/P'I$::3%9Z;::S:P^&]05
M?M/A661XKRZ\-Q:5<3I#))/#7ZEXA>$T.!/#[-N*)YX\;G&6++V\+3R_$ULN
M?UW,\!@IT^3"PKYC5=*GB:DXU8TZ2<^1RI1C"LE]!X-T<N\1O$?)N$,SPN,H
MY9FE/-'*M@^(.%^'\;">"RK&8VE)9EQABL!P[0BZU"FJE+%8VE4K4^>CA9SQ
M-2@I?VT^&?%7A?QKH]OXB\&>)?#WB_P_=DK:Z]X6UO3/$.BW+*%9E@U72+J\
ML9F574LL<[,H92P 89WJ_ 'X<_M,?M5_"$3K\,/^",OBGP+'<C;/%X:B\1Z;
M"ZG:#BWAT)8%)"J/D1,[0"<5^U/P4^(FO_%/X<:#XS\4_#7QG\(_$>H)+#K?
M@/QWI%WI&MZ+J-ML%PD:7<<9OM-D9\V6HP[X;E5?:^Y& _GO)\_PV;?N5&M3
MQ4*?M*L)X+,L-1:NHMTJN/P6$Y]6FX).<4]>9)R/TWQ2\&,^\-[9G4KY5C>'
M,7COJ> Q&&XMX#SW-:525.=:%/,LOX.XIXC>%3A3G&&+G*GAJTX.*5*I*-)^
MJT445[Q^,A1110 4444 %%%% !1110 4444 >!_M1Z WB/\ 9^^*%E$&\^PT
M*U\302)D202>#]:TOQ6\\; 9C:.WT:<,XQ^Z:12=C,#ZYX2U]/%?A+PIXJC9
M7C\4>%_#WB1'7&UEU[1[+5E9=OR[2+L$;>,=.*\\^.'CC1_!W@C4K+5;.747
M\7Z;K7AJWL8BJ"2'4=,EL;^>9W(58;:WOE+*,N[2(JJ1O(Y3]ESQ);:C\*]!
M\(^9-+J/P\TVP\-74LJA5GL(OM*:%-#M) 1--MDLBAPZO9,2H1XRWYU/QH\,
M8^(E'P4GQ7@EXFO"U,[H\+^PQKQ$L#5RU9C57UQ89Y='&++<)',_[.EBXXUY
M=_MJP[P[]H>LN$N(?[+GQ?'+*KX=E&&!J9CSTE".(HXMTJ7[EU%7=*5;$U*'
MMU2=%5U[%U%-J+^CJ**^2?'_ ,8_''AW]LK]G7X(Z9<:4G@'XE_#3XP>*/%5
MM/I44^KS:OX+MK6709-/U=I!-I]O$\KF[MXXG6[!"NR <_I5&C.M*486O"E6
MK/F;2Y*-.56=K)Z\L'RK9NRNMSQ*M6-&,)33:G5HT5RI-\]>K&E"]VM.>:YG
MT5W9['UM17GC?%3P.OQ+U'X1-JMP/'VE> K/XF7VD?V7J1MHO!E_JFLZ-:ZF
MNK"V_LN6=]1T#5(3ID5TVH1I DSVZQ3PN_SM?_M^_LP67A;X7^+(?%GB_7+?
MXUVGC"[^$GA[PI\+?B)XK\>_$1O 7B0>%?%FG>$_A_H/AV_\7ZUK6D:@MU?2
MZ+8Z1-J<GAW3-7\30VKZ'I5_?05#"XFHTJ>'K3;Y6N2E.5U.$ZD&K1?Q4Z=2
M<>\83DM(MJ9XG#T[^TKT86<D^>I"-G"=.G):M:QJ5:4'VG4A%ZSBG]F45\V^
M"_VN/@)\0=%^%NN^%_%VH7=K\8?&>N_#KP?97OA3Q-I.NVOCWPQ:7%YXD\'>
M-/#^I:9;:OX \2: EK/!K.C^,+31[[3;V,V-W!%=$15J77[4/P.L+#X[ZIJ7
MC5-*TW]FKQ!9>%OC'?ZKI6K:=:>&]?U+PQX=\8:=IMC/>6<,?B2?4-$\6>'S
M9?V VH+=:EJ$>CPL^II);*/"XE2<'AZZFM'%TI\R?M50LX\M[^V:I6M_$:A\
M32!8K#2BIK$47!JZDJD'%KV7M]'>S_<IU?\ KVG/X=3WZBO%/@U\>?"?QSM-
M6OO"O@_XX>%+?1QIK3?\+G^ ?Q<^!DVHIJL5Q-;2^'X/BKX2\+2^(H8X[=C?
M2Z,MY'IYFM%O&A-Y;B3Q'QQ_P4-_98^'GC3QGX$\2>*_&[:Q\-/$^G^$?BEJ
M>@?"/XF>)_!_PHU/5[JQM-*O?BGXVT'PS?\ A;X>>'-3DU"%]/\ %'BS5-+T
M&\MX+^Z@OWM].O)(7#"8JI4G1AAJ\ZM-)SIQI3E."DXJ+E%1<HIN<4FTKN44
MM6A2Q>%A3C6GB:$*4VU"I*K",)M)MJ,G)*32C)M*[2C)NR3:^V:*^5/BW^VC
M\!O@QXHN/!?B:]^(OB?Q+IGAVR\7>)M-^$/P>^)OQH;P)X6U(!]-\0?$:;X9
M>&?$T/@#2-0MR+VRO_%;Z5;W6GG[?"[VG[VJ_P 1OVWOV<_AGJOAKP_J/BCQ
M/XT\1^-? .F?%/P5X9^#GPX\=_&CQ+XR^'&JR:C'#XV\)Z#\,M!\2ZGXB\-V
M2Z:]QK.K:5;75GHMG?Z+>:I+:VVMZ9)<N."QD^1QPN(DJB<J;5&HU.*2;E%\
MMG%)IMK1)IWLQ2QF$BZBEB:$72:C43JP3A*3LE)<UTV[I)ZMIK='UG17Y>_%
M;]MKP)I'Q@_8U^(7A7XB^+/$/P.^,?@/XZ36WA?X<^&/$_C?Q#\3/%.B7O@.
MQT31-+^&/A;2-5\;^(_&GA2Y/BI=0\,:=H\VN>'8],\43:K86T>C:DUM](S_
M +<'[,MC^SZG[46J_$*;0_@JGB72_!VJ^)-?\,>)=$U3PKXIU;Q+8>$8]"\;
M>%-2TRV\2^#=2T[7]3LK/Q!:^(],T^7P]'*UUK"VEM%)(ND\NQD(8>?U>M+Z
MQ+V<%&E4;5?V]:@L.UR+]^YT96IJ\GM;F32SAF&#E*M%XBC%T(^TDY5::3H^
MPHU_;I\W\%0KPO-V2WV:;^L:*_/B\_:]EO\ XO\ @V]T+5O%>C?##4/@1\5/
M'EW\$/&_[-'QP\,?'_Q?KG@35+ZWC\3>&]+UGP39ZO;^'8H;>&&UT1[,:IXG
MB8:IH-K?V-Q',WC7@_\ X*"^(?CG^S%\*_C9X66[_9SU_6_CCX%\%>+S\6/@
M5\:+OP5X@T/7O&OB[PT?"OPTUC5O!5DWB;6]>M="L1<^*-+6YT/P3K)OM*\0
MWMA.BQG2.5XR48S]DXP<Z5.4I0J+V=2LZT80G'V?M&VZ$TW3A.*=HN7,[*'F
MF#4I0]K%S4:DXQ4Z?[R%)493E&7.H+2O!I5)0DTI24>5<S_6RBOF2\_:Z^$"
M?%K4_@UHFF?&7QKXGT/Q/8^#O$FM?#GX"_%[XB_#3P9XGU PN/#_ (W^+'@_
MPCK'P^\):MI=M<VE[XAL]?\ $%A-X?T^[M+_ %=;2TNH)7^FZXJE&K2Y?:TY
MT^>*G#GC*/-%I-2CS)7BTTTUHTTT=E.M2J\WLJD*G))PGR24N62=G&5F[233
M36Z::84445F:!1110 4444 %%%% !1110 4444 %%%% &OI#8FD7/WD&!VRI
MSG\C70URVFMMNX_]H,O_ 'T,#]<?C74T %%%% !7\'?_  =;_P#)YG[-/_9L
M=Y_ZM7Q77]XE?P=_\'6__)YG[-/_ &;'>?\ JU?%=?9<!_\ )1X?_L'Q?_IE
MGQ_'7_).XC_L(P?_ *D0/Y<Z***_=C\/"BBB@ HHHH **** "BBB@#Z _9L\
M/1:U\2M+O99-?G_L2YM9X]&\$:G8Z;\1M7DO5O(%_P"$%;4;6[M)-3T\Q?:+
MQI(6\BR=F +2 C[X" Z=%+ W@*$2:9;VLES9WV@Q?"?4[H>&/!1&GZ':?V64
MT[]I>VE4-J=RRM--JUQ(#*3%.TGD_P#P2[\:?!?PE^T<;3XR_LY>)?VF8O$O
MAV;3O _@KP?XT\4^!_$VF^+;:5YX=4TC4O"%W9ZO<W4UM*]H+:.4D+N:-2Q8
M'^B!-._8OCM8[&/_ ((<_M$QV45\-3BLD^*_QX2TBU,+&@U*.U6Z$$>H!(8E
M^VK&+G;%&OFXC0#EK^/7!/AI4CD&?8+/)8^I3CF#K8'+*F)PU6CB)U*<'&K&
M2C)T_8<DHM74U.]E&E(_ISPB^C7XF>+7"M3B?@O 95CLMI9KB\KQ$\3Q1P9E
M->ECL+3PM6=.>#SWB7*\?&+H8JA.%5X14:BG:E5J6J\OX>RVDHN+>"+4_$'A
M:>'6?#[2ZU!JVAS^/_!<K_$#X9)!KG[4=U8:;:W5_!9M)-J'@:&VGC>UU&WT
MVX#[(I4?^CRWT+Q^+>W _P""]>EQCR(<1CQ1J("#RDP@#>)%8!1\HW*KX'SJ
MK9 \/V?L=F749W_X(A?M(2RZR;8ZRT_Q;^/5Q_;7V.XM[RU765FNY%U9+>ZM
M+2YBCU!;E$GMK>55#PQE>D'B;]DL  ?\$,_C)@  ?\5#\1.@&!_S"OU/)[U_
M-7CUXO\ "WBC/AAY!'&859)'-EBO[6AQ3ECJ2S'^RW3]A')*==553>#JJ<L2
MXR473Y;RE69_H%]&CP(\1_"+#\74^+,AQ4IY[6R6>!604_HP<9Q4<OAF,:[Q
M-3Q'XLQ-7+Y/ZY1]E#*7"GB/WDL8I2HX?E]'O?"?C+5;*\TO4_\ @O)HM]IN
MIVMQI^H65UXDO)K:[LKV%[:ZMIX9?$ICEAG@EDBDCD!1T8JW!-?Q<_M*_#K1
MOA+\??BU\./#OCG1OB7H7A3QGJ=AI/C[PZI31/%=E<"+4H=6TU"3LMY!>F+9
MDA)(I%'  K^ON7Q;^R+;12W-S_P0Y^,%O;6T4MQ<7$WB/XA1PP00(TLTTKOI
M:HD<4:-)([LJ*JDL0 37\A'[3/C+P1\0OV@/BWXR^&W@5?AEX$USQGJ,WA?P
M FH3:J/"FEV:0:;'I1U*X FO'26REFDFDY,DS ?*HK/Z/]2K+-N(8TJE&I@_
M[.PLJWLL5Q3B.7$_6;8:ZS^A2H1O2^MW>'DZS:7/'DNU^1?3\PE.APIX?3QV
M7YS@,U?$.:1P7]H\/_1YR6C5RYY93EF7+/P9S7'YOB*M/%+*N2&<TH9=3A4J
MRHU%BI*$_#****_J,_R^"BBB@ HHHH **** "BBB@#J?#G_(/\:?]BDW_J3>
M&:Y:NI\.?\@_QI_V*3?^I-X9KEJF.\_\2_\ 2(E/X8_]O?F%%%%42%%%% !7
MI/PJ^*7B7X1^+;+Q3X<F9@A6#5M+>1EL]9TQG!GLKI 0I;&9+:4C,$X5P0I<
M-YM16M"O6PU:EB,/4G1K49QJ4JD':4)Q=U)/UW3NFKIIIM&5>A1Q-&IA\13C
M5HUH2IU:<U>,X25FFOR:LT[---)G]!?PP^*/A3XM>&+7Q-X6O%D1E2/4M,E9
M1J&C7VT&6ROH?O*RG/E2XV31[74Y.!Z+7\^'PV^)WC#X4^(8O$?@_43:7'R1
MWUC.&FTO5[56#-9ZG9AT$\3#(65'BNK<L7M;B%SNK]>_@O\ M/> ?BY;VVG2
MW,7A?QEY:"Y\.ZG<(L5U+@!FT;4)!%#>QL^0D$@@N\X1(IOO5^Y\,\9X/-Z=
M/"XZ=/"9FDH.,FH4<7+;GP\F[1J2^U0DU)-_NG.-^7\1XDX/Q>43J8G!0J8K
M+6W)2BG.MA4_LUXI7<([1KI<K27M.25N;Z4HI2"I(8$$<$$$$'T(/(I*^X/B
M@HHHH **** "BBH+JZMK&UGO;ZYM[*RM8VEN;R[FCMK6WB4$M)-/,R11J .K
ML,]!D\4FTDVVDDFVV[)):MMO1)+=C2;:23;;222NVWHDDM6V]D3U\D_M+_M*
M:;\)]*N/#/ABZM[[XBZE;%8(TV3P^&[6=63^U;X LANU /\ 9]G(/GF FF5H
M871_*?CM^VII^EQWGA?X02QZEJ9\VVO?&4T).GZ>1E)%T.VF4&^N@V5^VW2+
M;0%6\JVNM\<\?YC7]_?:K?7>IZG=W%_J-_<275[?7<K37-U<RG,DTTKDL[MP
M!_"JA40*BJH_,^*N.*-"G5R_):JJXF2<*V.IN]+#IZ2CAY[5:VZ]I&].GO&4
MYZ0_2>%N"JM>=/,,YI2I8:-IT<%45JM=JSC+$0>M.CU=.252IM)1@[R;>WMY
MJ5Y=:AJ%S->WU[/+=7EW<R-+<7-Q,Y>6::1R6=W8DEF)/;H*K445^.MMMMMM
MMMMMW;;U;;>K;>K;W/UU)))))))))*R26B22T22T26P4444AA1110 5IZ+K.
MJ^'=5L-<T2^N--U;2[F*\L+ZUD:*>VN(7#QR1NI!!#*,CHPRK @D5F44XRE"
M49PDXRBU*,HMQE&47=2BU9III-----70I1C*,HRBI1DG&49).,HM6<9)W333
M:::LUHS]N?V=OVB=#^,VB1:?J$MMIGQ TRW5=8T<LL2:BL:A3JVDH2/,MIR-
M\L"9:VD+1XPHKZ7K^<+1=:U;P[JMCKFA:A=:5J^FSK<6.H6<K0W-O*A!#(Z]
M5;&'C8-'(ORNK+Q7ZE? O]L_0_$T=IX:^*TMOX?\1GRX+;Q+''Y6A:N_"J;^
M-"QTF^D."[1J^GRN9) +"-5C/[/PMQQ0Q=.E@,XJQH8R*C3I8R;4:.*V2]K+
M2-&N^KE:G4>J<9M0?X[Q/P37PE2ICLHI2KX.3<ZN$@G*MA6W=^RAK*K0711O
M4IK1J4$YK[SHJ.&:&Y@AN;::*XMKB-9;>YMY4GMYXF^[)#-$SQ2QGL\;,I.1
MG(-25^D)II----736J:>S3ZIGYULVGHTVFNJ:T:?FGHPHHHH **** "BBE +
M$*H+,3@  DD^@ Y)^E "5P/Q(^)7A7X5^&+OQ3XKODM[6%62RLD93?:M>[28
MK&P@SOEED; 8J"L:DLQ&*\L^,_[3G@#X1V]S8)=1>)_&/EL+;PYI=Q&R6\N,
M*^LZ@GFPV,2'&^&-9[PMA&ABW&1?R&^)OQ4\9?%KQ WB#QAJ)N9(]\>G:;;A
MH-)TBV8\6VG69=Q&H7"O/*\UW/C=<7$K$D_$<2\9X/)X5,+@IT\7F;3BH1:G
M1PLG]K$2B[.<=XT(MR;7[SV<;-_:<-\'XO-YT\3BXU,)EJ:DYR3C6Q2WY</&
M2OR2V==KD2O[/GDFE=^+WQ:\2_&+Q;<^)=?D,-LF^VT/1HWW6FBZ8'+16L('
MRO/)GS;RYQNN)V)SY:1*OEE%%?AF(Q%;%5ZN)Q-6=:O6FZE6K-WE.<MVW^"2
M2C%)1BDDDOV[#X>CA:%+#X>G&E0HPC3I4X*T80BK)+N^K;NY-N4FVVPHHHK$
MV"BBB@ HZ]:** /T(_90_:@3P_\ 8OAC\1M08:+)(MOX5\1WDA8:3+*V%T?4
M97)(T^9R/L,[$"VG9H7)2:,)^HZLKHDB,KQR*KQR(P9'1AE71E)5E8$$$$@B
MOYKR 000""""",@@\$$'@@CJ*^U_V?\ ]KS6_AVEEX3\??:_$G@N/;#:7ZMY
MVO>'H_N@0O*ZC5-/4=;.YD2>( -!>*BF!_T_A'C:.$A3RO.)R]A&T,+C7>3H
MQVC1Q&\G2CHJ=5)NFK1FO9I2A^:<6<&2Q4ZN9Y13C[>;<\5@HVBJTOM5L/JH
MJK+652EHJDKR@_:-QG^O5%<UX2\8^&/'6CP:_P"$=:L==TJ=%87%E*&>$N,B
M.[MV"W%G,!UBN8HG[J"I!/2U^O4ZE.K"%6E.%2G.*E"I3DIPG%ZJ491;C)-;
M--IGY+4ISI3E3JPG3J0;C.G4BX3A);QE&24HM=4TF@HHHJR HHHH **** "J
M&J:IINAZ=>ZOK%];:;I>G6TMW?7UY*L-O;6\*%Y))'8@8"@X499CA5!)Q7"_
M$KXM>!/A/I3:GXRUJ&SE=&-CH]N5N=:U*3!*1VE@K!U60C N+EH+;AL2LR[#
M^0WQU_:2\7?&BY?3L-X?\$V]QYECX<MI2S79B8^1>:Y<@(;ZY'^L2W58K*V;
M9M@DGB%RWR_$/%67Y%2G!SCB<P<?W6#IR3DFU[L\1)7]C3ZZ_O)KX(-7E'Z;
MA_A?'YY5A-1EAL I+VN,G!J,HIKFCAT[>VJ6NDX_NX/XY)V3Z']IO]HV\^+^
ML'P]X<EGL_AYHUR6LX2&AF\0WD1(75=03.?(0_-86C92,[9W#2K$R?*%%%?@
MF89AB\TQ=7&XVJZM>L[M[1A%:1ITX[0IP6D(K9:MN3;?[KE^ PN682C@L'35
M.C1C9+>4Y/XZE26G/4F_>G)]=$E%)(HHHKB.T**** "BBB@ HHHH **** "F
MNH='0]'5E/T8$'^=.HH3L[K=:H-S^ZW_ ()Y^+SXY_8J_9U\0R2>9=2^ +?3
M[T%MS176DZEJ.G&%R.-Z6]O;MC PKKD9K[+K\K?^"-.N?VS^PSX1BWEO[ \;
M^-?#^"^_9]C;2;O8!@>7C[?GR^=I.[^*OU2K_BX^DUP_3X6^D3XY9!1A[*AE
MWBOQY3PU)*RI8:KQ+F.)PU*/]RG0K4X0Z\L5?4_VF\,,PEFOASP-F$Y.<\3P
MID4JDV[N=6&78>G5DWWE4A)OS?4]2^"FH_V9\4O!LQ8K'/JJV<[#M#<12!L]
M."R(#7ZG=*_('PA=_8?%?AR[R1Y&M:<V1C(W7*1Y&>,_/7[ R##N/1V'ZFO]
M3OV5><SQ'AOXI9!*;E'*N-LKS6G%N_)#/,BAA6DKZ1E4R&<ME>3D[O9?@7TB
M\*H9]P[C$K?6<HQ.'D[;O!XQU%]T<:E]VBZLHHHK_5$_G8**** "BBB@!\:[
MW1.?F=5X&3\Q X'<\\#N:_A$_P""AWQ3U;XP?MF?&O6M8G&N:=HOCW5/ ?A0
M3^(]'NM NM'\.^(OAK'!I/[-%W=Z?-<Z3\;H+V?4E\0SF4K-!*D47EQV4ZS?
MW=(Q1U=3M965@V <%2"#@\'!&<'@U_-)^T[X&_9,\"?'7QYX;UK_ ()"?&/X
MLW^E^+[[Q1;_ !$\#_%SXT)X7U_6_$!M-2U#Q9H%EHUV-+T+4=0O((FOETM8
M)4N;&!C(1% 4^_\ #_Q)X8\,<PQN=<28;,<1'&86&7X*>78.6+G1J2J>WK.:
MA*,J:J1HTX*>W+SZJ7+?W>'_  FXR\8,95X?X+H8/%9A@,-+-<50QF<Y!DL9
M82%:CA7.%;B#-\GP]=PJXFG>C0K5JZ4E-TU2C.:_G LH2T]G)/-X2DAM/[!B
MGU+Q5J/AT?#W3&&H11_9_P!IO3Y=)>2_^)YAS%I+LSL^HF)Y6;M^A7_!.S2_
M$MQ/\73I'_!0+Q/^P\RVWPM>YT+XC:]]G\2>.7F\ Z-)_:\,FEWFC63^'+#)
MMO"L.Q[BU\-2:3;/YACFEKZYDL_V,Y8;ZVE_X(>_M&R6^J7,=[JEO)\6OCT\
M&I7L+!XKS4(6NS'>W<3@/%<W2RS1N R.K &MNSU3]D6REGN%_P""'GQ[O;FY
MBLX);G6?'WQ?U^Z-OI]M%96%NMSKD6H3Q6]E9P0VEK!%(D,%M#%!$BQ1HJ^C
MXL_2.X$X[X$SOA?)\/G-#'YF\N]C5S' YQ@,)!8/,\OQU3VN)RI5<;#FIX:K
M",:--1E/V:GRPG6/Z*\$/HI>,'AWXDY#Q=Q#D>'>5993S2.(649WX$\3X]O&
MY5C,#15+)N-N,:_#F)7M<12]I+'4I3H4^>OA7'%4J,H^P_V'\0/^D]VF?^%3
MJ'_S35]R?L%W^M:%\4];T;Q)_P %,O#/[9!\2>&+J+2?AY+JEQJ.N:5?:;-!
MJ,VO:.T^L7YBCM]/MKJ._C6(![>1W+ H#7YE?\)/^R7_ -(,_C)_X4/Q$_\
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M2UNA+^TM9/\ 8&@C73XH_L/1O^$G;2X]$/B3^RK#_A(#HL5S<7D6C'6OL_\
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MQ?\ Z99\?QU_R3N(_P"PC!_^I$#^7.BBBOW8_#PHHHH **** "BBB@ HHHH
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M9=ZF/<X].D<)3>]_M=O,YZ?AHE)>USARCI=4\"H2\[.6+FM[VT/V\\7?M8_
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M.=*G+,L7PKE>'J1I6J2G_9U+'8C#1J.,JE7$SITIP****]\_%PHHHH ****
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M!_C3_L4F_P#4F\,URU=3X<_Y!_C3_L4F_P#4F\,URU3'>?\ B7_I$2G\,?\
MM[\PHHHJB0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI_A!?#,@74'U..?1'U#_ (26:6.Z@9QI+Y6(^Q_L2_M*>,_VL/@1I7Q@\>?
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M6O"26#S' 1C&4L9AU&4G&+=6"4G'V=TM=;>VI7>UJM-WM.-_TDHKXMMOV_\
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MP!\)O#'_  7)\<_LF?&;X>V?C7X$W^H?%+QQX6\-W$VJ:7I>K?#[7O#S^./
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MFJY95:%>4H9?";I5XUJ-*%)1K5*<Z=2@XNI2=.=Y>]%K\N?$'P6^*WA3X8>
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M(='#TY1C/$5U!?NZ,922<M6VGRQ=F?V6TH!.<#(52S'LJJ,LS'HJJ 2S' 4
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MQ(7_  __ &3OVL-5^''[*?[*OQ9T#X/^'O@M^R5XO^'>M0?&_P &?$'5M?\
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M?&[]G/P7X:\6_&3]E'XL?';P!\:O#WQ(^.MGXE\%_M#7W[1&F^%?'7CCXG>
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MM^"M:\8_#S2_#WB;P!?_  ]L?#%S=>(UNM0T"#2?#_Q!'CC3]/T*/6?[>OO
MNLVNDS:!JO[5Z!8S:9H.B:9<E#<:=I&FV%P8FWQ&>TLX8)3&Y52\>]&V,54L
MN#M&<5K45R8K'5<7"G"I"E'DG.HY4XR4JE6=.C2E4J.4Y*[AAZ2Y8*$$U*2@
MI3DWTX7 T<).<Z<JKYX0IJ,Y1<:=.$ZM2-.FHQB[*=:H^:;G-IJ+FXQBD444
M5Q':%%%% !1110 4444 %%%% #D&64#NP'ZUVW2N/M5W7,"^LB^_&>?TKL*
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MXE^$VKZA+JJ?#_QSH?Q*\4>$;/3CX?N+J[M-#U;1+G493:&&>XCCN T8^DO
MOC/X8_\ !3/]J_PQ>_&3P3K?PR_X)\?L4_LW7VCW^EVGC(:)XA\$_ WX<V-[
MI_@V\\1>,H#LOOBI\1/'&MZ4UYI>D2W#:MK%]=Z7HTMWI^G/>C\+*4$C(!8
MC! ) (ZX8 @$9['(K"IE5&U1X>I5P]5_671FI3E'"3QDN;%5<-#GA[.K4O)P
MGS-492;IQ4)3ISZ*>:UE*G[>G2Q%.+P_MH2A"+Q4<''EPU+$SY9.I2A:"G&R
M=6,5SR<U&I'K;Y_ 4_CZ^DM+?Q);_"V;QG=O:6L+6]QXPA^'KZ[(;>&)]1EM
M;6;Q*GAHHD37\]M!)J@4W<L,9D9?U3_:N_X+#?M(?$KXL&\_9;^)?Q2_9U_9
MZ\)^$?"/@3X5?"2.?PE)-X>T+PEHUOI7]HZDEO8:Y80ZWKLMNNH:JFF:C-9B
MXP(G8*#7X_45TUL#A<14HU<11AB)8>G4ITE7BJL%[5TW.;IS3@ZC]E%*HTY*
M+DHM*<K\U''8K#TZM/#UIT%7J4ZE1T6Z4Y.E[3DBIP:FJ:=23=--1D^5R3<(
MV_?[0/\ @L5\-=8^/_[$O[4WQB^&WQ<\7?'+]G_X ^,?@7\>?%&F7G@J0_&!
M;FUU*T\%^-=(N+_6-/GE\1.-1EN?&<NO0::&G)CTG[5"D8'P5^R?^V)X(_9\
MUS]M#5?$OA#Q?K\/[37P)^*GPH\*1:!)H22^&M9\?>,-'\2:;JOB4ZGJ%HDF
ME6%KILMO?KI+7MZUQ)&;:WEBWNOY[45RT\FP%*%2E"G.-.K"E3E!5)\L:='$
MU<52A!7]R,*M:?*HV2ART_ABDNB>;XZI4IU9U(RJ4IU:D9.G&[J5L-1PM6<W
M;WY3I4*?-*5VY\TW[TFW^BW@C]J/X">)/V!](_8L^/?AWXSZ1J'PO^-OB7XY
M?"3XA?!>U\!Z[!JVK^+O!^I^'M8\*_$C1O'GB/PV=/T>*^ETNYLM7\-'5]16
MTCO5>S$QA23F_CG^UUX>^)?[*7[%GP%\'Z-XY\*>-/V7+/XBVVO^,9=0T^PT
M_7)?&7B74-;T^X\)W6B:H=<LWLK>\CAO'OX;"3SU?[,9(MKGX-HKH67X>-15
M+3;6*J8V,7-N$<16IU:5648_RU(UJCE!MQ4I<T5&RMB\?B'3=)N"4L+2P<I*
M"4Y8>C4I5:4'+O3=&G&,DE+D7+)N[9^BW[!7[;FE?LD?$_Q]\<O'EG\4/BC\
M4].^#_C/P7^SW-)XA@UC0_ GQ"\:PPV$WCK7[CQ7K;W]DF@V%NDNDCP[9W]U
M/?2.+N!(41F];_97_P""S'[:'P8^/_PX^)?QD^.'Q/\ C?\ #'2-;F'Q3^&&
MI77AE(/B'X2UFQO--\0Z9.7TC3XKJ]"7QUG2XM2OH[*37-/TZ2^E$2O(OY'4
M5G6RG+\3+$3Q&%I5I8FE&C.52$92A2C&45"A)J]#XYSO2<9.<G.]U&UT,UQ^
M&CAX8?$U:,<-5=>$:<G",ZLI0DY5DFE6_ATXVJJ4>2/);E<D_P!*O%O[8?P0
M/[)?[6O[+?P\^'GQ'TS3OCE^U3X2^.7PTU+Q))X4DL_"G@CPW=7MU)X:\7I8
M:O=7$GB21KQDM6T2&_TE55?,O$Q@_#GP8\::;\,?BU\,OB%J5A>7^E>!?'/A
MSQ5?Z;I?V:._O;/1=2@OKBUL/M4D%HMU.D3)";B6*'S&!DD5<FO.**WHX.C1
MIUZ<%-QQ$Y5*SE.4I3G*C3H2ES-W3=.E"]K>\G+=LPJXNM6J4*DW#FP\8PH\
ML(Q4(QK3KQC9))I5*DFKWTM'9)'ZT^%?^"D7AOP9_P %3?B%^W=I7@/Q;>_"
M#XI^-_B"WCOX2ZC<Z)'XL\1_"7XDZ)-HWB#P??S0:E)X=.J,?L5_&?[2?3S<
MV$*FY4,9%\O^"W[77P=^".@_\%"O!WASP-\1)_"?[67PWU;X>_"2"9O"ZW_@
M2SN_B/H7C731XZ"ZP+=K?3].TF32B?#CZO(TOV8K%Y32RP_G-16/]EX.RCR3
M450P>':5224J> J^VPO-9ZSISO>?Q2BW&3<;);K-,8I.7/%R]OB\0FZ<?=J8
MZG[+$\NFD*D;>XO=C)*44I7;_5&/]J+]CKXG_L0?LT_LJ?'>P_:M\+>)OV>?
M&7Q)\5+XK^"OAKX*^)_#WB:/Q[>7$T-HT'Q!^('A?5+)]/@N")76T99)E 0M
M&=P_-_XB0_#B/Q;K4/PCO?'^H?#T- OAV\^*.E^&-&\=31-9P_:SKVF^#=7U
M[PW;2)?FY2U&FZM=H]BMO),T=P\L2<=16V'PE/#2JNE.KRU:E:JZ4IJ5.-2O
M5=:I.*<>9-SE)I.324FDDK6QQ&+J8E4U5A2YJ=.C252,'&I*G0I1HTXR:ERN
MU.,4VHIMJ[;;=_OC]IO]KGP;\=/A_P#L+^$- \*>+-$O?V4_A*/AYXON];?1
M6M/%&HCXBZKXT.H>%O[/U&[G6P^Q:@EGC6(M/N?M:/\ N3 %F?WOQE_P44^&
M?B7_ (*H_#7]ONS^'WQ!M?AWX(\4?"37[[P)=2^&&\=WL'P[TNPL=1@LY(=8
M;PWY^H2V;26'VC5X8Q&ZBYD@?(7\C**Q>5X-QY.2?+['&T+>TE_#S"JJV)5[
M[RJ13B]X+2-D;?VIB^?VG/'F]M@J]_9Q_B9?2='#.UMH0;4EM-ZRNS]C[?\
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M5\)6<]I?V]O!::O]M^SZM;01?'_@']MBX^&3^)?AYX2\-_%3X\?$/QM^T_\
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MBF3XK>*EDVC>J> =%= V!N"LWC5&90VX E%) !(!)4>/5XDR2D^66/IR>O\
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M</\ #30SX<\!>%-'9-DMMHUE)=)C;MO+N);J]7'4XNII1D\G&3R37<5_U9>
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M_P#R>9^S3_V;'>?^K5\5U]EP'_R4>'_[!\7_ .F6?'\=?\D[B/\ L(P?_J1
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M=%T;3?#FC:1X=T6W6TT;P_I6G:'I%JN-MMI>D6<.GZ?;KC Q#:6\,8P ,+P
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M_P"'=7LXX/%?A+?XF_LK0;O5)X[@/D3Z2+B\NL36Z >S?M/,J_\ !./XQLS
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M/#6B-\.M=M]/CM9X4O)M>M+B:XEM(KAY;.5F^2OBU_P4._;!\5_L[? _X_\
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MAX(^!NH>&?V<?%_B+XJ_&?XU_$K]G*Z^$\/CO1+)/A_\8/A?I6I7/B'3]?\
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M-EI2I9O?HWU5\)?^"IO['J?\%.9?VOM;_9W^.V@ZU\3/'^L>"O&OB;7/VJ/
MVO\ PJT;X:^-TG\!:SJ3?"VU_90T;7KOP]HWA6^FU>P\-CXEPWBM%';RZ_*
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M8;)L!DV:9+B(0IJGFF7YUBH4L/7JZ.W)1DXR]DXKZQ3J)^ZN4_ *BBBND_/
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M2GSX+#366Y<T[Q>#P3E356'3EQ-=U\4K)65=)W:;91117]-'P 4444 %%%%
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M#\R,4ROYJ?V0_B$_BZ]_9 G^ ?Q:_:>^(?[3NJ_&'XB#]JFP\7?$G]HOQ_\
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M)]1\.QW">,?$]RY\U;_0=2U6;3[?1%M3:A)-/U1)VFX ^SP   .   !Z #
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MY.T4E=MM[MMA1114%A1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MI;+=Q,VA:&8]3U=\?))L?-I9$D<FZE0ABIW(J9/#9K].\ 8          X
M'  '  X X%>5_!WP!'\/?!EEILR*-9U +J6NR#!;[?.BG[+N!(:.PBV6B,I"
MR>5YI4,QKU2O^D?Z%G@)'P*\'LNH9MA%0XYXT^K<3<92J1MB,'6K4/\ A)X>
MFVN:,<AP-5TL13O*,<VQ6:U*<G2JPM_"?BMQE_KAQ17GAJG/E&5>TP&5).\*
ML(S7UG&KI_ME:'-"5DWAJ>&C)<T&%%%%?UX?F04444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% "@$D =2<#D#\R< #U).!U-?,
M?@,_\+=^+_B/XL3?Z1X(^&?]K?#+X3DC-IJNNO<6S?%/QS #\EU&-1T_2? V
MBW9!ETRZ\-^,X;601:M<^9Y%\7_CGXZB\3^*_"6DW)T'1[;[?X=D6WM;=M5G
MAFB>TN;^&[NHI_(N;F.5Y=-EAB188Y+>0)),OFM]A?#7P]I'A3X>^"?#N@VD
MMCI.E>%]%@M+:X?S+O\ >6,-S<W&H3;4-QJ=[>3W%]JMVR+)=ZE<W5U(!),U
M?BGA+](OPY\7>)/$GA#@VIG<L]\.<SCDV=3S/*W@<)7A/%X_ 5L;E-?V]6I5
MHRQ>68G!N.+I8'%>R=2;PCI5(S7T_%' >?<.83AW,LU6$67YU0>.PT</B56J
MJK"GAZU"CBH<D8Q<(8B&(O3E6I^UA2M5YH2B=M3VBD50[1NJ-]UF1@K?1B,'
M\#4$PE:*40.D<QC<0O*C21I*5(C:1%9&=%;!95=2R@@,"<U^%W[)_CBY^#OC
MJX\%_M!6W[2VB_\ !0:;P_\ %#7+GPS\2OBYXOU/X _M@S::NJ:J][\&)[O4
M?%_PB\%Z7#;I%JVAZ!X6\!?"SQ?H*2PZ=<Z'KVGV[12?O&&P;Q-+$5(S]^A&
M#5&,5*<U)3<JC3G#DH4E#]]52FJ7M(2J1C3YJD?C,3C%AJN'A*'N5W-.K*3C
M"#BZ<8TU:$U.O5=3]S2;@ZO).--RJ*-.7[JT5^?.D?M_:#XB\)?LN^(O#7PO
M\1>(-9_:(^'WQ ^)>N^"=*UF"[\3_##P_P#";P]9WOQ)LY;6+2&7Q=XB\/\
MBZ]3P%9Z/$?#IUG6H+MXKJU:#[&_R1\5/^"@W[3GCK]D'XR?&WX%_#C]GOPR
MWACPSH.MZ;KN@?M=V7COXI?#^'6O%=AIMI#\0_A!J/[,HL_!_B]K-;S3]5\(
MZ]K%Z-,U-=4LHM1O)=*%W-M2RC'U9QC[.G24JT*#G6KT:<83G7J89<R=3G:5
M:E4B^2,F^1N*DG&^-3-L#3C*7M)U'&C.NH4J%:I*4(4*>(?+:GRI^RJTY>_*
M,5S6E)-2M^WM%?F5\0/V\?'/PDM_@I\.O'7PU^"&C?M#?%#P/J/C^_\ #_CC
M]J_3/AS\&M"\$Z#%86<VO7?QL\1?!N"\U/Q/KVJ7]E#8^"]%^%,ODS7LDDVK
MP:9:27U9=G_P4HG\8>'_ -G-?A'\$;/XG_$3X]_$;XP?!J^\,:5\9_#T7@KX
M>_$SX+)';>*_MGQ/TGPIXDL_%?PV?5UNXK'Q]H'AK^T+K0QIVNVG@RZDU!])
MLI64X]QC-48N$W44:GM\/R-4XUISGSNJHQI\N'K-59-4Y<CY9-N*=/-<"I2@
MZTE4BH.5-T,1[1.HZ,81Y%2;=1RQ%%.G&]2#G[\8V=OU)I=K;=VT[<XW8.W/
M7&>F<<XZU^2.C?\ !2WXG'PU>^/?&O[(LO@SX>_#KX]Q_LW_ !\\1#XYZ=KU
M_P""?B#?>+8?"VDZK\,-#M_AE8GXN^ [@ZYX)O+_ ,0:QJ/PIUC3Y/$UQ9Q>
M%[]=$DO+[USXA?&KP/\ !C]L;XU^*/&^L?%&#0/AQ^Q#>_%GQ5#'XYCU#X7V
M?A?PAXQL+C4+GP]\)9-%M!%\1[N%I(AXKD\8"/4+(?V*VEVWVG[=$/*\7"3A
M4II3<*DJ:IU*-=5)4Y48RIJ5&K.*E:O3DDVY-3A*,7"<9"6:82<8SIU+QYZ<
M9NI"M0Y(5(U91J6K4HMQ_<U$W914H3C*2E"27Z(T5\L? 3XR_'SXFW=A>?%'
M]FFT^$7@OQ3X4M_%O@GQ/H_QAMOB5>^1=O'+:Z%\1O#LOP]\!2>!O$]SITL=
M['8Z'J?Q!TM7)M)=:C93*/*/%O[9OC*#]IW7/V;? 'PP^%%YJ/A:[\%V&J:A
M\:_VD4^!/BOQ=+XQT>V\0I?_  3^'S_!_P"(<OQ=T'3=,NC876J:=XFT21?%
MFG:UX9N[&P?3EO[G&.!Q,JM2E&-*<Z--UJCCB<-*G"FI1@Y.JJSI74IQBXJ;
MFF[<M[FSQV'C3IU92JQA6J*E34L-B8SG4E%RC%4G256SC%R4G!1:3=S[^JO%
M=VEQ+<P6]Y:7$]FZQ7D%O=03SV<KJ62.\ABD>6UD=061+A(W=064$ D?$]]^
MU5\4?$WQ:^)7@?X#_L[P_%SP/\#O&7AKX?\ Q@\=:E\6K3X?Z_:^+M;T_1_$
M&KZ-\,/ LW@+Q39?$.X\'^%/$6@Z[K[ZYXZ^',0;41IUB]U/"97^'+3]JKP_
M^RY^T-^W)?W&B^']7\:?%W]ISX._#_P#HOC3Q_HOPD\%MKTOPU\9>(=2O?'_
M ,3]9T[7=.\%^']#\.Z/K.H7FI0Z'XEO[F[M(=*TO2+ZZOHF7>CE>)K*HE%*
MJJ%.O2I*I1E.<:E2A%>T2JWPZ5*O[;FKJ'N1;:4;R6%;,\/1E3;;=*5:K1J5
M7"K&,)4Z=:3]FW3MB&ZE%T;47+WY))MVC+]PZ*_*";_@J+IEA\*?'/BE_A3X
M<\<?%/X:_&[X2_!KQ5\-/@=\>/"?Q;\*Z@_QIO+(>"O$O@7XMP^&?#.F^)(Y
M-*U&SO-5T;6/"GA.[TO4_M6B7-RLML+R;Z \:?M._&;P7<_!_P"%EQ^S_P"#
M=7_:H^,G_"<ZKH_PCTGX]7;_  R\.^"/A[/IR^(_&?B?XX77P8MM2M[2WAU_
MPXB:9I?PAU74)=3U2:PC5[:P;4[B)97CH-1G1C!RE.*4L1AH_P .C&O.>M;^
M#"C.%25?^ HR3=357N.9X*:<H5922C"3<:&(=O:5G0IPTI?QI5HRIJA_&YHM
M>ST9]OTH5B"P4E1@%@#@$] 3T&>V>M?E[K7_  4>O?#WPSU?4?$'P/MO"GQM
M\(_M!6?[-GQ#\ ^,_BS:Z#\&OAYXYU'P\WC/2O$_BO\ :,M_ .K6^D?"S7?"
MC60T+QMJ?POL'N?&.J:9X0U/1=&-[!K+WM/^,&O>+?VEOV.=;\<:5>:%XC\=
M_#GX_:AI/A[X#_M,1?%K]GS6-"T3PW?:C;:SK/\ Q:KP+!\4==O(;9T\-W]N
M?#MMX4OO+D$NM ,H?]F8N,93JP5."C7DI>TH3<G0HRKOEC&MS3IRIQO&M!3I
MN+4H.=XJ2_M/"R<8TYN<I3H1<73K0Y/;UX4%SRE2M&I&<[2I3<:BDG&:@TVO
MTSHKX(_9+_;&\8_M4ZU<WMC\-?A'X3^'J:?JFHF&']I,>*/VAO"J0:C<Z;I.
MF_%G]G(_!WP[>?##7[FXM)K;7M)U'XAZJ?#^H136EO<Z[&B74OWO7-B,/6PM
M65&O%0JQMS152G4Y;]&Z<YQ4N\6U)=4DU?JP^(HXJFJU"3G3D[1DX5(7M;5*
MI&$FM?B2<7K9NS"BBBL#8**** "BBB@ HHHH **** "BBB@!\<;2NL:#+,0
M/KW^@KL8HEAC2)/NHH'U/=C[L<D^YK(TFVP#<N.3E8\^G1F_'H.V,GZ;= !1
M110 4444 %%%% !7\'?_  =;_P#)YG[-/_9L=Y_ZM7Q77]XE?P=_\'6__)YG
M[-/_ &;'>?\ JU?%=?9<!_\ )1X?_L'Q?_IEGQ_'7_).XC_L(P?_ *D0/Y<Z
M***_=C\/"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** .I\.?\@_QI_V*3?^I-X9KEJZGPY_R#_&G_8I-_ZDWAFN6J8[
MS_Q+_P!(B4_AC_V]^844451(4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% 'Z6_L?^,QKGP_U3P?=W(?4?!>J":Q2YO(VN9O#
MFNJ[P6^G6(42KIN@ZE97;7MR2R+=^)+.)F#31K7UG7X\_!+XCGX7_$+2?$-Q
M)(NA7:R:)XIB0S[9?#^HO%]HFECME:XN5TB\AL=>CM(E9[JXTJ&W"MYF#^PH
M:-U5XI$FAD1)89HR&2:&5%DAE4CC$D;JV/X22I^92*_*.+<O>$S*6)C&U#'+
MVL6EI&M%*-:'JW:KY^TLMG;\QXLR]X;'_6X1_<XU*3:VC7A%1J1\N>*C45W[
MTI5++W6+1117RQ\J%%%% 'ZY_LS_  ^TKX'? @?'7X>^*_@;XU_:L^(UIJ.E
M?#_3?$?Q\^!/@^T_9\\*WD7V:?Q9KVE?$#X@^&K^X^(6KQF1M&TZQMYWT6W*
M'5)M.O 8'\N_9,\3:=\#?CM\4OA_\?\ QAX3TVW_ &@/@WXY^&NJ?$/2_&_A
M/XG^'-%\4_$*:UN]"\1^(?%GPYUCQ=HGV2;7+)TU^X2[FFTC[;'J>II8V44M
MPGYM&-"<E$)/4E02?QQ3@J@%0H .<@  '/7(Z<]ZR=*_M%*5^?JE:2M\*3;:
MM%W:5MVWNVW]1#B2.'ED\\'@7AWD]O9T)8J-3 XF=6"ACZU>A'"T<1+$9@O=
MK5GC)2ITHTZ%#V=*E1A2_3WX$V-O^Q'X>_:"^)/CKQ_\+=6\6>)OA?XE^"_P
M@\(_#GXH_#_XK:MXJUOQ?_H\GB_4!\./$?B>T\*^%M!TFUGU&[E\776A7]U<
MR6>GZ=8WE[,8$ZO]IGP-X6_:[^/'A']HSX<?%KX-:%\/OB3H?@>X^(1\=_%7
MP%X%\4?"G7/"ME9:3XLL=:\ ^)]=TGQUX@$$VGW-WIUSX,\-^)8M<MWADTJ2
M^,R!OR6"JOW55?H /Y"@HA.2BD^I4$_GC-'LGS>TYOWC5G+ETY6HJW+?HX\R
MNW9M[JR37$=/^SH9+++N;)J56ABJ6%>,DL2L;1K8BH\14QD:"C.-6GBZV%JT
MH86DGAXT.2=/$4I8BI^Y7P__ &P?!VM_M8_MA?'3P?XST?PSI5E^SW'X<^#.
MH^-KC2=$F\27/@./PAHVA_8M(\0M;R7E]XC.B7&KPZ$]N^L1VMZ1):6MW"Z6
M_P ;?M=O\+?CGX8\+?M@?#KQ'X;T3QC\09X="^/OP9U'Q5;R>,O#_P 3K.R4
M3>,_#6CZK=)K>L>!_$]G!%))<V4-W::#J"Q:>+B1))%M/S_(!QD X.1D X/J
M,]#1@9W8&[&,X&<>F>N*4:*C)2C)II1CWO&,5'E?>]D[]):K1M.L;Q;C,RP&
M(R_'8>A7I8C$8W'MISA[',L7C)8I8W#+WO8NG&I6PDJ7-.%;"U>6?[RG1J4U
MHHHK8^4"O _VE?&W_"&?"?6XK6ZFM]9\72P^$M,>TNK6.YA@U!9+C7KB>UF;
MS[C2KGP]::GH=U+;QOY%UK%DKM'YJM7OR(\KI%&N^21UCC7IN=V"J,G@98@$
MG@#DD &ORM_:>^)<7C[X@'2=*N6G\,^!H[O1-,<>8(KS59IHV\1:K%',!+"M
MU<VEG9&!P%5M+::+Y+@%OHN&,O>.S2E*4;T,(XXFJW\/-"5Z,'T?/42;B]'"
M,[II-/Z/AC 2QF94ZTHWH8-JO-M:.HG^XAVNYKG_ ,--]SYO P,#H.!1117Z
M\?JH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !117H'PK^%_C3XS_$+PK\,/A[I$VM^+_&.JP:3I%C$I\M7E.ZXOKV7&RTT
MS3;99K_4[V4K#9V-O<7,SK'$Q'%F699?DV78_-\VQN%RS*LKP>)S',LQQU>G
MAL%@,!@J,\3B\9B\15E&E0PV&P].I6KUJDHPITH2G-J,6S?#8;$8W$X?!X2A
M5Q.*Q5:EAL-AZ$)5:V(Q%><:5&C1IP3G4JU:DHPIPBG*4I**3;1]U_\ !,7]
MB^?]K/XWPZEXIL)6^#7PON;'7/'ERR2+#KE^KK<:1X-MYAM0SZFZQRZD%D\^
MSTQUNEBE5PM?VD6]O;VD$%I:6\%I:6L,5M:VMM$D%M:VT$:Q06UO!&%CA@@B
M1(H88U6.*-%1%"J /G']DS]FKPC^RC\$?"?PD\++!=76G6JWWBWQ$L BN?%/
MBR\42ZQK-RQ59/+DN6DCL;=_EL[-8[>(*B@5])U_R2?3E^E)COI0>,>.S?+L
M1B:?AMP>\7D'ASEE7VE.,\M5:/U_B7$X:?*Z>9\3XBA2QE6,X*KA<NHY7EM3
MFG@95*G^N'@9X64/"[@ZAA,33ISXESA4LPXCQ4>636)<'[#+*517YL-EE.<J
M,&GRU<1/%8F-E748E?5/[-7PT_MS5SXYU>#=I.ASE-(CE7,=[J\?_+8 \-%I
MQ^<DYQ<B)2I4DUX)X&\&ZGX\\2:?X=TM&#W+B2\N@I:.PT^)E-W>RG[JB)#M
MC#$"2X>&$9:10?U9\/Z%IWAG1=.T'2H5@L-,M8K:%%&"VQ0'E<]6DE;+NS$L
M2>3P*_3OV>GT;Y>)?'7_ !%?BO+W4X&\/L=1J931Q-*^&XAXTH^SQ&"HJ,XN
M%?!</1E2S/'+X)XV>5X:7M:4\73CQ^-O':R')_\ 5S+JZCF^=T9+$RIRM4P.
M52;A5G=:PJXUJ>'I.ZDJ2Q%1<LE2D]FBBBO]\C^- HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "JUY>6NG6=UJ%]<P6=E8V
M\UW>7=S*D-O;6UO&TLT\\TC+'%%&BEG=V55 R2*LU\S_ !1ED^+_ (RA^ >D
MO(?"=A%8:_\ '?5+=F$:^')]MSI'PS2=#MCU+QR!&=8@9A-#X2EO+N ><JBM
MJ%'VU2TI<E."=2M4M?V=*+7/*UU>6JC"-USU)0@G>2,,16]C3O&//4G)4Z-.
M]O:597Y8MZVBK.=25GR4XSFTU%E/X3>&K3XL7^M?'7QEHL<NG>,KRSG^%.@:
MC:M;OH_P_P!*B6#0/$NH6NV&9M<\<A9/%C1:@!<:7H^JZ5H5[96]_IEWO^I
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MVU9S_<3=6BU4=3VD94ZDG*,XR4T[>]HK? FG?L=?$7PO\-_&V@^$_CGX&O\
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MS[4 7$54544850 H'8#H*=110 4444 %%%% !1110 5_!W_P=;_\GF?LT_\
M9L=Y_P"K5\5U_>)7\'?_  =;_P#)YG[-/_9L=Y_ZM7Q77V7 ?_)1X?\ [!\7
M_P"F6?'\=?\ ).XC_L(P?_J1 _ESHHHK]V/P\**** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ZGPY_R#_&G_ &*3?^I-
MX9KEJZGPY_R#_&G_ &*3?^I-X9KEJF.\_P#$O_2(E/X8_P#;WYA1115$A111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?HG^
MR?\ &%=:TVW^$_B"8_VQH]M*_@J]EN'8ZCH]NK2S>&3%,Q5;C2XA)/HZ6AB6
M2U2>T:WN;N>&5/SLJ>UNKJQNK:]LKFXLKVRN(;NSO+2>6UN[2ZMY%EM[JUN8
M'CGM[B"5%EAGA=)8I%5XW5E!'G9IEM'-,)4PM;W6_>I54KRHU8I\LTKJZU<9
M1NN:+:NG9KBS# 4<RPM3"U[J,[.$TKRI5(WY*D;]8MM-:<T7*+=I,_=FBOG#
MX!_'ZR^*=G!X:\2SV]C\2[2#!&R*UM?'$,"#?J6EQ1)';VWB':-^J:'"D<-[
M+NO="B1)SHUA]'@@\@Y'J*_',=@<3EV(GAL5!PJ0>C5W"I!_#4IRLN:$NCT:
M=XR49*45^0X_ 8C+L1+#8F-I*[A-7Y*L+Z5*;ZQ?5;Q?NR2::"BBBN,X@HHH
MH **** "BBB@ HHKQKXR_&G0?@_I:),(M5\::G:?:= \-YW+##*I%OK7B JP
M>STQB1+8VN#>:JH69(X=/DAN[CIPF$Q&-KPPV&IRJU:CLHK9+K.<MHPBM92E
M9)'5@\'B,=7AA\-3=2I-]/AA'[4YRVC"/5OR2O)I/C_VEOC OPZ\+MX6T::/
M_A-?&&GSPH5GS/X>\-72R6MWJDUM&01=:VAN--TM+LM";--4N);-S)IURGY9
MJH50JC"J H Z  8 _ 5KZ]KNL>*-:U/Q#K]_/JFM:Q=/>ZC?W+!I;B=PJ#@
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M5OO%/B_5Y#<ZSK%R$58X8Y+EW2RLK=(K.QME6"S@@B^2O#OV?9KOXC>*=?\
MB;XQN+G6?$GAS2M-\)>&9)XX8M)T"PU(WEWK]QHUI#$B1ZSKCVFG0ZSJ$KS7
M"6=G!96!L;6]U.&_^NZW\-/$GAOQ7\/>&>/N$/K_ /8'%6$J9AA_[3POU+,(
M3PV,Q675\'B<.JE:$)8'&83%4)2HUJV'Q%6,J]"MB,,\-6ES9[P_F'#N?YCE
M6;>P^N9946&C'#U?;4%"K2I5UB(5.6+E+$TZE*:4HQG2I<M.<*=5UX$B12R9
M\N.23&,[$9\9SC.T'&<'&>N#3=C[2VUMH;:6VG:&QG:3C ;'.,YQVK\@/V^]
M/UK0/CGX)^*?QO\ "/[0WCK]BCPY\)KNPU>]_9P\=>,?#6L?!+XNKXFU*]OO
MBI\1/"/PW\6>#?'OC[PE<^%VT"UM#I+^.[/P]+H.H2WOP^N8KR>]NNSOOVA?
M@YX&^/\ \//BM'X]^)GCKX;:9_P3W\>_%^'QW:_$ :EX"\2_#OP-XA\"7S^(
M[_X46_A/28==^*&NVNH1O'XK?6O#LNG$7^@7GANU>]GFT[]&CELYT:-6E.55
MUJ56=J=.,H1J4US?5_:*K?V_*KSI3A":3A*G&M"2F?/2S&$*U:G4C&DJ-6E"
M]2I*,W"HTO;^S=*WL;NT*D)U(2<91J2HSC**_4UHY%&6C=0" 2R,!DC(&2 ,
MD D#N!D<4ROQ0_9X\0^-OA;\<_V:O%OQ?\$_&3PIX#_:-T+XC^!O@=JVK?M9
MR_'&TEU_QX(?C%I%C\</A7<?!_X>V7A#Q%=>$O!5^G@77?"/CGXF67A>&\?P
MM?D0ZO<ZQIWJ?Q$_X*&?&72M2\7:S\*OV9?A_P"-OA+X2_:=TW]DV7QCX]_:
M/U+X9>-+WXER^*4\%ZQJ</PZTKX$_$B&+P=IWB'SDL+N3Q@?%&MZ:L&H6_A*
MW-Q]FCJ>4XGVRI4.2MS04U-UL-2IN]:=%0526(=*4^>G)<BJ.::DG"T6R89M
MA_9.I652DU-P]FJ.)J5$E2IUG-TXX=5(P4*BESN')9IJ3;2/U<HK\N=._P""
MB7B^+X?_ !_^.?C3]G_2/!OP!_9X\<?%CX7^)/&,_P 9(M0\:>+/'?PY^(L_
MP\TI_!/@G_A7EEH4G@;Q!?-9_P!L>+/&'Q \'7_A2_BURV'AC7=(TNR\0ZS2
M^&W_  4PL/$>K>-_"OC30OV>F\8Z5\ /B#^T!X%TK]GW]K/P[^T9IFN:1\,-
M,L]0\7>#OB#JFE_#OP5??#3Q?;MK?AZ/3TMM#\:Z#JT#^)+K3];G_P"$=2'5
MH_LC,+5)*@I*E)QFX5L//EDHQE*-H59-RA&<9U(J[IQDI5%&.I:S; <U.+K2
MBZJ4J?/1KPYHMRC&5Y4TE&<HRC3DVHU)1<:;D]#]4ZIVNI:;?R7L-AJ6G7\V
MFW)LM2AL;ZTO)=.O0BR&SU"*VFE>QO!&RNUK=+%.$96,84@U^>GPB_;:^*/B
M_P"(_P  /#'Q8_9OL?A!X._:F\/>*]6^"OB"U^,$/C[QDNJ^$O"NH^-[S0?B
M?X(M/ &@:+X,EOO#&C:MJ&FWOAOX@?$"WDF@MK*[^Q273O;<;\0/%EC_ ,$[
MK.:]T?1O!GCKXB?M=_'SQ[X[\=?%+XP?$&?]G;X#:'K]RB7]E8>-?B-;>$_B
MW#X#^R^')-,\(?#O3KOPY>#Q=/HTJ:EKT.IB>YGE9;753ZO)+ZS4BI8:E3J4
M*L*RC.K&K)UX571@J7L*RE>;E[2*ARKWI1;S&@Z?MXM_5J<N7$U:D*U.=&4H
M4I48JA*DJTY5?;TG&T%#V<G/G^%2_4FJ=QJ.G6=Q8VEWJ%A:7>IS26^F6EU>
MVUM=:E<0V\UW-;Z=;S2I-?3PVEO<74L-JDTD5M!-<.JPQ2.OD&E_%JXT;X"7
M'QO^+%IX*\/V^B> -;^(WB:/X7>/9?BSX)7P[I&G7VN07G@_Q]=>%? !\76>
MJ:%;6MY8WQ\-:+;S75X+6$S6\:7\_P"5>N_&CXW_ !O_ &G?^"5OC'XG?L]:
M!\)/!?C7XP?%+QQ\,M;T7XM?\+*U2?1+_P#9<^.D>F6/Q#T2\^'G@!_ _BO7
M-"U&R\1:5IGAK4/B)HCZ:NKVVI>*-,O[2RM=66&R^KB'6;<*=.A#$N<W4HN]
M3#X:MB/9THNI%UG+V-I.C[3DA)5'=.*E6)Q]*@J"2E.IB)X90A[.JK4\1B:.
M']I4DJ<E1Y?;)Q5;V;G)."L^9Q_<%D=#M=61N#M92IP>0<$ \CD>M-K\8?AC
M^V/;_ ;]E;X;:OX8\*ZQXBD\?_M#_%OX;V/BG]J3]HJ[TOX?^$+K1O$6HW%S
MJ7Q5_:*B^$^NMX+T35_LSZ5\/-)N?AW>V;ZO/8>%YM<@$RZDOJ/Q%_X*+:SX
M!U3X;?#R7PY^R?!\7?&GPN?XS:M+XU_;:TKX?_L\6W@/4=;U31?!K> /COK'
MP8N-5^*'B'Q8=)N+R+3M)^%.E:3I5JT5Q?>(!:30W4NLLGQWM'"G24U[2M3C
M)U*%-R]@Y*I)QE6?)&+BTY2ER<SC%2<I13QCF^"]G&=2JX/V=&I.*IUYJ/MU
M%TXJ2I+GE)23Y8KGLI-Q2C*WZFT5^=$?[?MCXK_9T^&OQZ^&?A[X0O:>.M>\
M1>$M;U?XU?M*>"O@S\#_  3XL\%ZMJ/A[Q+X?N?C/#H7CVZ\476J:QI.I3_#
MN3PA\/-9B\8>&;&Z\0:FWA/;#I\_!C_@II:W_P"SA\/_ (U:%\.O DFO^,?C
M5J_P&UN?7_CA#I/[-/@/QAX?BGN]2U_Q-^TYI'P]\306OPXU6WBM]-\&^-I?
MAE;VWB'Q=JFC^'+ZRT!;\:G%FLJQ\M%A]57>&:]K13C7BZB<)IU$X6]E/WYI
M0=E:7O1OH\UP"WKZ.A'$I^RK-2HR]FXS@U3:G?VL/=@W-7=XKEE;]4Z*_+/X
M@_\ !1;5_ $_PG\$7WA[]DZW^+7Q-\ ZM\63=>)OVV--\'?LUVOPYM]5N-(T
M+4/"O[0>K_!;^TOB!XB\2W,*&RT'0OA-'8VD4HN[WQ!%8*;L_8?[+'[1GA;]
MJ;X-Z)\6?"\>FVOGZMXG\)>)M+T;Q+I7C31=(\:^!?$6I>$O%VGZ#XQT3;I?
MB[PVFNZ/>S>&/%5I;V*>(_#LVEZT^EZ5+?/IMK%;+\9AZ*Q%6CRT93Y%-5*4
MUS-S2TISDU&3ISY9M<DN7W9.ZOI1S#"8BLZ%*KS5E#VCING4@U&U-O6<(Q<H
MJK3YH)N47*TDFG;Z)HHHKB.P**** "BBB@ HHHH **** "BBB@ HHJY96ANI
M,'(C3!D8?^@CW/XX')H NZ7:;S]ID'RJ<1 ]&;D%O<+T';=GTK?I%544*H 5
M0  .@ X I: "BBB@ HHHH **** "BBB@ K^#O_@ZW_Y/,_9I_P"S8[S_ -6K
MXKK^\2OX._\ @ZW_ .3S/V:?^S8[S_U:OBNOLN _^2CP_P#V#XO_ -,L^/XZ
M_P"2=Q'_ &$8/_U(@?RYT445^['X>%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 =3X<_Y!_C3_ +%)O_4F\,URU:VF
M:DNGVVN0-$TIU?1SI:,K!1 YU32]1\YP>67;IS1;5YW2JW136322:<O.5UZ<
ML5^:93:M%=5>_E=A1113)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** );>XGM+B"[M)YK6ZM9DN+:ZMY7AN+>>)MT<
MT,T962.1&&5=&!'(Z$@_>'PA_:UB\JT\.?%MY_,1WAM?'=I:M<L863?%'XHT
MZU5KJ8PRI)%'JNE6]U<3+=6MO<Z?;VNGO>2?!5%<&89;@\SH^QQ=)32OR5(^
M[5I-_:ISLW%[733C*RYHM''C<!A<PHNABJ2J1U<9;5*<OYJ<U[T9=[:26DE*
M-T_W7L;RRU33[35M*OK+5=)OPQL=4TRZ@O\ 3;S8D3RK;7MJ\MM-) )HTN8X
MY&DMI6,,ZQRJR"S7XK>"?B/XV^'=\;[P?X@OM),KV[WMBK^?I.J):S+/!;:O
MI4V^RU*S69$D:UNHGA=E!920*^M_"7[:;Q6BV_CWP6^H7<%D(UU7PG=VVGRZ
MEJ!;+7FI:=J&[3K&#&0+71HH$48"J,5^?8_@['T'*6"G#&4KZ1;C2KI><9M4
MY6V;C--[\BU2^#QW!^,I2E+ U(8JGNJ=1JE77E=VI3MJ^;FIM[*'?[RHKQ#0
M_P!H_P""_B"ZM[.V\:1:7++;1S7$_B>PNO#>G6L[[@UH=0U'$$[Q;?FEB_=M
MN4KP:ZNZ^,'PBM'5&^*?@"X++NW6/B6RO(UYQM=XCA6[[3SCFOGJF5YE2ERU
M,!C(R[/#U7IW346FNS3L^A\_5RK,Z#:JX#%QL[75"I.+?E.$91DO[T9.+Z,]
M$HKSBW^,?PBN95A7XH>!("P8^9=^(K.V@&U2V&FD.U2<84'EF( Y-8NN_M!?
M!?PY=0V]]X_TO4HYMX^U>$H9_%T$3K%YJK-_9.3&KD^7YA.U904/(J89;F-2
M2A# 8R4GT6&K7_\ 2":65YE6=J> Q<M4K_5ZL8INWQ2E%1BM5=R:2ZM69[#2
M.4CAN;J:6&WM+* W5]>W4T5K96%HK(DEY?WD[1VUE9Q,Z>==W4L5O"&#2R*O
M-?$/B?\ ;3TJ*%X/!G@B[O+P/?V[ZAXGOQ!ISP^8R:?J>FV>EM%?1S^6%G>R
MU4R19?RI4)4@?)/C[XP?$3XF/$/%OB&>ZL+=UEMM$L(HM)T"VN%B: WD.C6(
MBL4OIH&\JYNQ%YURH7SF8J,?08'@_,L1)2Q;A@J77F<:M9J_V:<).*OWG4BU
MH^66Q]!@>$,=6<98R<,)2T;BI*M7:T;24&Z4=-.9U)-/[#6_VA\6_P!K#0]"
MAO- ^&+1>(=>=%@E\5RQ,?#VDLQ/VC^RHI#'-K>H0JI@CNPD6D1O*E_8WM_Y
M AD_/;6-9U;Q#JE]K>NZC=ZMJ^IW$EW?ZC?2F:YNKB5BSN[G"JH)Q'%&J0PH
M%CACCC54&;17Z#EN4X+*J7L\+3M*27M*T[2K57_?FDO=TNH148)W:BFVW]W@
M,MP>6TO986DHWM[2I+WJM5K9U)V3?6T4HPC=\L8W"BBBO2.\**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K]4?^":/_  3X
MUO\ :R\<6_Q \>V-WI?P \%ZI&^L7TB/!)X^UFSD63_A$]"D90);.)PHU_4D
MW0VRG[#$9;K[5%;^;?\ !/[]@[QA^V9\0UDO$O?#_P &/"5Y;R>/O&*Q-&US
M@B5?"_A^1U\NXUS48QL+IO33H':[G 1,'^T+P%X#\(?##P=X>\ > ]"LO#?A
M'PKIEMI&AZ-81B."TLK6,(FYL;Y[F8@S7=W,7N+NYDEN)W>61F/^3W[1+Z>6
M'\%<JS#P9\)\TI5_%S.\ Z7$.>X.K&K'PWRC'44TX5(-QCQAF.%J*>74'>>2
MX2K#-L1&&(JY9&K_ %E]'7P&J<;8NAQGQ9A9T^$<!74\OP-:+B^),90GM).S
M>3X:I'EQ,]L96B\)3;IQQ+COZ5I6F:%I>G:)HFGVFDZ-H]C:Z9I6EV$*6]EI
MVG64*6]I9VD$8"106\$:1QJ!G"Y8LQ+&_17K'PE^%NH_$O71!B6U\/Z>\<FM
MZF 0$B)R+*U<C#WUT 4C49\I-\[X2,U_SJ\&\'\5>)?%V4\(\*Y?B\^XHXES
M!8;!X:,I5*M?$5I2JXC&8S$U&U1PV'IJKC,QQ^)FJ.&PU.OBL14C3A.2_P!&
M\SS/+>'\KQ&99A6I8++LOH<]2;2C"%."4*=*E3BKRG-\M*A1IIRG.4*<(MM(
MZCX&_"&?Q[JJ:WK,#Q>$M*N%:=F!4ZO=1'<+"V)QNA5@!>3#*QC,:[I 4K]'
M8XXX8XX88TBBB18XHHU"1QQHH5(T10%5$4!54 !5  &!5#1](T[0=,L]'TFU
MBLM.L($M[6VA4*D<<:A1T^\S8R[GYF8DDY-:5?\ 2E]&+Z.7#GT<N :>08&5
M',^+,Y^KX_C7B94N2>:YG3I.-/"8/GBJM'),J]I6HY9AIVG+VE?&UTL3BZJC
M_!OB!QSCN.<YEC:REA\MPO/1RK <UUAL/*2O5JV;C+%XGEC/$5%HN6%*#]G2
M@%%%%?TB?"!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 ' !)(  )))   &223@   DDD  $DXKYE.[]H+QA$Z GX(?#W6;N
M,S 87XK>/;!;S2KZ&"0@,_@/P8\UW8SS0D#7_%HNX$DB@\,!K[1\>:QJOQ4\
M27OP:\$:A=Z=H6G^4OQF\<Z7,T,NC:?<QI/'\/?#^H1$&+Q=K]HZ/JDUJXNM
M"T>YAG9HFNF%>[Z/H^E>'M(TS0-"T^UTG1-%T^TTK2=+L8E@L]/TVP@CM;.S
MM84 6."WMXHXHU X51GG)IX[+\OQ>78G 9K@<'F>'S/"U,-BLMS'"T,;@:N
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M'!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^@O[ _[
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M_?"_X4 <717:>3%_SRC_ .^%_P */)B_YY1_]\+_ (4 <717:>3%_P \H_\
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MSRC_ .^%_P */)B_YY1_]\+_ (4 <717:>3%_P \H_\ OA?\*/)B_P">4?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_71__$9KW_Y_E?V@44?Z[\3_ /0QC_X18#_YE\OS[L/]2N&O^A=+_P +<?\
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M )E\OS[L/]2N&O\ H72_\+<?_P#-/E^?=G\7_P#Q"3Z__P!'ZZ/_ .(S7O\
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MU_\ Z/UT?_Q&:]_^?Y7]H%%'^N_$_P#T,8_^$6 _^9?+\^[#_4KAK_H72_\
M"W'_ /S3Y?GW9_%__P 0D^O_ /1^NC_^(S7O_P _RC_B$GU__H_71_\ Q&:]
M_P#G^5_:!11_KOQ/_P!#&/\ X18#_P"9?+\^[#_4KAK_ *%TO_"W'_\ S3Y?
MGW9_%_\ \0D^O_\ 1^NC_P#B,U[_ //\H_XA)]?_ .C]='_\1FO?_G^5_:!1
M1_KOQ/\ ]#&/_A%@/_F7R_/NP_U*X:_Z%TO_  MQ_P#\T^7Y]V?Q?_\ $)/K
M_P#T?KH__B,U[_\ /\H_XA)]?_Z/UT?_ ,1FO?\ Y_E?V@44?Z[\3_\ 0QC_
M .$6 _\ F7R_/NP_U*X:_P"A=+_PMQ__ ,T^7Y]V?Q?_ /$)/K__ $?KH_\
MXC->_P#S_*/^(2?7_P#H_71__$9KW_Y_E?V@44?Z[\3_ /0QC_X18#_YE\OS
M[L/]2N&O^A=+_P +<?\ _-/E^?=G\7__ !"3Z_\ ]'ZZ/_XC->__ #_*/^(2
M?7_^C]='_P#$9KW_ .?Y7]H%%'^N_$__ $,8_P#A%@/_ )E\OS[L/]2N&O\
MH72_\+<?_P#-/E^?=G\7_P#Q"3Z__P!'ZZ/_ .(S7O\ \_RC_B$GU_\ Z/UT
M?_Q&:]_^?Y7]H%%'^N_$_P#T,8_^$6 _^9?+\^[#_4KAK_H72_\ "W'_ /S3
MY?GW9_%__P 0D^O_ /1^NC_^(S7O_P _RC_B$GU__H_71_\ Q&:]_P#G^5_:
M!11_KOQ/_P!#&/\ X18#_P"9?+\^[#_4KAK_ *%TO_"W'_\ S3Y?GW9_%_\
M\0D^O_\ 1^NC_P#B,U[_ //\H_XA)]?_ .C]='_\1FO?_G^5_:!11_KOQ/\
M]#&/_A%@/_F7R_/NP_U*X:_Z%TO_  MQ_P#\T^7Y]V?Q?_\ $)/K_P#T?KH_
M_B,U[_\ /\H_XA)]?_Z/UT?_ ,1FO?\ Y_E?V@44?Z[\3_\ 0QC_ .$6 _\
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M#WPQ\-W=F;41:3I]O/\ 8K4 _598(4 5(8D559%58T4*C$%D   "L0"RC@D
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M#U?Q=^S]X \;>+AXPUB?QC#<SC3AK&@Z/XW\3:+X-\3'275[%_%7A#3M1M]
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M^WM5&N2_$.[BTCQMX:\4:AX:U2Q707T6XL6M-$GL;2?^V72??:Q7-G!!&[4
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MA([;WP[^!GQ(UCQ3XC?4M!\$^ / VD?&GXJ>*?#^MZ?:Z[9?%'4DU;4-0M[
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MQ3XOO-)37=>\#QC2==M9ULH+?6O#_AGQ#=V]U:7<D<]WIT&G0Z?>(K*UV"U
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M3ZCJNF:;:6+ZK:6<IDN[E=2,-I^]^>?B=\#/C3\5]6^&/C#QEX-_9S\1^(?
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LH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img22994243_2.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img22994243_2.gif
M1TE&.#EAA .; ?<  /___P  ,P  9@  F0  S   _P S   S,P S9@ SF0 S
MS  S_P!F  !F,P!F9@!FF0!FS !F_P"9  "9,P"99@"9F0"9S "9_P#,  #,
M,P#,9@#,F0#,S #,_P#_  #_,P#_9@#_F0#_S #__S,  #, ,S, 9C, F3,
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MS)F9_YG, )G,,YG,9IG,F9G,S)G,_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P
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MH/Y8)F@4*?^:J3>,0L08E:SF6N.*DGT6:Z:+1N28.[H62Z,7H5FD3SH(>./
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M1H[?1%!I^(M,$*9>1D;44BO!1FZD#^XP ^6 *?IP#]\V ZI56]'52=B%$NV
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M3&855F?/:N:-D<3+VC#AJ;7IY>&'Q"ODH?( RTJUCASH@!LY)9JT2?&19L8
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MW_SN3S_\L\]][_O>_O2_?_?S7W_\]U___N>__Q/  "3 ^\N^QT/ =@FW!63
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M:%,Y101!@-F")5JLU5I_15AY6-A69=-&/=*FO="YHM-37:RJ]8)VF-F)=5N
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M/R0TFMZPISDC^D=^6E.BE22' Q(ZT'8HU*+SA,8OAQG27@:3I"(MZ4A]Z0\
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MD#8.G^OG.)](D^PZ"5&<#43@TJJ.IO$2!/]01MEF=+"Y]Q!Y*S7Q:.S1QLN
M)$\QN.3[L48@CWQ/'QT'$ZY)#NE!Y+XH[SNQO]9HC#''MV!T,#O7R$OP/21E
M<W)+MYK,ST<RC>S1.]!R0DO--NEDD\Q\^!FQH>#6;!)+\JX\4E :!>M-Q*Q<
MA*D>+%/T,$+N'AMK41D/=-12\\J3M%(.Y1'DG2[>\2+4=P211TH0"<5,.WK$
M$F]50=SI0ITNUI&55EMKG377+MKA=9[[9$R$5;%"DXR>>6*M====>ZW5'2],
MM=+(L2;3+Y'KYA$$'E&Y#16>8Q&)<M)46Q,L)KRLXN?$RSCUM%M1M16DRF)1
MS%//@O*[UKQYO&C_%M=_:^VU'6C##4V[2PNKYT%[?4K4I?'(';1._M!+[*OQ
MZ'TLRD[O,W7>B>G][DRN"N.Q,'AN53;EE55N61Y39\S'W*X6Q='?EEG.&6>5
MW8%,YGN^$NR[?.;1V>B=5WX'TR&]*M3!HI&.^E9=NW#GU\D@!MHEJZ")#V6J
MI<:9:G@X0Q*RZ8Z#QD=$DCW:;95G?9:>B",NM&&'5:IYT\2ND\>+6#\%G)Y.
MQ=T[M<*VNJ["POB%>^K'EZ55'F#K!D^KDB.C!V#(5P:;<ZJ55O7+RR?,AQXO
MJ/8\<L?%SGE6>EIC.BKS8DW=]=M;WS7T"5O;ZF#%Z.G5]MP[Q[T+F,O5_WHE
MJO31-S'-(U=]\]4?[UEA^-#.<'&BI^]>^N]3]F)2PQ%#))^=\$Z)43;9YM5]
M@=^/7V!YR!;4-*A*QRSX6V_F/^?^558_-GUG=LT93-$\!T#WX4R! *1'Q4;&
ME$+5PW\,_-\%+8@S>J@I*O?(#SU4UD ,KDR$SJI6(CJ8H'K((X0C;&$&_X>=
M")YD*B5*C#Q(Z,(*YA!I<[.1/O:R/1S"\(4\-&(+7V>G(YU/(ND[":4<!+T%
M3M%?5=SAP("U'3@UQ6 K)![KBD>\=FPJ._YPB@<'HSGP?9%S8&P9O9Q2#]*@
MKHUUI-X=O2<(S,1Q0HCHWQK#&$@W'N]@3O$'[__JX04VXA&08!SC/?[3"I6@
MBR>J20S4!&E'[QE/58AA&%:@42P$&F^0C#2>.O3X*$=EKR%.+$FE\D'!@,F/
MEO"S)2WGT:>F!&H>87O;+VOUCHC=;RGYHX?T?)E,M_DP,A($3=N4&4U@=F$>
M\VE*<X8X36GZ$I40NV:Y%+A-;:Y,85M$R4]"B9E>CE.<2.O9C%C)/!O- YGL
MM&>MX$$W% 'Q(:X<R8G.@XA9#I2*5S1HP/1(KQD693/0W.0B'^J%2RW%,0XU
M)40;637#V$8IF-%D1B^:R7>4JS-*48P@AI?)D);R7^53'E)2@\.4LA2DFX3'
M8TI*0VOD92?E<VA-@>K_NGE\Z!Y8L8UA+/I0E2K5<8\DGWF8V$I_@J1!WV$7
MRFZ9U5IN]9;TL"%)31(.!("#!>$XB= H.*L2'G&'1509[&)V+92$PP'@<, W
M2D*8_*R3H&YMZU_[6D'\(*XD=44 74TBM&SZ-;"-G2)CW0</THCL)&(%QV%-
MDATI$A&PC^VL BN&0I.0U;*9?9! />O8M4*V?^[0ZV!24HUVC*,+SY"(+#2S
MSM5^5H=]G<>82M.0>HQ#!O)PB#ZNIQB^II:YNU4MRS(F,<5\4B%3!<FFK$C0
M[!94N_[+9VUF1I++LF"L#J K.$8"F4^M]*.DO!4S/822\8X5 2QP@ -"DKE_
M_P45H[=[IWE,X@#[VG7 "! )9!3(WZ6";Q[L.LEXZRI@\XJD,)]2,$W=6RL#
M59:^!39K2#S*7A$K=58C!5!*K-&%;]07 >-PQRH<(AM,7KB]Q.LF=Z*JD'N,
M@\7?**Y">I36&B\XPYO;7:/.PT^&6/<C6(N,++D:9:UJM<$R(N9&+'M8PV;Y
MO.8=:WY!$\Y[_G)6X[/1+%[*$2YOF;Y=%NLXFBP<3+9SS"J3AYM$RY$.MYG-
M$+8K2,J55#H/N@L <LU'SLOBRR;:LN:=\$<2(^@ZLQ.J>>;(H@U+7DQO&K.0
M1NZD"?U6V<@L)$_0\GS)(8-$D]?']5A(UYHS9U#;\_^1J4)$]O!A#AFDNAPR
MZ#6C'> -!*A#%@:!M6R@'.I9PS>ZT<UQ=9G<D0-I;KO5/BAWW;>NS(RVOIGV
M $GZF. B\[=#H;FR>+N]Z/0.1LC]=7<@U3'4^)CDU"P&]PV'C.%WOU-!"P4)
MA,G+ I)@D\COQG"595C93']Y))A19,$A3M-4%@9"*8%&%X2- !F4XB'I%-:X
M00[17$I(N#Q&@ /64=2$>!PQQPQYQ#6YCJ>FR"'1[@APYCG+*4M9RAE[3UCK
MF@V4Q)2WG'VNG0ODIG./A*X??N6-_%ATMAY]93>ULL5*,E:!GV1'+F=M;YO;
M.7G\L#D<=GI)QK/<KQL][ '_RY^#N7WV@?>G?<YM^]2G6,T9Q18>QIV(#5%K
M=\%CT-G-:<@JVN'JX\X(951?.]Z%UX5Q3:Q/2EZ(S1OS']I=V]K=)2A<EU8?
MI)#F/^ND\4H-!QK<P-2 B<CFZ9E*JW)#$NM'H7T^&I]OW4>/D)DAC8"08JKL
M)!7V@$PN8C2?E%:43HTOUW?QG!K:<^YT)\C5SM><OWM;F7D[<K1*@4+S\.*#
MW.HSCY#EH8UYC6#.,47;^?NC?&0D6=KVO%OOK)$V*R.9F[!)*9EAE$V:CD^&
MTJPH% =X G":WHE0Q&,I<(Z>\.^7[NQ'.$HI"$72$K!E'@C/"G D?F)Q4"L#
MW48>_W!L,YYM*D 0WT30E_YK_UP02.(I(=2/(YRL?.#'\["MVF;OR;C(-E!*
M^P!I5A N17+*I*)HO[(/CR:P!/V-*)Q,UD8LHZ)OWIC"060J"96*WS)#.ZZ)
M1NAH_(AG #%FDGYB.V8,"\&G!>/#^\Y"%K0- ($0Y-0082+$;OII!C>B3: ,
M_OAP'HX/SY["@/2A^1X/LDA0NOJO"L'O_@JQLVIE"6>D ;\)1V)E\-ANC("K
M3&+I*7CGF:2N$7O&9)#D*=9'UBR1K?ZP8I8'*$P&$1CQ[AXO=/J$1M3BV&S$
MZSY1ZI0F$RG/2-!/JO P-B0DFSHO![T KE0I*@X&$7(O"O\?YQ!33ZZ@XG<*
MP^ T"1+/XS_H;RD:1/,* PSY9P=5I8-BYQX$P1F)1PLWA1R/JFW 4'STJ0D]
MD/I(Q,Q",/9,2?X<A0W70A] Y,GH"!V+IW[,;Q_Q9"*"D2,.D%(^A0_EQP_[
M1&@2\2E HSPPT&V2"(J01#6XH@;/<=GTB2.W@EY :-;J)QZYPA%:[QY8:-:0
M1R-!0Y*VPH#";=9JK4TJ<!6#@C=NL9Z4:5:@\04-SR^2@S_:;<PRLMF$$MFD
M WT2DB/8+S0$H1BK2! F)4*2SRL6LGV>;QVL4I7X3R:[@@3'))&L<1WH00RU
M2!X#PV0"$N*$4)6N1!V^XG"N)0[_U^$8*P>LFJ8>O/$>@TH?BR4[BE GF6=<
M$FFFV@OTB/ 7_0*WBN4H:^J1P!+)$,,Q(^(I/<*3**42:0F?:I #V1(JKB<_
M7'%S^H=L1#%)*(-:;@1X[$[X9M$[)C)H/ A''$^CZL1)MM$K(L-)EDN$2NSM
M(E%D1O,IO@!&0.,5Q6P=Y$&.["=AS@4K8D0RV,Z$>E%H[L78DJXP^J>!Y@&^
M9A%DAA(H-/.ZLH8^'JY7K$>5"H1(8.1T(@\T.XF,< HNDE,Q-,_".$<=]^,]
MX0*"[L]VW$$0F*V3_N,UX,(V3),_(V>,N&\++0=-3N@,(^<E#R139H*2KD(?
M1*;"/J=J_ZQR+STI!K>S(#RT0OAE/D64,2MS#2?$0ZWB/$="BX)C3GX304QF
M6.H":WHC7Y(D/1RC,.>"__3E1)(N3'X$,/('\-Y0.8=&G1AC\CA$6G)42,J'
M,0S-1+ C2]Y$,FI3)OK".0HF2EQP- ;C1'D"&F1!29?1,GVT.:#A4,Z"1H=.
M0@VC'K[ B<2Q;$S!GR*T0P 5V0*J UV$J-[T. &#'\K&0,8'*>ZE'WB#-Y1#
M.J2#3M44*T3$4HN#."P5&JB++^QT5$FU5$WU5)<B4U5U54\455WU56$U5F6U
M(SB456WU5M%B5G5U5WFU5]4/5X$U6*_"5XFU6,4" 1H@&QQ Z/^,M5DO8B),
M%"UB,%I/E%JW$VVL52"<U97*R\-,PK[H2M,,3"D6;5QIXK#,E27(*QQD0%R'
M@JP"KB+H2R/0U:[D+B36M5WGE2Q6C, ,2^C$JNG*:NL (,+ M;ZT0JP&#+_D
M-=&:(F#U];) 0L=XS!L.@!S@P3C0P0%@3"_J@5U9:1T0 !X>XAGDH6-W<AT.
M  &$31V*"A[ H0ML=158P!RLH100(!V <5L=QMX (%S33<  8,4&#,XP@FCE
M-5Z3HL#(H<,6CKR$;EU9# ':S, 4K;XJP,]8C+P*5F*WEFJ_05P)MB*4EL4$
M ">RS+X  %W7UEO;MEN3%@$"@ 7$%B/_RI:\#F L.LPB5C8;N@VOR%8&+$+"
MMFY?GR)MQU5LK;9NVS;3!&QKY=5>$0"O_#;@(/=M+\*^"I=K/Z)6!X(>6& =
M=NH=$& =^ $=$& 5_&$5W"'5UH&?2F'7NL X>J44UH$<9E<>>HWC!.(==JT=
M4'8@/E8&X,'7_$YDY<$?GN$=>LUE!6(5U&$<VN$9Z*%I68!XIV(=ON%\\F$<
M'(!HOL$=!*)XR6$=>%<?U$$&T,'5Y@$=D$5][V$5;K>V!((>TD$&S$$>8K 4
MU"%T._8>[K<<_&X5\-<:Z,$!=';)>!9OJC;+X+5A&?:\[%;+"FPII!;3UK:T
M)'AA+\MKQ6IM_]$+A*U68@$ @]E6T0!@P"K"L"XB8"6,A&^"TT08A"-WA">7
MOKS!L.Q*8EG8(IKNA=/U*]85O^JM8#]X(QQ7:J-BOB[K&Q8.',9AAVU8A,'A
M ,:KA \K&Q9M -ZV<AV &U*XKGXVPEJX6WO8(Q2"'MCU'=K!OF!L8V&,'@2"
M'U+-9 ] 9F7A?-)A9&\6 <BAJ-KA&XR+'E37&M8!'.:A('9,!F ,'G+6&MJ!
MCU<!'P0"=2<9'-;!.&!L%1# '7@**)Y!'6+6'63@CJWA$%A 9N-7(-P!'.2A
M&F1@'(JMJ X!'-1!(,JADZV!DVV6>G<*9Q-X(*!!E!-9%MZ8!58! /]@F1QV
MN69W^9$5V%2_%ER_-=VZ+2ZL.6_?%KV\MUP#KL_J*P$*UKX %RDL5V%M.&^1
M-E[GZVT%X&L1RV?)&;]8>%_]=;[.MB*NN'%#V"98;6V_EL?$EHC55M&$EM/P
MUB+V^87%(@!8V'$Q%XG)>875[7"==KZ(]JXHN-O\]H-5#6$'&G -RXEAN-[&
M%HLW]ZXZ-R'H 1QD0!]D 6W0 9EEP1S\6 9<^AG\ 1K60:PX[GXWN8!3[!M(
MM@M<NASJ2HX)XF-ON8_-@1\BV;C4X:;I2G6AP1W(JQV>6:NG@J>_88.*32#D
M(7RM 69W#:=)UAI\]QLR61Y262#6P0$X;A7_'* <K*$>5&W7AJT@\L$!R$')
MZ-BOSSH=^(& ;9:N@SG]2M6>O8R) :"CRXIA,_>$*]HM?-8BZ"N$Q^&\(KN<
MR5;K K;3S+FQR\IJQ0J,55B"LTR$5]:%/[AJF?B:V?9GT;7+RKA<Q<JS:8*T
M(/BR&H#/O%9BH_AQ!2Y@2QN&4[B!$58L*H#1T%4 'L!>ZXINS37"UFR)3UB%
M!XP%<+N>/S@&'GC1&J!<,7BS)7N\(SLC@$VL@E@CTMBE#0*.\X%=UT$=#D &
M3+8<N@!UC6NF@QH=6/D 2%;59*6^E%IX>8P<9@L!.$YD.2[5U"&2.18?]'NJ
M19=FI9=W?R*4OT'E_P8"9F7VD-NA?P49EM.A"]C5&N:!K*UAJC>YKLL: ="A
M"YJVJ0GB'>Y['63@EN7!CVE%?9O99H%Y9TGU:C4W&Q07HX7V(@3:NB7;+5A@
M'$YZ %:,6>75>[49(][9>X]X*1I@R06,BRO B2N"K@R,KO)66;^!BQO >RO"
MH?&*;@<W'!J@(@[  >H\;%/8&^K\(K0L(U:6R]N[)G[[[.I+&^1UPM16PBJB
MHY\\@]O; 5K,R^"BT!' RLG6 <8ARRT"7#6=TY_BG5F 6<D< $0=T1O67%ML
MZQ+ZM[^!6>_<S5=8;3N]KOK\(@+=T43"<X7Y(++UU7I=(.94V'T]V*TA6_\Q
ME=BK8EJ-'5L[KMF?W=B,7;%)M<\:O:+E><L:>[8)[-87^-O!/5;;["6$M=S-
M72A.E<6\X2*0G.'V3&D[_6H5-MSIO=[M_2[./=_UG<A'U; " "/(JI\A_5Y-
MW;PB6^#O/>$5?EOWO>$=OB 6/N(E?N*-E=<?_N*!E>(U?N,YWE17=;@262!D
MH1Q"?B]LRQID 1T.'"+>P1S:P1S$5R+>06=C]]=;I.-Q/N=UGLE4%1[:P1W:
M83KD01V.R1UB<![:H1WX:15HI>3IZ<5V61XTIV/E(1V@7AYD=Q7X@61-ENG5
M0?&LX1YJ917DX>3AFG?-MR"\WN^@ 1YFY>337AW_C.L>9B5X177G\3[O]9XQ
M,G6_K>$9UJ%C@=R _[H@VB&8GX&1 2#Q5^$>RH&2!Z*^JT$@#@' 5;P<BBWM
M4TQGYT&N=QF_K2$=TAH>,GD@8C<=9NL==F,=5'\@WJ&IWP' 2R$=H,'Q90'K
M[V7O=7_W>5\L+)XOU,$!9N5^DQ=Z3]X=;KD47D;QF/ZIUZ$=7J:0UR'F1=X<
M5"[QK>;.!()_=RJ4$UGT!2+I5?RI!2)_"4(=TIJ 4?;UT8: W^%7^*E6U'H=
M\B(??-?N]Z+W]7__^5\IMC/Q >*=M8'6NIBSMDY&.WCINA D**\+O'4"2\F
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M +4X X(MK)RN2OBX:OVH'.D\TOE@6:1#VM*=K(PG(2$'+#4F\8T^^B ^1>&
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M2J9E:J9G^A?^ *2CLZ:CP@\!TZ8 \*;]$*=S6J=PZB]VFJ=XBC!ZVJ=\ZJ:
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MON)+*::#1+138-$T;ZGC1&0A1*?#7VQ!IZ+BN/O;_[C]R[B.,@N.ZK=Z.\"
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7?(AA)5]R)F]R)W]R*(]R*9_R[PP( #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img22994243_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img22994243_3.jpg
M_]C_X  02D9)1@ ! @$ > !X  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &N!6$# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:ZIRE"^S9^>U[_P68\,:\"OPO_9Y^*_BJ1B5B:ZMM.D25@6'RKX=OM;?!.W
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M  %\%_\ RZI(_P!KW_@J%X5+#Q/^RO!X@-F3;W/V'3I_W\Y(42Q?\(_'J.]
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M2"OG#QK_ ,$\OV//'8GDU;X*>&K*_G9G;5=$-YIE^A?=O$9CN'M0&+!L-:L
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M>'_"^C>%O"-WX@;]HCP4UTNDZ)I]EI$FKMI\.ISEK@VUK]J:TADE_>,8HW<
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MM8O]/U6\CN8UGTV0>*]7BT2T>:WDDGCO+N>W$4MNJK,ID(;WW4O@Q^U%X_\
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MR6(IU'[=-+VE2DG)QM"1^CG[.?CG_@I'K?Q!T;3/VC?@?^SMX(^$S:5>&_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !16'XD\3>'?!^BW_B/Q5K>E>'=
M!TR$SZAJ^M7UMIVGVD0X#375W)%"I=L)&F[?+(RQQJ\C*I_&WXU?\%/O%7Q
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[D#;ON]EU?9&J-9U7+#[=-QC'$?<?]<Z7^V-4_Y_IORC_P#B*RQ]YO\ @/\
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M<?<['']RJ8^\W_ ?Y4U?OM^/\Q19=E]R_P @N^[^]FC_ &E?_P#/W+_XY_\
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M[BXF9(H88D4L\DCJJ@<FOB#P_P#\%-/^"??BKXHVWP4\._M<_!W5OBI>:O\
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MUC,'.M]6CB\++$QG+FP\<11=>+C=R3I*?M$TG=IQNNI]&I]T?C_,TSLGU/\
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M^/\ X%?$7P_\4/!46K:AH$GB7PS_ &@=-76=*E>WU#3LZE8Z?<-/:S*T<C)
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M6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MPV(:IUFW&C5:Y*6*2>G*FW[*LUJZ$I.^KI2J)34/LFBBBO$/:"BBB@ HHHH
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MAYX-TV>]T_39];U6;PM=:1I5O+?ZI=VFFV<EY<M&K3WM[!:Q%]\LZ("P\/\
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MOP_@N;F1XKK79YVL-7-I 5:WL(XOW01E(_03_@L+^S5\8_VH?V+[WX0?L_\
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ML/*&D6WA2^T&3P_HNIZ1;SS:9(VF:79>5$TUO&L<+M&?YP?V'?AY_P %DO\
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M-;NY\*:CXWU:741K%WX&TCQ1JEIK%MX?E=7BLU>62^2,"2 .Q6OU6_X);_\
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MOG^3)4ZGZ?U%(GWA^/\ (TJ=3]/ZBD3[P_'^1J9_"_E^:*I]?E^I9/W%^O\
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M2B]FB:=:C5O[*M2JV5W[.I"=DVU=\LG97C*-WUC);Q:5I/NC\?YFG4D8)"@
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MC))V::O%ILHHHKE.H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU#4-/TFPO-4U6^L],TS3[>2ZO]1U"YAL[&RMHE+2SW-S.Z0PQ(H)+.X'89)
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MOA)X;FGO7TK2-&M!'!K6J7EQ<:UKVH17OB./^R8M3C\/:7R/[)G[1MW\$/&
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M_;>"+/Q9KV@V&KZK;_#C5->UKP3')?VT5P@T#5/%&EZ+KUY9[7^674=+M)F
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MC'_!(3XD> )_V1/ '[)'B275-(^.GP=T/QYX3^+?PJ\3>$O%.E:AH$EMX_\
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M='1BKJ0RD@@U_F=_L_\ C#_@G!I7_!/3XG^%/BE^QQ\6/'?[9=UJ'Q /@?\
M:)\)_#+Q$_@OPG]JUL/X4NM4^)^GZ^^F:5;^%[%93K%N/"DSB!9K&6</.M_:
M?U7_  #^/WC7]E;_ (-_[/XWZ-\8/#7QX\??#7X$ZE<Z1XX\-ZU?>(=%M-:O
MM:32[+2XM9U:RT_5[NZ\*1ZHDC-JVFVUQ%>0I;>1-91V\\_M9OPJL#[*.'JX
MJ52KF<,LIQQ>'A2A7G47N5Z%6E5JKV+DU'][&G)WO%/E:/'RGB=X[VDL12PL
M84\MEF4Y82O.K*C&FTIX>M3JTJ3]M9N2]DZD5:TFN:+?[9>-OVC_ -GCX9^(
M(O"?Q'^//P8^'_BJ9(98?#/C;XH^!_"GB"6.YQ]GDBT;7M=L-1D2?(\EUMBL
MN1L+9KT/4_&7A#1?"]QXWUCQ5X;TGP7:::-:N_%^IZYIEAX7M=',8F&K7&OW
M5U%I,.FF%EE%_)=K:F-@_F[2#7\R'_!)G_@DM^RE^TU^Q]X._:G_ &U?A_;_
M +3WQX_:#U#Q3XYUGQA\2M?U[6)O#MN?%.MZ796GAEK2]TIM*-Y'8+J^H1#S
MH[?4[J6*P^SVD:Q']+/VRO@%X#_9I_X),_M+_!;X<R>(9_ _A+X(>-K;08/%
M>M2^(M2L[&>(S1Z=_:5S%%++968;R+**56:&W5(S(^-U>7BLNRZEC:>74,9B
MJV)ACJ>"Q,YX:G3P[;J*E5J8:2Q$ZDE3J7455IQ]HK232T?I8;,<PJX*>85\
M)AJ6'G@IXS#0CB:E2NE[-5:5/$1="%-.I!IRE2J2Y'[KB[W7Z@^#_&O@WXA>
M'--\8> ?%OAGQQX2UF%KC1_%/@_7M*\3>'-5MU=HVGTW6]%N[W3+Z%9$>-I;
M6ZE0.C*6#*0.0TOX[?!#6[/QOJ.B_&3X5:OI_P ,WOH_B/?:7\0_"-_9_#^3
M2Q*=23QO=6FL2P>%'TX0S&^77GL&M!%+]H$?EMC\U?\ @@[&D?\ P2A_9)2-
M$1!X&U#"(H51G7]5)PJ@ 9/)P*_-?_@B3\.? _Q3^*O_  6$^&OQ!\,Z9XI\
M">/OVD/B5X8\8^&M1C<:?XAT#6O$6OV6J:9J MI()WM[VUED@FV31R%'.UU/
M-.64482SSGKU>3)Z]*DG"G!SK0GC'AIR:<DHR4$YQ5[.5HMI:A'-JLXY'R4*
M?/G&'J57S3DHT9QP<<3&*:BW*+G+DD[74?>2;T?] W_#<'[%G_1WW[+W_A__
M (4?_-;7LO@'XI_#'XK:!/XK^%WQ'\!_$GPO:WMSIMSXD\ ^+_#WC'0+;4;*
M*&>\L)]8\.ZCJ.G0WMI!<6\US:R7*SP13PR2QHDJ%OX\/VV?^"<_[#?PR_X+
M!_\ !/#]GOP+^S-\-O#GP6^+7AKQU>?$OX>6-OK0T+QI=Z:LSZ?<:QYNLR7H
MDLSM$/V&\LU(53*LC98_NY^U/#^S;_P2._X)V?'W4_V=OA=X<^$OAN6UUMO"
MO@?P@EXD&N_%7X@:?;^';6:SCU"_NIGU:ZM;&&<*DX4QZ2OEQ94[ML7E& C#
M*X8&MCZ^)S:-*IAJ=?#X>G",*F)J85JI*GB*DE4YZ;DE&,H<K3E-.Z6.$S;'
M2GF<L=1P-'#95.I2Q%2C7KSG*<,-2Q2E3C4H0BZ?)546Y.,^=-*+5F_T;\#?
M'3X)?$_7-<\,_#7XQ?"OXA^)/#&\>)?#W@;XA>$O%NN>'C'=2V,@US2= U?4
M+_2=E];SV;_;[>WVW4,MNV)HW1>^U[7]"\+:-J?B/Q/K6D^'/#VBV<^HZQKN
MO:C9Z1HVDZ?:QF6YO]3U34)K>QL+.VB5I)[JZGB@AC4O(ZJ":_B&_9<^#GBG
M_@DY^UK_ ,$O?CGKDFIZ=X2_;H^&47@S]H2_U)REM>?$[XCZYJ/B&VO=>E:"
M+R_^$4\.^(= U4Q.ZRP7LD_FB8Y9OZD?^"IYS_P3M_:](/#?!'Q>#[JUF 01
MW5E)#*>"I((()%9YADU'"X_ 4,/BI8G!YA*$*6*Y%%\T<5+"8B/*I2BW3J0<
MHKFUA*'-9MFF SFMBL#CJ^(PL</B\#&4JN%YW)<L\-#%8>3DXIKVE.:C+W=)
MPFE=),^O_AW\5_A;\7M'N/$/PF^)7@#XH:!:7CZ==:Y\._&7AWQKH]MJ$<:2
MR6-QJ?AK4=3LH;Q(I8I7M9)UG6.1'9 KJ38\+_$SX;^-]4\2:'X+^(/@CQ?K
M7@V_.E>+](\+^*]!U_5/"FIKRVG>)-/TF_N[O0[]1R;/5(;6X'>.OY$_^".<
MD_\ P3U^)?[(\&HW][;?LX_\%//@9IU_HTUQ.JZ+X3_:8\":MJL<^CE62.TT
MNQUSPWJ5N+:YEN%N;^\8QE'CMEV_9'_!#>/;^U3_ ,%<F9<2G]K3QXLC,/WA
M,?B;6D"NQ^8[%4(H)(15"J H &V.X?IX7^TZE/$SK4,'2H5<+4=-1^L.IBW@
MZ\*B4G[.6'KPK4Y*/,VXQ>BDC# Y]4Q;RRG4PT*-?%U:]+$TU4E+V')A%C*,
MZ;Y8N<*]&I2G%R2M&;6K3/W)U7]LK]D#0M3U#1-<_:L_9MT;6=(O)]/U72-5
M^.?PPT[4],O[5S%=6.H6%YXHANK*\MI%:.>VN8HIH7!21%8$5[;X0\:>#OB#
MX=TWQ?X!\6>&O''A/6(FGTCQ1X0UW2_$OAW584D:)YM-UK1;J]TV^B65'C:2
MUN9461&0D,I _P ]K]D?QQ_P3-\&?%S]MP?M[?L8_%?]J?Q-J'[0.IWGP_UK
MX;?!O7OBC%X5T2$ZLNN:9K%]H_BWPVFF7FJ:D;>]M[>ZBNI;J.*283HJ[*_H
M4_X*8_M >'?V-O\ @CMX(?\ 89\(:I^S]X3^+NJ>#OAC\.-'_LN[\->(/ACX
M8^(<>OZIJMPFEW]YJEWI.N!K%K:6VGNKEXH]1NRD\<BQNO3C^&%A\7@L!AY8
MV5;&8BA0AB,30HTL%)5:4:LY4ITZ]2M)TN=)J5*-^6=FVDGA@>)95\)C<=B(
MX-4L)0KUIX;#5JU3&1=*K*G&-2-2C"E'VG+HXU)6<H7T;M^W.N?M6_LN>&/$
MESX-\2?M)_ +P]XOL[M;"[\*:Y\8OAWI/B2UOF("V5SH=_XBM]4@NV+*%MI;
M59B2 $)(KW>WN+>[MX+JTGANK6ZABN+:YMY4FM[BWG020SP31LT<L,T;+)%+
M&S)(C!T8J0:_GN_9W_X(+?\ !/KQ-^QW\/HOBC\+7^(7QJ^(?PIT;Q5XB_:%
MUC7-8D^*MGXJ\:^'[;7SJ6@:W+>3VMG_ ,(Y<ZBMKH7VS3]0=+:TA-XUU(<K
MQ?\ P;C?&;XF:U\+OVH/V9/B+XKU+QI:_LM?&-?!_@;7-6N)[_4?^$>U2/4[
MBZT^?4;R:6[FM;*[MH$TR"4O]GMC(OF$DYX,3E6 E@\=BLNQF(KO+:M&GBH8
MG#0H*I"M4=&-?#2A7JMQ556<*L8SY9*6Z:?=A\TQJQ>!PV882A169T:U3"SP
MV(G7=.I1IQK3H8A3HTDI>RE>-2FY0<HN-K-2/Z#/"WQ7^%OCG7_$_A3P5\2O
M 'C#Q3X)GAM?&?AKPMXQ\.^(-?\ "-S<^9]GM_$^C:3J-WJ.@SS^5+Y,.JVU
MI)+Y4FQ6V-@U;XK_  MT'QMHGPTUSXE> -%^(_B6U-]X<\ :MXQ\.Z=XV\06
M(ED@-YHGA6\U&'7=5M1/%+";BPL)X1+%)'OWHP'\X?\ P1BABC_X*=_\%B'C
MBC1Y/B/\/B[(BJSD#Q3@NR@%L>Y-+^VW#"W_  <0?\$[Y6BC:5?@M.%D9%,B
MC_A,_$QPKD;@,DG (ZFK>14UF-? _6)N-'*?[253DBI2G_9U/'>R<>9I1YIN
MGS)MV7-:^A$<[JRR[#XWZO3YJV:QR]T^>7+&#S">"]JI<MW+EBI\MK<S:O9:
M_P!'GQ!^*WPN^$NE0Z[\5?B3X!^&>B7-P+6WUCX@^,?#W@S2I[HC(MH=0\1Z
MCIMI+<$<B%)FD(Y"UH>"/B!X"^)N@0>*_AOXW\(_$'PM=2RV]KXE\$>)=&\6
M:!<SP;//A@UG0;V_TZ:6'S$\V..Y9X]Z;U7<,_R-_P#!9+PY:?#;_@II\.?V
M@?VZ/@/\2?VE/^"=<_PZL_#^F>%_![ZEJWASP?XFM-#F&NWNM^%[*XLK>[OS
MK*P:M#%J.K:);W44/G_VU:K&-/NOVQ_X)0:1_P $Z)OAO\0OB%_P3BUI8/AK
MX]UO0I?%WPUM-<OY=+^&GB72K"\9-)MO"&IRW5UX3O;R#59&U3RK_4K#4YK6
M+[)>RBQ<+GB\GHX7*<+F"JXJO/$TJ=7VE+#TYX"E.<W">$JXB-=U:>)I)-R5
M2C&,I+DC>_,KPN;U<3FN)P#IX6C'#U:E/V=6O4ACZL(04HXJE0E15.IAZC=H
MN%64E'WY-6<3]8:***^?/?"BBB@ HHHH **** ,3Q)X=T?Q=H&L^&/$%C!J6
MB:]IUUI>IV-S&DL-Q9WD30RHR2*Z;@&WQN5)CE5)%PR*1^"O[.GB+6?^"=G[
M9/B3]F?QU?2Q_ _XP:I#J?@#6[Z21-/L;C4Y!;>']3\^9DB14VP^%O$%W<,D
M<,NDR7C-(NUV_H%K\^O^"BW[*B?M*_!2ZO/#EFK?%'X<+=^)? ]S"H2\OS!$
M)M1\.B9 LI.JP0&*R+RB*UO'\]4+.P;]#\/\[P.'Q..X7S^IR\,\5TH8#'U'
M9_V9CHROEF=4KZ1J8'$.*JNZC+#SJ<ZDH1B_S[CW),=B,/@>)LAI\W$O"U6>
M.P,%=/,L#))9GD]6VLJ>-PZ?LEK)8B%-0Y7-R/T%HK\Z?^":W[4=S^T5\#HM
M(\5W7F_$SX6/:^$_%QG?%[JMO!"T6C^()TD*RO=7]K;@ZF4A2&&].S.9%!_1
M:OD\^R3'<.9QF&29C!0Q>78B="IRW<*D5:5*O2;^*CB*4H5J4OM4ZD6[/0^J
MR'.L%Q%D^7YUE\W/"9AAX5Z:E;GIR=XU:%5+2-:A5C.C5C]FI"23:U"BBBO(
M/7"BBB@#Y9_:P_94\$_M4^ K;P_KEQ<>&_''A2^?Q%\,/B-I2I_;?@CQ4EK<
M6B72)(KP:GHFJ6=S=:3XAT.^BFM=0TJ]N#"+74XK#4+/^?CQEX2^)_P4^(ME
M\&?CIX>AT/QSJ[RIX$\3Z/%<GP'\8K."2*)[_P "WEPTQ@UJV:XM5U[P;<W=
MSJ^B/=V%S.4M=5LHT_JMKS#XO_!OX<_'?P3?_#[XH>&K+Q+X<O9[>^ABN%"7
MNCZQ8EWTSQ!H.H(/M.CZ_I,SFXTO5K)XKNSG^>)\,ZM]UP?QSF'"U3V$D\9E
M56;E5P<Y6E2G)).MAIO6G+1.=/\ AU=;\DVJB^(XMX)P'$T/K$6L)FE."C3Q
M<5>-6$7I1Q,%;GC:ZA47[RD[6YH)TY?//['G[-4'P=\+)XK\464;_$;Q/:I+
M=F9 TOAS2Y5#P:-;[AF"Z9#YVINH6?SI7LY',4"QKXG^W-^TY_94%[\%O NH
M?\3*[C\KQUJUI*-UA:-R?#T$T9RMU=$!-4"L&BMQ+93*#,ZGF/B[\:_VD_V'
M? 7B/0_B*NK?&;X6-%'I_P -OVF2GV[Q%\.[2Y A33_VA=.!DO;AM%BQ%8?$
M^WCU#3=76,:QX[U'1+B2[,'P-\*_A_XI^/GCS3="T"XDU:]\1S#5M3\0M+]M
MM[?2IW$][X@NKT,\4L/E,SV\C2%;RX:&WA,DDR*WV_"F4QSW-,QXXXEQV$Q.
M#P55UJ%JBEAXRHPC5A.K2D^?#8? TW!4L-5BJDJRO*,N1NK\7Q/FDLERS <%
M<.X+%X;%XNFJ.(YJ;CB)1JS=.4*56*]GB*V.J<SJXFC.5.-%N,7%SM1]9_96
M_9VU#XY^,TEU"*>U\!>')8+GQ)J*J4%X^_=;:'9R,I4W%YY;M.P#B"VC<.H:
M5&'[<>//&_@KX%_#NXU[5%M]*\.^&M/ALM*TJUVQO<R0Q"'3='TZ(Y+SW#*D
M,?#L22[EV)W'@/P5X+^!GPZM=!TUK;2/#WARPDO=5U.Z=(S<SI$K7^JZA.V#
M)/.8U&YRS[$A@3=L0'\1/VI_VB-0^.OC61=.FN;?P#X>GFMO"^G.S1K=[?W4
M^NW4&0/M&H%2\ D42PV1MXI$CE1T7D_V[Q2XE_Y?8;AG*I^<?W4G\X_7L?R>
M?U>@NOL_WO6OJ?AEPXOX.(XCS2/^)>UC%;)^\L%@N;R^L5Y?94_W?AOQX\9W
M?[1/B#Q%J_Q'M+;6=/UUO)BT*X4R:?I6FP3+-IMIIJD[[2?39(K>XL]2MWCU
M*"_M[?4(KM;V"&=/8/V9OV\?B!^RVFG?#_X[W>O_ !3_ &>('BL]"^*,OVC6
M?B3\'+-B(XM.\<^6DNH^./ -H-AM/$T\=QXA\-P+>?\ "0ZSJ&G?V1:V?S92
M$!@58!E8%65@&5E8$%6!!!!!(((((.#7[#FO"V2YOEE/*<3@Z<,-AZ<:>#=%
M*G5P2A%1@\/.S<&HI)I\T9K2I&2;/R7+.)<XRK,JF:X;%U)8K$5'4Q?MFZE/
M&<TN:<<1"Z4TWLURRI[TY0LC^I7PUXF\.^,_#^C>+/"6N:5XE\,>(M-L]9T'
M7]#OK;4](UC2M1MX[JQU'3M0M));:[L[NVECG@GAD>.2-U96(-;E?RW_  -^
M-'Q;_8_\2-KGP>6X\7_"34]2FU/Q[^SK=WT5MIMS+>3-/JWB+X2WNH31Z;X1
M\774DD^H7.CS2Z9X>\3:O(USK.I6CSM/'_0Q^SU^TE\)?VG? T7CKX4>(TU6
MV@D2R\2>'KZ";2_%O@K6RK&;0/%_AN^2#5="U.)HY?*2]MHX+^&,WFG375FR
M3M_-'%7!F:<+5VZT7B<NJ2:P^84H/V;NWRTZ\=?85[?9DW&>].4K-1_HSA?C
M'+>)J*C2:PV8TX7Q& J23FK)<U2A*R]O1N_B24X;5(1O%R\A_:$_9(A\<ZU-
M\7O@GK=M\*/C]:P(D^O0V8F\&_$^P@Z>&/BUX:B"0:]:2*%33_%-G]A\:^'V
MCCBTKQ!!I<VHZ;??,?@3XJW&K^(]1^%WQ*\,W7PM^-_ART6[U[X>:O.L\6JZ
M7O>&/QAX UG;';^+_!.H2Q2BWU;3C.EC>1W>C7DTM_IMU(?URKPOX\?L[_#C
M]H;PY9:-XWLKRSUKP_=2:KX'\>>'+N31?'7P_P!>9$5=<\'^);39J.CWI\J)
M+D6TR17L"""Y5U"%/,R[.94%##XOGJX96C"HO>K8==HW:56BNM*33CO2G#WH
M3]+,,H59RQ&#Y:6(>M2D_=H8AZ7<K)^RK6_Y>Q34]JL)^[*'PU\6_BKX4^"W
M@'7?B'XQFD&EZ-%#'::;:8;5?$6N7\\5AH/AC0X"&:[UOQ#J]S9:1I=M&DCR
M7EY"/+89!^#/AOX<\6:OKNO_ !M^+"QO\6/B%!!$VF(S2Z?\-O!,#RSZ%\//
M#JNSFTB@6XDU'Q)=;FU#5]7N5M]5N;F#1=)@L,?XK^$/V@/!7QRT6?\ ;1M%
MB^&/@#7-0\-?LY?$>SBT6#X??$+Q',SZ);_$OXD6NAWMYIGPZ^(/B/3;JYTW
MPKX?UTV.G,^KG3M/O)-;GTVPNO?3GOWP<^H(R#GN"""#W!R.M?IF6TZ$<-&O
M1JTL0\1'6M2DIP4+IJE%V34DTG632E&=J;2Y'S?FF:5J\\3*C6I5</'#NT:-
M:+A.4]G6G'9Q:NJ+3E%PO.+?.N5****[SSCE_%_@WPWX[T9]"\3Z<E_9">*]
MLIDEFM-3T;5;8/\ 8];T#5K22#4M#UNQ+N;/5M*NK2_@62:))Q%/,C^Z_ _]
MMCQC^S^VE_#_ /:AUB\\8_"836^F>%?VC[BWC_M7PA9LZPVFD_'46,,5K'8:
M9&8X(OB@]O96LNFQ03>++K4M=&K:S/YE4<T,-Q#+;W$4<\$\;130S(LD4L3@
MJ\<D; JZ,I(96!!!KBQ^7X3,J#P^+I\\5=TZD;1K49M6YZ52S<;Z<T&G3G9<
M\7:+7;@,PQ66UU7PE3DD[*I3DG*E6@G\%6G=<UM>62<9P;?)*-Y)_O'9WEIJ
M-I;7]A<P7ME>017-I=VLJ3VUS;S()(9X)HV:.6*5&5T=&*LI!!(-6:_ +X/_
M !/^)G['FH"3X=Z?JGQ'_9[E=Y/$/P+2[1M<^']N[B6?7?@I-J%Q#91V-A\\
MM[\.IKK3[&XTUKR30?MVOQ:=IM[^UGP?^,WPV^/'@FP^('PM\467B?PY>R/:
MSM"LUKJ>BZM;I&][H'B31;V.WU7P]K^G^;%]MT?5[2TOX$E@G,+6UQ;S2_EV
M;Y'BLIG>?[["S=J6)A%J+?2%6-W[*K_<DVI6;IRFDVOU'*,\PN;4[0:HXJ$;
MU<+.2<XI63G3E:/M:5VESQ2<6TJD82:3]1HHHKQ3V@HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **H:KJNEZ%IFH:UKFI6&C:-I-E<ZEJNK:K>6^G:9I
MFG64+W%Y?ZA?W<D-K965I;QR3W-U<RQ000H\LLB(K,/Q:^/'[:?CW]I&YU/X
M=?LO:OJO@#X,Q7$VG>+OVC5@N-/\1>-5B+PWF@_!.QN%M[Z'3) 2M[\1KM--
MAS]F7PG/JH;4FM/4RO*<7FU;V>'A:G!IU\1.ZHT8M[RE]J;5^2E&]2=G964F
MO,S/-L)E5'VN(FW4FG['#PLZU:2Z1C=6@FUSU)6IPNN:5W%/Z0_:D_;P7P-X
MBU/X'?LY:7I/Q-^/4,,<7B'4+UKB?X:_!B.\A66'4_B1J>GS0>=J\=I+%J.G
M^!K/4+37=7AFM7B9(YXUE_/;PGX!FTO7M:^(7C;Q+JWQ,^,/BU3_ ,)?\3_%
M!@DUF]B>19O[$T"SMH;?2_"/A.VE5/LOAKPU8Z3I1\FVEN;2:XMXI$V/!/@7
MPM\.O#]MX9\(:6NF:7;R3W,K/*UUJ.IZC>3276HZSK6I2C[3JVMZM>S3W^K:
MI=LUS?W]Q<74Q,DK$];7ZEEF583*:+IX:/-5G%*OBII>VK-6=MW[*E=7C1@W
M&Z3G*I-*9^69IFV+S6M[3$2Y:4&W0PL&_8T5M>SM[2JUI*M))ZM0C3A)P"BB
MBO2/-/!?CGX5O?L&D_%OP=!;P?%+X22'7O"FJ2%+<7>E0SI<Z_X7UB\P)?\
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M)I*V.(P='$2]I452,U1='GI5:E)RI5'"4Z4G3E'FBW%-)ZQ=W%Q;=_)/@/\
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M2I"C3G6JR4*=.+G.;O:$8J[D[)NR6KLFSZ6BN+B,,D<\R*&)"I*ZJ"2<D!6
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MJ,Z]54\TQE+%8F,5!-QIPP\)8>+M=4ZL,-&,Y?'RSFHR5U;^1_\ X*#_ /!
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M;&U\5E]6C7HK#3I8>FZ:KU)5)2C6ITXU7*,IR<>:4DFT[:*W\POPM_X*&?\
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M-Q)K?BG6)1A(+#1M.2YO"KNANYHH[.%O.N(P?].S]F_X#>#/V8O@7\,/@/X
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M@6VO2:WKLOB _L3>*;_^WY-8U.37_MJ>!;^1+_\ MMKHZI]M1P)%O?M?VE7
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M36=$NM)USX>W_@;7O#5[HNOQZ/I=Q82+K]UJNDR7EVMR^GLD06N:CF2]DO\
M;IT\55R>OAJM9SK1G+$QS'VU!5:L(N4Y+"1=.G4?-RQE&ES1C=1Z:V76J:8*
MG4PU'-</B:-%0H2C'#RRZ%*NZ-.I)1A'ZW+GJ4_<;E&56,92LY?F_P")_'.A
M?M/_ +;?[67@SXX_LR?M=?M-?"K]EW4O#'P?^$OP\^ :Z<O@/P7+K6C?VKXG
M\9>*"WQ;^%.OW'CC78;71[#299=2UK3K2PT2XD6WBN+EY7^KOV0+?]HKPO\
ML??M8>#_ (T>!OC'\.O#/@76?B38?LVP_&V31X?BB?@I<^&H=8\.6^KW/ASQ
M'XDC+^&+^^OO#6GW,NKS:C]BT>V-Q<7$^^YE]H\2_LC_ !O^'O[1WQ _:4_9
M#^*7PL\&:U\=='TJW^/_ ,,_CMX1\:>-/AKXJ\5^&4:+PO\ $#PD/ OB'PQX
MM\.>(X+2^UC3=8MY/$#Z+J5B^DL=--W8F<_2.C?#;XO:Q\&/'G@KXP?$[P]X
MO^(?Q!TGQ#87&K>&?"S>'_A[X-76+!M.M-(\':/+YGBJY\/6:!+Z9_%FMZ]X
M@FO[B]5-6%C]DMH)Q684)T*%*B\.\/R9<O92EB76P]6A"FL3.G2:^KTY5*JK
M3JU(2?MX5.:7-5=HO#8#$1KXBI65?ZPGC_WL5AE1Q%&O*7U:$ZRDL145*G[&
M-*G-)4)P<5:DDY_E]_P3._9?&I_L0?"3]I-?%&O^._VNO%7P!O;;X7?%3Q[X
MH\5W-G\/7N?!>HZ)\/?#UIH$6MOH5[IGAP7MM#J&K:UIFK:MJOE&^EE2X5,>
M8_\ !/GQ%\!O!?Q8\ _"?]H;PM\>OV=O^"DNFF^'CSQ'\2M>\0RZ#^U#>:[J
M?B&>^T_POKLNK>(OA[XF\-W]AINE:I<Z-I_A_P "Z[I<=AH2VUZ4>^CN?UB_
M9L_9S\6_L^?L=?#C]FFT^), \;> /A8O@2P^*GAK0;=+>SU^#2GLK#Q5I7AW
MQ1#K-JZV%Z8;^+3M:M]0MYO)$-U#-&SHW@E]^R)^TS\:OC%^SQX\_:U^,GP1
M\2^#?V8O$6J^.O OAKX'_#SQOX2U_P :>/;C3X-%TG7OB'J_CCQ'XFL[>TM-
M-_M&XOM+\"V_A>TO=4U$NT!LK2SMK>Y9C2KULV5;%*.'Q%6M*A4ISK4\0H4X
MUWAJ-*DJ4J53!U'44)X6JJ48RDJJ=.4')S'+ZF'I92Z&&;KT*%%5Z<XT:F'=
M2<L.L36J5'6C5IXNG[-RABJ:JRE&+I-55-1C]\_$_P#Y)G\0.W_%&>(?_39<
M5_.M\.?BQ\1/ W_!(_\ X)O_  N^&?C+4/AUK7[3WQ0^&OP(UCQUHH@7Q!X?
M\':Y,=7\7?\ "/WETLMMIFJZQX?TO4-#AU"2SO6@347,,*3^5/%_2)XLT:7Q
M-X6\2>'XKB.TFU[0]3TJ.[EC:6*VEU"TDMUGDBC*O)'$TF]T1@S*"%()%?F;
MI/\ P3+L;K]@GX*?L@^,?B<T?Q"^ 5YX:\8_#;XV^!]&^P/X;^)_@R\@U/P[
MXDL-$\0KJQ;2IKBV_LW7=-O%N);S0[S4+:W>*XEBF3CRO%82A2Y,3**OF.#K
M<LJ;J)0IX?&P=:4.5QE"C5JT92@_>FKJ,9:VZ<QPV*K5G/#1=_[/Q5%2C-4V
MYU,1@I^RC+F4H3K4:5:,9JT8O64HZ7^=?VY/@'\.O^"=7@/X9?M9?LJ1>*OA
MO\0_A_\ %OP)X'\<VL7C;QEXHT'XS> OB#J<.D^+- \=Z-XNU[7K(W-QJ%AI
M^N:?JVAPZ3<V-]%=0HDEO>^5#Z;X0\=6G[+O_!1O]K'2_$GB;58?AK^T#^S?
MH?[4G@O1_$.M:E<V/A_5_ ME>^&_'=II%K>_:8;!OL'A2/5]0M;!XHXC>M(+
M/<Y=_8O$O[(G[2G[2&H_#30/VT/C!\%/$OP<^%_BG1?B ?A_^S_X$\>^#+WX
ML>-?"\1A\,R_%?6/'_B?Q6[>'M.EFN]8N-(\$MX9%]K4L,ER9;*TM[:*;_@H
M?^P/XC_;33X7:S\/OBCHWP>\<>!AXY\,:]XDU+0=2UC_ (23X6_$O2H-$\8^
M#K<:/=65WI\\]F+R73KP3"&TNKMI#&P!4]E/&8::H87'8Q5I5J.+HXO')5:J
MA3E4H5\'!RG3]M4=*O0D[J,E"G7Y%)I2C'DGA<3!UL5@L(Z*HUL)6PF"O2I<
M]14ZV'QD^2$_94U5H5X)ISBYSP_/*-W&4_SH_8R^.WQ(_9K^ G[=&H?&+Q3X
MAU_Q5K?P)L_VW_ 8\2WEW=W%A>_%GP9?ZAJWA31XKR<RKIVB_$+7_#^AB*%[
M(&::%+/38,B(?KK_ ,$\_A+JGP9_8Z^"'A7Q%JNK:WXKU?PO_P )YXMU76]3
MU'5;^[U_Q[=3^*)PUSJEQ=7:0VUGJ%C9PVQE\N!+;;&B@D5X1^UY_P $ZM4_
M:/\ B!\$/$/@CXEZ%\,O!O@W1O"W@/XT>%KWP]J.L7GQ8^%?A/XA>$/B39>#
M[*\M[F.UTJ2?6O!.D6<U]?P7,@TU[JT1DBG<5^HEO;V]G!;6=E$MO9V5O;V=
ME;K]VWL[.%+>T@7_ &(;>*.)1V5!7-FF.P^)H*5%QC5QE>.(Q=*$'%4GAJ*P
M]&%W&,7SWJUFJ;<5S1O:7NKIRW!5\-6<:RE*E@Z,L/A:LY*3K+$U?K%:?QRE
M[G+1HISC&7N223C9O\SOVS+?_@GU%X]T]OVUOBGJ.KZAJ&GB3P/\+-2\3_$J
M\TCP4(;0P:CKV@^&?@EID7B?1;C6T17O[WQCJ5_9W<B!](AMLN&\ _X)+_%:
M^\<_L@?M->#;#QQXE^('@'X&_%'XV_#GX,>,O%=_J-[XLN_A7I\'B!O!=KJF
MI:G8:3K%Q+I&F6EK;6ESJEA::ML&Z]07 )KZ,\4?L@_M$>!OVO/C'^U=^RQ\
M4O@=H6J?M ^ /!'@_P").@?'OX?>-_%]SHNH^!4^P:9JWP\UKX?^)O"5]IUC
M<Z/;V N]$UVYU;3VU>*[OTM46Z96Z;]CG]B?Q/\ LN>!?VF/!WB+XO)\6-5^
M/WQ0^(/Q&C\97_AZ#0]8MI?'$6KJW_"3V6E06&BW6JQ3ZH)KR3P[IVE:9)Y3
M+:6< 9<:O$8.&52H?7)UZK>75:5.I.;C1J0E?%1I4/JRAAW3C.<)5/K-1XI+
MVBBF^6.<:&,EFD:_U6%&E'Z_2J5(0@I5J<U#ZM*K7^LRE751PC.-/ZM3^K/]
MWSN*O+\G/V*_V2? OQX_X)A:[\:?BUXQ^+'C7XL:)IGQIUKX6>-M3^)7BNWU
M'X-CP;XBUS6M!L/ D6DZCIUM-:Q:M9+=W7_"70^)Y;A7%JLD5F&@>C^V[;:1
M^U)_P1U_90_:5^-.E_\ "7_&>YUG]G30K[QG-JVNZ?<7R:UXRAT;Q3>W6F:1
MJFG:)->>)?)N;V]GETR2:UN;^X;3I+3; 8OV"_97_8T\0_L[_L2W_P"R=JWC
M[0?%6NWFB_%#2E\;:7H>IZ;HL<GQ!N=7GM)VT>\N[C4&32QJ:+=(+H-<F%S"
M8]Z@>::[_P $X;_Q1_P35\%?L)ZK\4[.S\8_#W0_"]UX7^*FCZ#<+H,?C_P/
MJTVO^%]7OO#6HR7=]<^'%U)XEU;2_M*WMS;(Z6]U"[*X[?[6P_U^5=XN7+2S
MZG6PTXJJO99?-557=)1@G"E.U)U*22E-KF=.4N9OC655_J$*"PRYZF12HXB,
MI4G[7,(?5W155N34ZL'[94ZTFXP7NJI%**/%O^"CWP:^''[,7["EKX=^ 6AZ
MC\,=(U/]I+]F+4;Z'0_&'CB\NY[G4/CA\/HKW.K:]XEU?6$M[J"YGMKBRBOT
MLY[:5X9H'1V!F_:DE\&?%G_@H'^SO^SI^U#XOBT;]F!_V;M<^*/ASP?J'CV?
MX>>&_'_QBTNZ\.Z6S>*]:TK6M(U>^;P[HNI--HNES:IHMI<S:I?2XUEXC%9?
M27Q]_95_:,_:J_9AM?@W\9/B9\#-(^(]E\6?A3X[3Q9\,O WQ#T_P1+X?^&?
MQ#\,^,CIEQH/BGQ;KVO?V]JUEX>:Q-[!JL>F07=RMPMD($,%?#7QP^!7A']J
M[_@JKXJ^$>J^.;CX6:A\-OV1? ']KGQ)\+/V?OB[9?%*V/B+7H=*U#P'X5_:
M(^&/Q-\,Z19>%G&IIXHU?3])75+Z77-!MH+ZVBM+E9L<#5ISI6JXMRKX:.<5
MZV+7MJM6DJU++J-#$PJN$JTI<ZFH2C&=2-FFJ2?M(:XZE4A43I851HXF644:
M&$DJ-.G5=&IC:U;#3IJ<:2BXN+E"4HPG=<KJ./LY_!VD>)K;]C7X(?\ !2?X
MR_LQ_P#"?:I:W_[6?A/]GG]G_P",D7BSQ9XOUO0_"7C6T\.Z=XMT3X6KXOUJ
M^\+:G8>!?%M_XDL?!NJM!=Q7-[;&"YUB[CA68?7,'PL\6_"KQ]^S)XK_ &'O
MV'_V_P#X4?$;P]\3O _ASXW>,/C+<>%[GP?\2O@SKMS;:/\ $6]^)(N_C[XW
M2;5[&&YD\86UWX<\-Z3.NJ6"I%"+15L6]0\!_#5/VAO'O[7W_!)WXE?$2X^+
M7P$^%7@?X:>./A_\9/ _@?X:?"OQ=\$O'>KI'J5EX,.F?!WPAX)^$:ZKX;U@
M_P#"9Z#'IW@NV<QZS#!K:7Y63/Z$_"CX;_\ !0K3[GP)X=^-'[1?[/>J^"_"
MBZ8OB#Q7\*_A%XMT3XP?$&+1(E$=IKUSXV\2^*/AQIL'B5HHHO%,OAWP=H]Y
M';379\-W.CW/V:6'JQ>8*ES<TZ#KS4:M58BKC''&8*ME^%A@W-0I4_;/EC7G
M4H5H4_8UJW/2A:<IKEP> E4<.6-=4(MTJ;P]'!J>#QE''XF>,4'4JU/8KF=&
M$*]&=1U:-%QJR3@H/XC_ &T?!E[\5_\ @K-^QQ\)KWX@?$/PE\/O%/P!^,\_
MCGP]X'\47F@6OCC1+/6/ 9E\+Z\L:S(=+U"6:%[J[L8[/6HUM5CL=5LEFG\S
MN/V?_"NF?LI_\%0/&'[+WP<N-<T3]G_XI_LR:+\:)/A?J7B/7O$VA>$OB/HN
MO:]X3O?$/A:[\4:CK6N61\0:-X9TN+5;"359K W"37%K;6[S,!];_$/]DG7?
M''[=OP%_:^M?&VBZ;H'P=^&'Q#\ :AX$GT?4;C6M<NO&E]X8N[74K#6DNUL+
M*VL%T&6.:WN;2>:<W$;)*@C;?IW'[+.MW/[>NE?MB#QEHZ>']._9\D^"S^!#
MI%\=<EU%_$OB+7AKZ:T+H:<M@(M<CMC8M9FY\RWDD\[:ZJ/*>.HO!TL-*LO9
M1R2K1G1<9<CQ_P!:JU:-TH6E5BG3<:K;4%[JFES1?J+ UEBJN*C1_?/.J-:-
M52AS_47A:-*MROFYHT92512I.SE)<S@VHM9W_!2OX\>-/V:OV'_CS\8/AU>I
MI/CK0O#^E:)X6UR2Q_M%?#NL>-_$ND>"K7Q(MF65)9O#SZ__ &Q;&42017%E
M%-/;W,*/!)^1G[=?_!/[X=?"'_@F7X@^*GPV\>_$_0OBC#X)^''B/XP>-9_&
MFN>)?^&@;/Q7XI\):SXBT;X@Z1XBN[_2(+*XUR_M]2TRZ\,6'AZYTY;-+51)
M;RF./]]/VA_@9X,_:7^"'Q&^!/Q ;48?"7Q+\-WOAS5+S1YUMM7TMYQYNGZU
MI,[K)''J>BZC%:ZI8&>.6V:ZM(EN89H#)$_YA_%+_@GU^VG^T#^R_-^RK\8/
MVM/AE:^"O"VD^'=.\%>(/AS\-O%.D>*/'Y\)ZSITN@0?'FZUWQ#J]OJNEVF@
MV @FLOAS!X+^WZRT5[?-/;6\%O"91C:&&6$7UN&$E2S6&(QO/"I+ZSA.3#JG
M!*G3J*K[&4,0_9SLHRK1JQ3<7*,YMA*N(>*_V6>+C4RR=#"<LJ<?JV+<ZWM)
M<U2K3]G*M">'2J0NY1HRIR=FHR\!_:S^+VH>-/VAOV*/V.O$_P ,OV@_B[\"
MV_96\,?'CXB_"S]G0:1!XI^)FN:;9_V5X8TKQ5=:IXP\ W \":!<:)!J=[;:
M/XLTR\O[J>:TE\V,1J/HG_@GMX=^+_P]_:O^,?A/P3^SM^TI\!OV'_$?PWTO
MQ=X0\+_M$R>'YG\)_&NWUW1['6]*\#R67Q+^)6O1Z-XBTJZUC6;RVU75YK>.
MXM(Q:-!&B1/]"?&_]B3QIXA\4_LX?'KX#?$W0OAS^U%^S?X)TGX9V'B/Q=H.
MI^)?A3\2_AK)8V]GXK\"^/\ PEI]]8:\=+U!VU'4-"U+P[K6BZ]H][?R2?VG
M(%B6/Z2^!?AO]J*PU/6O$/[27Q/^%_B.>>UBTWP_X'^"'@C6/"?P^TZ-+B&X
ME\0W\_CO5?%OCR\\32B)K%(H_%D7AN.SN;ECHK7OV:Z@6(S##O+50P[P[A+#
MSI5J%6>)53ZR\5*H\32H1B\/*K*'LW3Q$I<\::E2ERJ,8-T<#76/=>NL1S1Q
M%.K1K4HX=T_JRPU.FL/4K2?UB-*,_:<^'A%PE4<:L;MN2_%?]A3]EWP'^UK\
M2/\ @HFG[0OB'XE?$CPAX6_:R\8:'X$^'-_\1/%>D^#O ^HW7A3P^^H>*=!B
M\/ZEI6MQZY=QBT@2*?6IM#LH[026FCQ74TEQ5GX::U^V3\8O^"3_ .T!\,O@
M7XN\5>-OC#\%OC7\7?@CX3U.36K2S^)GC7X,_#7XDZYHL7@K2O$UU;_98?&D
MO@&VMO"6AZW>QAY'L[>ZOKAKF26X;]1?V+OV0]?_ &6?$/[4NLZYXWT7QE'^
MT'\=]9^+VD0:/HU_I#^&=/U31-*TI-$U)[Z\NUU*\ADT]YFO+46T+I(J"!64
MLW _ W]C;X^?LX_ WXJ^"/A1\<_!FE_$[QA^TE\0/CWX>\1:GX#N=5\$7.C^
M,O&]_P"*S\-?'.AW=[+K=SHU_9WHT?7]8\):MX=\0B-7N= U72+DI(N];-*-
M2O7:KT*L*6)R>M@H8B%1X:+H4'#%/DC3YH0E*T<1RQ4JKM-\[BI+&EEE6G1H
M*5"M3E5PV;4<9/#U*2Q,O;UHRPOORJ6G.,%)T.9N-%7A[B;B_&/^"=_Q$_8B
M\1R?&'0/V8]%^,'P!^*6@^$M?L?C)^R[\7+SQ79>(].U/0Y[?38_B+=Z/XNU
MGQC)>&&Z9M%T/Q)X5\8KI%]I>HS27^BB\FM;BW_-B]^'WA7XN?\ !OGX\\9_
M$RUU3QIXI^'5[\5];\':YK?B?Q3-?Z3J=Q\:[;2WN))HM:A_M5$L&^SP6NLC
M4+.W14\FW3:*_:#X*?L=_&!?VD?B)^US^TW\1_AMXL^,/B#X1#X'^!M!^#'@
M_P 0>#OAMX-\%7%Q::GJ]]=6WB_6_%'C#7?$>K:OI]I,\]_XEFTRQM#=6]A8
M0M*CQ\Y\+O\ @G(/#W_!.KQA^P5\1/B+'K:>,[7X@07?CSP?I4NC"RE\4^,)
M_&.B7-KIFL2ZLS'2+X6*7T4TDB7T4,Z1^3YRF-QS'!8?$*M3Q=64UF62XJ<G
M4JUZD848XGZY"GB94J52M3I1J1I)U%&<HR]FO:0CSL>7XNO05&IA:48O+\XP
ML(*G2H4Y3K3PCP<ZF'C4JTZ-2HZ4ZC4&X0E'G?LY2Y%\<?'W]BSPE\,O^"87
MAWXP?LH:%K/P[^,_PN\"_!S]J/3KG1?&?C[45\5>*/ 7A3P[XGU71]3TW5?%
M&H0W>DZ_;VCVUUHEN+:QD0!$A12ZOU7QO^-0_;^^+G_!,3X.?"_Q'K.C>"?B
M/I^E_MP_%N^\,ZO>VES#\-_ &AF[\,^%-<;2KRSN([7Q!\0]3\-V%S97$L:3
M0A_/BFBQ%+^F/[+7PT_:#^'_ ,&K+X5?M.>*_@?\1+3PEX0\/> _#NJ_##P3
MXO\ "T>L>%?#OA>P\/RW7CK3_&/BKQ18WFLZDEG+<WW]B0:5HX$YBAT^*-0M
M?D!_P0?_ &=M-\->,/VQOCOIFN7OBSX>VWQ:\4?LZ?LTZU>R22)IWP1^'7B)
MX[S1].\TL%L&US2=(DB: A)%M@S%R004L5&6&S'%5Z_UG$996JSP6(;G55:6
M9T_J\(JI52GS8:5-8JE&:T]G52BK,53#3CB<OPM&A["AF-&E#&X=*G3=*.6U
M(XB<^2FW'EQ*G]6JR@]>:G=WLC^CE5"JJJ,*H"J/0 8 _ "EHHKY$^L"BBB@
M HHHH **** "LK7=9L?#NBZOK^IRI!I^BZ;>ZK>S.ZHL=K86TEU.Q=B%'[N)
M@,]20.2<5JU^;?\ P52^+TGPP_91\2:+IDY7Q'\4M3L/ 6DQ02,E^EO>B6]U
M&^M%0AF$ M+6RE/(']I(N"7!'M<.9-6XAS[*,DH753,\?AL(YI7]E2J5(JM6
M:T]VC1]I5EJM(/5'C<19Q1R#(LVSJO9T\MP&(Q7*W;VE2G3;HT4[.SK5G3I1
MT?O36C/D#_@G=H]_^TW^UM\>?VS/$L4EWI.F:O?>&_ -Q,FZ)/MELEG86X24
M;%DTSP4F@[9H5!%Y)(^V.3=7[QU\>?L&?!R#X)?LM_"SPNULD&LZMH4/C#Q#
M+Y8CN9]3\5EM;2.\& 3<:;I]Y9:20P#(E@D;<I7V'7O^(N=4,ZXJQ[P24<IR
MF-'(<FI1^"GE>3P^IX=TUI:-9PJ8FUEK6=T>#X>9-6R;A; K&MSS7-75SW.*
MLE[]3,\WE];Q'M&[MRHJ=/#7;>E%6;04445\,?;A1110 4444 %?#?[0W_!2
MO]A/]E#QRGPT_:*_:8^'?PG\=OI-IKJ^&O$TNLKJ']DW[.MG>M_9^DWT"1W!
M1O+5YEE8 -L"D$_<E?RJ_$WX?> ?B=_P<P^%O"'Q*\#^#_B)X3O/V8-?N[OP
MOXZ\,Z+XN\.W5W8?#VTFL;NXT3Q!9:AILUS93 2VEQ);-+;2#?"Z-S7KY-@L
M+C:V+^MRKJAA,NQ6.DL-*G"K-X=0:@I585()24G=N+Z'D9QCL3@J>#6%C0=;
M&9AA<%%XB-25*"Q#DG-QISIRDXV6BDNNY_0E^SQ^V3^RW^UEIU[JO[.7QQ\
M_%NTT[8;T>%M6,EY;I(NY99-,OH;+4O(QPUPMHT",51Y%=E4_0'B#Q#H/A/1
M=2\1^)]9TSP_H&CVLE[JNLZS?6^G:9I]I$,R7%W>W<D5O!$O W22*"Q"KEF
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MBVKI2DENR'&+J*;C%SC!J,G%<T5)IR2E:Z4G&+DD[-QC>]E9]%%%2:!1110
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MS)>/=.__  "M2BCFEW?]?\-^?=@HI;(S1ID(Z22],=4_^(H&EP@Y\R7\T_\
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M*[JBO&52:CRJ<U'^52?+KOI>VI[7LZ?-S\D.?^;ECS:;>]:_XA6!XI\5>&O
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?N;K:MK>^+?V??'/AW1#*Y("7VM7ULMGIL8.TO/<GRXP2S#"FO[IJ*_;,O\
MI \<X+ K!UEEF/JPIJG3Q^*PTOK<>564Y^SJ0H59]92JT9<SUDGK?\7Q_@'P
M3B\<\71EF6 HRFZD\#AL1!X5N3NX0]K3G6I4^D84ZL>5;.UD?@W^PW_P2N\0
M>&-7TCXF_M0:7HEA<Z9-9:EHWP>L-4M/$_E:U83)=6U_XV\56.-+UJVLK^&#
M4-(TC0+?2[8&&*#Q#_:P$T<O[Q(B1HD<:+''&JHB(H5$10%5$50%554 *H
M    %.HK\HX@XBSCBC,:F:9UC*F,Q=1**<M*=*FOAI4*:]VE3CTC'YMO4_4\
M@X>RCAG+Z>69-A(87"T]6E[U6K-I*56M4:4JE25KN4ODDM HHHKQ#VPHHHH
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MSX?]!6/_ /"VO_\ )'YX_P!C_P#!6'_HHG_!/'_PS7[27_S]Z/['_P""L/\
MT43_ ()X_P#AFOVDO_G[U^AU%'U^7_0+@/\ PCH__(^7Y]V']GP_Z"L?_P"%
MM?\ ^2/XQO\ @Y0L/VT+7]DOX$2?M,>*OV7==\*-^TGIZ:!:? SP%\6?"?B6
M+Q&?A9\2VCN=5OO'WQ'\::3<Z"NF+J44]G:V%GJ1U&739XKPVL5Y!)]W_P#!
MK%_RC6\6_P#9UWQ=_P#43^%]>6_\'8G_ "99^SA_V=9IW_JGOBO7J7_!K%_R
MC6\6_P#9UWQ=_P#43^%]?<XBJZWAW3FX4X?\*R7+2IQIP5JE;:,4DF]V^KU9
M\'AJ2H^(]:"G5J)90WS5:DJL]:=#1SDVVET70_I*HHHK\W/TL**** "OQ?\
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M'AN%D4LS8 /SY+_P4VUCPSH7BRR^!7[-GP3^ /B3QI&(=>\:>#+5;S5KR/\
MTOF:V?0M*AGN$:^NI8+F>:1[>>4S1 /G/BVF_MM^,M&_9<\2_LR:7X/T>VB\
M::IJVJ>,?B6^M:A/XH\2R:[J4E]JR:EISV8LY);VW>/39;LWK2-;Q+(R&1B!
M\Q1X(XQ619WP[A,#'+,BSW'Y)A5@J^)X>68X' .<9\1YC6KY)A<%@JM/$4J4
M,+0PL/K&+G&<I248\T9?35N-.$99YDO$.+QL\RSS(\#G6*>-H8?B#^S\=CE#
MDX=R^E0SO%8W&4IX>I5J8FOB9_5\+"4(QC*4N62^?;_Q]>^-OC9)\3?%%RB7
MGB/XEVOB[7+J1SY4)NO$5OJ%[,78G$,48=\DX5%XX%?I%_P52^+?PN^*7B_]
MG^]^&WQ!\(>.[70?"L]OK<_A37;#6HM(N)+G172WU%[*65;2=HXI7\F4K(HC
MD5U5XW5?R)HK]=Q7"V"Q.=<.YS"M5P\N&\)F&#PF$I1I_5ZE',,-3PKC4YDY
MQ]A3IQ]DH22;TDFDC\GPO$^,P^3<09/*E2KQXBQ67XS%XNK*I]8IUL!BIXM2
MA:2A+V]2I+VKG%OK%IGZZ_\ !2WXM?"_XD_#W]E33_A]\0?"'C2^\*^"K"Q\
M2VGAG7;#6+C0KN/P[I]N]OJT5E-*UC,LZ20F*X$<JR1NC(&4BOH+XK_'GX):
MGI7_  3ECTWXL_#_ %"3X=^)O ]UX\CL_$^FW,G@ZVLO#T=M>7'B1(IF;2([
M6X#03F\$1CD4Y7:59OP(HKYV'AIET,MR#+5F6-=/(*F?5*%3DP_M*[S^CC*-
M=55R<J5!8R<J/(DVX04^9<U_H9^(^8SS'/,R_L[!*IGM/(J=>GSU^2@LAJX*
MK0=)\]VZ[P4(U>>]E.7)9I'[M_MI_![]GK]J?XW7'Q6T/]N[]FSP?83>%]$\
M/_V/JNMZ?J]XLND3ZG+)<_:[/Q190-',M^HCC$(93&V78,,?B)XKT:Q\.^)_
M$6@:9K^G>*M.T36]4TJQ\3Z0KII7B&TT^]FM8-:TQ9'D<6&IQ1+>6>^1V^SS
M1Y=CR>?HKWN%>&\7PS@J&62S[%YKE^#PE#!X##8G!9;A_JE.@N5-5L'AJ5>O
M*4$HMUZE2R5_B;9X7%'$6%XEQM?,HY'A<KS#&8NMB\=B<-C<QQ'UJI6LY+V.
M+Q%6A0BI7DE0IT]7;;0*0D $G@ $D^PZTM?8_P"Q-^RCXH_:I^+FEZ):6LMO
MX!\,WMCK'Q"\1/$QM++2HIQ)%I$+D>7-J>LO$UO#:[LFU6[F<H(U)]K-LUP.
M29;C,VS*O##8' 4)XC$5IM)*,%I&*?Q5*DG&G2IQO*I5G"$$Y22?C95E>.SK
M,<'E66T)XG&XZO"AAZ4%=N4WK.3VC3IQ4JE6I)J-.E"<Y-1BVOZ&_P#@E=\,
M+SX<_LC^$;W4HVM]3^(6J:SXVNK5D*M!!=W;:9I3$G[_ -KT?3+"]4X $=PB
M\X)K]'JSM(TG3M!TK3-#T>SAT_2=&T^STK2["W79;V6G:?;QVEE:0)D[8K>V
MACAC7)(1 "3UK1K_ #1XBSBKQ!GN;YW6BX3S3,,3C/9MI^RA6JRE2HW6ZHTN
M2DGU4$VV]3_2#A[**609%E.2TI*<,LR_"X-U$FO:U*-*,:M:SU3K55.JUT<V
MK):!1117C'L!1110 4444 %%%% !1110!0U6?[+I>HW.W?\ 9[&[FV9QN,5O
M(X7/&-VW&<]Z_$?_ ((A6PB^'O[0=SNR;OXB^'25QPGD:'?1\'ONSGVK]DOB
M1JO]A?#_ ,:ZSNV?V9X7UR]W'<=OV?3KB3.%!;C;V!/H#TK\G/\ @BQI/V7X
M&?$O6/+V_P!M_$5_WFS'F?V;!=6WW\#?LW[?]C.WV'Z=PZ_9>&'B--Z+%9EP
M9AH/^:='&YAB91^4%S'YIQ O:^)GAY!:O#9;QEB9K^6%;!Y=AXR^<O=UTU[[
M_LQ1117YB?I84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_"*\3_\ RJH_X0/Q]_T('CS_ ,(KQ/\ _*JO[UJ*/^)FL5_T1V'_ /#Y4_\
MG5Z_TM3_ (ELPW_17U__  R4_P#YZ^O]+7^"G_A _'W_ $('CS_PBO$__P J
MJ/\ A _'W_0@>//_  BO$_\ \JJ_O6HH_P")FL5_T1V'_P##Y4_^=7K_ $M3
M_B6S#?\ 17U__#)3_P#GKZ_TM?X*?^$#\??]"!X\_P#"*\3_ /RJH_X0/Q]_
MT('CS_PBO$__ ,JJ_O6HH_XF:Q7_ $1V'_\ #Y4_^=7K_2U/^);,-_T5]?\
M\,E/_P">OK_2U_@I_P"$#\??]"!X\_\ "*\3_P#RJH_X0/Q]_P!"!X\_\(KQ
M/_\ *JO[UJ*/^)FL5_T1V'_\/E3_ .=7K_2U/^);,-_T5]?_ ,,E/_YZ^O\
M2U_@I_X0/Q]_T('CS_PBO$__ ,JJ/^$#\??]"!X\_P#"*\3_ /RJK^]:BC_B
M9K%?]$=A_P#P^5/_ )U>O]+4_P");,-_T5]?_P ,E/\ ^>OK_2U_@I_X0/Q]
M_P!"!X\_\(KQ/_\ *JC_ (0/Q]_T('CS_P (KQ/_ /*JO[UJ*/\ B9K%?]$=
MA_\ P^5/_G5Z_P!+4_XELPW_ $5]?_PR4_\ YZ^O]+7^"G_A _'W_0@>//\
MPBO$_P#\JJZ'P]\&/B]XKNX[#P]\+_'NI7<LT<$<(\*ZS:%I9F"Q)YE_:6D(
MWL0-S2!1_$P'-?W:T5$_I,XUPDJ7"&%A4M[LJF<UJD$^\H1RZE*2WT52#_O*
MVMT_HVX-3BZO%N)G"_O1IY/2IS:_NSEF-6,7OJZ<UY.VO\NW[.W_  2&^-WQ
M$O[/5/C7.OPA\(JT4MWII:'5/'%XG#O9PV5O+_9FEEUS']OEU&\:VD*L+"X
M9*_HQ^#/P3^''P#\$:=X ^&7A^VT'0K%$:9D57U#5;P($DU'5KS8LEY>SX+/
M(P5$+,L,<:';7K%%?C?&?B3Q1QS.,,WQ4*. I3]I1RK PE0P-.HE95)QE.I5
MQ%5*_+/$U:KIWE[)0YI7_8.#O#GAG@B$IY5AIUL?5A[.MFF.G&OCJD-&Z<)1
MA3I8>E)I.5/#TJ2J-1=5U'&+11117P)]V%%%% !1110 4444 %%%% !1110!
M\[_M;Z^OA?\ 9B^/.OLP5M,^%?C.XA&[:9+A=$NU@B0_WY)2B*!W/IFOD/\
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MMR3UR3"A//UK^3_]M0X_8_\ VG#Z?!3QP?\ RFFOZC;+Q;MLK$?8<YLK-O\
MCX_OVT38_P!3VW8_"O\ :K]F?5JR\(N/*4IRE2I>)-=TX.3<:;J<+<-NHX1V
MBYN,7.UG+EC>_*K?R#](",5QEE<DDI2X8PBDTDG*V;9SRW>[M=VOM<[VBN+_
M .$O_P"G#_R9_P#M%'_"7_\ 3A_Y,_\ VBO]'C\-.THKB_\ A+_^G#_R9_\
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MX)_X37]C+XKQPQ>9?^'X_#WB2QX!V?V;XETG^T&YY4#29;\[AD\8(VDUTO\
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M^#_$>GW>I:5K&J>.-<\<ZMX%\7ZGHT"Z7#K>C:+X3TV:_GU9O[/>U73)Q/\
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M^%-)O_@OX^L+*\\<:)XJ\,Z+KW@5;J^NK:R@3Q?IFBRR7EQ!:JAGFCC;M?\
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M?C+_ -D?^*?_ *@/B&OP+_9?_P"38_V;O^S?_@Q_ZK?PU7ZS^TY_Y-]X5?\
M99<1?^J3 GS/T>O^2HXC_P"R?PO_ *LCUC6_#NC>(K?[/J]C%=8*M%< M#>V
M\B<QR07D+)<1M&V&5/,:(LH$D;KE3RN?$W@P>;<W=UXO\+1\2/)$K>*-%BY_
M?RRQF.WURSC! <1P:?/:H@(^V-(0GHE ..G^?\]Z_P C<LXGQN"PBRG&TZ6<
MY YRE/)<Q_>4:#J6]I7RC$RC/%9'C9.,)O%Y9.@Z\J5*GCZ6.PBJ82I_4^(R
MZC5JO%492PF.LDL70TG-1=XPQ-*ZI8RBM5[+$1GR*4I494:KC5C\M?MD7MGJ
M7[&?[2M_I]S%>6=S\$?&\D%S Q:.1&TPGC(5E8='CD5)(V!21%8%1_3-:?\
M'G8_]>%C_P"DD-?R_?MA^$=0C_9K_:%7PHUE:VOB/X6^,+#7],OKN/3]'MS?
M6#(WB*&:8BWTU[0EKC5%C$<-\JF9HS=RS32?TY:!JFFZYH.AZSHU_:ZII.IZ
M/IE[INI6,RSV=]9SV4+0W-M,A*RPRK\R.IPP.:_V9_9R83+<-X5\=5<IQ_UW
M 8SQ#J8BA3Q#I0S/ VX9R"E4P6:4*3Y(XBE.#]EBJ*6%Q^'E3Q-%4*DJ^"PG
M\D>.]3$3XNRQ8FA[*K3X;PM.4X*3PU9_VIFTE5P\Y:N$HR7-2F_:T)WIS<TH
M5:FM1117^A9^*A1110!_/#_P6-_:(_:D\!?M2_L*_L__ +/W[4'B/]ES0_C]
MXBC\->,_'&AV7AN]M=-.L>(+K1H]>UJ#Q+$EI<V6B0(ET+8ZIHT;E&\Z_C1L
MK]P?L5?L]_M1?#/XCZ]XH^,'_!5/4?VY?![^&)-)A^&S^#?A[HUGX>UJ>^L[
MB#Q1+J?@[QAXBNUGBMH9]/CM;FVAAD2\:02EE53^2G_!>O1/A'XF_;<_X)L^
M'?C]/HMK\#];\2VNF?%FY\1ZW<^&] @\!77B^_C\1R:SX@L[NPN]%TY=/:4W
M6I6U]:3VL698[B(KN'ZD?\$^_ '_  2%^#7C/QCX:_X)W^./@7=^//&FC0W?
MC#P[\-_C?KGQ.UW4-#TF> QWLNEZ]XK\1R65G:7 A$ES9QVXWE5D9@W/VN*C
M&EPUEKI49J=?!XB5:=+)\%B:<[8ZI%SQ&9U/]KPLXTX\L/9*7NJ/O15[?&X:
M4ZO$>8^UK4W"ABZ,*,*N;XW#U8)X*C)0P^64_P#9<5"4Y7DZKBTW)J,FM?RE
M_P""B/[;/[?OPA_X*,?$^P^ OQ?\3CX(_LX?##P%\9/B'\$(;729_#7B#P$O
MB.?1/&MW+$-&N=<N;T)JNFRM#;:E &%O',&B2VE2?[+_ ."GO[<7Q1\,> O^
M";OQ*_9=^*^K>!_"7[3?QET,>);SPP^EW;>(?!6JZ#X;UE/#5[<7]A>HL=M-
MJ-U8ZD+:."X$Z3Q"6)T^7GO!?A[1?%__  7S_:>\)^([.'4= \3?L52:!K5C
M<1I+%=:9JVM16-Y&R2!D+>1.SQL5)CE5)%PRJ1^+O[4FG^(OV<OB3\ O^"=O
MC:]U"6W_ &</VXD^)?[/MY?0W4EGK7[/7Q<_L"_T+1]+U.X9SJ%[X1UZZUJP
MU9VFG,<EH\"K"(]H]3!87!8NMD]+ZKAE7P658?%55["G;&8;%8"I&I4K1Y6J
MM7"XOV,U.:<N6O*3=J5SR\7B\9A*&;U7BL2Z.,S*OA:4G6J-X3$X;'494X49
M.5Z5/$X5UJ;A!J/-0C%1_>L_=+_@L!^U/\>OV=_C9_P3PT/X1_&'Q!\+?"GQ
M3^./A#P_\5K32YM#MM*\5>%KKQ=H]GJECXANM:TZ\6VTU]-GN8KN>"YL/*MF
MDD:XC"^8O4_\%M?VP/&/P(_8^T3QI^RY^T/H_@WXD7/QU^&_AZXU7X;>,? ^
MO^(I/"NJ6?B=]9L'L/,U]AIMS+:V!NYQ8 QO' HGBW@/\@_\' _A'P[\0/C%
M_P $S? ?B_3AJ_A/QM\<?#?A'Q/I+7-U9C5/#WB3Q5I.CZUIQN[&:WO;47NF
MWES;&XL[B"ZA$OF6\T4JHZ_/_P#P6F_X)8_L%_L;_LD:!\7/V;_@-;?#;XA2
M_'CX:^$G\0Q>._B/XC9O#^LV_B6[U+3_ .S_ !7XMUK2P+FXTNPD-P+,74?V
M?;%,BR2!^;*\+E<X<)/$QG&O7JXNU.G@L-7HXMK&N*6,J5,12FE%6C']SB+1
MV2MROIS/%9I"7%2PTHNA1I8-NI4QN)HU\+S8&G*3P5.G0JPNVW.7[[#WGNVV
MY+^J/X.:_J.O?!3X2>*O$>HR7^KZS\)O 7B+7]7O&B26^U/4O!FD:GJVI7;(
MD4*2W=W/<74Y1(X@\C;$1,*/Y.?%_P#P4Z_;5T;]IEOVP=/^,GB.[_X)\1_M
MG1_LW6OPIB_LA/"-YX2:WUZTO?&-U>_V%+J,<.F6EB^L835FCN=6M[.$RP1R
M%#^Q_P"W7^TK#^R]_P $C;?QE9:HNF^,_%_[/'PP^&/P],4@%_\ \);XX\ :
M'HUA?6,6=\ITF6XBN[EE!$,1#R#:>?P[U/\ 8P_X*S?\.O;_ /9*N/V0OV4;
M?X#6VAW7QAN/'$/Q<O#\=(YK.>#Q_JFM0: ?$ITQO%.H6VG7%A+HJ:&7DBOK
MK38(8[B52N/#V"PD(8C%XV.7^QQ>8?V;3CCJF'HJ.&3;QM;"^W:O7H^TP\:?
ML;5(MR2:;1KG^,Q4I8;#8*6.]MA,#_:,Y8*GB*O-B?=6"H8KV"?+1JNG7E4]
MJW"5HMQ:3/ZROVEO'FK>%OV7OC#\2_ 6KRZ9K&F?"36?%WA'7;41/-933:/'
MJ&D:E;B1986ECBN(IXO,22,/M+*P&#^ '_!&']O7]K/Q3\2?!?PF_;7^+.M?
M%;3?VH_A/=_%G]F_QYXM&EV]^;OPGK&L>&/%W@X3:3I&E6+3OJ'AR\:QTTK+
M>2S3F\$OE7,=O%]*_L?_ +3]U^U%_P $4_'^MZ_<I-X\^&7PA\>_"#QXA+BY
M76_!NG6RV\US#*S21%M+OK&T 8*IDLI0H!5A7QK\+/V>?%GQ._X(?_L=?'[X
M-1RP?M%?L=W7B7XZ_"B^L8GDU#4;?P]\0?$%]XK\*QP08DU1];TNQ^SZ?ITP
MFM_MDCN(&>1LYX+ X?"X+-<NQ]*@JM3.J651Q<Z<'4PU1X7$SP]:G5:YX4I8
MBE1=51DE*A.I>+=B\7CL1B<;EF/P-6LZ=/)ZF9O"PG)0Q,%B,-#$49TKJ$ZJ
MH5*JI\T;QK0ARM:GZ!?\$]?VF?CS\8?^"@W_  4K^%/Q)^)>O>*OAO\ !;XC
M7OA[X6>#;Z/34TCP9I=EXBCL(H=+^RV,%Z[/:DQS/>7=UO))4(:\A_:O_;/_
M &N/VDOV^KC_ ()K_L(>/-'^"%SX#T&?Q!\<_P!H*XTS^W?$7ADV3:<U_9^%
MK&<#2T;28=6TAOL]ZTIUY]5=8Y]+&DN;WQK_ ((=_%7PY\<_VWO^"CWQK\)2
MR/X?^*^MZ5\0+"WN(G@O-,'B36;/4)-'U"-\%-0TZ21K>[&%_> X1.@\_A^*
M'A[_ ()P?\%TOCWX^_:56]\$?!?]K+PO=2> _BMJ$$B>$K*2\3P[#')J^JJJ
M65K;6$^BWD>M2RN@TH7FE-<8%[&6ZW@:-/.,QA#!4*F,P>086M@\%*C"4)XZ
M&$P:JS>&<7"O5IJ5:JZ<H2YYQ<I*31SQQM6KE&7SGC*U/"8S/<31Q>-C6G&<
M<%+%8N5&*Q"?-0IU'&C152,X<D)*,9131^S'[)GP!_;Z^ WC[6+']H+]M"R_
M;#^#VJ>&KV:#6O&'P_M/ 'Q)\->+8!=-90Z9::+JVKZ7>Z%.%MOM4EQ-%<)F
M545L*6_#3]D3QS_P4$_;I^(O[6\\W_!7[Q/^R=HOP:^--SX.\->$-5\,?"W6
M;/4]'U+^T[V Z,WB+6_!UW:6&B1V<=@(\ZNS^8K37B.-C?T5?#3]O?\ 8_\
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MX(UC3]'UV73KC35U";1/$6FV=[/:P7.9);%IL&TO5S#=Q$2Q$IS7X_?\$O\
MX-?\$,=-_9]_94^,OQK\<?L[^'/VQ;#3M/U[Q)/XI_:'\3>'O%NG?$)->U.R
MTDZAX('C>UT2SU![1].CATPZ*MM,LL#FV=Y=S>AET73R;'UIX65/&?VO*C)4
M,DP>85*;>%<W0E1Q:7U2A&JM94[RIR48J#39PYC-5,XP-&&*C4PG]DPJP=?.
ML9E].I_M4(*O&MA6_K5>5-Z1J6C4BY2E-63/U!_X+G?M%?'K]ES]C[P?XY^
MOQ5\2_##QU<?%;P;X;U'Q7X:CTM=2O\ 2[N[T^WU&UFCU;3M4MDBO@\K3*D
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M_A=X*\,_#OP+X?2XBT+P?X/TFUT/PYH\=W=37UU'INE621VUJEQ>7-Q=3")
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M=DDDE>R226AG"G3IQY:<(4XW;Y81C"-Y.\GRQ25Y-MR=KMMMW;):<GWA^/\
M(TVG)]X?C_(U!8I^\OU_]G-*WW%_#^1I#]Y?K_[.:5ON+^'\C0 Y/NC\?YFG
M4U/NC\?YFG4 3KT'T'\J9_RT_P _W:>O0?0?RIG_ "T_S_=H*C]K_"_T)5ZC
MZC^=3'JOU_H:A7J/J/YU,>J_7^AH)'I]X?C_ "-*W1/I_04B?>'X_P C2MT3
MZ?T%!4/B7S_)DB]!]!_*IDZ'Z_T%0KT'T'\JF3H?K_04"EN_5_F-7JOU;^0J
M8=?P;^1J%>J_5OY"IAU_!OY&LZ?7Y?J:2WAZ_JA4^\/Q_D:L)]X?C_(U73[P
M_'^1JPGWA^/\C4Q^U_A?Z"J=/G^@/]X_A_(4].A^O]!3'^\?P_D*>G0_7^@J
M1OX/E']!]3)]T?C_ #-0U,GW1^/\S05'9>B_(=3D^\/Q_D:;3D^\/Q_D:!1V
M^[_TF)(W\/\ O#^M"?='X_S-#?P_[P_K0GW1^/\ ,T!';[O_ $F).OW!]1_Z
M%2I]T?C_ #-(OW!]1_Z%2I]T?C_,T#6\O7]$.HHHH&%%%% !1110 4444 %%
M%% 'Y=?\%4_V=KCXM_ L?$KPM;2'Q_\ !62;Q58368*7UWX;A"S:]:(\7^DW
M$ME;12WVFVL>X_:S(8U#2$U] _L+_M$Q?M*?L]^$?&-[<+)XQT>W3PQXZA+#
MS1XDTA!:W6H-$.8H-7,37]J&Y,<ASC&T?7EW:V]];7%G=PQW%K=PRV]Q!,BR
M1303(T<L4D; JZ.C%64@@@D&OP&_9PU&?]@;]O;QM^SIXANY+/X/?&N[2Z\#
MWMY(ZV%K>7C/<>$+B2=_DFNT4KX4OMBI&E]JL;NV$Q7ZOD5^,.!,UX9DO:YU
MPBZW$?#J^*M7RJJXK/\ +*7VI*G:EF%*E%2E4J*48I<MG^5YXUPCQSE7$L?W
M63<6*CP[Q ]J5#-*:;R',:OV8^TO5P%6K*T80<)2;OI_0#1117Y0?J@4444
M%%%% !1110!_/1^TO\+_ -H[7/\ @L9\ +/P?^U9_P (-J?B+]G;XVZOX"U0
M_ 3X>^*?^%;^&(=<TU;WP>+;5M2AC\7'47>.3_A(]8,&IV(A,5O$Z3R8^KY/
MC;^U!^TQ^T[\8OV8_@#\5=%^!OA7]E/P[X"L/BQ\=;_X<^%OB/XI^(OQ6\8V
ME_<MX8T3P#K=PGAGPWX=L-+TF36-0U$ZE_:JWNI6MC:V'V)?/7L?BA\'?BCK
M/_!5/]F/XUZ5X*U:^^$_@[]F[XQ>$?%'CJ&33QH^B>)M?UG3;C1M&NXY+Z/4
MFNM1@AED@:WL)[<*A\V>,X!\DL?!7QQ_8=_;3_:B^-FA?!#XF?M)_ 7]L+_A
M#?&<UK\$(/#.L_$[X9_%3P38W>B:AI^M>%?&'B+P/I%QX+\0Z+J%K/IFN6/B
MFYO[;4--NK6XT<1S1W"_4^VI8BAA8_[#/%4<F@L)"I2P<8_6?[1E&I&HY0C2
MJ5(X3VDX4<2Y1NW4C#VLU*7R_L:M"OBI+Z[##5LZ?UJ=.KBY3>&_LZG*G.%I
MRJ0I/&<E.I5PRC+EBJ4IJC!J/0?!G]K/X]^'O$W[8_[*?QXUWPIXP^/G[,'P
M\/Q4\%_&/PWH%IX?TCXJ?#;Q=IE]J_A#7]<\!P?\2WPSXG\.7N[PQK^AZ?-<
MZ;=?V0FJ6]S-'J!E9W_!-'X@?MP_M1?"7X)_M4?'KXO>$/#7@KQGX%TVX_X4
MCX2^&?A>=?&G_$HN+)/B)JOCPW7]L^%KOQ)J36_B.+PAH\,]CI,$8TJ64"61
M8N=^%O[.7QG^(/Q(_;>_;5^(GP]O/AMXJ_:&^#MI\&O@S\#+^[LK_P ?:+X
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M^$M;\?>%K6^\2^&K*ZEOM.T7Q)!FVUO3],OKA(I[W38+Z.5;*ZGBBEE@V&1
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M';;1_#\>H26UMJ=Z\%NW;?\ !5#X+_&[6]*_9Y_:,_9>\!ZW\1OCI^SEX_\
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MMDW_ ,8;GVR;_P"9UPEV/=J*M?8;W_GSNO\ P'E_^(H^PWO_ #YW7_@/+_\
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MA"?^#BK_ ()9E2!\2/C+DD_\T!\<>N:%_P"#BK_@EF  ?B1\9?\ PP/CFO\
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M(\62S2K#_P )KH__ !.+739KZRAW1W<BG'#Y9.O2A6E7ITJ<J..K-RC.3C#
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MG77QFL/!7BO2]&U#2?%&O^"['5=2\/2ZA:V9L]9N;/4K*8WEM #@_P#!0?\
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M&?N*;C**_9ZG+]X?C_(U^6ND_$WQ]\&_^"H?Q$^'7Q#^)?B?6?@C\<?V</\
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M:.2M-2DXJFE4?[/@$$9!'(Z_6I<$D8&>?Z&OQ8^-1\>?\$]/C[^R5XH\(_M
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M/\1_VA=1_;$^,_BKXM^/?V==0^)7QJ\/>.O%^K>-/@7XE\-?$70CXK\1^!O
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MC&XGM8]:\/:Q9R366I:?)-;3*0)(KZVPAO;*U$T'F?5_[(?_  2-_;-_;/\
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MGPM\=:=XOOO!FJZMJ.FV.HV?C;PTOB/2++3VEM='GEE*>P_MS?LX?%_]IO\
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M8V=.6+Q^(JPP63Y92UQ&9YIB'R87"48+WFI5&I5IQ3]E14YZOEC+S9%\4_\
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MEM0RW"O7DP.74K4*,(OEE*,ZB2C*,8E%%%?#GVP4444 %%%% !1110 4444
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M (,?^JW\-5^^GQD_Y(S\9?\ LC_Q3_\ 4!\0U^!?[+__ ";'^S=_V;_\&/\
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M@!X,_:2\ ^,+?_@E[^R+\!+WQ?XJCT/QK\:?AW=FQ\>:!H_C'4(_[<U8WZ^
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M<L%C$A*P2L C%]KDA3A&VMACP=K8/!IL-I=7"EH+:XG53M9H89)%#8S@E%8
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M,$4<:VVHP*\JOZ%_P43/AW]E3PE^RU^Q]\ / 7Q8T+X8_M._'75O"WQ,\,?
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M,N:,HO>,EI*G4@[PJ4IJ-2G-2A.,9)I%%%%>>>@%%%% !1110 4444 %%%%
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M-0.H7-S_ &A?6LFB2327MKY-M(EQ&BQ!D9F\<T;]D3]HG]G[XK?&'QA^QO\
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M]P]>#33C)<L[.5.<X6DWT445\\?0!1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% %*ZT^UO'BDFC_>PR))'(ORN"C!@I./F4D $$'
MZ8K^63]G6+R?!WQ%AW;O*_:H_;/BW8QN\O\ :P^,*[L9.,XSC)QG&:_JHK^5
MS]GS_D5?B7_V=;^VG_ZUG\8Z_@+]I+_RCUD'_9X^$_\ UB_$H_8_ 3_DXE;_
M +(S/?\ U=\)GN=86M^&/#WB.,QZWI-I?DX(F826]VI7[I6]M)+>[&T\A?/*
M9ZJ1D5NT5_A_@<PQ^5XJECLLQV,RW&T'S4,9@,57P>+HRT]ZCB<-4I5J4M%K
M"<7IN?V16H4<33E1Q%&E7HS5ITJ].%6E-=ITZD90DO*2:/.U\!7U@0/#WCCQ
M5I,0(V:?=7%IJFE1#(_U=O):078;'&Y[]P0!E<\U]!_\$VO#_P <]0^!OQ2F
M^'WQ2^'GA'0X/VOOVJ;&]T[Q3\(=2\;ZG?>)++XF747B'7TUBT^)?A6&UL-;
MU#=>V.B?V3))HUNRV<FK:J4%P.!7J/J/YU]6_P#!)W2KV_\ V=_C ULD;!?V
MW?VQ6.Z54.'^+NH1KP1W:"3CT /<5_J?^S;XESC/^-?%&&;5\-BIT.#LJJK%
M++,KP^85:D^(,/"4L9F6%P=#,,<I+5QQN)Q$>>U2WM$I'\T?2 P&%P. X4^J
MPG3C4S+,H.FZ^(J481A@82BJ-"K5G1H6O;]S3A[ON_#H>J_%;P9^T?)\*/BM
M)XB^.GP]N]*MOA=\1KF\L?#'P0O_  W?7]I;^"]<FNK%M2O?BEK\4*7D,;6Q
ME%@[PK*\BJ[!17XJ?L[> ]*UW]GKX!W^JZGXDO\ 2[_X)_"B]LO#-SJZ)HVD
M6-UX#T">UTFT6PM+*]>VL('CM(Y);QI)4B#OAFPO](?QKT'4[?X*_&:66*((
M/A#\3T)$ZD[I? NOQ)P!T+NH)[#)/ K^?+]E[G]F/]FT^O[/_P &/_5;^&J_
M4_VD.?9OP_P'X88C)L=5R[$U^+\_IO&8:-.&,HJGDV"G&6#QC@\3@:J<G>O@
MJN'K25HRJ.*27SG@)@\+CN).(*6+HPKTH9%A9JE4NZ<V\P<6JM._)6A;[%6,
MX)Z\M]3V+3=)TO1K=;72M/M-/@50FVVA5'=1T$LQW3SXP.9I)#D9SFM"BBO\
M6,3B<3C*]7%8O$5\5B:\W4KXG$UJE?$5JCWJ5:U64ZE2;ZSG*4GU;/Z\ITZ=
M*$:=*$*5."484Z<8PA"*VC&$4HQBNBBDET1\R?MJ_P#)GW[3G_9%/''_ *;&
MK^ERT_X\['_KPL?_ $DAK^:/]M7G]C_]IP?]44\<?^FTU_3S9^&]6-E8D10D
M?8;(?Z]>JVL*D<@=""/0XR,CFO\ :']F;_R:7Q _[.34_P#65X=/Y%^D#_R6
M.4_]DQA?_5MG!DT5O?\ "-:O_P \8?\ P(3_  H_X1K5_P#GC#_X$)_A7^D)
M^&&#16]_PC6K_P#/&'_P(3_"C_A&M7_YXP_^!"?X4 8-%;W_  C6K_\ /&'_
M ,"$_P */^$:U?\ YXP_^!"?X4 8-%;W_"-:O_SQA_\  A/\*/\ A&M7_P">
M,/\ X$)_A0!@T5O?\(UJ_P#SQA_\"$_PH_X1K5_^>,/_ ($)_A0!SS]1]&_E
M2_P?\!_I6\WAG5SC]U#T/_+PG<8]*7_A&=7VX\J'IC_CX3T^E &%3?X/^ _T
MKH/^$:U?_GC#_P"!"?X4G_",ZOMQY4/3'_'PGI]* .?3J?HO\J'Z#Z_T-;Z^
M&=7&?W4/0?\ +PG88]*&\,ZN1@0P]?\ GX3_  H P&^X?J?_ $*E3[H_'^9K
M>/AG5RI'E0\D_P#+PGKGTI5\,ZN !Y4/_@0GK]*"9*Z:7E^:,!/NC\?YFE'3
M\6_F:WE\,ZN !Y4/_@0GK]*!X:U<?\L8>I_Y>$[DGTJD_A\I-_\ I()/G;Z-
M?Y'/#[H_W7_F*8.C?3^HKHAX8U?&/)AZ,/\ CX3N>.U(/"^L<_NH.1_S\+Z@
M^GM3NKQUZK\H@D]?.5_E='/#K^#?R-*O\7^Z?Z5T \+ZP/\ EE!T/_+PO<$>
ME \+ZP,_NH.01_Q\)_A335M^L?PY;C?ZK\&C ;JWT'\UI'^\?P_D*Z$^&-7)
M)\J#D#_EX3V]O:D;POK!)/E0?^!">GTJ^:/=&=GKH_A2V?3E_P C 3K^(_DU
M(GWA^/\ (UT*^&-7'6*#K_S\)Z$>GO2+X7U@$'RH/_ A/3Z4<T>Z^\<D]=-V
MK?),YY>H^H_G2I]X?C_(UT \+ZP"#Y4'!'_+PO\ A0OA?6 0?*@_\"$]/I1S
M1[K[P:;Y]'KRV.>/1?I_4TE=$?"^L<?NH.!_S\+ZD^GO2?\ "+ZQ_P \H/\
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M+=+I)=8@5PVS3[286DNN:G/"%%YKFHBUTZR#6JV6FW3>:]?M_P#!CX&_#+X
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M1R(R..S*0>E?K/[3G_DWGA3_ -EGQ%^.28"WWV?W,^9^CU_R5'$?_9/X5?\
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M1Q#C=72G"G.4Z<K:\M2,9);HUJ***\D]4**** "BBB@ HHHH **** "BBB@
MHKCO%GQ"\"^!+&YU'QEXN\/>&K.TC\V>36-6L[)TC.""L$LHN)2000L43L5R
MP4@$C\^OBM_P5B_93^'Q?3_"FM:U\7/$#LT-II_@73FEL7NU!)@N]2OVMIH!
MD%/,M-.U#+E0J,A+CWLGX7XBX@J*GDN2YCF-VDZF'PM66'@VKWJXEQ6'I*SN
MW4JP2C>3=DV>%F_$_#V00<\YSG+LNLKJGB<52C7FKV_=X92>(JN^EJ=*;OI:
MY^FU>9_$SXR?"WX.:/+KOQ.\=>'/!MA' ]R@UC488K^\BC)5_P"S=)C:35-4
MD# KY6G6=S*2"-G!K\7;C]JK_@H[^UL_]G?L^?!YO@OX,OYO*_X3/5ED%]8*
M7*122^(M9MK0P))&7D=;7P?=-E24E'EJS>C_  W_ ."2$?B35HO&W[67QB\4
M?%?Q+<3+?7GA_2;VYM]%BO 5WPS:MJ37,NH6DFS]XEEHV@EE;:-A7)^U7 .3
M9#:IQWQ7@,LJ1UED.0RAGN?2DK7HU7AY/+\OFU>U3$8BI%-:Q=U?XQ\>9OGK
M=+@?A7'YG3EI'/<]C4R/(HQ>U:DL1%9ACX+K3P]"G)K::L[97Q&_X*E^/?BO
MK]S\-_V'_A'XA\>Z\\K69\;ZOHTL]A9,Y(MM1M])"RV]G92':#/XODT6$!AN
M 8[:R/ __!,OXW_'S7[3XC?MQ?&/7=7NG;SXO .BZS+?3V-O,ZO+I+ZE%*VG
M:#:CK'!X>N+V*-AMW*<D?LA\./A/\-_A%H-MX9^&O@S0O!VBVD0ABM-'LDA=
MHP0V+B[?S+V[.X [KJXF((&"  !Z'2J^(F'R.E4P?A]DE#AJG*#I5,\Q7)F/
M%&*@URRE+'U8NC@%45VZ.!I15.3_ '=9-7=4O#[$YU5AC./L[K\1U(R52GDF
M%]IEW#&%DK245@*<E6Q[A)>[6QU23FM*E%K1>8_"?X-?#3X'^%;7P9\+_".D
M^$]"MPK20Z=;1I<ZA<K&D37^JWNW[3J6H3+&OGWEW))-*PRS5Z=117YIB<3B
M,97JXK%UZV)Q->;J5L1B*DZU:K4E\4ZE6HY3G)]92DV?I&'PV'P="EAL)0HX
M;#4(*G1H4*<*-&E3BK1A3ITU&$(I;1BDD%%%%8&P4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW>.QL)9CCG+3WOKF/EB*\9.VKA.-^HU55%5$541%"HB@*JJH 554 !54
M    8IU%%?&'V(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
E44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img22994243_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img22994243_4.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" ):!=P# 2(  A$! Q$!_\0
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M0:7;7,M]-:V-Y<1P-#;3.@VEJW9=V"3>B5WV1ZU1110 4444 %%%% !1110
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MG:5TW-2U6J4(RM]K34<</!N:LW%2G&,U)NW*KK10<=]'S2C?HKZ']FW[7O\
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MN7*XQKJFHN/:K&S;OJ[>2[W)C"":45)2=!U'+FTUIW:M;9N]]=G8^X/VI_\
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M&O#^J7$_A-VO6L-=_H4T?_@L_P#LL:W^TW^PK^RC:^"OCS%\2/\ @H)^S/\
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M4Z4)JE:FU>@Y*47\4TI-1LHZR3U;W:LK:']/WC+_ (*??L^^!O\ @I%\)O\
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M>TG&,M&K1A!QU;4;-RU=]K6[A'#QO&\97]G3E*.J=Y3DI:*+EI%:*VZU[/\
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MVOAK2WN;BWM9]0@NIHX6_%O_ (+W_M>?"O\ ;L^!G_!*[_@HE\+/!7Q)\?\
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M[<+ICZ%K/AT^$?%%CXJM_%EWX?A\.:SH5]H.J7%OK7V:PN/E_P#8&_X.-O\
M@GE_P4+^.6A?LY_#.'XY_"KXL>+TU4>!-"^.G@;PEX>LO'%WHNC7OB#4=+T'
M7? /Q$^).BV^J1Z/INHW=M8^(;[0IM2:RDL]+%[?S6EK<?S6>$/VGOC_ /\
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M/#?@[PU8XN=3U$V=I<W=U=7,MAHFD6<+7FMZMIMIB<_SC?\ !J996>A^-/\
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MD9]\_AR: Z%(L3O:Q/IYALW>UCA8_P :-OX6_P""EG_!6?\ X+-_ML_MN?\
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M6LDK2YM7O:S2W:(X>-]8R=HTN:.NCFKS>B<KJSLK6Z;V/]'S_@GW^WG\(/\
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M_P#&?]JWX&?!#1OBQI?B[]D#QC!X,^(M_P#$+POX>T'P[XENI_$GC/PHNK>
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M[C\#^-M7T>\\2^$X[IKBX:X30=3T]9FGF,@8RON\<_:5_;O_ &4?V/\ QM\
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M$U3P%X@\3Z'JFK>#]175M%T?5%OO#UWIURNHZ3IEZ)1<V%K+%XUXQ_X)R_\
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MUE&@-O 866]!B,$)0J8TV^C>$_CS\#?'OQ"\=?"3P+\9_A/XT^*WPO\ L_\
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M.N+BS72O@;XH\"WUW?+!9+%#:OIV@_L^ZQ8Z_NLI([)]?\.742PQW4-JT/\
M75^WG_P;?_L+_P#!0S]HC6?VE?B_\2/VHO!'C+6?"O@OP<WAGX0>-?A+X>\
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MM%LM$N7TK4;[0I_'OC_X?WFIZ5 M_<66FHTD</W=_P %&O\ @M[\(/V$-,^
M'A3P7\$OBM^U+^TM^U%X-T_Q_P#!G]FWX<02:=XMO_"6KVOF:1J_BR\L='\9
MZIHRZQJ"7NC:3I_AOPCXUUB_U'1?$'E:;]DT>>Z?^-G]MC]I#X$^$?VIOC-X
MP_X)T?"#_@IW^P7_ ,%4=2^..MP^(?@U\(I+/Q1^SM\8[Z'XDZA_;OB6Z\.'
M5-&^+N?&EO=ZQXGTSP7;?"[7?AC<W=U;^'+?P?#I&JW>M6WV9_P6H^$O[5WP
MS_:Z_P""<?\ P4N_:=\._M:^#_!4O[$?P?\ !?[5_P 3_P!@_P 1Q?#+XW_
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M-KXDTK4]1U76;6XU^>#39D;\>OVW?@E\4/\ @B5X0_9:\6_#KPM=:)%^W_\
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M]KZZKHK?P\)_V#R_]2\4<]'^)B_^PB/_ *B84****YSH"BBB@ HHHH ****
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M'ACNKSXP_L426EL\JJ46XNDM+M[>%F$DZ6MPT2L(9"OA?_!9GXSM_P $Y/\
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MTJ+QE+I'A72=-UO5O$&D1>!] T2UTVQLWGUJTCBO-1;ZX_X*+V=W)_P:\_\
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MIZIX%\0OK'AWPCJS:OX;N[B73+XZGX6\.WYGMW^UZ+IL_F6D7\"OP@_X)?\
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M16E[?6!U#39Y=.O[_3Y+:]G_  J_9X^('PK_ &,/AA\1OV)O^"@WC'_@O?\
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M/7'@_P $^.+BYU^&X@@,&GZE9:5IUS#-+))K5J\"17'[JT45*BE*4EO*U_\
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M6?\ \D4?\(MKW_/C_P"35G_\D5[!11]=J_RT_NE_\F'U*E_-4^^/_P @>/\
M_"+:]_SX_P#DU9__ "11_P (MKW_ #X_^35G_P#)%>P44?7:O\M/[I?_ "8?
M4J7\U3[X_P#R!X__ ,(MKW_/C_Y-6?\ \D4?\(MKW_/C_P"35G_\D5[!11]=
MJ_RT_NE_\F'U*E_-4^^/_P @>/\ _"+:]_SX_P#DU9__ "11_P (MKW_ #X_
M^35G_P#)%>P44?7:O\M/[I?_ "8?4J7\U3[X_P#R!X__ ,(MKW_/C_Y-6?\
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MNU?Y:?W2_P#DQ_4J7\U3[X__ "!X_P#\(MKW_/C_ .35G_\ )%'_  BVO?\
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M )-6?_R17L%%'UVK_+3^Z7_R8?4J7\U3[X__ "!X_P#\(MKW_/C_ .35G_\
M)%'_  BVO?\ /C_Y-6?_ ,D5[!11]=J_RT_NE_\ )A]2I?S5/OC_ /('C_\
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M_P#\(MKW_/C_ .35G_\ )%'_  BVO?\ /C_Y-6?_ ,D5[!11]=J_RT_NE_\
M)A]2I?S5/OC_ /('C_\ PBVO?\^/_DU9_P#R11_PBVO?\^/_ )-6?_R17L%%
M'UVK_+3^Z7_R8?4J7\U3[X__ "!X_P#\(MKW_/C_ .35G_\ )%'_  BVO?\
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M\$_\@JX_["$O_I-:5V%>+B/XU3_%^B/:P_\ !I_X?U9\V_%G]LO]D#X">.]
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M.BOS\_X2C_@IU_T2?]CS_P .5\4?_F8H_P"$H_X*=?\ 1)_V//\ PY7Q1_\
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M4?\ YF*/^$H_X*=?]$G_ &//_#E?%'_YF* /T#HK\_/^$H_X*=?]$G_8\_\
M#E?%'_YF*/\ A*/^"G7_ $2?]CS_ ,.5\4?_ )F* /T#HK\_/^$H_P""G7_1
M)_V//_#E?%'_ .9BC_A*/^"G7_1)_P!CS_PY7Q1_^9B@#] Z*_/S_A*/^"G7
M_1)_V//_  Y7Q1_^9BC_ (2C_@IU_P!$G_8\_P##E?%'_P"9B@#] Z*_/S_A
M*/\ @IU_T2?]CS_PY7Q1_P#F8H_X2C_@IU_T2?\ 8\_\.5\4?_F8H _0.BOS
M\_X2C_@IU_T2?]CS_P .5\4?_F8H_P"$H_X*=?\ 1)_V//\ PY7Q1_\ F8H
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MH_X*=?\ 1)_V//\ PY7Q1_\ F8H _0.BOS\_X2C_ (*=?]$G_8\_\.5\4?\
MYF*/^$H_X*=?]$G_ &//_#E?%'_YF* /T#HK\_/^$H_X*=?]$G_8\_\ #E?%
M'_YF*/\ A*/^"G7_ $2?]CS_ ,.5\4?_ )F* /T#HK\_/^$H_P""G7_1)_V/
M/_#E?%'_ .9BC_A*/^"G7_1)_P!CS_PY7Q1_^9B@#] Z*_/S_A*/^"G7_1)_
MV//_  Y7Q1_^9BC_ (2C_@IU_P!$G_8\_P##E?%'_P"9B@#] Z*_/S_A*/\
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M .&O^'7_ ,JJ /H>BOGC_A6OQV_Z.2U/_P -?\.O_E51_P *U^.W_1R6I_\
MAK_AU_\ *J@#Z'HKYX_X5K\=O^CDM3_\-?\ #K_Y54?\*U^.W_1R6I_^&O\
MAU_\JJ /H>BOGC_A6OQV_P"CDM3_ /#7_#K_ .55'_"M?CM_T<EJ?_AK_AU_
M\JJ /H>BOGC_ (5K\=O^CDM3_P##7_#K_P"55'_"M?CM_P!'):G_ .&O^'7_
M ,JJ /H>BOGC_A6OQV_Z.2U/_P -?\.O_E51_P *U^.W_1R6I_\ AK_AU_\
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M_P"W7_TLMZ\?KU,#_"E_U\?_ *3 \O'?Q8_]>U_Z5,****[#C"BBB@ HHHH
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M_MG?"[3OC;X0^"/QL^%OPF\8Z1X?\5?"#QM\84^#^GP?&SP#XIM;K4-"\?\
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MAG5/$\\NC-X-U_Q1X^T'P+X?L9?$[>'+VYLOBA;6OQ.\(1:+\2-+T._TCO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MSX,_]%W- 'Z=4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX57?C#2/ FI>.;O2Y](\,7GCB]\.Z1J_B"YT?PY::C)KVOZ%IVH@'V71110
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M5H5GZ3_R"M,_[!]E_P"DT5:%>#/XY?XI?FSWH?!'_#'\D%%?+'[;7[57A?\
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M^^3X1_#SP]I^K>'M?\;:_P"-/!?Q)\>ZS)KLP!^;_P"Q-^VA^T#^UO\ '_\
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M_P .]OV'?^C4_@9_X;W0/_D2OH#_ (1?QW_T4^]_\)/PS_\ (U'_  B_CO\
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M !I^#NOW>]X;SP9K6G+:6+M@F.SLYK-);>T)53]FBO$PPW+(#7"/_P $R_\
M@JI^SZS7/[+?_!1C4?&6B:1;E-"\!?%^/5A:W0CA"1VNIWEZ?%&ENGRA8IEL
M(_)!&8VP6/H_V_QC@7;-."GC:<7[V*X;SG"8V\4W>2P.90RO%7Y5S<D)5I-N
M,$V[M>O_ *S\?9;=9SX>O,*4&N;&<(Y_@LQYHW?-..6YO3R7&74%S*G3E7G*
M3C"-VVU_1[17\T&J?M-?\%]/@%<QQ_%']F;P/\<O#=C&TNJ>(_A7IFA7UU+;
M1*2WV2#1]3M[Y[W W@'PM)'+@JL6]E6K'AW_ (+W>%/#<MOI/[3OPN_:9_9Y
MU^:=K=8]2^&/AG5;2X*-&DMS%::YIGA#5(X8&<M/&D=[+'& RF4NJEQ\1>&J
M34,UGF?#M6]G3X@RC,,MBFN6Z^MU*$\!*SFHWABY)O1-Z7</%?A&BU3SN><<
M*UWHZ/%&19IE$4[1NOKM7#3RV5G-1O#&R3EI%RTO_2O17Y6?"?\ X*:?L;?&
M0Q0^%?VZ?!>EZC((]^E^.?#NA> KJ!I<!$DG\6:;I6F.Q)P3;ZA.BM\I8'BO
MS#_;W_X+4>)/V>/VM/AC\+/@[\3=)^(GPN\&7^F7?Q[\1:1X?\):Y'K%KK3)
M'?:/X-U'2Y)-/O+SP]HEW->X,BC_ (26SM[265[7S5/9FO'?"F3Y9#-\1G6!
MQ&!J8K#82%7 8G#XWFJXJJJ::6'JSO"C%5*]=IWA1HU9)2E%0?=GGB7P1D.3
M4\^Q7$.6XK+*N-P> IU\LQF%S'FKXRLJ46EAJT[PH057$XEIN5/#X>M)1E."
MA+^H^BO#O FH:G\2_!OAGQ_X*^,IUWPGXOT:QU_0-7L/#7A2ZM;[3=0A6>"6
M.>&W:)RH8QRA&.R9)$.&4@=9_P (OX[_ .BGWO\ X2?AG_Y&KZR$XU(1J0E&
M<)QC.$XM2C*,DI1E%K1QDFFFM&G='W%.<*L(5:<XU*=2$9TYP:E"<)I2C.,E
M=2C*+3BTVFFFM#T6BO.O^$7\=_\ 13[W_P )/PS_ /(U'_"+^._^BGWO_A)^
M&?\ Y&JBST6BO.O^$7\=_P#13[W_ ,)/PS_\C4?\(OX[_P"BGWO_ (2?AG_Y
M&H ]%HKSK_A%_'?_ $4^]_\ "3\,_P#R-1_PB_CO_HI][_X2?AG_ .1J /1:
M*\Z_X1?QW_T4^]_\)/PS_P#(U'_"+^._^BGWO_A)^&?_ )&H ]%HKSK_ (1?
MQW_T4^]_\)/PS_\ (U'_  B_CO\ Z*?>_P#A)^&?_D:@#T6OS$_:P_Y/W_X)
MQ_\ 85^/7_J$Z57WM_PB_CO_ **?>_\ A)^&?_D:OSI_:1TS6]-_;U_X)VC6
MO$LWB-IM5^.GV=YM+TW2_LGE^"M/\T*NG11B;SP\0/G;C'Y(*$>8] 'ZMT44
M4 %<?XV_Y!5O_P!A"+_TFNZ["N/\;?\ (*M_^PA%_P"DUW6V'_C4_P#%^C,<
M1_!J?X?U1Y?1117M'BA1110 4444 ?(OC/\ Y/S_ &;?^S1?VV__ %<O_!/V
MOKJOD7QG_P GY_LV_P#9HO[;?_JY?^"?M?75=%;^'A/^P>7_ *EXHYZ/\3%_
M]A$?_43"A1117.= 4444 %%%% !1110![AI/_(*TS_L'V7_I-%6A6?I/_(*T
MS_L'V7_I-%6A7@S^.7^*7YL]Z'P1_P ,?R1^77_!9G]F_P")7[57_!.KXY_"
MKX.^'M5\8?$^RUCX,_%;P=X+T+Q+<>#==\;WOP.^./PY^,.I>"] \5V6K:!J
M'ASQ)XKT#P3J^@^%]<TW7M$U#2?$M_I.H6>IVLUNK'\U/"7[)_PN^.W[8/A3
M5_\ @G=^R+XV_8(_9\G_ &'OVKOA9^V9X@UG]C7QU^P9X)^+_BOX^:#X=\+?
MLZ?"N;X.^/\ X7?"75_B[X^^#^OVOQ!^)NJ_$WPCX.\1^#O!.AE?"MW\1;K4
M?&GA_0)_Z<**DH_ED70_CC^T!_P3!_8C_P""2EQ^R_\ M&^#/VAO >O_ +#W
MP+_:>U/QO\"?BSX2^!7PJ^%G[#/Q>^&'B'XA_&+0/VH=9\-Z=^SM\5]'\?Z%
M\ ='O?A9H_P>^*'C_P 8>+$^)6A0/X8T2XTWQ<WA#^INBB@#XN\<_L*?"OX@
M>-/$?CK6/BO^VCI&I^*-5?5[_1_ W[>O[97PZ\%6,\D<,36GASP)X$^-_A[P
MAX4TH+"I32/#6C:5IT4CS2Q6R2S2NWS#_P $:O >DWO_  2O_80FEU;QM&__
M  SMX*0BU^('C:SC;;'= ,8;;7HH0Y! 9EC4M@%LMDG];Z_,7_@B]_RBJ_80
M_P"S>?!G_HNYH ^^_P#A7&C?]!KQ_P#^'*\>_P#S14?\*XT;_H->/_\ PY7C
MW_YHJ[^B@#@/^%<:-_T&O'__ (<KQ[_\T5'_  KC1O\ H->/_P#PY7CW_P":
M*N_HH X#_A7&C?\ 0:\?_P#ARO'O_P T5'_"N-&_Z#7C_P#\.5X]_P#FBKOZ
M* . _P"%<:-_T&O'_P#X<KQ[_P#-%1_PKC1O^@UX_P#_  Y7CW_YHJ[^B@#@
M/^%<:-_T&O'_ /X<KQ[_ /-%1_PKC1O^@UX__P##E>/?_FBKOZ* . _X5QHW
M_0:\?_\ ARO'O_S14?\ "N-&_P"@UX__ /#E>/?_ )HJ[^B@#@/^%<:-_P!!
MKQ__ .'*\>__ #14?\*XT;_H->/_ /PY7CW_ .:*N_HH X#_ (5QHW_0:\?_
M /ARO'O_ ,T5'_"N-&_Z#7C_ /\ #E>/?_FBKOZ* . _X5QHW_0:\?\ _ARO
M'O\ \T5'_"N-&_Z#7C__ ,.5X]_^:*N_HH X#_A7&C?]!KQ__P"'*\>__-%1
M_P *XT;_ *#7C_\ \.5X]_\ FBKOZ* . _X5QHW_ $&O'_\ X<KQ[_\ -%1_
MPKC1O^@UX_\ _#E>/?\ YHJ[^B@#@/\ A7&C?]!KQ_\ ^'*\>_\ S14?\*XT
M;_H->/\ _P .5X]_^:*N_HH X#_A7&C?]!KQ_P#^'*\>_P#S14?\*XT;_H->
M/_\ PY7CW_YHJ[^B@#@/^%<:-_T&O'__ (<KQ[_\T5'_  KC1O\ H->/_P#P
MY7CW_P":*N_HH X#_A7&C?\ 0:\?_P#ARO'O_P T5'_"N-&_Z#7C_P#\.5X]
M_P#FBKOZ* . _P"%<:-_T&O'_P#X<KQ[_P#-%1_PKC1O^@UX_P#_  Y7CW_Y
MHJ[^B@#@/^%<:-_T&O'_ /X<KQ[_ /-%1_PKC1O^@UX__P##E>/?_FBKOZ*
M. _X5QHW_0:\?_\ ARO'O_S14?\ "N-&_P"@UX__ /#E>/?_ )HJ[^B@#@/^
M%<:-_P!!KQ__ .'*\>__ #14?\*XT;_H->/_ /PY7CW_ .:*N_HH X#_ (5Q
MHW_0:\?_ /ARO'O_ ,T5'_"N-&_Z#7C_ /\ #E>/?_FBKOZ* . _X5QHW_0:
M\?\ _ARO'O\ \T5'_"N-&_Z#7C__ ,.5X]_^:*N_HH X#_A7&C?]!KQ__P"'
M*\>__-%1_P *XT;_ *#7C_\ \.5X]_\ FBKOZ* . _X5QHW_ $&O'_\ X<KQ
M[_\ -%1_PKC1O^@UX_\ _#E>/?\ YHJ[^B@#@/\ A7&C?]!KQ_\ ^'*\>_\
MS14?\*XT;_H->/\ _P .5X]_^:*N_HH X#_A7&C?]!KQ_P#^'*\>_P#S14?\
M*XT;_H->/_\ PY7CW_YHJ[^B@#@/^%<:-_T&O'__ (<KQ[_\T5'_  KC1O\
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MF5.-2G0JN3R_A_+YRY*F?9]4A_!PM%7>%PG,L3F-=1HT(M-R%_8X_8_^-/\
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M *A.E5^G=?F)^UA_R?O_ ,$X_P#L*_'K_P!0G2J /T[HHHH *X_QM_R"K?\
M["$7_I-=UV%<?XV_Y!5O_P!A"+_TFNZVP_\ &I_XOT9CB/X-3_#^J/+Z***]
MH\4**** "BBB@#Y%\9_\GY_LV_\ 9HO[;?\ ZN7_ ()^U]=5\B^,_P#D_/\
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M&TL],O+&5]1DDEN8K/ZG'\5\/Y9+'4\;F$:%3+:^!PN+I_5\75J1Q.9498C
MT*-.CAZD\75Q%",ZD882->4(PG[10<9)?0XSB3)<!+&0Q>-5*> K8/#XF'L,
M54G&OCZ3KX2C2A2H3EB:E:E&4U'#*LXQC+G47%I?=GA+]J?X"^.OCOXZ_9G\
M*>/HM7^-WPTT*3Q+XV\$Q^'?%ML=$T6*?PY;2W;>([[0+;PEJ#Q3^+O#T4MG
MI6O7U]&^H@/;+]EO?LWT%7\OW_!,7XR6'QR_X*Z_M<?&5?#>N^ ;;Q=^SWXJ
MU2_\+^,8X['7/"MYIOC3]GS2]:TS6@?+2)]-U#3;V-IIDM7:WC2>XM;.5I+:
M'Z3\8_\ !<=;_P 5>.+?]FW]C;XN_M'_  S^'5Q+#XI^*VAZKJ^BZ+9VML_E
MS:VUEH7PV^($.GZ!<>7<3Z7J'B/6- FO;-(+B>RL?/>.#Y[*O$#*ZF63S+.<
M9A\+"OG.<8'+8X7"X^M4Q6#R^NU2K_5:4,7BG)8=TZF*J^SIT:;FG*%%243Q
M,NXURZ>7RQ^:XFAAX5LUS3!X!8;#8RK4Q.%P-9JG6^KTH8G$.2H.G/$5/9PI
MP<US1I<RB?O=17Y'ZE_P5Q^%]]^PQXB_;3^'OPZUKQ6?"/C30OA[XG^$^N>)
M;'PIK.B^*M7O]'MY8+OQ%9Z3XKMVTM=/UFVU?2M4M]%G&K6[+;2VVF7T=_;Z
M?\U>)?\ @O#9:!'X=\;0_L8_&B\^ .M:C9:*_P ;[S5+W0]!O-:$"2:WI_A"
M+4? (\/>)YM.=;S[!;W?C3PYJ>HV]LL]YIFBM))!;^IBN/>$L&J+KYQ34<1@
M\/F%*5/"X[$1E@L5.K2I8ERP^%JQA252C4A6<W'ZM-1CB%2=2FI>AB.,N&L,
MJ3K9I32K86AC:<H8?%UHRPN(G4ITZ[E1P]10I^TI3A5<W'V$E%5U3<X<W] M
M%?D?^UI_P5M^'/[+?B3X 11_#36?B;X ^/GPGE^+>B>--!\2)I6I6^C:EISW
MG@NRTSPG<^'+[^V[GQ5<2:;:M+=:_H$>D1:BEW*MX()8:\M^(O\ P6&\:_"?
M]FCP]\??B-^Q3X[\!:_X@^.&K?"*#X5^//'>J>#M8&CV'@+1/'EAX_M]2USX
M26U]=Z9K%MK/]G6=B/#$%NUQ8W4\&MW4(4'3$\<<+X2KCJ-?-$JF6TU5QOL\
M'CZ\*%.5.A5A-U:&%J4IQJ0Q-*5+V<Y^UO45/FE1K*G=?B[A[#5,92K9BE/
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M;SX,_P#1=S7Z=5^8O_!%[_E%5^PA_P!F\^#/_1=S0!^G5%%% !1110 4444
M%?G'_P %<(Y)?^"=7[3:Q1O(P\,^$Y"L:,[".'XD^"YII"%!(2*)'ED<C:D:
M.[$*I(_1RBN#-<#_ &GE>99;[7V']H8#&8'VW)[3V/UO#U*'M?9\]/VGL_:<
M_)SPYK<O/&]UQYCA/[0R_'X#VGLOKN#Q6$]KR>T]E]9H5*/M.3FAS\G/S<G/
M#FM;FC>Z_A]@_:6_8>\8_L)^'?V9_#?[&^L^+?VOW\*P:';_ !2T#X5_#_3-
M4E\8C5[RY@\26_CKPGK=[\4?%1M;6XMK<Z+J>@K;:UM%GJ"K;0PLWUI^V/\
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M9?6CF&(P^(HXBHY5Z_U3 X+#\T8SDG4Y;_=5%%%?LQ^J!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!\T?LC_ /)%E_[*W^TA_P"M'?%>OI>OFC]D
M?_DBR_\ 96_VD/\ UH[XKU]+T %%%% '/^*?^0#?_P#;K_Z66]>/U[!XI_Y
M-_\ ]NO_ *66]>/UZF!_A2_Z^/\ ])@>7COXL?\ KVO_ $J84445V'&%%%%
M!1110 4444 %%%% !1110 4444 >H>"?^05<?]A"7_TFM*["N/\ !/\ R"KC
M_L(2_P#I-:5V%>+B/XU3_%^B/:P_\&G_ (?U84445B;!7RG^W3_R9G^U'_V0
MGXF_^HIJ=?5E?*?[=/\ R9G^U'_V0GXF_P#J*:G0!X%_P1L_Y1-_\$W_ /LR
MK]G'_P!59X:K]*:_-;_@C9_RB;_X)O\ _9E7[./_ *JSPU7Z4T %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2,RJK,S!54%F9B
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MLO(@_P">,7_?M/\ "CR(/^>,7_?M/\* .-_X69\.?^A^\&?^%/HO_P FT?\
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M/^%F?#G_ *'[P9_X4^B__)M=EY$'_/&+_OVG^%'D0?\ /&+_ +]I_A0!QO\
MPLSX<_\ 0_>#/_"GT7_Y-H_X69\.?^A^\&?^%/HO_P FUV7D0?\ /&+_ +]I
M_A1Y$'_/&+_OVG^% '&_\+,^'/\ T/W@S_PI]%_^3:/^%F?#G_H?O!G_ (4^
MB_\ R;79>1!_SQB_[]I_A1Y$'_/&+_OVG^% '&_\+,^'/_0_>#/_  I]%_\
MDVC_ (69\.?^A^\&?^%/HO\ \FUV7D0?\\8O^_:?X4>1!_SQB_[]I_A0!QO_
M  LSX<_]#]X,_P#"GT7_ .3:/^%F?#G_ *'[P9_X4^B__)M=EY$'_/&+_OVG
M^%'D0?\ /&+_ +]I_A0!QO\ PLSX<_\ 0_>#/_"GT7_Y-H_X69\.?^A^\&?^
M%/HO_P FUV7D0?\ /&+_ +]I_A1Y$'_/&+_OVG^% '&_\+,^'/\ T/W@S_PI
M]%_^3:/^%F?#G_H?O!G_ (4^B_\ R;79>1!_SQB_[]I_A1Y$'_/&+_OVG^%
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M_A2_Z^/_ -)@>7COXL?^O:_]*F%%%%=AQA1110 4444 %%%% !1110 4444
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M!)?_  =:_P#_ "TH_P"%3^ ?^@)+_P"#K7__ ):4 >BT5YU_PJ?P#_T!)?\
MP=:__P#+2C_A4_@'_H"2_P#@ZU__ .6E 'HM%>=?\*G\ _\ 0$E_\'6O_P#R
MTH_X5/X!_P"@)+_X.M?_ /EI0!Z+17G7_"I_ /\ T!)?_!UK_P#\M*/^%3^
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M);6W%S-]M_\ !(__ ()JR_LI^%=0^/\ \=U?Q/\ M9?&*T?5?%NK:U.-5OO
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M!0P[A2A3]O3Y/;**\Z_X5/X!_P"@)+_X.M?_ /EI1_PJ?P#_ - 27_P=:_\
M_+2OZ"/ZF/1:*\Z_X5/X!_Z DO\ X.M?_P#EI1_PJ?P#_P! 27_P=:__ /+2
M@#T6BO.O^%3^ ?\ H"2_^#K7_P#Y:4?\*G\ _P#0$E_\'6O_ /RTH ]%HKSK
M_A4_@'_H"2_^#K7_ /Y:4?\ "I_ /_0$E_\ !UK_ /\ +2@#T6BO.O\ A4_@
M'_H"2_\ @ZU__P"6E'_"I_ /_0$E_P#!UK__ ,M* /1:*\Z_X5/X!_Z DO\
MX.M?_P#EI1_PJ?P#_P! 27_P=:__ /+2@#T6BO.O^%3^ ?\ H"2_^#K7_P#Y
M:4?\*G\ _P#0$E_\'6O_ /RTH ]%HKSK_A4_@'_H"2_^#K7_ /Y:4?\ "I_
M/_0$E_\ !UK_ /\ +2@#T6BO.O\ A4_@'_H"2_\ @ZU__P"6E'_"I_ /_0$E
M_P#!UK__ ,M* /1:*\Z_X5/X!_Z DO\ X.M?_P#EI1_PJ?P#_P! 27_P=:__
M /+2@#T6BO.O^%3^ ?\ H"2_^#K7_P#Y:4?\*G\ _P#0$E_\'6O_ /RTH ]%
MHKSK_A4_@'_H"2_^#K7_ /Y:4?\ "I_ /_0$E_\ !UK_ /\ +2@#T6BO.O\
MA4_@'_H"2_\ @ZU__P"6E'_"I_ /_0$E_P#!UK__ ,M* /1:*\Z_X5/X!_Z
MDO\ X.M?_P#EI1_PJ?P#_P! 27_P=:__ /+2@#T6BO.O^%3^ ?\ H"2_^#K7
M_P#Y:4?\*G\ _P#0$E_\'6O_ /RTH ]%HKSK_A4_@'_H"2_^#K7_ /Y:4?\
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M*%%%%<YT!1110 4444 %%%% 'N&D_P#(*TS_ +!]E_Z315H5GZ3_ ,@K3/\
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M^TBZMKVWU'Q/XOT:]L=?UR[ENK2&:X%]>RVLA58TMHX8X8X_DG_AP+_P3/\
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MVGC;[LD,\+/%*AP<.CLI[&K%"::NG=/5-;-=P335T[IZIK9KN%%%% !1110
M4444 %%%5K2\L[^!;FQNK:]MG+*EQ:3Q7,#,C%7"RPN\;%6!5@&)5@0<$4?U
M_7WH/Z_K[T6:*** "BBB@ HHHH **** "BBB@ HHHH ^:/V1_P#DBR_]E;_:
M0_\ 6COBO7TO7S1^R/\ \D67_LK?[2'_ *T=\5Z^EZ "BBB@#G_%/_(!O_\
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M+WQ_N=.NC;^3>^$9?"7BZUE26%IY6MYOM^BBX*1H\D"H/](A5I6, &*^$_\
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M/2/&WA&8&V8K(9+?Q5X6T:>)6(S \L:+<J0UN95()_RB_P!@_P#X)Z_M@_\
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MX2^/?"OQ&\)R:E82>5?:>GB+P?JNLZ.][92_N[NT6\,]M)\DT:-Q7IU?B/\
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MQ2C&,8I1C%))))))(****HL**** "BBB@ HHHH **** "BBB@ HHHH ****
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M/7__  =^%/\ Y<T >@T5Y]_PEGBS_HF>O_\ @[\*?_+FC_A+/%G_ $3/7_\
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M<$\ZT!QUY('N.M 'D_[(_P#R19?^RM_M(?\ K1WQ7KZ7KYB_8_DDF^!UK-+
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M8*^4_P!NG_DS/]J/_LA/Q-_]134Z^K*^4_VZ?^3,_P!J/_LA/Q-_]134Z /
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M;8C@[*JU2ED67S@N,LVH2<74;M./#.!K1WQ&)BE_:M2#?U;"S>'DXU:CIO\
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M**_.CK"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#WAC]FWX-_";P1^S1^T9\7_V9)K[XE?M ?!JV^/WQ'^._CCQ5\"_%?@3Q?\
M$'Q1IVE>)_AWX!^'7A#QSX@\0_"SP?9>$O$^L)\/[[7/'&KZFW1_M:_LQ?\
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M?L[32NFO>(+=#)-\,O#T\A6&VU6*"-6EED8)'&B+NVHJJ%4?HY_PJGP+_P!
MJ^_\*3Q/_P#+F@#T2BO._P#A5/@7_H%7W_A2>)__ )<T?\*I\"_] J^_\*3Q
M/_\ +F@#T2BO._\ A5/@7_H%7W_A2>)__ES1_P *I\"_] J^_P#"D\3_ /RY
MH ]$HKSO_A5/@7_H%7W_ (4GB?\ ^7-'_"J? O\ T"K[_P *3Q/_ /+F@#T2
MBO._^%4^!?\ H%7W_A2>)_\ Y<T?\*I\"_\ 0*OO_"D\3_\ RYH ]$HKSO\
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ME%>=_P#"J? O_0*OO_"D\3__ "YH_P"%4^!?^@5??^%)XG_^7- 'HE%>=_\
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MOO\ PI/$_P#\N:/^%4^!?^@5??\ A2>)_P#Y<T >B45YW_PJGP+_ - J^_\
M"D\3_P#RYH_X53X%_P"@5??^%)XG_P#ES0!Z)17G?_"J? O_ $"K[_PI/$__
M ,N:/^%4^!?^@5??^%)XG_\ ES0!Z)17G?\ PJGP+_T"K[_PI/$__P N:/\
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M%%24%%%% !7YB_\ !%[_ )15?L(?]F\^#/\ T7<U^G5?F+_P1>_Y15?L(?\
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MK15F4445^4G<%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\T?LC_P#)%E_[*W^T
MA_ZT=\5Z^EZ^:/V1_P#DBR_]E;_:0_\ 6COBO7TO0 4444 <_P"*?^0#?_\
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MGAJOTIK\UO\ @C9_RB;_ .";_P#V95^SC_ZJSPU7Z4T %%%% !1110 4444
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M5,13Y93RS*\/6C+VDHNZ57,*U.6'I*2:>'IXMR2;I2?]/G[.WPS^*G_!<?\
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M2..-%+O([*J*"S$ $U\/ZC_P4V_X)X:3KUQX:U+]MC]F2SUBTO3IUW!-\9/
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MS5K^\OU\ >)O"OB/PMHMU#X<BGD>'3='\2V/BN5]9M80L<E]I.D31*FV;?\
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M47\/^"/#1N[%M?\ $VI);M;:1H\=W#/J%X\5K;EIY8XV-@5[JV]]/4_#Q_\
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MGTKPAIFMWG@OX?\ Q%\8Q:%X$\1?$/P:_;H^(5S^T[\6/V1_VM?@G\//V?\
MXH?#G]G#0/VL](\4_"OX_:O\?_@[XI^!U_XP\0^ /$>KWWC'Q?\  O\ 9R\5
M^#_$W@[Q5X>EAU30=5^'=SIU[H]RFLZ;XCN(X+BW22C])**_%#1?^"M'Q';P
M#^SC^U9XU_9#MO!_[ G[4_Q=^'7PQ^&OQLC^/3ZY^T#X:\._'#7)?"/P%^,_
MQ:_9G3X,:9X1\)?"_P")WBFZ\)H!X7_:3\?^/O"?AOQ[X7UOQ#X%@U-/$7AO
M0/VOH *_,7_@B]_RBJ_80_[-Y\&?^B[FOTZK\Q?^"+W_ "BJ_80_[-Y\&?\
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MPG!F68F#Y*OUJG*EC.(\9AISH8ERH992JU:%'$.7)1:Q]6.*=GA:,FL+!_\
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MD^&7P.\"Z!\,OA#X&\-?#KP%X7LH=/T/PMX4TNWTK2[*W@C6,,8H%$EU=S!
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M@ K\Q/VL/^3]_P#@G'_V%?CU_P"H3I5?IW7YB?M8?\G[_P#!./\ ["OQZ_\
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M0*Y_Z'SQY_X.+7_Y74?\(%<_]#YX\_\ !Q:__*ZO0J* //?^$"N?^A\\>?\
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M ,'%K_\ *ZO0J* //?\ A KG_H?/'G_@XM?_ )74?\(%<_\ 0^>//_!Q:_\
MRNKT*B@#SW_A KG_ *'SQY_X.+7_ .5U'_"!7/\ T/GCS_P<6O\ \KJ]"HH
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M\=:)H>N?%G2-.M/B+:^$?AGX"\/:-XGTW2],EM9O3OA=_P $^?VZ_@_^T/\
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M%M_#3_H=O#__ ('1T?\ "V_AI_T.WA__ ,#HZ]$HH \[_P"%M_#3_H=O#_\
MX'1T?\+;^&G_ $.WA_\ \#HZ]$HH \[_ .%M_#3_ *';P_\ ^!T='_"V_AI_
MT.WA_P#\#HZ]$HH \[_X6W\-/^AV\/\ _@='1_PMOX:?]#MX?_\  Z.O1**
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M]=5\B^,_^3\_V;?^S1?VV_\ U<O_  3]KZZKHK?P\)_V#R_]2\4<]'^)B_\
ML(C_ .HF%"BBBN<Z HHHH **** "BBB@#W#2?^05IG_8/LO_ $FBK0K/TG_D
M%:9_V#[+_P!)HJT*\&?QR_Q2_-GO0^"/^&/Y(****DH**** "OS%_P""+W_*
M*K]A#_LWGP9_Z+N:_3JOS%_X(O?\HJOV$/\ LWGP9_Z+N: /TZHHHH ****
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M_P"3]_\ @G'_ -A7X]?^H3I5 'Z=T444 %<?XV_Y!5O_ -A"+_TFNZ["N/\
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MW1]"UMM/T/4=1U.R^ /V$OV1/C[\"_@IXB_97^,7[/'[.&B_"_XJZ5\3M?\
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MC_C#8A_!NNW?A'P?:/XMTP>"?WVH ^;O%'[9/[(/@?Q)K/@[QK^U7^S=X/\
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M-4?\(_H7_0%TK_P7VG_QJ@#+_P"$\\#_ /0Y^%/_  HM(_\ DRC_ (3SP/\
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M:H_X1_0O^@+I7_@OM/\ XU0!E_\ ">>!_P#H<_"G_A1:1_\ )E'_  GG@?\
MZ'/PI_X46D?_ "96I_PC^A?] 72O_!?:?_&J/^$?T+_H"Z5_X+[3_P"-4 9?
M_">>!_\ H<_"G_A1:1_\F4?\)YX'_P"AS\*?^%%I'_R96I_PC^A?] 72O_!?
M:?\ QJC_ (1_0O\ H"Z5_P""^T_^-4 9?_">>!_^AS\*?^%%I'_R91_PGG@?
M_H<_"G_A1:1_\F5J?\(_H7_0%TK_ ,%]I_\ &J/^$?T+_H"Z5_X+[3_XU0!E
M_P#">>!_^AS\*?\ A1:1_P#)E'_">>!_^AS\*?\ A1:1_P#)E:G_  C^A?\
M0%TK_P %]I_\:H_X1_0O^@+I7_@OM/\ XU0!E_\ ">>!_P#H<_"G_A1:1_\
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MI''\6?VCD1$ 5$1/VC/BLJ(J@ *JJ JJ     ,"OIF@ HHHH Y_Q3_R ;_\
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MK!T\PS2"<J=?B2M#V5%WAEE-J=2JO'OV=?V;_@M^RA\*/#7P5^ O@31OA_\
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MZZKY%\9_\GY_LV_]FB_MM_\ JY?^"?M?75=%;^'A/^P>7_J7BCGH_P 3%_\
M81'_ -1,*%%%%<YT!1110 4444 %%%% 'N&D_P#(*TS_ +!]E_Z315H5GZ3_
M ,@K3/\ L'V7_I-%6A7@S^.7^*7YL]Z'P1_PQ_)!1114E!1110 5^8O_  1>
M_P"457["'_9O/@S_ -%W-?IU7YB_\$7O^457["'_ &;SX,_]%W- 'Z=4444
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MZ@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(T:*G.-&,W_*'B[X)^('B;Q1+-5GW#V#R?!48X/),OK5<S=3#8;W9UZ]?V>
ME2>+Q==RJUI0<E"G&AAU4JQP\*DOB'_@@/\ M^GXZ_!V3]ECXDZW]H^*/P2T
MJ%/!=W?W!-WXJ^%\!6WTNW228H)[_P (1E-&^R6PN+C^Q+&VU&Z<?O6']$U?
M!_P2_P""9G[$7[.?Q'T;XM?!KX&:1X)^(/A^WU2UTCQ#9^(/%][-:0:S83:9
MJ48M=4U^^L9!<V-Q- QFMI"BN6C*M\U?>%?K_!>6Y]D_#N RKB+%X3'X_+X?
M588S!SKSCB,'2C&.%E6>(I49_6*</W-1VDJD:4*LINI4FH_O/A[E'$V0\*99
MDO%F.P.9YGE=/ZE3S# 5,34CB<!0C"."EB7BJ%"I];I4_P#9ZLDIJK&C3KRJ
M.I5J1B4445]4?;!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 54U"_LM*L+W5-3N[>PTW3;2YO]0OKN9+>TLK
M*SA>XN[NZGE98X+>V@CDFFFD94CC1G=@JDU;K\/_ /@M[^V[^SY\(/V'/VF/
M@\?VE_ASX%_:&\=_#6]T'P#X)M/$XU'Q_<:A>ZEIJW4#>'O#-MKFO:/#?:4N
MHVB:CJNG6.FDRE)+R(%G3EQV+I8'"8C%5I0C"A2J5+3G&FIRA"4HTU*;4>:;
M2C%7U;1[W#'#^.XIS_*<AR^CB*M?,\PP>#<L-A:^+EAJ6)Q%.C5Q=2CAJ=2J
MZ&%A-UJTHQ:C3A)NQ\2_M4_\'57[)/P7^(6J> O@5\(_&?[2UKX?U&[TK6/'
MVG>*M)\!^"+R[LW,<LO@^]NM(\37_BG2VE5XHM7:RT>RNMC7.G-J%B]O=S]_
M^R/_ ,'0O["_QXNM1T7X[Z)XJ_9/URRT_4M4M+_Q9=-X^\$:K:Z9;R74EK!X
MC\+Z+:ZM;:Y<P1.]EI5QX6,-U(!:6VI37DD$$W^<EC'&,8XQZ>U=A\/_  !X
MO^*OC?PG\-_ .B7OB+QGXX\0:1X6\,Z+I\,DUSJ&M:[?P:9IUNHC5S&DEW<Q
M"6=P(H(RTTK+&C,/Q6GX@<12QBG'ZM4ISGRQP2PT7#WFE&$9PMB7+HG[5MMZ
MIZ)?Z;8SZ(W@Y1X>GAJL<ZP>,PN%=3$<3O.JJQ:=&#G6Q-;#5^?)84VE*52,
M<OIQA!>[.+3F_P"[WXK_ /!:?]M#_@HEXOUC]GK_ ((V?L_>*1HTD\^C>)_V
MK?B'I8TS3/#MM<*]NU_IWVV*;P]X*41,]S:W>L76L^*KA?(N-+T"RFMY2WVU
M_P $Q/\ @A7\.?V0O$K_ +27[3OBE/VG/VR?$=Y/XAU?QYXD^TZQX9\%Z]J$
MK7%Y<^$TUQ9-0U?7M[@3^,-;07[2J7TNTTJ 11)^Q_[-GPA\+_ SX'?#'X:^
M%O!7A3P'!X<\$^%['5=!\':!IGAS2$U^WT2QAUJY^P:5!!;M<W&HI<2W-RRO
M+<3,\LCLSDU[E7ZMA<F<ZU+'YMB)9CC:?OT(2@J6"P4I)-_5<(G**J1LE[>M
M*I6=DU*+6G\"Y]XDPPN6YAPEX?911X.X8Q;^KYE7P^(ECN)>)J5&4HQEGN?S
MA2JSPM5WJ+*\OI8++8*<H.C6BVV4445[Q^2A1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !7YB?M8?\G[_\$X_^PK\>
MO_4)TJOT[K\Q/VL/^3]_^"<?_85^/7_J$Z50!^G=%%% !7'^-O\ D%6__80B
M_P#2:[KL*X_QM_R"K?\ ["$7_I-=UMA_XU/_ !?HS'$?P:G^']4>7T445[1X
MH4444 %%%% 'R+XS_P"3\_V;?^S1?VV__5R_\$_:^NJ^1?&?_)^?[-O_ &:+
M^VW_ .KE_P""?M?75=%;^'A/^P>7_J7BCGH_Q,7_ -A$?_43"A1117.= 444
M4 %%%% !1110![AI/_(*TS_L'V7_ *315H5GZ3_R"M,_[!]E_P"DT5:%>#/X
MY?XI?FSWH?!'_#'\D%%%%24%%%% !7YB_P#!%[_E%5^PA_V;SX,_]%W-?IU7
MYB_\$7O^457["'_9O/@S_P!%W- 'Z=4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%4-4U33=#TS4=:UF_L]*T?1["\U35=4U&YBL]/TW3=/MY+N^O[Z
M[N'C@M;.SM89;BYN9G2*"&-Y9'5%8AI-M))MMI))7;;T226K;>R _,+_ (+
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M]I#_ -:.^*]?2]?-'[(__)%E_P"RM_M(?^M'?%>OI>@ HHHH Y_Q3_R ;_\
M[=?_ $LMZ\?KV#Q3_P @&_\ ^W7_ -++>O'Z]3 _PI?]?'_Z3 \O'?Q8_P#7
MM?\ I4PHHHKL.,**** "BBB@ HHHH **** "BBB@ HHHH ]0\$_\@JX_["$O
M_I-:5V%<?X)_Y!5Q_P!A"7_TFM*["O%Q'\:I_B_1'M8?^#3_ ,/ZL_#'XQ?#
M/X;_  R_X+:_\$UH/AM\/O!'P^A\<? O_@J5\3/&L/@?PIH/A.+QA\2/&M]^
MRKJ'C+X@^*8]!L+!/$'C?Q;?HE]XF\5ZL+O7M>O%6YU6_NYE#CO?V(II9/\
M@K-_P6]36)9)-;M]?_X)U0Z EX[/>0?"QOV26G\.Q:>KDF/PP?B?/\:IK!(P
MMN?$TWC*11]HDNF/O_Q _P""67[(GQ/^,,7Q^\8M^U9=?%^QN_'UQX<\:Z-_
MP4._X*$>$;[P':?%#4K/5?'OAWX7V/A#]J'0=&^%7@KQ)=:9I$=YX"^&^F^%
MO!4.G:)H.CV6@6NDZ%I%C9>D_M ?L!_LN_M,^-X_B7\4/"/C[3_B&_P^U'X2
MZQXX^#7[0'[0_P"S7XL\9?"W4]0_M:7X<?$?7_V<?BI\*=3^)W@:SU.2]U#1
M/"OQ#N?$^A^'+S6?$5QX?L=,E\2^(&U+$V/B_P#X(%V<-E_P33\!0Z')'+\.
MF_: _;:F^#C0PI#;'X13?MF_'A_ \U@@M;24Z/>Z>7U#07EC*2:%=Z:]B4TM
MK"&+V3_@IS\8OBUX&_9T^/'A#P3^R5\8OC7X6U_]GOX@7.M_%/P+XZ_9L\-^
M$/!%U<Z5K>GW&F^(-(^+/QQ^'?Q O[C3["&+7;FX\*>#/$=A+8WEO:V=U<ZJ
MEUI]M^A/@3P'X)^%W@SPO\.?AMX2\.> O '@C0M-\,>#O!?A#1M/\.^%_"_A
MW1[6.RTK0]!T/2K>UTW2M+T^TBBM[2RLK>&W@B14C0 5\_\ [=/_ "9G^U'_
M -D)^)O_ *BFIT ?)G_!'OQ/XCM?^"4O_!.6WM/ASXGU."+]B[]G:-+ZVU7P
M-!;W*I\,?#J)-!'?>+;6\$4T:I,@N+:WF59 DL*.C"OT=_X2_P 5_P#1*?%W
M_@[^'?\ \VE?#'_!&S_E$W_P3?\ ^S*OV<?_ %5GAJOTIH \]_X2_P 5_P#1
M*?%W_@[^'?\ \VE'_"7^*_\ HE/B[_P=_#O_ .;2O0J* //?^$O\5_\ 1*?%
MW_@[^'?_ ,VE'_"7^*_^B4^+O_!W\.__ )M*]"HH \]_X2_Q7_T2GQ=_X._A
MW_\ -I1_PE_BO_HE/B[_ ,'?P[_^;2O0J* //?\ A+_%?_1*?%W_ (._AW_\
MVE'_  E_BO\ Z)3XN_\ !W\._P#YM*]"HH \]_X2_P 5_P#1*?%W_@[^'?\
M\VE'_"7^*_\ HE/B[_P=_#O_ .;2O0J* //?^$O\5_\ 1*?%W_@[^'?_ ,VE
M'_"7^*_^B4^+O_!W\.__ )M*]"HH \]_X2_Q7_T2GQ=_X._AW_\ -I1_PE_B
MO_HE/B[_ ,'?P[_^;2O0J* //?\ A+_%?_1*?%W_ (._AW_\VE'_  E_BO\
MZ)3XN_\ !W\._P#YM*]"HH \]_X2_P 5_P#1*?%W_@[^'?\ \VE'_"7^*_\
MHE/B[_P=_#O_ .;2O0J* //?^$O\5_\ 1*?%W_@[^'?_ ,VE'_"7^*_^B4^+
MO_!W\.__ )M*]"KQ?XO_ +1OP$_9_L;?4?C;\8OAS\++6\&ZR/C?Q;HV@7%Z
M@8HTEE97UW%>W<2."LDMM;RQQM\KLI(%3.<*<7.<HPBMY3DHQ7JVTE\V;8?#
M8C%UH8?"T*V)KU':G0P]*=:M4=KVA3IQE.3LF[1BW97.F_X2_P 5_P#1*?%W
M_@[^'?\ \VE'_"7^*_\ HE/B[_P=_#O_ .;2N#^#W[57[-G[04D\'P2^.GPN
M^*%W:K(]QI_@WQGHFLZG#'%GS9GTNVNVU!8(]K;I_LWDC!R]>_4H5(58J=.<
M*D'M*$E.+])1;3^\>)PN*P5:6'QF&KX2O"W/0Q-&I0K0OMS4JL83C?I>*N>>
M_P#"7^*_^B4^+O\ P=_#O_YM*/\ A+_%?_1*?%W_ (._AW_\VE==J^N:+X?L
MI-2U[5]+T33H59IK_5]0M--LHE12[M)=7LT,"*J LQ:0!5!8D $U\6?%;_@I
MG_P3_P#@E"9OB5^UU\#-!((58+7QUI/B&[D<D@)':>&I=8N'8D$$"/"]7*CF
MIJUZ%"/-7K4J,4FW*K4A3BDMW><HJRZLZ<ORG-<VJJCE>69AF5:4E"-'+\'B
M<95<VKJ*IX>G4FY-)M12NTKI'U+_ ,)?XK_Z)3XN_P#!W\.__FTH_P"$O\5_
M]$I\7?\ @[^'?_S:5^*/CG_@Y6_X)0^"M1DTV'XO>./&<D98?:_!'PO\3ZOI
MK[)1&3'?W46G0.""9$P3OC&1R0#XSK?_  <^?L?3V+W?PM_9_P#VL/BX[QI)
M8Q>'OAHMA%?>9-Y2"*[O;Z2%5=5FD20AE8PO&,OD#RY\0Y'#F3S3!R<;MJG6
MC5EIO:-+G<O^W4[]#[C#^#WBCB8TIPX$XEI4ZW+[.KC,MK8"D^9V3E5QRP].
MFN[J2BDM6TM3^A3_ (2_Q7_T2GQ=_P"#OX=__-I7Y8_\%1/^"PGP^_X)G?#G
M1=2\8_"SQ#XG^+OC^._3X9?#63Q/X-LEU06(*7.O^(K_ $?6_$.HZ/X6L9\0
M3ZA!H]X]Q>;-/@59YE=?SU'_  <0?M"_%07&C_LR?\$GOVH/&7BDPEK*+QM;
M:EI.DEY)I8;62XGT?P[='RG:,B5(IRRR+)&LA"AS_/Q_P6E\*_\ !4C]J23P
MC^V=^UK^QEK'P"\!>$-"'P_L--T6XO-?3POIUQ=R:J+_ ,4VCW-YJ>AVMU=.
M4?4K^UL;(W,@BD\J5MM>)G?%,*>68FKDJQ&)Q48)PK1P&+EAZ,.9*I6G5J4(
MT;TX7:C*37-9R32:?Z?X8^!.(Q7'.1X#Q-GE&29'5Q,XU\LK<6</TLWS3$>P
ME/!9=0P6#S2KF/)C:_LX3J4*<*OLN>-*I3J2A->QV7_!V1_P4&B\8KJU_P#"
M;]EZ\\%F_,DO@Z#PE\0K+4?[+,A86D'BP_$BZ>+41'A/[3ET.YMBVZ3^R "$
M7^J+_@G?_P %H_@;^WS\'=;\?6'A:;X8^,_A]-8:?\5/!?BCQ]\.=.L_#MWJ
M,#S:?JVCZUXF\3>&)]8\,:L8;J+3]2GTK3YQ>65_8S6WF6GG3?Y:61C.1CUS
MQ^=?U#?\$./^"$OA[]NKPMXZ^.7[7^@_%'P=\%8CI.F?""/PYJ</@W5O'VK*
M]S/XCU@2ZMH>ISS>%+&W;3+2RO[.W2+4KZ3488+I?L)<_$\+<3<3XK,EAHR>
M:QJPJ2G2Q,E2A2Y8MJJ\3"C.5&*DE'EY)0DY*"BI2C)?TYX[>"/@?D7!4\[K
M48<!5L!7P5#"X_)*%3'XK,/:UX4Y8%9-B<QPU+,ZU2E*=65=5J6)H0I3Q%2O
M.C2J4I_UM?%7_@MG_P $]/@TVHP>-/CSX FU#20?M^C>#_B)\-/'NN0.%#^3
M_8_@WQEK6H23E2#Y$=N\O(&S) /P?XL_X.FO^"?6FI(/ /P[_:=^+=PK%%C\
M(_#;2-/BW XW2S>*O%>AND9 SF.">3I^ZP21]Y?"K_@AI_P2R^$,L%YH/[)/
M@;Q!JL$8B_M7Q_?^(_'$\JA@P,NG^(-8N]!+EAS)'I$;L/D9BGRU^A/P_P#V
M??@-\)XD@^%WP4^$WPXB1O,5? WP[\(^%#YO&96;0M(L7>8X!:9V:5B 6<GF
MOTQTN)*WQ8K*<#%W_@X;$XVI'56M.M6PM-M*Z=Z5K]&?Q)'&^"N6V='(O$+B
MJI#V>F9YUD?"^#JM*U7FH9;EV>XN$)2UARXY3Y7:335S^<:3_@OI^VM\8XK>
M3]D+_@CS^T=\1-(U(LEEXM\:R^);#3X2Y7[/<7%EX7\!:UI9M2I+3SS^+K*&
M(%,2N&W#,U3XF_\ !TM\?H[M/"?P1_9H_9.T'5(9&TO6;FY\"ZCXHT:*0GRE
MN;3QIXX^)$\VI0*07EO/ %K9NW_+BIW1C^JJBAY/C:W^]Y_F<UI[F$6$R^&U
MFKT:$J]GNOW]T]I#CXC<,Y=_R3WA+P1A9JZ6(XAJY_Q=B5::G3G[/,LUI96Y
MQ2497RMTJD;J5*S:?\D2?\$E_P#@M/\ 'NTA/[7'_!43XR>&XY;V2:^\._L]
M:E8C1[FPDW(T%Q%I/C[]G[2FGG@>2.2UET/4-,LY&62$7PB56^N_V5/^" /[
M!O[-MW!XF\8?LY?$S]J+XB"XDOKGQ;\?_%7PSU_1OM\TT5Q/-9?#O3?%MCX/
M>-[B);A'\3VGBW58IY+AQK!2<QK_ $145='AW*:52-:IAY8RO"S5;,,1B,?-
M25O>BL54JPA+1:TX0>BMLCDS#QB\0<;A*^6X7.J/#N58BZJY9PAE64\)X2=-
MMOV%1\/X++\3B*"YI+V6*Q%>+4I<R?-*_P"$?[2W_!#C_@GC^T[XDG\8^(/V
M-/&'PN\4W<,<%[J?P*\;?#_X8V-V(AA)9/"&G>*KSP)%=MUGO;7PM;WETV9+
MJ>>1F<^S?L9_\$L/V,OV$-?/C7X#_L@^)?\ A9'D26T/Q-\?>,?!/COQOIT,
M\#VMRF@:CK7C9['PLUY;22VU[+X7TS1IKVVFFM[J26":6-_UVHKKAE.5PQ/U
MR&78*&*YN98B.&HQJJ?6:FH*2F^LTU)]6>#B/$+CO%Y-_J[BN,N)\1D3I*@\
MIK9WF-3 2H*W+AYX:>(=.>'C9<N'G&5&+2<8(\]_X2_Q7_T2GQ=_X._AW_\
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M37=;8?\ C4_\7Z,QQ'\&I_A_5'E]%%%>T>*%%%% !1110!\B^,_^3\_V;?\
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M,O'_ /WUX$_^;BC_ (376/\ HF7C_P#[Z\"?_-Q0!W]%<!_PFNL?]$R\?_\
M?7@3_P";BC_A-=8_Z)EX_P#^^O G_P W% '?T5P'_":ZQ_T3+Q__ -]>!/\
MYN*/^$UUC_HF7C__ +Z\"?\ S<4 =_17 ?\ ":ZQ_P!$R\?_ /?7@3_YN*/^
M$UUC_HF7C_\ [Z\"?_-Q0!W]%<!_PFNL?]$R\?\ _?7@3_YN*/\ A-=8_P"B
M9>/_ /OKP)_\W% '?T5P'_":ZQ_T3+Q__P!]>!/_ )N*_//_ (*B_MX?&C]B
M#]COXB_'_P"$7[*7Q-^,/C#P[]GL8+)8_#EUX>\$VVH07@D^(/C:T\-^)M9\
M1W/A+P]/#;KJ,6DZ;(?.O;4WUWIVGBYO(_2R?*L9GN:Y?DV71I3Q^:8S#X'!
MPKXBAA:4\1B:D:5*-3$8FI2H4HRG)+GJ5(QUM=MI.*DXTH3J3NHPBY2:3DTD
MKNR2;?R1]P_%#]I#X _!/Q'X!\(?%[XR_#7X:>*?BGK'_"/_  Y\/^-O&.A^
M'-7\::SE%&G^'K'4[RWN-1G,DD4(\A&0W$T-L',\T4;_ ,Q__!9S_@HC\6OV
MP/BLG_!%C_@F5&/'OQF^+LL?AO\ :E^+>A3M-X9^#WPVEGA_X2WP]=>(;29+
M335336\SXA:FTL\D?A^2;P9H]CJ7B/Q/9V\?^?A^U-^U]^T+^V;\:=<^/O[0
MOQ'USQS\1=9O!/:WUQ=2V^G^&+*&<SZ?HGA#3(76T\.:+I1*BPLM-CA6-E\^
M1I+EGF;^H[_@TI_:_P#$?@3X]?%+]G72_P!DS7?BS/\ %JS?Q1XN_:0\"V%M
M=>,OAY8Z!:7%QI^D_$?7?$VJ:=HR^!-5U';;6$$6L:;J<GB&[LY8[/6W1(H/
M[:Q7T;I^#W#%3Q,QN)PG&'$'#.6?VE_J_6CA\'P_@\Z5>#HYE6Q.+Q%*KFN!
MR6F_K$,M5*C7S;'4:,(J-*H\-+YU9O\ 7ZRP<8RP]*O4Y/:J\JLJ;6L$HIJG
M.H[ISNU3BV]6N8_MY_X)U?L,?#7_ ()V?LG_  S_ &8OAL(KZ/PGIWV[QGXM
M-HEI?>//'VJ)%+XF\7:C$C,$FU&[01VT"E8[:QM[:%(T*OG[BK@/^$UUC_HF
M7C\_\"\"?U\<4?\ ":ZQ_P!$R\?_ /?7@3_YN*_B#,LRQV<9AC<US/$U<9F&
M8XJOC<;BJSYJN(Q.)J2JUJLVDE><Y-VBE&*M&*44DOHX0C3A&G!*,(148Q6R
MC%62^21W]%<!_P )KK'_ $3+Q_\ ]]>!/_FXH_X376/^B9>/_P#OKP)_\W%<
M11W]%<!_PFNL?]$R\?\ _?7@3_YN*/\ A-=8_P"B9>/_ /OKP)_\W% '?T5P
M'_":ZQ_T3+Q__P!]>!/_ )N*/^$UUC_HF7C_ /[Z\"?_ #<4 =_17 ?\)KK'
M_1,O'_\ WUX$_P#FXH_X376/^B9>/_\ OKP)_P#-Q0!W]%<!_P )KK'_ $3+
MQ_\ ]]>!/_FXH_X376/^B9>/_P#OKP)_\W% '?T5P'_":ZQ_T3+Q_P#]]>!/
M_FXH_P"$UUC_ *)EX_\ ^^O G_S<4 =_17 ?\)KK'_1,O'__ 'UX$_\ FXH_
MX376/^B9>/\ _OKP)_\ -Q0!W]%<!_PFNL?]$R\?_P#?7@3_ .;BC_A-=8_Z
M)EX__P"^O G_ ,W% '?T5P'_  FNL?\ 1,O'_P#WUX$_^;BC_A-=8_Z)EX__
M .^O G_S<4 =_17 ?\)KK'_1,O'_ /WUX$_^;BC_ (376/\ HF7C_P#[Z\"?
M_-Q0!W]%<!_PFNL?]$R\?_\ ?7@3_P";BC_A-=8_Z)EX_P#^^O G_P W% '?
MT5P'_":ZQ_T3+Q__ -]>!/\ YN*/^$UUC_HF7C__ +Z\"?\ S<4 =_17 ?\
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M '?T5P'_  FNL?\ 1,O'_P#WUX$_^;BC_A-=8_Z)EX__ .^O G_S<4 =_17
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MS#,5AJ:I898[&XG%K#TDK*G06(J5/94TDDH4^6*2T04445L>>%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5^8G[6'_ "?O_P $X_\ L*_'K_U"=*K].Z_,3]K#
M_D_?_@G'_P!A7X]?^H3I5 'Z=T444 %<?XV_Y!5O_P!A"+_TFNZ["N/\;?\
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MAUF698VA@,+B,32C>I0PKJMU<1*#M"=2G2="G4:A5K0DI)?Z'%%?S(?L0_\
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MHH **** "BBB@ HHHH **** "BBB@ HHHH *_,3]K#_D_?\ X)Q_]A7X]?\
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MM"O!G\<O\4OS9[T/@C_AC^2"BBBI*"BBB@ K\Q?^"+W_ "BJ_80_[-Y\&?\
MHNYK].J_,7_@B]_RBJ_80_[-Y\&?^B[F@#].J*** "BBB@ HHHH ***0D*"S
M$!0"220  !DDD\  <DG@"@!:AN+BWM+>>[NYX;6UMH9+BYN;B5(;>W@A1I)I
MYYI&6.*&*-6DDDD941%9F8*":_$3_@H+_P %\_V)?V%]4F^%>@ZIJG[4O[45
M\[Z;X:_9W^ [IXEUJ3Q'*XM].T;QCXLTZVU?1O"$UW?,EJ^FPV_B'QBF6EMO
M!]XB-C\PK+]D7_@MA_P6AEEU[]N/XJ:I_P $WOV+]?F6[TO]F;X3A;/XR^*-
M EA(@MO%KR/+=V9ND\J>Y;XB7=[<6]T]Q'%\/M,@80K^E9/X9YG6RZAQ!Q5C
M\'P-PQB%SX;-,_C56.S:"<>9</9!1C+-\ZE:2<<11H4<L5FJN8TFF<=3&04W
M1H0EB:R^*%*W+3_Z^U6U3I^C;GV@S[X_;C_X.&/V5_V=?%#? ;]EGP_K_P"W
ME^UKJ]T^B>'/A'\!S-KWAFP\0R2-:06WBSQ[H]GK-HK0WA5;G3/"UCXBU) D
ML5Z=*P)U^#/AG_P20_;Z_P""MWQ0T#]IO_@MOX\N_AQ\'-&G.J?"[]@+X4ZS
M=Z/H^C6UQY31-XPN=.U?48/#AO(8HGU4?VGXB^(.KQ-!9:OX@\."R&DP_P!
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M^"O 'B;XH^)].34--TR\TK13I?@3P?XCUXW7B*^TBRNUTTZ=87-UJ]U96%R
M>GT444 %%%% !1110 4444 %%%% !1110 5^8G[6'_)^_P#P3C_["OQZ_P#4
M)TJOT[K\G_VN/&'ANT_X*3_\$S/ -QJ:Q^+M?L_VFO%>D:.;2_9KSP_X5\+^
M"]-U_4!?):MID T^]\4:# ;:YO8;VY-^)+.VN8K:\DMP#]8**** "N/\;?\
M(*M_^PA%_P"DUW785Q_C;_D%6_\ V$(O_2:[K;#_ ,:G_B_1F.(_@U/\/ZH\
MOHHHKVCQ0HHHH **** /D7QG_P GY_LV_P#9HO[;?_JY?^"?M?75?(OC/_D_
M/]FW_LT7]MO_ -7+_P $_:^NJZ*W\/"?]@\O_4O%'/1_B8O_ +"(_P#J)A0H
MHHKG.@**** "BBB@ HHHH ]PTG_D%:9_V#[+_P!)HJT*S])_Y!6F?]@^R_\
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MPUXEM]'U6QU*?P[XC@L-.U6;0-=BLIYI-(UN'2]7TG4I=*U!;>_CL-4TZ\>
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MH:#8O#IEUKMSX>T2?4Y;9KN72[)Y6@3[K_X9/_X+!?\ 27GX,?\ BL+PK_\
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MC8W-Q<:9I\LCVD/NG_#)_P#P6"_Z2\_!C_Q6%X5_^BRK]>Z* /YK_$7[%_\
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MWN_[-;2QV]Q)'-(CI!,RB-OVAHH _G5_8._8T_X*_P#AK]A_]COPY%_P4D\
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MZ_X0U34/%.BW^CV'PF\4V^F:-K\.K:E=:'_2A10!_,W^SU^Q;_P5]TKXL?\
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MQ3X(T_PO?_M:7OB;P_9^%V^"^F7OB&S\)?%:)+BW\>:?';Z5X32*-]9_O I
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M]>UBRL#!;:GK5AX;\.V6JWL4U_:>']$M[B/3+7Z]_P"$!_X*>_\ 1U/[#/\
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M P /I2T ?@3^R_\ #7_@H[;_ +9/_!3JZTSX\_LI:#J^H?&#]F677?$OB/\
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MPV^&W@/X/> _"OPO^%_A31? WP]\#Z1;:!X1\(>'+*+3="\/:+9[A:Z;I=C
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M8;J9+331-.CR)9Z>'%M#^F1 8%6 96!#*0""",$$'@@C@@\$4H  P!@#@ =
M/2@#\"_^"5GPT_X*0Z=_P3A_8LL/#?QZ_9/\!:)9_L^^ H-/\&?$G]B?XX:Y
MX\\-VJ:>?(TCQ7K-O^V_X$@U/6K2$QQ7UY#X+\*QRRAMNBVN,O)_P3O^&O\
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M  4-O/V189O G[1_['>@>'_^&G_V_H3IWBG]C7XR^*]8.O6_[??[35OXMO\
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MHJJH& J@*H'H , #Z4M 'X(_\$\/AK_P4AL?A?\ M 1Z#\>_V3O!L,_[?_\
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M\4_M*Z)X;;]G?X0:5X&7XM71^,^@?%[XL?#G7O"D?@/Q#%I\.J+JGA.^U_\
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MFBWEE?ZE;_#[Q!XIF\/QWME'X@CTN:[MXI?VVH **** "BBB@ HHHH ****
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M:=<QO$\D3I/:7,,JM'))&RN"CNI#'^5_3?"7Q_\ A=_P29_:1_X(UZ;^S/\
MM#^)?VM=<UC]J_\ 9E^%7B2U^!'Q;N?V8OB!\+_VEOBYX_\ &O@W]HZX_:RT
M[PE=_LX^#/ ^A_"'XOMJ_B_P_P"+OB?I'Q/T?QOX*\0^!S\-YO%5UH7AK5/Z
MBOAYX.L_AYX \#^ -/N)+NP\#>#_  SX.L;J5#'+<V?AG1;+1;:XDC,LYCDF
MALDD=#/,59BIED(WD T/%/\ R ;_ /[=?_2RWKQ^O8/%/_(!O_\ MU_]++>O
M'Z]3 _PI?]?'_P"DP/+QW\6/_7M?^E3"BBBNPXPHHHH **** "BBB@ HHHH
M**** "BBB@#U#P3_ ,@JX_["$O\ Z36E=A7B=EK6IZ=$T%G<^3$\AE9?)MY,
MR,J(6W2Q.PRL:# (7C(&22;G_"4Z]_S_ '_DK9__ "/7GU<)4G4G-2@E)W5W
M*_SM%_F>A2Q=.%.$'&;<59V4;?*\E^1[!17C_P#PE.O?\_W_ )*V?_R/1_PE
M.O?\_P!_Y*V?_P CUG]2J_S4_OE_\@:?7:7\M3[H_P#R9[!17C__  E.O?\
M/]_Y*V?_ ,CT?\)3KW_/]_Y*V?\ \CT?4JO\U/[Y?_(!]=I?RU/NC_\ )GL%
M%>/_ /"4Z]_S_?\ DK9__(]'_"4Z]_S_ '_DK9__ "/1]2J_S4_OE_\ (!]=
MI?RU/NC_ /)GL%%>/_\ "4Z]_P _W_DK9_\ R/1_PE.O?\_W_DK9_P#R/1]2
MJ_S4_OE_\@'UVE_+4^Z/_P F>P45X_\ \)3KW_/]_P"2MG_\CT?\)3KW_/\
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M_(]'_"4Z]_S_ '_DK9__ "/1]2J_S4_OE_\ (!]=I?RU/NC_ /)GL%%>/_\
M"4Z]_P _W_DK9_\ R/1_PE.O?\_W_DK9_P#R/1]2J_S4_OE_\@'UVE_+4^Z/
M_P F>P45X_\ \)3KW_/]_P"2MG_\CT?\)3KW_/\ ?^2MG_\ (]'U*K_-3^^7
M_P @'UVE_+4^Z/\ \F>P45X__P )3KW_ #_?^2MG_P#(]'_"4Z]_S_?^2MG_
M /(]'U*K_-3^^7_R ?7:7\M3[H__ "9[!17C_P#PE.O?\_W_ )*V?_R/1_PE
M.O?\_P!_Y*V?_P CT?4JO\U/[Y?_ " ?7:7\M3[H_P#R9[!17C__  E.O?\
M/]_Y*V?_ ,CT?\)3KW_/]_Y*V?\ \CT?4JO\U/[Y?_(!]=I?RU/NC_\ )GL%
M%>/_ /"4Z]_S_?\ DK9__(]'_"4Z]_S_ '_DK9__ "/1]2J_S4_OE_\ (!]=
MI?RU/NC_ /)GL%%>/_\ "4Z]_P _W_DK9_\ R/1_PE.O?\_W_DK9_P#R/1]2
MJ_S4_OE_\@'UVE_+4^Z/_P F>P45X_\ \)3KW_/]_P"2MG_\CT?\)3KW_/\
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M_(]'_"4Z]_S_ '_DK9__ "/1]2J_S4_OE_\ (!]=I?RU/NC_ /)GL%%>/_\
M"4Z]_P _W_DK9_\ R/1_PE.O?\_W_DK9_P#R/1]2J_S4_OE_\@'UVE_+4^Z/
M_P F>P45X_\ \)3KW_/]_P"2MG_\CT?\)3KW_/\ ?^2MG_\ (]'U*K_-3^^7
M_P @'UVE_+4^Z/\ \F>P45X__P )3KW_ #_?^2MG_P#(]'_"4Z]_S_?^2MG_
M /(]'U*K_-3^^7_R ?7:7\M3[H__ "9[!17C_P#PE.O?\_W_ )*V?_R/1_PE
M.O?\_P!_Y*V?_P CT?4JO\U/[Y?_ " ?7:7\M3[H_P#R9[!17C__  E.O?\
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M0KQN'Q)K4$44$5[LBAC2*-?L]HVV.-0B+N: L<*H&6)8XR23S4G_  E.O?\
M/]_Y*V?_ ,CUYDL%5<FU*GJV]Y=7_@/3CC:2BDXU-$EM'HO\9[!17C__  E.
MO?\ /]_Y*V?_ ,CT?\)3KW_/]_Y*V?\ \CTOJ57^:G]\O_D!_7:7\M3[H_\
MR9[!17C_ /PE.O?\_P!_Y*V?_P CT?\ "4Z]_P _W_DK9_\ R/1]2J_S4_OE
M_P#(!]=I?RU/NC_\F>P45X__ ,)3KW_/]_Y*V?\ \CT?\)3KW_/]_P"2MG_\
MCT?4JO\ -3^^7_R ?7:7\M3[H_\ R9[!17C_ /PE.O?\_P!_Y*V?_P CT?\
M"4Z]_P _W_DK9_\ R/1]2J_S4_OE_P#(!]=I?RU/NC_\F>P45X__ ,)3KW_/
M]_Y*V?\ \CT?\)3KW_/]_P"2MG_\CT?4JO\ -3^^7_R ?7:7\M3[H_\ R9[!
M17C_ /PE.O?\_P!_Y*V?_P CT?\ "4Z]_P _W_DK9_\ R/1]2J_S4_OE_P#(
M!]=I?RU/NC_\F>P45X__ ,)3KW_/]_Y*V?\ \CT?\)3KW_/]_P"2MG_\CT?4
MJO\ -3^^7_R ?7:7\M3[H_\ R9[!17C_ /PE.O?\_P!_Y*V?_P CT?\ "4Z]
M_P _W_DK9_\ R/1]2J_S4_OE_P#(!]=I?RU/NC_\F>P45X__ ,)3KW_/]_Y*
MV?\ \CT?\)3KW_/]_P"2MG_\CT?4JO\ -3^^7_R ?7:7\M3[H_\ R9[!17C_
M /PE.O?\_P!_Y*V?_P CT?\ "4Z]_P _W_DK9_\ R/1]2J_S4_OE_P#(!]=I
M?RU/NC_\F>P45X__ ,)3KW_/]_Y*V?\ \CT?\)3KW_/]_P"2MG_\CT?4JO\
M-3^^7_R ?7:7\M3[H_\ R9[!17C_ /PE.O?\_P!_Y*V?_P CT?\ "4Z]_P _
MW_DK9_\ R/1]2J_S4_OE_P#(!]=I?RU/NC_\F>P45X__ ,)3KW_/]_Y*V?\
M\CT?\)3KW_/]_P"2MG_\CT?4JO\ -3^^7_R ?7:7\M3[H_\ R9[!17C_ /PE
M.O?\_P!_Y*V?_P CT?\ "4Z]_P _W_DK9_\ R/1]2J_S4_OE_P#(!]=I?RU/
MNC_\F>P45X__ ,)3KW_/]_Y*V?\ \CT?\)3KW_/]_P"2MG_\CT?4JO\ -3^^
M7_R ?7:7\M3[H_\ R9[!17C_ /PE.O?\_P!_Y*V?_P CT?\ "4Z]_P _W_DK
M9_\ R/1]2J_S4_OE_P#(!]=I?RU/NC_\F>P45X__ ,)3KW_/]_Y*V?\ \CT?
M\)3KW_/]_P"2MG_\CT?4JO\ -3^^7_R ?7:7\M3[H_\ R9[!17C_ /PE.O?\
M_P!_Y*V?_P CT?\ "4Z]_P _W_DK9_\ R/1]2J_S4_OE_P#(!]=I?RU/NC_\
MF>P45X__ ,)3KW_/]_Y*V?\ \CT?\)3KW_/]_P"2MG_\CT?4JO\ -3^^7_R
M?7:7\M3[H_\ R9[!17C_ /PE.O?\_P!_Y*V?_P CT?\ "4Z]_P _W_DK9_\
MR/1]2J_S4_OE_P#(!]=I?RU/NC_\F>P45X__ ,)3KW_/]_Y*V?\ \CT?\)3K
MW_/]_P"2MG_\CT?4JO\ -3^^7_R ?7:7\M3[H_\ R9[!17C_ /PE.O?\_P!_
MY*V?_P CT?\ "4Z]_P _W_DK9_\ R/1]2J_S4_OE_P#(!]=I?RU/NC_\F>P4
M5X__ ,)3KW_/]_Y*V?\ \CT?\)3KW_/]_P"2MG_\CT?4JO\ -3^^7_R ?7:7
M\M3[H_\ R9[!17C_ /PE.O?\_P!_Y*V?_P CT?\ "4Z]_P _W_DK9_\ R/1]
M2J_S4_OE_P#(!]=I?RU/NC_\F>P45X__ ,)3KW_/]_Y*V?\ \CT?\)3KW_/]
M_P"2MG_\CT?4JO\ -3^^7_R ?7:7\M3[H_\ R9[!17C_ /PE.O?\_P!_Y*V?
M_P CT?\ "4Z]_P _W_DK9_\ R/1]2J_S4_OE_P#(!]=I?RU/NC_\F>P45X__
M ,)3KW_/]_Y*V?\ \CT?\)3KW_/]_P"2MG_\CT?4JO\ -3^^7_R ?7:7\M3[
MH_\ R9[!17C_ /PE.O?\_P!_Y*V?_P CT?\ "4Z]_P _W_DK9_\ R/1]2J_S
M4_OE_P#(!]=I?RU/NC_\F>P45X__ ,)3KW_/]_Y*V?\ \CT?\)3KW_/]_P"2
MMG_\CT?4JO\ -3^^7_R ?7:7\M3[H_\ R9[!17C_ /PE.O?\_P!_Y*V?_P C
MT?\ "4Z]_P _W_DK9_\ R/1]2J_S4_OE_P#(!]=I?RU/NC_\F>P45X__ ,)3
MKW_/]_Y*V?\ \CT?\)3KW_/]_P"2MG_\CT?4JO\ -3^^7_R ?7:7\M3[H_\
MR9[!17C_ /PE.O?\_P!_Y*V?_P CT?\ "4Z]_P _W_DK9_\ R/1]2J_S4_OE
M_P#(!]=I?RU/NC_\F>P45X__ ,)3KW_/]_Y*V?\ \CT?\)3KW_/]_P"2MG_\
MCT?4JO\ -3^^7_R ?7:7\M3[H_\ R9[!17C_ /PE.O?\_P!_Y*V?_P CT?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MXOOB?_PNR7Q3KFM:!J^LZ_<>#WFL9]-\/Z?IV@7.L&?2=,@_L#PS'I'[=_\
M!07_ ()]1?MW_LD^%OV69?BS)\+E\,^/?@IXW'CF/P,OC0WO_"G]9L-5;3/^
M$9;Q?X5%M_PD<=F]JM[_ &_/_8SS)<FTU983;3:W_!0[]@Z+]O?PW^RUX>E^
M*4GPK'[-/[:?P._:_%W'X*7QL?&A^#5GXTLF^'A@;Q7X3'AT>)8O&,C+XL$N
MN_V*]@A/AK5EN&6&72^)QBD[4W%II6DG[S6NCLHW>CE9:L<:VE-3D[<U15+W
M:<&HJ*=EJE[UEJH]$M#XY^ G_*P+^W__ -F(?LE?^I9XOKC/V*2WA7_@OG_P
M6:\*:(EV/#_COX0?L(_$SQ%")$;3-/\ &6E?"N3PU;B&&*U5;:XUK3-2O=4G
M^T7+75U<K>W!,]N8([#]&_ /[%Z^!_\ @H!^T#^W4?B0VJ/\=/@3\(O@FOPN
M'A 6*^%5^%FJZUJC^)3XT_X2>\.NMKQU9(5T@>$]&&DBV>0ZGJ9N EO^>O\
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M&_\ "/\ _"LO^%4_#8_#W^R_^$B_X2K6_P#A,_[>S_:_VW^PO"G]E_\ (/\
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MOP3\;OA-HFE^+#!=-)'>:NVHV*>(;MKQY3?:G)-+=R2//*[?#W_!5[_@G/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
G "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img22994243_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img22994243_5.jpg
M_]C_X  02D9)1@ ! @$ > !X  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %I!5P# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQHYC<%7 P1@U[=7S5^V3_P FH?M%?]D>\>_^H]?5]*T %%%% !1110 4444
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M$:_M'0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW0-2L]8T;5K&7XV_LZ>7>:;JFG3W%C?6LH#>7<6L\L3X.US@U]N_M7?LO_\
M!U/XK_:/^,7B3]DK]O;]F7X>?LTZSXVU&^^"W@CQ1IGPWF\1>&? 4JP_V/I6
ML2ZG^R!XQU!K^WC#B=KOQ1KTV\_-J5U_K" ?E-_P=%?!?2OVF?\ @M'_ ,$T
M?V=O%7B'Q%X?\*_%SX7>%? >K:KX:>V?6M'L/$OQD\765[?:+!J,-SIW]H(C
M[XOM5M-"[JHE1U  ^8?VJ/V4?B?_ ,&V7_!2;]A2S_8I_;"^*OB_X<_M*>+/
M#=GX]^&'C35[ W>LZ='X\T'P=XCTOX@^%/#$&C^$_$F@:[I'BA)/!=[?^'%O
M])U_2+V_M9Y+BQMFB]?_ .#D7X._%KXL?\%8?^"3?P.U+XQWW@+XW>-/V?/A
MAX%UCXY^$[2ZAOO#_P 0[WXF^)=/U;Q]H-EX>O\ P9=121ZS]IU.RM])O_#C
MH&5+62P 54_:_P#8E_X-@O"'P6_:B\'_ +7_ .V_^VM\9_\ @H3\8OAC/97G
MPXE^)EEJ^E>']-U#2I;R;1+[Q*OC+Q]\6O%OB0>')[MM0\.Z4OC#2]#T_5GG
MU&?3;Z8VWV4 _/']IRYFE_X/*OV0LR3K$WPK\/R)"\C@1";X*?&Z<QE-VT%7
M?YEQC>,XR,U_=K7\%'[9'B[PGX$_X/$_V6_%GCGQ5X:\%>%='^%N@S:MXG\8
M:_I/ACP[I<4OP=^-EM#)J.N:Y>6&EV*SW,T%K;FYNHO/NIX+:'?/-'&W]GNI
M_MB_LQ1^ OBC\0/#?Q\^#WCC1OA#X!\0?$?QR? OQ)\&>,KGP[X5\/6%S>WF
MLZM:>'=:U&>QT]?L[1+=W20V[3$1"7>0* /XL_\ @X+\%_$+_@K7_P %7O"_
M_!.7X/>()[71/V.?V6O'7QH\<R6ZFXL[?Q_JGA^W\:WUD7YM8[[4O"ESX(T.
MVMY0UR]ZUS#"-X=*_7/_ (-1_P!LRX_:2_X)J6?P/\7372?%/]C+QMJ?P<\2
M6>IW!EUB;P?JLMUXG\!ZK?1R!;BV$;7/B7P?%;W"EXAX,9=Q4JB?RV?\$M/C
MS_P7)U[XY_MD?\%,/V$?V"/A[^U,O[8/Q-\56'BOQU\;%GUJQ\+K:^)]3\2S
M>!/ WE_'OX.WJ:7HUIK]AX=O6%KJVFIIVDZ9I-K):"P:!?I+_@@O\6/VE_\
M@G[_ ,%S_BQ^SO\ MP?""W_9?\5_\%"?"NN>*[SX3V+1#PG8_$?4/$NN^/\
MX<:CX<FMO%?CB&#PW<1_\+3\.Z);W'B;5)8;S5;?3VNT:-$8 _9+]N/_ (-D
MS^VSX]_:2_:'_:D_X*+?M#:SK>J:[X]\9_!#PO\ ;+*[^$_P:\+?V))<>'_#
MVHZ/XO77[BVT/1KFW+:Q#X-NO"EBVDB?[)#;WDLMTWYL_P#!IE^U-^U)XV\
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MY;>*K[3]*DTY+SQ%X?TOQ!!;:+:+/XK\2:N;&/0=#L-+6\NIII(V-O\ 6/\
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M%\:;S_@O7:?\$GD^%OPOC^#,OPYUCQ=/\27D\5GXG#5-+^&GB/QN(8MNN?\
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MY_A=X"\,"RTNRF\/Z?H_A3^S[]X]*NK^V2)I?$.G0V=C'%:BWE>0W%O\;_\
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\J_MG>'?B7XH^
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ML'PZFO\ 5-4TR;7I+F*V@_5SQ=_P2[_93\7> ?AOX :V^+OA5/AE)\19-/\
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M2I#W88N&)PVDJ$D%%%%;GAA1110 4444 %%%% !1110 4444 %%%% !1110
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MB'QF\;VGV+3O!E]X#TE;;Q:]^FFM8?$*]N[G3?#<>G7.V5@#^CA65E5E8,K
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M "OFO]C?_DU']G?_ +(_X#_]1^RKZ4KYK_8W_P"34?V=_P#LC_@/_P!1^RH
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MN8Y'G6732Z^P>!XCINUM6JG#D5NFH2J;IM/]LZ***P,@HHHH **** "BBB@
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M1116YQA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MAAXD\<^$?%GQ_P#$'PUT[2?V=K;7_AY927?B2QM?B%+XK>^N1%)'_9]K<?\
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M+GG@,RJM.RY)S<7\,C]C****^;/:"BBB@ HHHH **** "BBB@ HHHH ****
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MYM_!_P#P5E\.:M:W$9\/?'?]C^ZL;6:WD26TU;Q1X+\=Q:I;WMO<(SQW"?\
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M$7B7PK?+J7AW5X=?^&_BGPAXCAN=)OT2[M1%JZ0B95=XGVC'T)10!\">(?\
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MWA1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MLD;,C FS7S>VY]%OL%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6A!=H17;9+H%%%%06%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 ?-7[9/_ ":A^T5_V1[Q[_ZCU]7TK7S5^V3_ ,FH?M%?]D>\>_\
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MM8A7BFDY+W]8WTOLFTK]T^,\Q23> PZ3CS)M5TG%-)R3<OAOI?9-K7O]._\
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MSQGX<T3Q7X?O6B>%KS1/$6F6NKZ3=-#(%DB-Q87EO,8I 'C+E& 8&@#\Z_\
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MY>SBE*<OYJD]9U)OK.<I2;U;;"O+/C)\$OA-^T)X!UOX7_&GP!X8^)'@/Q!
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M/_ U/_D>C_A8J?\ 0(D_\#4_^1Z/]:L@_P"A@O\ PFQG_P SA_K1D7_0>O\
MPGQ?_P H/2J*\U_X6*G_ $")/_ U/_D>C_A8J?\ 0(D_\#4_^1Z/]:L@_P"A
M@O\ PFQG_P SA_K1D7_0>O\ PGQ?_P H/2J*\U_X6*G_ $")/_ U/_D>C_A8
MJ?\ 0(D_\#4_^1Z/]:L@_P"A@O\ PFQG_P SA_K1D7_0>O\ PGQ?_P H/2J*
M\U_X6*G_ $")/_ U/_D>C_A8J?\ 0(D_\#4_^1Z/]:L@_P"A@O\ PFQG_P S
MA_K1D7_0>O\ PGQ?_P H/2J*\U_X6*G_ $")/_ U/_D>C_A8J?\ 0(D_\#4_
M^1Z/]:L@_P"A@O\ PFQG_P SA_K1D7_0>O\ PGQ?_P H/2J*\U_X6*G_ $")
M/_ U/_D>C_A8J?\ 0(D_\#4_^1Z/]:L@_P"A@O\ PFQG_P SA_K1D7_0>O\
MPGQ?_P H/2J*\U_X6*G_ $")/_ U/_D>C_A8J?\ 0(D_\#4_^1Z/]:L@_P"A
M@O\ PFQG_P SA_K1D7_0>O\ PGQ?_P H/2J*\U_X6*G_ $")/_ U/_D>M/1_
M&::MJ-OIXTY[<SB8B4W*R!?*ADF.4$*$[@FW[PQG/.,5I1XER3$5J5"CCE.K
M6J0I4H?5\5'FJ5)*$(\TJ"BKR:5Y-)7NVD:4>(\FKU:5"EC5.K6J0I4X^PQ,
M>:I4DH0CS2HJ*YI-*\FDKZM([>BBBO=/;"BBB@#\L_\ @H!^T;\4_@GXP\!Z
M7\/_ -I#_A2%GK/ARZO[_2O^'5W[9/\ P4$_MJYCU*[MUO\ _A,?V9?'/A/0
MO ?EQ1);_P#"-^)+>ZU:Z\K^TX9EM+N!%Y#]A']J'XO_ !E^,NJ>%/'G[4G_
M  N?1K;P'K.LQ>$_^'/W[<O[!OV:_M-7\/VL.M?\+F_:0^(/BGP%JOV2&^N+
M7_A K/3H_$FM?;O[7L+J.Q\/:G'-]V_M>>._'7PQ_9H^,OC_ .&FK>'- \<>
M%/!EYJ^@:[XM?2AH&C303VRW>JWL.N7^EZ5?R:?ISWEWI^DWFH6L>LZE%9Z4
MDHEO(P?S5_X)U_MR_'']H3XC?#3X3?$:^^)=UJFD?"#XW>/?B-K?QL_9-\8?
MLA>(/B9I$GQ-\ Z7^SW\0_AKX,\?0:?)X@T.X\&WOBR+QZWP\;Q1X;\.:G>^
M%U\1ZOI5_KN@VFH '[<5X#^U!XH\9>%/@=X_O/ 'P9^)'QZ\5:IHE[X;TOX=
M?"G4/A=I?BZ^D\16L^E'4XKWXP_$GX4>"8=+T?[2+[5S=>,(-0-E'(-+T_4[
MO9:/[]10!_/)XS^#7BKXD_L-_L:_#GXL_P#!,3]LWQA^T!\$_@*GPN\&7?@;
MX^?L[?"R^^!_Q&T7P+X1\!W7BGQ1XT\"_MO^$?[2\"^*];\(Z'XHL$T&U^*=
MU_PCVCV\VO> [/6PWANXM^(/@%^W)X:T3XH_ ?5_@AXC^.&K_M:_"G]DWP]X
MJ_:4T#XA?"NQ^'7PJ\7^ +J\T+XTS_%NS\6>*_!_Q.UK^RO"2V.L>#-:^&GP
MP\:/\2/$+W&F>(M,^'5F_P#:R_T(44 9>BZ<=)T72=(,WFG3-+L=.,ZKY?F&
MSM(K;SE0E]F\Q[PI+;<@$MC)_CW_ ."Z/[,GBSX43_"G6]<_:G_:7_:&MM6^
M O\ P4(UVT\._'O6/@YJ.@> UT+X2>!-1FNO!,?PS^"WPNU:*[GBN$T]AXBU
MCQ'$MA"JV\,%W)->2_V.5_-7_P '#=K'=:/\*_,W9M/V/_\ @J'?Q;3C]_:_
M OX;M%N]4W,=R]QQ7?E2OFF6I[/,,$OOQ5)'%F4G#+LPDG9QP.+::\L/4/W%
M_8XN%N_V1/V5[I266Y_9P^!UPK-G<RS?#'PO("<\Y(;)SSGK7T?7Q_\ \$^=
M5;6OV%OV/]19MS2_LW?!N!B 0-UCX"T.Q8 'H UL0!TP!CC%?8%<=22E4G);
M2G*2ZZ.3:[=#MY)4_P!W-6G3]R2M:TH^[)6Z:IZ7"BBBH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^:OVR?^34/VBO^R/>/?_4>
MOJ^E:^:OVR?^34/VBO\ LCWCW_U'KZOI6@ KXY_;Y\6_M&^!_P!D[XV>)_V6
M[#X52_%72/AUXVOM/UWXO?%^'X)>&O!%I:>%-9N9O'-KXSU3X>_$'PFNM>%I
MHK?5M.L/'L7A3P+<R6Q/BKQKX;T>.ZOX_L:N2\?6OB.]\#>,;/P?IGA+6O%E
MWX7UZV\,Z/X^EOX/ VJZ_/IEU'I&G>,9M+T[5]2A\+WE^T%OKTNGZ5J5ZFF2
M736MA=S!() #\(?V&?BSI?Q&_:H^&$'PS\1?\$9?@Y81Z!\0-4^+_@'_ ()^
M?M@?#K]H#XT?M$2OX2EB\/67B?POHW[*/P.U;3M ^'GB.ZN_'-_JNE>+];B%
MTQAN+![3==O_ $%U^'_P?T'X@']O_P"".E_M%>)/^"8WP4^+W@#X>_$[7O"/
MP3_9;\::UKG[0GQ:\-^+O#T^E7TFL>'_ (@_#[X=^(=-^'7A..*3Q4NH^'K?
M6!=:E#+'=K:67G7#_N!0 5R.M> _"7B+Q'X6\6ZWHT&H^(?!7]M_\(OJ$\UW
M_P 2K_A(]+FT37/+M$N$L;C^T=*N)K*?[9;7&(GS'L=4=>NHH ^4?V=OV'_V
M6OV3]7\5:]\ /A19^ -6\96MIINLW8\3^-_%)M]#T^ZN+W3_  MX:A\:>)O$
M=OX)\&:?>75Q=Z?X+\&1:!X4L;F:2:UT>*1BU?5U%% 'YB_\$W69O&7_  4Y
M+$L?^'G7QA7+$D[4^ W[,Z(,GG"HJHHZ*JA1@ "OF7X^E_V?/^"W7[(OQ6CC
M&G^$/VN/@EXY_9^\;ZDJ;6U#QQX45];^&VF,P*I/YLL4:_.X>W12\<<F0!],
M_P#!-S_D<?\ @IS_ -I._C'_ .J(_9HKY]_X+L:)JOAC]G/X*?M7^&K6:\\5
M_L8?M.?"/XV:3!;C][_9[^);#PSXCF9LA1;6NCZI/=W:R'RVMX'+ [0*]C(V
MI8]8637+F%#$Y>[[<^*HRA0;OHN7$^QFF](N*ET/(SM..!>)2?-@*^'QZMOR
M8:M"==*VKYL-[:#2UDI.*W.[^"5W%\/?^"NO[6O@M8A!;?&'X2_#'QSIZ,H4
M3S^%]&LTU>ZB *@EM0UNZCE8*V3C?AAFOV"K\6?C9XATSPI_P5?_ &-?B9HM
MS%<Z%\;O@KK'@6SU: YM=6_M>ZU#4[!H7( D2?2[/3[B$G#[70@#BOVFKFQC
M=2AEE=_;P/U=Z<MO[-Q>*RR$/^W*.#I0Z-6LTK'=3BJ6+S*BE:V)P^+WNY2S
M3+<#FE6KLOXN)QE>IU^*]]="BBBN Z0HHHH **** "BBOF/]LW]I+P[^R'^R
MY\;?VC/$TEJ+3X7^!=6UK2K2]D$4&L>++E4TKP5X?9B\9!\0>+;_ $;1P58.
MOVTLO*UI1I5*]6E0I1<ZM:I"E3@MY5*DE"$5YRDTEZF=6K3H4JE:K)0I4:<Z
MM2;VC"G%RG)^2BFWZ'Y7W1;]O#_@LI:VB-_:GP#_ ."87A];Z[VO+<:+K/[4
MWC* BTB<*NVS\2_#FS?S0DCJLD5NY"MN^;][*_++_@C_ /LU>(_V??V/?#?B
M'XG0W,GQW_:(U?4?V@/C=J>J;GUV;QA\1)#K4&C:Q<,3]IG\,:9=P:,DJ[E(
MA<J[H5(_4VO1SBK3>)CA:$E/#9=2A@J,H_#4=*[Q%=6W^L8F5:LG_+.*VBDO
M.RBE-8:6*KQ<,3F-66-K1E\5-55%4*#[?5\-&C2:VYXSEO)M\SXU\(:%\0?!
MOBSP'XGM3?>&O&WAK7?"7B"S#*INM$\1Z9=:1JENK,KJC36-Y/&KE'",P;:V
M,5^,W_!$OQ?KW@/X??M#?L$>/[MG\=?L,_&K7O .C132%%N/A!XKN;OQ!\-I
M-)BE9WO=/TW3_M%G=:E:2361N9X8OW$C!'_;^OP?_:&3_ACG_@L7^S!^T9$/
M[.^%G[=OA*]_9'^*=R(UAL+?XKZ=MU[X,3+$-D,VL>)=7M4TNXO7(N%L;>Y4
M[PP$FF6?[3ALQRUZRK4/KN%7;%8",ZLHQ7>M@Y8JFDM95/9+5I(C,O\ 9\3E
M^8K2-&M]2Q+_ .H7'RITE*7E2Q<<+-MZ1A[1Z)MG[P4445XQ[!S/C'_D6]3_
M -VV_P#2VVKPVO<O&//AO4L?W;;_ -+;>O#:_*^.?^1KAO\ L7T__4G%'Y?Q
MM_R-</\ ]B^E_P"I.+/Y /VZ/V;_ (YZ/XW_ ."Q/[0/PS^$OQ0\277Q<^(?
MPV_9_P#$_@_P_P##'Q9X@O?C-\*/%'P+^#(\.^,?!-KI^C37/B>Q^$?C^+Q5
M>:QJ7A]-7MQ)/=:5<>3/IMRB?27BOP=<>&?^"OOAKQK\0_!]CI7@75?V1/V+
M/"FC:[X\_P""<7QJ_:[L/$?BWPYXJ^+;:UX5\"_&#P)9+X;_ &9?%WAM]7T.
M\\0^,/%8U&VCM[W2I;RRLDT=K@?TWAW&,,PP,##$8!Y('/ )YP*422 $!W .
M<@,P!SUR,]^_K7C+.:G)"$J+O'#/#>TA)*HX>RP=.+O.G.-X_5EJXN7+4Y8R
MBX0E'R%F\^2$'3MR8>6'4X32GR.GA*:UG"<;Q6%23Y6^6;BG%Q@X_P DOQ:T
MCXM_![XQ_'>/Q9^SU!\6_P!K_P"('[?7P\\0Z!XF^)/[$OQJ_:7TCXF_LJ>*
M_&'PX\.^ KWX,_M0_#C4M,\$?LGQ_ K2Q\0?%>H:/K.NZ;J,.HV+7E[HL<>N
M6]\.GAT;]M*;]L_P[_P4YG_9NM8_A=K_ .UU:? /Q+#%_P +>O/VE+C]D6_M
M)/@/I-EK7[-NH_!**PL_ .D7&K)\5]8\51?$O4KB[_LTZY<>';:,&8?U9B1U
M&U7<+SP&('/7@''/>D+MG)=LGC)8Y.>V<YY]*K^V9<JB\+&3=)T)N4YV]C.,
M(SITHQ45"/NJ4%)SY&VE>/)&#><-Q2>'C.7LG0DYU)<OLIQBITZ<8J/+%N"<
M%)SY&W:\5",/P>^%/[*7@GP+\3?^"S>N>%_V8?"'@J[U:2TTCX+ZYX;^!6A>
M&+G5M"U/]CCX;:?KFE_"G5=)\)V$VI:/J?C"/4[36+#P;<3V-_XK348;Z*;6
MA=BOG7XHZ7\;_P!D7]E/_@E;^VK\'?V>?BE\3/CI\'?V95_91\<_"+P9\/O$
M&I_$.'0OC3\&])U/PK>^*O",=I:ZG9:-\,OC?\,/ G_"3Q:VEDOA[0?$GB>7
MRC?F&UF_IJR>.3QTY/'T]/PI0S E@S!CU()!.>N3G)S6$<TJ>TA*I2]K%*C"
MI"<YM5*<,*\+.#>Z]I&3G=.\9RNM=3".9U%.$JE-58Q5*$XSG-^TIPPKPLX-
MWNE4C*4VUM-W6NI_(;XN_9/F_99_:?\ V!=/\8^&]+NO#>D?L?\ Q(G^,7Q/
M\;_\$Z?B[^WGX3\2_&OXD_&/X;^._$^BW'AGX4V[W/PY^(VJ0IJ5II7Q,UV\
MOHM%TCP_+;WFEWB7JQ+_ %TVK1M:VS1 +$UO T2B!K4+&8D* 6KJCVP"D 6[
MJKP#]TZAD(JR'=<[79<]<,1GZX/--K#&XZIC8T%4C)2HJJF[Q<9.K4]HY)*G
M&2;;2?-.:LHJ*BE9Y8S&SQD:"J)J5%54W>+C)U:CJ.22A&46V[/FE-645'E2
ML_2/AW_K=7_ZYV/_ *%=UZA7E_P[_P!;J_\ USL?_0KNO4*_5>$O^1#@O\6*
M_P#4NL?J'"G_ "(L'_BQ/_J56"BBBOI#Z(**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ KYK_8W_ .34?V=_^R/^ _\ U'[*OI2OFO\ 8W_Y-1_9
MW_[(_P" _P#U'[*@#Z4K^='XY^"?VM/#/[3OQ4^./@K]C?\ ;[^*?QP\._M*
M> ]6^#WQ=^''Q_\ V:--_9VU3]E;3=/\":3XS^$__"G_ (@?MI_#*TN!JGA_
M4OC)-:W'B_X)KXI'C[4?#VHGQI#HEK9G2OZ+J_"_]JGQC_P3ET[X_P#Q$T_X
MS_\ !:/XB_LR_$V#4=-3Q5\#M&_X*/>#?@II7@"Z?1-,:TL+7X::G?P7GA*.
M_P!.:TUE[>X5#<OJ+ZD"([M6H _7;X*?$GQ3\5O \/BWQC\#/BO^SOK,NIZC
MI[?#CXS7OPBO_&UO;6,D:6^L3W'P1^*OQE\"G3=55VDT](/&L^IHD3C4=.L'
M,:/ZU7Y]?\$T?B3XP^*7[.-[X@UWQEXG^*'@C3OBK\1/#7P$^,7C..Y?Q3\9
M_P!G_0]1MK;X9_%'6M5N[6QD\37?BBP:[D'BM;*UB\1P6T.K1PJMSEOT%H _
M+W_@IE\.M<^+/@[PKX$L?V1/CG^TLU]IOC2[\%>*_@=\</!OPJ'P;^*Z6%A9
M^"?$OQ2T/QO\:_@UIOC#X?OJ%Y%J=U;Q:=\:(8H/#^KVVK?"C6[:\M]/US[N
M^!N@^/?"WP;^%WAOXI:KIVM_$;0O GAC2?&NJZ1#:0:9>^(['2;6WU26RCL-
M,T2P^SBYC=$>QT71K.4)YMKI.FP/'90>J44 ?SE_\%9_V/M.^'^H:1^U_HOQ
M!^*'Q"^)?Q3_ &D?V>_@;_P@OC._\*3>$M!T'XX?$OPS\(=-TGP'_P (YX/T
M'5M&TSPA_P ).VN0VOB"Y\8ZEKK6@TR?6;'[2^H1_KW^PAHW@70?V2/@AIOP
MZL_L'AU/"$5S<6QF:X*^*+Z]N[WQM(96 R9_&%QKDQ4*B1^9Y:(B(JCRW_@H
M]X/U[QM\._V;M/\ #MM:WEUX>_;Y_88^(^LPW-_8V M?!/PT_:5^'WC7QWK9
M:^G@26W\/>%M(U+6+R.,O*;>U?RT9RJF[^PA*_@ZT^.7P"NG5#\&OC%XJLO#
MEL"<?\(3XDNCK^A7:JW*)=2WM](@'R["I!R37R%3-\"N-:6!H9EA*^,J93'+
M\UR^CBJ-3&8"K3E5S/(7CL-"HZV&CC,'+/9X.6(IP5:%&H\.YQ4^7[+*.'\'
M4\/N(<11RN.'Q>4\3T>)L/C/8S4:^%XBP^$R#BFI0G-.G%SQ^4<&/&K#.,:U
M6-.IB4ZL(2E]0_'OX-Z'^T)\'?B%\$_$WB/QEX4\.?$KP]<>%]>UWX?ZO9Z%
MXNMM&OI83J5MI&JZAI>M6=I_:EG'-I5^9]+NUFTR]O;<(CS++'^ O_!(C_@F
MM\"?V6?VR_VN-7^'?C+XV6/B?X!^+H_AAI6C:OXVT*X\+^.OAIXV\.SZC8_\
M)GHUMX.TZ\UV;2M3M;75+&[L[_3+2WUO3M-N6M7$)BF_I7K\M/A@3X&_X*M_
MM">%AMM]*^*W[.7@CXA6I8%/MWB30/$D6C:A#$H!622'3KF2X:0D$1@J2#@'
M]0RC%XA9=GV!IU91IU<O^L^S5K2G2Q6$C5;36O-AI58O71>\K-7/RS-\+AWF
M.0XZI2A*I2S!X9SE>ZC6PN*E12=].7$QI25M7*R=T['ZEUY'\=/@KX(_:$^%
MWBGX4?$"P6\\/^)K(Q"=%'V[1M3AS)IFNZ5/E9+35-*N@EQ:W$$D,HP\/FK'
M-)GURBOGTW%J2=FFFFMTT[IKT9[>(H4<50K8;$TH5L/B*4Z-:C4BI4ZM*I%P
MJ4YQ>CC*+::[,_-?]BSXT^-O"'BKQ!^Q)^T7J._XS_"BP6[^'/B^]8PP?&KX
M11EX]%\0Z9)-M^U:]H5M";+7;./$YAMI)XHKB+3-1OW_ $HKXC_;6_9BU7XY
M>%/#WCSX6ZA'X4_:-^"NI-XR^#GB^,K!)-J%J!-J'@K5Y_E$_A[Q7#$+*YM;
MEUM!=?9WG>&V:Y>NP_9"_::TS]IKX8G6[K3W\,?$OP;?OX0^+O@&\5H=3\'>
M-]/#17UM-:RA+A=.U!X9;S2+J2*-;JU+&+>L>]MJD5./MH)+5*K%:<DW]I+^
M2>Z[2O':Q\UDV(KY5B_]6LPJSJ\E.=;(<=6ES3Q^74K<^#KU'\>8Y6G&G5;]
M_%81T,7[U3ZUR?5E%%%8'U84444 %%%% !1110 4444 <]XL\(^%O'?AW5O"
M/C7P[HOBSPMKUI)8:UX>\1:;::OHVJ6<F"UO?:=?13VMQ'N"NHDC8I(B2(5D
M16'\\G[37[(OQ,_X),>%OB7^V/\ \$\_C1IG@+X)>$K/4/&WQ=_8R^--[K&O
M_!C7K568W;_".]MO/U_P=XCE$@&EZ#!,8+[47N+FXU28S)9I_1Y7E'QH^!GP
M@_:*\!WWPP^.7P]\,_%#X>ZG>6&H:AX0\76"ZGH=[>:9-]HT^XN;-V5)7M)_
MWL6XE0_)4\5Z66YA/!5HQJ-U,#5J0^NX24(5J6(I*2YDZ-5JG[51O[*JG"I3
ME:4)Q>IYV8X"&-I.4$J>-I0G]3Q2G.E4H56O=?M:2]I[)RM[6E:5.I&\9PDF
M?B7_ ,$8O^"ROAG]M_PMXG^&O[0GC#P=X+_:6L?B#XFO/"7AJYN[;1+?QS\/
MO$FI3:UX7T_PM+>&TMM9U_P@+J]\)W.D68;5KG1M&T;6V@N9KW46M?Z"Z_*/
MXA?\$2?^"9WC;PGJ?AW0OV7/A_\ "76KKRI](^(7PBL&\#?$#PQJ5L6DL]2T
M'Q)I<B7EG+#*0TL()ANH@89U9&R/DV/Q]_P4@_X)4'[-\8=/\4?\%#_V(-&V
MQQ?%GPC9)+^TW\&?#<)D2.Y\>>& V_QMH&BV:)/J&L6#S0:5HM@SRWIOKB.T
M;TL9ALKS;$U:N2S>#J5)<T<KQOLZ/.VE=8+$*<J$FY7MAZTJ52_NT95;J$?-
MPF(S/*L/2I9S%8NE3CRRS/!^TK<J3TEC:#@JT4HVYL12C4A9.56-))SE_0=1
M7SG^S-^UI^SY^V#\/;3XF?L]?$SP_P#$+PY,L2ZC!I]R(/$/AF^D3>=(\6^&
MKL0ZYX8U>+!$FG:S96EP"I*HRC=7T97S]6E5H5)T:U.=*K3DXU*=2,H3A);Q
ME"24HM=FD>_2JTJ].%6C4A5I32E"I3E&<)Q>SC*+::\TPHHHK,T"BBB@ KRG
MXA_\?NE_]>MS_P"CH:]6KRGXA_\ '[I?_7K<_P#HZ&OF>+_^1#B_^OF$_P#4
MNB?-\6_\B+%?]?,+_P"I5$\D\1^(M#\(^'];\5>)M4L]#\.>&]*O]<UW6=1F
M6WL=+TG3+:2\O[Z[F;B.&WMXI)&/+-@*BL[*I_-C0?\ @JQ\'K_X->(OVAO%
MGP0_:;^%WP4_L&P\2?!WXA>/_ G@Z'2_VE=+USQ=;^"?"9^$.G>%_B)XG\1:
M+J'C?6M5\+S>"]'^..C?![5O$FB>+-*\1:;93:%I_B?4/#_W]\6_AQI/Q@^%
MOQ$^%.O75U8Z-\1O!OB'P;J5[8E?MEG:^(--N-.DN[8-A6FMO/$R(Q"N4V,0
M&)K\=;W_ ()Z?ML?$7]C;PY^QU\4_B[^SAHFA?LZ:)\&[/\ 9E\<_#S2O'^J
M:YXVU_X >)=$NOAIXB^.NG>)/#FE67@L)X/\(Z5X<\0Z1\.9?%]OJ5YXH\2:
MHLZMHVC1WWY?@J6"G!O%347[>C&?-4E"4</*_/.E&*?M)\_+&::ER4VY*%_>
MC^9X.E@ZD6\3.,&JU)2<JCA*-"3?/*E%)^TGS<L9W4N2FW)0?Q1^J]$_X*9?
M#(^'?VG[OXE_!+]H7X$_$/\ 9+^#D7Q]^)OP1^*.C_"N?XE:C\*+S1?$&LZ3
MXI\&WOPW^+/Q"^&6M1ZL?#.KZ3#I]U\1=,U33]7ACMM<L])AFCN3Y9XL_P""
MT?[*/@[]B/P?^W1J/A;XTW7@?QIXQO/ .G_"2P\.>"6^.VG^+=#OFM/&FC:O
MX5O?B#9>%[>X^']K%=:UXT:V\:7<6DZ)975]')="+RVY;7?^"?\ ^TS\<M,_
M;I^)O[0OC+X#:%^T3^U5^R'>?LA> =%^$-Y\1=9^#'PZ\*C2/%,B^)=8UKQC
MX7T#QOJNJ^)?%?B"POM=M+?P_-#H^EZ!:P:1/>S7=RJ_.GQ&_P""*/Q,\7^(
MOVF)]+^,W@*#P'\4_P!F?5/!_P (?AQJEEXD/A[X;_M1^/? W_"!_%OXT7L=
MKH\H72?&.D76JQJ=*2;6\W<;SV<<B,3W4Z&3.=JU51Y9T925.M.5-I4Z*K4:
M<^6;<95:LVJCDW&%&HE*7NREVPH90YM5:JCRU*4I*%63IRBH455I4YVDW&56
MI-JHY-QA2FHRG:,I?;_BC_@K%\%_!OQJUCX4>(O@Q^T38^$/#'Q2^$OP7\8?
MM$C0_A5<?!+P=\1OC9X T'XC> M"\0+;?%N;XN107VA^)-+M;S7+'X4W^@6&
MK3-9SZH(U%PWME]^WO\ !_3O#W[<7B6Y\.?$=;#]@+4M5TOXRQ+I'AQKKQ#/
MH_PQT3XKW<GPXC'BH1:O"?#NO6EG$WB.;PK(VLQ75NT:6217\WS'X"_X)4^'
MI_VH_BS^T-\<_'WBCQMX?UWXK_!3XL?#+X,^&_'/B.P^$-MXI^$7P.\"_#"S
M\5?%#X;WND0:+XK\8V.N>'-8U#PWJ:W]Q;VFB7.E07$"7EO*B<#XM_8'_;"O
M?$G_  4V\(>&?$_[,;?!/_@H.WBW5[+Q'KVM_%JW^+OPYU[5_@'X<^$NCVMW
MX=T[P/>>"=6TF/6_#RZMJ5U#XB%ZFF7;K;6]Q=1+ <E1RJ;A&%51<:&'G5E.
MI*$)3=3#.O&+E?FJ1IO$:1M&ZBHQO%MYJCEDW",:JBXT*$ZDIU'"#J.>'=>$
M7.[E45.5?2-HMJ*C&\6Y>_\ B+_@I1JOA']ES6OVNO$_[ W[;&B_"S0?#</Q
M U"TNI_V.YO%J_"IO"&H^-+SXIQZ39?M<75F_A?3-*L88+S23J:^/)+[5-/3
M3_!U[;"_N;*?Q/\ \%*5\+0?LW:5<_L4?MAZC\4_VJ+KQPOPN^"&EM^RI-\0
M_P"QO 6A#Q/JOBCQ%JMU^U%:?"W2=$O?#[)JNF1I\1KO6W@<0W^CV%YNMAX)
M\&_^"<?Q7\&_\$W_ -H_]B.Z\$_LC_!?Q5\5O@IKOPN\,^)O@/XA^,_B/P?X
M@\1Z[\.]4\'W7CWXG1?$3PII6NZ=?S:C<VM_/9>%;;5;<VTU\(]LD=M$]W]O
M+_@G!\2_VF]3_8:UOPUH/[,OQ2M/V4[?Q;!XO^&?[2&K_%?P]X#\<S^(_ EM
MX3T_4])U;X7^'==\06UYX?U"#^U[.*^M8;>?Y([A'&Y*N-+*GB/92=%4_;8A
M*JJE7E=..&C/#Z_6'"TZ[<9?O4VUR^T@DY%JEEKQ/L92HJG[:NE556IRNG'#
M*="[]O*%I5VXR:J)OEY5.&LC[0_:7_;1T?\ 9@\$? SQ)XG^!7QU\=^-/V@_
MB'X6^%'@;X*_#F#X1WGQ,MOB%XI\-:KXGC\-:_=^+?BUX/\ AE9SZ/:Z)JEE
MK&H6/Q%U+2!J%J5TO4-3LY(;V3P:Y_X*N_"6\^$/[./Q2\!_ C]I#XIZ[^T[
M\9O&_P  / GP6\%Z5\&[/XJ:+\5?AQI_C[4_&OAOQ?-XY^-'@WX86 T&U^&_
MB5IM3T?XDZYI=TZ6:Z?>7?GL8K/[;?[ 5S^VY\+?V/\ X7>.[7X8Z?X1^#7Q
MD^'_ ,1/C/X$2[\8W'A;7O"OAWX>>)/"FL^#OAOJD-E::]YEGJNMV=SX5U+Q
M"NC2_8=+@N-1>WO";=OBGXL?\$D/CQXU_9?_ &1?V?[G4/V6_C%8_LB?M-?$
M3XBZ%X0^,MY\6?#WP_\ B/\ !#6_#'Q,\/\ @'P=XTU;P)X7U'Q7'XY\*GXA
M6TNHZG9VLVGZDOAG3Y9=0NI;FZC:<-1RJ=.BJU2,:SK5?:WG-05/EQ"I:^TA
M%ISC1NN:G)1E=U6IMTHPU'+)PHJM4C&JZU15;RDH1I\M?V>OM(IKGC1NN:#2
ME=UFI/V?WW\2/^"E_P )?@U\?_V4_P!FGXN?"GXY?#OXF_M9:/:ZAX?BUK3/
MAEJ7A[X5ZKJ7BC2?!&B>$_B]X@\+?%'Q!8:=XAU_Q?KNC>&]';P._CS0KK5-
M3M83K<:,TB\)XR_X*_\ [,G@WXH?M>?"R7PI\9-?U#]B_P %Z7XT^)GB?PYH
M'@F\\'^)H[WQ)_PAVK>'/AUJ5W\0+"^UGQ-X/\5QWWA[Q;9ZYIGANRTO5]+U
M*QCU&ZGMMK>4_M$_\$Q_B5^T6VAZM/KWP<^$NKZ!^POXG_9_\*:1X%G\<ZUH
M7PQ^/4?Q"\)_$;X7>/? VJ:WH5CK-SX(\!Z]X3T^\CN-2@LO%3W$,31:>P!8
M>(3_ /!&SXR#X6>-_"0^,?PTU;QS\3?V)M$^!_Q$\;:O:>+(Y?%W[1>J_''Q
M%\;OBO\ %G4S:Z+)</X9\6Z]XFU*6R4JVO)=3$7-C# %853H9.XTW5JVF[4Z
MD(U)\J;Q";K*5I>ZJ"E3Y.9ZM5+NQ<*&4N,'4K6G=0J0527*G]83=6,N67NJ
MAS4U!R>K52[=S]-OA)^WEX!^.'QJ^,OPE^''PO\ BYK?AG]G[4SX<^+WQY<_
M"BR^$_@WQDG@KP[X_E\'7NC7?Q3B^-]WJB>'O$MFT6K:;\';WPA?7MIJMEIW
MB6\FT^<#A/AK_P %,/AG\4/V;?CA^UYHWP7^.^F?LZ?!CP=\1?'&G_$K55^"
M=U:?&+1_A;)XCB\70?#+P]X;^-/B#Q?IVK6DOAB^2'2_BYX?^%MU+]IT^1DB
MAN&DC\6TG_@GW\;S^WWX5_:LGUC]G7X=Z/X)\*^.M O?B/\ ";2O&]C\=OCU
M8>(O"WAO0_!7@OX\^$+_ $BP^&&H^%/AE?6%_>Z5J^G^(-2U_74TS0_MMOI[
MZCJ\<'COA7_@E?\ '-=+_P""AYU#4OV8_@S/^V'^S9XK^!^@^ _V?E^)D7PI
M\0_$/Q';^*H7_:+^+VA^)?#NF'P[X_N8=6T_3+_2/AWIVK:4=.O==/VNZN(;
M!KA>PRJVM6"_=8*3_>3;3E54<3!VDG*HX?O.:,>6E!\DZ,)MU(+V&6<O\6"?
ML\')_O)-Q<JJCB(6YES3</WG-&-J47RSHQE[\?J/XI?\%7_@S\-IO'EYI?P7
M_:+^+'@OX*^ O!?Q'_:/^(_PPT#X77OA']G+PYXZT.'Q3I"?$B#Q;\6?"'B[
M7=7M/"LK>(]8T?X1^%OB;?Z=ID%P)86OH_L9[OQ7_P %,?V>/"7[36E_LMW>
MG?$*_P#%6O\ [-\G[3OA[QWIVD>'%^&>N^#)+;7;W1_"VG:QJ7BK3O$+?$'Q
M-9>'=4N_#N@W'ABWL=0A@8-J\$D5Q'#\3^+O^"9_[6VA6G[4OPR^!_Q3^ %G
M\'?VY_A_X \*?'76O'R?$.#XE?"77]$\ 1?#;QIXE^"NE:#X7U7POXS&O:+)
M>:OIMAX]U?PW':ZQ]FBD,5IYK5VOQU_X)0ZU\0_$?Q>U+P%XV\&>'+.;]B_X
M _L\?LWZAKL?B*?Q%\,OBG\!M3^*":+\0-?FL;":&;09_#/Q!&D&'2[B\U.>
M7^T&N;+8MJ[-4,H_=\U56E2=I1J3;4Y+#+FK1L^25.I/$-4XVYZ5-;M*=05#
M*OW=ZJM*F[2523?,UAUS5HVO"4*LZ[4(VYZ5-/?EG4_5+X!?&?PO^T7\%?A?
M\=O!5AKNE^$?BSX,T7QSX=T[Q1;6%GXBLM)UVV%U:6^LVFEZEK&G6^H1QD"X
MBLM5U"W5^([J5?FKZ#\'?\C)IW^[>?\ I%/7R1^QW\%_$/[.?[+'P!^!'BW5
MM#U[Q/\ ";X7>%O ^O:UX96_3P]J>J:'8K;7=YHJ:I;6>I+ITLH8VHO;6WN1
M%M\V)&R*^M_!W_(R:=_NWG_I%/6&6JG'/<#&D^:DLTPRIN[=X+%046FTFTU:
MS:N]S#+U3CG>!5)WIK-,*J;O>\%BJ?*[Z7TMKU/<J***_<3]L"BBB@#Q+]H_
MX)Z/^T9\#_B-\%==U"?2=/\ 'NAKIHU2WM[2\DTW4++4++6='OFL[Z&XM+R"
MTU?3;&>YLYXF2ZMDEM\H9 Z_+/P(_9Z_:YN_V@/#_P ??VQ?BG\ ?&&K?"KX
M4^,_A/\ "/1/V?/AEXK\#VMS:?%'7O!.M_$7Q9\1M2\?>*?&6JW6MWG_  JW
MP';Z'H_A"Z\/^%K+=X@FO-+O)I-)DL?L3XP:Y\7?#G@35-5^!WPY\%_%7XC0
M26RZ/X+^('Q1U+X.>%]1C>3;=27WCW2/AI\7+[2FMXOWD4</@;5/M+?NR]N/
MGKXI_P"";GQO_;+^-_PNU/Q!^U1\(_A=X,M(/&'Q:TOPQXW\$_'FZ^)VO>)I
M_#?QO^)/A.;P]K/@V/\ 9W^#6C^&-,\%:=H6G^&]"\0V>N^([SQGIVF0:_JV
MFZ+J5_=6] 'Z2T444 %%%% !7\H/_!?_ /:@\"6GQ$TWX266FV^N>*? '[-W
M[1?A#7-1.I26]OX:O?VFO!&@^&FMKVT'[FYFLO#FC:=K4!<2@/J"PX22-Q7]
M7U?@=_P5:_8&_9)NOA5\;OC/=?"@2_%+Q?X+^*WBC6/&$GC;XB7%Y<>);?1$
MU*QOX--NO%L^@VBVMX[O;:9:Z3%I,,6+:.P%M''"OQO&N?8_AO!Y#FN#K0H4
MEQOP)EN.J7;K.AGW%^2Y!1IT8./)*$\;FF%^NN=2#CEZQ7LHUJSIT9^/G>4Y
M_G6"JX'A_$X+"8A4,;CL75QE2M34LNRO 8K,L9AZ'L<-B7*MB:.$E1BIQA3D
MI.$ZD(S<X?:__!(S5AK?_!-;]CN_5F8#X/Z78$L"K!M)U/5=)9<')PK6153_
M !* W0U^C5?DM_P0[UAM6_X)F?LUJY4MI?AR]TPA/NKMU&XO0,9)#%;U6;)/
M+$C"D*/UIKZZD[TUWBY4WK?WJ4Y4Y:Z7]Z#Z'U&:T_99CC%:T9UY5H*UK4\1
M:O2TN[?NZD>H4445H>>%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4456O+RSTZ
MUN+[4+JVL;*TB>>ZO+R>*VM;:",%I)KBXG=(88D4%GDD=44 EB!2;23;:22;
M;;LDEJVV]$DMV.,92DHQ3E*348QBFY2DW9)):MMZ)+5O1"7E]9:?#]HO[RUL
M;<,J&>\N(K:$.V=J>;,Z)N;!VKNR<' XJM9:UHVI2-#IVK:9?RHGF/%97]K=
M2)&&"F1D@ED94#,J[B NY@,Y(K\7?^"@_P"T'H'[0/PWN_A/\$_"OC/XH6GA
MWQOH.J>*?'7A7P]JFK>$K"\TZ+5H$T"UDL[*YN-9O)9)I3=2V\26=DL$,GFW
M$=W;R'RO_@E%X%\9>%_VA?&E]K_@CQ;X9T^?X/:Y:K>ZYX5US0;*>\;QGX$E
MAMDN=2T^SMYKIH8KF6.%7:;RHIW5=B2$?F]7Q"A+BW \.Y?E\<QP.+G3I3SF
MAB:GL*567M55C3C'"3HXB-&5-1E4IXKD<W*',I4Y)_O>'\#ZM/PRSCCK/,[J
M9'G&6TL1B*/"F+R^@L7B,-#ZJ\/4K5)YG2Q>#GBH5Y5(4*V7>VC3C3J<DJ=:
M$G_031117Z2?@84444 ?-7[9/_)J'[17_9'O'O\ ZCU]7TK7S5^V3_R:A^T5
M_P!D>\>_^H]?5]*T %?%_P"W+^S+\2OVI/A-IG@WX5_M$?%+]GCQ1X:\56GC
M6VO_ (:>.?&OPXL_B)+I&G:E%8?#KXD^+_A;KGA'XLZ9\-=8U.ZL[OQ,/ACX
MW\&>+[B&PC@L-?MD>5)/M"OSY_;T_::\=_ %?@)X3^'WQ/\ V:O@9K'QQ^)&
MO^#[GXU?M617^K_"OP#IOA;X:^,OB-.9/!VF?%/X(WGB_7?$TOA.#PII-DGQ
M5\*II4^L?V_*NN)IAT._ /DW_@G5^S[\6_V,/V@/C/\ #CQ#^Q1\%_A-\-_C
MQ=^$=?T?XQ_LFO8:?\(9_%GPY^%FD:)XEE\5_#748+CQ]\/U\<:MINHZQI6N
M^+/%OC'4=?U[4/L6K7TNK2RZG=_MQ7XX_L!_MW_&/]L3QCH6M^,/C'_P3W\%
M>&9[/Q5I"_LU_!SXGM^T'^T!XWO/"<5SI]W\4=-^(VG?$WP1I7@+PE>:K:2:
MU%\/+OX#?$#5;/PQ) ;WXCI-/'?']CJ "OBB#]O/X/#]HF']G#6O"WQD\(ZW
MJEYXQTGPE\3_ !?\,]7T#X&>/?$'P^\-:OXP\:>&_ _Q/NYO[*U_6_#WAGP_
MKNLWUM%!%";/2-0>"XF-NZU]KU^$?Q0^"/Q8^.7[8]_=?#W]G3]I#X+ZW%-\
M6?"'QC^/'QE^+%C\3_V6O'WPIU_X9>*?".BC]G_X?>(_BG\0;[P'XNUKQ%JO
MA^>2]^'GP@_9V\0#0EU[3_$_B_Q!X;DU#PCXC /OG]F3_@H'\#OVK?&VK^!/
MA]H?Q=\,:I!X)TKXH>#M0^*?PUUCX?Z#\7OA3KNI7>EZ)\3_ (0ZKJTC1^-_
M!&JW%FTMGJMK';S-93VE[):1V]S%(WW'7XQ?L3>%_P!HGQU\6_@%XC^+7[-/
MQ'_9RTK]E7]EG3O@CX@O?B9KW@'68/B9\3[N"UTG79_A2? OBGQ+/J?PYTRT
MTJ'4+#QMXMM_!NO:X;Q;*;P'H[6[3R?J#\:_AKXJ^*_@E_"?@[XZ_%?]G?67
MU2RU!?B+\&;+X0W_ (TCMK1+A9M&2W^-OPI^,G@@Z9J)GC>]=_!KZHKVMO\
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M]))I6S#A7)L=>S;:O]8OJWON]PHHHKJ/""BBB@ HHHH **** "BBB@ HHHH
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M::=9R&-\ 'Y\_"CXC:E\"?VY/V1/V2_B!^R_^SG\+OCIXXM?C]+XK^-'P@^
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MQX,\2Z79:QX=U;2[#2-2\&>($NM'U"&>RN[>]OGMI+A9H74W$:.,/&A7]/\
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M?AS-J_A^_P#"EQK=CK2ZQHNOM;:K8:F;6SM9_M%I9Q6>JV][%]B34-'OMMW
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M#Y _:8_:E\5_ CQE\(?AU\//V9OBY^T[X]^+]G\1-7TWPU\*?%?P*\'2>'M
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M_;'_ &@;+_@HSXP^#7[0?QM\0_!'X7:C^T;XB^%/[.OPB\3_ /!/_P"+^E^
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MLS\D\SV[L"(N/HG_ (8M\-Q8>R^+7QFL;J,AK>ZA\::@TMNZXV/&))F0LH
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MXJC3K/KR8=U:C5W&#MI/^O.8)V]A@7+^6%/$3ET^S"NVOG97;UTT_?"/X\>
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M5E]LN$N'U&2=-/CT=9M=DN5T:WGOH^&R?4_Y_P#U#\JU-")_MO2.?^8C:?\
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M>%O"EO<0MXG\:ZTL;&VTC0=/+&:0R2[$N;YHFM;%'WREY3%!-\:?MP?\%?\
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M$O %YX \:^(+6V^+'A;5_#-KIVGP:CJ'C'QO\3AXDTBU&G3VVGWS?VVOZ$4
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M2^ =,L-2CW%WM]0TIY]/N+>1B2=\7V= <G."!Q7U37YT_P#!,J^N;;X$^-/
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M+\;3P%5I4L;/"UX82HY-J*IXF5-49MN,DE&;;<6ELS9HHHJCB"BBEP?0_D:
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MKR^&+WX"I,W]J:%=_$CXDZ>OAWQI<^#1!-X]M-,L_#'CE[W0+.UM5 /Z1R0
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MO?&.272I(/$.G:I$+NRC\*QS1"32O#$MM*DEG:*%>6%D>=GW5];?\+>\;?\
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M/@M^SUIH\.>+H4\10/H7BNV;2'O[K1)A)-%I.HZ/?M(%U!8X_M[_ (>!2_\
M1A7_  4Z_P#$-_$/_P U-?D>=Y+FV(S;'UJ& Q-6E4Q$I0J0IMQG%J*NGU5W
MN?E6=Y/FF(S7&UJ&!Q%6E4K7A4A!N,ERP5T^JOH?H-7G_P 5OB1H7P?^&_C7
MXG>)9%CT;P3H%]KERCN8_M4\"B+3M.1]K!)=4U.:STV%V&Q9KM&<JH+#XY_X
M>!2_]&%?\%.O_$-_$/\ \U-(?^"@,A&#^P3_ ,%.2#U#?L;>("#]0?%)!K@P
M^0YK"O0GB,GQM>A"K2E7HPO1G6HJ<74I0K<E3V4JD&X1J>SJ>S<E+DER\K\I
MY!G5GRY=BE*WNOV5[-I6;5U=)M-JZOM=;K\@?V&_VW?C=X<^+'Q;L_"OPG_X
M7 _QA\37WQ)U?PEIVI)IGC&T&EP7\UVO@W36(@UZ^CTF0O=:7$_G21V37:#9
M$YK]I_AE_P %!OV<_'VJCPGXDUW4_@M\0HG2"^\!_&73IO!&KVEY)@)9+?ZH
ML&C7UW(QV1V]C?7$KMPJ$G%>5>,/^"G/@[X=Z78Z]XY_8L_X*/\ A'1]2\5>
M"/ VGZKK/['NO6=I>>,OB7XQT+X>?#WPQ!,/$K%M7\:>._$_ASPAX?M<#[?K
MVN:;8*RR72&N>^)O[37PL^,NDG1/BC_P3)_X*(^-K%8WCM_[>_8@U2]N]/+Y
MS-I=_)XD:[TVY4DLEU930SHWS)(&YK]$S_%Y;Q1F,L7C. <SR7VE##4GBLHS
M)XC%QE0I0P\*E;#8O"4L%BJ4:%.C2A1I4\!57)S3Q<W)I<E+AKB"C!0CA<35
MLV^6I0Y8VD^:R<9.46Y2;NW)>\_=NFS]3X9X;F**XMIHKB">-)H9H)$EBEBD
M4/')'(A9721"&1E)#*00<$5+7\ZC:CXX^$L\^I_L@_!;_@KM\'(DD>X@^&OB
M_P#8\\3_ !'^%4SLS221C1->\937-M/<,S1?:I+J5859614V<NE_X*_?M+?#
MS4_"7A[X\?LK^,/AAKFFZI%J_B31O'WA6Z^&GB_QSX"GL=8TRSO=-\.ZQJFO
M)H$U_K427T-_'*L(DT:6Q-N()IDE\BCX9YIFM1QX<Q5',_<G4>$QU*IDN:4X
MP@Y_O,-BW/"5>9\M-2P688R$9RC[65.#YS#%X7,,NI.MF67XK"4E*$'6E3E.
M@YSMRQ56*M=IMI247:+TNK']%-%?G1;?MF?M-WMM;WMG_P $T/VG;JSO((;J
MTN8=;\'O#<6UQ&LT$\3B/#1RQ.DB-W5AP.E<GX>_X*#?&GQ;XE\?^#?#'_!/
M7]H;7?%?PIUK1/#GQ*\/Z;XC\(3ZGX(U[Q)X3T3QYH&D>((/(46E]JW@SQ+X
M?\36D2/+NTG6;">1HWG$8\__ (AMQDM'EF&3VL\\R!:]O^1I_6O9A[&N]L-C
M6NZR_,&NFM_JNVJU/U#HK\.?''_!6SX@>#OCGH/PYUO]EKQQX3NK!'T#Q9\*
M_$&NZ"?B%J7BSQ2-$N/!G]FWT-N=/TY8[:Y0K93;O[0&M*9G4P0&'ZV/[87[
M4@)'_#LG]J'@XXUGP>1QZ$1D$>X)![5T5_"SC?#PPU2KE6'C'%4?;4[YQDT/
M=<Y12O5S"G&;<5"KS4I5*?LZM-\_,Y1AC2DZ\JT*5+$U)4*GLZJIX/%U'"?\
MLXTZ$I4VFI)QJ*$DXRO&RN?HA17YW?\ #8?[4?\ TC)_:A_\'/A#_P"-5\L?
MM"_\%5OBK\%]8\&:#XL_9,^('P:UFZOK+Q3K.D_$W6=!FO?$GP_AGOK&^M]"
MCT^!OL$]Y?6TT4>J3DF![%U1-KN6,+X6\;8RO"A1RO#N<U)JV<9-4LHQ<FW&
MAF%6I9V2NH-)M<UE=IUW+#4W5KTL52III.=7!8RE&\FDESU:$()MO1.2;U2N
M]#]N**_-S1OVW/VC?$>CZ3XA\/\ _!-K]I?6-!U_3+#6]$U:QUWP?-9:II&J
MVD-_IFHVDHB'F6U[97$%S ^%+1RJ2JG(&E_PV'^U'_TC)_:A_P#!SX0_^-5S
MOPUXR3:>5X9-.S3SO($TUHTT\TNFGNGMK?9FJHUFDUAL:TTFFLOS!IIVLTUA
M;-.ZU6A^B-%?G=_PV'^U'_TC)_:A_P#!SX0_^-4?\-A_M1_](R?VH?\ P<^$
M/_C5+_B&W&7_ $+,+_X?,@_^>GG^?9A[&O\ ] N._P##=F'_ ,R^?Y]F??'B
M+P]H?B[0-;\*^)]*L==\.>)-*U#0M>T74X%N=/U;1]5M9;'4M.O8'^66VO+2
M>:WF3()21MK*V&'Q[X&_X)L_L#_#/QCX<^(/P^_9*^"O@_QQX0UBR\0>&/%.
M@^%4L=:T/6M.N$NK'4M/O$N"\5U;7$:2QN0R[E&Y6&17CEW_ ,% /C=8>.]
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M<_\ @I5\<OC)X$6Z\.?L7?%CXV:]X8D@TCQKXH^&&K>&[70!K$\375J#IM[
ML^GS7-EME:!2\659D*!@@X\=X)\3YI@*E>KDF&IT:6*HQE7PV:Y!2K2FX5-'
MB?K52C[./-!585*D:CG4H.$9+G<?UWPX\?/$CPNSOZSE&9XW.)5LLQ&"IY%Q
M2^)<TRBG1JUL-6>+P^54LPP,Z>+I_5'3HXBFW"%&>)A*+<DX^V?!+]B?6M,^
M&7AVU\:>.?B)X \8K<:U+KN@>%?%\%SH<!DUF_.FO:"PGGL(Y)]+^Q7%T;:9
M]UU+,9@)=X'JS?LI^.K<R-H_[57QKTF3&RV<3Z?>BWB#+B,I<.%F 10FY\'H
M_P!X"O//^&P_VH_^D9/[4/\ X.?"'_QJC_AL/]J/_I&3^U#_ .#GPA_\:K"C
MX/<0T*5.E#)J'[N$(*:XCRBG4ER1C%3E*CG%)<[M>3C&*NVTH]'F_CAXHYSF
MV9YMBL;#GS/,,9F$\%4X,R_,<OPLL;B9XF6%PE'.\CS2M'!T7-4:-/$8C$U%
MAZ<*5:M64&WZ"O[.'QVLU6*R_:_^)%U'N9VDU?0M'GN=Q(^0/%+M,0 X4@%>
M0.#2_P#"I/VN+(F73OVC]!O)ON+%K7@\R6NPGEBL"NXE ^Z0" >^.:\]_P"&
MP_VH_P#I&3^U#_X.?"'_ ,:KR_XB?\%,/B+\([O0-/\ B?\ L(_'7P'?^*[#
MQIJGAFT\2^*?"-E-KEA\._#DOB[QS>6"):RM-;^%?#,,NNZPV%:'3HI98EF9
M&0:Q\(^*I2C&GEM12E*,81AQ9@')R;2C&*>>R;;;22U;;MZ>;+Q9XRDI2QN4
M\)XV*4I3>-\)^#^7E7O3<I4^$J"2:2<W=64;WC9L\'_:X^!_[4/B'X@>'KKQ
M3H^I?&.ZMO!UM:6?B3X<^ ];DTNPLQK>MW']CZE]FLI8_P"UH;F>XO&.0QT^
M\L 1\HKV_P#91^%/[8?A_P"&=UH_AG7?#'PBT";Q;K%W-H'Q#\"ZXOC)KR6Q
MTA9=5LQ<6T<:Z3>B""WMPR [[6](8G '*?LW_P#!5V;XE^'M?M=>_9J_:A^*
M7CC1O$.J7EW;_LU?!#4/BOHNB>#-:U"\N/!J^(K_ $[5],BTS5$MXKW0Q;O%
M)-?)H)U:61FOB:^C_P#AX%+_ -&%?\%.O_$-_$/_ ,U-?,XWPLSS),^QRQ6&
MS58NG*5*K&C7J2C)3C2<90QD)JM6I5(<DHRE-\T)1OL?KN)^DIQKQ)X:9-P3
M0\/^"JV68&>'JX?&3X<P.,R^<\'5Q-ITN',1AY9%A*D:E>:C+#X2/LIJ<H).
MI4OVQ^%7[8-]@:E^T3X4LECYC.A^#I8G=CP1/YZ("H'*[<G=UH_X4)^TA>?O
MK_\ :MU^TN/N^3I'AJQ2SVK]T[9G5P[#ESC&2<<5Q/\ P\"E_P"C"O\ @IU_
MXAOXA_\ FIH_X>!2GC_A@K_@IU_XAQX@'ZGQ4 /J2!ZFM/\ 4W,WO@,X>V^,
MQ_E;;$KNOO\ N_-O]?O$"'^[<,\%X-=%AO#+@-63LVE[7A^J[2;3=W>[T:5T
M=E_PS!\8YCNNOVR?C,1*=US;VVG:%#;L'.988#O\V*$Y9(S]]$QW%/\ ^&1M
M?N?W6J_M)_&G4[,\M:/J=O;@LO*-YL+^8"AP<=#C!KQWP1_P5 \'?$K07\4?
M#[]C+_@I%XQ\.1^(/&/A.36M"_9!\0W=A'XG^'OB_7?A_P".M!DE/B:-DU3P
MEXY\,>(_">NVK(&LM;T34;-MQ@W-UO\ P\"E_P"C"O\ @IU_XAOXA_\ FIH?
M!>,E\63YA/9?O,1CZG\O2IBI))Z)I))IZKL_^(C^+:M[%Y?A+6L\!P+P/E\D
M].5J>!X<P\U.-UR5.;VD+ODE%MDGQ#_8EBU#P'XRBTGXA_%#Q?XL?PWJ\?A7
M2M<\8-:Z1=ZR]E*+&RU)9I4LI;&ZNO+CN1>21P")F\QP@-?$WPJ_8(^.,?Q'
M\&R?$GP3:VG@*/64?Q5<:?XY\.F^BTH6]P&:U&E:K)J/F^>8 /LB&;:6QA2Q
M'VK_ ,/ I?\ HPK_ (*=?^(;^(?_ )J:/^'@4O\ T85_P4Z_\0W\0_\ S4UP
M8CP[K8FO0KRRC,*<J#@U3IJ]*KRSC-*O&M"K*I&6D)+GBG!\NFY][PQ](KQS
MX7R+/,AH0PF9T\\IXBF\QS/+L5',\J^LX)X)U,EJY5F&587!5:7/]:H3G@\0
MX8W]^^97@>N67[%?[.=H%\[P*=5VH4)UG5M1U(NQ8$32>?-\\R@;$D/S*A*#
M@UUMA^RO^SGII9K/X,^ HG=!')(=$ADED4$']Y)(69V) )8G)/?'%?)/B;_@
MI_X/\&:EX'T?Q;^QE_P4A\.ZK\3/%Q\ _#W3]5_9!\06]WXS\;+X5\4^.6\+
M:!%_PD[&\UA/!G@CQCXH>WRBQZ+X9UB\>14M2&ZW_AX%+_T85_P4Z_\ $-_$
M/_S4UZ<>$,9"SCP^EV_V&CW7]S3=>>OJ?E6*XP\8<;=8KBWCVLI.\HRXCSI0
ME=IZPCC8P>K35XZ=+6/LC3_A7\--)).G> O"=F697)BT2Q!+)C:?FA;E<#';
MCI75QZ+HL)S#H^DQ$'</*TVRC^;^]\D"_-[]?>O@S_AX%+_T85_P4Z_\0W\0
M_P#S4T?\/ I?^C"O^"G7_B&_B'_YJ:Z(\-YO#2&4XB"=M(4%!=+:1275'RN)
MPW%N-ESXQYUBY_SXK$XG$2U45\5:K-ZI1OKT5]C] HX880!###$!DCRHHX\$
M\$C8JXR.#CJ.*ER?4_F:_/C_ (>!2_\ 1A7_  4Z_P#$-_$/_P U-<;X-_X*
MB^"OB(GBB3P+^QK_ ,%(/%B>"?&GB+X<>+GT7]D'Q#=+X=\>>$9XK7Q/X3U,
M_P#"3IY6L:'<3PPW\2>9"DD@6.>7#;;7#^=VTRW%I::>S:[6TOYKT.%Y#G4G
M>678N3?5TVWK9[MWW:/L76_V9?V?O$>KZIK^O?"+P1JVLZW?76IZMJ5[H\4U
MWJ&H7TSW%Y>74I;,L]S/(\LKD9=V)/6O9M-TZQT?3K#2-+M(;#3-*LK33=-L
M;9/+M[*PL;>.UL[2WC&0D%M;11PQ(/NQHJ]J^!O^'@4O_1A7_!3K_P 0W\0_
M_-31_P / I?^C"O^"G7_ (AOXA_^:FLJ?#.:4I2E2R:K2E-WG*EA84Y3>GQR
MA&+EJT_>;U;>]SU\QGQSG.'PF$S?&<29KA, E' X7,LQQ^/P^"C[.G22PE#%
M8BK2PR]E"G3M1C!>SA&'PQ27Z#5JZ%_R&](_["-I_P"C5K\Y/^'@4O\ T85_
MP4Z_\0W\0_\ S4U>\/\ _!1OP5IWCSX5:)X__9;_ &\/@[IOQ&^+7PV^$N@^
M.?B]^R_KO@OX?6?CGXH>+=+\%^!=+U_Q/+K][%H\6O\ BC5]-T:VO)K:2!;R
M]MXY"OF*3V83(<YABL+.>78J,(8G#SE)TVE&,:M.4I-]$EJ_(\["Y'F\,5A9
MSR_$QA#$X><I.G91C&K3E*3UV4=6?LA1117[2?L05\U_L;_\FH_L[_\ 9'_
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MK4OA=\,_!_@/4/$3^9KE[X;TF*PNM3;S&F_TJ92SLIE=I"B%$+')4\8]7?\
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MG'4UY?X@_9S^ GBHN?$7P>^'NK&0*'-UX:L"6"&0KGRXX^AED(QC[[5\Z_\
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M71U)#*P((->(^"?V9_@;\._'VK?%'PAX L=-\?:SI<.BW?B2XU3Q!K-W;Z3
MYD33M'@US5M2L?#UI)(2]S#H%KIJ7C_/=B9@"/=:*XZF79?5Q^%S2K@<'4S/
M X?%X3!9C4PU">/P>%Q\L/+'8;"XN4'B,/A\;+"826+HTJD*>)EA<.ZT9NC3
M<5-*I35&HE.DJ]'%*E-<U-8G#QJQP^(4)7BJ]"->O&C5M[2E&M54)152:97A
MO@#]G[P3\./C+\?_ (Y:#>>(9O&'[1]W\,;SQY:ZE>V,^A64OPG\$KX"\-#P
MW9V^F6MY8)<:*HEU87^H:J;F_P#WULUE!_HU?$W_  4Y^+OQQ\*6'[-WP5^
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MTS\6OBK\?- \:?M$1?MN>#]6_:3T/XTW_P )-#\:^)?V8M2_8BUFU^'/C+[
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M];\9V>CI<?"3PEJMI_;G_"2M#'/^W/\ P3J\:>-O'W['/P5\1_$?XB7GQ/\
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MCT*7QHOCC2?$>HZ?XZA\=OXRNM.\0Q:?#X>D\+V=M?-JD(!^]M%%% !1110
M4444 %%%% !1110 5\,^+?\ @GE^SQXT_:);]I/6S\2SXFN_%GA#XA:_\.[+
MXF^*K'X&>+_B1X T73?#W@OXC^,/@]!>+X-\1>./#>CZ/I5EIOB#4+&2Z1-/
MM&D\V2%7'W-10 4444 %>0?'?X&_#[]H[X7^)/A%\3K'4;OPKXFCM3+<:'JU
M[X?\2:+J.G745_I6O^%_$>FR0ZGX>\1:1?00W>EZSILT-[93INBD 9@?7Z*
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MQ)^&O@[4_"OA/6'UVPT'4O!OAW4X-$NM-O=2D,VM6[6X&KJ!'>&1<@_2VH?
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MVE?A5JUI??V@UAX3N-+M[*]O_L*3_@G7^S+)\3_V3OBTN@^)(/$W[&/@[5O
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M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\U?MD_\
M)J'[17_9'O'O_J/7U?2M?-7[9/\ R:A^T5_V1[Q[_P"H]?5]*T %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB\07&@:%-<HK:>@;E_V?/V%/ 7[.%SXCTSPG\7/VA_%WPJUCPQ<>"] _9_\
MB9\2+/QC\$OAOX5FF+0Z%\._"DOAFRU/1-/T^R)T?3HK_P 0:N;;1S]B#.%5
MU /Q>^)7_!7?Q%^U?^Q5^UUJUA\(_'_P%TKPW\"_ WQR^'_Q7\'1?M6),O@;
M4?B3X;^T:7XHU[Q]^RE^SQ8:#\3XO#AM;ZX\*_!7Q=\=M"U6UU2XLM \<:[
M;>;4OW4_9(_:4N?VL?A[JOQGT3P+%X4^$&N^*-6L/@EX@O/%]GK?BKXD>#-
MG?0M2\:^*?".G:5';_"^YN?%VG:_IVF^"=0\2>(/%EEI6GVT_C>P\$^+)M6\
M$Z%X7X4_X)E_";PS\*_B-\";WXU?M2^-_@AX\\*^%? VC?";QY\7;?Q!X-^$
M?@_P3KEAK/A7P]\(;<>%;/4_"VG:+;Z3I/AVS2_U3791X:TNRTQY7:-[B3ZO
M^$/[/GPY^!FM?%35/AI:ZIH&G?%[QL?B+XC\'QZBS^"M)\9W>FVNG:_KGA#P
M]Y*6_AJ;Q8;*UU/Q/;V,GV/4]:CDU86T%Y=WLER >W4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !7S7^QO_ ,FH_L[_ /9'
M_ ?_ *C]E7TI7S7^QO\ \FH_L[_]D?\  ?\ ZC]E0!]*4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %?-?[&__ ":C^SO_ -D?\!_^H_95]*5\U_L;_P#)J/[.
M_P#V1_P'_P"H_94 ?2E%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
F1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img22994243_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img22994243_6.jpg
M_]C_X  02D9)1@ ! @$ > !X  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" (/!7$# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)U65Y\WD.D1QB?3192%/L^O6>MS2Q)-=,S_(GQ?TCX[ZY_P60\;Z?^SAXO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]/FYKR"I>Z?0_P A1R+NQ<[73HOQ2?GYGK7]K:9T^WVF?3SX_P#&E_M;3/\
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M'QC\*T\%>*!=2QR7FL3PV\,:>K_ RW\9:YX)D\<?LP>.M:T9-#UK5O#GC_\
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M'X_R- WO\H_DA[=4^O\ 44^F-U3Z_P!13Z!#A]UO^ _SIS?<7\/Y&FC[K?\
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MY_/S'XT_X+A>#B@/@;P#XVP3,?,TVQU$-Y*[?(<IX@T([9]N\*I#,S9\R,$
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M<-6Q"NIX*I)X;'4Y1^*,\'B%2Q"<7=2:IN-T[2=CV:BBBLCZ,**** "BBB@
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MR4HKV:&(IXB'/3<E:RG3G%PJTI63Y*M.5I0FDT[-:IJ46XM-E%%%8FP4444
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MA]3_ "6G#[C?7_"F]A]3_):">B]7^425_NG\/YBG4U_NG\/YBG4#7V?\3_\
M;1Z=3]/ZBD7^+_=/]*5.I^G]12+_ !?[I_I0$>G^*/ZBIU/T_J*EJ).I^G]1
M4M!(4Y/O#\?Y&FTY/O#\?Y&@;W^4?R0]NJ?7^HI],;JGU_J*?0(</NM_P'^=
M.;[B_A_(TT?=;_@/\Z<WW%_#^1H >O0?0?RJ1.I^G]14:]!]!_*I$ZGZ?U%
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MR[ 990CALNP6%P.'C\-'"4*="FM$K\M.,4W9*[=V[:L****D[ HHHH ****
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MTK7;"XTO6M-L-7TV[1H[K3]2M(+ZSN(V!4I-;7,<L,BD$C#(>IQ7Y'_M)?\
M!'GX%?$^YO?&OP1U'4?@%\35:2]L[SPT]P_A>[U#_6E[G3(;JSU+3Y[J=5+W
MFGZJL,')739%^0;<^'K?Q(^QF_MTE[CV7O4^G_;KWU?6_P S_97&G#'O9)F"
MXKRJ&V3Y[6C1S:C36O)@LY45"LTKJ$,=3M&-HQDW9K]@**_G-\"?MP?M@_\
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MW"6MM-</]V)"W/<]%7_@3$+^-6*Y/Q5=F.WAM%.#.Y=_>.,?=/IEV4^^WZT
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M4:Y)\N;:<X^42JZC"@"N*^*O@47D4OB;28?]+@7.IV\2C-S O_+VJ@<S0_\
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M_P"2Q>*^OK_Q^4?\0ZS#_H88+_P"OY?]._-_=YB_XB%@+)?V?C=V_BH=;?\
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MSK>F:6+'2Q<6]F=2O#?74'V6P%Y=VMJ;R?R[?[3<V\'F>;/$K?RD?"/X*_M
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MNB0:%I&NQZ=+=>%+'4]5M(9H&U:4OX?\?_@S\=/@S_P2F_;7\"?%SP!'\&O
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MZ6>I+ );GQ)J*LKZ)I=O,DC1&X#G2E2E6FHQLNLI/2,8K>4GV7X[(\/B'B#
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MIRRC)H2]I@.':,[-*$7[N(S.247B,9)-PFN6BTHQ<2BBBN4_00HHHH ****
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MW\7?&%YXEU1Y(;&,M:Z#I1<F'2M+C=C%$J9VBXG+-<7<AW.TTK)O:.-,>\_
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MW[;\!>6(31_M$1&6!S%-%YD_A=/,AE7YHY4SNBD7YD<*ZD$"OYVOV&?VH_\
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M2J2P-!*K@J<ZSCRSITZ]?$.%-2;CRQ;BDDWYO1117T1\\%%%% 'VK_P3=O\
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M5(?]*T7Q!HU_!!?:3J]DR7=C=1)- ZNH->I)]T?C_,U,59O+502S8"@=23@
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MDW]A7$L:^(;>UO\ 4=(MX[?3[II/?/@=\'=6^,/C"#2(%FMM TYX;KQ+JL:
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MDZ5X;OH8[O3[G2[D&*[DU6QN5DMKV34X@%N8KB*2 P'R5C6.216\M^!GQ_\
MBI^QS>1V.B0:Y\6/V:GE+ZI\*WFN-7\=_"F)VS-J_P )]0N6GU/6?#-LI,EY
M\.;R74OLT$4$'@V/0[6*YBFQJ*]*E)4XNDX1J49652C.[A.VTKIJ4:D;ODJP
M:G&[2?+*47^:PS;,*>/EF<,3..,G/GG4O=5$VKTIP?NRHV2BJ37+&*CR\KC%
MK]\/A+\7?AU\<O >B?$KX6>*M+\8>#M?BE-EJNEW$<RPW=K*UMJ.DZC"K&73
MM9TB]CFT_5]+NUBO-.OX)[6YB26-A7I%?S3>&M0^)?P0\;7OQ8_9WUNR\/\
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M>-+W><O+;W/Q#\1Z/H%R7.2XN_"^CZ'=1L2?W<R+D@9KZW;^'_>']:X[X?\
MA"+X?^ O O@6'RRO@[PEX;\,221?<N+G0]'LM.O+S=U=[V[MY[N20_-+),\C
M?,YKL6_A_P!X?UKCS['0S/.\VS"DDJ.,S'&5\/%74:>&J5YO#4HIZJ-*A[.G
M%/51BKGV7#^ GE>19/EU6[KX/+,%A\1)ZRJ8JGAZ<<35D]N>KB/:5)M:<TW;
M01>K_7^IH7J_U_J:%ZO]?ZFA>K_7^IKR3UOM_P#;OZ@?OK]/\:_CF_X.*O\
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M,F?AF9Y'F64U94\7AIJ";4,1"+GAZBOI*%5+E5UKR3Y9K[44>*T52_M+3O\
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MH/\ XY19]G_7_#K[PNNZ_K_AU]Y=HJE_:6G?\_\ 9?\ @5!_\<H_M+3O^?\
MLO\ P*@_^.46?9_U_P .OO"Z[K^O^'7WEVBJ7]I:=_S_ -E_X%0?_'*/[2T[
M_G_LO_ J#_XY19]G_7_#K[PNNZ_K_AU]Y=HJE_:6G?\ /_9?^!4'_P <H_M+
M3O\ G_LO_ J#_P".46?9_P!?\.OO"Z[K^O\ AU]Y=HJE_:6G?\_]E_X%0?\
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M%>B^ _"7B?QMXENX[#P]X/T#5_$VNWLK!8[32=#L9]1U&X=F(55AM;>61B2
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MQ'R\CS__ (5-\)/^B1_"?_PV7@7_ .4%/;X3?"3>?^+1_"?H?^:9>!?[O_8
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M>F@TB_"3X1G=_P 6C^%'W2?^29^!^HZ?\P&O04ZGZ?U%(O\ %_NG^E'M:O\
MS\J?^!R_S\E]P1I4_P#GW#XH_8CY^1P"?"3X1$G_ (M'\*.F?^29^!QW]M!J
M3_A47PB_Z)'\*/\ PVG@?_Y0UWB=3]/ZBI:/:U?^?E3_ ,#E_GY+[B?9T_\
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MR=3]/ZBH7Z#Z_P!#4R=3]/ZB@?1>K_*(_P#C_P" _P!:L)]T?C_,U7_C_P"
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M3+(;9+E?'SW"P%CY2SO%XK2)Y@FT2-&BHSY**%(%0_\ #^;]I_\ Z(]\!?\
MOW\0O_FMK3ZCB/Y8_P#@:/ ?C-P*F_\ ;,>_-99BK?\ I)_5E17\IO\ P_F_
M:?\ ^B/? 7_OW\0O_FMH_P"'\W[3_P#T1[X"_P#?OXA?_-;1]1Q'\L?_  -!
M_P 1FX%_Z#,?_P"&S%?_ ")_5E17\IO_  _F_:?_ .B/? 7_ +]_$+_YK:/^
M'\W[3_\ T1[X"_\ ?OXA?_-;1]1Q'\L?_ T'_$9N!?\ H,Q__ALQ7_R)_5E1
M7\IO_#^;]I__ *(]\!?^_?Q"_P#FMH_X?S?M/_\ 1'O@+_W[^(7_ ,UM'U'$
M?RQ_\#0?\1FX%_Z#,?\ ^&S%?_(G]65%?RF_\/YOVG_^B/? 7_OW\0O_ )K:
M/^'\W[3_ /T1[X"_]^_B%_\ -;1]1Q'\L?\ P-!_Q&;@7_H,Q_\ X;,5_P#(
MG]65%?RF_P##^;]I_P#Z(]\!?^_?Q"_^:VC_ (?S?M/_ /1'O@+_ -^_B%_\
MUM'U'$?RQ_\  T'_ !&;@7_H,Q__ (;,5_\ (G]65%?RF_\ #^;]I_\ Z(]\
M!?\ OW\0O_FMH_X?S?M/_P#1'O@+_P!^_B%_\UM'U'$?RQ_\#0?\1FX%_P"@
MS'_^&S%?_(G]65%?RF_\/YOVG_\ HCWP%_[]_$+_ .:VC_A_-^T__P!$>^ O
M_?OXA?\ S6T?4<1_+'_P-!_Q&;@7_H,Q_P#X;,5_\B?U945_*;_P_F_:?_Z(
M]\!?^_?Q"_\ FMH_X?S?M/\ _1'O@+_W[^(7_P UM'U'$?RQ_P# T'_$9N!?
M^@S'_P#ALQ7_ ,B?U945_*;_ ,/YOVG_ /HCWP%_[]_$+_YK:/\ A_-^T_\
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MWGPZFN97*W5I:SW%[K.CZ=YJ>9/IMS"+GQ-HL[O&BZ7,EO%;J-M?O97X!_\
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M' 4  #@ "O5IT_JE.[TQ56-I;IX:E-?#_P!?JL7[_6E3?(WSSJ1A^8<5Y_\
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MFX14G'\UJ*_<W]GKX6_LU>"?^"<>G_M->/\ ]DG2OVE/'_\ PL35/#EQIO\
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M(.'>)L%2<(367T\LEC)UY2C&3]M7RZMBJ4*";:4(S52HMW!:/W/X+? [X;_
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M . _UJPGW1^/\S0#W^4?R0)]T?C_ #-2MT3Z?T%1)]T?C_,U*W1/I_04%_\
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M!8ZMR1IU*T<94@H<ZC17/:/]:7AKQ]X&U7]D+PA^WW>W>GCQY\/_ -ECQ/\
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M .W5V%%'/+O^"_R#E6FFSNM7O_2.0'A7!S]N_P#)?_[=0/"N,_Z=U&/^/?\
M^W5U]%'-+O\ D'*ETZI[O=;'(+X5VG/VW/\ V[__ &ZG_P#",?\ 3Y_Y _\
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M125<$X5?2;['\"2C.$I0J1<)PDXSA)-2A.+:E&2>J<6FFGJF@HHHH)"BBB@
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MTV2L4445PGU84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M ,$[O%S^,_V+OV?=3DF\]].^'^D>%RY;<0/"47_".+&3DDF)=-6+DDC9C@
M?:=?D]_P1?\ $3ZQ^Q!X3TN1B[^&_%_CRQ#$Y817OBK5-5B0\_=C%X53@83
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M/XO:O%DRZ7\,O'6HQ@'!+V7AG4[A0".0<QC!&/K7Y1?\$,M-2/\ 9L^(FN@
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M?_ \5_\ -'DON/PR_P"'"W[-O_18_CO_ .!GP]_^8.C_ (<+?LV_]%C^._\
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MZ/8_98_\00\;?_1IT?\ "I?^"F/_ $>Q^RQ_X@AXV_\ HTZ_06BC^T*__/O
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** /"?VHX7N?V:?V@[>)0TD_P4^*$,:G@,\G@K6T4'V)(%?G/_ ,$.YXF_
M8WU*U4GSK;XQ>/C,F,;1,VF>7@]\^6W88Q7ZB?&?23K_ ,(/BEH:KO.L_#SQ
MEI83<5WF_P##VHVNW<,%=WFXR"",Y!!K\CO^"&&K>;^SY\4_#FXY\/?%G59"
MA4#9_:K7?1\ OG[ >"3MQQC)SU0UPE9?RU*;^^ZU/S_-/W?B/PK-Z+$9!Q#A
MX><Z=3 XAKU48WT;=NEM3]NZ***Y3] "BBB@ HHHH **** "BBB@ HHKB?B3
M\0?#7PG^'_C/XF^,[FYL_"7@'PUK'BWQ)=6=G/J%U;Z+H5C-J.HS6]C:J]Q=
MS1VL$C1V\"-+*P"("Q%5&,IRC"*<I2DHQBE=RE)V226K;;22ZL4I1A&4I-1C
M%.4I-V48I7;;Z))-M]CMJ*^ _@S_ ,%$?AG\=[[X?1^ _@9^V3_PCOQ-;2Y/
M#'Q"\0_LJ?%CPY\-CIFL0_:+'7]4\;:GHT.B:5X?EA*RMK%Y<1VB(Z%GPPK[
M\K6OAJ^&FH8BE.C-W]V:M+1M.ZW33333LTTT94,10Q,.>A5A5AI[T'=:I26O
M5.+336C3"BBO!?BW\8/%_P ./'7P/\(^'/@E\0/BCI/Q8\9WGA?Q7XT\(1Q/
MH/P;TNVMK2>+Q=X[:2"5H]$NI+F2WA:)X6,MK-\Y P,Z=.=67)!)R<9R]Z48
M*T(2G+WIRC&ZC%M*]Y.T8IR:3NI4C2CSS;4>:$;J,IN\YQA'W8*4K.4DF[6B
MKRDU%-KWJBOA_P"$_P"VC#\8;3]L3_A$_A'XNO=<_9*^(/C+X<GPU8ZEI^IZ
MQ\5M=\*:)<:O;Q>$X+6#=8S^()H8],TZSOEGG6[N(M^X<'UWP)^T-X=U;P!\
M$_$WQ:TV3]GSQQ\<?LNF^&OA#\4M5T_2?',7C*?3-2UF;P+'9S&U;5/$UGI.
MD:CJ4]C8P-,+*SN;CRA%#(PVJ8/$TG)3I-2BX)Q4H2FO:4?K$7R0E*3C['WW
M))QBM)-2T,:>+P]51<*B<9*;C)QG&#Y*OL)+GG&,5+VON*+:E)ZQ36I]!T45
MR_C7QMX0^&_A/Q!X\\?^)M$\&^"_"FE7FN>)O%/B34;72-!T'1]/A>XOM3U;
M4[V2&TL;&T@1YKBYN)4BBC5G=@ 37.DY-1BG*4FE&*3;;;LDDM6V]$EJV=#:
MBG*348Q3<I-I))*[;;T22U;>B1U%%4=,U/3M:TZPU?2+VVU+2]4M+>_T[4+*
M9+BTOK*[B6>UN[6>,M'-;W$+I+%*C%'1E9200:O4FFFTU9K1I[I]F---73NG
MJFMFNX4444 %%%% !1110 445\F_M>?M7:/^R1X1^&WBS6?!FK^-H?B/\9_
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MH5*4[/DJPDXMQE%\M2$X1=1116Y04444 %%%% !1110 4444 %%%% !1110
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MXD_M]?'_ ."GQ(\)>-]"^.T'[5OPR_:P_L[X>ZUX5\,:IXB\+_$7P_X[^/\
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M'HVI20"+2H=?^%_BN30X[B\9)+V6X$D7RK_P5A_9GL_VDOVCO^"?'P>\/?\
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M39;3FO[ZPE)S;\W-R;\V%%%%9'T 4444 %%%% !1110 4444 %%%% !1110
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MW'HT]W-,VG0A?T9_M;3/^?\ M?\ O\G^-?F/^V &'QE_X)LO&I$C_MS/:LZ
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MU5OA\W^MB7*W-IM;\3UG^U]+_P"@A:?]_P"/_P"*H_M?2_\ H(6G_?\ C_\
MBJ\B_C_X%_6A_O'\/Y"GR;Z]4MN]O\QIWMYJ_P"7^9Z[_:^E\_\ $PM..O[^
M/CZ_-1_:^E\_\3"TXZ_OX^/K\W%>2+]QOQ_D*:/NM_P'^=-032=]]?R_X/\
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M_@_X#_2CV:[O^OZ?]+4YW=*RUM^-CJ_M5M_SWB_[[7_&C[3;_P#/>+_OM?\
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M_5:'W-"M3Q%&CB*3YJ5>E3K4Y+:5.K!3@UZQDF%%%%(U"BBB@ HHHH ****
M"BBB@ HHKY]_:2_:3^'W[,'@"/QOXXCUS6;_ %K6=.\(^ ? ?A#3)=;\;_$G
MQ[KUPECX;\$^$M*BV1RZKK6HS6]H+[4KC3]"TB*5M2U[5=,TNWN;V*Z5*I6J
M0I4H2J5*DE&$(J\I2>R7ZMZ)7;:29%2I3HTYU:LXPIPBY3G)V44NK_)):MV2
M3;2/H*HFFA218GFB65\;(VD19&SG&U"0S9P<8!S@^E?"WP\_;>N-<^*6D_!7
MXQ?LX_&3]FSXF>-?"^L^*/A-X?\ B;JWPCU^R^*\7AR""XU[1/#7BGX5_$CQ
M_P"$]*\3:;'=VDC^'_&&M^'-4N+:2YO;2VGL],U2>S_,']D[7-1_:+_X*;?M
M7^.OC;^P]XT\2>+?A-\3_AMX2^'7Q$\>>(?@#XFE_9/T?0O!-IJUG8V@3XFZ
MAK%M<>)-4UO4O%\-Q\++/Q4\<&KQV^J/:WT5W;P>E2RJM*&+J5IPHPPN%CB5
M*-3#5564ZT*,%2E]9ITZD'.4HRJ4YU.2<)4N659QIOSJN:4HSPE.A&5:>*Q3
MPS4J>)INBX4I5JCJQ6'J3IS5-1E&%2%/FC.-5RC14JB_HLHKX _X* _M'_$#
MX(^$_@]\._@PT%G\;OVG/C+X1^"'PW\17^CV^NZ3X(;7;^VD\6>/M1TF]*V.
MICP9X5_M+7K32KYEM-4N[.*SG98Y&-7/ 7[$FO\ PS\0^$/&7AK]KW]K/7O$
MVCW]M-XPMOBM\8/%7Q8\ ^-],FM[A=>TO_A6_BO59?#/A=]1O)8;K2=3T2%;
MWPU%;+::<7CED<\\<)%8>&(KUXT57]K]6@Z<ZDJJI/EE.3BOW=-U/W<96FY3
MC4]U*#;Z)8N3Q$Z%"A*LZ/L_K$_:0IJG[7WHPBI?Q*BI_O)1O!1@X>^Y327W
MG17Y/?LL:U\2OCIXJ_X*B?#;Q#\6/B/:P:+^TKJGP^^&NKV'BS4[;6/A;HU[
M\#_A=J=G:^!-0203^'K:QUW5;W5XHK$Q*+R\O)AMDN':OAJR_;@_:.L?V29_
MV&]5\4:V/^"E,7QGA_8BM/%<MQ=R>)+JSU!%>R_:B75X]]Y((/@Q,OQ0G\2,
MH"^((SYDPO-P'7#)J]6<Z=.K2E.E+">VC[R]EA\51C6^M2;7\##J2CB)?\NV
MXO521QSSFC3A&I4I58PJ1Q2I-<K]K7PM9TOJL%=7KU[<]"%_?2FM'!G](U%?
MS1?\%)?'7[6/[/G[07[*^F_!#X^_&>ZTK]G3]F#Q=\;OBAX)'B;5-;C_ &@]
M'^'OQ*^#_A;QL?B#9SS[?$>J0>#O&/BOQ';:A?+--;W&F0@,%RZ_JC^UU^U^
MO@7]B.#XY?"%Y=1\<_&WPSX.T3]G_2[7[/=ZEJ_CSXKZ=!-X3LH(%E'G7VGV
M]S<W=Q';K-+!<:>Z&(%6*3/**RAEU2E5IUHYC.5.GR\T71FJKA%5E)+E4H6J
MJ2;BH<Z;4J<DJIYM1E/,*=6G4HRR^,9U.;EDJL'34VZ/*VY.,W[)Q:4G-P:3
M4XL_0RBOQ(_X)+>(?VG[W]F']IOP=XP^,VL?'_XY?";X^_&SX6^#O'GQW\2:
M_J6G:EK'@O6=4T/0AK^H6,&KZSI_AI[ZSAENH-)M+R>VM&<6EM(ZJAA_X)]Z
MO^U'X>_;[_;5^#?[2'[2/B3X]WOAKX<?!#QO;6C6A\._#GP9K?C9O$K:OHWP
MY\&PS/::/HEJFFVT$5ZT5MJ&J &>_@CE'+K93*E+,X_6J$WEL83:BJO-B(2J
MT*7/2BX6A"+Q$&W5E!O:,9/FY2EFJJQRV7U6O!9C*44Y.DXX><:=:IR59*;<
MIM49I>RC..EY22:O^WM%?BC_ ,%F[K]LSPQ^SW\1/BG\%?VA+?X _"7X4>#=
M,\5Z@WP[AU(?&KXA>-%\1P6Y\.7?B2:"SLO!/@2WT]K9Y+[P_J=[K>L3W=]:
MWUA#:VEJ]Q[?^V=^U/X^^ O[+WP+_P"%?^(]&T/XQ?'WQ'\(OA5X8^(7CB"#
M4?#?@:X\8_V-'XO^)_BD:EC3+FU\&:!<:GXIN8M8FAL+V2R:*ZE6-W-13RNK
M5I8&I2K4:DL=B*V'5./M+X>5&%&I)UY.GRV5.LJDE3=3DBGS>]>*TJ9G3I5<
M;3JT:U.."H4:[J/D?MXUIU:<51BI\UW4I."]I[/FDU;W?>?Z?T5^:G[)'@C]
MFY_'2:Q\*O\ @H!\3OVJ/'OA[0)YO%?ABZ_;6N_C9X6S=RV]IJ/B"_\ A9IO
MB_6]%T*S34YTATS_ $"&UT=KBWL;>4R%3)]S?%7XC6OPK\%ZGXON/#7B[QC/
M:-%:Z9X6\#Z#>^(?$FOZM=EDL-,LK:UC^RV7VJ5?+DU76KK3-#T\$2ZEJ=G"
M0YY:^&]G75"FZE23Y4E4HRP\G*3T2A4DY)/1J4N71W:21TT,1[2@Z]14Z<5S
M-^SK1KQY8I-OG@E%R3NG&-[-:-W1Z+17PY\'/VV;;Q]\<'_9O^+'P,^*/[,_
MQHOO \WQ'\'>#OBCJ_PL\2+X]\&65ZVG:MJWAGQ!\(/B!\1O#;RZ1>QS17^E
MZAJUCJL<<$MTEF]LOFGPL_\ !5/PSKNA_&'Q-\+?V7_VD?BUH'[._C3QCX0^
M/&K>&--^'FBV7PZA\&^1<77B"WG\;>/?#"_$/3[G2AJFL2:=\+SXR\0:%9Z-
M<)XFTC1KJ^TBWU#6.68Z4Y0C14N6-*;FJM%T>2M)QHS5?VGL91J33IPE&HU*
MK^[3]HU$Q>9X*,%-UFE*52*@Z5;VO-12E5C*A[/VT94X252:E33C3?M&E!.1
M^J]-+H'$9=0Y!8(6&\J.K!<Y('<@8KXO^(?[=/P?\&?!'X2_&;PW9>*OBE-^
MT"^@V'P&^&O@;38#X_\ BKXA\1VT=U8^']%LM?NM%TK1YK:-RNL:OXIU70_#
MVB,%_M75K19H&D_/3PE\;M3^,/\ P6'^"=OXF^$WQ/\ @;XX\'?LB_$C3?%?
MPX^)D&ASW=B=0\7:M?Z+J.E>*O VO^+?AMXRL-3TF2VO3>>#_%NN_P!D37!T
MC6_[-UBUNK"*Z&68BK"O4G&5&%"CBJK<E'GE+"Q?/%4G.-3D]I:E.LHRITZC
MY&W/W2:^9X:E.A3A)5IUZV%I)1<N1+%2CR2]JH2I\_LVZT*+E&=2FG.*4$Y+
M]W:***\T]$**** "BBB@ HHHH **** "BBB@ K\!_P#@MWXENO$=Y^RW\!]
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MGB*=2BZO-*E'D4Z,U5I>RG*FHPGSPK0:A!J$6I<WX(_LR_M<?L^_LL_M*_\
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M:V.G:Q:ZFEW)8K#/!>NX2Y;]./C7\/O _P (/^"G/_!/_4_AAX3T'P'<>./
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M0HTL5F6*I1>-C3@W4G/#0HT9NA)0IU??<XQYZK_2WX__ +6.O?!K]J#]DWX
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M /RSS7WGU!7P=^Q[_P EB_X*4?\ 9],7_K(W[+%>H_\ #<'[% Z_MC?LI_\
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M'UQ_'_P'^M(?OK]/\:>Z,DK(PPR;D8>C*Q!'X$&F'[Z_3_&OFSZ81?N-^/\
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MNG4BU2O&SYH^TYD]&KIH_NO7[C?C_(4T?=;_ (#_ #K_ #X!_P '%/\ P5,
MQ_PLGX-'/7_BP/@?G\.W^>:/^(BG_@J9@C_A9/P;YQ_S0'P-V_"O37A_GJ27
MM,MT27^\U_+_ *A/ZL_*_EOC[(W_ ,N\P6O_ $#T>T5_T$]+/[C_ $'EZCZC
M^=*>K_C_ .A"O\^ ?\'%/_!4L8_XN1\&N/\ J@/@>C_B(I_X*E\_\7(^#7/7
M_BP/@?US3_XA_GO_ #\R[I_S$5_*_P#S"]-?N\Q_Z_Y'I^ZS'2R_W>CWB_\
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M=8M-!\+>$='N+I)8(+S5-3OHO-NI89H;"PAO-0N(S;VLI'T&O0?0?RK\H?\
M@KY97NG?!_\ 9V^*TNCKJ_@KX#_M=?"/XI?%"62*2>#0? <5MXD\(7OB:\@B
M261K'0M5\5Z3J%Y,(GCLK>&2_N#%;6TTT?9E]"GB<;AJ%9-TZE51E%2Y74T;
M5)2WC*JTJ::]Y.2<4W9'+F%>IA\+BJ])I5*=%N,FN:-._*G5E'6\:2;J-/1J
M+OI<]R\%Z[_P4LAO_"GBGQ[X-_9+U;PEK6H64GB+X2^"X_B/X=^*O@[0]6D,
M@2;XD>*/B#J_P\U[6O"MJ\,.MQ6'A2VM]<O%N#HZ6,2(I^1/!W[2OQ_^(?@;
M_@I!#JW[5W@;X 7GP/\ VK3\-_A/\8OB/X2\$OX1^&?@J"]L\:#J5I<Z;86.
MMOJB%]+M-0\0R7^IK=7D3+=LZJ#^Q2_$+P$WAS1_'S>-?"D'@?Q+'IEYX?\
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M?$+]MGX_V?Q5^. \9?&>_OM!\'^&+R_L+37?BIXGU7Q9H>A^)/&;^(=4CO\
MPQI,.GZ#H>HW4T:37>HO9V=JTPWAE5*<*=:,JTZ=>G1J4$I4J?,H4*U7,>>K
M-.$(82="5-SY6U&<)N$FO9RRGFE6$ZE&2HPJ4:E:G6DX5:BBYUZ-++U"E3:G
M.>*A7C-0YE><)04XI\\?T3_:!_:K\,:Y^PY\>?VB_P!E7XO>#?&?_")_#WQ7
MJ7A#XB>!M1\.^.-"LO$FBP1M\I=-6T2\N+)Y$,UE?6\\8WJ)82&%><? OXL?
M%;Q_K?[ OB'Q-^U-\/='_P"%G?LPV7C;XC_L^ZKX<\(VWQ"^.7B[5/ *:O/X
M[\*W,$%IJ.B:7X8U*9M3U73O#EI;Z48;.>%X8K?*#\F='U+QK/H?_!=RR\<O
M\);/Q))X0\$:OXJ\/_ CQAK_ (Q^%^F^,)OATND:M-I]WXCT?P_J=KXAN++1
MM+A\2VMQHUC)#J-JT9C*HAKVOX+?\G?_ /!%3_M']X@_]4_>5Z,LLH4,+B(1
MY)2@L37C5G2H5JGLY9'3QL:/M)0::A*I:-:FH/F7MJ2IS:Y>!9E6K8C#5)<\
M5-X>A*E"I6I4W4CG?U.5;V<9W3E&-W2FYIQ?L:CJ0OS?MK\5?VJ/V;?@9XH\
M(^"?C)\=/A9\,/%_CV5(?!?AOQQXTT+PYK/B:62_LM+1='L-3O+>XO=VHZC8
M60:)"IN+N"/.Z117RC_P3X_::\7?%#]G'XK_ !<_:"^(>D7=OX(^/?QX\-MX
MPU2U\-^%M&T3X?\ @CQ?=6&@I>3:19:3I8M-,TJ.-&U2[1[NZ0":[NIY6WGP
M_P#8RMO!/B7]I_\ X*P3?&V/PEJ/B6V^*UCX>\0_\)G-ITSV/[.5OX<\1'PK
M:ZB^L;!8^ FT]]>DFDE,&DLD<\MRP6%'7XB_9'^-OP6_9X_X)?>(_$5E\,O"
M'Q>\):W^W!\2/AY\!?!#MI,WP[OO%'B+XAZA:_#"XGUB<SZ;I7A"PMK436^L
MV27KQ6"0#2[>Z,L=<T<LH_5ZV&ITZU;%.OD\75Y:7*_KE&M7E'#SER^Q7+*,
M9.I4E&HJ:JR<(I0CO+,JWUBCB*E2E2POL<VDJ2E5YE]4K4:$98B,7+VS<E*4
M>2G&5)S]E%3;YW^V^E?M^_L8>)?A_P#$+XG>#OVG/@AXN\&?"ZP@OO'&O:#\
M1_#5]I7AL7Q2+2HM:OK>]FBTPZK=36]G9/<A5FN+B)$#,P4\I^P]_P %"?V?
M?V[/A]H7B;X9>,/"=MX^N_#S^(_%GP;@\::%XE\>?#^R74SIB?\ "3V>DLCV
MRRRO:.EP;:.%A>VZ!B[$5^8FJ:A\>9?^"L'PCM/CO8?LW^'_ !YJ/['_ ,<-
M'U'P_P#LZ^/_ !QXOEU7PW#I7B'6M(7XA:/XV\&>#;R PZJD-UH$G]GWJRA8
MF2< 1QK]!_\ !/C4];T[_@C#X8UCP!(Q\::/^SO\6I= FT2**YU6W\3Z;9^+
MIK".WBMR)9-7MM0BMS!:N?M!NDAB*;MJU.)RO!T<%SQC5E6KU,O="I]9IU*5
M&&+6-A*,Y4Z"A7CSX5S]I%4GRRA%*+A/VCPV98ROC'";IQI4*6/]M36&J0J5
MIX5X"<904ZSG1GR8OD]G)U4G&3?/SP]G^A\'[9/[*-U\8)/V?K;]HKX.S_&^
M+5%T23X4Q>/O#TGCI=8:U@OETL^'%OCJ)U!K2YM[@6@@,YBFC<)AA70_&S]I
MO]GG]FVST+4/C]\:OAK\';+Q/>7%AX>N?B)XNT;PM%K5[:6[W=S;::=5NK?[
M7+!;1O/*L(;9&C,V #7\Z_PN^!O[3WQZ_P""8GPP\*^''_X)Z?#7X8.=*^(U
MO\>M6^,'QAM/B#\/_BI:^,KG5/$_CO6[F7X7P:#I?Q/MO%-YK>F:I!>^*C%8
M:A=RZ5]I$4=ND?Z*_ Z%-6_X*U?M<6?Q5;0M7\9>'OV>O@KI_P *TU'R[F6+
MX>:AX?\ #MQX\N?"UGJ$8>#2]0\=S:E_;4EE$JF[FFMIV,;L&FOE.#H2KM5Z
ME2.#ABGB*,*E)U:CPU;"T(RA.-.5.@JLL2Y2I3C6J4(T9<TJBG&2NAFN+K1H
M?N:=-XN>%6'K3IU52@L11Q->4)0=2,Z[I1P_+&K"5&G6E5CRQ@X2B_;/V%OV
M@OB'\<OBA^W-IGBWQG9^,/"'PJ_:2OO!7PF>PT[P_;6>E>!/[+-Y96=MJ6A6
M-K)KL+L5ECU/5+G4;R52/]+9#@X_[8G[3_[27P[_ &G/V5_V9OV=;/X&6NK?
MM!Z/\5M8U;Q9\;="^('B/3M"3X=6WARXM[;3-+\!>+?"=U++J?\ ;DB2/=W;
MQ1F&,YC4L:\"_P""0-C\*]-\<?\ !1NP^"(\(K\*[7]L7Q%%X.3P%<:==^#8
M[ 6=R9D\/W&DR3:9)8K>FYYL97MQ-YJJVX,!A?\ !0SPU\0O%W_!2/\ X)PZ
M%\+OBC_PISQE=>$/VE7L/'G_  @GA_XC_P!GP1Z=X#^TVG_"+>)[FTTFX^VA
MHT^V23">R\OS+=6=B*T^K8;^W*U%TZ4*-/ U*D8UJ3C3A.GD_MHU*M&E&;O&
MJE5J1C&;<^:ZFV[YO$XAY+0K*I5E6J8ZA2E*C53J3A4S>-"=.E6J2@K2I2=.
MG*4H)0:LX)*WZ8^ /%GQG^%OP\\>>./VUOB'^SAI6E^&#)K:^+OA?HWC3X>>
M"_#GA"PTX3:K>>,+GXF>./%S_:8+E)YQ>VM_8645B%22W>8-*>P^"G[2'P"_
M:0TK6-<^ ?QB^'?QAT?P_=VUAKFI?#SQ5I/BFSTF]O(YI;6UU"?2KFY2UGN(
M[>=X8YBC2+#(R A&Q^0?[:7A7XK^ _%O_!/SP1^U)\?#\>OAAXT_;4\--XWU
MN_\ A7X0^%OA6WGTO24O_A;X=\5:=X=O[G0[JPN/B1;Z3/:WFKS1-+?F&TA6
M:5HHZ_::PT_X7V7Q$U*738?!-K\5+KPMIZ:M'9/HT/C>?P98W7D:6U]:0.NL
M-X>M+Q_L]E-/#]@BG800N'PE>=B\/1IT*==R]K5Q2JU*<\)#V6#A"A55%Q=*
MI0IU7*3C.4G^Z5/FIODGSMKT,+B*TZTZ"C[*EA72IU(8N?M,74G6I>VC)5:=
M:I22CS1BE^]]HU42G#DL^=^(W[0WP*^$%]<Z9\4OB[\/?A]J5GX1U3Q]<V'B
M[Q5H^A7D/@K19UMM7\4O;:A=03?V'IMPRPWFHA#;02'9(ZGBO-Y?VY_V-H?A
M7;_'"7]I[X'Q_!^[UV;PQ;?$EOB-X9'@Z;Q%;RO#/HJ:Y_:'V(ZE#+&\<MIY
MOFHZD,H(K\^_V@_!OA+QG_P6U_8DC\6^&]&\2Q^&OV7?C7XQ\/1ZUI]OJ":)
MXKT+Q#9G1O$>FI<(ZVNLZ7]JNA87\8$]K]HF,+(S;A/^R'\'?A?;_P#!47_@
MISXJC\#^'VU^1_@SI7]H3Z=;3O%IWBGX8>&]=\1VEM'+$T5M%K>K7=U>ZF(E
M4W<MQ,)BRRR!^F.78*.%C6JSQ4JBRZGF4XP=*,)1GCE@GAXN492C)N2JJLU-
M1LX.C.ZFN>6/QLL3*C3AA8TWF$\OA*:JRG%QP2QBKR491C):2I.BN5MN,_;1
MLXO]4?$/QV^#'A/P1X;^)7B;XI>!-!^'WC'4/#VD^%/&FJ^)M)LO#/B+4_%D
MZ6OAFPT;6)[E+'4+O7KF1(-*@MII)+V9A' KL<5O>)_B=\._!?B+P?X1\6^-
MO#'AOQ1\09-9B\#>']:UFQT[5_%LOAVVM;S7H_#]A<S1W&JOH]I?6=QJ*V<<
MIM(;J"28(LJ$_P J%WI=W!_P1[^'5I:M=R^&OAM_P48\!1B2]NVEL_"G@O2O
MCAI%I;K)<W+A++1M-N=4AACW,D%L+E>57)'ZP_MJ^,?"-_\ \%&O^"6O@^Q\
M3:#>^++35_CSXJNO#=IJMC<ZY:^&-9T+P%9:/XAN-,AG>\@T75;S2M4M=-U.
M6%+.^N-.OH;6:62UG5+J9+3IU53C5JU%[3.H2DH17+'+,-&O2DTN;E=1R2J7
M;237*]4WG3SFI.DZDJ5.#]GD\XQ<F[RS+$.A5BFW'F5/E;IM)-M/F3V/6_@E
M_P %6?V0_C=^T!\5/V>]%^*WPWTWQ+X(\:>&/!/@"^E^)'AF^'QNU+Q!H5EJ
M5XWP^TRWD2[NVT#5[J7POJ5J'N9SJ]I,L8V<+])ZU^V?^R7X<^+$/P)U_P#:
M-^#>C?&6XU&VTB'X8ZEX^\.V?C635;Q7>UTY= FODOS>W"Q2&*V\KS7V,%4D
M8KXM_8K:PMOV^/\ @JA!*EK'=0?$WX&Z@+98(_MJ6;?!#POMNH;6.,W1MY74
M[)(8RDTHPA>3%?F?^U;\>_'7Q_\ ^"<GQT^(_P )OA!^R?\ "+]CB^^(4%CX
M,O?%?C[Q1X1^.]]XD\,_%+PS<0^*- \+>'/!M_X%M?&&K:YI@NK+2Y/&\.LO
M96=Z;Y$,?E/M'*<)B<;"C2IUZ%"5+*H2J3Q5%J&(S##4JBDG4HQ=23;J36'@
MDZG+-QJT(*,#.6:8K#X*=:K4H5J\:N9SC".&K+GH8#$5*<HOV=62IQ2]G&6(
MGI34H*5*M-RD?K_\>?\ @J)^RM^SI^TW\._V:/B7\2/ /AW5?%NA>+=7\8^+
M-=^(7AS0M,^%%UH5IHEYX<T?QII]^XN[>]\>1:Q)_P (X3-;I)_9URSAD96'
MJ?PQ\>:QXN_:I^)7]F?M2_#+XA?"V^^$'P]\4>"OV>/#FG^&I/&O@1-<M]*O
M$^*&J>)+!FU[5O#'C>UN?/T1+TMIRQ:E;26;%1&:^%_&5TMS^WE_P25U'6)8
MYKK6/V9?CB);[4Q$9]3U6X\"_".YD5Y[@9N]1D9I)R@>2XR7D08R:\.^-%]X
M[TC]N;_@K=J7PK>]@^(VG?\ !.?P]=>"9-+"C48/$%MX/L)--ET[YD"WL-PD
M;V>UE=9UC,?SA12AE^&G2I0HQE2JU,KE5K5:TJ=:G.I_:T<%SPC.BI8>R7,Y
MTI\RIKDO[U250GC\3"I4J5FJM*GFD:5&E2C4HU(TWE/UWEG*%9QQ";DXJ%2'
M+*;]I]FG&G^OB_MP_L>/\5W^!2_M-?!)OC(FOS>%7^&8^(GAK_A,U\26\+SS
MZ$="^W_;AJL4,4DDEEY7GJJ,2G%>G_$'X[?!CX3W$]I\3?BEX$\!75MX4UOQ
MS/;>+/$VE:'<1^#O#;0)K_B8PW]S!(=%T=[FW74=053;VK31B5U+C/XY^*]%
M_9QT[_@A<LV@Q^$;;P1<? 31=>\'ZG;+H27%]\8Y=1T^]\,ZC972SA+KQS=_
M$JVT]%EANI-6FU"+[.F]XQ ,6Q\'R_$3]NS_ ()%3?'3P[;>(?'/AW]BGXA^
M/;V/Q):)<W>D_$W1O#GP_:#Q$\4ID$/B'3KF]OG\]CYUO=W%SN"2%U&*RO"2
M=2:GBJ=+#U,QHU8S]DZM6>7X;ZQST_=C&FJC_=SIR55T&XOVE7FY5J\TQ4?9
M1<,-.IB(Y=5IR@ZBITX8_$K#\E1\TG4E33YZ=2/LU72DO9TE&[_:3X/_ !X^
M"_[07A>;QK\#OBEX$^+'A*WO[C2[CQ'X!\2Z7XFTB#4;4D7-C/?:7<7$$5U"
M0?,AD99%P25Q7&?#']K[]EKXU>.];^%_PC_:!^$GQ(^(OANSO]1U[P5X-\<Z
M#K_B32;'2[VUT[4;N^TG3[V>[@M[&_O;2TNI6CV0SW,,<A5G4'\O;3P/X)O_
M -N__@JG\+=5\3V/PC^'7Q6_9D^'EWX\\607VG>'K'PWJ?BGX?:7X1U/QTU_
M?3V.EZ;?VNG7CW<U[=7%O%->(;FZGWN[TGP;\3_'3]COXL_L4_LF_M3_  X^
M WQF\">*+SQAX$_9H_:*^$$WV?X@^%?$?AKPO?:GH\_CKX9ZWH^CMHMEJG@(
M^)K+6?%OPYN_$FFP:C>:=;ZO);?VUYT\RRO#N-5TJE2=5X:CBL/0E.G3FJ4\
M$L95DYSIJGB71OR3I4Y4*KA:K&,N;V:N.9XA2HJK3IQIK$U<+7KPA4J4W5AC
M5@Z248S=3#1K-\\:E2-:FI7I3E%+VK_<^BBBO!/<"BBB@ HHHH *_G:_X*(>
M&M7_ &*_VS_@Y^W7X!M9(?"_C'6[?0_BAIUDNV.[O8[3[)XBB-M#\B_\))X4
MCO&-W<1LTFOW#W"L9N:_HEKYY_:G_9Z\,_M0?!#QM\(/$@A@.OZ<TOA_5Y$+
M-H/BBP87GA_6%**TOE6>IPVTEW#&";FT$UNRL)-IVH5%3J)RUA).%1=X2T?W
M;KS1\IQED=;/<EJ4L%)4\VP%:CFF35[\KHYG@9>UP_O:<L:RYZ$VW91JN3OR
MGM7AGQ%I/B[P]HGBC0;RWU#1M?TRRU;3;VUF2XM[BTOH$GADBFC)1QM<*2O1
M@00""!N5^$__  27_:&\4>#-;\<?L%_'*2?2OB'\)K_4U\ 1:K,!+=Z)IT^S
M5/#-O+)(8IGTV*6VU+1[:S,OG:;_ &K-PEFV/W8I5J;I5'!NZT<9=)1>JDN]
M_P [G9PSGM'B+)\+F5.#HUI*5#'82=U5P688=^SQ>$JQ:4HRI54^7F2<J<H3
MLE)!11161[X4444 %%%% !7R-\7OV&?V:_C=XZ'Q,\9>$O%FC>/I=*&B:KXK
M^%7Q>^,'P.UGQ1I4<L<MM8^-KSX,>._ <GCB"P9"FF+XN_MHZ7!/=V^GFV@O
M;N.;ZYHK6C7K8>?M*%6K1G9QYZ525.7*[7BY0:;B[*ZO9V5T95:-&O'DKTJ=
M:":DH581J1YEL^6::NNCM<^<]2_9+_9ZU63X%27'PVTV ?LUZ]<^*/@O#I>H
MZ[HUKX/\0WR1#4-7:TTC5+*U\07VI2Q?;=3G\30ZRVI:G-=ZI?&XU&]N[F:]
M=_LO_ Z^^)'Q4^+=UX)$OQ ^-?P]M?A7\2]?_M_Q.A\2> [.S2PMM".FQZRN
MDZ4([2-(O[0T6QT[5'V[WO6D)8^_457UK$Z_[17UC*#_ 'M3X9U57E'XOAE6
M2JR6TJOON\M1?5L/_P ^*/Q1G_"A\4*?L82^'XHT?W47O&G[BM'0^9Y/V/?V
M=I?V=-!_9.D^'RM\ O#%GX;L-$\!_P#"2^+@ME:>$?$=EXL\/Q?\)$->'BJX
M_L_7].L[\/<ZW-)<F'[/=M/:O) _;>-/@%\)OB%XE^$/B_Q?X5&K>(?@/J]S
MKWPJU ZQKUE_PB^JW=E9:=<70MM/U2TM-7\RST^TA\G78-3@7RMZ1+(\C/[%
M12^LXAN[KUKN=6HW[6=W4KQ4*\V^:[G6@E&K+>I%6FVM ^K8=)15"CRJ%*FE
M[.%E"A+GH0MR_!1E[U*.U.5W%)GRE??L1_LR:EX._: \ 7OPU6;PG^U'XAU7
MQ5\<]*_X2OQK'_PF^O:U!]GU.^-Y%XB2_P##_P!IA&S[/X8NM%M8OO0P1L2:
M]%^)'[/?PB^+GAOP%X1^(/A(:_X?^&/BKPMXU\$:>=9\0::-%\3>"K>:U\-:
MD+G2=5L;N_\ [-@N)8Q::G/>65UOW7MM<,JL/:**?UG$N49/$5W*$N>,O:U.
M:,W"%-RB^:\9>SIPI\RL^2$(WY8I)+#89*45AZ"C.*C-*E32E%3E449+EM**
MJ3G42=USSE*W-)M_'?Q,_8*_9<^+?Q*U;XM>,? >O)XT\2Z;IFD>,Y?"7Q1^
M*_P\\._$/3]&%RFFV_Q-\$> ?&WAKP5\2A;07<EHLGCKP_X@FDL8[6PED>SL
MK2"#H3^Q;^S+_P ,]2_LJI\+-,A^ KO=36_@*VU?Q';0Z5<W6M3>(EO= URW
MUB+Q+X=O]/UN9M1T2_T+6-/O-!N$@.BSV"V\"Q_4=%5]=QCC3A];Q/)1E"=*
M/MZO+2E25J4J:YK0E35U3<;.";Y;79/U/"<U2?U7#\]:,XU9>QI\U6-5IU(U
M'RWG&HXQ<U*ZDTG)-GRKX<_8L_9Y\,ZK\%]>MO#/BS6_$'[/=YXIOOA)XA\;
M_%GXM_$+Q!X8G\9Z>FE>(1-KOCKQQXAU7Q%;W6GHMM;6GB:\UBUTQ-S:7#9N
M[LW'?$__ ()W?LG?%SQEXD\>>*/ WB_2->\:PVD/CB'X:?&GXV_!WPYX\:R)
M$=YX[\&_";XA^"_"/C34YH?+LK[5O$^B:KJ>I:=;VFFZA=W-A9VMM#]MT4XX
M[&PFJD<9BHU%%P4XXBJI\LJCJRCS*=^5U92J.-[.I)S:YFV)X+!RA[.6$PTH
M<T9<DJ%)QYHTXTHRY7%JZI1C33M=4TH?"K'@GB[]F#X#>-O!_P ,_A_K?PWT
M2'P3\'/%W@?QS\,_"WAZ34/".B>$?$OPWU2QUKP7>:9I_A2\T:W^RZ)J6G6=
MQ%I5PD^DW(A\F^L;F!Y(GZ+Q;\#OA?XY^)?PT^,'BGPR-4^(GP?7Q$OP[\0'
M5M;M#X>'BRQ33=?QIECJ5MI&I_;[*-(<ZO87_P!FQOM?(D)<^LT5FL175K5Z
MRLJJ5JD]%73C62][15HMJK_S\3:G=&OL*&O[FEJZ3?[N.KH-2HMZ?\N9).E_
M(TG&S..\?_#WP/\ %7PAKG@'XC^%=#\:^#/$ME+I^N>&_$6G6^IZ5J%K,I4K
M-;7*.BRQDB2WN8]EQ:SJEQ;2Q31I(OS+\(?V OV7?@CXUT;XA^#O!WC'6?&/
MAG27T3PCK/Q5^,_QJ^.+^"+"53',/ EK\9_B#X\L?!%W/;L]G<:CX4MM(U"X
ML))-/FNGLI'@;[+HIT\3B*5.=&EB*U.E5O[2E"K.%.I=<KYX1DHRO%<KNG=:
M/304\-AZE2%6I0HU*M.WLZDZ4)5(6?,N2<HN4;/56:L]5J>/:+\ _A/X>^-/
MC/\ :&T?PJ+3XO\ Q!\)^'_!'B[Q;_;&O3'5O#'A:::XT+33HMQJ<OA^R^PR
MSRO]KT_2K6]N-Y6ZN9E  9\5_@!\)?C?JGPQU?XH^%!XJO/@[X\T_P")GP]2
M?6=?L+#1O&^DHT>FZY=:5I6J6.F:^]DK/]FL_$5GJNGQ,[NEH'=F/LE%2J]=
M3C45:JJD(*G":J34X4XP]G&$9)\T8*G[BBFDH>[:V@W0HN$J;HTG"<W4G#V<
M>251S]HZDHVM*;J)5')IR<_>;OJ<!\5/A=X#^-GPY\9_";XG^'K;Q7\/OB#X
M=U3PKXN\.W<]Y:0ZMH6L6LEGJ%F;S3;FSU&R>6WE=8KS3[RUOK63;/:W,,Z)
M(OG7A3]ECX%^"O%_PO\ 'OAWP9/:^+O@U\+=4^"_PZUNZ\4^+]6NM!^&VLW^
MB:GJ7AZ5=6UZ]@UIKB]\.:-+_:^NQ:GKD2V2PPZE'#+/'+]"441KUX0=.%:K
M"FW)NG&I.,&YP]G-N*:BW.'N2=O>A[KNM E0HSFJDZ-*=1**525.$II0G[2"
M4FG)*$_?C9^[/WE9ZGDWQO\ @;\+OVC?AOKOPC^,GAD>,/A]XE^R'6M .K:Y
MH@O?L-S'>6N=2\.ZEI.K0>5<11R?Z-?0[]NV3<A*G(^,/[./P;^/7A+PMX(^
M*GA#_A(_#W@CQ7X/\<>$HH-=\2>']2\/^*_ >IV>L>%-:TO7O#6KZ1KMK=:7
MJ&GVDP\O41%=K$8+Z.YMY)8G]PHHA7KT_9JG6JP5*<JM)0J2C[.I-14JD+-<
MDY*$%*4;-J,4VTD$Z%&I[3VE&E/VL(TZO/3A+VE.#DXPJ73YX1<Y.,97BG*3
M2]YW\7\;?L]_"/XB?$7X5_%CQCX4.L^/_@K_ ,)%_P *UU]]<\0VC^'3XKTE
MM#U]FL;'5;;3-7:_TQFMF;7++4F@),UL89SYM?,/AK_@E]^R'X+O/M7@S1OC
MEX/MQXDU3Q:FA>%?VNOVM/#GA&+7=:UJZ\0ZM=0^#-'^-EEX4A@U'6+V[OKO
M3HM'339I+B5'M#$Y2OT&HK2GC<92CR4L7B:<%%14(5ZL8*,93G&/+&2CRJ=2
MI)*UE*I4=KSE?.>#P=6?/4PN'J3YG+GG1IRES.-.#ES2BWS.%*G%N]W&G".T
M4D 8&/3BBBBN8Z0HHHH **** "BBB@ K^=__ (*/^+M?_;%_:]^#W[!/PYOY
MVT#0];L=:^*%_ISADM+J:V6^U:YDEC+PW4/A3PM+<WLMG<*WD:U:F,JLT>*_
M6[]M3]I[0/V3O@+XK^)VI/;W'B V\FC>!M#EE"2ZWXKOH9%TZW"*3,MI;./M
M%[=+&\5L@B$Q3SD)^!?^"1?[,_B?2-"\7?MA_&(W&H_%7X_SWFKZ3<ZFA>]@
M\+:K>OJ<NNLLJ'R;KQ7>22ZE;SV\@9M&NXH),+*T8ZJ"]E">(DM8WA13MK4D
MM[/=05V^[T]/S?C&K+/\RRW@;"2DX8R5+,^):E-M?5<BPM6,UAIS37+5S/$1
MA0IQUDJ<9R<7"5S]A?!7A#0O 'A+PYX)\,6,&F>'_"VCV&B:186R;(;:RT^W
M2"&.-,G:"$W$9/S,:Z>BBN7?<_1H0A2A"G3C&%.G&,(0BE&,(02C&,4M%&,4
MDDM$DD@HHHH*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_6-)@N&LY]2TZWU.*)KNRANT>VDGBW(LR-&3N!K:U+]E7]IO1O$7PQ\(:O\
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MU\7^%K3Q"EX8]%\1V:[(-3M397=FYD\O,4T$SRVES"6AN8)HF9#1^.?[+7P
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MQL4DC=64D&M"N0_2TU)*46I1DDXR33335TTUHTUJFM&@HHHH&%%%% !1110
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MH_\ Q"?]L#_YR=?>G_!.NXG'_!/W]AP">8 ?LC_L\  2.  OPI\+*H W<
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MO^_K_P#Q5?!/['S,WQC_ ."E!8EC_P -T0C)))PO[(O[*ZJ,GG 4!0.P  X
MK[C@?,<!C*^=4\)@<7A:D<IA.4\1F-'&0E!9KEL7"-.GEN"<9.4HRYW4FDHN
M/L_>4H_'<7YYGF91R7#9I4RJ=".9U:]-8# XO"U56AE>/IISGB,TQT94^2K4
M3A&E"3DX/VB4'&7W12@X((['/Y4E/C4NZ*.2SJH'J6(']:^U/FUNK=SY"_9A
M'D_$3]M[3D_U.E_M:36T';Y+KX ? G5'^4<)B>_FP%X(PY^9C7UN?OK]/\:^
M1?V3V%_K'[57B9#OM_%O[3NOZI:SCE+F+2OAG\,/"4LB/_RT6.Z\.3VQ; VO
M"T?.S-?71^^OT_QKZ3BQ..>58/XZ67Y%1JWW5>AD.64<0GVDJ].HI)ZJ5T]3
MY?@^SR&C*/P5<PSVO2:V=#$9]F=?#M=X^PJ4^5K1QL^HB_<;\?Y"E3H?K_04
MB_<;\?Y"E3H?K_05\V?22VEZK\H@/OM]/\*&ZG_</\Z!]]OI_A0W4_[A_G06
M?RW?\'1_B"ZL?@#^RYX:C$IM/$GQ.\>WMT5#>2)/#FC^$9K7SB!M#%M2F\G<
M<DA]O(-?Q5U_=]_P<J_"'5?''[$7@WXEZ5;M=_\ "G?BG976JPQIOEM]$\96
M\5EJ&IEL@1VNG_V% ;IN21/'@'!K^$&OW;@.<)<.8>,&N:GB,7"JKZJ;K.HK
MKSIU*?W'X?QS"<>(:\II\M2AA94GT<%1C!V_[B0F%%%%?9'QY'-_JI?^N;_^
M@FO[]_V[OAC^U'\0?@O^PW/^SQ_P4O\ A3^P'8Z9\$/*\3:-\1_CUK/P8F^(
M]W/9^%GT[4]+M=*BD378= BBNK6YGFP;)]3BC4$7#5_ 3(I:-U&,LC*,\#)4
M@9//&?:OV8_X*U?M]? /]N;PC^QCH7P?TCX@6][^SY\*-:\#^.'^(/A72M!@
MGUC41X3\B3PY)9>(->;4; -HE[YD]PFGNH-LPA8RLL7S6=Y?B,=F&2>Q2C3H
MU,?*O7GAJ6+I45/#15-U*5;]V_:37)!RU4FFM4CZ/)<?A\#@,Z]LW*I6A@%1
MHPQ-3"U:SABG*I[.K1_>+V<7SSY=''W7I(_0O_@AIX+M_#7CS_@HW^V-X\O[
M/XW?&W]F[PIKEKX0\;R:C'XIM?$'BB^N_%O_  D/CC3;Z[$M[K \1R>']-O-
M-UF6!#<6+>;'*)9I0OXU^+_^"K__  4!^(^@?%[PO\1/VC_&/CWP7\<=+UG2
MO&?@CQE,?$7@[3=,UYY9;NT\#:#?RR67@R.U$S1Z4VD(ITZ&.!+< 0ICO?\
M@E3_ ,%';C_@G?\ &'Q9JGB7P8_Q(^!OQA\-6_@OXQ>!+:XCM=1N])M'OO[+
MUG1GGAGMYKW2(]5U:)]+D2V758;T0MJ%D(%9_:?CI\4O^"%NE?#WXTZO^S'\
M!_VL?%GQJ^(VA:QI'@'0?C?=>'-#^$WP=U37I9FC\5^#QH%YJ.L?:_!_V@2:
M%I.J2ZC#J$-G!975Y SO=UA]5E0SC'5<7E=3,88I9;' 8FG0H5:>'AAX1IU*
M<O:3BL&J==O$<T;1FG=/F2BM_K4:^3X*GA<TIY?4PSS"6.P]2O7HU,1.O/GI
MU8^RA-XMSHM4+2O*+7*THR;/FV]_X)%?\%#-,^ 0_:>O/V?A#\#5\$VWQ#_X
M3/\ X6=\)I)AX-NDBDMM8/AF/QN_BL>9%-%+]A.BC45A<3/:K'EA_29^S5X,
M^-GC[_@@C^RCI/P"_;.\"_L-^,1X_P!2OIOC!\0?BGJ7PAT34-&C\<>*S=^$
MX_$VF(]S->ZQNC:'3&4)<B$EL%!7\8)^(?Q&?21H$GQ(^(DN@BU6R.@R>._%
MK:";-<$69T1M8.E_8@0"+/[)]F4@$1# K^@+X.?M\_\ !+WQ_P#\$PO@I^P)
M^VYHO[6T=U\+_%U[XPO;_P" GAWP<+6YU2+Q%K.KZ.;;Q!XAUJ0RVGV;5C'>
MVC:# XECQ'<[>:C/L)F=>A@G45/%^QSBCB+8'+G5E2PL:->-ZN%Q.)KT\3*,
MI)2O*E"3DER(K(L5EM#$8SD=3"JME%:A?&X]4XU<5*OAI*-/$X?#4)X:,E";
MC[M2=E\>Y\(>/H_C/I?_  4T^"_A'XZ_M1:/^V'XT\'_ !H^!>FK\</#7Q#U
M#XH^%-=TV]\1>&]2MM/\.^+=25;B\M=)69;"\@V*EO>V\T/S;,U_3Q_P5OT7
MPW^WC;?M<_L0LMD_[2O[*?P_\&_M6?L\.ULD&I>+/ ^HZ-JMK\3?"$5R@_?P
M:+I_V*ZAL-S7FJ7ILY8[=ULW>/\ DT^('C#]A[X:?M<_!GX@?L=0_M ']GKP
M%XR^'7C#Q#!\;K7P[<?$IKWPYXBTO5_$*:59Z%-:Z7<6[P6MR--MY;BW::8Q
M(\T2L7'VA^U?_P %4?#OB;_@JWX6_P""@7[+L/C&Q\*^']#^'/AZ]T3XB>'[
M31-7\0:%I5EJFB?$#0-5T'3=?UBTGT_5M#U>[BTLR:K)&U\MK=SVX%MY4F6,
MR[%XK%93B<-2J4JF"RNO5P]2="&%C#'4Z^$G3HUJ--N%".*A"M2J4HMQC2J3
M47HC7!YAA<+A<SP^(K4JL,;F="G7IPKRQ,IX&I0Q,*E:E6J)3K/#3E1JPJNT
MG4IPO;F9^K/Q>^!GA']H@_\ !O+\'/B5;%O!_B+1O%J>+-%NP;>74K/2CH=Q
M=>'YEE&^*>XN(1!-&RF13%)&R$[A5/\ :-^-G[=O[7G_  4+^.O[+W[.G[=G
MPP_X)\?#K]E[4])^'_PT\#>(/B1JGP:TKQY]COX/#EOI^EP>&[62X\9:QJ%[
M&MU9:,;5EL=-F@T_3T>%(EKX5_X*6?\ !7KX)_&_XD?L._$_]AOPS\0/AWK?
M[)7B3Q=XWALOB)X8T[1]+M-?\4:A9:J^E:1!IWB'5SJVE+=#4XYI9SIRF.YC
M,=JJHJ'U+X@?\%#O^"+W[6WQ3^&?[7'[4/P#_:L^$7[5_A'6/#'B7Q1#^SV/
M".N> _&'B/P5=65SH&HZ_J?B&?3KK58V_L^VADAM=*T>ZALU$%Q?ZA<[[Z3S
M*6 S"%+!XBOEN(FOJV9PI47A:&.J9?B\3FE;%1J5,%6FJ<UB</*-%UH\SIVU
M24E?TZN-R^I5Q6'H9C0@UBLMG5K+%5\%3S#"4,MH85PIXRC!SB\/B%.JJ4N5
M5&]+N+MG7W@;]J_X<?\ !>C]CSPC^V;\5/A]\9OC3I8^'22^/?AOI>IZ7HNH
M^%F\)^-O^$>BU'^V-*T?4=1\0P1K='5=5N+0M>M+"_GR[<KXQ^T=S_P<8ZIG
MG/[8_P /<YYS_P 4=X8KG_C;_P %2?@M\9O^"P/P?_;W;P;X_P##'P6^&4O@
M_2KG2!9Z=K/C_4]$\):#XETI-5AT/[=ING0ZA?2ZS;$Z2=9>.W2*5_[1F)"G
MYM^+?[9WP@\=?\%;+S]N/1;/QQ'\%[C]H'PI\48['4- L+?Q\/#6B>']&TN\
MB;P['KD^GC5FN=/G,%F-?,,D1C=KN-G*+ZF%P>/YZ=2O@W1G+A*>$G&E2A3I
M0QDL0IO#0A3]R$K:JG#W4MK:(\K$XO J$X4L6JL8\54\5"56K.I5G@X4E'ZQ
M.=3]Y..EG4E=M[ZL_HK_ ."PNA^'?V^_#W[:7P#TZ"VG_:F_X)X:OI_QJ\ 0
MQ6PCUGQS\!O%7ANTU_QCIL7DQ,;\>%[;4M3M-/TY)7N[B[TZVN_LN)?,2M\2
M\C_@H!_P;W"1&)3X)>+%>-A\X*^$X \94]'# JRGD,,'D5^)GQ2_X*G^';'_
M (*^Z[_P4%^!%AXJE^%'B;4O".D>*/!WCG0[33-<\6?#5O"^G^%/B'X;U;0+
M36=3T\7-_I8U5-">74[J"&[DM+Z6 E6@KZW_ &DO^"P7['/Q"_;]_P"">O[1
M?PF\%_&+1O@E^R)I?C+2_%6AZWX0T?3O%1M?$MD;>SM_"NC1>++^TU2.QD+-
M(;O5].WAB% 4*3Y%/*,RP]'+\+#"UIX=93F%:*MKA<;C,GGA\1@YK1P]IB[5
M**2?OUZL5901[$\WRW$5L=BIXJC#$/-,OHO73%8/"9Q3KX?&0:5I*GA+TZS>
MJA1I3=W-V^B/^"P?@?\ ;6\*>./VQ?BMX?\ ^"N'POTKX.6CS7UM^Q;H_P"T
MOXAMOBC!X<E\/:'8WW@"#X511BPCU'4IFNM3.BK*(KBROC<.?WS*<S_@WXT?
MQ?KW_!/C_@I5HGP^^+&B_ ?QMJ=[%9^%_C+XA\1S^#]#^&FL3?#:".Q\7:KX
MIM5:YT"QT:8QWD^IP@R6D<)E4945\2?MH_'3_@A)^U)X_P#CI^T3;6'_  4,
MM/VAOBG]L\1:;'+I/PXTCX<0^-8="L='T<75@+W4]4L]"(TRS-_&-1NK@@W#
MQR!F1%XW_@EA^W_^QO\ LV?LM_M@_LN_MA:/\<[SPM^U!)'IL]]\$?#^A:OJ
MMOX<O/",?AK5XUO]=UO38-)U0'SI+*9K#5(<%'DBR#&>F6"Q<^&GA88/$_6:
M=;*G.G+*Z&'J-4*F'=7DI0DUCE24)MSJVE5^&7NMLY5C<)#B..*EB\-]6J4L
MS4*D<SKXBFI5Z5=4G.I.*>"=5U*:C3I)QI[Q;:1YU^VMX>_:F^'OQM_90\%_
MM#?\%%_ _P"WWI^J?$;PKXD\/W7PW^.>M?&;P]\/[RQ\=^$=-NXM6?54C71-
M8UJ*\26R$2LUW9V=PS,!$%K^PKXX?!W]K/QE^WQ^S5\0_A+^WEX7^$_P1^'7
MPF\$^)OBK^R5#X[\1W?COQ_H>A7.N7/B'Q/;?!W2K*[L->TK5;.XT_24U6\V
M>;=:6UHI:2.)&_B&_:(U/_@E=X1U[X)>(_V"X/VODU#PU\2O#WB+XHI^T/!X
M,>TD\+:!K.D:I /",/AIH7GUH_8[M7BO)8H) 8(UEB+.Z_=G[6O_  5^^'/C
M/_@I=^R[^W#^S7:?$VQ\+_!?X:^!? /CO1/&&BV'A#7?%FFZ/K7B.[\5^'5M
M=-UWQ!#>Z#JFGZK9-$\UY"\UU \/E0*OG25F&5XW'QRU8:A*FZ67YS"<L3EF
M&H0]K5]BZ5.>$3E1P\\1RN-*K#FE%KVN[8L!F>"P,L>\37C457'Y1.$</F6(
MKR5&GS^UJ0Q3Y*V(A0NI5:4K1:?LMDF?27[-7QU^&_[1_P#P<K6OQ5^%'A;4
M?"O@W4/$'C_08+'6-!E\,ZSJ>L^$_AOJGA_Q!XBU/P]=16VHZ3>>(-8L+O59
M++6+2QUR W9CUFQLM16XMT?_ ,%<_ _[:W@:Y_:Z^)$__!7'X7>+_@U=>.;^
M*+]C+PM^TOXAU+XCV/A;6]7TO3H? =Q\+#&NGPR:&TXOM6T99!#:64,LH)VX
M/S))_P %%_V&O!7_  67\,?\%"/A)X8^,VG? [58O$&O?$OPM?\ @;0=,\8V
MGCOQ'X7N]%UC4_#7A^W\7W=AJ5MK.JW<VNZ@]QK6GNMS<S1QQE55CQ/[97Q2
M_P""&7QYU;X^_'+X>V7_  4$M?VEOBIJFM>-=$3Q)IWPZTWX71>.=7DMRR:C
M9VMS?:M:>'A%'(# E]=7"DJ/.<GAPPE>&9Y57^HXV&%ADN785QGE]+'RI5:.
M)DYT*U2LXO#SA"SEB:2<TFI16J1,\70GEN:4'CL'/$U,YS#%*4,=5P,*E*MA
MZ:A7HPHJ2Q$)RNHX>H^5-<CDW=GV9_P25\<^-/AA_P $5_\ @J-X]^&_BO7O
M GC?PI?ZAJGA?Q=X5U*XT;Q#X>U*#PIX52"_T?4[1DN+&[A5F6.>%E= Q .#
M7=_\$R/VD_C!_P %(?V+/^"@O[+7[9'BZ^^-VA?#WX':Y\2? 7Q!^(<KZMXL
M\-^(M/T^>]T:>]\37;2WFH3:'X@M+77M/GNI/-LTMQ;1;8<D_!W_  3(_;__
M &)/@'^Q1^U/^R#^V/I_[0-QH_[26OR?;KSX%>&O#^I7UKX8N=!T?3KHVVN:
M[X@L4TK5Q>::YA#Z-J4(MRKLQ=M@ZCQ[_P %,?V&?V8OV3_BG^R[_P $M_@]
M\8M%U+]H+2M1\._%[XY?M#OHL'CT^&]4T]](U'2].L] DO+34);C1I)M-LKJ
M.?1HM--Q]LDL[^:%0\XK+\36Q>;4:>65Y8K%9Q@\5@<R=&G&CAJ5&G@^>NL7
M*2G'D]E57LZ:E*;E91;DRL+C\-2PV5UIYG0CA<-E.*PV-RY59SK8BK5GB5"B
M\+&+A+F]K2DZDVE!+F;22/Y\YXOL]Q<VX;>+>YN+</G.\03R0A\]]X0-GOG-
M14?4DGDDDY)).22>Y)))/J:*_0#X,**** /[ _\ @U+\07<]U^VIX5<2_8-,
MTWX,^(("2?)^UZUJ?C?3[G8,X$GDZ-;>8<9*[.?3^Q).A^O]!7\J_P#P:U?"
M#5?#_P !_P!HKXWW]LUM8?$?X@:'X#T8RQE9+ZT\!:;%K,NH0OR)+)KKQ;<6
MD;#'^DVETN.,G^JA.A^O]!7X)Q?.$^(\R=-IQ4Z$';^>GAJ,*B]54C)/SNC]
MVX3A.'#N6*I>[CB)QO\ R5,35G3WZ<DHV\K6!>K_ %_J:L_P?\!_I59>K_7^
MIJS_  ?\!_I7S1])]J/_ &[^2%7H/H/Y5^/O_!;?P[\0]6_9#AU#P?\ %-_
M>BZ;\5O@K;^(/#\?@3P_XH;Q1>:E\8_ EKH%_P#VYJMW;:AH \,ZB\>JFRTU
M)8-?$)TW46CM9Y&'[!+T'T'\J^0OV\?V=?$O[4O[-7C+X2^"M8TG1/&D^K^!
M_%_A&ZU\S)H%QXA^'_C?P_XUT[2];GMDEN+/3-6ET+^S;J^@M[J6R2Z^U):7
M1A\B3ORNM##YC@JU24(4Z>*HRJ3G"$XP@JD>>3C.,H^[&[YN7FBUS1:DDUQY
MG0EB<#CJ$(SE.IA:L81ISE3E*?)>$5*,H/WI))Q<E&2?+*\6T_G#XQ?%O]I_
MX':;^SI^R[X;^,.@_%?]I?\ :B\6:]IOAWXW>*OA/X?\&>'_ (5_#[PUI/AZ
M[\0^(Y?AUX3?4] \2:MH4>L6O]C:?J$\%IJD]S-%J-Q:P6L#R;7A?XO?M&_L
MX?M8_!W]G;]HKXN:/^T-X)_:7T+Q:WPX^(]I\+- ^%'B/P5X_P# VCZCK^H^
M$]4T+P<]]HFL:#K&A:5-=VNL7%ZNIVVHW"6SVB649N33^+/[/_[5_P :M(_9
MQ^/\WA#X+?##]K7]EKQ9JNK^&OA]9_%+Q%X^^%/Q/\+:YI&@:?XE\+ZQ\2_^
M%>^#-:\#CQ)+HR/!>P^ /%;: D$68-8:X)AZ/PC\ /VB_C?^U+\-/VE_VJO#
M7PI^%6E?L^:-XDT_X-_"'X5_$37?C -2\3^,]$O=%U_Q[XL^(&L>"?A>+4VN
MG:G>:=I7A>S\&7"JT<%_/KTGSV1[F\*L/^^^H-?5\?\ 6_9QPOUAX]RJ_4WA
M'2CS*C;ZJT\(UAK>W]LK\R?GI8GZPO9+'_[Q@?JG/+%K#K *%!XQ8I5GRNM_
MO*?UN^*YG1]EHE;H/^"CW[0WQ0_9P^&WP1\1_"O4-%T[5O&W[3_PB^&/B&77
M- LO$,$_A'Q9>:C#K=K:VU\1'9W\R6\0M]2BS/:D,8P=QKR[Q!\6?VQ?B[^W
MA^T'^R?\(_BEX"^#GPT^&WPA^$GQ$A^)-Y\/-+\>^/?#FM>+=7\9V#:)I/AC
M6TB\.^)M*\1_V%_Q-[[7=4L;WPZFGV9T2.\?4KTV_M'_  4&_9G^(W[47P\^
M#7A?X:W/A:VU/P#^TE\*OBSKK>+-6O-(M)/"W@R[U"?6(M.FLM*U=[G6'2YC
M%C9RPVUO.P82WD  )WOAA^SOX^\'_MY?M+_M*ZM<^&G^'7Q<^#_P6\">%+:R
MU.[G\41:W\/]<\?:CKTFLZ5)ID%G9:?)!XETT:=<0:K>S7,BW2S6UJL4;394
M:N"I8!R<<++&1H8MQ56E3J2]J\5EZHN4)QE&<E1^L.G&:E%Q4TXN/,GI6IXR
MICE&,L5'"3KX3F=*I4IQ]FL+CO;I2A)2A%UO8*<HN,N9P<9*2C)?&?AG_@HG
M\7_AY^R!^T5XN^*^C>&/B)^T1^SU^T%J_P"RYI-SHEC/X=\*_$_Q_JWC4>#/
MA?XDU32M-MI5\-Z?K\M_H^I:_8Z4ET-,ADNX($FFC2)OLWX1^"/VT_AZD_BS
MXR_M,>"OC=X<OOAUKNIZQX;3X->'_AC>^"?%R:;;:MHTWA+4?##7S>*])MI%
MO],O[?Q4VF2RVRVU[&K7$DEO#\D:O_P39^(GC_X._MQ?#3Q3XT\.>#M;^.W[
M4<W[17P1\5^';F]\0#PWJOAW7K/Q7X#N?%VG7%GHC1M'KFFV4>N:78WLZM82
M7"6VI^;M<?7/PJN/V\?%OD>&_CK\.?V=_A=X3TSP#KFBZOJ7@#XI^+/BUK?Q
M(\3W.F)I&CS65IJ?PX^&5O\ "_2H]TVJ7YENOB'-*P73XQ$C&[6\4\$Z55X-
MX"+EB)SQ*G&CS*E+#865*.$]I%SC%8AXJ/)A+2C)15;]RH-9X98N,Z2Q:QSC
M'#PAAG"5;E=6.)Q$:KQ?LY1A*4J"PTN?%WC.+DZ5ZKFG^=?[-/[97[8.M?LB
M>.?^"@7[17Q7\&Z=\*OA%-\8[&'X.^"?AAX<>X^+.E>"O'>OZ#H/BOQ)XRNI
M8=3\ ZC]H2'PY<:/H$5YIW]G:"GB*YN5O-3NK=.?T'_@H;\4?AMJG[,OQ-\>
M_MS_ +)O[0>F?';XE_#_ ,"?%+]E3X4ZC\'7\5_!N7XTZE9:-X?7P'XG\*>)
MM3\;>/HOAAKFN6-IXIGU_2;"34-(TN_OF N75&^P_@#_ ,$__$FG_P#!-_Q9
M^P_\<M;T33]7\<M\7K35=>\"WMQX@T[3+7QS\1_$GC#P_>V<NJ:;HDMW<6EK
MJ.G'4+.6T@C,RW5HD\L6VX>W\#/@I^U?X:N?AUX"\>?LY_L.^&M*\ 7NCVFM
M_M(>$I9/$7B[QYH/A*:%(K[2_@>WPJ\(1?#[Q/XXL+)%EOA\:/%MOX&U+4&U
M"&V\6)IPL[_KGB,JE4Q\E0P4X1QE>$:<(X7#PEEZIM494)SHRJ2G[1U)RGAF
M\7=45&])<L>6G0S.-/+XNMC8RE@\-.=2<L57DL>YP=>->,*T81@J:A&,<1;"
MV]LY6JOF?KG[77C3Q]X8U3PTL/[;_P  ?V(/ M]87+Z3XJ^)%C\._$'BWQWX
MA00?:-)AT;XMZKX7\,VNBZ3:S)>&ZT'5[_6)IYHH;RVMK>19!\(:/_P4M^.&
MK?\ !.#Q?^T)IVF>'_%7Q(^'WQVUWX!^+_BOX%T9_'7@:Q\,Z1K36TW[1]CX
M9\&VVN0ZIX=LO#EYH^M7FBV0FTM+ZXFB^TFP19&^A_CC^RS^T G[:>I_M._#
MGX=? O\ :1\)>-O@MI?PG'P^^/GC;4_!5K\$M5TG7-/U&7QEX)@A^&OQ3TWQ
M9'XBBB-QKVC_ &'P5J<KZ3:V,/B>.&_GGMJ7[+W[+O[7O[*G[.'Q%\)Z':?L
MZ>.OB7XH_:.\:?%B]\#SC7/!WPO\:_#_ ,8V6C+>>"++5+71=<?X8:B)[6>T
MM]0_X1'XA:;;6UM'(VC7(O7MK3GH_P!G0P>']H\'B*JJX*K&$_J]"4DW4^M4
M*DXP>(48MPA.>+E*BVE4HP5%2D=%;Z_/&U^3ZWAZ3I8RE*<57KQBU"E]6KTZ
M<JBH.4K5)PIX2,:RBY4ZM1UG%'"ZE^VWXO\ V?OV5OBY^T2/VO?@'^W=X50^
M!] ^&/C#P]:^"/AM#X5^*7Q$O]'T+PSX4^*"> ;_ %3PWX:\&*VL6/B37M<\
M0ZAIOBG1+9[NVO-%CMH%G7DOA7^W#XX^'7[2'[,WPV\:?MV_LU_MM>&OVF=0
MUSX>ZSX?^$*_"#2/%WP8^(]OX7O?&^CZO96?PV\3>(-0\3?#^2S\/:_X8OM3
MUZ*SNX]0N=#N4AW74Z6V'K7_  2I^(/[0?B?]H[XJ?$;P[\&?V3/%/Q1\,?"
MK1_!7PO^".JZE\7/AO)XS^#_ (HT#QQX8^*/Q2_M/PI\(M&\5WT^L>'[3P[>
M>'=)\#Z#)-X2+VMWXCO+HO+-]N? +X=_M-?\)GX.G^*?[,?[&'P+TKPC!+<^
M(O&WPHUJ?XG>*_B#=Q6%QID%AX<T>7X1?!]?A,MW<7,.NW&K/XA^(1M;>QN/
M#D6ES+JBZQIVU6650P]=Q6&KU9*JZ\6L#1E3Y\'16'C0E2I.%25#$^V<IY:H
M*K.*>(BJ4E;&E'-)UZ"D\30I1=%4'_MM:-10Q=1XB595*JE35;#JDE#,O:2I
M0DU0E*I%M_5?[2OQ)\8?![X!_%GXH_#_ ,#WOQ)\:>!?!.L^(O#G@73H;VXO
M?$NIV$'F0Z?!;Z=;W5_.Q&Z9H+.VFN94A>.%"["ORY_9K_;.\4W'PC\7?M/^
M(_VX?A!^U/X!\&_ KQ-\5/B]\#O#OP_\*?#CXL?!;4?#NA7NKSZ=9^'_  _/
M<^-9I(_$EE+X+NK7XG:/X7=+5!JT+SW[K9M^N_Q0M_B3<^ _$<?PAU+PKI7Q
M&%@\GA6Z\;:7?ZOX7;4HBKQVNL6FF:CIE\MI=JK6[75M<M)9F07(MKH1FWD_
M'+Q?_P $[_BA^US\;;;XC_'WX._ W]DG0M,^"7QA^$VMM^SE\3M9^)WC3XNQ
M_&+POKWA.ZM/&6KW/PI^"FB:?X>\)C7W\5:7;WWA[Q?J=[XCL82-1TV"4/;^
M?EKP+PU>&,]C3BYN4Z[]A4K^SC!6H0H58.NO:R35.O@JD9TIMO$QE244>AF7
MUU8FA/">UJ24.2-%>WIT.>4[.O.M2E[!^RAK.AC(2A4@DL/*%5R;\&A_X*4_
M%7P%X2^#G[3'B_\ ;@_9*^*5A\1/B/X&TOXA_L/> -7^#EUXO^'W@[XIZO'X
M7TJT\#^.-#\3WOQ"\8>*_ VJZOX>U/6K;6=#M([FP&N)-A["!+GZO\5?&W]M
M7XL_\%%_C!^R1\'?BMX(^$OP@\$?!7X3_%.?XA77PXT/QQXV\.:GXAU;Q7;2
M:)I.@Z[+;:7XALO&L6FQP:A>:M<VTWA2/2HKC2HKN;4;B-.@^"'[/'[67P^L
M/ OP>\0_L^?L.-H/@*^TO1E_:JLEEU'QCXB\)>&YH)K/5I/V=D^%NAP:/XPU
MVQM?[*FN$^/U_;:-J%P/$9.L/;OI=U[O\./V9?B/X4_X*%_M"_M1:G<>%V^&
MGQ0^"'PC^'?AFVM-4OIO%46O^!];\::AK4FJZ3)I$%A:::]OX@L!87-OK%Y-
M/(MPDMK;K&CR]U?$9="6)E3H8'VD,)B?JLK86M3FY8K"?5;4:=&--5:5+ZQ*
M+Q$98J<+QQ47:TN'#T,PFL/&I6QWLYXK#_6(\V*I5(<N%Q/UGFJU:LJKI5*O
ML%+V#CAH32EAI)R;ARGPR_:&^,>H_P#!2WXL_LI>)?$ND:W\,/A_^RA\.OB1
M8"/PQI^E:U>^/]6\0:/H^N:[<ZE:R/(EEJ,5Q=2Q:&@-G8O*JP.PB4GYS\2?
MMP?M Z/\%_\ @K)XZAUSPXVM_LC?%3Q#X9^"[MX5T\V^E:%I<5G+!:ZY;F39
MXAN"))5>[O"DAW X^4"O>OC+^SY^TAX _;2;]LC]E[P=\)OBA?>//@C%\%/B
MG\/OBM\2O$'PH$,>AZVNO^%_%WAKQ9H?P[^)OGRP36UEIVI:%=^'K9;FT6::
M'58)70)\\Z;_ ,$]OVH&_9G_ ."E'PU\;>-?A3XO^*_[9'C'6O&'A#Q#HT6N
M^#O",=SK<46;36]*FM_$]]X;@L?+2U0VM[XD>Y$9NF,)E^SQQ066-4:U26"4
M9T<H@Z<E!3]M3Q=&.82G34?<3IQFZDI\JJTYWASI3Y+JO,DZ]&FL8YPJYM.-
M1.I[/V53"U98",*DFE4:J2A&$(<WLJD+3Y'R<WG_ ,2/VE/^"E'P5^$_[(G[
M3M[\1/@;\3U_:6\0?"+P)K?[.+^"F\*_#[PEJ7Q?\.65SX?\2Z3\8+6P;XC:
MB]K';W.O:WI=[X=CM(-6U*?1-/>XTBPM+RX^L?A]\9/VG?@[^W5X)_98^.OQ
M*T+XZ^$/CK\(O%GQ-\(>*]+^'_A[X;W_ ,,O$OA"]OGU'P4UIHES<-XL\.W&
MDV,LEAX@U%;;5C=/&EU;HH8OJ?'/]C_XL?$;]F;]B/X1>'[OP;'XK_9Z^(O[
M,_BKQ[+J>LZE;://IGPC\,?V/XK7PY>0:%=W.I7<MW\VCPWECI<=[#\]Q/8M
M\E>I_$;]G'X@^*OV^?V=_P!I?3+CPTOPY^%GPG^)/@KQ-;7>IWL/BB76?%EO
MJ\6E/I.EQZ5-8W=BC7T/VR>XU:SEA <QV\^T!HGB,!4I2BZ6 BY4<UBW3H4J
M<TZ2YLM490BI1ES74)QM.NGRXB=5)6JGA\=3J*:JXZ7+6RMI5*]6I!JHU',7
M*,I.,HN.LHR3IT9)RH1I-RO\Z_\ !:Z76(/V,+"?P[::;J'B*']HC]G&70+#
M6;JZL=&O=;C^+/AQ])M-8O;""YOK/2KF_%O#J-U96UQ>6]F\TUK!-.D<;2ZA
M\6/VP_V;/VK/V9_ _P ;OB]X)^,_PS_:PN?'/A@^'-+^'&D^!+GX,?$/0['1
MM9T?2_#OB/2!/JGCOPI<-K4NC)JGB2UL-5:TTA-0N[>&[O2@^B/^"A'[.GQ!
M_:@^!&B_#?X:W'AJV\1:?\9_@OX_GD\5:E>Z5IAT+P!\0M$\4:[''<V&EZO.
MVHR:9I]PNG6[6J0W-V8XIKJUC8S+G?M=?LS?$;XZ_&?]CKQUX*U70M(T/X&?
M$'QOXD\;WNH:G>6.O6^F^)/#^E:5I]UX4M;?2K^VU+4[2YLYIWM[V\TJ)56(
MI=%G.S+"8C"_4L+A:[P[C*><2K>UA&52FYX+#_5)0FTYT7+$4URRI.$IRCR3
M<H7B]<5A\3]<Q6*H+$*:CE$:/LYSC3J*&+K+$QG!25.JHT*C4E54E",N>*C*
MTE\$_M5?MG?&?]EJ]O?B=?\ [=O[+GQ!\2^%_BIX/T/QO^PCX;B^$\7B.S\*
M:_XWT_PWK^DZ!XOO?$%G\8+CQ1X:T"]DUWRM5\)V<MQ?VEQ9W$,%G']H?U+P
MU/<:Q_P6E\<W-A<-I=UJG_!/G39[*Z:"*[;3KB^\>>%)+:X:VD(AN6M))4D,
M$A$4QC,;D(Q-?+>H?\$U_P!L>]_90NOV08/AS^R-'<Z!XM?7/^&KM<\4:YXF
M^*GQEM+/XB/XPCO-<\+W/PLL]1^&?BOQ%"L;ZUKL7Q,^(B6DDD^G6=BUD2[?
MI=X0_99^)NA_\%$-2_:EO;KPFWPSN_V4-'^"L5M!JVH2>+!XQL/$WA[5IYGT
ME]&BT\:&;32[D1WPUAKIIC$AL%5V=.^M4RZA1K1I5L+*J\)F.'52E'#P]M3<
ML#+".4,/&,4ZEL1*,:SJ8E*\<1-N*4>*C3S"M6I.K1Q,:2Q66UW"K*O/V-1?
M6UBTIUY2DU3_ ',92H\F&;M+#P49.3^ _P!@+P7\>-'_ &\O^"C>N^+/VK8;
M_P .>!?C=X'E^*5IJ7P8^'N@VGQ&LD^$_AN[L+JX\11ZI]H^'=GX<T>2VTEU
MT7SK;4(K%M9OWANYI$'I'_!67]I+]G7XT?\ !/GX_:%\'?CY\%?BQK>FK\/-
M3U'1_AI\4_ WCO5;#37^(7AZ!-0O=/\ "VNZK=VMD\Y\E;J>&.!I?W8D+<5]
MB?LP_LO_ ! ^$O[2G[=?Q5\</X1OO!G[2?Q-\)>*_ UEIFH7FIZDNAZ+\/?#
M_A748/%6FWNCV5G8W,M_IEUY5K:WFK036;1R231N[0IC_MZ?L50?';]E#XH_
M!W]GWP/\)/!'Q!\;GPG%::E/HVG>"M,FM-#\5Z5K=U;ZEJ_AKPW?Z@(A;6<Y
MMH18W$;7!16$:NT@P>-PE3.<!B*LXJ-'^QK5:$</1H4_8T,+]8]LH4H\RISC
M..C7(H<BM&,8K58/%PR?&T*<)<U;^UG*E6E7K5YNK6Q'U=474JR4?:0<):I\
M[ESM<\I2?'_#W]H+XM:G_P % )OV6X=<T:Q^%MC^Q!X;^)VD0KX:L+C7;#QW
M=:SX9T./5I-:D=;B]T^WM=0G8:+,JVDLH5G88K\TO@=XR^-7[,/[0'_!6K]H
MCQ[^TG=>,_"GP ^(GA3Q%\3O"R?!/P#H\GQ>,?PI\+_\([;?V]:ZC)>_#VUT
MB"]TS0I?[!CN;>[M[277;_9=O+$?U=\"?LJ?$_PW_P %!)_VGM0NO"3?#:3]
MD?0/@>MM;:MJ$GBK_A--+\1>'-4N9CI4FC16 T$VNE70BOQJYNGE,*-IR*[.
MGE%I_P $\?%GC;7?^"GF@?%'7-!TOX=_MO>(_#USX*U+PO?W6J^(M$TK2O '
MAKP\]WX@TJ_TK3;*UO8-=T1IX["UU'48+NQ"B2Z@>9HX[H8K+Z/MH2>'5"OE
MN6PQ"5&E.I.HL?A98M0<J<IJM[!59RY&GS1C4^.G"49KX;'U71E&.(=:AF&8
M5,.W6JPIP@\#7CA7-1J1@Z+KNG!*:<>64H/]W.<9?)GA_P#X*'?%'X;:M^S)
M\3?'O[='[)O[06F_';XF_#[P'\4OV4_A3J7P=D\5_!N7XTZG8Z+X?7P'XG\*
M^)M3\;>/X?AAKFN6-KXIGU_2;"34-(TN_OCMN65'_?#X@W?BFV\#^);WP-=^
M%;'Q1#I$]QHVH^-[R\T_PGITB!7FU/7+JQL[ZZBL=.LQ<7S!;9HY9((X;F2W
MMY);B+\W?@5\$_VK_#5W\./ 7CW]G/\ 8?\ #>D^ +[1[/6_VD/"4TWB'Q=X
M\T+PE- D=_I?P/;X5>#XOA[XG\<V%D@EOA\:?%UOX&U+4&U"&V\6)IXL[[ZM
M_;9^!'BW]IC]EOXO?!'P)XS;P#XL\<:!9VNB>(3]J6S-SI6N:5KS:%JSV$UO
M?0Z)XI@TN7PSK%S92FXM--U:YNDM[WR38W/%CY8*IB\'""PU"'M>6M6I>PJT
M?82K1]G4G2PE.G#]U3<[QD_K,X**KJ,[.7;@%C*>%Q<YO$UY^S4J-"M[>G6]
MO&A^\IQJXJ=2?[RIRI2BOJT)N3HN4&U'\UO!/[:OQ ^'7[6O[-_PAO/VX/@%
M^W)X1_:*U;QIX-\4:#\+K+X.Z%XG^!WBC0[?2K_0M34?#CQ-KFIZYX>U*6_U
M+1[EO$5K97, T9)55KJ>X$7>>#_B?^W=^TY^T)^V_P#"#X:?&_X<_ KP-^SA
M\4?#WAOP+XW_ .%6Z1\0_&&KWVN^ ['75\&:_P"&]?%MH*>%8);U=5D\7VNI
M2>*#> Z6FFFP G;CO#_[%?[4OB[XR_L4_$3Q/\%?V2_V>_"W[+GB*!_$_AWX
M5>+-4\=>*/'EJOAO2-'F\20>-&^$OPS:R19=.;[/X*O]&U5AE[JX\87,LWEQ
M?<'[*W[.GQ!^#/QW_;B^)'B^X\-3>'?VB?C/X3\?_#^/1-2O;W4[?0M%^'NE
M>%[V/Q);7.EV$&FZB=3LIF@M[*ZU2%[0QRM=1R,85Z\55P%&%2I26!GB5@(I
M+V6#JP^M+,X)25*C3^IRJ?4;WY*<HNG=S<JBE(X\-2Q]:=.G5ECH89XV4F_:
M8NE/ZN\M;Y75K5'C(T_KFW/4C)5-(J,'&)\3Z/\ \%(_B_K?["7P7^(4.@>#
M[3]J'XT?&ZT_95TUIWE/@;1OB:+C5EU_QU-9"W,MUI>C^'M#U37[71H(9K2[
MUA;#29I4LKF62+SSXN^#/VI? /\ P4&_X)GZ%\??C/X1^/WAVX\2?'34O#/C
M^Q^'VF?"OQC8>()/#?P^MO$'AC4_!WAK[9X8G\,V]O;:9J>B:]'JTNN7-[JF
MJZ?J%C!::;87-UZ!H'_!-GXVV7[&?A[X7-XG^'VB_'WX2?M3ZQ^T]\)]2CN-
M4U_P->ZI'J=]_9_ASQ%?2:7H^J:=;^(/#NL:SH^IWMGINH'1I[N"]AMM5%OY
M#^F:K^S]^W)\>_VH_P!D?]HCXV:1\ _A3X2_9WU?Q_'J7PB\!>.O%/Q,U.[D
M\7Z-X7@N?'-I\2]5\!^ $OCJ5QI;:9#X E\$6"^'[?1X]5;QIKLNNR6&D;1J
MY?1JXB6%G@847_;,:CFH.M^]PM6&!CA924JRI24^2/LI*GS.HL0]:5\I4\?6
MI4(XF&-J5E_8\J:@YJC:CBJ4\;/$QC)475BX<\G5C[1I0=!655K]=:***^1/
MK HHHH **** "BBB@ HHHH *^</VJOV:O!'[5GP<\1_"GQI D9OHFO?#>NI"
MDE]X9\26T4G]FZQ8LV"&AE8+/%N"3PDAU9DC*_1]%.,G&2E%M23NFMTT<V,P
M>&S#"XC!8RC#$87%4IT,11J*\*E*I%QE&2\T]&FG%V<6FDS\ ?\ @G'^T]XP
M_9R^)NN?\$^_VIK[^QM<\,:O-IGPF\2:K*ZV%XL\OF67AR'4;G:'TC6876^\
M'W,[H&AN[/28HE=D5/W^K\X/^"A/[!7A[]KOP2GB'PP;;PS\>/!-J]UX$\6Q
MEK0ZF;4FZC\,ZW=P%9X[.[F0+8ZG&6N=&O&BO(TN(H3:OX)_P3@_;SU_Q?J-
MW^R9^U +CPQ^T-\/I)M#TK4->Q9S^.K32AY36-XL@1!XHLH(Q,L\+-:Z]:"6
M:W2UN+7R;OJJ1C7BZ]-6FDO;TUT>WM(KK%]5NGKW9^>Y%CL5PCF%#A#/*LZN
M78B4H<)YW6DW&O16L<DQU1Z0Q^%@U#"RDXQQ-%0A"TU"$OV:HHHKD/TL****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M ,^RC^Q_^"H__11/^">7_AG?VFO_ )]E>,_\-$?\%(/^B3?L'?\ AX/VB_\
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M/BG^T%X.^'WQ%T+Q;!\'+#6(WN=4U[3M8^#5G%XI^(NGP)XQ\0Q:=9ZEX?\
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M4ZL4IRI^U5*<Y04(5W2_>>PG*-;D][V?+J?9E(S*JEF8*J@EF8@*H')))P
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M<I^ZW&*E./ZF45^:^N_\%&[>ZO\ XF:E\%OV7?V@/VB/A)\'=4O=$^(OQO\
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MUNTETS6]+TO6],G)$VFZSIUEJVGR[@5/F6.H07-JYVLPRT1(!(!YKX=\?_\
M!+W_ ()X_$_5;K6O'G[(/P=\0ZG=W3WMS=/INMZ69;J155Y3!H>N:7:H2J*-
MD4$<0QP@))/WA_'_ ,"_K0_WC^'\A751Q.)PSE+#8G$8>3<4Y4*U6BVO=>KI
MRBS*KA<-B5!8C#T,0E%V5>C3JI?#LJD96^1^::_\$;/^"694D_L/_!K(SCY_
M''I_V.--'_!&S_@EGAC_ ,,0?!OM_'XY]?\ L<:_3!?N-^/\A31]UO\ @/\
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M5AUBJ5:@Y.'M(*TTKN$HRC.$K-I24913<6TI)--I,_#3XG?M'^"?VK_V\_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[C?7_"F]A]3_ "6G#[C?7_"F]A]3_):#/HO5_E$2IOX_^ _UJ&IOX_\ @/\
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MXCB,_@+Q;)%H'BF"XDP1:V<%W(MCK\B@JSR>';W58E# ,ZD$#[2K\D/VD?\
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M!>W\MK8B62.Q@MHF*5\M_L>_\EB_X*4?]GTQ?^LC?LL5]XU\'?L>_P#)8O\
M@I1_V?3%_P"LC?LL5])P#C<9F.;<1XW'XK$8W%U\FC*MB<55G7KU9+-\IBG.
MK4E*<N6*C&*;M&,8QBE%)+'.L%A,OI9#@\#AJ&#PM#&8B-'#X:E"C1IIY?C)
M-0ITXQBN:3<I-*\I-RDW)MO[IHHHK]%.(;_'_P !_K2'[Z_3_&E_C_X#_6D/
MWU^G^- "+]QOQ_D*5.A^O]!2+]QOQ_D*5.A^O]!01+:7JORB ^^WT_PH;J?]
MP_SH'WV^G^%#=3_N'^=!8J?='X_S-"?='X_S-"?='X_S-"?='X_S-7TAZO\
M-&<OM_\ ;I'_ !_\"_K0_P!X_A_(4?Q_\"_K0_WC^'\A5OK_ (H_^VE+[/\
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MU=S=<:>G?\$*O!M_?C5?B%^TK\3?%]W(1]IB_LC3K02JLQ8?Z?\ V@UV6DA
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;^T.O;[-V_[_ /TIW_"(?]/_ /Y+?_;Z[2BCGEW_  7^0<J[=+;O9'&GPED
M?;^G?[-]?^FU)_PB/3_3^G_3M[D_\]O>NSHHYY=_P7^0<JVM^+\O\D<<?"><
M?Z=T.?\ CWZ_^1J7_A%/^G[_ ,E__MU=A11S2[_D/E7;O^.YR \*X!'V[K_T
M[_\ VZC_ (17@C[=U_Z=_P#[=]*Z^BCGEW_!?Y"Y5IIL[K5[_P!(Y%?"VW/^
MFYS_ -,/_MU._P"$8_Z?/_('_P!MKK**.>7?\%_D')'M^+_S.3_X1C_I\_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y'X@?\B'XV_[%'Q)
M_P"F:]KKJY3QXC2>!O&<:#+R>$_$2(/5GT>\51^)(%73_B0_QQ_]*1%36G-?
MW)?DSX"_X)U?\H_/V'/^S1_V>/\ U5/A:OLBOC;_ ()UL!^P+^Q;:$_O])_9
M>^!VAWR?\\M2T3X<^'M,U&#/?R;RVFCR<'Y>54\5]DU_/.>_\CS.?^QKF/\
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M_P!AV(_]5V+/T3HHHK]./)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
4 !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img22994243_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img22994243_7.jpg
M_]C_X  02D9)1@ ! @$ > !X  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" )I ]\# 2(  A$! Q$!_\0
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MOZ/_ ,_T?_?$W_QNC^W]'_Y_H_\ OB;_ .-T ;%%8_\ ;^C_ //]'_WQ-_\
M&Z/[?T?_ )_H_P#OB;_XW0!L45C_ -OZ/_S_ $?_ 'Q-_P#&Z/[?T?\ Y_H_
M^^)O_C= &Q16/_;^C_\ /]'_ -\3?_&Z/[?T?_G^C_[XF_\ C= &Q16/_;^C
M_P#/]'_WQ-_\;H_M_1_^?Z/_ +XF_P#C= &Q16/_ &_H_P#S_1_]\3?_ !NC
M^W]'_P"?Z/\ [XF_^-T ;%%8_P#;^C_\_P!'_P!\3?\ QNC^W]'_ .?Z/_OB
M;_XW0!L45C_V_H__ #_1_P#?$W_QNC^W]'_Y_H_^^)O_ (W0!L45C_V_H_\
MS_1_]\3?_&Z/[?T?_G^C_P"^)O\ XW0!L45%!/%<Q)/ XDBD&Y' (##)&0&
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M(O%?BG5+K6_$.O:K<RWFHZKJE[(9+F[N[F9GEE<G$<>YB(H4BAC"QQHB_?\
M!W"E/-D\QS",G@:=1TZ-!-Q>*J0MSN4E:2H0;Y6X-2G44HJ24)7^#XNXIJ94
MUE^7M+'3@IUJS2E]5IRU@HQ=XNM47O+G34(-2Y6YQ:^\OVFO^"K'[>7[5^JW
MUU\2_P!H+QII.@W-S<26G@OX>:G<?#_PS8V$S!HM*N+3PD^C#7;:W VI-K27
M<\G+2,S$FOA&Y\8^,+VZ>^O/%OB>[O99!-+>76O:I<7<DP;>)9+B6Z>9Y0P#
M"1G+AOFSGFN<) !)(  R2>  .I)[ 5Z]8?L^?'W5?AS=?&+2_@=\7M2^$-C;
M2WE[\5;#X=>++OX<V=G!+%!-=W7C2#2I/#T%M#/<00RSRWZQQRS11LP:1 ?U
MZEA\#@:<*5&CAL)2O&G"$(4J,7)_#%)*/-.36F\I/75GY+5Q&-QM2=2K5Q.*
MJ6<YRE.I5DHK>3=Y.,8]7I&*[(]@^!W[?/[8_P"SGK5OK?PG_:$^)&CO!<"Y
M.CZUXBU'Q9X7GD+AY6G\+^)+G4M"DDG&]9)FL3*=[-NW<U_6]_P3*_X+^>"_
MVD]>T7X)?M8:?H'PH^+6J?9=/\*>/;":2#P)X]U0A(?L.I-.WE^&_$6H/NN(
MD:+3M!D=EL;.0W,MO _\,E*KO&\<L4DL,T,L<\$\$CPSP3PNLL%Q!-$R2P7$
M$JK+!/$Z2PRHLD;JZJP\O-^&\JSBE.-?#TZ6(<6J>+H0C"O3ET;<4E5BK:TZ
MG,K-\KC)\R]/*.(LSRBK"5'$5*N'NO:82M.4Z$XWU45)MTIVVG3Y7>W,I)<I
M_KS@@@,K*ZLJNCHP='1U#)(CJ2KQNI#HZDJZ$,I*D&BOY[?^"!'_  45UK]J
MKX*ZQ\ OC#XABU;XT? ZVLHM&U:\E":KXS^&CI#;Z5J%_N*I>ZQHURT^D2M:
MHLC:5IEO>7R27#S74O\ 0E7X+F>78C*L=B,#B4O:4)VYE?EJ0:YJ=6%]>6I!
MJ2OJKV>J9^ZY;F%#-,%0QV&;]G7C?E=N:G-/EG3G9M<T))Q=M':ZT:"BBBN
M[@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#U'0?\ D$6/_7)O_1CUKUD:
M#_R"+'_KDW_HQZUZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MEZ7^SPOA5])%Y=ZS#>^'-1^!WQ%1M'TO1[7^T[CQ!)K]K"$,L3648A,K@'Z
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M"L@:,%BI)SIT.>G*I*3BDIM6@Y)J"3=Y)I1NVE&]VWTMJ>KG7&2RO.\)DE#
M4L96KU<KI595,QI8.I"6;8F=##_5<*Z&(KXU4H4JN(Q4X*E2H4U!.I*4Y*'[
MIZS\=/AUH/QA\+_ ?4+_ %8_$KQAH-WXFT72[31+N[TTZ+9,B7%WJ&L1'[+I
MY#. D=P TF&*GY37KX!)P.2:_GS;X!_L\?&C_@I5\=?#_P 0OB1XE\.7>DZS
MHEYX6T&V\>'1O$'BGQU>FX:_TG0HFTZXDN-#LXK;3#<Z3;F(1?:@S7+>>H3[
M?_X*G^+W\,?LQV/AFT\1?\(HWCWX@>$?!ESK?VJ2T_LW19X[Z:]OYIX72<16
MILK>:4HZ%F4%G )#.5"//1IQE+FJ1@Y.4;).:4KQU]Y)/;1W6]W9<^#XNQO]
ME\5YSC\'@OJF28_,,/E]/"8]3K8F&!J3PSHXOGI)86K/$4U*-65XRIUXM45&
MC[2M^F"QL60'@.P4'@\D@9QGMFOF/X&_M*Z5\<O'OQN\%Z1X4OM$L?@EXO'@
MS4O%%YK%G>V.NZFB227+VMG!:0RZ<EJ(IA(ES<3L?*8[A7Y)_ :#P)\/OVO9
MM4^ GQZ\5?&OPOX=^ GBKQ3\>O'M_P"*&\2^%]<U2"TL6M[?05BM[:TTHIJ,
MB.U@7N;B#RQ$;E]K%N&^ WP,_:,U/]G'XI?M5^"/VO/%7P%\'^/-6^)'Q$U;
MP%I/@V/47\0?8;W5UM[JZU2?5(2K:S&4@@D%N1;PW@;;*4R;^K02?-42YE24
M)2C--2G)NSA'FE?EB[76TDVD['DRX\S+$XC+W@LGJU50KYY4S7"9?F&58R-?
M 99A<)&.(HYCBZF"PGL:>+Q]%5I4*JG[7#U:-*6(IJ4G^T7[.'[3&E_M(3?%
MEM"\(:EX=TOX6?$34?AW_:]]JUIJ4'BF]TM<W.IZ=%;6ELUG9B021+',]PY*
M9\SG%<!^T7^UG\2?@?XUL_"G@[]D#XW?'G3+C0H=8NO&/P_0QZ!I]S+=7-NV
MCS2-H6IJ]Y#%!'=2,)U BN(P4!!)XG_@EQX.N_#/[(?@W7-7MY8_$7Q%U;Q%
MXVU^YN4VWFIW6H:WJ2VNI7;  /+>6'V>?<%5<. !CDYG[<OQK\:ZGJW@_P#8
MY^ VHR0_&3XW;H_$6L63-(WP^^&Q=H->U^[CB96!GLDU%'5I;9K>&%;A9&W;
M1"A#ZQ*"C&4(MQ=Y244HJTIMQ:E96<K7WT71'JU,VS/_ %'R_-\5F6(P6:XS
M#X3$TI8/!8"OB\3B,PGSX'*L/A,51GAG6K*OA\*Y.FW#EG6G)*,ZB]8_8X_:
M^'[7WA_QGXEM/A-XD^&.F^#];_X1QG\0:[8ZW_:FLP8.IV$+66FZ>+6YTM9(
M#=0R^8X,R@A"#GW?XT?&3P-\!?AUK_Q-^(6IKIV@:'$JQQ*0U_K&J3A_L&AZ
M1;\R7FJZBT<BVMK"LDKB.1E1@A%</\,].^!W[,'AOX8_L\V7BWPUX;US4+,6
MGAC0=4U".+Q)XZUDE7U;4[>$1A]2O+J\F)>8[2(?L\9)V!C^87[8/Q ^/.C_
M +2>M>/?&'[*OQ-^,7P)^"FC7MQ\.KBQ;_A'OA]I.ORQ/%>_$+7I[C3]8AU]
M[%5M?L;;;*.WS./G,V4(THU:S4(\E/648N5G**:C:,IO5R>EVWRMO1VL7C<]
MS#A_AG#2S'%PS+/;TL)CL7A\%/$X?+\96IRQ-6OC<)E-"52&'P.'=U&-"G+$
M\M'FE1CB'6A^A7[(/[67_#6?A[QGXCB^%/B3X76W@_Q!%X=-OXDUFSU:XU2]
MQ=_;1$MIIUA]CDTY[9([JWF$DBO<1@E2"#]?U^77_!)9?%B?LT7<GBCP-K/A
M@:QXSUKQ;I/B76)@_P#PGEEXHGDO?[5TZ#[/"8M/LQ'''!,9;@72W0<&,)@_
MJ+6=>,85IQBK1C+E2NY;))ZMMZN[L]5>W0]KA'&XS,N&LFQ^85IXC&8O!QKU
MZM3#1PDY3J2G))X>%*A""A%QIQE"G&-2,55BYJ:G(HHHK(^C/4=!_P"018_]
M<F_]&/6O61H/_((L?^N3?^C'K7H **** "BBB@ HHHH **** "BOECXB_MB?
M!;X5_&3X??!;QKJ]YI.M?$J'4D\/^(Y+>,^#XM5TZX2V;1-4UTSK!8:E<3EK
M>&"4%C<^7 5!=FC^I^O2J<9146TTI*\6UHU>UT^NIRX?'8/%U,51PV)HUZN"
MK1H8NG3G&4\/6E3A6C"K%.\'*E4A.+:M*+O%NSL452U+4;#1]/OM6U6\MM.T
MS3+2XO\ 4+^\F2WM+*RM(GGNKJYGD*QPP00QO++([!4169B *^<OV?/VM/A!
M^TRWC)OAAJ5_>6?A#Q5?^%!J&I68L+/Q%=:;:6=U>7OAN1YF.JV$/VL(T\*X
M"IYA 5B$%&34I)-QC;F=M%?17"KCL'0Q.&P=;$T:>*QGM7A</.I%5JZHI2JN
MG"_-*--2CS22LG**;O))_35%%%2=04444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %1RRK#%+,YPD4;RN3P
M L:EF)/; !J2J&JV3:EIFI:<EPUJ]_87EDMTB+(]LUU;R0+<)&Q57:$R"149
M@K%0I(!S0!_%N?CM^S]\6+G_ (*?>&O!OA&7QK_P48_;1_:@U?X&?"?X:ZEX
M6U*YU/6_@=X!\>17'@CQEI'BN?3Y=#M/ <7A2WU37M0O?MUO-:ZC8:.#;NTD
M;Q_HWX0_8KO?VJO^"@/[1_\ PD?[1'[7OP7MOV-_@=^S=^S7X+\9_LZ_&;6_
M@]=>,+7Q3\/=#\9?$"+4]330;_\ X2;3V\6^%K:[NI$:,)J,-O+,JRJ /VX_
M95^ -E^R_P# 'X:? VS\3WGC>3P%X=M=)U+QKJ.F6NBZAXNU=%SJ/B*]TFRG
MNK33[G4YR9Y;6WN9XH2=JRN!D_0E 'XE?\$4OA-/X2\'_M??%>X\9?&7Q^?B
M]^UC\1M#LO%G[0'BF_\ '7Q7UG1_V?\ 5=1^!6DWWB+QIJ>FZ+>^(;:[M?!@
MN=$N)-)LXK?29K6UMC<PQ)<2=-^VWJ'B/]M3]HWP%_P3B\ G5[#X5Z.OAOXT
M_MP>.X8+JVTI/AAI>L?VCX6^ NG7#I#!KVJ_%S5-(M]%\>:0EQ'!I_P[\1-J
M327LIETX?L?10!\:3_M'>'K?XJ_%']C3X%^"]4F^-OP9_9U\+_$[PS;^(='N
MO#GP.BT[Q'=>)?"'P[\)2^.[-=4NK:[BU/P?)#JVGV/AV]DTG1'L[M/M+2^0
MO\\FG?"__@I[X1_:=_8=^$'Q9_95_9@U?Q[XW^/7C?\ :T^-_P 7_!/[5'CO
M6+?XG>(OA!)X59==\66&J?LZ:5_P@5OX?TCQ%96G@#P?!J/B>SUF^BUGR;K2
MV6X\W^N:B@!%+%5+@*Q4%E!W -CD!B%) .0#M&1S@=*6BB@ HHHH _C)_P"#
MI[]DO47U'X+?ME^&M)>;3;;2Q\(/B3<VD+"+3$74[[5/"NLZD4CV-+JE_K2Z
M)%,7+XLXD<!0I;^.6O\ 7H_:%^ 7PT_:?^#WCCX'?%W08?$/@7Q[H]QI6JVD
M@47%I*REK'5],G*LUEK&D78BO]+OHL36E[!%/$RN@(_S-/\ @I!_P35^-O\
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M_P"$1@_Y_9_^_<5=?10!R'_"(P?\_L__ '[BH_X1&#_G]G_[]Q5U]% '(?\
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MV>_A/\?;3PQ:_$_PO;Z\_@WQ)I7BKPW?++)9ZEI>J:5>P7J?9K^W*W$5M=F
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M]G^ZU>]^#'PK\*_#JZUZUM[+5YO#EM/;&^M+63S;:WF66XF010R?-&L:H%P
M. !7N]%%<56K5KS=2M5J5JDK)U*LY5)M)62<IMR=DDE=Z)66AW4J-*A!4J%*
MG1IQORTZ4(TX1N[NT()15VVW9:MW"BBBLS0**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;;[3K-KS54U:UNKK3QX>U*'4+;=IOAW5;5'O-%\56*Q6-WJ)TR%-3,=VJ/\
MJC^S?^T3\._VG_A;H/Q1^'.J17>GZE D6KZ4\B_VGX;UN- +[1=6MLB6WN;:
M8.(7=%CO+;RKRV:2WFCD;6="I"$:DE[LFT][Q:Z35O=;6J3Z'SF6\5Y+FN:X
MS)\)B>;&82E2Q,&^7V&/PM6*OBLNK1G*&+H4JC=&M.G_  ZL91:LKGO-%%%9
M'TA_*#_P6B_:H\8>(_C_ &?[/-MJ-W#\*? &GZ/K&O\ A^WD:WC\3>)[Y[O[
M2VK1JPCOK;3(;>!=,2X\Q(FN;MD6-I7W?C#XR\1Z/K<5G#I=@;=K=BSW#Q11
M/LVX$*"(G*="V< %5P#7ZH_\%LO#/P\L/VLH=?\ !?BNSUOQ1KWA:PM_B#X4
MT_?=/X5U73I+@V=Q=W4:/#]MUJ*ZD,^FK.]S8"Q5I[:W6YB,GXW>=#U\V/'K
MYB_XU_1O"4\(^'LN6#4(P]A#VZBDI?6K1]NZFS<W43?,_B@XN-X.!_,G%5:>
M)XCS6=7$1Q$Z&,JT(RIUE5A2A"RA0]V3C!TH.,94W:4)74TI7'D \$9'^>A[
M'T/45_41_P $+?VO?&WQ0T3XB_LT?$+6-4\47OPHTNS\5>!M=U.?[7<V7@:]
MOK72CX<N[V=WO;O^SM5NRNE"5C%8:5'%80;888HX_P"5[4=<L[%,+*DURY6.
M&&,[S)*Y"QH-N=SNY"K&NZ1V(15+'%?U1?\ !"W]C+Q[\(/#WCK]I;XFZ;J'
MAK6?B[H5EX;\'^&[^(073>"(-1MM9&MZC:R[;NSGOM4M2=/AFCC\W37CGV .
MA;S./)8%Y#76)=-UN>F\%>WM/K'/"_LW\7\)S]HEIR7YM+'L\ ?7O]8</]4]
MI[!0J_7^6_LOJSIRM[7[-_:^S]G?WN=+EZG]"%%%%?@I_004444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 451U35--T33K[5]8OK33-+TVUGO=0U"^GCM;.
MRM+:-I9[FYN)F2*&&&-6>21V"JH))K\-_P!KO_@I)\3/"E]\,_C9^S!<^&_B
M3^S)X=\37OA_XM7NF6;W&K7'B*WO9K&[\-:Y'J-NEWX?L)[+[-?>&M?MTM+#
M4KV\MD34)HVVUI3I3JRY8)>KTC?HK[7EM%=6>#G_ !'EG#F%>*S&I4:24_88
M:*K8KZNJM*E7Q2PZE&I+#83VL*F)JQ35*&KO)QB_W6HKQ7]G[X^?#S]I+X8Z
M!\4OAMJ\.IZ+K$"K>6N\"_T/5HXT:]T75K8XDM;ZT9P=DB+YT#PW$8,4R$^U
M5#3BW&2::=FGNF>OAL3A\9AZ.*PM:GB,-B*<*U"O2DITZM*I%2A.$E=.,DTT
M_D]0HI"0H+,0% )))   &223P !R2> *_##]IK_@I1\2]5_:C\$?L\_L;V^B
M^+IO"WB-I?BCKU]%:W'AO5;>P6:/7=)?5KA##I7AW0+?[5=:MXCCFM8Y=0M+
M&VTR^N([H"6Z5*=63C&VB;;D[1BEU;Z7>B\_*[/)S_B++>',-1Q.8SJMXK$T
M<)A,+AJ?M\9BZ]:<8*&'PZ:E5<%+VE2S]V"ZSE",OW0HKPSX&?M#_"G]H'0]
M1U+X:^-_#_BZY\.:C=:!XHBT26X5;#6],F:SU!K>WOHX+V71Y[N*5])U/RFM
M=0LVAN+>>5)%8^YU#3BVI)IK=-6:^1ZV&Q.'QE"GB<)7I8G#UH\U.M0J0JTI
MK9N-2G*4)6::=F[--/5,^%?VOOV7_'/[0?Q*_8\\9>$==\*Z1IO[//Q[TKXJ
M>,+;Q%+JT=[K&@V$NEO+8>'%TW3;Z"35G%C*(TU*:PLR73=<KEBKOV ?V7_'
M/[*'PK^(7@7Q]KOA77]4\7?'/XB_$_3[KPC+JTMA;Z'XP.CG3K&\;6-.TRX&
MJ6_]G3?;$AAEM%WQ^3<RY;;]T45;JS=-4M.1;::_$Y;^LG^"/)AP[ED,[GQ!
M&%;^TJGM%*?MI^R?M<)@\%/]S\'\# X=+M)2EO)A11169[H4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 455O;VUTZUFO+R9(+>!"\DCD  #H!G[SL<*BCEF(4 DU\^>*/
MB/J6JR2VNDLVGZ=RGF+C[5<C."S.01'&PZ*JJXY^8\&KA"4WILMV]O\ AS@Q
MV8X?+X)UFY3E\%*%G.7GJTHQ3T<I:=%=Z'NU_K^C:9Q>ZE9P/G'E-/&9?QB#
M%P/<J!7/3?$7PC </J9;DC]W:W4HX]3'$P&>WK7S [-(V^1FD?GYI&:1N>3\
MSECW]:3 '0 5NJ$>K;^Y?YGS53B7%-OV5"A"/3G]I4?3?EE37?:UO,^FO^%F
M^#O^@C-_X 7W_P 8H_X6;X._Z",W_@!??_&*^9:*?L8?WOO_ .!_5WY6Q_UC
MS'^3"?\ @JK_ /+_ .KORM]-?\+-\'?]!&;_ , +[_XQ72:)X@TOQ#!-<Z5.
MT\,$OD2,\,T!638LF LR(Q&UE.X CG&<@U\@U[I\(95^R:M;Y^;[4D^/9HHT
MST]5/?\ #TBI2C&+DKW5MWW:7;_+?Y'H99G>+Q>,IX>O'#JG.,]:<)QES1@Y
M1LY59JVCOIZ=#V2BBBN<^J"J.IZ;8:SIU_I&J6L-]IFJ6=SI^H65PNZ"[LKR
M%[>YMY5R"8YH9'C8 @X8X(.#5ZB@32DG&23BTTTTFFFK--/1IK1IZ-'\MO[6
M'[,WC7_@F_\ %;5/C3\)="D\:_LH?$R670_B1\.;^,ZAHMCI&KRYN_"FOP./
M+M;2-CN\&>)Y/)N-.OH-(LYM3>Z)67QWX:?%+6_V$O'WAW]IS]G2_P!1\=_L
M>?%K4(K3Q5X4FFDFN/"5_-AM2\"^*8,JVE^+/#1\T^&-:FCMO[;L;723)+J5
MK>'[1_6=XR\'>&OB!X7USP9XPTBSU[PUXCT^XTO6-*OXEFMKNTN4*.C*X.UT
M.)(95Q)#,B2QLKHI'\U/BK]B;XS_ +*7[2 ^$WP^\":S\;_V4_VDK]M U3PD
MZRR6NDZ=<-Y\\M[J BDMO#OB'P-&KZUH?B!ECC:WTFR748[^V^T12^G0KQJQ
M<*MG-1M+F=E6IK?F;VJ02O&3:;[K=?S]Q9P9C.'<?ALRX?6)IY;/'1JX"6#I
MSKXGAC-L5445*C1A&=2OD.8U)*CC<%&,U1<U.G3E_"K?T8?"#XN>!?CG\//#
MGQ-^'6M6VN>&/$MBEU:SP2*TUI.!MNM-U"'/F6NH6,X:&X@E56RJRQ[X)8I'
M_/W_ (*0?\%!=,_97\*CX>_#JXMM:^/OC.S,.@Z;!&M\?"5G>E[:+Q!J-L Z
M&[,GF'2+&9)/M,\#-)!)&%5_RB_9T\<?%']@K]K+]JS]FCP5XJ3Q+X'\$?"'
MXQ?$;3],UN*:XT^'Q#X+^$1^)/A:>&)98&BN(C<V.BZY)#Y,&I0V,DT$%HTY
M->;?LX^ ?BS\0/@[\:/^"C9T*\^/7QOTSQUJ?AGPIH=_ ^I_\(KK-M8:9J.J
M?$671Q&ZZTOAJVU?2SX?T6V6"UMI+2YFO8+X3MLF&%IQGSRDI4O<=--V<W4U
M@I-Z)+KW73H=^/\ $3-LSRBGE. PE;+^(Y/-L+GN)HP>(AE5/(E2CF^*R^G2
ME*KBJ\_:P6"I0UA.?O5/<51^:75M=?LRZ;<WWB6S3XH_MV?'R)XXM#UNQB\7
M3?![2O%+9%QJNEW\5_;ZG\3]=) ATS4[>]DT&VT\R7&GVPNX6?\ 2;]FS_@A
MI\)=4^%.F:U^TQ_;K?%'Q')!K-[I/AK51I]GX2LY4:5/#[F%9(;R^/G :I.A
M>W$L$:V1B0R*?9_^":O_  3[UCP3>3?M2_M,6]SKWQS\92-K&A:5XA!NKSP?
M#?D3RZEJ2W +CQ)> PHL3QQG28H-B+YDW[K]LJZ%FV,P4Y+ 8NMAY2M[6I0J
M2@JEDE&"BGRNG#6UT[O6[>KZ^ N!(.A3S?/,).E1J49PRG),1*4GA\/7:G5S
M#-MOK.;X]J-6K*I=8>')3A&"A2IX?\Y_@;_P2I_8G^ VO1>*_#?PDT_Q#XGM
M68V6L>-+N]\2+:*Q)"Q:3?W$FANZ'#1SW&FS3QLJM'(C#-?HI###;PQ6]O%'
M!!!&D,$$*+%###$H2.**- J1QQHJHB(H5% 50  *DHK@Q6-Q>.J>UQF)KXFH
ME92KU9U'%=H\S:C'RBDKZV/U["8'!X"FZ6"PM#"TV^9PH4H4E*7\TN5+FEYR
MN_,****Y3J*E]>V^FV=S?W;F.VM(7GG=49RL<8RQ"(&9B!V4$GL*XS_A9O@[
M_H(S?^ %]_\ &*T?'4JQ>%-:W''FV<D*^[2# 'XXYKY4K:E3C--N^]M/*S/G
M<XS;$X"O2I4%1<94N>7M(3DU+GDM.6I"RLET>[U[?37_  LWP=_T$9O_   O
MO_C%'_"S?!W_ $$9O_ "^_\ C%?,M%:^QA_>^_\ X']7?E;Q_P#6/,?Y,)_X
M*J__ "_^KORM]-?\+-\'?]!&;_P OO\ XQ1_PLWP=_T$9O\ P OO_C%?,M%'
ML8?WOO\ ^!_5WY6/]8\Q_DPG_@JK_P#+_P"KORM]3VGC[PI>,%BU1$);;FXB
MFMAGUS.B#'OTX/I7712QS1I+#(DL4BADDC971U/1E=258'L02*^.=-TF_P!9
MN5M-.M)+N8E0VQ28XE8X#SR8(BC!!R[<#!-?4/@_1+K0-#@T^\N/M$XDDF?!
M+)#Y@7%O&Q)RD>TX(X)8D5C4IQA:TM>SWMWTM^/WGN91F6,Q\IJMAXJE&+:K
MTU*,'--+DM.4KMW;]UOEMKN=111161[P4444 %%%% &-JWB#2-#5&U.]BMS)
MDI'R\K =66) TA4=V"XR>M<U_P +-\'?]!&;_P  +[_XQ6%\2_"EYJ:PZSIT
M3W,UI$T=S;("TCP@AEDA49):/#;T4;F!!R IKP(@@D$8(X(/4'T-;TZ<)1NV
MV^J6EO+:_P#6A\MF><9A@L5*E&C0C2T=*=2%2?M(V7O*2J05T[QDDO=>CZ-_
M37_"S?!W_01F_P# "^_^,4?\+-\'?]!&;_P OO\ XQ7S+16GL8?WOO\ ^!_5
MWY6\[_6/,?Y,)_X*J_\ R_\ J[\K?37_  LWP=_T$9O_   OO_C%'_"S?!W_
M $$9O_ "^_\ C%?,M%'L8?WOO_X']7?E8_UCS'^3"?\ @JK_ /+_ .KORM]-
M?\+-\'?]!&;_ , +[_XQ1_PLWP=_T$9O_ "^_P#C%?,M%'L8?WOO_P"!_5WY
M6/\ 6/,?Y,)_X*J__+_ZN_*WTU_PLWP=_P!!&;_P OO_ (Q1_P +-\'?]!&;
M_P  +[_XQ7S+11[&'][[_P#@?U=^5C_6/,?Y,)_X*J__ "_^KORM]-?\+-\'
M?]!&;_P OO\ XQ1_PLWP=_T$9O\ P OO_C%?,M%'L8?WOO\ ^!_5WY6/]8\Q
M_DPG_@JK_P#+_P"KORM]-?\ "S?!W_01F_\  "^_^,4?\+-\'?\ 01F_\ +[
M_P",5\RT4>QA_>^__@?U=^5C_6/,?Y,)_P""JO\ \O\ ZN_*WTU_PLWP=_T$
M9O\ P OO_C%'_"S?!W_01F_\ +[_ .,5\RT4>QA_>^__ (']7?E8_P!8\Q_D
MPG_@JK_\O_J[\K?37_"S?!W_ $$9O_ "^_\ C%3VWQ$\*7=S;VD%_,\]U-';
MPJ;&\4-+*P1 6:$*H+$ LQ '4G%?+U7]*D$.JZ9*QPL5_:2$^@296/\ *DZ,
M;.W->VFJW^[^KORM=/B/'N<%..%Y7.*DU2J)V;2=G[>U[7MHU=[/8^R:*:C;
MD1AT95;\P#_6G5RGVZU2?<**** ,K7=#TCQ/HNK>'-?L+?5=#UW3KW2-7TVZ
M4M;WVG:A;R6MY:S!2K>7/;RR1L49'4-N1U<!A_+A^TM^SUXU_P""9_Q7U?QW
MX.T&X^)/[&WQ@D?0O'_@'40;K2X]*U.1DN_"NM$".+2M5M#._P#PA'BI393I
M.=*M'OI[NVD6OZI*X[X@> /"/Q1\':_X"\=Z)9^(?"OB;3KC3-7TN]C62*:W
MN(VC+QL06@N82WFVUS$5E@F59(V#+6]"LZ,G=<U.5E.#ZKNMK27V7T/D>+N%
M*/$N$I3HU5@LYR]SK93F2BI.C5DK3P^(BTU7P.*C^ZQ6'FI0G"3?+*SC+^5#
MX:_$WQ#_ ,$^?B!X<_:&^ NK:C\4/V*/C-?V\>K:6TKF?0+J21#J7@[Q#;_)
M'H'Q \.+,!HU_<PVD>MV4NE)<)J$2 '^IKX3?%?P+\;? 6@?$CX<Z]9^(?"W
MB*T2XM+NTE5Y+:;8C7&G:A #YMEJ-FSA+JSN%CFB)1RGER1NW\Z=O^QI\<OV
M6/VE)OV>= \!ZQ\=/V2_VD9Y]-U'1IP18:3HSNZ76J76JM%-:>%O%G@B"=[V
MTUG;%'+;+8/=0W448:3ROX!?$3XG_L1?';]O/]G[X:^,I]2\(?"KX._&;QKX
M?AUJ'[3!#XK\"Z)X?U/P]JT-ME$MYHU\136M_P"2$6\6UMVPNWGMK4HUX\T)
MJ5104U+;GI\RBO:*UU4C=)NROV_E_)^%L_S+@NN\'FF7XK#9-B,PKY?B<N<9
MR639U##3QLI9/5JRY,7DV8T82KTJ4:KEA)2Y9-IPJ8K]#_\ @J#^WMJW@C9^
MRG^SM<3:Y\;/'>-'\2:CX?)O;SP=8WZE!I-E]F$O_%37\8GDG11(VCV-I<O?
MQ0F:,C\8/#'AGQ3IUS;_ +(/[,RCQ?\ '/XI2PV?QW^)NC3_ &J/3[82))J?
M@+0?$*.\4'A/1+C$GBKQ/:7/E:_J.FZ='I>JFTO9(+FO\,/A-^T'XH^$-C^T
M'\,?"WB'XD_$KX^?$SQA\+[[QU:I+JNJ^!9]/N+$WTS)''+)9WWBO[6TT&MO
MMCT^UT6\B11]I8C^E#_@G[^P?X5_8[^'R7.J1V>N_&7Q9:07/CKQ7M6<VDDJ
MK,WAW1[A][C3["0^3-<K(3J,L*S,2FW=4I4L)2Y4U*=_A_GJ*UY2ZJ$'\,7N
M[/S/.PF$XA\2N(?KV*IXG+LNGAJ=18FTHTLKR/&0C4HX+*YR7LZV:YM1?-C,
M;3YEAZ,ITM-:,?0OV)?V-O O[&WPJM_!_A](=4\9:XMIJ/Q"\7^6RS:_KD<"
MQF*U1\?9='TY2;33+9$C8VT44EV9KK=*?LRBBO+G*4Y.<G>4G=M_U\EY']%9
M=E^#RK!8;+LOP]/"X/"4HTJ%"FK1A".[;WE.<FYU*DFYU)RE.<I2DVRBBBI.
MT*Y35_&OAW0[UM/U*\DANDBCF9%M+F8!)0Q0[XHG0DA3D9R.]=77S#\2)EF\
M6WI4Y$=O:0GV:)75A^?/X\UI3BIR:=[)7T]5_F>5F^-JX#"QJT53=25:,+5(
MRE'E<9REI&4'?W5K?J>P?\+-\'?]!&;_ , +[_XQ1_PLWP=_T$9O_ "^_P#C
M%?,M%;^QA_>^_P#X']7?E;YK_6/,?Y,)_P""JO\ \O\ ZN_*WTU_PLWP=_T$
M9O\ P OO_C%'_"S?!W_01F_\ +[_ .,5\RT4>QA_>^__ (']7?E8_P!8\Q_D
MPG_@JK_\O_J[\K?3T?Q(\(2ML74I <$Y>SO$&![M"!GT&<GM6U9>*O#VH,4M
MM5LR^%(229(7;=T"K*4+'U !(/!%?(] ^4@KE6'1E)5A]&7!'X&DZ$>CDON_
MR-(<2XQ->THX>:ZJ*J4V_1N<TGYV:\C[7!! ((((!!!R"#R""."".AI:^6?#
MOC?6= DCC$S7M@&_>6EPQ?"DC<T4A.]'P.-S,G^STQ]&:%KVG^(;);VPDR.%
MFA;B6WEQDQR*<'KG:V '4;AP:QG3E#7==U^O8^BR_-</F"<8WIUHJ\J,VKM=
M90:^.*ZZ)K=Q2-JBBBLSU HHHH **** "BO'M<^*L6F_%:W^%5O!ICZG+\.I
M_B(TLNK6YU$6$/B:W\,F,: NV^^P_:;A6;6?,-HL^VR*><ZM6_\ \)7J7_/"
MS_[YF_\ CM5*,H\O,K<T5*.VL7L].]O4F,HRYN5WY9.,M])+=:]K^AZ%17GO
M_"5ZE_SPL_\ OF;_ ..T?\)7J7_/"S_[YF_^.U)1Z%17GO\ PE>I?\\+/_OF
M;_X[1_PE>I?\\+/_ +YF_P#CM 'H5%>>_P#"5ZE_SPL_^^9O_CM'_"5ZE_SP
ML_\ OF;_ ..T >A45Y[_ ,)7J7_/"S_[YF_^.T?\)7J7_/"S_P"^9O\ X[0!
MZ%17GO\ PE>I?\\+/_OF;_X[1_PE>I?\\+/_ +YF_P#CM 'H5%>>_P#"5ZE_
MSPL_^^9O_CM'_"5ZE_SPL_\ OF;_ ..T >A45Y[_ ,)7J7_/"S_[YF_^.T?\
M)7J7_/"S_P"^9O\ X[0!Z%17GO\ PE>I?\\+/_OF;_X[1_PE>I?\\+/_ +YF
M_P#CM 'H5%>>_P#"5ZE_SPL_^^9O_CM'_"5ZE_SPL_\ OF;_ ..T >A45Y[_
M ,)7J7_/"S_[YF_^.T?\)7J7_/"S_P"^9O\ X[0!Z%17GO\ PE>I?\\+/_OF
M;_X[1_PE>I?\\+/_ +YF_P#CM 'H5%>>_P#"5ZE_SPL_^^9O_CM'_"5ZE_SP
ML_\ OF;_ ..T >A45Y[_ ,)7J7_/"S_[YF_^.T?\)7J7_/"S_P"^9O\ X[0!
MZ%17GO\ PE>I?\\+/_OF;_X[1_PE>I?\\+/_ +YF_P#CM 'H5%>>_P#"5ZE_
MSPL_^^9O_CM==H][+J%BES,L:R-)*A$88)A'*C 9F.<#GG\!0!J4444 %%%%
M !1110 445E:Y>?V?I&HWG.8+29EQC(=E*(>>P=E)]@:%JTNY,YJG"<Y:1A&
M4GZ13;_!'@WQ&\42:KJ;Z5:RG^S;!]CA>!<72C$C-ZK$VZ,#U7/<BO-:<TCR
MLTLAS)*S2.?5Y"7<]^K$FFUWQBHI)=%^/5GYCBL34Q=>IB*C;E4DVD_LQVC!
M+HHQLDO*[U;8444UWCB1Y99$BBC5GDEE=8XXT499WD<JB*H&2S$ #J:9SCJ*
M\3T#]I#X#^*?$E]X/\._%/POJ_B735U!KW2K5]1#PKI*EM2V7<^GPZ?<M:*K
M/(EK>3NR*SQ+(JL1T5C\9/A7J?P^NOBOIWCO0;[X:V27,EWXTMI+J31;>.RN
M%M+MY)!:_:=MM<L(92MLVUSW4$AN,E:\6KVM=/6^UO7IW.6&-P51-T\9A:BC
M&K*3AB*,U&-'E]M*3C-J*H\\/:MV5/GCS\O,K^E5ZE\*+X0:[=63'_C^LSY8
M_P!NW+S,1_P 8KYCO_C)\*M+T?P7X@U#Q[X?M=%^(UY9:?X#U)YYWM_%E]J,
M"W-C;:.(K>2::2YMV69/-BA14.9&0@@7-!_:#^$6D_&*S^%B?$?PVGQ3L9]]
MUX$-S<+KZVRV<>I7:&)K86N\Z4XNM@NBQA<$*6(6IG!RC)6>SZ/>/Z)VOVZG
M9@LTP>$QN%K2Q>&C;$4*=I5Z2<GB8^Y"*<[RJ5:4I3I02<JD?>@I+4_1:BO$
M/&_[27P+^&OB_P (?#_Q[\3O"_A7QKX].GKX0\,ZK=R1:IKSZI=/9:>ME#'#
M(K&ZO(Y+:'S'C#RHR@\5N^(OC;\)O"?CSPG\+_$?C_PYI/Q"\<F0>$O"%U?#
M^V];,6S?]DM(UD9<>8A7SS"'# IN&37%RRT]V6J;6CU2W:TU2ZM:'Z5_:.7I
MU(O'8-2HUJ6'K1>*H)TL17Y?84*J<[TZU;GC[*E-*=3FCR1=U?U*BO+?B3\;
M/A-\'V\/I\3?'WASP7+XKU:#0_#D.MWP@N-8U:Y)$%E96Z+)-))(00K>6(L\
M%P>*O?$SXL_#CX-^'3XL^)_B_2/!OA[[5%9)J.K22A9KN97>.VM[>VBN+NYF
M9(W?R[>WE944LP"C-)1D[6BWS.T;)ZOLN[]"YXW!T_K/M,7AH?4XQGB^>O2C
M]5A.+E"6)YIKV$9Q3E&57E4HIM-I-GHE-*(Q5F52R$E&*@E"5*DJ2,J2I*DC
M!*D@\$UQ'PZ^)7@;XM^%;+QO\.?$5GXJ\*:C->6]EK5C%=Q6UQ-I]S)9WD:)
M>V]K< P7,4D+EH5!925++@GN:&FG9IIK=/1KY&M*K2KTZ=:C4IUJ-6$:E*K2
MG&I3J0DE*$Z<X-QG"2:E&46TTTTVC^4'XW?\I1?VYO\ LV7]H;_UE.PK]%O^
M"$:J_P"QCXI1U5D;X\>-U96 964^%/ (*LIR""."",$<&OSI^-W_ "E%_;F_
M[-E_:&_]93L*_1?_ ((0_P#)F7B?_LO/C?\ ]17P#7I5_P#=(?X,-_Z0S^>.
M"/\ DXV+_P"QSXA_^IV5'[3T445YA_184444 %%%% 'F/Q5OA;^'HK0']Y>W
MD84>L<.#*,9&>)$]O7K7SK7I'Q.U<:AKRV43[H-*C\H@'A;J0DS^Q^01#\!S
MV'F]=E*/+!>?O??M^%C\\SK$+$9A6<7>%+EHQ?\ @7O_ /E1S^5@HHHK0\H*
MZWPOX0U'Q-< QJUOI\; 7%ZZG;[QP#@22XZC("Y!.>T/A7PS<^)M16V0-'9P
ME7O;GD".+.3&A[RR#Y5'5=V_D U]3V5E;:=:P65I&L5O;QB.-% & .I..K,<
MLQ[L2:RJ5.71?%_Z3_P>R^;TW]W)\H^NMUZ_-'#0=DEHZTD]8I[J$=I26K?N
MQ::;5+1M#T[0;-+/3X%B1>9)" 99G( :25\ LQP/0  8'>M>BBN1MO5N[[L^
MYA"%.$:=.,80@E&,8I*,4MDDM$%%%%!04444 %%%% !7F'C7P!!K$<FHZ1&E
MOJJY>2,?+#?+U*L /DGZ;)!D$ H4R^X>GT4XR<7=;_GY/R.?$X6CBZ4J->"E
M&2T?VH2Z2A+>,EWZ[---H^+)X)K::2WN(G@GA=HY8I%*NCJ<%64]"#45?1OQ
M \'+K5LVJ:?&!JMJA+*, 7D"CYD;'_+5  R-R2%\OOFOG,JRDJZLC*2K*PPR
MLIPRL#T((((]179":FK[-;KM_P !]#\^S# 5<OKNG.\J<KNC5M95(>=M%..T
MH]-&M&A****LX HHHH **** "BBB@ HHHH **** "C++RIPPY4^C#D'MT/N*
M** /L/0[U-1T?3KU,;;BUB88]5&QO_'E-:M>4_"G6!=:3/I,KYGTZ8M$I/(M
M)@/+4>NUTD)QTW#ZUZM7#-<LI+L]/3I^!^FX'$+%83#UT[\]./-TM.*Y9JW2
MTTT%%%%2=84444 -*(65RJEDSL8J"R[AAMI(RNX  X(R.#7\BGQ2_P"3\/\
M@J)_V;Q^TQ_ZB/P^K^NVOY$OBE_R?A_P5$_[-X_:8_\ 41^'U=V!^*O_ ->?
M_<D#\B\7/]SX:_['M3_U4Y@?K=_P1$56_8?M=RJVWXP_$QEW ':PN], 9<@X
M8 G!&",GGFOU_K\@O^"(7_)C]O\ ]E?^)O\ Z6:97Z^UAB?]XJ_XV?7< ?\
M)$\+?]B3 ?\ IB(4445@?7A1110 A(4$GH 2?H.37R%XBO1J.NZM>*08YKZ<
MQ$9QY0<[!D]<#//&:^E?&>L#1/#U]=*X2XDC-M:9."UQ,&" =^@8\5\H?_7/
MY\FNBA'XI?)?F_T/D>)L0G+#X9.[CS5I^5_<IK[N=OR:WOH4445T'RH4444
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M10 4444 %%%% !7'>/Y&B\'ZVZ\$00#\&O;93^8)KL:XOXA_\B;KG_7&V_\
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M9P?-N7&V)=N<E=Y!<X(4<GWV;BXAM89;BXD6&"%&DED<X5$4$L3W/ X !)/
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MPSC7J^S]HH04I-0;C!_JIX/_ &QOAAXY_:P^*?['>@:)XUE^)7P=\*:'XO\
M&?B&6PTD>!K>R\0;_P"SM/MM0CU>36&U1PBEX9]&@@ EC*SMDX^L*_BM\/\
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M:M?=%TOX:^"-9\43JSA3+)9PB.VBCS]^4W$T3K&H)<(PP1G'^9+\4/B3XO\
MC'\1O&WQ4\?:G+K/C+Q_XDU3Q/XBU&0D"XU'5+J2XF,,?W(+=2^(;>)4AA4E
M8T4'%?<<&Y'2S/$U<9BX*IA,&XI4I*\:V(DN:,9IJTJ=./OSC?WI2IQ:<7)/
MY7.,=/#4XT:4N6K63;DOBA36C:[.3T3Z)2M9V:YK7]?USQ7KFI>)_$^L:GXA
M\1ZS<27>K:[K5]<ZGJ^I7,K%Y)KW4+V6:ZN'9F8YEE;&<+@<5DT5^K?['O\
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M3X0_\@?5O^PJ/_2*VKUNN*I\<O4_1LG_ .1;A/\ KV__ $N84445!Z04444
M?(7BQ6_X:WLFVR^7_P ,VWJ[_+\7>3O_ .%HZ<=IE+_\(#YN.1'Y?_"9;,M&
M_P#8GG"O5:\J\60O_P -;V=S]FDV?\,VWL O/[.\3>5O/Q1T^0VO]KF]_P"$
M,\PJ/-_LS^S?^$I95-TE\-(26W;U6MZ__+G?^!3W^>WEV,*'_+[;^/4V_P"W
M=_/N%%%%8&Y\=^#?V+?A_P"#_P!LGXD?MM_\)7XJU_XE_$7P#I?PW/A_5[70
MAX:\)^&],F>?RO#US;6<>L^9>N8OM8O+J5&^SP[0"#GS:3_@G-\.W^)W[6OQ
M=3XH_$:#QO\ M=>#8? ?B'58K+PJMQ\./#<,2PFQ\!W/]G?:)(YHE6.5-<>\
M1E4$C-?H;1UZ5VK,<;&3DL1/F>'H85NT'_L^'E3G1I6<6E"$J5-V2O+E]]R3
M=^-Y?@G%1>'C95ZV)2YIJV(Q$9PK5KJ5^><:DTVW[O-[JBU&W\V/_!2W]D_X
M+? 3]D?]DWX!Z;\+?VZ?BXGP9UJ5? /Q._9$T_1+CXN>%+F/3=2BOM8\20_V
M?/HEHVKR23S/>6%C#<QWEW&(9$B8J;7_  1M_8T\9:3X^_:E_:<\2_#_ .,G
MP<\*?'+P#HOPK^'4'Q[UFXU_]H:_MK"PTZ'7_B#XVDU>ZOY;76+O6;;4Y[2T
MOHX(E#6\=I;+I(@C'])BR75HQ"23VS, 2$>2)B.HSM*DCH1GV-12222L7E=Y
M'/5Y&9V..F68DG'UKTWQ#BWEE7+N5REB)U)5\3.M4G*:JXF&*J*-"RI0<ZL(
MN3]Z-N?E@G4DSS%P_A5F5',.91CAX4XT,-"C3@HNEAWAJ<I5E>K-1I2DDG9_
M I2DH11^6D'_  2E^$UI^Q1XI_8<L?BY\4['P'XW\=W?CWQ;X\M[#P</'.NW
MVH^(9?$&HZ9=1-I9T)+&],QTR::"TCO!8JK1S+./,K]%X? OAY/A];_#*XMG
MO/"L/A"T\$S6KN]M+=Z+:Z5#I!622T:%X9KBWA#RO;O&5E=C&5&*M>,O&_@O
MX<^&M3\9_$+Q=X;\"^#]%C6;6?%7B[6;#P_X>TF%B0LNHZOJ<UO96<;$$*\\
MR D$ DUB^(_BU\*O!W@>+XG>+_B7X#\+?#6>*RG@^(/B#Q3H^D^"YH-2S_9T
MT7B2]NHM*DBO]K?8Y%N2MQ@^46P<>;5Q6/QBBZLZU;FQ56M%J&LL765+VLHN
M$5>K)4Z7NI^ZE'EBKZ^E2PV!PG,J<*-+DPU*C).?PX6DZGLXR4Y-*G%SJ>\T
MN9RES2ET_#6\_P"" G[,7@CP\^K7GQN_:G\>^&OA[XSB^+'A7X77FN:9K7AG
M3_[&ENM2N/!/AKP9/'<:$8-=FDMHY-1.FOKZM96RV]]&'FW^6?!7XV_&#7OV
M@?VJ/^"MWCC]BS]I71O#/@CX/>'/@A\$_P!GW4/#UTOQJ\0):WEJFNWVC>#F
M@"HGGZ3ILTU]%IJP7<&7M7F"D5_2K9W]G>V=OJ=A>6]WI]U;)?6FH6LZ36EQ
M9O'YT=Y!<Q,T<EL\7[U)T8H8_G#;>:^:[K]N_P#8PM-<?0[W]L?]F^W\2VVH
MKHTFD7/QM\#QZS!J[3K:+I3VDFN"ZCU W+I;"S*"8SLL03>0#ZU+.\RQ4:\,
M50KYI4G!493;JJ5#"U*M*>*HQCAH1C!XMT*<)UI)SC&,^76<FO*J9-E^%G0E
MAJ]'+*<9NJH)4G&MBJ=.<,+6E*O.\UA/;3E"C%J$G*/,U&,4?F9_P3L_9/\
MB#\2_P!F[]LCQU\<])\>? CQM_P4!^)GB[QE>6LK1'XE> _ >K76L0:!82V&
MLK<VNEZB-!U.&V?2[VUC^RJ9(9K:-TVK]2V__!,#X0P>'/V,_!I^(?Q G\(?
ML4:FVO>"/#<VG>$GT_QYXD-A?6*Z_P"-V.F&>*^C:_DO431'M+<7D<4WE[@3
M7Z6&1ICYK.TID ;S&8N7#<AMQ)+9Z@Y.:\,\:_M/_LT_#7Q99^ OB-^T)\%O
M 7CG4'M8[#P;XP^)'A7P]XHO9+Z6*WL4M=#U/4K?4)WO)YH8;98X&,TLL:1[
MF=0>.>:9CBL16J8;GI^UJ.LJ&'@ZJI1CAG@XJ+<9U.6EA7[%2;]V+<ERR=SK
MAEF787#T:>(]G/V<(TG7Q%14W5D\1'%MRM*%.]3%)5G%+WI)1?-%)'C^E?L0
M^!-*_:<_:#_:N3QUXWN?B/\ M ?#ZP^'$MI-%HB:1\--&L+&.S2[\$/#:)?3
M7\LJR7\C:W+=QK<S.J 1!%7PP_\ !*'X(2_L.>)?V$;OXA_$RZ\"^*_&%UX\
MU3XC8T"U^(#^*;G6)]9&I/%:6D6@71AN)EA\BZLY+>X@@B6YBD^<-^H4<D<T
M<<T3I+#-''-#+&P>.6*5%DBEC<95XY(V5T=25=&#*2"#3ZYHYICX.FXXJI%T
MI825.R@N66!@X81KW?\ EQ%R44[IN3E-2D[G3++,!+G4L-!JI'%0FFYOFCC9
M1GBK^]O6E&+D]U9*#C%6/YQ_V\OV0?$6A?LH_L]?\$P?@XGQ_P#V@?$_Q,^+
M?A[Q#J'Q_P#B4OB/Q%%\.="\-R11:AXC\8>.XHWT#195MKR.+0= BU"UM8_L
MER4T\*Q)_;O]F+]G#X<?LG_!3P3\#_AA8&W\/^$=+@@O-4N8X1K/BG77BB&J
M^)O$-S"H-]K.J31J]W=.SM)Y:$'KGZ!6:5$:-99%C?[\:NP1_P#>4$*WX@U'
M6F*S7$XK"4L).35.->MBZ[YKO$XNNUS5IQ2C""A3C&G3IPCRQM*6LINV>%RS
M#X7%5<5"*=25"AA**Y;?5\)07NT82;E*3E-RG4J2?-+W8Z1CK^=W[<G_  3@
M^'/[=/B3X,>,_$_Q<^,7P;\7_ [4+V]\)^)?@]K%IH^L3P:G=0W6HV-Q>70:
M:P%V(!:OJ&E/:ZG':2W%O%=)%/*C_-GQ^_X(@? CXX?$R\^*.B_M"_M.? _6
M/$?A/PYX.^(NG_"KQJ+6Q^*.F>&]*LM$AD\<7&J3W%]JD^IZ=8K'JZM,T5_+
M//=7"RW+"6OVDHHP^<YIA(4:>'QE6E##PJTZ,$J;C"G6J1JU(6E"2E&52*J)
M3YN2=Y0Y6V+$9-EF*G6J5\)3J3KSIU*LFZBE*=&#I4Y7C-.+5-N#<>7FA[L^
M9:'BW[.W[/OPL_98^$?@_P""7P:\.IX<\!^"[1H-/LFFGNKJ]N[F>2]U+5-2
MO+B6:XN;W4]0GN;R8O*T<#7#6]JL5M'%$GD7P!_8K^'_ .S[\=/VD/VA-%\6
M>*_%WCS]IK5]'U/Q<WB>UT*.V\/6FA6EC::?H?AV?2[.WO'TR(6*SXU&6>7S
MIYCNP1C[&HKE^MXG_:KUIMXU6Q4I/FE77M8UO?E).3;JPC-M--R2NVCK^J89
M?5DJ,$L'KA8Q7+&A^ZE17)&+45:E*4$FFDF[6/RE_:\_X)(?!_\ :W^.^D_M
M$R?&WX^? 7XAVWAVU\)^);OX'>)HO#7_  G/A^TN;JYCTWQ!>[TU"""3[;<P
MW TR>V-S#($G,@CC"^O:K_P3J^#>I?%_]DGXLIXC\8V<7[&6@W^B?"GP$5TG
M4O#5W+?_ -GF37-?U'5+>Z\03:S$^GJ\=Q#?C<UQ.7)^3'WZ 6( !))P .22
M>@ KC/B!\1?A[\)O#\WBSXJ>.O"/PU\*V]U;6-QXE\=^(-,\+:#!>WK.MG9R
MZIK%Q:V:7-TR.MO THDF*.$5BIQTQS3,YPP^'AB:TXT:=3#X>G&,92C3K4Y4
M9THI0<I<U*<J<;N4HPDXTW%.QRRRO+(SKUY8:C"5:K3Q%>HY2@I5*-2%:%23
M<U"/+4IPJ2LHQE**E/F:3/B;5/\ @G5X#F_:*_:$_:1\-?%KXF>"/$W[27PA
MG^$OC?PQH=CX2NO#=@+AH!)XXTB35M,N]3;Q/Y,=Q;B&[N)-*$=]<-]FWK$5
MY+7_ /@EA\%]>_9.^ O['C?$#XAZ;\-?@/X\\,_$"WU33[/PM'K_ ,0M3\-2
M-<K9>,D;3O[/CM-7O_+U#4Y](AM;QKF,>7*$9U/Z765[9:G9VNHZ;=VVH:??
MV\5W8W]G-'<V=Y:S*'AN;6XB9HIX)D(>*6-F1U(*DBK5)9KF,72MBJB=!T73
M]V%XRPU*5"@V^2\G2I3E"',W9-O=)JGE>7R]I?#0:K1K*I[T[2CB*L:]9)<U
MHQJU81G-1LFTE\.A%;V\%I;V]I:Q+!:VL$5M;0)G9#;P(L4,*9).V.-51<DG
M &234M%%><>@%%%% !7I'AC_ )!,7_7:X_\ 1K5YO7I'AC_D$Q?]=KC_ -&M
M0!T%%%% !1110 4444 %<7\0_P#D3=<_ZXVW_I=:UVE<7\0_^1-US_KC;?\
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M:\7[+;P1"1IK@-&N&7GV0E02"\8(.#ND1<'T.YA@^QY_.OQ(T.V\7Z=\%O\
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MNJ+XE^QZO\0M*NO#D4&B)--'._AGPY%*FN:CJ4]O8&-A<36]B^VOX<4!"*"
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M/MM(U0?\(G\59-VJ DI\/-78#-G;@#*/(,Y4Y!QQM(SGCU#_ (:5\'_]"?\
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M\7==\2^,?$ UJ[7Q6NHZM=)I'A^"RU'45TG3X[&-H8DL4^T. -_5?M.?M_\
M[=EO^VQ\4?V1OV)O@I\(?B./AA\)M,\7>*O%WQ0NK_1]"\$:_>VUOKYU+Q;X
MABU.VL8M#N=!NH=/T_1##:WMSK$D,RZGY<RVX_0+]@K]ECQ]^QY\#M'^#/Q'
M_:.\5_M)2Z!-8V>@>*?$^BQ>&K3PKX2TFV_L_1O"/AO08M0U;^S-&TO38[:
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M@U2]OO"^AF\^R^']-\$PZ_;BQCFBU&ZCOID\0/%<)]E46T0@/F_8OQ<_8F\
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M_P"NUQ_Z-:@#H**** "BBB@ HHHH *XOXA_\B;KG_7&V_P#2ZUKM*XOXA_\
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M*?"=C?+I=_XM\(V.JNRHNDW_ (HT"SU5W<@(BZ9=:C%?.\A("1BW+.6 53D
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M--I[IM'LTYQJTX5(7Y*D(U(MIQ;C.*E%N,DI)M-.S2:V:3 X[*JCT1%1?P5
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MG;P6,<Y$D<P4%Q^^5%<U/.\PI>QY*E->P^J>S?L:=X_4I5IX?[/V*E>I5?\
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MWZ:1T7D%%'/]UO\ OEO\*.?[K?\ ?+?X5SFX44<_W6_[Y;_"CG^ZW_?+?X4
M%%'/]UO^^6_PHY_NM_WRW^% !11S_=;_ +Y;_"CG^ZW_ 'RW^% !11S_ '6_
M[Y;_  HY_NM_WRW^% !11S_=;_OEO\*.?[K?]\M_A0 44<_W6_[Y;_"CG^ZW
M_?+?X4 %%'/]UO\ OEO\*.?[K?\ ?+?X4 %%'/\ =;_OEO\ "CG^ZW_?+?X4
M %%'/]UO^^6_PHY_NM_WRW^% !11S_=;_OEO\*.?[K?]\M_A0 44<_W6_P"^
M6_PHY_NM_P!\M_A0 44<_P!UO^^6_P *.?[K?]\M_A0 44<_W6_[Y;_"CG^Z
MW_?+?X4 %>D>&/\ D$Q?]=KC_P!&M7F_/]UO^^6_PKTCPS_R"8NW[ZXZ\?\
M+4T =!1110 4444 %%%% !7%_$/_ )$W7/\ KC;?^EUK7:5Q?Q#_ .1-US_K
MC;?^EUK50^./^*/YHY,?_N.-_P"P3$_^F9GRW1117<?F04444 %%%% !1110
M 4444 %%%% !1110 45\&_MK?%;XK> ]=_9U\&?"_P",'A3X%CXL>/?$7A_Q
M/\1/%W@SPEXVL-)TS2=&L-0MDBT[QIJ>CZ)!-//<2QF>;4(7(*JNX@"MB_\
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M,6WQ.^*?BKX=^#O@U\8-3\*^#?$>N^#==^.ZVG@D?!^V\7^');>'5O#0N?\
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MN#G (^81K@98$;LX4Y!KFQ>+H8*A/$5Y<L(;):RG)[0@KKFE+HNBNVTDVNS
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M#_R!]6_["H_](K:O6ZXJGQR]3]&R?_D6X3_KV_\ TN84445!Z04444 %%%%
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M_P"?^;\HO_C=']MZM_S_ ,WY1?\ QN@#U2BO*_[;U;_G_F_*+_XW1_;>K?\
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MYZ_'?_@KM_QY?L'?]GO?#O\ ]$Q5^Q%]_P ?MY_U]7'_ *.>M)?PZ?\ V_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %>D>&/^03%_UVN/_1K5YO7I'AC_ )!,7_7:X_\ 1K4 =!1110 4444
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M<?\ HYZ_'?\ X*[?\>7[!W_9[WP[_P#1,5?L1??\?MY_U]7'_HYZTE_#I_\
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M)+.&_E%\1-*Z-M_0'_@GW^Q-XL^(_B]_VR_VKX+O7O&'B.\_MWP'X7\11%C
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M]1\5^+O&!7P\GBZXU#5=??7KV&)H]+72_LTCR2:<HELGE2P;:CK*JR#[-!#
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M% 'K'A#5OMME]BE;-Q9@ $G+20$G8Y^ARF.RJ*["O ["^GTZ[BN[<X>(\KG
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MIW@RQOO&^D:48]"CD>>>"\U;2@&U>1;@6[M=S0+;*RM*_P +:/I&F>(_B_\
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MX?R0_P# 5_EY+[CPC_AF']G_ /Z)9H'_ (&>(?\ Y=4?\,P_L_\ _1+- _\
M SQ#_P#+JO=Z*/K&(_Z"*_\ X.J>7][R0>SA_)#_ ,!7^7DON/"/^&8?V?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.Z\8^#+&XDL[_P :>#;"\A;9-9WWBSP]97D+GHDUI=:E%<1.?[DD:M[5:O\
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M_P!QQO\ V"8G_P!,S/ENBBBNX_,@HHHH **** "BBB@ HHHH **** "BBB@
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M&6HZDFG6OQ"GCFU'XA?":.X=5MY/$TX3[=J-DL?%Y=W"W=C$L$?V1XRT^_\
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MF9\MT445W'YD%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<5X!M7HXE+J^6F[?)5-3O? >:)-K$X%OHN>LK[=?8^O]/3QFBO4+GP-8./\
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M0A.I.-.G&4YSDH0A%.4I2D[1C%+5MMI)+5O0;##+<2I#!&TLLA"JB#))/?V
M[DX ]:],T7P?;VP2XU+%Q<8#"#&8(CV# _ZQAZD#!'&:V-#T&VT>$$ 2W;J/
M.N",G..4CSRJ9/08W8!(XK?KX'-^(JN)<J&!E*EAU=2JKW:M;IH]Z<-[6M*6
M[:7NGZKP_P (4,)&&*S.$,1BFE*&'DE.CAGNE)7<:U5=6TZ<'I!2:4VU55%"
M(H55 "JH   &  !T '%.I0"> "3Z 9K*U_6M+\+Z)J_B/Q!=II>B:#I=]K6K
MZC<)*8;'2]-MI;R^O95B225HK>VAEF<1QNY5"$5FP#\NDY-))N3=DE=MMO9=
M6V_FV?;RE"G%RE*,(0BY2<FHQA"*;<FVTHQBDVV[))-NR1J45YWK'Q8^'OA_
MP+:?$O6/$MO9>"+]-/>RUY[/4Y(KI=5D\K3A#9P64NI.]Y)A88ULS(Q(^4 @
MUW;7MI'9G49;F&"Q%L+Q[NYD6VMXK4Q";SYY9S&L$8B(=FF*;!P^T\53ISBD
MY0FDY2@FXM)SA;F@FUK*/-'FCNKJZ5T9PQ.&J2E"GB*%2<:5.O*,*M.4HT*W
M-[*M*,9-JE5Y)^SJ-<D^27*WRNUFBO#/!7[2?P8^(GC&Z\!>#/%E[K?B:SCO
M)I88_!WCFSTB2&PDBBN9K/Q3J/AJS\+:C$KSQ"*33]9N4N0S-:M,B.R][\0/
MB/X*^%GANZ\6^/=>@\/Z#:/'$]R]M?:C=W$\S!8[73=(TFUO]8U>]<;G6RTJ
MPO+LPQRS^3Y,,LB5*A7C4C2E1JQJSY7"G*G-5)J7PN,&E*7-]FR=^ESGI9GE
MM?#5L;1S#!5<'AW45?%T\50GAJ+HJ]55:\:CI4W233J<\UR+65D=M7,:OX7L
M-2#21*+6[P2)8P KMR?WJ# ;)XW<E1T!KGOAC\7?AW\9-$N?$/PX\1#Q#I=E
M>OIUZTNE:WH5_8WL9;-O?:-XCTW2-8LG<(SPFZL(EN(@)H&DB97/I%:4JV*P
M%=RIRJX:O!VDFG"2Z\M2$EJN\9Q:?5$SIY;G.#@W]6S#!5X\]*K3G"M2G%W2
MJ4*]*35][5*4TT]I'@NH:==Z9.UO=QE6'*./]7*N<!D;C.>A! .<\8YJC7O6
MH:=:ZG 8+J,.O)1\?/&Q'WD;J#ZX/(X->,ZOI4VD7;6\N6C/S03$$"6/G!ST
MW#!##J.,]1G] R?.Z>8KV-5*EBXQNXKX*L5:\Z=]GUE#=;IM7M^4\1<,U<GE
M]8H.5; 3GRQFTW4P\I?#3K6T:;TA55E)^[)1DUS9=%%%>^?*A1110 4444 %
M%%% !1110![[\(?^0/JW_85'_I%;5ZW7DGPA_P"0/JW_ &%1_P"D5M7K=<53
MXY>I^C9/_P BW"?]>W_Z7,****@](**** /*[[X66.H_%F+XJ7.J7)FB^'$W
MP\70T@5(/*F\3V_B4ZM]N$WF><'MQ9BT-N8S&QF\[< E=E_PB^E?W;C_ +_M
M_A71454I2E;F=^6*BMM(K9:=O/4F,5&]E;FDY/5N[>[U_):'._\ "+Z5_=N/
M^_[?X4?\(OI7]VX_[_M_A7145)1SO_"+Z5_=N/\ O^W^%'_"+Z5_=N/^_P"W
M^%=%10!SO_"+Z5_=N/\ O^W^%'_"+Z5_=N/^_P"W^%=%10!SO_"+Z5_=N/\
MO^W^%'_"+Z5_=N/^_P"W^%=%10!SO_"+Z5_=N/\ O^W^%'_"+Z5_=N/^_P"W
M^%=%10!SO_"+Z5_=N/\ O^W^%'_"+Z5_=N/^_P"W^%=%10!SO_"+Z5_=N/\
MO^W^%'_"+Z5_=N/^_P"W^%=%10!SO_"+Z5_=N/\ O^W^%'_"+Z5_=N/^_P"W
M^%=%10!SO_"+Z5_=N/\ O^W^%'_"+Z5_=N/^_P"W^%=%10!SO_"+Z5_=N/\
MO^W^%'_"+Z5_=N/^_P"W^%=%10!SO_"+Z5_=N/\ O^W^%'_"+Z5_=N/^_P"W
M^%=%10!SO_"+Z5_=N/\ O^W^%'_"+Z5_=N/^_P"W^%=%10!SO_"+Z5_=N/\
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MS-"/6>$?G*@_K7T%&-J(O]U%'Y "OGR(XEA/I-$?RD4C^5?043!XHW!!#(C
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M2SR--/*50*#)-*[RRN1NDD=I'+,Q)DKX?-<VQ&:UHSJ+V5&FN6CAXR<H0O\
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M1.N?7J^,/^">NC?$70/V/O@OI?Q2COX?%4&@3/%;:H-M_9^&9KJ27PE97$1
MDMGM/#SV%O\ 99U2XMO+\F=%E1E'V?7Y'G%.6'S+%X.6(I8N.7UJF7TL31A3
MA3K4<%.6'I5(^SBE)3A34N>7-.=^:<Y2;;_4<IJ1KY?AL7&A5PLL?2ACZF'K
M2G.I1JXN,:]2G+G;<>64W'D7+&*7+&,8I111117FGH@3@$GL,_E7A6M7 N=6
MOY@=R&YD6,YS^[4G;_,]R/3TKV'6KX:=IMU=9 =8V6('C=*P(51GN>?RKPOD
MDDDDDDDGKDG-?:<)8=WQ6*:]VT:$/-_Q*GW?NU\V?F_'V,C; X"+3DG4Q557
MUBK>RHK_ +>O6;3VY8OJ%%%%?:'YN%%%% !1110 4444 >^_"'_D#ZM_V%1_
MZ16U>MUY)\(?^0/JW_85'_I%;5ZW7%4^.7J?HV3_ /(MPG_7M_\ I<PHHHJ#
MT@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N+^(?\ R)NN
M?]<;;_TNM:[2N+^(?_(FZY_UQMO_ $NM:J'QQ_Q1_-')C_\ <<;_ -@F)_\
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MHM*5E"O2O[U&LHIS@UO:[O"6TH-/ND4445PGJ'\]W_!;#_DK?[%__81\2_\
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M.5;V.%J3A+ U8R>&<J,E3I]!THHHK[0^,"BBB@ HHHH **** "BBB@ HHHH
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M1FF85<TQV(QM6Z=6?N0O=4Z4?=ITU_ABE=KXI.4MY,****[#SPHHHH ****
M"BBB@#WWX0_\@?5O^PJ/_2*VKUNO)/A#_P @?5O^PJ/_ $BMJ];KBJ?'+U/T
M;)_^1;A/^O;_ /2YA1114'I!1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %<7\0_^1-US_KC;?\ I=:UVE<7\0_^1-US_KC;?^EUK50^./\
MBC^:.3'_ .XXW_L$Q/\ Z9F?+=%%%=Q^9!1110 4444 %%%% !1110 4444
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M%?//_#7/[*G_ $<A\%?_  X.@?\ R51_PUS^RI_T<A\%?_#@Z!_\E4?4,?\
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M @A@<$=*=7*;!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!A>*/$NB^#/#7B#Q?XDO/[/\/>%]&U+Q!K=]Y4D
MYM-*TBSFO[^=8(@TUQ)%:V\KQV\*M-,ZB.)6=@#Y'X!_:9^#'Q-^!EQ^TAX,
M\37NH_"*TT/Q!XCN]=NO#^L:9JMII/AA[Y=9EN?#-];1:W!<0KIUS-;VDEHM
MQ>VWD7%LDD5S"S_*7_!2[XTWGP^^'?PI^&&@Z)XK\4^(/CI\6O#?AV\\.> _
M".K^/O&%YX \)W]CXP^) TKPAH##5M5%WX+TS7+)_LX*1AG:0,B.I^._AC\6
M=!BTC_@IE\"-%\%?%'X:^"]3^$&O?&[X2>&OB]\+_$GPE\0P^%-1^'4/@+4K
M#2/#'B>."]N--M]8\(ZOJDEW;1"%IKJ<%0ZNQ]G#97[;!QQ,HU.:5:+BXRCR
M?5HUZ6'JMQ<7+G=2JW"7-RJ-"JI1=TUQU,3R5W33C91:=T^;VK@ZD-4[<JA&
MTDTFW4A9]_TW^#?[;?[/_P =O$UEX/\ !-]\2-&U_6-*N];\,VWQ2^$'Q"^$
MEOXTTO3PSZA=>!;[Q]HFBVOC)=.C"3:@OA^2^-G!<6DUQY<=U 7XK3/^"CO[
M+.K>)++PY%J7Q>L+>_\ &0\ 0^.]<^ GQ6T+X21>*2[QBQO/BQJ?ARW\"64!
M="HO[C64M,E1YF6%?.O[-WP_^/\ \>-2_9$\?_%7X3:#\'?AE^SGX%\0:GX3
MU"/XH:#\2?%/Q0UKQ18V=GIL]K!X=MM-D\"Z/I0T6&ZU33-:AU"35HKY;:*:
M%[61V^*=+D^-D/[,VE:=\3_$'P_O?V(O&'[3FH^'OB/;>"O#FMZ-\;O &EW>
MHP2P>)+[Q9KFNZWX1U70([B%(M1M]+\'Z?J<9> PZE;AF#]<,LR^=6K#GG>$
MJ5-TX8NC5<*DZF*CRPK4L/4I8BK*E0IU(4/W7OS=&57VEHK%XFNH0E9>]S2N
MZ4XWBE1UE"4U*$5.I*+G[WNQ4U%Q=W_0-=_%/P18^-=4^'MSJ=RGBS1?!MYX
M_P!1L!IEZ\$7A6PCBFNM02_6(VDTT<<T;+8QR&ZDW82,X-6OAM\1_"'Q<\$Z
M%\1/ 6HSZMX2\2VHO-'U"YT^\TN>YMSM.^2POXH;NW/S#Y)HU;VKY&\2!!^U
MW\1A'@Q#]D;Q2(B#N!B&F:;Y9#9.[*8.<G-=/_P3VB?_ (8Y^"C[?E_X1Q3G
M(Z8B[9S^E>55PM.&$5=.?._JFC:Y?W].O.>G+?25./+[VEVG>ZMU0JRE5<&E
M9>UVO?W)4DM;_P!]WTU=MMC[1M[::ZD6.&*20EE#&.-Y-@9@NY@@)"C/)KPK
M]GCXWZ;^T7X#N?'F@>&M8\.6UMXQ\;>#3I.JW-IJ-\]UX'\5ZSX4O+Y9=.7R
M1;7]QHLM[;0D>=#;SQQSDRHYKXN^.7@?P9\>OVY=!^$OQPUG6+3X9>!/V<M4
M^+'@G0[+Q;K/@NS;QO;^,ETF^\?R7FBZAI=UJ][X4T:>^E@AN[FYT&V6P6;4
M=+NEAEW?F%X%OO%&J_ ;]D7X(>%/#>H_'CX6_$G]H?\ :@M]=\&CXRZ9\&4^
M+J^#?$_CG6/"MEJGQ7:"-42TN[*RUM;+1IM-O=;F;[.9WCNECKMP^54ZV'NZ
MK5:7U>JY."A2HX>='&UY\M2I7ITJM24,,M*GL(0FN5UE%SFL*F+E"HUR7@O:
M124FY3FIT()N,82E&*=71QYVUKRWLG_4"8)A((3#*)20!$8W$A)Z )C=D]AC
MFG/:W,1426\\9<X0/#(A<^BAE&X^PR:_ ;QKX<^.7P#_ &;?$_@'XG_"7QK\
M,_@_\1/VJ?A9H7A'X&_#7XJ3?M!?$ZR^"?B:_P! TGQY\//#GB3PSGQ1J]MJ
MQ76KB+3;>Z;Q7YNJ21Z?K%L6M?(Z'P1\$_#_ ,+_ -FK_@H/\5_AQ\-?B_\
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MK/3+"\U.\?[-,\J65A;R75U+' B&68QPQ2,(XE9W*[5!8@5^!^@7GP:_9O\
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MXK$5.3^T*N3X+#PJ2E0][&T*F-E4O&#E2C)1K4W&33H\\MY1C(\<^(_[5OQ
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MZ_[_ %E_\E4?\(+XO_Z 5U_W^LO_ )*KZLHH]O/M'[G_ )A_JS@_^?\ BO\
MP*CY?].?)_?Y'RG_ ,(+XO\ ^@%=?]_K+_Y*H_X07Q?_ - *Z_[_ %E_\E5]
M644>WGVC]S_S#_5G!_\ /_%?^!4?+_ISY/[_ "/E/_A!?%__ $ KK_O]9?\
MR51_P@OB_P#Z 5U_W^LO_DJOJRBCV\^T?N?^8?ZLX/\ Y_XK_P "H^7_ $Y\
MG]_D?*?_  @OB_\ Z 5U_P!_K+_Y*H_X07Q?_P! *Z_[_67_ ,E5]644>WGV
MC]S_ ,P_U9P?_/\ Q7_@5'R_Z<^3^_R/E/\ X07Q?_T KK_O]9?_ "51_P (
M+XO_ .@%=?\ ?ZR_^2J^K**/;S[1^Y_YA_JS@_\ G_BO_ J/E_TY\G]_D?*?
M_""^+_\ H!77_?ZR_P#DJC_A!?%__0"NO^_UE_\ )5?5E%'MY]H_<_\ ,/\
M5G!_\_\ %?\ @5'R_P"G/D_O\CY3_P"$%\7_ /0"NO\ O]9?_)5'_""^+_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
' %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img22994243_8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img22994243_8.jpg
M_]C_X  02D9)1@ ! @$ > !X  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %'!3@# 2(  A$! Q$!_\0
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M!37O!'B"&W:ZGNM*\1ZUK=TT]LNJ:!J=I=6MRD-QI.LV\S1 %':S_P %4/\
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M8V<&H7O@?P!XQ\86=A<N\=M?77AGP[J.M6]G<21?O(X+F6R2&5X_G2-V9/F
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M/J5I)JDVB2K(\]HSZ;!"WF^3:"VN/H[_ (('_L-6?PX^*G[6O[6U[^S;XG^
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M[_C]\=?]CK=_^F/0*[>N(\'?\?OCK_L=;O\ ],>@5V] !1110 4444 %%%%
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M7RS^E6KJI3_VB.+I16&Q<E[2<W/$R;]K?WXS4G.,8N)\E_\ !K__ ,HT9?\
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MX/NOAEX/_P""HG[3OA'X6ZK=W-WK_@+P5H4/A70-9EO8([74)[G2]/\ '/\
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M[!__  44^-O[)WPD^)7B2?Q+KOPAT_PWI?BW1]#N[LNTZ>&-0FU;2C;I!O\
MLVG2W%A_:%KID<&GW.HWZ0)*?D3_ (+F?!KQ5\!?^"?W['WP!\5>(OBC\>])
MTK]H"SU/XF?M@>-[;6_%/Q#^'H:XU#4+_P 3-9Z'>;$GO[37=3M]*M-2GN[6
M+3]!M]*LIAJ,EK=P>S#-\)F6:Y=2PE;#5:-7-:&,IT)4\P>)PT:&&J+V:CBI
M_4J,8V5/V.!NJCC"=*/-&"?DSRG%Y=E685,51Q-*M3RNM@YUXU, L-B95L11
M:J-X6"QE9R;E4]KCG^Z3G&I/EE)GS+\*OV,OV;OVT?\ @HI^R+J7[,/_  3P
M^)?P*_9A^$'A>>__ &I_^%Q^!O$7@?PSK7B/0].O9= TNW:\U?[5J_BK3O$<
M.G6G]LV%[;WFM7,1U6_L_LUI.L^MX;_8I^%/[=?_  7P_;Q^$OQSO/%%U\)/
M#*I\1/$/@+PYK=[X?LO'NK:3IOA/0_#EEXBOM.EANQIFBR:S=:E'':M'=27"
M1PQ7-M"]QYWFNE?&[XA>!/VIOV1_"'_!*[_@HO\ M<?MPZIXN\>:58?%OX;_
M !:LO%FN?#S0/!L.JZ+_ &C=:_/X@TG3-.L=)OM+GUXZJYM(9]!ALHK^WUQ+
MEXTK^FGX&?\ !-;2?@I_P4+_ &D?V][?XLZKX@O_ -H3P[%H4GPUG\,6-A8^
M%W:;0YKJYB\11:G/<ZFN=!@6WB?3K0K]IF,DC^6@;',<RK9:JE2IC*M&5;(J
M^%RJ%3Z\\?3KK,:-2I4Q"Q=-5:56HE-T:\E"+IT::@TZ4&]<NRZCF/LZ=/"4
M:L:.>4,3F<H+!+ U*/U"I"$,,\+-T:M*FW%5:$7-JI6FYQM4G%?E/^V3X._X
M)?\ @G]JKX?_ +,</[$GQR_;[_:2^'/P(\$^!_#?P1\):]J>J>$OAC\+O"MC
M(V@W-]+K7B;0M#MM<N-/O8;G5M2O!?NT-Q92W5S:W,R(_P 8_P#!)GXI^,OV
M>/%?_!;'2OA[\//%OP(T3X5?"?Q7\4/ WP \2:Q_PD.H?!_QCX>M_&":3I,[
MBYO+"ZU'18YK:"[N(Y)Q=V]A9PS3SI &/[=?M7_\$B_$?Q>_:^3]MG]F?]KC
MXA_LC?&O7_"5KX%^(NJ>%?#&D>+[3Q+H%M9VVF?:+"VU2_L(].U"73+*Q@N8
M;I=1L)[G3[&_CBM;J#>W2_L0?\$@_ W[&OQ3_:6^(=[\:O'?QZLOVG?!&F^$
M/'FE_%'3;"YUC4[B<7DWC?6==\26EWYFM2>+[W4;]WLCI]G'IUE<BS6:Z,0G
M?SHYQE<<GJ4*F,KXNK7P6"]IAL3/'59_6Z.-HUL13C"?_"?1HN$9NC.FG5FG
M+VM12;C/T'E&9RSB&(IX2AA:5'&8ODQ&'C@J4'A*N#J4,/.4H/Z_6JJ;A[:%
M1JE!J/LJ<HI2A_/A^PS_ ,$R/V9/VFO^"1'QX_;4^+&I>,-1_:CNM._: ^(-
MK\:+3QUK5IKGAG5/A[H6I:E::'<VKZ@VCZE9^))[28>*5UJTNK_4;+6VAM;J
MQ*P./;?V&_%G[(7A3_@WNL[W]MZ;QO/\$+S]H'Q+%<^%/AQJ6IZ9XN\?>)K+
MQI;:QH/@JP;2KNPN)['59]/E;6()M0T^T&EV]S+/?6YCC:OLWP=_P;HZ1X/U
M[QI\.K#]MS]H"R_8G\9^([SQ1JO[+.@W$^A6FLW,N3I^B>)/%-IKIMM4T>P9
M+**[NH?#EIJVM66GV\%U<V]UMU"+Z$TW_@AG\+KG_@FK!_P3P\9?&/Q1KT6C
M?$;6/BMX2^,.F^&]-T76/#WC&]U&XN;&8^&#J%_8:EID5C=7.F:C83:C"U[#
M=2RP7%E/%;RQ]>,SW+,0YQJ9QBZU&MGN!S"E&E1Q%*KEV"C"LITJ$YQ:A/#M
MP4H45RQTG0]I.4U'DP>1YE04)4\GPM&K1R3&X"JZM;#U:>8XR<J#A6K0A).4
M*Z51J55\\GS0K^SA&#E_-U^U7)\.?A/\=/\ @G?\;/V7/^"=GQ?_ .">$%U\
M;?!4_A_Q]XMUY+3_ (7#H-QXD\)3VEK'HUIXCUK4[8C2;R9M3EU9H)]5TC69
M;.Z2XB(-?<__  4#_8M_9?\ $_\ P7Z_9)^%WB+X5:7>_#_]J'1M;\=_'7P]
M)KGBFUM?B#XPNM)^)T\FK7EW;:[;ZAI4]Q=^'="8VWAV\TBU:2T14MU$\RR?
M>OB'_@@A\0_BRGP2U?\ :*_X*)_&KXR^+?@/XU\$:IX!_MKP9H4/@W0/ _@^
M^LKR7PMIOAM-9,S:YK0TO3(KOQA?:G=7J06HMY+.Z!65?KK_ (*2?\$G+;]N
MGXF?!?X_?#O]H#QE^S3^T!\#XI;'PO\ $#PMI4>M++IK7[:I9,($U/1-0TW6
M-)OIKN2QU*RU/9);WEQ9W=G+&X=:?$&71KX&-/,JL''+\YP-?&P>9U/93Q5I
MX&I*IB;XRM&E4;DI)-TJB<J<*<%&R608^6'QLJF70GS9AD^-H8.HLMINI##6
MCC:<:>&<<'1=6FN22;2JTVE4E.3DC\H?^"FWPI^'_P $/^"H7_!#_P"$GPM\
M.V_A+X>_#[7- \-^#O#EM=:A?0:)HMG\3[!;>R@O-5N[[4IUC#MF:[O+BX?/
M[R5N*K>'_@YX#_X*9_\ !=O]L'X:?MBV]_\ $/X4?LN>!7T_X5?!C4M:U?2/
M"\B6=[X7T5-4FL=&U*PN9T$FLWVO7LEO/!)J-]J&F/?O+:VD5L_ZH?$7_@D;
M<_%/XM?\$]OC%XX_:@\=>*O%W[#5II::QK/B7PS8ZSKOQLU+3=>B\2R:OKNL
M7&M";0KN_P!1C^S3>7'JWE6!18V::,,V9^V3_P $<[3X[?M)I^V3^S3^TU\2
M_P!CG]I2]T>/0_%OBWP#8V^K:+XRM(+.WTZ"XU/3%U#1+NVOY+"VM[35'6_O
M+#6(;2Q:ZT]+FU%S)PT,YP$:.&H/,9TL4LHQV"69JEB93PV+K9G+$QK.2A]8
M2Q-"ZE6I*=6G[7WE?G2[:V3XZ57$5UE\*F&EF^"QKRUU<-&.)PM++:>'=*SF
ML.WAZUN6E5<*4_9>[[O*W^:?["/@;2?V)/\ @O+^T?\ L8?L[WVKZ=^S5XQ^
M!M_XZU'X<OK%[K.B^#==M_#WAKQ-IHMGU*ZN[B)M(O\ 5K[1[6XFGFU1[#5[
M>SO;B:.#</B;_@CG_P $V_V;_P!N/X3?ML^-/VC;7QCXQB^&OQ#\=^&/AMX5
MM/%NLZ'X7\%ZSK&DZIKE_P"/=.TW2;JU2[\7/=1V,<4VI?:M-\BR2.ZT^\$A
MV?TO?L ?\$J_A_\ L1^*/BA\9/$GQ5\>?M'?M,?&>*2U^('QQ^)*V\6K2Z9+
M.MY+I.A:7'<7YTV"YO$BFU*\N-3OKW41:6,&^UL[6*T%O_@G/_P3*T?_ ()^
M?#K]H'X?:?\ %S5OB=%\=_B!K/C2?5+_ ,+6/AN7PY!J6E3Z5#IT-M:ZGJ2:
MA+#%<-/+=226Z/(JHD"(2:>(XCP].EF+P>.K+&3PV0X:&-C3JTJV/JX)U5C<
M5S<JJ4W*G-0O6E"K4@DG=R<4L-P_7G4RY8S!47@X8G/,3/!3G2JT<%2QL:#P
M>&Y$^2HH3A*;5*,J=.HVU9*,C\__ /@V!\8^)=;_ &%_B+X/UO5[S5=+^'/Q
M\\4Z)X7%Y/)-_9NE7^DZ/J,^GVB.6%K9#4'NKR*VC8Q1RWD^Q5#8/S5_P<A?
MM(>$-6^,/[&7[&WB:Y\277P[A\<Z+\?/C]I_@K2KOQ'XE?P;8:I-H6FV-AH%
MF5DU'4_["C\8WMG SQJC75K<2.(0Y7]M?^"8G_!.G3/^";?PC\??"O3/BGJ7
MQ83QS\2M4^(+ZUJ7AFS\+R:<M[9VMA;Z6EG9ZEJB7!B@M4DFNFGCWS.P2%$4
M9Q/ W_!,_1=#_P""D?Q3_P""BGCGXIWWQ%\0>+O H\ _#[X;ZGX4L+72/AGI
M4MCI&F7,UGK#:C>S:G<+INFWMC;-_9]@%BUW5I)=[SUR+-<KI\2YEG/.ZE"$
M<1B,#"$*E*6)Q=2E&E!)RHR]BXRJ5*WM*E-)2@I6DVHRZGEF9U.&\MRCE5.O
M.6'H8Z<YTZL</A*=656=U&K'VR<:=.C[.E-N49N/-%7E'^8^/_@H1^SQX9_X
M+@? +]K7]GO1/B3X$^#/QET?PE\"_C/I7Q&\ 7WPYBMAK5A:?#N/5;"QN;B[
MAOM-T)+7P-XBN)4D:2$Z/<0I%&9(9!]U?\%??V:_CAX7_;]\+_MQ^//V1F_X
M* _L;^'_ (1P>%-:^#B:M>2_\*ZGM;6\76O$"^';2*^DCFM9Y6\06>IOH^IZ
M/>M<W,&I2:?=6]K?6?[&?\%._P#@F1X%_P""CWP?\&?#V?QDWP>\7?#SQW;>
M-_"'Q T/PO8:W=63-8SZ=K&CSZ>U[I#/9ZK"]G<F6*^CEM[[2K"95D5&6O%/
MC[_P3*_:[^(?B2Q\0?!W_@I[\;O@Q;Z[\+? OPV^*OAB#PGIWB#POXKO/"'A
M*V\*:EXT\-Z5-KMK%X.UGQ9%#+?:M#8&5X[R>22'422-O;2SO+)U<LQ5*M#!
M5J.7XG*L71QLL=7D\)"=/ZO*.-P-"E6A6G2G5C"M2CSTW3C"2Y6I/DJY+F4*
M6986K2EC*5;'X?-,+6P<<%0BL5.,OK"G@\;6J49THU84I3HU).$U.4X-23BO
MR]^/_P &O"'_  4)_P""1/PVMO\ @DE\/=4TKX7^ _V@]1\??$G]E75-=U#2
M]6U*ZMK;4;OQ-X&5M0UVYBU"'3]7U6SU72]$L];73]0T^^%SHOE7MI:VJ>S?
M\$P_CY_P3GEUK]J#PA)^R'J__!.G]I'P%^SKX@M/VD_!"7OB&PTN[^%/AVW6
MX\4>)M GDDB>+5="DN8;Z.ZN] M/$RP7UI-!>ZQ&YF/VCH__  1OD^#7[)7P
MM_9X_9&_:Z^,_P"SEX_^&7C_ %WXGW?QGT*&QU&\^)'BSQ/I*Z1KL'CKPI%=
M:;IEUX>>WALETC2([B6'2$LH]POYYI[A[/[,/_!&GPO\-_$O[1WQ6_:C^/GC
MW]K;XY_M0_"[6/@Q\0OB!XBTZP\'0:?\//$&FP:7K&F>']*TR>_,.I75M9Z=
M'%JEQ<M%86^G6EM9:="OVA[C.KFF53P..PTLPQ,J'UO$5L%&#QT,QFZN*HRE
M+&RDOJ6,HSI4_:QEB)?6:<HJ"M*]]*669I#'8'$K 8=5EA:%+&RFL%++X*CA
M:D8K!QB_KN$JPJS]E*%"+P\X.4FVK'\R/[66A_L(>-/V$?B%\0OV*O\ @F+^
MT'HO@WPKJNCKX>_;^\=^(&M(X]2TOQ/I^GZCK&K_ -J>+]3U[7UUMIFTF6&#
M38[6WO\ 4()S'875GLC^EOVG+_QM^S_H/_!$K_@KO!<ZAJ>KZ=X&^%OPH^/6
MN%[B:^U[2+33'LH9=>OF9Y[N7Q-\/KOQCX?N)I7,DTUC:EG^T/ P_272_P#@
MWI\9+\%O%'[+GB#_ (*,?'C4OV7$DUO5/AQ\&M/\)>'=*T?0_$U]</?:-J_C
M&YCU.:;Q;I^B:DYU*3PY;_V-INIZCB_!TZ8%6]E_X*<_ 3X,_LT_\$,/&O[/
MOQ2\17_B_2_A!\+? ?@[X<>)UTNUT_7];^+6BZ]IL?P^O['3$FO+>R>\UIFC
MUF**>8P^%9-=V2,_->JL[R^IB,NP>%Q-7,56S6MAZL:CQ]>O4RW,L-'"3C4J
MXU*]7F<:E2C04*$:D(.G!VE(\K^Q<PIT,PQF)PU++W1RRAB*;IK 4:-/,<NQ
M#Q<)4Z>"D_W?*I4Z=:OSUG"4E4DFXQ7RW^QI=Z=_P4)_X+M?M%?M?:=<P>)/
M@O\ L=_#ZT^&/PFUB,BZTF^\3Z[ILWAVSU'37(>(B2TN_'NMJR!&6>?3YPYD
M@4O_ %/U^$__  ;Q?LOR?L\_\$\_"'BS7-*;3O&W[0VO:C\7-<-Q"\-Z-"NT
MCT?P3:7"2JLJ+'H%@FH1(P4#^U7?8'=V?]V*^-XCK4IYG/#8>3EA<LI4<LPS
M=M88./LZD]-&ZF(]M4;6_.?8</4:D,MAB:ZY<3F56KF6(7:>+ESPAKK:G05&
MFD_Y HHHKP3W HHHH **** "BBB@#B-'_P"1X\9_]>7AC_TFOJ[>N(T?_D>/
M&?\ UY>&/_2:^KMZ "BBB@ HHHH **** "BBB@ HHHH **** /Y0_P#@Y<_:
M.\)+=?LC_L<>(]8U:R\&>.?B3I'Q>^.I\-V%QKFMVWPP\-ZM'H<,5MH5F\=Q
MJ5W.EYXCU"RL!*GVJXTNW^:+Y)E_/W4O^"AW[*OAS_@M'^R_^UC^R^?&_A7X
M/>.?#'@SX _&_2?&7@._\ 6^GZ=<VD7PWL-0M;>\GEBU*RTW2%\'ZM-/F-[>
M;PZ?.?$QD7^F^T_X)F:9JG_!3/Q+_P %%/B-\3W\>NOP[M? 'PR^$6H>$K1-
M(\ 0QZ)9Z-<:@NLS:C=G4I3NU^\@C_LNU*W6OW$KR$V\.;?_  4Z_P""8G@#
M_@HQ\#-!^%@\26?P>\5>$?&ECXR\+>/='\):?JT]DR6=UI^K:3<Z?'<Z1)-9
M:K:W$;.Z7J-!<V=M,(Y"O'WF7YSDF%H9=EE6->I0G@,30Q^+A4E"C3J9HE+%
M*>%>%E4Q$L/[/#PC4A423I)TU))\WPV/R?.<56S',:3H0KPQ^%KX#"U*<9UJ
MM/+-,,X8M8F-/#QQ'M,1*5*=.7\1JHXN3Y/Q$_X*R?!K3?VBO^"YO[$GP.UO
MQ5XM\'^&/BI\&AX1\8:OX%U:31/$MYX+N;WQWJ7B3PW9ZM#E[.T\4Z?ITFB:
ME(JR?Z#>SLL;NJ"J7P?_ &9_AK_P3\_X."_A9^SI^SA%KWAGX)_'']GSQ*_B
M[P)?>(M5U>RN([OP'XQU&YAN+F^GENKZ-=7\)VNI6+W4TMQI\UU<K;3I&Y0_
ML=KW_!+"_P#%O[9_[%_[9/BGX_:EJ_BC]E+X2:'\.M<T5_!EJA^*&LZ+H.L:
M/)XKN=3.MN^A2ZO/K5QJ.H6<=M?A)T AFVRL$] \>?\ !-ZU\;_\%-_A%_P4
M7;XJW>GS?"SX;ZEX#'PL7PS;SV^L37N@^*M CU)O$K:G'-:1QP>*9KF2V&F2
MLTUG$BRA)7*J&>X6&$HX'ZY.6%APUC<%5I*G65*>92J5WAVXNFFY6]DZ=5KE
MIWMS1;F5/),3/%5<=]3C'%2XCP6,IU74H^UAEL:>'6(2FJFD;JK&I23YJED^
M6246OYP/V3?^":7[&7Q(_P""U7[:_P"S!XQ^%!U3X+?!GPI'XP^''@__ (2S
MQ9:'0O$$>L^!YOMXU6TUF'6+]4EUB^;R+Z^N(%^TJ"A"1@?;WPE18O\ @Z ^
M.J1C:J?LOSP* 3Q#%X+\ "./)))1, JI) (W?>YK[!_:4_X(R^,/B-^VUK7[
M;'[-O[8_Q"_9:\;?$/3--T+XJV7A;P]!JMSK6DVT.EVFK0Z%JT>L:5)8IKMI
MHVF&\L[^"]AAO[1+ZWE20A$^EO"'_!-2R\*_\%.O'/\ P4:_X6UJ&H7'C+X5
M+\-Q\+I?#-K'%93MI.A://J\GBA-2,MRK0:%'<I;#283]HNI5:7RXTS6*SS"
MXB%6K4S*K6=?AB> CAJD,5*6'S"V"C53<H.DWBYT9U'5A)Q?L[U9)N-XPN28
MK#SI4H9;3HJAQ)''/$4Y86,:^ <L5*DTH355+"1JQIJE.*<?:6I1<5*W\V'_
M  21_P"";G[.'[?7QO\ ^"B]Y^TE%XM\4>'_ (=?';7=)\->!-(\6:KX;\/Q
MZWXJ\3>/Y9/'%];Z1<V\^H:]HT&FK8Z*UR7L;9+F[\^"Y\P1KF_L0_M+?&K]
ME?\ X)M_\%E_A[\-?&FNZGI/[,?CO2O#'P4\5&ZEO'\&+\0_&6I?#K7K_19_
M-*V$L.F6EOKUL;39!9Z[*M_;QJ99 ?U&T_\ X-\O'OPYUCXQ_$/]G[_@H'\7
MO@I\6OC!\0/&^K:[KOA/P\NG>&M1^&OC/4)=3;P+KNA6/B*"YOM3TB^NKVZL
M?$T&HV\@-P85L8@JRK^@G[)O_!(?]G3]F;]C?XK?L?ZM>:S\5=(^/\&LO\<?
M'.OPVVF:_P"--2U:Q%A;75E#;-=1Z+'X;1(KGPVGGWT]EJ2/J<US<7,\AKKQ
MW$&5S^L3J8Z>98>MB<EE0RV6'KQCA(X"I1GC:B=:$:-L1"$Z:Y'SU?:-5$HQ
MTX\#D&9TWAXPP4,NQ%'#9Q&OF$<11E+%RQU.I'!TVJ,G5_<3E"H^=<M+V=X2
MYG9_@IHG_!)G]D3Q!_P1.N_VSM;B\17_ .U-J7P)U7]HF3X\7/C;Q#+K5MXU
M@FN-9CTEH9-3_LZ;35^S_P!BW'G6_P#:DEU)->_;8[[8R^%?M6?M1?'7X[_\
M$F?^"2?PH\>>//$NGZ?^TK\8M?\ AU\6O%TU])'JWB_PE\-/$ND>$/#+:SJ?
MGF;4;1K/Q&-2OX;UFCU2[T6PNM065X3G]5[/_@WV^+-KX&G_ &:/^'EGQT'[
M%5SK!U*?X%P^%M,BOIM/.J_VHWA]]<_MIM/2QDE"R3-'HXLI+X?;VT<N!#7Z
M$?M;_P#!(C]G;]IG]C7X8_L@:!<:G\)-+^ ITN^^!7C?0H8M4UKP3K&EV$]A
M/<7\5Q):_P!N6OB..XEF\2QFYL[F]U#[/JD%S!=V<!!_;^6T\5A98G,9YI%9
MU7QU*M+#XC_A,PE3"UJ-&G&.(A"3E3K5*-9T<.I4H?5TX-S<4-9#F-3#8F&'
MR^&62_L>A@:M%8BA_P *6*I8FC5JU)2H3E%1J4:=:DJ]=QJS>(<9V@I-?SD?
M\%?/^"9?[-G[ 7C']@'7/V;W\8>'-*^(/QWT/PUXL\$:OXLU+Q#X?U76/#$_
MA>[M_B#:6FIW$\FG>(+R*[GT_5FL\:?-#<VZP068C\N;[6_:^2'_ ()S?\%U
MOV<?VOWEC\/? _\ ;5\*-\.OBQJS,UMI%EXLBM;+PQXAGU:0N(_*@"?#[QHC
M3,!Y\.K2(@6VY]AU?_@WU\=?%"'X6^+?VB?V_OB[\:_C%\*?&_@F_P#"GB;Q
M1H9OO"7AWX;^$KN.]N_!'A_PO>>(9IH-2\07-IIL]_XGNM2FG7[!##]BDS),
M_6?\'-VE_"J?_@GEHDWC1I3\0].^,_@F+X*QV444NI7OB:ZM=2M_$=GL;]Y_
M94WA!=5FU$PG(NK?2]H:;R%+H9I1QF*R7*WF%7-WB:.:95F6(]E7A*=/,)TI
M4*D77C&<U0E"G-5)>]%4&VHKENJ^6UL)ALXS-8"GE4</5RO-,NP[JT)1A4P$
M)QK4YJA*4(.M&52#A%\K=:*4I/F2\E_X(I:3?_M<?M^?\%%?^"F'B6V>XT?5
MO',_P,^#5[<B1PFA65Q!)?BPE?!$&D^#M"\"Z;&H:1 =6OXC\\(D;GO^#HFU
MU6^\.?\ !/.QT+4(](UR]_:2\0VFBZM+%]HBTK5[G2/"\&F:E+  WGQV%])!
M=O#M/FK"8\'=BOV+_P""1_[,(_9)_P""?W[/?PLO;);+Q;J7A5?B/\0!L:.:
M7QM\17_X2?54N5D1)1-I=M>:?H(65?,C@TF&%L^6*Y'_ (*D?\$R++_@I3X7
M^"6C/\:-=^"FK_!'QWJWCK0M=T3PQ8^)I+V^U33+2Q1'AO-3TMK.;3I["UOK
M.ZAFD(E5E>(C:1Y-/-\)3XMI8RI45++L#*>"P\U"=2,,+AL)4P=!J$(SDXS:
M51I1E_$;:M<]6IE6+J<*5,'"G[7,,:J>,KQYXTI3Q.(QE+&5TYSE",94XWII
MN4?X:2>Q#^Q1^S=_P4J^%/Q.O?$?[7'[;_@K]HSX67G@Z]TRS\!:)\+[?PI>
MVWB*XN+"73]:;519V[F"TM(KRWFM26^T?:5+I\IQ_)/_ ,%'O&WB+_@E_P#M
MJ_MU_L^?LB_$#1M*^%/[7/@+0+OXE^'-/34I(O@G=_$2[_M36=-C-BK1:;JM
MM!>ZH=+GMQ=7-MX+\90:6\7VZ*W2OZG_ -F?_@G%^V%\#_C+X1^)/Q"_X*C_
M !\^/'A#PW'JXO\ X5>,_#5C;^&/$DE[H]YIVG#5'C\174@@TN\G@U%(XX=T
MKVJQ"2+=YB^:_#7_ ((;?#6W^'7[;>E?M"?%2^^//QA_;;U2^U+Q5\8]2\(V
M6CZMX&9-1FU_P_\ \(GI\NIZH8Y-(\2M:ZM*3?01W-MINGZ,B06%N1)T9=FN
M6Y?C\5B<7C,)CL-6P^$I2PF!RZ>$H5JD<9":JRH2PM&DIX&%.6(4N52JRG"G
M"3O4MSYAE68X_ X7#83"8K!8BC7Q56.+QV80Q5>C3EA)0=*-:.*KU7#&SJ*@
MX<SC2C"=2<8VIW_,'_@KM^SS\+_V2_\ @AY^R9\+O@AJ=AJWAG1_BI\)O&4'
MCO2?+">.?%7B?PSKOB?4_B,EQ$$,CZ[J=V-2TR1B9+334TVS6399QD>"?\%5
MO^"=_P $?V'/V*_V9OVVO@?XR^(UC^U6_COX;:_XH^,7B'QYK.L^*OB-XE\7
M>&[GQ??^(+EI[O[/97NGZQ:K=6:Z3';P?V0TMA?"]1C,WM?_  5\_90\;_L3
M?\$7O@Y^SAXR^,MW\=8? '[2^@6_@[Q1>>&1X;N](\%7^F>);K2O"$ELFJZP
M]Y;Z)<S:@MA=R7$;0V5U;Z;'$MO86^?JGP%_P0%N_BN/V>KKXX_MN?&WXL?L
MI_#C2?!GC;X>?LW>*;:.[&B)J&D:?K%]X0G\3S:F]H- ^TRMIRW-KX>AU)M!
M#:5&]H',R^OA,QH8+"8'&5\XJ/#+.<ZK5I*A7G+.:/[E^RE%17(ZCJ)^SQ"A
M23FY.2E2A?RL5E]?%XO&X.CE$/K']D9/1I)XBA%9157M?WD9.;YHTU3:52A*
M=7W(Q46JL[>$_MH:AK7_  4&_P""J/\ P3S_ &+?C_K'B+1/V>_$_P"S5X*^
M.?COX;Z7J][X?LO&GCC7_!7BOQGJ^GZD;&YA,^^X\/67AN&0$7.GP)JR:>T5
MQ,):I>._V?O '_!,#_@N!^PCX+_8T37O 7PY_:=TU=!^*OPDL?$&JZOX?N=-
MOK_6?#][?O::O?W4K6L,4-OXB@-U+/)I][HMS/ISQK*\%?LM_P %!O\ @D_X
M,_;4\9_"3XV_#_XN>,/V9?VD/@;;6^F_#WXL?#^QM;QH=$LKJ6]T_1]3TIKC
M397CTNZN+E]*N[+4;:6TBN[RTDANK6X,2\+^R'_P2$G^$'[2EM^V9^U5^TYX
M_P#VQOVE=&T.30/!?B;QCI%GH'AKP+:SV5QID]SHFC1WFIS37XT^ZNK:RF>Y
MM;?3Q>7LL-H]U<&Y7R:6=X"&7THK&2I4(9/C,#6R-4:[A7QM>5;V>*<N7ZK*
M-ZE.I*M.:K4_8J$(MM(]6KDV/ECZDGA(U:\\XP>.I9TZU&,Z&"H1H*IAE%R^
MLJ5J=2FJ,(.C455N<DD?@)^TQ\(=(_8\_;6_:X^+'_!5#]ASQI^UI^SC^T#\
M4-2U'X<_M->'-<U#4G^%?@_6]>U&70;#1X;34;6TTF]T[1K_ $[1CH%_J7AG
M5;.ZT:'^PGO[>X@67ZE_;CUOX7Z]_P %.?\ @@=XD^#NJ/J_P>OM!^%4?POU
MN[FO)Y[OP>OC#2]/\.?:+G4P-0;46T\6=M?+?;;\WC/'=J)F(/WQ^T%_P1T_
M:G_:"O/B1\,O$_\ P4Y^+UQ^R3\4?'.H>,-=^"^M^!-#\0:_IFG7_BP^+8?!
MVD>,[W4Q,-"T6]6WBT:.:V%O EI:/-I\OD^6_J?[:O\ P15^%O[2_P '_P!E
MWP)\)?BAXJ_9]\=?L=:3IF@_!3XB:5;#Q!>VNCZ7'IDEO#K,2WNCW9U*'6-(
ML?$%GK>E7UC=V>JBX>.)XIUCAZ(YUECJ9=/$X_FJ?5L9@L1+#1QTL#AZ%;+5
MA*%>6#Q$%['$*I:-:&"4J4H1<[W:.=Y+F2IYA'#X#EI?6<)C*$<1+ K&XBM1
MS%8JO1CBZ$W[;#N"<Z,\:XU8SDH;)L^'O^"B1B?_ (.#/^"5@!C::'PW(" 5
M:6(2:EX[(# $O&)%S@' =<]1FOC;0OV)OAM^WK_P7I_;]^#7QJUSQ=%\']"T
M^'XG>,/ _A76KK08OB-JGAV/P9X;\*:9K]_:.)DTW0[GQA?ZQ$8D:X,\0MX)
M;9;B69?U-^#_ /P0HO\ P%^U3^SG^V-\1OVROBK\<?C5\)_$-]XE^).N_$/2
M(M3/Q#N$TNZTSP]I&@R3:U++X/T30X;R6,PDZO->;FG+P2.(T^SO@-_P3;L_
M@C_P43_::_;WC^*UYX@F_:(\(+X6'PUD\,6]A!X7:;4?">HW=X/$*:G/+J86
M3PI#%;0G3K7Y+Z9I7+0QAL?[;P."H>RP682G7P_#DLNH8B&'KTF\9_:?MU[)
M3AS0_=-U*=67+:T9-TZON1V_L;'8RO[3&8",*-?B*.85\/4KT*J6#_LQ4/WC
MA/EG^\BH5:4>;FO*-JE*\I?SZ_\ !50OIO\ P4._89_X)]6/P7^+?[1'[+'P
M-^">@ZGH?[*7P^\2M8^(OC'<Z7X=\5&V_M#4+Z\L[76UT+3?">E2:I/=LDXT
M72?$,%B;:YOGF/O?_!,SX'_M(_"K_@J?>^//A!^PG\?OV(_V(_BA\*O$.E?$
MOX9_$?4K&]\%Z5XQTC07U#0]<TE+?5KNVBO;_P 46.E6>EQ6L4U_:VNI:S$7
MCTZ65(_UT_X*#_\ !+/PS^VOX]^$OQ[\"_&/QI^S7^T]\#R8O 'QD\"V=IJ5
MP-.-W)>1:9K>E7$]C)=+93W%\VGWEKJ-M-#%J-_9W4=]97)MTT_V-_V)/VM_
M@G\6+CXL?M-?\%"OBC^U(8O!^L^$=&^&UWX5TOP5\.[&36+_ $>[_P"$GO-.
ML+^[?4=?L8=):SL9GBA$$>H7K^:_F;*SGGF$ED<,/3KX=5GEM?"8K"XF.8RJ
M5<55K3JRQ5*%*^ G6G)PJQQ-=JM3FG&3E%*)I')<7'.IXBI1KRHK,:.+PN)P
M[RZ,*6&I4J=..&JSJVQ\*5.,9TI8>A>E4@TTE)RD]'_@L-^T\/V3O^">O[0?
MQ%L-0%AXQ\1^&3\+?A[M<K/+XQ^([-X<M);8CYO-TK2[G5M=RO(32FP5)##^
M)CXQ_'G]CP?\$MOV3O@O\)9?BI8_M@_L[_$\?&;4_$FI?##5M%\.7?B'QO=3
M77Q"LXO&;W#)-#I\UKX3GTR]D58K[_A&(BD<3W*&+^U[_@I1_P $X3_P47'[
M.?ASQ!\8+_X>_#3X-?%"7XD^,_!=CX:AUL?$N:.#3[/3;&:^FU6Q723I^GKK
M]A%,;6^7R_$5U-Y7FV\-?97Q<_9S^%GQ@^#?C[X):[X5T*R\*^/? >L^ ;I[
M'1--6XTW3M5TF72H+FQ/D*5N-+#0W-F=ZE)K:(AU(###)LZRW*,%@(RIU\3B
M9YC/&XM4:KPZH1I1>%HTJJGAZJQ5.="IB*CITYP2]JXN:D_=WS?)LQS;&8Z4
M:E'#X:&7PP>%]K2]NZ\JLUBJ]6DX8BF\+.%:EAZ:J5(3;]FI*#BKR_"#_@H;
MI?[07_!4_P#X)#_LW_%+]E33KSQUJ6M:S\//BC\6_A)I&MC2=2^(^B^'M"\0
M:'XV\&1.;NQ&I3Z7XV*7LN@FXCN-1AL6:SAGOH+2%_(/^";7B[]CSXP6?[6O
MP-_93_9G\4?\$[_^"A]Y^S5XF^'?B7X>:[J7B*'0[EX+>.WLO%FCSWDB>3JF
MB^*;S3I+ZZU'0]'\1V%AJEO=0MJEJTES#]F?"'_@C_\ M ? +]CKPI^S1\%_
M^"@_Q'^&_C#X:_&[Q1\6?A[\2O#/@BQM+%=#\5:&VF:E\-_%OA.?7KJWU[P[
M)JLUUXFC=KQ%M]6NI]MG+'+N3IOV<?\ @CGKOPU\7_M'?'GXV_M=_$SXP_M9
M_M$_"_4_A3-\=](T/3/ MY\-]%U&RT^S_M;P;I.GW-P&UZW71]'CM[JXNK>V
MM;'3DLK6TA,\UR=_[0RJE@,;@J>8Q^KT\97K99&A3S"G5E[7%49P6.H2I1P>
M+PBI04I*K;$4W3<*<7=&'U#-*N/P6-G@)*O/!X>EF4JU3 5*473PU6$Y8&NJ
MDL7A,5[6<HQ5*]"HIJ=22:DS\'OV!M+_ &9/V-/C1\!/V=?^"EW[!WCGX)_M
M56/QCCUSX9?MFG7-;U#3_'WC.Y\4J_AF/7=4T[4/LE[HGVR^MM'DU#1+[Q)H
MMU;RV4NL6&F/<2SM]I_MA0?\$S?BS^W%^TEX/T;]AW]J;_@I)^U-#<11?%^U
M^'^J:A-X+^#MSIFA:7X;7P_X:OM7\1Z%I>A-I<MBBWYLM/O8;773=P6MY=3)
M/:0_8^C?\$6OC?\ $_XN?!/QI^W#_P % ?B'^U3\/_V<_%MOXS^%_P /;OP%
MHGA*:?6K"XTVXL;CQ7XAMM0OKJ_:232K%]3D2&2[ODMEMEO+>*25FW_'_P#P
M1@^(5A^UG\;OVDOV5?VXOB7^RYI7[3MY<7OQS\'^&O!VA>(M0U"?4KIK[6_^
M$1U_4;RW711?:A->ZCI\DVGW%WH-U?W2V%VUKY=NG75SC*ZV->+EFM>GBY8"
MJJDJ%?-X9<\3+%TJBI4Y>S68T:,Z,9598>DH4(UHPIQJ*',<E+*<TI8*.%65
MT)X6&-I.$:]#*IYDL/#"SINI47M/[/K5857&G'$5.:NZ4ISE3<VK?SF?LK?
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@"G>Z?8:E#]GU&QL[^WW!_(O
M;:&ZAWCHWE3I(FX9.&VY&>#5B&&&WBC@MXHX(8E"10PQK%%&@Z)'&@5$4=E4
M #L*DHIW=K7=NW3[@LM[:]PHHHI %%%% !1110 4444 %%%% !1110 4444
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MHI#"BBB@ HHHH **** "BBB@#B-'_P"1X\9_]>7AC_TFOJ[>N(T?_D>/&?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0U?X3:]-JM]9:)I<-MIUK=ZG-''-J%Q#;I+>3(LMPTD@#4 ?J51110 4444
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MEB'3C[9-T(QHMJIS)NE&--VO!*-CX-^,/[1/Q(O?%GP5D_9I^)WPK^(WP_\
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M(P2:3IDD#:E%K+0O86K1-K$-W'J$.K&-HBAU**_ABO8KXC[5'=Q1W*2B9%<
M'Y0_M@_ME_$_]E7P=^SEX!T[Q$_Q ^(]Y\2O@!X.^/WQEM?A3X@\1^$DM-:^
M)OPO\#>/= CTKX>Z%JF@^"OB1X^MO'+:YX8T#6FTR/1_"Z75_I]O?ZE/H%M>
M?KC6,_ASP](+T2:#HSC4M3M-;U$/I=BPU#6=/^Q?8-7O0T!^U:G9?V;IWV2_
MG\RZMOL%EY,J?98/+V: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHKD?&_C_P/\-= NO%/Q!\6^'?!?ARR'^DZUXFU>RT;3HV
M()6,7-]-#'),X!\N"(O-(1B.-CQ3C&4FHQ3E)NRC%-MM[)):M^2(J5*=&$ZM
M6I"E2IQ<IU*DHPA"*5W*<Y-1C%+5MM)+=G745\#S_MT0^/KI]-_99^!WQ1_:
M0=B8HO&NGV,?PX^$"3[S$Q/Q&\>1Z;!J-O;2 M<S:!I.KQO&"+)[N7$=?(/[
M;\W[35E\!?$WQ'_:?^+'ACX,^ -&DCGT3P%^S5X>\6^)?&U[XLN8+JW\-Z/J
MGQ5UB\TFVT2VO+R1;.\U<>'3I9:4E;:.;[*5[Z.75IU:=*M*&'=248J$WSUV
MY-))8:#=9-W7QQIQM=N2LSY;,>+\!AL%B\;@*&(S>GA*-2O5Q&&BJ&5PITHN
M4YSSC$JGE\H1BFY+#5<5635E1DVD_P!@8/B1X N#XM\OQEX;5? >L#P_XSDG
MUBRM8?#&M-IMEK"Z=K,]S-##8W)TS4;*]"3.H,,ZD'*N%^<_%?[?'[)/A2ZG
MTQ?C+X>\8Z]"YA7PU\,X-3^)>OSSC($$.G^"+'7&\UB"%\UXD+8&_)&?Y,OV
M"OB!\'-2_:*M?#W[6/AO5/BOX%^*4Z:<1K&H^,]<NK3XC7%U:KX9UZZTS1M6
MAE\17.H3K_8-W)J5MJ3QPWD,Z(D=O(&_M4\)?#WX;?#BR2T\$^"_!O@>QB@6
M,0^'= T?P_&L"@$+)]AM;4LHP"WFDG(RQSFNW,LLP^4UHTJ_UJNYPC.#A[*A
M2E9)32J-5Y2<9W4H^S@XIQU=U)_/\(<8YKQS@:V-RU9-E4<-B)X>O3Q'US-,
M93<I2G0E/"TY972I0J4.1TZJQ>(A5J1K>Y3]FZ:^11^VMXR\3%%^%/[&G[47
MC5)RHM]3\4>%] ^$NA.K#<)9;[QYKME?10XP<II,TWS >1D$4DOC?_@HOXJ?
M=X?^!O[.GPKLYTS&?B%\5O$OCC5K7>?D-Q;^"/#=CI[NBX,L<=VPW?*KG!K[
M$U+XB?#_ $;=_:_CKP=I6UMK?VEXGT2QVMC.UOM5]%AL G!YP,XKC[S]H7X#
MV"LUW\9?AA$JDAF_X3GPW(H(&X@F+47 (')YZ5YWUFC'^'@J'E*K.O5DO5>U
MA2?SI'UG]D9C6_WOB/,W=ZT\#0RW 4?2+^I8C&17_<ZWYWU/G"#X7_\ !0/Q
M"Q;Q)^U-\'/A_"ZJK6OPR^ I\074.<EVBU7XA^*+Z!W!PB&30PFS+% Y!"/^
MQ[\6]:</XR_;G_:5U4,"9X/"_P#PK[P!:RNWWBD/A_PH6A0\[(TE/E\;6!&:
M]L;]K+]FI9A;I\;OAU<3D[1%9>([*_<L6V[5%D\^6W87:,MD@8R1E\G[5'P"
M0N$^(MA=E!EAIVD>)-4;H.BZ;HUT6))VJ%!+/\B@O\M+Z[63O".'I]O9X3"Q
M:_[>]ES_ 'R?7NQ_ZMY=)?OZV;XK6[6)S[.JL&[6;]C]?6'5^T:27D>'1_\
M!/CX:76X^*?C)^U7XU,AW3KKG[0WCJQBF[[3'X5N?#FQ,\[8V4GHS,.*NQ?\
M$W/V-V$?]K_"BZ\6/'C][XT^(/Q+\7R2-G):8^(/%]^)"S99PR[6))*G)KV.
M#]J3X)W3^7:>(]?NFVEL6WPW^)DPVC@MN3P>5P#P3GAN.M6Q^TE\*W)$4_CN
M;'4P?"+XLRC'0-^[\%-\I['H>U'U_&[+%UXKM"K."^2@XI; N%>&T[RR/*ZT
MOY\1@Z&*F]GK/$0JS;NE=N3;ZGAC?\$R_P!@]V9W_9I\ LS,69F?7V)+$DDE
MM:)ZGUX' X%?3'PA^"?PM^ OA>7P5\(?!]AX'\)RZG=:R=!TJXU"73TU.]C@
MCN[J"+4+R\-LURMM"TR6[1Q22*960RN[M\+?$;_@K#^S=\-/&FN^!]9T'XKS
MZEH%Q%;74R^"9M)61YK6"Z5ET_Q'=Z-K5NNR=<+?Z9:2.,2)&T3QNWWE\'OB
MEX>^-?PT\(?%3PI!J5KX>\::7_:VE6^KP16NI16WVFXM=MY;PS7$44OF6[G:
MDT@VE3NYP(J8K%5H\E7$XBK"Z?)4K5)QNMGRRDU==';0[,)DF38"M]8P.499
M@JZC*"K83 83#5E"5N:'M*-*$^65ES1YK.RNM$>E4445SGIA1110!Q'@[_C]
M\=?]CK=_^F/0*[>N(\'?\?OCK_L=;O\ ],>@5V] !1110 4455GOK*UEM8+J
M\M;::^F:WLH9[B*&6\G6-I6@M8Y'5[B98D>5HX0[B-&<KM4D %JOSX_98_Y/
M(_X*<?\ 99?V=/\ UD?X0U]_07MG=2W4-M=VUQ-8S"WO8H)XII;.X:-)E@NH
MXW9K>8PR1RB*4(YCD1PNUE)^ ?V6/^3R/^"G'_99?V=/_61_A#0!^@]%%% !
M1110 445P7Q%^*?PW^$7A]_%?Q0\<>%_ /AQ)DMCK/BK6;+1K%[F0$I;0S7L
MT0GN&56800B24JK-LVJ2'&,IR48Q<I2=E&*;DWV25VWY(SJU:5"G.M7JTZ-&
MG%SJ5:LXTZ=."WE.<VHQBNLI-)=6=[17(>!O'_@CXF^'+/Q?\//%GA_QKX7U
M R+9Z]X9U6SUC2YWB($L27=E+-$)HBRB6%F66+<N]%W#.GXA\3^&_"6G'5_%
M?B'0_#.DBXM[0ZIXAU:PT73A=7<@BM;8WNI7%M;"XN92([>$R^9-(0D:LQQ1
M*,HMQDG&46U*,DTTUHTT]4T]&GJATZE.M3A5I5(5:52*G3J4Y1G3G"2O&4)Q
M;C*,EJI1;36J9N45DRZ]H4">9-K6DPQ_VE::-OEU&SC3^U[\VZV.E;GF"_VE
M>M=VJVECG[5<FYMQ#$YFCW-M_$7A^[O=1TVUUW1[G4='#'5K"WU.RFO=+"+&
M[G4;6.=I[(*DL3L;F.(*LL;' =246;%%9<.MZ+<A6M]7TNX5],BUI##J%I*'
MT>8N(=64QS,&TR8QN(K\9M9"C[)3M.*UOXH\,W>I6FBVGB+0KK6+_1D\1V.D
MV^KZ?/J5[X>DE2&/7;2PBN&NKG1GFECB35(8GL6ED2-9R[J" ;M%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110!P</Q4^&%SXA_P"$2M_B/X#G\5_;9--_X1F'QAX>E\0_VC"TBRV']BIJ
M+:E]MB:&99+7[-YZ-%(&C!1L=Y7R)H?@;P1#^VC\0]9B\&^%(M83]GWX/:LF
MKQ^'-'35$U2Y^)OQY6YU%=16S%XM]<* )[H3">4 >8[8KZ[H **** .(T?\
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M<^"-1_X1Z+0=.T#Q9K%EXM;4+KS+&QO?"%]KNF:G=03)IM[=K&S#]3OV*/\
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MP_MX?%NC:A<^+]1\<:LVA>$AH-MIUW=SZC9:[JZ/I]CJL$;:6]U')$UXC(V
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MN9$81:MJ+QS1JMFV_P#HCK^ []LG4="U[]JC]H;4M3U#0OA-=:?\5O'OA!M
MDUU[FR\ >,?!5Z91XA^)EQXHT/7-9\8CQWJTS>,-6M$N;6Q\2> -6TC1O"*^
M&9(UUNZ][A^CAZN*K/$4W6C##5DJ2G2AS<].4)N]2K3?P.4(N*:C.I&4Y4XK
MF/R[Q6S'-<#DN71RO%PR^=?.<O=7&3H8ZO[/ZOBJ-7#P7U/!8N*_VE4L3.%5
MPG6HX6K1P]+$SG*D?UZZ-^U'^U/XCTG3-?T']A37-1T36]/L]6TC4(_V@_A<
M([_3-0MX[NQO(@EG*OE7-M-'-'B1CM<9P<@?1WP6\??%WQY::_/\6/@9/\$K
MC3KC3H]$M)_B%X=\?MX@@NH;E[ZX$OA^SLTTO^SI8K>$Q7(E:Z-UOB8+"X/S
M+_P3@_:+^$_QA_8C_9W\?^%[O0O!FAZOX3&AV?AJ]OO$>DII.J:"\D=]HFG6
MWQ&2P\4+%:6S6UY!IMQ]N32+"[MK"UU"_L+2WO)OT%CD25$EB=)(I$62.2-@
MZ2(X#(Z.I*LC*0RLI(8$$$@UYN(J4;U*=/"4*:4Y1C5A/$2DU"5KIRQ5:C*Z
M6KBIQ]Z\96Y6?8Y3A<>X83%8K/<RQ4IX:E6KX"OA\IHT5.O04G&:IY)@,PIJ
MG.7-"-1X>KS12KTU[](^1O'OQA_:IT'QCKFB>!OV2+;QSX5L+T0Z-XQG^./A
M/PT-=M/L\4AO#H5YH=U>Z:1,TL'D3S2N?*#[MKC')#XX_MLNV%_8FT6-0N?W
MO[17A%B3GL5\-J.G8C/?-?<CSP1NJ2311N_W$>1$=^<?*K$%N2!P#R<=:ER,
MXR,^G?\ *E'$4HJ*>!PL[))RE+&7DTDFWRXN,;MJ[45%*[LDK(TJY5CJE2I.
M/$N=48RG*4:-*CD')2C*5U3@ZF1U*CA!>[%U:E2HTKRG*5Y/X6'QH_;DD+%/
MV,?"D: @*)OVBO# <\<GY?#A'7/2A?B]^W>Z%A^QY\/HV.[:DO[1NA[A@D#=
ML\*L,'&>">*^Z:*/K-+_ * ,)_X%C'^>+?\ GN3_ &-CNO$^?/\ [A\/+\LA
M1\*GXJ_M\L@V?LE_"A';;_KOVB;8J@)&[=Y7@QB=HS]PG..,]"K?$O\ X* N
M56+]E_X)0\G>]Q^T!=R)C'&!#X&WYS['.1TP37W311]9I_\ 0#A/_+KR_P"H
MKR_%A_8V,Z\2Y\]NF1KM_+DBWMKUU9\*_P#"P?\ @H3(V$_9Q_9^@0+DF?XZ
MZ[(6;/1?)\"<#&/O#J#ST%2+XY_X*&.6)^ 7[.$(!&U9/C7XK=B,<G,7@,KU
M]@?;O7W-13^M4_\ H!P?W8E]N^)?;\7T#^Q<5_T4>??^!90ORRA'PP/&/_!1
M)ER/@E^S!&3G"R_&3QT=O) WB+X>N".A^5R<>AR!X=^SUHW_  49^&7PRA\)
MP?#[X$:]_P 5K\3O$!U/XG_%WXF/XG0^+_B5XK\5R6++!X!NQ_8.E-K+:9X2
M"W#$>%[31R4C.84_5BO"?V</AX?A=\+XO"1\1>._%.WQQ\5/$']K?$>"2V\3
MX\7_ !.\7>*_[.,,L]PXT+1_[9_LGPJ_FE9?#%GI,J)&CK&A]:A_T!X/_P !
MKO\ .NP625^O$&?/2VM;+EVU]W+(ZZ?B['B/]O?\%'G=%7X;_L=0*<[Y)OB?
M\7Y0, D86+X<AB2>.AZY. #4@U/_ (*/22'/@_\ 8OMHPG!;QW\:KEV?=R,+
MX#MPJ[><_,<C&.<C[@HI?6H_] F$_P#!=3]:O4:R2KUSW/7ZXG"+_P!)P,>Q
M\0K<_P#!1URY?2/V+K<;AL1?$'QLN?EP,EI#X;M^=V>!'C'?M3E7_@HTR9=O
MV,8I#N^57^-4RKR=OSFWA+\8)_=ISD5]N44?6NV&PG_@IO\ .;_KU8UD;ZYQ
MGDO7'QCU_N4(^GIYZGQ5]E_X*(,JC^V/V.XG.W<1HWQCF"#(W[5.J0;\#."2
MF?09XD;3/^"A;LH'BW]D"!?FWM_PA?QAN6/'RA4/C"V YZDR=#G!(P?M&BCZ
MV_\ H'PG_A/#];]OZN']A0ZYIGC_ .ZI77;^7E[?BSXO71/^"A#N=_Q"_9%M
MXPHP(_AA\7+IF?/.=_Q,M JX]-QR.G/'YS_\%*_VAOVP/V=O@;<^'/&GQ0^
MM[J7QG&J^"=-TCX:?#+X@Z'XOMO#LEACQ3KUIK^M?$O6['34M;6Y@TPR3:'=
M-,^K!;9XIHS+'^]%>%_&GP9X]\8V<5GX.M?@]);2Z1K-AJEY\3O#>LZY>V7V
MZ%88IM$FTN^LX[2..,S2W2W ?S)4@9614;/3@L;"&*HSK8?"SI0DI2A[*E2Y
MN76/[SV51KWDF[1U5U=7NO'XAX=Q&(R;'X?+LVSJCC*]'V-*L\=C<9R1JRC"
MJUAOKF&A4;HRJ17-5C"#:J2C-1Y)?B;_ ,$I_P!H?]JKXS_"6Y^#/@CXH?!;
M1+WX(66GV&EZ;\4/ACXY\5^)M2\$7\DW]DWL.N:'\2O"ME=6.BW(;0D@;2_M
M-G:QZ:LES.LJ%?U7CT#_ (*"JN)/B=^R3(V3\R_"+XL1@C/'R_\ "VWP<=?F
M-=Q^SW\-_'_PZT;0=%\3I\$[O1=%\$Z'X>TK7/AOX8UK1]?U<Z79V%I#?:K?
M:AJ%Y:75I?VUK]LF6V4>9=R),CF,<_2]5F&-IU,77J4,/AHTYSYTG2I57S-)
MS?.Z4&^:5Y-2C>+DU=V3,>%^&\5A,BR["YGFF<U<9AJ"H2J1Q^-P:]E3TH4_
MJ\,;B*<?8TE"BITYJ-54U4Y8N3BOBXZ+_P %"4D;;\0/V1+B+:-I?X9_%VUD
M#?Q95?B5=*1V&&![G'2D;2O^"A:E2GC3]D"8;AO1_ ?Q@M\KSG;(OCBXPV<
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MC +SD"0>)O U\9@.GSD,PZL>U1?V;OVI=/ .C?MY^/YF3[@\4_!KX2:\C#C
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M.FGQ*_@+PLRMN!B3P[\/8_#B20%&,;1ZC?:CN3&XE\N>^\(?!7X2> <-X/\
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MWAKX;:#K$&L+I'AFSO/CG!%-H&K:IXBT+Q-!INJ7^JW.BR7VH:/XA]+^$/\
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M\2)KLBF5;:&_TNXL8/$5E-HH /"[?_@DKK.FKXUBT7]H30=-35M#@7P?>O\
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M_P#%VJ1Z)XW\?? GPWI7Q"\;:!9^+M+BU^#]HWPAX9T:^LO@[8:5X4_X25O
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M7R7^H_9X=%\3?%76+L:-<Z7J<W_",MC4(8M+D%S_ $,T?TZT ?SK?%?XJ?\
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M0MHVCII,ERJZ):WNJ:9^Q$*VMM### MO;P'"6\4(CBA.X-($A1 J<J&<*@Y
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MZIX1?PEIG_".^&[5[C3I+W5=2![?_@G9\#_A=^SK^T+_ ,%(_A3\'/##>#_
M.B_''X$W^FZ$VN^)/$C6]WK?[*OPFU+5)CJ_BW6->UR?[5>S23>7<:E+% &\
MJVCAA58Q^K]?GQ^RQ_R>1_P4X_[++^SI_P"LC_"&@#]!Z*** "BBB@ KRGXN
M_!'X8?'7PA?^!_B?X5L?$>@:C/:W<L;F2SO8;VR)-I>V>I6;P7UK=0 LB2Q3
MJ3$\D+AHG9#ZM10!YY\,?A1\/O@YX1T;P-\./#&G>&?#>A02P:?9VD;23#[1
M*T]U/<WL[2WEW=7<[O-<W%S/))+(W)"JBKPWQO\ V:/A-^T)_P (]+\1=/\
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M??!GX0W]_"&5;3P=X:^*^L:6)BUIXTL;^WCGKZ$^!W[''[//[/>LZEXQ\ ^
MX[WXH:_8Q6'BOXU>/=6UCXC_ !J\7P1A2\7B+XI>-KW6_&%U933+]H;1;;5+
M/P_;S'_0=)M(DCB0 ^?8_C!^W'^TI_9__"AO@[IG[)?PJU17DG^,W[56E-K7
MQDO=,<F.*[\"?LP>'-8MGT*[G"O-:W7QJ\<>%[VS3R9;WX>7R2>0?AS]OO\
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MCZJ@'B?5VMU:SM[N;5=&TG5H?%FM6UIH(CN)?['_ -ESX6>#/@W\ _ACX%\
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M1:CXEE\/ZI9Z]I5]]O@O8[O1]5@U_3['Q#-K&@3:5JM_XAM8->U"\NM7C6\
M!^*?_!4G_@J?^SC\0?\ @CY\;]!\<3>-? 7QH_:H_8#\:>+_  K\/M,^$OQK
M\?>%K/4O&&@^(/# TJY^+WA+X::A\--*L8?%&D:M:P:GXL\1^&2-(BL]:U2U
MTNTO[<O^Z_[% Q^QK^R2/3]F3X"C_P Q7X4KXV_X*^^#_"WP\_X(R?MZ>!/
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M-5U&2^AG2W\,^'+"YU/7-9CAM6GN;NRTVQM+FXN9+.&<JL3*%9\*>0UOX_\
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M6C_#>PUS3O!MS)*IA\[QYJ_A;3H),B[OK=0S#SK_ (77_P %'?C18Q2_!O\
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M-U\)OA7\.[?Q%8MIOCB_N+CQU>2>!]7U#XC^(UOI;#QA>WND&WM(?[$6^O\
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MQAXA;P/%X":&%K>Y\1Z?\1+75_#VJ^!9DMI6MKG6M,\0Z/*;:5[>:Z,$C1L
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M<N&X>R;"1J<_^SNI6S#.,36ING;6O&$<-)3NN2G-QL_:,]PHHHK@/J HHHH
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M)=!AUC2;BVLUL]2CM+:.U';_  [^"_P=^$":M'\)OA/\-/A>FO26LVNI\._
MGA?P2FM2V2S)92ZLOAK2M,&HR6B7$ZVKW@F:W6>98B@D<-Z70!\F6>E?M?\
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MFBT\:MJVH:B+87=U-*P ^V_;N^)^O,%\&_\ !.7]NO5D<92[\4^&?@=\,K4
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M^&['2)+H*=2U0^=?Z_K4PV[KK7?$.HRW>MZU=2,H>2XU.^N96?G<, #OZ**
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MF*V8T1#\JJ!;HH _+[_@M:JK_P $CO\ @HNJ@*J_LA?&M550 JJ/!>I   <
M < #@#@5]3?L4?\ )FG[)/\ V;)\!?\ U5?A2OEK_@M=_P HC_\ @HS_ -FA
M_&S_ -0S4J^I?V*/^3-/V2?^S9/@+_ZJOPI0!]-T444 %%%% !1110 4444
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M#SP/X6\;>)M,GLM/M_#&J>-]-;0;Z+7I/$-U%+!YG[/_ +2WQE\,?L\?L_\
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M%:S\8;GPI\!OB#XZU;5/$J>/-$BTSP;??%&V\-7,7AB]UB3PQ9W)N];AT_\
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M_P#@HS_V:'\;/_4,U*OJ7]BC_DS3]DG_ +-D^ O_ *JOPI0!]-T444 %%%%
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MNXO?$GCCQIKMP#<:MXC\0ZC>W\Y\NVA>WL+:TM+?W*@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "OC/6)3^U;XUN_"5A(L_[-WPX\0>1XYU."
M3?:?&GX@:!=K)_P@FG7$+F.[^'G@S5($?QM<*7MO$OB*U3PLGF:=IVM^?M_%
M'Q3X@^+WB^__ &>OA;J]_H]K8):M\>/B9H\K03^!O#^H0K<0> O"VHB-X_\
MA97C&Q<AIX&:3P5X>F?6Y]FIWFC1-])>%O"_A_P3X<T7PEX4TFST+PYX>TZV
MTK1M)T^)8;2QL;6,1Q11H.68X,DTTA>:XG>2XGDDFEDD;JC_ +-!3?\ 'FKT
MEUHP:359]JDD_P!RM'%?O=&Z4GXE7_A8K3PL=<KPU1PQLU\.88BE*TL!!_;P
ME":MF#7N5JJ^H-SA''TEN1QQQ1I%$B111(L<<<:JD<<:*%1$10%1$4!550%5
M0   *?117*>V%%%% !1110!Q'@[_ (_?'7_8ZW?_ *8] KMZXCP=_P ?OCK_
M +'6[_\ 3'H%=O0!\G_MV6&NZG^QQ^TK8>&O^%3C6[CX/^-%L9/CI!X>N?A%
M;LNDS23W?CZV\72P>$[C0+.U2>ZN(/%$T/AR66&&/798]+:Z<?D;_P $!+!+
MSX:_M<^']1U_]G+XB^&X/BKX>\-0:U\!?"O[)WAWP9XLTV+PA=VESJ.H>&?V
M78&T-])\0:?-:W&E_P#"Q@GBJ:UN-0TI],M],T^&XU'](_\ @JI&TW_!.+]M
M"%/["$DO[/WQ CB?Q+<^&++18IGTF18)[N_\::QH'A+3I+>4I/9:EXCU>ST;
M3K^.UO;]IK>![>7XK_X(I_&_1?VG?@5\>DM?'GQD\86&G^)M!\'W^L^/_&?[
M&FH:]ISZAX("W:>%?$O[# T_2-,FC2;[3]O\5SV_C"UU$PWVCR6UH(V4 ^(O
MV&/#OAF7_@JY\2-6T_3XK1O"G[0O[3O@?P]::-^U9^Q]X-T/0?#GA1?$_A_2
M/#T/[#_A?X:6_P >=-M]'TZWCL;&]3QRLFI6<=I\1-3C_LW4+C3$_JEO;^QT
MZ))]0O;2PAEN+:TCFO;F&UBDN[R9+>TMDDG=$>XNKB2."VA4F2>9TBB5G95/
M\=>H?M^>!OV,/VT]3N=!^#5[\0]"\%_&[XT?"KQ1=:]\>?V2_B3^T-J<?@&5
MM!\1^/\ 6-(UGX0:;^UKX:DU>35(Y_"W_"5_$2^NOB5J5SI_A]]9OE\2Z++J
M?ZF?\%>?V=/VZ?V@/'/[(6L?L]Z!X1\;?!7X,_M%?LV_%;Q)\/V^('B'P1XR
MO_'OAWX[^%M0U7QEXIL(/"VJ:%XD^&_@7X:6NKL^DS:S::EI^HZUJOB.'1?$
M=_HNB:<H!^X=GJVE:C<:A::?J>GWUUI-PMGJMM9WMM=7&F7;1K,MKJ$,$CR6
M=PT3+*L%RL<IC97"E2#7P1^RQ_R>1_P4X_[++^SI_P"LC_"&OSB_X)^_L;_M
M>?#?XE?M*R7.BZO^R_XUU/P!KW@CQ/\ M$:MIW@?XG:;^T/\9-4_:N^+GQ;T
M7XWZ)X/'BB=O%5CI7P3\6:)X&?5_'UOX:URREU@>'K>Q>W\)0JGV=_P3V\+?
M$KP9^T9_P4F\/_%SXJI\:?'-M\<?@1-J/Q!C\":)\-TU2TNOV5?A-/IMF/"7
MAZ]U#2K'^RK)HK$W$%T\E\8C=3JDCLH /U6HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHKQ[Q9\>OA9X0U&?0+OQ/%K?BR%"?^$+\'6=
M]XR\8/)DHD+>'O#=OJ6H6C2R QK+J,=E:JP)EN(T5G4 7X]@GX2>+P!D^3I/
M _[#^E5Z/K_B/P_X5TNYUOQ-K>D^'M'LT,EUJFM:A:Z986Z $YENKR6&%2<8
M52^YCA5!8@5^3/\ P4!O?VNOBY\$K6[^$O@+Q5\,_!FG:_:77BS3=1\4:'IG
MQ%\6:7/+#!HS/HFEW=S_ &-I.GZJ;>ZO=.N/$"ZK<336CW&F)'82E/K+]G/]
MGG6K7P)\._%G[3$]Y\3?CMINB1?VA>^+M7?Q-I/A.X:67[)9>'](8_\ "-VF
MJ6FG?8H-5UZUL)M4O]3BN[HZK.LOF. =L?C/XU^(Z)#\!/ DNJZ7/,T1^*/Q
M'AU+PGX!A@4D->Z%I$D,/C#QJO'^C-86&DZ-<DJ5U\)O9="Q_9]T[7;^+7_C
M1XFU3XR:W%+%<V>E:Y#%I?PXT*:)E>,Z'\.[!SHSR1,H":CXCD\1:LVT,;Y6
M+9^A@ H"J %       &  !P !P . *6@"*&&&VABM[>&*"""-(H8(8TBAABC
M4*D<42!4CC10%1$4*J@   8J6BB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@#B-'_P"1X\9_]>7AC_TFOJ[>N(T?_D>/&?\ UY>&/_2:
M^KMZ "O@_P#X*8^'[GQ1^Q/\:-&M? VL^/Y)XO!$\FF^&_\ A)W\1^'K2P^(
MWA*^OOB/X>M?!+KXOU+6_A996UQ\1=+TCPV)-6U>\\,0Z;!;W*W4EO+]X5^<
M_P#P5BT^'5OV"_C7I3ZDEC=ZE>?"VQT2RF\(S^/K3Q7XFN?B]X#B\+^ -0\&
M1>+O =MXCTOX@^(6TWP7JFFZQXNT+0'T[7+J77K^'28KMJ ,O_@E3X7T;PA^
MS5XBT3PUI?C'_A%+7XX?%&#P;XZ^(5GXWTKQQ\7?!-A>:9I/@OXD>*-!^(EE
MI?BO0=6N?"NG:/X3ET^]T?1K26/PE%JFDZ58Z3J-E OU1^UA\5_''P)_9J^.
M'QE^&_@C2?B-XU^%_P -?%?CG1/!^O>(QX3T/5'\,Z3<ZM>2:QKHM+^>UT[3
M=/M;O5+N"QLKG4M1BLVTW3D6]O()8_F__@F)=ZD?V=-;T#Q+\-OAE\'O'/@G
MXP_$7P=\0?AC\)_A;IWPD\+^#?%^DSZ7->::_A_1/B/\5] U;4;K3[W3-7D\
M5:#XVU+3-<L-2T]TALKF"ZM8_P! ]8TC2O$&DZIH.NZ;8ZSHFMZ=>Z1K&D:G
M:PWVFZKI6I6TMGJ&G:A97*26]W8WUI--;7=K/')#<02R12HR.RD _';X/?\
M!3OQYX\_:!\)?#[Q%\-?"<7P^USX1:%X@U"S\'3>+O$7QM7Q[/\ LR?#7]IK
M6-9T/P#9V5\-:^%MUI7Q"'@3PT]F)O$=[XJTW<TD\5VMK#ZA^Q7\1-+^*/[:
M?_!13Q;H^A>./#EE<']DFS72_B'X)\1_#[Q+'):?"/7@\TWASQ58:;J\5I-Y
MBM:W<EJL%TH=H'D5"U??^C?!CX0^'/&%K\0M ^%_P_T3Q[8^#-.^'5GXUTKP
MAH%AXKM? .D-$VE>"X/$%K81:K%X7TXPP_8M"2Z&FVPAB$-N@C0+\??LZ_\
M)_G_  4<_P"O7]C_ /\ 51>(: /G7]FG3;;Q5_P5I_;;\;37,%Q<>"_ G@[P
M790*9#<67VFQ\*"X+YA\@03C3W2+R[EI_.@N1-!%&(9)OHC]E'0T\5?M:_\
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ME@TFXU[4+C2-(N/LEI90O/HFFRVVDR2B#S)/L8>>:YG,EQ* =31110 4444
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MTJSM]/TS3=/LX4M[.QT^PM(X;6SL[6".."VM;:*.""%$CB1455%^B@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "OFGXP?$OQ3?>(K?X%_!:>V
M;XKZ]IT6H^(_%,T4-]H_P7\%7CR6Y\::]:NXCOO$%^R2V_@;PK(4DUK4$?4K
MP1:'IUY++<^+GQ:URSURU^#GP>M[+7OC5XCL%O6DNXS=>&_A7X8N)#;R?$/Q
M^8Y(PEK"?-'ACPR)8]4\9:K"+.S2/38-3U&R[;X2?";0OA'X=N=+T^\O]?\
M$.O:C-XA\=>.-==9_$OCKQ9>HBZAX@UNY4!$9]B6VFZ7:B/3-#TN&UTK2[>"
MTMD4],(QHQC6J).4M:-&2OS6VJU$]/9)_#%_Q9+;V:E?QL16JYA6J8#!5)TZ
M-*7)F./I2<94MG+ X2HO^8R<7:M5B[X*E*Z:Q4Z7L]3X8_#7PS\)O!^G^#?"
MT-R;2VDNK_4M4U*X:^UWQ)K^ISM>:WXF\1ZG(!/JFO:W?R2WNHWLWWI)!# D
M%I#;V\7H%%%82E*<I3FW*4FY2DW=MO5MGJT:-+#TJ="A3A2HT81ITJ<(J,(0
M@E&,8Q6B2222"BBBI- HHHH **** .(\'?\ '[XZ_P"QUN__ $QZ!7;UQ'@[
M_C]\=?\ 8ZW?_ICT"NWH ^&_^"B^O_'S0?V3_B6W[.G@,^.?'.IZ3J6GZC-!
M\1/ GPXU7P/X230=:U36_'N@ZC\2?!OCWP=KNMZ"VFV<5AX7UCPU?6VJ-?O+
M(OE6<B/\0_\ !&GP;\7OAW\!?C+^T'^TII'BW0=1^.G_  KWXUP>+_&'Q2^$
MGQ)N]>^'%I\)M,ET/4!X:^!7PJ^&'AOP1+H?AZ.*'4=,?P_JGB+6KDM/=WTW
MV6UMH_NG_@H7X%_9C\7?LJ_$KQ%^UQ\)-4^-GP;^#^DZA\8=5\ Z%'X@N=>U
M._\ !VBZLL!T6Q\.:WX>NK[47LM2U"RBM[W4X-(5+R6XU1X;6![F#Y__ ."4
MOAKX#^&OAS\3H/@)^PM\0_V%_#UUXG\-S7_A3X@>,/ OBY_'4B^&T33-?T.3
MP)\9/C%8Z9INE:=Y>DFSNK_0I2P1H-.G@ N  ?DC^SW\9?ASI/\ P43\>_M*
M_%CXU^#/$GPZ\?\ Q7^*$?AKXI:7^WY^R=K?@GQ#\.-1>]@^"O@JX_8^\+>!
M+CX]:CK.BK'X?TK3O#UUXJOM=TGQ+96?B?4;2":VFTZW_K&4AE##.& (R"#@
MC(R" 0?4$ CH0#7F-A\$O@QI7B^;XA:7\(OAAIOCZXFDN)_'%AX!\*6?B^>X
MESYL\WB6WTF/6I)I,GS)7O6=\G<QR:]/H *_/C]EC_D\C_@IQ_V67]G3_P!9
M'^$-?H/7Y\?LL?\ )Y'_  4X_P"RR_LZ?^LC_"&@#]!Z*** "BBB@ HHHH *
M*** "BBB@ HHHH ***XSQE\1/ GP\LEU#QQXMT#PO;29\@ZSJ5M9SW; D>78
MVDDGVN_F)&U8+.">9V^54+<4 =G17SE'\;_%GC*>:V^$7PA\5>(K(*1#XW\>
ME_AEX&E+ ".:Q&LV5SXTUF%6.YC8>$5MY55E6^C)#AD?PI^+'C6-V^+7QAO[
M*RN,^;X,^#-I+X%T5(F'-K=^+KN;4O'>IJ02DDMGJ?AV.9.#9KEL@'HOCOXQ
M?#/X:I&/&7C#2=+OKA@EEH4,DFJ>)M3E;[D.E^&-)COM?U*5VPBK9Z=-\[HK
M%2ZY\\?XG_&#QJ8$^%OP@GT/2[C!/C/XTWLGA*SCA/*W%AX&TD:GXRU+>A#Q
M0:LGA3?TDFB!#'TGP-\)/AM\-HF3P5X.T70[B7/VK5([8W>O7[MR\NI^(-0>
M[UO4II"2TDU_?W$CL2S,237HM 'SB?@7XA\77)O?C#\6?%WC"V< 'P3X0DE^
M&OP^13DM#<6'AZ\?Q3K<>2RL-<\67L$J';):8"A?8?"'@+P3X T\Z7X)\*:!
MX5L'(:6#0]+L].%S(!CSKN2WB26\G/\ %/=233-U:0FNMHH \?\ CY_R23QA
M_P!<=)_]/^E5[!7C_P ?/^22>,/^N.D_^G_2J]@H **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#B-'_ .1X\9_]>7AC_P!)
MKZNWKB-'_P"1X\9_]>7AC_TFOJ[>@ K\Z_\ @H1\1$\'Z=\"/"?Q'\)^'-6_
M9+^*?Q*UKPA^UKXH\4?#[5_B7H_AGX?V_@/Q'KGA#2K_ $/11/<>'[/QO\1-
M.\.^'W^(<^GW]KX,NC9W 6ROKZQU.R_12OEW]L#XTS_ WX)>(_%>A>+_  ]X
M6\>RO86G@&WUW2=!\2OXBUQM3L!-H]CX5U_XB_"JUUL26$EPVI2#QUH"Z)IO
MVC7+B]2"P=) #P[_ ()A/&/V;M9LM'\(:%X<^'^E_&WXPV/PE\1Z%\._$/PL
M3XL?#$>*I;OPU\5M2\'^++J\\21:MXE>ZO[*[U_5KAIO&,>C0>+X$BLM<MHD
M_1.O@3]A?]I3]I#]H#0M?;]H/X#>!/AO/I5M:7OAKXA_"#XT>#OC%\-?'4%Q
MJ>KZ?<Z3=#PY?ZE=> ?'^C6]AIVJZ_X,?6_&VEZ?9:_IZ6OC;4;J*[MX?ON@
M K\[/V?ITM?V\_\ @I'=2?ZNVT[]D2>3G'R0_![Q'(W)X'RJ>:_1.ORW\$:J
MFA_M6_\ !6+6Y'\M-'^'/[-VJ.^<;%T_X ^,;MFSVVB$G/M507-*,?YI)?>[
M&=:HJ5*K5>U.G.H_2$7)_@C\W_V>?B5)\+?^"9'_  4I^/&DB>]\:^-/'?Q4
M\/:#<*AMY]1\:>/+32_ /P^M+*5IG\^7_A,/B#8PVL@V%[F?;Y.[(?\ HJ^%
M'@BT^&7PM^&WPWT]42P^'W@'P=X(LDC $:6GA/P[IV@VRH   BPV"!0  % P
M .*_GQ_9KM_#7B?]B/\ X)]_!E+&!;C]HO\ ;LT'Q#XATF6)0WB'1?@/K'BK
MX_>*+Z:-26N;('X-^'M/NW)#+]NCSL W#^DRNW-)<V8XQVFK8BI&U27-)*$N
M1*^NBY;15[1C:*T1\YP5#DX2X=O+#S<\IP==SPU-TJ,WB*4:[J*#C%NI-U'.
MM4:4JM9U*LM9L****X#Z<**** "BBB@ HHHH ***K7MY::=9W>H7]S!96-A;
M3WE[>74J06UI:6L3SW-S<32%8X8((8WEEE=E2.-&=B%!- '\^W[(FH7%I_P5
M=^/L4_CGPYXGU'QAJ7Q4UB^\=Z+_ ,)3=CQAHND^)/%WA/0/A)?07'PZTGPM
MX6U7P"O@E[2UL+7Q[K4FJ?\ "H/%VOZ5;WR^(->NK+]\_#HU5;74!J^I66IS
MG7_$!M);%!'';:4VKWATG39PJ(&O=-T\V]E?.0QDNH97+N26/X6?L8ZIX'UC
M]OCQWK?@OQK\.O$.K^+?&O[2?BWQ/I/A'Q)^S=K7PO/AO5-3T:+P%XJ^#'_"
M$ZI>_'.?XBZSX>M="F^-7_";!]$MM5U'Q;*EGI#7NE_VI^ZGAX:N+74/[9U"
MQU&?^WO$!LY=/4)';Z0=7NSH^GW $<0-]I^G&VL[]L,6NX96:20DN0#>HHHH
M **** "BBB@ KQ[XP_"WP-\0-$N-5\5Z--?:IX7\/>*?[!U&SUK7M#OM/35=
M-7^TH8[K0=3TR>6VOOL%G]IM;EYK:;[-%OB.VO8:Y[Q=_P BIXG_ .Q>UK_T
MVW- 'A_[-7PL\">#OAYX"\6^']&GM?$?B/X7>!+/5]5O-<\0ZS<7-G#H]KJ$
M5G$-;U748K&SCO;NYN([2PCM;>-YG"1*NU1]":AING:M:3V&JV%EJ5A<J$N;
M+4+6"\M+A 0P6>VN8Y(95# ,%D1@" 0,BO//@C_R1GX3_P#9-_!/_J-Z;7J%
M '(/\/\ P0^O:7XH_P"$5T./Q%H>D2:!H^LP:?;V^HZ9HDL,L#Z58W,"1R6U
MAY,TL:6L16*-7(C5.,<M+\']#@\-VOA?PYXD^('@^RL]>'B"&[T'QKK4^JFX
M*&.2PFU#Q'/K\T^BS*?GTB;?9JX62&.*0;J]8HH X63P[XQCU?Q)J5E\0+HV
M>J:0+3P_X?U3PYH=YI'AC6(XHT35TN+&+2==U:*1T,EUIM_K)BD,C^1/:_+M
MS-OQAL8_!5NDOP]\0L+N6+XAZE.GB#PU(;!KA3!>^$M,@_X2*(WD=J6$]CJN
MH)!-.%,=[!&Q"^FT4 >;R>+?&UA8^+K_ %+X8ZE<#0[Z&+P[8^&O$>@ZUJ?C
M#3);AHI-0M;;4)?#\&DW%K!LNKC3;^[,KH7BLY[N9 CV(OB+I_\ PD/A_P ,
M7GA[QKIVI^(M!;7H)[GPGJ\VB::D4$EQ<Z5K7B33X+W0-+UNW2)U;3[G45>:
M0*EH]PTD8;T"B@#SO3_BU\-=2T*/Q-#XTT*VT&;5FT&/4M7NQH4#:TH).EXU
MM=/D6^(!*V[1B1P"45@,UWL=U:S2R017-O+/"$,T,<T;RQ"10Z&2-6+QAU96
M0L &4@C((-5]1TK3-8MFLM6TZPU2S=TE:TU&SM[VV:2([HY&@N8Y8B\; %'*
M%D(RI!KE;CX:> ;C6/$7B(^%-'@\1>+-$?PWXC\06-L-.UW5]$=%C%A=ZQI[
M6VHM'&D<8@=;E)K8HC6\D;(I !W-%>;#X8:3:V_@ZRT7Q#XX\/V'@N_DO;*R
MTWQ;JMQ%K$,UPEQ+IGB>36I-6NM=TQF4QI#=W'G6\+O#:W$"$!8H_"GQ"L+?
MQF;#XHW.I7VNZA'?>%/^$H\*:!>Z=X)A^TO-<:5;V_A^/PS>ZWI\D#BV@?5M
M0EU"V$<<IO;AMZN >@:G9-J6FW^G+>WVFM?6=S9KJ.F2QP:E8-<PO"+RPGEB
MGBAO+8OYUM+)!,B3(C/%(H*GY ^#'@KQ0GQ<^*]OJ_QJ^,OB;2OAGXM\/:9H
M>A^(?$>AW6DZC9ZSX"TC6;J/7H;7PO93Z@8]0U6>:W:&YM/*\JW4[Q&V_J/V
MAKWXL:/\+O$\UIJ/A6/08/ -U'XE\0:;?>)/#/C*V\1,T4*WGA:.T^W6=IIM
MP[A7-SK-MJ&G1R22P7=R\:*_P[8Z;XC\)>)?''B3PYI.L:3X^MOVI?@'X<C\
M,S_M ^+]?T:]T'6M'\*P7D.J:S=/=6_B*UUF.9;:?^U/#UU=:9:W311'R].$
M3 '[#T5P#2?%*3Q'K\*V?@*T\(C0'_X1>_;4?$%_XC?Q2\,'EC7M)73-/TR+
M0()S<ASI^M2ZC<Q)#M6U:1S'4ATKXL3Z=X6%]XQ\&V6K6FHR3^,'TOP9J4VG
M:WIGVA7@T[1(=0\5/=:)<"V!AGU&YGU422MY\5E H$- 'I5%>;W'@_QE>#QG
M#<?%'7;:V\1&-?#?]D:#X7L;SP-"DS2-_9EY<Z7J/]JW$\16"6?6X+Q%1=\$
M,,IWCE?##^$/$OCBZTC2?BQXK\2^*_@E%I?ASQOX>A\1V\5D^J:_HXU?3;OQ
MMH^FZ?9V=]J]WIEXEW T8@MHBB+]F6:!U#49-2:3:BDY-)M13:BFWT3E)*[Z
MM+=D2J4X2IPG4A"5:;ITHRE&,JLXTYU7"FFTYR5*G4J.,4VH0G-KEBVO<J@D
MNK:)F26X@C9(WF=9)8T988QN>5@S K&B\O(0%4<D@5Y;>_"3X=Q>%]<T77CK
ME[X;O=3D\4ZS+XC\>^,;OR+BT#7$EP=8U#Q$;S3-*M8U>1[""]MM(BA5C);"
M-3C,\,C]GSQEJZ_$GPC??"WQ?K%WX:U'1T\::%K'ASQ+<7/A316MM.UFS76;
M.\OA-H^G/<6=EK $S6]O+<6\-^RR31JZ+.ZN?B+X L[+3M1NO&_A.'3]8U(:
M/I-\_B'219ZGJQD6+^S+"Y%V8;N_$KK&;2!Y)P[*I0,0*J7/Q/\  EK=>*K%
MO$-M-?>"+,7_ (IL;&VO]1O=(MCMVF:TL+2YGFF;<NVUM8Y[EMPQ"<UG:3>?
M!G0SX5\*:%=?#+2&U>)-;\$^&]*G\+6#:I%J$%W>1ZOX7TBT:(WJ7UM8W]TE
M_I5O*+J"SO)Q-(EO.Z=?I_BGPMJDD46E>(] U&6YOM9TV"/3]7TZ[DN-2\.W
M#6GB"PB2VN)&EOM"ND>VUFU0-<:9<(T-['!(I4 ')K\5?#L][X)M+'2O&VI)
MX]@DN=(U"R\#>*'TK3[:-UC:;Q-J$VF0P>& 6<&.+6FL[B1 TL<+1JSBNGQ'
MUN\TSQ3>Z5\*/B-=7OAS61H]GH^HP>%_#]UXJ47#P2:QX<N=9\36NGRZ*@0S
MBZU*[TV:6!D:&UD=M@Z)OB+\/EU?P]X?;QUX.77O%R:C+X4T0^)M%&K>)X]'
M:1=7D\/::;W[9K*:6T4JZB^G0W*V312+<F(HP'8T <0-=\9OXAT[3X_ 8B\/
MW6B&_O\ Q'=^*-*CFTS6&MY)(]!;1+6&]N+QUN%CMKC4K>[^Q)YC30&Y2/#<
MU]L^.=[X=LYH="^&.@^*6\02QW]G?:_XE\0:+%X77'DW5M=V6BZ'=RZY-R'L
MY(([& 8(O)SE1ZY10!^/>F>(?!WA;XYZ#%\2IO"4&E6W[0'[0%_+H]W\+_$E
MQXD6WU32?%#:;J6J:_)9:A8:[IEX\L4FF6VG6#>3'-;SO<8MY"OZ$_LNVTEG
M^S_\+;>2TGL"GAI"EG<V<VGS00R7MY+;H]E<103VO[AXV6&6&)T0J#&O0<%\
M8/B?\.=*^,WP&L]3\>>$=/NO#GB[QP?$%M>>(M*MIM$%S\-=?@MCJT4UTCV
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M\9?GLG'"0=JTKZKV\K/ZO#JXM.O)62A!255?.RS3%9LW1R!0^KMN-7/J\.?
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M[3]U=V^GWUQ:'4X?AKI=JUQ!:RRP"X6;QXUYY+2K&)4M[::Z*%U@@FF"QL+
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MC3_V$-!C ."[7_A.:0Q@]<.EJRN!]Y-ZGY2:ZL##VF-P<+7Y\50BUY.K!/\
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MWQBUK2+C2_#%EXD637K<ZI>0V/B[Q7K>C:8;F>S\.:?8?Z+%;_:'AT:NMKJ
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M\E&E^%O0I8+/I?Q,]PT?^P;)H4K;;?6,=C//=/?;0^#YOVO?C+<L5T']@_\
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M%GQZ^+'[-47B+Q5?Z[I/PPT+0_!E]>VUA-:65N=;U=?$VE:M=Z+J&KRV[O\
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M]GOOC1^U5J/C"^LT*$I)?>&/@Y\(-<LYYMQ4-96WCB.,$,IU%01)6=#\&?\
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MZ7I$)EU;5;F0_+%:Z;975Q(Q"I&Q(%>--\:/BW\1I7L_@A\'=1L='GMP]O\
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M&6(Q-:53$5Y16D95JDW&-HII)(****S.L**** "BBB@ HHHH **** "BBB@
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MDX Y->.?##5]*OO$?Q:AL]4T^\E;X@M,D5K>VUQ(T(\'^$4,RI%*[&(/\AD
MV!P5)W BMJ=2$*=6$J<I2J1Y>95%%12E":]WDE=\T%?573MH]3S<7@\3B,5@
ML12Q5*C3P=257V4L+*K*I*=*M0J)U5BJ2C%T:TE!>RDX5$IMSC>!VW@[P#X)
M^'NF+HW@?PIH'A33%)8VFA:7::<DSDEFFN7MXDENYW8EGN+J2:>1B2\C'FNN
MHHK$](**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y<_:$_9V\4?
M'RQU7PVWQX\=?#_P)KNCZ?I>L^#/#/AKX=:A9WT]AJ8U0:G_ &OXD\+:MKUM
M<SSPV22PVVHQ6HBLD"0J9K@R>L?#+P9XS\%Z9J5EXU^+'B3XM7UYJ N[/5_$
MN@>#/#]SI=J+>*(Z;;6W@O0=!LIX&F22Z,UW;S70DF:,3"%41?2Z*U=:I*E&
MB^3V<6W%*E24DVHJ3YU!3O)0BI-RO)12=['!#+<)3QM3,(+$?6JL%3J2EC<;
M.E*G%U'"'U:>(EAE"G*M5E2@J*C2E4J2IJ,IR;****R.\**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** .(T?\ Y'CQG_UY>&/_ $FO
MJ[>N(T?_ )'CQG_UY>&/_2:^KMZ "OSY_P""IWQ#^('PK_81^.GCCX7>+->\
M#^-]*@\!VVD^*/#6K6GAW5=+M]:^)O@S0];D3Q-=>'_%K^%+*;0M1U.WU3Q9
MI_A3Q-J_A?3);O7])T'5;_3X+27]!J^)O^"B?CS1/AK^Q_\ %GQAXCM="N]&
MT]?!UG>1^)_BI\4O@GX=B_MOQWX:T.WN];^*/P6T?7_B5X/TNRNM1@N[W5/#
M>D7CK;PR1:DL6D27\T8!SO\ P39\1ZQXI_9JM]5UOQY?_$>]/COQA;CQ+J7[
M2$'[5%R\$$UD(;+_ (6O;_"GX-1W$5H&(CT#_A"XVT8/M.IW_P!HS%]]U^<7
M_!+G2;S3/V;=9NKGXC_#KXB6WB'XQ_$CQ'I$?PK_ &A/B-^U)X+\ :1J5SIH
ML_AQIGQM^*R6_C3Q<?#WD274HU#3],@TDZLNE6=E]GLTN;G]': "OY.OVI_
MMM\=?^"X+_!+4-+O-8T6W^(?['WQ0U^RM%< Z5X'\,:1XRN7O9$'RZ5O\$6J
M:FC,J7%J7M6.)U!_K%K^>'P[H&N:K_P<"_$WQ-X0EM;[3-/^%7@>U\=75K-8
MW2Z=IFD_"1+%K&Y)DDDMKK^VM9TF&2*()=Q--&LJI%+\WH9=95:\W[-JG@L9
M*U5V@^:A.DHO1W<G448+3FFXJZN?*\7<T\#EN&@\5&6*XBX?IJ6"CS8B*HYI
MA\;*<5=<M.G#"RJ5ZG_+JA"K4L^0_H>HHHKSSZH**** "BBB@ HHHH ****
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M\/7^EKYA_P -,?L[?]%S^$W_ (7_ (7_ /EG1_PTQ^SM_P!%S^$W_A?^%_\
MY9UZ?_PC?A7_ * 'A_\ \%>G?_&*/^$;\*_] #P__P""O3O_ (Q1?#?R5_\
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MS'8_LP>$=-MR@*WGB'X_Z4&5CC(>RT/P'J[?+SG;<X..&/%?4WF1_P#/1/\
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M\2Q7?AZ]TF?4GTRTT:[\-7-G;Q"X"0_K9%%%!&D,,<<,4:A8XHD6.-%'141
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M)8_]&\^)O_$BOVE__GOT?\.$O^"6/_1O/B;_ ,2*_:7_ /GOU^Q%% 'X[_\
M#A+_ ()8_P#1O/B;_P 2*_:7_P#GOT?\.$O^"6/_ $;SXF_\2*_:7_\ GOU^
MQ%% 'X[_ /#A+_@EC_T;SXF_\2*_:7_^>_1_PX2_X)8_]&\^)O\ Q(K]I?\
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M4:FBJ ?+?_#A+_@EC_T;SXF_\2*_:7_^>_1_PX2_X)8_]&\^)O\ Q(K]I?\
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ML?#%EIP724\/Z?I\^AK_ &'<::S 'F/_  X2_P""6/\ T;SXF_\ $BOVE_\
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MGZ_0NB@#\]/^%Y?\%%O^C"OA=_XF1HG_ ,Y^C_A>7_!1;_HPKX7?^)D:)_\
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M *,*^%W_ (F1HG_SGZ_0NB@#\C?VAOVZ?VW/V9/@WXV^.?Q*_8*\"_\ "$>
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M7E_P46_Z,*^%W_B9&B?_ #GZ/^%Y?\%%O^C"OA=_XF1HG_SGZ_0NB@#\]/\
MA>7_  46_P"C"OA=_P")D:)_\Y^C_A>7_!1;_HPKX7?^)D:)_P#.?K]"Z* /
MST_X7E_P46_Z,*^%W_B9&B?_ #GZ/^%Y?\%%O^C"OA=_XF1HG_SGZ_0NB@#\
M]/\ A>7_  46_P"C"OA=_P")D:)_\Y^C_A>7_!1;_HPKX7?^)D:)_P#.?K]"
MZ* /ST_X7E_P46_Z,*^%W_B9&B?_ #GZ/^%Y?\%%O^C"OA=_XF1HG_SGZ_0N
MB@#\]/\ A>7_  46_P"C"OA=_P")D:)_\Y^C_A>7_!1;_HPKX7?^)D:)_P#.
M?K]"Z* /@_\ 9_\ VJ_C)X^_:(\=_LW?'3]GG1_@GXQ\)?!WPC\9],O_  [\
M8=-^*^DZ[X=\5>,?$O@M+.62R\)>%I=)U"RU#PS<SLDL=RD]O/$R,I!S]X5^
M<'PR_;(_9:^*7[<?Q&^%/PX^'GC7Q#\9_!UGKWP-\>?'O2_!EE/X$M-3^%1B
M\:Z]\(]3\41:T_B.T'A;4O%TS+J5_P"%;3P9=>*KG4_#NF^)KW7K6?3T_1^@
M HHHH XC1_\ D>/&?_7EX8_])KZNWKB-'_Y'CQG_ ->7AC_TFOJ[>@ HHHH
M**** /R=_:O_ &A?&=U\=?CI^R%XX\.VGA?X$:W^P+\1?C)I_P 1_!EU>>*/
MBYJWB*U\;^%?AW?V5AX1:"RT>UTRW;Q<EA8:-)=W^J>)KR.=S?:):O DO\^W
MP7\#?&_X7_$K0?%_Q]L/^"A]I\*_A[XZ^ WB_P 0ZA-^R%X]TBT\5Q?#GP3)
MI&CZ):ZE>ZU?(M]X,\=KI'@[PG=745Y<:_I.N)<:+:W,5@A?^R7QS\(?A?\
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M "'7Z1T4 ?FY_P /+/"O_1G7_!1W_P 0G^+7_P AT?\ #RSPK_T9U_P4=_\
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M-=\7WWB*P.LZ1\-IM,N;F(>)6UZVU"UTC78=,@LY]8O?ZRJ* /Y6?AGX:M/
M_B3POXSUKP7_ ,%*M?U_P;\3+WXE:)H^F_\ !.KXM^'OA]<SZIX=^%'A;5-
MU_P5:^('TK5]&GL_AQJ7B'3[;RK6+0O'GB33O&&FQ#5?"5C-?T]'\+Q>'M&\
M5Z1I'PS_ &\(9M>U"YU%-<F_X)>_%6ZUSQ NK7OPIGU?2/B;=ZAXIU"V\9Z1
M8VWPM6/P:(K'3+WPQ>>*-6ODGNY88_._JRHH _FC_9UNO 7P$UWX6>+K[X!?
M\%"_B7XW^''BRUUN7QEXD_X)S?%6'Q!JNA6_P!M_@?\ \(_8ZB^M:C>Z(\4E
MN?$]A<1W=W8V:WVHZ2=-G:<:@/H+0OCG\+/ 5]^U7XH^&/[,_P#P5,\->/\
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MPGTCXG_#&STI=)N['XN? _6/@MKEQ\-+J73K&W3PUXMFM+36O#&IM/<K]&?
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MPE\8^!?!<GQ5_;E\-_&#XD:E\+_BE9?#RR\ _LF1?%RZT?5?A)X[O=+3PO\
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MOA;\ /#&@VLO@O2O#J1^";?P7XP^'/Q%UVRO;#Q%>PZ?+XQBNM!L+*2ZU(*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!P_@[_C_P#'?_8Z7/\ Z8]"KN*** "BBB@
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< !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img22994243_9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img22994243_9.jpg
M_]C_X  02D9)1@ ! @$ D "0  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &I L$# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M (#^*?@_P_\ $/X8>-O"/Q'\ >+=.BU?PKXY\!^)-&\7^#_$VDW!80:IX?\
M$WAZ]U'1=9TZ8JPBO=.O;FVD*L$E;!Q^/W_!OM_RC5\,?]G-_MU_^MH_':G.
M$Z<Y4ZD90G"3C.$XN,X2B[2C*,DG&46FFFDTU9JX1E&<5*$E*,DI1E%J491:
MNFFKIIK5-.S6Q^U]%%<AX]_X3[_A$]5_X5?_ ,(?_P )S_H/]A_\)[_;7_")
M_P#(2L_[3_M7_A'O^)Q_R!_[0^P_8_\ F)?8_M'^B^?4C/G#X-?\G8?MG_\
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MM;]?Z***\$^\"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MFJB>*PV"E6C3DZ%6H_N2BBBO)/J@HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /A+XS_ !0_:Z^&.OZ!
M]BL_V<+OPM\0OB_I7PO\ _:K?XFW&OVO_"67NJ_\(K>>,/*U#3].A\G3M/3_
M (2"XT7[;Y=ZS?V=I]S PV?1WPI_X7Y_Q/O^%X_\*@_YA?\ PB__  JG_A,_
M^HC_ &U_;W_"7_\ <)_LO^S_ /J(_:_^7:O(/VNO^;8?^SOO@K_[LM?7U6W[
ML=%K?6VNC0!1114 %%%9VKZQI/A_3+W6M=U/3]%T?38'NM0U75;RWT_3K&V3
M&^>[O;N2*VMH5R TDTB("0,Y(H ^4OV1?^;GO^SOOC5_[K5?7U?#G[%_C+PG
MKMQ^TA9Z-XET/4[W4_VF_BQXPTZRL]3LY[V]\*:PWAZ/2_$=M9I*;F71;^2*
M2.UU)(C:2RHT:REP5KZ:\>?%_P"&GPS6)?&OC#2-'OKD V.AB5]0\2ZF6#;%
MTOPSID=[KVI%V78OV+3IU,C(A(9U!J2?,].WY(#TFD) !)(  )))P !R22>
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MJ6K >0?M"?\ ) _CA_V2#XE_^H7K5'[/?_) _@?_ -D@^&G_ *A>BT?M"?\
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M[M8M5TQYFLM0BMKJYMX[N"9(;B:,+(W[-> _ '@/X6>#_#_P\^&'@GPC\./
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M'K::V@CDAT33'GF?3]*C9;&S>:5K>"-I'+?;=75GS2MLDDO7K_PWW@%%%%9
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M^^-7_NM5]?54_B?R_) %%%%2 5\@_&7_ ).P_8P_[N*_]5MI=?4WB&RU;4M
MUS3M!UK_ (1O7;_1]3LM%\1?V=;:Q_8.K75E/!IVM?V1>O'9ZI_9=Y)#??V=
M=NEM?>1]FG=8I7(^*M9_9=_:$\0>+/!?CC5_VN?M?BGX>_\ "1_\(?JG_"@_
M!%O_ &1_PEFFQ:1X@_T*U\00Z=J']H:=#%;_ /$TM+W[+M\ZR^S3LTIJ-KMN
M26DEK?K%KHGU8'W;17(> M&\6>'_  GI6D>./&G_  L+Q3:?;O[4\8?\(YIO
MA/\ M?[1J5Y=67_%/Z1+-IVG_P!GZ=-::7_H\K?:OL7VV;;/<RJ.OJ?Q_KS
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M HHHH **** "BBB@ HHHH **** "BBB@ HKD/'O_  GW_")ZK_PJ_P#X0_\
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MF)@?UV_,#YP^#7_)V'[9_P#W;K_ZK;5*^OJ_.+P;?_M8>$?BQ\9_BA_PR?\
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MFLSW"VDN5^]%-VT;=]'UTZ] /TIHHHJ "BBB@ HHHH **** "BBB@ K^&?\
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MM3_A%/#6B^'?[2^P_:?L7V_^R+*S^V?8_MEW]E^T>9]G^U7/D[//EW=?110
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M>_X6A\&/^%0_V?\ V7_8?_%Q?#?C_P#X2'[7_:/]I_\ (O6MM_9/]D_9M/\
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M_P#4+UJN^\1>+O"GA"T:_P#%GB;P_P"&+%59S>>(-9T[1K4(N S>?J-S;Q$
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M:U?#5J56G.E5HXC#5IX?$4*U*I&-2E6H5Z52C5ISC&=.I"4))231^XU%%%0
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MI;IJ/B_5A&L&C^'+I[F"0^??VG^T#^UMA/#Y\6_LN_LXW@4MXFNK8:/^T?\
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M%GI5S"M_=6!0H5<35A0H0=2K4?+"$;7D[-O5M)))-MMI12;;239PYEF6!RC
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MUGXBT#1] GF'B"[U*?4M)EO[VSTG2[.UU?3;W6VL/Z3?VCO@W9?M#_ 'XS_
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M."VM+2V2."VMX8U6.*&&-(XT4*BJH JW117,>NDDDDDDE9):));)+HD%%%%
MPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /
M//BI\3_#7P<\$:K\0/%NF?$35]!T:73X;NP^%?PA^+'QT\;S/J>H6VF6QTKX
M9_!'P5\0OB/KL45S=Q2:A/HGA34(=(T]+G5M5DLM*L[R]@_G_P#CC^TQ^UW\
M/=:_X*&?%GX2_M@_%[Q7\&/@EK/[.WP!\,>&_BW\*/V7[>W^$WQR_:7^(/PI
MU[Q[XTT*#1/V:?A/XXM_#?[,GP2^,'@B'PWX<^,_B;Q_<ZAXJU#Q"/BG%KLW
MAAHK[^D.O-9?@Q\'IM$^)/AJ;X4?#67PY\9=0U;5_C!H$O@7PO)HGQ6U77]%
ML/#>NZG\2=*?2C8>.=0UKP[I6EZ#JU[XH@U2YU'1=-L-+O)9K&SMX(U3M"K4
MK5(.MR8>K'#456G1HU*M7$9?&K1Q:4:O[NOEL<VP]/&T(PQF6XO$X+'8%1Q&
M$]I+6,XJ-*%DHO$X>IB)RIQJS5*A.=>$L/K2DI+$0PT*^%J5'AL=A98G#XEJ
MG-0?X=^&?^"M/QE^ /P!\!W7Q!_8_P#V_?\ @H?XJO/CI^V7\&7^+'['/[-&
MC?$B>[\/_LQ?M!Z_\)_"?C+XNZ9X"A\!>"O"7B?XA^'[>RN8%\(^'=*\,:[K
M/AWQA>:)HNA65JFE6_H'_!N5KK^*?^"5GPS\32:+K?AN3Q%\?/VTM=?P[XFL
M3IGB/0'U?]L#XVZ@VB^(--9Y&T_6]+:X-CJMB9'-I?P7%N78Q[C^T'@/P!X#
M^%G@_P /_#SX8>"?"/PX\ >$M.BTCPKX&\!^&]&\(>#_  SI-N6,&E^'_#/A
MZRT[1=&TZ$LQBLM.LK:VC+,4B7)S^/W_  ;[?\HU?#'_ &<W^W7_ .MH_':N
MC$3A4K2G35HM07-[*G0]I*%.,*E9T*/[FA*O.,JTJ%']S1E4=*E^[A$P2]ZM
M)05*%3$XJM2H*K5KQPM"OB:M;#X.%>NW7Q$,%1J4\+#$5G[:O"C&K52J3DE^
MU]?#W[6_['6F?M VMEXA\'S>'/"7Q)T^>5[K6+W3%M[7QC:2VEA8Q6GBG5=+
MLI]7>?2;?3;./1=1D@U4V-HMSIPLFAN89K+[AHK%-Q::=FBC\L?V9_\ @GF_
M@3Q4_C'XW2^"_&,=E:7EMHO@FVLG\1:#-<WL+6K:GXA&O:9:V5T]G;R7/V'3
M$TZ]A2\FM=5&H07.GQ6[_I+XX\*Q>./!OBGP;/JEYHD'BG0=4T"?5M/TSPIK
M5[IT.JV<ME+=VND>.O#?C#P9J<T,<S.ECXI\*^(M!NB/)U31M0M'EMI.IHJ:
MT5B(5*=5<T*L)4YQ3E&\)Q<9).+4HW3>L6I+=-.S+ISE2J0J0=ITYQG!M*24
MH-2BW&2<79I.TDT]FFM#\E?!?_!'#]F[P'\+-,^%GAWX@_&32+32O$/C+Q7:
M:_X2L?V>?A<]EK_C37/A)KUW?>'?AQ\'OV?_ (=_ ;P#%IEY\%_"$ECIGPW^
M$/@[2=1U"Z\4>)_%5AXC\:>)M5\2S97Q;_X(K?LM_'6#PUK7Q>\4>-?BC\8-
M'\7>+_&'B3X\_%KX3?L4?&OQW\1;KQQI_@31=>T[Q3X&^-7[)'Q$_9WT.Q&@
M?"_X=>']'O/AA\#_ (>>(_#VB^$[>PT/7M/CUKQ4=?\ U_HK1U).M]8NE6Y*
M=)3C&,7&C3C2@L/!125/#5*="A2Q&&@HX?%4:%"CB:=6E1I0A-W[-T>:3IN>
M(JRA*3DI5<4ZDJM:;DVYUE.K4JT*LFZF%K3E6PTJ-5N9^3GA?_@EWHU]XG^.
MDGQ-^+WQ'E^%'CGXB^-_$OPO^ 7@/4?AUH?PC\ P^*?V?]!_9^L?B!;Z5;_!
M?1_%FF?$C1?"'_"5:?I/@Z'QMKWP)T1[O2/$NF_#G_A*K:._L>O^(/\ P2=_
M93^(_P"TA\-/VHM:T.PD^)'P[TKX=:3=-KWP4_9'^*0\;)\)[>.V^']_JGC#
MXX?LW?%'XM?#[5O#L<43V^I? +XD?!NZN+J"SO[Q[B^T[3KFT_32BDI23P<K
MWG@</EN&HU)>]4E'*<#/+L%4KSE=XBM2PE2I2]I6YWR.G3BHTL/AJ=''V-/V
M=6BU>E5GF<O9[0HPS?'PS+'4,-&-OJU"KC80K^SH\B]M[2O)RKXC$U:WP0W_
M  3L^";)\"HSXH^*6/V??#7ASPMX,(UOPEG4]/\ #'Q+\-_%.PF\3_\ %$8O
M;R;Q!X7T^SO)-*&BP2:-->6\-O;WLD&HV[?AS_P3I^"7PQT/X:Z!H'BCXIW=
MG\+/&OP"\>>'Y=7UOPE<7-YJ_P"SI\%[;X%^";;67LO!&GQ7&FZIX2M8]1\5
M0V4.G75]XC9[O2+S0],*Z0OWS12IMTJ"PU-\F'CF-+-HTE\*S*CC7F-+&6W]
MK#&MXF+OR^T=^6VA<H1E5QE>23K9A@EEV-J?:Q.!6#J9>L-4?6FL'5J8>RL_
M9S>M]3\F_$/_  1Z_9[\4>.?A5XSUOXI?';5+7X,>*_AE\0/A[X0UD_ 3Q)H
MGA?X@_"KXER_$O0O&7A3Q%XI^ FN?$_X?:AK=Q<WOA/QQHWPS^(7@KP?XU\(
MWUU%X@\-7GB-U\2)]&?LW_L-^"_V;_%&G>*;+XM?&OXLR^$O &J?"WX4Z3\6
M]1^&5WI/P;^'_B/7=$\4>,/#7@3_ (5Y\+?ASJM_%XQ\0^&?#6IZUJGQ$U3Q
MYKUNGA[2-'\/ZKH?AZU&D-]L44Z$I8:$*=!^RA"IC:T%'[-;,</#!XZNF[R]
MOB<%3A@*E:_M?[/3P$9QP<I4752U5-32:E#!TY6BHWI8"<JN$HMP46Z-&O.>
M)C1_ARQ<YXN<)8F4JK****D HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *_E)_X+UZ=X_3]HCX4:IJB:L_PVG^$T=EX/F9YFT"+Q/;^*-=F\:06T6_[-
M#KKV=SX2FU641+/=::= 1YYX[.**T_JVKE/&G@/P-\2-#E\,?$/P9X3\>^&I
MYX;J;P]XT\.Z/XIT.:YMMWV>XETG7+.^L))X-[^3,]N9(M[;&7<<^CE6/66X
MVGBG2591C.$H7496G%Q<H2::4EZ:J\;J]U\GQMPS+B[A_%9+#&O U*M3#UZ=
M?D=2FYX>HJD:=>FI0E.E-K7EDG":A52G[/DE_(W_ ,$<_BW)\#?C5\0_'OC)
MO&VF? ZY\ IX8\>^*-&\*>+/$W@GPYXGU'7M-O? ^I^.9O#>FZI;>'K:.#3O
M%-M9>)=7@AL],BO-1AFOK.TO[MI/ZZO"/C+PCX_\/Z?XL\"^)_#_ (Q\,:M%
MYVF>(?#&KV&N:-?Q=VM=2TV>YM)MA^614E+1N"D@5P5$'@WP%X%^'.A1^%_A
M[X+\)^!/#,4T]Q%X=\&^'-'\+Z%%<7.T7,\>D:)9V.GI-<!$$\JVX>78OF,V
MT8^:_%W[&?P^DU[4O'OP1U[Q+^S-\4=1:2XO?%GP>DLM,\.^)+YI#.L_Q ^%
MM_;W7PY\=(\[/)=3ZIH,.N7'F,4UVWE2":'?,<=A\TQ=3$2A/"RDH0B[JM!J
M"48NJHQA.+MK*</:M1M%4W:\O.X2X;S7@O(\-E5+$8?.Z-*=:O6IJ,\#B*=2
MO4=2I'!3JUJV'K4T]*="O]24JDJE:>+@I^RC]@45\.#XS?M-? WS+?\ :"^$
ML7Q>\$69DQ\;?V:M+U*_U*VL(4!2^\>? /4[S4/%^D2A%>;4+[X>:]\0=/0+
M+<'3=)MU6$?2GPJ^-/PH^-_A_P#X2CX2^/\ PSX\T9&2*\ET'48I[W2+J1=X
MT_Q!H\ODZQX<U55YETG7K#3M3@'^NM(S7FU,/4IQY[*=*Z2JTWST[O92DM82
M:UY*BA476"/K,-FF$Q-3ZOS3PV,Y92E@<7!X?%I0MSRITYZ8FC!OE>)PD\1A
M92OR5YK4]/HHHK$]$R]<UO1_#.BZMXC\1:I8:)H&@Z;?:SK>LZK=0V.F:3I.
MF6TM[J.I:A>W#QV]I965I#-<W5S,Z100QO)(RJI(^%?@SHFK_M5?$C1OVK_B
M#8:AI_PE\)F['[)'PUUBTFLO.LKV)[2]_:0\8Z3=I'/)XK\9V+O;_##3]1MX
M1X-\#W']L6]J==\2OJ4-7Q3O_;;^)NI?#>S+R?LE?!OQ1%;_ !6U1"WV/]H/
MXK^'+R&[C^%.FMCR+[X5_#W4H8+KXDWA,T'BOQ7;VOA"TC73]'U>]NOT%CC2
M)$BB1(XHT6...-0B1H@"HB(H"JBJ JJH 4    5UO_9H..V(JPM+O0HS7P+M
M5K1?O_\ /NB_9N\JE2-/PHWSG%1JO7*<#74J"UMF6/P\[K$-7M+ X&K'_9N9
M-8G&P^M14:.$PM7$OHHHKD/="BBB@ HHHH *_-[_ (*8_L2:Q^VE\'O#VD>"
M=8TO1OB7\.?$%SXB\)'7I)X-$UJRU2Q6P\0>'+V[MX[B339K]+?3+[3]3-K=
M0QWNDQ6-S';VNHSZA8_I#16^&Q%7"5Z6(HRY:M*2E!M75]4TT]XR3<9+JFT>
M=FV58+.\MQF59C3=7!XZBZ->$9.$N6ZG&4)QUC4IU(PJ4Y:VG&+::NG_ "X_
ML4_\$:?C58?&OPMXX_:E\.>#-%^&?@?58M=NO ]UK/A_QS=?$*_L5,^DZ->Z
M;I;:UX>'A1]06";Q'#KERTFI:?!)HJ:1-#J<U]8?T@:;\$O@SHS2MH_PC^&.
MDM,8FF;3? /A6Q:5H"YA,IM=)B,AA,DAB+Y,9D<IC<V?3J*ZL?FF,S&K&KB)
MI<L%",*2<*<5>[M'F;;D]92DVW9+11BEXO#'!F0\)X.I@\KP\IJM6=>MB<8Z
M>(Q56;A&FE*JJ5.,:<(1Y84Z<(03<Y<KG.<I4K+3=.TU733K"RL$D8/(EE:P
M6JR.!@,ZP1QAV X#,"0. <5=HHKSCZI))6222V25DOD@K\F?'/\ P1=_8M\<
M_$B]^(C67Q)\*6^J:L=9U3X?>#_%FEZ9X O+J>Y:[U"&*RO?#&I^)-'T_4IY
M)#)IWA[Q1H]GIT3BVT*'2+:*"&+]9J*Z,/B\3A)2EAJ]6@YQY9NG)QYETO;=
MK5Q>\6VTU<\O-<BR?/*=&EG&6X/,88>I[6A'%T(5?93=E)P<E>*FHQ52"?)4
M48JI&2BDN<\(>$?#7@'PMX?\$^#=&LO#WA3PKI%CH7A_1-/1H[/3-*TVW2VL
M[2$.SRN(XHUWS3R2W%Q*7GN9I9Y))&Z.BBL&VVVVVVVVV[MMZMMO5MO=GIPA
M"G&,(1C"$(QA"$(J,80BDHQC%)*,8I)1BDDDDDK!1112*(YH8;B*2"XBBG@F
M1HY89HUEBEC889)(W#(Z,.&5E*D<$$40PPV\4<%O%%!!"BQQ0PQK%%%&HPJ1
MQH%1$4<*JJ% X  J2B@+*][:[7ZV[!1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7XH?\ !OM_
MRC5\,?\ 9S?[=?\ ZVC\=J_:^OQ0_P"#?;_E&KX8_P"SF_VZ_P#UM'X[4 ?M
M?1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5\T_%3]DWX/?%+7X_'9T[6/AS\6;4QMI_Q
MD^$FL3^ /B9;M%PD6H:]I""W\5Z:4S%+H?C73O$FA3PLT<NFL""/I:BKIU*E
M*7-3G*$K--Q;5T]XNV\7UB[I[--'/B<)A<;3]CBZ%+$4^934*L(S49Q^&I!M
M7IU(-WA4@XS@]8R3U/S"^.'QQ_:L_8;^%_BWXA_$=? ?[47PN\-Z=#;Z9XUA
M*?"3XM:1K>K:A#H_AR'QQX8L;;5_!GC329=5U#2[34];\$KX3U6WLUU'6)O"
M[10,H_ K4/\ @L7^V'XON?$&C>,_&&DZ;X#\:[-(U^P^'OA/1O#WB;PIX8U"
M^MUU_P#X5KXDG:XU?2_$;Z)]NT[1]6\1ZGXA?3I;I;Y&34(+:^M_ZSOV@O@?
MX0_:0^#?COX*>.S>Q>&O'>E0V-S>:;*(=1TN_P!.U&RUO0M9L7<-$UUHVNZ9
MINJ0P7"26EVUI]EO(IK2>:)_P!^'7_! SQ39_$ZRE^*/QJ\*:Q\(=.U07-S#
MX2TS7K#QQXHTJWN%=--FM;^$Z3X5EU.!3%=WMIKGB1]-WM]ECO'"3+]/D^*R
M54,1/,J5!8I2YH-4&^>G&,7'V48ITJ=7G4D^2-)23@W=<S7XUQ]DOB)/,LKP
M_"&.S&IDTZ+IUH/,J<'AL34JSC66.KUIPQN)P3P[I2IRKUL94IR6(C%P;HQE
M_1%\*?"7@3P+\-O _A+X8Z19Z%\/M%\,Z3;>$=,L(VCMX=%DM8[FTF8N6FN+
MJ]6<WU_>W3RWM_?7-S?7LT]W<32OZ!4%K:V]C:VUE:0QV]I:00VMK;Q*$B@M
M[>-8H88T'"QQ1HJ(HX55 '2IZ^6DW*4I-N3DVVY.\FV[MR;U;;U;ZO4_::5.
M%&E3I0A"G"E3A3A3IQ4*<(0BHQA3@K*$(I)0BDE&*26B"BBBD:!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MWG_!/'XE?\/"?^&Q?V"/B!IW_" _\%/_ -K'X:?LL?\ "?\ Q!_:U^%'V_\
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M_&#[%\3;?2H/%W]H>+O&W_"O]8:#P[:_\(W#<MIDOZ?_ /$+C_P0H_Z,9_\
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M_P!K^;]C#2OAG\?/B1\0O#]S\,;3XG>+/AAX'\/>+_!GP<D^,=AK6I_#R_\
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MZ***YC8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:Q6/C'Q--KHN/"OAK3['5+_4M.T?7M2N5L;'37GD],K\:?B_^T'\4?!6H_\
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M9X^#GPS\3>)=*'[1?QC7Q?<_&JY\ >.?B=XW\2Z/\3K/Q3%\1/AQH=EX1N?
MM\_PV^$_B3P9\/;C5)X$7P?#I"3Z/J'W9^SUK7C&+_@G_P#"7Q-\?]?\2ZEX
MT;]E?PSXD^*WB&XUG5_#'C&74KCX:6^L>)KRX\1^';G0M?T3Q+ LEP)M?T>\
MTG6[/5(GU.TN[+4$2:/DQ=&GA<OQV8>WC.&!H95B9PY)0<Z&;X/-,9AZE-N_
M-%4\IK57:+_V7%Y=6ER5Z]?"87IPU6IB,=@L%]7JPECZV8T:$WRR<Y9;5R:G
M62CS*+FO[;PU*<74C&.+HXNC3G6H4Z6+K>P_$W]H7X7?"[X+_%7X\:AX@M/%
M7@3X.Z-XXU/Q<_@74=#\1:C_ &E\/7O[3Q+X/L%&KVFF-XTM-:TZX\--X?U'
M5--GMO$@&D:C)87"RB/UW1]1_MC2-+U;[%?:;_:FG6.H_P!G:I%%!J>G_;;:
M*Y^Q:C#!/=00WUIYOD7<4-S<11W$<B1SRH%D;^<_PU\"+'0?^":'[*/@'P9X
MD^(&E?$O_@H1\1?V:D\8S^*OBO\ %;XS:-IO_"R?',O[2?Q2U_PK\.?BSX^\
M:^!],U&W\)67B[4?%EYIFAV__"8/'/J/Q G\13R7%U)ZG\7OC!\8/V4?%W[?
M=I\'/B1XW\6Z7X5\,?L3^!/!LGQY^)OCCXA^&_ ?[0?[1_C[Q/X7\5_$6\\1
M>,F\>M\/_">C^%O$7@/Q1JWA;PUH5C\,=#DM[232O %K;3S6-]Z]?)E3K8W!
M4IU)XW#YU5R*G2JPC3G6Q^%>38><80IU*L(X7%8_/*&#H8J52:^L4Z=.5.G!
MXFO1\ZGFGM88.OR4HX;$Y=2SF,Z56=6,LIS'$XVE@Z\JU2E0C*OA*&4XW$XF
MA3@D\+]8Q,JD73P>'Q/[W45^<7[*7P6^.O@GXR>(O%'Q&^*<.F6<'P__ +)\
M9? FS_:R^-G[8?\ ;OBWQ#K6GZGX:^,>I^(OC=X2^%\'P9)LM%\8:-IOP\^$
M?PE\'>!=934[N[$\MOX=TC2-)XSXS>/].^)7[4OQX^''Q<^*/Q!^#/[.?[)O
M[//PV^*?B.X^'_Q;\<_ W5_&OC3XLZOX\>+Q/K'C?X<:[X/\>7?A;P!H7P\&
ME:+X;TCQ"?#/B3Q3XEU*U\1Z=K][INEZ98^97PM.C.*>)ISI4\+B,9C:L.6?
MU2CAE7E.W).5/$3Q,:5%X"-*K:;S#!4\?++:JQ]/ =E'%3K4JLUAZL9_6,-A
ML)2DI*IBZF-J8.C07(X*I1]C7QGL\;S4Y>S6$QE7 _VC2^I3QOZH45_/O^SG
MXC^.?QS\,?\ !.;X?WG[0GQ\L;[XU#]IK]LOXK^+9/&-W8_$/6?@#'?W7AGX
M4_#K5YK"UM+#1- US3/B[X%2T:RTRRM]$O/#T^M^"8M%\56FA^(-"W_"'Q>^
M)^E_#Z'X0> OBI\2Y/!_QY_X*B>/_P!ESX;?%'Q3\0_%?Q)\>_#7X%_#_3M2
MO?B+8:+\6?B/J?B[Q7JWB'7_ !!\+/B5X5\!:UXK\2ZOKGA^;Q7;'0+N:?P[
MI%C#W3R6O#$RP3JPCB7*=.G[6%6GAY5,/Q%A>%\9&I6Y)2I+#YKB:Z25&I5J
M87*LUKNE3E1PE+'8+-*3P\,:J4YX/WY5JM.=*I4A1>19KQ+AZM.C&?[R.(R;
M*XXB//.BE5S/+*-.555J]7#?O)--%;0S7$\B10012332R,J1Q11(7DD=V(5$
M1%+,S$*J@DD 5Y9\#/C%X<_: ^$W@GXR^#M-U[2_"?Q TN37?#4'B6'2;?5K
MK0FOKNUTO6'BT/6=>TY;'7K.VAUO2#'J<MP^D:A8O?06-\US86WX@>*?BM)\
M-+O_ (*C:Q\&/C7\<_B!\)_V:?V9_"_P<^'.@^._B]\1?C=H47[4OQ=7Q9<^
M(+70_%/Q&U?QAXK\::_IFIR_";0+4^(/%7BD^$]1USQ!X<T1M%TJ]N=+3T'6
M/B;XG_8(^(T?[.GA;7-?\4:GXT_80_9L^&_[)'PDUC7]0NM)U7]H+P%XJ\4?
M!Z_C\/Z(SO8:.EY;>+O ?C+XHZOI&FVT=MX1\):GXFUHK9:$\\&<<M=2ER47
M4Q&.Q\,OGD>$4(TZN/E6R_.<UQ&%]ZK*E&O4RNCD>.PS]I*E*GF2CSRTFW+'
M>SFZE9T*&$P=3$TLUQ,J_-1P2ACN&<LI5ZC="-3V=+,,YS/"XI.,)T99)C)R
MBU&T?W6KS2W^))N?B]J7PD3X?_$M%TOX?Z;X]N/BC<>%TMOA#.^JZ]?:%;>!
M]-\8SZC'-JOQ A73KC7-2T#3=(NK?2-!DL;W5=2LYM4TRUN_R+^*6D_$OX'Z
MY\#&^)/QS^-7QE_9_P#"^A_ W]FJ?QW\&/VCO%'AOXX?#_\ :^UGQLGA;6?B
M5\4_!5CJ\-G^T1IGC2_\3^%GU/P)XXOO'MKX'LM'O"_P5\1:5J%]>1=OK'B3
M]HGXUW?[>MI\$OC#;:%XL?\ :%\ ?!GX$^%O%?Q$OO!=AXB\*? +P=\.M=_:
M*\,?#K4;*RUN^^'_ (I\;ZAXD^(GA/4OB1X8\)WVL>']1MM+UMFAAT/2-2TZ
M5E\'S5*.)H8FA!YA>O:M3POL<-F&3Y4L54:A+&0C2CQ%E>>3HQPDJKRN=*M1
MABU6]BZ>-DW&E4HU,-4J_P!FJ$:DJ7UA5\3A<?F<\'&$I+".O.&1YOD\G4Q<
M(4<?A<:JU3"PP^'Q-?\ 8BBOC3]A'QCX6\>_ =?$G@Z3XVVVC#Q]\0O#,_AG
MX\?$C4_C'XK\&>(O 7B>^\">+_#FC?%G7=?\9Z_\1?!J>*O#FL:GX>\3ZKX]
M\:M<PZE-:V&JZ;I=I9>&-!^RZXL50^KUZE&[ER<MG)03:E",U?V56M2>DE[U
M&M6HS^.C6JTY1G+JP]5UZ4:CBHR;G"<4ZCY)TJDJ52#]K2H58RA.$HRA5HTJ
ML))PJ4X3C******P-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!#!XSLFMX&M/%$2+KELT$)AOD,:%?0Z*I5:J=U5J)^U]M=3DG[;GH5/;7O\
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MY-7;9PEY\+/ACJ-E\0-,U#X<^ [[3?BP9&^*>GWGA#P_=67Q+:;0K/PO,WQ
MM)]/>#QD9?#.G:?X=D/B*/4B^A6-GI#9T^V@MT[%+"QCL5TR.SM$TU+1;!-/
M2WA6Q2Q6$6ZV:VBH(%M%@ @6W$8A$($038-M6J*F3<H\DFY0Y(4^23O'DI0]
ME3ARO3DITOW<(VM"'N12CH5LU):24IR4NJE5E&=22>ZE4G&,IM:SE&,I-M)K
MQ_P?^SS\ ?AY8^&]+\ ? WX/>!M,\&^)M6\:^$-.\'_#/P7X9L?"GC+7]*O=
M!UWQ;X;M-%T2RM]#\3:UH>HZAHVK:]I<=KJNI:5?WNG7EW-9W4\,G3WGPO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
J%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img22994243_10.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img22994243_10.gif
M1TE&.#EA[@*\ ?<  /___P  ,P  9@  F0  S   _P S   S,P S9@ SF0 S
MS  S_P!F  !F,P!F9@!FF0!FS !F_P"9  "9,P"99@"9F0"9S "9_P#,  #,
M,P#,9@#,F0#,S #,_P#_  #_,P#_9@#_F0#_S #__S,  #, ,S, 9C, F3,
MS#, _S,S #,S,S,S9C,SF3,SS#,S_S-F #-F,S-F9C-FF3-FS#-F_S.9 #.9
M,S.99C.9F3.9S#.9_S/, #/,,S/,9C/,F3/,S#/,_S/_ #/_,S/_9C/_F3/_
MS#/__V8  &8 ,V8 9F8 F68 S&8 _V8S &8S,V8S9F8SF68SS&8S_V9F &9F
M,V9F9F9FF69FS&9F_V:9 &:9,V:99F:9F6:9S&:9_V;, &;,,V;,9F;,F6;,
MS&;,_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D S)D _YDS )DS
M,YDS9IDSF9DSS)DS_YEF )EF,YEF9IEFF9EFS)EF_YF9 )F9,YF99IF9F9F9
MS)F9_YG, )G,,YG,9IG,F9G,S)G,_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P
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M,#8)#P#Y"(+FF22V)U]\]&Q9GS_RZ/4DG?S,XI^3_SV9(P!&\@A .]GDXR,
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MF\VM;G?+E;&V\3"ZQ4<-'2<>%U)N<<2M87%KJ%7>.O>YT,7(T&:!#F]XXPH
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M82_A0<#&$O#P3#%11H+Y1GP#0>!4$O, #E8Y/<$I#^^ /P_)$CN13#LD$.:
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MTCX_2><##]B5H'NM846/^2U/TO0@ ^\WE)D_]<EO]<MO^<'=#[Z-&XH_\^;
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M$1VA!4 Z7/4Q>2P0)?H !]K.I0]RD';'X?B.A4&$<( N@B@'?"*7A5B9>S@
M@D@'#]$4?U@',[H\?) 4??"&'H.6P/&'VN('</ *>@@'M'J3!:,5_ID_C?&[
M@I"!=7B'=&@'RR,N>V' ^D"(!T0>>- T +B'# 2 ?-@&"IL4>?@&@IB';ZBD
M;2J0]/.^\^L^\ .[Z9H=*'S"\3._*R03)J1"];/"**S"(7DT?M@&>N ';] 2
MV2J(<& !_P (!P]9!V_HB'4(!W*(H(3@AD#"AP.(H&]8'0#X!@J"!V^@0RYT
M0D+$PB\LF4@[1$/T0D9$Q$9LPD6,1$C<0I*SQ$O$Q$RTQ-E#@$Y$@ "P#F]
M@ /0$P3(!C#B!E-DB #HQ(1  %'L1&\ 18-@15F\GP-010=A10'01#IYQ<5H
M1<4(QH)XQ5$\Q:[Y1&+\/)(31<9(Q6/LQ6B4QFFDQFJTQFL$(T_T1 #0QE84
M16_@QE_<QF\$ !9  (,H1FYLQG3LQG-L1W ,QW-$QVX417,D1@18PWN4QVUD
MB':,QW@TQW-L1@" 18+TQFY4QWCL1&@$  _81GR41W6$2'!<R/^"R(9Z3$=]
MA$5M-,AL*,98?$B0%,B);,5.-,=UU,:!_,=P1$>,[,1:O$=EC$A/W,B8;$>&
MQ$A1K$5W1$F:7$F(+(B<],1OH,EAQ,:C1,JD5,JE9,JF=,JGA,JHE,JII,JJ
M[,5UP,K5B* K6(=V4(?)^8C5D+F<@(>N5 QUJ,,M^4JL',N<P$J=^,J3X,JV
M-(BU+(AVD RT+(BO=(=U4(>^?,N<L$L 6(V^3,N[5(<^/#FO7 RT+"7&0$L$
M9"C 9 RSM ZMK,QV.,Q(6PV=8$N&,ARZ7 RL?$R&&$R\Q$NP- @1FHUU6!6L
M3"G1G(RUW,S)D,V3: ="^0BV5$RW+,W_LV1,X RJU7K,U)S-VZR.SW00L=',
M9AJ5KD1.J]3$OOS-1O)+U1R5,ZI-O)I+Z>S,:,1,Z329Z\1*W?27U:C.FQ!+
MR Q,\73/H().K^P"AGQ/Z4P'\O3+=_!+M,1+M"P;__1+VUS+ "5-O"0*O"P(
MK6Q.^7Q+L81. .!/ D7-O/Q. 55-O'0'M(RY 25,Z&Q-  4 KLQ0L83!KHS+
MR6B';>)0V^PY!I4,O,2,.NS*!371@?)+O(1-&B7/";W.O6P'P-3*!X7.]CPY
MR>#*QRQ0'_71^.Q/K;1+M$0'K\11_I12'Z7.PM1+_.S0#(T@*67+SM3,&G6'
MU/S2,:5-O>11_\DHT/YD403M4#*]T;R<TM8,S0AR4L ,S1O=DO\4R[\,3.($
M3  =4.@<44+=SP_U2MA4TRFM2]3\31RMTRSE4$>%5">=#3?=43^5#"QUT#X5
M4 Q-3-)<S^[\5#75""]55"GMS[D<TOITU5>%U5B5U5FEU5JUU5O%QJTH"ET%
MM%WUU5X%5K'@56']56(-UF%%UF)-UF-5UF9EUF<UUFA=5FEU5FJ%UFG%UFK-
MUFO5UF[EUF^UUG#=5G'U5G(%UW%%UW)-UW-5UW9EUW<U5[@XKW6-5WJU5W>M
M5WR]5WC=UWSE5WT%V'\56'\EV'XUV( M6(0]V(%=V(1E6(6%6&A-O_^%O2"%
MD",CBEB'U=B&Y=B,[=B'!=F-]=B1#=F/%=F2)=F355F39=F4'=>)#=A[^(:.
M@(?]X4$X1-F<35AXT(;#0R!MT(9Y:-F1D(<#^-D#*H>DTMFA75F7==JE?=JF
MA=JIE=JJ9=JKS5B8_=<,/:-WR8=U0(< '(E^(".KC=JM&(>CA;EM4 =*0P=7
MHI6VI96Y18?,0 =SD#_YN]OW2X=6*8>[-8>_71*?A;G#*R6LI5K$-=O$/=O&
M9=S'7=S(5=S)K5:ME5S+8MO+95R5(]S#"P>,I=ITZ-D#&ET?U-S3I5S(35W4
M=5S65=W67=W8+5;+55Q]R%S9#5E\" <T@@?_4Y&O"[D0XAG98AD(?<B&)P&
M?D"'6,%=UW7>YH5>V)7>UZ7>YYW>>*7=J+7=P[W>@TT'M^E>9]6'<!C3OMP(
M_1Q3S:R8Z*U>]K7>]@U?^)7?]Z5?>LU>JMW>^M56[$&';%@9>$@'I=5?9OU1
M@_$&9(K? 59@]V7@!&[@^7W@T[W?R,W?"-;5?@B'SAW=PULR!U;6=U!;PD5
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MC6W%AYF]+_NK!SZ/82UF7<)YC:J6C=<@@PAO<R8WUB*.\@-"8JHMAT>/8W7
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M032&0QG%>2;>L7NQK&5+?GAEZ)A?=G6\8<PPM!U77FYYTWA>&9"!F'<A0Q?
MK(_&\<,?SA.5\QX\YBV+N<\%[+)1\/$.V=0WN'S.<FJ@AXA\S"(?K27#3AB=
M#U$1,85L'NPLG FQK78A@UV !T3Z4>$Z#P119-@SJOU\:"$">BK@X(TZVH/3
MS@;8>O+H$T- !>:CD&,=#[D'.!+SIH=$1Q^**NE+=@* <,@.&HH*B3O"H:%[
M?#<?RO5'/V8!W/]\>&,X$>F'<M%V)_?(4-1+5*27QK!I1/3CB!C\S_+4[=.(
MW-D?%<X!J%.-:%7K6X&M;M9A]L:?;TAPUX'R+,_J(0_!8 HHW)#'H:I"CW!
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M'3V4P[& PSBX \%8BOG!C3E!SI4YS$-D6S[@P+44BY. @W+I'/V00^QQ!3^
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M<XNB0/\[;2U?OQ/_--Y8 =#+N,4&!#5)=;*1J#R 11V))TZ[0(R@YWPT*\-
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MCE+XW)@L5R7IQ7[40_>";P<XMH&/C5P% $SQ!SH&- X]CH/KX\ '-,@1W&\
M !]CQ,>A*@X >)A#+OZH" #*,:!T/(KL_0@'/68QCGOD8QR$_X8_Z*$<^($>
M=&_T_,$=U$(/LB$?8 ;U_('6 . )Z,$?R 'VQ@'S+A ?P $ 9: ?YN%0VN%0
MWD$M_SKB^B#"'##*',0+'.Z!'\CA'OKA&_*!__C!BP#@]@!0]]R!][AB/
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MFH 4RH\K M7U !Z<5VO<P66SX0!P'&OJX5/6@4GF3U)'$WW\ 1^^@1NX;H"
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ML:3L\SY>;JD=^0Z:YN$ TP\R0,^YK>:XC46"QP_/9I W89 L_HUA8X_%LMH
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M/3I%TY:YQ:,DQEA1PW[ AZ]K5AF!AJ(<#%1"2M5C(J9DD%.:5J4L/T6CUO&
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MK* '&6 !&<A3NNONXX;7^(YFZFCN6QUNSP9N+J3M348 %D  <"!P B^5;T"
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J2%&F/<5N]K.C/>UJ7SO;V^[VM\,][G*?.]WK;O>[XSWO>M\[W_D>$  [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>19
<FILENAME>clym-20251231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2026-03-04T20:15:59.8687+00:00 -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://climbbio.com/20251231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2025" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:clym="http://climbbio.com/20251231" xmlns:srt="http://fasb.org/srt/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd" namespace="http://xbrl.sec.gov/ecd/2025"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" namespace="http://fasb.org/us-gaap/2025"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2024-01-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" namespace="http://xbrl.sec.gov/country/2025"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" namespace="http://fasb.org/srt/2025"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2025"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd" namespace="http://xbrl.sec.gov/cyd/2025"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" namespace="http://xbrl.sec.gov/dei/2025"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" namespace="https://xbrl.org/2023/calculation-1.1"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>75000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
        <link:definition>75010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>75020 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>75030 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical" id="StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical">
        <link:definition>75040 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" id="StatementConsolidatedStatementsOfStockholdersEquity">
        <link:definition>75050 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" id="StatementConsolidatedStatementsOfStockholdersEquityParenthetical">
        <link:definition>75060 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" id="Role_StatementConsolidatedStatementsOfCashFlows">
        <link:definition>75070 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" id="DisclosureCybersecurityRiskManagementStrategyAndGovernance">
        <link:definition>995457 - Disclosure - Cybersecurity Risk Management, Strategy and Governance</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentation" id="Role_DisclosureNatureOfOperationsAndBasisOfPresentation">
        <link:definition>995467 - Disclosure - Nature of Operations and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>995477 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedParty1" id="DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedParty1">
        <link:definition>995487 - Disclosure - Asset Acquisition and Private Placement with a Related Party</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurements" id="DisclosureMarketableSecuritiesAndFairValueMeasurements">
        <link:definition>995497 - Disclosure - Marketable Securities and Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" id="DisclosureAccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>995507 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureRelatedPartyTransactions" id="DisclosureRelatedPartyTransactions">
        <link:definition>995517 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureLeases" id="DisclosureLeases">
        <link:definition>995527 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureLicenseAgreements" id="DisclosureLicenseAgreements">
        <link:definition>995537 - Disclosure - License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>995547 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>995557 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureNetLossPerShare1" id="DisclosureNetLossPerShare1">
        <link:definition>995567 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>995577 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureDefinedContributionPlan" id="Role_DisclosureDefinedContributionPlan">
        <link:definition>995587 - Disclosure - Defined Contribution Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureRestructuringCosts" id="DisclosureRestructuringCosts">
        <link:definition>995597 - Disclosure - Restructuring Costs</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureSegments" id="DisclosureSegments">
        <link:definition>995607 - Disclosure - Segments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSubsequentEvents" id="Role_DisclosureSubsequentEvents">
        <link:definition>995617 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>995627 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>995637 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyTables" id="DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyTables">
        <link:definition>995647 - Disclosure - Asset Acquisition and Private Placement with a Related Party (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsTables" id="DisclosureMarketableSecuritiesAndFairValueMeasurementsTables">
        <link:definition>995657 - Disclosure - Marketable Securities and Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" id="DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables">
        <link:definition>995667 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesTables" id="DisclosureLeasesTables">
        <link:definition>995677 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>995687 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureNetLossPerShareTables" id="DisclosureNetLossPerShareTables">
        <link:definition>995697 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>995707 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureRestructuringCostsTables" id="DisclosureRestructuringCostsTables">
        <link:definition>995717 - Disclosure - Restructuring Costs (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureSegmentsTables" id="DisclosureSegmentsTables">
        <link:definition>995727 - Disclosure - Segments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails" id="Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails">
        <link:definition>995737 - Disclosure - Nature of Operations and Basis of Presentation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsDetails">
        <link:definition>995747 - Disclosure - Summary of Significant Accounting Policies - Schedule of Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails">
        <link:definition>995757 - Disclosure - Summary of Significant Accounting Policies - Schedule of Property and Equipment Estimated Useful Life (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>995767 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyAdditionalInformationDetails" id="DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyAdditionalInformationDetails">
        <link:definition>995777 - Disclosure - Asset Acquisition and Private Placement with a Related Party - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyTheFairValueOfTheTotalConsiderationComprisedOfTheComponentsDetails" id="DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyTheFairValueOfTheTotalConsiderationComprisedOfTheComponentsDetails">
        <link:definition>995787 - Disclosure - Asset Acquisition and Private Placement with a Related Party - The Fair Value of the Total Consideration Comprised of the Components (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyScheduleOfPurchaseConsiderationForTheAcquisitionBasedOnTheFairValueOfThe" id="DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyScheduleOfPurchaseConsiderationForTheAcquisitionBasedOnTheFairValueOfThe">
        <link:definition>995797 - Disclosure - Asset Acquisition and Private Placement with a Related Party - Schedule of Purchase Consideration For The Acquisition Based On The Fair Value Of The Net Assets Acquired By The Company (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfMarketableSecuritiesConsistedOfAvailableforsaleSecuritiesDetails" id="DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfMarketableSecuritiesConsistedOfAvailableforsaleSecuritiesDetails">
        <link:definition>995807 - Disclosure - Marketable Securities and Fair Value Measurements - Schedule of Marketable securities consisted of available-for-sale securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" id="DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails">
        <link:definition>995817 - Disclosure - Marketable Securities and Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCertainBalanceSheetAccountsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" id="Role_DisclosureCertainBalanceSheetAccountsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails">
        <link:definition>995827 - Disclosure - Certain Balance Sheet Accounts - Summary of Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails" id="DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails">
        <link:definition>995837 - Disclosure - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails2" id="DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails2">
        <link:definition>995847 - Disclosure - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" id="DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>995857 - Disclosure - Related Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" id="DisclosureLicenseAgreementsAdditionalInformationDetails">
        <link:definition>995867 - Disclosure - License Agreements (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfLeaseExpenseDetails" id="DisclosureLeasesScheduleOfLeaseExpenseDetails">
        <link:definition>995877 - Disclosure - Leases - Schedule of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfCashFlowInformationRelatedToLeasesDetails" id="DisclosureLeasesScheduleOfCashFlowInformationRelatedToLeasesDetails">
        <link:definition>995887 - Disclosure - Leases - Schedule of Cash Flow Information Related to Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfAnnualFutureMinimumLeasePaymentsDueUnderTheCompanysNoncancelableOperatingLeaseDetails" id="DisclosureLeasesScheduleOfAnnualFutureMinimumLeasePaymentsDueUnderTheCompanysNoncancelableOperatingLeaseDetails">
        <link:definition>995897 - Disclosure - Leases - Schedule of Annual Future Minimum Lease Payments Due Under the Company's Non-cancelable Operating Lease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfOperatingLeaseLiabilitiesDetails" id="DisclosureLeasesScheduleOfOperatingLeaseLiabilitiesDetails">
        <link:definition>995907 - Disclosure - Leases - Schedule of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" id="DisclosureLeasesAdditionalInformationDetails">
        <link:definition>995917 - Disclosure - Leases (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>995927 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" id="Role_DisclosureStockBasedCompensationAdditionalInformationDetails">
        <link:definition>995937 - Disclosure - Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivitiesDetails" id="Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivitiesDetails">
        <link:definition>995947 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedInBlackScholesModelDetails" id="Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedInBlackScholesModelDetails">
        <link:definition>995957 - Disclosure - Stock-Based Compensation - Summary of Assumptions Used in Black-Scholes Model (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardsDetails" id="Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardsDetails">
        <link:definition>995967 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfShareBasedCompensationExpenseDetails" id="Role_DisclosureStockBasedCompensationSummaryOfShareBasedCompensationExpenseDetails">
        <link:definition>995977 - Disclosure - Stock-Based Compensation - Summary of Share-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails" id="DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails">
        <link:definition>995987 - Disclosure - Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfNetLossPerShareAttributableToCommonStockholdersDetails" id="DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfNetLossPerShareAttributableToCommonStockholdersDetails">
        <link:definition>995997 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Net Loss Per Share Attributable To Common Stockholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" id="DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>996007 - Disclosure - Income Taxes - Additional information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetLossBeforeTaxProvisionFromIncomeTaxesDetails" id="DisclosureIncomeTaxesComponentsOfNetLossBeforeTaxProvisionFromIncomeTaxesDetails">
        <link:definition>996017 - Disclosure - Income Taxes - Components of Net Loss Before Tax Provision from Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToProvisionForIncomeTaxesDetails" id="DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToProvisionForIncomeTaxesDetails">
        <link:definition>996027 - Disclosure - Income Taxes - Schedule of Reconciliation of Statutory Federal Income Tax Rate to Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" id="Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>996037 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfValuationAllowanceDetails" id="DisclosureIncomeTaxesScheduleOfValuationAllowanceDetails">
        <link:definition>996047 - Disclosure - Income Taxes - Schedule of Valuation Allowance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetails" id="Role_DisclosureDefinedContributionPlanAdditionalInformationDetails">
        <link:definition>996057 - Disclosure - Defined Contribution Plan - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureRestructuringCostsSummaryOfRestructuringCostsInStatementOfOperationsDetails" id="DisclosureRestructuringCostsSummaryOfRestructuringCostsInStatementOfOperationsDetails">
        <link:definition>996067 - Disclosure - Restructuring Costs - Summary of restructuring costs in statement of operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureRestructuringCostsScheduleOfRestructuringLiabilityDetails" id="DisclosureRestructuringCostsScheduleOfRestructuringLiabilityDetails">
        <link:definition>996077 - Disclosure - Restructuring Costs - Schedule of restructuring liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureSegmentsAdditionalInformationDetails" id="DisclosureSegmentsAdditionalInformationDetails">
        <link:definition>996087 - Disclosure - Segments (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureSegmentsScheduleOfForthDisaggregatedResearchAndDevelopmentExpensesDetails" id="DisclosureSegmentsScheduleOfForthDisaggregatedResearchAndDevelopmentExpensesDetails">
        <link:definition>996097 - Disclosure - Segments - Schedule of Forth Disaggregated Research and Development Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureSegmentsScheduleOfForthDisaggregatedResearchAndDevelopmentExpensesParentheticalDetails" id="DisclosureSegmentsScheduleOfForthDisaggregatedResearchAndDevelopmentExpensesParentheticalDetails">
        <link:definition>996107 - Disclosure - Segments - Schedule of Forth Disaggregated Research and Development Expenses (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" id="DisclosureSubsequentEventsAdditionalInformationDetails">
        <link:definition>996117 - Disclosure - Subsequent events - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="clym-20251231.xsd#DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:href="clym-20251231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:href="clym-20251231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="clym-20251231.xsd#Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical" xlink:href="clym-20251231.xsd#StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:href="clym-20251231.xsd#StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:href="clym-20251231.xsd#StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:href="clym-20251231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:href="clym-20251231.xsd#DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentation" xlink:href="clym-20251231.xsd#Role_DisclosureNatureOfOperationsAndBasisOfPresentation" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="clym-20251231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedParty1" xlink:href="clym-20251231.xsd#DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedParty1" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurements" xlink:href="clym-20251231.xsd#DisclosureMarketableSecuritiesAndFairValueMeasurements" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:href="clym-20251231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureRelatedPartyTransactions" xlink:href="clym-20251231.xsd#DisclosureRelatedPartyTransactions" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureLeases" xlink:href="clym-20251231.xsd#DisclosureLeases" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureLicenseAgreements" xlink:href="clym-20251231.xsd#DisclosureLicenseAgreements" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:href="clym-20251231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:href="clym-20251231.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureNetLossPerShare1" xlink:href="clym-20251231.xsd#DisclosureNetLossPerShare1" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="clym-20251231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureDefinedContributionPlan" xlink:href="clym-20251231.xsd#Role_DisclosureDefinedContributionPlan" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureRestructuringCosts" xlink:href="clym-20251231.xsd#DisclosureRestructuringCosts" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureSegments" xlink:href="clym-20251231.xsd#DisclosureSegments" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSubsequentEvents" xlink:href="clym-20251231.xsd#Role_DisclosureSubsequentEvents" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="clym-20251231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="clym-20251231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyTables" xlink:href="clym-20251231.xsd#DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsTables" xlink:href="clym-20251231.xsd#DisclosureMarketableSecuritiesAndFairValueMeasurementsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="clym-20251231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesTables" xlink:href="clym-20251231.xsd#DisclosureLeasesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:href="clym-20251231.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureNetLossPerShareTables" xlink:href="clym-20251231.xsd#DisclosureNetLossPerShareTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:href="clym-20251231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureRestructuringCostsTables" xlink:href="clym-20251231.xsd#DisclosureRestructuringCostsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureSegmentsTables" xlink:href="clym-20251231.xsd#DisclosureSegmentsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails" xlink:href="clym-20251231.xsd#Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsDetails" xlink:href="clym-20251231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails" xlink:href="clym-20251231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="clym-20251231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyAdditionalInformationDetails" xlink:href="clym-20251231.xsd#DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyTheFairValueOfTheTotalConsiderationComprisedOfTheComponentsDetails" xlink:href="clym-20251231.xsd#DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyTheFairValueOfTheTotalConsiderationComprisedOfTheComponentsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyScheduleOfPurchaseConsiderationForTheAcquisitionBasedOnTheFairValueOfThe" xlink:href="clym-20251231.xsd#DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyScheduleOfPurchaseConsiderationForTheAcquisitionBasedOnTheFairValueOfThe" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfMarketableSecuritiesConsistedOfAvailableforsaleSecuritiesDetails" xlink:href="clym-20251231.xsd#DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfMarketableSecuritiesConsistedOfAvailableforsaleSecuritiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:href="clym-20251231.xsd#DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCertainBalanceSheetAccountsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="clym-20251231.xsd#Role_DisclosureCertainBalanceSheetAccountsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails" xlink:href="clym-20251231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="clym-20251231.xsd#DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" xlink:href="clym-20251231.xsd#DisclosureLicenseAgreementsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfLeaseExpenseDetails" xlink:href="clym-20251231.xsd#DisclosureLeasesScheduleOfLeaseExpenseDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfCashFlowInformationRelatedToLeasesDetails" xlink:href="clym-20251231.xsd#DisclosureLeasesScheduleOfCashFlowInformationRelatedToLeasesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfAnnualFutureMinimumLeasePaymentsDueUnderTheCompanysNoncancelableOperatingLeaseDetails" xlink:href="clym-20251231.xsd#DisclosureLeasesScheduleOfAnnualFutureMinimumLeasePaymentsDueUnderTheCompanysNoncancelableOperatingLeaseDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfOperatingLeaseLiabilitiesDetails" xlink:href="clym-20251231.xsd#DisclosureLeasesScheduleOfOperatingLeaseLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" xlink:href="clym-20251231.xsd#DisclosureLeasesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="clym-20251231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="clym-20251231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivitiesDetails" xlink:href="clym-20251231.xsd#Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedInBlackScholesModelDetails" xlink:href="clym-20251231.xsd#Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedInBlackScholesModelDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardsDetails" xlink:href="clym-20251231.xsd#Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfShareBasedCompensationExpenseDetails" xlink:href="clym-20251231.xsd#Role_DisclosureStockBasedCompensationSummaryOfShareBasedCompensationExpenseDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails" xlink:href="clym-20251231.xsd#DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfNetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="clym-20251231.xsd#DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="clym-20251231.xsd#DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetLossBeforeTaxProvisionFromIncomeTaxesDetails" xlink:href="clym-20251231.xsd#DisclosureIncomeTaxesComponentsOfNetLossBeforeTaxProvisionFromIncomeTaxesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToProvisionForIncomeTaxesDetails" xlink:href="clym-20251231.xsd#DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToProvisionForIncomeTaxesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="clym-20251231.xsd#Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfValuationAllowanceDetails" xlink:href="clym-20251231.xsd#DisclosureIncomeTaxesScheduleOfValuationAllowanceDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetails" xlink:href="clym-20251231.xsd#Role_DisclosureDefinedContributionPlanAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureRestructuringCostsSummaryOfRestructuringCostsInStatementOfOperationsDetails" xlink:href="clym-20251231.xsd#DisclosureRestructuringCostsSummaryOfRestructuringCostsInStatementOfOperationsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureRestructuringCostsScheduleOfRestructuringLiabilityDetails" xlink:href="clym-20251231.xsd#DisclosureRestructuringCostsScheduleOfRestructuringLiabilityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureSegmentsAdditionalInformationDetails" xlink:href="clym-20251231.xsd#DisclosureSegmentsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureSegmentsScheduleOfForthDisaggregatedResearchAndDevelopmentExpensesDetails" xlink:href="clym-20251231.xsd#DisclosureSegmentsScheduleOfForthDisaggregatedResearchAndDevelopmentExpensesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureSegmentsScheduleOfForthDisaggregatedResearchAndDevelopmentExpensesParentheticalDetails" xlink:href="clym-20251231.xsd#DisclosureSegmentsScheduleOfForthDisaggregatedResearchAndDevelopmentExpensesParentheticalDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="clym-20251231.xsd#DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://climbbio.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails2" xlink:href="clym-20251231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#IndividualsOnly" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/srt/role/srt-eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd#eedm1" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd#eedm" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_BlackbirdClinicalAgreementMember" xlink:label="clym_BlackbirdClinicalAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserve" xlink:label="us-gaap_RestructuringReserve"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_PreFundedWarrantMember" xlink:label="clym_PreFundedWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_SharesConvertedUponAcquisitionMember" xlink:label="clym_SharesConvertedUponAcquisitionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancingReceivablePortfolioSegmentAxis" xlink:label="us-gaap_FinancingReceivablePortfolioSegmentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_DevelopmentRegulatoryCommercialAndSalesMilestonesMember" xlink:label="clym_DevelopmentRegulatoryCommercialAndSalesMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_SeraServicesAgreementMember" xlink:label="clym_SeraServicesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_BusinessCombinationConsiderationTransferredSettlementOfPreExistingLoan" xlink:label="clym_BusinessCombinationConsiderationTransferredSettlementOfPreExistingLoan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_ScheduleOfRestructuringLiability" xlink:label="clym_ScheduleOfRestructuringLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_Pre-FundedWarrantMember" xlink:label="clym_Pre-FundedWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherExpenseMember" xlink:label="us-gaap_OtherExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_ShareBasedCompensationArrangementBySharebasedPaymentAwardContributionPercentMaximum" xlink:label="clym_ShareBasedCompensationArrangementBySharebasedPaymentAwardContributionPercentMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LatestTaxYearMember" xlink:label="us-gaap_LatestTaxYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_NumberOfSharesOfCommonStockOutstandingPercentage" xlink:label="clym_NumberOfSharesOfCommonStockOutstandingPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxYear2022Member" xlink:label="us-gaap_TaxYear2022Member"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_FirstDayOfOfferingPeriodMember" xlink:label="clym_FirstDayOfOfferingPeriodMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_MilestonePaymentAmountReduced" xlink:label="clym_MilestonePaymentAmountReduced"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_LongTermMarketableSecuritiesMember" xlink:label="clym_LongTermMarketableSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_BudoprutugServiceMember" xlink:label="clym_BudoprutugServiceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_SalesMilestonesMember" xlink:label="clym_SalesMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedparties" xlink:label="clym_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedparties"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_MilestonePayments" xlink:label="clym_MilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_JuneTwentySevenTwoThousandTwentyFiveMember" xlink:label="clym_JuneTwentySevenTwoThousandTwentyFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_ScheduleOfBalanceSheetSupplementalDisclosuresTableTextBlock" xlink:label="clym_ScheduleOfBalanceSheetSupplementalDisclosuresTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:label="clym_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_LegacyProgramExpensesMember" xlink:label="clym_LegacyProgramExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_VestingOfRestrictedStockAwardsShares" xlink:label="clym_VestingOfRestrictedStockAwardsShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_TaxCreditsReceivable" xlink:label="clym_TaxCreditsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_ConsultantMember" xlink:label="clym_ConsultantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_PrepaidResearchAndDevelopmentExpenses" xlink:label="clym_PrepaidResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_AccruedExternalResearchAndDevelopmentsExpense" xlink:label="clym_AccruedExternalResearchAndDevelopmentsExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_DefferedTaxAssetOperatingLeaseLiability" xlink:label="clym_DefferedTaxAssetOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_FourZeroOneKMember" xlink:label="clym_FourZeroOneKMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_AmountOfIn-ProcessResearchAndDevelopmentAssetsAcquired" xlink:label="clym_AmountOfIn-ProcessResearchAndDevelopmentAssetsAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_AdditionalOfficeSpaceMember" xlink:label="clym_AdditionalOfficeSpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxYear2023Member" xlink:label="us-gaap_TaxYear2023Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_FirstAnniversaryMember" xlink:label="clym_FirstAnniversaryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxYear2025Member" xlink:label="us-gaap_TaxYear2025Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_IssuanceOfPromissoryLoanInConnectionWithAssetsAcquisition" xlink:label="clym_IssuanceOfPromissoryLoanInConnectionWithAssetsAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_UnvestedRestrictedStockAwardsMember" xlink:label="clym_UnvestedRestrictedStockAwardsMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_AcelyrinAssetPurchaseAgreementMember" xlink:label="clym_AcelyrinAssetPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_AcquisitionAgreementMember" xlink:label="clym_AcquisitionAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_MilestonePaymentsDue" xlink:label="clym_MilestonePaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="us-gaap_BusinessCombinationsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_ShortTermMarketableSecuritiesMember" xlink:label="clym_ShortTermMarketableSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_DeferredTaxAssetsResearchAndDevelopmentExpenses" xlink:label="clym_DeferredTaxAssetsResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_PensionMember" xlink:label="clym_PensionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_UpfrontPaymentPaid" xlink:label="clym_UpfrontPaymentPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_CLYM116Member" xlink:label="clym_CLYM116Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProvisionForOtherCreditLosses" xlink:label="us-gaap_ProvisionForOtherCreditLosses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_CommonStockIssuedInExchangeForIn-ProcessResearchAndDevelopmentAssets" xlink:label="clym_CommonStockIssuedInExchangeForIn-ProcessResearchAndDevelopmentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedBenefitPlanTextBlock" xlink:label="us-gaap_DefinedBenefitPlanTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_IncreaseDecreaseInOperatingLeaseAssets" xlink:label="clym_IncreaseDecreaseInOperatingLeaseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoninterestExpenseOfferingCost" xlink:label="us-gaap_NoninterestExpenseOfferingCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_RecoverableResearchAndDevelopmentTaxCredits" xlink:label="clym_RecoverableResearchAndDevelopmentTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel12And3Member" xlink:label="us-gaap_FairValueInputsLevel12And3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_MabworksAgreementMember" xlink:label="clym_MabworksAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_PerformanceBasedRsusMember" xlink:label="clym_PerformanceBasedRsusMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_TotalDevelopmentAndRegulatoryMilestones" xlink:label="clym_TotalDevelopmentAndRegulatoryMilestones"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_FairMarketValueCommonStockPercentage" xlink:label="clym_FairMarketValueCommonStockPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarliestTaxYearMember" xlink:label="us-gaap_EarliestTaxYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US" xlink:label="country_US"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_DefinedContributionPlanEmployerContributionAmount" xlink:label="clym_DefinedContributionPlanEmployerContributionAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="dei_EntityIncorporationDateOfIncorporation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_ProbiogenSalesMilestonesMember" xlink:label="clym_ProbiogenSalesMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_MarchTwentySevenTwoThousandTwentyFiveMember" xlink:label="clym_MarchTwentySevenTwoThousandTwentyFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_SubleaseIncomeMember" xlink:label="clym_SubleaseIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_TaxCreditCarryforwardExpirationYearStart" xlink:label="clym_TaxCreditCarryforwardExpirationYearStart"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanAxis" xlink:label="us-gaap_RestructuringPlanAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionTextBlock" xlink:label="us-gaap_AssetAcquisitionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_TaxYears" xlink:label="clym_TaxYears"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_TotalMarketableSecuritiesMember" xlink:label="clym_TotalMarketableSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_IncrementalSharebasedcompensationexpense" xlink:label="clym_IncrementalSharebasedcompensationexpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_AggregateGrossSalesProceedsUnderSalesAgreements" xlink:label="clym_AggregateGrossSalesProceedsUnderSalesAgreements"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_PercentageOfAnnualDeductionOfTaxableIncome" xlink:label="clym_PercentageOfAnnualDeductionOfTaxableIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_ProbiogenManufacturingServiceMember" xlink:label="clym_ProbiogenManufacturingServiceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_EffectiveIncomeTaxRateReconciliationAcquiredIn-ProcessResearchDevelopmentRelatedParty" xlink:label="clym_EffectiveIncomeTaxRateReconciliationAcquiredIn-ProcessResearchDevelopmentRelatedParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_NetOperatingLeasePaymentsMember" xlink:label="clym_NetOperatingLeasePaymentsMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_StockOptionsMember" xlink:label="clym_StockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxYear2024Member" xlink:label="us-gaap_TaxYear2024Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_OptionToExtendMember" xlink:label="clym_OptionToExtendMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:label="us-gaap_RestructuringAndRelatedCostIncurredCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_EliemTherapeuticsMember" xlink:label="clym_EliemTherapeuticsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherExpenses" xlink:label="us-gaap_OtherExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxYear2021Member" xlink:label="us-gaap_TaxYear2021Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_TwoThousandTwentyFiveInducementPlanMember" xlink:label="clym_TwoThousandTwentyFiveInducementPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="us-gaap_MarketableSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_AcquiredInProcessResearchAndDevelopmentExpenses" xlink:label="clym_AcquiredInProcessResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_MilestoneMember" xlink:label="clym_MilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_FairValueLevel1Level2AndLevel3TransferAmount" xlink:label="clym_FairValueLevel1Level2AndLevel3TransferAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_AtTheMarketEquityOfferingProgramMember" xlink:label="clym_AtTheMarketEquityOfferingProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_AcelyrinIncMember" xlink:label="clym_AcelyrinIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_StockBasedCompensationMember" xlink:label="clym_StockBasedCompensationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_OperatingLossCarryforwardsExpirationStartYear" xlink:label="clym_OperatingLossCarryforwardsExpirationStartYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_TaxCreditCarryforwardExpirationYear" xlink:label="clym_TaxCreditCarryforwardExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_ExchangeAgreementMember" xlink:label="clym_ExchangeAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_AfterFirstAnniversaryMember" xlink:label="clym_AfterFirstAnniversaryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_DirectExpenseMember" xlink:label="clym_DirectExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_AmountOfPromissoryLoanSettledInConnectionWithAnAssetAcquisition" xlink:label="clym_AmountOfPromissoryLoanSettledInConnectionWithAnAssetAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_GrossOperatingLeasePaymentsMember" xlink:label="clym_GrossOperatingLeasePaymentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_PersonnelRelatedMember" xlink:label="clym_PersonnelRelatedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_TotalRestructuringCostRecordedMember" xlink:label="clym_TotalRestructuringCostRecordedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanDomain" xlink:label="us-gaap_RestructuringPlanDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_GB" xlink:label="country_GB"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_LastDayOfOfferingPeriodMember" xlink:label="clym_LastDayOfOfferingPeriodMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_DevelopmentManufacturingAndCommercialMember" xlink:label="clym_DevelopmentManufacturingAndCommercialMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficerCompensationAmount" xlink:label="clym_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficerCompensationAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_AggregateBeneficialOwnershipExchangingStockholders" xlink:label="clym_AggregateBeneficialOwnershipExchangingStockholders"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_JanuaryOneTwoThousandTwentyFiveMember" xlink:label="clym_JanuaryOneTwoThousandTwentyFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancingReceivablePortfolioSegmentDomain" xlink:label="us-gaap_FinancingReceivablePortfolioSegmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_DevelopmentAndRegulatoryMilestonesMember" xlink:label="clym_DevelopmentAndRegulatoryMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_CompanyStockOwnedByRACapitalImmediatelyPriorToAcquisitionMember" xlink:label="clym_CompanyStockOwnedByRACapitalImmediatelyPriorToAcquisitionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage" xlink:label="clym_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:label="clym_TwoThousandTwentyOneEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_CommercialMilestonesMember" xlink:label="clym_CommercialMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_UnallocatedExpenseMember" xlink:label="clym_UnallocatedExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxYear2020Member" xlink:label="us-gaap_TaxYear2020Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxYear2018Member" xlink:label="us-gaap_TaxYear2018Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_CashCashEquivalentsAndMarketableSecurities" xlink:label="clym_CashCashEquivalentsAndMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_StephenThomasMember" xlink:label="clym_StephenThomasMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRestructuring" xlink:label="us-gaap_PaymentsForRestructuring"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_DevelopmentRegulatoryAndCommercialMilestonesMember" xlink:label="clym_DevelopmentRegulatoryAndCommercialMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_RouAssetImpairmentMember" xlink:label="clym_RouAssetImpairmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_ProbiogenAgreementMember" xlink:label="clym_ProbiogenAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxYear2019Member" xlink:label="us-gaap_TaxYear2019Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_UpfrontPaymentMember" xlink:label="clym_UpfrontPaymentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_TenetStockOwnedByRACapitalMember" xlink:label="clym_TenetStockOwnedByRACapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_EmployeesIncludingExecutiveOfficersEarningContribution" xlink:label="clym_EmployeesIncludingExecutiveOfficersEarningContribution"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_UpfrontMilestonePayment" xlink:label="clym_UpfrontMilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_NotePurchaseAgreementMember" xlink:label="clym_NotePurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_EsppMember" xlink:label="clym_EsppMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_SeveranceAndBenefitsCostsMember" xlink:label="clym_SeveranceAndBenefitsCostsMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_CumulativeChangeInOwnershipPercentage" xlink:label="clym_CumulativeChangeInOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_SharesExchangedForPreFundedWarrantsValue" xlink:label="clym_SharesExchangedForPreFundedWarrantsValue"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_CrhAgreementMember" xlink:label="clym_CrhAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCosts" xlink:label="us-gaap_RestructuringCosts"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_PerformanceBasedVestingMember" xlink:label="clym_PerformanceBasedVestingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RisksAndUncertaintiesInEntitysBusiness" xlink:label="us-gaap_RisksAndUncertaintiesInEntitysBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_ManufacturingServicesMember" xlink:label="clym_ManufacturingServicesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_SharesExchangedForPreFundedWarrants" xlink:label="clym_SharesExchangedForPreFundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_BlackbirdClinicalAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Blackbird Clinical Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_BlackbirdClinicalAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Blackbird Clinical Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_BlackbirdClinicalAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Blackbird Clinical Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested, weighted average grant date fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Cash Flow Information Related to Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetirementPlanTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Plan Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Reserve</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restructuring Reserve, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Restructuring liability, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Restructuring liability, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_PreFundedWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre Funded Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_PreFundedWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre Funded Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_PreFundedWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Funded Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_SharesConvertedUponAcquisitionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Converted Upon Acquisition [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_SharesConvertedUponAcquisitionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares Converted Upon Acquisition [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_SharesConvertedUponAcquisitionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Converted Upon Acquisition [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of non-cash investing and financing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancingReceivablePortfolioSegmentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financing Receivable Portfolio Segment [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Agencies Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. government agency debt securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_DevelopmentRegulatoryCommercialAndSalesMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development Regulatory Commercial and Sales Milestones Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_DevelopmentRegulatoryCommercialAndSalesMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development Regulatory Commercial and Sales Milestones Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_DevelopmentRegulatoryCommercialAndSalesMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development Regulatory Commercial and Sales Milestones [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Excluding Accrued Interest, Allowance for Credit Loss, Not Previously Recorded</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_SeraServicesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sera Services Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_SeraServicesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sera Services Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_SeraServicesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sera Services Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_BusinessCombinationConsiderationTransferredSettlementOfPreExistingLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Consideration Transferred Settlement Of Pre-Existing Loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_BusinessCombinationConsiderationTransferredSettlementOfPreExistingLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Settlement of pre-existing loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_BusinessCombinationConsiderationTransferredSettlementOfPreExistingLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of a pre-existing loan that was settled as part of a business combination.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary, Sale of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsidiary Sale Of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Conversion of Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exchange of common stock for pre-funded warrant, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock Issued During Period, Shares, Exchange</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Exchange of common stock for pre-funded warrant, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_ScheduleOfRestructuringLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of restructuring liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_ScheduleOfRestructuringLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of restructuring liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_ScheduleOfRestructuringLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of restructuring liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets obtained in exchange for lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease liabilities arising from obtaining right-of-use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_Pre-FundedWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-Funded Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_Pre-FundedWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre-Funded Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_Pre-FundedWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-Funded Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Aggregate grant date fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options grants in period, weighted average grant date fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share based payment award, purchase price of common stock, percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other research and development expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Liability Assumed, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities assumed</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total liabilities assumed</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Marketable Securities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, options exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCostAndReserveAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeveranceCosts1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Severance expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeveranceCosts1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Severance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_ShareBasedCompensationArrangementBySharebasedPaymentAwardContributionPercentMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share based compensation arrangement by sharebased payment award contribution percent maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_ShareBasedCompensationArrangementBySharebasedPaymentAwardContributionPercentMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Sharebased Payment Award Contribution Percent Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_ShareBasedCompensationArrangementBySharebasedPaymentAwardContributionPercentMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The maximum amount an employee is allowed to contribute for the purchase of common stock under a share based compensation plan, as a percentage of their earnings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net increases recorded to income tax provision</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Loss Carryforwards [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LatestTaxYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Latest Tax Year [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LatestTaxYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Latest Tax Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of restructuring costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Costs [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_NumberOfSharesOfCommonStockOutstandingPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares of common stock outstanding percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_NumberOfSharesOfCommonStockOutstandingPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Shares of Common Stock Outstanding Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_NumberOfSharesOfCommonStockOutstandingPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of shares of common Stock outstanding percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets, Valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Valuation Allowance, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Valuation allowance as of beginning of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Valuation allowance as of end of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock options to purchase common stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Jurisdiction [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxYear2022Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Year 2022 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_FirstDayOfOfferingPeriodMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">First Day of Offering Period [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_FirstDayOfOfferingPeriodMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">First Day of Offering Period [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_FirstDayOfOfferingPeriodMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First Day of Offering Period [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_MilestonePaymentAmountReduced_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment, Amount Reduced</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_MilestonePaymentAmountReduced_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of reduction in milestone payments due upon performing specified services.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_MilestonePaymentAmountReduced_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone Payment, Amount Reduced</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Fair Value, Long-term marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan, employer matching contribution, percentage of employee's eligilble compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Common Stock, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Common Stock, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of additional options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_LongTermMarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long Term Marketable Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_LongTermMarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Long Term Marketable Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_LongTermMarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Marketable Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Basic and Diluted Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_BudoprutugServiceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Budoprutug Service [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_BudoprutugServiceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Budoprutug Service [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_BudoprutugServiceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Budoprutug</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss per share, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share attributable to common stockholders, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of options outstanding, beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of options outstanding, ending of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities Consisted of Available-for-Sale Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Asset Acquired, Asset, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_SalesMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales Milestones [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_SalesMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales Milestones [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_SalesMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales Milestones [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedparties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable and accrued liabilities, related party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedparties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable And Accrued Liabilities RelatedParties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedparties_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The increase (decrease) during the reporting period in the amounts payable to related parties and the amount of obligations and expenses incurred, but not paid, from related parties.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetirementPlanTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Plan Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidationItemsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation Items [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount due from the Company upon achievement of specified milestones, as part of a license agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Milestone Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock-based compensation, including 162m limitations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitments [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Cross-Border Tax Effect, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Cross-Border Tax Effect, Amount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect of cross-border transfers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of options, forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value of options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_JuneTwentySevenTwoThousandTwentyFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">June Twenty Seven Two Thousand Twenty Five [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_JuneTwentySevenTwoThousandTwentyFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">June Twenty Seven Two Thousand Twenty Five [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_ScheduleOfBalanceSheetSupplementalDisclosuresTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Balance Sheet Supplemental Disclosures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_ScheduleOfBalanceSheetSupplementalDisclosuresTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tabular disclosure of supplemental balance sheet information.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_ScheduleOfBalanceSheetSupplementalDisclosuresTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Balance Sheet Supplemental Disclosures [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Property and Equipment Estimated Useful Life [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment Estimated Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tabular disclosure of the estimated useful life of physical assets used in the normal conduct of business and not intended for resale.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. federal taxes at statutory rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and stockholders equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Increase (Decrease) in Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_LegacyProgramExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legacy Program Expenses [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_LegacyProgramExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Legacy Program Expenses [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_LegacyProgramExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legacy programs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Reporting Codm Profit Loss, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_VestingOfRestrictedStockAwardsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vesting of restricted stock awards.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_VestingOfRestrictedStockAwardsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting Of Restricted Stock Awards Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_VestingOfRestrictedStockAwardsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted stock awards and units, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Role of Management [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_TaxCreditsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax Credits receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_TaxCreditsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credits receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_TaxCreditsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credits receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforward amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Available For Sale Securities [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_ConsultantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consultant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_ConsultantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Consultant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Liabilities, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_PrepaidResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid research and development expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_PrepaidResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Research And Development Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_PrepaidResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid research and development deposits and expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table Text Block</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_AccruedExternalResearchAndDevelopmentsExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued external research and development expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_AccruedExternalResearchAndDevelopmentsExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued External Research And Developments Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_AccruedExternalResearchAndDevelopmentsExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Carrying value as of the balance sheet date of obligations incurred through that date and payable for external research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign Currency</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Operating lease right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total gross deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_DefferedTaxAssetOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deffered Tax Asset Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_DefferedTaxAssetOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_DefferedTaxAssetOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Acquisition [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_FourZeroOneKMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">401K [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_FourZeroOneKMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Four Zero One K [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_FourZeroOneKMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Four Zero One K [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net change in cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total potentially dilutive shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Related Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contracted terms (in years) outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_AmountOfIn-ProcessResearchAndDevelopmentAssetsAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">In-process research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_AmountOfIn-ProcessResearchAndDevelopmentAssetsAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amount of in-process research and development assets acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_AmountOfIn-ProcessResearchAndDevelopmentAssetsAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of in-process research and development asset acquired in business combination and recognized at acquisition date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of stock options, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_OwnershipDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ownership [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_AdditionalOfficeSpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Office Space [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_AdditionalOfficeSpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional Office Space [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of shares, Unvested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of shares, Unvested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Purchase Consideration For The Acquisition Based On The Fair Value Of The Net Assets Acquired By The Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Gain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock reserved for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Marketable Securities, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State taxes, net of federal benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">State taxes, net of federal benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Share-based Compensation Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other expenses, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses and Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Deferred Tax Assets and Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxYear2023Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Year 2023 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale and Maturity of Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from maturities of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Maturities of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share based compensation arrangement by share based payment award</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Assets, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Fair Value, Short-term marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue Arrangement Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_FirstAnniversaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">First Anniversary [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_FirstAnniversaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">First Anniversary Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_FirstAnniversaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First Anniversary [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Loss Carryforwards [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Asset Acquired, Prepaid Expense and Other Asset, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortized Cost, Long-term marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based payment award, award vesting rights, percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxYear2025Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Year 2025 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair value of restricted stock vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value options vested and expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_IssuanceOfPromissoryLoanInConnectionWithAssetsAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Promissory Loan In Connection With Assets Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_IssuanceOfPromissoryLoanInConnectionWithAssetsAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The cash outflow associated with the issuance of a promissory loan in connection with an asset acquisition.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_IssuanceOfPromissoryLoanInConnectionWithAssetsAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of promissory loan in connection with asset acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_IssuanceOfPromissoryLoanInConnectionWithAssetsAcquisition_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Issuance of promissory loan in connection with asset acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income (Loss) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_UnvestedRestrictedStockAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested restricted stock awards [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_UnvestedRestrictedStockAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unvested restricted stock awards member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_UnvestedRestrictedStockAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unvested Restricted Stock Awards [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_AcelyrinAssetPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Acelyrin Asset Purchase Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_AcelyrinAssetPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Acelyrin Asset Purchase Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_AcelyrinAssetPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acelyrin Asset Purchase Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitments [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition, Contingent Consideration [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Total Consideration Comprised of Following</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Consideration Transferred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted, weighted average grant date fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instrument</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_AcquisitionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Acquisition Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_AcquisitionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Acquisition Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_AcquisitionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisition Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_MilestonePaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments Due</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_MilestonePaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount due as a result of achievement of specified milestones, as of the balance sheet date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_MilestonePaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone Payments Due</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Acquisitions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_ShortTermMarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short Term Marketable Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_ShortTermMarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Short Term Marketable Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_ShortTermMarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Marketable Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Activities Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance, (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforward</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Subject to or Available for Operating Lease [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 8)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_DeferredTaxAssetsResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_DeferredTaxAssetsResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Research And Development Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_DeferredTaxAssetsResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from research and development expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_PensionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pension [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_PensionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pension [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Unvested, weighted average grant date fair value per share, ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Unvested, weighted average grant date fair value per share, beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_UpfrontPaymentPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payment Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_UpfrontPaymentPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of upfront payment paid during the period as part of a license agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_UpfrontPaymentPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront Payment Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Forecast [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expenses, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_CLYM116Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CLYM1161</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_CLYM116Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CLYM116 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_CLYM116Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">CLYM116 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProvisionForOtherCreditLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Provision for Other Credit Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProvisionForOtherCreditLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Marketable Securities, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect of exchange rate changes on cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Interest and penalties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination, Penalties and Interest Accrued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Examination, Penalties and Interest Accrued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Asset Acquired, Cash and Cash Equivalent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_CommonStockIssuedInExchangeForIn-ProcessResearchAndDevelopmentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common stock issued in exchange for in-process research and development assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_CommonStockIssuedInExchangeForIn-ProcessResearchAndDevelopmentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The value of common stock issued in exchange for in-process research and development asset as part of an asset acquisition.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_CommonStockIssuedInExchangeForIn-ProcessResearchAndDevelopmentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in exchange for in-process research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedBenefitPlanTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Benefit Plan [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedBenefitPlanTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average number of shares used to compute net loss per share, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average common shares outstanding, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_IncreaseDecreaseInOperatingLeaseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of increase (decrease) in operating lease right-of-use assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_IncreaseDecreaseInOperatingLeaseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_IncreaseDecreaseInOperatingLeaseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase (Decrease) In Operating Lease Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value options exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Expense Information Used by CODM, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CODM Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoninterestExpenseOfferingCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Offering Cost, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoninterestExpenseOfferingCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoninterestExpenseOfferingCost_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliation of Statutory Federal Income Tax Rate to Provision for Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Leasing Arrangements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, right-of-use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Operating lease, right-of-use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_RecoverableResearchAndDevelopmentTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Recoverable research and development tax credits.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_RecoverableResearchAndDevelopmentTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Recoverable Research And Development Tax Credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_RecoverableResearchAndDevelopmentTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recoverable research and development tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock in private placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock in private placement, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition, Consideration Transferred, Transaction Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel12And3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Inputs, Level 1, 2 and 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel12And3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1, Level 2, and Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_MabworksAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Mabworks Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_MabworksAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Mabworks Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_MabworksAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Mabworks Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease option to extend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Existence of Option to Extend [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_PerformanceBasedRsusMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance-Based RSUs [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_PerformanceBasedRsusMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Performance-Based RSUs [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfRestructuringDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Type of Restructuring [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Benefit Plan Disclosure [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss), Foreign Currency Transaction, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gain (Loss), Foreign Currency Transaction, before Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign currency loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_TotalDevelopmentAndRegulatoryMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Total Development And Regulatory Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_TotalDevelopmentAndRegulatoryMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Total Development And Regulatory Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_TotalDevelopmentAndRegulatoryMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total Development And Regulatory Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_FairMarketValueCommonStockPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of fair market value of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_FairMarketValueCommonStockPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair market value, common stock percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_FairMarketValueCommonStockPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of fair market value, common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarliestTaxYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Earliest Tax Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarliestTaxYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earliest Tax Year [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_US_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">United States</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_US_lbl" xlink:role="http://www.xbrl.org/2003/role/label">UNITED STATES</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_DefinedContributionPlanEmployerContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution Plan Employer Contribution Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_DefinedContributionPlanEmployerContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Contribution Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_DefinedContributionPlanEmployerContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Defined Contribution Plan Employer Contribution Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, Date of Incorporation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity incorporation date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Expenses and Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities and Other Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_ProbiogenSalesMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ProBioGen Sales Milestones [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_ProbiogenSalesMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">ProBioGen Sales Milestones Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_ProbiogenSalesMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ProBioGen Sales Milestones [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_MarchTwentySevenTwoThousandTwentyFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">March Twenty Seven Two Thousand Twenty Five [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_MarchTwentySevenTwoThousandTwentyFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">March Twenty Seven Two Thousand Twenty Five [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_SubleaseIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sublease Income [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_SubleaseIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sublease Income [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_SubleaseIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublease Income [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Description and Basis of Presentation [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature of Operations and Basis of Presentation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_TaxCreditCarryforwardExpirationYearStart_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforward expiration year start</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_TaxCreditCarryforwardExpirationYearStart_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Expiration Year Start</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_TaxCreditCarryforwardExpirationYearStart_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The year in which tax credit carryforwards begin to expire, in YYYY format.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease Payments:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities assumed</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Liability Assumed, Liability [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringPlanAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Plan [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related and Nonrelated Parties [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Acquisition and Private Placement with a Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Tax Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_TaxYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Taxable years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_TaxYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_TaxYears_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax years which are open and subject to examination.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_TotalMarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total Marketable Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_TotalMarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Total Marketable Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_TotalMarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Total Marketable Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_IncrementalSharebasedcompensationexpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incremental Share based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_IncrementalSharebasedcompensationexpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incremental ShareBasedCompensationExpense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_IncrementalSharebasedcompensationexpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Incremental ShareBasedCompensationExpense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Reportable Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of reportable segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_AggregateGrossSalesProceedsUnderSalesAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate gross sales proceeds under sales agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_AggregateGrossSalesProceedsUnderSalesAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Gross Sales Proceeds Under Sales Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_AggregateGrossSalesProceedsUnderSalesAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The aggregate gross sales proceeds available under a sales agreement to sell shares of the Company's common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_PercentageOfAnnualDeductionOfTaxableIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Annual Deduction Of Taxable Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_PercentageOfAnnualDeductionOfTaxableIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The percentage of annual taxable income to which net operating loss carryforwards are limited.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_PercentageOfAnnualDeductionOfTaxableIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of annual deduction of taxable income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of options, vested and expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_ProbiogenManufacturingServiceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ProBioGen Manufacturing Service [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_ProbiogenManufacturingServiceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">ProBioGen Manufacturing Service Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_ProbiogenManufacturingServiceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ProBioGen Manufacturing Service [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_EffectiveIncomeTaxRateReconciliationAcquiredIn-ProcessResearchDevelopmentRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquired in-process research &amp; development, related party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_EffectiveIncomeTaxRateReconciliationAcquiredIn-ProcessResearchDevelopmentRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Acquired In-Process Research &amp; Development, Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_EffectiveIncomeTaxRateReconciliationAcquiredIn-ProcessResearchDevelopmentRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of reported income tax expense (benefit) from difference to expected income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to acquired in-process research and development from a related party.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title and Position [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total expense recognized from matching contributions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of options exercisable, end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_NetOperatingLeasePaymentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Operating Lease Payments [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_NetOperatingLeasePaymentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net Operating Lease Payments [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_NetOperatingLeasePaymentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Operating Lease Payments [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_StockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Options [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_StockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_StockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock Options.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units (RSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Asset Acquired, Asset [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxYear2024Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Year 2024 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_OptionToExtendMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option to Extend [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_OptionToExtendMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Option to Extend [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax settlement, percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Settlement, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Tax Settlement, Percent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">US Government Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedCostIncurredCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Severance costs incurred during the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedCostIncurredCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Cost, Incurred Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based payment award, description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign rate differential</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Foreign rate differential</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unvested restricted stock units [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average number of shares used to compute net loss per share, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average common shares outstanding, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_EliemTherapeuticsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Eliem Therapeutics [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_EliemTherapeuticsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Eliem Therapeutics [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_EliemTherapeuticsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Eliem Therapeutics [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment to, related party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Share, Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Share, Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxYear2021Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Year 2021 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Liability Assumed, Other Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_TwoThousandTwentyFiveInducementPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025 Inducement Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_TwoThousandTwentyFiveInducementPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Five Inducement Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_TwoThousandTwentyFiveInducementPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Twenty Five Inducement Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Certain Balance Sheet Accounts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Valuation Allowance [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized foreign currency transaction (gain) loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrealized Gain (Loss), Foreign Currency Transaction, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Treasury securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based payment award, number of shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">General and administrative expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Liability Assumed, Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash operating lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_AcquiredInProcessResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">In-process research and development, related party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_AcquiredInProcessResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Acquired In Process Research and Development Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_AcquiredInProcessResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of in-process research and development assets acquired during the period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_AcquiredInProcessResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Acquired in-process research and development, related party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, options vested and expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_MilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_MilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_MilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Issued Accounting Pronouncements Not Yet Adopted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Annual Future Minimum Lease Payments Due Under the Company's Non-cancelable Operating Lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_OwnershipAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ownership [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based payment award, option vesting period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_FairValueLevel1Level2AndLevel3TransferAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value transfer amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_FairValueLevel1Level2AndLevel3TransferAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Level1 Level2 And Level3 Transfer Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_FairValueLevel1Level2AndLevel3TransferAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair Value Level 1 Level 2 and Level 3 Transfer Amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Term of Contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Current operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets and liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total research and development expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Leases [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortized Cost, Short-term marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Components of Net Loss Before Tax Provision from Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_AtTheMarketEquityOfferingProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At The Market Equity Offering Program [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_AtTheMarketEquityOfferingProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At The Market Equity Offering Program [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_AtTheMarketEquityOfferingProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At The Market Equity Offering Program [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_AcelyrinIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Acelyrin, Inc. [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_AcelyrinIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acelyrin Inc. [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_AcelyrinIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Acelyrin, Inc. [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Businesses, Net of Cash Acquired, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cash paid in connection with asset acquisition, net of cash received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_StockBasedCompensationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock-based Compensation [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_StockBasedCompensationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock-based Compensation [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_StockBasedCompensationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based Compensation [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Restricted Stock Awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate grant-date fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Aggregate intrinsic value outstanding, end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Aggregate intrinsic value options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_OperatingLossCarryforwardsExpirationStartYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards expiration start year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_OperatingLossCarryforwardsExpirationStartYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Start Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_OperatingLossCarryforwardsExpirationStartYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The year in which operating loss carryforwards begin to expire, in YYYY format.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforward expiration year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Expiration Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax credit carryforward expiration year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for amounts included in the measurement of operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_ExchangeAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exchange Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_ExchangeAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exchange Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_ExchangeAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Exchange Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_AfterFirstAnniversaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">After First Anniversary [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_AfterFirstAnniversaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">After First Anniversary Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_AfterFirstAnniversaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">After First Anniversary [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities and Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_DirectExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Direct Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_DirectExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Direct Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_DirectExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Direct Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other long-term assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Noncurrent Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_AmountOfPromissoryLoanSettledInConnectionWithAnAssetAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amount of promissory loan settled in connection with an asset acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_AmountOfPromissoryLoanSettledInConnectionWithAnAssetAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of promissory loan settled in connection with an asset acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_AmountOfPromissoryLoanSettledInConnectionWithAnAssetAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Settlement of promissory loan in connection with asset acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Prepaid Expenses and Other Current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Cost and Reserve [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Tax Credit, Amount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net assets acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_GrossOperatingLeasePaymentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gross Operating Lease Payments [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_GrossOperatingLeasePaymentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gross Operating Lease Payments [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_GrossOperatingLeasePaymentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Operating Lease Payments [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Assets, Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_PersonnelRelatedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Personnel Related [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_PersonnelRelatedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Personnel Related [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_PersonnelRelatedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Personnel-related (including stock-based compensation)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Conversion of Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exchange of common stock for pre-funded warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Exchange of common stock for pre-funded warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, options forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeited, weighted average grant date fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related and Nonrelated Parties [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_TotalRestructuringCostRecordedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total Restructuring Cost Recorded [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_TotalRestructuringCostRecordedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Total Restructuring Cost Recorded [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_TotalRestructuringCostRecordedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Total Restructuring Cost Recorded [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringPlanDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Plan [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted average exercise price outstanding, end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted average exercise price outstanding, beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_GB_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">United Kingdom</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_GB_lbl" xlink:role="http://www.xbrl.org/2003/role/label">UNITED KINGDOM</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_LastDayOfOfferingPeriodMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Last Day of Offering Period [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_LastDayOfOfferingPeriodMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Last Day of Offering Period [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_LastDayOfOfferingPeriodMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Last Day of Offering Period [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OpenTaxYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OpenTaxYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Open Tax Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_DevelopmentManufacturingAndCommercialMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development Manufacturing and Commercial [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_DevelopmentManufacturingAndCommercialMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development Manufacturing and Commercial [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_DevelopmentManufacturingAndCommercialMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development Manufacturing and Commercial [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficerCompensationAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-deductible officer compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficerCompensationAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Officer Compensation, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficerCompensationAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of reported income tax expense (benefit) from difference to expected income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to limitations on executive compensation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued payroll and related expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total undiscounted lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Leases, Total minimum lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total undiscounted lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_AggregateBeneficialOwnershipExchangingStockholders_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Beneficial Ownership Exchanging Stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_AggregateBeneficialOwnershipExchangingStockholders_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The aggregate amount of beneficial ownership that exchanging shareholders may own to be eligible to exercise pre-funded warrants, as a percentage of shares issued and outstanding.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: imputed interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: imputed interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_JanuaryOneTwoThousandTwentyFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">January One Two Thousand Twenty Five [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_JanuaryOneTwoThousandTwentyFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">January One Two Thousand Twenty Five [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancingReceivablePortfolioSegmentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financing Receivable Portfolio Segment [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_DevelopmentAndRegulatoryMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development and Regulatory Milestones [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_DevelopmentAndRegulatoryMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development and Regulatory Milestones [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_DevelopmentAndRegulatoryMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development and Regulatory Milestones [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_CompanyStockOwnedByRACapitalImmediatelyPriorToAcquisitionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Company Stock Owned By RA Capital Immediately Prior to Acquisition [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_CompanyStockOwnedByRACapitalImmediatelyPriorToAcquisitionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Company Stock Owned By RA Capital Immediately Prior to Acquisition [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_CompanyStockOwnedByRACapitalImmediatelyPriorToAcquisitionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Company Stock Owned By RA Capital Immediately Prior to Acquisition [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Annual Increase Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The automatic increase in the number of shares that may be issued under a share-based payment arrangement on the first day of each fiscal year, as a percentage of shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares of Common Stock Outstanding Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock issued during period shares employee stock purchase plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based payment award, expiration period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_TwoThousandTwentyOneEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty one equity incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_TwoThousandTwentyOneEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty One Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_TwoThousandTwentyOneEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Prepaid Expense, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.0001 par value; 250,000,000 shares authorized; 47,766,338 and 67,255,434 shares issued and outstanding at December 31, 2025 and 2024, respectively</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_CommercialMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Milestones [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_CommercialMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial Milestones [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_CommercialMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Milestones [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_UnallocatedExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unallocated Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_UnallocatedExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unallocated Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_UnallocatedExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unallocated Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principles of Consolidation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive loss:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxYear2020Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Year 2020 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares of common stock issuable under the ESPP [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income (expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxYear2018Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Year 2018 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/netLabel">Income tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective income tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock for the acquisition of in-process research and development from a related party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Tax [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income (loss):</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary, Ownership Percentage, Noncontrolling Owner</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minority Interest Ownership Percentage By Non controlling Owners</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk and Significant Suppliers and Manufacturers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_CashCashEquivalentsAndMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents and Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_CashCashEquivalentsAndMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash Cash Equivalents and Marketable Securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_CashCashEquivalentsAndMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents and marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidationItemsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation Items [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_StephenThomasMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stephen Thomas [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_StephenThomasMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stephen Thomas [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_StephenThomasMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stephen Thomas</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRestructuring_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Severance costs paid during the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRestructuring_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Severance costs paid during the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRestructuring_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Restructuring</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accrued compensation and benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued payroll taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Cost [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_DevelopmentRegulatoryAndCommercialMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development Regulatory and Commercial Milestones [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_DevelopmentRegulatoryAndCommercialMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development Regulatory and Commercial Milestones [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_DevelopmentRegulatoryAndCommercialMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development Regulatory and Commercial Milestones [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock in initial public offering, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of shares, Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares, Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Subject to or Available for Operating Lease [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss per share, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share attributable to common stockholders, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_RouAssetImpairmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ROU Asset Impairment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_RouAssetImpairmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ROU Asset Impairment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_RouAssetImpairmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">ROU Asset Impairment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Forth Disaggregated Research and Development Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingSegmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Segments [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingSegmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Segments [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title and Position [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_ProbiogenAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ProBioGen Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_ProbiogenAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">ProBioGen Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_ProbiogenAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ProBioGen Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Patent costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxYear2019Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Year 2019 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Benefit Plan [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_UpfrontPaymentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_UpfrontPaymentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront Payment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining lease term - operating lease (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Information [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted stock awards and units, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardDateAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Date [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Consideration Transferred, Equity Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateBondSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Corporate Bond [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateBondSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Bond Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateBondSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Bond Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardDateDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Date [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_TenetStockOwnedByRACapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenet Stock Owned By RA Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_TenetStockOwnedByRACapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tenet Stock Owned By RA Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_TenetStockOwnedByRACapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tenet Stock Owned By RA Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Stock Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Pre-funded warrant issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_EmployeesIncludingExecutiveOfficersEarningContribution_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employees Including Executive Officers Earning Contribution</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_EmployeesIncludingExecutiveOfficersEarningContribution_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employees Including Executive Officers Earning Contribution</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_EmployeesIncludingExecutiveOfficersEarningContribution_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employees Including Executive Officers Earning Contribution</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_UpfrontMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront, Milestone Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_UpfrontMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront, Milestone Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_UpfrontMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront, Milestone Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_NotePurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Note Purchase Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_NotePurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Note Purchase Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_NotePurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Note Purchase Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average discount rate - operating lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, net of current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease liability, net of current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Lease Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense) [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense):</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Antidilutive Securities Excluded from Computation of Net Loss Per Share Attributable To Common Stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Jurisdiction [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Securities Available For Sale [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_EsppMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ESPP [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_EsppMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">ESPP Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_EsppMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ESPP [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and fixtures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Acquisition [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accretion of discounts and amortization of premiums on investments, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accretion of discounts on marketable securities, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_SeveranceAndBenefitsCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Severance and Benefits Costs [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_SeveranceAndBenefitsCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Severance and Benefits Costs [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_SeveranceAndBenefitsCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Severance and Benefits Costs [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_CumulativeChangeInOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cumulative change in ownership percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_CumulativeChangeInOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative Change In Ownership Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_CumulativeChangeInOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cumulative change in ownership percentage.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_SharesExchangedForPreFundedWarrantsValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Exchanged For Pre Funded Warrants Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_SharesExchangedForPreFundedWarrantsValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The value of shares exchanged during the period for pre-funded warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_SharesExchangedForPreFundedWarrantsValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exchange of common stock for pre-funded warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_CrhAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CRH Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_CrhAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CRH Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_CrhAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">CRH Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Security, Unrealized Gain (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorOpinionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Opinion [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total restructuring costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restructuring Costs, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_PerformanceBasedVestingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance based vesting [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_PerformanceBasedVestingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Performance based vesting [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_PerformanceBasedVestingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance based vesting [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RisksAndUncertaintiesInEntitysBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risks and Uncertainties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RisksAndUncertaintiesInEntitysBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Risks and Uncertainties in Entity's Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_ManufacturingServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Manufacturing Services [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_ManufacturingServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Manufacturing Services [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_ManufacturingServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Manufacturing Services [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_SharesExchangedForPreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exchange of common stock for pre-funded warrant, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_SharesExchangedForPreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Exchanged For Pre Funded Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="clym_SharesExchangedForPreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The number of shares exchanged during the period for pre-funded warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number shares remaining for issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation, weighted average amortization period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued professional fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, and Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, and Short-Term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents and marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Accrued Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested and expected to vest</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_BlackbirdClinicalAgreementMember" xlink:to="clym_BlackbirdClinicalAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringReserve" xlink:to="us-gaap_RestructuringReserve_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_PreFundedWarrantMember" xlink:to="clym_PreFundedWarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_SharesConvertedUponAcquisitionMember" xlink:to="clym_SharesConvertedUponAcquisitionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancingReceivablePortfolioSegmentAxis" xlink:to="us-gaap_FinancingReceivablePortfolioSegmentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_DevelopmentRegulatoryCommercialAndSalesMilestonesMember" xlink:to="clym_DevelopmentRegulatoryCommercialAndSalesMilestonesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_SeraServicesAgreementMember" xlink:to="clym_SeraServicesAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_BusinessCombinationConsiderationTransferredSettlementOfPreExistingLoan" xlink:to="clym_BusinessCombinationConsiderationTransferredSettlementOfPreExistingLoan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_ScheduleOfRestructuringLiability" xlink:to="clym_ScheduleOfRestructuringLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivable" xlink:to="us-gaap_InterestReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_Pre-FundedWarrantMember" xlink:to="clym_Pre-FundedWarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenseMember" xlink:to="us-gaap_OtherExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_RestructuringCostAndReserveAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_ShareBasedCompensationArrangementBySharebasedPaymentAwardContributionPercentMaximum" xlink:to="clym_ShareBasedCompensationArrangementBySharebasedPaymentAwardContributionPercentMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LatestTaxYearMember" xlink:to="us-gaap_LatestTaxYearMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_NumberOfSharesOfCommonStockOutstandingPercentage" xlink:to="clym_NumberOfSharesOfCommonStockOutstandingPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxYear2022Member" xlink:to="us-gaap_TaxYear2022Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_FirstDayOfOfferingPeriodMember" xlink:to="clym_FirstDayOfOfferingPeriodMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_MilestonePaymentAmountReduced" xlink:to="clym_MilestonePaymentAmountReduced_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_LongTermMarketableSecuritiesMember" xlink:to="clym_LongTermMarketableSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_BudoprutugServiceMember" xlink:to="clym_BudoprutugServiceMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_SalesMilestonesMember" xlink:to="clym_SalesMilestonesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedparties" xlink:to="clym_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedparties_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="us-gaap_RetirementPlanTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidationItemsDomain" xlink:to="srt_ConsolidationItemsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_MilestonePayments" xlink:to="clym_MilestonePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_JuneTwentySevenTwoThousandTwentyFiveMember" xlink:to="clym_JuneTwentySevenTwoThousandTwentyFiveMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_ScheduleOfBalanceSheetSupplementalDisclosuresTableTextBlock" xlink:to="clym_ScheduleOfBalanceSheetSupplementalDisclosuresTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:to="clym_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_LegacyProgramExpensesMember" xlink:to="clym_LegacyProgramExpensesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:to="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_VestingOfRestrictedStockAwardsShares" xlink:to="clym_VestingOfRestrictedStockAwardsShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_TaxCreditsReceivable" xlink:to="clym_TaxCreditsReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_ConsultantMember" xlink:to="clym_ConsultantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_PrepaidResearchAndDevelopmentExpenses" xlink:to="clym_PrepaidResearchAndDevelopmentExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_AccruedExternalResearchAndDevelopmentsExpense" xlink:to="clym_AccruedExternalResearchAndDevelopmentsExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_DefferedTaxAssetOperatingLeaseLiability" xlink:to="clym_DefferedTaxAssetOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_FourZeroOneKMember" xlink:to="clym_FourZeroOneKMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_AmountOfIn-ProcessResearchAndDevelopmentAssetsAcquired" xlink:to="clym_AmountOfIn-ProcessResearchAndDevelopmentAssetsAcquired_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_AdditionalOfficeSpaceMember" xlink:to="clym_AdditionalOfficeSpaceMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="us-gaap_AssetAcquisitionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxYear2023Member" xlink:to="us-gaap_TaxYear2023Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_FirstAnniversaryMember" xlink:to="clym_FirstAnniversaryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxYear2025Member" xlink:to="us-gaap_TaxYear2025Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_IssuanceOfPromissoryLoanInConnectionWithAssetsAcquisition" xlink:to="clym_IssuanceOfPromissoryLoanInConnectionWithAssetsAcquisition_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_UnvestedRestrictedStockAwardsMember" xlink:to="clym_UnvestedRestrictedStockAwardsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_AcelyrinAssetPurchaseAgreementMember" xlink:to="clym_AcelyrinAssetPurchaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_AcquisitionAgreementMember" xlink:to="clym_AcquisitionAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_MilestonePaymentsDue" xlink:to="clym_MilestonePaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsPolicy" xlink:to="us-gaap_BusinessCombinationsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxPeriodDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_ShortTermMarketableSecuritiesMember" xlink:to="clym_ShortTermMarketableSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_DeferredTaxAssetsResearchAndDevelopmentExpenses" xlink:to="clym_DeferredTaxAssetsResearchAndDevelopmentExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_PensionMember" xlink:to="clym_PensionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_UpfrontPaymentPaid" xlink:to="clym_UpfrontPaymentPaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_CLYM116Member" xlink:to="clym_CLYM116Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForOtherCreditLosses" xlink:to="us-gaap_ProvisionForOtherCreditLosses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesNoncurrent" xlink:to="us-gaap_MarketableSecuritiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_CommonStockIssuedInExchangeForIn-ProcessResearchAndDevelopmentAssets" xlink:to="clym_CommonStockIssuedInExchangeForIn-ProcessResearchAndDevelopmentAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanTextBlock" xlink:to="us-gaap_DefinedBenefitPlanTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_IncreaseDecreaseInOperatingLeaseAssets" xlink:to="clym_IncreaseDecreaseInOperatingLeaseAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" xlink:to="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoninterestExpenseOfferingCost" xlink:to="us-gaap_NoninterestExpenseOfferingCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_RecoverableResearchAndDevelopmentTaxCredits" xlink:to="clym_RecoverableResearchAndDevelopmentTaxCredits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel12And3Member" xlink:to="us-gaap_FairValueInputsLevel12And3Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_MabworksAgreementMember" xlink:to="clym_MabworksAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_PerformanceBasedRsusMember" xlink:to="clym_PerformanceBasedRsusMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_TypeOfRestructuringDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_TotalDevelopmentAndRegulatoryMilestones" xlink:to="clym_TotalDevelopmentAndRegulatoryMilestones_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_FairMarketValueCommonStockPercentage" xlink:to="clym_FairMarketValueCommonStockPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarliestTaxYearMember" xlink:to="us-gaap_EarliestTaxYearMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_DefinedContributionPlanEmployerContributionAmount" xlink:to="clym_DefinedContributionPlanEmployerContributionAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationDateOfIncorporation" xlink:to="dei_EntityIncorporationDateOfIncorporation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_ProbiogenSalesMilestonesMember" xlink:to="clym_ProbiogenSalesMilestonesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_MarchTwentySevenTwoThousandTwentyFiveMember" xlink:to="clym_MarchTwentySevenTwoThousandTwentyFiveMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_SubleaseIncomeMember" xlink:to="clym_SubleaseIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_TaxCreditCarryforwardExpirationYearStart" xlink:to="clym_TaxCreditCarryforwardExpirationYearStart_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringPlanAxis" xlink:to="us-gaap_RestructuringPlanAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionTextBlock" xlink:to="us-gaap_AssetAcquisitionTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_TaxYears" xlink:to="clym_TaxYears_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_TotalMarketableSecuritiesMember" xlink:to="clym_TotalMarketableSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_IncrementalSharebasedcompensationexpense" xlink:to="clym_IncrementalSharebasedcompensationexpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_AggregateGrossSalesProceedsUnderSalesAgreements" xlink:to="clym_AggregateGrossSalesProceedsUnderSalesAgreements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_PercentageOfAnnualDeductionOfTaxableIncome" xlink:to="clym_PercentageOfAnnualDeductionOfTaxableIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_ProbiogenManufacturingServiceMember" xlink:to="clym_ProbiogenManufacturingServiceMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_EffectiveIncomeTaxRateReconciliationAcquiredIn-ProcessResearchDevelopmentRelatedParty" xlink:to="clym_EffectiveIncomeTaxRateReconciliationAcquiredIn-ProcessResearchDevelopmentRelatedParty_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_NetOperatingLeasePaymentsMember" xlink:to="clym_NetOperatingLeasePaymentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_StockOptionsMember" xlink:to="clym_StockOptionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxYear2024Member" xlink:to="us-gaap_TaxYear2024Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_OptionToExtendMember" xlink:to="clym_OptionToExtendMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:to="us-gaap_RestructuringAndRelatedCostIncurredCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_EliemTherapeuticsMember" xlink:to="clym_EliemTherapeuticsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssets" xlink:to="us-gaap_OtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxYear2021Member" xlink:to="us-gaap_TaxYear2021Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_TwoThousandTwentyFiveInducementPlanMember" xlink:to="clym_TwoThousandTwentyFiveInducementPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_AcquiredInProcessResearchAndDevelopmentExpenses" xlink:to="clym_AcquiredInProcessResearchAndDevelopmentExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_MilestoneMember" xlink:to="clym_MilestoneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_FairValueLevel1Level2AndLevel3TransferAmount" xlink:to="clym_FairValueLevel1Level2AndLevel3TransferAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_AtTheMarketEquityOfferingProgramMember" xlink:to="clym_AtTheMarketEquityOfferingProgramMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_AcelyrinIncMember" xlink:to="clym_AcelyrinIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_StockBasedCompensationMember" xlink:to="clym_StockBasedCompensationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_OperatingLossCarryforwardsExpirationStartYear" xlink:to="clym_OperatingLossCarryforwardsExpirationStartYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_EarningsPerShareBasicLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_TaxCreditCarryforwardExpirationYear" xlink:to="clym_TaxCreditCarryforwardExpirationYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_ExchangeAgreementMember" xlink:to="clym_ExchangeAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_AfterFirstAnniversaryMember" xlink:to="clym_AfterFirstAnniversaryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_DirectExpenseMember" xlink:to="clym_DirectExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_AmountOfPromissoryLoanSettledInConnectionWithAnAssetAcquisition" xlink:to="clym_AmountOfPromissoryLoanSettledInConnectionWithAnAssetAcquisition_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCostAndReserveLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_GrossOperatingLeasePaymentsMember" xlink:to="clym_GrossOperatingLeasePaymentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_PersonnelRelatedMember" xlink:to="clym_PersonnelRelatedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_TotalRestructuringCostRecordedMember" xlink:to="clym_TotalRestructuringCostRecordedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringPlanDomain" xlink:to="us-gaap_RestructuringPlanDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_GB" xlink:to="country_GB_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_LastDayOfOfferingPeriodMember" xlink:to="clym_LastDayOfOfferingPeriodMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OpenTaxYear" xlink:to="us-gaap_OpenTaxYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_DevelopmentManufacturingAndCommercialMember" xlink:to="clym_DevelopmentManufacturingAndCommercialMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficerCompensationAmount" xlink:to="clym_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficerCompensationAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_AggregateBeneficialOwnershipExchangingStockholders" xlink:to="clym_AggregateBeneficialOwnershipExchangingStockholders_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_JanuaryOneTwoThousandTwentyFiveMember" xlink:to="clym_JanuaryOneTwoThousandTwentyFiveMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancingReceivablePortfolioSegmentDomain" xlink:to="us-gaap_FinancingReceivablePortfolioSegmentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_DevelopmentAndRegulatoryMilestonesMember" xlink:to="clym_DevelopmentAndRegulatoryMilestonesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_CompanyStockOwnedByRACapitalImmediatelyPriorToAcquisitionMember" xlink:to="clym_CompanyStockOwnedByRACapitalImmediatelyPriorToAcquisitionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage" xlink:to="clym_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:to="clym_TwoThousandTwentyOneEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_CommercialMilestonesMember" xlink:to="clym_CommercialMilestonesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_UnallocatedExpenseMember" xlink:to="clym_UnallocatedExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxYear2020Member" xlink:to="us-gaap_TaxYear2020Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxYear2018Member" xlink:to="us-gaap_TaxYear2018Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_CashCashEquivalentsAndMarketableSecurities" xlink:to="clym_CashCashEquivalentsAndMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_StephenThomasMember" xlink:to="clym_StephenThomasMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRestructuring" xlink:to="us-gaap_PaymentsForRestructuring_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_DevelopmentRegulatoryAndCommercialMilestonesMember" xlink:to="clym_DevelopmentRegulatoryAndCommercialMilestonesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_RouAssetImpairmentMember" xlink:to="clym_RouAssetImpairmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingSegmentsMember" xlink:to="us-gaap_OperatingSegmentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_ProbiogenAgreementMember" xlink:to="clym_ProbiogenAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxYear2019Member" xlink:to="us-gaap_TaxYear2019Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_UpfrontPaymentMember" xlink:to="clym_UpfrontPaymentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateBondSecuritiesMember" xlink:to="us-gaap_CorporateBondSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateDomain" xlink:to="us-gaap_AwardDateDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_TenetStockOwnedByRACapitalMember" xlink:to="clym_TenetStockOwnedByRACapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_EmployeesIncludingExecutiveOfficersEarningContribution" xlink:to="clym_EmployeesIncludingExecutiveOfficersEarningContribution_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_UpfrontMilestonePayment" xlink:to="clym_UpfrontMilestonePayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_NotePurchaseAgreementMember" xlink:to="clym_NotePurchaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_EsppMember" xlink:to="clym_EsppMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_SeveranceAndBenefitsCostsMember" xlink:to="clym_SeveranceAndBenefitsCostsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_CumulativeChangeInOwnershipPercentage" xlink:to="clym_CumulativeChangeInOwnershipPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_SharesExchangedForPreFundedWarrantsValue" xlink:to="clym_SharesExchangedForPreFundedWarrantsValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_CrhAgreementMember" xlink:to="clym_CrhAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorOpinionTextBlock" xlink:to="dei_AuditorOpinionTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCosts" xlink:to="us-gaap_RestructuringCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_PerformanceBasedVestingMember" xlink:to="clym_PerformanceBasedVestingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RisksAndUncertaintiesInEntitysBusiness" xlink:to="us-gaap_RisksAndUncertaintiesInEntitysBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_ManufacturingServicesMember" xlink:to="clym_ManufacturingServicesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="clym_SharesExchangedForPreFundedWarrants" xlink:to="clym_SharesExchangedForPreFundedWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="87.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="88.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorOpinionTextBlock" order="89.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_AcquiredInProcessResearchAndDevelopmentExpenses" xlink:label="clym_AcquiredInProcessResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="clym_AcquiredInProcessResearchAndDevelopmentExpenses" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_2" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_VestingOfRestrictedStockAwardsShares" xlink:label="clym_VestingOfRestrictedStockAwardsShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_SharesExchangedForPreFundedWarrants" xlink:label="clym_SharesExchangedForPreFundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_SharesExchangedForPreFundedWarrantsValue" xlink:label="clym_SharesExchangedForPreFundedWarrantsValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_15"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_16"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="clym_VestingOfRestrictedStockAwardsShares" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="clym_SharesExchangedForPreFundedWarrants" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="clym_SharesExchangedForPreFundedWarrantsValue" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_15" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_16" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoninterestExpenseOfferingCost" xlink:label="us-gaap_NoninterestExpenseOfferingCost"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoninterestExpenseOfferingCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_CommonStockIssuedInExchangeForIn-ProcessResearchAndDevelopmentAssets" xlink:label="clym_CommonStockIssuedInExchangeForIn-ProcessResearchAndDevelopmentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_AmountOfPromissoryLoanSettledInConnectionWithAnAssetAcquisition" xlink:label="clym_AmountOfPromissoryLoanSettledInConnectionWithAnAssetAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_IssuanceOfPromissoryLoanInConnectionWithAssetsAcquisition" xlink:label="clym_IssuanceOfPromissoryLoanInConnectionWithAssetsAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedparties" xlink:label="clym_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedparties"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_AcquiredInProcessResearchAndDevelopmentExpenses" xlink:label="clym_AcquiredInProcessResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="clym_CommonStockIssuedInExchangeForIn-ProcessResearchAndDevelopmentAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="clym_AmountOfPromissoryLoanSettledInConnectionWithAnAssetAcquisition" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="clym_IssuanceOfPromissoryLoanInConnectionWithAssetsAcquisition" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="clym_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedparties" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="clym_AcquiredInProcessResearchAndDevelopmentExpenses" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_StephenThomasMember" xlink:label="clym_StephenThomasMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="clym_StephenThomasMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedParty1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionTextBlock" xlink:label="us-gaap_AssetAcquisitionTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_AssetAcquisitionTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="us-gaap_MarketableSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureRelatedPartyTransactions" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureLeases" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureLicenseAgreements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureNetLossPerShare1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureDefinedContributionPlan" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedBenefitPlanTextBlock" xlink:label="us-gaap_DefinedBenefitPlanTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedBenefitPlanTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureRestructuringCosts" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureSegments" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RisksAndUncertaintiesInEntitysBusiness" xlink:label="us-gaap_RisksAndUncertaintiesInEntitysBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="us-gaap_BusinessCombinationsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RisksAndUncertaintiesInEntitysBusiness" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessCombinationsPolicy" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:label="clym_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="clym_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="us-gaap_MarketableSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_ScheduleOfBalanceSheetSupplementalDisclosuresTableTextBlock" xlink:label="clym_ScheduleOfBalanceSheetSupplementalDisclosuresTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="clym_ScheduleOfBalanceSheetSupplementalDisclosuresTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureNetLossPerShareTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureRestructuringCostsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_ScheduleOfRestructuringLiability" xlink:label="clym_ScheduleOfRestructuringLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="clym_ScheduleOfRestructuringLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureSegmentsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="dei_EntityIncorporationDateOfIncorporation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_EliemTherapeuticsMember" xlink:label="clym_EliemTherapeuticsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_AtTheMarketEquityOfferingProgramMember" xlink:label="clym_AtTheMarketEquityOfferingProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_AcquisitionAgreementMember" xlink:label="clym_AcquisitionAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_AggregateGrossSalesProceedsUnderSalesAgreements" xlink:label="clym_AggregateGrossSalesProceedsUnderSalesAgreements"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_CashCashEquivalentsAndMarketableSecurities" xlink:label="clym_CashCashEquivalentsAndMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoninterestExpenseOfferingCost" xlink:label="us-gaap_NoninterestExpenseOfferingCost"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="clym_EliemTherapeuticsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="clym_AtTheMarketEquityOfferingProgramMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="clym_AcquisitionAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="clym_AggregateGrossSalesProceedsUnderSalesAgreements" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="clym_CashCashEquivalentsAndMarketableSecurities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_NoninterestExpenseOfferingCost" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_TotalMarketableSecuritiesMember" xlink:label="clym_TotalMarketableSecuritiesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_USGovernmentDebtSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CorporateBondSecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="clym_TotalMarketableSecuritiesMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel12And3Member" xlink:label="us-gaap_FairValueInputsLevel12And3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_FairValueLevel1Level2AndLevel3TransferAmount" xlink:label="clym_FairValueLevel1Level2AndLevel3TransferAmount"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_TaxCreditsReceivable" xlink:label="clym_TaxCreditsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProvisionForOtherCreditLosses" xlink:label="us-gaap_ProvisionForOtherCreditLosses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel12And3Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="clym_FairValueLevel1Level2AndLevel3TransferAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="clym_TaxCreditsReceivable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProvisionForOtherCreditLosses" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_SharesConvertedUponAcquisitionMember" xlink:label="clym_SharesConvertedUponAcquisitionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_NotePurchaseAgreementMember" xlink:label="clym_NotePurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_TenetStockOwnedByRACapitalMember" xlink:label="clym_TenetStockOwnedByRACapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_AcquisitionAgreementMember" xlink:label="clym_AcquisitionAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_CompanyStockOwnedByRACapitalImmediatelyPriorToAcquisitionMember" xlink:label="clym_CompanyStockOwnedByRACapitalImmediatelyPriorToAcquisitionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoninterestExpenseOfferingCost" xlink:label="us-gaap_NoninterestExpenseOfferingCost"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_BusinessCombinationConsiderationTransferredSettlementOfPreExistingLoan" xlink:label="clym_BusinessCombinationConsiderationTransferredSettlementOfPreExistingLoan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="clym_SharesConvertedUponAcquisitionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="clym_NotePurchaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain" xlink:to="clym_TenetStockOwnedByRACapitalMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="clym_AcquisitionAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_AssetAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain" xlink:to="clym_CompanyStockOwnedByRACapitalImmediatelyPriorToAcquisitionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="srt_OwnershipAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_NoninterestExpenseOfferingCost" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="clym_BusinessCombinationConsiderationTransferredSettlementOfPreExistingLoan" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionLineItems" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyTheFairValueOfTheTotalConsiderationComprisedOfTheComponentsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyScheduleOfPurchaseConsiderationForTheAcquisitionBasedOnTheFairValueOfThe" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_AmountOfIn-ProcessResearchAndDevelopmentAssetsAcquired" xlink:label="clym_AmountOfIn-ProcessResearchAndDevelopmentAssetsAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="clym_AmountOfIn-ProcessResearchAndDevelopmentAssetsAcquired" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfMarketableSecuritiesConsistedOfAvailableforsaleSecuritiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_ShortTermMarketableSecuritiesMember" xlink:label="clym_ShortTermMarketableSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="us-gaap_MarketableSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_LongTermMarketableSecuritiesMember" xlink:label="clym_LongTermMarketableSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CorporateBondSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="clym_ShortTermMarketableSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_USTreasurySecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="clym_LongTermMarketableSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_USTreasurySecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CorporateBondSecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCertainBalanceSheetAccountsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_PrepaidResearchAndDevelopmentExpenses" xlink:label="clym_PrepaidResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_RecoverableResearchAndDevelopmentTaxCredits" xlink:label="clym_RecoverableResearchAndDevelopmentTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="clym_PrepaidResearchAndDevelopmentExpenses" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_InterestReceivable" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_OtherAssets" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="clym_RecoverableResearchAndDevelopmentTaxCredits" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_AccruedExternalResearchAndDevelopmentsExpense" xlink:label="clym_AccruedExternalResearchAndDevelopmentsExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="clym_AccruedExternalResearchAndDevelopmentsExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_AcquisitionAgreementMember" xlink:label="clym_AcquisitionAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_SharesExchangedForPreFundedWarrants" xlink:label="clym_SharesExchangedForPreFundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_SeraServicesAgreementMember" xlink:label="clym_SeraServicesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_PreFundedWarrantMember" xlink:label="clym_PreFundedWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_BlackbirdClinicalAgreementMember" xlink:label="clym_BlackbirdClinicalAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_AggregateBeneficialOwnershipExchangingStockholders" xlink:label="clym_AggregateBeneficialOwnershipExchangingStockholders"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_ExchangeAgreementMember" xlink:label="clym_ExchangeAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherExpenses" xlink:label="us-gaap_OtherExpenses"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="clym_AcquisitionAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="clym_SharesExchangedForPreFundedWarrants" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="clym_SeraServicesAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="clym_PreFundedWarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="clym_BlackbirdClinicalAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="clym_AggregateBeneficialOwnershipExchangingStockholders" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="clym_ExchangeAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherExpenses" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_ProbiogenSalesMilestonesMember" xlink:label="clym_ProbiogenSalesMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_AcelyrinIncMember" xlink:label="clym_AcelyrinIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_MilestonePayments" xlink:label="clym_MilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_ProbiogenManufacturingServiceMember" xlink:label="clym_ProbiogenManufacturingServiceMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_CrhAgreementMember" xlink:label="clym_CrhAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_MilestonePaymentAmountReduced" xlink:label="clym_MilestonePaymentAmountReduced"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_ProbiogenAgreementMember" xlink:label="clym_ProbiogenAgreementMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="clym_ProbiogenSalesMilestonesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="clym_AcelyrinIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="clym_MilestonePayments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="clym_ProbiogenManufacturingServiceMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="clym_CrhAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="clym_MilestonePaymentAmountReduced" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="clym_ProbiogenAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfLeaseExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_ShortTermLeaseCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_VariableLeaseCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCost" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfCashFlowInformationRelatedToLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfAnnualFutureMinimumLeasePaymentsDueUnderTheCompanysNoncancelableOperatingLeaseDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_GrossOperatingLeasePaymentsMember" xlink:label="clym_GrossOperatingLeasePaymentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_SubleaseIncomeMember" xlink:label="clym_SubleaseIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_NetOperatingLeasePaymentsMember" xlink:label="clym_NetOperatingLeasePaymentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="clym_GrossOperatingLeasePaymentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="clym_SubleaseIncomeMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="clym_NetOperatingLeasePaymentsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfOperatingLeaseLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_OptionToExtendMember" xlink:label="clym_OptionToExtendMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_AdditionalOfficeSpaceMember" xlink:label="clym_AdditionalOfficeSpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_IncreaseDecreaseInOperatingLeaseAssets" xlink:label="clym_IncreaseDecreaseInOperatingLeaseAssets"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementScenarioAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="clym_OptionToExtendMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:to="clym_AdditionalOfficeSpaceMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="clym_IncreaseDecreaseInOperatingLeaseAssets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_MilestonePayments" xlink:label="clym_MilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_ProbiogenSalesMilestonesMember" xlink:label="clym_ProbiogenSalesMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_AcelyrinAssetPurchaseAgreementMember" xlink:label="clym_AcelyrinAssetPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_DevelopmentRegulatoryAndCommercialMilestonesMember" xlink:label="clym_DevelopmentRegulatoryAndCommercialMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_MilestonePaymentsDue" xlink:label="clym_MilestonePaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_CrhAgreementMember" xlink:label="clym_CrhAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_DevelopmentRegulatoryCommercialAndSalesMilestonesMember" xlink:label="clym_DevelopmentRegulatoryCommercialAndSalesMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_ProbiogenAgreementMember" xlink:label="clym_ProbiogenAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_DevelopmentManufacturingAndCommercialMember" xlink:label="clym_DevelopmentManufacturingAndCommercialMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_MilestonePaymentAmountReduced" xlink:label="clym_MilestonePaymentAmountReduced"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_MabworksAgreementMember" xlink:label="clym_MabworksAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_DevelopmentAndRegulatoryMilestonesMember" xlink:label="clym_DevelopmentAndRegulatoryMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_UpfrontPaymentPaid" xlink:label="clym_UpfrontPaymentPaid"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_CommercialMilestonesMember" xlink:label="clym_CommercialMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_SalesMilestonesMember" xlink:label="clym_SalesMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_MilestoneMember" xlink:label="clym_MilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_ManufacturingServicesMember" xlink:label="clym_ManufacturingServicesMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_UpfrontPaymentMember" xlink:label="clym_UpfrontPaymentMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="clym_MilestonePayments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="clym_ProbiogenSalesMilestonesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="clym_AcelyrinAssetPurchaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="clym_DevelopmentRegulatoryAndCommercialMilestonesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OtherCommitmentsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="clym_MilestonePaymentsDue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="clym_CrhAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="srt_ProductOrServiceAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="clym_DevelopmentRegulatoryCommercialAndSalesMilestonesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="clym_ProbiogenAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="clym_DevelopmentManufacturingAndCommercialMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="clym_MilestonePaymentAmountReduced" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="clym_MabworksAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="clym_DevelopmentAndRegulatoryMilestonesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="clym_UpfrontPaymentPaid" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="clym_CommercialMilestonesMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="clym_SalesMilestonesMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="clym_MilestoneMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="clym_ManufacturingServicesMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="clym_UpfrontPaymentMember" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:label="clym_TwoThousandTwentyOneEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage" xlink:label="clym_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_ConsultantMember" xlink:label="clym_ConsultantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_FirstDayOfOfferingPeriodMember" xlink:label="clym_FirstDayOfOfferingPeriodMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_TwoThousandTwentyFiveInducementPlanMember" xlink:label="clym_TwoThousandTwentyFiveInducementPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_LastDayOfOfferingPeriodMember" xlink:label="clym_LastDayOfOfferingPeriodMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_PerformanceBasedVestingMember" xlink:label="clym_PerformanceBasedVestingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_FirstAnniversaryMember" xlink:label="clym_FirstAnniversaryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_EsppMember" xlink:label="clym_EsppMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_AfterFirstAnniversaryMember" xlink:label="clym_AfterFirstAnniversaryMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_StockOptionsMember" xlink:label="clym_StockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_JanuaryOneTwoThousandTwentyFiveMember" xlink:label="clym_JanuaryOneTwoThousandTwentyFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_MarchTwentySevenTwoThousandTwentyFiveMember" xlink:label="clym_MarchTwentySevenTwoThousandTwentyFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_PerformanceBasedRsusMember" xlink:label="clym_PerformanceBasedRsusMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_ShareBasedCompensationArrangementBySharebasedPaymentAwardContributionPercentMaximum" xlink:label="clym_ShareBasedCompensationArrangementBySharebasedPaymentAwardContributionPercentMaximum"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_JuneTwentySevenTwoThousandTwentyFiveMember" xlink:label="clym_JuneTwentySevenTwoThousandTwentyFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_UnvestedRestrictedStockAwardsMember" xlink:label="clym_UnvestedRestrictedStockAwardsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_NumberOfSharesOfCommonStockOutstandingPercentage" xlink:label="clym_NumberOfSharesOfCommonStockOutstandingPercentage"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_EmployeesIncludingExecutiveOfficersEarningContribution" xlink:label="clym_EmployeesIncludingExecutiveOfficersEarningContribution"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_FairMarketValueCommonStockPercentage" xlink:label="clym_FairMarketValueCommonStockPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_IncrementalSharebasedcompensationexpense" xlink:label="clym_IncrementalSharebasedcompensationexpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_24"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="clym_TwoThousandTwentyOneEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="clym_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="clym_ConsultantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain" xlink:to="clym_FirstDayOfOfferingPeriodMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="clym_TwoThousandTwentyFiveInducementPlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain" xlink:to="clym_LastDayOfOfferingPeriodMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="clym_PerformanceBasedVestingMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain" xlink:to="clym_FirstAnniversaryMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="clym_EsppMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain" xlink:to="clym_AfterFirstAnniversaryMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="clym_StockOptionsMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain" xlink:to="clym_JanuaryOneTwoThousandTwentyFiveMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain" xlink:to="clym_MarchTwentySevenTwoThousandTwentyFiveMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="clym_PerformanceBasedRsusMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="clym_ShareBasedCompensationArrangementBySharebasedPaymentAwardContributionPercentMaximum" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain" xlink:to="clym_JuneTwentySevenTwoThousandTwentyFiveMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="clym_UnvestedRestrictedStockAwardsMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardDateAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="clym_NumberOfSharesOfCommonStockOutstandingPercentage" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="clym_EmployeesIncludingExecutiveOfficersEarningContribution" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="clym_FairMarketValueCommonStockPercentage" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="clym_IncrementalSharebasedcompensationexpense" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_24" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_18"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_18" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedInBlackScholesModelDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfShareBasedCompensationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_Pre-FundedWarrantMember" xlink:label="clym_Pre-FundedWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="clym_Pre-FundedWarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_EarningsPerShareBasicLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfNetLossPerShareAttributableToCommonStockholdersDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarliestTaxYearMember" xlink:label="us-gaap_EarliestTaxYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxYear2018Member" xlink:label="us-gaap_TaxYear2018Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_OperatingLossCarryforwardsExpirationStartYear" xlink:label="clym_OperatingLossCarryforwardsExpirationStartYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxYear2019Member" xlink:label="us-gaap_TaxYear2019Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_TaxCreditCarryforwardExpirationYear" xlink:label="clym_TaxCreditCarryforwardExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxYear2020Member" xlink:label="us-gaap_TaxYear2020Member"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_TaxCreditCarryforwardExpirationYearStart" xlink:label="clym_TaxCreditCarryforwardExpirationYearStart"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxYear2021Member" xlink:label="us-gaap_TaxYear2021Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxYear2022Member" xlink:label="us-gaap_TaxYear2022Member"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_TaxYears" xlink:label="clym_TaxYears"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxYear2023Member" xlink:label="us-gaap_TaxYear2023Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxYear2024Member" xlink:label="us-gaap_TaxYear2024Member"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_CumulativeChangeInOwnershipPercentage" xlink:label="clym_CumulativeChangeInOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxYear2025Member" xlink:label="us-gaap_TaxYear2025Member"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_PercentageOfAnnualDeductionOfTaxableIncome" xlink:label="clym_PercentageOfAnnualDeductionOfTaxableIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LatestTaxYearMember" xlink:label="us-gaap_LatestTaxYearMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_EarliestTaxYearMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxPeriodAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxYear2018Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="clym_OperatingLossCarryforwardsExpirationStartYear" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxYear2019Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="clym_TaxCreditCarryforwardExpirationYear" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxYear2020Member" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="clym_TaxCreditCarryforwardExpirationYearStart" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxYear2021Member" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxYear2022Member" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="clym_TaxYears" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxYear2023Member" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OpenTaxYear" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxYear2024Member" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="clym_CumulativeChangeInOwnershipPercentage" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxYear2025Member" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="clym_PercentageOfAnnualDeductionOfTaxableIncome" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_LatestTaxYearMember" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetLossBeforeTaxProvisionFromIncomeTaxesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US" xlink:label="country_US"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_GB" xlink:label="country_GB"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="srt_StatementGeographicalAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_GB" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToProvisionForIncomeTaxesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_EffectiveIncomeTaxRateReconciliationAcquiredIn-ProcessResearchDevelopmentRelatedParty" xlink:label="clym_EffectiveIncomeTaxRateReconciliationAcquiredIn-ProcessResearchDevelopmentRelatedParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficerCompensationAmount" xlink:label="clym_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficerCompensationAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="clym_EffectiveIncomeTaxRateReconciliationAcquiredIn-ProcessResearchDevelopmentRelatedParty" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="clym_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficerCompensationAmount" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_DeferredTaxAssetsResearchAndDevelopmentExpenses" xlink:label="clym_DeferredTaxAssetsResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_DefferedTaxAssetOperatingLeaseLiability" xlink:label="clym_DefferedTaxAssetOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="clym_DeferredTaxAssetsResearchAndDevelopmentExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="clym_DefferedTaxAssetOperatingLeaseLiability" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfValuationAllowanceDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_FourZeroOneKMember" xlink:label="clym_FourZeroOneKMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_PensionMember" xlink:label="clym_PensionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_DefinedContributionPlanEmployerContributionAmount" xlink:label="clym_DefinedContributionPlanEmployerContributionAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="clym_FourZeroOneKMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="clym_PensionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_RetirementPlanTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="clym_DefinedContributionPlanEmployerContributionAmount" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureRestructuringCostsSummaryOfRestructuringCostsInStatementOfOperationsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanAxis" xlink:label="us-gaap_RestructuringPlanAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanDomain" xlink:label="us-gaap_RestructuringPlanDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCosts" xlink:label="us-gaap_RestructuringCosts"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_RouAssetImpairmentMember" xlink:label="clym_RouAssetImpairmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_SeveranceAndBenefitsCostsMember" xlink:label="clym_SeveranceAndBenefitsCostsMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_StockBasedCompensationMember" xlink:label="clym_StockBasedCompensationMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_TotalRestructuringCostRecordedMember" xlink:label="clym_TotalRestructuringCostRecordedMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringPlanAxis" xlink:to="us-gaap_RestructuringPlanDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringPlanDomain" xlink:to="clym_RouAssetImpairmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringPlanAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringPlanDomain" xlink:to="clym_SeveranceAndBenefitsCostsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringPlanDomain" xlink:to="clym_StockBasedCompensationMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringPlanDomain" xlink:to="clym_TotalRestructuringCostRecordedMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureRestructuringCostsScheduleOfRestructuringLiabilityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserve" xlink:label="us-gaap_RestructuringReserve"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:label="us-gaap_RestructuringAndRelatedCostIncurredCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRestructuring" xlink:label="us-gaap_PaymentsForRestructuring"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserve" xlink:label="us-gaap_RestructuringReserve_3"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringReserve" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedCostIncurredCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_PaymentsForRestructuring" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringReserve_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureSegmentsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfReportableSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureSegmentsScheduleOfForthDisaggregatedResearchAndDevelopmentExpensesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancingReceivablePortfolioSegmentAxis" xlink:label="us-gaap_FinancingReceivablePortfolioSegmentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancingReceivablePortfolioSegmentDomain" xlink:label="us-gaap_FinancingReceivablePortfolioSegmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_DirectExpenseMember" xlink:label="clym_DirectExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_BudoprutugServiceMember" xlink:label="clym_BudoprutugServiceMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_UnallocatedExpenseMember" xlink:label="clym_UnallocatedExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_CLYM116Member" xlink:label="clym_CLYM116Member"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_LegacyProgramExpensesMember" xlink:label="clym_LegacyProgramExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_PersonnelRelatedMember" xlink:label="clym_PersonnelRelatedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherExpenseMember" xlink:label="us-gaap_OtherExpenseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancingReceivablePortfolioSegmentAxis" xlink:to="us-gaap_FinancingReceivablePortfolioSegmentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsDomain" xlink:to="us-gaap_OperatingSegmentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_ConsolidationItemsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancingReceivablePortfolioSegmentDomain" xlink:to="clym_DirectExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="clym_BudoprutugServiceMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_FinancingReceivablePortfolioSegmentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancingReceivablePortfolioSegmentDomain" xlink:to="clym_UnallocatedExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="clym_CLYM116Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="clym_LegacyProgramExpensesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_SegmentReportingInformationLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="clym_PersonnelRelatedMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OtherExpenseMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureSegmentsScheduleOfForthDisaggregatedResearchAndDevelopmentExpensesParentheticalDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsDomain" xlink:to="us-gaap_OperatingSegmentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_ConsolidationItemsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SeveranceCosts1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_SegmentReportingInformationLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_UpfrontMilestonePayment" xlink:label="clym_UpfrontMilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_MabworksAgreementMember" xlink:label="clym_MabworksAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_TotalDevelopmentAndRegulatoryMilestones" xlink:label="clym_TotalDevelopmentAndRegulatoryMilestones"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_MilestonePayments" xlink:label="clym_MilestonePayments"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="clym_UpfrontMilestonePayment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="clym_MabworksAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="clym_TotalDevelopmentAndRegulatoryMilestones" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="clym_MilestonePayments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://climbbio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_VestingOfRestrictedStockAwardsShares" xlink:label="clym_VestingOfRestrictedStockAwardsShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_SharesExchangedForPreFundedWarrants" xlink:label="clym_SharesExchangedForPreFundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_SharesExchangedForPreFundedWarrantsValue" xlink:label="clym_SharesExchangedForPreFundedWarrantsValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="clym_VestingOfRestrictedStockAwardsShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="clym_SharesExchangedForPreFundedWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="clym_SharesExchangedForPreFundedWarrantsValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://climbbio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoninterestExpenseOfferingCost" xlink:label="us-gaap_NoninterestExpenseOfferingCost"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoninterestExpenseOfferingCost" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_StephenThomasMember" xlink:label="clym_StephenThomasMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="clym_StephenThomasMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="dei_EntityIncorporationDateOfIncorporation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_EliemTherapeuticsMember" xlink:label="clym_EliemTherapeuticsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_AtTheMarketEquityOfferingProgramMember" xlink:label="clym_AtTheMarketEquityOfferingProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_AcquisitionAgreementMember" xlink:label="clym_AcquisitionAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_AggregateGrossSalesProceedsUnderSalesAgreements" xlink:label="clym_AggregateGrossSalesProceedsUnderSalesAgreements"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_CashCashEquivalentsAndMarketableSecurities" xlink:label="clym_CashCashEquivalentsAndMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoninterestExpenseOfferingCost" xlink:label="us-gaap_NoninterestExpenseOfferingCost"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="clym_EliemTherapeuticsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="clym_AtTheMarketEquityOfferingProgramMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="clym_AcquisitionAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="clym_AggregateGrossSalesProceedsUnderSalesAgreements" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="clym_CashCashEquivalentsAndMarketableSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_NoninterestExpenseOfferingCost" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_TotalMarketableSecuritiesMember" xlink:label="clym_TotalMarketableSecuritiesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_USGovernmentDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CorporateBondSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="clym_TotalMarketableSecuritiesMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel12And3Member" xlink:label="us-gaap_FairValueInputsLevel12And3Member"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_FairValueLevel1Level2AndLevel3TransferAmount" xlink:label="clym_FairValueLevel1Level2AndLevel3TransferAmount"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_TaxCreditsReceivable" xlink:label="clym_TaxCreditsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProvisionForOtherCreditLosses" xlink:label="us-gaap_ProvisionForOtherCreditLosses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel12And3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="clym_FairValueLevel1Level2AndLevel3TransferAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="clym_TaxCreditsReceivable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProvisionForOtherCreditLosses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_SharesConvertedUponAcquisitionMember" xlink:label="clym_SharesConvertedUponAcquisitionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_NotePurchaseAgreementMember" xlink:label="clym_NotePurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_TenetStockOwnedByRACapitalMember" xlink:label="clym_TenetStockOwnedByRACapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_AcquisitionAgreementMember" xlink:label="clym_AcquisitionAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_CompanyStockOwnedByRACapitalImmediatelyPriorToAcquisitionMember" xlink:label="clym_CompanyStockOwnedByRACapitalImmediatelyPriorToAcquisitionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoninterestExpenseOfferingCost" xlink:label="us-gaap_NoninterestExpenseOfferingCost"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_BusinessCombinationConsiderationTransferredSettlementOfPreExistingLoan" xlink:label="clym_BusinessCombinationConsiderationTransferredSettlementOfPreExistingLoan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="clym_SharesConvertedUponAcquisitionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="clym_NotePurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="clym_TenetStockOwnedByRACapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="clym_AcquisitionAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="clym_CompanyStockOwnedByRACapitalImmediatelyPriorToAcquisitionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="srt_OwnershipAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_NoninterestExpenseOfferingCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="clym_BusinessCombinationConsiderationTransferredSettlementOfPreExistingLoan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyScheduleOfPurchaseConsiderationForTheAcquisitionBasedOnTheFairValueOfThe">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_AmountOfIn-ProcessResearchAndDevelopmentAssetsAcquired" xlink:label="clym_AmountOfIn-ProcessResearchAndDevelopmentAssetsAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="clym_AmountOfIn-ProcessResearchAndDevelopmentAssetsAcquired" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfMarketableSecuritiesConsistedOfAvailableforsaleSecuritiesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_ShortTermMarketableSecuritiesMember" xlink:label="clym_ShortTermMarketableSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_LongTermMarketableSecuritiesMember" xlink:label="clym_LongTermMarketableSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CorporateBondSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="clym_ShortTermMarketableSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="clym_LongTermMarketableSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CorporateBondSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_AcquisitionAgreementMember" xlink:label="clym_AcquisitionAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_SharesExchangedForPreFundedWarrants" xlink:label="clym_SharesExchangedForPreFundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_SeraServicesAgreementMember" xlink:label="clym_SeraServicesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_PreFundedWarrantMember" xlink:label="clym_PreFundedWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_BlackbirdClinicalAgreementMember" xlink:label="clym_BlackbirdClinicalAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_AggregateBeneficialOwnershipExchangingStockholders" xlink:label="clym_AggregateBeneficialOwnershipExchangingStockholders"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_ExchangeAgreementMember" xlink:label="clym_ExchangeAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherExpenses" xlink:label="us-gaap_OtherExpenses"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="clym_AcquisitionAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="clym_SharesExchangedForPreFundedWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="clym_SeraServicesAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="clym_PreFundedWarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="clym_BlackbirdClinicalAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="clym_AggregateBeneficialOwnershipExchangingStockholders" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="clym_ExchangeAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherExpenses" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_ProbiogenSalesMilestonesMember" xlink:label="clym_ProbiogenSalesMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_AcelyrinIncMember" xlink:label="clym_AcelyrinIncMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_MilestonePayments" xlink:label="clym_MilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_ProbiogenManufacturingServiceMember" xlink:label="clym_ProbiogenManufacturingServiceMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_CrhAgreementMember" xlink:label="clym_CrhAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_MilestonePaymentAmountReduced" xlink:label="clym_MilestonePaymentAmountReduced"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_ProbiogenAgreementMember" xlink:label="clym_ProbiogenAgreementMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="clym_ProbiogenSalesMilestonesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="clym_AcelyrinIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="clym_MilestonePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="clym_ProbiogenManufacturingServiceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="clym_CrhAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="clym_MilestonePaymentAmountReduced" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="clym_ProbiogenAgreementMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfAnnualFutureMinimumLeasePaymentsDueUnderTheCompanysNoncancelableOperatingLeaseDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_GrossOperatingLeasePaymentsMember" xlink:label="clym_GrossOperatingLeasePaymentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_SubleaseIncomeMember" xlink:label="clym_SubleaseIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_NetOperatingLeasePaymentsMember" xlink:label="clym_NetOperatingLeasePaymentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseContractualTermAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="clym_GrossOperatingLeasePaymentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="clym_SubleaseIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="clym_NetOperatingLeasePaymentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_OptionToExtendMember" xlink:label="clym_OptionToExtendMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_AdditionalOfficeSpaceMember" xlink:label="clym_AdditionalOfficeSpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_IncreaseDecreaseInOperatingLeaseAssets" xlink:label="clym_IncreaseDecreaseInOperatingLeaseAssets"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="clym_OptionToExtendMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:to="clym_AdditionalOfficeSpaceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseExpirationDate1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseContractualTermAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="clym_IncreaseDecreaseInOperatingLeaseAssets" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_MilestonePayments" xlink:label="clym_MilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_ProbiogenSalesMilestonesMember" xlink:label="clym_ProbiogenSalesMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_AcelyrinAssetPurchaseAgreementMember" xlink:label="clym_AcelyrinAssetPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_DevelopmentRegulatoryAndCommercialMilestonesMember" xlink:label="clym_DevelopmentRegulatoryAndCommercialMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_MilestonePaymentsDue" xlink:label="clym_MilestonePaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_CrhAgreementMember" xlink:label="clym_CrhAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_DevelopmentRegulatoryCommercialAndSalesMilestonesMember" xlink:label="clym_DevelopmentRegulatoryCommercialAndSalesMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_ProbiogenAgreementMember" xlink:label="clym_ProbiogenAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_DevelopmentManufacturingAndCommercialMember" xlink:label="clym_DevelopmentManufacturingAndCommercialMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_MilestonePaymentAmountReduced" xlink:label="clym_MilestonePaymentAmountReduced"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_MabworksAgreementMember" xlink:label="clym_MabworksAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_DevelopmentAndRegulatoryMilestonesMember" xlink:label="clym_DevelopmentAndRegulatoryMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_UpfrontPaymentPaid" xlink:label="clym_UpfrontPaymentPaid"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_CommercialMilestonesMember" xlink:label="clym_CommercialMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_SalesMilestonesMember" xlink:label="clym_SalesMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_MilestoneMember" xlink:label="clym_MilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_ManufacturingServicesMember" xlink:label="clym_ManufacturingServicesMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_UpfrontPaymentMember" xlink:label="clym_UpfrontPaymentMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="clym_MilestonePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="clym_ProbiogenSalesMilestonesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="clym_AcelyrinAssetPurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="clym_DevelopmentRegulatoryAndCommercialMilestonesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="clym_MilestonePaymentsDue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="clym_CrhAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="clym_DevelopmentRegulatoryCommercialAndSalesMilestonesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="clym_ProbiogenAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="clym_DevelopmentManufacturingAndCommercialMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="clym_MilestonePaymentAmountReduced" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="clym_MabworksAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="clym_DevelopmentAndRegulatoryMilestonesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="clym_UpfrontPaymentPaid" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="clym_CommercialMilestonesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="clym_SalesMilestonesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="clym_MilestoneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="clym_ManufacturingServicesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="clym_UpfrontPaymentMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:label="clym_TwoThousandTwentyOneEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage" xlink:label="clym_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_ConsultantMember" xlink:label="clym_ConsultantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_FirstDayOfOfferingPeriodMember" xlink:label="clym_FirstDayOfOfferingPeriodMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_StockOptionsMember" xlink:label="clym_StockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_TwoThousandTwentyFiveInducementPlanMember" xlink:label="clym_TwoThousandTwentyFiveInducementPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_LastDayOfOfferingPeriodMember" xlink:label="clym_LastDayOfOfferingPeriodMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_PerformanceBasedVestingMember" xlink:label="clym_PerformanceBasedVestingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_FirstAnniversaryMember" xlink:label="clym_FirstAnniversaryMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_PerformanceBasedRsusMember" xlink:label="clym_PerformanceBasedRsusMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_EsppMember" xlink:label="clym_EsppMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_AfterFirstAnniversaryMember" xlink:label="clym_AfterFirstAnniversaryMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_UnvestedRestrictedStockAwardsMember" xlink:label="clym_UnvestedRestrictedStockAwardsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_JanuaryOneTwoThousandTwentyFiveMember" xlink:label="clym_JanuaryOneTwoThousandTwentyFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_MarchTwentySevenTwoThousandTwentyFiveMember" xlink:label="clym_MarchTwentySevenTwoThousandTwentyFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_ShareBasedCompensationArrangementBySharebasedPaymentAwardContributionPercentMaximum" xlink:label="clym_ShareBasedCompensationArrangementBySharebasedPaymentAwardContributionPercentMaximum"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_JuneTwentySevenTwoThousandTwentyFiveMember" xlink:label="clym_JuneTwentySevenTwoThousandTwentyFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_NumberOfSharesOfCommonStockOutstandingPercentage" xlink:label="clym_NumberOfSharesOfCommonStockOutstandingPercentage"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_EmployeesIncludingExecutiveOfficersEarningContribution" xlink:label="clym_EmployeesIncludingExecutiveOfficersEarningContribution"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_FairMarketValueCommonStockPercentage" xlink:label="clym_FairMarketValueCommonStockPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_IncrementalSharebasedcompensationexpense" xlink:label="clym_IncrementalSharebasedcompensationexpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="clym_TwoThousandTwentyOneEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="clym_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="clym_ConsultantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="clym_FirstDayOfOfferingPeriodMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="clym_StockOptionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="clym_TwoThousandTwentyFiveInducementPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="clym_LastDayOfOfferingPeriodMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="clym_PerformanceBasedVestingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="clym_FirstAnniversaryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="clym_PerformanceBasedRsusMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="clym_EsppMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="clym_AfterFirstAnniversaryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="clym_UnvestedRestrictedStockAwardsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="clym_JanuaryOneTwoThousandTwentyFiveMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="clym_MarchTwentySevenTwoThousandTwentyFiveMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="clym_ShareBasedCompensationArrangementBySharebasedPaymentAwardContributionPercentMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="clym_JuneTwentySevenTwoThousandTwentyFiveMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardDateAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="clym_NumberOfSharesOfCommonStockOutstandingPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="clym_EmployeesIncludingExecutiveOfficersEarningContribution" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="clym_FairMarketValueCommonStockPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="clym_IncrementalSharebasedcompensationexpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedInBlackScholesModelDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfShareBasedCompensationExpenseDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_Pre-FundedWarrantMember" xlink:label="clym_Pre-FundedWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="clym_Pre-FundedWarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfNetLossPerShareAttributableToCommonStockholdersDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarliestTaxYearMember" xlink:label="us-gaap_EarliestTaxYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxYear2018Member" xlink:label="us-gaap_TaxYear2018Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_OperatingLossCarryforwardsExpirationStartYear" xlink:label="clym_OperatingLossCarryforwardsExpirationStartYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxYear2019Member" xlink:label="us-gaap_TaxYear2019Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_TaxCreditCarryforwardExpirationYear" xlink:label="clym_TaxCreditCarryforwardExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxYear2020Member" xlink:label="us-gaap_TaxYear2020Member"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_TaxCreditCarryforwardExpirationYearStart" xlink:label="clym_TaxCreditCarryforwardExpirationYearStart"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxYear2021Member" xlink:label="us-gaap_TaxYear2021Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxYear2022Member" xlink:label="us-gaap_TaxYear2022Member"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_TaxYears" xlink:label="clym_TaxYears"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxYear2023Member" xlink:label="us-gaap_TaxYear2023Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxYear2024Member" xlink:label="us-gaap_TaxYear2024Member"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_CumulativeChangeInOwnershipPercentage" xlink:label="clym_CumulativeChangeInOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxYear2025Member" xlink:label="us-gaap_TaxYear2025Member"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_PercentageOfAnnualDeductionOfTaxableIncome" xlink:label="clym_PercentageOfAnnualDeductionOfTaxableIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LatestTaxYearMember" xlink:label="us-gaap_LatestTaxYearMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_EarliestTaxYearMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxPeriodAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxYear2018Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="clym_OperatingLossCarryforwardsExpirationStartYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxYear2019Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="clym_TaxCreditCarryforwardExpirationYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxYear2020Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="clym_TaxCreditCarryforwardExpirationYearStart" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxYear2021Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxYear2022Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="clym_TaxYears" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxYear2023Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OpenTaxYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxYear2024Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="clym_CumulativeChangeInOwnershipPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxYear2025Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="clym_PercentageOfAnnualDeductionOfTaxableIncome" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_LatestTaxYearMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetLossBeforeTaxProvisionFromIncomeTaxesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US" xlink:label="country_US"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_GB" xlink:label="country_GB"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_GB" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_FourZeroOneKMember" xlink:label="clym_FourZeroOneKMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_PensionMember" xlink:label="clym_PensionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_DefinedContributionPlanEmployerContributionAmount" xlink:label="clym_DefinedContributionPlanEmployerContributionAmount"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="clym_FourZeroOneKMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="clym_PensionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_RetirementPlanTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="clym_DefinedContributionPlanEmployerContributionAmount" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureRestructuringCostsSummaryOfRestructuringCostsInStatementOfOperationsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanAxis" xlink:label="us-gaap_RestructuringPlanAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanDomain" xlink:label="us-gaap_RestructuringPlanDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanDomain" xlink:label="us-gaap_RestructuringPlanDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCosts" xlink:label="us-gaap_RestructuringCosts"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_RouAssetImpairmentMember" xlink:label="clym_RouAssetImpairmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_SeveranceAndBenefitsCostsMember" xlink:label="clym_SeveranceAndBenefitsCostsMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_StockBasedCompensationMember" xlink:label="clym_StockBasedCompensationMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_TotalRestructuringCostRecordedMember" xlink:label="clym_TotalRestructuringCostRecordedMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestructuringPlanAxis" xlink:to="us-gaap_RestructuringPlanDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestructuringPlanAxis" xlink:to="us-gaap_RestructuringPlanDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringPlanDomain" xlink:to="clym_RouAssetImpairmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringPlanAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringPlanDomain" xlink:to="clym_SeveranceAndBenefitsCostsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringPlanDomain" xlink:to="clym_StockBasedCompensationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringPlanDomain" xlink:to="clym_TotalRestructuringCostRecordedMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureSegmentsScheduleOfForthDisaggregatedResearchAndDevelopmentExpensesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancingReceivablePortfolioSegmentAxis" xlink:label="us-gaap_FinancingReceivablePortfolioSegmentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancingReceivablePortfolioSegmentDomain" xlink:label="us-gaap_FinancingReceivablePortfolioSegmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancingReceivablePortfolioSegmentDomain" xlink:label="us-gaap_FinancingReceivablePortfolioSegmentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_DirectExpenseMember" xlink:label="clym_DirectExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_BudoprutugServiceMember" xlink:label="clym_BudoprutugServiceMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_UnallocatedExpenseMember" xlink:label="clym_UnallocatedExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_CLYM116Member" xlink:label="clym_CLYM116Member"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_LegacyProgramExpensesMember" xlink:label="clym_LegacyProgramExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_PersonnelRelatedMember" xlink:label="clym_PersonnelRelatedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherExpenseMember" xlink:label="us-gaap_OtherExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancingReceivablePortfolioSegmentAxis" xlink:to="us-gaap_FinancingReceivablePortfolioSegmentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancingReceivablePortfolioSegmentAxis" xlink:to="us-gaap_FinancingReceivablePortfolioSegmentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidationItemsDomain" xlink:to="us-gaap_OperatingSegmentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_ConsolidationItemsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancingReceivablePortfolioSegmentDomain" xlink:to="clym_DirectExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="clym_BudoprutugServiceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_FinancingReceivablePortfolioSegmentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancingReceivablePortfolioSegmentDomain" xlink:to="clym_UnallocatedExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="clym_CLYM116Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="clym_LegacyProgramExpensesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="clym_PersonnelRelatedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OtherExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureSegmentsScheduleOfForthDisaggregatedResearchAndDevelopmentExpensesParentheticalDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidationItemsDomain" xlink:to="us-gaap_OperatingSegmentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_ConsolidationItemsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SeveranceCosts1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_UpfrontMilestonePayment" xlink:label="clym_UpfrontMilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_MabworksAgreementMember" xlink:label="clym_MabworksAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_TotalDevelopmentAndRegulatoryMilestones" xlink:label="clym_TotalDevelopmentAndRegulatoryMilestones"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_MilestonePayments" xlink:label="clym_MilestonePayments"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="clym_UpfrontMilestonePayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="clym_MabworksAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="clym_TotalDevelopmentAndRegulatoryMilestones" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="clym_MilestonePayments" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/srt/role/srt-eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UsefulLifeDescriptionOfTermDomain" xlink:label="us-gaap_UsefulLifeDescriptionOfTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UsefulLifeDescriptionOfTermDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheets">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="clym_AccruedExternalResearchAndDevelopmentsExpense" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="4" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_AccruedExternalResearchAndDevelopmentsExpense" xlink:label="clym_AccruedExternalResearchAndDevelopmentsExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="clym_AcquiredInProcessResearchAndDevelopmentExpenses" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="4" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_AcquiredInProcessResearchAndDevelopmentExpenses" xlink:label="clym_AcquiredInProcessResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="clym_AcquiredInProcessResearchAndDevelopmentExpenses" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="clym_IssuanceOfPromissoryLoanInConnectionWithAssetsAcquisition" order="6" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseExpense" order="8" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="clym_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedparties" order="10" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="11" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="12" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="13" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="14" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="16" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" order="17" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="18" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="22" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_AcquiredInProcessResearchAndDevelopmentExpenses" xlink:label="clym_AcquiredInProcessResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_IssuanceOfPromissoryLoanInConnectionWithAssetsAcquisition" xlink:label="clym_IssuanceOfPromissoryLoanInConnectionWithAssetsAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedparties" xlink:label="clym_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedparties"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCertainBalanceSheetAccountsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="clym_RecoverableResearchAndDevelopmentTaxCredits" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="clym_PrepaidResearchAndDevelopmentExpenses" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_InterestReceivable" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherAssets" order="4" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_RecoverableResearchAndDevelopmentTaxCredits" xlink:label="clym_RecoverableResearchAndDevelopmentTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_PrepaidResearchAndDevelopmentExpenses" xlink:label="clym_PrepaidResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfLeaseExpenseDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_ShortTermLeaseCost" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfOperatingLeaseLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToProvisionForIncomeTaxesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="clym_EffectiveIncomeTaxRateReconciliationAcquiredIn-ProcessResearchDevelopmentRelatedParty" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="clym_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficerCompensationAmount" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits" order="7" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" order="8" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="9" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_EffectiveIncomeTaxRateReconciliationAcquiredIn-ProcessResearchDevelopmentRelatedParty" xlink:label="clym_EffectiveIncomeTaxRateReconciliationAcquiredIn-ProcessResearchDevelopmentRelatedParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficerCompensationAmount" xlink:label="clym_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficerCompensationAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://climbbio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="clym_DeferredTaxAssetsResearchAndDevelopmentExpenses" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="clym_DefferedTaxAssetOperatingLeaseLiability" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="7" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_DeferredTaxAssetsResearchAndDevelopmentExpenses" xlink:label="clym_DeferredTaxAssetsResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
          <link:loc xlink:type="locator" xlink:href="clym-20251231.xsd#clym_DefferedTaxAssetOperatingLeaseLiability" xlink:label="clym_DefferedTaxAssetOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="clym_StockOptionsMember" name="StockOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_UpfrontPaymentMember" name="UpfrontPaymentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_RouAssetImpairmentMember" name="RouAssetImpairmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_PercentageOfAnnualDeductionOfTaxableIncome" name="PercentageOfAnnualDeductionOfTaxableIncome" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="clym_AccruedExternalResearchAndDevelopmentsExpense" name="AccruedExternalResearchAndDevelopmentsExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="clym_MabworksAgreementMember" name="MabworksAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_NumberOfSharesOfCommonStockOutstandingPercentage" name="NumberOfSharesOfCommonStockOutstandingPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="clym_TaxYears" name="TaxYears" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="clym_MilestoneMember" name="MilestoneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_SalesMilestonesMember" name="SalesMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_ScheduleOfBalanceSheetSupplementalDisclosuresTableTextBlock" name="ScheduleOfBalanceSheetSupplementalDisclosuresTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="clym_MilestonePaymentsDue" name="MilestonePaymentsDue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="clym_FourZeroOneKMember" name="FourZeroOneKMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_ShareBasedCompensationArrangementBySharebasedPaymentAwardContributionPercentMaximum" name="ShareBasedCompensationArrangementBySharebasedPaymentAwardContributionPercentMaximum" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="clym_ShortTermMarketableSecuritiesMember" name="ShortTermMarketableSecuritiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_SeveranceAndBenefitsCostsMember" name="SeveranceAndBenefitsCostsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_UnvestedRestrictedStockAwardsMember" name="UnvestedRestrictedStockAwardsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_AcquiredInProcessResearchAndDevelopmentExpenses" name="AcquiredInProcessResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="clym_CommercialMilestonesMember" name="CommercialMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_ExchangeAgreementMember" name="ExchangeAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_AcelyrinAssetPurchaseAgreementMember" name="AcelyrinAssetPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_SubleaseIncomeMember" name="SubleaseIncomeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_SeraServicesAgreementMember" name="SeraServicesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_OptionToExtendMember" name="OptionToExtendMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_PensionMember" name="PensionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_DevelopmentRegulatoryCommercialAndSalesMilestonesMember" name="DevelopmentRegulatoryCommercialAndSalesMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_PreFundedWarrantMember" name="PreFundedWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_TotalMarketableSecuritiesMember" name="TotalMarketableSecuritiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_FirstAnniversaryMember" name="FirstAnniversaryMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_SharesExchangedForPreFundedWarrants" name="SharesExchangedForPreFundedWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="clym_LegacyProgramExpensesMember" name="LegacyProgramExpensesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_DirectExpenseMember" name="DirectExpenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_RecoverableResearchAndDevelopmentTaxCredits" name="RecoverableResearchAndDevelopmentTaxCredits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="clym_IssuanceOfPromissoryLoanInConnectionWithAssetsAcquisition" name="IssuanceOfPromissoryLoanInConnectionWithAssetsAcquisition" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="clym_TaxCreditCarryforwardExpirationYearStart" name="TaxCreditCarryforwardExpirationYearStart" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="clym_AggregateGrossSalesProceedsUnderSalesAgreements" name="AggregateGrossSalesProceedsUnderSalesAgreements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="clym_ConsultantMember" name="ConsultantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_CLYM116Member" name="CLYM116Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_PrepaidResearchAndDevelopmentExpenses" name="PrepaidResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="clym_DevelopmentManufacturingAndCommercialMember" name="DevelopmentManufacturingAndCommercialMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_LastDayOfOfferingPeriodMember" name="LastDayOfOfferingPeriodMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_EffectiveIncomeTaxRateReconciliationAcquiredIn-ProcessResearchDevelopmentRelatedParty" name="EffectiveIncomeTaxRateReconciliationAcquiredIn-ProcessResearchDevelopmentRelatedParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="clym_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedparties" name="IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedparties" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="clym_TotalRestructuringCostRecordedMember" name="TotalRestructuringCostRecordedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficerCompensationAmount" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficerCompensationAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="clym_TwoThousandTwentyOneEquityIncentivePlanMember" name="TwoThousandTwentyOneEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_OperatingLossCarryforwardsExpirationStartYear" name="OperatingLossCarryforwardsExpirationStartYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="clym_AfterFirstAnniversaryMember" name="AfterFirstAnniversaryMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="clym_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" name="ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="clym_TaxCreditsReceivable" name="TaxCreditsReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="clym_ProbiogenManufacturingServiceMember" name="ProbiogenManufacturingServiceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_NotePurchaseAgreementMember" name="NotePurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_CashCashEquivalentsAndMarketableSecurities" name="CashCashEquivalentsAndMarketableSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="clym_UpfrontPaymentPaid" name="UpfrontPaymentPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="clym_StockBasedCompensationMember" name="StockBasedCompensationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_EmployeesIncludingExecutiveOfficersEarningContribution" name="EmployeesIncludingExecutiveOfficersEarningContribution" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="clym_GrossOperatingLeasePaymentsMember" name="GrossOperatingLeasePaymentsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_DevelopmentRegulatoryAndCommercialMilestonesMember" name="DevelopmentRegulatoryAndCommercialMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_ProbiogenAgreementMember" name="ProbiogenAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_IncreaseDecreaseInOperatingLeaseAssets" name="IncreaseDecreaseInOperatingLeaseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="clym_UpfrontMilestonePayment" name="UpfrontMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="clym_CompanyStockOwnedByRACapitalImmediatelyPriorToAcquisitionMember" name="CompanyStockOwnedByRACapitalImmediatelyPriorToAcquisitionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_TotalDevelopmentAndRegulatoryMilestones" name="TotalDevelopmentAndRegulatoryMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="clym_PersonnelRelatedMember" name="PersonnelRelatedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_EliemTherapeuticsMember" name="EliemTherapeuticsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_ManufacturingServicesMember" name="ManufacturingServicesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_DeferredTaxAssetsResearchAndDevelopmentExpenses" name="DeferredTaxAssetsResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="clym_LongTermMarketableSecuritiesMember" name="LongTermMarketableSecuritiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_AmountOfIn-ProcessResearchAndDevelopmentAssetsAcquired" name="AmountOfIn-ProcessResearchAndDevelopmentAssetsAcquired" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="clym_ScheduleOfRestructuringLiability" name="ScheduleOfRestructuringLiability" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="clym_DevelopmentAndRegulatoryMilestonesMember" name="DevelopmentAndRegulatoryMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_AggregateBeneficialOwnershipExchangingStockholders" name="AggregateBeneficialOwnershipExchangingStockholders" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="clym_BudoprutugServiceMember" name="BudoprutugServiceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_AdditionalOfficeSpaceMember" name="AdditionalOfficeSpaceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_FairMarketValueCommonStockPercentage" name="FairMarketValueCommonStockPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="clym_AmountOfPromissoryLoanSettledInConnectionWithAnAssetAcquisition" name="AmountOfPromissoryLoanSettledInConnectionWithAnAssetAcquisition" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="clym_DefinedContributionPlanEmployerContributionAmount" name="DefinedContributionPlanEmployerContributionAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="clym_SharesConvertedUponAcquisitionMember" name="SharesConvertedUponAcquisitionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_TenetStockOwnedByRACapitalMember" name="TenetStockOwnedByRACapitalMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_CumulativeChangeInOwnershipPercentage" name="CumulativeChangeInOwnershipPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="clym_VestingOfRestrictedStockAwardsShares" name="VestingOfRestrictedStockAwardsShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="clym_EsppMember" name="EsppMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_JuneTwentySevenTwoThousandTwentyFiveMember" name="JuneTwentySevenTwoThousandTwentyFiveMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_FairValueLevel1Level2AndLevel3TransferAmount" name="FairValueLevel1Level2AndLevel3TransferAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="clym_SharesExchangedForPreFundedWarrantsValue" name="SharesExchangedForPreFundedWarrantsValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="clym_BlackbirdClinicalAgreementMember" name="BlackbirdClinicalAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_PerformanceBasedVestingMember" name="PerformanceBasedVestingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_UnallocatedExpenseMember" name="UnallocatedExpenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_IncrementalSharebasedcompensationexpense" name="IncrementalSharebasedcompensationexpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="clym_MilestonePayments" name="MilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="clym_CommonStockIssuedInExchangeForIn-ProcessResearchAndDevelopmentAssets" name="CommonStockIssuedInExchangeForIn-ProcessResearchAndDevelopmentAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="clym_JanuaryOneTwoThousandTwentyFiveMember" name="JanuaryOneTwoThousandTwentyFiveMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_CrhAgreementMember" name="CrhAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_AcelyrinIncMember" name="AcelyrinIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_FirstDayOfOfferingPeriodMember" name="FirstDayOfOfferingPeriodMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_AtTheMarketEquityOfferingProgramMember" name="AtTheMarketEquityOfferingProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_ProbiogenSalesMilestonesMember" name="ProbiogenSalesMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_AcquisitionAgreementMember" name="AcquisitionAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_BusinessCombinationConsiderationTransferredSettlementOfPreExistingLoan" name="BusinessCombinationConsiderationTransferredSettlementOfPreExistingLoan" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="clym_MilestonePaymentAmountReduced" name="MilestonePaymentAmountReduced" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="clym_TaxCreditCarryforwardExpirationYear" name="TaxCreditCarryforwardExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="clym_PerformanceBasedRsusMember" name="PerformanceBasedRsusMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_StephenThomasMember" name="StephenThomasMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_TwoThousandTwentyFiveInducementPlanMember" name="TwoThousandTwentyFiveInducementPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_DefferedTaxAssetOperatingLeaseLiability" name="DefferedTaxAssetOperatingLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="clym_MarchTwentySevenTwoThousandTwentyFiveMember" name="MarchTwentySevenTwoThousandTwentyFiveMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_Pre-FundedWarrantMember" name="Pre-FundedWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="clym_NetOperatingLeasePaymentsMember" name="NetOperatingLeasePaymentsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Feb. 27, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CLIMB BIO, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001768446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">83-2273741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">20 William Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Wellesley Hills<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">866)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">857-2596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CLYM<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,767,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">PricewaterhouseCoopers LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Seattle, Washington<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Portions of the registrant&#8217;s definitive proxy statement for its 2026 Annual Meeting of Stockholders, which the registrant intends to file pursuant to Regulation 14A with the Securities and Exchange Commission not later than 120 days after the registrant&#8217;s fiscal year ended December 31, 2025, are incorporated by reference into Part III of this Annual Report on Form 10-K.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorOpinionTextBlock', window );">Auditor Opinion [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Opinion on the Financial Statements</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Climb Bio, Inc. and its subsidiaries (the &#8220;Company&#8221;) as of December 31, 2025 and 2024, and the related consolidated statements of operations and comprehensive loss, of stockholders&#8217; equity and of cash flows for the years then ended, including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorOpinionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X<br> -Number 210<br> -Section 2<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorOpinionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 35,685<span></span>
</td>
<td class="nump">$ 87,229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Short-term marketable securities</a></td>
<td class="nump">65,395<span></span>
</td>
<td class="nump">63,690<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">4,769<span></span>
</td>
<td class="nump">3,953<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">105,849<span></span>
</td>
<td class="nump">154,872<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Long-term marketable securities</a></td>
<td class="nump">59,572<span></span>
</td>
<td class="nump">61,610<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">505<span></span>
</td>
<td class="nump">490<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">288<span></span>
</td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">1,530<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">167,744<span></span>
</td>
<td class="nump">217,187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,269<span></span>
</td>
<td class="nump">705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">4,459<span></span>
</td>
<td class="nump">4,069<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">256<span></span>
</td>
<td class="nump">157<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">6,984<span></span>
</td>
<td class="nump">4,931<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">285<span></span>
</td>
<td class="nump">375<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">7,269<span></span>
</td>
<td class="nump">5,306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 250,000,000 shares authorized; 47,766,338 and 67,255,434 shares issued and outstanding at December 31, 2025 and 2024, respectively</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">449,762<span></span>
</td>
<td class="nump">441,727<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">435<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(289,727)<span></span>
</td>
<td class="num">(229,876)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">160,475<span></span>
</td>
<td class="nump">211,881<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 167,744<span></span>
</td>
<td class="nump">$ 217,187<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">47,766,338<span></span>
</td>
<td class="nump">67,255,434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">47,766,338<span></span>
</td>
<td class="nump">67,255,434<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clym_AcquiredInProcessResearchAndDevelopmentExpenses', window );">Acquired in-process research and development, related party</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 51,659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">46,713<span></span>
</td>
<td class="nump">14,336<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">21,170<span></span>
</td>
<td class="nump">16,025<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">67,883<span></span>
</td>
<td class="nump">82,020<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total loss from operations</a></td>
<td class="num">(67,883)<span></span>
</td>
<td class="num">(82,020)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency loss</a></td>
<td class="num">(291)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">8,323<span></span>
</td>
<td class="nump">8,132<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="nump">8,032<span></span>
</td>
<td class="nump">8,123<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (59,851)<span></span>
</td>
<td class="num">$ (73,897)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (0.88)<span></span>
</td>
<td class="num">$ (1.53)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (0.88)<span></span>
</td>
<td class="num">$ (1.53)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of shares used to compute net loss per share, diluted</a></td>
<td class="nump">67,812,145<span></span>
</td>
<td class="nump">48,163,301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of shares used to compute net loss per share, basic</a></td>
<td class="nump">67,812,145<span></span>
</td>
<td class="nump">48,163,301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (59,851)<span></span>
</td>
<td class="num">$ (73,897)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized gain on marketable securities</a></td>
<td class="nump">412<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (59,439)<span></span>
</td>
<td class="num">$ (73,872)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clym_AcquiredInProcessResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of in-process research and development assets acquired during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clym_AcquiredInProcessResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clym_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Related Party [Member]</div></th>
<th class="th"><div>Private Placement [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th">
<div>Common Stock [Member] </div>
<div>Related Party [Member]</div>
</th>
<th class="th">
<div>Common Stock [Member] </div>
<div>Private Placement [Member]</div>
</th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th">
<div>Additional Paid-in Capital [Member] </div>
<div>Related Party [Member]</div>
</th>
<th class="th">
<div>Additional Paid-in Capital [Member] </div>
<div>Private Placement [Member]</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss) [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="nump">$ 107,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 263,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
<td class="num">$ (155,979)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,626,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted stock awards and units, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">10,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,676,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,868<span></span>
</td>
<td class="nump">$ 119,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,867<span></span>
</td>
<td class="nump">$ 119,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,560,047<span></span>
</td>
<td class="nump">31,238,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">5,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized gain on marketable securities</a></td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(73,897)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(73,897)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2024</a></td>
<td class="nump">211,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">441,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="num">(229,876)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,255,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted stock awards and units, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">929,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">$ 65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, Shares</a></td>
<td class="nump">21,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clym_SharesExchangedForPreFundedWarrants', window );">Exchange of common stock for pre-funded warrant, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,440,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clym_SharesExchangedForPreFundedWarrantsValue', window );">Exchange of common stock for pre-funded warrant</a></td>
<td class="num">$ (86)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(84)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">8,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized gain on marketable securities</a></td>
<td class="nump">412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(59,851)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(59,851)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2025</a></td>
<td class="nump">$ 160,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 449,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 435<span></span>
</td>
<td class="num">$ (289,727)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,766,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clym_SharesExchangedForPreFundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares exchanged during the period for pre-funded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clym_SharesExchangedForPreFundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clym_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clym_SharesExchangedForPreFundedWarrantsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of shares exchanged during the period for pre-funded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clym_SharesExchangedForPreFundedWarrantsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clym_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Parenthetical) - Common Stock [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoninterestExpenseOfferingCost', window );">Stock issuance costs</a></td>
<td class="nump">$ 86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoninterestExpenseOfferingCost', window );">Stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoninterestExpenseOfferingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for cost associated with issuance of security by investment company. Includes, but is not limited to, legal fee pertaining to share offered for sale, registration fee, underwriting, printing prospectus, and initial fee for listing on exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoninterestExpenseOfferingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (59,851)<span></span>
</td>
<td class="num">$ (73,897)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">8,054<span></span>
</td>
<td class="nump">5,557<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Non-cash operating lease expense</a></td>
<td class="nump">201<span></span>
</td>
<td class="nump">220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Accretion of discounts on marketable securities, net</a></td>
<td class="num">(2,274)<span></span>
</td>
<td class="num">(757)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">97<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clym_AcquiredInProcessResearchAndDevelopmentExpenses', window );">In-process research and development, related party</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">51,659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Unrealized foreign currency transaction (gain) loss</a></td>
<td class="nump">18<span></span>
</td>
<td class="num">(42)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(816)<span></span>
</td>
<td class="nump">1,942<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other long-term assets</a></td>
<td class="num">(1,514)<span></span>
</td>
<td class="num">(200)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,564<span></span>
</td>
<td class="num">(963)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clym_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedparties', window );">Accounts payable and accrued liabilities, related party</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(177)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">372<span></span>
</td>
<td class="nump">1,445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(207)<span></span>
</td>
<td class="num">(327)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Long-term liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(54,356)<span></span>
</td>
<td class="num">(15,562)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(186)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of marketable securities</a></td>
<td class="num">(108,078)<span></span>
</td>
<td class="num">(132,197)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Maturities of marketable securities</a></td>
<td class="nump">111,097<span></span>
</td>
<td class="nump">20,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clym_IssuanceOfPromissoryLoanInConnectionWithAssetsAcquisition', window );">Issuance of promissory loan in connection with asset acquisition</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid in connection with asset acquisition, net of cash received</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,645)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">2,833<span></span>
</td>
<td class="num">(121,092)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">10,979<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Pre-funded warrant issuance costs</a></td>
<td class="num">(86)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of common stock in private placement, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">119,750<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="num">(21)<span></span>
</td>
<td class="nump">130,729<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="num">(51,544)<span></span>
</td>
<td class="num">(5,883)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">87,229<span></span>
</td>
<td class="nump">93,112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">35,685<span></span>
</td>
<td class="nump">87,229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clym_CommonStockIssuedInExchangeForIn-ProcessResearchAndDevelopmentAssets', window );">Issuance of common stock in exchange for in-process research and development</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">41,867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clym_AmountOfPromissoryLoanSettledInConnectionWithAnAssetAcquisition', window );">Settlement of promissory loan in connection with asset acquisition</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,036<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clym_AcquiredInProcessResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of in-process research and development assets acquired during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clym_AcquiredInProcessResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clym_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clym_AmountOfPromissoryLoanSettledInConnectionWithAnAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of promissory loan settled in connection with an asset acquisition</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clym_AmountOfPromissoryLoanSettledInConnectionWithAnAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clym_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clym_CommonStockIssuedInExchangeForIn-ProcessResearchAndDevelopmentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of common stock issued in exchange for in-process research and development asset as part of an asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clym_CommonStockIssuedInExchangeForIn-ProcessResearchAndDevelopmentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clym_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clym_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedparties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to related parties and the amount of obligations and expenses incurred, but not paid, from related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clym_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedparties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clym_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clym_IssuanceOfPromissoryLoanInConnectionWithAssetsAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the issuance of a promissory loan in connection with an asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clym_IssuanceOfPromissoryLoanInConnectionWithAssetsAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clym_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpensesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (59,851)<span></span>
</td>
<td class="num">$ (73,897)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text"><p id="item_9b_other_information" style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">em 9B. Other Information.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Director and Officer Trading Arrangements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The adoption or termination of contracts, instructions or written plans for the purchase or sale of our securities by our Section 16 officers and directors for the three months ended December 31, 2025, each of which is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act (&#8220;Rule 10b5-1 Plan&#8221;), were as follows:</span></p>
     <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
      <tr style="visibility:collapse;">
       <td style="width:17.163%;box-sizing:content-box;"></td>
       <td style="width:15.743%;box-sizing:content-box;"></td>
       <td style="width:22.545%;box-sizing:content-box;"></td>
       <td style="width:11.262%;box-sizing:content-box;"></td>
       <td style="width:18.044%;box-sizing:content-box;"></td>
       <td style="width:1%;box-sizing:content-box;"></td>
       <td style="width:13.243%;box-sizing:content-box;"></td>
       <td style="width:1%;box-sizing:content-box;"></td>
      </tr>
      <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
       <td style="border-top:0.5pt solid #000000;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name (Title)</span></p></td>
       <td style="border-top:0.5pt solid #000000;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Action taken<br/>(Date of Action)</span></p></td>
       <td style="border-top:0.5pt solid #000000;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Type of Trading Arrangement</span></p></td>
       <td style="border-top:0.5pt solid #000000;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Nature of Trading<br/>Arrangement</span></p></td>
       <td style="border-top:0.5pt solid #000000;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Duration of Trading<br/>Arrangement</span></p></td>
       <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate Number<br/>of Securities</span></p></td>
       <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      </tr>
      <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
       <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:pre-wrap;border-left:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stephen Thomas</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"><br/>(</span><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">)</span></p></td>
       <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">Adoption<br/>(</span><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">October 14, 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">)</span></p></td>
       <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rule 10b5-1</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;trading arrangement</span></p></td>
       <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sale</span></p></td>
       <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">Until </span><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">August 8, 2026</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">, or, if earlier, upon the completed sale of the maximum shares</span></p></td>
       <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">150,000</span></p></td>
       <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      </tr>
     </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=clym_StephenThomasMember', window );">Stephen Thomas</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Stephen Thomas<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Director<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">October 14, 2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">August 8, 2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">150,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrSecuritiesAggAvailAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrSecuritiesAggAvailAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=clym_StephenThomasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=clym_StephenThomasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management, Strategy and Governance<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><p id="item_1c_cybersecurity" style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1C. Cybersecurity.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risk Management and Strategy</span></p><div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have implemented and maintain various information security </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">processes</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> designed to identify, assess and manage material risks from cybersecurity threats to our critical computer networks, third-party hosted services, communications systems, and our critical data, including intellectual property, confidential information that is proprietary, strategic or competitive in nature, and data related to nonclinical studies and clinical trials involving certain of our product candidates (Information Systems and Data).</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We manage, identify and assess risks from cybersecurity threats by monitoring and evaluating our threat environment and risk profile using various methods including, for example: through the use of automated tools, including but not limited to tools for monitoring, remote wiping, threat detection, intrusion detection and prevention; conducting (</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">through third parties</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) regular audits and threat assessments for internal and external threats; subscribing to reports and services that identify cybersecurity threats; analyzing reports of threats and actors; conducting vulnerability assessments to identify vulnerabilities; evaluating our and our industry&#8217;s risk profile; and evaluating threats reported to us.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depending on the environment, we implement and maintain various processes, standards and policies designed to manage and mitigate material risks from cybersecurity threats to our Information Systems and Data, including, for example: risk assessments, implementation of security standards and certifications, encryption of data in transit and at rest, network security controls, data segregation, access controls, systems monitoring, vendor risk management program, employee training and penetration testing.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of our cybersecurity risk management program, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we maintain processes to assess and review the cybersecurity practices of third-party vendors and suppliers</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Prior to engaging key third-party vendors and suppliers, we conduct a security assessment and, as appropriate, include security requirements in contracts.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We, like other companies in our industry, face cybersecurity risks in connection with our business. However, to date, risks from cybersecurity threats have not </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">materially affected</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and are not reasonably likely to materially affect our business strategy, results of operations, and financial condition. For more information on our cybersecurity related risks, see &#8220;Risk Factors&#8221; under Part I, Item 1A of this Annual Report on Form 10-K.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governance</span></p><div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors considers cybersecurity risk management as part of its general oversight function. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The audit committee of our board of directors is responsible for overseeing our cybersecurity risk management processes, including oversight and mitigation of risks from cybersecurity threats.</span></span></p></div><div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management team provides periodic updates to the audit committee regarding our cybersecurity program, including information about cyber risk management governance and status updates on various projects intended to enhance the overall cybersecurity posture of the Company. </span></span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">chief financial officer</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, with the assistance of third-party technical advisors, leads the operational oversight of company-wide cybersecurity strategy, policy, standards and processes and works across relevant departments to assess and help the Company and our employees to address cybersecurity risks.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our third-party technical advisors include consultants with over 20 years of experience in IT leadership as well as subject matter experts in cybersecurity that have extensive experience managing cybersecurity programs.</span></span></p></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have implemented and maintain various information security </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">processes</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> designed to identify, assess and manage material risks from cybersecurity threats to our critical computer networks, third-party hosted services, communications systems, and our critical data, including intellectual property, confidential information that is proprietary, strategic or competitive in nature, and data related to nonclinical studies and clinical trials involving certain of our product candidates (Information Systems and Data).</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governance</span></p><div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors considers cybersecurity risk management as part of its general oversight function. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The audit committee of our board of directors is responsible for overseeing our cybersecurity risk management processes, including oversight and mitigation of risks from cybersecurity threats.</span></span></p></div><div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management team provides periodic updates to the audit committee regarding our cybersecurity program, including information about cyber risk management governance and status updates on various projects intended to enhance the overall cybersecurity posture of the Company. </span></span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">chief financial officer</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, with the assistance of third-party technical advisors, leads the operational oversight of company-wide cybersecurity strategy, policy, standards and processes and works across relevant departments to assess and help the Company and our employees to address cybersecurity risks.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our third-party technical advisors include consultants with over 20 years of experience in IT leadership as well as subject matter experts in cybersecurity that have extensive experience managing cybersecurity programs.</span></span></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The audit committee of our board of directors is responsible for overseeing our cybersecurity risk management processes, including oversight and mitigation of risks from cybersecurity threats.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors considers cybersecurity risk management as part of its general oversight function. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The audit committee of our board of directors is responsible for overseeing our cybersecurity risk management processes, including oversight and mitigation of risks from cybersecurity threats.</span></span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management team provides periodic updates to the audit committee regarding our cybersecurity program, including information about cyber risk management governance and status updates on various projects intended to enhance the overall cybersecurity posture of the Company. </span></span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">chief financial officer</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, with the assistance of third-party technical advisors, leads the operational oversight of company-wide cybersecurity strategy, policy, standards and processes and works across relevant departments to assess and help the Company and our employees to address cybersecurity risks.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our third-party technical advisors include consultants with over 20 years of experience in IT leadership as well as subject matter experts in cybersecurity that have extensive experience managing cybersecurity programs.</span></span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">chief financial officer</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, with the assistance of third-party technical advisors, leads the operational oversight of company-wide cybersecurity strategy, policy, standards and processes and works across relevant departments to assess and help the Company and our employees to address cybersecurity risks.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our third-party technical advisors include consultants with over 20 years of experience in IT leadership as well as subject matter experts in cybersecurity that have extensive experience managing cybersecurity programs.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management team provides periodic updates to the audit committee regarding our cybersecurity program, including information about cyber risk management governance and status updates on various projects intended to enhance the overall cybersecurity posture of the Company. </span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Nature of Operations and Basis of Presentation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 1. Nature of Operations and Basis of Presentation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Organization</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Climb Bio, Inc. (the Company), is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company&#8217;s pipeline includes budoprutug and CLYM116. Budoprutug is an anti-CD19 monoclonal antibody designed to treat a broad range of B-cell mediated diseases. The Company is currently developing budoprutug for the treatment of primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus. CLYM116 is an anti-APRIL (A Proliferation-Inducing Ligand) monoclonal antibody currently being developed for the treatment of immunoglobulin A nephropathy. The Company was incorporated on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 18, 2018</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in Delaware, and its corporate headquarters is in Massachusetts.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 27, 2024, the Company completed its acquisition of Tenet Medicines, Inc. (the Acquisition). In connection with the closing of the Acquisition, the Company issued and sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,238,282</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.84</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share in a private placement to several accredited institutional investors (the Private Placement). The Company received aggregate gross proceeds from the Private Placement of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">120.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, before deducting offering costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (see Note 3). </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 8, 2025, the Company entered into a technology transfer and exclusive license agreement (the Mabworks Agreement) with Beijing Mabworks Biotech Co., Ltd. (Mabworks), for rights to develop and commercialize CLYM116 for all indications worldwide outside of mainland China, Hong Kong, Macau, and Taiwan (Greater China) (see Note 8).</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risks and Uncertainties</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, reliance on single-source suppliers and manufacturers, availability of raw materials, patentability of the Company&#8217;s product candidates and processes and clinical efficacy and safety of the Company&#8217;s product candidates, compliance with government regulations and the need to obtain additional financing to fund operations. Budoprutug, CLYM116, or any product candidate the Company may develop will require significant additional research and development efforts, including extensive nonclinical studies, clinical trials, and regulatory approval, prior to commercialization. These efforts will require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance and reporting.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There can be no assurance that any future research and development will be successfully completed, that adequate protection for the Company&#8217;s intellectual property will be obtained or maintained, that any product candidate developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if any future product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales. The Company operates in an environment of rapid technological change and substantial competition from other pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and other third parties.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of Presentation and Principles of Consolidation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (U.S. GAAP). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Update (ASU) of the Financial Accounting Standards Board (FASB).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying consolidated financial statements reflect the operations of the Company and its wholly owned subsidiaries. Intercompany transactions and balances have been eliminated in consolidation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Liquidity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since inception, the Company has experienced recurring losses from operations and generated negative cash flows from operations. The Company has an accumulated deficit of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">289.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of December 31, 2025 and expects to incur additional losses from operations in the future. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2025, the Company entered into an Equity Distribution Agreement (the Distribution Agreement) with Oppenheimer &amp; Co. Inc., as agent (Oppenheimer), pursuant to which the Company may offer and sell shares of its common stock from time to time through Oppenheimer having an aggregate offering price of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in an at the market offering. During the year ended December 31</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, 2025, the Company did not issue and sell any shares of its common stock pursuant to the Distribution Agreement.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company believes its available cash, cash equivalents and marketable securities of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">160.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of December 31, 2025 will be sufficient to meet its projected operating requirements for at least the next twelve months from the filing date of these consolidated financial statements, and the Company anticipates that it will need to raise substantial financing in the future to fund its operations. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company may finance future cash needs through the sale of equity, debt financings or other capital sources, which could include income from collaborations, strategic partnerships or other strategic arrangements. There are no assurances that the Company will be able to raise sufficient amounts of funding in the future on acceptable terms, or at all.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 2. Summary of Significant Accounting Policies</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (JOBS Act). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued after the enactment of the JOBS Act until those standards apply to private companies. The Company has elected to avail itself of this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts and disclosures. Accordingly, actual results could differ from those estimates. Key management estimates include those related to the accrual of research and development expenses and the valuation of stock-based awards. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Foreign Currency</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s reporting currency is the U.S. dollar. The functional currency of the Company and its subsidiaries is the U.S. dollar. Monetary assets and liabilities resulting from transactions denominated in currencies other than the functional currency are remeasured in the functional currency at exchange rates prevailing at the balance sheet date, and income items and expenses are translated into U.S. dollars at the average exchange rate in effect during the period. Exchange gains and losses resulting from remeasurement and foreign currency transactions are included in the determination of net loss.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Information</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. Significantly all of the Company&#8217;s tangible assets are held in the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Concentration of Credit Risk </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">and Significant Suppliers and Manufacturers</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company maintains its cash and cash equivalents at accredited financial institutions that may, at times, exceed federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company&#8217;s investments in money market funds and marketable securities are held in segregated accounts at a third-party custodian. The Company has established guidelines relative to credit ratings and maturities intended to safeguard principal balances and maintain liquidity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is dependent on third-party suppliers and manufacturers for material used in its nonclinical and clinical development activities. In particular, the Company relies and expects to continue to rely on single-source suppliers and manufacturers to supply it with certain critical materials related to the Company&#8217;s product candidates. The Company&#8217;s development efforts could be adversely affected if a supplier or manufacturer is unable to successfully carry out its contractual obligations or meet expected deadlines. If a supplier or manufacturer needs to be replaced, the Company may not be able to complete its product development on its anticipated timelines and may incur additional expenses as a result.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company considers all highly liquid investments with maturities of three months or less from the purchase date to be cash equivalents.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Marketable Securities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company classifies its marketable securities as available-for-sale. Marketable securities with remaining maturities of less than one year from the balance sheet date are classified as short-term marketable securities. Marketable securities with remaining maturities of greater than one year from the balance sheet date are classified as long-term marketable securities. The Company reports available-for-sale investments at fair value as of each balance sheet date and records unrealized gains or losses as a component of stockholders&#8217; equity in accumulated other comprehensive income (loss). Realized gains and losses of securities sold are determined on a specific identification basis and included in other income (expense) within the consolidated statements of operations and comprehensive loss.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When the fair value is below the amortized cost of a marketable security, the Company estimates the portion of the unrealized loss that relates to credit</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The credit-related impairment amount is recorded in other income (expense) in the consolidated statements of operations and comprehensive loss. Credit losses are recognized through the use of an allowance for credit losses account in the consolidated balance sheet and subsequent improvements in expected credit losses are recorded as a reversal of an amount in the allowance account. If the Company intends to sell the security or it is more likely than not that the Company will be required to sell the security prior to recovery of its amortized cost basis, then the allowance for the credit loss, if any, is written-off and the excess of the amortized cost basis of the asset over its fair value is recognized in other income (expense) in the consolidated statements of operations and comprehensive loss. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> credit losses recorded during the years ended December 31, 2025 and 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1&#8212;Quoted prices in active markets for identical assets or liabilities. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2&#8212;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. </span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s cash equivalents and marketable securities are carried at fair value, determined according to the fair value hierarchy (see Note 4). The carrying values of the Company&#8217;s accounts payable and accrued expenses approximate their fair values due to the short-term nature of these liabilities.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comprehensive Loss</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprehensive loss includes net loss as well as other changes in stockholders&#8217; equity that result from transactions and economic events other than those with stockholders. The Company&#8217;s only element of other comprehensive income (loss) is unrealized gains and losses on available-for-sale marketable securities.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Asset Acquisitions</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In determining whether an acquisition of assets and related liabilities should be accounted for as a business combination or asset acquisition, the Company first determines whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets. If this is the case, the single identifiable asset or the group of similar assets is not deemed to be a business and the acquisition is accounted for as an asset acquisition. If this is not the case, the Company then further evaluates whether the acquisition includes, at a minimum, an input and a substantive process that together significantly contribute to the ability to create outputs. If so, the Company concludes that the acquisition is a business and accounts for it as a business combination.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the asset or group of assets, which includes transaction costs, allocated on a relative fair value basis. Goodwill is not recognized in asset acquisitions. In an asset acquisition, the cost allocated to acquire in-process research and development (IPR&amp;D) with no alternative future use is charged to expense at the acquisition date.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property and Equipment</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:0.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;margin-right:0.13%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful life of each asset.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
         <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
          <tr style="visibility:collapse;">
           <td style="width:59.18%;box-sizing:content-box;"></td>
           <td style="width:2.88%;box-sizing:content-box;"></td>
           <td style="width:37.94%;box-sizing:content-box;"></td>
          </tr>
          <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated Useful Life</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
           <td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5 </span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">years</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
           <td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="-sec-ix-hidden:F_2a7e8018-774a-4c44-8376-7e8c696ec434;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shorter of remaining life of lease or useful life</span></span></span></p></td>
          </tr>
         </table></div><p style="margin-left:0.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When an item is sold or retired, the costs and related accumulated depreciation are eliminated, and the resulting gain or loss, if any, is credited or charged to operating loss in the consolidated statements of operations and comprehensive loss. Repairs and maintenance costs are expensed as incurred.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for leases under ASC Topic 842, Leases (&#8220;ASC 842&#8221;). In accordance with ASC 842, the Company accounts for a contract as a lease when it has the right to control the asset for a period of time while obtaining substantially all of the asset&#8217;s economic benefits. The Company determines if an arrangement is a lease or contains an embedded lease at inception. For arrangements that meet the definition of a lease, the Company determines the initial classification and measurement of its right-of-use asset and lease liability at the lease commencement date and thereafter if modified. The lease term includes any renewal options that the Company is reasonably assured to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its estimated secured incremental borrowing rate for that lease term. The Company&#8217;s policy is to not record leases with an original term of 12 months or less on its consolidated balance sheets and recognizes those lease payments in the income statement on a straight-line basis over the lease term. The Company&#8217;s existing lease is for office space.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to rent, leases may require the Company to pay additional costs, such as utilities, maintenance and other operating costs, which are generally referred to as non-lease components. The Company has elected to not separate lease and non-lease components. Only the fixed costs for lease components and their associated non-lease components are accounted for as a single lease component and recognized as part of a right-of-use asset and lease liability. Rent expense for operating leases is recognized on a straight-line basis over the reasonably assured lease term based on the total lease payments and is included in operating expense in the consolidated statements of operations and comprehensive loss.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Long-Lived Assets</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Long-lived assets consist of property and equipment and right-of-use assets.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company reviews the recoverability of its long-lived assets, including the related useful lives, whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset might not be recoverable, based on undiscounted cash flows. If such assets are considered to be impaired, an impairment loss is recognized and is measured as the amount by which the carrying amount of the assets exceed their estimated fair value, which is measured based on the projected discounted future net cash flows arising from the assets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses consist of costs incurred in performing research and development activities, including salaries and bonuses, stock-based compensation, employee benefits, termination benefits, facilities costs and depreciation, and external costs of vendors engaged to conduct research, nonclinical and clinical development activities as well as the cost of acquiring and licensing technology.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upfront payments and milestone payments made for the licensing of technology are expensed as research and development over the period to which they relate. Costs for research and development activities are expensed in the period in which they are incurred. Payments for such activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid expense or accrued research and development expense. Determining the prepaid and accrued balances at the end of any reporting period incorporate certain judgments and estimates by management that are based on information available to the Company including information provided by vendors regarding the progress to completion of specific tasks or costs incurred.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent costs</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All patent-related costs incurred in connection with filing and prosecuting patent applications are recorded as general and administrative expenses as incurred.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-Based Compensation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company measures its stock options with service-based vesting or performance-based vesting granted to employees, non-employee directors, consultants and independent advisors based on the estimated fair value on the date of grant using the Black-Scholes option-pricing model. The Company measures compensation expense for restricted common stock units based on the fair value on the date of grant using the market value of the Company&#8217;s common stock. Compensation expense for the awards is recognized over the requisite service period for employees and directors and as services are delivered for consultants and independent advisors, both of which are generally the vesting period of the respective award. The Company uses the straight-line method to record the expense of awards with only service-based vesting conditions. The Company uses the graded-vesting method to record the expense of awards with both service-based and performance-based vesting conditions, commencing once achievement of the performance condition becomes probable. The Company accounts for forfeitures of share-based awards as they occur.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company classifies stock-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#8217;s payroll costs are classified or in which the award recipient&#8217;s service payments are classified.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#8217;s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to the provision for income taxes. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. Any resulting unrecognized tax benefits are recorded within the provision for income taxes.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Loss Per Share</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net loss per share attributable to common stockholders is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net loss per share attributable to common stockholders is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, adjusted for potential dilutive common shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In periods in which the Company reported a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company reported a net loss attributable to common stockholders for the years ended December 31, 2025 and 2024.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Pronouncements Not Yet Adopted</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU No. 2023-09 (ASU 2023-09), </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which requires, among other things, the following for public business entities: (i) enhanced disclosures of specific categories of reconciling items included in the rate reconciliation, as well as additional information for any of these items meeting certain qualitative and quantitative thresholds; (ii) disclosure of the nature, effect and underlying causes of each individual reconciling item disclosed in the rate reconciliation and the judgment used in categorizing them if not otherwise evident; and (iii) enhanced disclosures for income taxes paid, which includes federal, state, and foreign taxes, as well as for individual jurisdictions over a certain quantitative threshold. The amendments in ASU 2023-09 eliminate the requirement to disclose the nature and estimate of the range of the reasonably possible change in unrecognized tax benefits for the 12 months after the balance sheet date. The effective date of this update for non-public companies is for fiscal years beginning after December 15, 2025; early adoption is permitted. The Company expects ASU 2023-09 to require additional disclosures in the notes to its consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03 (ASU 2024-03), </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Disaggregation of Income Statement Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which requires additional disclosures about specific types of expenses included in the expense captions presented on the face of the income statement, as well as disclosures about selling expenses. The provisions of ASU 2024-03 are effective for public business entities for fiscal years beginning after December 15, 2026, and interim periods beginning after December 15, 2027. Early adoption is permitted. The guidance is to be applied prospectively, with the option for retrospective application. The Company is currently evaluating the impact of ASU 2024-03 on its consolidated financial statements.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Asset Acquisition and Private Placement with a Related Party<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combination [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionTextBlock', window );">Asset Acquisition and Private Placement with a Related Party</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 3. Asset Acquisition and Private Placement with a Related Party</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Background</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company entered into (i) an Agreement and Plan of Merger and Reorganization, dated as of April 10, 2024 (the Acquisition Agreement), by and among the Company, Tango Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (Transitory Subsidiary), Tenet Medicines, Inc. (Tenet), a Delaware corporation, and, solely in his capacity as Tenet equityholder representative, Stephen Thomas, providing for the acquisition of Tenet by the Company through the merger of Transitory Subsidiary into Tenet, with Tenet surviving as a wholly owned subsidiary of the Company, (ii) a Securities Purchase Agreement, dated as of April 10, 2024 (the Securities Purchase Agreement), by and among the Company and several accredited institutional investors (the PIPE Investors) including funds affiliated with RA Capital Management, L.P. (RA Capital Management), pursuant to which the Company agreed to issue and sell to the PIPE Investors in the Private Placement an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,238,282</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shar</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">es (the PIPE Shares) of the Company&#8217;s common stock, and (iii) a registration rights agreement with the PIPE Investors, pursuant to which the Company agreed to register for resale the PIPE Shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 27, 2024, the Company completed its acquisition of Tenet in accordance with the terms of the Acquisition Agreement. Tenet was a private, development stage biotechnology company that was majority-owned by funds affiliated with RA Capital Management prior to the closing of the Acquisition. Immediately prior to the closing of the Acquisition and Private Placement, RA Capital Management beneficially owned approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the Company&#8217;s outstanding common stock. The Private Placement closed immediately following the closing of the Acquisition. The Company received aggregate gross proceeds from the Private Placement of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">120.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, before deducting offering costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The offering costs were recorded as a reduction of additional paid-in capital generated in connection with the Private Placement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the effective time of the Acquisition, by virtue of the Acquisition and without any action on the part of the holders of common stock of Tenet, (i) all issued and outstanding shares of the common stock of Tenet and (ii) all securities convertible into shares of common stock of Tenet were converted into the right to receive, in the aggregate, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,560,047</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Acquisition Accounting</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounted for the Acquisition as an asset acquisition and accordingly, total consideration of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, comprised of the fair value of common stock issued of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, settlement of pre-existing loan of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and transaction costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, was allocated to the assets acquired and liabilities assumed on a relative fair value basis. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth the allocation of the purchase consideration (in thousands):</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:86.24%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.76%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Assets acquired</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;In-process research and development</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">51,659</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Cash and cash equivalents</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,204</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Prepaid expenses and other current assets</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,861</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets acquired</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54,724</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Liabilities assumed</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Accounts payable</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,603</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Accounts payable, related party</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Accrued expenses and other current liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">192</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Accrued expenses, related party</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities assumed</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,972</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net assets acquired</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52,752</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The value of the IPR&amp;D was expensed in the consolidated statements of operations and comprehensive loss, as the IPR&amp;D was determined to have no future alternative use.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/805-50/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities and Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Securities and Fair Value Measurements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 4. Marketable Securities and Fair Value Measurements</span></p><div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketable securities consisted of available-for-sale securities as follows (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:52.899%;box-sizing:content-box;"></td>
         <td style="width:1.879%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:7.897%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.879%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:7.897%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.879%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:7.897%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.879%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:7.897%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8197;&#8197;&#8197;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cost</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gain</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Loss</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term marketable securities:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,874</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,976</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,296</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">123</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,419</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total short-term marketable securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,170</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">225</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,395</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Long-term marketable securities:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,341</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">177</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,518</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,022</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,054</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency debt securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,999</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total long-term marketable securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59,362</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">210</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59,572</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;">
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:52.899%;box-sizing:content-box;"></td>
         <td style="width:1.879%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:7.897%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.879%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:7.897%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.879%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:7.897%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.879%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:7.897%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8197;&#8197;&#8197;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cost</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gain</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Loss</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term marketable securities:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,519</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,537</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,130</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,153</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total short-term marketable securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,649</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,690</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Long-term marketable securities:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,982</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,955</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,146</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,154</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency debt securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,500</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,501</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total long-term marketable securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61,628</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">58</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61,610</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, the Company&#8217;s long-term marketable securities have contractual maturity dates between one and two years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables present information about the Company&#8217;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:54.489%;box-sizing:content-box;"></td>
         <td style="width:1.94%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:7.439%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.94%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:7.439%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.94%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:7.439%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.94%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:7.439%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value Measurements at December 31, 2025 Using:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Assets:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,320</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,320</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,473</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,473</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82,494</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82,494</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency debt securities</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:25pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:4.627%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total marketable securities</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,473</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85,494</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">124,967</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74,793</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85,494</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">160,287</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:54.489%;box-sizing:content-box;"></td>
         <td style="width:1.94%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:7.439%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.94%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:7.439%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.94%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:7.439%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.94%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:7.439%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value Measurements at December 31, 2024 Using:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Assets:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85,612</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85,612</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54,307</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54,307</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67,492</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67,492</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency debt securities</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,501</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,501</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:25pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:4.627%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total marketable securities</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54,307</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70,993</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125,300</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">139,919</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70,993</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">210,912</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash equivalents and U.S. Treasury securities were valued by the Company based on quoted market prices for identical securities, which represent a Level 1 measurement within the fair value hierarchy. Corporate bonds and agency securities were valued by the Company using quoted prices in active markets for similar securities, which represent a Level 2 measurement within the fair value hierarchy. There were no transfers into or out of Level 3 for any of the periods presented.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/940-320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph b<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 5. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued Expenses and Other Current Liabilities</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:72.446%;box-sizing:content-box;"></td>
         <td style="width:2.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.598%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.598%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued payroll and related expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,891</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,997</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued external research and development expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,816</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,237</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued professional fees</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">693</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">746</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other accrued expenses and current liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,459</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,069</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 6. Related Party Transactions</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equity</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 11, 2025, the Company entered into an exchange agreement (the Exchange Agreement) with RA Capital Management and an entity affiliated with RA Capital Management (the Exchanging Holder), pursuant to which the Exchanging Holder exchanged an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,440,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock, beneficially owned by the Exchanging Holder for a pre-funded warrant to purchase the same number of shares of the Company&#8217;s common stock (subject to adjustment in the event of stock splits, recapitalizations and other similar events affecting the Company&#8217;s common stock), with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. The pre-funded warrant is exercisable at any time and does not expire.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Exchanging Holder is not entitled to exercise any portion of the pre-funded warrant if, upon giving effect or immediately prior to such exercise, such exercise would result in the aggregate number of shares of common stock beneficially owned by RA Capital Management, the Exchanging Holder, and their respective affiliates, collectively, to exceed </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the number of shares of common stock issued and outstanding immediately after giving effect to such exercise, as such percentage ownership is determined in accordance with the terms of the pre-funded warrant. The Exchanging Holder may increase or decrease such percentage to any other percentage not in excess of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%; provided that any such increase will not be effective until the 61st day after notice from the Exchanging Holder is delivered to the Company. In addition, following the date of the Exchange Agreement, RA Capital Management may exchange additional shares of common stock beneficially owned by it or its affiliates for pre-funded warrants, subject to certain terms and conditions, including the Company&#8217;s written consent.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company determined that the pre-funded warrant did not meet the classification of a liability under ASC 480, Distinguishing Liabilities from Equity. The Company concluded that the pre-funded warrant should be classified as equity based on an analysis performed under ASC 815-40, Contracts in an Entity's Own Equity. The Exchange Agreement did not have any cash impact, and the shares of common stock exchanged for the pre-funded warrant were retired.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2024, the Company issued shares to RA Capital Management and affiliates in connection with the Acquisition and Private Placement (see Note 3).</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Service Agreements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result of the Acquisition, the following legacy Tenet agreements effectively became agreements of the Company.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tenet was a party to a service agreement with Sera Services, Inc. (Sera Services), a wholly-owned subsidiary of Sera Medicines, LLC (Sera Medicines) to provide research and other services to the Company. Sera Medicines is an entity controlled by RA Capital Management, and Dr. Stephen Thomas, a current board member of the Company, owns a minority ownership in and is also a board member of Sera Medicines. No services were provided under the Sera Services Agreement for the year ended December 31, 2025 and, in March 2026, the Company terminated the agreement. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to Sera Services for services provided under the Sera Services Agreement for the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tenet was a party to a service agreement with Blackbird Clinical, Inc. (Blackbird), an entity controlled by RA Capital Management. Under the terms of the service agreement, Blackbird provided consulting services to Tenet in connection with its clinical trials. For the year ended December 31, 2024, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Company paid approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to Blackbird under the Blackbird Service Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In October 2024, the Company terminated the Blackbird Service Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Lessee</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 7. Leases</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company leases office space under a non-cancelable operating lease in Wellesley, Massachusetts under a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-month lease agreement that expires in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_0ecb2fd9-391a-4200-85ea-df3460e76587;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 2026</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The lease contains rent escalation clauses and an option to extend the term of the lease for an additional 12-month period at a market rate determined according to the lease. At the lease&#8217;s inception and as of December 31, 2025, the Company expects to exercise its </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">option to extend</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the lease, and therefore the period covered by this option is included in the lease term.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2025, the Company amended the lease to add space to the existing lease for additional fixed payments totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million through 2026 with an option to extend the lease through 2027 for additional fixed payments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. As the Company expects to exercise its option to extend the lease, the extension period is included in the lease term. Accordingly, the Company recorded an increase to operating lease right-of-use assets and operating lease liabilities of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company previously leased office space in Bellevue, Washington, which expired in January 2025, and Cambridge, U.K., which expired in June 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of lease expense were as follows (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:70.12%;box-sizing:content-box;"></td>
         <td style="width:1.78%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.78%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease cost</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">250</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">243</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term lease cost</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Variable lease cost</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">259</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">329</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Supplemental disclosure of cash flow information related to leases was as follows (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:70.12%;box-sizing:content-box;"></td>
         <td style="width:1.78%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.78%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for amounts included in the measurement of operating <br/>&#160;&#160;&#160;&#160;&#160;lease liabilities</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">256</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">350</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Operating lease liabilities arising from obtaining right-of-use<br/>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;asset</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">216</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">510</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted-average remaining lease term and discount rate were as follows:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:70.148%;box-sizing:content-box;"></td>
         <td style="width:1.301%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.625%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.301%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.625%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average remaining lease term - operating lease (in years)</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.0</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.9</span></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average discount rate - operating lease</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.5</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.5</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, the annual future minimum lease payments due under the Company&#8217;s non-cancelable operating lease was as follows (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:82.44%;box-sizing:content-box;"></td>
         <td style="width:2.08%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.48%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Year ending December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">293</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">298</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Total undiscounted lease payments</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">591</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: imputed interest</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Total operating lease liabilities</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">541</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Total operating lease liabilities in the table above are classified on the consolidated balance sheet as follows (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:82.44%;box-sizing:content-box;"></td>
         <td style="width:2.08%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.48%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Included in the consolidated balance sheet (in thousands):</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current operating lease liability</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">256</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liability, net of current portion</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">285</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Total operating lease liabilities</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">541</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 8. Commitments and Contingencies</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating Leases</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s commitments under its leases are described in Note 7.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License Agreements (Budoprutug)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result of the Acquisition, the following legacy Tenet agreements effectively became agreements of the Company.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Acelyrin Asset Purchase Agreement</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 11, 2024, Tenet entered into an asset purchase agreement (the Asset Purchase Agreement) with Acelyrin, Inc. (Acelyrin) and WH2, LLC, which was subsequently transferred to the Company by operation of law upon the closing of the Acquisition, providing for the acquisition of certain assets of Acelyrin related to budoprutug (the Transferred Assets), including certain assigned contracts. Under these assigned contracts, the Company (i) received worldwide licenses (with the right to sublicense) to certain patents, know-how and other intellectual property rights to develop, manufacture, use and commercialize budoprutug for any non-oncology indication, and (ii) assumed certain liabilities of Acelyrin arising from (1) governmental authority action or notification relating to budoprutug, (2) contracts assigned to the Company pursuant to the Asset Purchase Agreement and (3) the Company&#8217;s ownership, lease or operation of the Transferred Assets. The Asset Purchase Agreement includes customary representations, warranties and covenants, as well as standard mutual indemnities, including those covering losses arising from any material breach of the Asset Purchase Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Asset Purchase Agreement, the Company also acquired the rights and obligations, including financial obligations, under a license agreement with Cancer Research Technology Limited (CRH), which Tenet subsequently amended and restated in the CRH Agreement (as defined below) and a cell line development, manufacturing services and license agreement with ProBioGen AG (ProBioGen).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Asset Purchase Agreement with respect to any &#8220;Product&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (as such term is defined in the Asset Purchase Agreement), the Company is obligated to (i) make total payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">157.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to Acelyrin upon the achievement of various development, regulatory and commercial milestones, (ii) pay royalties in the single-digit percentages, subject to specified reductions, to Acelyrin on worldwide net sales in a given calendar year, and (iii) make non-refundable and non-creditable payments to Acelyrin on sublicense income with rates ranging from the low single digit to mid teen percent depending on the stage of development of the most advanced Product at the time of such sublicense.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The royalty term continues for each Product on a country-by-country and Product-by-Product basis beginning on the first commercial sale of such Product and ending on the latest of (a) the date when such Product is no longer covered by a valid claim of a royalty-bearing patent (as such term is defined in the Asset Purchase Agreement) in such country, (b) the expiration of any regulatory exclusivity period for such Product in such country, and (c) the twelfth anniversary of the first commercial sale of such Product in such country.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is obligated to use commercially reasonable efforts to commercialize at least one Product in the U.S., to the extent a Product exists under the Asset Purchase Agreement, and to achieve specified development, regulatory and commercial milestones for such Product set forth in the Asset Purchase Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent a Product exists under the Asset Purchase Agreement, if Acelyrin asserts that the Company has failed to meet a specified diligence obligation under the Asset Purchase Agreement within specified time periods, and such failure is finally determined through a dispute resolution process, Acelyrin may elect, in lieu of a claim for damages, to repurchase the Transferred Assets at the then-fair market value of such Transferred Assets, as Acelyrin&#8217;s sole and exclusive remedy for such breach.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If, within a specified period following the top line data readout from the first Phase 2 clinical trial of a Product, the Company receives a bona fide offer or proposal from a third party to sell, transfer or otherwise divest all or substantially all of the rights to the Transferred Assets or Products, or grant an exclusive license or exclusive sublicense to such third party to develop and commercialize Products under specified terms, then prior to entering into any discussions or negotiations with any third party in relation to such a transaction, the Company shall provide written notice to Acelyrin of such intent or receipt of proposal. Acelyrin shall have the right to negotiate with the Company the terms for a definitive agreement with respect to such sale, transfer or grant of the rights to Products for a specified period of time. If Acelyrin does not exercise its right to negotiate or the parties are unable to agree on the terms of a definitive agreement, the Company shall have the right to negotiate or enter into an agreement with a third party with respect to such transaction, subject to specified conditions.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company may not sell, assign or transfer all or substantially all of the rights to develop or commercialize a Product unless, as a condition to such sale, assignment or transfer, the purchaser, assignee or transferee (as applicable) assumes in writing all of our obligations as set forth in the Asset Purchase Agreement with respect to the applicable Products.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records expense related to milestone payments when achievement of the milestone is assessed as probable. As of December 31, 2025, the Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recorded expense related to milestone payments under the Asset Purchase Agreement. On December 31, 2025, the Company filed a complaint in Delaware Superior Court against Alumis Inc. and its wholly owned subsidiary, Acelyrin, relating to a dispute concerning the Asset Purchase Agreement as further described below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">CRH Agreement</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Asset Purchase Agreement, in January 2024 Tenet was assigned a license agreement with CRH and, in connection with such assignment, Tenet entered into an amended and restated license agreement with CRH (the CRH Agreement) which was subsequently transferred to the Company by operation of law upon the closing of the Acquisition. The CRH Agreement granted the Company a worldwide exclusive license (other than specified patent rights and materials, which are licensed to the Company on a non-exclusive basis) under certain know-how, patents and materials, or the licensed rights, to research, develop, test, manufacture or sell certain licensed products related to budoprutug, for all therapeutic uses except for oncology indications. The Company is permitted to grant a sublicense under these licenses with CRH&#8217;s prior written consent. CRH retains, on behalf of itself and the charitable company Cancer Research U.K., a worldwide, fully paid-up, perpetual and irrevocable right in the licensed rights and in certain intellectual property owned or controlled by the Company that is necessary to exploit the licensed products and used, conceived or generated in the course of exercising the license or exploiting any licensed product, or product-specific foreground intellectual property, for the purpose of non-commercial, non-clinical scientific research.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is obligated to use commercially reasonable efforts to perform all activities set forth in a mutually agreed-upon development plan within the timelines set forth therein. The Company is also obligated to develop at least one licensed product in an autoimmune indication and to pursue worldwide regulatory authorization for licensed products. The Company must use commercially reasonable efforts to commercialize each licensed product throughout each of the specified major markets as soon as practicable following receipt of regulatory authorization for such product in such market. Additionally, the Company must use commercially reasonable efforts to make the licensed product available through the U.K. and negotiate with relevant regulatory authorities to make each licensed product available through the National Health Service in England and Wales within a specified time of the licensed product being made available elsewhere in the territory. If the Company fails to meet one or more of these diligence obligations, and such failure is not remedied within the specified cure period, CRH shall have the right to terminate the CRH Agreement with respect to the relevant licensed product.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is obligated to pay CRH a mid-five figure digit fee on each anniversary of the effective date. The Company is obligated to pay up to an aggregate of &#163;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">106.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">143.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of December 31, 2025) upon the achievement of specified development, regulatory, commercial and sales milestone events, including: (i) payments of up to mid-six figure digits in pounds sterling for certain development milestones, (ii) payments of up to low-eight figures in pounds sterling per indication (for up to three indications) for certain regulatory and commercial milestones and (iii) payments up to mid-eight figures in pounds sterling for certain sales milestones. The Company is also obligated to pay tiered royalties ranging from a rate in the mid-single digit to high-single digit percentage on net sales. The royalty term continues for each licensed product on a country-by-country basis beginning on the first commercial sale of such licensed product and ending on the latest of (a) the date when such licensed product is no longer covered by a valid claim of a licensed patent in such country, (b) the expiration of the exclusivity period for such licensed product in such country, and (c) the tenth anniversary of the first commercial sale of such licensed product in such country. The Company is also responsible for a sublicensing revenue payment ranging from a rate in the mid-single digit to mid-double digits for any sublicense revenue.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CRH Agreement shall remain in effect in each country in the territory until the expiry of our obligation to pay royalties in such country. Either party may terminate the CRH Agreement if the other party is in material breach that has not been remedied within the specified cure period or if the other party becomes insolvent. CRH also has the right to terminate the CRH Agreement if the Company or one of its sublicensees or affiliates challenges a licensed patent, or if the Company is acquired by a tobacco company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records expense related to milestone payments when achievement of the milestone is assessed as probable. During the year ended December 31, 2025, the Company recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of research and development expense related to the milestones.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ProBioGen Agreement</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Asset Purchase Agreement, Tenet was assigned a cell line development, manufacturing services and license agreement (the ProBioGen Agreement) originally entered into by ValenzaBio, Inc. and ProBioGen in February 2021, which was subsequently transferred to the Company by operation of law upon the closing of the Acquisition. The ProBioGen Agreement granted the Company a non-exclusive license under certain know-how, patents and materials, to use cell lines in which ProBioGen&#8217;s proprietary technology is applied, to research, develop, manufacture, use, sell, offer to sell, import or export budoprutug. This license includes a non-exclusive sublicense by ProBioGen of certain third-party patent rights, limited to the use of budoprutug.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is obligated to (i) make payments of up to &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of December 31, 2025) upon the achievement of certain development, manufacturing and commercial milestones, including the start of a Phase 2 clinical trial for budoprutug, and (ii) make milestone payments of up to &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of December 31, 2025) upon the achievement of certain sales milestones. If the Company elects to contract ProBioGen to perform certain manufacturing services for budoprutug, the milestone payments would be reduced by &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of December 31, 2025).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ProBioGen Agreement will remain in effect until the services are completed for the service-related component and until the payment obligations expire in connection with the commercial license component. Both parties have the right to terminate the ProBioGen Agreement if the other party becomes insolvent, or materially breaches the ProBioGen Agreement and fails to remedy such default within the specified cure period.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records expense related to milestone payments when achievement of the milestone is assessed as probable. During the year ended December 31, 2025, the Company recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of research and development expense related to the milestones.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License Agreement (CLYM116)</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 8, 2025, the Company entered into the Mabworks Agreement, pursuant to which Mabworks granted to the Company (i) an exclusive (even as to Mabworks and its affiliates), sublicensable right and license under certain patent rights and related know-how (the Licensed Intellectual Property) to develop, manufacture and commercialize Mabworks&#8217; proprietary antibodies associated with Mabworks&#8217; proprietary antibody program, identified as MIL116 (the Licensed Compounds or CLYM116) and products containing the Licensed Compounds (Licensed Products) outside of Greater China (the Licensed Territory), (ii) a non-exclusive, sublicensable right and license under the Licensed Intellectual Property to manufacture the Licensed Compounds and Licensed Products in Greater China and (iii) a non-exclusive, sublicensable right and license under the Licensed Intellectual Property to develop the Licensed Compounds and Licensed Products in the Greater China in connection with certain global clinical studies (as described below).</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the Mabworks Agreement, the Company paid to Mabworks a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upfront payment, and the Company is obligated to pay a total of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon the achievement of certain development and regulatory milestones pertaining to the first indication for a Licensed Product, additional lower amounts upon the achievement of certain development and regulatory milestones pertaining to up to two additional indications for a Licensed Product and a total of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">832.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">upon the achievement of certain commercial milestones for all Licensed Products. In addition, the Company is obligated to pay Mabworks tiered royalties in the low-to mid-single-digit percentages on aggregate annual net sales of all Licensed Products in the Licensed Territory. The Company is obligated to pay royalties on a Licensed Product-by-Licensed Product and country-by-country basis from the date of the first commercial sale in such country until the latest of: (i) the expiration of the last valid claim on the Licensed Intellectual Property covering the composition of matter of the Licensed Compound in such Licensed Product in such country; and (ii) ten years following the first commercial sale of such Licensed Product in such country (each, a Royalty Term). The royalty rate is subject to reduction on a Licensed Product-by-Licensed Product and country-by-country basis under certain circumstances. In the event that the Company grants sublicenses under the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licensed </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intellectual Property, the Company will be obligated to pay Mabworks a percentage, in the mid-single-digits to low-double-digits, of certain consideration received under such sublicenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company agreed to use commercially reasonable efforts to develop, obtain regulatory approval for and commercialize a Licensed Product in the U.S. The Company has also granted Mabworks a right of first refusal to develop and commercialize in Greater China any product the Company controls that contains an antibody directed to tumor necrosis factor ligand superfamily member 13 (APRIL). Mabworks has agreed not to exploit in the Licensed Territory any product that is directed to APRIL during the term of the Mabworks Agreement. The Mabworks Agreement also contains a mechanism for the parties to collaborate on global clinical studies in the future, where the Company has a right to perform clinical studies in Greater China with Mabworks&#8217; approval in the event that Mabworks elects not to participate in such global clinical studies. Unless earlier terminated, the Mabworks Agreement will expire on the expiration of the last to expire Royalty Term. Either party may terminate the Mabworks Agreement for the other party&#8217;s material breach, following a customary notice and cure period, or insolvency. Additionally, the Company may terminate the Mabworks Agreement for any reason upon 60 days written notice to Mabworks.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recorded the upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as research and development expenses in the first quarter of 2025 in the consolidated statements of operations and comprehensive loss. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records expense related to milestone payments when achievement of the milestone is assessed as probable. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2025, the Company recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of research and development expense related to a milestone.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Legal Proceedings</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of its business activities. The Company records accruals for estimated losses when available information indicates a loss is probable and reasonably estimable. Significant judgment is required to determine both probability and the estimated amount. The Company expenses the costs related to its legal proceedings as they are incurred.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 31, 2025, the Company filed a complaint in Delaware Superior Court against Alumis Inc. and its wholly owned subsidiary, Acelyrin, relating to a dispute concerning the Asset Purchase Agreement seeking a declaratory judgment that the Company&#8217;s budoprutug drug candidate is not a Product under the Asset Purchase Agreement, and that the Company does not owe a milestone payment sought by Alumis in connection with its development of budoprutug. This matter is currently pending. The Company is unable to predict the timeline for resolution or the outcome of this matter.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of the date of these consolidated financial statements, the Company is not party to any other material legal matters or claims.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Indemnification</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless, and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third-party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the Company has entered into indemnification agreements with members of its board of directors and executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. To date, the Company has not incurred any material costs as a result of such indemnification provisions. The Company is not currently aware of any indemnification claims and has not accrued any liabilities related to such obligations in its consolidated financial statements as of December 31, 2025.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 9.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-Based Compensation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2019 and 2021 Equity Incentive Plans</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has outstanding awards under its 2019 Equity Incentive Plan (the 2019 Plan), but is no longer granting awards under this plan. The Company&#8217;s 2021 Equity Incentive Plan (the 2021 Plan and, together with the 2019 Plan, the Plans) provides for the grant of incentive stock options, non-statutory stock options, restricted stock awards, restricted stock units (RSUs), stock appreciation rights and other stock-based awards to the Company&#8217;s employees, officers, directors and consultants. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any shares that are returned under the 2019 Plan as a result of cancellation or forfeiture become available for grant under the 2021 Plan. Further, the number of shares of common stock reserved for issuance under the 2021 Plan automatically increases on January 1 of each year continuing through and including January 1, 2031, by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of the total number of shares of common stock outstanding on December 31 of the immediately preceding calendar year, or a lesser number of shares</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">determined </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">by the Company&#8217;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s board of directors. The number of authorized shares reserved for issuance under the 2021 Plan was increased by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,362,771</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares effective as of January 1, 2025 in accordance with the provisions of the 2021 Plan described above. As of December 31, 2025, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,124,834</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares remained available for future grant under the 2021 Plan. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The number of shares reserved for issuance under the 2021 Plan was increased by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,388,316</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares effective January 1, 2026.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the 2021 Plan, options are granted at an exercise price no less than fair value of the Company&#8217;s common stock on the grant date, except in certain cases related to significant corporate transactions. Options expire no later than </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the date of the grant.</span></span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2025 Inducement Plan</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2025, the Company&#8217;s board of directors adopted the 2025 Inducement Plan (the Inducement Plan), pursuant to which the Company may grant nonstatutory stock options, stock appreciation rights, restricted stock awards, RSUs and other stock-based awards with respect to an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,250,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock. Awards under the Inducement Plan may only be granted to new employees who were not previously an employee or director of the Company or are commencing employment with the Company following a bona fide period of non-employment, in either case, as an inducement material to the individual&#8217;s entering into employment with the Company in accordance with the requirements of Nasdaq Stock Market Rule 5635(c)(4). On September 30, 2025, the Company&#8217;s board of directors approved an amendment to the Inducement Plan to increase the number of shares of common stock authorized for issuance under the Inducement Plan by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">750,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares remained available for issuance under the Inducement Plan.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Employee Stock Purchase Plan</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s 2021 Employee Stock Purchase Plan (the ESPP) allows employees, including executive officers, to contribute up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of their earnings, subject to certain limitations, for the purchase of the Company&#8217;s common stock at a price per share equal to the lower of (a) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the fair market value of a share of common stock on the first day of the offering period, or (b) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the fair market value of a share of common stock on the last day of the offering period. The number of shares of common stock reserved for issuance under the ESPP automatically increases on January 1 of each calendar year through and including January 1, 2031, by the lesser of (1) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the total number of shares of the Company&#8217;s common stock outstanding on December 31 of the preceding calendar year or (2) a number of shares determined by the Company&#8217;s board of directors. Shares subject to purchase rights granted under the ESPP that terminate without having been exercised in full will not reduce the number of shares available for issuance under the ESPP. The number of authorized shares reserved for issuance under the ESPP was increased by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">672,554</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares effective as of January 1, 2025 in accordance with the provisions of the ESPP described above. The first offering period began on December 16, 2025 and will end on June 15, 2026. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares had been granted or purchased under the ESPP and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,736,779</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares remained available for issuance under the ESPP. The number of shares reserved for issuance under the ESPP was increased by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">477,663</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares effective January 1, 2026. </span></span><span style="font-size:10pt;font-family:Times New Roman;"></span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Option Valuation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of stock option grants is estimated on the date of grant using the Black Scholes option pricing model. Volatility is estimated based on the historical and implied volatilities of comparable publicly traded companies as the Company does not have sufficient history of trading in its common stock. The expected term of the Company&#8217;s stock options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The relevant data used to determine the fair value of the stock option grants during the years ended December 31, 2025 and 2024 is as follows, presented on a weighted-average basis:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:62.72%;box-sizing:content-box;"></td>
         <td style="width:1.6%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.04%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.6%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.04%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.0</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.1</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">103.6</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Option Activity</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outstanding stock options consist of option grants with service-based vesting conditions, typically </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% on the first anniversary of the grant date with the remainder vesting monthly over the following </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The activity for stock options is as follows:</span></span></p><div style="font-size:10pt;font-family:Times New Roman;">
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:47.26%;box-sizing:content-box;"></td>
         <td style="width:2.06%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.02%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.54%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.02%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.06%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.48%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.54%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.02%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Average</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Average</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">of</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exercise</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Contractual</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Intrinsic</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Price</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Term</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,817,751</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.49</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.87</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options granted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,766,696</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.77</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,341</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.04</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options forfeited</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,135,329</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.85</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,427,777</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.81</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.05</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,727</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested and expected to vest as of December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,427,777</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.81</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.05</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,727</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercisable as of December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">631,921</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.24</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.00</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">331</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate intrinsic value disclosed in the above table is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock for those stock options that had strike prices lower than the fair value of the Company&#8217;s common stock. The aggregate intrinsic value of options exercised during the years ended December 31, 2025 and 2024 was less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted-average grant date fair value of stock options granted duri</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ng the years ended December 31, 2025 and 2024 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.45</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.56</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, respectively.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Stock Units</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has outstanding RSUs with service-based vesting conditions and RSUs with performance-based vesting conditions. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The activity for RSUs is as follows:</span></span></p><div style="font-size:10pt;font-family:Arial;">
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:63.113%;box-sizing:content-box;"></td>
         <td style="width:2.921%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.223%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:3.381%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.362%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average Grant Date Fair Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested at December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,228,876</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.17</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,084</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.62</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">929,563</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.27</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">92,500</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.44</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested at December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">207,897</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.50</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total fair value of restricted stock vested during the years ended December 31, 2025 and 2024 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-Based Compensation</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth stock-based compensation expense included in the Company&#8217;s consolidated statements of operations and comprehensive loss (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:62.695%;box-sizing:content-box;"></td>
         <td style="width:2.079%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.574%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.079%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.574%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,503</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,032</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,551</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,525</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,054</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,557</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense for the year ended December 31, 2025 included </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million related to performance-based RSUs that vested in the third quarter of 2025 upon achievement of the performance conditions. As of December 31, 2025, ther</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">e was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million o</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">f total unrecognized compensation cost related to unvested awards expected to vest, which is expected to be recognized over a weighted average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.9</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 10. Net Loss Per Share</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic and diluted net loss per share are computed using the weighted-average number of shares of common stock outstanding for the period. The Company issued a pre-funded warrant in December 2025 (see Note 6). The shares of common stock underlying the pre-funded warrant are included in the calculation of basic and diluted net loss per share because they are considered shares issuable for little or no consideration under ASC 260, Earnings Per Share. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table shows the computation of basic and diluted net loss per share (in thousands, except share and per share data):</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:64.307%;box-sizing:content-box;"></td>
         <td style="width:2.1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.077%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:3.439%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.077%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59,851</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73,897</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Weighted-average common shares outstanding, basic <br/>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66,692,145</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,163,301</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Weighted-average common shares outstanding under the <br/>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;pre-funded warrant, basic and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,120,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Weighted-average common shares outstanding, basic <br/>&#160;&#160;&#160;&#160;&#160;&#160;&#160;and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67,812,145</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,163,301</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Net loss per share, basic and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.88</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.53</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share for the periods presented because their effect would have been anti-dilutive:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:64.32%;box-sizing:content-box;"></td>
         <td style="width:1.64%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.54%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.96%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.54%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options to purchase common stock</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,427,777</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,817,751</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested restricted stock units</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">207,897</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,228,876</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares of common stock issuable under <br/>&#160;&#160;&#160;the ESPP</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,944</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total potentially dilutive shares</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,659,618</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,046,627</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 11. Income Taxes</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of net loss before tax provision from income taxes are as follows (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:64.387%;box-sizing:content-box;"></td>
         <td style="width:2.1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.537%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.44%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.537%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">United States</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59,579</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67,137</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">United Kingdom</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">272</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,760</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59,851</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73,897</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents a reconciliation of the Company&#8217;s expected tax computed at the U.S. statutory federal income tax rate to the total provision for income taxes (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:62.873%;box-sizing:content-box;"></td>
         <td style="width:2.04%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.163%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.38%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.163%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.38%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. federal taxes at statutory rate</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,569</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,518</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;State taxes, net of federal benefit</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Acquired in-process research and development, related party</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,698</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Effect of cross-border transfers</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,303</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Non-deductible officer compensation</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">293</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">575</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Foreign rate differential</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">237</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">211</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Stock-based compensation</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">83</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">588</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Tax credits</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">403</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Other expenses, net</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">228</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">123</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Change in valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,284</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,076</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effective income tax rate</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The significant components of the Company</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;s deferred tax assets and liabilities are presented below (in thousands):</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:64.387%;box-sizing:content-box;"></td>
         <td style="width:2.1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.537%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.44%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.537%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Net operating losses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,202</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,725</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Intangible assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,447</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,946</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Research and development expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,824</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,388</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Stock compensation expense, including 162m limitations</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,400</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">432</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Research credits</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,104</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">702</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Accrued compensation and benefits</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">332</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">303</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Operating lease liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">113</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">121</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Other expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total deferred tax assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,459</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,630</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,368</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,492</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Net deferred tax assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">91</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">138</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Operating lease, right-of-use asset</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">106</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">112</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Other assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total deferred tax liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">91</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">138</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred tax assets and liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, the Company had federal net operating loss carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which may be available to offset future taxable income and do not expire but are limited in their usage to an annual deduction equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of annual taxable income. As of December 31, 2025, the Company had state net operating loss carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which may be available to offset future taxable income and expire at various dates beginning in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2038</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As of December 31, 2025, the Company also had U.S. federal and state research and development tax credit carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, which may be available to offset future tax liabilities and expire at various dates beginning in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2039</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As of December 31, 2025, the Company had foreign net operating loss carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which may be available to offset future taxable income and do not expire.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Utilization of the U.S. federal and state net operating loss carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Sections 382 and 383 of the Internal Revenue Code of 1986, and corresponding provisions of state law, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income or tax liabilities. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50% over a three-year period. The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception due to the significant complexity and cost associated with such a study. If the Company has experienced a change of control, as defined by Section 382, at any time since inception, utilization of the net operating loss carryforwards or research and development tax credit carryforwards would be subject to an annual limitation under Section 382, which is determined by first multiplying the value of the Company&#8217;s stock at the time of the ownership change by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before utilization. Further, until a study is completed by the Company and any limitation is known, no amounts are being presented as an uncertain tax position.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As required by ASC 740, management of the Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets, which are comprised principally of net operating loss carryforwards. Management has determined that it is more likely than not that the Company will not recognize the benefits of its deferred tax assets and, as a result, a valuation allowance has been recorded.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The changes in the valuation allowance were as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:64.387%;box-sizing:content-box;"></td>
         <td style="width:2.1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.537%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.44%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.537%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance as of beginning of year</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,492</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,856</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Net increases recorded to income tax provision</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,876</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,636</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance as of end of year</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,368</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,492</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The increase in the valuation allowance for deferred tax assets during the year ended December 31, 2025 related primarily to an increase in net operating losses. The increase in the valuation allowance for deferred tax assets during the year ended December 31, 2024 related primarily to increases in net operating losses and capitalized research and development costs.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company assesses the uncertainty in its income tax positions to determine whether a tax position of the Company is more likely than not to be sustained upon examination, including resolution of any related appeals of litigation processes, based on the technical merits of the position. For tax positions meeting the more-likely-than-not threshold, the tax amount recognized in the consolidated financial statements is reduced by the largest benefit that has a greater than fifty percent likelihood of being realized upon the ultimate settlement with the relevant taxing authority. No reserve for uncertain tax positions or related interest and penalties has been recorded at December 31, 2025 and 2024.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is subject to taxation in the U.S. (federal and various states) and the U.K. Currently, no historical years are under examination. The Company&#8217;s tax years starting in December 31, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_1ed21085-1747-4238-9882-f67da405f9c3;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2018</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> are open and subject to examination by the U.S. (federal and various states) and the U.K. taxing authorities due to the carryforward of utilized net operating losses and research and development credits.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined Contribution Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanTextBlock', window );">Defined Contribution Plan</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 12. Defined Contribution Plans</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.204%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has a 401(k) defined contribution plan. Participation in the plan is available to substantially all U.S.-based employees. Company contributions are discretionary but the Company has an employer matching program pursuant to which the Company makes matching contributions of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of each participating employee&#8217;s eligible compensation. For the years ended December 31, 2025 and 2024, total expense recognized from the 401(k) matching contributions was approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to the Company's restructuring in 2024 (see Note 13), the Company had a workplace pension contribution scheme for U.K.-based employees. For the year ended December 31, 2024, the Company made contributions to the pension scheme of approximatel</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">y $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (m)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (r)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 715<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477317/912-715-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Costs<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring Costs</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 13. Restructuring Costs</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2024, the Company shifted its focus from developing therapeutics for neuronal excitability disorders to immune-mediated diseases. In connection with this shift, the Company ceased its operations in the U.K. and separated from seven U.K. employees in 2024. The costs associated with this headcount reduction were fully recognized and all of the related payments were made by December 31, 2024. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A summary of the restructuring costs recorded in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2024 were as follows (in thousands):</span></span></p><div style="font-size:10pt;font-family:Times New Roman;">
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:34.227%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.683%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.683%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:16.203%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:16.203%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="11" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">ROU Asset <br/>Impairment</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Severance and  <br/>Benefit Costs</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Stock-based<br/>Compensation</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total<br/>Restructuring<br/>Cost Recorded</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,778</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">944</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,722</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">475</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">161</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">636</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total restructuring costs</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,253</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,105</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,358</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/420/tableOfContent<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 14. Segments</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker (the CODM). The Company views its operations and manages its business as </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating and reportable segment, focused on developing therapeutics for patients with immune-mediated diseases. The Company&#8217;s CODM is its </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_486ead36-778f-4db7-a0cb-c45b1a00e08c;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">chief executive officer</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Segment profit or loss is measured as net loss presented in the consolidated statements of operations and comprehensive loss. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the purpose of evaluating segment performance and allocating resources, the CODM reviews the Company&#8217;s financial information on a consolidated basis together with certain operating metrics and evaluates net loss against comparable prior periods and the Company&#8217;s annual operating plan. The measure of segment assets is reported on the consolidated balance sheets as total consolidated assets.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:11pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the significant expense categories included within net loss presented on the consolidated statements of operations and comprehensive loss, the following table sets forth disaggregated research and development expenses (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:65.513%;box-sizing:content-box;"></td>
         <td style="width:1.92%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.323%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.92%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.323%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Direct research and development expenses:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Budoprutug</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,045</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,982</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">CLYM116</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">1</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,964</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Legacy programs</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">2</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">201</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unallocated research and development expenses:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel-related (including stock-based compensation)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,232</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,990</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other research and development expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,365</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">163</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total research and development expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,713</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,336</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3.35pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.695pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes the upfront payment and the associated direct transaction costs incurred in connection with the Mabworks Agreement for the year ended December 31, 2025.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.695pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes direct expenses related to the Company's legacy product candidates ETX-123 and ETX-155.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of Presentation and Principles of Consolidation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (U.S. GAAP). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Update (ASU) of the Financial Accounting Standards Board (FASB).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying consolidated financial statements reflect the operations of the Company and its wholly owned subsidiaries. Intercompany transactions and balances have been eliminated in consolidation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of Presentation and Principles of Consolidation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (U.S. GAAP). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Update (ASU) of the Financial Accounting Standards Board (FASB).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying consolidated financial statements reflect the operations of the Company and its wholly owned subsidiaries. Intercompany transactions and balances have been eliminated in consolidation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesInEntitysBusiness', window );">Risks and Uncertainties</a></td>
<td class="text">Risks and UncertaintiesThe Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, reliance on single-source suppliers and manufacturers, availability of raw materials, patentability of the Company&#8217;s product candidates and processes and clinical efficacy and safety of the Company&#8217;s product candidates, compliance with government regulations and the need to obtain additional financing to fund operations. Budoprutug, CLYM116, or any product candidate the Company may develop will require significant additional research and development efforts, including extensive nonclinical studies, clinical trials, and regulatory approval, prior to commercialization. These efforts will require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance and reporting.There can be no assurance that any future research and development will be successfully completed, that adequate protection for the Company&#8217;s intellectual property will be obtained or maintained, that any product candidate developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if any future product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales. The Company operates in an environment of rapid technological change and substantial competition from other pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and other third parties.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts and disclosures. Accordingly, actual results could differ from those estimates. Key management estimates include those related to the accrual of research and development expenses and the valuation of stock-based awards. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Foreign Currency</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s reporting currency is the U.S. dollar. The functional currency of the Company and its subsidiaries is the U.S. dollar. Monetary assets and liabilities resulting from transactions denominated in currencies other than the functional currency are remeasured in the functional currency at exchange rates prevailing at the balance sheet date, and income items and expenses are translated into U.S. dollars at the average exchange rate in effect during the period. Exchange gains and losses resulting from remeasurement and foreign currency transactions are included in the determination of net loss.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Information</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. Significantly all of the Company&#8217;s tangible assets are held in the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk and Significant Suppliers and Manufacturers</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Concentration of Credit Risk </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">and Significant Suppliers and Manufacturers</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company maintains its cash and cash equivalents at accredited financial institutions that may, at times, exceed federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company&#8217;s investments in money market funds and marketable securities are held in segregated accounts at a third-party custodian. The Company has established guidelines relative to credit ratings and maturities intended to safeguard principal balances and maintain liquidity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is dependent on third-party suppliers and manufacturers for material used in its nonclinical and clinical development activities. In particular, the Company relies and expects to continue to rely on single-source suppliers and manufacturers to supply it with certain critical materials related to the Company&#8217;s product candidates. The Company&#8217;s development efforts could be adversely affected if a supplier or manufacturer is unable to successfully carry out its contractual obligations or meet expected deadlines. If a supplier or manufacturer needs to be replaced, the Company may not be able to complete its product development on its anticipated timelines and may incur additional expenses as a result.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company considers all highly liquid investments with maturities of three months or less from the purchase date to be cash equivalents.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Marketable Securities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company classifies its marketable securities as available-for-sale. Marketable securities with remaining maturities of less than one year from the balance sheet date are classified as short-term marketable securities. Marketable securities with remaining maturities of greater than one year from the balance sheet date are classified as long-term marketable securities. The Company reports available-for-sale investments at fair value as of each balance sheet date and records unrealized gains or losses as a component of stockholders&#8217; equity in accumulated other comprehensive income (loss). Realized gains and losses of securities sold are determined on a specific identification basis and included in other income (expense) within the consolidated statements of operations and comprehensive loss.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When the fair value is below the amortized cost of a marketable security, the Company estimates the portion of the unrealized loss that relates to credit</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The credit-related impairment amount is recorded in other income (expense) in the consolidated statements of operations and comprehensive loss. Credit losses are recognized through the use of an allowance for credit losses account in the consolidated balance sheet and subsequent improvements in expected credit losses are recorded as a reversal of an amount in the allowance account. If the Company intends to sell the security or it is more likely than not that the Company will be required to sell the security prior to recovery of its amortized cost basis, then the allowance for the credit loss, if any, is written-off and the excess of the amortized cost basis of the asset over its fair value is recognized in other income (expense) in the consolidated statements of operations and comprehensive loss. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> credit losses recorded during the years ended December 31, 2025 and 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1&#8212;Quoted prices in active markets for identical assets or liabilities. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2&#8212;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. </span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s cash equivalents and marketable securities are carried at fair value, determined according to the fair value hierarchy (see Note 4). The carrying values of the Company&#8217;s accounts payable and accrued expenses approximate their fair values due to the short-term nature of these liabilities.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comprehensive Loss</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprehensive loss includes net loss as well as other changes in stockholders&#8217; equity that result from transactions and economic events other than those with stockholders. The Company&#8217;s only element of other comprehensive income (loss) is unrealized gains and losses on available-for-sale marketable securities.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Asset Acquisitions</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Asset Acquisitions</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In determining whether an acquisition of assets and related liabilities should be accounted for as a business combination or asset acquisition, the Company first determines whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets. If this is the case, the single identifiable asset or the group of similar assets is not deemed to be a business and the acquisition is accounted for as an asset acquisition. If this is not the case, the Company then further evaluates whether the acquisition includes, at a minimum, an input and a substantive process that together significantly contribute to the ability to create outputs. If so, the Company concludes that the acquisition is a business and accounts for it as a business combination.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the asset or group of assets, which includes transaction costs, allocated on a relative fair value basis. Goodwill is not recognized in asset acquisitions. In an asset acquisition, the cost allocated to acquire in-process research and development (IPR&amp;D) with no alternative future use is charged to expense at the acquisition date.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property and Equipment</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:0.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;margin-right:0.13%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful life of each asset.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
         <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
          <tr style="visibility:collapse;">
           <td style="width:59.18%;box-sizing:content-box;"></td>
           <td style="width:2.88%;box-sizing:content-box;"></td>
           <td style="width:37.94%;box-sizing:content-box;"></td>
          </tr>
          <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated Useful Life</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
           <td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5 </span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">years</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
           <td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="-sec-ix-hidden:F_2a7e8018-774a-4c44-8376-7e8c696ec434;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shorter of remaining life of lease or useful life</span></span></span></p></td>
          </tr>
         </table></div><p style="margin-left:0.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When an item is sold or retired, the costs and related accumulated depreciation are eliminated, and the resulting gain or loss, if any, is credited or charged to operating loss in the consolidated statements of operations and comprehensive loss. Repairs and maintenance costs are expensed as incurred.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for leases under ASC Topic 842, Leases (&#8220;ASC 842&#8221;). In accordance with ASC 842, the Company accounts for a contract as a lease when it has the right to control the asset for a period of time while obtaining substantially all of the asset&#8217;s economic benefits. The Company determines if an arrangement is a lease or contains an embedded lease at inception. For arrangements that meet the definition of a lease, the Company determines the initial classification and measurement of its right-of-use asset and lease liability at the lease commencement date and thereafter if modified. The lease term includes any renewal options that the Company is reasonably assured to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its estimated secured incremental borrowing rate for that lease term. The Company&#8217;s policy is to not record leases with an original term of 12 months or less on its consolidated balance sheets and recognizes those lease payments in the income statement on a straight-line basis over the lease term. The Company&#8217;s existing lease is for office space.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to rent, leases may require the Company to pay additional costs, such as utilities, maintenance and other operating costs, which are generally referred to as non-lease components. The Company has elected to not separate lease and non-lease components. Only the fixed costs for lease components and their associated non-lease components are accounted for as a single lease component and recognized as part of a right-of-use asset and lease liability. Rent expense for operating leases is recognized on a straight-line basis over the reasonably assured lease term based on the total lease payments and is included in operating expense in the consolidated statements of operations and comprehensive loss.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Long-Lived Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Long-Lived Assets</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Long-lived assets consist of property and equipment and right-of-use assets.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company reviews the recoverability of its long-lived assets, including the related useful lives, whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset might not be recoverable, based on undiscounted cash flows. If such assets are considered to be impaired, an impairment loss is recognized and is measured as the amount by which the carrying amount of the assets exceed their estimated fair value, which is measured based on the projected discounted future net cash flows arising from the assets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses consist of costs incurred in performing research and development activities, including salaries and bonuses, stock-based compensation, employee benefits, termination benefits, facilities costs and depreciation, and external costs of vendors engaged to conduct research, nonclinical and clinical development activities as well as the cost of acquiring and licensing technology.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upfront payments and milestone payments made for the licensing of technology are expensed as research and development over the period to which they relate. Costs for research and development activities are expensed in the period in which they are incurred. Payments for such activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid expense or accrued research and development expense. Determining the prepaid and accrued balances at the end of any reporting period incorporate certain judgments and estimates by management that are based on information available to the Company including information provided by vendors regarding the progress to completion of specific tasks or costs incurred.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Patent costs</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent costs</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All patent-related costs incurred in connection with filing and prosecuting patent applications are recorded as general and administrative expenses as incurred.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-Based Compensation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company measures its stock options with service-based vesting or performance-based vesting granted to employees, non-employee directors, consultants and independent advisors based on the estimated fair value on the date of grant using the Black-Scholes option-pricing model. The Company measures compensation expense for restricted common stock units based on the fair value on the date of grant using the market value of the Company&#8217;s common stock. Compensation expense for the awards is recognized over the requisite service period for employees and directors and as services are delivered for consultants and independent advisors, both of which are generally the vesting period of the respective award. The Company uses the straight-line method to record the expense of awards with only service-based vesting conditions. The Company uses the graded-vesting method to record the expense of awards with both service-based and performance-based vesting conditions, commencing once achievement of the performance condition becomes probable. The Company accounts for forfeitures of share-based awards as they occur.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company classifies stock-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#8217;s payroll costs are classified or in which the award recipient&#8217;s service payments are classified.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#8217;s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to the provision for income taxes. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. Any resulting unrecognized tax benefits are recorded within the provision for income taxes.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Loss Per Share</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net loss per share attributable to common stockholders is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net loss per share attributable to common stockholders is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, adjusted for potential dilutive common shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In periods in which the Company reported a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company reported a net loss attributable to common stockholders for the years ended December 31, 2025 and 2024.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Pronouncements Not Yet Adopted</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU No. 2023-09 (ASU 2023-09), </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which requires, among other things, the following for public business entities: (i) enhanced disclosures of specific categories of reconciling items included in the rate reconciliation, as well as additional information for any of these items meeting certain qualitative and quantitative thresholds; (ii) disclosure of the nature, effect and underlying causes of each individual reconciling item disclosed in the rate reconciliation and the judgment used in categorizing them if not otherwise evident; and (iii) enhanced disclosures for income taxes paid, which includes federal, state, and foreign taxes, as well as for individual jurisdictions over a certain quantitative threshold. The amendments in ASU 2023-09 eliminate the requirement to disclose the nature and estimate of the range of the reasonably possible change in unrecognized tax benefits for the 12 months after the balance sheet date. The effective date of this update for non-public companies is for fiscal years beginning after December 15, 2025; early adoption is permitted. The Company expects ASU 2023-09 to require additional disclosures in the notes to its consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03 (ASU 2024-03), </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Disaggregation of Income Statement Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which requires additional disclosures about specific types of expenses included in the expense captions presented on the face of the income statement, as well as disclosures about selling expenses. The provisions of ASU 2024-03 are effective for public business entities for fiscal years beginning after December 15, 2026, and interim periods beginning after December 15, 2027. Early adoption is permitted. The guidance is to be applied prospectively, with the option for retrospective application. The Company is currently evaluating the impact of ASU 2024-03 on its consolidated financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479405/805-10-25-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesInEntitysBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the risk factors inherent in the entity's business, excluding risks associated with certain significant estimates or concentration risks.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesInEntitysBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-4<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clym_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock', window );">Schedule of Property and Equipment Estimated Useful Life</a></td>
<td class="text"><p style="margin-left:0.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;margin-right:0.13%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful life of each asset.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
         <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
          <tr style="visibility:collapse;">
           <td style="width:59.18%;box-sizing:content-box;"></td>
           <td style="width:2.88%;box-sizing:content-box;"></td>
           <td style="width:37.94%;box-sizing:content-box;"></td>
          </tr>
          <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated Useful Life</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
           <td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5 </span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">years</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
           <td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="-sec-ix-hidden:F_2a7e8018-774a-4c44-8376-7e8c696ec434;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shorter of remaining life of lease or useful life</span></span></span></p></td>
          </tr>
         </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clym_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the estimated useful life of physical assets used in the normal conduct of business and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clym_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clym_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Asset Acquisition and Private Placement with a Related Party (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combination [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Summary of Purchase Consideration For The Acquisition Based On The Fair Value Of The Net Assets Acquired By The Company</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth the allocation of the purchase consideration (in thousands):</span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:86.24%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.76%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Assets acquired</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;In-process research and development</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">51,659</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Cash and cash equivalents</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,204</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Prepaid expenses and other current assets</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,861</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets acquired</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54,724</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Liabilities assumed</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Accounts payable</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,603</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Accounts payable, related party</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Accrued expenses and other current liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">192</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Accrued expenses, related party</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities assumed</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,972</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net assets acquired</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52,752</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of business combination. Includes, but is not limited to, recognized asset and liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-41<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities and Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Marketable Securities Consisted of Available-for-Sale Securities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketable securities consisted of available-for-sale securities as follows (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:52.899%;box-sizing:content-box;"></td>
         <td style="width:1.879%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:7.897%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.879%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:7.897%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.879%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:7.897%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.879%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:7.897%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8197;&#8197;&#8197;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cost</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gain</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Loss</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term marketable securities:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,874</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,976</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,296</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">123</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,419</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total short-term marketable securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,170</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">225</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,395</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Long-term marketable securities:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,341</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">177</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,518</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,022</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,054</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency debt securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,999</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total long-term marketable securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59,362</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">210</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59,572</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:52.899%;box-sizing:content-box;"></td>
         <td style="width:1.879%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:7.897%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.879%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:7.897%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.879%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:7.897%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.879%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:7.897%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8197;&#8197;&#8197;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cost</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gain</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Loss</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term marketable securities:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,519</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,537</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,130</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,153</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total short-term marketable securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,649</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,690</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Long-term marketable securities:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,982</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,955</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,146</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,154</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency debt securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,500</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,501</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total long-term marketable securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61,628</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">58</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61,610</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables present information about the Company&#8217;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:54.489%;box-sizing:content-box;"></td>
         <td style="width:1.94%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:7.439%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.94%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:7.439%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.94%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:7.439%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.94%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:7.439%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value Measurements at December 31, 2025 Using:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Assets:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,320</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,320</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,473</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,473</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82,494</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82,494</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency debt securities</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:25pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:4.627%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total marketable securities</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,473</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85,494</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">124,967</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74,793</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85,494</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">160,287</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:54.489%;box-sizing:content-box;"></td>
         <td style="width:1.94%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:7.439%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.94%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:7.439%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.94%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:7.439%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.94%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:7.439%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value Measurements at December 31, 2024 Using:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Assets:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85,612</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85,612</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54,307</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54,307</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67,492</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67,492</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency debt securities</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,501</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,501</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:25pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:4.627%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total marketable securities</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54,307</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70,993</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125,300</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">139,919</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70,993</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">210,912</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:72.446%;box-sizing:content-box;"></td>
         <td style="width:2.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.598%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.598%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued payroll and related expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,891</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,997</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued external research and development expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,816</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,237</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued professional fees</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">693</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">746</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other accrued expenses and current liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,459</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,069</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease Expense</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of lease expense were as follows (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:70.12%;box-sizing:content-box;"></td>
         <td style="width:1.78%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.78%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease cost</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">250</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">243</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term lease cost</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Variable lease cost</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">259</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">329</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted-average remaining lease term and discount rate were as follows:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:70.148%;box-sizing:content-box;"></td>
         <td style="width:1.301%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.625%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.301%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.625%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average remaining lease term - operating lease (in years)</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.0</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.9</span></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average discount rate - operating lease</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.5</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.5</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Schedule of Cash Flow Information Related to Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Supplemental disclosure of cash flow information related to leases was as follows (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:70.12%;box-sizing:content-box;"></td>
         <td style="width:1.78%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.78%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for amounts included in the measurement of operating <br/>&#160;&#160;&#160;&#160;&#160;lease liabilities</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">256</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">350</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Operating lease liabilities arising from obtaining right-of-use<br/>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;asset</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">216</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">510</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Annual Future Minimum Lease Payments Due Under the Company's Non-cancelable Operating Lease</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, the annual future minimum lease payments due under the Company&#8217;s non-cancelable operating lease was as follows (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:82.44%;box-sizing:content-box;"></td>
         <td style="width:2.08%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.48%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Year ending December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">293</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">298</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Total undiscounted lease payments</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">591</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: imputed interest</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Total operating lease liabilities</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">541</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clym_ScheduleOfBalanceSheetSupplementalDisclosuresTableTextBlock', window );">Schedule Of Balance Sheet Supplemental Disclosures</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Total operating lease liabilities in the table above are classified on the consolidated balance sheet as follows (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:82.44%;box-sizing:content-box;"></td>
         <td style="width:2.08%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.48%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Included in the consolidated balance sheet (in thousands):</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current operating lease liability</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">256</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liability, net of current portion</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">285</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Total operating lease liabilities</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">541</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clym_ScheduleOfBalanceSheetSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental balance sheet information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clym_ScheduleOfBalanceSheetSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clym_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activities</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The activity for stock options is as follows:</span>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:47.26%;box-sizing:content-box;"></td>
         <td style="width:2.06%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.02%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.54%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.02%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.06%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.48%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.54%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.02%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Average</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Average</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">of</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exercise</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Contractual</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Intrinsic</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Price</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Term</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,817,751</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.49</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.87</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options granted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,766,696</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.77</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,341</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.04</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options forfeited</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,135,329</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.85</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,427,777</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.81</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.05</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,727</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested and expected to vest as of December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,427,777</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.81</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.05</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,727</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercisable as of December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">631,921</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.24</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.00</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">331</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table Text Block</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The relevant data used to determine the fair value of the stock option grants during the years ended December 31, 2025 and 2024 is as follows, presented on a weighted-average basis:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:62.72%;box-sizing:content-box;"></td>
         <td style="width:1.6%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.04%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.6%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.04%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.0</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.1</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">103.6</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of Restricted Stock Awards</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The activity for RSUs is as follows:</span>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:63.113%;box-sizing:content-box;"></td>
         <td style="width:2.921%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.223%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:3.381%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.362%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average Grant Date Fair Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested at December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,228,876</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.17</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,084</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.62</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">929,563</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.27</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">92,500</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.44</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested at December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">207,897</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.50</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total fair value of restricted stock vested during the years ended December 31, 2025 and 2024 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Share-based Compensation Expense</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth stock-based compensation expense included in the Company&#8217;s consolidated statements of operations and comprehensive loss (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:62.695%;box-sizing:content-box;"></td>
         <td style="width:2.079%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.574%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.079%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.574%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,503</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,032</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,551</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,525</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,054</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,557</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table shows the computation of basic and diluted net loss per share (in thousands, except share and per share data):</span><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:64.307%;box-sizing:content-box;"></td>
         <td style="width:2.1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.077%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:3.439%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.077%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59,851</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73,897</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Weighted-average common shares outstanding, basic <br/>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66,692,145</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,163,301</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Weighted-average common shares outstanding under the <br/>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;pre-funded warrant, basic and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,120,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Weighted-average common shares outstanding, basic <br/>&#160;&#160;&#160;&#160;&#160;&#160;&#160;and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67,812,145</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,163,301</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Net loss per share, basic and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.88</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.53</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Net Loss Per Share Attributable To Common Stockholders</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share for the periods presented because their effect would have been anti-dilutive:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:64.32%;box-sizing:content-box;"></td>
         <td style="width:1.64%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.54%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.96%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.54%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options to purchase common stock</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,427,777</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,817,751</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested restricted stock units</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">207,897</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,228,876</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares of common stock issuable under <br/>&#160;&#160;&#160;the ESPP</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,944</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total potentially dilutive shares</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,659,618</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,046,627</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Components of Net Loss Before Tax Provision from Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of net loss before tax provision from income taxes are as follows (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:64.387%;box-sizing:content-box;"></td>
         <td style="width:2.1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.537%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.44%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.537%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">United States</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59,579</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67,137</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">United Kingdom</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">272</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,760</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59,851</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73,897</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of Statutory Federal Income Tax Rate to Provision for Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents a reconciliation of the Company&#8217;s expected tax computed at the U.S. statutory federal income tax rate to the total provision for income taxes (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:62.873%;box-sizing:content-box;"></td>
         <td style="width:2.04%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.163%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.38%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.163%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.38%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. federal taxes at statutory rate</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,569</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,518</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;State taxes, net of federal benefit</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Acquired in-process research and development, related party</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,698</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Effect of cross-border transfers</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,303</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Non-deductible officer compensation</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">293</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">575</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Foreign rate differential</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">237</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">211</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Stock-based compensation</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">83</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">588</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Tax credits</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">403</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Other expenses, net</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">228</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">123</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Change in valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,284</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,076</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;word-break:break-word;">
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effective income tax rate</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The significant components of the Company</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;s deferred tax assets and liabilities are presented below (in thousands):</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:64.387%;box-sizing:content-box;"></td>
         <td style="width:2.1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.537%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.44%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.537%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Net operating losses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,202</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,725</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Intangible assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,447</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,946</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Research and development expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,824</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,388</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Stock compensation expense, including 162m limitations</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,400</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">432</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Research credits</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,104</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">702</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Accrued compensation and benefits</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">332</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">303</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Operating lease liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">113</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">121</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Other expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total deferred tax assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,459</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,630</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,368</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,492</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Net deferred tax assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">91</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">138</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Operating lease, right-of-use asset</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">106</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">112</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Other assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total deferred tax liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">91</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">138</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred tax assets and liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Schedule of Valuation Allowance</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The changes in the valuation allowance were as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:64.387%;box-sizing:content-box;"></td>
         <td style="width:2.1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.537%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.44%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.537%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance as of beginning of year</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,492</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,856</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Net increases recorded to income tax provision</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,876</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,636</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance as of end of year</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,368</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,492</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Costs (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Summary of restructuring costs</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A summary of the restructuring costs recorded in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2024 were as follows (in thousands):</span>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:34.227%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.683%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.683%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:16.203%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:16.203%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="11" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">ROU Asset <br/>Impairment</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Severance and  <br/>Benefit Costs</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Stock-based<br/>Compensation</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total<br/>Restructuring<br/>Cost Recorded</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,778</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">944</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,722</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">475</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">161</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">636</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total restructuring costs</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,253</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,105</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,358</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Forth Disaggregated Research and Development Expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the significant expense categories included within net loss presented on the consolidated statements of operations and comprehensive loss, the following table sets forth disaggregated research and development expenses (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:65.513%;box-sizing:content-box;"></td>
         <td style="width:1.92%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.323%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.92%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.323%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Direct research and development expenses:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Budoprutug</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,045</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,982</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">CLYM116</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">1</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,964</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Legacy programs</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">2</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">201</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unallocated research and development expenses:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel-related (including stock-based compensation)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,232</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,990</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other research and development expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,365</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">163</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total research and development expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,713</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,336</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3.35pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.695pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes the upfront payment and the associated direct transaction costs incurred in connection with the Mabworks Agreement for the year ended December 31, 2025.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.695pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes direct expenses related to the Company's legacy product candidates ETX-123 and ETX-155.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations and Basis of Presentation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 27, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Entity incorporation date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct. 18,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 289,727<span></span>
</td>
<td class="nump">$ 229,876<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Issuance of common stock in private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 119,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 160,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | At The Market Equity Offering Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clym_AggregateGrossSalesProceedsUnderSalesAgreements', window );">Aggregate gross sales proceeds under sales agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | Acquisition Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Proceeds from issuance of common stock in initial public offering, Shares</a></td>
<td class="nump">31,238,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Issuance of common stock in private placement</a></td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share</a></td>
<td class="nump">$ 3.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoninterestExpenseOfferingCost', window );">Offering cost</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clym_AggregateGrossSalesProceedsUnderSalesAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate gross sales proceeds available under a sales agreement to sell shares of the Company's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clym_AggregateGrossSalesProceedsUnderSalesAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clym_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationDateOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when an entity was incorporated</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationDateOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoninterestExpenseOfferingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for cost associated with issuance of security by investment company. Includes, but is not limited to, legal fee pertaining to share offered for sale, registration fee, underwriting, printing prospectus, and initial fee for listing on exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoninterestExpenseOfferingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=clym_AtTheMarketEquityOfferingProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=clym_AtTheMarketEquityOfferingProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=clym_AcquisitionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=clym_AcquisitionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Property and Equipment Estimated Useful Life (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration', window );">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</a></td>
<td class="text">Estimated Useful Life<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482190/360-10-35-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>Segments</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segments</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded', window );">Credit losses | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding accrued interest, of credit loss expense on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) with no credit loss previously recorded.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Asset Acquisition and Private Placement with a Related Party - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 27, 2024</div></th>
<th class="th"><div>Apr. 10, 2024</div></th>
<th class="th"><div>Jun. 27, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of common stock in private placement, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 119,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,868<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Proceeds from issuance of common stock in initial public offering, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,560,047<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 119,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Proceeds from issuance of common stock in initial public offering, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,238,282<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=clym_AcquisitionAgreementMember', window );">Acquisition Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clym_BusinessCombinationConsiderationTransferredSettlementOfPreExistingLoan', window );">Settlement of pre-existing loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=clym_AcquisitionAgreementMember', window );">Acquisition Agreement [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=clym_AcquisitionAgreementMember', window );">Acquisition Agreement [Member] | Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Proceeds from issuance of common stock in initial public offering, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,238,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of common stock in private placement, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoninterestExpenseOfferingCost', window );">Stock issuance costs</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=clym_AcquisitionAgreementMember', window );">Acquisition Agreement [Member] | Private Placement [Member] | Company Stock Owned By RA Capital Immediately Prior to Acquisition [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Minority Interest Ownership Percentage By Non controlling Owners</a></td>
<td class="nump">43.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=clym_SharesConvertedUponAcquisitionMember', window );">Shares Converted Upon Acquisition [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=clym_SharesConvertedUponAcquisitionMember', window );">Shares Converted Upon Acquisition [Member] | Acquisition Agreement [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Proceeds from issuance of common stock in initial public offering, Shares</a></td>
<td class="nump">5,560,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clym_BusinessCombinationConsiderationTransferredSettlementOfPreExistingLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of a pre-existing loan that was settled as part of a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clym_BusinessCombinationConsiderationTransferredSettlementOfPreExistingLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clym_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction cost incurred as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoninterestExpenseOfferingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for cost associated with issuance of security by investment company. Includes, but is not limited to, legal fee pertaining to share offered for sale, registration fee, underwriting, printing prospectus, and initial fee for listing on exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoninterestExpenseOfferingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=clym_AcquisitionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=clym_AcquisitionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=clym_CompanyStockOwnedByRACapitalImmediatelyPriorToAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=clym_CompanyStockOwnedByRACapitalImmediatelyPriorToAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=clym_SharesConvertedUponAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=clym_SharesConvertedUponAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Asset Acquisition and Private Placement with a Related Party - Schedule of Purchase Consideration For The Acquisition Based On The Fair Value Of The Net Assets Acquired By The Company (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 27, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract', window );"><strong>Assets acquired</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clym_AmountOfIn-ProcessResearchAndDevelopmentAssetsAcquired', window );">In-process research and development</a></td>
<td class="nump">$ 51,659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">1,204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,861<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets', window );">Total assets acquired</a></td>
<td class="nump">54,724<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Liabilities assumed</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(1,603)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(192)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities', window );">Total liabilities assumed</a></td>
<td class="num">(1,972)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Net assets acquired</a></td>
<td class="nump">52,752<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Liabilities assumed</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(101)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">$ (76)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clym_AmountOfIn-ProcessResearchAndDevelopmentAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of in-process research and development asset acquired in business combination and recognized at acquisition date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clym_AmountOfIn-ProcessResearchAndDevelopmentAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clym_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent acquired in business combination and recognized at acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset acquired in business combination and recognized at acquisition date, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of prepaid expense and asset classified as other, acquired in business combination and recognized at acquisition date, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability assumed in business combination and recognized at acquisition date, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accounts payable assumed in business combination and recognized at acquisition date, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability assumed in business combination and recognized at acquisition date, classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset acquired in excess of (less than) liability assumed in business combination and recognized at acquisition date. Excludes goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-41<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities and Fair Value Measurements - Schedule of Marketable securities consisted of available-for-sale securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized Cost, Short-term marketable securities</a></td>
<td class="nump">$ 65,170<span></span>
</td>
<td class="nump">$ 63,649<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Estimated Fair Value, Short-term marketable securities</a></td>
<td class="nump">65,395<span></span>
</td>
<td class="nump">63,690<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent', window );">Amortized Cost, Long-term marketable securities</a></td>
<td class="nump">59,362<span></span>
</td>
<td class="nump">61,628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Estimated Fair Value, Long-term marketable securities</a></td>
<td class="nump">59,572<span></span>
</td>
<td class="nump">61,610<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate Bond [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized Cost, Short-term marketable securities</a></td>
<td class="nump">31,874<span></span>
</td>
<td class="nump">33,519<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Estimated Fair Value, Short-term marketable securities</a></td>
<td class="nump">31,976<span></span>
</td>
<td class="nump">33,537<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent', window );">Amortized Cost, Long-term marketable securities</a></td>
<td class="nump">50,341<span></span>
</td>
<td class="nump">33,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Estimated Fair Value, Long-term marketable securities</a></td>
<td class="nump">50,518<span></span>
</td>
<td class="nump">33,955<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized Cost, Short-term marketable securities</a></td>
<td class="nump">33,296<span></span>
</td>
<td class="nump">30,130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Estimated Fair Value, Short-term marketable securities</a></td>
<td class="nump">33,419<span></span>
</td>
<td class="nump">30,153<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent', window );">Amortized Cost, Long-term marketable securities</a></td>
<td class="nump">6,022<span></span>
</td>
<td class="nump">24,146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Estimated Fair Value, Long-term marketable securities</a></td>
<td class="nump">6,054<span></span>
</td>
<td class="nump">24,154<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government agency debt securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent', window );">Amortized Cost, Long-term marketable securities</a></td>
<td class="nump">2,999<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Estimated Fair Value, Long-term marketable securities</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">3,501<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=clym_ShortTermMarketableSecuritiesMember', window );">Short Term Marketable Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">225<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=clym_ShortTermMarketableSecuritiesMember', window );">Short Term Marketable Securities [Member] | Corporate Bond [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=clym_ShortTermMarketableSecuritiesMember', window );">Short Term Marketable Securities [Member] | U.S. Treasury securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">123<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=clym_LongTermMarketableSecuritiesMember', window );">Long Term Marketable Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">210<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(58)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=clym_LongTermMarketableSecuritiesMember', window );">Long Term Marketable Securities [Member] | Corporate Bond [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">177<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(43)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=clym_LongTermMarketableSecuritiesMember', window );">Long Term Marketable Securities [Member] | U.S. Treasury securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=clym_LongTermMarketableSecuritiesMember', window );">Long Term Marketable Securities [Member] | U.S. government agency debt securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=clym_ShortTermMarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=clym_ShortTermMarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=clym_LongTermMarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=clym_LongTermMarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities and Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">$ 124,967<span></span>
</td>
<td class="nump">$ 125,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">160,287<span></span>
</td>
<td class="nump">210,912<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">35,320<span></span>
</td>
<td class="nump">85,612<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">39,473<span></span>
</td>
<td class="nump">54,307<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate Bond [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">82,494<span></span>
</td>
<td class="nump">67,492<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government agency debt securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">3,501<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">39,473<span></span>
</td>
<td class="nump">54,307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">74,793<span></span>
</td>
<td class="nump">139,919<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">35,320<span></span>
</td>
<td class="nump">85,612<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | U.S. Treasury securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">39,473<span></span>
</td>
<td class="nump">54,307<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Corporate Bond [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | U.S. government agency debt securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">85,494<span></span>
</td>
<td class="nump">70,993<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">85,494<span></span>
</td>
<td class="nump">70,993<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | U.S. Treasury securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Corporate Bond [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">82,494<span></span>
</td>
<td class="nump">67,492<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | U.S. government agency debt securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">3,501<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member] | U.S. Treasury securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member] | Corporate Bond [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member] | U.S. government agency debt securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Certain Balance Sheet Accounts - Summary of Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 4,769<span></span>
</td>
<td class="nump">$ 3,953<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll and related expenses</a></td>
<td class="nump">$ 1,891<span></span>
</td>
<td class="nump">$ 1,997<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clym_AccruedExternalResearchAndDevelopmentsExpense', window );">Accrued external research and development expenses</a></td>
<td class="nump">1,816<span></span>
</td>
<td class="nump">1,237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">693<span></span>
</td>
<td class="nump">746<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 4,459<span></span>
</td>
<td class="nump">$ 4,069<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clym_AccruedExternalResearchAndDevelopmentsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for external research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clym_AccruedExternalResearchAndDevelopmentsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clym_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 11, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clym_SharesExchangedForPreFundedWarrants', window );">Exchange of common stock for pre-funded warrant, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,440,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=clym_SeraServicesAgreementMember', window );">Sera Services Agreement [Member] | Acquisition Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Payment to, related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=clym_BlackbirdClinicalAgreementMember', window );">Blackbird Clinical Agreement [Member] | Acquisition Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Payment to, related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=clym_ExchangeAgreementMember', window );">Exchange Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clym_AggregateBeneficialOwnershipExchangingStockholders', window );">Aggregate Beneficial Ownership Exchanging Stockholders</a></td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=clym_ExchangeAgreementMember', window );">Exchange Agreement [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clym_SharesExchangedForPreFundedWarrants', window );">Exchange of common stock for pre-funded warrant, Shares</a></td>
<td class="nump">20,440,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=clym_ExchangeAgreementMember', window );">Exchange Agreement [Member] | Pre Funded Warrant [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clym_AggregateBeneficialOwnershipExchangingStockholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of beneficial ownership that exchanging shareholders may own to be eligible to exercise pre-funded warrants, as a percentage of shares issued and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clym_AggregateBeneficialOwnershipExchangingStockholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clym_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clym_SharesExchangedForPreFundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares exchanged during the period for pre-funded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clym_SharesExchangedForPreFundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clym_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=clym_SeraServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=clym_SeraServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=clym_AcquisitionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=clym_AcquisitionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=clym_BlackbirdClinicalAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=clym_BlackbirdClinicalAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=clym_ExchangeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=clym_ExchangeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=clym_PreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=clym_PreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Lease Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 250<span></span>
</td>
<td class="nump">$ 243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Lease cost</a></td>
<td class="nump">$ 259<span></span>
</td>
<td class="nump">$ 329<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term - operating lease (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate - operating lease</a></td>
<td class="nump">8.50%<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Cash Flow Information Related to Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of operating lease liabilities</a></td>
<td class="nump">$ 256<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease liabilities arising from obtaining right-of-use asset</a></td>
<td class="nump">$ 216<span></span>
</td>
<td class="nump">$ 510<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Annual Future Minimum Lease Payments Due Under the Company's Non-cancelable Operating Lease (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Lease Payments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="nump">$ 293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2027</a></td>
<td class="nump">298<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(50)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 541<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Operating Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liability</a></td>
<td class="nump">$ 256<span></span>
</td>
<td class="nump">$ 157<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">285<span></span>
</td>
<td class="nump">$ 375<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Additional Information) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">21 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2027</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 259<span></span>
</td>
<td class="nump">$ 329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Lease option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Increase (Decrease) in Operating Lease Liability</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (207)<span></span>
</td>
<td class="num">$ (327)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clym_IncreaseDecreaseInOperatingLeaseAssets', window );">Increase (Decrease) In Operating Lease Asset</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member] | Additional Office Space [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member] | Additional Office Space [Member] | Option to Extend [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clym_IncreaseDecreaseInOperatingLeaseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating lease right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clym_IncreaseDecreaseInOperatingLeaseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clym_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=clym_AdditionalOfficeSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=clym_AdditionalOfficeSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=clym_OptionToExtendMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=clym_OptionToExtendMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br> $ in Thousands, &#8364; in Millions, &#163; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 08, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2024 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Jan. 11, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,713<span></span>
</td>
<td class="nump">$ 14,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=clym_AcelyrinAssetPurchaseAgreementMember', window );">Acelyrin Asset Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clym_MilestonePaymentsDue', window );">Milestone Payments Due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=clym_MabworksAgreementMember', window );">Mabworks Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clym_UpfrontPaymentPaid', window );">Upfront Payment Paid</a></td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=clym_DevelopmentAndRegulatoryMilestonesMember', window );">Development and Regulatory Milestones [Member] | Mabworks Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clym_MilestonePayments', window );">Milestone Payments</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=clym_CommercialMilestonesMember', window );">Commercial Milestones [Member] | Mabworks Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clym_MilestonePayments', window );">Milestone Payments</a></td>
<td class="nump">$ 832,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=clym_MilestoneMember', window );">Milestone [Member] | CRH Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=clym_MilestoneMember', window );">Milestone [Member] | ProBioGen Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=clym_MilestoneMember', window );">Milestone [Member] | Mabworks Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=clym_ManufacturingServicesMember', window );">Manufacturing Services [Member] | ProBioGen Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clym_MilestonePaymentAmountReduced', window );">Milestone Payment, Amount Reduced</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=clym_UpfrontPaymentMember', window );">Upfront Payment [Member] | Mabworks Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Development Regulatory and Commercial Milestones [Member] | Acelyrin Asset Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clym_MilestonePayments', window );">Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 157,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Development Regulatory Commercial and Sales Milestones [Member] | CRH Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clym_MilestonePayments', window );">Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 106.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Development Manufacturing and Commercial [Member] | ProBioGen Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clym_MilestonePayments', window );">Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Sales Milestones [Member] | ProBioGen Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clym_MilestonePayments', window );">Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 7.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clym_MilestonePaymentAmountReduced">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of reduction in milestone payments due upon performing specified services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clym_MilestonePaymentAmountReduced</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clym_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clym_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount due from the Company upon achievement of specified milestones, as part of a license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clym_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clym_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clym_MilestonePaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount due as a result of achievement of specified milestones, as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clym_MilestonePaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clym_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clym_UpfrontPaymentPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront payment paid during the period as part of a license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clym_UpfrontPaymentPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clym_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=clym_AcelyrinAssetPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=clym_AcelyrinAssetPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=clym_MabworksAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=clym_MabworksAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=clym_DevelopmentAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=clym_DevelopmentAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=clym_CommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=clym_CommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=clym_MilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=clym_MilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=clym_CrhAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=clym_CrhAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=clym_ProbiogenAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=clym_ProbiogenAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=clym_ManufacturingServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=clym_ManufacturingServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=clym_UpfrontPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=clym_UpfrontPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=clym_DevelopmentRegulatoryAndCommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=clym_DevelopmentRegulatoryAndCommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=clym_DevelopmentRegulatoryCommercialAndSalesMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=clym_DevelopmentRegulatoryCommercialAndSalesMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=clym_DevelopmentManufacturingAndCommercialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=clym_DevelopmentManufacturingAndCommercialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=clym_SalesMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=clym_SalesMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2026</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Jan. 01, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,054<span></span>
</td>
<td class="nump">5,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation, weighted average amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of restricted stock vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of shares, Vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">929,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,503<span></span>
</td>
<td class="nump">3,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,551<span></span>
</td>
<td class="nump">$ 2,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Share based compensation arrangement by share based payment award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">672,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number shares remaining for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,736,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Share-based payment award, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company&#8217;s 2021 Employee Stock Purchase Plan (the ESPP) allows employees, including executive officers, to contribute up to 15% of their earnings, subject to certain limitations, for the purchase of the Company&#8217;s common stock at a price per share equal to the lower of (a) 85% of the fair market value of a share of common stock on the first day of the offering period, or (b) 85% of the fair market value of a share of common stock on the last day of the offering period. The number of shares of common stock reserved for issuance under the ESPP automatically increases on January 1 of each calendar year through and including January 1, 2031, by the lesser of (1) 1% of the total number of shares of the Company&#8217;s common stock outstanding on December 31 of the preceding calendar year or (2) a number of shares determined by the Company&#8217;s board of directors. Shares subject to purchase rights granted under the ESPP that terminate without having been exercised in full will not reduce the number of shares available for issuance under the ESPP. The number of authorized shares reserved for issuance under the ESPP was increased by 672,554 shares effective as of January 1, 2025 in accordance with the provisions of the ESPP described above. The first offering period began on December 16, 2025 and will end on June 15, 2026. As of December 31, 2025, no shares had been granted or purchased under the ESPP and 1,736,779 shares remained available for issuance under the ESPP. The number of shares reserved for issuance under the ESPP was increased by 477,663 shares effective January 1, 2026. <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clym_ShareBasedCompensationArrangementBySharebasedPaymentAwardContributionPercentMaximum', window );">Share based compensation arrangement by sharebased payment award contribution percent maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Stock issued during period shares employee stock purchase plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Options grants in period, weighted average grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.45<span></span>
</td>
<td class="nump">$ 5.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option | First Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based payment award, award vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option | After First Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based payment award, option vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Employee Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Share based compensation arrangement by share based payment award</a></td>
<td class="nump">477,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Employee Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clym_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage', window );">Number of Shares of Common Stock Outstanding Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Employee Stock [Member] | First Day of Offering Period [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Share based payment award, purchase price of common stock, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Employee Stock [Member] | Last Day of Offering Period [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Share based payment award, purchase price of common stock, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=clym_TwoThousandTwentyOneEquityIncentivePlanMember', window );">2021 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Share based compensation arrangement by share based payment award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,362,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number shares remaining for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,124,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Share-based payment award, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Under the terms of the 2021 Plan, options are granted at an exercise price no less than fair value of the Company&#8217;s common stock on the grant date, except in certain cases related to significant corporate transactions. Options expire no later than ten years from the date of the grant.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based payment award, expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=clym_TwoThousandTwentyOneEquityIncentivePlanMember', window );">2021 Equity Incentive Plan [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Share based compensation arrangement by share based payment award</a></td>
<td class="nump">2,388,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=clym_TwoThousandTwentyOneEquityIncentivePlanMember', window );">2021 Equity Incentive Plan [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clym_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage', window );">Number of Shares of Common Stock Outstanding Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=clym_TwoThousandTwentyFiveInducementPlanMember', window );">2025 Inducement Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Share based compensation arrangement by share based payment award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=clym_TwoThousandTwentyFiveInducementPlanMember', window );">2025 Inducement Plan [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number shares remaining for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based payment award, number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=clym_PerformanceBasedVestingMember', window );">Performance based vesting [Member] | Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clym_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The automatic increase in the number of shares that may be issued under a share-based payment arrangement on the first day of each fiscal year, as a percentage of shares outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clym_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clym_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clym_ShareBasedCompensationArrangementBySharebasedPaymentAwardContributionPercentMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum amount an employee is allowed to contribute for the purchase of common stock under a share based compensation plan, as a percentage of their earnings</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clym_ShareBasedCompensationArrangementBySharebasedPaymentAwardContributionPercentMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clym_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=clym_FirstAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=clym_FirstAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=clym_AfterFirstAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=clym_AfterFirstAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=clym_FirstDayOfOfferingPeriodMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=clym_FirstDayOfOfferingPeriodMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=clym_LastDayOfOfferingPeriodMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=clym_LastDayOfOfferingPeriodMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=clym_TwoThousandTwentyOneEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=clym_TwoThousandTwentyOneEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=clym_TwoThousandTwentyFiveInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=clym_TwoThousandTwentyFiveInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=clym_PerformanceBasedVestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=clym_PerformanceBasedVestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Option Activities (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding, beginning of period</a></td>
<td class="nump">2,817,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted</a></td>
<td class="nump">5,766,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of options exercised</a></td>
<td class="num">(21,341)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of options, forfeited</a></td>
<td class="num">(2,135,329)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding, ending of period</a></td>
<td class="nump">6,427,777<span></span>
</td>
<td class="nump">2,817,751<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of options, vested and expected to vest</a></td>
<td class="nump">6,427,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options exercisable, end of period</a></td>
<td class="nump">631,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price outstanding, beginning of period</a></td>
<td class="nump">$ 6.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, options granted</a></td>
<td class="nump">1.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, options exercised</a></td>
<td class="nump">3.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, options forfeited</a></td>
<td class="nump">4.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price outstanding, end of period</a></td>
<td class="nump">2.81<span></span>
</td>
<td class="nump">$ 6.49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, options vested and expected to vest</a></td>
<td class="nump">2.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, options exercisable</a></td>
<td class="nump">$ 6.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contracted terms (in years) outstanding</a></td>
<td class="text">9 years 18 days<span></span>
</td>
<td class="text">6 years 10 months 13 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest</a></td>
<td class="text">9 years 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value options exercised</a></td>
<td class="nump">$ 19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value outstanding, end of period</a></td>
<td class="nump">11,727<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value options vested and expected to vest</a></td>
<td class="nump">11,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value options exercisable</a></td>
<td class="nump">$ 331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Assumptions Used in Black-Scholes Model (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">103.60%<span></span>
</td>
<td class="nump">104.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.30%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Restricted Stock Awards (Details) - Restricted Stock Units (RSUs) [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares, Unvested | shares</a></td>
<td class="nump">1,228,876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, Granted | shares</a></td>
<td class="nump">1,084<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of shares, Vested | shares</a></td>
<td class="num">(929,563)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Share, Forfeited | shares</a></td>
<td class="num">(92,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares, Unvested | shares</a></td>
<td class="nump">207,897<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested, weighted average grant date fair value per share, beginning balance | $ / shares</a></td>
<td class="nump">$ 7.17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, weighted average grant date fair value | $ / shares</a></td>
<td class="nump">4.62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested, weighted average grant date fair value | $ / shares</a></td>
<td class="nump">7.27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited, weighted average grant date fair value | $ / shares</a></td>
<td class="nump">5.44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested, weighted average grant date fair value per share, ending balance | $ / shares</a></td>
<td class="nump">$ 7.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Share-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 8,054<span></span>
</td>
<td class="nump">$ 5,557<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">3,503<span></span>
</td>
<td class="nump">3,032<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 4,551<span></span>
</td>
<td class="nump">$ 2,525<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (59,851)<span></span>
</td>
<td class="num">$ (73,897)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding, basic</a></td>
<td class="nump">67,812,145<span></span>
</td>
<td class="nump">48,163,301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding, diluted</a></td>
<td class="nump">67,812,145<span></span>
</td>
<td class="nump">48,163,301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (0.88)<span></span>
</td>
<td class="num">$ (1.53)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (0.88)<span></span>
</td>
<td class="num">$ (1.53)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding, basic</a></td>
<td class="nump">66,692,145<span></span>
</td>
<td class="nump">48,163,301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding, diluted</a></td>
<td class="nump">66,692,145<span></span>
</td>
<td class="nump">48,163,301<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Pre-Funded Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding, basic</a></td>
<td class="nump">1,120,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding, diluted</a></td>
<td class="nump">1,120,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=clym_Pre-FundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=clym_Pre-FundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Net Loss Per Share Attributable To Common Stockholders (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive shares</a></td>
<td class="nump">6,659,618<span></span>
</td>
<td class="nump">4,046,627<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options to purchase common stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive shares</a></td>
<td class="nump">6,427,777<span></span>
</td>
<td class="nump">2,817,751<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Unvested restricted stock units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive shares</a></td>
<td class="nump">207,897<span></span>
</td>
<td class="nump">1,228,876<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">Shares of common stock issuable under the ESPP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive shares</a></td>
<td class="nump">23,944<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation Allowance</a></td>
<td class="num">$ (39,368)<span></span>
</td>
<td class="num">$ (28,492)<span></span>
</td>
<td class="num">$ (20,856)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Tax year</a></td>
<td class="text">2018 2019 2020 2121 2022 2323 2024 2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clym_PercentageOfAnnualDeductionOfTaxableIncome', window );">Percentage of annual deduction of taxable income</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="nump">$ 55,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clym_TaxCreditCarryforwardExpirationYearStart', window );">Tax credit carryforward expiration year start</a></td>
<td class="text">2039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward amount</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="nump">$ 9,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clym_OperatingLossCarryforwardsExpirationStartYear', window );">Operating loss carryforwards expiration start year</a></td>
<td class="text">2038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clym_TaxCreditCarryforwardExpirationYearStart', window );">Tax credit carryforward expiration year start</a></td>
<td class="text">2039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward amount</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="nump">$ 63,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clym_OperatingLossCarryforwardsExpirationStartYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The year in which operating loss carryforwards begin to expire, in YYYY format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clym_OperatingLossCarryforwardsExpirationStartYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clym_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clym_PercentageOfAnnualDeductionOfTaxableIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of annual taxable income to which net operating loss carryforwards are limited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clym_PercentageOfAnnualDeductionOfTaxableIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clym_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clym_TaxCreditCarryforwardExpirationYearStart">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The year in which tax credit carryforwards begin to expire, in YYYY format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clym_TaxCreditCarryforwardExpirationYearStart</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clym_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in YYYY format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Net Loss Before Tax Provision from Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (59,851)<span></span>
</td>
<td class="num">$ (73,897)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(59,579)<span></span>
</td>
<td class="num">(67,137)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_GB', window );">United Kingdom</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (272)<span></span>
</td>
<td class="num">$ (6,760)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciliation of Statutory Federal Income Tax Rate to Provision for Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">U.S. federal taxes at statutory rate</a></td>
<td class="num">$ (12,569)<span></span>
</td>
<td class="num">$ (15,518)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clym_EffectiveIncomeTaxRateReconciliationAcquiredIn-ProcessResearchDevelopmentRelatedParty', window );">Acquired in-process research &amp; development, related party</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount', window );">Effect of cross-border transfers</a></td>
<td class="nump">1,303<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clym_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficerCompensationAmount', window );">Non-deductible officer compensation</a></td>
<td class="nump">293<span></span>
</td>
<td class="nump">575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign rate differential</a></td>
<td class="nump">237<span></span>
</td>
<td class="num">(211)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">588<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="num">(403)<span></span>
</td>
<td class="num">(86)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther', window );">Other expenses, net</a></td>
<td class="num">(228)<span></span>
</td>
<td class="num">(123)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">11,284<span></span>
</td>
<td class="nump">7,076<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Effective income tax rate</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clym_EffectiveIncomeTaxRateReconciliationAcquiredIn-ProcessResearchDevelopmentRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) from difference to expected income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to acquired in-process research and development from a related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clym_EffectiveIncomeTaxRateReconciliationAcquiredIn-ProcessResearchDevelopmentRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clym_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clym_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficerCompensationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) from difference to expected income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to limitations on executive compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clym_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficerCompensationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clym_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) from difference to expected income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to cross-border tax law.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 28,202<span></span>
</td>
<td class="nump">$ 22,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible asset</a></td>
<td class="nump">4,447<span></span>
</td>
<td class="nump">1,946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clym_DeferredTaxAssetsResearchAndDevelopmentExpenses', window );">Research and development expenses</a></td>
<td class="nump">3,824<span></span>
</td>
<td class="nump">2,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation, including 162m limitations</a></td>
<td class="nump">1,400<span></span>
</td>
<td class="nump">432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research credits</a></td>
<td class="nump">1,104<span></span>
</td>
<td class="nump">702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation', window );">Accrued compensation and benefits</a></td>
<td class="nump">332<span></span>
</td>
<td class="nump">303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clym_DefferedTaxAssetOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">113<span></span>
</td>
<td class="nump">121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other expenses</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total gross deferred tax assets</a></td>
<td class="nump">39,459<span></span>
</td>
<td class="nump">28,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation Allowance</a></td>
<td class="num">(39,368)<span></span>
</td>
<td class="num">(28,492)<span></span>
</td>
<td class="num">$ (20,856)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Operating lease, right-of-use asset</a></td>
<td class="num">(106)<span></span>
</td>
<td class="num">(112)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other assets</a></td>
<td class="nump">15<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(91)<span></span>
</td>
<td class="num">(138)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets and liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clym_DeferredTaxAssetsResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clym_DeferredTaxAssetsResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clym_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clym_DefferedTaxAssetOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clym_DefferedTaxAssetOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clym_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Valuation Allowance (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance as of beginning of year</a></td>
<td class="nump">$ 28,492<span></span>
</td>
<td class="nump">$ 20,856<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Net increases recorded to income tax provision</a></td>
<td class="nump">10,876<span></span>
</td>
<td class="nump">7,636<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance as of end of year</a></td>
<td class="nump">$ 39,368<span></span>
</td>
<td class="nump">$ 28,492<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined Contribution Plan - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=clym_FourZeroOneKMember', window );">401K [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Total expense recognized from matching contributions</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=clym_PensionMember', window );">Pension [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Total expense recognized from matching contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | 401K [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Defined contribution plan, employer matching contribution, percentage of employee's eligilble compensation</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (j)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (j)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (j)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (j)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (m)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=clym_FourZeroOneKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=clym_FourZeroOneKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=clym_PensionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=clym_PensionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Costs - Summary of restructuring costs in statement of operations (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Total restructuring costs</a></td>
<td class="nump">$ 3,358<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Total restructuring costs</a></td>
<td class="nump">2,722<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Total restructuring costs</a></td>
<td class="nump">636<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=clym_RouAssetImpairmentMember', window );">ROU Asset Impairment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Total restructuring costs</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=clym_RouAssetImpairmentMember', window );">ROU Asset Impairment [Member] | Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Total restructuring costs</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=clym_RouAssetImpairmentMember', window );">ROU Asset Impairment [Member] | General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Total restructuring costs</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=clym_SeveranceAndBenefitsCostsMember', window );">Severance and Benefits Costs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Total restructuring costs</a></td>
<td class="nump">2,253<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=clym_SeveranceAndBenefitsCostsMember', window );">Severance and Benefits Costs [Member] | Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Total restructuring costs</a></td>
<td class="nump">1,778<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=clym_SeveranceAndBenefitsCostsMember', window );">Severance and Benefits Costs [Member] | General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Total restructuring costs</a></td>
<td class="nump">475<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=clym_StockBasedCompensationMember', window );">Stock-based Compensation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Total restructuring costs</a></td>
<td class="nump">1,105<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=clym_StockBasedCompensationMember', window );">Stock-based Compensation [Member] | Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Total restructuring costs</a></td>
<td class="nump">944<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=clym_StockBasedCompensationMember', window );">Stock-based Compensation [Member] | General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Total restructuring costs</a></td>
<td class="nump">$ 161<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=clym_RouAssetImpairmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=clym_RouAssetImpairmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=clym_SeveranceAndBenefitsCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=clym_SeveranceAndBenefitsCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=clym_StockBasedCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=clym_StockBasedCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments (Additional Information) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>Segments</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration', window );">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</a></td>
<td class="text">srt:ChiefExecutiveOfficerMember<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription', window );">Segment Reporting Codm Profit Loss, Description</a></td>
<td class="text">For the purpose of evaluating segment performance and allocating resources, the CODM reviews the Company&#8217;s financial information on a consolidated basis together with certain operating metrics and evaluates net loss against comparable prior periods and the Company&#8217;s annual operating plan. The measure of segment assets is reported on the consolidated balance sheets as total consolidated assets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of how chief operating decision maker (CODM) uses reported segment profit (loss) measure to assess performance and allocate resource.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Segments - Schedule of Forth Disaggregated Research and Development Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 46,713<span></span>
</td>
<td class="nump">$ 14,336<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">46,713<span></span>
</td>
<td class="nump">14,336<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Direct Expense [Member] | Budoprutug</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25,045<span></span>
</td>
<td class="nump">5,982<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Direct Expense [Member] | CLYM1161</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">11,964<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Direct Expense [Member] | Legacy programs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">107<span></span>
</td>
<td class="nump">201<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Unallocated Expense [Member] | Personnel-related (including stock-based compensation)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,232<span></span>
</td>
<td class="nump">7,990<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Unallocated Expense [Member] | Other research and development expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,365<span></span>
</td>
<td class="nump">$ 163<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes the upfront payment and the associated direct transaction costs incurred in connection with the Mabworks Agreement for the year ended December 31, 2025.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes direct expenses related to the Company's legacy product candidates ETX-123 and ETX-155.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivablePortfolioSegmentAxis=clym_DirectExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivablePortfolioSegmentAxis=clym_DirectExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=clym_BudoprutugServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=clym_BudoprutugServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=clym_CLYM116Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=clym_CLYM116Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=clym_LegacyProgramExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=clym_LegacyProgramExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivablePortfolioSegmentAxis=clym_UnallocatedExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivablePortfolioSegmentAxis=clym_UnallocatedExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=clym_PersonnelRelatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=clym_PersonnelRelatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments - Schedule of Forth Disaggregated Research and Development Expenses (Parenthetical) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 8,054<span></span>
</td>
<td class="nump">$ 5,557<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>212</ContextCount>
  <ElementCount>342</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>83</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>75000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>75010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>75020 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>75030 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>75040 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>75050 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>75060 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>75070 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995457 - Disclosure - Cybersecurity Risk Management, Strategy and Governance</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance</Role>
      <ShortName>Cybersecurity Risk Management, Strategy and Governance</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995467 - Disclosure - Nature of Operations and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentation</Role>
      <ShortName>Nature of Operations and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995477 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995487 - Disclosure - Asset Acquisition and Private Placement with a Related Party</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedParty1</Role>
      <ShortName>Asset Acquisition and Private Placement with a Related Party</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995497 - Disclosure - Marketable Securities and Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurements</Role>
      <ShortName>Marketable Securities and Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995507 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995517 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995527 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995547 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995557 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995567 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/DisclosureNetLossPerShare1</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995577 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995587 - Disclosure - Defined Contribution Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/Role_DisclosureDefinedContributionPlan</Role>
      <ShortName>Defined Contribution Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995597 - Disclosure - Restructuring Costs</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/DisclosureRestructuringCosts</Role>
      <ShortName>Restructuring Costs</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995607 - Disclosure - Segments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/DisclosureSegments</Role>
      <ShortName>Segments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995627 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995637 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995647 - Disclosure - Asset Acquisition and Private Placement with a Related Party (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyTables</Role>
      <ShortName>Asset Acquisition and Private Placement with a Related Party (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedParty1</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995657 - Disclosure - Marketable Securities and Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsTables</Role>
      <ShortName>Marketable Securities and Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurements</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995667 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://climbbio.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995677 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://climbbio.com/20251231/taxonomy/role/DisclosureLeases</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995687 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensation</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995697 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://climbbio.com/20251231/taxonomy/role/DisclosureNetLossPerShare1</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995707 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://climbbio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxes</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995717 - Disclosure - Restructuring Costs (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/DisclosureRestructuringCostsTables</Role>
      <ShortName>Restructuring Costs (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://climbbio.com/20251231/taxonomy/role/DisclosureRestructuringCosts</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995727 - Disclosure - Segments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/DisclosureSegmentsTables</Role>
      <ShortName>Segments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://climbbio.com/20251231/taxonomy/role/DisclosureSegments</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995737 - Disclosure - Nature of Operations and Basis of Presentation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails</Role>
      <ShortName>Nature of Operations and Basis of Presentation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995757 - Disclosure - Summary of Significant Accounting Policies - Schedule of Property and Equipment Estimated Useful Life (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Property and Equipment Estimated Useful Life (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995767 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995777 - Disclosure - Asset Acquisition and Private Placement with a Related Party - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyAdditionalInformationDetails</Role>
      <ShortName>Asset Acquisition and Private Placement with a Related Party - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995797 - Disclosure - Asset Acquisition and Private Placement with a Related Party - Schedule of Purchase Consideration For The Acquisition Based On The Fair Value Of The Net Assets Acquired By The Company (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyScheduleOfPurchaseConsiderationForTheAcquisitionBasedOnTheFairValueOfThe</Role>
      <ShortName>Asset Acquisition and Private Placement with a Related Party - Schedule of Purchase Consideration For The Acquisition Based On The Fair Value Of The Net Assets Acquired By The Company (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995807 - Disclosure - Marketable Securities and Fair Value Measurements - Schedule of Marketable securities consisted of available-for-sale securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfMarketableSecuritiesConsistedOfAvailableforsaleSecuritiesDetails</Role>
      <ShortName>Marketable Securities and Fair Value Measurements - Schedule of Marketable securities consisted of available-for-sale securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995817 - Disclosure - Marketable Securities and Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails</Role>
      <ShortName>Marketable Securities and Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995827 - Disclosure - Certain Balance Sheet Accounts - Summary of Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCertainBalanceSheetAccountsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>Certain Balance Sheet Accounts - Summary of Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995837 - Disclosure - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995857 - Disclosure - Related Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995877 - Disclosure - Leases - Schedule of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfLeaseExpenseDetails</Role>
      <ShortName>Leases - Schedule of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995887 - Disclosure - Leases - Schedule of Cash Flow Information Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfCashFlowInformationRelatedToLeasesDetails</Role>
      <ShortName>Leases - Schedule of Cash Flow Information Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995897 - Disclosure - Leases - Schedule of Annual Future Minimum Lease Payments Due Under the Company's Non-cancelable Operating Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfAnnualFutureMinimumLeasePaymentsDueUnderTheCompanysNoncancelableOperatingLeaseDetails</Role>
      <ShortName>Leases - Schedule of Annual Future Minimum Lease Payments Due Under the Company's Non-cancelable Operating Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995907 - Disclosure - Leases - Schedule of Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Schedule of Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>995917 - Disclosure - Leases (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails</Role>
      <ShortName>Leases (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>995927 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>995937 - Disclosure - Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>995947 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivitiesDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Option Activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>995957 - Disclosure - Stock-Based Compensation - Summary of Assumptions Used in Black-Scholes Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedInBlackScholesModelDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Assumptions Used in Black-Scholes Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>995967 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardsDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Restricted Stock Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>995977 - Disclosure - Stock-Based Compensation - Summary of Share-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfShareBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Share-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>995987 - Disclosure - Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>995997 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Net Loss Per Share Attributable To Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfNetLossPerShareAttributableToCommonStockholdersDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Net Loss Per Share Attributable To Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>996007 - Disclosure - Income Taxes - Additional information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>996017 - Disclosure - Income Taxes - Components of Net Loss Before Tax Provision from Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetLossBeforeTaxProvisionFromIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Components of Net Loss Before Tax Provision from Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>996027 - Disclosure - Income Taxes - Schedule of Reconciliation of Statutory Federal Income Tax Rate to Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToProvisionForIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Reconciliation of Statutory Federal Income Tax Rate to Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>996037 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>996047 - Disclosure - Income Taxes - Schedule of Valuation Allowance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfValuationAllowanceDetails</Role>
      <ShortName>Income Taxes - Schedule of Valuation Allowance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>996057 - Disclosure - Defined Contribution Plan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetails</Role>
      <ShortName>Defined Contribution Plan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>996067 - Disclosure - Restructuring Costs - Summary of restructuring costs in statement of operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/DisclosureRestructuringCostsSummaryOfRestructuringCostsInStatementOfOperationsDetails</Role>
      <ShortName>Restructuring Costs - Summary of restructuring costs in statement of operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>996087 - Disclosure - Segments (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/DisclosureSegmentsAdditionalInformationDetails</Role>
      <ShortName>Segments (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://climbbio.com/20251231/taxonomy/role/DisclosureSegmentsTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>996097 - Disclosure - Segments - Schedule of Forth Disaggregated Research and Development Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/DisclosureSegmentsScheduleOfForthDisaggregatedResearchAndDevelopmentExpensesDetails</Role>
      <ShortName>Segments - Schedule of Forth Disaggregated Research and Development Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="clym-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>996107 - Disclosure - Segments - Schedule of Forth Disaggregated Research and Development Expenses (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://climbbio.com/20251231/taxonomy/role/DisclosureSegmentsScheduleOfForthDisaggregatedResearchAndDevelopmentExpensesParentheticalDetails</Role>
      <ShortName>Segments - Schedule of Forth Disaggregated Research and Development Expenses (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="clym-20251231.htm">clym-20251231.htm</File>
    <File>clym-20251231.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img22994243_0.jpg</File>
    <File>img22994243_1.jpg</File>
    <File>img22994243_10.gif</File>
    <File>img22994243_2.gif</File>
    <File>img22994243_3.jpg</File>
    <File>img22994243_4.jpg</File>
    <File>img22994243_5.jpg</File>
    <File>img22994243_6.jpg</File>
    <File>img22994243_7.jpg</File>
    <File>img22994243_8.jpg</File>
    <File>img22994243_9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="604">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="14">http://xbrl.sec.gov/cyd/2025</BaseTaxonomy>
    <BaseTaxonomy items="42">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="8">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>97
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "clym-20251231.htm": {
   "nsprefix": "clym",
   "nsuri": "http://climbbio.com/20251231",
   "dts": {
    "inline": {
     "local": [
      "clym-20251231.htm"
     ]
    },
    "schema": {
     "local": [
      "clym-20251231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    }
   },
   "keyStandard": 314,
   "keyCustom": 28,
   "axisStandard": 32,
   "axisCustom": 0,
   "memberStandard": 32,
   "memberCustom": 45,
   "hidden": {
    "total": 9,
    "http://fasb.org/us-gaap/2025": 6,
    "http://xbrl.sec.gov/dei/2025": 3
   },
   "contextCount": 212,
   "entityCount": 1,
   "segmentCount": 83,
   "elementCount": 741,
   "unitCount": 7,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 604,
    "http://xbrl.sec.gov/dei/2025": 42,
    "http://xbrl.sec.gov/cyd/2025": 14,
    "http://xbrl.sec.gov/ecd/2025": 8
   },
   "report": {
    "R1": {
     "role": "http://climbbio.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "75000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
     "longName": "75010 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_135efb28-52e9-4b39-b859-c79c58e3ffaa",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_135efb28-52e9-4b39-b859-c79c58e3ffaa",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "75020 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_135efb28-52e9-4b39-b859-c79c58e3ffaa",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "U_USDollarShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_135efb28-52e9-4b39-b859-c79c58e3ffaa",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "U_USDollarShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "longName": "75030 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "clym:AcquiredInProcessResearchAndDevelopmentExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://climbbio.com/20251231/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical",
     "longName": "75040 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R6": {
     "role": "http://climbbio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
     "longName": "75050 - Statement - Consolidated Statements of Stockholders' Equity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_c2a2497b-98c5-4d07-ac31-0ab57e9c6f6a",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c2a2497b-98c5-4d07-ac31-0ab57e9c6f6a",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://climbbio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical",
     "longName": "75060 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "shortName": "Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_1f63916b-0391-41c4-8463-6860486b9487",
      "name": "us-gaap:NoninterestExpenseOfferingCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1f63916b-0391-41c4-8463-6860486b9487",
      "name": "us-gaap:NoninterestExpenseOfferingCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
     "longName": "75070 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R10": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_e1c23734-80c9-41dd-8d11-0134db853cac",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e1c23734-80c9-41dd-8d11-0134db853cac",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://climbbio.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance",
     "longName": "995457 - Disclosure - Cybersecurity Risk Management, Strategy and Governance",
     "shortName": "Cybersecurity Risk Management, Strategy and Governance",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentation",
     "longName": "995467 - Disclosure - Nature of Operations and Basis of Presentation",
     "shortName": "Nature of Operations and Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies",
     "longName": "995477 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedParty1",
     "longName": "995487 - Disclosure - Asset Acquisition and Private Placement with a Related Party",
     "shortName": "Asset Acquisition and Private Placement with a Related Party",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:AssetAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:AssetAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurements",
     "longName": "995497 - Disclosure - Marketable Securities and Fair Value Measurements",
     "shortName": "Marketable Securities and Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://climbbio.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities",
     "longName": "995507 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://climbbio.com/20251231/taxonomy/role/DisclosureRelatedPartyTransactions",
     "longName": "995517 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://climbbio.com/20251231/taxonomy/role/DisclosureLeases",
     "longName": "995527 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies",
     "longName": "995547 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensation",
     "longName": "995557 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://climbbio.com/20251231/taxonomy/role/DisclosureNetLossPerShare1",
     "longName": "995567 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxes",
     "longName": "995577 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureDefinedContributionPlan",
     "longName": "995587 - Disclosure - Defined Contribution Plan",
     "shortName": "Defined Contribution Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:DefinedBenefitPlanTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:DefinedBenefitPlanTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://climbbio.com/20251231/taxonomy/role/DisclosureRestructuringCosts",
     "longName": "995597 - Disclosure - Restructuring Costs",
     "shortName": "Restructuring Costs",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://climbbio.com/20251231/taxonomy/role/DisclosureSegments",
     "longName": "995607 - Disclosure - Segments",
     "shortName": "Segments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "995627 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "longName": "995637 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "clym:ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "clym:ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyTables",
     "longName": "995647 - Disclosure - Asset Acquisition and Private Placement with a Related Party (Tables)",
     "shortName": "Asset Acquisition and Private Placement with a Related Party (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsTables",
     "longName": "995657 - Disclosure - Marketable Securities and Fair Value Measurements (Tables)",
     "shortName": "Marketable Securities and Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://climbbio.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables",
     "longName": "995667 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesTables",
     "longName": "995677 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationTables",
     "longName": "995687 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://climbbio.com/20251231/taxonomy/role/DisclosureNetLossPerShareTables",
     "longName": "995697 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesTables",
     "longName": "995707 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://climbbio.com/20251231/taxonomy/role/DisclosureRestructuringCostsTables",
     "longName": "995717 - Disclosure - Restructuring Costs (Tables)",
     "shortName": "Restructuring Costs (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://climbbio.com/20251231/taxonomy/role/DisclosureSegmentsTables",
     "longName": "995727 - Disclosure - Segments (Tables)",
     "shortName": "Segments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
     "longName": "995737 - Disclosure - Nature of Operations and Basis of Presentation - Additional Information (Details)",
     "shortName": "Nature of Operations and Basis of Presentation - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "dei:EntityIncorporationDateOfIncorporation",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "dei:EntityIncorporationDateOfIncorporation",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://climbbio.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails",
     "longName": "995757 - Disclosure - Summary of Significant Accounting Policies - Schedule of Property and Equipment Estimated Useful Life (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Property and Equipment Estimated Useful Life (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_bed1b934-9767-4736-8d75-5898620908e6",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "clym:ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_bed1b934-9767-4736-8d75-5898620908e6",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "clym:ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "longName": "995767 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "U_Segments",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "us-gaap:NumberOfReportableSegments",
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:MarketableSecuritiesPolicy",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyAdditionalInformationDetails",
     "longName": "995777 - Disclosure - Asset Acquisition and Private Placement with a Related Party - Additional Information (Details)",
     "shortName": "Asset Acquisition and Private Placement with a Related Party - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:ProceedsFromIssuanceOfPrivatePlacement",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_29397fb4-e48e-4a21-bd44-1d67c539182e",
      "name": "clym:BusinessCombinationConsiderationTransferredSettlementOfPreExistingLoan",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyScheduleOfPurchaseConsiderationForTheAcquisitionBasedOnTheFairValueOfThe",
     "longName": "995797 - Disclosure - Asset Acquisition and Private Placement with a Related Party - Schedule of Purchase Consideration For The Acquisition Based On The Fair Value Of The Net Assets Acquired By The Company (Details)",
     "shortName": "Asset Acquisition and Private Placement with a Related Party - Schedule of Purchase Consideration For The Acquisition Based On The Fair Value Of The Net Assets Acquired By The Company (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_17e50103-a558-453b-9429-8e636ff6a3b8",
      "name": "clym:AmountOfIn-ProcessResearchAndDevelopmentAssetsAcquired",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_17e50103-a558-453b-9429-8e636ff6a3b8",
      "name": "clym:AmountOfIn-ProcessResearchAndDevelopmentAssetsAcquired",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfMarketableSecuritiesConsistedOfAvailableforsaleSecuritiesDetails",
     "longName": "995807 - Disclosure - Marketable Securities and Fair Value Measurements - Schedule of Marketable securities consisted of available-for-sale securities (Details)",
     "shortName": "Marketable Securities and Fair Value Measurements - Schedule of Marketable securities consisted of available-for-sale securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_135efb28-52e9-4b39-b859-c79c58e3ffaa",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_135efb28-52e9-4b39-b859-c79c58e3ffaa",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
     "longName": "995817 - Disclosure - Marketable Securities and Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)",
     "shortName": "Marketable Securities and Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_428a9132-cc2d-4fef-8e17-79b45da3689d",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_428a9132-cc2d-4fef-8e17-79b45da3689d",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCertainBalanceSheetAccountsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails",
     "longName": "995827 - Disclosure - Certain Balance Sheet Accounts - Summary of Prepaid Expenses and Other Current Assets (Details)",
     "shortName": "Certain Balance Sheet Accounts - Summary of Prepaid Expenses and Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_135efb28-52e9-4b39-b859-c79c58e3ffaa",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R46": {
     "role": "http://climbbio.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails",
     "longName": "995837 - Disclosure - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details)",
     "shortName": "Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_135efb28-52e9-4b39-b859-c79c58e3ffaa",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_135efb28-52e9-4b39-b859-c79c58e3ffaa",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://climbbio.com/20251231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
     "longName": "995857 - Disclosure - Related Party Transactions - Additional Information (Details)",
     "shortName": "Related Party Transactions - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_e56178b2-2c10-48d7-b80d-784d82a747b6",
      "name": "clym:SharesExchangedForPreFundedWarrants",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3a734757-e1ee-40b3-8578-67d0507ee846",
      "name": "us-gaap:OtherExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfLeaseExpenseDetails",
     "longName": "995877 - Disclosure - Leases - Schedule of Lease Expense (Details)",
     "shortName": "Leases - Schedule of Lease Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfCashFlowInformationRelatedToLeasesDetails",
     "longName": "995887 - Disclosure - Leases - Schedule of Cash Flow Information Related to Leases (Details)",
     "shortName": "Leases - Schedule of Cash Flow Information Related to Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfAnnualFutureMinimumLeasePaymentsDueUnderTheCompanysNoncancelableOperatingLeaseDetails",
     "longName": "995897 - Disclosure - Leases - Schedule of Annual Future Minimum Lease Payments Due Under the Company's Non-cancelable Operating Lease (Details)",
     "shortName": "Leases - Schedule of Annual Future Minimum Lease Payments Due Under the Company's Non-cancelable Operating Lease (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_135efb28-52e9-4b39-b859-c79c58e3ffaa",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_135efb28-52e9-4b39-b859-c79c58e3ffaa",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfOperatingLeaseLiabilitiesDetails",
     "longName": "995907 - Disclosure - Leases - Schedule of Operating Lease Liabilities (Details)",
     "shortName": "Leases - Schedule of Operating Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_135efb28-52e9-4b39-b859-c79c58e3ffaa",
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R52": {
     "role": "http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
     "longName": "995917 - Disclosure - Leases (Additional Information) (Details)",
     "shortName": "Leases (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:LeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_135efb28-52e9-4b39-b859-c79c58e3ffaa",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "longName": "995927 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e8ccac22-cccd-4604-a52d-f88a9f26a088",
      "name": "clym:MilestonePaymentsDue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
     "longName": "995937 - Disclosure - Stock-Based Compensation - Additional Information (Details)",
     "shortName": "Stock-Based Compensation - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_80658773-af42-4dbf-91d7-91c7e6c647c7",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_80658773-af42-4dbf-91d7-91c7e6c647c7",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivitiesDetails",
     "longName": "995947 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activities (Details)",
     "shortName": "Stock-Based Compensation - Summary of Stock Option Activities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedInBlackScholesModelDetails",
     "longName": "995957 - Disclosure - Stock-Based Compensation - Summary of Assumptions Used in Black-Scholes Model (Details)",
     "shortName": "Stock-Based Compensation - Summary of Assumptions Used in Black-Scholes Model (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardsDetails",
     "longName": "995967 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Awards (Details)",
     "shortName": "Stock-Based Compensation - Summary of Restricted Stock Awards (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "C_c751770e-5639-4fb1-ae0f-ff557e717b97",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c751770e-5639-4fb1-ae0f-ff557e717b97",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfShareBasedCompensationExpenseDetails",
     "longName": "995977 - Disclosure - Stock-Based Compensation - Summary of Share-based Compensation Expense (Details)",
     "shortName": "Stock-Based Compensation - Summary of Share-based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R59": {
     "role": "http://climbbio.com/20251231/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails",
     "longName": "995987 - Disclosure - Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details)",
     "shortName": "Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1f63916b-0391-41c4-8463-6860486b9487",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://climbbio.com/20251231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfNetLossPerShareAttributableToCommonStockholdersDetails",
     "longName": "995997 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Net Loss Per Share Attributable To Common Stockholders (Details)",
     "shortName": "Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Net Loss Per Share Attributable To Common Stockholders (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
     "longName": "996007 - Disclosure - Income Taxes - Additional information (Details)",
     "shortName": "Income Taxes - Additional information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "C_135efb28-52e9-4b39-b859-c79c58e3ffaa",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_135efb28-52e9-4b39-b859-c79c58e3ffaa",
      "name": "clym:PercentageOfAnnualDeductionOfTaxableIncome",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetLossBeforeTaxProvisionFromIncomeTaxesDetails",
     "longName": "996017 - Disclosure - Income Taxes - Components of Net Loss Before Tax Provision from Income Taxes (Details)",
     "shortName": "Income Taxes - Components of Net Loss Before Tax Provision from Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8c7ebad7-98a1-4e64-b935-7123699f4e44",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToProvisionForIncomeTaxesDetails",
     "longName": "996027 - Disclosure - Income Taxes - Schedule of Reconciliation of Statutory Federal Income Tax Rate to Provision for Income Taxes (Details)",
     "shortName": "Income Taxes - Schedule of Reconciliation of Statutory Federal Income Tax Rate to Provision for Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails",
     "longName": "996037 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "shortName": "Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "C_135efb28-52e9-4b39-b859-c79c58e3ffaa",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_135efb28-52e9-4b39-b859-c79c58e3ffaa",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfValuationAllowanceDetails",
     "longName": "996047 - Disclosure - Income Taxes - Schedule of Valuation Allowance (Details)",
     "shortName": "Income Taxes - Schedule of Valuation Allowance (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetails",
     "longName": "996057 - Disclosure - Defined Contribution Plan - Additional Information (Details)",
     "shortName": "Defined Contribution Plan - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "C_f3c7c70c-8584-4bd4-8cb7-4ec3bb217286",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DefinedBenefitPlanTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f3c7c70c-8584-4bd4-8cb7-4ec3bb217286",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DefinedBenefitPlanTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://climbbio.com/20251231/taxonomy/role/DisclosureRestructuringCostsSummaryOfRestructuringCostsInStatementOfOperationsDetails",
     "longName": "996067 - Disclosure - Restructuring Costs - Summary of restructuring costs in statement of operations (Details)",
     "shortName": "Restructuring Costs - Summary of restructuring costs in statement of operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "C_80658773-af42-4dbf-91d7-91c7e6c647c7",
      "name": "us-gaap:RestructuringCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_80658773-af42-4dbf-91d7-91c7e6c647c7",
      "name": "us-gaap:RestructuringCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://climbbio.com/20251231/taxonomy/role/DisclosureSegmentsAdditionalInformationDetails",
     "longName": "996087 - Disclosure - Segments (Additional Information) (Details)",
     "shortName": "Segments (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "U_Segments",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "U_Segments",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://climbbio.com/20251231/taxonomy/role/DisclosureSegmentsScheduleOfForthDisaggregatedResearchAndDevelopmentExpensesDetails",
     "longName": "996097 - Disclosure - Segments - Schedule of Forth Disaggregated Research and Development Expenses (Details)",
     "shortName": "Segments - Schedule of Forth Disaggregated Research and Development Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4a576f93-6b66-4d5d-b1c0-bff422cdc503",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://climbbio.com/20251231/taxonomy/role/DisclosureSegmentsScheduleOfForthDisaggregatedResearchAndDevelopmentExpensesParentheticalDetails",
     "longName": "996107 - Disclosure - Segments - Schedule of Forth Disaggregated Research and Development Expenses (Parenthetical) (Details)",
     "shortName": "Segments - Schedule of Forth Disaggregated Research and Development Expenses (Parenthetical) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "C_80b88047-d92c-4121-9779-7cec8fdafae6",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "clym-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Expenses and Other Current Liabilities",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "totalLabel": "Accounts Payable, Current, Total",
        "terseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r1008"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "terseLabel": "Accretion of discounts and amortization of premiums on investments, net",
        "negatedLabel": "Accretion of discounts on marketable securities, net",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "clym_AccruedExternalResearchAndDevelopmentsExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "AccruedExternalResearchAndDevelopmentsExpense",
     "crdr": "credit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails2": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued external research and development expenses",
        "label": "Accrued External Research And Developments Expense",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for external research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Accrued Liabilities and Other Liabilities",
        "totalLabel": "Total accrued expenses and other current liabilities",
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails2": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued professional fees",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total",
        "terseLabel": "Accumulated other comprehensive income",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r15",
      "r53",
      "r115",
      "r768",
      "r797",
      "r798",
      "r1316"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r8",
      "r15",
      "r597",
      "r600",
      "r668",
      "r793",
      "r794",
      "r1173",
      "r1174",
      "r1175",
      "r1228",
      "r1229",
      "r1230",
      "r1231"
     ]
    },
    "clym_AcelyrinAssetPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "AcelyrinAssetPurchaseAgreementMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acelyrin Asset Purchase Agreement [Member]",
        "documentation": "Acelyrin Asset Purchase Agreement [Member]",
        "terseLabel": "Acelyrin Asset Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "clym_AcelyrinIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "AcelyrinIncMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acelyrin, Inc. [Member]",
        "terseLabel": "Acelyrin Inc. [Member]",
        "documentation": "Acelyrin, Inc. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "clym_AcquiredInProcessResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "AcquiredInProcessResearchAndDevelopmentExpenses",
     "crdr": "debit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      },
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "In-process research and development, related party",
        "label": "Acquired In Process Research and Development Expenses",
        "documentation": "The amount of in-process research and development assets acquired during the period.",
        "verboseLabel": "Acquired in-process research and development, related party"
       }
      }
     },
     "auth_ref": []
    },
    "clym_AcquisitionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "AcquisitionAgreementMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisition Agreement [Member]",
        "documentation": "Acquisition Agreement",
        "terseLabel": "Acquisition Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1087"
     ]
    },
    "clym_AdditionalOfficeSpaceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "AdditionalOfficeSpaceMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Office Space [Member]",
        "documentation": "Additional Office Space [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance",
        "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r814",
      "r1228",
      "r1229",
      "r1230",
      "r1231",
      "r1317",
      "r1385"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r1100"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r1100"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r1100"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1100"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Stock issuance costs",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r69"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "clym_AfterFirstAnniversaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "AfterFirstAnniversaryMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "After First Anniversary [Member]",
        "documentation": "After First Anniversary Member",
        "terseLabel": "After First Anniversary [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "clym_AggregateBeneficialOwnershipExchangingStockholders": {
     "xbrltype": "percentItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "AggregateBeneficialOwnershipExchangingStockholders",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Beneficial Ownership Exchanging Stockholders",
        "documentation": "The aggregate amount of beneficial ownership that exchanging shareholders may own to be eligible to exercise pre-funded warrants, as a percentage of shares issued and outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "clym_AggregateGrossSalesProceedsUnderSalesAgreements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "AggregateGrossSalesProceedsUnderSalesAgreements",
     "crdr": "debit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate gross sales proceeds under sales agreement",
        "label": "Aggregate Gross Sales Proceeds Under Sales Agreements",
        "documentation": "The aggregate gross sales proceeds available under a sales agreement to sell shares of the Company's common stock."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r1145"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1058",
      "r1069",
      "r1079",
      "r1112"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r1061",
      "r1072",
      "r1082",
      "r1115"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r1146"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r1100"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r1107"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r1062",
      "r1073",
      "r1083",
      "r1107",
      "r1116",
      "r1120",
      "r1128"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r1126"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureSegmentsScheduleOfForthDisaggregatedResearchAndDevelopmentExpensesParentheticalDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r463",
      "r469",
      "r478"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "clym_AmountOfIn-ProcessResearchAndDevelopmentAssetsAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "AmountOfIn-ProcessResearchAndDevelopmentAssetsAcquired",
     "crdr": "debit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyScheduleOfPurchaseConsiderationForTheAcquisitionBasedOnTheFairValueOfThe"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "In-process research and development",
        "label": "Amount of in-process research and development assets acquired",
        "documentation": "Amount of in-process research and development asset acquired in business combination and recognized at acquisition date"
       }
      }
     },
     "auth_ref": []
    },
    "clym_AmountOfPromissoryLoanSettledInConnectionWithAnAssetAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "AmountOfPromissoryLoanSettledInConnectionWithAnAssetAcquisition",
     "crdr": "credit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of promissory loan settled in connection with an asset acquisition",
        "documentation": "Amount of promissory loan settled in connection with an asset acquisition",
        "terseLabel": "Settlement of promissory loan in connection with asset acquisition"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Total potentially dilutive shares",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "us-gaap_AssetAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionAxis",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Axis]",
        "documentation": "Information by asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r801",
      "r1312"
     ]
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionConsiderationTransferredTransactionCost",
     "crdr": "credit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition, Consideration Transferred, Transaction Cost",
        "terseLabel": "Transaction costs",
        "documentation": "Amount of transaction cost incurred as part of consideration transferred in asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r990",
      "r1313",
      "r1314",
      "r1315"
     ]
    },
    "us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionContingentConsiderationTableTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition, Contingent Consideration [Table Text Block]",
        "terseLabel": "Summary of Total Consideration Comprised of Following",
        "documentation": "Tabular disclosure of contingent consideration in asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r1312"
     ]
    },
    "us-gaap_AssetAcquisitionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionDomain",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Domain]",
        "documentation": "Asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r801",
      "r1312"
     ]
    },
    "us-gaap_AssetAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionLineItems",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Line Items]",
        "terseLabel": "Asset Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r1312"
     ]
    },
    "us-gaap_AssetAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionTable",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Table]",
        "terseLabel": "Asset Acquisition [Table]",
        "documentation": "Disclosure of information about asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r1312"
     ]
    },
    "us-gaap_AssetAcquisitionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedParty1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Text Block]",
        "terseLabel": "Asset Acquisition and Private Placement with a Related Party",
        "documentation": "The entire disclosure for asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r578",
      "r1312"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r85",
      "r111",
      "r139",
      "r141",
      "r142",
      "r179",
      "r194",
      "r211",
      "r215",
      "r258",
      "r305",
      "r306",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r314",
      "r315",
      "r585",
      "r589",
      "r632",
      "r755",
      "r756",
      "r764",
      "r852",
      "r948",
      "r949",
      "r961",
      "r1008",
      "r1023",
      "r1024",
      "r1036",
      "r1257",
      "r1258",
      "r1339"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r117",
      "r139",
      "r141",
      "r142",
      "r258",
      "r305",
      "r306",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r314",
      "r315",
      "r585",
      "r589",
      "r632",
      "r1008",
      "r1257",
      "r1258",
      "r1339"
     ]
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Assets Fair Value Disclosure",
        "totalLabel": "Assets, Fair Value Disclosure, Total",
        "verboseLabel": "Total assets",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r611",
      "r612",
      "r996"
     ]
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "auth_ref": []
    },
    "clym_AtTheMarketEquityOfferingProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "AtTheMarketEquityOfferingProgramMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "At The Market Equity Offering Program [Member]",
        "documentation": "At The Market Equity Offering Program [Member]",
        "terseLabel": "At The Market Equity Offering Program [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r1041",
      "r1042",
      "r1065"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLocation",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r1041",
      "r1042",
      "r1065"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorName",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r1041",
      "r1042",
      "r1065"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1149"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfMarketableSecuritiesConsistedOfAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized Gain",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r232"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfMarketableSecuritiesConsistedOfAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "terseLabel": "Unrealized Loss",
        "negatedLabel": "Unrealized Loss",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r233"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "label": "Debt Securities, Available-for-Sale",
        "totalLabel": "Debt Securities, Available-for-Sale, Total",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r272",
      "r611",
      "r625",
      "r626",
      "r627",
      "r628",
      "r752",
      "r922",
      "r996",
      "r999",
      "r1006",
      "r1242",
      "r1321",
      "r1322",
      "r1323"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "crdr": "debit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfMarketableSecuritiesConsistedOfAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Current",
        "terseLabel": "Estimated Fair Value, Short-term marketable securities",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r272"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfMarketableSecuritiesConsistedOfAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Noncurrent",
        "terseLabel": "Estimated Fair Value, Long-term marketable securities",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r226",
      "r272"
     ]
    },
    "us-gaap_AwardDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardDateAxis",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Date [Axis]",
        "documentation": "Information by date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r1264",
      "r1265",
      "r1266",
      "r1267",
      "r1268",
      "r1269",
      "r1270",
      "r1271",
      "r1272",
      "r1273",
      "r1274",
      "r1275",
      "r1276",
      "r1277",
      "r1278",
      "r1279",
      "r1280",
      "r1281",
      "r1282",
      "r1283",
      "r1284",
      "r1285",
      "r1286",
      "r1287",
      "r1288",
      "r1289"
     ]
    },
    "us-gaap_AwardDateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardDateDomain",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Date [Domain]",
        "documentation": "Date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r1264",
      "r1265",
      "r1266",
      "r1267",
      "r1268",
      "r1269",
      "r1270",
      "r1271",
      "r1272",
      "r1273",
      "r1274",
      "r1275",
      "r1276",
      "r1277",
      "r1278",
      "r1279",
      "r1280",
      "r1281",
      "r1282",
      "r1283",
      "r1284",
      "r1285",
      "r1286",
      "r1287",
      "r1288",
      "r1289"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r1123"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r1124"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r1119"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r1119"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r1119"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r1119"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1119"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r1119"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r435",
      "r436",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r1122"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1121"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r1120"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r1120"
     ]
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r1220"
     ]
    },
    "clym_BlackbirdClinicalAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "BlackbirdClinicalAgreementMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Blackbird Clinical Agreement [Member]",
        "documentation": "Blackbird Clinical Agreement [Member]",
        "terseLabel": "Blackbird Clinical Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "clym_BudoprutugServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "BudoprutugServiceMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureSegmentsScheduleOfForthDisaggregatedResearchAndDevelopmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Budoprutug Service [Member]",
        "documentation": "Budoprutug Service [Member]",
        "terseLabel": "Budoprutug"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination [Domain]",
        "documentation": "Business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r801",
      "r972",
      "r975",
      "r1303",
      "r1306",
      "r1308"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r801",
      "r972",
      "r975",
      "r1303",
      "r1306",
      "r1308"
     ]
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyScheduleOfPurchaseConsiderationForTheAcquisitionBasedOnTheFairValueOfThe"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r525",
      "r526",
      "r527",
      "r528",
      "r534",
      "r535",
      "r536",
      "r537",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r572",
      "r573",
      "r574",
      "r577",
      "r983",
      "r987",
      "r1303",
      "r1306",
      "r1308"
     ]
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationConsiderationTransferred1",
     "crdr": "credit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total consideration",
        "label": "Business Combination, Consideration Transferred",
        "totalLabel": "Total consideration",
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer."
       }
      }
     },
     "auth_ref": [
      "r562",
      "r574",
      "r983",
      "r984"
     ]
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "crdr": "credit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyTheFairValueOfTheTotalConsiderationComprisedOfTheComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Consideration Transferred, Equity Interest",
        "terseLabel": "Equity consideration",
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination."
       }
      }
     },
     "auth_ref": [
      "r983",
      "r984",
      "r985",
      "r988",
      "r989"
     ]
    },
    "clym_BusinessCombinationConsiderationTransferredSettlementOfPreExistingLoan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "BusinessCombinationConsiderationTransferredSettlementOfPreExistingLoan",
     "crdr": "credit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination Consideration Transferred Settlement Of Pre-Existing Loan",
        "terseLabel": "Settlement of pre-existing loan",
        "documentation": "Amount of a pre-existing loan that was settled as part of a business combination."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyScheduleOfPurchaseConsiderationForTheAcquisitionBasedOnTheFairValueOfThe"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets acquired",
        "label": "Business Combination, Recognized Asset Acquired, Asset [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyScheduleOfPurchaseConsiderationForTheAcquisitionBasedOnTheFairValueOfThe"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Asset Acquired, Cash and Cash Equivalent",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Amount of cash and cash equivalent acquired in business combination and recognized at acquisition date."
       }
      }
     },
     "auth_ref": [
      "r1307",
      "r1309"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets",
     "crdr": "debit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyScheduleOfPurchaseConsiderationForTheAcquisitionBasedOnTheFairValueOfThe"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets acquired",
        "label": "Business Combination, Recognized Asset Acquired, Asset, Current",
        "documentation": "Amount of asset acquired in business combination and recognized at acquisition date, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1307",
      "r1309"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "crdr": "debit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyScheduleOfPurchaseConsiderationForTheAcquisitionBasedOnTheFairValueOfThe"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Business Combination, Recognized Asset Acquired, Prepaid Expense and Other Asset, Current",
        "documentation": "Amount of prepaid expense and asset classified as other, acquired in business combination and recognized at acquisition date, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1307",
      "r1309"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyScheduleOfPurchaseConsiderationForTheAcquisitionBasedOnTheFairValueOfThe"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Liability Assumed, Liability, Current",
        "totalLabel": "Total liabilities assumed",
        "negatedTotalLabel": "Total liabilities assumed",
        "documentation": "Amount of liability assumed in business combination and recognized at acquisition date, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1307",
      "r1309"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "crdr": "credit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyScheduleOfPurchaseConsiderationForTheAcquisitionBasedOnTheFairValueOfThe"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Business Combination, Recognized Liability Assumed, Accounts Payable, Current",
        "negatedLabel": "Accounts payable",
        "documentation": "Amount of accounts payable assumed in business combination and recognized at acquisition date, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1307",
      "r1309"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther",
     "crdr": "credit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyScheduleOfPurchaseConsiderationForTheAcquisitionBasedOnTheFairValueOfThe"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Liability Assumed, Other Liability, Current",
        "terseLabel": "Accrued expenses and other current liabilities",
        "negatedLabel": "Accrued expenses and other current liabilities",
        "documentation": "Amount of liability assumed in business combination and recognized at acquisition date, classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r1307",
      "r1309"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyScheduleOfPurchaseConsiderationForTheAcquisitionBasedOnTheFairValueOfThe"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities assumed",
        "label": "Business Combination, Recognized Liability Assumed, Liability [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyScheduleOfPurchaseConsiderationForTheAcquisitionBasedOnTheFairValueOfThe"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less)",
        "totalLabel": "Net assets acquired",
        "documentation": "Amount of asset acquired in excess of (less than) liability assumed in business combination and recognized at acquisition date. Excludes goodwill."
       }
      }
     },
     "auth_ref": [
      "r983",
      "r984",
      "r1307",
      "r1309"
     ]
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationsPolicy",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination [Policy Text Block]",
        "terseLabel": "Asset Acquisitions",
        "documentation": "Disclosure of accounting policy for business combination."
       }
      }
     },
     "auth_ref": [
      "r523",
      "r524",
      "r530",
      "r532",
      "r543",
      "r551",
      "r555",
      "r983",
      "r985",
      "r988",
      "r989"
     ]
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Nature of Operations and Basis of Presentation",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r1168",
      "r1220"
     ]
    },
    "clym_CLYM116Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "CLYM116Member",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureSegmentsScheduleOfForthDisaggregatedResearchAndDevelopmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CLYM1161",
        "label": "CLYM116 [Member]",
        "documentation": "CLYM116 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalent",
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r108",
      "r925"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
      "http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfMarketableSecuritiesConsistedOfAvailableforsaleSecuritiesDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r626",
      "r627",
      "r628",
      "r1319",
      "r1320"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r73"
     ]
    },
    "clym_CashCashEquivalentsAndMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "CashCashEquivalentsAndMarketableSecurities",
     "crdr": "debit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Cash Equivalents and Marketable Securities",
        "documentation": "Cash Cash Equivalents and Marketable Securities.",
        "terseLabel": "Cash, cash equivalents and marketable securities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "totalLabel": "Cash, Cash Equivalents, and Short-Term Investments, Total",
        "terseLabel": "Cash, cash equivalents and marketable securities",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r1172"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Total",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r60",
      "r136"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation",
        "totalLabel": "Net change in cash and cash equivalents",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r60"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1098"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r1095"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r1093"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails",
      "http://climbbio.com/20251231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r112",
      "r113",
      "r114",
      "r139",
      "r142",
      "r168",
      "r169",
      "r171",
      "r173",
      "r181",
      "r182",
      "r258",
      "r305",
      "r308",
      "r309",
      "r310",
      "r314",
      "r315",
      "r320",
      "r321",
      "r323",
      "r324",
      "r326",
      "r328",
      "r330",
      "r331",
      "r332",
      "r333",
      "r335",
      "r632",
      "r804",
      "r805",
      "r806",
      "r807",
      "r814",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r840",
      "r861",
      "r884",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r1152",
      "r1223",
      "r1224",
      "r1232"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r144",
      "r336"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r1099"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1099"
     ]
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLicenseAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "License Agreements",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r581",
      "r582"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "clym_CommercialMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "CommercialMilestonesMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commercial Milestones [Member]",
        "documentation": "Commercial Milestones [Member]",
        "terseLabel": "Commercial Milestones [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 8)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r77",
      "r766",
      "r839"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r299",
      "r300",
      "r909",
      "r1252",
      "r1254"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock reserved for future issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "clym_CommonStockIssuedInExchangeForIn-ProcessResearchAndDevelopmentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "CommonStockIssuedInExchangeForIn-ProcessResearchAndDevelopmentAssets",
     "crdr": "credit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued in exchange for in-process research and development assets",
        "documentation": "The value of common stock issued in exchange for in-process research and development asset as part of an asset acquisition.",
        "terseLabel": "Issuance of common stock in exchange for in-process research and development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails",
      "http://climbbio.com/20251231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://climbbio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r1026",
      "r1027",
      "r1028",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1228",
      "r1229",
      "r1231",
      "r1317",
      "r1381",
      "r1385"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r840"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Common Stock, Shares, Issued, Total",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r47",
      "r840",
      "r858",
      "r1385",
      "r1386"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "totalLabel": "Common Stock, Value, Issued, Total",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value; 250,000,000 shares authorized; 47,766,338 and 67,255,434 shares issued and outstanding at December 31, 2025 and 2024, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r321",
      "r327",
      "r767",
      "r1008"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r1104"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r1103"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r1105"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r1102"
     ]
    },
    "clym_CompanyStockOwnedByRACapitalImmediatelyPriorToAcquisitionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "CompanyStockOwnedByRACapitalImmediatelyPriorToAcquisitionMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Stock Owned By RA Capital Immediately Prior to Acquisition [Member]",
        "label": "Company Stock Owned By RA Capital Immediately Prior to Acquisition [Member]",
        "documentation": "Company Stock Owned By RA Capital Immediately Prior to Acquisition [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r119",
      "r121",
      "r126",
      "r753",
      "r778",
      "r779"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive loss:",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk and Significant Suppliers and Manufacturers",
        "documentation": "Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r629",
      "r630"
     ]
    },
    "srt_ConsolidationItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ConsolidationItemsAxis",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureSegmentsScheduleOfForthDisaggregatedResearchAndDevelopmentExpensesDetails",
      "http://climbbio.com/20251231/taxonomy/role/DisclosureSegmentsScheduleOfForthDisaggregatedResearchAndDevelopmentExpensesParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]"
       }
      }
     },
     "auth_ref": [
      "r83",
      "r139",
      "r140",
      "r146",
      "r147",
      "r179",
      "r195",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r215",
      "r216",
      "r217",
      "r305",
      "r306",
      "r307",
      "r308",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r759",
      "r948",
      "r949",
      "r1257",
      "r1258"
     ]
    },
    "srt_ConsolidationItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ConsolidationItemsDomain",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureSegmentsScheduleOfForthDisaggregatedResearchAndDevelopmentExpensesDetails",
      "http://climbbio.com/20251231/taxonomy/role/DisclosureSegmentsScheduleOfForthDisaggregatedResearchAndDevelopmentExpensesParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]"
       }
      }
     },
     "auth_ref": [
      "r83",
      "r139",
      "r140",
      "r146",
      "r147",
      "r179",
      "r195",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r215",
      "r216",
      "r217",
      "r305",
      "r306",
      "r307",
      "r308",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r759",
      "r948",
      "r949",
      "r1257",
      "r1258"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principles of Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r933"
     ]
    },
    "clym_ConsultantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "ConsultantMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consultant [Member]",
        "documentation": "Consultant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CorporateBondSecuritiesMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
      "http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfMarketableSecuritiesConsistedOfAvailableforsaleSecuritiesDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Corporate Bond [Member]",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate Bond Securities [Member]",
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount)."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "clym_CrhAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "CrhAgreementMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CRH Agreement [Member]",
        "label": "CRH Agreement [Member]",
        "documentation": "CRH Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "clym_CumulativeChangeInOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "CumulativeChangeInOwnershipPercentage",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cumulative change in ownership percentage",
        "label": "Cumulative Change In Ownership Percentage",
        "documentation": "Cumulative change in ownership percentage."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1050",
      "r1139"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1050",
      "r1139"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1052",
      "r1141"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1052",
      "r1141"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1054",
      "r1143"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1052",
      "r1141"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1045",
      "r1134"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1046",
      "r1135"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1046",
      "r1135"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r1044",
      "r1133"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1044",
      "r1133"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r1044",
      "r1133"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1047",
      "r1136"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1049",
      "r1138"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1049",
      "r1138"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1050",
      "r1139"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1053",
      "r1142"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1051",
      "r1140"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1048",
      "r1137"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
     "crdr": "debit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfMarketableSecuritiesConsistedOfAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Current",
        "terseLabel": "Amortized Cost, Short-term marketable securities",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r1244"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfMarketableSecuritiesConsistedOfAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Noncurrent",
        "terseLabel": "Amortized Cost, Long-term marketable securities",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r1244"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded",
     "crdr": "debit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest, Allowance for Credit Loss, Not Previously Recorded",
        "terseLabel": "Credit losses",
        "documentation": "Amount, excluding accrued interest, of credit loss expense on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) with no credit loss previously recorded."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r276"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfMarketableSecuritiesConsistedOfAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Table]",
        "terseLabel": "Debt Securities Available For Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239"
     ]
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Summary of Prepaid Expenses and Other Current Assets",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Tax Liabilities, Gross, Total",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r44",
      "r76",
      "r503"
     ]
    },
    "us-gaap_DeferredRevenueArrangementTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredRevenueArrangementTypeAxis",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Revenue Arrangement Type [Axis]",
        "documentation": "Information by type of deferred revenue arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredRevenueArrangementTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredRevenueArrangementTypeDomain",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Revenue [Domain]",
        "documentation": "Category of obligation arising when an entity receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Intangible asset",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": [
      "r1299"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total gross deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGrossAbstract",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets:",
        "label": "Deferred Tax Assets, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets and liabilities",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1296"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1296"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating losses",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1299"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other expenses",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1299"
     ]
    },
    "clym_DeferredTaxAssetsResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "DeferredTaxAssetsResearchAndDevelopmentExpenses",
     "crdr": "debit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenses",
        "label": "Deferred Tax Assets Research And Development Expenses",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from research and development expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development credits",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research credits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1299"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation",
     "crdr": "debit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued compensation and benefits",
        "terseLabel": "Accrued payroll taxes",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation."
       }
      }
     },
     "auth_ref": [
      "r1299"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation, including 162m limitations",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1299"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfValuationAllowanceDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets, Valuation allowance",
        "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation Allowance",
        "periodStartLabel": "Valuation allowance as of beginning of year",
        "periodEndLabel": "Valuation allowance as of end of year",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities:",
        "label": "Deferred Tax Liabilities, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "crdr": "credit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "terseLabel": "Operating lease, right-of-use asset",
        "negatedLabel": "Operating lease, right-of-use asset",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements."
       }
      }
     },
     "auth_ref": [
      "r1299"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesOther",
     "crdr": "credit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Other",
        "terseLabel": "Other assets",
        "negatedLabel": "Other assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other."
       }
      }
     },
     "auth_ref": [
      "r1299"
     ]
    },
    "clym_DefferedTaxAssetOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "DefferedTaxAssetOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deffered Tax Asset Operating Lease Liability",
        "terseLabel": "Operating lease liabilities",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r388",
      "r389",
      "r390",
      "r392",
      "r395",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r421"
     ]
    },
    "us-gaap_DefinedBenefitPlanTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedBenefitPlanTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureDefinedContributionPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan [Text Block]",
        "terseLabel": "Defined Contribution Plan",
        "documentation": "The entire disclosure for defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r391",
      "r393",
      "r396",
      "r407",
      "r409",
      "r411",
      "r712",
      "r970"
     ]
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedContributionPlanCostRecognized",
     "crdr": "debit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Total expense recognized from matching contributions",
        "documentation": "Amount of cost for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "clym_DefinedContributionPlanEmployerContributionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "DefinedContributionPlanEmployerContributionAmount",
     "crdr": "debit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Contribution Plan Employer Contribution Amount",
        "label": "Defined Contribution Plan Employer Contribution Amount",
        "documentation": "Defined Contribution Plan Employer Contribution Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Defined contribution plan, employer matching contribution, percentage of employee's eligilble compensation",
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, Depletion and Amortization",
        "totalLabel": "Depreciation, Depletion and Amortization, Total",
        "terseLabel": "Depreciation and amortization expense",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r132",
      "r179",
      "r197",
      "r215",
      "r927",
      "r948",
      "r949"
     ]
    },
    "clym_DevelopmentAndRegulatoryMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "DevelopmentAndRegulatoryMilestonesMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development and Regulatory Milestones [Member]",
        "label": "Development and Regulatory Milestones [Member]",
        "documentation": "Development and Regulatory Milestones [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "clym_DevelopmentManufacturingAndCommercialMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "DevelopmentManufacturingAndCommercialMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Development Manufacturing and Commercial [Member]",
        "documentation": "Development Manufacturing and Commercial [Member]",
        "terseLabel": "Development Manufacturing and Commercial [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "clym_DevelopmentRegulatoryAndCommercialMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "DevelopmentRegulatoryAndCommercialMilestonesMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development Regulatory and Commercial Milestones [Member]",
        "label": "Development Regulatory and Commercial Milestones [Member]",
        "documentation": "Development Regulatory and Commercial Milestones [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "clym_DevelopmentRegulatoryCommercialAndSalesMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "DevelopmentRegulatoryCommercialAndSalesMilestonesMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Development Regulatory Commercial and Sales Milestones Member]",
        "documentation": "Development Regulatory Commercial and Sales Milestones Member]",
        "terseLabel": "Development Regulatory Commercial and Sales Milestones [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "clym_DirectExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "DirectExpenseMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureSegmentsScheduleOfForthDisaggregatedResearchAndDevelopmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Direct Expense [Member]",
        "documentation": "Direct Expense [Member]",
        "terseLabel": "Direct Expense [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r433",
      "r464",
      "r465",
      "r467",
      "r979"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r1041",
      "r1042",
      "r1065"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r1041",
      "r1042",
      "r1065",
      "r1108"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r1086"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r1039"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Jurisdiction [Member]",
        "terseLabel": "Federal [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r487"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r1097"
     ]
    },
    "us-gaap_EarliestTaxYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarliestTaxYearMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earliest Tax Year",
        "label": "Earliest Tax Year [Member]",
        "documentation": "Earliest identified tax year."
       }
      }
     },
     "auth_ref": [
      "r1295"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net loss per share, basic",
        "totalLabel": "Earnings Per Share, Basic, Total",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share attributable to common stockholders, basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r127",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r166",
      "r168",
      "r171",
      "r172",
      "r173",
      "r178",
      "r319",
      "r468",
      "r521",
      "r580",
      "r608",
      "r609",
      "r754",
      "r780",
      "r937"
     ]
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasicLineItems",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r169",
      "r171",
      "r173"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net loss per share, diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share attributable to common stockholders, diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r127",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r168",
      "r171",
      "r172",
      "r173",
      "r178",
      "r319",
      "r468",
      "r521",
      "r580",
      "r608",
      "r609",
      "r754",
      "r780",
      "r937"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r175"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureNetLossPerShare1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r174",
      "r176",
      "r177"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents",
        "documentation": "Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r1332"
     ]
    },
    "clym_EffectiveIncomeTaxRateReconciliationAcquiredIn-ProcessResearchDevelopmentRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationAcquiredIn-ProcessResearchDevelopmentRelatedParty",
     "crdr": "debit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired in-process research &amp; development, related party",
        "label": "Effective Income Tax Rate Reconciliation, Acquired In-Process Research &amp; Development, Related Party",
        "documentation": "Amount of reported income tax expense (benefit) from difference to expected income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to acquired in-process research and development from a related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount",
     "crdr": "debit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Cross-Border Tax Effect, Amount",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Cross-Border Tax Effect, Amount, Total",
        "terseLabel": "Effect of cross-border transfers",
        "documentation": "Amount of reported income tax expense (benefit) from difference to expected income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to cross-border tax law."
       }
      }
     },
     "auth_ref": [
      "r492",
      "r495"
     ]
    },
    "clym_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficerCompensationAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficerCompensationAmount",
     "crdr": "debit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-deductible officer compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Officer Compensation, Amount",
        "documentation": "Amount of reported income tax expense (benefit) from difference to expected income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to limitations on executive compensation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxSettlements",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax settlement, percent",
        "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, Percent",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Tax Settlement, Percent, Total",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements."
       }
      }
     },
     "auth_ref": [
      "r1221",
      "r1226",
      "r1291",
      "r1292"
     ]
    },
    "clym_EliemTherapeuticsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "EliemTherapeuticsMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Eliem Therapeutics [Member]",
        "label": "Eliem Therapeutics [Member]",
        "documentation": "Eliem Therapeutics [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails2": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee-related Liabilities, Current",
        "totalLabel": "Employee-related Liabilities, Current, Total",
        "terseLabel": "Accrued payroll and related expenses",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "totalLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total",
        "terseLabel": "Unrecognized compensation cost",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation, weighted average amortization period",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock [Member]",
        "verboseLabel": "Shares of common stock issuable under the ESPP [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "verboseLabel": "Stock options to purchase common stock [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r1264",
      "r1265",
      "r1266",
      "r1267",
      "r1268",
      "r1269",
      "r1270",
      "r1271",
      "r1272",
      "r1273",
      "r1274",
      "r1275",
      "r1276",
      "r1277",
      "r1278",
      "r1279",
      "r1280",
      "r1281",
      "r1282",
      "r1283",
      "r1284",
      "r1285",
      "r1286",
      "r1287",
      "r1288",
      "r1289"
     ]
    },
    "clym_EmployeesIncludingExecutiveOfficersEarningContribution": {
     "xbrltype": "percentItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "EmployeesIncludingExecutiveOfficersEarningContribution",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employees Including Executive Officers Earning Contribution",
        "documentation": "Employees Including Executive Officers Earning Contribution",
        "terseLabel": "Employees Including Executive Officers Earning Contribution"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1038"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1038"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r1151"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r1038"
     ]
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationDateOfIncorporation",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, Date of Incorporation",
        "terseLabel": "Entity incorporation date",
        "documentation": "Date when an entity was incorporated"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1148"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1038"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r1038"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r1038"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1038"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r1150"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1091"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r1144"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r1144"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r1144"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails",
      "http://climbbio.com/20251231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r100",
      "r101",
      "r102",
      "r123",
      "r124",
      "r125",
      "r148",
      "r149",
      "r150",
      "r152",
      "r159",
      "r161",
      "r163",
      "r180",
      "r259",
      "r260",
      "r285",
      "r318",
      "r337",
      "r468",
      "r511",
      "r512",
      "r518",
      "r519",
      "r520",
      "r522",
      "r579",
      "r580",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r607",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r648",
      "r650",
      "r668",
      "r776",
      "r793",
      "r794",
      "r795",
      "r814",
      "r884"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1101"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r1058",
      "r1069",
      "r1079",
      "r1112"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r1055",
      "r1066",
      "r1076",
      "r1109"
     ]
    },
    "clym_EsppMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "EsppMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ESPP [Member]",
        "documentation": "ESPP Member",
        "label": "ESPP [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "clym_ExchangeAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "ExchangeAgreementMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange Agreement [Member]",
        "label": "Exchange Agreement [Member]",
        "documentation": "Exchange Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r1107"
     ]
    },
    "clym_FairMarketValueCommonStockPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "FairMarketValueCommonStockPercentage",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of fair market value of common stock",
        "label": "Fair market value, common stock percentage",
        "terseLabel": "Percentage of fair market value, common stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r611",
      "r612",
      "r619",
      "r996"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r611",
      "r612",
      "r619",
      "r996"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r394",
      "r395",
      "r610",
      "r612",
      "r613",
      "r614",
      "r615",
      "r618",
      "r619",
      "r621",
      "r626",
      "r683",
      "r684",
      "r685",
      "r922",
      "r959",
      "r960",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r996",
      "r999",
      "r1006"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r611",
      "r612",
      "r613",
      "r615",
      "r996",
      "r1322",
      "r1326"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueInputsLevel12And3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel12And3Member",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Inputs, Level 1, 2 and 3 [Member]",
        "label": "Fair Value, Inputs, Level 1, Level 2, and Level 3 [Member]",
        "documentation": "Fair value measurement input including quoted price in active market for identical asset or liability reporting entity can access at measurement date (level 1), input other than quoted price included within level 1 either directly or indirectly observable for asset or liability (level 2) and unobservable input reflecting entity's own assumption (level 3)."
       }
      }
     },
     "auth_ref": [
      "r996",
      "r1261",
      "r1263",
      "r1320",
      "r1325",
      "r1327"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r363",
      "r368",
      "r394",
      "r612",
      "r619",
      "r626",
      "r683",
      "r922",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r996",
      "r1006"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r363",
      "r368",
      "r394",
      "r396",
      "r612",
      "r613",
      "r619",
      "r626",
      "r684",
      "r922",
      "r959",
      "r960",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r996",
      "r1006"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r394",
      "r395",
      "r612",
      "r613",
      "r614",
      "r615",
      "r619",
      "r626",
      "r685",
      "r922",
      "r959",
      "r960",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r996",
      "r999",
      "r1006"
     ]
    },
    "clym_FairValueLevel1Level2AndLevel3TransferAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "FairValueLevel1Level2AndLevel3TransferAmount",
     "crdr": "credit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value transfer amount",
        "label": "Fair Value Level1 Level2 And Level3 Transfer Amount",
        "documentation": "Fair Value Level 1 Level 2 and Level 3 Transfer Amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r611",
      "r612",
      "r613",
      "r615",
      "r996",
      "r1322",
      "r1326"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurement",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r394",
      "r395",
      "r610",
      "r612",
      "r613",
      "r614",
      "r615",
      "r618",
      "r619",
      "r621",
      "r626",
      "r683",
      "r684",
      "r685",
      "r922",
      "r959",
      "r960",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r996",
      "r999",
      "r1006"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r996",
      "r1319",
      "r1320",
      "r1321",
      "r1322",
      "r1323",
      "r1326"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfMarketableSecuritiesConsistedOfAvailableforsaleSecuritiesDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r261",
      "r262",
      "r269",
      "r270",
      "r271",
      "r273",
      "r274",
      "r275",
      "r317",
      "r334",
      "r595",
      "r606",
      "r622",
      "r631",
      "r634",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r762",
      "r777",
      "r958",
      "r996",
      "r997",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1009",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1245",
      "r1246",
      "r1247",
      "r1248",
      "r1318",
      "r1321",
      "r1322",
      "r1323",
      "r1324",
      "r1326",
      "r1327",
      "r1328"
     ]
    },
    "us-gaap_FinancingReceivablePortfolioSegmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancingReceivablePortfolioSegmentAxis",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureSegmentsScheduleOfForthDisaggregatedResearchAndDevelopmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing Receivable Portfolio Segment [Axis]",
        "documentation": "Information by the level at which an entity develops and documents a systematic methodology to determine its allowance for credit losses."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r97",
      "r98",
      "r99",
      "r261",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r957",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1167"
     ]
    },
    "us-gaap_FinancingReceivablePortfolioSegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancingReceivablePortfolioSegmentDomain",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureSegmentsScheduleOfForthDisaggregatedResearchAndDevelopmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing Receivable Portfolio Segment [Domain]",
        "documentation": "Level at which an entity develops and documents a systematic methodology to determine its allowance for credit losses."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r97",
      "r98",
      "r99",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1167"
     ]
    },
    "clym_FirstAnniversaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "FirstAnniversaryMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "First Anniversary [Member]",
        "documentation": "First Anniversary Member",
        "terseLabel": "First Anniversary [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "clym_FirstDayOfOfferingPeriodMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "FirstDayOfOfferingPeriodMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First Day of Offering Period [Member]",
        "label": "First Day of Offering Period [Member]",
        "terseLabel": "First Day of Offering Period [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign [Member]",
        "label": "Foreign Tax Jurisdiction [Member]",
        "documentation": "Designated foreign jurisdiction entitled to levy and collect income tax outside country of domicile."
       }
      }
     },
     "auth_ref": [
      "r487",
      "r488"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss), Foreign Currency Transaction, before Tax",
        "totalLabel": "Gain (Loss), Foreign Currency Transaction, before Tax, Total",
        "terseLabel": "Foreign currency loss",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r637",
      "r638",
      "r639",
      "r640",
      "r881"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "crdr": "credit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unrealized foreign currency transaction (gain) loss",
        "label": "Unrealized Gain (Loss), Foreign Currency Transaction, before Tax",
        "documentation": "Amount, before tax, of unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r859",
      "r1034",
      "r1330",
      "r1331",
      "r1384"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r1062",
      "r1073",
      "r1083",
      "r1116"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r1062",
      "r1073",
      "r1083",
      "r1116"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r1062",
      "r1073",
      "r1083",
      "r1116"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r1062",
      "r1073",
      "r1083",
      "r1116"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1062",
      "r1073",
      "r1083",
      "r1116"
     ]
    },
    "clym_FourZeroOneKMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "FourZeroOneKMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "401K [Member]",
        "label": "Four Zero One K [Member]",
        "documentation": "Four Zero One K [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r1096"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and fixtures",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "country_GB": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "GB",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetLossBeforeTaxProvisionFromIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "United Kingdom",
        "label": "UNITED KINGDOM"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "General and administrative expense",
        "totalLabel": "General and Administrative Expense, Total",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r863"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureRestructuringCostsSummaryOfRestructuringCostsInStatementOfOperationsDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative Expense",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "clym_GrossOperatingLeasePaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "GrossOperatingLeasePaymentsMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfAnnualFutureMinimumLeasePaymentsDueUnderTheCompanysNoncancelableOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross Operating Lease Payments [Member]",
        "documentation": "Gross Operating Lease Payments [Member]",
        "terseLabel": "Gross Operating Lease Payments [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r1041",
      "r1042",
      "r1065"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r65"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureSegmentsScheduleOfForthDisaggregatedResearchAndDevelopmentExpensesDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "terseLabel": "Income Statement Location",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r286",
      "r287",
      "r292",
      "r591",
      "r592",
      "r593",
      "r594",
      "r616",
      "r617",
      "r620",
      "r633",
      "r634",
      "r635",
      "r790",
      "r792",
      "r868",
      "r921",
      "r922",
      "r983",
      "r984",
      "r994",
      "r995",
      "r998",
      "r1006",
      "r1302",
      "r1304",
      "r1352"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureSegmentsScheduleOfForthDisaggregatedResearchAndDevelopmentExpensesDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "terseLabel": "Income Statement Location",
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r292",
      "r591",
      "r592",
      "r593",
      "r594",
      "r616",
      "r617",
      "r620",
      "r633",
      "r634",
      "r635",
      "r790",
      "r792",
      "r868",
      "r921",
      "r922",
      "r983",
      "r984",
      "r994",
      "r995",
      "r998",
      "r1006",
      "r1302",
      "r1304",
      "r1352"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "terseLabel": "Income Tax Authority",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r487",
      "r488",
      "r499",
      "r508",
      "r982",
      "r1298"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Domain]",
        "terseLabel": "Income Tax Authority",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r487",
      "r488",
      "r499",
      "r508",
      "r982",
      "r1298"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r143",
      "r483",
      "r487",
      "r496",
      "r497",
      "r498",
      "r500",
      "r507",
      "r513",
      "r515",
      "r516",
      "r517",
      "r761",
      "r800",
      "r809",
      "r982"
     ]
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Interest and penalties",
        "label": "Income Tax Examination, Penalties and Interest Accrued",
        "totalLabel": "Income Tax Examination, Penalties and Interest Accrued, Total",
        "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations."
       }
      }
     },
     "auth_ref": [
      "r1294"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToProvisionForIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToProvisionForIncomeTaxesDetails",
      "http://climbbio.com/20251231/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax",
        "netLabel": "Income tax",
        "label": "Income Tax Expense (Benefit)",
        "totalLabel": "Effective income tax rate",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r92",
      "r139",
      "r162",
      "r163",
      "r179",
      "r198",
      "r215",
      "r486",
      "r487",
      "r514",
      "r781",
      "r929",
      "r931",
      "r932",
      "r982"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r484",
      "r485",
      "r500",
      "r501",
      "r506",
      "r510",
      "r803"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r494",
      "r982",
      "r1291"
     ]
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "crdr": "debit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "terseLabel": "Foreign rate differential",
        "negatedLabel": "Foreign rate differential",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r488",
      "r491",
      "r982",
      "r1291"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "U.S. federal taxes at statutory rate",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r487",
      "r982"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseOther",
     "crdr": "debit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount",
        "terseLabel": "Other expenses, net",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r982",
      "r1291",
      "r1293"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r982",
      "r1291",
      "r1293"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State taxes, net of federal benefit",
        "negatedLabel": "State taxes, net of federal benefit",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r490",
      "r982",
      "r1291"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationTaxCredits",
     "crdr": "credit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Tax credits",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount, Total",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount",
        "terseLabel": "Tax credits",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r493",
      "r495",
      "r1291"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "clym_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedparties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedparties",
     "crdr": "debit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued liabilities, related party",
        "label": "Increase Decrease In Accounts Payable And Accrued Liabilities RelatedParties",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to related parties and the amount of obligations and expenses incurred, but not paid, from related parties."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r1219"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "clym_IncreaseDecreaseInOperatingLeaseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "IncreaseDecreaseInOperatingLeaseAssets",
     "crdr": "credit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating lease right-of-use assets.",
        "label": "Increase Decrease In Operating Lease Assets",
        "terseLabel": "Increase (Decrease) In Operating Lease Asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities",
        "verboseLabel": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r1157",
      "r1219"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other long-term assets",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r1219"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Long-term liabilities",
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpensesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidExpensesOther",
     "crdr": "credit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expenses, Other",
        "negatedLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "clym_IncrementalSharebasedcompensationexpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "IncrementalSharebasedcompensationexpense",
     "crdr": "debit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incremental Share based compensation expense",
        "label": "Incremental ShareBasedCompensationExpense",
        "documentation": "Incremental ShareBasedCompensationExpense"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r1062",
      "r1073",
      "r1083",
      "r1107",
      "r1116",
      "r1120",
      "r1128"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r1126"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r1043",
      "r1132"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r1043",
      "r1132"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r1043",
      "r1132"
     ]
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "terseLabel": "Patent costs",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r713",
      "r714",
      "r715",
      "r717",
      "r934",
      "r1250"
     ]
    },
    "us-gaap_InterestReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestReceivable",
     "crdr": "debit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCertainBalanceSheetAccountsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCertainBalanceSheetAccountsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Receivable",
        "terseLabel": "Accrued interest receivable",
        "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable."
       }
      }
     },
     "auth_ref": [
      "r1171",
      "r1387"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r196",
      "r215",
      "r948",
      "r1176"
     ]
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Marketable Securities and Fair Value Measurements",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r95",
      "r225",
      "r227",
      "r623",
      "r624",
      "r1348"
     ]
    },
    "clym_IssuanceOfPromissoryLoanInConnectionWithAssetsAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "IssuanceOfPromissoryLoanInConnectionWithAssetsAcquisition",
     "crdr": "credit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance Of Promissory Loan In Connection With Assets Acquisition",
        "documentation": "The cash outflow associated with the issuance of a promissory loan in connection with an asset acquisition.",
        "terseLabel": "Issuance of promissory loan in connection with asset acquisition",
        "negatedLabel": "Issuance of promissory loan in connection with asset acquisition"
       }
      }
     },
     "auth_ref": []
    },
    "clym_JanuaryOneTwoThousandTwentyFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "JanuaryOneTwoThousandTwentyFiveMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "January One Two Thousand Twenty Five [Member]",
        "documentation": "January One Two Thousand Twenty Five [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "clym_JuneTwentySevenTwoThousandTwentyFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "JuneTwentySevenTwoThousandTwentyFiveMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "June Twenty Seven Two Thousand Twenty Five [Member]",
        "documentation": "June Twenty Seven Two Thousand Twenty Five [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "clym_LastDayOfOfferingPeriodMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "LastDayOfOfferingPeriodMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Last Day of Offering Period [Member]",
        "documentation": "Last Day of Offering Period [Member]",
        "terseLabel": "Last Day of Offering Period [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LatestTaxYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LatestTaxYearMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Latest Tax Year [Member]",
        "terseLabel": "Latest Tax Year",
        "documentation": "Latest identified tax year."
       }
      }
     },
     "auth_ref": [
      "r1295"
     ]
    },
    "us-gaap_LeaseContractualTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseContractualTermAxis",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfAnnualFutureMinimumLeasePaymentsDueUnderTheCompanysNoncancelableOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Axis]",
        "documentation": "Information by contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r667",
      "r1156"
     ]
    },
    "us-gaap_LeaseContractualTermDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseContractualTermDomain",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfAnnualFutureMinimumLeasePaymentsDueUnderTheCompanysNoncancelableOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Domain]",
        "documentation": "Contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r667",
      "r1156"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfLeaseExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost",
        "totalLabel": "Lease cost",
        "terseLabel": "Lease cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r657",
      "r1007"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Lease Expense",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1335"
     ]
    },
    "us-gaap_LeaseExpirationDate1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseExpirationDate1",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease expiration date",
        "label": "Lease Expiration Date",
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r666"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "clym_LegacyProgramExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "LegacyProgramExpensesMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureSegmentsScheduleOfForthDisaggregatedResearchAndDevelopmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legacy Program Expenses [Member]",
        "documentation": "Legacy Program Expenses [Member]",
        "terseLabel": "Legacy programs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfAnnualFutureMinimumLeasePaymentsDueUnderTheCompanysNoncancelableOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r655",
      "r667"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfAnnualFutureMinimumLeasePaymentsDueUnderTheCompanysNoncancelableOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r655",
      "r667"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease option to extend",
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease."
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Annual Future Minimum Lease Payments Due Under the Company's Non-cancelable Operating Lease",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1336"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfAnnualFutureMinimumLeasePaymentsDueUnderTheCompanysNoncancelableOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total undiscounted lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "terseLabel": "Operating Leases, Total minimum lease payments",
        "verboseLabel": "Total undiscounted lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r665",
      "r1222",
      "r1227",
      "r1349"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfAnnualFutureMinimumLeasePaymentsDueUnderTheCompanysNoncancelableOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r665",
      "r1222",
      "r1227",
      "r1349"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfAnnualFutureMinimumLeasePaymentsDueUnderTheCompanysNoncancelableOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r665",
      "r1222",
      "r1227",
      "r1349"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfAnnualFutureMinimumLeasePaymentsDueUnderTheCompanysNoncancelableOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Term",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1334"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r649"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r37",
      "r38",
      "r39",
      "r40",
      "r41",
      "r42",
      "r45",
      "r139",
      "r141",
      "r142",
      "r258",
      "r305",
      "r306",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r314",
      "r315",
      "r586",
      "r589",
      "r590",
      "r632",
      "r838",
      "r940",
      "r961",
      "r1036",
      "r1257",
      "r1339",
      "r1340"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r78",
      "r770",
      "r1008",
      "r1023",
      "r1024",
      "r1221",
      "r1225",
      "r1249",
      "r1329"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r107",
      "r139",
      "r141",
      "r142",
      "r258",
      "r305",
      "r306",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r314",
      "r315",
      "r586",
      "r589",
      "r590",
      "r632",
      "r1008",
      "r1257",
      "r1339",
      "r1340"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "clym_LongTermMarketableSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "LongTermMarketableSecuritiesMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfMarketableSecuritiesConsistedOfAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long Term Marketable Securities [Member]",
        "documentation": "Long Term Marketable Securities [Member]",
        "label": "Long Term Marketable Securities [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "clym_MabworksAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "MabworksAgreementMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mabworks Agreement [Member]",
        "documentation": "Mabworks Agreement [Member]",
        "terseLabel": "Mabworks Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "clym_ManufacturingServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "ManufacturingServicesMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Manufacturing Services [Member]",
        "documentation": "Manufacturing Services [Member]",
        "terseLabel": "Manufacturing Services [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "clym_MarchTwentySevenTwoThousandTwentyFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "MarchTwentySevenTwoThousandTwentyFiveMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "March Twenty Seven Two Thousand Twenty Five [Member]",
        "documentation": "March Twenty Seven Two Thousand Twenty Five [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term marketable securities",
        "label": "Marketable Securities, Current",
        "totalLabel": "Marketable Securities, Current, Total",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1170"
     ]
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term marketable securities",
        "label": "Marketable Securities, Noncurrent",
        "totalLabel": "Marketable Securities, Noncurrent, Total",
        "documentation": "Amount of investment in marketable security, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r1170"
     ]
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_MarketableSecuritiesUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesUnrealizedGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://climbbio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Security, Unrealized Gain (Loss)",
        "terseLabel": "Unrealized gain on marketable securities",
        "documentation": "Amount of unrealized gain (loss) on investment in marketable security."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedInBlackScholesModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r188",
      "r301",
      "r302",
      "r303",
      "r304",
      "r426",
      "r459",
      "r460",
      "r461",
      "r479",
      "r615",
      "r711",
      "r789",
      "r791",
      "r799",
      "r830",
      "r831",
      "r890",
      "r892",
      "r894",
      "r895",
      "r897",
      "r904",
      "r905",
      "r907",
      "r908",
      "r919",
      "r920",
      "r956",
      "r962",
      "r978",
      "r983",
      "r986",
      "r987",
      "r999",
      "r1000",
      "r1004",
      "r1005",
      "r1019",
      "r1259",
      "r1341",
      "r1342",
      "r1343",
      "r1344",
      "r1345",
      "r1346"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r1099"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1099"
     ]
    },
    "clym_MilestoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "MilestoneMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone [Member]",
        "documentation": "Milestone [Member]",
        "terseLabel": "Milestone [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "clym_MilestonePaymentAmountReduced": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "MilestonePaymentAmountReduced",
     "crdr": "debit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone Payment, Amount Reduced",
        "documentation": "The amount of reduction in milestone payments due upon performing specified services.",
        "terseLabel": "Milestone Payment, Amount Reduced"
       }
      }
     },
     "auth_ref": []
    },
    "clym_MilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "MilestonePayments",
     "crdr": "debit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone Payments",
        "documentation": "The amount due from the Company upon achievement of specified milestones, as part of a license agreement.",
        "label": "Milestone Payments",
        "totalLabel": "Total Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "clym_MilestonePaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "MilestonePaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone Payments Due",
        "documentation": "The amount due as a result of achievement of specified milestones, as of the balance sheet date.",
        "terseLabel": "Milestone Payments Due"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedInBlackScholesModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum [Member]",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r188",
      "r301",
      "r302",
      "r303",
      "r304",
      "r426",
      "r459",
      "r460",
      "r461",
      "r479",
      "r615",
      "r711",
      "r789",
      "r791",
      "r799",
      "r830",
      "r831",
      "r890",
      "r892",
      "r894",
      "r895",
      "r897",
      "r904",
      "r905",
      "r907",
      "r908",
      "r919",
      "r920",
      "r956",
      "r962",
      "r978",
      "r983",
      "r986",
      "r987",
      "r999",
      "r1000",
      "r1004",
      "r1019",
      "r1259",
      "r1341",
      "r1342",
      "r1343",
      "r1344",
      "r1345",
      "r1346"
     ]
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary, Ownership Percentage, Noncontrolling Owner",
        "terseLabel": "Minority Interest Ownership Percentage By Non controlling Owners",
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r1119"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r1260",
      "r1262"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r1127"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1100"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "totalLabel": "Net cash provided by (used in) financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "totalLabel": "Net cash provided by (used in) investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r61",
      "r62"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetLossBeforeTaxProvisionFromIncomeTaxesDetails",
      "http://climbbio.com/20251231/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://climbbio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "totalLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r62",
      "r81",
      "r102",
      "r105",
      "r118",
      "r120",
      "r125",
      "r139",
      "r141",
      "r142",
      "r146",
      "r151",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r162",
      "r163",
      "r170",
      "r258",
      "r305",
      "r306",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r314",
      "r315",
      "r319",
      "r322",
      "r325",
      "r329",
      "r468",
      "r521",
      "r580",
      "r609",
      "r632",
      "r775",
      "r860",
      "r882",
      "r883",
      "r929",
      "r931",
      "r932",
      "r1034",
      "r1257"
     ]
    },
    "clym_NetOperatingLeasePaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "NetOperatingLeasePaymentsMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfAnnualFutureMinimumLeasePaymentsDueUnderTheCompanysNoncancelableOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Operating Lease Payments [Member]",
        "documentation": "Net Operating Lease Payments [Member]",
        "terseLabel": "Net Operating Lease Payments [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Issued Accounting Pronouncements Not Yet Adopted",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r1099"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r1062",
      "r1073",
      "r1083",
      "r1107",
      "r1116"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r1090"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1089"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r1107"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r1127"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r1127"
     ]
    },
    "us-gaap_NoninterestExpenseOfferingCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoninterestExpenseOfferingCost",
     "crdr": "debit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Cost, Expense",
        "terseLabel": "Offering cost",
        "verboseLabel": "Stock issuance costs",
        "documentation": "Amount of expense for cost associated with issuance of security by investment company. Includes, but is not limited to, legal fee pertaining to share offered for sale, registration fee, underwriting, printing prospectus, and initial fee for listing on exchange."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r1383"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "auth_ref": []
    },
    "clym_NotePurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "NotePurchaseAgreementMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Note Purchase Agreement [Member]",
        "label": "Note Purchase Agreement [Member]",
        "documentation": "Note Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureSegmentsAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r949",
      "r1236"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureSegmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r942",
      "r954",
      "r1236"
     ]
    },
    "clym_NumberOfSharesOfCommonStockOutstandingPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "NumberOfSharesOfCommonStockOutstandingPercentage",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares of common stock outstanding percentage",
        "label": "Number of Shares of Common Stock Outstanding Percentage",
        "documentation": "Number of shares of common Stock outstanding percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OpenTaxYear": {
     "xbrltype": "gYearListItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OpenTaxYear",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax year",
        "label": "Open Tax Year",
        "documentation": "Tax year that remains open to examination under enacted tax laws, in YYYY format."
       }
      }
     },
     "auth_ref": [
      "r499"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Total loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r929",
      "r932",
      "r941",
      "r1235",
      "r1237",
      "r1238",
      "r1239",
      "r1240"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfLeaseExpenseDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r658",
      "r1007"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Expense",
        "terseLabel": "Non-cash operating lease expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r1333"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfAnnualFutureMinimumLeasePaymentsDueUnderTheCompanysNoncancelableOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease Payments:",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfOperatingLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfAnnualFutureMinimumLeasePaymentsDueUnderTheCompanysNoncancelableOperatingLeaseDetails",
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability",
        "verboseLabel": "Total operating lease liabilities",
        "terseLabel": "Operating lease liabilities",
        "totalLabel": "Total operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 0.0
      },
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfOperatingLeaseLiabilitiesDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities",
        "verboseLabel": "Current operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfOperatingLeaseLiabilitiesDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, net of current portion",
        "verboseLabel": "Operating lease liability, net of current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfCashFlowInformationRelatedToLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for amounts included in the measurement of operating lease liabilities",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r653",
      "r661"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets",
        "negatedLabel": "Operating lease right-of-use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate - operating lease",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r664",
      "r1007"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term - operating lease (in years)",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r663",
      "r1007"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforward",
        "label": "Operating Loss Carryforwards",
        "totalLabel": "Operating Loss Carryforwards, Total",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r509"
     ]
    },
    "clym_OperatingLossCarryforwardsExpirationStartYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "OperatingLossCarryforwardsExpirationStartYear",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards expiration start year",
        "label": "Operating Loss Carryforwards Expiration Start Year",
        "documentation": "The year in which operating loss carryforwards begin to expire, in YYYY format."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetLossBeforeTaxProvisionFromIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r509"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetLossBeforeTaxProvisionFromIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]",
        "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r509"
     ]
    },
    "us-gaap_OperatingSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingSegmentsMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureSegmentsScheduleOfForthDisaggregatedResearchAndDevelopmentExpensesDetails",
      "http://climbbio.com/20251231/taxonomy/role/DisclosureSegmentsScheduleOfForthDisaggregatedResearchAndDevelopmentExpensesParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Segments [Member]",
        "label": "Operating Segments [Member]",
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r216",
      "r948",
      "r949"
     ]
    },
    "clym_OptionToExtendMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "OptionToExtendMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option to Extend [Member]",
        "documentation": "Option to Extend [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails2": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued expenses",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_OtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCertainBalanceSheetAccountsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCertainBalanceSheetAccountsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other Assets, Total",
        "label": "Other Assets",
        "terseLabel": "Other assets",
        "documentation": "Amount of assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r110",
      "r763",
      "r949",
      "r1023",
      "r1024",
      "r1036"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Noncurrent",
        "totalLabel": "Other Assets, Noncurrent, Total",
        "terseLabel": "Other long-term assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCommitmentsTable",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Table]",
        "documentation": "Disclosure of information about obligations resulting from other commitments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossTaxAbstract",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherExpenseMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureSegmentsScheduleOfForthDisaggregatedResearchAndDevelopmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Expense [Member]",
        "terseLabel": "Other research and development expenses",
        "documentation": "Primary financial statement caption encompassing other expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherExpenses",
     "crdr": "debit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Expenses",
        "terseLabel": "Payment to, related party",
        "documentation": "Amount of expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r56",
      "r1023",
      "r1024"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income (expense)",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r993"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r1099"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1060",
      "r1071",
      "r1081",
      "r1114"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1063",
      "r1074",
      "r1084",
      "r1117"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1063",
      "r1074",
      "r1084",
      "r1117"
     ]
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1088"
     ]
    },
    "us-gaap_PaymentsForRestructuring": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForRestructuring",
     "crdr": "credit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureRestructuringCostsScheduleOfRestructuringLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Severance costs paid during the period",
        "terseLabel": "Severance costs paid during the period",
        "label": "Payments for Restructuring",
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r1218"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Pre-funded warrant issuance costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "crdr": "credit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "totalLabel": "Payments to Acquire Businesses, Net of Cash Acquired, Total",
        "negatedLabel": "Cash paid in connection with asset acquisition, net of cash received",
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of marketable securities",
        "terseLabel": "Purchase of marketable securities",
        "label": "Payments to Acquire Marketable Securities",
        "totalLabel": "Payments to Acquire Marketable Securities, Total",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r1243"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total",
        "negatedLabel": "Purchases of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1098"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1098"
     ]
    },
    "clym_PensionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "PensionMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension [Member]",
        "documentation": "Pension [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1090"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r1107"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r1100"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1089"
     ]
    },
    "clym_PercentageOfAnnualDeductionOfTaxableIncome": {
     "xbrltype": "percentItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "PercentageOfAnnualDeductionOfTaxableIncome",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage Of Annual Deduction Of Taxable Income",
        "documentation": "The percentage of annual taxable income to which net operating loss carryforwards are limited.",
        "terseLabel": "Percentage of annual deduction of taxable income"
       }
      }
     },
     "auth_ref": []
    },
    "clym_PerformanceBasedRsusMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "PerformanceBasedRsusMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance-Based RSUs [Member]",
        "documentation": "Performance-Based RSUs [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "clym_PerformanceBasedVestingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "PerformanceBasedVestingMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance based vesting [Member]",
        "documentation": "Performance based vesting [Member]",
        "terseLabel": "Performance based vesting [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "clym_PersonnelRelatedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "PersonnelRelatedMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureSegmentsScheduleOfForthDisaggregatedResearchAndDevelopmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Personnel Related [Member]",
        "documentation": "Personnel Related [Member]",
        "terseLabel": "Personnel-related (including stock-based compensation)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1264",
      "r1265",
      "r1266",
      "r1267",
      "r1268",
      "r1269",
      "r1270",
      "r1271",
      "r1272",
      "r1273",
      "r1274",
      "r1275",
      "r1276",
      "r1277",
      "r1278",
      "r1279",
      "r1280",
      "r1281",
      "r1282",
      "r1283",
      "r1284",
      "r1285",
      "r1286",
      "r1287",
      "r1288",
      "r1289"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1264",
      "r1265",
      "r1266",
      "r1267",
      "r1268",
      "r1269",
      "r1270",
      "r1271",
      "r1272",
      "r1273",
      "r1274",
      "r1275",
      "r1276",
      "r1277",
      "r1278",
      "r1279",
      "r1280",
      "r1281",
      "r1282",
      "r1283",
      "r1284",
      "r1285",
      "r1286",
      "r1287",
      "r1288",
      "r1289"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r1091"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r1147"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1090"
     ]
    },
    "clym_Pre-FundedWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "Pre-FundedWarrantMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Funded Warrant [Member]",
        "documentation": "Pre-Funded Warrant [Member]",
        "terseLabel": "Pre-Funded Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "clym_PreFundedWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "PreFundedWarrantMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Funded Warrant [Member]",
        "documentation": "Pre Funded Warrant [Member]",
        "terseLabel": "Pre Funded Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCertainBalanceSheetAccountsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCertainBalanceSheetAccountsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Total prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1172"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCertainBalanceSheetAccountsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCertainBalanceSheetAccountsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Prepaid Expense, Current, Total",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r277",
      "r278",
      "r926"
     ]
    },
    "clym_PrepaidResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "PrepaidResearchAndDevelopmentExpenses",
     "crdr": "debit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCertainBalanceSheetAccountsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCertainBalanceSheetAccountsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid research and development expenses.",
        "label": "Prepaid Research And Development Expenses",
        "terseLabel": "Prepaid research and development deposits and expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://climbbio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement [Member]",
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "clym_ProbiogenAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "ProbiogenAgreementMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ProBioGen Agreement [Member]",
        "documentation": "ProBioGen Agreement [Member]",
        "terseLabel": "ProBioGen Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "clym_ProbiogenManufacturingServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "ProbiogenManufacturingServiceMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ProBioGen Manufacturing Service [Member]",
        "documentation": "ProBioGen Manufacturing Service Member",
        "terseLabel": "ProBioGen Manufacturing Service [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "clym_ProbiogenSalesMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "ProbiogenSalesMilestonesMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ProBioGen Sales Milestones [Member]",
        "documentation": "ProBioGen Sales Milestones Member",
        "terseLabel": "ProBioGen Sales Milestones [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercise of stock options",
        "label": "Proceeds from Issuance of Common Stock",
        "verboseLabel": "Issuance of common stock for the acquisition of in-process research and development from a related party",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Private Placement",
        "verboseLabel": "Issuance of common stock in private placement",
        "terseLabel": "Proceeds from issuance of common stock in private placement, net of issuance costs",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from maturities of marketable securities",
        "verboseLabel": "Maturities of marketable securities",
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r12"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r219",
      "r716",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r923",
      "r928",
      "r931",
      "r932",
      "r963",
      "r964",
      "r1018",
      "r1019",
      "r1020",
      "r1022",
      "r1025",
      "r1155",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1255",
      "r1256",
      "r1351",
      "r1353",
      "r1354",
      "r1355",
      "r1356",
      "r1357",
      "r1358",
      "r1359",
      "r1360",
      "r1361",
      "r1362",
      "r1363",
      "r1364",
      "r1365",
      "r1366",
      "r1367",
      "r1368",
      "r1369",
      "r1370",
      "r1371",
      "r1372",
      "r1373",
      "r1374",
      "r1375",
      "r1376",
      "r1377",
      "r1378",
      "r1379",
      "r1380"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r219",
      "r716",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r923",
      "r928",
      "r931",
      "r932",
      "r963",
      "r964",
      "r1018",
      "r1019",
      "r1020",
      "r1022",
      "r1025",
      "r1155",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1255",
      "r1256",
      "r1351",
      "r1353",
      "r1354",
      "r1355",
      "r1356",
      "r1357",
      "r1358",
      "r1359",
      "r1360",
      "r1361",
      "r1362",
      "r1363",
      "r1364",
      "r1365",
      "r1366",
      "r1367",
      "r1368",
      "r1369",
      "r1370",
      "r1371",
      "r1372",
      "r1373",
      "r1374",
      "r1375",
      "r1376",
      "r1377",
      "r1378",
      "r1379",
      "r1380"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r105",
      "r118",
      "r120",
      "r133",
      "r139",
      "r141",
      "r142",
      "r146",
      "r151",
      "r159",
      "r162",
      "r163",
      "r258",
      "r305",
      "r306",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r314",
      "r315",
      "r319",
      "r468",
      "r521",
      "r580",
      "r584",
      "r587",
      "r588",
      "r609",
      "r632",
      "r755",
      "r757",
      "r774",
      "r813",
      "r860",
      "r882",
      "r883",
      "r991",
      "r992",
      "r1035",
      "r1175",
      "r1257"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r666"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r666"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Property, Plant and Equipment, Net, Total",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r666",
      "r760",
      "r773",
      "r1008"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r90",
      "r91",
      "r772"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r666"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]",
        "documentation": "Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value."
       }
      }
     },
     "auth_ref": [
      "r1251"
     ]
    },
    "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertySubjectToOrAvailableForOperatingLeaseAxis",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property Subject to or Available for Operating Lease [Axis]",
        "documentation": "Information by property that could be leased or is available for lease."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertySubjectToOrAvailableForOperatingLeaseDomain",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property Subject to or Available for Operating Lease [Domain]",
        "documentation": "A descriptive title of whether the property is subject to or available for operating lease."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_ProvisionForOtherCreditLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProvisionForOtherCreditLosses",
     "crdr": "debit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provision for Other Credit Losses",
        "terseLabel": "Credit losses",
        "documentation": "Amount of expense related to credit loss from transactions other than loan and lease transactions."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r79"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1088"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r1088"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedInBlackScholesModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r188",
      "r301",
      "r302",
      "r303",
      "r304",
      "r361",
      "r426",
      "r459",
      "r460",
      "r461",
      "r467",
      "r479",
      "r615",
      "r686",
      "r695",
      "r711",
      "r789",
      "r791",
      "r799",
      "r830",
      "r831",
      "r890",
      "r892",
      "r894",
      "r895",
      "r897",
      "r904",
      "r905",
      "r907",
      "r908",
      "r919",
      "r920",
      "r956",
      "r962",
      "r978",
      "r983",
      "r986",
      "r987",
      "r999",
      "r1000",
      "r1004",
      "r1005",
      "r1019",
      "r1028",
      "r1253",
      "r1259",
      "r1322",
      "r1342",
      "r1343",
      "r1344",
      "r1345",
      "r1346"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedInBlackScholesModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r188",
      "r301",
      "r302",
      "r303",
      "r304",
      "r361",
      "r426",
      "r459",
      "r460",
      "r461",
      "r467",
      "r479",
      "r615",
      "r686",
      "r695",
      "r711",
      "r789",
      "r791",
      "r799",
      "r830",
      "r831",
      "r890",
      "r892",
      "r894",
      "r895",
      "r897",
      "r904",
      "r905",
      "r907",
      "r908",
      "r919",
      "r920",
      "r956",
      "r962",
      "r978",
      "r983",
      "r986",
      "r987",
      "r999",
      "r1000",
      "r1004",
      "r1005",
      "r1019",
      "r1028",
      "r1253",
      "r1259",
      "r1322",
      "r1342",
      "r1343",
      "r1344",
      "r1345",
      "r1346"
     ]
    },
    "clym_RecoverableResearchAndDevelopmentTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "RecoverableResearchAndDevelopmentTaxCredits",
     "crdr": "debit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCertainBalanceSheetAccountsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCertainBalanceSheetAccountsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recoverable research and development tax credits.",
        "label": "Recoverable Research And Development Tax Credits",
        "terseLabel": "Recoverable research and development tax credits"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1055",
      "r1066",
      "r1076",
      "r1109"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyScheduleOfPurchaseConsiderationForTheAcquisitionBasedOnTheFairValueOfThe",
      "http://climbbio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r145",
      "r146",
      "r224",
      "r385",
      "r408",
      "r672",
      "r673",
      "r765",
      "r771",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r857",
      "r889",
      "r1382"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyScheduleOfPurchaseConsiderationForTheAcquisitionBasedOnTheFairValueOfThe",
      "http://climbbio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Member]",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r145",
      "r146",
      "r672",
      "r673",
      "r674",
      "r675",
      "r765",
      "r771",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r857",
      "r889"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r145",
      "r146",
      "r672",
      "r673",
      "r1338"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r145",
      "r146",
      "r1338"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r145",
      "r146",
      "r224",
      "r672",
      "r673",
      "r675",
      "r864",
      "r865",
      "r868"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyScheduleOfPurchaseConsiderationForTheAcquisitionBasedOnTheFairValueOfThe",
      "http://climbbio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r145",
      "r146",
      "r224",
      "r385",
      "r408",
      "r672",
      "r673",
      "r765",
      "r771",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r857",
      "r889",
      "r1338",
      "r1382"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureRelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transactions",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r669",
      "r670",
      "r671",
      "r673",
      "r676",
      "r810",
      "r811",
      "r812",
      "r866",
      "r867",
      "r868",
      "r887",
      "r888"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureSegmentsScheduleOfForthDisaggregatedResearchAndDevelopmentExpensesDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Research and Development Expense, Total",
        "label": "Research and Development Expense",
        "verboseLabel": "Total research and development expenses",
        "terseLabel": "Research and development expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r482",
      "r921",
      "r929",
      "r930",
      "r948",
      "r1347"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureRestructuringCostsSummaryOfRestructuringCostsInStatementOfOperationsDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r1056",
      "r1067",
      "r1077",
      "r1110"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r1057",
      "r1068",
      "r1078",
      "r1111"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r1064",
      "r1075",
      "r1085",
      "r1118"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
      "http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfMarketableSecuritiesConsistedOfAvailableforsaleSecuritiesDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock [Member]",
        "label": "Restricted Stock [Member]",
        "verboseLabel": "Unvested restricted stock units [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r1234",
      "r1264",
      "r1265",
      "r1266",
      "r1267",
      "r1268",
      "r1269",
      "r1270",
      "r1271",
      "r1272",
      "r1273",
      "r1274",
      "r1275",
      "r1276",
      "r1277",
      "r1278",
      "r1279",
      "r1280",
      "r1281",
      "r1282",
      "r1283",
      "r1284",
      "r1285",
      "r1286",
      "r1287",
      "r1288",
      "r1289"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r1264",
      "r1265",
      "r1266",
      "r1267",
      "r1268",
      "r1269",
      "r1270",
      "r1271",
      "r1272",
      "r1273",
      "r1274",
      "r1275",
      "r1276",
      "r1277",
      "r1278",
      "r1279",
      "r1280",
      "r1281",
      "r1282",
      "r1283",
      "r1284",
      "r1285",
      "r1286",
      "r1287",
      "r1288",
      "r1289"
     ]
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureRestructuringCosts"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Costs",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r289",
      "r291",
      "r294",
      "r298"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostIncurredCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringAndRelatedCostIncurredCost",
     "crdr": "debit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureRestructuringCostsScheduleOfRestructuringLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Severance costs incurred during the period",
        "label": "Restructuring and Related Cost, Incurred Cost",
        "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r293",
      "r295",
      "r297"
     ]
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringCostAndReserveAxis",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureRestructuringCostsSummaryOfRestructuringCostsInStatementOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Type [Axis]",
        "documentation": "Information by type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r131",
      "r290",
      "r291",
      "r295",
      "r296",
      "r930"
     ]
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringCostAndReserveLineItems",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureRestructuringCostsSummaryOfRestructuringCostsInStatementOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Cost and Reserve [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r293",
      "r295",
      "r296",
      "r297"
     ]
    },
    "us-gaap_RestructuringCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringCosts",
     "crdr": "debit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureRestructuringCostsSummaryOfRestructuringCostsInStatementOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring costs",
        "verboseLabel": "Total restructuring costs",
        "label": "Restructuring Costs",
        "totalLabel": "Restructuring Costs, Total",
        "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_RestructuringPlanAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringPlanAxis",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureRestructuringCostsSummaryOfRestructuringCostsInStatementOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Plan [Axis]",
        "documentation": "Information by individual restructuring plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringPlanDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringPlanDomain",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureRestructuringCostsSummaryOfRestructuringCostsInStatementOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Plan [Domain]",
        "documentation": "Identification of the individual restructuring plans."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringReserve",
     "crdr": "credit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureRestructuringCostsScheduleOfRestructuringLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Reserve",
        "totalLabel": "Restructuring Reserve, Total",
        "periodStartLabel": "Restructuring liability, Beginning Balance",
        "periodEndLabel": "Restructuring liability, Ending Balance",
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r296"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r69",
      "r769",
      "r796",
      "r798",
      "r808",
      "r841",
      "r1008"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r148",
      "r149",
      "r150",
      "r152",
      "r159",
      "r161",
      "r163",
      "r259",
      "r260",
      "r285",
      "r318",
      "r468",
      "r511",
      "r512",
      "r518",
      "r519",
      "r520",
      "r522",
      "r579",
      "r580",
      "r596",
      "r598",
      "r599",
      "r601",
      "r607",
      "r648",
      "r650",
      "r793",
      "r795",
      "r814",
      "r1385"
     ]
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetirementPlanTypeAxis",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Plan Type [Axis]",
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r392",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r428",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977"
     ]
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetirementPlanTypeDomain",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Plan Type [Domain]",
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r392",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r428",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfCashFlowInformationRelatedToLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for lease liabilities",
        "verboseLabel": "Operating lease liabilities arising from obtaining right-of-use asset",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r662",
      "r1007"
     ]
    },
    "us-gaap_RisksAndUncertaintiesInEntitysBusiness": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RisksAndUncertaintiesInEntitysBusiness",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risks and Uncertainties",
        "label": "Risks and Uncertainties in Entity's Business",
        "documentation": "Description of the risk factors inherent in the entity's business, excluding risks associated with certain significant estimates or concentration risks."
       }
      }
     },
     "auth_ref": [
      "r185"
     ]
    },
    "clym_RouAssetImpairmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "RouAssetImpairmentMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureRestructuringCostsSummaryOfRestructuringCostsInStatementOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ROU Asset Impairment [Member]",
        "label": "ROU Asset Impairment [Member]",
        "documentation": "ROU Asset Impairment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r1127"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r1127"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://climbbio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "clym_SalesMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "SalesMilestonesMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales Milestones [Member]",
        "documentation": "Sales Milestones [Member]",
        "terseLabel": "Sales Milestones [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]"
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r103",
      "r104",
      "r164",
      "r427",
      "r1153"
     ]
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Summary of Accrued Expenses",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Net Loss Per Share Attributable To Common Stockholders",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfMarketableSecuritiesConsistedOfAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Schedule Of Available For Sale Securities [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Marketable Securities Consisted of Available-for-Sale Securities",
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value."
       }
      }
     },
     "auth_ref": []
    },
    "clym_ScheduleOfBalanceSheetSupplementalDisclosuresTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "ScheduleOfBalanceSheetSupplementalDisclosuresTableTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Balance Sheet Supplemental Disclosures",
        "documentation": "Tabular disclosure of supplemental balance sheet information.",
        "label": "Schedule Of Balance Sheet Supplemental Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination [Table Text Block]",
        "terseLabel": "Summary of Purchase Consideration For The Acquisition Based On The Fair Value Of The Net Assets Acquired By The Company",
        "documentation": "Tabular disclosure of business combination. Includes, but is not limited to, recognized asset and liability."
       }
      }
     },
     "auth_ref": [
      "r983",
      "r984",
      "r1301",
      "r1304",
      "r1305",
      "r1309",
      "r1310",
      "r1311"
     ]
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "terseLabel": "Schedule of Cash Flow Information Related to Leases",
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Components of Net Loss Before Tax Provision from Income Taxes",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r1300"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1296"
     ]
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyScheduleOfPurchaseConsiderationForTheAcquisitionBasedOnTheFairValueOfThe",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan [Table]",
        "documentation": "Disclosure of information about individual defined benefit pension plan or other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r28",
      "r29",
      "r30",
      "r31",
      "r388",
      "r389",
      "r390",
      "r395",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r421"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Basic and Diluted Net Loss Per Share",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1233"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table]",
        "documentation": "Disclosure of information about basic earnings per share by class of stock. Includes, but is not limited to, two-class method."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r169",
      "r171",
      "r173"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation of Statutory Federal Income Tax Rate to Provision for Income Taxes",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r489",
      "r982",
      "r1291"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Share-based Compensation Expense",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1319",
      "r1320"
     ]
    },
    "clym_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Property and Equipment Estimated Useful Life [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment Estimated Useful Life",
        "documentation": "Tabular disclosure of the estimated useful life of physical assets used in the normal conduct of business and not intended for resale."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r666"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r145",
      "r146",
      "r672",
      "r673",
      "r675",
      "r864",
      "r865",
      "r868"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureRestructuringCostsSummaryOfRestructuringCostsInStatementOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Cost [Table]",
        "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r293",
      "r295",
      "r296",
      "r297"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureRestructuringCostsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of restructuring costs",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r66",
      "r67"
     ]
    },
    "clym_ScheduleOfRestructuringLiability": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "ScheduleOfRestructuringLiability",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureRestructuringCostsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of restructuring liability",
        "label": "Schedule of restructuring liability",
        "documentation": "Schedule of restructuring liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureSegmentsScheduleOfForthDisaggregatedResearchAndDevelopmentExpensesDetails",
      "http://climbbio.com/20251231/taxonomy/role/DisclosureSegmentsScheduleOfForthDisaggregatedResearchAndDevelopmentExpensesParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r25"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureSegmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of Forth Disaggregated Research and Development Expenses",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r25"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedInBlackScholesModelDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardsDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r430",
      "r432",
      "r434",
      "r435",
      "r436",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r467"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of Restricted Stock Awards",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activities",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r11",
      "r70"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table Text Block",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1037"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r1040"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetLossBeforeTaxProvisionFromIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r184",
      "r221",
      "r222",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r755",
      "r756",
      "r757",
      "r758",
      "r827",
      "r828",
      "r829",
      "r891",
      "r893",
      "r896",
      "r898",
      "r904",
      "r906",
      "r907",
      "r908",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r924",
      "r938",
      "r963",
      "r965",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1021",
      "r1028",
      "r1351",
      "r1353",
      "r1354",
      "r1356",
      "r1357",
      "r1358",
      "r1359",
      "r1360",
      "r1361",
      "r1362",
      "r1363",
      "r1364",
      "r1365",
      "r1366",
      "r1367",
      "r1368",
      "r1369",
      "r1370",
      "r1371",
      "r1372",
      "r1373",
      "r1374",
      "r1375",
      "r1376",
      "r1377",
      "r1378",
      "r1379",
      "r1380"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureSegmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]",
        "documentation": "Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r947",
      "r955"
     ]
    },
    "us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingCodmProfitLossMeasureHowUsedDescription",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureSegmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description",
        "terseLabel": "Segment Reporting Codm Profit Loss, Description",
        "documentation": "Description of how chief operating decision maker (CODM) uses reported segment profit (loss) measure to assess performance and allocate resource."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r944",
      "r952"
     ]
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureSegments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segments",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r179",
      "r189",
      "r190",
      "r191",
      "r192",
      "r194",
      "r199",
      "r200",
      "r201",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r219",
      "r220",
      "r223",
      "r942",
      "r945",
      "r946",
      "r948",
      "r950",
      "r953",
      "r954"
     ]
    },
    "us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingExpenseInformationUsedByCodmDescription",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureSegmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Expense Information Used by CODM, Description",
        "terseLabel": "CODM Description",
        "documentation": "Description of nature of expense information used by chief operating decision maker (CODM) to manage operation when segment expense information by category is not disclosed."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r201",
      "r215"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureSegmentsScheduleOfForthDisaggregatedResearchAndDevelopmentExpensesDetails",
      "http://climbbio.com/20251231/taxonomy/role/DisclosureSegmentsScheduleOfForthDisaggregatedResearchAndDevelopmentExpensesParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r218",
      "r221",
      "r943",
      "r944",
      "r951"
     ]
    },
    "clym_SeraServicesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "SeraServicesAgreementMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sera Services Agreement [Member]",
        "label": "Sera Services Agreement [Member]",
        "documentation": "Sera Services Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "clym_SeveranceAndBenefitsCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "SeveranceAndBenefitsCostsMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureRestructuringCostsSummaryOfRestructuringCostsInStatementOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Severance and Benefits Costs [Member]",
        "documentation": "Severance and Benefits Costs [Member]",
        "terseLabel": "Severance and Benefits Costs [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeveranceCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeveranceCosts1",
     "crdr": "debit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureSegmentsScheduleOfForthDisaggregatedResearchAndDevelopmentExpensesParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Severance expenses",
        "label": "Severance Costs",
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "clym_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Annual Increase Percentage",
        "documentation": "The automatic increase in the number of shares that may be issued under a share-based payment arrangement on the first day of each fiscal year, as a percentage of shares outstanding",
        "terseLabel": "Number of Shares of Common Stock Outstanding Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Share-based payment award, option vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r979"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Description",
        "terseLabel": "Share-based payment award, description",
        "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Share, Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Number of Share, Forfeited",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r451"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited, weighted average grant date fair value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r451"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r449"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted, weighted average grant date fair value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r449"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of shares, Unvested",
        "periodStartLabel": "Number of shares, Unvested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "terseLabel": "Number of shares, vested",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r447"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Unvested, weighted average grant date fair value per share, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodStartLabel": "Unvested, weighted average grant date fair value per share, beginning balance",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r447"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of shares, Vested",
        "terseLabel": "Vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "verboseLabel": "Number of shares, Vested",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r450"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "verboseLabel": "Fair value of restricted stock vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested, weighted average grant date fair value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r450"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedInBlackScholesModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedInBlackScholesModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedInBlackScholesModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedInBlackScholesModelDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardsDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r430",
      "r432",
      "r434",
      "r435",
      "r436",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r467"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based compensation arrangement by share based payment award",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1290"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Share-based payment award, number of shares authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r981"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number shares remaining for issuance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of options exercisable, end of period",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, options exercisable",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value of options exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of options, forfeited",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of additional options granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of options granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r442"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Aggregate grant date fair value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Options grants in period, weighted average grant date fair value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate grant-date fair value",
        "periodEndLabel": "Aggregate intrinsic value outstanding, end of period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodStartLabel": "Aggregate intrinsic value options exercised",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of options outstanding, beginning of period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of options outstanding, ending of period",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r438",
      "r439"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price outstanding, end of period",
        "periodStartLabel": "Weighted average exercise price outstanding, beginning of period",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r438",
      "r439"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value options vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r454"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Number of options, vested and expected to vest",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r454"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, options vested and expected to vest",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r454"
     ]
    },
    "clym_ShareBasedCompensationArrangementBySharebasedPaymentAwardContributionPercentMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "ShareBasedCompensationArrangementBySharebasedPaymentAwardContributionPercentMaximum",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based compensation arrangement by sharebased payment award contribution percent maximum",
        "label": "Share Based Compensation Arrangement By Sharebased Payment Award Contribution Percent Maximum",
        "documentation": "The maximum amount an employee is allowed to contribute for the purchase of common stock under a share based compensation plan, as a percentage of their earnings"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockAwardsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r435",
      "r436",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, options exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r443"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, options forfeited",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, options granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r442"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r437",
      "r456",
      "r457",
      "r458",
      "r459",
      "r462",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Share-based payment award, award vesting rights, percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1264"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment award, expiration period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r980"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedInBlackScholesModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r458"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value options exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contracted terms (in years) outstanding",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and expected to vest",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r454"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Share based payment award, purchase price of common stock, percent",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": [
      "r1290"
     ]
    },
    "clym_SharesConvertedUponAcquisitionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "SharesConvertedUponAcquisitionMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Converted Upon Acquisition [Member]",
        "documentation": "Shares Converted Upon Acquisition [Member]",
        "terseLabel": "Shares Converted Upon Acquisition [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "clym_SharesExchangedForPreFundedWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "SharesExchangedForPreFundedWarrants",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange of common stock for pre-funded warrant, Shares",
        "label": "Shares Exchanged For Pre Funded Warrants",
        "documentation": "The number of shares exchanged during the period for pre-funded warrants."
       }
      }
     },
     "auth_ref": []
    },
    "clym_SharesExchangedForPreFundedWarrantsValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "SharesExchangedForPreFundedWarrantsValue",
     "crdr": "credit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Exchanged For Pre Funded Warrants Value",
        "documentation": "The value of shares exchanged during the period for pre-funded warrants.",
        "terseLabel": "Exchange of common stock for pre-funded warrant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance, (in shares)",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfLeaseExpenseDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term lease cost",
        "label": "Short-Term Lease, Cost",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r659",
      "r1007"
     ]
    },
    "clym_ShortTermMarketableSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "ShortTermMarketableSecuritiesMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfMarketableSecuritiesConsistedOfAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short Term Marketable Securities [Member]",
        "documentation": "Short Term Marketable Securities [Member]",
        "label": "Short Term Marketable Securities [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r138"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r487"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails",
      "http://climbbio.com/20251231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r112",
      "r113",
      "r114",
      "r139",
      "r142",
      "r168",
      "r169",
      "r171",
      "r173",
      "r181",
      "r182",
      "r258",
      "r305",
      "r308",
      "r309",
      "r310",
      "r314",
      "r315",
      "r320",
      "r321",
      "r323",
      "r324",
      "r326",
      "r328",
      "r330",
      "r331",
      "r332",
      "r333",
      "r335",
      "r632",
      "r804",
      "r805",
      "r806",
      "r807",
      "r814",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r840",
      "r861",
      "r884",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r1152",
      "r1223",
      "r1224",
      "r1232"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails",
      "http://climbbio.com/20251231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r47",
      "r50",
      "r51",
      "r100",
      "r101",
      "r102",
      "r123",
      "r124",
      "r125",
      "r148",
      "r149",
      "r150",
      "r152",
      "r159",
      "r161",
      "r163",
      "r180",
      "r259",
      "r260",
      "r285",
      "r318",
      "r337",
      "r468",
      "r511",
      "r512",
      "r518",
      "r519",
      "r520",
      "r522",
      "r579",
      "r580",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r607",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r648",
      "r650",
      "r668",
      "r776",
      "r793",
      "r794",
      "r795",
      "r814",
      "r884"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetLossBeforeTaxProvisionFromIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r184",
      "r221",
      "r222",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r755",
      "r756",
      "r757",
      "r758",
      "r827",
      "r828",
      "r829",
      "r891",
      "r893",
      "r896",
      "r898",
      "r904",
      "r906",
      "r907",
      "r908",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r924",
      "r938",
      "r963",
      "r965",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1021",
      "r1028",
      "r1351",
      "r1353",
      "r1354",
      "r1356",
      "r1357",
      "r1358",
      "r1359",
      "r1360",
      "r1361",
      "r1362",
      "r1363",
      "r1364",
      "r1365",
      "r1366",
      "r1367",
      "r1368",
      "r1369",
      "r1370",
      "r1371",
      "r1372",
      "r1373",
      "r1374",
      "r1375",
      "r1376",
      "r1377",
      "r1378",
      "r1379",
      "r1380"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://climbbio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r149",
      "r150",
      "r180",
      "r320",
      "r321",
      "r323",
      "r326",
      "r650",
      "r716",
      "r802",
      "r815",
      "r826",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r840",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r862",
      "r863",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r884",
      "r931",
      "r932",
      "r1029",
      "r1382"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r103",
      "r104",
      "r164",
      "r427",
      "r1153",
      "r1154"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://climbbio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r149",
      "r150",
      "r180",
      "r224",
      "r320",
      "r321",
      "r323",
      "r326",
      "r650",
      "r716",
      "r802",
      "r815",
      "r826",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r840",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r862",
      "r863",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r884",
      "r931",
      "r932",
      "r1029",
      "r1382"
     ]
    },
    "clym_StephenThomasMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "StephenThomasMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stephen Thomas [Member]",
        "documentation": "Stephen Thomas [Member]",
        "terseLabel": "Stephen Thomas"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r1059",
      "r1070",
      "r1080",
      "r1113"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r1264",
      "r1265",
      "r1266",
      "r1267",
      "r1268",
      "r1269",
      "r1270",
      "r1271",
      "r1272",
      "r1273",
      "r1274",
      "r1275",
      "r1276",
      "r1277",
      "r1278",
      "r1279",
      "r1280",
      "r1281",
      "r1282",
      "r1283",
      "r1284",
      "r1285",
      "r1286",
      "r1287",
      "r1288",
      "r1289"
     ]
    },
    "clym_StockBasedCompensationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "StockBasedCompensationMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureRestructuringCostsSummaryOfRestructuringCostsInStatementOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based Compensation [Member]",
        "documentation": "Stock-based Compensation [Member]",
        "terseLabel": "Stock-based Compensation [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesConversionOfUnits",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Conversion of Units",
        "terseLabel": "Exchange of common stock for pre-funded warrant, Shares",
        "verboseLabel": "Stock Issued During Period, Shares, Exchange",
        "negatedTerseLabel": "Exchange of common stock for pre-funded warrant, Shares",
        "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r27",
      "r46",
      "r47",
      "r69"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Stock issued during period shares employee stock purchase plans",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r46",
      "r47",
      "r69"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Proceeds from issuance of common stock in initial public offering, Shares",
        "verboseLabel": "Issuance of common stock, Shares",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r46",
      "r47",
      "r69",
      "r804",
      "r884",
      "r900"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Vesting of restricted stock awards and units, Shares",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r69"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivitiesDetails",
      "http://climbbio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Number of options exercised",
        "terseLabel": "Issuance of common stock upon exercise of stock options, Shares",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r46",
      "r47",
      "r69",
      "r443"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueConversionOfUnits",
     "crdr": "credit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Conversion of Units",
        "terseLabel": "Exchange of common stock for pre-funded warrant",
        "negatedTerseLabel": "Exchange of common stock for pre-funded warrant",
        "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r47",
      "r50",
      "r51",
      "r69"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r46",
      "r47",
      "r69",
      "r814",
      "r884",
      "r900",
      "r1035"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock upon exercise of stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r47",
      "r50",
      "r51",
      "r69"
     ]
    },
    "clym_StockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "StockOptionsMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options [Member]",
        "terseLabel": "Stock Options [Member]",
        "documentation": "Stock Options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://climbbio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r50",
      "r51",
      "r63",
      "r842",
      "r858",
      "r885",
      "r886",
      "r1008",
      "r1036",
      "r1221",
      "r1224",
      "r1225",
      "r1249",
      "r1329",
      "r1385"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity"
       }
      }
     },
     "auth_ref": []
    },
    "clym_SubleaseIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "SubleaseIncomeMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfAnnualFutureMinimumLeasePaymentsDueUnderTheCompanysNoncancelableOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sublease Income [Member]",
        "documentation": "Sublease Income [Member]",
        "terseLabel": "Sublease Income [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r647",
      "r678"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Member]",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r647",
      "r678"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r647",
      "r678"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r647",
      "r678"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r647",
      "r678"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r677",
      "r679"
     ]
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]",
        "terseLabel": "Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table]",
        "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group by type of sale. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://climbbio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockLineItems",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Subsidiary Sale Of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Valuation Allowance [Table Text Block]",
        "terseLabel": "Schedule of Valuation Allowance",
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance."
       }
      }
     },
     "auth_ref": [
      "r1297"
     ]
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Certain Balance Sheet Accounts",
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity."
       }
      }
     },
     "auth_ref": [
      "r1169"
     ]
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r1106"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforward amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r509"
     ]
    },
    "clym_TaxCreditCarryforwardExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "TaxCreditCarryforwardExpirationYear",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credit carryforward expiration year",
        "label": "Tax Credit Carryforward Expiration Year",
        "documentation": "Tax credit carryforward expiration year."
       }
      }
     },
     "auth_ref": []
    },
    "clym_TaxCreditCarryforwardExpirationYearStart": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "TaxCreditCarryforwardExpirationYearStart",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credit carryforward expiration year start",
        "label": "Tax Credit Carryforward Expiration Year Start",
        "documentation": "The year in which tax credit carryforwards begin to expire, in YYYY format."
       }
      }
     },
     "auth_ref": []
    },
    "clym_TaxCreditsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "TaxCreditsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Credits receivable",
        "label": "Tax Credits receivable",
        "terseLabel": "Tax Credits receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Axis]",
        "terseLabel": "Tax Period",
        "documentation": "Information by period subject to enacted tax law."
       }
      }
     },
     "auth_ref": [
      "r1295"
     ]
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Domain]",
        "terseLabel": "Tax Period",
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": [
      "r1295"
     ]
    },
    "us-gaap_TaxYear2018Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxYear2018Member",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year 2018 [Member]",
        "documentation": "Identified as tax year 2018."
       }
      }
     },
     "auth_ref": [
      "r1295"
     ]
    },
    "us-gaap_TaxYear2019Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxYear2019Member",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year 2019 [Member]",
        "documentation": "Identified as tax year 2019."
       }
      }
     },
     "auth_ref": [
      "r1295"
     ]
    },
    "us-gaap_TaxYear2020Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxYear2020Member",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year 2020 [Member]",
        "documentation": "Identified as tax year 2020."
       }
      }
     },
     "auth_ref": [
      "r1295"
     ]
    },
    "us-gaap_TaxYear2021Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxYear2021Member",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year 2021 [Member]",
        "documentation": "Identified as tax year 2021."
       }
      }
     },
     "auth_ref": [
      "r1295"
     ]
    },
    "us-gaap_TaxYear2022Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxYear2022Member",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year 2022 [Member]",
        "documentation": "Identified as tax year 2022."
       }
      }
     },
     "auth_ref": [
      "r1295"
     ]
    },
    "us-gaap_TaxYear2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxYear2023Member",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year 2023 [Member]",
        "documentation": "Identified as tax year 2023."
       }
      }
     },
     "auth_ref": [
      "r1295"
     ]
    },
    "us-gaap_TaxYear2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxYear2024Member",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year 2024 [Member]",
        "documentation": "Identified as tax year 2024."
       }
      }
     },
     "auth_ref": [
      "r1295"
     ]
    },
    "us-gaap_TaxYear2025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxYear2025Member",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year 2025 [Member]",
        "documentation": "Identified as tax year 2025."
       }
      }
     },
     "auth_ref": [
      "r1295"
     ]
    },
    "clym_TaxYears": {
     "xbrltype": "dateItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "TaxYears",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Taxable years",
        "label": "Tax Years",
        "documentation": "Tax years which are open and subject to examination."
       }
      }
     },
     "auth_ref": []
    },
    "clym_TenetStockOwnedByRACapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "TenetStockOwnedByRACapitalMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAndPrivatePlacementWithARelatedPartyAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tenet Stock Owned By RA Capital [Member]",
        "label": "Tenet Stock Owned By RA Capital [Member]",
        "documentation": "Tenet Stock Owned By RA Capital [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1241",
      "r1337"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "clym_TotalDevelopmentAndRegulatoryMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "TotalDevelopmentAndRegulatoryMilestones",
     "crdr": "debit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Development And Regulatory Milestones",
        "documentation": "Total Development And Regulatory Milestones",
        "terseLabel": "Total Development And Regulatory Milestones"
       }
      }
     },
     "auth_ref": []
    },
    "clym_TotalMarketableSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "TotalMarketableSecuritiesMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Marketable Securities [Member]",
        "label": "Total Marketable Securities [Member]",
        "documentation": "Total Marketable Securities [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "clym_TotalRestructuringCostRecordedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "TotalRestructuringCostRecordedMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureRestructuringCostsSummaryOfRestructuringCostsInStatementOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Restructuring Cost Recorded [Member]",
        "label": "Total Restructuring Cost Recorded [Member]",
        "documentation": "Total Restructuring Cost Recorded [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1098"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r1105"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r1126"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r1128"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfMarketableSecuritiesConsistedOfAvailableforsaleSecuritiesDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r317",
      "r334",
      "r595",
      "r606",
      "r622",
      "r631",
      "r634",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r762",
      "r777",
      "r996",
      "r997",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1009",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1245",
      "r1246",
      "r1247",
      "r1248",
      "r1318",
      "r1321",
      "r1322",
      "r1323",
      "r1324",
      "r1326",
      "r1327",
      "r1328"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r1129"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r1130"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r1130"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1128"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r1128"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r1131"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r1129"
     ]
    },
    "clym_TwoThousandTwentyFiveInducementPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "TwoThousandTwentyFiveInducementPlanMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025 Inducement Plan [Member]",
        "label": "Two Thousand Twenty Five Inducement Plan [Member]",
        "documentation": "Two Thousand Twenty Five Inducement Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "clym_TwoThousandTwentyOneEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "TwoThousandTwentyOneEquityIncentivePlanMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty one equity incentive plan.",
        "label": "Two Thousand Twenty One Equity Incentive Plan [Member]",
        "terseLabel": "2021 Equity Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureNatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfRestructuringDomain",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureRestructuringCostsSummaryOfRestructuringCostsInStatementOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Type of Restructuring [Domain]",
        "documentation": "Identification of the types of restructuring costs."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r131",
      "r290",
      "r291",
      "r295",
      "r296",
      "r930"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "US",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetLossBeforeTaxProvisionFromIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "United States",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
      "http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfMarketableSecuritiesConsistedOfAvailableforsaleSecuritiesDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. government agency debt securities [Member]",
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)."
       }
      }
     },
     "auth_ref": [
      "r935",
      "r936",
      "r966",
      "r968",
      "r1350"
     ]
    },
    "us-gaap_USGovernmentDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USGovernmentDebtSecuritiesMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Government Debt Securities [Member]",
        "terseLabel": "US Government Debt Securities [Member]",
        "documentation": "Debt securities issued by the United States government."
       }
      }
     },
     "auth_ref": [
      "r1350"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
      "http://climbbio.com/20251231/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsScheduleOfMarketableSecuritiesConsistedOfAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Treasury securities [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r935",
      "r936",
      "r966",
      "r968",
      "r970",
      "r996",
      "r1350"
     ]
    },
    "clym_UnallocatedExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "UnallocatedExpenseMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureSegmentsScheduleOfForthDisaggregatedResearchAndDevelopmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unallocated Expense [Member]",
        "documentation": "Unallocated Expense [Member]",
        "terseLabel": "Unallocated Expense [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r1125"
     ]
    },
    "clym_UnvestedRestrictedStockAwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "UnvestedRestrictedStockAwardsMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unvested restricted stock awards [Member]",
        "documentation": "Unvested restricted stock awards member.",
        "label": "Unvested Restricted Stock Awards [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "clym_UpfrontMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "UpfrontMilestonePayment",
     "crdr": "debit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Upfront, Milestone Payment",
        "documentation": "Upfront, Milestone Payment",
        "terseLabel": "Upfront, Milestone Payment"
       }
      }
     },
     "auth_ref": []
    },
    "clym_UpfrontPaymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "UpfrontPaymentMember",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Upfront Payment [Member]",
        "documentation": "Upfront Payment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "clym_UpfrontPaymentPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "UpfrontPaymentPaid",
     "crdr": "credit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Upfront Payment Paid",
        "documentation": "The amount of upfront payment paid during the period as part of a license agreement.",
        "terseLabel": "Upfront Payment Paid"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r89",
      "r183",
      "r186",
      "r187",
      "r188",
      "r755",
      "r757",
      "r939"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureIncomeTaxesScheduleOfValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Net increases recorded to income tax provision",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfLeaseExpenseDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r660",
      "r1007"
     ]
    },
    "clym_VestingOfRestrictedStockAwardsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://climbbio.com/20251231",
     "localname": "VestingOfRestrictedStockAwardsShares",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting of restricted stock awards.",
        "label": "Vesting Of Restricted Stock Awards Shares",
        "terseLabel": "Vesting of restricted stock awards and units, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r1094"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted-average number of shares used to compute net loss per share, diluted",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding, diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r173"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://climbbio.com/20251231/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails",
      "http://climbbio.com/20251231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted-average number of shares used to compute net loss per share, basic",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares outstanding, basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r173"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r1092"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-5"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/942-320/tableOfContent"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481501/840-20-50-4"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/808/tableOfContent"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "b",
   "Publisher": "SEC"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1404",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1404",
   "Paragraph": "b",
   "Publisher": "SEC"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1405",
   "Paragraph": "a",
   "Subparagraph": "(4)",
   "Publisher": "SEC"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1405",
   "Paragraph": "c",
   "Publisher": "SEC"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481003/205-10-S50-2"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SAB Topic 1.B.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-7"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-2A"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-2"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-4"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/420/tableOfContent"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715-20/tableOfContent"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(j)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(j)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(j)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(j)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(r)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-7"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-8"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480606/715-80-35-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-9"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-3"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-4"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-5"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805-50/tableOfContent"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "715",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477317/912-715-50-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-4"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "805",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478072/944-805-50-1"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-6"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-18"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-10"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-18"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-42"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479908/805-50-55-1"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1405",
   "Paragraph": "a",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1405",
   "Paragraph": "a",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1405",
   "Paragraph": "a",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/210/tableOfContent"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(r)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1207": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(s)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1208": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(t)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1209": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(u)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1210": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30"
  },
  "r1211": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31"
  },
  "r1212": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32"
  },
  "r1213": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33"
  },
  "r1214": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1215": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1216": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1217": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1218": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r1219": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1220": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r1221": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r1222": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r1223": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1224": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1225": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1226": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1227": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r1228": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1229": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1230": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1231": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1232": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r1233": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1234": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1235": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1236": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1237": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1238": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1239": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1240": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1241": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r1242": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r1243": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r1244": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1245": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1246": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1247": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1248": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1249": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1250": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r1251": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482190/360-10-35-3"
  },
  "r1252": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1253": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1254": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1255": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1256": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1257": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1258": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1259": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1260": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1261": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1262": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r1263": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r1264": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1265": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1266": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1267": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1268": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1269": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1270": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1271": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1272": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1273": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1274": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1275": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1276": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1277": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1278": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1279": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1280": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1281": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1282": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1283": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1284": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1285": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1286": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1287": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1288": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1289": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1290": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4"
  },
  "r1291": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1292": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1293": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1294": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r1295": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r1296": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1297": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1298": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1299": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1300": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1301": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1302": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1303": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1304": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r1305": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r1306": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r1307": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r1308": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r1309": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-2"
  },
  "r1310": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r1311": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r1312": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3"
  },
  "r1313": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1"
  },
  "r1314": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1"
  },
  "r1315": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2"
  },
  "r1316": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r1317": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1318": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1319": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1320": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1321": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1322": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1323": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1324": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1325": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1326": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1327": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r1328": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1329": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1330": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r1331": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r1332": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1333": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r1334": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1335": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1336": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1337": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1338": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1339": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1340": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1341": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1342": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1343": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1344": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1345": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1346": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1347": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1348": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/940-320/tableOfContent"
  },
  "r1349": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r1350": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r1351": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1352": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1353": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1354": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1355": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1356": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1357": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1358": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1359": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1360": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1361": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1362": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1363": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1364": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1365": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1366": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1367": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1368": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1369": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1370": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1371": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1372": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1373": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1374": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1375": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1376": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1377": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1378": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1379": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1380": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1381": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1382": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1383": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1384": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1385": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1386": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1387": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>98
<FILENAME>0001193125-26-092546-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-26-092546-xbrl.zip
M4$L#!!0    ( )8Z95P!G9Z6-8D$ !__-  1    8VQY;2TR,#(U,3(S,2YH
M=&WLO6M7&\FR)OQ]?D6-]YPYW>MUXKQ?<'?/PMC>A[/;Q@/X[.EYU[N\\@JU
M6ZBTJR0;]J]_(TL2" P8&PD54/Y@0*I+7B*?>"(R,N*7_W5R/"@^Q[HIJ^&O
M_TXV\+\7<>BK4 X/?_WWK?WMG9U__U^__;=?_CM"Q>NW.^^+]_%+L>7'Y>?X
MNFS\H&HF=2Q^VG_W<[$S')3#6/R?5WN_%Z\K/SF.PW&!BJ/Q>+3YXL67+U\V
M0BJ'3368C.%=S8:OCE\4",T>OEU'FS\O7MMQ+#8IIA)AAC _H'B3B$VA-C0E
MXO_!>!/CA=NJT6E='AZ-BY_\ST6^"]X]',;!()X6;\NA'?K2#HK]^5N?0S/]
M1K$U&!1[^;:FV(M-K#_'L#%]Z-$8Q@/&9-C\^FRAZ5_81E4?OB#&F!<G^9IG
MTXLV3UP]".79M?G/]DJ*L7PQ_?+"I>,K+Q732\>+EY87&K!X-7L!XSB&KL7Y
M]3#R?]YP>?[:V>;L\I.OKK_0O_SM_-+RY+KGDMR,/.5YQN>7#ZOA>YCYNO17
MWQ;&]8OQZ2B^@ O1<'KE6:N:\JHV00_(B__S[O=]?Q2/+;K<]4F##JT=G=V9
M;./:^V9?P/U4S"_V@]/CLRO]H#QVKJQ:2<Q7$<K(_$IH*,H-;;[1#[B/(TS0
M^9V^F@S']>G%>6ZBWSBL/K^8?7FQ4:?AFHM/PX4+RY,Q@N\NM&A^[?E4O!C7
M=MBDJCYN%U2>*8&P7FAA] $U$W?U2V=?7GAQ4X^_'E_X\,)%DW%]K0B:%_#M
MV=#&\NI7PQ<7^]M4G!)UTSJ87G'6,9 H>M4"H_A%/!G'85.Z042Q%;QV=!I$
M-_#"N%P[)I<GXNI&W30+E"),$9'/?OMOQ2]'T0;X6?PR+L>#^!O!Z&^_O)C^
MGC\]CF/;(B>*_YR4GW]]MET-H?EC=  R]ZSPT[]^?3:&7KUHX>A%?NJ+V6-_
M<54X+9KQZ2#^^FQD0T;S33TZ>7ELZ\-RN&DGX^J_E\>CJH:E-'[Y+UA4(9YL
MXI?H2W1_EF.4GXN:\E\1V?"/23/>)!C_V\M1U92Y,YMU'-BL EX^:UL;RL_S
MEX6R&0WL:<:!_.TOY<EF;E.LI[^6(<1A^^LY4!0EC/K;3T0*JJ)1*'C#$(\!
MP[M51,HIZP+S00C]K!C:X_R66&Z^&<)PG6[#,-1VL)/;_[=X.AN:D_%>3#!H
MGS1V6F,.#S74(TXH048I@Y2/7J=@DXTP'Q@01DG-N?SEQ86F7=U2$SUQ20ND
M2%"(XTB1Q=PA@1-6(CB5G%ULZ19HPI"UX=N!/?RA%A93.?KU&0C>9BI/8D#)
M#@#/?VM_W*K5&N/ 4]#(61F@U2"+QE*;AYL+$AEQ@BRV>J["WX*:MX,/\*0J
MO(7/FA\;X[=_7-/*M[7UK>*?-E-&XXGF#!:*MX@["8.;J &!\ +;P(WS=-[,
M&<)O;E?'Q^4X-[;9&H:\5$#>@<64\:O&$B9B<E0C02,\U#&#G!8&>66\T)&E
M9&'N)L-R>L/'3Q_W7\.J;\K-83F ]59/8-#G/9DW_9JN$*N"9!0C>#*\BT&G
MC L)269TLD(J3O@=N@(M%51RB["P',8]"62DXR@Z%V34,'PF_G!7+LH.M2IJ
M3#12"M['/>=(,R41?.JED=%#YR[WY$-=C6(]/OTP (B!OKP!(!OECGUL8IH,
M?B]3?!T;7Y>C_-[==!#KXS=G&/WF'*(O]YM'@2,(+'+!@+SA$)%S,NLWJJ.G
M3-L$';N)#?SE%FV[U9K"T3N:@D',$!@74$E(BPAK*C$N<512:'5Y7'Z/0,3>
MG(S*:>\RW25W!X4 CT'!GJ)C>- 1.HVV?O8;(XA0E$GQK7I#8J $ ZX1!:_F
M,)+(:$U1DBI8CD4RGEWNS>XH#@_LR1_Y?3^$"\!.-/!V8C)YQP6%R_)OM*",
MLOP;S_^)6W6 :PFZAH%<*IT0!R0&8/8.>2X<L1A'K/WE#NS'PSSQ>S$K0UAK
MVU4X!FU2?B[#Q X.LD8& ?DPTWR[]5_K:C+:K:?K=!SC>WC:K<3V=L-Q'<GZ
MR_91&=.;D^@G6?'NIE3Z6+^+QR[67XW-BXNJMHXIUH AL?GMETSM-YN624.[
MBI;J;V8B^^NS!@C!(-/J]K.C.C<[\V4TI\8;)TT GM$^?O&9[9]--:G;OUK3
M97/6]W9B<M_S2E ,H)S3/#$)F:P[#?$J2B^Y\NK9_-;8*O;Y7V7(?Z<RUD7;
M['@E^]W>^=M%-7[YYM_F'UU\^JA5:_._P+"HQWE!_C9G]9C,[SO_[JR9X?Q2
M6&:,G+]B^LW\[_E+7EP8FNM&ZC92TJV1$K<?*;',D4I8<* 'Q(!@\< B8"\H
M6R>L2<(X B"PZI&:=7@*(=,_ [SL9#0H?3F>KLXBE,<9':KA@FX$O9.!8^ND
M;)[]EA?9YL&7ZN"HFC1V& Z^P--.=X<QJZ7QZ0ZLLF%>]/FN^8J_\E5G W?6
MH@<RE402AAW.F@;@@3N"G&0<&<RX4]@JB5,'A'[J>1C_-O5-@6)59P^:??-C
MG3<2B"V8#X$#+Q<@S,X+(%@XB.@8&!/&=U6.]V(#--*/)S5HSBR>"P*]/Z[\
MGZ^ ZP"+/0:6T+1:\1OR^V-OWJZ:S.)FGKQI&Q8N!&[BC^#[U_%S'%0MSP/^
M!4^,*UY-:U(AQ!(<P434R@FPFP28?)1K(*4"LR")X<YT5:#VQ]#K=H):Z,N2
M4PU;8^C"I&;V50U;"5N60-T&DM\"" ,WG/BVB:N!XP60$=D!?BX3=P(9*JTC
M %LT86#&,8*A@BT8V2KR1,'<IE9T52;.O/@[P[SF\]T+D_1[-3S,IN,[6_\9
MQQ8X^#YPY!K8>FR6)1O;MLGXD7]DN?QL!U>)9 T6!$COJVH8;MV$NPK(!="X
MDX#PA+$!V\]Z,*6Y3\"F.&@AIX*7@7MOZ,IYYU*TT$VZX*]Q",;9 +[>"L?E
ML(3;6C?F[;3!<K0BZ* Z;U] (UY!<U(Y;G*35R H75!%0IF@DT",,PS6C#!(
MZT!0=& (&LZU#[2K4I4][;MIJX;9.HR70&>[/MHZK&/[\;*DYF:86^ N>_%P
M,K#CJL[J$2S^? ](TSZ@4O.NA/_&H#+OC'U-/=[<RUV?-B+_^<Z>E,>3XY5"
MVFPO;2F0IDAP(CFDLLAQKSTRG ED!'?4.1)Q=WG0;33.Q_V#.MIF4I\N7^.M
M3.?>53J6I_ ,]2P2C*S$#G$,OYFI^#&!1?*6I=!5Z=C+VV\Q?  ,/SW(VXQ3
MWWWSZG3QF\MVT/DWRY*26[+UK1!:YZD=?+!EV!ENVU$YMH/'J?&,5U3;@%QD
MV9KG#FG+*?+<*9V4!]'JK,9[:\OZO^Q@$E^!A&1@:>?V;1W_.8E#?TF>SBY>
MN+39RS"064_/O+]#8B+'-'J0$VD0IYP@8Q5'@5/K!.$&U%=G)>9&-?'.#B?)
MSGCP/M#QTB]/0]U$SS[4E2NKPSB\+4GKCC XRHR0#%F3-^EEA-\"-RAJ;V'V
MC!&*=%48ULY9SN'K[-?_@!YE[]_I[YD_7X-@.\/19-RT5Y 5-&;%6-H=1N45
MV'5Y5T];X-M1<N0,RU$RE$EC$H^<=TUVLUESQF+^&JO#VHZ.2F]GHC*+U@.Q
M?6P[+@&3P(E'UH.!Q!V32.?8$4'!9"*21L%<U^;J-LB_Y>/@%!;-5M/$\8<)
MK'S;Q"Z8ZFTPS]Q:?QQ6.ED.:N18F9@2PLEBQ+DBH/N$1=;*1+$2DM#854E\
MHAJG9^_GXFLPYL2*B#AQ+@?A8604X<C*''%DF ZALX3M9B"%"9O&/"T=/J]Q
M7RR\_=7 ^C]=68?M03ELU?'JB'P'G 8&<ZZ-BL@%JX'U<X^<=P1%#_)DE3/"
M]$Z#[A!=@P41+%F$I<@ARO!L2ZE'@ 38*<=<"K:KT[54LWE9?H(Y'7J4P4U&
M$,*)4BA0)4%:DLJD&P@.5HPKH=4]1/3U!&=]!.?C_E^KS[$>MD(_"^5_'=WX
M 7*=?  32XHB3AYQ"O\YXRC2Q'-E-!>4KSR*]T<,_.TJGSHM0QN M@.V_J49
MVAVU(=O91]D^=MF[:,-#$+P(TN$&\4-5CQ,TIIJ]:]%N+.OH;QF9=NLF[ Q]
M=1S/7!R_5]Y>XEK;O__QCA#Y.(F5%IQ;)Y$T!"BZS!0K@@ #%&,I50H>=TYB
MOW=SS?O)\:0EU+OCHY@/)HSJ>)2?EH/5\NRO%%_8$O'%$$,T<8C9"+/%<^"B
M"@81RRV.UIKD.DN#'X F6"8#=CS2"+I%29FM7B/RYGE$(FCO:321A94';/_H
M3"T]9OF!0F-@"K.$D5(A@3*W!!D/_V&86"."HT)V-B+TEM"X%\>V',;PQM9#
MF.N'L[HBT<Q1@I1UP+.<<\@*PI%)UAL%W MWU[[<G[BF#*6M3W,\VFYJ5]3%
M:7ES/!I4IS'>)GR[,]S7$LE,BA0)ID$W <@A'8%8*-!7QD21S_EV=4YNMK[W
MCX"2KB6::YG30VVRU(M\P!",;$T-TLH;)!GA&,@#X%EGE\PRC&S:&]F/A%I9
M38(6PJ.D/$5<Y)W99(!:D:A *6#!0V?=15OPA% .VA/*YR/_YL0/)B&&MW5U
MG%7U9&RG)_[G>OE#K/>/; TB=_4#OCK0-:Y+#_;.BA1(!WR&5D=M*0N(.6<0
M5YZ!\I<8$:VTHQ%D0'?V3&!GR%D'2+8U3! "-K*C"N:1QX"<X1HQ3XD6VB89
M^]B^3L?VD?:@KUX*LIM (A$8!:$!V:FA2.=#SQ9;@1F+ECC656'H([V_GDX+
M-)-BCH1O#>ADD",&7@ K'O. I3*="W=;)N5D3YQR/O# %6L#CM8(I)0(8- J
MCIQ0 H7HM*(,:[UZU?0#9(S?FHS!I0PO9:$'SS&!04J.6<13<LC88)&2UL@D
M-2CXSH;X]#'9#S!499FK/ 7@F$X@87+P@?8$:9I3N-&0\E:+,KZS6RHK2Y)S
M>]8S<4TK'.,WG^&_3$LO"LFE"U;,<^3M><ZE2^\"?PY[Q9Q(H!E43AV1.-(J
M^KQ1((F7*6G568?$+;S1'VI Q7$6&_]X PP=]21$C9%B#.Q0&3PR!!H24F)"
M4&^9Z=Q1Z/4?S5C;7+E\B!1I+QGBCB1D7(K(4VP-<<)S]3#V5CN>B6.OFK2G
M1':.1Z#J'_/2#\PQWJ9_ O;J';),>B0#QBJG0<C)BCLF3C]\JN4[!&-<UF=9
MG,X5>RL9;ZM)_7]C70&Y^-NC="\[GF/UL$:4!IZS00EDHPO(A>2\P2IXWUWW
M\MHWF#LQ@9+Q0$Q.I9J/GD@%M%[G[0(<HN721])96G^3<_>==5^J^L_FG@/0
M/XY2#>/[P9[>@QKX+HFYD #N;A)CN-*,H<12SN^%#3*4&K +96">D.A<=^,7
M>F]EOT%^+LE"$!N!&I,D!$@RR+2+7B)OM) F>8)Q9[&ORS&]7>"J,L#$6K!U
MB+-@I@J+-$L,>2N(44(+ZSN[7=JM='&/^TB5T\%3X@W"JHWV"F#31 *Z+7)!
M6!(R==>KV=J<BZ=K[^?,;2<]80 =^'80<^'2.XF.%1IC;9&Q!N@S-C;S((4"
M5MF;&4*PG4U\T2D>U*&=I:>RF0.R&V0D8*SS7-Y$>052K F22LLD'$]2=%9V
M^YRX9[/HI"""$D1]3O&5LM]%V8"D3UFI!>QDYQQR9\KKBZW;GB]ZR\JZ@6$[
MW4V[*<5V>MO1N.M"7[T3L'<E97$,A$69 XQ]+LV#.9A3BBA$B<.&)\4]Z>36
M4'^H]Z9#O:\FH1K5D_%D'IOY2&4WLI1KE<E\?(TGDI!5.6I:B>"#89'CSOJQ
MGT"(F8N!.)/K^"BI@*_DHPQ!"22TT9)B@W5W,U]<6R'PU>G782!O)_6P!&J3
M"<S;\B3_]F FR6/FN$FY'DC.8B6U0%IZC:(6./& +>]>=-LJ\/]ADDF/>?!4
M&^0URR4;HT<&QY +@3+E+>=,=-<3<@69_-VNA$NNB/&MCL,^3'WLJ:7<*(>,
M]@(!>.141PP:8IU0T7B95F_:?!^0+C%[A><$FJ4H@JYRQ*W&R AKVWA+8X3
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MR:346<)\2WZU%\>V',8P![''B432$(<M09(IGFL&&60Q]XA)Y2S!PF#=V<C
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M55)6Q"%5<E$*C(PR&I#5Y6-%$2-F93"1IZ!X9W>E5[<?UIT%8PCAN<9W@OD
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M4##)LG+D@D!+<TBF5I(V(XLT&0Q9>%F&P<Q)?%"R- !-",6:?.%THXT7 Y(
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M-MFLKR;5=$O;B!XG30Y>?GQG %"&&]#PBG9-%\GJ+8UYE6ZJAGXZ^/#JY\/
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MS33%3Z^Z1E.J?(V)[</!!*]GGA>&*!1N@*PQN42=I$E>K1M=(%)+2+JAJ,'
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MKX'F-P:2K=8;H8!909^''<"M$?V%&T:(%50! W<#_ X8M> Q)AGC^IS 1&>
M1\DK$'V["T*)IE&>=0QO4K<YWY/%@C89;9!4_9"VIO^A>2BC;5$OTP4MO&Q-
MI@/=#A!W^\P8?T#@=2N/HFTUIWVP:+,08(C$G+<YC;0S:5L$33J6M:*=:;\6
M6Y<;8XW4C5.[5QD\5N[(.\7%138;TP::+GV6YDYABV]R(NZ9=&@FH=(>WG56
MS@)D.VV8TQ4M#[3,?:BF>2;(UE\S>JT 2T!L*P,<?B[YWQ"2$5"]8R-@09DY
M/DI^!B@UGWO.(.D/ V<1]F!6"HBT FX4BE!_9-PU)LXM"\:XG(E8X[C5!GL"
M4,). -"NS]-ZQH_VY-X_.)6]5CC@JA*&,G5^Y0ZN_V:HN\?K M/-/KY[.WY_
M"@%A""LZ.EOI'!(5KQ2(R+I[:55B\!&<RS3ZZ[/.C-R >X52GXF>TR.G:)<L
M\XEO(]K9I40'_)Q>C&?%&F&#3R@<8IMF4\K\3W3L@G%TM=4."*L#W.H=_+UZ
MV7%^Z+K=[!NLAO*"OC/MVC;3K_,$TI:E,-Z@C-S6+IN:E(Z\-0RZS7PL38,9
M1SS6,=$1.>7P#'HR&E&2B5[74?(TXX8&P?9'$EI5Z9B>QN* #)(M!3=VQ$N!
MG!,]4,[=OV!)DK;# (Q_&2$3X^NRT/^)A;8Z+EX@SK7UJEX^W^W%5HYVUN3W
M,)G; I-YL(?)[&$RWP=1T(TI\7SY$7[379NO6^!!#I[3W^Q96UGVAY.42R+C
M(J63K==:4TJV)J@K> GZ4:3L/4K>_4NJ#=VB@;NF*W!T4 %_MEKTM"T6*?-=
M_%)G]-"CY$-63_#SAW6:EX.5(@[DITJ$(>4;]@TL[25)CT:;E3CC4#N.#ID4
M=NP;(6F48L8X:^CY/ 4+>2*ID"-(:8;K8AZET6N(YXB&$S_,TZ$YQ$[B@QD%
MT,O(WL%]9A?Z@<S/D^.?7KF2$?@@9ME_Y$U9R!,!L=9U7M4^NOD8E>@[S\)E
M$]^.;VM".2,,@O6?5KT>J9OPO B.I,D_^X?,F!WRY6 %QHU@Z(Y1(::+SU8_
M+DH0\3MVY9_9MZO2?#6C\0UJ-!^VS29;D:/ZJEVW3?)SO47>CC9ETS;7&BK=
MJK,I+M9\>/7S=T=3=[7%\NIG*=9H^G3D::E@Q*]4O>%*+#A5S !TD^#,O]"A
MU^(Z0DA/960-0B7LY,ZK>I&6,>T+TM&@(>&8E8OGRI7S"8FOWT&O$K$Y02^>
M'G,IIEG++"H&T"E]W(M+*1$=#Z*ONE([)U](A90F.:_ +'[PXS^/DSEM->%C
MY_]RA_>AZ%FF)ED*]7(_#&&Q.9U+ZM%RD*/DM,GY/_J'9W1@3B99*I;SUQRK
MAS8YU&_.\EF;0OKY-'J<BC.'N9 '80:&GDNT(0+(EAWZ'4D&H9)2ABXA<UZA
M"=\ES6G=Y7.FM6&ICE=OT(#F8+[E+-:?Z!+LA$PCTK)6<G5"" )-0EDYUSQA
M6L"@AJ-8GTM>^Q&-0=8V,Q5(6A[2JCA%*\3MDWS&TI[E+. .,6803)(0&#/I
MGSL,;:9RU;5F\F:5:S5%^_P/$Q*>TJFGZ'!>R;K,.X2%R$=6KH)A["6&+F$U
ML=E82 >4TDM)W&YS?O([*7=_[%)?F$Z\8U0R\HD&*]KPU%G293:D_=UDNNJ$
M\2-@!#R#/ZZVT<-LM<0U5?>)Q0Q0EG,L3*(+/)75[-QY;;I7!/H'?./"P4!B
M2X7L"AY-P-.1"JUA*=6_:LL(3^'%6"_3!6-$P/)7Q9K(@5P[=Q%@H2NB-(:6
M*'*'&;1D./T1LY+#\ FC%H-KCDPJ>(9$8R&4*@(L"FR(%+<QZ9D*W3 C7V^0
M3(M(=@@*@-NR.I-_UFFSY.&>I<VT!<%8TQ\KSZ5 '*J:I\5)J<EW,VY3T+D&
M4U@]9Z"_:.H(E_W&<?I%'&&XS1HV:%D5N;0.=\@SZWRQ$(8Q6@T5HQKH"> O
MN@G!6_RDI_8JIY"B)E=^D6DY)F*4T:9==YZ467T&:Z]7#-8'UL-&%[4KT$ZK
MA3 ;XKG2O)93A=Z8V42V?#@)ULUVNL0RNM4&[WO!.O3KJ>I?I/FJ49$9;E.P
M(OO(470)!]E(%U<I2BWAP4AQK;NJ)P:=9 M0B V6/Y&Q1Y\\U^TY<Q]NZ9$8
MI^5V1HX1+2*:L>H_+9<E7::?2?(4'I264E;D@1XEO^'+S.Z"_Y46H?->8+Y$
MYQ>0DP2?5"_I>1"#PHQ54T58''RBF[HEAZ,V_&:66!TS9?-NZJ(IN1/+O%HS
MO2D(T[;3:DUWKQ ^0PA=01B>9]&%X2PBZ,P("$_5VB0'\-=J%!;2B3BH7K.#
M\RR"HIHSR"<Y0/5D)9\5?8F&6Z18'OT/0"5^-<Y!RVA(-L:7/T:N+>X?/8?4
M/"&!YLZ2 5]GY ]4!\K@-$2?I*[#*(EVE V79_2U>")+177P\0"](+DC;H1B
ME_SD*_DO/?XXX)WC+%3LR74&[N6*/$8@E.!0::(@* I6)DPF-YGK>M=9R.OX
MP4<8&D]A[Q0(6++U(VJ"%?72M\+";ID!6(R-X3*#O(?9=YE.VY5J)#$26H(W
M?A].%4\V^UTRV;<K Q)GX8,4R,T<[_>&?_C2GBQ8[G(C7J@@U,08B$2D1^+[
M_"QRL"'WF+'<03\I^3@.])-R%^_&W0_GPN 90CU=9@:%3+.W#*5)&<5:K1C9
MIW$SYP@Z/$L=*FPE'\5A"Y$YL=[\%&$CV"3WC#610% LVD2'9L9TI %IK12?
M=G9%AQ[TL_<?>$Y?/CM]\R$R^))BPA" 'Y29!Z4R]VXV\-5CP  ^+3)5?H8I
M3"MFDK92)X"/SPUG\T7$$MTE3=CUUD%3L'IEI#47/[_S&3IEFHB),.V*;55E
M1>& ''T:Q<I8I^F:Y417#NJ5F08GOWKNONNF]D<J%\@->J*69PCG6:X\*]V$
M$'] **N%\UD+56["C9"VV9C6Y^UIU+@QE=:_S\;O+?H%9=^W9$RU-^K!99U]
MZ*M^^>9Y5,F-(57I;GY%S9=\A3*M]?)9O9:?>K!@R[>+A5&&J[4I)!DFJ!+Z
M,O:H5\F,V^&Y<<LIRG'JVA]OR#?338I,FL%Z#<-QU795S3)1?ZCDS,CX^!OJ
MQ+M:M7RHQ2YM%RNAMY1&-->')C(B9'&W+(%1D<ENX)E34,GQ9S!RA%O\^M(@
M2PU??<JJ)\@]4J@C3!=/H3C"KU6ZWCPFSEAE WGG2Y!V4:^BE8ZYS_\+*\>Z
M'K2%#W+6PD40OX_4M_'UWIQ.CKP/[4OTK\0JX]6-M6U[L-^M!/L]W(/]]F"_
MKPGV^TY*7A0_I5( 9<+RH&),\T&G9RG$50ZZ)8WW$0#MLD-4 D!AVN)<D@".
M6+U$<=IYR74?QG_S>12)U&HTVXTS)+MK]>3&H#(QSD$5@2/$T_<'3;H&Q_8Y
M^89QU[_S;+U72],4.+4!LM'HT$8@(Z"WE167>+:1._ELR>P3ZAS",Y2W+*$0
MW9!\IPIK5KS.G9<6)J\&3F'V*:"*Z.5&V"=[)9P9 6>!SW$$1 ?2RS6X2F["
MJ[L]:=%O@:=K)]-VDY894D<OR.1HWONOO,!O\!AW,MC6T$,/!LE%?7C&@(&@
M>A$J<TS0''G\^&&R6ORP*C23Q;)Z]/^X **4,]#T-;G$ALDR*];)E+%,@/&&
M*3O/:H.NTF<6^?#!Q:FX\&R:TQ5:2#1)*'2&."#@7^SV;&E)J7=#(Y^1BA;C
M0.2N6F82MBQE<I'6<J=M:!VJZVJM\X/B;3#&K*3H4.91/SNFB:&7&W0Z,9I/
MP4M>'/$H.2V[<R])1@ENX5.@ZL?&G/.-(0#*!M9D#%IH5%!S6:W(HT[1.J8/
MB6AYPKG&>08R<Y_]\,X$+9DH7=YI<ENV='L$E2O&=1V\^?5=<Z@?-+D]!7\A
M+9V>T018*,J%L_2L$BZRHN)S)8Q5-8EZT2+DO/.';+WIG*5V5,Y\RF= SN2R
MJV-Z(1VS66YYB=%6R6KA<&K!,UCDJ9\S2]/;] Z1]#3+U&@C+7&_/_5NSJEW
MM?SQJ__S^OCXT;<ZTO8'V 5.]?^7EBU"(V<'.(/"(8@*\+U.)^=5_:E)3A=U
M)@XO2^?AA:B$+9]_CN4BJZ=YRDP#^N)'W'\"?JS3=^]?OD*1R7%DT<WJG'/%
MQK)&F_D7/NYJ\;JCDTFO.-Q;.Z,/08UBE:5X]GE;.) B3!N,%4=Z;#G&:K'Q
M6QD6QL__^N'IZ8L7(=Z%J0+CKIS%Z1N!M7#(IT6J+MNDD@-E3O8X=7C-C<:T
M/HQ@#&9PR"&J" PK@T#2U=[&W= BV?NH;BPKBM8X \YP@ FYV?BU+1$5SFSV
ML(@;9Q;-R( \H*0!9\;:;2 E>;MH8!"1/,,DIY&]@41ZB2<,+$VD%9BJYRV7
M UVQLB'FROL#KQ(^Z#GL8MHTU53-F(B"<,M'TS; W.7J 1:0!I?&5S)1(]<;
MPHJ^N4*ZY/*&95#%9)^D0M(I[^%_N5WA_2E=$GB':<Y9*W9;7_\R2C[\#HQ:
MZ401 U@8C6#2%@4"W'6V6I-G6^6SH\#HYBH<)SAEU"5\PZ,#R\W:<L:M(E!I
MM].#C"+X5P)PX0I1CF^Y;-KZ+#]+BR['M.[/QGI.>$)BEAO)VR8-V?OI4MFM
M'4_F9MDVON=#DY4\HH '(V#QM#(4N=PUGN+E(D!TV%QDGS-4NS =*DCM5A:
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M0<VJ8NPW>&)4D_1YI"$72KD-::EQ?<BS1GC!G8 0R$Q>H-0VHLAM@]0X60D
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M2(Y8BVJ,R9FV#!?C\9?9HM(V, 4YXD/A:*S0I2DAZ?^4B4U5BX9>5;/$Q!G
M\KR&O'/)67[!V_GTB.Y.1KYH1QF]Y37'DO9.C_SGY<)L#J-RB@U<<RNM- /Q
M)!C[9B92]6>]M&60?9,L" 5A\5J1-]E;!V[RY0Z]O8 O"-UR8-IG5=:H$@1>
M(Y)"D$'J/X@6(%EXD_/Y&;UDI1^41[#H6QZ3]\O04P9OY**)PYK$^O 5UWB:
MXCTU.'/1,AC,SI$9D7:A[Q$;<-4P%@<@5H 8)2ED\>NV)7=U4V26H:J[0:YS
M0=JRX/.7N[3=_'=6NPQBI7O0!B+8#SM_:_M8EH4?HI^0DU'Z'UJ?5BCDY"KV
M/L-&9/1<=?/%#ZYR736:[:TYSD"[V[KM>%=7UML !WU?T!32KC!GOU$49PIP
M& O\OTC/850^M&RNZN09O1P(Q=,GZ#@\I9B;W#W&2S!H7X1[L1)1-IWQZLQG
M>8I\E\=7A,5;[P\R+3T_PL5O&+!':?.<9>0.UI(:^;V=+?C/[ X'I>M<+&FX
MUJ^8F5&_>E;Q!2H42'S*Q3+YY NV,).3K<U&SD0/I>0EE"ZZ[<$[_0A-"RYE
M/H(<)>&ZEL*=)O"E^R&R[6N4%*8^/>]ZU .O6@^'2KK9Q2ZX&]&!4^LV4:Z\
MW9\5L+RO3"[:?";,LU;%9D<-W:L>C.IG:D"3^9IWG&9T;B[4*ZJZWDW(S,O^
M-KDD]O4X,&# M-"MFB0"\[BH/HX]/1K:G$I/8F?;3FS94!']@ML=]*KK*E,6
M5]Q-2*W%R>N+C_UPX$  /F25PEA<"QX!KL @'(X"(:W=10P(PX4@5";];;C8
M<ZC&T< [!C :&>:H>P<U,>[R,@Z-R9LLI;<X\I@CU'\BY!$[,$ 6>+207FAM
M;O,@8FXDWG1A/059"^T^IMFA)\K6TG4^ %1JG"E=(S&QT2MK%!9&66V Z'(8
M+7NY+A$@49/%+E-0K=SDC/H=<G2PR^H,BZIA2MI)!F$-)CC;T)*;ZQ&?H6&C
MUN*\HIV39SC<ZN2]KN#DWT?_.AJ%VW/$A]T6O2:S<4LKFU;3.F/\%;M!=+*>
M5>)P2A!E&K/Q/C&)2EO]P^ ]\:38>1?Z**F&MIKY@W^3,7U2+?0PG]=%E6_B
M^[GMA#NB06<D[A:#$1&\.CH*'>D4$D3L!V@(:FY9E)W@.[$O1K/6O=E(4RY<
M5E:+-<7&S)1E</!Q1PY52R'%NI(Q,(C"A2XC^=D);[(Z#U_<;,Y=]>[_0OE3
MN9K9J"JE*1/AA(%7JB!#!)HXP+#VJTA).Z'8H;3,7^B;AE=B JR\=*:887+1
MF%TN*ZS"=M<7CTA8#I5'R-MY*ZTRXC,+SM6PF"H8TS_D"UAUO>W"0UQ!N.9/
M%9$9?-$;MF;"D>0,,9;^3%^EOU>6H);HMV(A3[H"WHS8%9]##9)A%SX=^SGK
M#EY [K(_L6[ <\?D6^=?MO $I3=@\A-5H$+8&$BU_+O,L=?^1:.: 8"-(TZP
MGITL*934SU)6/^NNK8TRX/&]A]?Z\,W?I$H&]"M3$D"?#KA19O@L%X7(9,V2
MWQA\-U!&,#S:X/,*OQ)S@?J[9T63G0OOGDN'UB#UVW+B]5P*9ZYL!G-CW()R
M'RX!].MG.^I?R!=P02A72GB#*?H<9UMG3H<&OLJNW*L4T)12M1,[#.6ZW/OJ
M3LS^3/3G"S"D'!(R+\0<\8^*$0F<<BYY<U[3 Y LSUX%!)L[Q_PM<'T!R'**
MG%[8@K/G\P0E]?L_'=][=/3$H68/_NOXP?VC1^[GE//TO33=X4Y([:7 H5&(
M&N(%RUO+IVB8JR_$H?^3L;]]P"_FJ\D_1],E3=EPZ=".D-6%]4:97QLZ"$-X
MWLX]P!(J6@MRE\'KK[D(X<[[ ]Q/OBYB5T',=Q@-YDIP*H_K=</SSW_9V&[L
M8;H'5-U*0-7Q'E"U!U3M 57]Z0S->N=$:RZ(+G$ZD^]:LRRI-9)$/18I-UZ8
MKRAG7MQM 9[X^)>^ZP2N@VL>D9SO90C]GA>["ZK_IS#Y?;?\R\'Y_>C[ZBA]
M_UW)5E\19"^_V8VL'TH(7 "QS\H_ ["_[";Q.E.^[5PB]#I,*4NH3GY6ZVN'
M7[CH\+M9U4X*YWA97VZ0N-9[W%5WOU]AD<B*PC%)L:KWSO]*_7OL!8:0>,@+
MORRW?6B"&9.H'2U>'#^+8+O@88#IN"B>R[4(&WQ%ZLG=MEQ._(+U%X$F2Y!=
M.=I$7#MPGTG&C.=TLP8\UOLBQHUX;HY185=,J>I*:8&<$QI< ,MLT7H#D3&(
M+YW/\R+G[L(I]D<&,OJ^J1[I<M'F4-?+S'9^4TW2Z;1R)#'[%7,3H09!P_7=
M!AQ<I=-Z$%/P-7K?&0TP\"J@M$)'N<#E(\@!;;'_1K/Q'RE]9^0Q5OXB9.9?
M9)/:$!''=_G('YC:&%H1HQWB*O^5X0Y63K,%(>A%1EFX 038@&I=Y]F&Z[*>
M4BM7&"1JL,,PB2XURTA!H()C=T!U8>?70BS^U8.4!1WE M/J3D/@-DZVP1P&
M)$:,YQV+DQ"!349T^56N(=7&"VL$H[BCZW$HX^R8%/KI3EHP]Q\]^.GXWM&]
M,"5\?/3XSV>$!S*O78-U <]"2!O#M 'U1CLMAKLP$(6$X!Q'!L1/W(-,]I_]
M<?3H3XY._OJ3]_(!>^_DVS^WE-JXKTNJY4+4%%B> (E@;W+'.=M==!(T]Y::
MT'A/,E4A8M?5=MS1<;CAKK#J[JI%VW7"LL9A+[+V@;-WBNJ0F=(0/OKGL6'\
M\ D:AA)P^<M8NB1L"N"8/!O"<PI\R1DV.^#<Q8^2IQ5$NK5GYK*2Z]!S7R6
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M__[P[N/;0T=0YKJS'+UBD#"G%]%DT]9F67C_M)WW"O/DP\Q@HDZ_& _WO5@
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MR\,NF>$F5@7,=R59U-H/YE6$4)!Q'WG9]2#9F=*;=?[$7^QZEOC<,*@U>:$
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MJ#>+\=TCV8%7K\_N.)3WM%CFM2QLK!6NM""%+/FYR.U$^:5@$:A<1(:*LSL
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M0G$035NQ1B*!<537T-K8N([*?&K<7R7W:&U9_/)]L5HK P<&A2Z@&JD"M0E
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M4<\D1< 1#Z2TR[B%#/=::*_=1(1W"]RO[(!4-8'G0_LZA(%5!Z\$;A0''X=
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M>LEAY4)):ZABV@C]F ;(OF^2E>7"%=ND!U4%@8@>I*RXZ4J[F&J)9-GKFD_
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M<87/\H?W4:)1",A& 6;*:,O])7I!?&.?VOGHL"XX2Q*30)\-+U$K)74C"0K
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M:R5]&U8Y/?Z,2MU\N6:.TG=P0>A7_L"-\DXCLR!L2L$C)QAM'\5"K\Y.?+*
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MGI*>A7]NR\DF7PT%W\*WNTU53(DPL#5NPYE4P_&$>-95&-\F!U,%B=;O$OF
M<H78W,82OQ8E[E7@W1-2ZWDN<N_C+9#1SR.OL9!@D%RM?-L)U3OW3G0%\[[(
M)'(_/SLMGIL9V6WU.3)S.'!-OG7JN$R\Y^+: O#&@N]$'80;$B9#R$BA\[:B
M]^Z>/+C)>&H\\,C#0YJ).2/1<,F+@3RV%M+R""S%^V(>5L9:?.01>"8P^-K!
M'!#JYW!7@6(@94%ZOSL)RH,QBUPW.A=1B@'+)XX-(/-<Y=E3KQSEM7 Y^O&J
M*84%AZ@:5:F-V0WU NP5^F<]T8?E!]S[4#WAB%R&SNJ'M4A0<6HE>K>=R"Z
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MIV_KZK7:&97]MTO243W]%DOK7C:YT!<[>4+_F:AR79BR%_5"JK.O"P+%"&Q
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MX[(8W^#%/M UL&F:=];S%]Y],)94&S[-I)^/GC*OZV:+',2B7&RPW*/P%M_
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M6X8W@DL$5%-KI[ F4$K+>P6_Q]SAMD;>66E/F&9< X?J>FC-'AX^?/CP]Z+
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M^+%KQW AZ7TXZ91%T%^N;>F%BY1C>;Q-5@I@Y4X[9'^6A?F*G.:*99PV%+P
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M\Y[DML=^AX56A2H Q1$GN\/RY+=TV=%F1YN]]F"'D9K =C%DS3 >"-=MS]U
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MQ].#=1IKH*::/3YGM,O1+O] NW1]M[[8=Y[R)1L3.)>L=5@^R>E&T&AD%(J
M@8.F\N&2B6+N1WL?[?UW(>&)"B;! IA6<[-]SA!9NB@MLAK(FN=96D]^8.GZ
M&6 (;VF?9CPK!;$M.],;Q;I#(B,D\(>Q=Z7%UQ/-ZG$L:BM*B)I'^Q_M_W>Q
M_W"#Y^8&4]>U!([ UF>^?VCR[L6K]\('?K5,UO:WW$3!G31-J.H9\3E=*.',
M55[2)2AZ3%SQ%$5&0<WJ-:)^,H7)5PW@^S4%N8P8<\!YN7&,_2GIW!J7WKCT
M;C 8#6'3 ;+H/)6"OB5U "Z>LS]%IXMDER^GNAI-=S3=FS#=H-JAI8U51G]
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M 7H>@:[$"> YB[HU=#&@7"594KNAVZ3WKN>JYI4FQ/WA4=5_[+Y4=+94= "
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M4RO/RU!6E,U VH]H#NE2CE7P@J0<FXFDE:)$7C8/LY(?HE2,RTA&S+M=(_;
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MK79UTM2 "AUA7-ZME=FB]>=<[RQU1!:W]]2Z1W[DR8#K9.:L9<$F<F XRK?
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M>?PG%%,>_&<^^SA%U]Y[]DDRJTBOF9 8[3]%P:(;EK 2O6JAUFO):D/_,1W
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M"Q*&5#./JG7C]O<\NK"IJ+YT"7K/#DLAR71*Y C1 ])$[#UPWRF08 8Q_==
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MK0!! 9 ;%T<8CZ5>,!7+:!35422/(OG117)3$2,0II"FLBAE&JCNL-L%,ML
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M<QVTQ$'AUKX7."K!1"G/=AFMN=:\HL_#?A1P[BF)G:((3F5>F?>IR< 87<*
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M[VZ1RTS774ER-,:46C(Y67W?(#!N1DE8F1OI:@?AU^A%]2&O.G E3,N].XF
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M N40#%AYZW44K<3=<UWJQ_ -CKHX'O=-\UNZ<T2NU#)D!,74QX<OE8K9)(
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MB2!P]IWG[V.,X/>(R6PR-0-.NW>";W,3W?F+<.XX/6,03''(UDV[E_'5W$7
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MG3?ZYP55.=ZL47:=/!LX*1/?AO=\:24C/Q?^3>(ARJ\F^5%"8=0Z_\-Y!06
MD\X/PJ!L=7V8_GC<=Y)2E"C"ML$-[^36&Z1A+ZMFY^/FG!OYF-S\_,_]EXK2
M FE.LCMIYKI%I_(T2AK2-8J.Y*P?B=3C\^:*BY>YO^@C+>O5UF#+B&5R2355
MD[F9^0DE;_/JUC ,SA0NA>)WX0W<%\G[#'D!F^XWJ>\00]I0]1EW52I[>I1
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M'4]6?Q$!QVR\A M-@!(++(B5E^Y"%K*L=N1,$GXGA%YK\5UT5T&%TI?]$/T
M:T:4G&$"=L9[0R#K>$)VY!XWIY=$2$/.;($N"P"QS;Y&.4GTQE<M$3#7Q,:H
M$^Y&SU'//#B3/OOJDCZ0&P5(HDC'++Z2FMN$F-TKI_)TJ [Z,XY0&W:!.@ S
MAUHPL@Z="&Z^DGR\72BQ%;19_)P;U#@S]LS[;!I_6^WCCIS(MQ-'G4,K3/_5
M)+<!EL!YEKWO^ 3S@-1K0=GXR9.X[:\PD[YW_DW32["6#YSG_N(#T%1&HLYV
M5Q2+X-1B"0:'(# ]2[X6>[2<^>R+<'(6M5;"LOF?/9K!-XVGH#-.2(&X@#^N
MJ7J]VZ4/:)OC =HHZ- [GA8$K*Y*@76@U;AN5KL&TUK82$]!CZ339O(LGB-<
M*N#W^I3^7N+LMVG.>)1%PKFFKAC3_<*695:.P\"1I0 91EPL"3'BD]4O9 -:
M9#L,;V[74"J, J;')I(L$_ Q0@Y-&\D58\6OF/:X2HX$KX)V_^9M_T'X\F+$
M>86*RM1T$)ZC=/X"\^MQ4HE892G?,]Z?T?;,.! \SX !EE0!B\\3#1E%G'#3
MD9P,[7FYATM2',! \MEVDRQF#EN3'4J<U 3#5:#IC1UYK&7*,4+5MP_>;QC>
MITB/W@(7+9F$:7<W&BTPUQ>%ZD$&2LRAJ"4[DEBV,U@UXK8$IW89)8]NEFJI
M.Z#> J2NH3R;\YR<Q 1DS0=-.!(-JJU3\=3%BX9"S0P&I5"B7WJQ[_VD"<^K
MEOQ!.82<!6L-?2T_2@0FY*72%WF)M4,I[ZX]U3CFKK E[.7@M;:WY$T+^OH.
M)UN.L*[[".OZ[LLCK.L(ZSK"NA;FIS/-F*;$!$F;S;7IO-XOQM.'V/*@JV0>
M%*WLY&,N?\H/YNE"-CM3NI0\E,D+0AC;Q'6A\&O5P4N=C/V9T$OQ0Z?RMN8W
ML_*0EH3H*<W7Y0Y'SE))4ZAM"=Q-(G_C,O;!V9J*O#*SES5E%=I)F?[L28:S
M.IAE4_.'K:83RIF<:Z;=2>_&>514]'-J+"/N^0^W+;UG3\IXDM?T!4\NI2_9
M-=#<U+=$'H\5H9&7:UPIVI50#2QXLOIQ:.FC"Y"/Z40P68R_2WE!.5//#W^=
MZG(\KK'6B( \RGDA\R04%LN5'E;GYMLMUMHM"TG%_?A*JXY=8U>JEZ NNM8
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MWI&1.\6\^)%_WE5EFWTL9<([#_ &1)^2MZ<>(X)\VUMS0]ZQ?\EF5W7S(:B
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M%<HBQQV=P"49 :*I['>1E9A^(\X-?771XLP8@\9'@@'.!5(_E9::+6<;@4=
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MU\1CC+)\A2?!G)<0;Q.Q&H]U5_A7%HT?.36O/)I%%SA01'TQ2M7R$!SI4]U
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MRG7+.PVSQ&$J N^>:4D52<\7P+T(Q<U%A5$2_[3^9%/TF9.:8NX"&FRY1/(
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MLI1A=2#>:+%DQP6+P4W'76YY3'I9=%+1-SGO,P2'NP#9HF=$5\.-7@63#LY
M E\RM:3":$P>TQ GY$66FR>]N9[K;:\_$/-@]0917NT*+%],"5+@6LA2([AV
M0*"QG^'AP]@UJ?O8& 6,6M$A/!O9Y00&:I%> [2A>+'@X!:U:'>+ \2"K&=B
MS[@1(PAT>9X%M371IX?.)<^I1UB2++HX]/-^6::AOLQ%XY$2LQV4I3W"4+P2
M/C[4*%O\#+/4(@\MTM$QZ#BFIB,?S;!?N 6ICO65_F#=@GVJ3]7-OHI&8N/5
M82#?97;%R&1EGKQAJ\O,9A>2%\.'E@YF%:J:NXS\@G0BPBTY!6 5(E;/BG P
MMG]N,AYR#CU#?6]S>\'$<1%]Z9UMW=JW!9Z?;P@W6>&$(+F1D:/E25NJ_H^.
MT*H4!9FLJ\ZS<_8VK6LN"^+]740X*M+F:PN>BY CWJI;O9O\$FTH]J#78,0H
M[/0[G_F,J%CF^G>$=/2-*&GP'[D 4&F!PM\2S0"/0,\\T&RP0]E",VZJ?E3
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MY3:A"XR7ZG)>:69KM(_1!A_X5$BV?DE=.YVOQ;B<[-OO/0AB]^!UF:==$ M
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M\K'W_-V_7__\??RVR3<BTNIC@6B0<IW\]?AX]S19HA P#GBB;)*0?+!8,4U
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M56^>T/&NYM:WXL7"Q%MY0164ZF$GCRL-W@EQK..W6%G2'\JK??!PW(B>FY;
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MU4<3R45VS86-041'NVRA$=8BNX2'I$()GQKI\4,P\5[ L8Y%?$.N)_8>GG>
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M_J+A9I5GW4#&#0D)X(G6*U47(Y>1BYBT'=_>/T 00W?!A!)!BUA&N5'ZE*%
M#>GT4*Y3H-/R.K[^]H4D$%D=IYG/QS_SN;^W-PU]3D.?#W7H\_ W$@3ZS0@"
M/=P0P#WH&&"9'.XF/Y.\TIOP-)\J*,2B&(=RZ9L:5(6A\H>-^-^(2S_5*AW^
M1*GJ2T@6($_.J8?]DR\SO$-I4$Z =;G14;ASK:WKTUMTKE5:@"]'E$4=9M*-
M@P/.L(.^@']#>/'GO]>P:(]^0^GUW]ILX;KU;X':Z@$OW0>]<L$ZCG:37^"9
M)N_HF28_A&?Z2(9)_\09[2D0?9R!Z/X4B$Z!Z%T&HI_]:&79/-3MZLW9V_<0
M.'SJ#G^'8?GQ;TS>^!L$4;\U'K[9_L84C0_UP3W\??X8]OE BQF L7ZVZB5S
M8/Y(XH,I?((1D^\,#_ OHL.,[917J+;<)&_Z9GY!>DX09/)WD<I8!)$?20AQ
M[\]?GKQ)#1['@[F/_DC$M8I29JCVGI0%S;C+K-J_LS;/_DC^R4HL\O2XT$E$
MM^LEO"M%\/[X\__Y19&[;8&]C+/^'"(H2&R(0GC?TLF_W/CPZWE72^GSR,Q8
MT$#:F]=X18/#*07M589\U\HI?@WG["=G3-\J0O9?Y$;(58BW(>_R--?"&3V'
MG]RLZ5&#Z. DE>J[6!?^Y^@D/7EVDCX_W4O:BZQA+[M!6$S"][EVODG>+.Y!
M[!\FALZ=#@)9"L23I$*I@H4BO8WCDO;#!>IJHU@0KKVLXDI"^"P?*-%/B\8?
M%C3:^#A7%S6-";!>.L,DKBK\"\[MPU];IS>)'Z,[07;9KL&F"3:/\<9F3?U!
MS\-3-Z@H5+G/Z#Q]JZOLAP(1;?!\WA"TXFFN+J4*JG!XBL0LLX991E=9P4I\
MI-R>R\-J_=R(*(RQYR:6=&Y,H>840>YXJIZYC+$%S[J:B.?M*X&OX.$'7*CX
M+1S)H\H;G"<,N)CY%D;P"<<\<:C Y9?U2OE5X]&P7[TH=;BP5;;UQJS+P&U*
MQ;I:Y^3R\8)WD[-P\:1)!X]8)2L\EPL>4,^@*HM*OTR<S!GK(V*)#IZ5P)&W
MP*()XH-?SFEF/>E7-#1MQ-)$)9>5T[=,"8V*\>K;M*.+J1]<[.DOX&$*E9+T
M0TG@/JEJ:SV-:O5NN0UDMLT=A-J*4)H\DM*QL;[=NZSD'0QI(3'_<+@D0[;P
M-#W5#WVC'-"+&K4@$VG^:Q<  4$)0WV'ZAC':01SR\&SH3MH"1J$8J.<D+7^
M$2M7NA_7\Z\A1-?AA3"-]"+9?WYX& ,(<%$,M%X\[08BG9.7TLT?]!I.!T-R
M3WE5W"J#?IIKXIH:_)]<CWKV&VZ0S:7+'ZP988_OV?B8V(.YR/_WK3S%_V_J
MISS^?LK!U$^9^BD/%=AS\EL8JVH)(]"W2.7W</WW@_;<L+F<[!HN9=\O^,$_
M68H&SY MKBVXJ.53L9>:BM%GWH;,[;7/W!Y)C^#^Y7C>4P: RF^8#^3QX\W,
MXR5@[6:V*WQ((\EQTEZ0TLL,QQ>S7$AG?I<)\\ Z,[<PHW"&-L",^!1<!J@(
MG6312U)C9]31[CA0B:BXD9J(&=J:-=&[[09IS1M)-I)WJ"$GR9&=KXPP4'24
MK0\1MBHNUL.=N[)U5U1SO?GDVT8[AT OHJLM,RGNZ+23[PX$=1U?*X4_765-
MOE/6]0<\NGGHS-9(K+B.Z!UQ:B00Z^$9X%4R5RYUW9*S6*=W2?4HK:%8W2$L
MNFI9(SP1#R'SY">[U]&EW 9>1K2.ON)")LKJ0WFQ6+C&<L0835/^(#P>)+3D
M]XH$F$O6"9JMM8:U[<D-+.(6ZXM)91:8A[LF>L7QX._VDT;L,B]1E:FNT,P)
MVO?6'^0G.<#/<H"P1#YA*?Q)\VB?Z= >B_KIO>^A2&:!-'7?W$[W28K3GN@;
M,X)SE\R*FN;CX++.UW[Z12?MJ<PLY6]<'ZNZ$X+RF6N['0Q(,3BE;EFV<K#,
MYBI7)W.=R$Y*O(<5]HZ7CD=+R >O8$F3@R@+(AHG]UT@J;K;6;J\H/T-/ 1.
MSG"AG9H)L[XHN7J_*E8.<QCT09X/G1FNYEAI)C>!_F,'E@P.V^$=;-*7JW*A
MSLW06>8E%OS@Z<!SH=E!G:YU*0W][:BLK6T.P!U=8,Z4!H%3_\#,K.L2'&H!
M>R]2TRGOZ9_E1;XIGW%/B\08_!;&>^(R]V]QB\FF/!BZA)N'Z_2[G[?:17'>
M4RL6-L,_$\\=X&_%$O;,9@XYV_+\X.#Y\Z.#H\/?]G9_7YW_)<G*;O3WFAW3
MXWMV<K#Z^$+R_</]$_CA+__U,-[E4[9A\GZ./1!5-SR[\ZC[8[9V]I'.JQ&
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M-S^/.?8\:PBNN3_R.9_4 S8Z+5Z>ZYB3$.C3B1ECWSG5B9$2,  N2$K :90
MUQOY_ND+'"]>"R![CECYZ>%_AJA,K+P^$M\<Z29%62X,__L*2F+EA,K$RG=-
MC3/LD6&=OC[SG'GY$-+G3NWB.4>?&\[*5K.>\XVC@ _*W,X/]B2G24Z3G-Y5
M3I/[K&=RFHPO8NJGAS\Q]7-FZN1((Z;>0Y@24R>F3DQ]]^:2Y%#K ?X?93#9
M20:1]>"$]CN8;'XC"BW-HGPJM)=5YMJK/@PGZP&DSV)DRNXJS@FY?F^GJ! T
M^P%-(GE"TMXC*4&32)Y(_J*0=)#0I*Y!JY4N0^D:] &Q593SRL*C#(F!^UW[
M"MTS]*KV6!+L-Z%\9)FGSVT@Q*7(%G%80M1A<EC#,@EQ+P=QB<,.$;H#1-2A
M<%@C, AM>QK0)P]1KSU$/^<%'&.F18NB$%ETITWRDBIIABYC*3^/\O-.D71M
M]D!0GW-V'F5<$T<GCGYR5":.WG#TTT_V(7Y._)SX>7_@3_S\G/FYZ9\^5$$<
MO3^96=0V^L!MHSL%.",M$W/J&DVZ .D"I N<7A?P1WH/\A;.61DX0_3O*RB)
MDQ,J$R??/0.M!SF^Q,F)DQ,G/SG\SQ"5B9.W\18*H)^U>VX/:7&G=NZ<H[/M
M-S&GS+;+D\OFV$3N%.>+<")Z+YEW94[?]4Y$[P;WP0AI)QCY3M\$]<J97)BH
M)MN+>'P?3H!X_$!XO&>-_*!OO4:)QQ./)QY_ZA,@'C\,'F_8(]UV^TT*O6?Q
M^ZT_A5\X[+M/7+5]]T.O>Q88XO06=_\C_%NOY]\RE^K;E?DZF8AO+$X+$>$4
MM"N@@,4T>QVGY6S"[Z[PVS6D&CN &_C^RE>ICSW\Y)^+<IXF=_5:Y+U,9/'K
M65ZF\N&%F/!Y>BL )[_AQG$S#7I^VQ*]'H75 T=3L9:E2MSZKPKS=V4)^SY'
M0W<V'N)-XRFNUIUFDS2#-<UY,;_BBWG^>OD+. 'U\8Q?"^4T9CP!,%SQR5=^
M5[Y^\<,J=BRS)#S;%E_6SWV_Q_L\LGO*R?:&)J,)+TL\3[B]NDG^"W^+XL4J
MR3H; +XEY?B[4\YS7.Q?%;J$^20^#'S?YM,9+](RS[0\T>8W0ON'X$6IO0>
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MR,3P22L\/]@1BS@>B[")11"+.#_8$8LX$HO8*6&/^,/IAA%L;S3NQT@\ORK
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MH6=ILPA&P0M[JMH!?^5%@6TD&XE:C8K<*/'T>[14*>?$-U%$:27-59/*7#;
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MHL44_6R16,['$!RUW/J=EUKB7==4<FTB2Q1YV]L +  ^E57?(TE3.58KH;T
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M1E7'WD[CW5'M?^O6G[4I4[6.UZY*):LT_/F>;LU5(N.C6Y=\%?5GU<*AV1M
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M%0/)OXS7K^ZKPY0/@E_L=KQ%W?IW:47EDMLC7PXN1$O!!0R*C&3)_P;?9S5
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MP+),VV0<O9MV&"0LM,$@M:(P,H+8<&UO+YG#QQ I-M7W]M\.I2CJB:IU<Z#
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M)FL2DC3C693*X#]\("=WCY<0*TYO$9]^A'_K[?Y;&MW?KLS7R41\8W%:",D
MK@ .BVGV.D[+V83?7>&W:V0Z=H#:<$.5,TH?>_C)/Q?E/$WNZLW)>YG(XM>S
MO)2]0*X*,>'8]QVH_!M"$J'3$/RW+0GV4> _?O9+M0_U7Q4OZ0MB&(:U\1!O
MBA5W2II-T@S6- <4N>*+>?YZ^0LX ?7QC%\+Y15D/ $P7/')5WY7OG[QPRIV
M+#-Y/-L67];/?;_'^SQ^_)23/26/6Z+):,++$L\3;J]NDO]B E_Q8I5DG0T
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M\%N@FS;8/Y:C.TG$K>2DR=&V,?)=LF>(@LF>(4PE3*6D"D+<(2$NL5C"U//
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M[*E[0FS"8!)1A]=UQ]@Y=HY3':<ZQ\XQ[L%0TLE7QZ;.H+^BZ54H\RS JNY
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M\$D:^2I*:489W5*#=,O6M8^KUVZ('$_=5+#]<<-=IGIOW'#C<5]3ACUPQO=
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M+I#"_P$_N\?]EW' ?[P*7^=3_8.HHK;'ZQ7087%>OE9%,YORRU?X[@9+'L7
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M[V\G4'YFM-Q'H* \:>WWWQ?GNBYD-],T$"'+DHAH*7U"@\@G6<@$2?,T2_S
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M;!G#;6 (R&/F4PT:?V;LEC/&;BT] Q;1@"I)I)\'A$9"$<Y]0>+ 5WD<9T'
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M.U;?9V$(&[UV7:L3&F:V%^(&55<D(Y][.2]J WO2+>I2<WFV=46FTR<"N=#
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M>H^Y]GM5$O=26*UVRF@V6V4,^O3@B,GQFFN/$']@29HKG<0D$CXEE"E-!!P
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M:AC'K&$V0 D, 1#T* [9KZM8GC59LA6S8Z DKXW4(*8JY!76"&)"<$.^+!\
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M*(+KPQN *#$1P"F_!#/,?L3>*_#](__7[O-F2,^LT:\:VS5=K_*.^=XO@U7
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MWFQJT08SB*_R']>[%-QD?7\&-W0[V?ZYG3=+$("N]*(C;V/2LSE(G^OB NV
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MUS7EZ'%=^^".^I3[F1%C@28T#4*2I2PAV$^,T3C(1;@IU4#X:1Z')-04I%H
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M(@(B O:!K1$!$0'WBH"$9JZ(TT"-4;7**14$M!P<45Y3EH/G8I\(>+PI7P1
M!$ $0 3 O=/^L &09:^CT ZDJRY@E!:\=*;@H>=<\I 48;L(>NXG ZSD";?H
M[_49[@Y@"M+7I(#WKL2_48O\.JVT>?D)2%]IP1RFQ=*C)NU#)R62#\F'@GP
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M=_/,DZ/^.IV$7?>*M8;U,X/35ZG&JC^$H4%1&&%HR#"D,@L%=RA0*^L 0Q?
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MMN?O":N+E<Y!^.QK6#F#-88#CT2S GG"2-WG%"I%P$/M@("W;Z9&P$/ >WG
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M[+$%=*R0+)C;8$.T=I9&!MJR#.40#M9K!S)X'IS-5C"-H;3CE=]OK*+&!.
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M(/(VJ%DBA+$Z@8_.@% B@ ^>0@HT$Z>]E9;MV5NC3)YP0A#9>JL&]KNK]DB
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M8MOX.EU ,!K!2N4@L9PI5TERS9_=)?UQI0G_5A3A[VE6*7ZCXO=B,4M7);_
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M! *L9D@))IFV;A?<M0VLOI^Y'S8F[H_U_AW+;W$!A^&UR$&9)M"<[)JNT7^
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M3'V,<AC:5S<^-,UY70K10.#EP+B+MG?JIW17F+KX"TO$](B0\!0QR'@ !,D
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MV7Y_M3KU%FJ5:3<,!5@RZC0Q"D#O)*#6>B"A4L :)SF#6D.^A[V1@ BID1Y
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M=]-+:V8=AWQC)/S&B/8M0?(4#+\]X)U-ZGC_58,OIKL =G'N_=??E68>>2J
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MDE+-27 $:M@'_:1FB.]G[L>&'?XQ3Q^]LIAF.?I%5A5958SJ5RZT E1<.Z2
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M-*G)192 @D@0J%;64!$T<_L]?S0Q@2/@>,A ;A 83U&4M! CCY63ZG@]IOI
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ML37Z!-0S!$ H136-; \0S26@5D.@C#/ 4LX%)S J\&0/$ H&%1330# 4%?Z
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MZ&JUL)]TM2E-31>4O,-3JYPO%+GJZPH/M)3DM<3U#\>A74!24QJ P1RFJ'L
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M@\E84=I/S::T9^B=55.D79%V R/I(NUNEW96*.524I1V4 "J"8IRCT=3/J!
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M!<:"PR(S^R\S2\Q^4(Z##/O3$U'1UP4_5^UG6!@'0P]^%+"#TZM"V$C+*>-
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M^J9%Q[+CQ4\.\'L=E6??I9(7>/S%+X@ACTH&[#&MEPS IV4 <JJX18P#[D0
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MC\510A]5FGVK?;.0L^>]F-V=+^V'EH[4&'*(?YT8[TYW/ULB:VS%%=7GX?<
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MVP_[HN)C9SJKZIDQ:<JN,>?J[6/^Q32L[FY:_W8MC:;#& ,J8T\D?I01WX]
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M-\9N$/A!E*6ANS'-Z6EI9(B3]_;NPJ]96][("Q-KK:WWX"A5O>_362'_K@-
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MNAC[UF'?.ALFR>ZX$F'7\+X___#)>?/FS3T%_RZ/ U'W\Z+@__-B4,GG_D2
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MRJ?]Q/./2LRJO,E5C6EI9))#'K\_$?R0YFP['+^W;\*3CTC:3WQH_7B-W">
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M&"*&B"%BB!@B9AUBF,I!*D/$$#%$[/00L\)EQ93T05+2WM%2-<J!0XYZ]VE
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M"!E"AI A9 @90H:0(62G!QD6AJ%'BD@BDBAG$3*$#"%#R! RA PA0\@0LE.
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MK<4_BDLUYICK1=K$P#02G)68(<$AP2'!#04\)#@DN",A.,SUGKR?AX A8,,
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M@E]%B98Y*BLQ<C0((_(R.QUFYYYN*H7Q]/OFF?BQK&20-5^&O[LEX#&B_Y,
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MXJ?B#^#F[9]/W[X]??>6\51-=S [D3H3<*%\GW8B0A4#GF>G;DQW90:B\A1
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M$U:X=N0AP!R_?IUYHQ\-LR';3-Q<EQ=\6[!'I[J3N[:%3#<#H\C>;W=1TN
MWE#:7%3  9-HYERVF^,#:LL;8^$S:I NH]C=P0JH4TH4"BW(#)/)<3<M0$W=
MZIHU)^.VN][M0WA/[UH#L)MJF!-E:_-B8Z8#M-BW95+H0V'B XFANJA61W2F
MV"!>0A >TOBS2B5(UZHF\O&(?W"1OZMP^*LO.S4\'+Q7N#L3DZ;5]'MU,$_=
MZYGS(+)"SX7I%9!,C5NVNNRT2C&4P\*#4(SQ/Q3E&/_BU\_WQ8'.?I@^D@#/
M7>;XXCXFS#<$#E\!XA^JWU?FX!Q(1.M&PU=4N ^X(@7]OC%_GO)5[:YKK;@
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MP,.U-L9E'*V)+\!\/%S]%5A9;@D94^KB;29PZYT(K[0-"N?+/8WAT=1DOQE
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M-@-=N9%M>7A67<$WQ0.BJ>346K<US/.5&T;QF>^[3R"86S6)1%J+FY3/4<T
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MA"QIZO%^#)VF5T6G>LNP6B *4,L>JRZ])#.B5!@)XU&+TJ4'@>.[7,N^S@9
MM1:/GE5Q\K8OFMH:Y@T^0L6;4^T*TYNS0K5P$@JO-#A.0_DGNMPVGM#3T3>G
M9G,<9C6WO%O+1>LZW^&-\E!SG04=?&>V'<*+5=7G"V-YID-OS5,WFNRT04'H
M&Q$>1& 0_T,)#N)?_/KAO'CM9C^8WXV*T?LJ9&BQ=O_\WL6:$XLV-U8$;Y7#
M:IW&6[.G9KU,TUS!\$F>QKK?8"-X5]5KH9MJ:-(J"F^Q^\/N,2@F(2O_;C+
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M7:]P4=73?[F>U)SFOL.NEVW@.= M#F ^<"YN5%4&K"I.[-B840V5S!295]$
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ME:X &T#W<M=GWW-WYFS1P:M.75X2ICW.>3X'CYZ[L;CHB;]*A$;L!![^<!?
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M6O)6U.COEHHITWA>9CZU)CTNIV)*77 99S/?S"*#R.67&),C>]4W="2NZ)$
MC"R;"A4MM0M=Q\NWEV=9-E(KA$52"CM>EHMZ!=0[H]&3@SU8D0Q*R$=K.>@]
M7TC\(G.]0/$P2#9;^-<2)7&ER(0R&'S0NI9>,8<(GGQA[2&.$O9!YOA@[@,\
M&AR_5EXVY%N$:7]VXRUZYL'3^P#D$25.?*5$2F1^>_;!AGZY:^(%_H:&W\WW
M:*A.LPYCX5J>=SAC<0K4685W#(,(ANMPX_Y&O<-#4"QU1S<NGOVC0D@KT[#+
M=HCL#@Y?UB'">X134RI+LEZ1?V*_YI<@@I"Z&Y]GD8$C',&U+):S OVRV9\>
M7Y[37%RB/2(;)&J+;!&K;1J\V[0-3$[:*HS.[+ 5.2?).[1+K-9P<#"XT:%P
M%'EGR!/"R)X&ZU,@S)%8CXJM)@_74+*68"X*%E-V'+Q5HFTM@+L2Y"W3)4X)
M :Q5.3F.C7+VC0V2R6LEYYV7R@OW/( W/X?/C2E=A??)HRW_ MEJCYEPN4%M
M]00U<17-X-G#>D'2;N EJW:$*#UA(E/:%WT.0+ ,8*:R93!MC(&DGBUO0X[H
M,[%I.+1@3M8*;P;N^$(>*:Q3.&D]6)DI6M-3JDK#[Y_Q"<&>%.5#@%B%A#8.
MQ4AFM@%BN@.9'Q&)'9=QQ,BP;$Q!_=#.)L>C ?&]& /$E1Z<;XV38-C42^VK
MNHRU=#CUL8)"J[7B_C)"UWD1>/ IP(7R1'/ <BBRJW]S<'5XN2)&OEI)CT94
M]?8!.?T3O+FR;U0A?J3OP_CAF!G.([/17U!$S/*N?8=^^3L=>ML(^[P@1A@U
M N06W_\*APEM3*2K$L]GEM8]<G'UC0'O5W+$<V*Z$.4G82*G&-7-2:4T>QL&
M<!<B=O$U0U""FW 9 J[H&!->TZX=@]A[!;_\-PV#E4__/CY,X8]OWOY=CX?9
M^'ZG2JXD)$@)'9?(T?2^()7JYB(-<K&B+?X?@2! ^L6;/(M/PA_@7L]_H93D
MKKOE<& 167_YQ=[BW8R8+AS59D1H_PG/!YVU?J(&<_$2* \4OLQ5X/TE%8'%
M*AZ [#8'W1&)$9"T&:" 9<]0"6R #YWK<]@!'#;V@69]TI'/!II#EY\G\8P8
MA0^7T2.,H$C.,[-(F0H"L. <UTM0CLT<F&'B8 :I<P6/2O2_3R3B<<F,/R9N
M16U;]9Z6K?,WK=(^OI6K<(KTQ+D8&:I<1 S3&^Z#&%8)MS2EHQ=IB;=4,2(%
M +B"TSC2I2,/!BG(YW$@M7EX*+&9MU8(0B.":SO,=69DZ@@U4/,$TQ0SH8^1
M%ZXYVF"I9F"R(B0UXISN@=,G'9#]K-^/[=D1'FOBAE9)',46RWY;"!JZHW@B
M,W2 ' SVNP4D2U!Z71&ZE?:\A+C],AO-X5QA.G*V: :UM-!,1+X%(00=*J+O
M2)#U<O9+J#;$"<.RLK_&C,)'*_R-<LUSE!(\5L92 TMKT-JQ<IB/4&EE<^8H
M%>ZDQ62=U?K:/Q6:CVH_+6Y095JCD/9.U95W-3S="QU+G1O55\"Q%)RYC0FD
M8;>=;8F/:XDVOX)AJ#:Y]1F.=#3P*9EB ]O![M'ULVPK(;6#C>_^&R\$444H
M-YT9<5Y5(]65"P+:+KX,PR"\",*0,H/'""^WU&I5D3F&L&9(UHXFOS4F@K($
M@\Y[.+C\#5<K< P9-3)"AFTO(:E?17JJ(QZG;AG[-.8XFWU)Y"X/:(B]/3$_
MJ?)L(<D>/J8A_9BS@7V=)C"<%^8(LQ&LGGWHZ-;=C](QI52TF"JYQR.<79%M
M>?^ 4_@2SO[AB.6"'.'T"!(DEZ@OG?D,GHJ-W*/8 "_\8G8<=G-9WFJ]=FUZ
MO[?L<=FY,HJ$DR2,IAX#R83L%(4)0VR5XO#9M;P*&8*O/Q@EIAB*SZBBSDG2
M/19^FK 2M#$U.@6GS&D?Q2%;=!'S*7G86KZXSSX%/+>\PR_?OJ.T9]<DG"BE
M*YQKB$_(9T'_=SY$L&3"^&60YA>8138"I:NJ'U4J3J?]A8^LQ[_;H<_EJBBM
M3$WK,DL+)M[&BF=/='Y0/8=&.LO(!G!]I8]O_='E.CC.01DDNQVZ\&(**.C6
M5J3#C%Q'V/T9KM3#EN9\JO@.6_GL!R6<>[5FWZ"%G&M6B%2MD/,#^PD7N>5K
M=XX;]6JI\"G39!7'T0KI%DX%]XGR*&88V]7ZP?HRW.Z7491IE#CV]0F;-U@(
M+ +\K.#X?6N%,^HN9V!854?GN?8T1.L4E>QYU?J9#;)^PBS++(KGLQ]2RT,%
MWP=85N?,9W_X''=2OBM=X/%+).L$P5Z<R-@!Z,A7.5JY?%IYWN?FMQ&ZA\=^
M#IS[.U7=7(%,9!+:80:NU3EL8UTG#/B%M7?A^.%Z.>Q8^$0=6-Q729R$5.KY
M)O'=$$T)'2"1C3%'7=X<D>T=_0#4^74P*TO*]9IS[<[,-:I%4YO%!XI),_9;
MS 0Y(B9&):,INB6SLF<GKE /CA(LMT$8GZ*+ MF9L.-/R):8&\4=0;U<!=$C
MXD>5C)J9TH0D69-6DVTNN"QN AM#=429P:X773..2CT>7B.L::+B!QE.-3K5
MF.2V*F,WYMSY_ T@<XL^\E2FQ\IMI3UQ ?QFS_S+W=X+#I2*E-PUZJ T?!?S
MJDAG &Z+O BB.!H-R5>E.,MT4"=2AG+8KA"7._9!;@>CJA+#8UBC3^%C^EA6
M6LX,3]6RISX%?A;$+;K"5(>S'ZNYEK,'"6O<\+$ZV:#D  :8?ED"L+&CQI"_
M M/.3>K!PJ1NWA#A+:49&UAC!?C.U$W%E,?&=",P@<.& 2T:?UY/@[=5I4,T
MJ5>8B]W":U/A^4:'!M&V\4",;CE$G\ ;S.>X9B>,\E46I2($^$EXSY 719)+
ME 'XX2;]2&[TI64U.RY>.B2L$T3T@NE3V2#E4.NS@5+SAF>]21]:6@*IRX)3
M"5,*9>VLIY.C/5>@9_%GEC(Z)@7)6<>C$D&\VZ#,?X(J,"**W)^MU/%W1AVZ
M2=:&UDTP(\NYG+KP'O$1HW 34HX@HR$-&KKSO7OS[OM1?G6X&IE?(%+2%JC/
MO/6I$V$8*UJ"8 -^M&*&8(%9'<LZL,&9''@[/+:7Y4W"/2?;XND=*U1C1\]_
M/L^#.@@[WH[+L<",*&UGYSZ?>OVC>8X+4?SCH4U*8?RZ=NXDG'B&F:A:8Z/L
ML37Z=7./I>DXK G5U'=6#G:=X^YLJW7F8\WME&=)O U"5 N.LWQA&@BN][-5
MO9^5=U:,E')[H7-E&:Q_1^-6H7X>Z-^9N2@JGO/")I[U3SM(;V52VC08<=SU
M=5<76LC3U>I'))Z66;$V*A&7:U(-1R=I5H@C9[[2L473O#*-!6?J4^#;HXSF
M7/LAIRTC=Q0\J(;R.D8TF<BGX:=DG,#D&MQ)0P\6>U?L@7&>&IT<(#7Y;<S,
M<2X<*8K='7/HS%RR,3;4K"../"COX(+R$U75@@!C(WRETHM!4,X)"QR\3 \\
M\#@\KO-#-8$1(U,':/:[&X^<%:-Z4.;%SW3#*#[S?1<!4ZWP, X!%(D1A9HF
M#-!)>"CB@)9XX62/@)-<;AWM4U).V1)$44[BO!F:8EY*;%F^!XP*R-'6DE!^
M1A:KTS\8YE,&>BF!9YE_TK6#((MKEYDZ<V U>=,4RXD*#WHN1?"2(HVO,-M*
MLRC_;8KTP%2U!P=,GI3)X/1(DT<Q<F);5<47GI"LNT2),@O1KTZ.LNB$8DMF
M);4)L(58G((X>[;#M'__ILR%;O1KL5ODDFR28)LZ'Y5:AB(GLQ18O4F?:V:,
M%4-1%-E_?J81'K<LO1A*>S:* YNA03 3J QYFF[1+9Y2+F+HV:)GOXOA+&FN
M3RLTTB?\'Q;UC6,5BK'::QNKS*K]PV16[1_TV<9F"_+_F<7A7_O<RY&IHM*L
MW>.7@@[$!<Y!AEYVHF@O7N:EK/5GH\,3 0=K#'R3>0"XB^FQ X9,.7#3715?
M\UK.#3S(NBAPXH)Z"/ K!?GX;+,)62#-M0]KSH]<>_0QDY*$,1,TY=H6CN-\
M/3/IEXJ.(1P!?OTRHO/!2OZ<#?NE,NSX=0'E.YO"E(EY%SS3Y4C/^]7Z-@QV
M;A0%X>$FL/QK_R+P?0X;^HL;;Y67'\?N&#BVJ:?_:DVR%@DV"7R3K%&"K>;0
M3WB[7\=H%-1XB.C"\IX$2;SV@F=\]P>VRVP0F-R=I79WE2 )B^RSP?-P\#"%
M2C9XK!)\JX#C\H[.E_Y=Z_C5!8]T&97BD!SYB%2&9BYU3++H(B4@]6_P[(X<
ME_5GG+M;(=Y8):SOC3(M:^4 8UV,B)0MMU88'Y3LG"/L:3()#"-)%)JZ+&H9
M  Z3.BL"GL9!J*XNKFL G[3-VFP\%B*94M C$<!4CX>EQ[PF(1[OTH<<BU)D
M\MC A+)Y8",A0)<>BI:P=!PIDP5)I)7/'6ME7C%B!C:]PC1FI$6 [9G&:3RS
MJ7< $9]=^A(N,(UL&7<$"=+"#))B$:;4CY?#(K#SU\MI_J@US:8".Y9/(UE(
M'EG][;A<WC(I9"$W9Z0-.5(GT[DXZ3K.M3A(\A3&3#\W)AUV*AI(8J;285^P
M/*P;Z$(.DW62N-P2JND)R9HK8,#JC\G5,A(UP"T\OV5^!)B<B' 16. J\+S@
M64.6M0H'ASS[^!3A7I!OQV?TM%72Q\Q:H\M%?EZ59HZ98]537>-D(@3B1]=W
M=\EN_-4A",TN%XSNM*>WO_/;W#X B3B2-K="@DOV(^:%.1XS'.='-<.54I&R
M(BS=S3&8Z$S/H+I-&35T4'LN)BG=L#'%E'1DG1JIYQ[3-']<-CHC-'U9-KJ,
MG"8EWT2,Y-V3R]S,_*A,!;:IU (9Z+[V!_)4O)04 !4\'0DK^1>^B;E)MXL\
MRZ[]?1)'-QC^.@[P1 V:XD1/""-+],&?3,A5#H5&,QOW=(.+X8[NT7_5WYP]
M1BQI]5#)@9,C*3TXD@7%><^ CZY'HSCPJ;B,H_>#I9^4E)1I(O)^9A^)*7I?
M8?"W.."KD\#'B%BH<4\\!J)KV5L75AJ;*\0\W%/;7;L@(>QD3Q 3C8&MH&/
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M)/$\(G_7(:S5BEBQE-&ZN@]UJOR#C#]%U:QUNR7/,"ZRCZ%#!// 5QI>C([
M"J97X%&;(W:UA:T@90:'M(^@(,&KI'-F2>:)?PUE496_%9ZR-:6$UE0R2,-6
ML$CVH>..U9+[7),*IUU-*XB4\X*Y"9S?Z GM4UU:4T1#BVI6D'=P^K0ZZ$C%
M*O5 <"\+,+O"&?FSUD!F=AA6L+\MT*7R(&E9=WHI@IU9\^5-])%+2&J=8!E\
MI*Y7/*B9R=\$XFEY'<!YL,ZNDB1.+N($$^K"TE5Y8.^O8<7B;<P'+EM:A(%:
M'?_6N97)7;'G;Q&(ZJM@HW; KGR>? %R,)%KN&'=$/&<KV"[5)R%F\I9<(#D
M"*+SY3( P6'C:J'0&LI./A,E8SH5">8)=0&MI%#85]:.[7]H?*((Z,;T+52S
M0P/C%_"@X3O]+F;!WOX(8&E=.[>#U47<2CT[:GJ^DS4Q[<SC[=NQ@@%5?9/^
M5:DN:041N%(3LH+%FH?XWQ&09Q;N-\T30E?<"G*J\F=9ZI003Z@EZ"E*B!LB
MW-P7F(]SLHP3HB%\D(:M8%&C3XX>-+U%-2O(DQZY'-.;26T\TZ4/\W>]160"
M%.]T:8(Z-S*Y^)<'0\L8_E7S3&-!*V9/A7S<@$[74-P*<C1A;G0.$,<R]M#8
MPLNH7]0=F[""; G:6&3_84&?&@DIA#N=JQ8+!%#VY.J2?&_@SJQ@I6;Z02#T
M,<-*AG8:?@A3H;'#$M*V807AFB<XU5;V?<?K&[&"=(60Q2[8%MY*;>M:06@5
M K:&_PH''%V1TD^%3IX?](WL&+8'*YA6G'<U]Z8R-'(7S^1.35G!AHLXA*^8
M*0\6NO3&+F9OSSYI7=T*<HNL9S^T28WV@P7*)3$JJA<G?HIF1'PZP=+ZZF;4
M/P'#Y.H2G(JTSHU807K%G*R?.65!*TA0\5;_2M27MH*8@S5T(AUPH<AE#T*>
M0_'?&O%CO.ZL8*<*0K4><IE;Q%0LZMB$%613@8&-MCEEH+*@%22TM=,VO+T[
M-F$%V<W)RW7>K/MK64%<3R>>\YVZ 1U71NQN>N,>3=$ZBZ( _1]=%3Y^0S$K
M5D/A\!ZG:>DLO6W$@]Y?S0KRSL=*'L,C5[D^1#P/)\ABTS00*Z:@8@*I7 >S
M-<*R_)OAFC9?DP<U9 4+#G81H__#,5UHC%7*4ZJZ+WJPAJ$[LH*%Q9OUQS8/
MVQ\M.F+'L_?_1(W])8SD/%K:K.=!TTB.>Q)*!")$(QRTZ/2^B/$GR7ES]O*2
MD!<W(^/#8Q\\F.DE)F$)I;"7ZR!-XV1W&[O1#<(Y1\Q+\.<@6TG7('.&J E5
M![=DQWJ4#7-_@SLM]0,ZY ;E3W,5*\B24TQ+,6ZZQT%#<2O(D1PV1 :4JMFD
M(0"P;>7I=^43]QM3HL9I'C4MZDQ/V,PCX0X.0'H(W&\3;P5'Z@S.1GK,ZMPP
M6U2R8GG68K(JD5CJ7YL2Q!_>GA4,J:8IT@:!*@M:04+5"1!C/^!"AT$B$%?@
MTW=WFTRS!S5D!0L4;^7RD/&F8+JV3RK*N]2?W"/K:Q %Z^VZOBEK'ZV8F_&>
M$(TX@?0C.O1/]+[I.#@KIBK/@%+0I87;4A>UX?[.SZ_]M[:NJ!VS(=;&3;2!
M=QK%,&NPT3<4MX*<*JQR8W9/3=GIEU<M=^KEMHX)IBIDQQSD?CGY:E%YY7",
M:W^.&N=M@OYM<  &G1Q_!NC "I8I1(,&-P5]:2N(0?@]>A_I0THJ1:P8=CU7
M>,OL$)72TQ\?CRLXT# B6^7/HKFF6M2Q8I;H6W#K9=0?EL)]4$U&D=RAI0?=
M(>U8P@"E;JH1'&)?'2L(8SY"DK)8*TK+A:P8NM[LW,U(;04Q(N_3X_;Y7\3+
M%O$\D8V:92@ZG>3>N1$K2)<T+ZA/$IH)3^/5V5!\^DN@YIK6$0.[8WTKYD]*
M$M@&&[6A^/3S=X\*>97=I?[5"MX;"!^W3/G2?ES3KZ:G#?PCRCA]]VY0QX*I
M%[%B77TA$>;.@U-GYJ^#B((UH\\=/WCTJHI6%:T@L4/B+UN!8&=;/\CBY#I(
MUC>EI57[.+EF^]$CD0MO3T3&]MQ4H;?3E[)BN=0A#,O.=FE3*&6+FM.?5A>W
M__CZZ=.?=)E?Y*]6S @%D<'[&$5;:L*C,0 HWVOC@?05K"!)I09H]H-LKF$%
M4>HDTEIK;$-Q*\AA,*7SI0Q=.H]Z@:3F<*B70;J)4S?\DL3;#8K\0>K1!\Z6
M^/P2 A%(Q;7I1V7%Y!3)'#4' /]JQ6!5*>[UVEM]:2N(D=(PNVNN'X?WDAOR
MB.F;*",)+#4>3JVY*+LT8079@[KRLPTI;<&6=H@!>[1 #"EP=!@*PTTD#C6*
M1]X&,[,NO0S0J!7K[9(L8?9]GN3\/G2;@=(:BMN'<E^D/[V/.93;/,DAYU,)
M9;X]DOT!;5HQSQ7MA@CNK6GBT;;JJ6:^4P/3[_I]N;4U^[I=M>E?OP) 2SQP
M&U&VY$)6+,:^J-8<*@<OI7((@M)C;[S>[&!FQ0&&:P%8H@U**F8?/]]A;O*.
MZ<Q;-F4%&^"1&G!Y3N!(8?8E"G">*I^ZS36L($K"%:/OL=RW'X&T8'>7P;2Z
M^-QT;\\*ADCV+$GZQ*,9'0"DI$@:X:5=92M(5:5L[9HE6ZL4&:QQ*U@E[-0H
MCV;\_;$1V CZ%W"+:M,+,K@E4>0"7JL?$SE825V:Z5#7/NE=D3.J$+Y[R_&]
M6K=ET>=H5'*X(KR\,P)+VJ.D:-9]BYI6$%G!I-J#PJDK; 4IBI 99=2(Y-JE
MDUP.;,H*-NB\V%I[_+6N;@6Y*E?[3Y_A%.[HGB_7L8*PF?^O;<KCV^("(PP]
M#FXB&;"Z]O)Z(&SA"HQ<YD/,=8Y80.L%,G:?5C!6@Y1[096+-U'-HPM'GJ,*
MO^G0Q/NW:@5SJ,9U%8=PV*7,M4=Y$=1*32_'?76?W^+DUW1?I)&FG!7<IX$7
M\R4'M$4HX[:0P.UJ6D$DLQ>7U7Y7WX(T(U1,8DJA17SU#7Y0FITZ-6 %R;FF
M$)Z#M:W3&'S5IN+T>P].>ZK!@E+T%?N0;G41%/JB5LP4ODP1,UX*>VB(S]$5
MMH*4)]2W7:59L(8UI-37E$M8,>BZ_:L0/&^;,.U:5;2"1'I>X4:^66^2^)7I
M@/3":D-Q*\A!U[_@)6+A79[\9L"T..B[T9ASIT/UZ<\Y"HTEVYG1&^<%46+B
M9)='FM;U1"WK3>Z?>B6G?N/_P<U32IW:6'#Z.<+''7.RHT\..1^N$GVO=24K
M=MN5FX0!+!<.EJ<_-I0%IYT=E$R3W2]/CR7VY[].OW3X'4)]MH+G+75G@HN$
MIYQ)Y-_K:;8/:\&2+8^OUV03,P47!F5@LEOI)_7^WU?+BAU36&+JB4&Z&/3V
MU;:"V%:Y3Y2:GS85I]^A]TG\',0O)$+0V+2X.76/C<;B5LQ8U24 3?\WD1^\
M!C[ZC 8938,A?*'F"?7IE>PG=^Z:T)<NM:!<1=LUJ6_9T3N;?F5\1>/;X@VH
MVSTBA/OB+5ZLXFWJ1C[[]3IXU67N[5!W>D(?M\!ZZCFE!C#4%K)BN>-MB*NH
MP6A<*F'%H+OBIT"!NSA*2G JC8_703NPS]+\%42#)'##<#>C7C% 2_( 5,41
MW*"[V^!7$NX6<;44O)!H-*(F^]>X/5FQ[H3GN.0*!C//5;WW\.;"A\G>W,O=
M6[%Q!0G7 ?0D@[L+-5?%CST]C5NW:<6JR%&!=*@2I0+37UC*9#_ \H")#O@Z
M?<S<I/Z8:EO1BEE1AQQC9JP"=ZQ)T]^EOA4$#QG6(O_2P*.1N[2"K25K LI"
M>O1M14%+2%"[D)SOY"\=4<45M:T@MNHJU G5UZZ+1:CBF4:NP7U&4<Z*:P9O
M!(7RG7^P@L=:E]@6-OZV=2V8"[1W=(#5VU/>$B4IMW-<8#K29!&_:;2BM6+3
MSP>-NL*5(KMO>9+[%F'Q&;6):5O1BKTE0N:8>HLMI!=ML(*^].3+C:__G8AX
M175(=:VIRDR_T/+,-5^2.$VIUE4X0S]%/J&YO@K/J_I9W;'^] 07YL'Y<A9%
M6S3S^EN/I4.$FX<%M:$23N4)T[*J%;MK_+1';$<J]=:&^K:"T>J4F<U*TWUU
M+-@HPA3SU8VV2Y>_6[BW\#[SC;Z.%3-6<^[]$L?^6Q"&# ,#%FF0/THUODNM
MZT\_DVTB&\73NP[4('G!R.^YVMR/THL5JZ47QH]J^?1J</)0^P<\P]7H<M(G
M.V8N=--TOOS9Q8LGFR<TUR:/7B?WP%Z2?TSYUU09,7]00U:P@!U"31G#Y0)V
M##F$1S$> 6HIXJK^].E6<_+GPF7L4>A5IO2_BGQTQ:F^%Y2%)M_\U.4 O8:$
M#X(*9T-9R(JEE=MMN8V6/DKR'_\[( E>1CN]W-:I 2M(UGBX8?ACH8O7"#G[
M*TZ^EVZ\9<*!6&=9!I<FW>G7H?M2W5#ZDE;,4]\GDP3*,MZ[K-;)]-+M'<G*
MICAA?].\4?:4GYX@ZL7,^:WS%JH5L6,)%\%/>8HSX9O6,FA*6\\* BO)5Y^B
M "3WQZ<V*3X5%:P@:4@3+2]BR"!<[LT*9DK.QTK]SM4W!'PE/N),X &\97?0
M?'GE)A&<1RD(>_3\;0%3,T0/=C!-['[^R&)YC37&9FUA*TCAELO/WW_^H_Y,
MJ!6RV7OK$;,+D)<=[, OB)R#I[,ZKJ]70]/?NN4@9,V]JRIDQ<+;$RQ@2TA
M&4M['];:MT>2P4-2:Q#LWHH5Q#\]L@V ([HDSUF3L;UM'2L($S@[Z [-=/YP
MX4@BG91S!@.Q4_6GANCM =NW@F&:9'WXPKYA"09\'>!1RZI6D'GPHW,?..<
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M)B$K8'-N"J.PZY@A: _FU)YJ5I!73X>N1315D=FA^E'@7U_'%&0E33'VB06
M[Y@)F!:&/Q<K>%YDZ@P_X_5BQ5KAC@Z?O__\O=YX4BMDQ=!OUG#E)C0K37(9
MI)LX=</Y\C9&G[%7$"KHVFUQ7!W2SN1*$V8"NM\^P["NP]BM:4QJ!:R8LU'
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M@IFL>A2G'K@:BUOU*RXQBACIJFA)*%ILUKWJ7C+4)[HL1E&\[%(:6(6[KX(
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M1UF\-?T>X^,$0WR//N%CI9OT%+X\/4-M5]KILM3RUWGL]A-,OMTA0.0I@"6
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MO/]/.:JHVDT/;GZ(!B)<]+4 YG>2,+\S??BHH'*]IKP>%B#_7A+Y]Z,1./E
M5^1H_V8!3+](PO2+:0+%]VY43H<MQE4M+$#V[Y+(_GT< KS)#EF8YRFYV9,4
M,/?1YGL$4+*'1ZPF^<2BMNMJW0H=+0#X'Y( _V,<@&LPB#D^RKSP P@ROS",
MXZ\3.UZAVM%05NAM#.H'+)G+F0MH+>VPT$N:9_N)U/HFT$4XY?CV7SY,BXJ/
M4##5-E&3,H5J!=#>BC4,^VGG*0#-9KD("J,:/9O@]/!;!"P2!M8F2,(+8%F@
M,3QC+19%-_TN J<!XD+GF"XB[F'@Y<>SS"\"-XD;CV+XG_L+:!7F)'0R+(*.
M!K IJ2.[B%?0BLQKB-MH$3@J,;/?QHQT<Y69T3U>BR">(8=0RB,WQJMZZ]!3
M.7JUJV\,:&PZ>B/15.F('"/Y@-N$]:Y#6%JA<9BPI'RJ8Y3)=9N<WG?(22LT
M#I-3QY^\B)J\2H3S2X=PM$+C,.%07>>+* :L1#Y_[Y"/5F@<)A^5,()%U"=6
MHJI_=*A**S2N4Y5*[,08=9-=)"UJ-,9TX-CP:K!.#5JE-[L&F-K(KX\H?H,)
M_BIYI-KHLSXJ'.E188+2QE+PW^IEX+_4:4T_@GB'O.,>^EY(>;[#;SOME,&N
M.PGJRRY^6RU33H#_MUW\]K-?F :+69=_J2==_L/7+\_=$+/Z!PN?X?3N!9?>
M,CI4ELG"IVAJ=/WQFD'7^ <[[FT%1YR *<XU';T48\T%PP8SFWFV(*G[L:(9
M-GASI9D+[1U+K+SB0E2<&Z2E)8)B=K$ZRFR<W-U3IF6R03^M\S,] 3^.?!C"
M,E$2X?89%HU.=R @Q82K3D_X%GB):^4U1J[KKA9*G1<MH[V5U3^7U9^O002V
M,+U*RXVM-KJUPZ*%:_F&;5"U0O4:5*T&!G,4S<^Y;K=;X!,[=PO4]ERN_#\S
MB!G5??03/K$^2))S<?M&9?LG$)*'%H\>2D]=]66\#YG+*B.QG!M$+'7Y;4"H
M.N_!?5M\X: &2.-S3)@N,6%CZ:$\MYOM%OH $:LE_FNQL;15C_01V_A!&>W6
M6M\'B)=-9 Y() $5OB <S;;ETS;O7! %!,W]NXD3X55YT=BV05,%RBC>#8U^
MMBV)>E33/?,%K?(PMBWX[!X>GNM-P\#F06F+;**5=EK;H1HKFA(T"\JKM48:
M8K: O8A',)(@CBG=+R)47Y%8+U4(%A' KYMV%=6/1<2RZV&R8JUE$9'<>L!4
MU8$6$>NL!]JF#J4UD-7>_"'CT62IJ2TBJE4/BDKJWR)".H?BVM4@S[*\7HTH
M3KW0M _M"?_GJ\"1UJ,GHN] [Q73'2FUX:2'K+>FCT0<%CC)!)WLR>VOG'Y;
M903S!AZWO9H-K!NG2)[T:)TL6\P#\!),.U<(D1N)Z.P2A"?H;\,2RU,?Q\%W
M&(:8#=YC#A?MB-12_"3-.#A#V+#0QE[P+.:\'IH=@#T(SX8A#&'#-E3>W-2<
MOZI#V+ 1Q40;X'X&TK=3IY?QY53<N#$QP5JH78POI$*8W"SEOY54T[+T1$$I
M02;*3L91/F45</UG^=5Y5,"$-XI5RY7;O'-ANN;/VBF$^A'][)J8YZK9U?(D
MOMK!^313@W-DN]JSO9)79+.Q/9//=1@EA<>BR<^CB%EO<@J7/.-F-V!LD5.I
MN8F8)9)3KDYI'H =R!>!F9P^S8!-I+0N) VXAK/+U8K78 A9*NP=WGECINOP
MMKU%>C";PW$=9CM98VHD&%[7*#,*:%0?D1V4IWA>Z=8?K:"U#^R+Q=@-O62U
M&)S&B.ZRZ&6W7KBY9JI%Q'!-2;9T^]<8T5U.$ZR:B6T1$5PZK \M&7+>V1EU
M*'RHF=I!;X#6#*_NT8.PYJ"N\"VB\PW#$D1@]6G'R:"K^07PS,D+02.R]G3/
M :;<=^/*P\QS'[^^MX3Y7FKF&+TX9LF'CWGNU;S0@TUWER)\ZH=H$69>_42(
MS]<H%K>"#&^CO@!E-C(;0P(C8LV)4@1?,S+Z8^A%5T$ BX7>1]L8'?+/.BD<
M/($4HMSM1M;U@K]$R50K:&SL*NG/AYJU5MA<<Q3.79RA_P=0O(G _Z46#V>U
M,GDG$S(O[4$$G?H(/ ARULKU-;VT[@DN35[HDY=B!AKM6K\7.=KYZQTRH#$0
M.G:_^B!(JP0J(QA;9NOQ3(<HDWJBW%3B:F-,FJ7[B8@PC$3B]6^:F=DCWG58
M%QGM\[%V ]O..?&]D/=ZNPC^!0*U(]WIJS]6D\='FO_.SIVE/LCT%$LEG>ZO
MDT[KD_<#'K(#<V+MW^V0Y?F"6E.,9TM%<T]M*Y('*R<.34);2M2>O*#7T0T'
MBU&+0': B-6J[JTFNLS]) ^2Y,YYXQMRTMQQDN9X'3%NKLFZQ^)S73%R$>;#
MP8=0)+.LU$<K#3= (9AUQ"A5Y6WQ^&[=^+_-EL]??!0E27(,@K(!1X8R>J:F
MCD)X#MT:F9Z,13L\ 2R(9GZ:H5QD3]+D.3L</'0BY1NZ/]U'5<&>S;:,=HLC
M-_//]%:72^H)0&]\MP>_ES&;%[E1.UO&=8"PVQMTX7#>1% --"H]32ZKQCCW
M&$J25]76GJD+?&KTUG9,/S^H>=K:*Y)'5";ECWQ_"]P<C,GF?%O.R2$>P8Z=
M;+/=GA MS[$?S+LD^W>L[#*T>W>>XBP/];@_'#V(" -E.WJ8;8T!^1%+L\@C
M;U^O@@.,(#F8)%VPS/4AUU<SW,_XHD(DCJ;Q^"+?5S;JHBZZ9YC&_K?>"R;.
M]'CM-<\M?UK6.Q/$+(/E]8 ]1ZE^=NAYD@)J4[/C"(%SMWX*Y=^V,4I"TIP[
M8ERYM(,670I<%$(R\B/=BR,AF2T*28'\QB2]4CR:>5ED2=VK,A6SQ;9%^%H'
M*$!<WK8,7Z'2;2DI6L_=DR-[((6"_<(<AI>?2YKPNU*;A-(U;Z?@^*3V,']O
MF"J]R2G>TY6OLLEQ1J?#*@^$^VZR>=K06U,L3[[,:LY-[9AXF]W=1WY&3A8G
MP;5L;V/+>_1.>0[(NQBUYLI8#[.Y'?NC3EA??['Q;E"U@]!!6-#[97WH\8[X
M(I2*BZ!DLY,14^#-!CT&@QI%TK/F!7@M[3V#74X\\WGM7:[H"1QC1'*6">0X
M9G-CM^OGC.@:1-@F4R+:W7F3&$O@=#"^B"IUG.0:^NW-A:!T**,T"S;.QY<$
M!->GFS@X? ")CV#.%B3I3'8T:Y9/)G8?!9BE!ID7OA!>@'GM8YSD?&.#/J(X
M.VY(0>(#3%, /GL'<$N809*7WHRR0QE6*0F0ON]9!>$CBK<P)54(/@&/<.#_
MCK^3G5>G(-G1[+BD16RY>2?S.. RG#\#P*)PVD7(SBI8#6;IR[ W7X"DQMMA
M#,G;)HOTI3!+W2#3Y8\VKKK4YFFL :=[W,#;[5"AIG(#HMQ\WW$'(R_R<V75
M!_"-W(Z/>-W;.(1Q"0DG$%^VMS&926*"W&!]^?Z3IN.XB:,$3R'(J2IWO5%7
MP6UJ;$]ZH@4WZIC5VAHQW#F+0,WANG-K2"[7I_)'N4<1\B,9/B>,9%",AH9+
MB%?/"!_(1XA,P6;%O!ZV+8/+<OE]=*>4@@CXW,=SS&;6,*#&67L0O/*1ZFKG
MRT:V1Y#31S.U7&=!?$19FN'+"+U!GT,QK*::9_0%"]YY^ZI@"7M*S+::YW3S
M\.]/[][]DSV1=@/-7W_ HKI_PEK-#GF'LVC.G@NON?:\@"B)HPB$I4>)ER"0
MVM*<Q$8*CL@\$:,TM$-+5E1SFDJS@@HQUWAH&96C"1E3PE_-K5V+S!!9?*YD
MID%!.:<G80G^<X=.0F]HDI] /I\[6LK6H3KS%$UOF#5W$ZO3[+.W%'I2T<RD
M']K.G*Z43 75^6-J8HO ZL(+4EDHGOLKHN'W %O_7H2W7.W0=@P#BT!(TU'E
MRG5S?W2E1F5< ] R(B_TT)R<-#/W^ HUXF/9^*9[Z><"5#R[XAIJ(A%J\ICO
MQ1ZDT/=">^).UJB%-6IAC5I8;M3";#W35;*2_ 7[.^8:VJV,3??JK),^[_%%
MT4M[P?>H2W:VT1JY>J16CY2-&M42/5*KOV \?T'O.EH&%S-@UIBMR7LHZ<F*
M%M,9=\VI\=EK O[,B%K^!N;UZ+V],J'LSFJN.]CQB&DX2C_!$"1I'($R504U
MUI'1U'#AD2N$2$D=P:L:>EMSVD0]D>0J"CYC"J__Y07_*<&B)"9DOD5$=13-
MM//)>_T>HV_)U0X!P,_:SVIJ3OMLGZ]^S4+^>6RTMV4)7$JAM[5EZES+$JVI
M-1,_'7DEFUBM;9F^*(,>L_D8)14:)OD\0] N"\D I^J^Z:*LU%4WZ^M<@M2Y
M]1M9(J<*1)$Z$H,E'"Q"-^**%RWY7?4RG[L./E"ZJ>B.*5C,'3BA5-)2NNGW
M_R+.)D^ X&!4W]<+I"06^^(0W<)0XE=5H9+<PA!BRPK2,MPR0A0E^1-#QIB]
MI526JBAR]BCAAH1X7:0?-I"3!+!*VHD#4O8;=JS$';OL4-MQ%1I7N[Q 4/UC
MLMGF92KV<8CA2&[_S# 0YFS 51B?R/K;;VC.9G">"]=*TVYD?K+%3A,W"F8>
MY&;G6&FX?0PNI4>WK/GW&AI,-Y&'Z#YZ*#TU%;WK4_,7;AEJZ0&L6*2@+'6O
MH8N3_HKYMY>%)@,5O=Q%30B=I"7<;!NDP3?;BSN:*S*!X!M&^C'T?+;W1-#8
MJ"49!M!#IP;$ E,XO?T<B<K\B6F>8BYA41H:FW3G N9N KVMNU,W3S(D\VL<
MY63-I9A^.W-'F 3,))LL35(O"M@%>OKMS'G^JXB61P\&]]&-=X18^>3[^;E]
M-+NV?L<*-T:H+"4&_5R=(LSZNX>"I$"2YNV2ZF<.=M_/#EG.ZO(74N3T(; G
MV8W?0/'(BK\%TOW-*@SW29*!X$-12Z^H2I0C3]N4CRA.V$K1H,$,WG<I9J(@
MN/50A&?+CYMA-+9MYW[WP@SDOVUR@TUR^P,@'R:UM41NTSCCV+;D@KXTK)DW
MD&V+SO?G)H[>L */9[K9?HD@LPR+VABV+;78E@O7RAI$\T58?.;VA[\GQOG@
M+D:/"-QEQ%KY1^[/ID=]R'2;?J8Y?0R<;M'7-E+*9_49?,]_&7):ZKZV+:W8
MDX%KZW8V*.G^;Y:DN17^)6:(L/ED7[L1[T\ :T@)3$&9B*A8&*GTNRO<"#1J
MGNRSQ@#]Y*%OH"RVX^,=)X7SOD0(>"'\"P0?L4CSP!;H)#N;*T<&TD*,YJRA
MW88RU=K11/73U6Y5,LT@_?_(JP,0_-=_I"@GI_(?XR@%/]+;,#>T_==_),6S
M#I:;K_*3P2C].8"'RLOGA2'#N<=T [5<>QV_"\>--QB)_^PAL?7"^A6K]%+W
M>&3D9Z_@)_RO1">J2V0QEL[V:/(].#:C$.2&G)\.+=5CV-;W73]6+_R\Z3\%
M+;M7MPBHJF^HG<^O[[]P!)/2L#<)*)49T6YP)$Z*M'6^56F7X5.Q&@RITR-T
MN+08B 1XCD#".SR:,9G-V6'[>EG,8T;G1"8"I D#PW/C"!+<XZ$%BMF<"JZ+
MK@D#Q1$VQM+[:HAYX9O-4&U&0)_@W?<G.KYN::(7^"7'@.&]?0= 11RW&9*+
M3X2"*]AQ'.1/B+P+>0Q(?K&%-"[U-SL.CC2]L%S28ZS_[XX0!\^E/08N_W $
M%Z[?>PQ@_ND(,"S?^!B8_,L13)A.]#% ^=464.1]\F/ \)MK,)0NTE'4%SL=
M)N(0@5' L$^)E0PJ& 4-:Q28Z:(01L'1.FE?-OA@%#2L$V\[T0IRBRY?R[9?
MPUK^5K95%6%].#O_A[,WH9<D$N^YF.WMCC>K[T;RWRK?+V.5%PUI[B%/8TNX
M#Y$H#5V<M/FG4^O[U/5]ZOH>#XM%<81%+H#UC'-9I<UV"X@.0E@B8_Z"3FN8
MIS5.]C'"//ORALT(3*N6,H45JR%2"]-AR9NM@ R*;. (!%+Q.<,PF$U@SAKJ
MN>103S%]L%6#-6IKC=H22YT66.=R$!+@_VT7O_T,_*"PQ]U' 7R#08;AVT2A
MGKQTS8\4$KL?U((Z_@LI-]/X,%6U8#;3_7 U!<<]B%[VF!3H,V$VLYEQB5"N
M_7BT]5M KFI%>VY.KR3_:NX5.#W!Y-LG+_**=*;/*<(G>'>ZBH*/\1M $1%B
MM=*Y?RKI'/^AIG/\EZ^JTV(40[AH*"V:N/ZETBS2P\<QM<CKV$/!9OL!(N#C
MP9--'@^QVZ<OF+BO\2>_R2Q18A2C"R1R#4Q3 #8(7_3^^6]/(#G&6&S &W 7
MHPN6/G1\2TF[)RE<0-X/>IU(%RWV$<4^2!*0X-VX(O^?D IS ?X%;D^D_F@4
MY(WQ'U_PM[TT42(%/1^R"*9[+!'NR)X&=Z'7S0LV<!!3RROG@S>DJ(*'H1^;
M->C^I)64<>D)H8UD:J%/,5']ZDDJK8W=V?R^O>PA*IY=W$8[;S?D/-.',+^T
MQSC)A?-D@ZISE32/DCKGDAG1U,+K;:@8!+Y,RJL%^GG057W[2*Y=?5#[]WTH
M7Y(>UAP$*4#0"\/3U78+R.N0#7H"7H*5V]?P] "_@?#T$G=;/8$=)/I4E,H?
M" W?,4\GQ)J%4IBT>//E="(_K*MTH@B,KH]9)!_6&ZN#QUSV ?,'2<09BY+=
M+W$NXNJ_=?O#.Q?4H,.@EIL]AUNK'/5B76BZ8H)VF08X)S!5+4(2='B1M66>
MV&HP0*D W[7?..K)-,DW&X0_)_0T\$[M!K4YX:N-G<ILU#R!,\8K1T9V@M=]
M8QUYCGUT3DA-38,,ZZRC.3[&(CY5D^^<X)N&(@?8EAW-PV*>1D=FG:8PG(IU
MZC"!.YHK9WS:53"9SPE#-VAW9/ GR&DTH4*J8L%W-!N2^:N,8OAW)/R6Z#-?
MZQC<SUZ*_[O9;C#[RX6=!!_T:R^!R6;[V*Q?7STU*P@M_\</)%-=F)A+[T![
MP-"S,\B\V'VP(.U#-:\-*G)H? +I/@[NHS>08/)KS/;ZU&]\;L9-&J'S$UJ]
M<P& !4;X#S4T^"]?;_$%1#[MQP@?N8+L\$6QV;;^J;-@A8X6[+>S+\U?\-B;
M[15)'%:P3<[TZ6W-)?VH)T(XWF?,V>I_:6;PY5?W5!QE6<N].+\&X_7/;0C!
MX66/+ZPCR%+H<UX L9KJW8@$I8U-P'^K-P#_Y>L3@8@ZQ^ZODT[KD_<#'K(#
M<V+MW]<<*3H795^.%!D:IK#W]F]V'BL+\OQ87*^1P62O4LPVB^1]A?1W?AN+
M5<X=\NAL0Z7GM+P.ZU-<7M?ZW9IJU(W4\1^P3NA#5BX<B8ZZZ<,OLEP2W7"'
M )N+B5H;Y,&Q#T"0W*'X<,Z30I3>-K-E\F2ISFM2NPN3VK&H;X>I:(>ASFL#
MD)L^.>_(ER@ */^7BM*H]995A]"\@ALOV9/_$1;YAC]5B-2T;*FTR2OT-I>'
MC#K'YSTQG %T**P)M.T9,( -TBD^_'FRW_QB%LND[>:6<<%&4A0E!MCLMV:3
MLR*;G)2-E)X61H<ATM&@5G7X5(R5-H,BGV!H!(.UP?1$T^;JXII.6PG_5"UW
MCF##2W W%CBSR7PWT)Q;Y0]B6E =Q85A#B+KI5@Z'5WDFO90X8J>;=I#+B14
M2^WY%+0.B"-KI-T2LHL<E]M/F<U0780W6<IG+G)HA\YLQFH"D4'6'^ H3"()
MHNT_</3EQW"&(N.8L!D4X\Q$H-K8C-T4S(7C3'+T3<OPLR;KEW+T#<5P8.RK
M?3!EF6!IN(8YR!P-K!\(CXKWS=$@^>'G3,5QYWKI8'75BNGP<[U\L*:+JN4Z
M=+Z,L#(H#A05&/!,Y#D['(B8NWV&NRA_&(LE5]^/LR@E*F <8A4 ),_^'@09
MP>G.@R@O<_L)>*1_SBU,/Q>I)D7>M^4\[0%ZKS#,^7PYT6 3/1'>CXHG;W@W
MT?FO^:N8WMYWW,AZOV',A:YC&;R7*/K&-P_1]:GZXW]#@#!WV9\>P!L(.:\A
M)#N;7USS_/9GRHV_5AMC.4LU'X[\A"\G++ND("!B'CY;'6F/_J_<&/6+AC0&
MQ*<X J="ZK_+HH"_1$9C<R&>.>NLJ*R^K!D%2>3[F3^+]]$Q2Y.<$;[C;@JO
MA]'(QSZQ<ZX#3H>52=CRB./+<Y',C##W#^ UK6T$W$4+N]G'0%09AUT,X[TR
MPWAO>B=NRN! <!U'@21=\?M8<4JN=B B>N' T\+MKCD<_R5.O9!F_V._:1%U
M<39D>!0]N6DCT:A=.A+'P@E?4M,CJ3#*:2Z.0,4+#)T(J]G$B>J0X9HHLO0E
MQV$:G>%)J&IS@5#%BD(]H#35SV9PI$-+M-M4NSX[ELII,WIR=Z18H6X'*UW"
M]1Q!BW=-3@?7;&)L==^48F.!XX"9NS/G YW.N_*]"W1EQUTIJT4X'I2IFZ4)
MC%2.QVF.>0'P[6".QW'J D[.#.=(^,SPR)E'%)-,U*1V"H'KF">G3E)X(+'V
M7Q*PS<('N 6F8VG.TWP,R7H:<^W=Z?V\$:*.YI)Y]':A-TMN>E79[B:3?=#G
M=7TB#Q,X'DJ9GO8MBTR-&[@ATW.>RS+O3V5.LN9RJLMK]#3GDLP0OE6(;2\*
M[N /\B>^RXO3P>:]^0 2'\'\\MUL25SX+;DT\^SHMU%V -3$S/K'-P;1 ]9"
MP#X.@_O#$6%1[R ,?^#U<-99*"\(M*+HI6]:1\QQ'..EPJ7;B:X7<W]'T.$9
M*\>#9S9NO&%G3.I^G2LR?1&I90'BW-$V(R+_C%E1DY&BF^:!M-G*:/)$R4I%
M<\6/?^ZX,I,CIIU!+Z/6\CG3+69!Y7,&94?-R'&K*CY%N^=")6!M.+N]^:C?
M]>F58(V./+UJQOR\Q]?)+^IO/IK=-,<&5]\KOE2X6XE+DOSAESR]R1:@JP/A
M^9TIJ_?7'=?L_;A! %\^R1/P 7RCL#=V.V.$0=+E'C"C_''[PSO J*C""_#M
M25Q!I#YO^<(:7[0HJ^_R#IVHCF)LN;=YO4OX!JH9/WDIP!L11SX,83YQ_(_/
M($U#:D+["P8R:6)\@T2#N8O1)MT#5-#?0TR*C[+-AIP^QI;2]NM>O6&ICIP?
M/$DB$MS^\,,L($$*!9U59!>&\7>2,P&WJ]?Q.4X?$7B#<9:$)[)S*& 2^/C?
M==8LN:8]GSKO!5NLM!D+:Q+#F0Q*6A^\V'@&QPFI;XG7CENA%)-^J<GQCD?_
M*6)#UQ,<C^E3O\64%0_'@_?4$1JBJRPF]:*D;K.87(L3*DB.> \:3_](9'LS
M\6T4='.\_@'3_=43R-,L/WHD*-1&-T)W(2(/ KN]V4P8C2GQO #TML:F?ITE
M&+\D:5(2^2,"_!!!<3_-ELBB^,!-C!4A1$*9C^4'BV^STRQ(]3-H^L$B(^9-
M3UB&C#+02(0M#-*4ZJIY$S#S!(\95AN\!$B4;>4UMXKBV>X>5NM)RP]OOD<
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MEK)-73JD<;Z %_!:NKENL- /@_*!PMD9BO6?=P(6(36$;72:NX$'DFFGK\D
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M7 )A>M7(LJF7D"-KI?$,U<7.B0,(G7V,LMC,TV$U)#*);EE1""S.Y_YA5W)
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MZ@U:7Y"8)EJZZEH_<!NH"CJ.\$Q#] >]D>;>%F.2HLU0#BB@K&"EMRG :,*
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M?)B I'7;WA-9-$J@/R:7D/JTN1"4,!\7!/1E\HL=278V[U@OWLW39_DY+BW
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MR)E<+$CS/'X"DS75H .&BC&%6$>S<IA/D.Z\L782T=GQ)_\.($^7KAU_L^L
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MDH7N9,8PF),QA2CGLF1B+_A+G*?PC,8639[[.)[9W/4%7*PY,9ZFW,49^G\
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MEJXQVKX@NO;&*+Z+RI-9I8JMZC$1[UXE?8C-QO.LI526BY0+4,M056ZMW2P
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M98BJ:K&K'8AXV9RCRI>!K><,*"1\1A;:1:V]IKU+??RJUW2WL/\/4$L#!!0
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M,D35%[$W!Q#QZG&!)E\EMIYSH)#P!5EIE[4.VK:1^NC%H.U:L/\+4$L#!!0
M   ( )8Z95P>6_SWI/T! 'R[ @ 1    :6UG,C(Y.30R-#-?,"YJ<&?LNW=0
M4^N[+QXK(AOI78F-+B "@HC)5C<@04 ZTJ(B0D! FD2-R9;>V5*5EDTSAA:1
MIK30V<(&I$M 2!&1)EDB84G:C>?>N7?FGN_W-_><._>/,[_ORJR93+)FO>_S
M/L_S*6]6^!_X5(@XPMS2'+)K]RX(6O""\&<AER&[_B^/GS?YO[W'+GX'1.+
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M2O ALR)\B*A@G@L\G Q':-2%]R=SF\/NY4-HCN0?T)6-@7%>&R#$X70)/C'
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MAV#:77Y\R#>+;=H_+/Y2WO$R 9X]QHU"N:_(S 7.$3YD"4!V/);&O32]P(?
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MGLSMQXF##JSH*:P(YBKWI3LKNHU;U;[O"[2A/XHQ@=69X=CGTN+3:EJM2",
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MYK%IOO OV(!<ZDJ K41RZ<'*RO+A0D>\^3+QY(Y1V-"P7FC'XH,X'3R@?C/
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MQBZJ?1JAK+)<P6/LT[C.*QB!1J(WXND;L?#7%JD"Z1"#DQJ57'#.[.%)@G*
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MZIMQ3[/9Q^)'UP\LN3YP))@;Z-E47_7Q@-8MEE0X%,J_;6X@-L]]?SDL/%Q
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MI-B>LK%.Z+XCCVF.N+=9F4@\&+XRGFUAAG#->^9,T+!/F59Q"UVRB\ES'AT
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M. KXFE4/!JX;V%![\6(KTF)1+8X=-X;M/$8WK??YY9)8=3:6HNS"C\&+:V!
M*6$]U'<.,M';)7V2OHG>E\9PH]7'HL[\>JAH+T88\*80%I[/LIULQGYOH"]&
M5['LR8B44-@Q6$ ]CEHY.58O474_KC[&^H$+WX<16Y>P U<U.97&PVGZ*7('
M%$GV)>7F%U+>%(J;*0=<J/4&ARG)#\+()Z8C['='?6RMCMJE?/55L JJ\E$R
MZ;=U@-3>#^RQVRZ:'&$?H!%9(ACJ3 (.ZI\*=@2@S/.LJS3K=5^Z3 =&M%45
MI0?$T+I)$CF/3).;Y8)#HUY94*34>=3W.$JC#!EE53L2]&TD-3.WM63(,_9I
MZ0_67T4 U&-49FRKQ<TEV730X+)89=G4BM"2H22AH9K&2,FQTZPL\0MSJF_,
MFB_)NB/Y5W5]XXAZ:=+^:]DKX0=->EX3"N,Z*/-Z-L420:^CL2KIMHQ[<8HZ
MDC]^FN3K&N5^[3^?XA:@/.'0.8X_84(PL[??V=&K^AJQJ)QA[K@PGV76'Z0S
MOY!9E#7):X_UYPVGV;G$;R-<T&PQ%\2XR@7=P;,#\8\<Z(+_M]MJOW5@)"]P
M06_)F-VJ7JM/3K2+&\Q]6$[5A>X6=!^L]M<:MA%U["F]DG(5Z<."O_;C*'ZN
M<B*1-7<9"0R(N)_.M.3HI]W UN*B7KD/PZ&2:=4]ZC?=ONZ$:(8HG\@=B.>"
M_(E)TL* .ITXJYW$.17#$V>U?$]0 G1P=[AET107U&X'I\(27$MJJI !,/[5
M/P/>JL7!I1A-D=M/M5(W?U:X[N@XXOF><4&&-J[6@@GE.K8/_'ON,TX-9=HA
M5D:E L0?/DQUT<_D@K(#"947XN5;=)7O5>JV*S?:I.2:W?+ORHIRXZ"'4[P,
MZ6:0XE][^F>K,(0-$CX%^FZ@.PVR A'<XH(2,>]$4U/3VMD!F(.P[J/OQ\3'
M(J-7($+K,G1=F'" DY/8><G)5#5K05/=G^Z_9?3)+O9R=#DSD!.M.L"^3J*
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MYVG@CU_2-CQ%9#H2Y8M5J\CGAVM70Q"EW457-)T,;_=%G7W7^8XES"[AR*-
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M(B >,80=Y4@#P]2!)RPY6B]E("%470RYVNVZGA#/4J'TG1USZS-U'--2RA:
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M<.[(H+-J_JO&3-F]*Y#SUXF3.BQA<<ZACTQ#3)M^[3P],YU$CV&DC."DQYV
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ME"::;[(R!*R(<>3&UC;91Z=")0]1&W6RM=].8?Q_LL2!*Z%4J"#0ODC!_*%
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MR8EZ[YUT_!@6D/E>'<K7O2&]I#@D<-F:XEA8X7XV8UZK*Y4*$YPDUR9O6U3
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ME[15M$NDC<R&R\[(.D](N.^?W>/W^GE:H,V'K&TTQ2%?(V?_X*Y(\(Y[(7E
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M3).8M)_LNC+P5/*JR]9EP&A^_]]C$HYI3XU&[HXZTD6$1QUFF5%1[7Q-$J1
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M2<4!N8 Y\'K8+.SKK=]/,Y41LD)IXP).DUL)C)M-\EQ ]VY._?<"SD'=%-X
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M##U'_^7OH0_>K"MB?M*(^_/ZV,WWA;,__"0XM7KP4,QY7M7+=Q$@$Y-;IF7
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M^^()M;L2D#/QLL(=P 206)/<:TX_:&O%=;,C\.CW$YR71+ 8O.WTB-[DPK>
MQ' E-VB3E_>.YN'.LD<V1@*HFG&?JUNPN>Q$E@H1.)[%V<W3]!UJ# TTHZ]#
M$K2'LX_3 ]I51'5'BID@7R^.?H'[6C%N9V5/U[#+21I?-AP;/'H653D5XG)6
M%DT&69K]FDE;F$0:D_Z 8<K49AT9X>@BPFA//+<RH,3N7.5!5]KI3>##=<9U
M;?TIAU&+ >_'=M2*U(K%HY%5%[ UU4[1=IF&TS[A$X<ROD(\*IMKA\K*UN4.
M"XZ$T6LW:M.??GW8'1@J"MX>>SC]> %0_.&T>V5A?&Y%POM7'(DH91:(.MH!
M9.Q?2>;HPQ,]:=>:29 84*U4>P .L& /[W-"F3>]H?6U(W?X.<'*QII[>C#Q
M(80EF[F<DS;/A+"Y)F\(XWL_O>"D<_"$K5C%J"X0CQAGLA2$&,8DF*(SRP")
M1[Z/,J1)-I+ZXLV4:":T5*GOW:_\XTL9Z//-IQ &]+IQ*-KC@U[W1;R@O7K,
M^2ULRWY([UP[,E[X5S^+.L9;$WTR([#O'FXFSTRG"9LB%&73(]>J<*AF,.4=
M>GKQSFDIAW&7!<F1+->H\EK2,.Q 97U=AKFE2<2O#K;7%,?-23!*=SFGFZ.$
MFAFES$R;\JYFL8]GP*I7*% RZJ&G!G5T"4_3)6;DX<K<;8.I;ZD+YRW0BZ,T
M\WQH0V1,<5Y6U:2;O] ^77Q\SYM=]'*F#>>+IQ [@[.3=9K'8;1=MC3MRIF5
MV&P@?;FQF&'6=V[(Q#H,2F\,  +/5HWH1^ZRS9OK:4BN]5B@VR\YF07-O"88
MP"]P=MM0-3H@BE%;.+T$:C+K/'6#5U]#@?=O*\I'22].JWQAZ?K.3)FW.6U>
M='W]W2"[")T$7)=N\MCZX3IZL%PO@F+ /'5\?[13[JD/D\(L"2:X;@ TDX6K
M.9CAYW.LP;>U4<MLJ$^C#S2^5!.Y9T+8*-S&6@][,>";K8I4QH:QZ.> 50*=
M0+5#SPB/@3G\2.8=ANQ'RQ3D56/8^,:E$8Q6_JVP5XCC-.WD%]")6M2KLW?)
M)P:"T(%7?DIOOPCU/%=\^V[4$NL$NY(C@S!CEW"$HSY(&2FFF%C2?,EJ,?H$
M>6@?,=+@5!-U+IJE]&*RSR>8)+QO>L%,96#=]ECK,F<B0$.LT&_BZ\#D(3'S
M[=??*I8M4E,Y_.SR[[@: DO<ES[+KOV1&>W.B)RQ 6V)^@S:9F+M3YT<LRWZ
MCE6HI"FF5FA6V!,^<T:&UN5U'3YMYX=%"FHCAC*D-F[>W?W[31#<[_=*J@M8
MKI#U5<5-!V4T=0%Y'[)I8P+\PU<-?NT;4^2<<Z+SO'?5.?9SW#H8?@Q;51Z,
M6WF*8_)CN #T->_[7,"M5N28OC!;?]L3+&WNW@^<Y/<HP!#+EVAKW!6E]F8H
M%"P$5V>VNUJ@$Q'FQ5"^J\,U\L)M85)IB[(UL5FR50L&MR6=).E61157XT_J
M#X^2()23*F[(%G_0#"JL4CTR?Y#NQ2Y=WA]V G\UKBW[24G>@XH?'I_X!(_R
M?\,=9\GSTD6+)[>5"Z@=/.0#)Z#7V)E-YM0-,JXC]Q8=V8]5=/>378XA109T
M'N,<&F4!?<G)$6YWW9WAWF?JF@?0G<E%W:_<W4^B-=\^[-E\O2:OMO[, JGO
MVL<2-Z!S&"+4.,[N,"(X57:T15B2%<GC/Q 5U!6UC;;2UL</<8%+.?=CU1F/
M[:J;OV":]$MM \-NT86.= ?"7DWEN-4V-;S+L_&2*'I6KPGR!S,T*TJ8)^%
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M=\I]%9!?A8J.)WYX8A'\S7)U]!MZJ9P+V&[ ,,>XLAQ'D$&X^YXB-(/D%2[
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M>WC+,V+?I_FX. Y4C0_Q7P9>.A"4$7C)P76+JKW-H7U7N];<K[X%?9X.K2]
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M?*WS5F^L^S_LO0=44^NV/QHK("(=!(0H4E1*+!0%)#::" @*2(V(E( 0%9
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M8Q&82@7>YLZB.M;<ZL7/3_7VR]?]/_NKS?\YO][,W.JSJD:M;>D-@0F@=*;
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M_B1JSZMOI5SQ>L$9%Z5E)J7\?CD^L@^G(B(E'7)C]TI*FUK%PYF+,:J<-A>
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M8RZJO,'@X"T/A(> ;XE^8Z(;TPZ=NCPUD@E99EK],S#DO]=W%-XY9V)25[9
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M0V"IP<W8,R2?0U2;=E'?0/9?M[]5L:[7)^J@4<D?^YBN1R[7U:8K,!N,/[[
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MLTVLIML(6]:C2P,34 VT2B"&NZ2CO0=(XG@J@R@TPN^50-KL)1!+UM\>S=>
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MO>7=L57K*::/U^]S/#!8%QDQ_S\<KZ<M;YS#CP'4QN:;4 EB;6O3QV-(>4P
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MY*>OFGU(]RUK;C([?=[:1^?HOO-;XA?=A$;@65@\30'_:P_OW. $1ED8RK6
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M<:(/OS\/YZROJ8\QC\U+HVGWP77)]J;\2J?VZW\2CRR<DOWRE35CS;L@[L4
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ML&P$59/@.1C4!=7IF7B@EI539!1 ,\Y[5ZML^O-4,J_S6>OK>L6!GC\T411
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M:*VG^59ZX@:5N["X?&G1&T/NR/NE^.6C.R%6#W.8O%;D7K(R<8M-G4@JD76
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M[.OYXF%]Y-B)\XFOM_07T:'I0@]9D8L3B"TD6C2KT0JC:<8)*6K$SMY??SC
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MRZU4ALI[WG8092_R)MD!5N^@<?X.O(BJ4?6-M: ZBH;U\HR+G1I%[6]L-.N
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MO8)0\UG29.=V[,WZ==YT^%G-S]$/NG]_?7_C'<:<P=('I=M8Q]Z"P45@L#M
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MYDYYJ67<'%@8//\58VXPO5?GT<^G;XYJU?M!#M+W<:TLQ89,X$<4$_4&+'0
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M%1]QG!I(O_*DL 6!U^EW:L%48EJZ=HNO ="$<W3^)CYRAQ];AF!;E]!L?7%
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M(#%'@DD0VV60;]O$VX&'8W?_:B!Q;71-BB\%NM-X04]I^>?Z')VE%I0?A:Y
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M#ZAA-F]\$,0V9MIOG7ST<N!R8VVVX*,98G"<04Q+1#D@-J#C-,O3!^'_+2W
MS:-#?YQI6KKCHM;I1U):YMN;ATR^*?E1<MIC32PMT1 H]HE%U6&4)O*O-6G<
MFS$2^47AN5OI-DM\\[TY=RD]]:*E7;"28Y+RU;STU,;V%[,WTW(ZPG_A,#:.
M'TKDV\B%<NE)DZA7_QZ _^!J[?F$OR:W6OXM F;_'JF ^.(_# /_/01C_Q$J
MLN_;$W/_%@*M?P]5:X[BH>9_\@SZ_[OC+R<?GT2]@"Q9W8RNF<S"M>G;[XW^
MO,TZMOF8ON9Q76@@1#SMTDO$Z5W[+X+LL-^$_GL]R9D:R0'QN'- [Y=1PU#Z
M_<C"_2:D,WS^')H'38T@, M\-B<XH'L#CSB@*N>^"/I-'@[HG"R$W4U#[WL7
M0@;@WVW(T$TY[KL5)Z'9!HK%A(=0\/_=\4'UBE](:';H%:%K63H+]]N]^\\T
M,TR[<#F?3V?^V*ZA_+IB6.JIF:8R8T\:^<4#S+#[SG- D[E$[2&8S;:G#3>"
M!VQWI=P4YKF*E.ON]?,$Q;<'_]&@N$/KC\']^/=<3(OYA2W]-:0JB(0?NJYP
M2Z$<8>LP&LBT+P-21D@:B0KCVF !CT_G*P)PKO/GGJ6L6+1-W+4"-.Y\/=R<
MTE"B=5=RL.:QL+Z'_V1YA4[)EO_5PDM.[:E&V9><G2UW[-T<5&:6'7RGJLGI
M:1B;"&G[AS8W7V6F/_5X16L2KJZN'ES_:]"RWB SPEO^8OV[X]6E)P?_[K\'
MA#,K7MK]]NW9^F\0V .HVQXX!=V [4O]3(1115_1@G^?T++:B4<?9\K1T-TT
MOX(SXT:_9\\?H@T_]T=)3=9BQM75Y2:"@S:_WFT=#SX>2;>Y'JDIE^1@D$'1
ML\\@5SK8AR]^RRBK*%VFB%5G"!<O!<RN,[(J)C,48!?2L=9]-OYJ_2<"RY4L
M5$S?EQ7G.C<T#\1R9ZR[1X3M?CLB[!Q6AM0$4FL0A_J@(C_1!Q$X!^#VXE.O
MWZE[2?C3GU:S6XS!U.8NLO-WYN62@-F?=MHQ;RHV4A[Z/8RT-]?>".'CEA S
M)7U+31N[A% _!25M\3[/F8S2R3LM@:6UGR@2%DWB;5J8\\6Y_IHVL/3F04WK
M]YMI@:LID@F*9:>+$Q1!Q2GY 5-(.ZH*Q?FYL2R@05Y(P@LQKU!Q/2-QWSU,
MJ!P0^3R!%.A\G1J<[%WO!_L./;ZQYT1;V^^8,Q)2'?+3BCX."XD^7V;_0MH!
M>ZQM*(L/EG1SZ=ZO6[DVL/K@+-V'UK/O,\5M+&TN9&3(#>N*-Q=)E?^P*)WT
M&E;LWQ[<4OE:,EA>7-;24K!-GA^?EE!7K\7&S,[."_N=;VUK?77[^3&O&VX6
M]S+']<:N^#QTO&$A\OM.G8#(5C.Z(;7_/=[0=Z'!&,?=I!O5=D FN'?6_,49
M $T3U::>KRG;V-\J%=MW+(R#DN1T-'UY([TB AYG2^:Z_ZD6="NO-<5!(1<@
M4K/[N51G*R$V%A=ZJ]0,K6E[Q&04^CA03[PVW;@@Z)>5T]5XP59+QVTY]?+'
M[,K?ZK[T.FWWDWVELQQ#!__TEOSIHS<1[1::MZ9,>^$C8>G@;N=X)SUP(C0#
MEK/G[J=045+B=B'3 E8A?A57E[?$:Z99G9Z..3]N5UZ<^^!AFD6'[Z,FD0;2
MP@D@JF]V.Y6$YO/-P<4;69$%S$;,1QL%3O13[*=VDYUOY*M5AV\9](SK!ZGC
MU+?E4XZ=B9<H?37UVW+7#'EE\Q'#!7F0RBI,--9##7,U _L4X'5C4LBBCL:3
MRCR 0P2;MT_)._K^!'"[_"YO UJ<82^SC\_%')#G"ZTQ$XK6G\+P94)C;1S/
M2$PV,U\&6C[<&'QMENS7$W'&LG1M8AIS;2*O"$P;5A#G@.:&(7IC<)^U0JH-
M=(X;^=&?"T)^D+K(+;4*1*3+V!;2I'3C(9K7R%DGMV)5=]JBPC5 1U?E%FS%
MNF/BF]5<0'F+J79#=?F'4DE@?;^?8=75.1%AJ-)E:#>Q7:L:O*E1L]386=_9
M^&9KNR:H!OM[EL362LHU3(*IDX5@1E*4O95@;.VW\ID2UYXOZYDN#B'X+X.G
MLM6' P+M/7B<P9X)B357F\Y!GTUA#/P?6N"=]3 JYW.;]CP&&YTQ?H5'4>H;
M\.-,<QKV&N!%J;$B\;S0]H":T)Q[&1H"_NF &+']8XV6Z*QG=A7P2NWC&^^G
MY3=OSEWQ"U8E+6>1Q2=%7UV9!W09>NQ1:*,UO:6,>1A0H>E2SG% ,5LU&D@3
M/RJE1Y*04#:FIK&4(R65?-WOX0]^O=KEE@*5AZ]Q.=2_RGGM;1Q7^R_E5<&2
ME*S2JI=@@LGZ3_!;%CH9YW;,+;18JWO.<E<;EXZ9);O:%"]CQ2=R,Z]M[-@G
M..>%/^[3+IDQ0W2)?$(P2#NIQB((@CN7[+K=^', FH(3N&GJ1X;P  3SKE&D
M:?%7VX CFQ?\W1R9-[ZZO5?+GVJ:O//[@<4")>',6P&I-7**@YH9=S$2YQ0'
MU?0&U3PLU3RT)JRU-J?+/]IEW*4HM@ZJ]=NEA63<S<_S%DVWUKZ78WU9LI7;
MW7J%G2NQ?^*28<SSN91)-"_[-*&;_RD"X8E.C"<%.N)E3<A7S\I=2>^[NL!0
MTH8IQ(K>6[2\7JZ9=; ]. ;>H-&OD03A-]9A^E!%HS#^<##!)UG*<H:MO)Z-
M/S?6F+@E936-NS7Q\U?C,.1&6ZP=[7#:UR^_IUTI)8;(*_=;7*U,=S4R/=9O
MG^EO*5@A>3&]XHCX5![E&"R]*]/"YD%"5&,>5CCS&Z[:USFCY-A8Y9)R:(UX
MN>5WC/A@:)5(0'O("P5=[>WR?NN.\XASPG9N;_YK&?Z_V!D05[4)/@>?CIH4
M_"+IIGAH3X/-&\(!'='L /0K?+FR>F&@ZW$ [D5[S0<#]#.F=\6'"2LJQ:X]
M0]X 516IDFT,;GTU=1S7NOJAYT[/E$S ?F7*M>44_:(T_:+,4RZ8^.F_"0V6
M?O57=-JU;U=E9,2K*HZ7/A= YSFB30JI%@N DM&L]D@LVCLUU8WT]-0299PM
M".PYMJY<RXP3Q1^E'?GVT67MNZ8F\.1&?L+GTQX7?:P0-9?89U#CD+?RE]KU
M%\8AW499%SZ^^TF3P,5_$<PD33J%Q6+%W"7Z'QT]D01CSQ0=F^P-D76_"F8X
M)53DDMXV*+M\NH?^ C%;@!0<1&B< .8DYX^65I 07D9]#H&+ZQ;E=N_#^"8>
M+RY_\5OZ]&:(E85LM:Q'^(UFB>W?Q)6A#B%]T,<\B"2HT,T.X,[^K2SG=/W;
M11Z65RM4/ZN4?>A5I9P)?"^49)8"_O#MY#6YP]*".Q9PLL^+>64:.LHH))VV
M<\1K7DA[2/G[#-$A+ N>YYWI#:G]]KGFF"74=8@V22YR$DNVU):S$HNN,!>+
M)<Y@60.]>?I9(4YV">\;_(UG!.*223 =QW>M<=C-$!>_1E;^XXN1B0U)Y"7+
M4A_+4I+&YV_AKT0HWN$1QU-*N?/!8/V[OY2O'.;NY94-+@'J4Y@T+#3+;<.Z
MKM$TGEAMPUCYWI6XG[GQ4M7FVY\["M-5CAF:/L7!?_8MFB<SY2@[(.\O(3U-
M3Y.6AIZ3CR=TN=A>('WXGJ]H*Y9)$79X6BIF%' KI.Z%DA?549%\6S(LTTT8
M_:QUX$6#\?&/54L228_(..<C22]N^E+>I:4[T(1Q*.>2:'\;&P?__AM!%F:A
MBL4)K->_;OR7%OV?,)PVD$K=UI!V]\M)>5/QGH26 9R^K7ORTO(QK6WM8\'M
MP[?+W21N28Y$[[[><P$2?\LAB^_R\Y8QU(9CWJKM+/ZL5%Z;S%>JF,A6+6FH
M]\.6P!)M+B:E<\\_]_A3Y,FS(; \Y9X;.<M)695;EV4FK+6Y=4/)S,[?+@V6
M"+/ ':>V#,@<]5"YT00DT8T/TG:B<?9FM.SH(/72=D'_H]II"R[4#\6'.VC<
M@CL7F0H;;2J_3W[I>M,TL'K6SZ!7-\>[Y=V:9'\VSH^^7YO\-+!\;<;?;7Y[
MVC1+Z6"=\\T4QS&B_*M6Y^3)DLIWIY$KC-^8LC.=Z,@21&+/J)N'_VS@BQS'
MKWD35WRTAU^VYM#%$LAWXN4&M#X^%PWM#11\;J/B3O=*Z(?$C&-J2X/5LWOW
MM_ -6.OCT]GS4M/AOVZ/XQIEKO8OP<CCRV+OW*=<Y4S;6O#/]P7H>W:&:$-O
MV;/ ^]>LLWI5?VBR3TT.,J4'@2?@U/?,:W#/3-6' <X"V=-TE0L5NIED)SD1
M^(5N^_>^,-=:N+38=-WKG,G<98;_+P@_J16B.DSJ.]D7XBDGY92B<);UP=^$
MWP;CPK"X3<;7\=ICI"^[O6[3CL8ISW],5@YZ_R0V+F)+H:?]: <Y^?'.IJ18
M3&.@?:_DU-ZKD#"ZFIQ972%LLI8][">\%PFY5]]<$'QVFK?V_.>E;N&T^I)[
M"*%^MAB0O4C@1UZEVF!938M<D>.;92Q'G<;1#5F&#"NSR6(A5\^G40Y-]9/5
MS-6_@AL67.=N#HR[V+76:M!?<$!IAV@C[+]6>CD@UE7M0:92< )>-;:' WH7
MVSV$.\F>R0GNN<>*.0ND5KJQ^W*"4U> YP3!&;M8(DJL<* =2U1161"<!92M
MK/+;GR:3U>//-RQY^JN^D]-DY_RYM.#!G5R#A)*=Q; &]) B6'7;K;2,2MTC
MXK6(OOD1]TL_\H)N[QJ,O7B+X;6#N7TG!*B:*FLNYP9IEF6:??LEY=0^IL4!
M/<&K(#V  *IAMUML+S11]L*XD1!)P.")E9*VAYOK\>SVLI(SL5:CC9<OCAOF
MN_=ZRDTM.T694^>CO"H"VCO71]?:GTY6#AI12+I;MZGN%-L$]4[!1<9.W&.-
M)+6??IVF/-%L-208F*-*>4XWJACFNJO9.E&;,VD=I#WBQH+8VK[,5W9V(%D%
MQT^LZB-]WDT^I1;2N#?=6!3YRSZB%)A9C&0:>-UDO>NT)^\( CZFTT8(XPN(
M/3('E'P/>,8!'5O8 E.V#A$O(K5;:=D)0=]:QZK/-$\Z][K!8UQ7V'^-XI+[
MWV ^O#L6OS_0AVY*W5*A+E (O1HQ>%7 GHHFM]#1F[LT'TID]P;\CS3F-5IP
M;TT0I4=6G4J(86HN0@57V_$Y=P+->],0B38=TR74QAE-Q8E:S!]&3JOO.^M;
M%17'@X6<0GH_YOO>4;(CMH[V3A)G+^0KM=<W:7NB":44RR:-2#_;8\MA$=*5
MY:2UJRX(FZ1RQQH/ ^"QXT0>"<:7%EJA? '57YQIJ1VT;[XQ!)[U6415,:YL
MH.O[\RFO@XV-$,'=H@N"$0N'KA0CTDPGC.0B(T62)*,'XF?,C4^*Q2PCTCP$
M(I9GWEJ(^OW\BV3L_:0+;;!0CTW6TCB&FB]LV&JNHQ+IN2T E@:AAP-3%<P[
M--L4J#<'E"1[B%M/^FPA3&O O=Q?5G[2/!ZIZWVNY0\CC8#;/#$[1EZ:LI*C
MPTTOVSN?6]^11X\NS*7LD66K:(5T,<!Z<2%Q01 EB BF@/ML$V2E@>Q(ZH1[
M-G&? XI'*F&8!M;7?-\%B'XWCRB>Y\_R:R0(KGW4AH._IJ/+7CTX@(D?)%F)
MQ1"OEI(D6RU?QT_A1&=T9,7?.&><.::D'.;B9W#!W]XRQ#YW"ALS?,Z9'RZH
M=S44FXB]*EQN<3[ST6V*Y:6,9<K6:1J?]MV<J ?I+P+O<D#F*OUBE-3H.7I4
M.CU8$A['DT0!KG- XBF-MR?0)#%CZ=3>:5F10+V;:#]T  <4F,LRDWHF.'XD
M]M.XDRX;<0U.>T(V:V,X(3HH'-"6$A5-^HM5R70B-#BF$B''F")XJNU6,O7'
MX@<[;0Z(*,#?+XE.,=9>@PIV.A8ATBFE;"5:;<E3KUH@UJEALC&@2\BL@\IJ
MK*D80*CMHY.X&S%RII;0_V@#$FE8IVF\+/(Z&E" /FO4$!NAM@N >R7["+TX
M<>9C(("DI!7, _^5AO"Q#!9&Y+I8B]G07F1KKL[SIKK:"EW^)KJO4)!C_[Z6
M(N:9[)9)'<0H.ZR;3KW8N!IM>2I?T3+B/LDUS,R!_&LBR8'B-Z2_(FECF>SF
ML'I'QJ#)_ZIE!L4RPF\F2?GC26R$@6UF/ZSS\EJHL2_NJ[45;"(\T( #<IG6
MYI=1L!C?W-86L'68W-[:U/JJTS-^OF![G[V_?:WF_N;6+?.<Y76RR^)S>;]S
MK^RLCOH9X#-Q:VY!'47^.0];B@-T=-H+7E6OB4W/%J17KK6,8OJR2LK\=6 C
M/NC;CX+EPV;GW8;5NGK5TXAR_8,#OTBC1G8T^UXW[-88XP*PX<[","5(<= [
M-2:4LX@G9-LMG[?,2*#D+9"B4GZ_.B@<$L<^0(/$U1HID2"B:[KV ]6 ^O)W
M/>U576N!=_6W3FW-M] ND:";?1S0X6G FNK#_:,1W L^CAJ;ATPT@64\? L;
M"W))&G$<D/\82@1A[S)J+(74!T9H_!YC/PDQQE+MDPH%>D;G2M:;'V<.9UA@
M?$,:2G*"Y1N2C)ML9VU"0M ==./NQ:6D3'-7Q_",R3/:XA6#I_Q0WY6:TS[B
M'K&<L W)^DH#>PGUM74/>LQR2M>44TY$G%Y2./91J<,^T)4#^EV;C#\!K)&"
MI9#^P#!5X_IXYY4 <N&S?5WBY>#>_1JF@3\"[= $5( 3ET>+1\^W3-9J*V'?
MP8_Z6U4E6UE/>,77WD?UG5M]$A7\2Z(&T4'OI/KT0 \@Y8 :LD9"X:%.(5HD
M?9(:V</5;&XS*".$+CEVZQ )_FS^-/"T&D&Q&]?>24(=FF[*3.R3+.Q-/>&/
M%QU%VD64HP-=@$N.$UK-R+G>IBW(.U1\">!.)W% SQ,1YE>!#G)PLJBL\#C4
M6^T8(KV_0-E8GQ83?;GY%2V'''P$2.^_],7#'R4_^?-2>(NYW?1*NHN[M=/T
M1U*2:'/IDE&M\(-/LQ,XFP;,%8>WJRVP7+AG-^G+DE-NOGJ 4P6/>?[W]_IA
MAN:Y+O?":N*Z8=$28XX!!A%3=RLF8?M9&B>+)!V%_5OG,_4K.U]UNJ4J[TVB
MG9@6M6Z %W%V)SZXN+5@B+AO5E3]M=NWKFER>C:P.CO,_'Z#Q7$UPP$A52O5
M,;.;?WP_NQ0[@N8A!(Q$023M%S-CGE7ZSRHDL8V1/*,<D._.(>!0KYOV-]3I
M5%)6BU]P:$O[1TQI616)_[*53=:BR\):'2*+_+ MP;Q>[&&983S4F'N13)@+
M4$@;HJ],(-$,&Z0EJP!YAJ'&%*-Z[Q$+P8 )6;B CQI4 DGJY(<F:!/B"P5_
M'HH(+&%:C).G7CSF1SSI+7YZIO'SW8F5I$=%Z9FL9*0[3=B$RUXR$$*RE?B"
M"+.D\3!/)5K-J/W<^+/%4[R%UE48K64(.0%@7<9G=1A/?-,ZU?\:CFV.)\]:
M.0XHE[T+K8(%.;8I3=WL_$FR$;F@K?G*)BCSVO3>T[_OMTTLQVJ%YQ4_PI@G
M1BM>,4LU6C,L=ZB /1B =;\OKWR9J3(\E22]G=/XR]M'G+UL!Q_>2<7KLT?A
M]<Y$VP1)VU3MX%DW^&R')X"804G0[A$8%I^8 0 _)? L) D.-A*C!9#11%O>
M\UT5B">+,A\3RQ [UZ8ZA?QHH@M$+Z*HY(9I$,2&VH_3@E@Q96GH+3FJ(M(-
M>$63A:3.'V6]T2K\/-!O;$0+3F;KL<<A_!S0_4(I #[ EFQLG.J$4J#1>&DJ
M-L'(KBJ?CT(,Q'W=D#WIZT5E-U4D@]]'WXE1G')XKWPUMTK:FK??/IS*9FGO
M5IC"5NB"R:X?*[M<>G(P?.F9US[FD6Q"EB*.KY\JKQ@2\%2_8-]K;)E\NT3#
M[Z^J08<B2>LGNLH%TPX4R=#H:S;5YR(8SJ8H?O9PH1A;QZ^PV;S'-N:'/[P1
M'--YF7$%>10HI'CY,$Q1$ZB#K!(U;?UP&<FG/CW&4"HZ"JE$1I\D]/QU9PKC
M$F%U--;F75N]&16(&FEZ8YN-V*#X; DRSB"A !;2V^5%3YKB%J6O7J3LQ CP
M 6"0 Z+'1U$@FU]IYREFM+WH\-0XPDEC"%.E>7I70'?Q=S>G1'*7PDVJ9R8-
M;$O=)<341*#?N5V:!9[ OKO]M3Y87W3<FM>A@N]2R1'EP,EDMR;?CYY;SK*6
M0B6ZKA.9KCWY6.40R^(R0O-:I4WCN]T2F[R-JXU+D@D7PBO&J\1K_>VR+_M.
M/R^1?(61S-0X-OR>6+BO7TR0YX#N#&G,MEP#B"5?-@JD@6_&!X .DO5R$44&
M3G_!JF&+HL8?Y\U#8U:(V?C#-%VB%)H7T='[>"0Z7.V)^62GFY$=9M8\F,1H
M@$9CFY.%KC^SWZWO_. I<3O@R3FWS'!R*=8R?#ESSN82/:Q"?%BO8Z" VZQL
MODQ[I@B=HCET594X)2Z'?*OB[>Z0GRRNO)J'.9K3F'>V+2.MJW90L;C-YNW_
M4>)5B<Y<=+\F<\+<S&3/XTG4ZE.I<N.2TS/%?QBJ/**T)5E(+%(''U=%VK/
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M3?ZLL1F\%AS.NMI/UMM6W5$[GT">#;>X_4K&1  .*,=QR__F!C?14ZSZ3KO
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MB]E8C/(D,='E3$]%YG;VA+FOP!;]XG X";Z]E5#H$[=#T$C;CS4#'\R/N&6
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M)U<,I+.ID'B98#]T2_(\<']LL@EF#M_H:C1FBC+9-0DIM7("B#\!,$1P(TX
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MY?]Q#EC:I#"3=B3[^<N(:ZE,M[V+GNMX4C!'#H2D&11KR?%H3V?2G]"E9+J
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M''@;L@Q]O: (+$N\HA@3_W1G<]% W3104CX'R3H>KE.W"6504>!9A*7U/0D
M,VQJT,4>\(QORWL%2!9@LYV;+36S#TB<&];P)I):M9:49;%DZXGYC0J;*=_T
M8CUBA<B3,'((N<*B[6F,#SE)R[")/>/A+1XV*^7-"K]J>Q2C86JZTVD\BSRD
M@5CK8SM",]U.)HLP_$N /RGR%,00(3Z7$-_S+P![9#W8WO)('EXA&MI4D% '
M-R!%]N.F"GK=$ (=J$2X$W'K(5$,UYO/2%QX13K7PVT[$!/(>@D&T1D/Z BE
M[H[00&;HUBF>'?UUZ(^"9?E"LA5L:QFU<Q>/%/3D/]K>J5V (?'(+@=^.3O3
M4X9K<KC8=6AJ1]$GU6!B?[T-  )S]H2Z*S?>;A)^.$)*Q$Q#=D#TZAXK(YR^
M7'A'%:DGE2/1!GZ&K+,]CXKY?8TQR](9$KI#&2/YPNVY3Y<(;>[/! _<3#/X
M[M5>R] @IFBZDN-[2E;,T#Y+G\91UEG9BA5QQ5SJ4A7@[\>21>T38__UVV=^
M7/XF_WS*P_9_#KK)76'G_H0_GN8R/E_&8&XV92?F'Z%QV?=' FB[O*R*SC)0
MW>K,JX/SSA;E_T^MZ-(>E:6%!DK[=I*-W/ZQ!S[P &HQ[894%AIH:0OY5W/T
M)XHZ_/J4YUK5)6QM?V*E&FJ"3R)/2?[^D#;X->977B_RAQXK#61^!2D?8*:+
MV$8(_]\<)?P[ K4%:: WR&3PMKG/R2F@LT?_OY\\#"X LJAOV0NP(N2P/Z<K
M+W_SKU9,'9$GX@ 9AU#XWBY4V#N^N!5</[MG:HC#Q5S</'QZYN>%ZOOMJ9<M
M#1SF^$_^$"4B L"QCIQC[2+XK8!(X[$=<Y$;DC8^M5^80\KGV8;FH?8\^59B
M49<^ZC;3%]T'_ ]9 .?F4)-6DIU9G$"RK0%%"S\\R)KUQ%54OW)!K]?%,:Q>
M);&2Z-2B)Y%KO9Z,6.SB$WMA$WQ8ZJ90\TRQ0T*LM>*?B0X5GK;#WX9-F&S&
MU_F[F 3?U4!9;Z>3]WK([59X=GG1?.53'%I?GMH-=N$Z=-GQ(EW@-(-^*#C_
MG]UY],S-LKFI/F;D5I;I3ZV+#".0\9*BT8\.P8S22LJ&L[:/ISX)&)4_SX\\
MOY8_9][^=B!%<4PIU\?%?KE6E2W7V56X:9NL%33AZQ!LZU.+72\Y?_D_I>[J
MYT,CU*Z]=1"Y+02EH_.\V+VO)D'W8UQH)OSPCY NIRG=5R0:T^U&O0YC]V%S
M:W;T2=84.M_2?)W^CW_5AN2E+-QMD)+2-K-6PBF[]'AD3+4RI2K.[!=NWKY\
M]^C\97T" Q?@0S:E*$%CH-R!5;?5>D-YXE5A!?<L'>*9:TLURW:_<DK>?XTU
M,_K\@,T _"R!1TTN@9+2:Y]Z(T-PC_5\AHT^Z^L5 PEMZ&'H;Z/J8AX]OW!+
MKL\S!TA6_PH3E0;;/YC&I'HUB>NSIFV'^QSAU^8\)E),/$:=:_YTG&Y>1D'Y
MOT4 [+J<,^Q]/CZ<:7/V1H+<Q/NE*_DA>4]C>-_X_1X2E?7]L)(7\=H8@:<.
M0R_*:;,"%\=O?[GFPPLD\*J(<"Q$,\N:/Z@2[TRYU('X^D^)L^1=Y1^IENZB
M5B+YF/H"+&][($D3%FO^TK@0N,@;&&\V$6"Q%<PRYA8T[OS/<]CN@=HHN&/"
MU.M*O4B#\Z^TK6%$*W[:@,ND-B0NPC\7%=OU1^9WC_9.**D-*)492\K(-JUL
M?O\7'&<SF6<8(LZ IM?C30J6 5 *H=$,=B6B'K]--EK'0]7^M8U*D:S3Y4W4
MG%J'8X"X$<-3:?H+[7TXAG6&D3-:KY0+W$[=.?_TPRQ.TD"$BI^'2'^NF<"C
M(@]I165=FZCZ#'OO?S8M_2=\Z<YI-824<'0]..L6KP5ZRP"^PY^H/;K+5+NU
M=[_)3/=J]']^ B7!Q8N /:S&:!1%QTMH.J/&YJNG6@#+X>_+QAT[K5^D_%UO
M&.!=7,0*X^,3#+@PY[3%8*S6@.NR0W!WZ+@J+B"QS"XLXD;+<4!I-M8T;NFB
M49P>7_H%CH&;"@S0[WUP.G(07#'1BMB<1M*!1/*GQ%R/?3#CP/-^7TO/.6$D
M)"'"IEI%M27B\AW+!"H^?IF+J!F>JB^2J3F8!,;]_M'ZM73/LGOAH%">VK_;
M[D/LLS1P=)TG7@^4O>C<L-F(M/SF7,@YB]9TG'3E&IMN*)11"&DSIC N9OP;
MJ?@1N/\<9AXSD-GA7+$.D[O:LK#4+\9E;EFL+OC;GN^P=@N>]. )%:_7C,/"
MV?3-:)]L!71.UZ9SQ"UH=+O*!RA0U:LA$=/TZ5O;ZXY*FPTKLZ3DB?G!^KHK
M[#<8GB_MUZTK=%'9)BAT>!%6&-BHNX%(?>^%*BF\%U[F-A$XOU5)%.O\[+Z[
ML@G_FB.6#UE\P6(@.*"8#V9C>7[+[JN:GH':9-_7A53WW8I39.9PO0*J-P&8
M:(Z@LE:^=^%7\?'?0I;5=='2L <V5NXU>:Z2XY!J(3N/VK8B [%4 PFQ? .)
M"HE6Y=.5_D*(_2>:6 @_6.[_RZ8T$2:]MI&J9%B;I"HCHW"4\4HP\!>[6M%H
MF/N<?'-G1ZS90P/V.X8::H+L2;SGUE^82(:(I@@[%;FJ+0RV#MA[BZI]&=%R
M_[DP';PS:6W5,?5Y7T3WOL2K.,OL:P9=9^^+I7T'L1AH1Y06EK48A[[>V-X]
M??D5_O74XCYIL;>&R8)OOU22O@I$U+Y.8FR[F<KW^/+=*TG6!-<="-$-?AV(
M5#[6K<(N+7(UX<I>6C[N?J)4'W;"9K]VMO\I#>2B]RQM^^+\KZ @,2IN)H(Z
MCKR41<CJR0M^T**KL9J43&!E?7#G"^9CTE?Q6HJ2F/5'B2QU4YM,%7OK05*,
M@>":9-57EN?>+#=[\6*I:]Z*';8,N\NVC(.JC17\?F2)R1>9@;(%MTK6;GV$
M?=5A3DSTR53,344YSOJ;Y7S.W,RMU-\1B58V/_>&A7[TV?D;6MAS7T0+Z=[X
ML2JC*;^1_TM5$9TC^L0?V<V#=(< =N#&FIGNQ<L>8#=25M?0NZ;/*I]RM>:/
M7@9>G"^TUQ<XI_QFO>%MF8.#D6A3%H]I+:?U;R4H#-E]BP9R<T>Z*N"&\#-Q
M>PJXT>X%I<Y8_%H*5PD;3H05R YHB#7O%$N:!8(M,B>@5UP2W3>Y'N>*+(-1
M=:\ND_ZLS_>_%Z:CKQ=TZ%&6&&CG7&9Y?O]/K1#VJ<Q3OS9F"0E9LGC%>^?]
M#<S\$$]"]U1>'KV)2".,8<!O283=[V%@Z$BF6<[D:YV\LAT3-=G^&DF+OD?6
M#8\%G5_\:(78Z"5+CR7_G8,>L5G)R=?*>M?XU-@/!+KX7IAO>OG&/"S$RBTG
M@N5<T2Z?0)8T['K50?<!**7P%R+=FI(X7F7-:I47RB6AU\'XIDJO1EWM4:E5
M;OK&O[< [KW(?50L-I&4ZOD(67<SR97OGJ]%5%I2L3AL\*95NG-^LC+.?3<O
M94;A#%"VV(]@&]/4]>[*V5+K&W?F23CF8G,8N&)^KS7CX6?_-ZEEH3,.4$[J
MH+:"2XX#T7@2(_:6!O+>\!B(?BM\._P>YZCU>^<(.$O\\S4ASQT/&JA"I%@B
M\3()U:U-OYR-%M4D=-HWO):(LETM[6T5I8X.H]2J*CU%K-*5;"^3U>RQK('<
M<]9_5P8HMP"+1*7G^8J>3(PTD,W0+&2AZ^E,"U9LL7>]'\*J'EBA%S1A^J\8
M7N/R_U'WE?\Q6-\KOT'P(L;YIV.0OG@1'(?A)Y)C0O$O="-0O[1E(9$@>XWN
MY%GQ,H0Q9Y'#OOE>B3;3CTJF5$1.W863$DVEJBWHI3U-?;R1N@\\A-AB]A%
M+=EYFFK/5G@BF-(]9A"\:+\[*52./'9F2+>J2T+AQYE=LY]<B:RVQ(+XIA1^
M (KMO$$\^64;$TM(YC&9"<A99[@Q_\,CJ'[>;I3M"H= R<N**\[6ST2/FFX
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MVZ1SV"S5^\E:![>U#*SPU3YY8M&! B\.FX_N,7G&&M3)9=! ^IUB[B+L@1A
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MO9_W4?N5HEF#0VT6(@J+C 6S4'3(RNNAPJ^"57L*7H9:+GP.%"[PV I!$N3
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M'ZAO&"518@HO-GQXCH?BV1? QQNWJPWFD!RO;S(<%(='SNA.'8*?(9_N71C
M(R..$8UB5U58!3QX0K=_9\C(/+XKZH[S:G^9M/-J9Z\T1<MJ.S^VH,8SG7@]
MC3MZ*85NG=A_[=3%^069><_<^Q8P&R)O<A$DYR\VHE\E^.O7C#5TXJ\>N]JE
M.H7N/K'R)Y+WK,8/U#DKAZ8#!4LHL^#W?Y[;U__-!_-<GZU+J%%;+-4.JM ?
MYYR\TEX4\=]%O]J@%T%P*/[%G2M;QW>NO+Q[D0JZ2Q=!OQ39+>2979O3C?RM
M"D"I_<RGCF*T5.TKLGM  VT-0T^NZ?U 'B6('!QG4;,XCJ5.K3.!$EQP:'%2
MB#@/MR".OJ3($(;&B(O]G4)>3+:L9>ZINM4>5MM'*?)YGK)EA)GMEW=BKC\T
MEA0WN-A!QO/L!)93'IPD4,+)9E"*-/'Z^].4,4Q0VX%+/?LS6N28S!80%#?G
MP?&X9E\/N2.EV2THRS%HW#KW Q"@,H710*)9775D[L#%$S4#A[7M5AI(,AF8
MIX&@CF ::,R1J^Z7^HM=XP0B!OMMC2W"TE_3^K*+C;8H-XFW?*36SN[VMPQ[
ML4)&4DFABI2$VH2EY0DNT0CY>((@N,9$@,:IZXD(2-MX\UP=5@KEU=5AQ$-N
M%J>Z>&?*F3P2MQQA8?-@+]^X52?M8Y%\DH7QK#$Z'#QIZ3SC"*O#^T1H<FHR
MXY$)WW%V,(1GGCFS+AI#[_#MCT-MJ<O9WD/DDUFOE>*"_?AWGZYZ;NT!SY,5
M>C'-67$TD!.8%\Y,#*I9^CQ$QC#; 1$C9\H7YV[;AG1Z8XKG']<DA7K*\.XZ
MMV3@N,1'SQ5\@0!BHY3\%&P=F:<]F 8JMT)#BZ!-2 JG*SYK>XVT1<A_A1?Y
M:==C#>8-L%D=E]>6&UP0J.^8N9X-ZG%XNFS\70YN$?:LMW+44R+NW)</KR1'
M]-']FN*Q<"^[&  97?7L!9;(#-Z&RXNH9IY5%[[9&9Q2<>DG01'V9;**D3?A
M3T[I:%QNGI%>P34387UZ7T?Q%Y8LHJ.?\C-M-/6%+4/ZKW>:"<+_M(M?2I./
M^ET:T_//FDEZU?="^LKV3[ ^"^/)U:"L7VL43KJEM<C.BXC)139-YB4FR?TZ
M^K7[,TWAW.S]S&R:=XL>>V1E.WSP%OV(GI27[\][7B">%VEG>X7A; +0V4%'
M0/7N\<!=@$A"07RG1J>#3I^P_.2O2;14\5VNIBM%=]V?N-"/ICTI^ZGC\\2)
M378,-WNO=A>?UWZ,*8$A&5YW.=O<HE/N;7_F$CET0^UYD-2(I; HCPZS2?ZU
MJ@IEE-E(M?-)R7B>T9]A*8/BOQ/:??_X_ESP21JZL6@Q5&^3J<KVJN=WOXAU
MCU7OHXI[J2A6O^QH=3WM$>:>O-9K<T_?F>ER;>6;6BLL^S#A@-D>83%B!D$4
M2Q 2,!WO3A-X^JFM)?6V47ZH2LU8S(I 9;LA]JV#+FCI5Z!@0D(ZWC;/T/):
MJ4FUA(EOF"%'8E(1)=<.,MD6*'%*Z";2DC9&5*Z*M[LR2.D9#2MG@W-RM@R:
MR+-#3%%N:PUMGYHR57D#PD(<K_$*Z\!;11<J9YJI8\?\,.1R;&\B;_'EV5&"
M3(?)-)=I!5=ST2J!\X[:#TY*YT!%'7O=2OLS(;PBK%HV;T& S38R"#TOG8H*
MTZ:T_"V8^*1YK^_)C4_EZ_5JH5SC.SL5>J6=]M-_/IXN]%N B"L5BV!.Z05S
MUU)T T&9L]VV8ME1NI/I_*^+16UL'J#>KME^.;^N4;>P ?VH0@1OGRLLK7M)
M\:QK_P=2">0SJ8G/1CS??BYJ(SH_^0I6^T/PK._DLTZ@;IWE0O< $_:=04DZ
M*;4FL7Q\ZL]P3]ZBG1G*9%ZC9K1;;9%'UOHR83D,R\"O9NNQ4U)HHB(-G[=%
M"Y#;_KU0] _\C878T[=?L*GEW^@J+,40106&E2.#"3=/Q^U&1<9*I;E4T)&R
M5^>\3GC+.M*DS3&';MN:S$=1 5+(&HC1-M;^.@Y8%N1[(#@N>^^MW/S&1-U^
MV+ Y#=3+C][-\0ROG'N\D17/\E[05.)'-5>B\4I],/*K"([N,(^(W#$BA2U!
M$Y1'HVXA+\&=2CPT$.^7_\I2>Y_#=</E6SW%B^VJV?H"-;E?R.BN;A)+5Q_W
MGTGDW4>^+&@Z36K#9)Y_Z_*)9 O =9F5 \:R*Z,%T2?2)<*5JCSJ[Y9LCL^.
MB!/S,<5,B<E"\DL9^3U]!Q?'O'9KLS?#Q7^6,A^*4#BS\ /8>-9M#&ESIHL$
MOP74D,X16&-WX&:%->B\,E3YW3 OX;J ?(F$OG]B_MB/R_?H7D<KWW0P5/+X
M'1V.ILRDX:5>#/",VTR+L.8[P;(X>KENRBL/*<WI23=+9]B+>]2=RW$!/\[@
MNA<C5/FB2H\#:UK!#Z^%YX^+C+WOE$>Q$S,@VQY 4MH%+ PA@LI_X>WZ%D^<
M?#'U) D[\?JVU+"5L$J>QP%AS3S#'<OFF%OI+RE%5O_+0^$>[!\<(*1TO]M^
MOO-\V>?,YH74Z06!P*<J)P_/#C%>>0H".0L&U=) 5'J,YUF8TF'.5.'WY^AA
MQSY-'NT"=U]7H<F9%NYLUV1Y.67@:X+-R]96ILL/]%;=+W*]D[^!64(["I&$
MT22=I5]M$K&:.C5]K*]4Z%>S]+ZC'6PEG34.RWK42R9VY,VE&#_^DWJSWISW
MTF7/RM.4I\'LCT6 3JKF;!8W0JEIKGB[SYY&)[=@"CMU2]_;W0-=5MVSIK<4
M_:_$/%C*GHN?2G\>\(*5Y5IEP=@,@XG*$^D1=8\7&58EDY\J(SQ0,H=O(]O,
MW1TDRIIONYF_.+ZW+&V8NVSP:$#-V,)80I@KIT/;97LN(R?A9]->Z3>1E--$
ML1.ZR-@IX48%GT3BB72OT'6L6POL4_"0*C=AA<:&[]OM#])@?A-6/*HX\8Z$
M>3XTT[,)RE8<(?78R W+OLFZM!).(E4=]IZT4.4 <+\(B_;U?Q5R.X4W@WU.
MZEPDNCLX[D7]7 _]%EJ:-.X9ZAJQ3YY]X"4QL>,M]LD(,"-$1_>F, T*+(6>
MI&%W16PNVB26:C9>&5+DS;7WF"S%MK[V?(>7'HL13G>;K+&XA0Z%Y0<[&.:I
M53H.FZ>FE_PJ_DLGO+8'_O8QX^K[M9_Y(LQ1 876<3<I=?)]$U4:4^)6>?PV
MQNN36#_IF\F&#8$=Q14\7!?HKIWBEDYM3LFKC[D"+R4QMKU]\Z6K2HHN@L_@
MO/"',5T0@@'Q79L%<I;RE+08NQ37Y]PVF5T:\2JN+[_UDFVO;_?LUY:PGW*F
M"H/Y=Y/.-'(M9QRY[I"*Q%&]=4R>]?KU*@7T ^Y*9WIGLAU1Y7SBSS2SN&<R
MWPIWBSYTRJ5(0(<%=:(>7]I3ZNGSZ\F7KZ[HDY$<KSQ!2Y;BE#=U%72.=:[T
M#0FDKKQ[?VO-@L%012#8K\(@C#_5IQUE EGE--.%#7S\KY/;2L.&AE2^QS??
M/+B:'D$O>O[RG2N1N>-F>N17)U.G3 %,U:K;X2-+P:5)!ROK'23=S'B>*+CW
MWI6P,A(T&DDPJG2<+S.ZC^O-1.*(,O]HH7^97S=[5=?H^3?EU#19X,_#%0;
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M&DN*I3+7SS0)"5 9O? Y<LZXQ$4.^#4@IQ#F/*?]%=QB/F,T8V\3H2@^]CW
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MQ%F0L6E(;^S<"0-!/XGT#<D)*!S9[.K/@"W)OHQ3&+/8\RUE:P[X#"#I8[8
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MV']IQN-J22F1A@WULZ6M>LTM$P^GWG]H]6DZ%RN(2:89GC"<>WY<A&"#A>%
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MDJG/>(4%\[2K!6?93[1I0*8$WZ"=)&94%Y!*V_SG2)\^AF+2X5_'UG_78>H
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M0D/C44W92>0!$KIO6#?AA(&+=A5*SL.!F!!\L(9>[*5&_]@3!HX0MI3+0-J
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M7D$L#=<N$7>%[%F$=O)U6!Y][:&.KG#:6%FY@'E"B/KFT?@X:\]Y]G<3&4O
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MGJ8[FWW^HJBH=>FO7<_(P)ZYI6. A7E6 ).^$'?@T.LMOG^EILP9]SC)T?@
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MV+,G,7J<;Q1G6_ _*LM-4!8]%AX3%1*@[R42J7AE(ROC3 ;]%N"&>O_H!JQ
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M-_7N8TAM@ZRDQ_'"]W0$D]&\M75M:LE<UDS/H<#34X4I7%MP<1.LE:*T</'
M_^43B#YQ(0I<[^C-928CXTY$158R#IM)7;$!70P=*\G6V,.2<71EYOJ@5/]M
M>:14/>N\];J>(R6%+-3W C 7)D&))U_N4P-GIEPPN OP[12=^;6K>>_]^O$U
M=/FR;=#X6VY51-Y=)2K4I7^J9>*Z\<_KRBN&Z1]8X$ 6.=Q>Y:D@4R@J20TB
MG-(QH2^=2(SK[4_)Y]6!?X64Z"I>Y*?^LCX.] UJV#15N8P&G7THWVR3WK9-
MCR^'!BL5>?':;:KIY@<5;3+=8"W,U3F(F/YM\B<&",B0V'U@45<8UUX 1_6>
M<4U^FSZY1_"^28'9IHNO9MB0?K97> 1C:NR'>6?D#,HVK%YD3&C[*9@:^K",
MCH])F0Y+M/<GR/VHR)&P8)T"^G\OUWD ?9Z0NIH%93'4]"A>, W4;RZN'%6$
M:G7W%*YN#(XRW$NUO[.=C7=K?3KI$B2I/-0XSGW4'(/0)M!;'.PRP<,=9@[F
MK@@:^ME/!TB[V/H\TV]BK(!:6:F%TSI_\<3:W_S'V?E&2I8\I;FO%I9(B,'8
M7(01X=^S._&]ME_"A-X:"J3)I3@:3$UE&W+\+&:$/ZP-^VDXN#<#T)%UTD[3
MGIWXEJ@,E#M\OF:>DU*,@DEXZHIWRUBY!A0(-%5]6=^![K?%5>0U9-PKSX*B
MTGYNWEDP\_Z@M'W@4IBL[["6MFSS]$6ROO#?\+59UO.U69I-=W>V>7]QGNG)
M:MG^S(V-/+:31P8!KB*4D=0;,P\ -REDQX&GOIZY."RYUD%WY_5;<GSZM>EY
M"Y7]@C1CM@- ',(0!5?&SG?%:6C!T]4TX]VE=W:PN2\>%E;*?1PV\%%_18^Y
MSJU?[)_(]N$E(!S)T7D'VL6.":JD#("8M>DGBU?T<#F_JS-0"WDR_8//@4'Q
M-!6+;;R&OA/ (#\PXX#J+]\O==82]\ZIO+XX29B:AAWPWL/ IE],^4F.E]3[
MIA:QGV;IS9.,]#3&[D8I-0A,UOWIKRR<:;=B82_2C>M,2INO,G <3W"1#'E4
M_Z7-OR!.DN3W6^ZOU\M_#W3Q.97S!;>0)M4?HBG_$-_)1RJ@8VWY(L9&QX1Z
MSY"1(LRE*AZOMT+RPDR58NU.K86^ UM+H+X_,M]D576WC!5L*G'W_A-&SC)H
MCSJ[52)$_]VN&O<N//P=6+5?0SV2R'"34,T\8&;QW-X,&[3+X"(.'+'H6?_@
M*"G9:X98WBG18U/9*F[[$:RJZ6(E.K)7N1S1*NEJDTY]%R4=.M_":R%EH0JI
M3BGB*.Y(^N45FK\ H<MZTP^BJ5M?<Q5Z7=ERZ\WU6V_HE5KRHC(7PT0HWJ3]
M7GE@?7'K*OCZ9B>TYLF>XP]NQ#[BTUO@ESTAWKP<ZZ<'U?-=^!F!UQ7IQ-K6
M%[<5P?_$]ZY6E(FR5SC!C"+-"0?Q9B7"N*G[7&??\!58EB@L =*.O?D@#:Y)
MJC!2%#S;$-H1F!.R^H-P^5B_*KEQA!%#)JY;U6>CV_0@#,0!NHZ0T#QP#K+N
M#'5H'.LVDO7,-CVRM%_K!\[NO>-26,F7%*Z3 >0X\)RJ0'9NJ;>>P(ABI'NR
M.7F81C&+42F)*E[ =*3>4W6'/VH<-^MQ3_70D5;UJ&X&Q&">?Y+BB%&-M!Y(
MYTJGE1FH8K8?8Z@)$,A*L^?]OCO]UZ_W-]<?IO^SI5@8[)RJ6[?+FY9Q=K_;
M5B8:_[GJ !R_PH1:PDMS[+#3EN7PT_L]&%=LSZ.#'"7V-3;':OCQ!O\R@QMT
M$YS\JNV[-? Z;_*0/M1ER=_FHIG<WC]&2:)VR"WSN:.I,BC.PNQRBPKE0K'Q
MXB)0Y?+;"+NI.0UYZTP5-39YQ?5!8&I0X<Z+GQ,)SNEUJ863SND[A:%39 $"
M&@L(/Q/(ZP.S74C5<ZKH,/YFG7<'WESP: /2:676-Z8^OK+):L_EPZ#OKJ^7
MYT=$6UIRDCF=@VQ,3HB0<ZJK#*>QLHI!OV0I$$!4$W=5V[S&=-O/_%#\IUHP
MEF\DK6<1'FZ,DW[:V-Z8R5,!:RD.@52YQGU7M>5B&R-+DWD();W(-_QB_/*4
M*D(+)J!\.*0@ W!3A+2)D(P4F30E)AVFZ0?@/%?'8BVC;WHX"CPT3S]U2F@F
M,U9TK>;.:-[&>9W):J.0W9H(UV/O/^DKM"/][62KGC-PW F3"XG_'3=$WF:C
M*7.D4I-GDBT,A[=Y"D?+8)39TWS4M(53L. R>"1>084%N[T0)YJKX>63+M6!
MD=;H8K&303I\(7&*X[[U]'2Z6$R4Q):I3"6JZ8^]&TIUH1D,I0[W]]V]B=$;
M;-&^UT,46_M0I#$^U,08HP*.)M?DTDKTNT#TW>R=XCX]W[G>-BE>GEIK/6\A
M:;:.BLPF*XJ)(STUN<A6D2<PU (EOCM7A/0[_@3P CB_M<P^_6N,Z4>S5+Y-
M.KW5HS9,[8<T!P,IOWHQ5RDJIYS-DW\H?L>/PZ:0UQ]ND;!GUX<)>9<&?)7&
M.*(*R/Q9M&7S#-+XK^E7A262WK&H_RO*=FQ&,B/<Z2(;X_O#B0#6$T5R7@_@
MYN8-*;65ER>!A0X;W,OQI0O/.&YP.PQP=>*>NH^DHQ@H7A9@V$_=RW]V1<=(
M<\T_S6%F?0_R&BINK-9+*;)7%RQ)M)RPL^199KTV\C%V?)J=A$. 2"Z:I.6Y
M'. ?2^5H>?ANV:H\IY?TJL9OQ2*0^;HMZ[Y45WA+2<PRFXI9ME-\=AF^PHA!
M'%0F-A%6<?&>8,+N_D_#AK\!%]C1^Z@<<T[EOAO';GIM?UM!$LRB)?A4_THN
MXW1#%QN&7,.5B&H>+Z$C"K1!6',2/AVM1S3^(H,C,.*$TCE' "L<C%T6UK/W
M=)UI")&VL7EQTOZH_8HGD4\%K4'!$Q,%NI>O3U8VVJD&<)##LJK@T.5^P5+A
M:%.<2&U7KKLOFU-3<R=HZ.[/"<'R=Y@W9H?V9)$F% FM14KZH-"6A!U1PF*M
M0$/YEB'7.R<R6;_N"%\Q5)J3BN-5ZTAASN>_NY)CW)]$YT(0$;@JV@<7(<!Z
M)D=_D+IJ^C$/:Q1]I]Y/@>VMW3/T..L6A?T VQO.Q,2@P&,H%J-^&%W98A"#
MK%OO(P]+=/*E.KTJ>[\_8?)&\(WT1-%QAJF5?Y$="RBZV3R'S2&$P]2PM M5
M6M"I3SZGZ@?PP@,/ATYSPJYO9'"#X-0$,-8X@5^,;-%P9&ZVN0\]HVUJS-!*
M,9Z:UU+*\V89^OYS627'JYMF^Z7?D07WO2IQ77:,N&7EGRR#Y$15BYS*7$P-
MHL)MN[I9 ]CHHBN7BH,&>(S;ERF/.59"'OR&&055NX\[S&V'>NH$$1'F)+43
M@\FPFTH5SS5"B^ T8P37PW>G&64\'A@N9#E,3;&ZN*VFZ6PX/7#2GQ[$4JSC
M/Q\!N?3X<(N5U'ZR@SP.._O"[LA. 1,^(VP(I[XK1(>2!)DS9GA(3Q[MA=!&
M#W3=Y/GD*,S/1G;+P0.BCQBCO4_ 53!;W8_-5A,_FM0>SF?G\N$4D2S:T"/^
M-&3H56W:V-*)DN@JI3^VWXI4'8Q8RJY5<9#-2D ^NYQ&!H^:BN'9]]6/@;^<
MW(7_;#Y0>IZCYFO;6 FU***>#[C-44G(FTNU&NFD/:W6O(30&@]CW^KD(+_(
M#X21H_N#=[%HZCE'BEGOO%$[C+A"9VOO"$_I7E8@G145VT'/J,AW7J;7=U?^
M.)-K&-]M6)@=25R\Z7"3#>H0-@FX7"FEJ;Z9F9%H!L0AW=!,-G [(M]911%T
M/J DZN#4 ,O/1X[**9X="W*G"Q/.,QG7L,'ONYZ^G'^]!+6-"-:0.LK4?X;J
M(9AG\_.W98[W3>3=#9LRJ4^2WMW)+((A;Y8B#&]95RH4%->RVG.W)9=1LW=D
M-(\OC_T6GSJG0D/&\)._-R7[-.D10:2\ 75#V^.>3D8*'F\0R@NI4CZ10;Y$
M<FA>,RPMKF#KG9Z@A#'&=3*3&CH%HU1V9E<,4-+?@H,RQ[VY68*\A,D"O,AN
M;:1K4G2N CGOE88^H8NGJ9:$ZSU"1H2)0X.I>P"QN:(D9$^BL55;;<,$.DR<
MLJ!%&KE0+9W\<#^S%)/(7^=4K/!Z\XE?/,-PV9\?NT)"U?8>V<N]+T\3U>6$
M[E<8BJKY%*D:T1A)R)B:^L9Y^>@W5*^Q-GJ ^O!.1HHEL?DT9IX/"LM[Y++T
MFU"BPH43"5G ';'!=N'Y8[>X/V:$E1T4B6=U($Y&@X, 6XGI%"7+?, OR'+
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M\+ JI.%]Y;-;HW]<W]5PEDIR)W_1E1S6O'>&RZ6BZ'G[/<DPA>?U:]K1>C-
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M&!%>G%,)]1&.NOWW(<+Z#J.0"(#W04=,V85H/W(BA)=X!_P8VRRS9<TT1DA
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M7A@=0M-L1C,D"$.VB2@0+:P_),H90->Q#/*-Z .<-[C 4X'SG(K2]2B)> <
M%: )8XA^*HU3^O+AF.2+N<<8GTB T*_?U2-+Y^NFJJ8B0D*1UVO7.U<&6CH>
MQBW&PCA4CNN91Y=4C4_F\TI9G[TH9.>1I]"Q=J^Y++GV.E5E8IA3@X&&>_4Y
M76CL=:[U>E7]V=-2<[[=8A@KFXW7'0@HTE>A&_@E5B0Y*DU^X#05.$)1B^=[
MS<1-$[A#LZ&.&ZCU2RGI-E&B-@(AGGBT!?PHTHFI>Z#KUPXL>Q:6=Q_D/2J
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MJ/KG=-_*'MZES&+B6P1%65]H&?K:9T5IZ$;A7?;!1L2E(<UHZ&3(4B6Z>6;
M]CB0;T[?!SW9,83T4HLE!Z3!T\T[ M][%,8BF+:\-T.[('6S7AYKL-JN5\/!
MP<&IP7/J)\>>=ZT<7T"'HI<J#?79!5T63!CJ'RS-T?89L65U<X4N\];KZ!31
MWXFN\Q9^$OBQX,@NW0K9Y0VSR'&<M"6QM35VM-Y?E>A5Z)RY11<,^(-))<GQ
MNWF<)WQ=SSFL]W:T[AA:?P.?TQ>F'LSO+#,'Z#\7R55N228Y5QBEN]J^T+&Y
M[WAF63]$]_)F2=Y77)$-SWDH:0([TQ#1,!;ZP!:<7.;< G/(5+4L]]FPT+6&
M.:?&'#B!-P1>Q%.&(&V5)?SM)X?;ONI .,P@?E:$OUB!-)'T)2((J3=^0!";
M@#<6TRW@1([XF'8J.57PBZ=[():GF>>XP96PJQ4S*77-&W.1/&L1A<PKDN_U
MSLD4R-!L9#+W08>Z^%^C>R-NTXF#A/A%@43JSK,>E066"EH(:4S+2Y3IGVLY
M[;#<G'<*<;3%&C:'])5G1?=D,[( Y#KO_8+*DD^)[N\?*/Y8:WGTV^PJ0HH=
M&_!V^<F0C7[L5=611)X)U^A)Q<Q^)Z?S'0_Y+F)4^".J_)XG'3!UE:);Y625
M^)7+7Q?N=XZK]N $'3'13J5/2BTF^K^)=0QJ!ULX$9Y_8@BO*$*AX5;4>.^
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M)1US\9H8^>:;FQ#B[1V,(JP.LDM8B[%-O A\XO?'9N<Y5R85N@'KO1,H.#L
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M'25O)\#K<S=+/)E:[*[]'(SH5\AA'=QAS.05%(YR5EX"[<^2Z9=^2%RJ]1N
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MJ V4SR.<,TU,SRYY28J'922"G!2=A$^)Q\@ 11U9A_=!_4X! 48\+/].67"
M0 [Y[]X31L9$5)B#2=!IW:A!Z7+7AN]I- BG_!CK"/=C#H.'^Y;<O$59:FS\
MY -AWLPSA%*B\&Q" 6; P*\,/*H@D>F\#WJNJYYQ-F:3/@5KCNOTB'',_1>Y
MBKTG>!@0H8=Q9+8*T(8 CO&J71IMQ")M4!F(4\!('[6[SI@&$? ]8ET[H=MT
M[JY=YO"D \94/CSQ0?N])!_3V$N4ARMJCC!UVU4G:)"MA^0D\F)\4-I*GKFQ
MTNP3<]N4XG*3RW0-ZG1I;]7E:$6#2O*)9FI6#3PWKTBL_R1Z[(F9>HL3KG^1
M(S++/=&R:W40&,9@>:".3GEN9,[<I9EV!9Q:Y_F[AH7MT66=>0+6GMC\5T)Z
M7$XFLFO'ORA4M^3%F<Q^(K+Q8E=)0M.7FI=TEQ;U;Y7[(%VP+D<G86FJ9^05
MCI?.&HG"**;$YJN.HU7U4XR.Z6[V1;::/\6+QG!_=OU<LV=GC3FY+.X18$^:
M&V*NAWH];H$>>\#]!EEJDE,'&G>/'+R5?KL$6G@OWNB\_',P:/$OP(+%TY<O
MV>0UA19;^E-Q-NL.=;.J\OV[9 ;=;JYYN2_!Z(&7Q';CO?5-"<R#-I0_Y?EO
MJW_5$H^!0(:'WHOM* L\<-SX>J5BH!)J-;AF3S0]%!EU=QT>K:HR4*)4MIWA
M-+.6]B0^+77;58:S#WH5M"%NK:'E!A7S3B&8B 4"30/()+.)^'0?&K'%>"QZ
MAMW0$K@,I/<4QJNOIN3\CZ>' 4X ^P'2BV.KZG.+%Z2JG)O_]XT2PQ&.^3[H
M=IPE+66O[4^TJ+7M[?\<X/X/VJ%?N(VL76O.WWO)7'U4. /;U7+MO/.XSI"A
M*W/Q%><\_:PJ<S'%2)"><YQJ9+=$.BTI[,08^SU[7*@_\&B0I4\@?]O<Q7Z%
MDTE;<CHL;XXP>Q_4O: .1-.T8R@-83F5QN5K.]KO9</L <LBCN:HD5GE:MHA
MO&!BMD0B63L>CC+M:C_?DN8TIH0XM@]"(@TBDC)?E#K-.(\$&B'RTQT4[\BJ
M9;17XYV3G&R2U-(*[&WSG*W2TL_:9*Q_6 9#7R^7'X,CQ<X5#Y>A!NI7U01T
MRL:2S.P(TN-%UO!RE=Y+N5>S9JUBKUT-AN,47&G*HIBR \V&Z9,7I=RSG&YD
M.P"K)=R)=F&6_,8?1D!<NT9"]^(QM"'3I0<CQSHE!VEORI^UO ]$,_9!?,B&
M,9\G4S**N WOD>P+)M8) B)LO3UB^U%,+XZ,2 *K \$W@%'6$9H<GNE-3^F2
MYYL!$BP!; ':VB"E&\(W[6.%Q)RG_B*)(% &,UT6$_>:?=*@4R1_+RIX\-RM
M*3\=(6ZPM1/V@<=>IE)DAO=-\?6!2@F;.7CW>*@O5&"@V)6@JKM%%E,J3"63
MN:/=X:ZZH=+0=C&/ S&':V?$$*1M/75FH](]3A"^*RM5S?HM?D< RLJ;=@?5
M]G,CNYA)ZOOOZ)<>\"7F]Q<T[5?Y<DV?T%)*2>(MUT826Z7*@0>=]/G?ZYOZ
M%N+LL&>)#OHO78K39TW_>J&0<T]_$L*$X0"UH:R-:W@,55HB#B.%1(C\PL;I
M-Y.ZMUX\B:XW8P!.N]>=S2L)+UM]L0(U84>?///*J&H+V9G__H*]^7!NUD4S
M(Y=59R[/L!"M<;+GD]GDUIF-.V:CGH4Z&-%S'Y.1]D6# ]0$FW*PMW@N_8\7
MZIN1ED]B1[A@N:WM@G3)N4KE?BE=(SNU$-_@8*7B7%6;9;B%B?77)#QQ>[$3
M.RMQ@^F]\7H7R3G*RHQF:(N@;^Z5H<V7(,*K^;H-3:/+HSKE(Z?6><M];5"5
M6UM+D_[^9#T!32^J!NE01J3KFRFEMB(N+V77@=N[#ZH)B-\"7T#_3=T'^1XH
M-5N6?"?DH)J>0)O1L$< SZ5_ !_"*D7XGM^Y:\%=.P>SN?WL*EBK;3QD2'AA
M8,W\FN6M>G+$/9</XDX:'B]]*,HJ!!?-+GM\_+][Q:H,-;4WT3!TZZ85(789
M-M0KD"'M4SKK.*\SVSKZ,5 422LWG1XN$<@AQ(;^A>_?79WZBER%(?%.]2M#
MQ4W./NKA"T4^NVJ""<VVTF#*[AVS7<BU NQIY XI"BQTDS4@:U89JG__$^>J
M%R,A)59?[XB5M(ZO%I[>8I[FJ40Z^\JUPU-L9!%+IFRZ[/)S/\G766[T,UTZ
MV-@&6"P]95J0IAS'E>'H37#L:-K/$V@CKR2:OQ?YE<^N(4[#DEC:5A-H?1_^
MY;+KC]LE:B>^[BJD*%BULLKZ_X@8N[GR&TQ<('N[G%Z)0H\[Y\)7'N>IPGQ3
MQ])7QW,50P>]0\44BDOR]4*(=)\;&<=.P:W+<A46S^49U$3)7V-(VN)Y>Q>V
M+X6E613]YN%*+[(? G]V+Z!!_QET/D*<Y#REMEKN:C54TDC1^R!QK'>"9:PT
MNYR.B)II+] J.P#AX(+_'%6C'OUBT'83RELL!.U'M4*E+ IBPE\QWO%+[IB_
M;[\,>!YHNLM[Y9R+X:RT#H/%+FU N6_#9E<?\7![QXV0&!-'ES_*X0>"/<,)
M@-[/;O=+SS?: 2)+I$]Z(7TJV_VU9A=RIN?W0E:1>1AA=>09A$_U^OF_Q$&)
MIWE!R>_NGCCJ7?.A0LW+UL^:MF;7-8%U"GF OVK*:W2_J<;N\:>5V+IR^(_'
MN,NV7DJK/3=L".#XIY5>:IB%/ WC*ZV0AJB"$ZVVCP.7N^#=(YDPO(KSR<#:
MT(/A4M:5?KT>@'MO ^SLF)MCA5TXFCF]80$^OGPN<ZA.^5A2U0<_6MQO*3^_
M!RPUU,/"6U,_9Z\KE8K.#YYZ8(*8@,RT</GX=V^CH4!U ,2+$H<5I7@CIM<[
M,4+,E!=@,;1",I;73#^V7IOWX>2. SNY.),MO1QEL-"BV;PF7>:3G3AYCW%8
M^>Z_4XS?8E27(]'=MD4.0B:2<1ZKXP0SA_CR8YMN^E>;@V$"16QK:!$,J@75
M5!W@C =^KKAF4,_\3;CN0(3A38V;;=+PFU?/$8Z7$ EP"ZJ%B65&O_Z)V>W=
MOP^ K0>M.PF&<+LI9/U>[0,&,W)C#;*QP!&&_ NL'-JZQ!VE=I/UPM\O5-WR
M&#!U^QUE4N?/,DLDR<0%)S5(NEX2D_OF%XY\X_4+IL,&[H#QS[/14Q _?H?N
M]M,L#$5P4Y>I3"=TIIPT_M>L0*%=>A(=P>"7[\[V+Z?;$-?$XY0R/'Q+!@,P
MS>;N"^3NUSF^3^\MK/_9- ZB]E>+%L#358=UUCHSKEZWQ6GXC'9/],"CQ/8^
M=%;Z_"B=5@FB O=2O^4')!/A>4[CB67P/.?7:029YHSJ\<=D;_T C W^!DX'
M_V1E2'_+K'%'<REE)F5).0YR-^(\6P/8IBTF[I@4,"D'!0AS%:T 1#/=I]X_
MVY!N(-&W>-8P<I-&ZJSS)JR55QR]D#TY]=60EAQ-1)>IP[C]F.%$^,6+T0I?
MN5>Y4^YR0-:N*J8'=P@M7X1:Z<S7V<O2X)Z;]>5>S+*B;NCL!2&D4%E6D[]V
M4WCG'V873&DL#"S\N!(@QY7A-?J-K9,Z-[.R-*->X 6@QNTT]2;52O0N!OL+
M==L3[#.<3""#<-VRJ]<;Q52#C4T&/K=BSE)#<E[".\<Z!J"\,,=GNJIV>!ZM
M7_/2@8FI\"^NM?Z;N,+%:H?-)CRF7UZ$$\$:[,O$BH)5.#;4=D%@I -;-S>&
MBN'WO,E4[M:6[N*/6C"8^F[D4-FVE_I03WQ5*]7(T!L;>NU7LM;2;6NIM@#V
M 8R]_(B9D3\.AG"N %FL-$9L]SXH:1]T*B3)WX-E28O!A]+2(^GR4>0<F2']
M;H/[R[\.BG+YIZP^IS'Z.*FH-LV5^FM5&R^D_H'R>MP^M#:7(J)QBR7I;(>/
MPTM?SKAM H]6Z;6V*E BW63D;IGUPH*"V\;]0BZ[8J2OH#Q8N@_[^.VFHGSZ
M.R^7J]Z V:7ZV'-EK\R4I3\]W^_OH+ /@K:Z['IP3D-J$9N^NYH<(^ I2_X.
MM?TJ9@(L#"PSJ7"60KYHZDAG_@GF_,3F>+XTZYDC<MM!&)5JTGJ?["<LLZ=H
MY_"Q]<Y=SE6F9V]V0)=\ N)4^UFDO436CL,+=#!M1 RQVHR8+J*TU8V&JFA7
M:3X"3RB()X0:W.KG?9>I@NX];B86Y#NL4OEMZ=LHP3U7="Y0) ,Z;)..OSJ0
M9""<=3G,@HKGFUGX$31?=_)=\T29%5%?X)&1YTFCZD3;\])4DN2T0K:=FEGY
MHKGI_=<[5!H"4)6(X4@=I$P+('HWS,?]",MOJU,P'J,/O%PP!,Q+Y[Z]!NJZ
ML;P8A6]I#Q?^8D9P/B'AJ)"U1$P/5HH[%F$T]_E&R?)-*8E!+A]F"L&#.?$-
MPK0B\:""WR\**3-QFU[,17L@G)G*F].YCETR-Z2\VI%("AEE_-O\OM$W @(;
MNS\6QV2L_="A/%"72!\;%%S1%4MANPL,&*59VUY /<DP4U1#G6R?Y1ORKE@=
MWL;UJ#1*Z<LH-@]=C(>YLH+80.L-_]R(F3=KF$&1P9)_B#+A"?.)J>GPC-D]
MZQ1VX5YRNS*W^[\:2&0M=+$KF8UQ%&^<%-J,!0=(2Z28]I, KFM!*:6O,4OD
MYL/_OOQ^08N ]_\"M$YD3(YFFJ4?U92:@^ASS]UDTB'BZU:<\VTL;@'SEPX?
M;78DW@ 1HQ,@:R'BU,6N(_FT\T_\WN*?O9WU=5G3)*?<K>AS96N:3IB@AEF?
MM8L',YTY5K8*(VDZ9Y0UP[,SKHR3[":)5PAR]^>6E=+2S,R*4\DUW??6[MGI
MVHLV$:E%9K:)9Y#0O)/61;!+2->J<8;H3+Q?><-LV"Z#G;-7A99A46G[H UM
M&O^1SGR-46VL%R2JB+:2\/UWXZ@SM4?Z%9!0!GQ:DQ/GCHS[K[@(UB!YO9/N
M:8)7-A_N@YHN''N[M]6+8%I;QF 4#V9>*4?W +"Y\O^Y=(8MI8BB%::V6GE#
MM6-D^L*JT89C&QJADAI?8AT#^/_L1#7X*<;.Z*(\A9H3WOZ%CN8D%M8\=>?O
M2TM%M_?)W%@80W1]5"O[G!&^I?8:IHW2/'_?;X^8L,+.97UE?U;;9@=RE1!F
MHUV&+@^ODQ7K%VI;()Z;_YWU;+\/.MDNQ)V4#MB@$-"V@,WN=<RD?/U" 0O1
MC9 HR>E@:4>#3]\LLX@H1E\9S9[\Z=C6/*'[JEB5/AI6L@_R_)Y)T]EM*3Z;
M Z'Q<,12Z.[E3&]VZ5[^/L@/*\)QW"L"BW,_04[2F2M12^0FYLLURBFNXK?F
MN/%?@N*KG]Q[:.NBU-^\1@D0D9&CU+5-+X(/:_KZ!:?3F+^MG5JSM *S,^6$
M<]?&*C>_I-=<(-[\O"L!:W$?RRXNA5LE*A2F._O\',F>#'RC>KWB%N,$O-ST
M<]\=HP*7F5TO^,N]"5/K2:+J0&!04*I/E>,/;NTJKB%K@\A8_*R]I+QQG;5%
MP_;)A*=$Y:L>P$@36 ^MW,24W7I5+R^"2EZYGG"[CHF+:G6A7Q,Q86G'ZKJ)
M0X2<4 VS/?H[.CN8?]NEQW]=^<VKZ9\*.;KW#NN+/<D=FUH\9L3+S'DO3>B"
M3&^S/0$DA;?])"JXNY&=G94<RG_8/,=ESZ$'<EHKI+^J/IKE3BF=Y<MIN2;W
M8]>B^L9?Y-9W<$>TNK&ON6;G:$5YAVU0TB/8N=-Y3L-Y!D"CLGO%6:5Q+]VK
MUUWFH[QT3_2,ER[GN0Z*."<4Z%L8CW9Y+*N,1:G!8H2,K?!7>U2A%P(3<S"_
MEB6O#D!/6ZL4QF]=^3\UY_B?EIN9MMCZ1+PH=(+S^O,,23ETB%%);F;US^N4
M7NE?>6ZAUT9A>S-U^[I),_)+N!>519?!%)9VIX\&E$_J4?T\7-87G@(2B:'6
MSU9W!Y69G_(\_X%^9HNOR^GXTV[4S#_XES0.3F?D8@;2!Y8IHOI^ZN-%723X
M'X*IX-6A7XE.TUEWR[X^C3FB62 %:_!(ZEQZV&DP$!H8NDI;[57_@S=X;3Y4
MM-L"*-/>&<DR@VF6T9M%/PI'P;( ^$-?HW]_;Z2G[N?9V3TMIV%!HY_#OE0B
M\:A>39_OHY>&OHZ,AH9$;Z'9V<*NPZ=^1L4)/5U)?DIPX.A__9/Q:$5OZ'+B
M+8*1B=\;1IW:S]*MJY-]="2];"# 9=A.K;]_?L&B!??=G8__E+@@;V1)*B&J
MRZKKNN+]@AOIJL:*HRH=3B&F!](?C&,OQMNG7?IZS?#V^!:?I^$#Z\-_7YX-
MU!ZQ3KDSM7H,?7-7857QM[:$;S)%0_R)=&A+,+?!23G[BS=AIR0R^=J/$Z3&
M<F[D/LA;@G_DW,ZE+W^2G#'#)/% A%C@4?]*_5A\(K[K<YBV:M_9#&3X0I[C
MP!H;T8,Q8&1JI[!LSZOW:0X&;8A,KN>'N!L\^6DI6:19P?#U>6)M++:WA+GR
MWZK1TZQ>1"3W,+#+[.J%\+2K^%Q:SS_,^IJFET"WT.)K>J3<7//FY2V)?R(U
MZS^LU9JJJ8N&\O#@GVYU4::5V1C 8]>P9U<5"*"Q<6',LSKS >;OF/JO9G>?
M35F16;)["\2*AJ)KX[Z*$T,+11'!8>Q"<53)X]%WZFF_(L0F3CW1RY?U\*&S
M1)FCW5TRTJ<KX3I%B00>F&1IYR7K)-3U=[UET,#D>+,S/SII!">Z<FR1P?>H
MZJH*8J>=G'2031Z/7DZ(EPY>S>^=?KD#1+F=']LA@EW*QQ[FJOM@)5MEF>7=
M!KCX$/[;ZW)R5(XOP\^\!R/R*=0N:[A^7(<B@'#I\PD(+@%#ZN3#(U).6@F7
MF:X+*<8IIW:G1IA=A;PM)O5  ,TPCBBB!U'=V('@0YG37 7]6#F,<8S26*LR
M??K"7TSEV%^2%7=9^O&/ZKJ Y/G?>7J#77]&/G_?$BB+_$@=C:V+=;W>^[;W
MB#8QJ?L@DL_N(02-GBCA[4P2/=7(]U?@\,=%T%QEY[*708&1RXDK@Q)?[9]"
M^);???0RTCPE(!#/_ET057#2O]+L"K4D_6XA 5Z\?-(JR$=9,4QRGC0T ESQ
M9>\P*7'U>89L'L"BM(\>$<X53A+IEI?Y_BMVUZLJH_1A5O4B@*#]@E]O\S<R
M%J\3JRHHG_E[>"8PKGYVE)_VPW)UFR-DR!:;V@?=VP=-(RW,Z;#\F8!>RV3G
M/$(*VJO8]88'A8F)#]EU">!#:?UQY?6D4'\!63:3?DJV69939 M8Q[@,!INU
M#P(4"7T'P&?Y7OY5UF(];I-$Q\6!KP+S!-]MZ:RN@_+BB-:>1/O2*/QK,<&/
M%T^')MUWSXG ]E#G:MZ-W1J-^G1_.DQ:#R\:9K:'XGY ,.THG[?8M(-"RE$#
M^.C:<@L U90Y/Q+_7</(@[D/LF$FU>_HII?S?VEPR)JZ;!I\K:[5Q"7$:B"U
MR/N4^J]AG<&Z.PDQ1&:F>=K7NO['PHZ<73#Q)0D6XY'8JJAJDY.B<"&D3"TL
MQ_\2VU:U-RA:U8[$G+N8^/[!GR] @L['6N KZEVKDG7Z33%H:#4JX*GBE9_!
MYB)P 0S=P7VR8EERH#!:^VL88_?1/BCR=<#BR5F(CW:4!?FYUR/T*2;OS$"0
ME(ODW>M'A4_TP"??4I8R*4RWRT\.?<*(HOKH.A*U9^\U\#'3&,59SKI[F^O\
MKRWE8\CF\Z;==TIE!G$6Y-=64#'DU.914\ZM:&(0Y,L7C%!RVSZ(9@SPI)#(
M$0?#Q:/#'>:K0,DL$3;-BQR)S<PG;:5H-=9'9H' CD1\^IJ<[(3VER-O-G3S
MM&9OULV]5U^/MEVNQE0EZ[WL8\)N)F$WSEC3AD54NI7V)NP=;UOR&5Z[1M"O
M+S+;DIJRT$&)/9YP%XR_C%;;!SWZ@*(*O;7V\=V@O5HFR4R398+LLJ=[TR@W
MWT.6VB'BY*V9</;(7A[D[E9,FEX%6C^"5D*A:N8V(PZ8F,CVHA8Y/+^04<%1
M?'JLM5IVS'FQ./Y#ZI&4-]BEVL53K1 F@OUS[Q^P$&"O8RG T0&4=R\!\F;W
MDSSU]?*E@$ALL>*O@5:9RK]G9-;[!9Q=RN/P04[]5>O<$Q>9I%YYLL/F-@,R
MDT/O+2A%]3*6OD<'TX=,NPT^Z//8 G%TOYF V/@[UQVW0D#G)BHK"R_V'6M*
M03X-AU?L@SK0'_9!L47H8U^P'UXSM2E[=GG(Q@$Q#5S<#RV^+MLD*!K2.9V$
M#KWM9M+N\Z8W"3FAD-^8J&D0-JG#TN*?UZG]^/2G1JP>_1GS<7X@[JZ/QWGM
M^/PCQU3A^*/?J:UI43-C\,)LLX"]VE7(#]XQ[(;8@4Y:/26&*?7Y_[RF9"VW
M_,:^W6U]XI[PXZ1*X3__[P9:O&?=?M["+;Z6X.[<A52BFW95*&S22^Y?P!RZ
MGR7/P'931/M4OL":W19RF!L?9(#._B73R, O3PT-_JI*8 3T7F3292(D+*LE
M9KZ22^:'SM1^8+FL3M96L*T6,!OE@Y 9>Y,XL?2SC8,Q N\2V*X6>B-+N&@=
M-]TO_SP469^4^''[Q:GF2G9+*2K%*N-OD%BV7_C0_'Q>75HV9T29U=5UBM'M
MKL#TUJ#'2^*$?F@HR5P:NB2YQ&+9/KY @+8KB?Z4HA5ETB\ZVB4/JM$?OT&[
MW3&6=$"/_RF]9R?H+=7!,8X=J&W7Z/:B$KJ K/B"V-[F>I=,I>!H-2W'4&OZ
M66CQ0\9Y6,6JB4B@?0;!$O=-387T?G%FEKX/ZM(487_8*VE59=6Q\7N%8"'M
MF/9#Z N3W$,H&9I@'R2I_8B%)5V 6.)J1"KB0(  TFJ[#"N_LLR7C^ R4@+@
M+-OK*+LW>X+YKFO\Z-L9YCFF$>HT%ID=LFI0:8-7HP;:^<"1.G3Z?)Z=JN'J
MB?YU7_G+R;U]1V!Y9BJZ<%(M#.\X^A(S4.DR4)P&74M+M"/G%E:E^6'^6",R
MN&?VR& =0*8#<01\^H!U.%@QBN\TQ1MQA.,$;-)(ISDP +L+\6D7\4-9%'[N
MBR@'"CL9-YI9C:]^[\DC7@;P/,Q\S*\4<=XZ^VE!G5#M[]J#:+VUB79XNFOP
M#7(8?!1H9)C&[X-\M$$<&U96C$XY5AH5W-%L&476CFP^"&H.Y#^'EI7NG;P8
M@D?QS8"GY<@+/NWGDWDW="UN6E)U=L.MN K5V?QR=DGP>A]J[M,R1;CN-S5_
M'0:\J%P55BQK<!EO@G<.55<+),*$<V7,7I^A'I^86^$-HOKG%#D-08M7;6SI
M!3 HWM&N$I;A" ]5A!:G*Q6.C!FH_Z#2#LIFYQ9=#-<1(.F+J-WN1L0B>-LU
MT994\&$DY+21.0-R:@B[A$MNSJ\PNB@8N<(TKLK.IKQJ55G0?MAJZ,>2@;4U
MC'[_DA%05.UX*6--7A3K!Y%%V= AO=A8R"FL%^X,^EX:&T,-$13F6+%T&U-:
M+RX%",Z@+-V8_AF,Z\&TN-]MVE98$:"VMW/;R@5W=&8/9[4+SO/%9+7;DWU.
MJ3FY&^BZ2<&C'A2I0H'$2U&V:KV)XVN[ 5Y2O14T'IB-#>SQMI]* ^/M$M["
M+LD)JF6=Z'?S](JR ;R2YR1F< 9V"<\[!+OPN%ZIB<2KN+U@$O@ZUUM*JJ_*
M@/%7(D.*'L]!4O;P'%,B=W*=E< . A3IV!DE*MU[XX#+Z0)Q1;, P13P\BQ!
M76_U8IUWR8X([UY0J)D(V8/T"%\;JGJ-!RPJAKY68K(I&>%'G17[\C81(A ?
M+"_:&C#?%4"',BFOVB^AM#OW01*0AZ1H]I-LAQ=H,P)PC\YUL[&9"-$T[=@'
MB16UU#8AA%&'IVSK6F.[G95R&[(,WM6]]#6CV1^N>FI_3K@P>QO9JTH)',[P
M@1,=/H_CI0;P5S%KQ9YJKU_F1,T%]"L47LV7LZZ8ZC'K+V[ZHV9MYV$Y:U.V
M6A:,:"M9D83ZGV'"&XU<]M0+*5JM?/N@8Z*LK6ZL%&;D-<J7;385V[$X$]G3
M?G84(X1&3'#U4#)F[\;1NK26IV29$0G?10'%3XI3'/!4]BVE?9 Y<WPGJ1?_
MY'NF9>#1"@5P!WUQ-JT+(P+PLRP9K8L"K=<C2M": *,4+=C*G#-@9QTOJD0:
M8'O4+:.WZ(86-USTZNNHRRTM;AZ/M,YFKFH*53K;7!6T-B+)\G;FEO;E%]-@
M%Y/01HM&:\-1'F!H+3N8/;X"LR8.JD OV5C7//Y8;1-MUEO1I-H;G(XW:950
M4+U13^ QL&;_P[93'8<3AJ1, @.#FK8UQ9C=B ;!!+3%KC%J<,FA2_O%DW9-
M*D;JO_5W2#=$"L Q$)$8:=_L!X0R'_OVLY1Q]$5F"V(TP,B"D2*P.G-L0Z+A
MV4)*A&Q^R]. <I\G2<=ZTT(8TQ@--*86,&;9+ EV#85U[/1\C69M]3S;>O$(
M<VX6*?[XF[L@*SHVEJP9WK6CU48PYW._LZ"=!N/VCFE5?C^7?,W^^R2O\,V_
M;!*K'=_ <F5U1^ )W3=.5JI:3IND52RK]/I;^:<&)RH5P7UI"<]D3*5BT[UU
MKP;95%3_S,';7V!7E14-2D%/7H:66Z4O+<,$.&-F>NTO__WGN!E(H/@?T$[:
M<X@T$-Z):-B./0A9<S, 6XPVG%KLXBH +-;E)>T8\-D&"A[KY9N]V*FIU=,:
M3)K]UOEQ4>DU 55EX="I-YI#R&1'2%O87[4?^RZ9UH-%DE*>A?6F3$MP3UZD
M)1EV.6?%$H!#=%X,_YI#8W-2Y1>,$L62GW,6B G=U#.\?2\-5J.W &D8B\Z8
MM0AFYUVB,S[^\#]G/"GU1,G.QX;( ]55O)GOU^D^+,8ZW4D<.!G6BAS)M)TO
M*<Z]7_1@4O?R&9V'$^4P9%&4;U G-;8^3UJX^XKJ%9UTHI87?%A \TJ3F_).
MUL[>57G<,_4?$C;[H)>O@#[:/NAY@-<!ZJ@#D0S]Y^#CN.<'4<[]"_TW-A',
M#_C*4GKD95?=CXQJU+LI=^4K?")KFMM]^E5.DD*Y_<:*]H7*%E]8DX!W^5ZA
M^NN'!_129DG=D".Z9K\MQ;DC#I,4WM:K1%0XC+4/2OD-2<P_](EC4]!3MC#M
MA&S>C@(+N3N9T4=><25'\W]9>E8\W'[VF'4MKW7JF5M]8$6^72M!=NA$;ZY,
MV1<BJ<+#]@M#VL8Z9!Z#LDU7AZ?[6*BELE];)[Y5U^T(&H83KY0AM8IVVA4[
MU>!$ 2]KZR]Y5X8S' <J9 @2O%>A*GO\A>T71RF^@N( A5T I.SJ<\![."-C
M>HYE)/@<4P#'NDEO+V*,"*(0'3/@!!;/>V>>Y) \R^LU[6/?MSA.%=-:]2%[
M#IWVP3.(V=D.G_*]QHT=<KT0&KLD/WN/04L#LF@K4:WZ+!M&7S=$!D/=!]7[
M)_S;PV(PPB*->&E[\E# RVM)\V:WLWYLN]+ZSID%N=%62(F\Y,-1-!CP#?/?
MV9M(0V5R9?II8U7")?E."<20 KDP:!*J:V:4RX_TKT?:II46&8>+;?HY=;HF
M0?N15[\Z.OOIJP:%.]>[3J@-A3OKGH?:KN(MFD=F^FWV1@QL8/K-/I@^:U?*
MRU#L:2"R$RP[R7&BH8S$Z!8.YHUMDT:J?G0WPU[[&=FYI9K:R!YG"W+^6]*M
M\S^6+6X,3$HJ"F_:#@@_BU]*#4Q+(--GT+6)12$;FRJ-4EIC"8&^MC/C6XGI
M15+J,V9F[EI:0V[NEZ#6$0R%[&<Z^2^,1>&2__MK@7"8VU0@MBYS']1NXEM6
M%7;;=>0\]LG%%$"H[X=<QNC_TR+J_V?&J/^UW14N[ULZ:?K\^WU0@^ +-&(W
MX!L;\]<>#GV5-B*S-M.0@B6L&;3E[8,2-7[9Z+]8PMVF/FB,L+L_:7MN=7ML
M'W3?M44-&:=8\@M2NTC>XIPI8 G:CMX';NZ#CFX##K2M:1S-/BU ZW4A, )G
M;L>NL*K'^M[\!19C6F04,'FZ9I\D.SA09RU9H=WPLKG/:PUPX<@_CPM;$]U-
MLQBL>M:[F: >:-(5:E%LY55+7HM>F[2RZL6N#+.?0<-VHM3$>TTA=WY7OUV
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M;+KE9"=:-?_53^+*K'-/L4*COU.J9I'2)3AZ2Y*Z*U5K8Y,LR[M"U?3O"SU
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M3<)%._A'NV"RF:*#LO)#Y2,*J8&)^18^IZAB4G:Y\P9U1*GI\:(;UHEK]RX
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M/- ^R9$'RFE;?&C$WEM=6Y9 %NM\G[Q @)'?TM8K][^F-LXU @5EP!:-&\O
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M_O#LC3&_=@CJ"+2&PNS!QY!/S?R>2/K]M4BNX7Q-RJUDOOIQ+.P;R2#?(YX
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MP:\V:E^BOR:7C]$J3T.SN]+W^O/_=#>]_RS^XI+%-5G/PW_\'82,*"N)Q?!
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M$2"I<;,XG2%8+7.MP(0KH4@#2F-XOC*K="R1YEF;[C,\ES7>_:C(JH%,2?/
MZC(KBI<_R%/5:2W[ID4\3$(J,4:A@@@1VCWD,%0 *;:*O'"(U3H)H/'9HA^H
M8#R.C:[<].!GO@8%'=462()RVM!5)\-^6DN_7A/\'>&:] =1_G3,9>+F/L9N
M)T?.?/];ZV%CX_",Z1$(]CK[?!I-XRO=([GW'$T!P0OS#37;ZLT.C!P*EXAU
M*BG);FK&!LNG&"T039W4(K*T="N!(]#2\-].4M+L7=Z)* $&,^"WF(Q/GCW9
MQ4Y3AN?^Q/$KXN*(H7T]J),#57!\9X?85".;0I<C<[QVV\=Q)<\MME53*)L9
M3*]/]GD_LYUXP-Z53$O4XOOYFS%UL=;[%T8'=%/:3E!=_S4S.%R\V:O7"U^W
ML2Y\WTA]DVUS'T.JI=_2(">X+];EXMFCOD@9LH7WF>.M]E4K'F ,A0PYC^'$
M_.M8J15+BG[3'L9T&A-5I*'SI-+I9IE+HXN&L7,XUI[)U+*'Y.*8U5"@9E$>
M67[[F"UY8/7'<WP][WX8T;J&>$KYL3E,H>T_I$*2&K:$X?\R^HG)/=Y<Z^-P
M,3Q#<%K#A,IRG^K2%(/0;M8^ NF,5/V"B?P&0NY#9FH_WXO]1(!OO:*'T.R0
M(]#&OLT\2F7W0L-@<U?-">2PEC004 "'Z(UIG:3?I,[M;9;&,<!P5$]K K&C
MF3R\.U.2;#Y1?;K%DOEBP)V%CY9>6=;^Q\*Z&ZZF(G\\Y$Y;7,J#^!<+@$UF
M^(MO/P265'OA-6D,SF/:+K$T#%Q5H'-C&3)T6^HP/CX/TH=F>C2&I0O0+.FF
MA[F]!:P+9Q&7Q+<7;.AJP-M%?KJVN%%&W&_S\ >97V!1 H6G.8M8HKLK5!,,
M\0\2+;O5D$K&^99A?2WD]1\MZCR>^)..U_#J:1@K_X>IR?48R7X7'L[UJ1[U
M-\'7:ZP>('03NEN&KQ&<N-_O^L9-.NG *XP#)BY921<FMY6:R>2\&"Z"++Z#
M\J*>)<\T+S)U&K$L*O0,LP*_]V. <"I>#W!72&CSIHQW9R/SEBPFVE26MKAO
M%Z'/KD;33N*; X??K=JQ81G9=V7>M69Q.CP4G*0F;\Y6 7C&N32JX?X' /+W
MU(]<\[)#%"A<<!@-R%/O>P@]@7A$T5'<XH'[.8[*GVO(-&0S%20]*_WGIGO@
M,^MET!3[YF('7]WH$6@Q+].1G2ITO*""49OU%+S1F!(-+3A/O]TV45!'X>L!
M3F7-*TT&A 9:4*\4BJH8MNN:3>ZQZ;BG,":?;T?51$$6L:VBM33!54BC0J+&
M+9?C.:N/WIRE_.AQY .B2^U#2XQND?HV;SJ5#*M$M+D(RZDUU]<#.:[> :1V
MV\(DEB<3R^/B\.]Y11YK_10!I%M+R$EKIJ@DYY@OZTOEDW /U< W9@79=_)5
M9'M&PRP^N(3]50)9$E(CE1%%?'O%65HN";V/7'+)!;'5%(OG%L_K2RHGJM[[
M56;MD'PF//H_S*N62\.S!W<L(MT>>_3+WG)=+=V\CJ*9P5&+X,2_9S?'RJ7Q
M'X!SH1M]BD3=!;-^!S@H?02BYGP[!GC*LKZC$MOX#?X*%M"N&]J3^?/.:NT7
MV$9L'/\$E<A$@!"M%X] &Z\":)X(8V YE,H8FMU_-LJ0!;\Z0'6!HY'_U&7U
M,*0HQWX<$**Z2(5&- ,Y-)G;'R<EDQ:U[AWHM;2U]DS]9*I'CG^I/-9C2T#O
ME\ZKAUE*CVU><[,#]QY]3^L4_4,(@(#H3HL*)Y'="R<TS*DJ5J.[WM'[T/K
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M_4:):QA&0F RZZ:'<J+@GNSW]V.)AWE2OB6U;Y[DU*U@^1=RWBI,M\HLU41
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M:BPTFO1. N/>->Z.(JD3<&GR A[-K*B'$*E:K07>"O4="]L%$CR:,,5D2FE
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M\3IB@!2NE;VL6=,417S&SV;LE_A+\1CTU(U]>!A?K#9Y4[AP^_N! *%V[LI
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MHO$JLKI6EX5FT'+5ULK!6*@%:KVG)/;!ZG?,E[)U7>74BY9676J,2]'=BRI
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M!A/U(Q6RETP(I,)5(>!1GF^>+[0@RW+!Z_1$EHE44FWH3MG;R;ILZ)\[^U'
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M_2=2-8+U'P2[4?#[U;A6;>&(U&QW#-\?#LBII*%Z;MPC-Q^Y#R8NF35*&*.
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M=?7/L?GFFY,X'/9#R0I"!',PY$RLWHS$R.<MY1J6V;O:/RS6]?GUNJRY+I9
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M;Q-8(49L&%X%NL'Q_^M/C<<PKX EE"IL'PW>M=O3!&9,9[O@*+U7CZK<C1#
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M183AS<# NM@-^.HE;^FWQXZL;<^@\L@U=%0?&R;B3:POB0(5;$;N1@CBZAU
M$^_J#<B58394U;>=2<(>;AR!-_3,KBRH\7<TUL<'C2#L-2)3WWY,S&XL^N1R
M[<!/+OY?G07XA] B@PT[R%2F +,)>#@MU]H>\@(KZ-QQ016SQQ<E%))OHCC)
MSL4+V>J9.5C:K- ,=._C>+>&2.RDBKJ>:#?K3&W3.>V&MB038?Y8[2*\&S@Z
M'XT\ZP+5TX.CR$$UBQ0QY EG1Z9V*_"A.K<4DOD3E.FNB<VT:_VHB##=JPHN
M_A+>!#*UE;:*-%[Y7%"L^U!F*#'X!G6CM.:CDBCC9Q^!FZDQ@CR#R]NW\GF(
M5I#[32-42QLX"?EUU>)"F JE>L-7 R>".%<?.A-.85XYMPYHY)>C8NEQ=,]<
M>K.2_ \B%^HNA5=Z:B".P(,4Z)DK] !%..%P%ZAPKFMB*4]Z<).;PP<I!$QW
M4TX@E?$F0%Y:U=O@<JST^-6L[H$J*/(?IP$_MZ.6WV$119;HOY$RT#(88 9Z
M)'W(ZATXLC >H0O(O$F8/8K7&D?PD#[Z*2."&0G[X[RFVU4B%<TWX3.9!OE,
M6=:/K*_D-V0KE!"-Z\E9UR/AC68S."HCN;N&@VF2UJ43VX.*W=X9B%EC'BS"
MH([7D%7</!@UR5;8\0OZU=@\OF=H/LX]B4E5Q91):CXF0K;I%:YSM-I77_P1
M_*6-/6.^EWM2AJ[RE(D"):D[]CW$6*>9,I7X#DF<\D^:9JS:L@/9%Y@U!HB)
MWP8W5<1Q"7;#3.. ZD[/L;',YIWH1C8L=K/?>:"AO2IC,R4FA55($,$;##&-
MYRB'H5TG@)*LGB2ZG0&0HK-Z-#KXB5W]RFG53 E0,_Y)YB17-:64ZE:QV%P0
M)N1W9T1=-*Q*QS[D[KF6E.LP^'U+](ML[A[N4Y#J=@1TB8]N'X,\C6')@<'=
MX2@TU .*C(W?!.9CS@[CC1A3>QI=$#9[^W%)U5A;D)MO,69C*7LU_6+R9ABZ
MP:6QN*@CWQ_$T@-G3]$AO9*E5J6ULAHC[@2F+BAJ 3#M=ZY 'MRQ4B-!7&&[
M\E-VF4,A^[K6I[GH/!PI;,[[\4/T">^?)R\C^PLHYQ%2N^9XHV9@(.;V* I3
M$RVH4Y(U-W#"YV)G-<[T2E0W@9_L%1P61()B:=4YAY"JB9UT-.?-2>FT"F0&
MMA1ZO*7MV3Z"T",Y_WV(-5S,&G35&NE0-Z,%@(*T%<$F].F&Y,,6N[I&Q8OC
M<#YTUR3QD9H*WRS4P;"2.&OF\U&%>RFT<=,^C="EN*,ZA9'6&)%L;3GUDF-!
MG1\:GAN8C.K-^P/%@1<MQNT:90_1-Z@/6^>CF7;$$RN>.>8@JKO*W61$W68,
M;PIZF4!EY8Y.BTEZ*ZVQT4@A7([9$+UV;V]V(A-S9DLEEM+ T>L7%UH9<0*@
M]*['MN8UJ5L((!OI'P3?S!P'B=$-4]S<.-^@!$[4R26)/Z R>CBGK4Y[W\?M
M&:DQ_$7ZGJYY8 L9('.<@4446**SG4@]Q,1!O!2H7,_8L^Z4T H/HW%T6<0[
M2421(*L-@_K!=:8Q(T?OTBYUZ(M1=4Y5Q#$K7<R*RE<=F['Q[L*IF\XO-R*>
M[.6Q9'UF3WT',[;;P8 W'=*C*R5MN\%=OY,L!U$2.GAS7)RMZV+Z>DRQ="[3
M;LUQ^Z9M?],_EO(D!N_D_MV>'GRAG_,5QZB:_5>_:#8,FYSHJ@@:5M'@QZ'?
MV^?KV]55-"ZX$2B0_Q*OW.)WW(*.BG<5!Z[/6P*S5$*BJ][HT!J7@GU;6Y0Q
M^($2&62L7&7I.FK_\4=[ZSK=J >KPL>4J >]^N#'(.30+)W0HQ+#4ARMQO.5
M."R@>53P>KA7T+V1J257F1@4U[+(>YB3@Z,C>DE)G!E@<:!] __T#>J*;$U?
M%1\#%8_7!3E[=ZJ?@Z:T<6K%=K8+ZAJ$J<2D^&A2^.\US$YJ,HBQI$'R68\*
M7/6P9=UX7I=H2&/8ZI$!Y^RE74O3G%Q=B]JZQB>A1LD$GX%X5\%1O',9AB4#
M*,T^W4P*LQQTVWM^,@6KTIW$1SV%<VDT9LEB=;*Q^JXY5P'&\\8/-LZ0]:[(
MAO%0]4IE4,R(RRT8G-1@_XT->]2AALO1'V,I,\V2Z;-12'5(DQHZVU6&QS)0
M1S&9F7EB%H=<,1B.N)(AMR&R$9U+8OP&<-54:J9N,H)$" [<7L>&>6$?"IS=
M(CSID,5?;P=R,XL9\)B.\Y]NCW3 T;@?ZWTW-*.\/N%5_0E>TLTE..1\UP-<
M!TIL!CO)%3W:\;QT0";6MR&L;>_2#TRC@JR,X0WN(N^:/G&9[2$HI13GW"M8
MA_>&/-RQ!:XX 3;, O2LTER9]RWW<8IH]V/8CJEQ<1N^VBL,XCXPC7T8=6TP
M*"Q)H1N)^EW.IW*E8]17,.9>M;)2QE[PU;URO$=(!=[)3(:N^:3CW)<%%->6
MA0"$HDJ( .O1]\X-?:@JR5LMPXVS> 8DH%BZ3$SQ8.+0C$]K< +^(&U:X89Q
MU0I9N\KGI[5C\3\<BTG\O_RY5W497J!4<]3 J@+@9/&'V?UFJXB1"MK B1KJ
MWUMII,X'2-X](HMO&V@!KU=^#VI+ZTEX*)FB.&R>=L/^D14TOFN"(]'\XEC2
M5-J ,,Z+V@Q"VT*K]]#7(*_#6<_<7D&20(*KX[V@@?A9(9;80@'+M,J_:E6-
M#3MZ$QOZ?M)F[*HX;XC2T+(E;,^F@*(2N+YO_;-B$=Q@<T\HJ;N=LZ=#?EBY
M0V)FD7ARG,HZ]6D+%3,#!S^FS5EJ)E6O;<V*+H;>89T:KE9WN66@&1>DQ$&-
MW.GZ[DPY[4Q%$+U^$'DB1N&\" Q Z9E4;@,)-$*D)9,+_(/ C7LRS50&U=FP
M/M&6TYBQ#D[@.>0.NO?FB0'S">Z"TC.F*"Y<5D^$3/R2P[VJ0&/$BQL<*SW\
M/RQZX(FN\I!1$5Z]M7;XS'C#K CD#;E?:PST:$/Q%K^J2^NR,PO=.)R-XGF+
MV*[P.Y=O-/PM_>/US^@\LM_N#:8!$-QG =GU@ZIO!OA? %!8=V:$5 -D30M7
MI;8^A[ :E !ZR-@\?0-OO\]]0Y7NZ9I"C;JS,0)Y@JFSEB)A4/39>(6)-RCS
MA9I^8@RQ$9Z \"C#H?7'4=[$F#R>^G"K7W[XX&K(G38R(PQ^;_0MAQ[VPF/R
M#H$<T2PE7/(;D9(*O9+BH/!Y;]:%?5**/3V&FD2>KKN][#I=Q!JL6^JXF$Q+
M6H\GB\UH^<7#^9B:%9#&)/8:T\5M3N\(U:8%&*L/R9<NE*XHT0\_+3!$K79Q
MZO,H.\8Q<>GFK8.K\0H_.&DUW<FBF-DC"-7212*?FDJT0"@\D0WS#!?M<=49
M4]/:@K:X.+O1]?/4)),U@I#+\LRYNH;/?NL=__Q<UGL&G1\>NGK/+96^3H$W
MJ#Q%J,S-1HYK4'@[Q'!7^WO@IR*D%EMGLDH<<3(W0)F$JCFHL\+;Z5X%C7 4
MUT\/CMD*6]6U>B;'FD0<FM$"#TUV--^=M(^5:HBS>H2R**WYF^(-Y\6$SG9.
MZSH/;VT$ ,,.H'UDP?YLL3CI^CH&%6.-J["H!\D_1:*CZA=WCF,*M@=Z[9<5
MN?,APNZ#[_0PC=K,:QT70/[QSAP.:-4=L.^U:R5VY5A,6-N0+^$(O5D[\X\V
M*Q;)87CU,K(F76VD^FY"VG;,>'7#JL_JYK3^0'U>.-+[3D/BP:VZ>&8&%(4%
M>J=^E_#914TD=#L9/47RS^(X.S]!>2A.:-P>%*261IR=9EX94@S<U5417 R>
M[,)D;Q?3?MG-]F9'I%3<7,J<@1.X73\438FV:3=R%R%4:>M/B?467=R"2Z'!
MT<QSDQV%]#9Q_6M0 .U8A ;>$(B-O;NF5!FX/+ R1>1B:NXSF*G%]9GI+=%!
M[DCSYU[:-]]B[]Y)AX4W&N 3"" ?/>L9RA/^%*F<?'4$H<+H'D)8^WIXT @G
M\3>&U*><G65-<O6I._ >B]A9;CS&OT8IQP*93NJ*>?>#I<5GUMIAY8 [4N\'
M^ :B#B\2ZP2[<X],KMM";X%6);0-\/.I"NL\3O_/T>IJE0+6I[%50:?,C_,]
M#R;.7YR%7-?10VN>KYQ-$Z9$'8J>K=W@'LY6V&!TH84C]'R<:KJ7G:O"NB:'
MF * :WY8J0.FXWCVS#)=HV5&%GI.V]7=EJNZ27E2N>*+ERQ:TA1YF"/X5+HU
M>,27_M?A9DS(-'S[*91?BG._V0R0>M:C9P74%2KVIYS *?QE@!)3F1R#/U"-
M-P"_I]',T)V38[F%.*)#K.W89B[*NF6DRG=M2T_&DG?QP91/IH#K_93+*!/O
MF@^%8 X]*P9O#2I/.:5US2B!653BDP[M"8:""I?K0B_@S8;QK*KU^]KM4K=W
M>DF'2])*'%5]1/)R[OX,^&)Z[T[RC6?GW&KL0;_D8L*$<^_,A4:H IAG,,>N
M"*"$<6BSX3/ O9=OZ4F71A;7]U4@@-48T/C[_(7WGW"/[V!+,[X_0ZB=/[BR
MI+"A[PIE@!LND!]]S_H&%$W#BJ/Z9@[LY5O$*C8D_R&TSCS)AG$RKTU*%;];
MJH.BG;M5EUL5@\=^2CO[RNP*['SGW-5LURB0^49&U2RA80AQ\)XSMW!G@<L"
M?/^/'B/-(,<V,GHO6H)$?TSWKEXK'F*=W3=M/Z.8NA*U4B,WT$NA;%ARPP>D
MW#]MJ6O&=J)VL#V' HH\0G77B#4HH0.<I-")W-#4F]  ''?GC")H\&%Z-AJA
M2?=F!BO',9*LJ:UWX7<!5#+3F"8N:M8QK/BR)<T6H,0Q70[DV8?I^Q\O(QB,
M(L^QAK8C+H$HZC66-'3()T)H$._,T"8[10BW[=51KP&QC_%&))P+ C$CXW#N
M2@A=S^K=,MK78E4%<SBC"Q,9G"W["/7G?H2VRX8E$840PL#/7J?UY(AS.!<_
M3\@?R*$?>5SMW7'DD]HRZI@+;MZ1:-KQJ68@D1E&J^%$+Z9>:+B&-Z,GG\89
M?NPDI7_YH_]NEIA@Y^Q^V%^3A'>?:T=WHP3)J@)II8MH/K4/@IW&^7CD<Z3R
M<A[/6$/CL-KZ22BJ<Y87[T9+H>N9])H^?XGD&V=:_N&D?S^E![F=>8%[9%+A
M1_^?>\4=%Y8G28_(ZC1B(NHX,Z <;S2*X/>@8]>Y<,@Q,.+ 4L2YUZVF;-AQ
M7+)9 VC;O5/2R-<UZ5M,>CH0O>71$NFX'CCEV\6SR89%(V68ID0&#R13+4T,
M*X,>S-N"1D_QMGX%.:)ZUK3^A3RQA"[[BPX&X2$2*66XM)Y68H+:9_UI\W<=
ML-&F[L&;?1=@.ZWQS-%QU@6(V#T+1PCG3^.-@+I^&C%IYV-JQ &,$_X8R&DQ
M&)@<*R'74@L^:RYS6K;""NIHU(<$^;G[<8W'K))1ZJM;\5,^/T5RV]N+OG \
M(F!5GE%X@F8AH\T:'HC3> 1A7 -9&X6Y&#+FME]7XY6ST&!X=4((-F"NYB#S
M#FCTK/%AP_#WH"1F (T"^R!16#=[(W+([!\8RLF[YC%9B4&9O+ZD\<DG3P_0
MC$/;CB(U< K7AN]VP#42%%MGNZ;OA:L8@J?'C;J#'WN"I^HR_/ ZI6.A@<V6
M(2(]0[T3^^3K*;&)V%-*&]KR/:R&.H!SMVH>45N&GX*R_:);#;,(#/1AC(38
MOKGHN^SK1V?#>E2B7<6P<DQ[NIX%-4$ZH6)I9SH!![=K:QA2%W4D98\<W"J)
M9TXW@&MM,JLJ+[^X4(O[4?%G(6>]#^0LJG/=8'41Q E.=?-]@3S734:+!DU=
M73"?>M3W*I8>:DX&IBJJ2.:$?7YMYKR=#$W04+%Y$B A"2F-N]K-- *,HLD>
M+[\LYAT&GF5YS4VMNCL)^-)VI]%TF>Z!PSB=GQ;D)C?>Y1EI4#.ZXX-_VN'&
MJ=ORL#VS HJ"2H<>TV3?Q\P^D= >8ZE J$XG^SBR]JX^1F3T6<V^6^+PB1"#
M4BIQ&JREX:[MBTNA@LE;<&YG-"[A6H,J!L19].CL-12(&VRV[9F(]F1.?3+J
M&4C\Y##A,R,\QH3G0RC:>E?-1%_W3DU4<I2ZN.?/'FO\]=>M0UOAYP9L8FW3
MK#[Y-BR[Z)U,V5;2[=;)?;_6M.JGF.-TF7M07H&&^LR&,>R[_1)#^Y[=8[HS
MV+ #RSNNR7X8KJQHLIX,5;MQ3^9&:VO*?$L'&H:W +>+W4LF]86&&8U@219-
M*0+[_,]ZS(4&*\,..3IA<IR>F5$*Y1&XF$80FK[GU->'XL6+5N"EA]5,=9-Y
MF-+ 0#33@I#_&6\+5HTF/UUK'!M4F]88FW487:EAHDJ<ICG3Q#,V>OBN7T;9
M[K.O=5Z\#91$GS[8Q4GCCHLX"5'+<.[;3X 5B9-0X5RXQCMJ9X1V*R&*#3O5
MN#S+(<K%U]TZDQ3N[Q%\?'&<SQD7N3:JK*ZD0:?KAK4)1NL9F4+SH#,],.\@
ML3,T+W8NB9O.W3U%_ .3O1\&.B+T'V3F<>^;<Q0_KMFZKB'+9FAUZ^B6"C]&
MGRKP;/Q"'ZFGV"?+>SQ5S?("Q\QI^V\RB82[*D]90E CHX;3&RG_B6Q?M$
M7JVLJ27M<P&/DAE(V8)S(;@Y!1N:E_(2[PAR]'@.JU7TNTF-Y,E!OC2LF>&@
M14:P6*IAU6%B3S+/XB!NHR?;_AE9=/?/+]R3?#3EW )<&U6$D$+S]=&$;LID
M6YQP]):0' M\&L0EL#WIB_P>KF(_YNO15C>"G/!N34]SFH)%U%JB#^]+*3['
M&,BBUHC@TK8CH2N,Y!/865[%372<A,RP+UF71CS)5![>@A^ HIS0QW#)=LD]
MD\5Y"56.N-2!Z\/9&]W6&/OU\\2)C<4;+C</HV6!^;X!_AG3?=\K_9P^R[4
M8)-V]1:50 Z[QS5DCCD5SF6G\<2&MG7Q:4R]S\,=?*; #D;PTDV+LL5LE_<%
M,\N6([Z*DF%_7T99R]8,^(HRX+UH4>K</O_2I!,>^1FVT9/CLGV8=X?Q?+YT
M;BYH2A\P3%"N\BJ#[*E->7(N9U.QZ:S^]M9&4.G;,\NURGFB@O &Y6#$.%&
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MRXD-B[OUR-DGV,FLMY;_$_86]YB/PL9&%Y&7=8FI"3PP9G#S0WZ]V1919"G
MO6]R.]^7I@&LCJ4 #'2FBVJ?1EW,N#IJ59@L4_ 2O 8>) L& POC8Z1KSYQ;
MMO=,@:B^+-9%H"9VG>F(?%X$47I"$3,:#8 G5*4^#>_2_-FE)^N*2?TX/IQP
M.GORW4_;'Y)-J3M7A'G>=>G MI84?DA>@WZ"*E0"KU*'N#>1%R$XU\YI#?6
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MP#BM]2Q#\;V)#FG;)!S!Z LQI1'X7)W(<B^?:6U+\M7'/V\ 9IG!GXWN1S^
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MHWCTB$_P#OQ#>]N ?%;UHV%>66IN+'Y,:B-4-KHQ!FA&ZQ!-K%7*S_N].@U
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MP^+7(1YK+Q9=(=Q$L8F::Y*QTKA?''=:<GFM,MRVK7%:;2_L]0PFX($*KG+
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M??@D2\PK!JOXO\7F66R7&]M-]I"3[$):F7=WZ!YH.A]*L)!_;2?M&.>HOVH
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MLW[9*V;^6;9CH:&Z2\&F![=<EKH0IJZ;0)2G0MA:"_:V&<V*>9W%26,NSDC
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M!H& &[D-$7[CVJS4<RSA=+3?+@+R5F).<E^K%G5N)KL@]PE(UDJ4DFO'T%M
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M.BG:/%C_3[&ZE(%"9[&"6\8$"TC[Q>2R!P6[(GIQ8]YM4>%M"'VV)PQL\=X
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M*O1W*(C3\;A^'1=UW?X0^W__=LN,++X#LAZOV>50V7XPJ1K[E!C=W/J"7S:
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MV$1?"OBEMK@E>]_C-?___#]Q("M#_P=02P,$%     @ ECIE7.#1XILXB@
MVXH  !(   !I;6<R,CDY-#(T,U\Q,"YG:68<6G54DWT4'CDD-D)1NA$%$0D9
M#9+2"DAWB'1W#Q@BW2 IC:1TZ6#$@-&=CNX&"<%]\/W^V#EW]][G/L]SW[WO
M><^9_%LYB)#I 78;U@4 @,%@   ^ , * $@' %!W7]Q'?'P /BL 7SJ #P7@
MP]PGK?@ 5E8 JW2 %0I@A;FO3><#I%L!TM,!Z2A .N:^%<4'0%D!4.D % J
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MI^]N[%V$0J6C,'>^WLF]8W&73,>@TC&8>YOOMV)U7WMO-.;>]7OOK.Y;[^W
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M/?<!MEZ!EZ)!?B+>;B2/^,&5SV$*G?%%=2IG61BMTO=',ANCY[@EL2W_3(@
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M.5P=A&]2K[U%A$=4KQ=_KZN='"!(-N2LQT&SUVM/QAH7 )Z1\TN2=P]5<#)
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M:T5]'49!)];>/2Y%"&5D=J+:'Y,@<D)#53,]<]_ %^>U[?&%+CMN]UI4>>5
M7SJ3 P'<UW9D >SO5]=H-E!49-)9:VLT0HP@Z]$&Y;_E0 !MO]-RRUC%&]'4
M)53))AI!>!A:[G9-^R9H;+DX2;MFU*S=\VX2 NQ8%S.(J!YYVMS%/_D!UJK>
M!_SPQH9Y.%I!IT,!GG*-*:Y M$10@3E RTX?O[)_S]!G/.D:++X9?)T$%UKH
M.K?%=CVL?:Y4@KS2]JF@C_@#>Y516L6 O&"&63D^K(,"BIPZMO*"MIQTO/*L
M@!S7<^W7$U-L[YC*/;6\SL;8PI).;O*>T![*2LIP(SOC;O/S+W3@UF==/#<-
M'%!O5UM_)>2;K:DH'(K$FJW*-ZO^;(TM%AE_#42H<,)FU"%Y2^UNGS7361&X
M8L/?M; "9AP?%M8:&!>4 C]8WUU4AZLP],KK"S]2U.6F"B,XE^8R8!&UX3 D
M+BE]J?I SK-9"[ZS#_NSS+/BQ%;$ICL!-:WN8OM5^MB&8^Y9R#\\2L14 Y[-
MUJA''W%>#-<12YT%TFP!?RAR P0-EF?_\AA\\SEG3YT&TCBR9EJ\ATOE9RXT
MNS4E()[P0=WO0K-.8LDCIBAYHZ2O?O H3_5(SREW"S_WDXF="O#]!*U/Z]EU
MG;[3]+96U"KY S2+'G.C#M'XF.([Z..)Y\S1@FT5MT8N(@/R8NB'T@2)9L\!
M\ (;K^6NIXUK "34:V_-<@ZEOV5JH7LWZ@:(Z$"QM?K&Q+"B=CG"MU']_CNY
M1N_S++8]/]V,)NLR(F.H_M&O$CY'UC07'$%>9]!0Y-,;_([ZTG3SN@.':O_;
M!7MRPV;Q0%DZ:9AQA<,06-/H1)R>AS@O<B.604SD-.,><O/SKSPFAI&/O3>:
M@PIQLHMZU.XO>C?P\33#$=7?]EE_^!05GV0MY6&+Z4? $S(7=;+PP&IFVG]2
M6_(KOT(1\9=.<*,.1'-6YG+0<[#G:80/(VE69F^4C/O;T2I$WVIQTE)UTIJZ
M3^/JWWG&]>Y"'VFAV02!UAG^G27^,;]7F7J 3<H/%89ZND%2/[\7P[J=EIMO
M:;EH,[CO1  UEA0 ))2L2HEBQ=TOJ-@4(ELG'C.)-"RO84'B)?TI4,6(&W*)
M4FPZ-X&I=BA!HLS MVSCV[.*BI]?@B-FR@S1X+?R;W=GFJ=/+1[Q1YSCU8<K
MZ@J;HV\!E\0XD[(9[RT#F4B)^V5*'VF.GPKV,;QOJ^9;>Q'E?K3THQE42!>T
MG[5JV1I$^>>KKFFA:O3ZEO);V:,/2@'&VZ_9;%+MV[R)WS)6__WS:0.;!;-)
M\):7W!K-E [MKX;HOGG@$( _C;QJW)NI-O^ZM<SZ9W^VT7DZ.^5OB^]2N]??
M,5CXNY:L'G/P10CKY>_QDP:&T%2ZGR<K!5=TO$>^%T&K%PVC2[50&=7 I:)G
M@;*"[7^^G+S[:OK#).IIRUOJAVQNDK"8X!T<ZQE$37E=*9U9&4!8EDR5CU':
M&K>\W>E9>'X'*/<XBM$ZT<F5CE.K.(')-00"7O5']7BPM4@[O816)?YZ*=)"
MOIXD$;W@E"(TEE.<(OIKQRE5=NJR)(VT63-;YF*'F0L#W5L?DWWU<]HY2^]$
M;E[1UC]N3$#=H(U'==-[G?K.2A;O/5FGU,SE;,OHG3&9:VY^[@+[HTKN*.K9
MUY"\4ZJ9N\'[M%*&\;C;7;?B.%8*"/ABI/N%!UI% %$:;^#I7IIM$N%1EK-X
M/B:[Z2,)5L[5\$R5S3*H&I>]]AC:^U R-PN6-6NYWBNO^?$#H[2CA *KG)US
MT=1V3VV;EOP36]2V[!$9]FX<4Z&D4_(E:-C1* @$M0I)K50;^'PF S:DU*VD
M_J6U/\\I87[R4MDI^V/F%9=[3=/BGHA78^DT*0!;+N_W_?R?H&CG&9F16#$>
MP^[;-5/L7-4]O!L(^ PV51(#W(Y,I:GN([GV^NY1'-0%M!)A315,<RS3"KRV
MR+V=_2T^N(X$==AO)R1B8Q([+@7L L>E"$H50Q*4RH$38DS?&B95!*F;5'^[
MQTU.Z?^U@<@N8^I39%:0C:,R-G[K =.:%^NC:I:0**E)3\,%4X6]>ZXF\ILT
M>F.*;EPI?Z9&GO2/.ZYE27[L1LGH^&,9+A03J)A?%PAA4YG^7:ZELYG(>YY@
M\%L;>>@W)C*;!(\2:MDQCU./(4RAB/S>:^?A:I7#^!YC^>A/LQ)M+6[<M$P5
M@[$F3-6KX$A\=V,9Y$[1<X/KG44E\<C3,56(LCZRJV14[@37.!_GRT\ENO;A
M^?>(ONL-# QPC<4I BZ#NJ(5#]+6HO\ZY)1=;^&6$-'_+G\_?DZX^%OW_3KE
M@/VV4U?YR!]"O%("#QAD&X[ED09)^,2&VN6[[*#B:G+J0LEW=<%462TT.C1^
MW$U%"P9\W7?S,+%TU8X4#Q*[:6LG7DA$<E#?=^]AC*",R6:Q!Q! 6L8\!O;7
M.S_M+]4A)YLE_$K>3VBN+K1X_R%?FI6^I_^X([=T:\+=G/SH['J2CW"7(U;+
M'JNK$H D?]!.#/J-?\^V2CX@-^2?&E2:[6WP"8P<20WXV?B$GL#,%HUSI+IU
M1'!.H<@AL32 D\ZN_%IR?;4GXAG1U1O<//J#AM=>,882NG(C1&E<NQA-AUXG
M:E./(2L%4EJY2W;.O4G2H T /+5R0/#K1*KYF-D;^5?% G[D/0[7$CG?Z,O%
MDY.,K.@L<SN]RTDN[K&07&G"]P!J_$.3;.[5Z[!=O$Y_ %&:7R>QA,I,J3QQ
M @1:R97^3XZ+*4.",OH5Q^/<:MY[OSWTGVW=+=S>J% I:9(-PO1 3<U  ___
M(9SMYI$4Z\J%N3*1S_F'T3DAF(YBXUX](7 C7N95ZJI23&%>!I6NLS*H>'-6
MQ4;&P>/"*93[)[,B1TKH3S&Z@>V?QPMT3.#R[KHZ@9C4_S*#F&9W5=/VQDM9
M[W^XM:^R;'2O #]89ULK&E282K=0&(V#$@GK6C[Z_+%2/0ZNY9%4%#UHZ%K^
MVO6T$Y@DL<AW71.<ZPXKESQ4F/\*MZP).]Q_M']M\X7"NFZ0A%6*:[TLR_A3
M@5Y4520-*K6PG!BTLZYQS;HT,_(DI-%HL]I945#>_0$7;)\3)"\5EFV1T61W
M#O#4^7EM*4'$0'M6),RYY62W/!>2_O&PQN\YY3). R)R^E^76\?@L/8>'A3Q
M8X0TY<.'G^A A$R?I\&![''BCC0&X+S"/NCZ@YWHD/9?PGYAX\.F)F0AGE4\
M0H_G\VT &\Y4OYF)E7:2'X=N%%$Z8]!"2(QD[(1L1[3P@>,=JE6B[_.=1Z1"
M<;0WCJ2*85WC 8:J[VA2D:^(H>L38G*+Y!+].O/MZ#CO+:4=L):M%LQA@2MB
M\.\3NIZP7O':X](#[&C63^+W]N8U2!]TERR/OQMQ-J\"T<TZMV#XH)%O@.Y>
M;)K_#C%\-E[WOMH?>[9Q.9GJ G+U+T(VD!;#?I>Y@%R/5UO"A>&9YL9ZJMCT
MU."<./@O[WK+14HG"M.P<8 <";@WF!V:E<9.,#9]=^6]K86X[J1S)03%(F!.
M>OL_)M.CUYRD>_YC%;'GG-:-N?N_U(/Y##E99MDYM0YWI>K"9PNM@S]:_A1V
M5VI"++N#Y+OGG),4?MC)#J,:R)87=48]YWM%6CZE44]]N2S)7]'+5:A*V@QK
MBU@\59ACF1],$VEW9CS-(3>7O/"TMK1;KK_WN8UT88OAJ@0QH6<0=_)R6T?P
MX4KR'[00WCP=2K+TZAJ+%CI+E^,VC5C)T GZ!C'Y'<]4,$6L>]E]&+E;L4$,
MQ;NCY?''\;^%0(A5=I Z3IT=N1%7,"42VOI3(F%/@4@B50UQ=R J(&=X>4-2
M5=:RF,?+V"V2ER47+4_F;)Q&[,B *\*D$=*5JZ,76N#1T8<<CY(2G?:3M2QT
MO\S6I9Y7-Y+*Y)6/*D](0X*SG(=P.P.*0\?TP+*DI!N^ME&/6M'H,V=LAK&+
MDF)F94TO],CO]]^5VUK/<[I21/*:SH>S^E2?1#J/(V9T7W]Z:GB,9MQ'L0$3
MH<(4>QG[M=<K[5R<2T.?'VUH[FYT"RGX(<?\_JV!=95[+,<C9GM6SO6_!BE:
MOP#3[*LK3/;SXX9AG/L&,B6)&.,6T9.+C7G[JTBWCJT"Z;2//H>>-M.1GL$U
MP8O2#F=U/ +'L%]IFE@<C=U(Q]5XVK\GAN+#PW[/O7(2Q2MZ5]5E!?_YR"V^
M&+F-)HS]_O[WZCG!>9?QF0^M'['>LYH!(UE)LIQCQ(L9\\;/$2"^9W6Z*!)>
M%!DSBH4<547O3TT*7L51KZH1Y?'*^6X_'ZV(4>IA22%Y EB()(3&BO#%I1,)
M7^"IE704%]Y$KW>;QY_17*I9(1KC-/7BM7.\,X&0'SAJ#KG8JYYH4?(7&$Y*
MH3_B!9,09Z3+ZTGK%#JK% DK^T3B (87XGH)8NX)YGQAI$YQ2MGNI&$HOTH4
M Q:2\OZYPON8P'2:&PSQ?3>4_P*:S19%3I[XG#GQKEYBYPSJ5@S\ Q"+,_,J
M<(UUDXLKY*"5IY%N+H9<GNAE%*-[K!.<^9(*Y9(V-H6O =2;3'2Z;H3XEO68
M-V&\*LUZ_XH@0GR4<JTO/R<FMX4Q!G<Q;75"]#:H67N5T\E?]LGQ>97:=DQ:
MEZV!">5^MQ@^8;Z7T\PO9]U?Y68ED "I5_'BG^<3OH0DQMHF,C.S)-$E\_^"
M.->#[]*:7EO3H#'$UR!T'%_JFGOB>6+:167:AIPZ;(=^$X^Z7P;CL01O8<#&
MQ9!L&V/N[6<S82FOLM2;)GV,TWTD,,0QUN;IQ! U;2OHX N-U\25FY@2O0RN
M0<V)6,@2[B5+,60-0$UJ3I'J9JP]KZY0F=P=I^Z<0(.>D"/QCY2; #<  /AI
M(36^>-FD+/T/+NWN8&X:S K@20Z0^JB> -;MAEP@Q2[9(1*8D#6S%Z3IU!.N
M&7,[+.> K+<<KJF3229KY)FSI/GE\A<X/N<K3/"##!?^L L:,,"1NIU7XQI#
M#]6%3 # 9Q.0K0EFTTRE'J>H=;FTU%VT>(_YL3F+%S>DH=+O7XQZ1TD0]R_P
M/0F>?T6/LV?Y&K3S')!)(D^3TMO2TCS2;B[S:G/3ZMLTQ?3!JT72:VKWE\U4
M6KL@EQAQ4G_Z,#T6T[ W(;EL1R1YI,601#-6^QAR9J!G!6-"PA;OR41F;CK$
M04SOFA3R:48N*+Q@G?\=V%EW^/U+@UVE%Z6*_@/TAV?J/P+%6Q9RO8.R*(_?
M C(4?3G>Y$H2*!]4O@,*%.GF6/8_>.=RQ],A1O):C%)_\N$)GIU:(+2Q."B3
M%#*7RS+Z@/5T0BTV787$*<MS-Q6;5,1C\)YWC^W'#OT1NT($ ' H9H(G2VWD
MSZ]AR?7A(?;=C"K;C1+&<MT@R;E/P,;BE"K2D$8\V(^?DON7H .2_#KV+4LS
MN&3+0=H@7\8@S98B]T%$V<T"ZB(F9(8$\!OYE&<!\Z^7>]<,?-CIT%0,V9@H
MWS2#!!6#I]88S]G%3<3!CNFLMQ-@TWJGA4"V4WS !R!D@T9_-U%O63XBHQN"
MYG9/2'@[%"#J4 _V?4%> 8R_C'E1UY3'%U%4Y/G>14<XB/'>BAJ!63[1:V(*
M^J!+F%(<8HJG5P4"@J])?#; [73@-BW(]2>*E^G@"3,PV7O03@.8\0_)8*OZ
M_1B$I@UX!\/.Z@Q@04-(7H.OBL ;$]54P8H1Y!'/[]'U!9"_U;=R*'H<1Y(6
MDT2\7J62^AXM(EMT+%"'M&*JY:IDLP(C^47)(DQG F']Z=3M RP[./!E3.4.
MGCHX G") \^6)EZI03;$_&$*U;]QU,$")B;%$"R0"5=DNXD'GW:^!IB!W\B#
M.QKNDQR3L,?GG#F"LWKY>D". GI\K^@<X=?BZST.-XZT1;*&IK2-/@)5FH;O
M2E@?"0SYX\T@.+.:0 6PX \CWP4"$H_YZ(*B6RX"';&GY4Y"3 *X\31@'2?V
M&R=Q)T%(JBQXQPQ2K 76_F1Q90:9,Z-AW >?%X'/'+W. ! <QDQC0 0@!HX0
M"Q5K1JRI04YIP-<TF0\IF-;O1M2]-A\/)[?[>N^4)HTTO="$@Y:2V3C5@B6)
M,\'!LZQD..^]W9?2X3*EC,273F9LT^ 37 9NVL,L'K*"K^.?%"G>$PA,)%;Y
M6[,30]NH!J%8)!W<R=?<%,R,B&0%<0;^8($V@QN*ODY[-<W:R7>>9LQ_KF(H
M!V\6TVW4-Q/O05*1D+H-<GUNR)591TNO\^FL 1H90=D%(93KK/23.M?S_9N#
M?&<FF Z\)O[8^?T[.;M-HJ1=/,1\FQP4"=E+[J14JH-0=<&[DG%X$@G_9^Q2
MK]P,FKA^%%RH=5!3=4_]8$F+^,!OS1*3"[G!^1T$0AHPW7K'!?+UX,VA$LF1
M]J#)IX^3;.FJ/++[($JOBF>^=LW9-?5PW@^X1EKD?ZD8[C6\D;S"64Y\Z'%^
M2?SB)6> ?)_$KY@A3XX;AGSC]C*GFSX3H7ZI:XZD2O#>$_ ZYNL7?\AO''@H
MUEYC2;/7MC?42"PJSL&!'9)(4R97#XXV(L-C/BAK<9Z=\?IL@I>F68XD>]->
M#6@I"<Q,04[4FD7-@T\4P0\U:"*N[L6P!Y&X9-*.N%R($6CKI?4"U NV,HEK
M7+1@XBKS531'8F2EWL.?J6C-LEN?5('-D[+WDDN7,>##">\3? .P^_/O)P/G
MTP\9KZR3FMC.,:\N\728;J:P+P5OS"%KCF^/V%,RVMDPTI'V8E@T\K&^9_HL
M#VO^+XB+6'28;8>0#"0".(81Z@VM?C]' PZD %,%5@LT^ )P9H]?@S\BXP
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M_HTBGKC104@'&&E-\>X,=A4CLAH#-O9'=%Z1W")%YLP@.H^[2#C8C8M!=^C
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M"\8RS[I,2%6[9.XX)D&-8<A]UGII#6W^S;J,R(#X&!V9\ZKLC,V+ABL81G-
MT_1#DZ/SQN8;U4('R0**8:&S=*@YDO$Y+B/HDLRX[$TD.;HUR)91@Y:.'92T
M1J9LAB:;>1.B!U+&DW&8@X)BN";"X,\GB-%K5,_9T?,$;,K=(5 0$LU;R08
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M^Y-G_Z)_]M-O@,$'^2X_ ,8'@$D']K@O^:Q'  $@?(!   X  ($.PB$@J!
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M#AVSB0%E[%?L\31SX_ R#GX6.P_-C,G#SQ_:ID7,1,(G[29R?@D4,'TP9=>
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M%E$H%9'%]7[R!W-M+O-0('[='4VM6R198&1#2:1%7V3]8F0K7E0[;50W5]2
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M!]004$R.*XT=_B([;O+A*O?G(3/\.V=--)-%T A#UI)W1'IY6).RG"&,*)9
MY?[CZ.O8T=._^809Q?JNM4]J"Y,^Y/O'1Y%?_%<8CQ!\)S'XT8/U]H8%)G>S
M]I)[>'JZIK[%A\G6X^%G_-5*6&4)XGU!S2_9/,<@9_7"(5'.(!A9TV!&)2'W
MI;[&$/-,0I:#KN+A9U-U8N%[72/O8%X86FP^LFH^^)P]QDS:3*/TH[$H9J);
M"BR*KE^)?#][F)R<D.-\\D>^LU.2$3Q7^#6)(PC1@UXK6AP2=%X;_<+>$/DF
MJW!C_FML/N>Z>'Q/WO;&\-<TR@ L@2FFW.]: FQP28#)D9@XP> MIVJ)3H]L
M"9OLV&_[*&79F]]5?=\8(LAE^[$53U5E;N\3*;[<7QPJB%%*D'PJ(3&]SU6X
M"_O2,14DAY0K#A.,6^+46I6]*;$#,(1'2U.HCOLL$;,NIFA^%RF+4:0G(3&K
MS- C85. ?L("M^M']V"'OLX!5Z;V;6KNZV(PUK$?X*0&Z](/S2H(P 05QW93
M1:-30M>:T_4IP(HT0E/ 9L0W^;;I"[!$N%6(E3IH4(]CT[F.0UN&HCTI>NFL
M8<7-H@$VT;4_X=Y6;!J1P6G_\M0=&1.R,R%C\[_'6CLRE<N!@P=!QO3]<TA$
M@J]YY/]Q*NE+^P-TNH+P5?9DT]BMUWZGJA1#;)$Q?D/V+FD V6LZY,CFL*6*
MN9+I)T$$:H>J96J5>OUI:D?J5;J=/@B$ZL"Y..0Z>]T2S,*11N"RLE>[0^5*
MHLU17:>EJXU.E_OF0V&D*_-&5R#J.FK%)_O-_J#5F& BK0OCD23&[P,96I?@
M\4S^==GTNU.#GNBO[7.A:,*\R9=@Q88BK@;HR*(%Z"$2]='E8.5EIU.OM);C
MI*W/<4%\ 4%; /_B#,64V\N QVV^K8+"YO'*;&85H?F)2._)[6)W+%LR6^_9
M(^/9A7>-2?M%V_OB*K=" UV[T_/ZSY1G3+9K6UQQE7N;G:2@98YP ;$;[E9L
MI?O*WX"LJ#M_26ZOO;](GY^585GR/;&"]AO;]_ G,[T:+D-)X%&EWY&X[K1*
MDCX?S@P2>(!WJM@^F\ YL)TM4M1)4<2*L7ZE^FG,6H:P?O1EZ'[C4EYZP">*
M=91NNWU:FKYVI4YZ.8VR7A8T(0:28U\PKI?C7 \"R7/O%]3+\Y[^_@@R33$/
M43!Z@)^=$()Y_J$@"DVG<YH40]=-G!1&X,=6%O\LGC@M064RJRQ'49DX(\.;
M.3LC)TK%KJ)$]<PVIR3'.#>E\JU_5DU3V*117<LZFEU#VW879T[/=4YM3L,>
MH4G3P)0_>='85Y=C42W5>W[)(#=37=LXGQUW&5SO/9>J]71>G*WU\.YVV6$8
MYY.._12[ZZK#'/'MJN.N,^>J^PR"D$Y5! $*=9&>-LI&7@S]>QA;+RR_(G"#
M28NVC<PSG#\]%SL;#N[(UZL))0P\&ARI!>$-=&%.:II)U2%A4B,AR7C_#*6H
MKX4H\!=FX&UZC*3-=*4[['X87,TABJ1HK;.45+XX>E/LV'3NMHB?*OA(_DI0
M"Q?]C)]0Y#3\N#E_;O1XR^0[\\1B<!$QO+'BP\&<9K1;AJ#8/45!^GUB:X1J
MU#V%.;CI;-BD;DZ8U#S7!#EU(NQXX!$]0^NN+T7I8G%IKN4++L])N"W"DZ41
M)>+5@1W\SU2P0"P:P6D0"B.2/Z,8OCAXX)XH.-AV[87BT"%98,6HI+"(/6DV
MD&07O3TU?)FH4$M"W]Q!DY1WJYJSB]AVBC@I]=^B"7(Q<<<$TQ6Z[21N6P9?
M"F:PH\"H@<]NZN.5]YZJV-=5_SU,S<%)A^[X'G,E9*B'K^T:"<((#Y@>O%BA
MX/7XYR .MJO-/,*X5 AAWHD3[0S?Z#ULR>=%\& ;E+XD$+\4&4EYC4/X?A75
M[J\?\<V)"V?1^4D@\$P+1W8P0"1ZBY!*C&3 N%%PH! U> QY=?7E#!6?"$X)
MC59R7P?OBY,3H_]L6W)?$WN_&7??Y_,ZC<X_P?V,=>_U]#HT/OWM%W>[AP,\
MF26 \EHD3-B!BI4_A+DSFNH<4O*)=C"^;R.R1S@D4O@Z)/9<74B@.3X9F%<3
M(/ \:"+P[PF'^F(%<XN%=FVLGJ-+//WX4L;2*79N'__.2O=S]$*K *)#K$MB
M_M[#%9((O0WV-Z$"8G'JCJ%HIIB$66(*9IP1APHCI=[(?.:EGTBJ"='*,14B
M1/T:,AK]0/^&G=0[6*H.40[H-GI)$%'^K/]@J;NU\1XI$G#AO"UIZ8NO@HXJ
M/9&6I!$N2ZH#&_7G:"T$_*J+S+]F-,0XG&U*$BKV[+)@''73"8N]Z/C?HW]8
M-DL;_^YNAOYFV,F] (Q*-\80'?@1<E.E-7P]CP</ '3IG<4[Z%<PB548$GF2
M4A47U6!BY4%$DA2%TP+4JD9,[*&T&%1C*8?8+@E>1JSF+@U>+@[OL_E4URRT
M92P>PHOGX2EEEI#[.:2GHN&-$06[N"18+.S+M2B-\'[12WCJ3D6YBUAJS[6I
M-S7-5=H&6^KL\FBTS<]5N?9;RD/2JFL\U"I\KRWU'WD6J["2RT-Q- 2PE&+[
M.6Y(H-$F0*//A%J#(DUUB4D5)J#()3'9^;JL0J 9\Z/6F$M30]XJT)P[4GNF
MZJ:AVMG:2HUW>;(WN2F_LM+*T7-Y]F2^N07!QC9P67L-Z[:Y5[S*/G14>^_/
M3<N(G(VC<[O.OK)K6V)_J$&/MN8)>7+%.K&E&TRY[EE,<_OR=94;@N?:Q?Q[
MP,9%A+((^8]BC'[]9U@_+U\L%@ 1A(8-IMQCF$'_!HNK<X^_IH6/876+]:X5
MK<DFL)QP]9WH0B]&T9DSLX[!!UO-/F+$+Z'B3YN8,BF_:3CL(S[K;.'DM_1W
M6)_Z84;I$0RV=(.:[ -,.O2(UU,&86Z0")KK$HON"O2?#:$1\?$B+(&;QCI>
M[';1^1E&=-MN(X<H&@RL%5O(OQ9'=1$ODW\!]U@\4T:-)>I3!ROV6$,7^ZW!
M7S+6,\"<V:EC3DU P9*.?89O2Q.">Y?9KGQFGT^YOEN/(&H\YIJZM(9.[6NS
M?2)F_"O%V38=YW/5QE3Y5S;6<B;KY*J@IR26]V?;N*5 8\9QA@7?Q-*LO<UU
MF<&SA49]VGQ=U76%M>Z^.M_2=.Y+0\D7.7/]3^F+@R_L=:&95F#FY:4,=8Z&
M=,9CT\"'Q3-M2;W&3FL;U^7E=41.]X?SM=N;Q14U1*?LF6<-'S.MN9)YYP['
M2H.!0Z/(0^JK5KA.&Y]]PE4=J]L.J/WJHM>_US9FI][KZ%.)=L(U6-^[;@J!
M<U<-OK'$N4&\,;=^>]]^&J+[GPFIAHD42,#AZZ3PK/5'V^!ZK\T ^99V5T;;
M\&]/\Y;C;K^^Q9S]/.K8YW6Y&[,>W\BX7-F5Y/28/I<[UP3I'LA]YAG+M+$<
M0&E:T6X]C3\>3:R[NMUY?&Z3 ]<Z%/8][?-^JA$T9KHN$>TX9J]N6XH?/ZM?
M\#[9SN195HET:?VYNN]Z>AMP_>+4.[%RK"CIM<F@$ZNN^5QA1G\D2X+^8_A7
MP053*U^K28+[N,S:93J43Q9L<*I.F8=3S,E_J/#]8:XXZ[HL]/G(Y-3C3_/:
M36TU_XFM(/1Q=3_KMBW6FP%ES7XT-.MB@%G@(.GSCW%FZ-VX@L!E?.S]7TN]
M!V;\9Z#'+^\-Z-ICKZ_#9;7@R_X/P8==2>C]G(+W0?WZTXF"X%/]A/?IX]K+
MU2_?V\OOOD^WWZ$O^[^@'[L!E-V/HUV#HMTN[YH1C+L1G;J1@H3LVIN[\GF[
M>5M0KMK?%P@)CX:J=R/U\_)A!/%B0MHQV#HP^7JPQ(1UX02['ML_. FC>@E_
M*.A!G267B?P 0XOWDS8ECLLOA2LE3A_&]]V[_)9P6W]6PL0>JJ@>Z@9>O'^M
M.&P]/3(]S2H]# V]0-G76X](6CGF>R<1%J]>@@QAJ@^B@>\_52*+0)\<4.#Q
M_#A6F*&]S-R0\%I"45!''^NL*#5$%%\%"/S72X<M1D<I)D0IS,CW6P@HMF+!
M1XO=)^GT6XI25*"A.XGWH\-2BP!?W]<5,;X@,7G@3W0B,=&=7C&V?F4Q<7K5
M?B4QL0^6")5_^N2CQ.4*^A6N?N,MM]!$=NON].M=]7^'']#''C"@'#!DDS!@
MH_B6(6Y2(/:UH_\K-I^ZJIBR3K]XQH Z48=$N;BICH2-E82BL836TX!I$'<)
M:5TL*+*2D-L9*/*H+<K-UTK^Q Q([[:!E[3%'O1:D;##%+=*'%"ID+!X&E1U
M8A^HEW3@&PHBD@R>';1;D0PB CK3??3V'X*&_!X,-1ZJ3P^VW)'R(QKRNY*T
MQ.;A;Q],J)"*TAE*;)#Z 9&2<GJWQ3N0DCB<6C"<UC"<_GLX8W8X\Q^'7:M4
M*/Q(-K9TLNK71)WA'PW==N[  .RO1=A#1?##,4XC<5XC959 :V"Y5AQ2.=>@
M_^:G!ZR(>Q1>YP^]:8"Z9"+I EF9!LJ1?&.91N/AG'3ITBCIV*"1V-^C[;,R
MY?]Z-V=:0.0?LZUD\BDA.42R?4&CO[U&^Y^2T6IENKQDRQ)EVR R0QFC0[*@
M"K:?#%O#XU>0"?BQ2>RQ*<JQ:38Y(Z+F/IW1/#'9 2>9>9VQA<2QWJ@QUW<\
M(RNCP[\AJQV0->-VJ">@6C0PJAH[Q1<&0&8L6ITNF<HELZ@ZMJ\JNQ\UOF0E
M]]=)[@_E"$.OW&B%S'J%[.K5.$Y#<V^"5 T7GJU;'XQ0ZR,!2N[!NY\YHO6_
MQ_]F3!Q5R!]6C#U6*!SM3&1N5QS#3YQ@3Y["3[X^;M7ORCMYQA!,)A&=)Y&"
M)Y&3%-G]T9;]8GZU3&Z0HGU8540]1EVKB?R H(3V/+E,JX3)/H5Q/(EYK8C#
M/X4CIX3E/(6?-$5@K639/968,DF\.T4\%A;EEH"".OT/;_H/K3(I@A*1W#2%
MVC2VM3*9[C2MLS)UH3)=\#1=HS+YF#+%JC)E_S1==#0R&\),7JA83JADRP^H
M>@N26 D2QS&03SB(M1#H(13$1CS#$0T4]E,!50+Y>I XG%4\S!#&2A3QQ*=$
MV6?%DF+:-Y 2NZ<^!:N^2B$TF9*.GOK:.474.9EH-CO@IOJU454L6M5R@X/3
MI!+JQ$1E/[,CHK:4AT2UJ:+.R*A1J4*I-3??-@>%J&WEA6K(87$WUJ@' \4
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M)8>O$FX,!O?9GO2=QX8=P@)7JOZ[!&4S?+CN4M(/-J3L9Z)P+AEP:SFH UB
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M+5A@'$YZ %:,6>75>[49(][9>X]X*1I@R06,BRO B2N"K@R,KO)66;^!BQO
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M$M?1)%@/7)>(Z.H]?"9#';QW&]NI.^1.X#UR^)"NNN=.WCJ'#[MZ_0HVK%<
M9,N:/8LVK=JU;-NZ?0LWKMRY=.O:O8LWK]Z]?/OZ_0LXL.#!A L;WLM/K.+%
MC GZ4_Q8;&1KDQ]6_GJY,3UYUJ!=])JY:^C&I$LW/HPZM>K5K%N[?@T[MNS9
MM&L+-HT[M^[=O'O[_IW;MO#AQ(L;/XX\N?+ES,D"?PX]NO3IU!\VOXX]N_;M
MW+M[_\ZVNOCQY,L#CPP^O?KU[-N[?\_>O/SY].O#OX\_O_[]_/O7K0]@@ (&
MYU^!!O\>B&"""B[(8(,./@AAA!).2&&%%EZ(888:;LAAAQY^"&*((HY(8HDF
MGHABBBJNR&*++KX(8XPRSDACC3;>B&..$#I#33/,,./CCT$"^2.10A8Y9))(
M+GEDDT8^J:2344+)))525CEEEEAN>6675GZII9=A@LDEF6*6.6:::*YY9IMF
MOJFFFW'"R2:=<M8Y9YYX[GEGGW;^J:>?@0+*)Z%G-N-,-="4U8\__@#0Z*.1
M0NHHI9)6.FFFF&YZ::>6?NJHH_WP5TTS/BIYZI*I'KDJD:VFBBJ5K[JJJJRV
MQHIKK;FR>JNNOO*Z*ZW!POJKL,42"^RQM";+K+'-(NMLM-#_3KNLM-52.VNV
MO3Y[;;?:#NOMMM9^JRRYW)H[KKC8JALNN.BNZRZ[[[9;KKSV#ODC-8LV.BJ_
ME/;K#\ "_TNPOP8'7##"!_=;5JBCND=-O?%.+''%Y]YK<;H47[RQQAG#^S&]
M'(<\;\D8CXPRF29W#'+*+7O,[94KDWPRS#:_3*V3O+HL\LT]X]PM,\X$3+2F
M_&YZ]*5)_TNTTDTS;?33HU:J7JDRUPSTS((&C?7/7FOM\[M5F-,UV%F7S4PJ
MY/RA,MHL?ZVN*#*,<NK87E\=[Q;E\,R,W'D<ZK:OS8PBP]^!\VSVEHG/[.,?
MXZ0"I#'EY''VVXL?;N0S"0^\\.:>_W<.NL*B,]PH8. @$(X#IP.@.NJMHP4.
M"^$@4-8 L<\>3EO.$&LYYO#F40X""!P@PQ\^JHV -\(C,,X6QNR<APS?L)UD
M]+-_0XXH.X?M.]P4CQ+.%M[3W/N0J<PNO#<L5 'YK'^$PS8SHSBP=_>7E_]C
M%3(\S\S[U(M<!0>, F_%DH;<JL"R/"!@%-+H7_@4US7Y)2]^1))&'LC!P/$A
MKF8-7%45$! __&U0&L:0 0)_E <':(][(F0A^994C4Y)S6&<FJ&H:JBI&\HP
MAT\+55^^@0 6( "(0@1 $%LGQ"0"X'2S*R( B(B T['  6NQAJE>N,&.I>*#
MQBM2*O( N?\_3,]()1QCX\9A#E&4@QRP^@,"3O@C&8"C?5S#WZP 9\<GF2,<
M=+PCQGBGK#NEJ@KA&."/_@ .<AC+1S)@XR+91< L!O*1L1K%-\3GHW+P<4U^
M!!>K%+A"3[IJ''OKI. \YJ,MP(^4M$K%.&2 Q;:I25L&1$ >.D@G4P)R:\UP
M8_Q<J<B<N5"2Q+R9YC@WNL\E,W3(;.;G^(*Z(:(EFK0C2^K 418F4A$ UR1+
M%!$0 +4X X(MK)RN2OBX:OVH'.D\TOE@6:1#VM*=K(PG(2$'+#4F\8T^^B ^
M1>& 3;JR''^0'NHHB,@M?-",HB ' ASPC>(%B7"Q0T#]F*%*V:G_L$BBB,%#
ML4>Y(KU/>"8T(:[\( /AK>^52(J>\+X1@^>)@@71 Z(H&NBXX3%/?$*RG@-8
M0#TU7E,&HIB2#.K7P \:4E@SI2 Y]G=(^ 50>>3HHTN'6(ZB%LD<0D2 "4'8
M0/D9E 7E^*!6Q?H-%DS1<,3:HDXM*E*'XNY_6QA'(7YTP%/]09,_K0*5?/FC
M$E8AI\H+8?\<*CSXI8T<BI0G!=]II ]2U1S@8)L!UU<D_>WU>GX-DC'( 40$
MD$.!=-/5!6]:!1:<U8$*=8#RTGG'@B82 3Q-VP>;6 5C!$ENH9TG,XY:US?^
MR*VX-<9E'QJ.1H:1MD4RX1_(X5K?^F@4_XA]XSUUU5 A'L"602JH6EE 5"'I
M3[<.I&!&9\?66)JSF"USQJ>.%K7X(FV&2X/O?.5;.KU\\QO3[&HV?UJ6*:[N
MB4>4(@($H)9=#G/!.3,KLT8AW">)L91(2NUJD9>'48CB#Q\\H9(8.R1SF-&L
MY3!C_X082@NGTJM(RBM>Y1A&H JK'+ ,:^1,^N(YI@T<%&8&**54PDT>DJ$1
M;E*'W9E<)+GQA-=%\D6GY4;PHN_)J@H@_PK! DPRPQRB%:D9_P#4L$*X'(T[
M@):;\53^E?A_HV !.E[LUQL+V4@*3._Q'MC 48S# <\3[*E(VS@9)\M'Y-AD
M,T1QT"(YH*J+S?^>D@ ;1T<&.GYN3"\YVNE&0[J2N_E#P JWX(W_N1*>5+HT
M/B&=28OR[WS!K!68_U>W&J/0MS!FJEHIR(SQAK7.PV5EJBC;/D0+^K?I3$7P
M2MLWZ2XIM13LK@ [.%-'0KBVA6Z?A6V\7@9KD'M"@Y0RG<G,;XN[<U3+2T!5
M9Q9R&'%V98DF"[(INVJ>Y9MKZ1%[M_TRM>T/VZX")2X;6&U:M9EL4A)%*@R>
M!]7B,D@*)"5CP1C/$A9YG;!=9W@%:V31-I*@^/P113$8SRU$E'V=?BHY.,Z,
M!K*SCVO4U0?YE[]BLY17YXMS<RO>/^DJ,!SEX-^A'5HX9NFO2 !'0!__O1@.
MFU>AG?,S7/XVJ>=%']4<AC2@">-Y/O%)PP]@%6EE@?3!5Y[\#QT?$B([2W1F
M%+J1Y!@L_R[[A[ ^5<FR"R^M+NOT\?ZHEK?,M:&?M/*4S]3IOVVL*]$N/P>P
ME;$I+Z\7R1$#P=L2EXB$M9'&8=$J5$&A_,2K ^(\W2SW;\_A(.NI58=!G(+W
MJ9L/I;^9%,!0.G#CK3^2&^_J(ZO#47\KU/VDZ:SP9:':B^-@P5/+.HJ.JW*
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M_OO_&O_JUW__H0N_X8"W=AM ='LV=BM =S/ ?@@W<-LV!GQ !XQ ;X/ "91
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M^]TSSCWWN_?[Z^R,F3_VWFO._<PUYUS/7&,1%X@; &H=#6T-P+7KUP"0JQ^
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MGT%#'CI]D*.: *KH:9"ES4"@N@\XT+.5<7IP'<G^_6O*_:,:2JCBA0&LEYY
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M%X)-1, N1Z0/%]KBS!7A"%J444_\Z8KWVPQBI"<"+(7Y^R_U,G@V\+^I:2!
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M/'L_(BVL@9F?IZC*..)'6NE(45V8;]@\HB5Y8'V):E.\'[BP;7V9IZ1Y(6&
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MDM<)6=/ 5FG8^6T#(N"*F>!67]9KGL/4GI4ZN^Y.@2(/7%LSZW<2,^=.?1)
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MT$:QK<&B@CC#$U-3\=&#55GC@H*<U1^MTB?PB9X?AU>=ATZ(/U -7[T%3"Y
M/U]?B,;:87)A=XD 5]"2]>9\GP&[=NGR/GBSGN&J3FMTO /+)DTNK4=-G5#J
M3'_-VPIX[/DTHO+;"S_;LR]42Q=8N\NJDTL#HZN"((^[L452EF09H+8IJK&S
M:FD_\%+;__"JFL\DMGW(>!3 4;Q,ZJPFX/+<P8+]E8"(R6=(Q69):M(#B^#)
M3S,U1;,N)'J5LJYP8=FBMKE'I KK9DGB%"+/7,1>*?G0VT+:5H<5=,(FI?*6
M?#KV0EG_O;FCR#]#!$C8R6.:L+$XA@L9B!9N:VL=Z74++X N:GA2?<71W$VS
MWEZ+K$TLD<TNW4AH)+.:&O2/Z0BJR9E7,48S8?]>QL/<1#V][A F"II;KVI)
M7,^#9F.>)?[H &7592/A-[A6^+S_&*?NHLQ[:,Y]'UGNLR!IB5[4MH;%1WN?
M1_U]>Y"8[]5"U&[S1E6?=I'5U>6\'5(9XA3DD_T3=-%1#U[_*!2:V;(*7,Y(
M3:D4/FFV/3AL.-V"45WTGW\G OP)7-_,4Z&>N&-T(-8;37F&%$]:ISZABB0"
M[IY4CU*(:B)[>*\*XN+KS.#T&3,SQM]B6<X5:U*9YH'4O<QQ<X]9>GUC6-ZB
M$5N(7D3B^AV/GD=0;ESB)B*&B_SXU2G;A1<[+LR]4LJ\>7(+?&II8[MD!;+.
MN>T(]K1O:XKR3Q".R;*3')<2OI".P4J'ODLIJ;Z0OV RSY#$NI6+<U>.UC_(
ME(;#8TUW+M35EHVPNT)UR<W1<)/ZT4,.Q3]5T+5CQ631D^X),[OD$T)4EIT>
MVF!KO;=@2;'WSU6<;9@/@*CPS]$F5BV%G[11H#M7(<8A'9 G9-XZ(W6P9Z80
MVF_@+MGL*_GX>\/-(>$Z,@PHZ2HB85<1Z3P_W8?@) + 1$ DUQVH[GWN"RKK
MV?IC.'.>25-_(&ET\YC[@2S-FZ<M\[5>?G374Y[6D<^JD<97FN_-H-NR4/?'
MRU7IA4::K:PJC1)LM> !(4CKU_(.Z.;=4(<R?JH[2BM![N-P.<-,29LZ:6?>
M6Z63E>[?+SCUUY-/REJOZE 'L!8RT6NP)+ZA>2BXF=7EC*9"M;XCB$ <YC8]
MQ."PV^NC 92EHY]2Y#QKCPX/CFNS34:?NL 3G<E1,H[L;T-37+2*P4XO/B I
M=+E;GR9)N7P8E_2NJ!D"Y-YXXYJGD%8N%  >S]/JU,G3TJ&+/Q30%E3?;]*.
M5'A?S1H@J,\@.,S/,IWF0B;F4N/,N,7[*T<M^C_L3(>!1XD DJN>+-SRB?)J
M+J*5J=>IHRE#2ZQP=4L#PMOZH3B+9W&3$3"X-S*DZ'N7K+Z8"' !+NMBC2[K
MN9#_C;3WC&JJ;=[%L2)-E%X$5'J7+AC)(PH(2.]!B("4$#$B($$#46G2I4N-
M"*%#:*%#I"N(2)=.@J T203"%I+PYWE__P_O6>N<+^=\2-;*3M;.W-<]>^::
MS)79EJ%?,")M%REET)/QX@SNTV0X_-&"J.AEWW^\BXZ8#J&&HY$:XMCUJ[.?
MU':\M#)7:-D'/BO3$:Q/*Z$GX@N,-5?+[5G>%)N!A@Q 8[G7^[12"WB?X:0^
MX)]=*WZW L3D]47>8(94; \:)\A%&">O6*8VN[(,F(W$9=<^L_3]E;E[N"=F
MO@ZK'*>;[^#2U=&S4=0[%.7^[,5I]#_T]ZA398QOSP.F&AH7616E)LVC*W\'
M;#ALXRKG?XR*C\R\<'(LR'(HF!!A(!1MB^SB7@PGTD*6AB/RSE.D>\S?Y(F/
MT<27T.=@&3I3T333LMB48N\6TP\9S80VOF?[]BYWY ?_\NT8);9$UN2)732S
M(5I%>)O5N^I<RY5[F^9@\ZQ8SC+5NE0H\:XQ2VG[U>D*%8'GT5]SGVM<T6^R
MS9'KLL3J/!^/,#(PU;. ?%6%]<(E$CIU,,5[/,1]\%D&_B^!N C([].XV7IU
M5C.)[:>H,X!\*3QKXHNFCF=.HZX</GU]?2E1ZN(Q.8_8\GVP>,1T4ZGXM>3Z
M'QG<")QM0\3<'#]>/SMK>MNL Q]#';2H;8Y<[_O]E:2BSO]LZLF-V2%?=:7:
M?M!3=7-A9G:;U;(.;OZ(%8<*)7'VGT%GWN3;Q2;;M<:4GMN!K%/;&SR1CUSX
M>;8C>X@4.270UP@?VU1$V2KU:8;BY!1^;W,0]E^]A*E.-!=AJ01*-N<,<U'"
M?!3C/F)ZQ!FF>Y$27]BA_S7*OWQ])F?$V.-BL&_P>^^9AG3S=YTL)JL69D9,
M7+KU@#\%2BSN'3[S'64$N"XGG@>V/T+2VH<F,F)HVBCE^LRE^KC!@%73I"$V
MISN@S_E-D;++>A4C3 ,.I>&](\6L^.JF+)LRI^F)<KU*G4"EJF;IZS)?U^:?
M-@96$V.[)DOMTBZ9B59"GNZO654:8^\ZUO\ELF@;#!7^3:Y[]CSO=>@1$XDP
MFJY[Q!2UAQN*1S#8CJT_W4I>K2O]!=G>:B6[FTRJ.QOL&TVH'Y:"W*1KQP,&
MFQ\AMB14 +.[>2;PUN#WSR*-KBH+\R1-L8=,]1TQ-2(V@\C]2_TO"=Z8-V+U
MRB]1TN0;I!RJW>+Y#JEU7%4B!]"Q;#'V6"-6H#[%]\.<CV150*M3]G?&E*L/
MZ!W4SWXFOJ)VL^]\5MXI86;(_50;\KLW+;4K3U>*L*;^@VG:3_M^?VYUO/&P
M[E+'AU(9=[*US0>L;3^OGG&J[8<5R[+$9#E3_0$[8U/YQ=L;M_:S&:=HI1-_
M8XZ)-$0,D+QCLOKY, #%<W?NL;TGI<2.5=>M G4E\A0]&;[KU>6B0%Y,!"D2
M"<* EF,=A3\<Y9H/TY4F]Q&*,TTC&XGT9WT<YH83%?$]%F:^@1RZJPN_YX;8
MK?Y:50$CM04Z@((GKX%#A90\AV##>XK \WJ;+",\O]5%*YCZC#V\%,ONR<VS
M6OV]0O-*E\I/&_G1"A)&SLPXYP<IVU1JU/[;FO"'$/#[_(/$XCV-G8PMWD.7
MT"^$6I<,XI 7-148(7*&/8?&_/XY1M,.(2UN8<0=VAL:T]=),^._#LS*2'=]
MMU8SOZRQGHZO[ED255[2HO&P4:7II2!#Y7""%V[&G1C5B^"YY7MS]I?HI?%
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MWI1?TC7JU6@N<WN::?IG9 "(-+HQ K'N6O65@8Q4#HI<.V+Z)L*;6^ASX$+
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MEZ!]5]Y+]]R$]XA=1-V9"0TKB3<>NV?.AWQA.KJ[I;EC<8MJA'!OJDZJ$AV
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M:-GO'%D+V<4W?LI4G.C?V@MNNQWM$.<KS:Z',[[.CI=F':B\/IYPBE.H]/J
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M9&PY[&W&ZF]J'C$Y3BI7!@S)F]0U$<8#V=:6&^IJ:^NCBYI;FILRDV4>1$K
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MDL!'B\W)_<5'8F+-K<V9ZH49AO;7 P-%V:TM(CU5*-.>D^WUE,9OIOL3&9U
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M+@%V8>M)G\/W?)X)W7@3E9Y5K>"H*ZXA2YGY1X&<R_<N3!>0;'V66.R/ZTY
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MLB&>\L^715_*_T+8&L=_4PR>XVE6C,UMJ$:G^PZR372K/6Z1]LS@/[R=*9W
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M&+"@\BB,<!"!LJ8*H40G N3\J-W"FG,!U+UG"CQ(XO9/78=Q1J17GTW*=G:
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MJ4G<D]1\M&U(EQ T<^<00&)=.$DE*E+NNIT;D+^Y#-K$'@RG,T'84%:\?,2
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M&\HXS!&7:J=#MY'UJTBU(VK+(-]<<*EIZ/G?"C4I/?F]K2"M+OW.]&VBS0\
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M(?@5*3.(I.Q#(Q*/[1G)9"YC%J+'E_!/<XZ&5S0N?%GJ5_3V]OR&Q&;&AI[
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MR+2'IG__T:J\]<=.5F]I_MGXI+$A,32-,M2_K]'55_E(NV 4@2Y/DE4F&4A
M.A+1&LOR0,S*S*R&M$/KI*EL^<@75-T:<390^$\ \TX''A6'9*?-V'MX<+,I
M_.0[HLKF"6K:)QB<9_=9SOE*L\29%\>0(L81A7]Z+[C6U3LT7K%AHUR_%.C#
M GL,#@I!@-2\/&R#<A9WVUW*B>2$5XWU%&FH>"4FIH89U*L=53*_%^9>D8/[
M_(LC8L*"0W#;EQ@YK)S]O,HSX3;UN#&.L!9I461'.:"<'&6 !?NN]4=GIC!^
M$6<+#WDNKL.Z I(.[[0:)S8V!A6V-];]MOISW9GF(N?WGRQA2KP)/<SQ8( '
ML!3I :H<(2 44-4J#$W*,K5FJOLRCW>!=RP>-FUB3I>R'1E]W5J-=.VDOK.,
M)6YB426BP-@ 1]L#_;75Y?T (KSHFQNS_A7K0;@SOC!.)K2L;4<R5EE!K4 .
MB-GQCYFX]B,-,S44\E*'7<Q%C*#J=H.I6R4JBGQRRZ"I7:)*&FC=05"O=12]
M.[EDH7=W?9D_EGT&,P6%].E@QN5,N8T87;004_LQ]HZV$*+/F*&=V,?',642
MXMO^^UJ$M>KXV'(R<C<YFI!I:DU'FL38V1NRK>AL.X8F(6%'.]+^<O??=QLU
M=AJ_7L]0^]GB[R5:GD1R:U034QUK,S5/,)I#(?1JU9PK7?B<IJ^5BM=52@[;
MUD5\YE/6&=F\N>&OE2C5]4/%R6UC;%_E+]F,G'BE7^<:6>Y>JH5KN9^H5EBO
M:J65X^8Z[?=K?%]N_CZ+/6F")4O1Y;D&WK#OC8PU^A#)\2"V7V%?61?M@03Z
MI("1:T!D(V:**FH&X1R=-8TL2Y8@R<DS'KS6F?GOO^M'N9\G1X*K$%U#23]Z
M+2R2KF6/_7QN;_G^7 7/E8F]4JHQ4<DT3.BQH0%-"JU%OA]^7E0S>>T7=*N]
MX%IK]E) MLIPSQ/29&B$U?'AH\[\8K^+*O9 _;K;(80;N#A<,S@=HZR'/=EW
MP!>%'(0*]AD \E;L@T H'?M8^]0TQX1N)RA"4J\7GZSJ;.>-SD4LDCOSOUOT
M3&LV+JNGW'IF]*W'73A!Z^K5,OS3E:W[PT4UN:HTYLO(RA,P*?,,SU9_%6@T
M8E,GOWWC_;WYNIEBQD04;YSLY)P^8[#F(K0_?OKKW!?&TT'NZ7<:)7O]53:P
M)=@0QW^P)P@K);X' 7_V=<SP$U0]C4"")NV!Q#G\*U@9"GDU5 I5?@D87=%.
M-BXV=DS3 \NN+VO-M6TIA(?5> 3]^8*K#[RW86A@..%CGJ+4NYL'K@(LAMQQ
MS;L<T5#6JTF.#3W873Z1T K>IK[@39<*3' L&A$P S/Y&8Z ?PR-($L)$N\@
M!"7V]_73KOR,-9_MIV<J1$\*7!SSX::1",W*.ZKL*PBHH!YXT6*5K]]1F",#
MP.DE$O0#P'^*4V2H[W@O\&H5+D"ZR7A/$/N9)0_@R"'+<E.5A;L>G9.FPLM2
M$I3IE^_N^S>W=K2GA@(JV&TP';IH;R:!A(+[5-:I?#UA*S=7<<>1RXK3K;)V
M'GN@^!Q:**E735!DT.Q$!^3B3-XRSI1UZYN/,>/JZ=:N[J#C=P^X+#A*)1:^
M2!CR$PMR+T\K3QM2<J]+N.#Z L['ISK%FI%5^Z'XM5SI6.1OT4+G](?*":3^
M6?*-EYFIY5[\7OQQO6K>/\6,Y]&W?Y^&^MN[O?#EKS9Z/0X>5UD:=.&L<]/[
M3-!7N(6\OS!+D*1!;5$@"<YT[V"<'6=1&9),S<]+2^2$73+N"'P3TI&@A\(K
MZS:5E'',YSC0%\DO8D[=*11MF;KQ-AFS;Y/[37G"F[@C6#]\G)P84[R^'HE1
MG^'L"RO^M;1(GU"7Z4@O=B]VJ,,%*+LW9UQ)GJ%8! ?4>"P0[_I_6[$+?E46
M9XFRWGFXSUN;,]# /5"R_"%3BY6LE&@)HO81P-"*T?$/3P_E^8M(R7SUD.E'
M@\?S3J,LZ/8%C[?QFE_]VB8K<)X,AR<!^C\Y$KJ"^E\;A;)5/\(VE7I[>XO%
M9Q\X:?:6Y/7NMR[N8HR)D?/RY.$]T"UI5'F*M?\E[X4J$W#*\TK+0?VPO-5D
M\F2\C)MR8MG+'S>C),G?EQOOU':(C4I3?#<W1NZY,6:*D:JV^2?27P*>+=DY
M#:_T,:\\L3*57^]/E!6O2L5DVQ@M$-[O+NI2>?P_);(B6-RV/M5-X[X7-4%T
MQX,<C>D>1Z;:]RN,:XD?^FNV*.!$#'_0$Q3.LG-V0FQW%^U7"U]8>OOH1W)P
M,ZWG((]?F^G)'H(V\^WHKRR"95 %=+Y_,$<X3L B8VUE*+T'AJU9!IIW:;XX
MOF3I_@==596U\T'&9%*7U;,@9'!0>)V')V+QR-:T!*CPSWFR?#-X1V@EE/)]
M57['AZV!=@9D7R!PK>!_3(7V4WB*,=\0(6G9D!D[EE8#B)GU5R&H8'U\$N\L
M(X]5XA=>OC@OT"OB\WJFE35#[R;8N7I5N6\0_'#SN'U:;%Y[A W*XD.ET;^A
M/68P4/0UX#$3 I6" ]&"8(_V@B$AQ":5D;,0=,TCL,.SP64S#OG.U*0ZR/-V
MJ8MF9?&! DB/U0DIUYK8^Y&;'05NE0X57U:M*I30KD'7_C0GRDZEK_&[_AFU
M3K6CJ%3]]BL.]%,JM"+,W+3*Q1!L*Z^8'W.K';78G*R';^GF13H-G,^ UKO\
M:>%235)[",K06X0%Y3<$.>C*4\_=05R:K\Y_2$Z#G'W&K/8$KJ\&.])AJ3L_
MY1_[]?>=F=-O/$)\\R3(.+,D6+_!LRU[:0D[X -.^=P)$Z]7=+_Y/!K:OM/^
MA.V,[9?%^H,IL%6'@OTHQP[&E 2P(C[@>P(,&ILV?DF\:T0-RTJ3#3L\[SRI
M"Z(HSI4J?0L)#0THN)J-]"IB)TY5M"X>2&,)L&#<#%,+M@F/U+&_B@\:5W?X
MR)X[7]*8%K9PZ:!HN>JJ]5?OF$?68*63#R9VM;[J'['70 1V7-%Z[/W4>\!O
M^?G#JNY]U- (3&N."*P?_K*TGNDP-CX(!4= !990<'I5UO./6H_ELSC@>GL\
M (?U,6;+E99^CB=).*,*W"=YDQT=!F\W0B,%FCMW>+-$+L9M6<N[M64S\N54
M:EUO/ES?#1:1>Z-8U6&ZQ-9&U;XIP,'Y2VB&OQOOQ3&!XZ\W;SN7)Z=7VK"]
M!^1A$6[NGZ8W^]G^#JU%Z1)==98JY63"2CGU2)\,YCW\924^"7,@,#J+**O@
MPJT@W-&T^B,+'I0SZNDN7;L&T!A_U#]N4GZE1,;>U/SZ_'4IA3ZL_J.EE )+
M#)25?53$JBCHQXEC5YYC6PC;&^QK0)^F-.L&=J';&RBGC?-MREW$T=82.5AF
MFET7XVO^*+T7:3O;FN'[N\>D;-/>(*URM"ZPO> \HF!R]3HJW1UN@X[EYF$#
MQRGUK)MM@"$SAQ[P9E2!?K& C$LP,W$41^LR#$D7H?W" ):&(T&/ V\W"B#@
M5+07'DE=I+05)!62EOOKAJHN1=WO$+A]RN(P6I])7('%8Q&[@!H^M4]HL^]"
M)W"]!FW ?8(^P&U"VS!:6!B@VY]I.P^D^2;93IORT> 4!5H6B7I\0]Q7/*RV
M.E4_%FKCX_S')_Q2>]P?BKI=7I&,H&=X):*S0PT(7!/;NC777N^>W6BG56XA
M<JQ)N%$UO+;&5J?DRD)5K?+.Z2;CO"NN#OEB5IEGKUM")&W4]#9F(A!^2'>B
M0V%QD$IGYVMSYW3ER.%-(_8%CFP%JG"1I0^<_J\(*S#"UMD##<36>5)YLQ@1
M;NE_1T.E/T&UD$NU9W] ^5&S4\2NJ+0(QX1Z.A?!'J"4)#U">V'I=O)'-AL/
M?X09M@\*E-SZ:N1^\^=[>0%3+T;]$+5%.74/='-W'LO: P%.3&DB5:0'3!O/
M6#X'C(318G!\'%O@?-/'Q7VV%PK%**81LOH,;=IB)$-N,Q/:J$FFAA5C795Q
M%=?2++W$?X(/</0=*=)#A+9?'.$H.HQDEY4&/V FAI*G56>:R7-N,Z"/>!"T
M.C.J7UMV<T.NTG^%6(66923%882:ZFF]-_9G%_!\J!JEM? ^^OTY9!#&_2HO
MGJ,"A/Y7L'#J*YJ?1LV0;X5O_ZH#M ?2JK2336$,/$UB?\KI\B=O39QQDJWJ
M#5\-%=X/ML$BOA1/E3+FU3Y9QH.LA[*M<P'$*..+XPN52?423]6\/TX]WQJU
M:G1+KD\/&[Q1[P]XW/@XK>K"&L_77W-."'1AZ=>'3R94JS9YR_WE)G/!S^=:
M6D1MST492"E8REH^I53GTG2]RWQ3@-5)O%6DK*>>-^*=D0HT>0\4+'_$EP/;
M \6U8(;D^?&84V@+1@%Q5Y1S !B'9J(OKF!%?0/%^XPF-'YF'7B&UL9K('5E
MM:_E!_IN?ATTN8C0;_/8CO12*L2>_^\<0O4JS#"6X0J6Q(Q0^;3T1T586*":
MK1M(@"@"\%I4EB_3((&FG?Q'JQ>/<OA%,A/O9EJ5-R+SK4D0P\2(SC8O?OWK
M#8(#]F'(X)#OY^2].!;<[$BJ#&:)< "+W()+!W:%/&)$T9)(4!!"[A#.>CI$
MO_'^UF#!LF1WVW2#?D6WEX Z\O '_TQD3)'-E^*/5N_4CBYB2H:V6QH_\I:[
M8#O)IO[EU4D_=A>^.<:-KUA4P&7O^UAR[.B:*.1&H\"+:LU_TKPSY^?;GKW^
MKODI9XRR63Z,VM3FLQ-4&UFP5JRWBO#V?\O< WG6NV=,)E2ZJTZ%U2U>\]TL
M])[ E+V9]:CKK)G@?A^KF<UP4PGG6M(")QN'?[\NMW)V$ZTUN6 3;F10-AO%
M$<6O#F5 [^#GL:OC@^ D6&T%L&7.X.65H;R\LX?8EFB3!A25U&4=UXB^TNZ?
MIU1$',?O@>YZ25W^US+,7W1J\>- UB'<$UP'G"/"ILT-R -GX<EF:F@#YBZ)
M*T!/-^,'PNC0=#E]W&#A6@J6]OPN!T;'\2/-SDSTG=J0.]--F#S5W#FGO?-3
M4W>+*"XG]WHJ?U33U294-1-*=:3(KP0\A@9AX^2%^@YQ_@ZVDN='VS&6=I/T
M[4;E(MMG?G04/^S"M%6,;2F&;49KE8LUU=X(R/2ZT]6:$G*S\*"BX^\DIMV^
M4&$'\3Y FSG49OP@F#)%R\/']6A6 %$.#%BRF0S'@.GPA)XEC^/?,H[H.B0O
M%])&/;G)^M-4$/1\_NC99B"<+XY';6B%=8Q>;.L19SRS,DB4NBDQ2XO/TYB5
M3 \U5;/;,G*X:EQ]J':JIHXM97&26[Q=KC91+_K1N_Q"NW#3:3IA(2 MXVIS
MQ+GBYFKY^EL?MV)LPEWK'1>&6Y63;"NT/D-TJY7OE&L?X#;PM!%R>MP7A%M9
M\UO[NN,X(1":1OAKD>7.&!K*2B8(0 ,N55RBXU(*OQ0%</-H&>IDF&=UNNG!
M>Z;\S[T#_T5$M5.@:7HC(^S:+ZT%H^E6Y>LX0+DC":/-N<BMY^D COW0EHX=
M588T2YXI3XS5)B^?9!!V1)23OF#Y.<B.N8@8V5!;AFD^7)BGA)Q87SXSV=26
M<>?;HMO,EXY,^J1.X >K%!$N/Y/ 4F16)Z-=V$;H:$"0:6@.A+.=,*,\_DF,
MU#PJBTPY44V')T"%>9!W?J$!=,)?P#Y#><;^3.R)Z+VTZ#2MIVE'[)I-PP?^
MZOAFPZT^Y9$/K>@[#(2RREY._\2?Y$W"17@20.;#G5M3:.@*-DYNWV@J,]@.
M&5JG.PM(AM^!73=F:):VJ;U*2H.S"N>Z1.)JR^O7?F5MNPM-SSW2B2>^S5B<
M8'P5)H[E(<0"4MS,FIG.-4R]&BMML%IS4DL$4[C -*C6N4 M_<:2C&!D5N16
M@[5>F.CF1*.M493CYHB@0R%QNE'Y9_)D.K?:3$[H7IXUY%5WB!T3SA+E%J#Y
MV)Z<*_M,E5*](T"73X$+FYZFA5)&!B'RC\QDJ)S+3-^<E=V#FX:^H@SVIISJ
MAUL,7F4E,FRK("SMBK#JS]I6$Y6=0_F%IC 7FS!W# 0);W<<U 84]T [!Q@C
M*_"T'K?5T'3HX3Y]C@^@0+OH8(^8'*<'9&#^JSJ7TQ3X"J5NR]2?(2S<9%;T
M'6AO9^0G-2X/REFW='3U=2*?*76&3L/GNUD6<WL@?]Q)WG37V.O56(E!)]X'
MK.Q/7!KE,L0L UL!38S@NER>;*V8T%?NZ^GVL?TFI??K&5[3LE4K6^VH6&[+
M/>A!K%]H%JXEZPTUM>_H?I8;[R^$DW8E,9/PDV87@1B2)^Z?KY'P0][K/%UF
M[QXH=9P(EUF/BFK>BC+6YY:L3_SD^@UX=B2AS15@KS_H^YSY5)'6>W<RP_8G
M!6_>H'KK?O2\RJW33K2R]6OWR&97IK[$*ZE;"XV(J35-H;^JV4&N^WM&!*I>
M:W1PN[?0)G.;\5-5XVIO;^"(P.YP9;51O\V'+R%Z;K2O9^D</QX_E2G".L.4
MP4E&@!>R+(%^!A\]_S%-$S.TJKS=S;S_G?S ][_?)T[$Q!I DSNBH6EM.,EW
MJ)M==R8BH,(HV*!Z!3PH.GT2OE[V#>F5AAU-HR8MBP&O]T!'?@/?![$BFI&.
M$%0U;6:7'!O:3_G20<>*CF(K-J/D(3NM'9W9@6TUV#8G#>EMAN>6PK66#DO'
MLTL&J=SG@"I;EG,#3K&F*^^$L^TYUD P?3S=[!1PV8P/D+X$Z.Q[DY,H$UK'
M8[186%A0[>:O.?=E[5F.TZI@%"FZ'5]-N?J="N0'ZPY^6/*:]S"?+!\:0VOM
MQ]Y],!C;;]QSDWT8?1E(DVLO/=\&/#I,S3*5K[0K%U!%NZSR<_S*O"D;A:2N
M%IU)[814N*5>MM*/:V-/?IO=?_HQ7$9<_F2]"WDF=]8_FUZM[-P8_21!DHYY
M?0SUS+G2N<W8J19B,^U47*Y]I[="86RH@+[UP15Q,\A*6WOLW,NX:MN$"PZM
MC"P^XZ>HZ7J'#-O,W$W](S1^ZQ+V!;LGZ##F+Y;&?OK6!LY*)&'.888AXBV,
MW57HP.Y?'!ENS8^M$HE!C-DTC.RKPI!(,#6AQ\*LIW\LP<B0>,-H!T)H(&O.
M4ZFS_=43T.4$T2Z"&Y.P>HU+Z-/"]NN8G4!K,^5:RE'*=#-<)>\C5'RWYWS]
M,L6;R*"^@4AU,\83] <G\1I?%=J8?*2+CL0'$@8PX<$<<_GQU,!7HH0J:/,<
MT9$"_J^^5[UV KQU+97'Q[G<RBB(-[VX CVQ23AN*D+? PE8-Z!@Q#Z)EPQ.
MAZ_Q%,>/CA?U6$8:9U\?"8_EIAS)*W]T(5763&5:$_,WMI]O#Q00;$CT/<=]
MU6>R4?AY-\U,;A'MR;3>5_-Z6[!FFS-!U$,8653*:L_$CUV]EUY'YO1*SEPI
M_$O8LOTX^=TAT5=.^=(Z9!C^9['5=<\&AD?BFIM[?H#C)B.UUDWU^\U*^UNU
M5DC' #>5>AU7HH-1,4' *NGEBZ<3E<=#9-4BEE0^MRDD%_]6[9#SML7-U V#
M?1'[0(26YUVKJRL_]EPMZ^\C( ZHLBSUM\C67ZDJS__?UMRV=&>(V*6%QV_>
MKX!@TJJ6-SM:3.HT'K2+3_HXD.<3Y+M3_AEW_OM3L7LC)GA_S5S[M&T81)83
M\VQ:E0.,A!5M,P$?"-*YI*#TQVLY)312>LO27"K^K\G989>W\I0KG4K]<G,G
M;L]T)ID-Z]I*N)TWQ4@?_9+'S5/+.U/OCG1\D"$?Y.[9>.JG=0;I.EGF\9G1
MECI6Q+>/1Q3$AI=Z*VTC%LLM34R,9TJ,G2;84Y[G/X$!Y0=96+8];Y8JA[T[
M+DQ66LZI0OQ:EF8(DMYU*;+]FZ_/>\7GWKVN-W[X[./V0%>AAXI9[1<,8;NR
MZ(?L(VB9QRL%VQV,EH&=N_\BC=L3P.FF%MKY"J]Q+LSKP<$*/9*'/@9UQ7[.
MS[8 O<WGE[Z?QY*-X9U9<SW?I#;4(^PT?/_IQ-O[""= ]?-#4[/JI(C9_(R
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M3=:<J5CH[7?""YFUG^H-7@<$R);+E5MS0?J7$C$^P&\-%->S]R\REESNGK3
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MQFA3>3^'B6!3>2/KAJDU"6?#&<H:5+%$PK0DB^1WE-&#^:/K,DR2RDXT"R!
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M,.;-8?Y# Q9?NQ?5==T^7%I,E.\(V:I<-QL5Z#C2QTT&5<>RR;=D9%F:&]6
M_ICK*P_J^Y4R4V 7%Z(]YR;CHAX&WC5V_)6%IKQH>SFM%L*-"[5I]%?8&D'+
M6SE,><YJV1#O_59!\4"C?F2W3*/#8PU>LG .>GAP&GD@N_^NF^]!H44<N'U<
M'!RV5'.N:\96\S;9!6KQJC8K);H62/(]?2<8A23I''HFG3CF7U'V'F W_^AN
M>(T2B/0;2)\)]%G*W:*/VKWT;U6=]UH-D;6ILK79LLZL,H^<M%&8:MT/+ZOQ
MN_<2_[W)V$$LLIB!!9*L X097U/+Z$HGGPZ!U^AF)X43N]4'$,%A2B><".RF
M\=SBVT7SQ>=70,>^S 1F79&_N)Z@?,_[!AH77)5W>=7[%% !N@B=[P%RT&6+
MJ"M?7,0F.B!G!HKSFT'%AHXHZ>2D"UFRE7WWJ=Q,<_8HN6O +@Z:Z%!3*YJ-
M)ZK7WDI79C"?Z +.I/XOW0M/HM@O7'MPX\>U!Z(\!YB=/)HK[.E)4H>]"B0.
MR>#<CVU#4UO)^U\67!A._ESV2;:ZH=54KD=/VW18R3$/DDCUCI -Q]S^&:Y-
MU4GG)@3OKX#$KDL37[OJ"DC^ M!GX6LUR8/NOM!G[NA5+;9=5IU;YKOCL$:9
M0=K;C_FE)SP$5&K6SZ6J'S"(;9DDH-6;<#<QR+IW>26$#RO80>:#UO \S?>U
M,,W#&X1CYLU@@;1'D0.1[">?=(97G"^== G!7I&F,YRH^L2R5'_^]MROFB8,
M+G)-;BR$ARIIH53Y?0,?7Y"MYN=5_:T_X&#>^ODLQ?VD6H>%,;-X/FT ?AEF
M&&#0F.Q%#+CB.WB]<$7QXO8YCK()ND6QW!&;5PC'"\XUO%^GZC8;Q71NR*3N
M1!PRF+CR,^59\0KD_-L>ZTP9JPIFRRJ3P%?YFHUK&0WXX'5>?GD!G\+IPAW^
MKBMW4LK=/ZNW!5:8EVKTE\I\3E^+-;&Y<>1HPA63B1"'HL7@6@V^D7=)P-2Q
M'N!;%X'D+Q!N&^$#!__2[)4OA=S*&T?G4/0[9.Y-(<W/3Y T<,^L(:X/SXW]
M.M4H:Z:Z;]K6L5.UDX:']^#5=M'$5KB'_%7FFR3XFQ!M$(2Z24Y^X+U+-R Q
M=L%X96 \AD6E6PAK0LVO,?UCZWBM<?.U#\&9"=Q8/Z4L[PGFZC\&]<)Y&")T
M\$GZH7?C6-)1:)<.505>;N1* *91FBXJ- :%*HS<Q9X"^ _RW&],ACSL"(.)
MJ$_FKAN0+TX%P.&E4!-^D<6E@Z](K=+4U"M\2##;^ZFRLO*%\IEDT_07 28A
M,L@Q(>6\O.B4S59#'Z-?6O.B55%9850#*ZX<7%YR[>3+4C%\!7/YW&B^I+?6
M?;=/9:7,/X<X7TX5?Q!Z-\)MA14+TM7R4>;"WC)C)?U3A,CF=_=\:U]BR2^6
M^H%/J(H#C(*2_OA,-R44LE.']:8Z[A+S;PTXCX>$!_F7;X:E, ?Z!W'<G'VI
M?O-IDH%Q4=8+\L/$6Q_+:X:DS)#!.S,5-;@]P;TPM9T%VB-H(25P^H ]ME"P
MP[D".K#L>49; B:^D)MN^O(YW9B$L6G_&UL"52,:-KS<#:R&.I[\4T]:2@V0
M2#?3(=P<1\,_]QX++$5.V/W:7&%G^7:FJ%VW2&]+_WCL"$U^T(F[HEGUV^YN
MKWGAZVM/]+YO'B<Y0O /='_NU11E,#UGWT32N9J)V17D4(H659?H_')OQ7*F
M \24$LGM>XS^D:;"0%? V,E'29%L2WZYF7O&A58SM3!FB:J*AZHES4>AG(;O
M^H>2?Q]=7U5^L57@$1=54F5+4<]]8:)\4DW0S-S2DQE2*$;:X0W$/A:7I+_,
M.@7H$>3P33>GA@.YLAPL$+N?#R6^(W=<U:WR-087!JVR'%U&FK\B) 71?/.[
M85+%73=H3_X7!/P'!$;VYV4IW63@7W0#]IU]&JCI0RAYR6F"RYDLF82VYZ1A
M01?H@J_(6/;$PVV]>HD*8K[UF !5K4=>4*=*-M7DY,FX/YI-#W?PRD>KO#0'
ME2,XF.:<Y'1L]TN6IKE]!.$Z@ A%3@@,J\PF@+P+$US$J9D!'IZO;Y)"]HI>
MPLX1:$'2KXMP6FJ?OL.]?"@CHJ\?O7C-CZHD/*Y\ZYJ(2NCMML8N(XQITC 5
MOYD@BD5YU[1Z?Y;QT#VS?J4LXH_"(;*MGY-BSSB64+(YV]]6-6]D;%ED8$49
M92\U-D%+&3KUF5BFEO*A-[HN48-*J3)F ?9Y%M-TYQ4,G_- !?47$92L\&,:
MYKZB;7,^IG4:?2\^.]#+9VU$)*M4K,:GU.F!?PWFE>RX=S'&?*?16"S][+ U
M%B_^KQ-+KP<I[;>W^S?-_WNT-TNK?L_[[X3;PNAP.0*L2QT_]_@HH0.,A'HH
M_U/[9$K%+*"7U_TA*2>F4=!NJL-AQ<Q7SY9-L.=8^6:MXI[P[RZ,5"XHOIIS
MVYDLSLCZM(G/1OC)-S*DR/#D708?79(T#]TGFBVT.2_8)^=\)F&BE"M*;QL0
M@0D%8F]G?@<+:ZPY7,>!ZS]/']+6DT%SMI0,O OXP"ON%.#EA_FF-I!]"FB<
M34#G[:>V@5+DJND@FCXUXQ&.50US>7'-OB9X*0'"=' N-+) @.I</'ACDNY/
MX'^.UGXUCVUNCI37D9^Z&B\9=P@751J]305^[[&H2JVX3J)ZB+6N3]Y-;RM;
M1:O(^YJ/1_FWA_._LDCHQW<@9.QE@I)0B8%M,8K[)DH34ZLT6)M5FO*6>DEF
M^RG@+U"=:FF-KZ-1'SL^:L!T*D3^SM:2/4FR6_!U\72'X+*_[KGT^=X"Q4RF
M>G)\+XN-1UR/'>U5QC))A9MT<CA&62L>/@ZR;EPP'+#'[83X*^RQG*A9-39C
M</LU3QUJ4'*U!./=YS6K>K8/O.+N9TM:ZHM*"_L-1VK PJAF-#6Z]DR7%-V3
M7)"UC&+:>/735&6O2.$Y:H^'Q:#,&Q^LNZ_B;[M+Z?-S]V"M[WA;2F^)_@>3
M,XMZ[\7W3X5,RT<;GTKKVP=%&BK2]PRSKBBM^327IK_,F#&W; >!L002O^%5
M<X5L()O)U1J8@4._=#]'>Y5C=74U8AK-5W,+(2@Z%7+O1,T$%\)FY=!9CPM.
M51W:.@78G%U]+]>X"S)OB#)-GI^G#2.3\)-#,W@-K[;6EG3U&U$:XEF3RI[
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M@1-J\/*XDX(JWD&Q;0Y?L?O]/OLV.(   *BF  #G-RX!Z!<US9?2#LJ:2:>
M-E"-MV=SVO#9>I_H;,._P/-O;F# 6SY&"P%4]E\E_VT;<]%T%P[Y1^,X#7FH
M/+,5B?R-*RP_AEN9/4=NP?/_",=.@M[_V(HLG+**_TX7/,9951S#+<R!0:2
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M(O "M !G0^HOK?9NS@F3GU[\4(F5*"Q_G/"35.>0-:'EQ;A<11.,_ YO.!H
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M>RW=C>K$[P1FA;G78V;]2S3>+A*W;>K!@M^P 1QNGVI;:Y<V3P$*MTF9%@V
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M;F'&13 *F.=C5(F ,UB'+W&A&U,C=#Z0!BCQ377V_G1WX8HT[.*]N,E;36'
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MF402;46UF$CK6Q3"&,OK",&\TL4O;Z_<,Y7R$/!*+FE^L+NC]=K'0Z=&H#O
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M_V%:1S&TZGJY*&VW.Y:4_S H !E=71,O79S]0"WXAMJ6&$:^>KRDJJYZ*N5
MQ#P)IW/&N27X(V[H!<8I3GV\S.8-ZJR1>QQ8LTF7W6N<W7&9*0"VA-!0 =*$
MHMMOC:D?1AKS$G.[-7@22X-TLDMU<4W/'JAYQG;OC/SHJ2J)Y&__>I:H3KM(
M=PYPE7[73@]YS+3N> 4CF$I3UI1L*K<1L>BUX&8W>3=:,.XYX>T)%(:5[U*K
M(8K[Z'+J)-L%VZ-N#T[:557)HG%;RV6F<2[-NJNOS@$1TFR@WM,#B%O8BH6_
M^3[MOLP12''<M /+;3HV:VHGOZXODH^2T7S\GU9;_Q\NFM<TEPH)RIV+<P)'
MC\X*)*?N&E!-*L2SV_K/<VTP$7T=<\U:V5]=O*:G &XQT.V\K$7S]MM0Z%8!
M]4.?L4GK$(Z+FMFA#V&=+B061=1,0[>CHG5<$DF3&%;PO2+&!A?;4VNW+O_H
MXA[C ^%/Z)4G]Y]1*YXHXR_UN>&D.QG"%^Z"'N_B1J+(;-//4S-]ZYHC/X+5
MVYTV5R7B!F]IRGAW?NV87B<9G0/J*)3L5!FE:%]?%=+- 3\'2'C_B%&-=# \
M//9N+&LYJ+$5E_Y.=(&Y$L/0,\;=!K)%'WVDV-AJO)@CR]]\%Y/*P'G7U6\&
MBM>_/J2 JT]\Q?\EJ3NE\$F1)V$U[)TCL^> #B:B,"XM7O!U_$?E' ;"PGNG
M6D+N6V0APU&(U3^37*(:%G*/TE^[X.Q!#:,&8@87C7\YW">EDR?Y:H!]QC_F
M^I3(-XDE8-ZVI6S/H-MXZ3Y#^N$74''<6VX9+D^4^^Y=HG+OQSXVFX/RELQY
M.1SG[9Q!NQQ086T#^6=Y'/$M?K^#0DFA I60ZSCEB ,O#J)FCU*B6_EOKL,4
MY2-V$Y7;P,%4O7<;\^\SQH_F\UMJ&Q_M2+I%0L:US_C>J!N,J#"PI7&]ZOMU
M6.;K+)>!">V#3IE61B:C)JM%A4"=KXP&%)V%P*'^Z!SNYUF^$:\05Y=J8\S_
M>']&<DB#N<%<UI_*0]SHYZ<%<^_=;3)-<<"0:=_?6L*_0& TYY+)UY*7=V<<
M#G>C%ZGSIT.%0H<M5Y?-)NJF]I&Y?"3>KYP92XO?WNY";98,995EIM82#)WO
M8R17F@EWX*5!KAM>W\'@S.!!B.?VG03<[*I@QC7L4X(!2PPG#X>WQ=O+5L>Z
MUP@)NGU!+^4ETEG*"O.KK?7CM=C?58Q[)MR)GXL%NA;:P\T=#U7[/4C:O>H"
MV?A09_46U:Z!%(1P9$_7?I>SZ)WQRLC*YX49#0I\DOH>>Q/A-HH4G9M"^ZF&
MD,CMUJGT-/R\[<_;>I4[ C9.J<:N.I==C#AO.BU[\RI963B=&)Q2)GFG ?EV
MZ+=B#':ZUXOX2$.</$1^:JB"%G"',9(9!./4%[=4=U;N4\++I7)7G.%UDT;D
MY($J[]X&QF;"8RW,H)Z$_<*D2DT]8?7=Q^KJ+ZA+VHC$\-?J2CJ7J)ZNT=ZE
M#621O2)8]8&5088:!LXZ:"J7$#7NC6)SL[_]J5NNO]JTP.S1=/?P?A=N'6BK
MDJ%L F<_<BE<'\"4B/3?@5%@!!U9B$B]3/VNCN\]BK;5JH XW:DA7!UF,DK2
MRK<_RQ\XFL(II,I55/^T_9G_*!_7=W0]>$[O6N3& J?%AT!%DEYH/Q")[@'^
MR$5']9*OYYI,:;!M3)\#P$0X/H(+7,GMB%E-_C[9:H"])\)FR(T.\.'T%W$;
MFYILU0MDF%%\X2_<(K8X,]*->,_+2BQ? M) =? ZY>!*HEF?K61:2[Z[I:^N
MNOS,0@^?$^3SF*>D"].LHU8CLNTG<^<MIH<=,&I(!/;(K8.ST+L17N'H$'>4
M*O>SC]$G_K5W:I%^74!13&%62*7"3]L4MRO+DII-K9K+I(9$N?YGWJ,0>_2U
M+>QGE_UTA5+S+"^NNJ(">&391%NJ3DIR7)Y"$8\?21O+=XW8/B/1:H--9(#D
M#\NMWC5F?-'LV>#!^8'J0R%7*O*[OCW@9AE=!^ 5H,I7AZB%S^Q.'W,/Y24"
M\;L/)KX\Q;MS*;]K52Q:?+#QJI)U/N$S5<_+PHN<@I=Y(]N88HA"ICY&8KXF
M@:WF&4:G\\(>KW,#UC&O5KW#DF:-9%]9SEDBODP__,BERNK 8\/#HR50<+&B
MHN*JR]-'+K?>7;O\='I?\3^6ML*@[9RA$]7$]&7T5JI''NG.65ZA0:65(_YI
MA!^%#_*Q[G3(U1JR%CZ&"N&"_D3[W[UK-R1'8%NXIM"BQ[A30O[\NVJK5A'M
MPO$)AU=<T2]\6<(7D_K"0=D(J;PS$58_Y"@U'A:7E(0=DJN@]XE(8^9[H @W
ML#9PKW/S$#,I;=OP=9A*LHJ;R/\)_(. =<K"EHIS>6%+2< Z)20>N-SW<9F!
M:.K6X]:UR-'. $DS^(0TCFR.8X\%:<:K\WFIYE"D87<>\75Z,5( /C&=[_0<
M_3GH46I[#BA8"X,"L8OO>9GQBPGJ F6VFZ$<!-?8$DC8_<F7Q3&XV5.#24GG
MEKH<5:<@ :'\U(?O>>),HZ+QOSM@8C"\;SJ)>;-[099XW^DT"$*M%V9$F.X:
MS.;N!G)H=+MQ4="9S9+Q#7>EUU>B*A8_F1MJ5&-';CC^KI>9UQ]B>M'0 !>3
MKS!%+\ ZJW*1JP@"\ A$3#V5)@XZ9II/H=Q"@A]-0&D5N;./?4C*A %WG;D'
MF-0YOUE8)#*;_@3[@SJ)4UTG5CP5\NX,P?BDR^V/D)18ITD\K878Q^[5 Z<R
M?VFCC-(M9(J0FH=AE7L*^/Z$N_DA,?0F(@Y+VD-<<R[7;V>K5'WV*F:_)KVV
MKF0+&6B2(CII'SL?X2[_Q![)>*8_ILWZI__DT;\>1B90T!T5\1SP;A(2UJDV
M$JOIY#5C[)BI2Z#+NEX,]2=6%_S,W>;A-_BMI=R-H!Z\8MA>.E73*X4J%^A7
MN.X/+IG1$0*G(7Z? \@T\J=&6J=\H;W .G;TKQ8VV\5P]6O!SDLSZ*1Q[644
MF[$75IK*'GUY73!0W GGX&4XX2DYJVPC*2E,WW*)D20$ZZ0Y!SQ3HH@2'OJ3
M"]6#BM=\00!V[X99>9,<B,49GS).^+B(RSVV13\7V/"KM>J)J[%T!D\:IA2#
M+.[$DRHO<C_D_]'*%+)XU>63R"B:P NF,KN4@O@Y!E*T8TMQ1; 7_E1=?Y E
M!&E&YHF"KN1V^B2XQ:="J>E<S/P(,RUGA\^WQ51T5CAM#:Q]2RVRUKB-%$J'
M='8"@12LWWG['+"TF,L4BJEWY#XKAKV<FE87P /-LA47KY&D QICT4#6/+D_
MA$U>452;M%(8UD/'_CNTMWT*JN4E4!TBTW^4=S9!P21!2UX1&@RCH7PD97Q5
M]!*"BOBL:_'Q*%09>\I1=R9O5(.,OATC\O3]Q=UJ]J'&ST5-C=!!'X6:6M5-
MR<K*K>VENKIWW'8&UL_JD<CZZ%L-]0UOV42>ON-(=8[D<+9($"FP>#1FP?C@
MS>7));>L^XDCU5+U8@7Q'/UGP&M7SN*OWF,R,'J=UG#/1ECT'KN$JA/?EV^-
MP=+?9 82F#)2@_HT;7J'A(&,"DB/LQ@0B27OA;;7D'C_7HX07O@MR?4VKPS>
M*T+=4G*BJ)$@'>47[_=/1"Q+N'M:X ,A"0-6PR_5@G')YNJ:^!9L;OA.+P5:
MMO- V+NMN@4=B; N#;ZQJDX!$/^:$6:[F!.8@OUSDU>\.;_5Q=1=O<S7A&PA
M/%AUXCB;,UU;,C323P];74E4R@R>0N%8W^)R62'@#C+O),EFF2[0 #\=Z<<M
M>LCC9C^%>(HY&%(;F*%-MG=PL%?3YBJ#T[3$?EMQCG?4L5 ^]+![/.I7:4RY
M;]NODEL;L^OO86?6_EFRPF];WJ@^;8],WL.95MO-SLQV2_;VC,L5/NG;4Z4I
MG"8$GWJ&SN4HGK6I^Y9U*/+H:IVED201CC](*D0?+\%ZRT7&7+WF8+W0VR3M
M&&6&RL[ (-HQHE=W($(J%NSFJ2CZ4KBI)?)W"!J 9W-#-]5V+/WZ^N.Q@K.5
M#'I8ZDFW24J3N1-KD?XASY];LY9&IJ]%!G&0_82:!:J!M+OLU-&].!<QF] K
M3"8Y_!7.0?JOIF?&BC-\LS,]2GO=5_A*SP&>N41QZGA-T.TJTJVS%"0/$+O6
M\?EY\QC)A-"I/J2)UF2I&$76YY5 E9$?-7%I^ @LLRTJ1CIMTV9RVZ&W/KV
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M7*BRA_.<BGH8KS&QB94<5*D*9*BLQ#Q,$S5Y'F,]XZ@JX$^;I+.AWZSV86!
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M;!)A:QEFT;OF'DHK8XQT!<(EH(;^A$+\3(B8E@%*Z4_:)A OT-*H:VTUZD)
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MZXNR7^'"__MQ(H?0>?/DKE0 .@,=>+V#S<,H(68XH.<<$ SDI_7/7[-,V&
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M^B0@W\5!\BTRE5I$%3M-LVX8/,ITG%4P430P"[;,'827</5G>?2_;-8$.'-
M^UOI8F',DQ3"F$5;D\:(!N8P8$]"U$%()@A[^N%//@+9KW-M[5&>[:>\#-AK
MLUO6*30>Z7O+EB<>PC5W<0@LA&8#WP-,=@BR6Y9FR/M1A'9/RNJD"Z6)2)6E
M$</]L$+OPM[: <_:*AR7 A<7CFIU%\S7#O3M\]?.SCWQ/MPHU\C-^O7>P'&I
M/*E!?L4&?>WOTVOQ6+"5YM=!HX;Q"^D-X\L!M[^[JA!$CREW[DHC_/H09>;#
M[:J79!N,"H<W[7':F&9[HO?JF"=UBRE,9B0"_K0Y!@'X:Y8L\6</Q84=\$L=
M3;H\2>)WW3NRD?:^RD'?!LG)M%6W(*%BJ0?YAVV/7B6;!ED"G3RDX]?9O(XS
M<X )+:-C;E8L3@.W#R<<=)76Y>DD!W@=CVC&"0(Y.M=I$\Q*#L@9%6T?)Z2J
M[=ERW#3+/^#(K=_OFOZ\T?."9A/)].*RI$56(?/\#()G*?LLW;IBYEFD!N$P
M8$A*9<O0I4M]7<U/#FH$2W1M63;5GZ@=JJY->7#T<[/F#*X:3^* (![35SB@
MD$O?D4[[Z=G%WC/>L4<0*.JL":WI8S X9-GP,U@2&;[>5CEIVPT)+S]0\,0;
M'XRW\U309[4>=64/JOAHE;Y$:;]1D3HID313(3[TDV_LC66J=E>1]F-SO#'X
MWMRQ(KQ8CT*-?^4:W5@,+AF3.<>7B I*X?-]M(:7-KH_&'?CPU!I9,.MI$D/
MXQ35RW(?L2YT_(K]KF70;59>DW;0?E9\$)0F#ZMFO=$YGS,59$G'KO 4 *N.
MTDKTOE@OS2N&)-U#M*-A,U Q0'?=I*:FHE_]WDBC65E/"7+-".-Z/*[>V-/G
M$ >4098B(HD3_(Q:KL"R[%&B&+?4,5&?&0T/NBE,E7]!I6FU'+_<GC+;8H<G
M88XM3O/1#Z11O1!MT[+T0]I3*]/E.7 ,WLG]]=AM0[S3A+[&X^_Z&EA[FPA&
MXS#7+P %Z>+=\TBB>'JWV;"N%'"Z;0*[O$0ACX-;IP6&?&,0AQ=7"PC1WF@H
MTQ-PE$ND)[0X&CIBK>J_N0QMQEV^@;OJY:5Z)UCQ82 A\BGD4".2:UD'5A'&
MK6_<G]+7C@'@:"&<5! 4R**%MJ?+KL;HZHPS[WZB"XQ&!=D\H48&J4*C59@V
MI:BN+3OO8[:+38>'&_7?.BU,3!4-$'Z$G)4*'GHT]D"E<M0T1<A\9UK/:K@
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M@%#:,S:ORZX<ND?WV#>F/MVPC7RP21[=J0V-A#]G7GD'9#\KI!%:,0?AU.#
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M+_5:Q0G"J7Y:+)5'N&_@&KN-O0,+U T@"8<L6#C)X(=;,)M08JR+*4;1Y%I
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M0$:L@1IJ3%-(HNV'*D;6,.#  !NA9@0" 9NJKU&W26;%D13"F6+<H^8L4N7
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MM2+<WSK!_@^1IJH_9VDPH, X+;0'<Y0A32407;A8?$!B;X^.M)C".$2U8#6
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MH%(KP#*BK"\KS7X4:VR3G69G$+]FG":M+N,T&N%4=+7<P.PXGX6CX5\6SF=
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M5XXZY!CF%>J=[W,L2T\T/DX(=I<MG*PT=M5#(@>LB9_?4(*F:]TJK4PHM1_
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MH=#*DI=F+37-X\;G6W_.CKXGTVVS'Y%E^ E]$"J&VL=P?NLY\X@=6(^ZQ:G
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M&)0=@,C[7/!>O>V!"Q.#>J,O<#_N9<=C%I^"Q7F@ -UX7\5NAF73O]P/Z-.
MPR)4.'A@UD !XQ;_MMU8I\C_SDR[X73<EE/W*=?O864I0SJK9RR4LU.YZGQ$
M_Q<-7B70K1'9QM >W1,HNURFS:=MLA ["+!:5*%S9OHS#<F#W0?HWXHXC12.
MIN>,OL/1=0P]*Z14"FYV\P-,:G64GXU,/!J^O7;)4P%.6!YSP7DFW(T(\)(J
M_%0FET>?N1[SS/6ZWPV:IXY>ILW\XS"WC#7[N\45U09:3:]07M67,Z-OKFM<
MOU/7&.U<F]J".SJ=P;AOGY%7K>;H7.C867:X-SSM;GPF M#*+V*8]Q):LC?@
M5?/( BL QX!?Y> @AZQ"J5#1U;-(@4N,Y#2)_GR[ ,.62L O\G#GQ:KYJV,6
M$1VF48@#5V\E&3W0]-VE@3,(>/)&"<N&.[07.$!.7S@&D.D(Y@O&= L]GP?J
M[; B^H#?QA3T."C84>S<!WQ/=-.S4R)PYUV 1Y0FP_AP"KR<^BKB#;.5D.Z%
M=%I3"CX!I3OI)O% QZ'!HPGD)F8+G;BXW">+-U-BE@-*#,U^[M$9;?;%*B3A
M;:G$&-O*[^$+7Z!N!"JV$'S7]OF<E7)A@IQ;4WWSAM^=,/OS*P3Z-=UXK"1:
MC>W( \6AUJ$BIA+U0(L-'^/<9I%DZAGFT[U[YA1=02OZ3O^>\SKI:5=WZ^.-
M D="2ZNFO\*7T:*["7]>._]"$GZM5$*'>%-:; !ALC=H&J0^7E15;95CRYG;
M&4NO6&$9&+Z6,34C>D["S:6>WKR[)5WL:[T=)>O^M?Z@XV6"*8([QGKV:HK9
M/=9C!+T7]6P/AN&!%(T(VZOW>:#GOH1GY%D39@5C=(/! @?Y'@),*)L2?;#?
MO9< M>K-\W0O2A3[C)$#G.)P=&$-JVCJ:4"0!_[VJNS?WJY.U&<!VU?UZVU-
M$B954\R13.:;C]B),U3]_*CPY_E1;25BEN<^CIVKR_CGG#7HUJ,MV+ [7R;X
M84@X:TXQ6@)E0]\BUK9N9?% S05L22$^H%9V&M'C^SNZL15&_9BD4EV@";=6
MX.G[I'ZUVKNU99H/,@=:N^AI,(-.&1GW)J\UI]7AG(L_ A,C]"2;G)^7F?H*
MUK@59JBJ7?MHEE-X+YT)O?[D^/2323_!!3O5^^47KE?"CCD+'1FYUNOOKSX6
MGT<1G!EZ6*V2&8OPDQNO5 A0-Y_/*&QB%O0[I!/:!#84&!*+T+1N$S:&/KH)
M94%0 4 )A?P(?2X+D0"1 "[2=!-+M1B;/V8!\*"Q!'!YV1'/<$O5:6Y;4)CY
ME>GT;0$NY.,"EQY8WKAWF-.)_H2198-YH(.ZZ<Q[C.[ZY[[L0WSI9NJ+L@3.
M.1,_75_;"\SB@H&X"0<@L<(;&3?_)F1Z1@Z6BKKX,%3AYY70M@OM(LO6[<N$
M;&.9 1B@+I*&!J'.0EM@ [JS_%CM'<V$" &KC*A!3*M!<H+^L2AOAZ2=9"_Z
MX".(# !_R]5C;'A^V4HQM14N+.2V-*[[*K2-L:&*96?P;=4Q=*_VWQTWK@&Z
MC#=>XX1 +.D\TY>NV,Z0IU5O+-%X(-%+U<CSQ/:.ATGE./9%H&1QV)GHJ_?2
M(])V3DC]>?-4 TJA03[XQ7.=CCN9\JF2AZ;/$EU+)412LX[DZTHE#7S"7; Z
M9I\IVSY<X)9;=L?LR$B#@G%+]IF:"Q_J[._E-><Q]%>I]912PQ<RQU)[W,MD
MAR2<\"$A8Q_5^MV^];E7U-J2G!-VMWRLG<(^Z+WG\"EW6'8Z5)X0XD B4);[
MK]"_E]!;S'W\!\$M <.5"<9A95'TN;>E%QGN/3BY>;C1,W'?L\ C^E:_<4:4
MY]/V?!.3%-HCF$/:0K39.E<0SR#0W#?5Z?(>P!8CUGDB+"([A9\13:/JV,?'
M?_%YCD>0>##X(&5&)Y1]P$!PXVLN*V2/![IZ7:=J\EM?[MWY+8/=]O^789%5
MP(*B3G[BS[$HX$QW)AYQOP3X+$*/ 9IV[XAFW8E57K/1N*& ;SFJ3S[G>!3G
M3C=_G(:=T*^C^"=W:S1JZ)<)6SDEFOY1;XFWMC#2N#> :7%;#HZ]O>[16I%Y
M;C [_[1^DU.?EY!-I6<NUC@QYNF6OV>>1+!EQ5WLIKZ+1$&S36$(NY%U4-(1
M9OKPOYV>O@7?8V930B7<&*HI!D*AJN:??K$:G=TF<<IBGI\_>US^.3\_>DK@
M3OB5C(T_5?>#Q/\T.&Q?0;,O#K@XXIAP2G))?<3.4B_#=;Y29=Q:92Y8V[JX
M_/"'^WE^ART^W"]RS/"7G*]4-\SSERP*;<VQ:_?_8<4],LRH=XGOZ3[,*3#=
M9S*/Y(%H!2GZZ9IS)AYZRFBPG=NTO*;'UX36_-$Z9)K=:=4L5XNBOV1RQ,<.
MX3[A9K,7L])9IFPQNF[OL*(!N6SU['#C0G1([AKZ5-<5K&MW1X#VM^%EJ58/
M:ZWIZ;9%6IC 5ZL-V^<P]"RV#=L/(['ZF1/>@":%66Y80*<.[.E^L8C4<I>&
MR+8%>3^M,.;KXN'Y=NEES?J>0.7Z#@*J?EO'- ^)4'V',B/:Q=[I+KZ_H)8G
MA_<]]7'%.>]L2WM?<\/^RLLZS'OU*M1*>=V/%Z3/44W)IHS]8M(KWZ3.Y-S]
M>+MDA<[U\G0L59$!?(.S7>'#9R+EPJU??=AXGJ;YHV5;]/_)4>K?#YPA0SG)
MSNG2Z'=JEAX0%F8")LS0S33'X4-XJGU]5#%][=!#0UV'$- [7$GD3SY5T=V\
MN'A,SJ%PD#)(Q$H VX*["1"U:=U&4_!M27^Q]ZI);(MZA>5O>EM_/FB2^N6*
M6ETL9Q)(,%K?\/LQE"Z]VC:E3?#J-D:DQ,TE6[;7-+_N1QCIKT</DAQ?@1ZJ
M_V]UQN]@;O- N^*F?# *M&+QWUIW8]_ K1H/<:':T/5O(ARY)^QY]/"#]G.
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M;V0\O&8\/+R3MK?P[]>[,6DN G<7=_CC%^43IF=<!:"'\8;2N+6ISOH3/4$
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M..^$V>>.,/41]+A,@MF.R,K7",2..P]T"9=/"-$E%5AP\EOY C FJ7UQ.'#
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M 4 I(ON .:8%@&?=0*'C%UOWLK,,,,D0'<8H<6L?"1/HC6SO[Y;I OQH(B>
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MNO\@MF4G%64+-QBHI&.IM\+[:0Y'WI\8%9^#Z_4?;(5KU3UW$3HBHIU/ /-
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MPZ71NL_A=.-ZIA5F>MEFLI@.3VWH:^>,L-]B5->GGM2-&CB4(E[\NF+?Q#@
MK4W=^15Y5HYX?T>.P/:9.0#UKQ#8:*[.+[(FY4)F2)R_4KD<:6:4,X/=GR2)
MJP!AC*A'&J<?$OYNO>#>S3+"/9QR=^FM%NV:ZJ<Q'KWZ\FJV13_O+%7>[Y59
M2T>]4#3!AM^Z"0)V1CV9"/&QCY9,>YZO')2ZL<"W\L3;O[^>[#T3 ,]Q+^QV
M6D&Y[ZJ*BD%NB%#R'E;I3B5+NRI/+-M?K+ 6?/NFM-#Z$2PK"/;B !0CR\[
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M7>K(&9SR#S>;F#-M$;-O&B>7K5\8LFU*$T&&_YL2S-;BZB.L]K /=Y5IMT<
M>8=X Z-R./+I 2C.0(=2A729"KWZ.E!;QL%ATI 74-^SF@C\MOI$H;6CL[T
MF?MZY7&:4W'88[ETMRONJ>\?MGZPBDGHKCQFV.BL.59,M\XT,-@8:)I C"7=
M?_/FS8:9^>N!OG4-S\//ANAZAO[QV5,%T,-FR8Z;EN*^?=47A#W>I&>:U3W*
MR)MGYWG\LK6I3^>$8SU&  7LMAXS'&FH4 N *9W'-$X"Y^9A7#EJ")V6ZL8*
ML"[L(-6V1'.FXZS)=JTIW[].27C'2%FHTXXOA^53;#VNP1C_<G/-%#.]6"M&
M[CQ,Y:9SA48,!PJ8$]R2M8GRZ%/T_)%4UOG"C=/9HO;$,\3VCP97@[W8Q>YM
MHF%9C+"VQTP]:EM'X^NJHA9V.4WA-4V'(Q )/*/"CL+4,ZFP1-G+*)9Y];KI
MT11\!!Z%HR[$%[LA'/80IPJ^#83HM(XVU6=?$;OL<NS[_9=22 ZOB0^T3P,X
ML[H]2</V23YW V F=+'$'SO@KG)X:_-'?_5* Z6W:@7Y\EMI726?7.".)J$(
M+]\7<_VAUX9Z3V5M&&,UB1&O;J#R'AA6U[$NA,,N%$B,YA*L3]JN3_5&>,[*
M\Y9GVI:-,=0-RL?"PC"9THF'=-UK;!Q3MT^XF=KHQ,C;119:EI3H._K<G-%1
MU+U>-AEJ\S636G6?=!IZ/Q604]B.97JR+N&6'9Y58<31EX%;@3B+4>)9KN)_
MOP@VT*&V?PI8J6EY3M81G07'50<F-[*$9DSEAQN3-()/O.R2^W0"#6-,<4..
MP8Q#:B#)6C >SD>,Z%C5-MK.8S;V>4?8TF=[^&GT-3KZ8K&UF]$_F[N." ?8
MDWOU9$:[FHG9>/5C4KZ_3&];QQ"3R17R:_D<,6R7#G0IZP#T!TOU^WK!B4D#
M(<JP@]M8 T"I'=,>-C$'/"D1?E+;QMWB+^4[#,^T3VB/7%SF7-"I_USW^G/>
MCP-0\Y=IJ#!IZ?/.IU2J28HW[#10\2X;RZNA&OCSL]G&LO4DCGGR -0]7O*U
MT&#584*!.*Y1DGHG3:6Q_1)/^^[SN7CA[M69:+/7 >KXR87#6L.7]$(-5'T'
MM==NY)6/%[I29>S++6W>?';4MXI,RE8A]BF<'UHG7^H:=XQ.&=)\?\7=1D2Y
M-E-RO(S/3N6C8ZBI[HV+E9EZY?7I&7!-I DK<A0^K?[Z '3D,3L3NE2$K?/9
M>LG\BUN<UPS$\*Q3TS]A4NNR8NQ2]*4*])]T;.*#RI *9+@]_?-*%QT7][-]
M""NX-O:IZ\K+XC4AQ- CQ++CUY9(K[%EWE^'N &,IVEL6=!<&&\"9_882L!#
MHO!'CH"O/48,J%KF-8 OPT7F4<M4#SRNH@V:@+Y9N<ZP0ER"!>+]+J[9M_G7
M(:=R,LR/7'PS9[1U#_6<)[6W4H!/MS$A=HI8;U:B_PBE43Z1K/ 3+SF6%-'P
M)1-\?V.WHGDP'?EOWQ?=CF-BFXWE%#=)Y G:)&+B[=3E3:W/1C^]E*TR.I-L
M&)Q)ZR]/U;W'H KND>&O"YL:(UTJ*EY[-C<U-=^4V],1TN\]VB&8XH8H\4J1
MDZZO>[L)KX$TZ+!.;3*6V*^QWLDP1B60? #BP^Q2FN(I[,.]DM^R*5!)(-&!
M3HQ_ R2KS8[M6(\&&@@4K]<F.K0W-4_8RSSV#'RD;R*1IYI4\(@;\%!VUL@V
MDANDPX#(DHSQ%#7P&&#BRM7F^.7V."L9M1!8+'V >NT*?^-+&8'29JK%U5L?
M%>P//_6[G3#XOACKC#M$XGZ;%[.XV+3#$EYDG*3[?WU-0"MU C[%J,L4R[^W
MF_IV8+03^@79RP+V'V^>.Y>(/074DZO.J5MNG_O#\M]B@=757PLZ&KWC^,AH
M_8P:QZ<HUHSER6!'LY8V7=2-=.N$: <>-T(G-DAZJNZ:=*)\US*MOBPI_Y9]
MGX?RO:!FB;=&U#**GX>\?BVB=>PK0[ASL=EZ#M<]LK5* _?#&\%]I-C%0X:2
M%A0F5@9M/NW?<8TRT&'W]C/"$)+"69_2S;69>-"P[;PQ^^ERY/?K>-=_CSWN
MZ0=Q^C;@M "Q[<6231ZR U3X .2Q YB-9)REO01VJ^90.1NF'SM.S:V+<7=T
MU6^23A\#HN\:R\-?BR?0<,"%,+( <@G/$C5?\NF&"!II.8^0X;-7F%TZI903
M098+TG3I65N']EN0=E+DU-5/C@($X;7-[S7:G[@9C_DI8$)>I-GO)''.T[X5
M82D[IQ$%DH!+< F0>*.C=4Q[6WW=X/*Y_M#234ETUGYR\OM[./5PY*L2&,7=
MA5K;&HVFIL#_[G6G_?!;T7POXOP*7KD[X!"M:.3<*'7#ZFU)R)S]Z-7UD9BN
M>XI??M:?>"PE&%<%TW+DL2Q0V)A_P3 <LYY*#D#T6:69%N?_].O_BMN^Q%1"
M8]FIQ+,#-#(C#@BL0NO3S9UE8&:2?\>LWJ++)@4H-*8ZTQBU/G)3SEDXN:EQ
MI3]N$:IJ8AB#$Q8\KW]BMV*YB9;,KL<^.  =]H.(8&11@5U8,/'TI_@>B#!'
M!Z@.C"4>GUQI?.7RF5RTV%N$;(N>:7J=IA< OQU)5C5H;SUVB\UD-RNTLEN@
M2['8&FC_2-*;(5N@6:QW,<I-?*+#2RVS95)#"WL:N3\296!^M//])1,Y!;?Q
M'Q''(F[7BW1VC!M./KZ0_WQ*C"7=R-T 3Z$/ V>9LI@^[ EM\Q$^M"2,UQ02
MA[Y:J/74+9LZ!.9S+(TM<D0^GC(%S_DOXRS3[5N;,QH;M[>WWT^_A,E]Z(],
M/;5,3SV4/8:/(7]U3 IP?][KD.'C(G#=*Z^ZTT^KE:*<4IYW+4/9UDRM\<)D
MSD[%BWL7$V5>V14H"&91:$Z8RP+&FM'2%CZO/]\I<2:H+A\?>X1KR#LSGY:8
M8+G..<;YA*69D68K&(HTPVCZ32J,I;P(85V:_ODO2X.G1R-2UH!;H;&41(B0
MQ8GQ.2#<IL!"ZL:$VD_DJ^VO5Q@?U_<,$3?*?ZFTSV-.8+MX20%<P7H .M$
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MELTR=&9W&1]C*(X6!/)R-)X_Z."IXE9)9CG+@]:QOT?F5J[+-KCGZ="&X6$
M&5H\M_$T)5V^ZFOL"?W7-?4=.OQE"P;G)* FXV7[6"OK,.AUUFQ=R2L/)9N2
MX]]U8GLC@J*=RLRJE+>MK!^A!X62)OG,'E;P)7R\F]><?:7QHI;RAX:2]T4N
M_#_-)MY0RR;_*;'J4PO:[;X36MXRF+'>/K(0M)*J027TC\Q@.7P*3$? A>$_
M2CR7.K-(.9K]#IL(/=[Q9!ER'+A)U8G#G'=!^Z9W9;?=G9V.S^UU(()H=PM
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MW<]'O*TN],+;MND>IO)@KMU%>N]@,('/\ !T+FG%NB*QC"^]>,/2UL?2<E7
M ,]O)HCG<;):(9=G1+P)V>R00W1';2K(ABD:9VK+6X90[&RB_/H>I:JP>@Y
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MGS8*8_&Q211+1K[?Y,K[;[\V)S.=L[9:O_YR,/(*:[$R$GE6\_\: P@?6CX
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M)C"?RY8[*R7PF?)%.V"5^9"S@&N\3A>+\P&PM,5;D+K8[JH32,DHHDBZ'<U
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M>&B%U&?]OMGU+Z\04SI7&*<-TB3\Y]M]WA^ EG"+-!@A<E&,M/12\NA>E)8
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MY*_?(*_4&MRK+SN7]M!_?/61G[H]-D-6BUV-QC)=N,BDB;T_\BS'LKG"%]X
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MQ+=M)5!YT2AR\,/"NBLKL = [XI$#6GZ67?1FL&CJ!.Q1WYDE)42:U]3L_*
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M;ZRP!?Z(AFZT/T K8\N2K7S&]F<VPVGGK&B>U/F>CA/1E&A&,<+;:12NK9F
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MIADI9+B/E-<1;?)_*X3>VEYM]DL86Q0T=;P7:<A( #X,.,Z<@@C@5MX,D(\
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M)/359+4W7TK)B1_2:G\V62BTF2J$3^^WF6VAJ%+7""-LZB,I[?[D"<JCT9V
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M?.-R K(9/1)G(N1,O\YXQ3Q.M<1G WG;-0+:_?'(N9:>)5VR5W.>+][8N"X
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MR DHS425P-VH/*3XJ5T6,N>ELWX=?J.XRRB'6G:I=!]JT2*%Y##QBNJNN>R
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M7 0DG7^'R9%']G/LF,8B9M>![&Y0;H7WT7CS1*QL7!O4HO7U:LL$W5CXMNN
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M?!]]1E@[_5=1B6*OI K.)^5K=K%Z\RG*MBE^^J;X[PT<-P[6[;T,GSJ$9>>
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MQJD78?QC2=!HP<H/;QR\9:)C6EQ*"F6?"2TG3K/:_I6)R ^V_7+[(X#O]4<
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M*:H$2#2%D?#[4]&<<6-3<U,8GQ9A)GM@:?=KQV_CQN:F3\$9V'M<6\C>@XP
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MBWEZ771=B4I24>DH27VDP*!P["+4&:5L[UOGN:9K)CTH)K:#W<0<W5ZC$['
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M@2R)"P:74'$%S'MY;QR<2TR;T;=V&7E+<5A15YL-L_CYG):&49*THL[(GD=
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MK%6/.%@$4D^+D1^>8?LO;O$7O[SY;XJP-99"C*8!3G)1KM$ +STL:("<ZS3
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MZ=E$IYFP!9VC*;7FX +.U+^/:VZ@:V&+[IFJ>30 =IW*7=#95'SIX"%!F](
M(12\"X0$3<&JA_=7EQU,T5MPEF-)")5CP((:?)<&0$Q0Q%<Z#_-L@XU<3E%M
MT)ZA1E^;,2U>ZJ&34^N0QJY__1#BX1D4:@J@KLG\!5K'%?/OY<'42F7\N%47
MJ388;/V%?OI@B7T>RZ;/;,)7"O]N8'%TRI2N,2/$W!Y];$)<55Y_<XS+/?3$
MXK<U)P)^OT]ZEHCTGHV2"Z!H[[@#_ZS$F_?]4GD+7LM?IP'4THOX0T)C[[Y?
M"]U=THQ''GBW5F_^:9:O[#1YW..DK$Z@(-Y40#:D]:C!W?2NI%/$+>Z.WCG=
MRW=,A1#RUYN.AJQ("#\YY"P$0_WF9K,EBZ?\"3 .:\J,_7$8<!MDFVMUFP98
M1ZE<S3<%RD@E8MOL.R^FV 5"0EC4![><K?_);S&HT!Q6  !V%NC:[:2((ZH#
M@%N:].?1 QG7W]VHW: N&]E'_ *GWJ1:(W*WQHM'9#^=ZD<^!R_1X7&D&$F-
M>CPMW'L<8+O7^P!A_<=&E[1D[13C] A4+#Z6931,>[<$:79( ]RU.),<]N;M
M8H\VI=[D6,($9?\$]H80?#R_&K&YC=LOR%";F#64W* NQ/[C<[HS7*O'#/9V
M<@3V9]KT5])&CV1-.4TRGQ0[Q2AW;>_PT&C@XOHV7?G@P5H)\9G;ZMAT"F?&
M'N@.I?3)+SAVR.P%VN[Y"<W/0MF(P[D^E W+ZW-F?KG;2/<_[[B08C>+?/;P
M7\I8N@?@MK3D2J\;$A/G@;L#NE+>X*96(/'<_/A3-_NM:3CJR^U> VRIQ-\D
M6L'A[P%"5R1\NK0).=HP[7>[?@F/V,Y;U97Y,8?WV&$JVG0*HP?5VN-%,N*R
MH4'T^C'#@_%D3@,^ZN'%E*7ZMZSL*C0 W>8B#)-F/+$:$O\4'T0=R;=%4 ]Y
MKK1? K"#59AM9._)9?T=3'"4=!)EU5SL] 7@X-2_Y1_]]:\I1SOQ/KT:0".-
M CI\,%K_2U.^?H>2=,S$MP4LIAMYB<G?$1MP^:_M-S1 GLN!<?$E &)0GLW[
M&'%/FLZT.OZ3JD[_KL(3$NP^][T S[=I@R=%=_.RO ]:[F"\>('\HJ!=T$/%
M\_O7IY#BG9ZRHKJX\WI>\F]^B*4+?&B.\)"DVI 927''*,1\)ERZAGSWR-!-
ML+<+^\+8X!$!W<4FHE]LYY9A]3HE4[OMXU3#C7OE3QH)X]4*]=VMTX8,E=7R
M%Q]$'+)4FO2T,1 "NZ! "-FDU_[\,,4,/Z-[-79;=[S\45M]V.?/HC'.6AZA
MQ1&\X5LS^1\;8#JGJQM9U6F Z* %2ZE3^&\BGRI%\+H5]>D6)5_B^];ZJ8]W
M'O@9%#&WR/S\A=YWGTAQX0_5^4+A8W_ZP*=QO\M6.0%VNUL^/W^7F?N $(RB
M3^E?KP:&ZYOT#*6FF#FWU6H-IXB"7<[*N. 5>W*CP!=@LFYT'XJDRHRTF!78
M:54N]P7P?9!+-1&M1#U:\BZOO/QLI]#*<6=*$WK5RN1<F!:6E2I-1\M*5!GX
M8(YX"WGPB(&\8CVT?2EE;@W$XKU_-<6NG<G-NM\@8Z_?;4&2__W="X+@5_-C
M&/2[/!L;I,)=I/YQ%G:^A'IQ/""7;)9;#XE&MLO&3'FNHV8]!./Y5%PB90.X
M);FTBWOAUA V.^6I#:@8KU^_2D7-'7[FV[4@X.HRO\KD'&"9<P%6E!)6*2O]
M-$'FZI>%?9]>IS?>EJ4/L1(]C\QTS0134I4Z9+3/07KK?2EV%]*1USGPY>/E
MK3E\<B8!05#%)%SFJ7>ZPYUFF;_;T(DD,S<T_^XW8R,PY%>I]3,4>HUTJRDG
M-<RMQ&UB2#/ )<S1AV>L8JSELTB4JUADCO+C-P)V0OQEXJ<%FR'O^N3B?))\
M4FR,XY/U%0KTU4P,M7**CR7DXI-2K%.>),?GX^C7]%UQUD5U#IK<QOS_>SS0
M)T>5'#./B+IXL84(Z0)R_\KA(.R'\WT<4QC0F.T8NV_NE' QT/"6VZW46/Y.
M'6$\AQZ[I*Z\^X($+D\C57>L])O\JC&*R;3,V/=9O#@NW#>K<";E<2;T7OS:
M."H:95P?4O=K^,_OYN6+!ME*FO8F6<NC#OP5MH4C>N;?OK49'Z/ GH,OYFJV
M8A16D"TZ/"LQ3R*G[Q-N18KPM8F.N0A8#E=0NN,,/G!R*RI:5"9P,RR'3VTF
M]T$'<F/G"$:Y\7-UD-@M*C.UG<HP5G\^LX@WG1Z;M_<Z7.KKDPROV.GVL/Q"
MX2A@E.0[X62+<2^T(R=+F>)SN?I0Q@T<#7"Z@8"-4BBF2L)QAS]I@/-P*?N^
MC'A2R-C2+!J??6N_S8=$#)7Z;2_6W#!+N#&ZY>W_[* PPA#4Y$H#/.Q\JF[6
M:2KN#!=V+%W:*G2T8>JP\EPU75"%":'XX@T,TO0CLT=2B++K,JK$2)6 Q\F4
M7JZ> S2G15E:4. +-/)A5O$"N?9&I"[L]O,D6.UA=E)9UF.'L@15E<.F=!&4
M,4KY-JRZ@!X?Z"$JO"BH!L0#TVX>56>E?A6T?P_1'I(>614=OV3!5FM8]]9:
MK]+=KX/;WB/C53VN/,*Z(BW3?]9C8I/N1,@76-8V0-"MWD]8%HJ"&_Y8\)O\
M[HJ93H"=_:]KG&N"WPJ6"ALF&LX)6EF^FM<10=2VG[S5OO8L+>T#[SC)_!9=
MGKWNA7JXN;$^(XT/W<N[$CY[UNQ*%/_0Z42E82-N!C/ "7/)3POP6[T^#(("
MYEQLVE?P62P?[#HG0U.>UE7D=SE*W#;]>@-'+EVH5AWQ\TT19A3_&/KC9GN0
M5'B])X[O546.CXPRHB.:W9E)C\?H-@08@0XVZ2<\K$E0E3F?)L$1[R)>?#<E
M/U9R 5GWWTGE^G="M0"[#![PP$7I+'R<.H4X'$?PKQ\68);\2/ #V$VBRM6%
M^W^VRTRK?H[>%LL\LH Y9$AW-KQC*2Q;2ZR8Q3['NLE2"L;IF,PE+A*43P.8
MJ.I8A*5.6838H9JU-^!_ZFMT5=  3YQ#VA#3MM<VUY_,?2&I??NGRL; /U4V
M2 T4CB.J/FY1]CAG</,%#5"6;(>)_6>5P /1#J(!?LZHR]%1G#/]UU$.&D A
MV6[#XUC]^"UBQS:(CGJ?&!C2 !47^:G00SH>:7P:?9QPT_#8 @?^2UT=\86%
M3#?M)YD+BM2\PP'$+6S--B63;V.2!G ^)D!H +.&J+)#/?)>.0UP"GZS-/SK
M'!/U2NF+T=H@L"4 Z&O @+B%J%D\<_P6ZTPXIPL[259D25R7 I]K4>:N;BC0
MOB*GM-%W9Q523L7E'BCF<-,5Z=(%2=1YWC#G\OOF,AP)V3'U 1TG_SFL^9WP
MS+4_.2:"P'7'9<BT"?4!#4#*I %J)!>1Q[<RJ)@-\&)//[55&KNG:['SXL@=
M\>4]'(<@:<+^4.!QS!JUDZKJB5T?H4/+>RA$W5RM(E5?D:Z?R<]TU%O>< [T
M&7(?="#EFWMT]3KV\,,W%G\C342A-OZ%)O?#$_\O"^0&=1A4P_=I;LKO@0TT
M)H<KW,M[A.GR" Q2^*8H"*W'RE_^=&T<+^-<RYF:IB>07;$L<8I!R6%OB6<Z
M?=F2@N;3 Z4YWE!B]6(<T..*+%-1>'^(4I(_>%*78K<H6IAL?<$JRN[YP-/4
MI\II0&!B^X1M_=/OI0\KM-S<,4Q%&#X7 4E=:3'>C <4EE&L(PTP74"ZVM)$
M%-LH(,IL+Z [W[HDD7;QRV@IC7VO=K=*]$?"AP)5%;6]_%M!#KF:C:WCHM,?
MI54[2L-6YJ$4GDP\J;9,<QXX9=)A/?<I]]6M'5'4WE11=@DV&C[Z/5&D.=S#
ME'@N07['=[/8C<-MZ(S41 DG%(P)V%WI^6->\Y!-($JGB&)$X$TNM_5,W\C8
MKQ-'D^/T,YY\]R[?O\\5:A!KF";KV/)"1^R+R#+VOFU DH^4X]VN"^$Y-[E$
MWC>BHQ?O2@VNKD+=XO/XI9H5EG"ZHR7ZDHU]QB%4?S)(!?]1A7(JUY Q*FX9
M)INKV^;T>L!^*X>S.:66M6:-Y.]N%I>:;!2+^TZYN8"E>Y=NA!TA^E6=(;=K
M WA- 0)<^Z#2EGMYJMS(>T.L,>+KP_XVN:.AUT*F1#L&.!\YD\KTAK@[?ZM,
M,1[Q>'N*T0XG>$KD-5FR.[W&ZHUG9F&H_^ABG,EPO;+WG9U[<F0_O;Z?YZLL
M'U>FT@ ,%X[_;,EM;H:>@X_/U3J7(;RX*FK)G9WL/]QDO"Z?0-0]B9H%<[I9
M9]7VJ,X/A.65=V/'.KI*5V3/75OA""#SQ<BU78TST)/H,HW2ZY)/VY+KWV5.
M65T(YDTLXN-0N)4K(K4X4 B[5Y:B*Z^T&'W30###75:^$Y?CU[E_WEW"Y^MU
M[C73SI)6,U7SBYPOK5>R1RN.ZC5A0H0"*K/1T16*M9Z2/PT0\S!(SZKU6G50
M:"\O6G-,M6<-M;DT*C_$$Z6H<+@24>?+.!VBU9I'#O]N[VK]+;7"FKU<QC];
M V<4<4X./5"7YMJ#_]SO!V'*>*(\JVTV_$TNJU.J.%-7Z8<H3"798* CX#*_
MJ04N(PO%2W+YL12\I9\]8K83/R'[M40^,PW(I\V^&."/9O9+6>V;VAF-?Y+V
M:YP^67Q1>_B??GYKW.:%:1!D7TAY!X $@IH[9P5KZY #.?J.YK4U_O'SX55Z
MUQI37M]AX3;H]FV_?QHYB*$##7/924,\,0S<D3%>3_3K.C? 5I0[;Z>,J@ZM
M/_U69E^2]"'CQ&N3KW6X>M:/#XL_ZR%#Q?#P*PO,L3EZ2<O*"5,&12 6<\N@
M6YB0QG2>Z,+RK1G=*EW%Y&?Z.;S0+HK:ZSN#RM]\-YKZUG+$>'05EC'0&7Q*
MSI6RMC2TKO>A]<IJ?7!NUV!\+@O\G.O..I:K)0 _>.:[]JD?[\<5^!]C6V+E
MZ+&VUO_ME+Z)Z>OKDDMNXX%R26<GVS'=T\BI,BKS[2,;,"EP@P[5VUC(<E2H
M))5+S>H)WSBS;:&QWH*T\]30IR0M>VT;"./,+=.4E&#W@5\T !L-,)_$04XV
MC^N9JT_OD>6&61"EN_K#@O''5TG+<YJQ!)XYUJD/A1-R:[Q)GL<+5JY33$Y>
M!0ZVN?6VIY*?W"KIA5D\[Y?0MGJBS)J7LS*25/]K+"A8%2N;:5'_0.M*H8EU
M]PQD$731^6#=OQ$4Z7.0K>QVX;=:P@/DE7C[L1*I>^8.R/!U0Z!&5L:4^[?)
M/^>$E\#5R!C,#XKB<325@QS=V[3;-^[2<]B6($7B?? SSDMK3H=%NC4[)=KU
M)KE-GY>=W_M$XM1G IC");N(Z!V XQ84-[N)2+NQK>P6<LNI_'6Y.4-'Z,VR
M_L(V%'<%VO560?G3H) %TK7O7C_0(O#/,"6R(6$.SQOAA<^-:F,=:A'*G[IW
M.1:G77/?KN#T+1F9N:^MS;>?WZZLO'KI13@ $"(DT7;%84?%[#H<]"1%R3WK
M_:KIX W;=TCNQ^\GI%!2899-2@Q&=DU*@D:F=+@9:*40:-JBWK5BYA"_N+&%
MY1B-3]4-OLHWY?3C1F1278KYR:Q4S]"7Z<TV0L8&'KHIUL/!R Y$!(1-G9%L
M/M&>RT(1+B0;:C0PC]Q%VVBEJT3V];Q1H):%-FRJI.7)];2%+?U(TI=DK;5
M&VG"W6*Z%FZDKBU4!ZP_]E%87C/O>BQA4.]>+THT0%DGFF3E6NGJYQ8Z$+[#
MA)@M/469E3P5SDKXNSY$,\N[F<36.1AD*_!KB'OQ%[[^CQ6J_]MBL6NR('O"
MEL)P7(1U18:KY*ORPB\1BPJ._H+)-K^EH]Z7R9^P/-LB$S"3H.:G;W[\PO)
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MRI.,/\N&R<-%V3A]5]QP+B/%BAYO/:F?YW@C9P96.L_+GO6PL.E;5V?XV$S
M?Y#CM.S,FWJ@*@=W?"TR;"O[UTE*/?$,F@8XG4?N)K0M;8.=05.9W53.JA<9
M03!PA?W:!Y [;.L^"LHRZSIUH;3P#36S\&O\]:]W70*WPGA^6UG$P#Q21BS=
MK9:%SX</JY[Q8;;J8>N6O":A''^#F5UW52LYW,++:@VF[H;'GG&NSY&HU+G+
MD-#L(91B4&D4;^RE'F@CDR/T+5#GHYF)]Q?=];N$&)@VG3/%D,^]=\\!#;6I
M_#+7=DIMK<S.)T<=+DS=?'X5PF*YFG/%.?ET[@>(ON\I@.@4'U_!GV.+*>YD
M[R^,FXQ'PD%EG2;WC"571AZ/J:J\UKE\MK(JZ!WF)[-0]-:L_H9<[/0KS(_#
M*(_0T)=!*^$"!6^L1'0<=3B&VRVT+8P%K'18"]GO7(H7W =/S%[LI0$^TP"=
MB0+=!I N3))9[].9X%:NU*H #X?1V9J4UNA6L5#1O&69TPNLC)17L'L+ME+"
M4)>[*NCP!8D;]:WC1/]?$T_-=6^09C?\K=?@NF07*HOXT75W'0&B5@*1J^/<
MYR@S*-NL1P>O@WB =-%?+*_Z-%BN""UXYN=*O_BM=I[*'' DX/&PD$@QCS8X
M=T7=O+YP3?#!^LJ5^XJ=@9PJ*7,UMLB9^Y7(<#3(("B=%$KF6Y25)]?B^3JQ
M',%'E.U-))-KPRSTW=)!)G78^:CAP&AKT"XNMTFR2P%)%D-O^)4W!JLS!(D9
M7K%RFBYPJW:[_Z#U8:]S-3KEW?&HC8;F, # G)Y 2.;9-OVBA!//:H@"WNJ_
M*<B.<VVQYXUTJ4Q/#K2>9'M$L>PXJMNM9!MXE);<XV25!K$.J7A2%90Q:I[^
M+![6-$/'1PW@C1?%Y0F@33Y"QG2?D[$"4,!U*E0=W\B?MK/&)9$8;_+4'%]U
M_ULTY5;#1@P-H"U.L* !SHE%(0X<(&IK<P0=&N![@SDSZ)/]I:II8=US;Q8A
M[&XOMTY[.GKY9N8+]/7 S2X]8C67I:APD<1I@#R+WERR+X5^CR\IXWSM!Y(M
MT\B2!A*X9D<EJSFL/CX\W0)NMEI4T!WTD<\IA2"D%X;=?+"530-L]H9G5U#%
M0B%ZDV%J= Y5<70%,=P'XZ&;00P^EVII?@9S%$KM;0)G+U.'(&R8^!LBA6X7
M17#[T.O@>R_*G=]=30%B+WA^S>8_<QH(H &B->#=X#T)\BZ]-Y!8&N! KFD&
M1&5R.N)WG7.9)$S]-CJ2JT%N8CC7!3'9'YF=5S;]L#E]YY;<Y,P^.7S.P[>
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M1_YWMLS^?_F_)B#:Y/\ 4$L#!!0    ( )8Z95Q<2SCXGL<" -=J P 1
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M[OMIT(21" >_G!)\&7HPOXQ:!3FZ9XR<_A5Z1:RIKFM&>A->MA7QY'ME%0*
M0AK@1!>H\Z85-R?Q->@V89*<H4.[7&':6B F);,WAHX9#32Y2$;2S&@"2[?^
MA:Z@MMLQY4N#B96?1EN XK/]Y0OI=AIFYM1EU)D>02]QG'Z/NA:(?D 3@8P1
MK[FV?/T>BMLM$6F8^XYJ"UP3?,T.?H5/L@^ZHK!6=2R99*=:6=[9P'4?*J_)
MH_F]KAXP/QZ=]3HLFDBRNGK.>HC6XA5>(<.+OM"AG5]8A9L$(UR1QI74L;'=
M25NR5=KT!QW7;IPH,[!P.71VU>ZGM\Z,']Y7?_-M>\/+%U)!^;41=N686_/[
M!]MS/+V\(HV<+<*MBV]7A.<V+PQ_4L3+D7(1GX>XX GF3;),0\(<YO(6"494
M$W+Q.V/3_B9]4+N-LQ9G#!%Y>'23EJ1K\YP"SS/86%Q.SI6@XUEY5Q>Y2ZD!
MH0V-9%LN>R^KMO\:MMSKJW_9U?M*OB(4"6(@_N+<)UL1H95#YVS#[0K+1B:3
MB158'5@+H-V%'6XP*<Y0\;.QB27L_8UE8N8&PN>0W\]/9ADXWY\_4N%S#@PL
M%C>;NF>?XT>.-$ZP HY]:)="><HW^##&L+?<"@(5X:H>#/"S<&09)5%O)3U0
M.4 +4B5&_A0I,1'47D[U.19H*29UH/4F.+H4CV=D>%+UPS(J(;J=MB;W7;;E
M=.!A4#TIDKXE;)VDS$C=KYE?P]"#/$XWLGJO43.12>Y3KK*@. 4%,68E351
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M9,M\!7][W9/W#=SL^YIMQ=;_\$]0G-W[RER"X_R02E.H?,5&6$]K.U),[R&
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M_$WIBP_=S>[\'D?J4?X!??^OKX/@UL#G!U0ZPQ=@&O39'E_>_6R:H,5>"SL
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MK5'@*B8;RT323#O-#9L''P&?4Z(2+']I!A&9RFAI8490X8B+HUBF>T'ZV7?
MNZBL9WQP\$VCR;Z[83HA^+C&0ER:X&L6/*7+ P*F*'9P(]NA4/?&5"_@,YP-
M\$4;NT^\N[8GR!OI49]X'NJIX!#*<>_6-]2E..LZ8^I/S3_*<JO)>K#]2TW)
MN4]4\8PW"KM&28:_Y22E?S4Q;*LBNZKNJK74[[Z70-,/ T:+0KU>-.3SV>O;
M\)50Z+G>A3=.OPRC]5!(R* K$/5W?KZ.T>.HX)-G6G.&')L<_>>O+%%Q5WJN
M))@Q!*\_7JG)6;YOWH6^(/<GM];X'VT[-N#+K%6;CH'HGZFA-.A8JUJK2'%5
MB0<8+]&(BW"%'9@4(&=CBK=#"99\]AK(ES-A E:D1Q_PT]W#B2/>4:X!#:1G
MBAY'M QRK(NS63947>%,X#]Y0K>R@8)V=5%HK++R?]:[BQ^QGRW/^\/UV@QX
MW$%'B%*P#40N%>:Q4^]8NRD]].VHS=.>CR$,W]P"2@66@R%1>42!@#/5@,A$
M&7Y1'F:0S[1"-ZE/9O/5+H!QYA):DQ2#MU+9=$UZ]]NEL?APEW52WHOJEI7;
M9N5WX/]^4VZ ?X>9^4IE_'&=R:'"2%O:(C9)[0"%W1 CM 61$O=$3@[>W!9@
M)"DQYC1)XN.+T"1VP"[#4[E+/&_::6PR+.],MC46(1M2E;6[%# "C#XF"58T
MSFG.,RZ\]7W2?$QB5^5#<TJ_D6]?5/ )]Z5]4(CW""6Y&XX5)$DLW:L?["SX
MYR;A*;FR]GKVL#>9-A,O_P,0<!@;* +D&K(I0'4;4#H"^9W8C2AC4I@D-C6Z
MM:IU/LP5BGX((4_TM1D\FEEN22FIPDY$Q&%3:NRZ3155X[X^K2]:;P?41NN\
M*EK8JPY'BVEL9IA27R9?O?6"2!D7-:+G*A#SXU+DZ*0DE>^Y),HTB9W79VN1
MO<!(/S!Y@B;V,MT%-/T"T-+L,+H7(:IO:E?!9ESL)$T/1]G?RO)2T/5G-CH'
M!7Q0UU4IX9DM?L#^4C6L-+)2=U>DH!>Q<[U!Y\GU%5=,GT87Q(QV'6:VVLS6
M96VO[,(U!PP\+&#-^.)$K7.*&:H'Q0)6I^=L.).8#:M-I^Z*U._4>YC@< IY
MEQ2M!]$X6.TH_/PZL5)MU1M5<YVZF7PJGF$^$K$\L0](CTC]!4Q@=-;L@1GC
M4@VNI?9^140+D_<TC?T8K0FU<M!;72PD1'.2U<7^-HQ89$J*_!F,36KS+'UO
M,9$K16Z&<G]A#D6917JUTCZT]#,)!^5]ZM<2E&=-[>Z[I$M8'H(O2*+JD&$!
MW7AC*NYM(B#KB'.OCP;&Y!%0?FPU3FW:1V#BV7="+%35:N/PP.6LZ\S]-7[R
MS]SOM8DU$06Z$TR7+UA6<KQ-NF6P[95'*QI>(L#CYB=86FZ?AZO^^-YB7%BT
MZF_UAO\P[&A[JATFUO02:DHV?[R3/C&Q_^'M'V/<-M_@;3_G]JM/I2,JX 4K
MXM>GS:'X2.>?%F2SWZYY7W#U*-#V?)I;OB"CG"L:2A^;<U5LHW;XLL-H8X63
M%?.7%#^1?P(8O!6-5+8Q.Y1F(A#3TBE&$$<BTH3B)OU:ZT'_#)<=3_ A&XG:
MI.6N^6HH_I=AI<4- O5FE<?#D/\4"%*OJ@67!S5SO]U2_$'M\*&*'U";$'.^
M\#3]'7($/4ZJGM>L:(3)1D0P1&FIMU%ZV5O5NN'8S7;HK1 ?"Y=&>(US!T4_
M41X':MYQB:P)5__0E"NUO$V@-L%<<RG<W*B?J$3</-1SY4E !&'KJAC<KB&'
M@(Y*/5NU#EQQ8X4OU68MS5""(I;2A35JX-?W#P2-=(,<#^!GDVU%C\/-]#8P
MNA!KE>O!SYG1)W(%&^_"Z*<?/,J)C*-T6^YE/[]&K_=0[EA6G"2-<1V>,[A4
MH2 (TE/\0GJM7L#5RJXW4'>HA]CUGPJ!CL O'_UN$FK5)N$L$] U*_%07%-Z
M]'V_@![.>^\'3WN>_AUS7:_Z<W1I.FT!MC.;R\H!;'Q-Z&FM_H)/I_]\6#DZ
M\_BCHIMMXT]T:#5#*@UUU#I$A-+@LSQ@56XH;T2 -W:'^IU(=Q%/NX5<KT;-
MH Y"P\"L&,U%&)(JY(%@#>W.HDR7A. ZY=]!2ZQZ2Z!'+2FW*C'2&V+9YO!B
MY+,+B]UH7=)4$#^^PE7!6+V-;0>E\RCE7R2,)80:3 >U@9;"VD(.4%5\5OVS
M^%^7DV)VBE_Q04"6=:@-Y8)Y2NKF-3:RMQ/)QRX!8YZ]W1<C3-[>ER:$<C?U
M>N\T-WK VR?Z[*_6'B,DP-7:L0$MODTUO-HO8[A8 ?+/8BM2=KQ.6#$^=@"U
M"55_:>W1;PZ'>^()$NL0J_/MK/J 6I_]O>GW'Z<*_W\XM9OL]\?Y*V\;*DZ?
M+1]*LS?],OLHL.+R@O"Z,*3]P;[*^*ROYRIW]!R/RA?BB-:3L5&U][Y379'U
M,+)-JK5$"E\(+V^!4B4(8_)_ -M.S C[--!T!W6 ' S5B,>P.B3+8+B/[+TC
M?P:ZZL0Z"6BNR8I&YE+,T%*1=O >SW?VLDU0&$_86/5DZOO57,G8K,K=.1KB
MP^DY9EBI3^51#0AJY,Q9=3]J';#T]G'4!X@W:9M4;+ZBD7SY3K_;9J=[/'8R
M:@^I2II<6WCXGW\M7D"X;;RVPUX6\\PGY\?+X(&TIPCBBAA*O7PN!:$J4JZY
M(I&M)1N @HY@(K=8!TIX5'NO/!R[3KEA7^OCLJ+:Y)* :B20#EGY#S?8;GT_
MVG86%V=46!%AONO>PV G7!"(5&M;P_,T#*Z]('4?&S@)MV5%X]GRG*AD(F)%
MHZ%M8IOJ?ML!.+:)A^C 25Y@3 G@Q3?7 I&<,<;.&:,0JW: UY2T9(WAFNS+
MDLK6N5*!96[QWF%E$#IC;!XP)7CYW(VJ]'MLFO' L'1+/*QJVQKG-]42K*^8
MF1)F2PRG?0M\SLW\]+K"XA_&7-_9Y<<#T:V$V<MYQ>PIXU*\">9.0Y85UV1+
MV97JJ;B%PM#J\!;6_4C=A<*GTTY%U?XM,645$T%M?P>/8@,$NH-E;[8 @O5U
MW:;/G7*5(W!M)L#X*C3@48W@]A?#L_$7Q(AHDDJCK%52574L>\MT%P+H(<%D
MM'E*T*9D%VB/^,7UQ6[5B87ECI:A5&DRL%!U?#E->2F:6($=J:TC )%^?=>C
M=>*/+?011V20)8*#N(/=@/X-.<*6('F%^*I5&%[1N&I[F[(9;+P7'VTQ_RE9
M:KU.(D^LB$#M;&Z^2R>K=Q:L*SE5YRSD?K^9TC,Q]-.%%0T3!S7<Q-MYU Y8
M!<3UU$;!?/.*QGH^- 8XBYM5&=%%MO)+4##H/YG\(&XY57";7>]"%'L-0%=P
M5.#H9''&$^])JW$#J6WVDE4W&S&=_]T\#;3I&C*%NI@?[(=R/R01;"*R'3,I
M%MMP9X9Q^W(^BF+"W'6*_[SNTM ?X0/=9'3K3"T2*NK;:6,RR"%5+H28BM.4
M5VBX56$B86R7VA9DSV,4QDJXOSCHM$!8(0UF6$<@6B7DSVTIKZN"O'S _#3F
M_$F?(6:1KQ?H7@A:2A8=C9O\O;?DBH_OTXMU'*<! C&FDP'MYRNW6:JUF7#A
MA4([Q'3(2C"?J[ @P7BN>DQQ:4J,PFY2ND&#4K:6AR0#*S3EJ]<#@ML-B$VD
MV,GES@1D1X%MJEV"4=?$O[@ZT4OK1Z<,SF3=+<\M4=V.8HP=56L9PS-%@Q0J
M6=& ]56*Y"!WDC+4VJGB\0B,J=(#0G\>4=J"-*[@#NOHL"U9AU%[UYB#3FJY
MPN >8/U(.H/=%!$80Q<7V>AL9UE[5^]Y[\&X'_:)+2ZD F>1(\MJ+=@\-L#2
M=UM$XLO9T N1%AD-&L@+5"5*9W$K%]#DRI"HYIHI$9/(T_7]M;]O6$)/=+D2
M76'GX,,[^'YVZ_30D7P]7M07JZ>2-V4FAY^\/V>Y'U-P,?NU<4:N]_4'<3.R
M*J=C%Z\$1O7E%OWT=F?=9_\_3Y\^P \F]N.15#7LHHW^2L-2M58WW(Y+T.IE
MP5*X-=GD&QGR9U" PHV$5P2)-?DU/NLLTPD+3&>,OF/BTE70O)2(2%O2"8[D
MFF\>1IE#[(Z0PVS0H>PAZ5&"92 @NO,)F#X*5;Q![:,,( $?$63-4!JVRO]1
M9:(O882E7/0SV=PMQ0\1PL_)E!^4EP"=&6%L-OED%13/=2S>5,A%CYGK#Y(/
M3Q+POX+YF8NV>BL:G9H2;ZLNM2:@8M^*PO<00]H+@]V8+6(8^0O52+@"-->K
MWX@:&'/=L,1TW:7PL<\0R0U>-#WE)3 V=0F)<&5$3!@.*G&3"5L^O[;IG2Z@
M92JITN.:IP!JHKU5%57_/722T[*<N91@T[>=Z:WS"R 8H<G+@%CEUCUJG=7U
MF'J0KR(:HG91-D&."F]2U3D0S1%EF<0FDUVEK<; &^36MJ!)>HKY(6]GSO=K
M+:EWE$>E2&W2BH9O7UM0M'C>%CM MIX<WZ/6:V[HO+;4'/6UT,WXF-.6AM*W
M'P:ECPIH*&7;\&G_46)YZL'6G*2$EM(=?_Y9=> 8WL:[N?G:/,%4.*?Z%PH"
MEN43\"#M)J]5,=$XVIB56GO#)!+:3YO[!DR*L^AIJ&WA= ,ZK\6?^P)U&,Z5
M_-+P.%UYR>1QJK2VK((4VU4PT2P1Z12=MDTKZ,/UQ QW2RQSUMM^(R@,U*^I
M0) ,.L3H]**.C4G1RFULZ><Y7_&*QIV6%8T,&[6F\A"TIP)2> )#)0_AX1*F
MI'S%DI OT=O46W$FCHDEPPU!\P8<?Y95*U0H'8]W[[\\%%V5,65_BKC$>$<<
M<Y3/J^ZQQ:W(.L?Y;PK-52QM\P0U)S$\;P-Y B#HFG>\D"KAIRDW2# &,V@=
M]1%X1DQD +.NA5+W(@G#\"+$Y\6QDVKL"*C7LDX32FY,0>(FLNOZWM-RT>IU
M3SVV6(P>L95C5+?4YI1_J8T5&<I+"A?R%=7]VK8$<4:6LP_D"?KR8D(.U^7S
MB_>!#L5Y-R"#3O6/ VV.TJ+]L_6D4*[0-K/&Y9@9BUDJN+D>%$ZH<C&-TU\[
MMQ!'_O3D*=Q+#U3N'4;;"],'+:WP%;_K5[XZ]L0RJ/B@URB_X,</+1$[&R_V
MS'PC?J>>IS^C=JYH"/'BIKDRH%Y"G4\%"W]1E5##B9I-V0TK&J;DT#Z_:4(;
M\;$ M.QR2N44CMU**(%B@(COL1P=P<;P./C3#=,53I_N/[D?3=<_AMH]2#FP
M>GL-?*@QZ-_HT#[;3#M!"GKGDNQ.L0O4\0078Z(2=&)NFV_K<PF:1"*@^/._
MV[6'<9<I!T#,+?*.A_PGW.?!(].Q$]8TKF,<&?^DH_1X\F 6;_@]%AZ3?"!1
M_AWF 2L%AKPIL>LPV18L;YWL07#^A&9=$SEQ\H<N:R83J"\+4JKMJA(P?A>B
M:H)\@*6ADD<-RS=FK,O>!V9AS_391[/ZKK%IYU3EZ# 1M ^KW-FMB%:NGC))
M#X@HU@-H/'I*3 'M)3*S2;T1Q'+C;1%CI-PSD/>*QB9Y\R,XZKR+ENEG'5=:
M2S#;R(XO0,WDAF ?&:> =:L2^ND1KBFPIH?%M'RE3<[Q].PZ^)AY-L/?A\",
MZ0MBQH_7'_SC<]$9TJO7!WWD-QHNEKW)/^@7<_K[XX:@&'0\:\WJOD!H (,0
M>LAOJ$K1X;24%AIO]*HJC[(C6!D"U0%'+P(.68^5D8V 6=F @VX-">]!W"X
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M\/D7:!>L< =4V2PM_(J&(?FHPIWL#=T3RW3(6$#TDB[<# 6= O<EBTUUG;&
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M/W-;BTE#UM/GEL'<ERT>L%-DB-92=,GGH3 )6%Z;",BD'AS$>M+GERV[IX;
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M%7VF0S(1MF"QL)]#U218=4+UF1[XA#KT$1KQZ CQ4#FFJ##7L1K&]!!I_Y>
MT@N;"1J8P+9T=?@UQB;1D/7^'G>+[)RX>+_VI">T\"7^Z(N/?.VUV[7@S\B<
M.)8VT0CT =*F1+N8JKW@U<MJ\MY_7?$#,H^)LIKPLLE01#K?6,3M0NG/#GJE
M)%O-FHZC8[<L)YT8W5!UFWU91-,"@WHB+(:9/XO)6T!R-T)_5&+)"0?864TX
M5W79/U)G'974,-SD&\'[YCM4;S&P74*SJ[QYSS!+[R&E"!F+&J?) I39>-76
M:6I3?U<V.2TDO6?!',8AWTC,)[CWJ.P*NR8/8)IJ+U>4@?H=);M-=S(#L$4G
MDDS[,]Y22D/HRN<OALH^7%QJT^HY4]DT88M)?=*"[O^+R//BAQ>SFKF>(^.8
M9]^6VVEC,%F@\O[\DIN[+$5Y;VT'WE7CE0\[^,%MH",0K5Y<[;:(#0<:VFL^
M@%:<*^:C0*V'_J;YDE,;?_DOK$S\:(@=O?!W2T^WSCK9S6'5)L6.81*2$.!1
MS(DP L4U1"< M]RM#LI+G[DAW'D'G76BJ)%L6*Y#JE$*1 _,>HVS]1N1U$4U
MC2[51E\M'<;GD\/+LJWK\ND+6%LTNSJ<D3@AP4Y,3K3]R$H&EN<RY3:@I[ G
MC[25@)*=59; #P#9(E)I0JW"&PP2+EQCZS2ATZ';ED*_7+!;2$":@U!?0!V(
M\-#JB",5T_^$1\RN1)1>OKCUP5GSAI;@\3JRN[_?J_E"= ^97;UKI*^^A/)X
M3-%BZ5RC6KO?00?BD&.C9];N=P0JJ6<'%Q_H0:^&4#G0]7R%6;;'NP0?M\M'
M!ZW R(327L'MP<5PK!]W*=<&%;XE!,.KN%E2&KW%.?'IB9)T(6P3B'II:?(.
MKBM ;2&DM$=H Y4%D0\)H1T(O8%XO@X8R0DQ*HR[6W0^^V&,J1O][IURC$M"
MG?_XF>F6A KZ@PHF1H=YH#NKO/3_;\"I-VJQLTLU>D![[W@E=JF-?F69<1DJ
M#IKKE_]"&@P,V5HL]R#U\]>S$)A)PQ86"^BF2FN%J*N(/6.$2\L!:9/\D\QW
M..+EA[-/8Y9#;A@U/^6'8:3C?4DZ=.9E9N:6V#;/' 1$80W>!"9G!7P*RYCH
M(NWIT);8>+W#DPP)G';$=JDS)Z4/<J2H8\I]((ZI4X\I9)D\'XP/S86=4/^:
M;F(T<BNY=3L;T[;OD_"01])BGNS((NS,(]CD[DJ+"3^7%?/H=VFO04:P==YO
M?WSYTA5^/,IZ6ZSW/OH MES-G!'"I$J:;V K8O;9QQ;:2^A5EX4.+/+OHJEV
M](VB_I=MR*-<(NPL@#X-7A1(/(6.E+3XF!W- PK7:.#SPK'B=AG/J "WWFDE
M[M;6G*+4G&U=AO5,_^XL^+*_,G-5(](W4DBZ"K@'*O.1Y]T"!.R;\%\G[0!V
MAX6G -;1RK^I,I,&<)(NJ':]@_]P6>A%W%,.7I4L:<L31^(EN\;]8_!Q(N==
MKO?NJ.ZO754*#8UBX%$_?<X?H]<OIZC9C561R9,==[5$:V<K+-I^:^UL3^9[
M[(O;KC[;/_/R*L*] M?KV7Y&KR=U4I]1.$@HN6,8Q,MWJ-X@(:S=R=\FR!W_
M 9XOD3<C#*3+O+@&^SBD</\[HLU9$10AT)_J4Y9_]BWX?.@\JZ0LK8 ^F#@<
M?D%>&EX[1D]5*(\RKPNFYKX#$%G"@"-^BZJ?O1ZQC;@9F&37L3.6^! UDF,%
M_6DNN^BB[79V\=\=)T*] ;_LLC.Q(6_N&@4&HAY'A/811^[>;>X[G#9IC4*7
M/;@K&[X@1__5REMQ&TVY0.COI([UR*Z O2+J#X0IT:K&2_)UI"$1!]3ZAT<*
MR3D(:P4,\,PC!@#\(%_/$R/ZIP#C##BJ=*:(<7W)<+@I''HJ= $2/CUJ6SWM
M$O7E=MC[D%[C7$+/_W:KKI>!F2*:+F%!I#GWL]R4,-6MLA^!*=Q%_=L)/3(T
M:"7"&Q*HZ.$XZ]9AQWY=0GH(X#9/J\>:WOG0,(&>N7+G4Y_D4V>^[T5XONL!
MN7V6WX&4+N2I?X<>-1=$Y);? I"<58T?% < 2=4-A!G!I@,)(=K\\<U+/>]U
M(/X80$V_\.@Y[MLK3%F,4PBI..X;N_\0YT*N%?'MF6]AM"[^W^QUR!B=C?P.
MMB5I[1;EN##;:W*&RZ$:DRP(2)'?=6R\*E!>G KM#D'0JSBNW[<M%+DFW&+^
MV]#3>^)*%S%;O*HQSI;Y@^'R(**U,@.>)#W//ZJL5KD00O"FBGU@\*K&)G*G
MCA]9GQ ! 7V=8P<)C9Y 9:D ">FR(L*E]Q/?$:A=+G:?/K88 +S0?KNN_##*
M'5M7:YZ7:S"C+&2>[S&D5T":P=6VV?-\DBI;$J*?$']64DD_JOI;W$;363\2
M=4%WP/-7UIWHMG>J;0IUON"$6WZ-GVC UA]J+[+/CKJX%Y_:X+NN9?Z"[O.I
MO\%[<GU2-]J4&0JEJ Z2_E,7*L9=-(O.=\P(1_ >H"\,HL!#]<=-?%L]12@#
M,.#TB/]#)\ D&'\DHUWK:*7#^)=)?? ;X-S#WL9,  I>LK>K]$&NB-&A'DA-
M-M^ 44)D!FN;%-H)2R=C$_)&5?JT#5]6NJ8RX5:R>Q9Z?#G9EZN8BCJS?$B#
M."5K5C:0S_>_#Q+:$B\K'[-V<H!:82Q8Z $0I XL(RD[IP2M!]Z$G1MTJ$U=
M)UQ(8P:+L#5/2KGX*0QN$8.KQTELGK<6;8J$>7V]U/KU:_U"W.DXI2'[AR<D
MW.$7)2/L0ZS)N%6-S$6;=*:K<%5#*Z8H.HVYIS1F<COP.1MCD9:K_B<$<S?$
M/O/1>\XMP[OW*C!/0\^<"?E-2W><UVZPIX"^$=N'.+"6BA8D^A5G8I!-D)>T
MZV0+![>]PB>+;69BJ#H5*7P'F\:K=D=\YOA)GZ37CXU].)RU@QO*,<^)/'IF
M+NQ*4)K"HYS YK1H9L-=K[04IBM09=.D'>_HAFFB"?PB+K9;Q^=$6VC*?[AY
M06BM[;\VVR9"VR]N^\<:Z-K;8#_LNJO^W&C<74->4BN*'7H?PD'=1&JSM$%O
MSDNH)LF,H"E$7G6HO+78OX'H "2E,[6$=H<_G1D)? I,W6R2V'HV8HQVWSW&
M:,QIZ3'Y\^AN$_67-8B:(#1![*I.U^O5_.^G-I#R!*JO<&>"X0"_G0V99R:+
MW'=^[.E$''H.E.0^ZA7E_M5;/:/W(#0L9795XZ!*JAIHF;FD>N'A:N<0@OOT
M?S\$\PLTD[V99$S$ A'U %\,X^ U%*%@$LTQ>Y;U(U@L6( 0EMNO<*>39+PG
M13S&3>;IJM@6RS)>8DU4=,T9^J><[D'5(._KAYZ+ZT_:W.^76Y->)Z%U%Y$Y
M2<A&F[GEB](DCE/(^6(A.ZM 80)>A'62(1C>SOLAB;EG2T$12H>1N5AL9X6Z
MIFUQ<(1SBG&MXZU)/2XR:]. YKO;)QOF6N(EC GN4S71H!T;F$(;J-82XY30
MC*I!O "& E-BR%68??T"#:XO1;5;;@>O"\UJQP_\U,1\ ?"SX_O0QTIFAGSW
M,Y[??57QM\]/F:,IT9F#Y"C46,JO+/!TS1=T8])+-W6=J%<T1%ZWI&,C6.;T
MN<@%'TC6::YD74_@\7P_Y^D'(MR7-&GR<*2PXV#,[&..P46TUH"AIR9.GJ!Z
MG42E+ZUJS!GCI'].XGD]/H +\?@00M_F!IQTK@F(+\+=?5KT:-)Q5>/&[T27
MT+3!)3,S:3G$V")ICG' 5UG<E(]@/'H1BKO4_* X$.? ;4SE-C(\_U@N/_<]
M/W8Z]DE)83@W!%TCA.J1HVAC%#$LFWE8#6+9ZO"EOJ1D3<(!<H$:LPIS6=:*
MGT&RF&I,")W[IJR$@)YP+Q$9$EOT-O-CV*K&(W?EO13LIW[YT+A-7SCR*FD3
MT1A$B\@9$4X@!D@7DCGL[8JPX7V.[*Q)>P#V-WR/$*:O\!MI*J]Y  L";]*^
MF/I1'X/<4UP_>IV9]EISGIF@Q.C H3[F,R5KMF]I\YZQ"%G0 BZQ655T9<-$
M?1*N/@F+QS._IP3_KWUROZ[B.-1$X2[_2=7+6^X:J*Y\@MB+16H@#&*I>AOK
MS8Z_>@PQ1Q.\R?JY'J;!P;!C-;([&.L=OX=G*M9:*A:N:OP!XZUMWI!;J^L-
MC'R'XN!U$2U/74$?.T,0=Q9M8?T"I@J<G@'W0+QX >);5UDEA78A= ?B!L<#
M1^);D^OV+>U9"@I]YD:_ 1RY; T=D!@>JMK>\7OLZ]"O8VX+J8RE$]5#MZ.V
M3\[;SQ9)2%C4,<KF=VO7.PL[J 9+E#R2D?(!:3V(%4=GA CIJQHY+IH=R/05
M9)?;Q2=#.\>QT&WQ"Y!Q B, ^^@'>YUYVN%[OP9K:VR(^Z#8 &Y/EE[AR*ZU
M@C"@9%8\<N<A\J8#.W<4N94)179)G#L&/5+6EY@^!>_8YTT>:GQGG7YRZ&RJ
M*3^$XA=#6XC$_ED8D.GV9U:M?6_*'&-A]K,O/XG.F!Y_)R#M(NX&0Z6U':84
MSD(.58>Y3HI]Z=+:OJM>0%Y[$'V! O^YIJVN!-<X@S"5^CUX_(5!P\,6?L(6
M[SEQD"B]$X=]N[A6S9Q^5RATB5D3,I67TUZ&*H-.@28M0>W4=)<K"I.AI8_<
M\E%'Z T1E_,7)3UHY<V58P66M4G"'\H_Q.ZIF.Y-MNZ-NK!C97/6/EJ*[7)S
MBRNM!QU^5'*!]WTYD'R%^PZ@9",;1N=ZI-]" 'XFPD7UEOPCP@',;F<% VEL
M:;00PEG(X(W>/!%T7F4E; OHMK0<P3<A[<'B]VHWMZ&/)?J^%D6RGB@BE,7(
M:#1O<_^O7)6;8AUH*VWA="2A4H58:#9?&ZXCW=O/"6K8MV?GYZLXL9MV2/JQ
ME@3&U0BQGP\F^(\;AVZ9;I ]_FXEHRM;D5'(]VA/,(&F&H8:_00&51#/2#NA
M6Q'0#UYK31DL#Q9T6AYX04]YOTAO!%.$**.(Z7_LFJ*F1ARS<:[N].AKMO7>
MVY_\E/?;]Y-Q8368Q+G"J)1IWJCI9]S.-SSP9"NV+5^I@\Q$-XQR^MS5G,<0
M[@.@7JYJ;&9M(0VJ;,$?1 M7V9!5C9@%'34%R"N66KUTB5K52,?O(T*B<"()
MS.-ZIT0]D_5@3@QK!Y>YTZA<F;WA+256QKOBLV4G.1=Y@P]X0\#=SAVH,6<1
M8^ZTF WN,)X[*_=5_ G>2I(>Y8VK-D>*R;Q# HOEK'@[E,@G0IG>TZ>9W11,
MCDE^PM3>-\)HV4Q(.@/$#W[@>:8D",>6+'S0U).J+J://$GUVA*BI*DL5>T1
M.\#&C51Y,/$TD+"J06%J K?55$MGKF7JQF*?<7?)CK9A:'<1^<8\RV(:8I0-
M?.MVN89IF<INZ@LD-)T/3=D>Q>):M:W,E)T2^D]XOX4/$)DTT2><@]BZ)+LL
M?QYC6E!9)R;%!=O8Q\_17G-/9E_\.F(_#BU" \<I[X,ZJ8 ?[+V5H'^N1HPV
MQZQJ;(/CA492?"8Q^LD7=W_4YE "M6=R[S 371N#V.9[^N<A:^#S542]\DYT
M]40P)LA4V47G9]H[^.J)SQ1Z-\JA8N3<)[D;:6#E&$7-)7A0 ;*=2@F!I-/W
M)% A7ZC;5<9JDIMWJW3F6TC;;=X32B4H=A^]T-3G';K'NNGNRFL3^T?T6Y+)
M /V#T/-E3?[>>_>DU.Q^M#1@:[?\KN_UR8)BTC=<<]/PRH6_EI%;6&81"D2Z
MT&Z*L[!N0K&7 7RF"D#$]@\@Z@A5N&BI.XBSJW.@:;L+7EV <FZ!ET\\:VQL
MX"[^Q@TZT=!$;VYNIF>9[/ 0J+:H>OF-R+F/18_(C:-S$@ F^.V*X$A]53OU
M1HD&&%'T,O>.V+0,M.*LF,[\8*'[3WAF<X/M%L/U*14&P?BHA++$L43#B:+6
MQ@FTY^R'K^1T]@^DC41KJ3&%B0:J!#T=Y+2(?6!]G4T&:3=8+ES@T#818)UH
MO03PB:/9\Z5^*#;";&!QPJ?;I3,IA%5_J8B:\23!;.CYL./VNQ=W2GI]9@W\
M?:V; Q?U<?,+,P;^'AK_?[[(4#1P&::@DA5FTK5M^.)^91CYV092UJI&NQ=;
MT*K:M)9@8GS7R7X!]>4P8H2RA8V5!+ESF3ZU1"/0U5&930CU&=E'IB\6ZP3Y
MOR,:2V%=02S;H?B-Z9WOP)0C(+EV)RUM?E$9>GIH\<N2F<D\$LX6?#;SJ5GK
M6.L\+[+%9N+$2IHB&F,MY5AQ+(:GNJ'ORWQ\HN^<*OL0OK-B?+SCC?4#NSC3
MG6>WW"1%*VL1!\%&U:;Z50W-#:0!*N /Y>G+4D"&-$#FHWQ,TIHNT0;6>NVE
M11@W#O6GP>@X3<&#)Z78JID(ZZ%%Y$:(V1?+W>#A)&$K37N&Y0A,EJ<(V(8\
M\-K($<-%T],]YE.[_1I1=UR:;E?%Q1UO\9[O[]N96!34ZAJYP24^@'+HU*SW
M_L^?/N=7YP>UI#C-T1.1H<@_:> O-FHDHG-47+:FPD-NK@A7EK!QJQIC_8+T
M3G2.#-V0WKFP[54DLK-1@-SRX"(14D$0GP&@:7 /(<J /SD18U0XPK(%45%V
M:121-DH/X\3:26\8KM]WA:U&HXC_=2;31PK^01J3!;7&Z(T]:9_!PR+(-E"S
MD]SX!:S%U87Y2(^.=TX:O"-:"*I5NR :TS1=:2JE$_(CX5KX$9;YJ\NETT6+
M@ZL:D3-/,:*9;U_[55J%(E0F$CB-!^W5M <IJ&.M!S=(80+J7";0*W#L_QMN
M)>K/NF)^)6JYLR]1WJY'=!V,GS5K<\'R(;$E5D5N29T(ZY&?@6:&*->F@P4%
M9-F5LZ:B&1=93B$[IV7Y)3N3O)4L*$>;(0575VS2XZ) ?;6;J387RMT4B:'8
MF"=6#"XRVO?0"2DU=^F!O<_I8*LAA^\L",@5RAIK(C@?.?C'Q)^</A\WFCE3
M7]C\N*R"%&7C\A>Q^7-!8X5K:*VO0]MH6RLRTNNU_Z=/%T_->,,E7[M7-9@W
M%P8<YB?F%U,AL]=@(*R*<Q@IR.62VX/9PN,?E"R(OC/G%?(\'2R_,#HKW:\X
MC4H? $\I3N)_L$:>)^OT0CJ;AX.$W\*JTNZ/ZVQ?&+HNA\KW$T.EL![^6*\@
MN@=J0G0I%!IG(O83]P+.G1,!PIL]&91L>X6631[<]:SH./Q0BLCJ(1A.]U':
MC_I?FU1% S+*CHA]@%?DNLY>])2NU$8 [8I:$ZD$RU4Z7Y\!$F752[0IN3UD
M$<*C' MW$8GZXFE76;L!NZ6)K^WGGKG'KB1>ER-FC5Q4LWNL&E+)G$+_?0<F
MW&/?K6J$HQE4A1E9KKTFWXR,R8V6W0'94BM9&>"90Z=N!F'M?4+J#4M'T$>X
MH#'=XOSWHAE>YXM_3 LT&[&),.7//5 Y]M(>)QC=6!(-<:S/K2K>0>?6!'I'
MS!2D[S/%'3E<^^VU@H9/^BU_M/2!=WQY;]+KRD\G#WKU52,BCH_?P]0]F&R)
M(_^"!OX*DGA*?40V"B,SF1< [82"-H6=_"S$.F4AXB?[ J!1:)P1*0U\]E#%
MOQ+Q3(1:3R@.SA;.KSV01#G5Q!Q84KJCG@%&M56$RRBP#?>X+>M,K$SBS(.[
M0A==@735YK:'1'UE[:J&X!X5.-&FK]*:H39:L"5D^3Y"DGBIY[H=$0WA@,@H
M.Y]NC+2_TY36H0DZL#<PG5;HJFP1[&81T[3MS3)TR]2UA<Y\E/--._O%V6QM
M6C\4W,O@Y%H)80HCLDIG##PMC!Y>@!\"7K&@"C@@F6R$)_&ZWJ8+4!FDK8"*
MBJA/P6&C\<DUJQKG,2.CIA5OC!+_>>7ZZJ_FD0&7[N=4(()M C)D>FK[JLW3
M_HMZPH])=J"_F)]!;D1S(-?_4>R55I8*4EWV/.(Z2@YUH2UV#,=/.V*G)8L6
MKIW&)"@X6SFCTATD>E7'&)'VMKY+L#O8?R;[OZ&XQ6IFZ5[ZX:;3-363!W!'
MOEZ.O3-7X,^E+P\-OJLQW?]I\HZG8=_.9'LL)B6\:9*%C5QV5]O#\-+H6C\X
M(WV!LT(O$7TUR/01VYRT%0LUQ*G</*6[7(\K#B<\(MB*G7/'.07$_?@?PYQJ
M\&Z%[=_GNE] .\VV6[6,ED66P4,NTZ>F&!)]-?CN@6Q1#:)-R-&T]]EK_2./
MD=M_%2D?T+,EFN+"3M1-8\1N;CQD$__+E=S/MT38-N<3 +6=GUWT0,W$XL/1
MOL/Q,0I_D;^@'A(ZM)A[+'SKUU6-HZ$6B:L:7Q<$A1)_$7J\1[5UK8]S*FG$
MB=I([F;_#=4B1@+Z8LMT(!&9VV)@:IR#^%GA!I#G)'+_<37\I1K[%?MSXW'Z
MIZ2HK#BF6Y4%,ERZBW)I)8$IB[!JNZNLMX,W_D^.]+J-PJQ?.BL#E7?9./Y8
MI"Q]5'%$>EG,G'0"7<74FPAC8*3<N,L$9T^7'.*<?-\KANB#WMS30'16O"34
M>]3!]W+'"C^;'F[E/[R4NRX0J&>U8E,NY(X4L-FO- ,ORN[7?.TZ>C!K.'02
M-]8T'NIV<^Z/>CDK^?'^PL8I;)'?I9S)/-6,][1#X2GRKWPZ2F'N!D!DB> &
M^<^$58T.M ;K$#%&68K$4=-84) *7);YO?LYW0N\&?5P=M#"A8<VG0DLBLZ*
M:Y*G^G3^%1MA#A2#T1TE]D/,LRD5L<8N?O\XR'V*J_<C_UC5 '_Q/*ZL6-7
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MC,O[=GK?GQGRV[OU8,["&\G>H*9)6>YP44/@%W(0U5"=.,7*=;(KH(<Z)WP
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M'P5LA+BG- R[\O:Z<)QO0+C"%27=@$?9WWH\V[)MJ"G5RVYNOG.@WP$^?+B
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MDO*.L+K:J#\J@HZY]\#9"OG J8A5UF$V%3-.%'AK&N*MQL@D%;OZ)B/$,%9
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M8/WY6D6!Q<WJILRLVO3RVO-*ZS8.>(&=P+2^CSC#*1A.?B55%]]1I[O$R70
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M)0R2E*LPEW;K,]@2(#5*)SW6"[+@/*!T2@,C0H_VV'O%JG=91^R7D\&Q]W>
MI;SXN.+PA54ETG2W-\!V. 3SLCQU#1#&@;=&/Q7#6[F(X1)9]O3-_&_4_[ [
M.LW"(R;JJX@)M+:[N?Y% _5<Z7C8N#D<+Y^Y]G"OO&&PASOG:1\8M]3HR)6@
M[T=_"G(\!"IS:674\<UHQOV2R-NO7LV4'0R?R7SN4$6KK_S0?_A@F;VAP= ?
MYWPZ;^T++%-&SWW4WGJWVO;_;F'S_WL%SO^3@_0E7U)" +WP(D"9JWZDP?T"
MP%NUIB]"V1)N,LN)]2S ?#Q%RD\DU&@E-U*XS)7"LR;'AN9R"?K5J';MD'T3
MGN(!&2H>WSEW0OK)WB2Y%]E82HUYDW(?/CET[ EP&0 ]^:-X.<8; 6DT%J"H
M-A4ZI QX I>!^.;SF!,0F_G#5<WC;OUN&XZ/V?#3ML]R#>"/'02C3;70>.WY
MN\URU[-OA![711\\!NZ"\W_(K'7UOZ_KJ1&_>YS:/;+G66?0+T6#8W4%M/UC
M@]G9?]S%ULDP8K.,L^V-[XT&3V4TBW7"W< OZ<2_:JJTV+_I331B*%<&J8N
M"-*PLVQFNDZUC=$A95_B?8V<RFTU70\9I?"VTWC;P/ED&]1X;X6(9NK0I^ V
M$B24JP%5DRSSROZOP<[1C<N<J9%!IXX12P)\LF3TQ8H4)NN9B#YMJS)D=6EP
ME4EYT863_H1E/&-J #ZE)EUOO6(66,W\;C"T <)2BS[UUR!WW9<!0 IO$XUG
M*53H?=C2>-3>0'541<XA#\\>_K"#!=1T=K[CQA+]^7'.F^LXFY/^+/4)M!XK
M"Y_OC9C\9SZ4^B-&ENB*.*@;U8Z0<$8\6C6X+Q$JR&E>X#QEBY;A4TVWD];:
M ^O"'CMQ$G,] ZWON[B>^^>>J3+96TJ2;/E*8U9A2"%5^$W7]NLT/^Z7[N=4
M9>Z&VZSV'PQ\+M3@:H]D2P[EGKMFVO,&\][:'+KPY[NIVU+^5UWQOQ_VVZN#
MR+XIQ56//][U7/G3>%0CXX\C&RI&0O9]>VSUJR\;)1NN+.V&W6MF/F$LZ%D9
M"?VQHK69]$'[B0;W,(&_X$T-2KPX=RYJT\%??>-]+_@?Y+_HH_SQ[F#+H;QO
MO9]3GP6-M(NMV]!0M@;78L,%NMFH]S$-[H,[ 4RCB3]B1/2&'X#\$=SL'CHG
MXG>2WV=K<!;4N6V4KD,SV"E?,S0X9+-H'H&QJ!WD:'!;?#6XY8\Q(NM&^F0?
MB@W(<-K ]S_.)!PL1 ;=L!]_T/J?&B0$E2'5Z 3PX<1G<Y_-?3;WV=QG<Y_-
M?3;WOX6Y0TV]4:Y.YOD?1I^EO%IC?7'HP^E]_K\VG,P<#CEU_OJ7T)7?OG,;
M.0ZD\U\98AS_Q'+^;,[[ZL*T$J??XZ_IW:BJS$3];R#7)J56+7^^*720553(
MZ7EW^;:=[^ZFSN)=_EWV?S)J!SZP@"JZ.H>HJ-7@RK+1%2I*D/^_Z$1:;PW@
M5VAP/W_0X 8:?;L]X'_P5<O9Z-T3WZ=NK3A_^S\_4'B9W!HS +F[^ 7*<NRR
M'%3N=]]GN*]*KRE>N>O!JG7+UC?CH(/ ?[GCF*0;V R6VZ+-2LJ"MV&8_ZWM
M$4<L;E+?B41!!+C;Y]MM/E9UAP<M&V.XH"GIO\VKP7^]5NQ2 UZ#_R>JN@];
MB([_'[C#9W.?S7TV]]G<9W.?S7TV]^_FFH8NEQW;8SXX6)SY56 TGW-&%5W?
MSM]^WOG/AOM2']L;EU:LFYLVM=+@?M?5X-3U&MQ$2!-#?4$Z^;QZP[V[.;GL
M^AR__<2RF,D7V[VW]N9<.Y[SZ\'YG+.*9Y%>WJM]W0WK+OFZ&^#^!\<7DZ88
M#_K]2(<ZP5R#ZZ/MG[9F@V3D2@5I>A,1O1'@?R)XAQD\2&I;,!.U:G#+.##@
MQQR%0I6=ZM_=OF3,? <'0OW*!^I<E@[B#07?*J0%&\%14*B<TXI/=G.&+-(K
MIHRSDR.] [\#V==<? O@^*/]]NS582)>8B%E0A3757'G 34@ZQ9UN_"QXP%W
M+M2I+%-G\T\O9]J?4^U'^TA?D$+3 &//LKV2"70W\P1\$<PBK/6^O>//A>E@
MX^R.\<W@ JTRK.0!E5CF45C33^TLI78Q-AD];J>\J5*:JBOY8< (7;E.7<B7
M%+*VJ?]@F3 #X//8@HC>*J_##:J?F8&/U84SC:XJOTDW/!BJH,KQE[.%;E_"
M9A=5SE.\E1 E08,[S;G",^Z/<%D"?NP JF=:RCJ[S)I-S7H;[0L8OXWZ@8O;
MU?3RA\=<'*$"5+M8@UOZ.P1<FU68=9"E@ [:3,&Q-@3!N?MJ!BB>ZMS&4RIB
M(/+;8*-68<"40\3Y$ EW _,P7"B?T6=P?]RYMQC./9K1M_%"WWMYJX/GJ91'
M*M\3P*G2X9'PG"!%46%1N%^6<.%"P8GSNJ_3U>FOK,Y18T.BSWX(' L("GRV
M02G\QG.+;>MF+_W*78]J*>EB< ^I]AC0;.^V ?90?)@<UX=#H%9E.^P%UOKG
M*..\%/P5J!$J!$R8:\ %D?! OE)]MIJ+#S.VJ4V871.Q;404YK3LUHFS%5GY
M3/%1=!BH)BEVJIS>F6Z&,&_GC,0_)6UP6\>PE+8_DG--&&P!J?H&DP#MN'7Q
MSN/B\_?#G(CQHQ*NP#GBHM&^JIJ!KP=#(9^K-\:".HMJ;I)^,<K^FO"K+^4/
M0A5>X8E-G(&ZE!1*N Q4U\:[K4"?.QDEH*Y,*]"CC;_J7<R,@)]"+@\3$3-F
M38AKJ#FGR\VY26[/+ JH(7$KH^GAW@T_F71^O1(?J<$E8 L1I<']P%&Z:'"M
MF9"'!G<K%:=><I=/(DFW+K[,!7HMU6P2^)J)1?>;DVQX/TE23)G%QG"J&]E-
M,0 ^_>,VOL?)^N-'5(\-6PG5>L#P1PUNE7\; 3V]];.!SP8^&_ALX+.!SP8P
M ]9+OE<7 ^'$+] >_E>H-KJX42-KY<00Q=2H_0++<!#5@_EM,6WC?]R'G;UJ
MA^@[HOY"R(5'GP[M"OC+YF1-Y;ZZ+-D;Y_CS*R]<;_[MBP7WQ5>Q_^VI6(.V
M'(G V&(9H%KNKL'=$T8])L #&ES;@NT&#S <2)[SR.YU-U28;OUW<O<OWZ%S
M_V!B+-;RK<I!@QNYBXX""W6 A%,S-QCIAYKJH\VO-;@21D$^&]H)*-<0U#^T
M)!KX'G_[W7\FCN^-,9I8W:W2&@$F[([<.;;P7_X-7HGN!E(IN:[OF&NPF0"V
M7.QH8Z?FKX-W2M*]9/BT6?[5A?;X>R^I0T(_P@IT%3,(GI-?_&60*.DOS_6&
M0T';IQK<&M86F@-T_'B'14%4 7QP0>CQ,##]D%].YT\U]8W);XA)%- 7&(F6
M\=O%*U@O G2%BB^DI&NH"\A-0^B2[J5,FCI-@SLS,_*"KL\@/R6-G&H/4+++
MT1X2CK6>$:YL;>V;RC&ON+,EX-DOO*'(/%<]K[']+\;I==:?9/ 7@(PM$OMC
M?O$0:"8CQ!WEYXJG."O==J*ME(?+[MSK,GGI">Y5_MR'A-+DW!26=F--JDDR
MR81$2X0J"D^<VS8ZJ5.(V(-'$GH>]D5PN5L*9G-;2> A_G!:FP:G[V(.5GT'
MMY:\G 16\\QIG&6\#0QT1JK5L=%,>1'.A<ZWQ@<'4:3L5H*H^"@<<4)ER_2
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M0[1("SC>;L-](L(#4=S):)P?.Y&BC-D+#'"IB?/-,,]9^;6:*[C+I<I"9;8
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M:K.[?9GQ1U)L?J__J%O0;,FGS.\7PI"_T2Z!)NG'U:JVHD87CX$'"K%IW)Y
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M_X#U.N;E4_(B=VP%)9509;!'B$P!$9KEI<4N(^H.- &A+UDZ<XM\(45!M'^
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M :)5(W0L*5+\)\9D&2&UE3AY>J 6/]HM^!GUDBU+"0J6]L-)?ZU%)1-JR%'
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M6-^;X3]NR37=TF /&^AE<0%66Q0.@3!U1'6P?G*@VSR<:IK*Z(Q*_VM5D=;
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MF<%PY%8CR\TN1HZK]ZX/=+O*.M-T]O[<W$2-5="\M!/N8B*XAWGUE>R5--C
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M&8-3IA8\QP7Y>/$#B:*DEXP1EV"-*1>GEZCQ&&U.A=VB#=5"C?Y I:G$/^O
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M>QDG:Y=VR>E.Z#9VU"?1H< BT"M>.O55$%^EWF299K5W@ ^L[QC",Z"?-['
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M^>A5_I1> )J!&:E0UW)357&&&@Z-Y\3M>X_81#-O#UDG@.:I-MPI':$J%7Z
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M&JGD[CE;OGS!-LNCP.+9S$N6)X3T B*Z52M/C]\]](OJM'@!V,XO(7F))(Q
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MHM_'U) B@')'H>[X&D(6LYP3+(6N@]L-]\V[>TH3?N3FJ3855[E%ZEW\ SJ
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MD=3P#&-85NIFFZ/,:R/W[G/=R)W*]&I;W+I%1 000H8RA*7I^X"><2H<0B\
M@OB9W;;]S*>4-CN;_;,79,A.=VD7Q1WS7AGHE<T4NO9LO!;;R3>F'7I B=;C
M]R&X?<F@'#^U8.P>F">%]JV&3? X>FB*C@O-N%N4N;H<6[CJF)5^4(LZ09P#
M9/&K7+17LX/SF,D4<M7RO=C@X^-M9$,UZ%YX_(4(X:P5)%^1\>CEBH'7DC-"
M'4XS3^VIR-U3#9) %&G-=+$;VH!:\]FQ9@U(G3BS?^3YL %,/:E5%VT0&7#Y
M"M<' [N5+S?4Y&AA91?V">18WK21Z(6+[C!R3PU6*M<AT!J8+,JGNM$<7LV2
MQ*XWI9D9]!K#+Y]^7BE[ L_-P=,+I<AULB_RO4:DWY_1E=,M>S>: RVX0KSZ
M><K66ET_ 2\WLF"VP@:M">U<0)QFYK0?AN/G43W\P5C(/OC9\=F@G\$D[98"
MYJ>MS^)WGY8&M-S6LZH,;,EFCHK0FUX*WA_VF#$XE_-#B#B). WDD@9340((
M,,V2/(L+H:C_!JQ?J*>!XW'Y'C^UI_R*#^>(G:OGETR,,#:P^FYB<-LTTF/B
M)QG5>1X/4Y^2[VY7&T/Y8A+QN)[:'4>&'J ^S_N@#-YB)35G7C_&</6'&3U%
MW9LXX,YT]\BUL$P9.*L\8.\Z.BQ6.GID*#?LL?G6!.,(AL7SB39-=Z)NHAK5
M'E"UKS#+L:C#\/AY.R"2]$FZ^X>4%"T]*3K\MV:W\6SR3V?"K*QX6]ERQT0]
M3  FT6F@DG/65/ZQ-F.$:[[)V3E5Z?/K>"[!G(4SS^L#6RMK"!)\&P617;5B
MQ@K53^PP<55K\81^[K4%I0^.'MEZ=9KX$_VLQS]5;QIB"*_+W9/[SNIXY^S5
MJ1QV+?>Q28)=D^<!(HU/UN8-=9.J/;U/#W<P_6YWVZ?!K.SJR&8[[2_P7+6<
M_8T-.F1PIM*=$VR/HWS6I[Z3!AC)1M.AT52Z^F'8N2-[=CIEAV>^-H]TU_%(
M3\-N_]D=__A8UF/#E0XHU7T=D!O,4-NME.&E0PX$\AQ\U0 \((-%X!Y3?:75
MTP.1=TK[RW_27BG0>J.DE?<>.@.M\@868\]HT$,ID@UI7C>A/FG=*NWXL^;8
MK_/CXE5WH[W;QI?*=KQ$N]/W$4?IIRDU10+0_,SEG_%*ND[2!;+RX.HO0=QN
M]*#5D/ 6&+)Q"*H%YZ7W,3/;%=QE)^ZC @9CO&3C316*O#ERO/KB[_S19T?K
M$[/MSS\@_0M/8CX+-B=OGR+8C>#<P]\,;_&J6@RQ%L;B1D5SUEBKXQOF$DB^
MH*]4H%5.C:=<2#B!>+Y,UL P,/PYA?XX6]=<<UM_<M.HD3>]TZ>RZI6*GZB8
MA:U=VF6U4SFG\E/;Q12'GE'FU=+TC5+?F!QU/C]ZU/;2NZJ:=YV.Y_W\3BA5
MB*ETDT @F<>WN.3NBR1C8)$P5##_6MQ8VUI!'W?PMS7YY"]3\.EO;_FHC40E
M24D]?<750")W>5W!R)A6HV>GYMA(R[WRIJ!7?T\;XH1M;<0_N'GC9BTF^%E#
M&;&4YM'Q+M6QJY^W]8;C Z<]24Z_20J:;3&COT(P*^LF>;_R//P_S L!S$=L
MT.<4=68V?LJ8#7+3I[1%JT/_\KS>\[W)"L\/H8B0C3V<]+\9RE1IQH Q5VDV
MC/LA',_F@ Y+U97>E=$.#J2 ;M'8H*73!JT1-!\VR&N"E7WZ1;)R_?Q?R? O
M) W&OQ32A;*X=QNX]C)C97<;N%JL*A.[4>)H '\QR@5%&MD],=R5K%!C];#=
MGMF"^OR.#0J$[)R$"*&VCHZN+/?]M/F+5H;/!3BYY,-SJ#XY#ECA;#!T7VAC
M!JMJD-]YR6JW\\)?']O[2WG__H7A9Y:@ C!Q10WX+G41! SHI!S$"G !UL3%
M/_9)+-^;+3MQ9JGP^(<;LY<&6*]KO8YAF6<_&,!D1VD_APD''SOT"B86QQ:[
M"R?7V@C$$X8+ K=6K#67;,NLU<*5')[EI9X\B%:TL)+)#'YR[:7+C4/B[1IB
M7CFBW'$E]H))W1.5X@X!5\I$]7"!H_FV<3H7U.RR\LSEI@U0]!],#%*2U0-M
MS$UOEX?/=6->K$RTG*LES\7G>3UKRC4Z1>/*V#)4VS \P"_2\^/<<-I9,JH)
MIY^/C=(WU+!NR;GTK7S',&UB [8C@.H\RM)DS7D=HH'7%&F-E)NUU#N7:'1\
M19#4T5=C"!4#&PHF\2STDU5$-5 7<%,K^HBA^OFHI<()JZ<D&$[Q>>MIUX\N
M[FYO(^AFJWBJ$&6.(5)-+\BD#S"KL=5K7'0K(+AJ9FGN(%*D7W885B@?/TNU
M"2&O&;R^^'JHY!6N 4]C-4M>$3CB.>VRM'?67?&;;#.K(6Q-CV VLJI9H/1^
MVGIX\XVRI[[5R&IQ^NS[GJZ^WYH:&['-24X*JK7!E/2#)].<=%Y<O'BE"L1X
MJ"LL(*PAKDM'Q52]TE=+/Y7![YOMGTAP>H]VS]'ZOGK#6\DQP-OO>7'.A]1B
MNUH=YK5JAT7Q<,B!##XR(FC@%L.R^V>T;X?NY5!-'6-YC+UP;'?H?@M&?3=-
MS8?G3K$[_\/*U3&#$GZQ"[7W3N\>>ZPR+0A9L&2=?/@!\O5;>!%#RPG"^.C\
M;7&5>T<&**(K J(PJKH;,%#%\!O25'7;6._22W_YO+=X!@@Q:[N;W:I_H[HJ
M<-BRW.U/YQVC Z\NW;AV@-?E6F(L^.80%/;'+:Z#U/:SKO'&6<9JQ/>IU._5
M-J+IE8.FMV/+K,-6*%7#C[^@N=4"M,5,+%3U&S>ECE'Q#^#:IPMA!%U^@^KC
M]@(&LA:CH:^S3>P%[*X\JW0H2^QQ*M'Y/A)+6;!ZU:=D"]OE,[H6#?QG^8S^
M*R_G+_)K'&0NO\Y)4^8YWH_IQ3 OA%4Q]?^*)=9ASW;$?S=N5PX6-S__KRVN
M_S=W+Q:FH=?*=L(1!YAQ+ F;^<%4J1/.X^K/7]GL1^@/RS7G]WCICDD["4XN
MG5-C@[ZVW!O A1^_NV5O-7+MT/OO,XDUBY][?>HC_8ZT0TYW#W62J-A/'J;R
M@G::%</HXPNZ;TOK5E_@;F?:)M^&&:GTGNWP/29I[9_G<QK@PW-9.+YT:76\
M-%1\(2LB:U'N\1NLCW"DM?7IAUFEF=L02@A1(&'N0*L@AG$)**%\$NU@<5&)
M62WQS11#Y(:^/J\^/#L_P.]=KJA&L&*0;Y#D1,3M[/@I;E]?8\8:O)\^QVR&
MD*JD5,99AW;;^[0JUB .,_/70A8X,"\=$C@G;F;TJ"KP;@(GV._LH:2;;QIK
MU22LZDD]8*(I^8FISN+M9>31MF"C$6UR[NK CA.J\QHCY#GR Z1I.JAH/QOD
M4Z"T;1A$UE[]5.()A=W+2%O=5]/DUMXD<]BSUP<%,BWJOI?*7;E<_UJ<OSR_
M7 O7R7J$X"*I'T"<IJ;'D-03VL6&6L&D=;XE*NR>0$(8[[$PIKI50_/OCXC[
M6WFJ7\TC&HU^?I/USXN4R?XT379H;-<.#%OQ>142ZTNU>.8;2SETJG2B!ZVU
MUN!17@5(^O"-B%I]OW-UZ:TB*Z!($)XZNN3\[I7E U]_Z[ 2%8&CH;YBRCN7
M1O/H#/U'XQG4&6D;W5Z[7,@YJ"G,@<%B)D%(V6Q0H_.J^_4\^M-2"!&2IKU3
MAS"GH2G'6\5[DS'A8H-/PZ:.1D!A,00G]3/^EVZ(8?QD!BH"M2=L5 DLCN=$
MU[EF^TZ>.Y2S3[GS0P=9 7,[7HI'\ V UJ8Y5&O7+(]F53ED+^B:-PT.G47D
M*I(9^R4;9?NIDS?W/L09&(EDP;K6*96V&&0M#'^O++"AP*WAIJ.\XCG.]HWY
M?6LWI_C;J]6?GH3[L([<CW!II$&(BD;<0.!B1^')F&Z4R*FVH;!) Z[GEMY*
M05XGK,RZ3P^6+*T%E>>7B4Z$@AO$C(9N#GTR^RUI]9/>Q'>."^T'<_;ZD8!"
M3:"  @;D0AA"_?3H#Q#2<S8(VYL1%AS5-7=$L_I5,.,\58#\Y<F25$&=.WR<
M)A=C0=LS;#)U_.Z7:']S*CY^/=^JOFU<'?>F>XB\;2U*YIM(_<Z]\/3NH7)I
M >M4FEB/^O10!VFCM5S<YPS &!2VBQ=0(PR7+MXPE6M3:'F6M?3:,>NDFL?U
M"A5#B_#ISQCN#Y]3*JH<Z"]OA2VUJ#K:/PY6M \,!;)>C$U0QSAB"S)?X/VL
M!"A^M=1Y.@\01XNA0!Y@HZIWU(48=X%BSIXHA3H>.#1SS1V3H'<NK>SC<HZ1
M6.3%03:(&YSX)<.5M@^2?^!1F4O58%4HI-%_K6;V6!-UH0'P[VW!KVE[SV?P
M%L48&7UH5X1+D_$QV+2;$A]+/^"@QS*$X.=8YNJK.&!S7'1I7IU[*>FF7\MH
MR-KP$9NOG/1NMSROG>-O)D@0@A?++-XT!'=")1 V*%1%X-R1=A!K,.\<OA:>
M2R[+*=%I:<SHS O)^E%T>'.'J]!2HDV9(.ZV?,_#UBU-;] #MV,RP$E*&8+R
M+/[HQ@\9L:C (D#1.?[$:'CI#CC12 K9YY97UI-?9A[[NGZ\_5Q/&6ETG1S\
MN).Z)NYY;M:Q-UD*2!BVWQ'2HLY]U?H#KA_;#Z/V\M!$G#,7A5^^#KOE> :U
M4NY/'(69.&&@6AV4VZG;#D&R9M,#\[<B9>JO$%2T516N#C.LBV(EP;H$KD.'
M^D_7Q\NO;"Z/H)W2;AC"%(C.Z"<7JGM,0Z]DG'))LA ^*591]8==QJR4V.[Y
M;"XSY%"3B%YS!AL$PW]\0[>E1B1N>NJ16[7(@P<"\(*MP26:34.GYU31#[3>
M<'_S2S<M_$(9I&2O/7_-HY)=?)46Z<S9?TC)150W"?X#]#FSW=I55A\$&U]\
MAS[]5)4#4R>KS;+7Z[Z)?3-(P1]9EI($2JHBC[SOV:.2DPOV:YY>Z%ANO\3"
MJ];6KG+^UDXDCP\/'ZRM#7Z>=NWA[.S!<86K\3(\CTR.!KSL%5=P,'&\ MJ+
MQBRLVB2Y5*U\-(LQ.(/.F2W8:"D\3FV'\#K:66LRVQ 3>Y[X.98_GY%U*C=R
MO%XFKY0>_"?S8;OE?>*( RUK,=5"37G%4=93N;2@6']DO.]'#-Z]J*.Y&P7(
M:3.$I\D#95B6WFYO1&17$9:9:N=NA$'M:"',QMMYX=G7$C,->PK\2^$$4EEJ
MQ%G&>]4UA'*-J_39BJ'/:4<$OW.VXL/M9Q#[Q[>4,8+(3@C5A0WZ2'"A?FJI
M;<=3<XDMZ%Z!A*!SO%"KD. ZAB$U[,X2_;[,T PGQQ?6>A/U8L-=W[7MC8<E
M*TUS(DU&XOK%<$/'T=.0F+W*BR^%#10'9M!%<&'R^KB$7;Q/EY9.RH,[XG<<
MI;44^J7?0QJ9HV7'9'/J'&5&6FTWX!C>5^I"D&#)3'6"<^OUE\<,I,#[DE*?
MKXL9B^8:[T^)?;$FJT 1:D?_G &X6(<$F,_;14\GF#,;#2*JOFY;,4?=TA_M
M>",'Q)L>490_Q_3GZ)S$4S7QDFJI9[&-YY4] #1A.P[;9 /^(WA*UV86Q8TB
MK8XF6*7_H$QTK3]LUVC,(:\%JR.X:,JV *SJTDN1C+6(*:[4-0/WRJX&3:'+
MM49/2\QD[-PKTS_^6<.9I.84Y%&$.FVMM$E*![A#"CGF:EV3Z0;/[\H3>1VB
M9! BI/+'LI/VF1:LG<$-L4L*JPD+UP2ZBXY 2(_ U,M%*>+AL[GSD(\H>EC>
M.%UG_NFF0/RV0$S(7J*2==J!8C)O\*'MX?,R 9>;F@_W]?%H9/G9]TL=ISX,
MUZ4*M]X@?=VYM.'=P-(EMVOV5PS=2I54).OTQRS[Z,(VOH^@F55U"PHM+UM]
M!2"LD]]"[D\D</!=RMFR8U/I8*$T=!').^""8$QQ-U:CJOVM0E.QI9!YI86=
MW:3Z>YO?4)V]X-\,O-'3@4D[Z@C4ZY&Z-'QF%%D,(4M9<;5S<8MTFPUI_OJ"
M5!JP\7L%9/BD4W8JZ%K[;JGS<U3G._P>;V8.(Y+ZA@2.16H!-O,)W5%B!@H0
MLO8'AC+YIR:$)]!VD"LI1'.Z -SC)8U/L<6_Y#*.7UZWK/?4.^ZT[M#0DFLW
MLEJKUKX&O.7$O2Y4ITJK/7IYZ@<!Q8F#0BQ!./[R<'@*GJ^Y"Y)2*/NAU"H\
M;"=G&#D@FEBWU:8K9TD+^6Q^2SK-_7.>;W-D#&HOBFJ'!V0'UW9V!(*&&.>9
ME8A]\VV69#8H&1>)#>%A7!MK-?.97]'/CG?MR2B&5W>+6U?7H*ZN#%RK"J[!
MW:V/L?5]]I7B+3ET?CLW9I87B**(2I :+D_W(-@@B<QQPC6E:W#(.5+JF]C&
MNI/I6>.>]RDS:,B[>@=W>SOB4">9^G1<6D"Q7PD.&ZY.ZZ+YZ4*/VP?MR0M-
M\_!S3R-<6YKW>4!NT;EL<EDC5M$A5:-5IG*D;\5R^G:71<(XVF;*AEM/*V '
MCG*$4,^K SJB)'""$6\@JC%A+6J^P+[#&;F_( 0I&J0]99/$N-X OT=?9,E)
MB1X!D 27L2_-0V6Y:U-VY8]3@LO+5NW>JK!!_FGXLA ^5*<7A/1,2O6A?IHR
MO9*JU6 Q<3"%8BC=,ROX1,)/^>3C.:*7R! ZR26U8Z,GY7:IUNOL2_*,%VS0
M538(D,>LQ>R>Q@(R(LG@26-R;B+".9RL(#V&@,X'J 5C!7C@XD-).YIYS<E;
M[@,:EC$N^%L^0U@%]7S7T<]'K$("5535UX,A%7@NSJ967-0DFMBJ2/X4U8UJ
M;DHB6:%<AU;#C_MWNB7<9SA2>.=X K6OU#2[\<^^+D-8)%P>^Z8Y>6S:LF*)
M9@(+^^K[4-.4QRBS!PQZ)?1 9[CP?)?7Z5O-!ZX/JJ:K24H3#;2),ZY/KMMF
M(]U< @W.9_H=2;VEEEK"+,KUUT3G#Q.,IRR%4PE12BDJ30:1V=$VLN2DST!-
MRK[[MET$H_[&&E,- 0OAMFP5E3M]K@62<G(%/'=+$HJ=8FG48NNS&*>J!%PE
M,V,92K7/ .3IV7MG/)'C^/VSYQ[4[?T(KSON%*)J:H%KSQ5>Z'J'BI]\X1YO
MH'*1YJ5%40=4H0PA8\(='">.8,O2J\/:S3=:#:G?*4VOA50()W-8A(X-V V?
MWR)?\L[K"=5W>YS-6"AAG=A@5D&69*2.L4$$U_DB5N3H%AL48X@/Q/J&<=SO
M$0#S%/,40XK"OYYM^*.OSZR;$6^WYS?)AWLD)Q9PC+/]91+>[7^TBP[E%&Z%
M'&*8=BO#PDKXD!*>JS-Y(S?1E4FUE$U*SI&B?>2%\,AKIW7?J][>PIXL(*VI
MAMVT4KU94( OW\=9]N'=)GQBLBX&,)K>-YTR>!RQN1.5&,+WYMC]KU#3=!-7
MT2.G^B7M8GV_2YOVQ;# Q;LE96Q0,8;2S!*S280R*C"+5;TL?D_.=>)@H:UZ
M(0SA"<_Z>%>^81-_\GJ*TU!KF2-?W1\,J F,IZKR-J^PHUC'L3><;:J98RZF
M^*737@J[I\^(;! +H:7<5?,&,^Q#@.K#+7OI2W.)3%0MSJ'5H>'+ &!KJ);+
M/9^WHZ_=L[2%RO#9/L@&)7Q%=4)07X. 6C8HWIXBR@8I*?SEI\H_?[!!B>Z<
M9*$$NOE$_2B*E$_9_8W>2-R1,^GN>%*)[/T00$4^^>B1/2&KT%0N4*$UA'SK
M^X/W^ILEK)-.'/7,SY";64I>1AML4%7&Q/9'AU;[$98PX(QF#+NL?YMC!:&T
M 3KD(HI44D0-G5A]1,VD>P-) AT08?B<+?"#,B 5P@?LLQEE"&#@UBMFN:ZF
M6#SMAD90_>39P1>P]?#0DH&C=TKO+=+#F@5QI7=B?I9P N8$JC.0H5T-_+!E
M)K$@P(OIKD<(D_'U+?S#J=P4K8J!?/@/IY:@?#;HH/M*+@?NVFCWG'TK,Q4<
MMSKL,4 QQ0YO)CZ#/H*^7V<<761Q<W,67(WYA^K-=DWD\#V!C'85A,+(NC/!
MDM;UO9L&7S:4$WX=%:W,.A)PBB:0B,,<7!*OB3N0?:?JR2:FR6-ZZ;97.3K<
M/SC\Y_J.%+('CQ-=:Z;=L0(<=Q01&C3U;@CX]^J:F4\!C<:E2UZ'1VH6S$($
M@13BO;B!^$?D:@GSO<?4UL,/JJEA^$3<')SS"HBUI7.CD@*;KM0("!476AY*
M,=!X?[(DH?O:28J:"ZU5ZQ%U3>_FS29G^]@[!M'AQOQ>SRI4%OF[A2KSKRF-
M$)P[QOME+?=6 !]OG M)&;A=*#- >]7R>AQJ4<:GJB*U[_3;6Y K&#L;B;A"
MX^0>GV7'RO141163&R9N6]%U0ESN!^J_Q3JP0=,6R0 OBSN&^H.>#]CN'&&(
M !$[5^'YW;/JP$^RZJD=$UIZ&V7-_P+M0&.D<$Y)Z*'4VEHXXFU(Q61G:5GI
M.5'G']HMHSF5@N/J=1C&4O[Z%$N1:$\8)EZ#>9^Y]>XTMGH,'=]K5YQ,L.^Y
M$F=NFJ-4")8P$T@MYKMX-+ K1UG 3-#ZK&VUA9!=,C.*WTOGF2'?16^G9T'#
M:#?-E>'*"UCA2Y458R5NIZLM2NVQ2Z.Q2A?,>T)3,R_M$O1^5/@[KMQDT,\2
M.B<+?JR"ISMQDFH!9L!Z\M9F&V)H1YH->BL"W5%&81-8V CBO6VO?WGFJLL&
M_<K%'_/+@VG[?0Q%U$0O&U3:L4&;(V8PHZ#;#AS064=(_?7NRG%C1@H(C0^;
MZA+P$C<@B>0I38#R.U\)29P]-6;@^1RV+7I?]!)6/+YJ]MS8MZV#G$#'4_?T
M:G]4Q?&[E Y7-\$[MZ_%)M0MX]/7$U O!SGF)=11>(036B ,&^9C1 09_* 9
MTAS2C9ERIB\Q<>N,\\5%\1 <M$,7J0ODSJ/BPR "RVY>]>VGQEBG&*ZO((<8
MPA1W\XZ)5K%2N(9ED=U(:;+[3\U+SV:" YJCRH(8SA:*D_KR=Z>#93+5#MNU
M?2[QPS03,!K.@6MN;U7=@WSO;!, 2UHC::)WD!N=P<'3[H /#=TQ//MIZ1%\
MA*R>@5"F273=#G0Z$ND\=0^>TKE=UUC2MI:%?_,&ZTXPQ!;)#)6$>A5 $W>I
MN4(F7ZC?QU.OA !*:FAJ"/W>&,H/-<GE 6DHBFF7A%L+)/P \[8?8Y@ ;22!
MO? !I!K#$M @18Q@"]0&N\X0*0*\<'<GFG^<9K7Z;J.);O'@GNJ@B#K+<MPF
MI/DH929[JO&-VXW5J9:-NRT;T1%'A^VP[H%#@71\V]'5M;*1NS__!WMO M34
MUJV+QFV#BA+I$81LD;Z+#8@B)BH" D)$! 2$;$":@( (2)20J/0@H("P!2'2
M=T*D"4@CD7XK(A Z 24D$9%^12$L2<,+_SFOZIZ]]__._]X]Y[ZJ6Y=B4:0J
MS<R:WQCC&V/.^8W@CZO0/Q_4[P;_HQ0?"2;*]2$R>*(+K@+7B.(BRP4XJ3J^
M^V]7 DCEFM/(B6+^Q3ZVP%U5B[/T-R#6EE;W#(7Y.\<V(&H"S_0@8 ,R]@3_
M ;E>;JB'+M3[6?'/=QU#_@RH_WA5&5HPG+>V3L)&<+:,;)?V,\!,3.W\:[33
M"/E4)'EPI?=XEU3.W-+<G9U7&?%*GJ<=DD0ELY^8I^7+-)B5=*F_NYQJ?B3>
MWJ\^S\QG8D#[:J%:V]%G7_)E-M<$3(X\M/U4\#G%3$6 A2=C'W#68.X4*@*Q
MA87LH,6Y'!K$J4^1=F)"#5H:*N8R=@7X^?GZR9TTUCF;_O6VM22YV;4PT_.*
ML5(*,FU9Q)NPGS+5@B:[@=V=C[')]!FN.',J)G;RM)SI>[8]0C7LDI33J3O2
M?J_[D@P=!#XY;K(L:K2U4?OGX"+L4D/5A>(LQDP'(1$-./>-)R*VXJ2:6$+W
M**[(B,9/^BXG67UCDYH$R4\3GPWD;[.VE0>4SLN^N-D+O<\U^/Y6(;NXH/'K
M<W;*G*\DX3)M.UZ8>X)'1.S'HNC2;0011ZS3&_[>P5\'=1./#XN_3^VQ9F>;
M7FZX8CJD%V[%?/]Z6&]_:PZ;C:E4/D7<^KU48%._&P2&''RSWTYCV/-9+O^5
MYPF?A+4C8SV_MMHFV'H GB=B2SK?9:N?P"OKVW1R!Z@1I:@V;H:<SZIX\*C"
MUX\&92L':XO;?H9[ZSD2VGN/7'KXV[1YPA-$\1O^3H#8CA8"@]X@MO7K]@EC
M3[49&.=$T2E0[Y$J!TRFR1/7?=$C'SZ,;!?X.=W];26?IK.KWYO-E>11KD0>
MM-I7;"7Z[^UPK2,/2N3+G-ML@.J6\O#RIK[^(79C,-U\7Z'YYG,.666?,#ZW
M+U+LX<&=G6I=1^*M_^U)O^;%:R3\YTM2_Q^O_WWDWX^$)(N!0>W4;X#O.C\N
MMY<A[T@[TW]P1,])_JASD'.3F0=Y(!B[['5_];3CUQ.J*32K:O')BX_>L=IZ
MY!Y/-\8L:G-.8F R E<_-F,+"OP@ZB+(*W<\6X)!;PV!QK=LJP;;2S\Z.UB6
M.KD(',R>I9!OS9@P3&"QTS5T:Y!?GMF>.KL?SB:+VRY?H#P1O/P*=!<.!Q(X
M5_EOT/6F[="QY&Y*G=>]#8A'#W3<MUWA"'@0:/QA2HCER[((7;0=H.D9,)P5
MUCHI-ZJS^ )W?OU*ID(3'27Z^4W-W*3D0/-YO40$E2$]I%+%K0(WZ6T_6*6_
M8).+PX()G,,T;"I?6)B#(;0:X?=RPV'BS>+T78A?L13VR0Q;<(U.DYEMD1MN
M@6..2_=S#4%U()1]!_ 8C38TT\E]@5'8GM#5V%F4JC3>N5@<HT-3OY)RRUQZ
M>F2)'5CKDC1RR^]5IR97NTG.Y)EL0E#]\?C>XP5?1ILK,Q^Z-12L?U;^Q&\K
MR8L?ZEC;*W#1CEZ\B 4!"C3Z7_#^PT/2#L(!2B>\-V<%(:#$T<B4W3]/3=4O
M]G+4^0-(^0V(=_)8_A2I<Q'.$.HBCAE=&0A&CF]M,T#&<#WV%K<O^J(SKM15
M#7QEX0OI/;!MV.0K]93^U6S-:X/<@PS4/F?0RY%*WBO>\6C6@%S -A/P@-;S
M? ,NFD>D>"3+8NNGH/=Q!";A88OJ,%<=Z*;S9NXAA'&FO.=R]&@22]JE%A@>
M[8;MQVF#EG2"+);3J0 !-?,^SQ'%<);YV-"VQJ5"ADSS23^ZQ=[CRY=&%P\2
M9I!LY"A?A"NVV=U^*A=9T[?PFDX;;VG[.LC?=0J MZ*%N48L:;8QKY(OB5UV
M!FNF>.+L#V B,R >+:V'CD=N,]RW 1%I1K/0W7<GRYDE"$6<-4*XOP7.O<I2
M(!?BD,/-*.8N?UWLE_QU6:"/*[',5F01.OIVX;3Z$8?G0@V('? XQYE64HP"
ML@D\R^J^P,O!JW"O 5.C&?:@.]#-+AU!R%W%OZ>)<L.WST0U6^8[@1:M,*G5
MQ5!K%BR&3-DS6Z>//T@EU?Z!6"--JS)6BZ,#"%/C1%#%CW)O2?>C88C*YH(4
M.GEJ:C O"5,$+B*[D6-W)YR2+1,KX%OGWQK2]BV%2(CZA\7J7?UT\06['C9,
M_F>;6!=<#'@%! QJ#W:FPT4&J%\08F4QX-&UB<ZU/!AC1PPK@'UC(!@M>75;
M5(;#8"U)"F<W@#M;//['=S.9^I&510.6K!#&]<*8?(NGP%_H@ED=+PFMFH3?
MANO!\$H73?R'G%VW4TZCVT7++KP-;=2R*,^O.B,=)'')[&"HFL@;6*6N/9'0
MYL#H6U>Y*^"1(ESU#4A/)I*NQ?+BB9\F;$"$\ *..=T+N;M7<H8&I&-K^'$Y
M H(90=E-^/XU&;0P=-B G.]#"Y!%BT+^##JC$&%\9XVKG*.U <GS(@DPL-Q&
MY#;D\\7ZI @#QT8%3B"4CN)?ZQ=Z/N 2O@'9Y96 _/94X$G!4T#Q!D3'>P,2
M6=-)7+DH\+I<^<T.PQFZ6[[]_SA(="*LWGY3H*P5607O@CX0I&O-I@![YLH(
M#E,VYD,1%T/O\^X-FH)'CT?T%3G,?\OT6/WD5^;L\Z*^CEW?=4)IH-;YQK[Z
MRPXGP'DFD2M1P\[<K'1C\YUX&82I=)?=HS=6BB,68.("RM_KFDO5QATIF'35
M<0>*7JJF=[?W!?E[1.FEIS [UO9CN2==BR<UYNIH<D\#9T2F5UECX897:K3F
MM\<61O#;>C ]XIEN@>1O6L9:"-D'M9Y/]'$F!S^<N"%?4!52\JH63\@"G[8]
M=5$]^NX;TR.+)>4<GRO@C>4.ENIN/UYXNL:U:]GNT1'?T^!N'::.%H]_<F$*
M,*RY.KZB+"2^!)V8Y^]N!S8@;/2(Z1O4 P/Y36V2'QU4XSS0B4Z(<LVZ6@5\
M;2@Y'/T>?.=W9#PP7!PY;M,N==[GF))5R*Z5K-_\H9'X;AI@3I#&<A@'"'6F
M7(EV)Y@<TMOY%F/P&K#<KNT80@&@;=\83W16>A$S%I&)AVR:J%4'+GE?.C,I
M0^461OFM"AF=7!=G;_U'SVE]7I1N6':H)8AA$.)H\LV6-Z!)"%VP_0H00HO5
MF7D5TM R:*B3,O==/T9W%UPHDV6L.UY4--")J"E%6QQPL9\-_0L"*B]*BWQU
M6%*)#NR*CRP\5^ [C8/'E*X^+%8O(1?'=E_Q.?+AF(_O#6/SP%:Z<N^JP8$-
MR"(T1H=^<2+N"/8&IT.-[J6E=Y5QRW]/V]#ZB&F*K2.UT].V4*8=^6&V>(E1
M=CEZZU9]>(GKSPW(N <M3\G[<5?"@<"R/$6U*^<O25I+GK&UO?1+"43PL\6*
MA/@;4_BK%7 &5YC]WO_BDR$KLII]E+_8#>S/)G/O]([X'\M_L1O3O]RPY]"S
M><V</]O-P-_8]=9^GZ32,DRCRM.2><=>7LZ3 HR4_MV<TC(?_<-C'S'C(9%B
MSBXTM/,GPYN.XXY.QDIK^N(&QGN.-*<8Y*48]G40Q)>XL.?S"AHLKXBE9CTZ
M462V/K/K-6-O4"=BSV!PN)SYX%18UF=3:TKCZ*%Z<BWY@7ZZ0V&(K>W2!2%P
MF5>$]!7<\VZ^R"&PB8'ZF,7?M>K.($31 !3A%U^IV\A:P4P>O*DXJ,-7GS B
M-!)$O/6#G$V+:=\RK,?(?='-ZML',IP^!S#04K&U@WF8)^Q/TJTG6K0[W,I'
M.@?>GO!2B3*T%V.9(([>N6WQX%F#^U)G*3-(R\DJR2&-_JSJ3K3BT&R71+X=
M6>>&E<J)$(F\.;N23]X#R=V7T6FN\C,G'8\XS5_GN?]#43,6/TP '"C)DXJ"
M![<%]_Z0WOSFP8(/?(4<2QB[A/>J(N\U>4"Y7\?9+T1>^DWC*F5LZ;>!2H;T
MB-VCV<OM#*A"SX&BMAD4D!::L4:A( $K**B\MM J"#_=H E"'K<3&)W@NI*Z
M,2$L%!,9EUO?!#YF63C?=TY<>ET>"??(=^P[/>B-EQK,T98SL7CZ)7[_JERO
MJ?7K.:0[=,R>;KH !33;837+"TQ R!:HC\ AQ5!E/M5S+;L)$N!\1XI3ZXYB
M)DIN#O"YA" S_'Z;Z%@+U8KS\]US>_UV5H!7D<.XH]%JS%_ 1+)/P#*%XWH$
MV>F2<+O]'Z"TL*.D@D+!\QJ\6I<U?BFD\T2F.=*IXP-FN,UC@##V\^(!-3K&
M(.WS'1/87F7X"[?K98SK]0+D!RM27VN(AEJC>Y%)^4VI=0G_LH%P^Q?^.Z#_
M_\(^?]#B:;OX<KA;8!B#$@63QDG2EV/1(LT!!<[>>'4@.3YX(MS>9'AEHE:#
MA?*[^5#,.\NO,_O+#LT>X5?/FZMSA$L./I7^%T;E:V[KTU]N1=[]1&TD_X1M
MH6/:M%6%1MJ7PMUI<V=+VVZF7(YD#.4K96(*.JB8HE1+W4%[R].RF&^#3OE]
M!$_TF#T[G)>$D!3$Z^U(3U(47PZT!FC&Z6'EX4+MP'OJY)RTO\NRW:A>PD^2
M'FG?O+[E_:#R^<PH?J%!GE*]5LGS<*%_,?SK%<&EX[L9OLS C\],CNV/+S<
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MY'7G@ [*-LK4$X(0SC2@D'N;]YSZ@3WY@_EZ\=E 7TC1K,];#\G/K[E7$9*
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M]!U-'A^O*N_-_U9L147;M'#V-:2V(J>**=7V;U")A!I*=T \1:Q9N7(^1Q]
M+JPQ><?:[Z836?H,4F0PQT(>:3&J-W'!GWMRBB('AK;?;5(IO1-XZI.OK#%O
M:,!@K%<W/= H0&9'!E>TAF^M+XC+- 'YU> ](ZS:87THYK[?"?R=:\!,FVPQ
M5RR+OZLG/*QXTB(HD".-_S!H/DO"/OB\)Q5W%%CY+AD]81N_<[@PW637 >^$
M)A^-$EM8/A$HPPG@?Z9\F:MNB/JW"JJYYH<-"/T**,V_;T\#+V.)_U9J+07@
MO%](%*" A?Q'379 C71J Q)E,X5>WXXFT,T8A'\4;W<7OZ&L[&[9@+2E=FQ
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MV395U=>-MAS",KXJZX\.&@;&5=3N/;P!Z:AO-SB?<G'\]N, /_GW:Z%%C*6
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M!!$\B1+7KM+[V$F%08=F6Z3K'T->-21?:C$[9' 5_F7FZ<C6F.IFEX"GML'
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M9&3GQY#3^RMFANV$M4W8%A/PVO;";^-1V5&OARD1M8NG.O Z33%O7S75#NK
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M=(K.L]V3W<AMH PSED<O=(KDP"E%*] 0XFQHS7@#-!8JBU%:W)#IYWG4-7M
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MG/SB*]:?WH6M<:7)W;8;BEOG^^X-#_-\3PB5P!&9@VY"7GY>'N:ECEL ;,W
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MWTGQPJ)4EY@V[TW(SONH"IIS!<#J\E)F5'=N0J8)]FU 0MKW$&%_M^QDS-X
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M^W1</RM(#M;DZ,,3;Y>R\=)X<(E:>^'E2*$-\4K=]%)>0-AP8/[>KA2_07A
MI1NNKLSA!U8^DDDTJ@N]$5S*#N+.(FK,5[ \^R&<R/F-YX5)OZ!_ >\\06,9
M>IS\CGVH#+IG4ZH0VYXATL+P&K+#RDT%88YE8^\;(@1GA69SD#&ZNJ5 50S3
M2F[=\T#?TM2UW7C '?$!RC3C/$)0XLC ^>HTY"]P?E"7VM^'W8.:85Z+Z25)
MPQ!/>X,9,GT$VN1*)P-!:TZ99V2G1./WH!Y8H,.HJ<K.[XO'UA::@)(+BOK=
M1S><LYP'$4W81/S6.MR'%W31E70*Z8,+S:@SEB&S0@2^V0!FF92UN&(:?Z\)
ME"7?3WT;)!-S":GP&7YLA*N,A*?+QT6E6O7^R#8N\%CZAFQX()W!3.(IWPUN
M'[(1M_(=(#$=.4_@N\_0-R%WD3LCH'Q+9&$T9 X&XJGWV?I8@-YY>ZA[:*=-
M@0K@EXH^01=V"L?N!!-<AW?++]PW/'''4G/RQ7@1:>Q \XM$7\0Y^6,PK,@E
MO>?OCO1XUPU)H"J2P]PTQ6SJ^Z[/AYW.U&K62M'T$XM#FXD-R*T>=DVPW7;*
M):.;%FB<<:[L88M97<KU)8?."X764U5N8[,+)\J#2S7-1EPR&O.<<)_P7,$@
MEB=:@(%G2Y)?DK;[<!Z0*%D;I%7#8)8Z6WT,AF5Y\NR3.]JEPI7[ENEFUDA]
MS%5>Q.P::=L^F<45QCG5-S%ZOBT6J/I_:7.J6'*+FTP@7J77 4V/8;Q$!-LI
MU:C ,U-0X#IKT1[-GWRN@Y/$-9GK#V)IS(#9-IS'GK0$VJ69 0!QGG'9N6-?
M##6S==:SG^(XH7VIK?F]SH$T@S2YF\W,7)8+CXP#6$H>MHG;SC.94IA1<ATY
M%JZ"JGB9(Y))10J#13,]^#WL;;1S:+W".P263'=.4SLPV@<7&6^S?K*(O/K"
M&(.C!;7[V#8$/9X6"@^XK%T(F',%3'C&_#LGMYIKN 3E0US!";$-0Z;5J,'9
MG=@4M\B$-FN&, Q!VX3$-\&5D$+5"3+=,@6'7P +"4JL<R*&[6%=.<X)--T]
M2]E&K=SVBD W#N<+(5365NZ8!!^5#?H)985>UO<PL_K-%\ST<KUZ[>+>*[8]
M<I@@I%A\[Z5OTX]RCIVW@0H[>5^7O4H2B!\(U$#==BP?)3I(G,OR3,I2=\X\
MCSA0YAS0>\PQM,S2<>2AC[7IZZ,M3Q?4K8_.6!\B4<E< 1\UMMA.7?! _^I-
M<N,KSB/<:E(X-BW]&8B33M5=/<@L0VON16X?6OG:<<B<<6C,K&;C5C0R%N)V
MIBQYJNTV8W%XJ8HTO,"6#PZFO\""*D:Q[KW+Y4_CPAC+=-^A[FW/*K2;V?M2
MR_V'O8[>EW,Q=F";)=/X7JC[!E]L=!9^QS]E/,E66-XZ_\#@CX/+H'2=./?1
MHD<3@)MD^WK@Q SXC0['5PMIN_?>'DJMUD+[T%9/T*P)R1C5#]@N<YKPI:5W
M_;0KS326]=$WWQNLCRI8BQPR^$!RQ2BA3P!J7;9\*!<JOEMT%RKR)4(4+5KD
M"H9U*>T&"C+]"L&P[ASIW%W1 ^='PBMV%3;4-T8;4@^DR*07!%S\], \1*T7
M*H,*2J[341XX<HA1H$J2#"6*J/?H:%5GCW5>=KVZ4T$QMHM2)^\*\]()+] H
MT!!I\ULIHQZRC]^9QTA_6ALVN>,N,:',+ )3+75&5$./*1CHY&LD9^GD42SY
MT\.3&*GZ.UG[IXNOJ:3+M_3EOP?&\I\-LO(_+J5""O[G#@_LA]-(CFI#51<O
M8]J^"7FE0>=VB6]"%@U+;TK1:(A4!S:RR*02 01L0A*^>YM*.JMV_BVJ1<1W
MWS^#,'W/?^_?VNS80H;X\]/0_Q>1Z$F6.V9LJUNU#_F>DA&XP#CPU6 4ID=H
MN*V:5*_EEI ,<T 116*H^=J'O[X.>S;WT.A(]^Y5PF(Z,O#!&15I^[(-49?Q
M]78^R['&P3"[NA&#8*6^98?Q1D_+>05MA/5HY:]1N3/+RR\2TH3<K=Q1'PMH
MM_*5DU3\;@J63'Y%T*QM^Y  S_#-C,QT>4';)L-Q'Q#,@#%K;O5M4F!-,\-,
MYZQ%1)CWC:Q%M43T+>W:FI'@:F*V/; 6J]"3,36;J'1*MS\T06SB]?7G'B).
MEK+O5(>"K+;]]JO*J'WUFWQTMYBBVTO?AZ7?*R_/%@_(VM_ -<SC.D/7I"\=
MB]H1,W##TH#!1O9D?LH"WKFK$K6LDE!YHS(*1GOKU8IUJWS*#8KH\N$>3Y;5
M^Z<0E$QLW4*/[0R6>8]AS@M1F.VC*NTXIPE>"AF/!6X2%:Q+S97R57YS0\78
M-.1>#:(."?3FJW4G[]6;6C)>!K,=GM==/'N-/!8<QI4$JA/:1*E$_LXYB9&K
MZ[K"*#_+NN%P$ZAMG/;*.L?(]I[V:O"31 A$Q=_H^,# _EN7KZ1/X4YYMFEW
M/SP6I)DF8NB;TG])8ZS_RL]\)^[PX_E'V4-)?<Y9S(?D@_+!C6:QZB,NGX(W
M]LITH3![7GO?30V@UVLY!;:D1>5.(%<O]H4E9S?TT9<'HFR*/W:/D+1W&ZC;
MI?[T*.')\GK"Q/\[I",7/H8Y#=]='5VPC8'HA28K'7D/VP:P.ELO3Y,2T2ZT
MX-.*1N=&*G^%R&3=>B3G5V!F%:2I&9[#Y'YUU5HA?M$A),G8/_2143>4[3UN
M:1]@IF>YVK1NH>U^^V"%0:DE\7;#YPL$^\; \?V6J?(7,BT; \<>Q!F'+W8>
M?U?R<<Q[%T'=HE1RYMP7OP(A5]66EAS-J"!420&-=DM<=E^TY!$K@Y%7SL>*
MD@S]'IC[GC75ZCFD2GJL.[,)X0H1JP,18I<YR23*PSFQ;.8CSC/T&73'WA8P
M@YIO+"K%-@849P>$@I+SQ5%SG@H]V:V.:>2KC)UEH2$43[&B!U^Y++O&N.(,
M*GE:B/F)TTBBM)%D(GAASQI78+ 4E4#E7PDH0:H^9N"8=R</C!G(H=V+!O3-
M3283OUO9,?.AW=E-BUHYHMV>2A?1%C37_AF8>9.<]Z@!]C./.($IGN%XQ<G=
MZ@TNY W8=JX*1. 5 YDWR4!MAQXJ^MU46PA]T-+0[-'@]>A31:C;)^XBSP-]
MN48?KA:[IO:TQBV9K)/TM&[JP_(^^TH=C!OP4=MM%C; >K-ZPB;+14ZE=.)(
MGX7Q]<APQY)B-58J7(I*$CK\_.IDSWEM+59JT"@AZ0WZ*+.IZU/XDIGAX0]<
M6(]=MHG4L>?CQ=V.!_=Z'1 1TBL[G6KYT <, D2YP@D H==V!TBB\6*=(+I?
M#_8^M#&R=_4TO1>N/M'&1WO4AZ?,!CG\YC%K<;2V/"#;FG[GMMF5).X/NP:<
M68I*:,#$"64): /6%P\>Y>7(,ZRC(.DT@]GNS>!CWF78QE?3Q]8=&)$71W70
M1CM6)&Y--,L4[ &^9!1]-JZ8KDE]XFDY,2_U0$_S]% TZ7V$U&0"M1(GJN&0
MYIE0YI95WHZ*"AS-?9!1X1RANZK1HA,28/"Q(/V3F]+.(#HVZ7&C%D:Z6FX>
M//_B\ ^U3-^(+/=L[YKR[!K"W9?>-4GXL1K)SVXIUQO4!,.B[2O+QV[D%<7+
M!A<FS<W)$E=7:6FR^^(-DF2]$[>'GI&TBSM'2Y6R/S;L)":I<1<BI2WITHJQ
M_X> 5_X<.H)DL_Q-@EFS"<GXP8N"0WG2Y4*?Y!8:.T$P^<.FDI _+.C^Q>$H
M8%]ID+E=8MA%P]G@!*XA@H%)Z1=CR^.I'+M/ZW:F4>9)_XJU_F^MXWY$RO'\
MSD_N((GI3VHB<ZN0H-KJG0A/*5)"[":DYA9VR>O00C'[/)(3:[X)L3M<R'/3
MQ]__SP.*BL_8A.PCZG,[F<@-:RE_9\Q?W[O$(-*0M.SYH=O0[=ANZ&NE* :2
M^A.L )9[\2*V:?#]Z&/-C+2L::5B.C1.2=EV)]MT9#VJA2H_3HIE7\Z2V<#'
M1%C[6;C/"J"]J6$EX$+7^T"'("Z$@8B%!1,^*VD,D_9@%-&G&48KI9N0'3LX
M[7!YM#Q8S!BE1ZX063Q/WPEK,V)\HXMV;T+2$$KPPY@1&23_)B2HK-%6',2_
M)(NR#1DQ='(*5YE]'IAD:T.GOIT)440E4\?[DQNM96R2UKJXAT=7#!H8@J<0
MO.E:=0AB62.Y0T@I@[4/TS^H2MDLZR6, G< -"6R(T@,I7R@NKMC_UBCD(("
M21)59"L FO??GJ6C?$X_'V\[5>@_C')QJ&'P)X;/0D]/S-B^_ZYH[E '\C'%
M.>EP.%L(5*?I3B'I,BL,UC%_DA!78Q$IT;@)F5:CDV(1P4/)I :952'6278@
MV%R:#$W$2L/5 @J,.-$DOU7='B\=,%UEI+\"%4^GJ011%45M@(4XM!YU"JU+
MY<B8C:H4?W/HN?VC?R@:"YS'?TCF"C+)#6NKNC3R-*)O3IT3#X=SAUM%FAFC
M-.=FE@G:#'1B!;)/@WZ4(46VR CV,@?96\M]I\0'D&)@1@SRN1&NPC)4!+,7
M9463CJE *9QB:/](^^YY>ZU7_DL+QVF28AM'HN0CFLCW25=P4PY<@5$&H1=;
MG\Y)1_B2[I-^^?(=E]:QB['0*^Q KUZ5 <R9%F!<"4AG1H$.--&I93?0A+K&
M2Z?Y#5/=$+^P54<[U,%WW4P<V'T)VMFZ2HY%0_VYVJ/\T=@[S_CFUR0Q4X@Z
MT7MLBTKP1!^I$;DRR\MT9,";/]>']J!<>A%[.V1!;$^.=*F\N?+B]+N$"E31
MJ./(VH/CER(;.AJCJ?;GIHH%EVS[$( 94@XTGN$*N+-VF8?1AG9W[N?DLR6I
MJI,-SSX4F]]PZFK_<%#V1N4VYQ5K3'(@=B=7+,BM=*ZE$JT+1E4$&?U 7.T8
MC]#E1]UF76AO[8H)B[P501@(#=/;=?>U0=I'C>AS$)<%,EL,9SH\OW7FE-O9
M%ZQI\Y"PLD9I<#B869]YLOF\F)79N0L7[]N]5,F[X<^WGLR5&.+;A+Q?H-JR
M#S7@N.>+__B : N:K^MN_+*(!+=.W=,=L5V(0NQ[&4N>%MPA;$+DG^PF@;8P
MT4W(&7P< B@:0?P\@OOC@T8$%?J>]%FH%$OI&-V$I&Z5.W+C-B$G/35Y"L;$
MLP/O'MF$4&$ @B."D=R$="6?VX1\?(/XFR=CFY!8[.E-R!.=3-X(6;9<0W.V
M\H8,9UMX-5MF&LLHA_#,4.RWE[S0^SCHL D1U%;F&<!#?_),TX$KQA'BWFUU
MX0JM(L!Q*(#[C%S?,4("D+S0NN\9G^X_6?._E#7%=#+?H2LA\BAK)Z?'CT"<
M^38GQWI]B5MWRY_42[R\8+&/#]F+6XUC2"]S1;9M]>?U1]0:=9.4S NW6GQL
M0BYY8EE87I:21HR8430R TOIGB<<@A0#30X OW-RO>*9S"[;72C%CPE.H\&7
M:L;9%_G<NHEGAS;:>8HOBID+Y?8AZG:!".#2=%?(=#&SZ44N5:W+4_GLZ&H(
MS*IHT7C8VJAG3K^NIN&BH5#4BQ-!0RN;D-U>ABG,;/B^3&^%N8FS4&=LISR"
MDJLDL>5@N=UX8;CHTO3.]%!&1N_-HV0Q.")H+3C@5F09VX9QL-+H=EI22%S;
MI34KP*3"#=0_^] 4BB?X_S9W7J6UI2  $4#Y#A5%G1&C.:%*>Z9FK_J)@A%F
M)9?F1!P7HW3VTW<(5-_Z%%YQ1O/-E8?%'$(R\6(OQT+_70^VD28MC-V9D^KA
M[F[EN.C]A91/,$XV?RW9,4$J*1 ?@XNA1+OF]@*V,1&X;6!(EY?8^W62,.C7
M/6W36#0=<%LUINCB&4* FS,^6''^@[;6U6!*4[1>?FW?DP<W;,]L0@06[FU"
M/H<!!*ZD&\]?JSH3_EJJ_B"^+G3QAP1UFQL/%XX?M[EQS?YAR<S#4M49WE=P
M$^_SY?:)J[X\D;U%P6[L9:MO0N*DTWG1PD/L'Y]DEOV-'N#^6J2<]OT'O<AQ
M6_;?#M/N__;(+^Q$LM4*>%% X5 7'K0+@+(?F__Q@1O^#ZKT-SI[4@X+%*"@
MW 2$()9J6H+]Z@O]PWW@'U6I^*^U%?)/MOR3+?]DRS_9\@^PA:\?PZ_&U^<E
MJ0) &-+I#^X@Z%__&)#8I_*=V2Y6'' R>I>R;>,KY=_,O[3&G(2:8%[9]R(Z
M9=6B71>BL4F;D(:K[ZV%*FL&=Y,:D+T7#^2H7ZBSD*RM:[NA?,3X2%VMO<#&
MM8XKG'0Q95!-,K2\))1]D5.<+@9Q/&L[K4^K*]*X^TOY,\'R+6B7E]5/_?__
MBBV1%E#8'.^>G.@3/;?K8\ZM^?1+?^FI,Z!5Y:2<9N!\2^6FX+_TU.F'_J5(
M:1$<HH9,S] F$EDGD &MI$Z<,&CD 5I0/?4OU#5':=O2CGA8" _U^B^XAX^7
MXL^-E;X87A]4-]RUWGYZQJ:1Y.M][,I/&VTZ+#D:>.1QY997Z3$?/2NA!,)I
M?%/U\:^6I99)#QYD%)OI>4T$LNO*;([>*)/D*J>A3U%)HH>/:6'%:($CI8]\
MG(6$K(2MEF5S,DWREL;*GYE97HO;U0>?+G%L.>C\\)9'N2FB"D&I032)]B"F
M^6GX^$T()0M?)_QR GV+H>!0-]QAN-P:W-,W:E/;KC=@%/WEN]"^^6ZKVMJ0
M5=W[1L_;XLGG9%H-/U4ZF(8A>1-<J[82 ["8JB ?%1'=L3WZ1&ZR$.H[5 Y5
M=$XYV9Z!3:XJ3%G:F/U6-2_V^EAX3;W+4>;1)Z;!>[WSH.]LP0,+;(FO"Q2U
M[@K<= 7]$D_335F6W.&CMG0%#M+I@;:5'= ?Q_948Z[OR>TC-_=TJ%D-5X)%
M&WJ*%/P%_+FL "+M.KDUDP[<=$CKH]7"@GL,/+66CQ<*7KSV2\CCZ]PSV("X
M 4K.C]!'N94VOG:'6IP?!MSH=7B0'??RN*HOKH\..TLK%\'M"=VIE+^7H/GL
M9[80,#A^5<EE^V0+KK>I]G&[Z[,6VD%Y6(WCY:UUU@VYC2=_IR3I[UR8(]A.
M6Q*E?A-2_X,M,6/9"MXIA$'E28&KUZ85L#O1 D!C3W-VD]%&T:/UU#/]S;?1
M+MI/ KY9#@^(/$Q6NQ_A:IFK(*J#N@;-E4GIHARRE4@F"DIZM\VOWF3&'JA6
M?^=NML<^KR#=NF!!!)B[U?NX2D&%NM(LD7/%E<!J@\O+?'R:XZ0GFU076AK7
M-6QO7YW48Y.E%&NRU*BL:,N;SF#L3#4SG',/OF<)*;,)\;>5F_E\4WTO@'+O
M<A867DA%8ZM*SC/GH$!\K&]:\&DF=4S@RR=_@W8=\MN.\9"K*T]RPKD.;$4@
M@\G<A,2D<;5=T38@ W&?Q+/BH"HY&G8Z! VEF)A\"?Z"#F8&7%3F]L4O:8:
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M1^KVK;*C90VWJVV/2>6T'EWYEY]K_M^_=/YTRBOL3X_7_X)V3J ZH3\/8/=
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M"P#UK^TO)R'/+)$36!'(QTV[TS75KY>V&X-#=2\'NTI+1 05M$2;R)6>B9V
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M^(9%S.\:[,G+&"!;I;>(,5'DE+ J\^>]PZB84XS1/1 W[<P<C -N;+"_M<S
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M;2@=SX>N?7Y?7-S_'61?-3;H7"HU6$C3M%I>]GO $9G9,E*M ^9ZL\#?2P^
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MKK@Q*#>"@R)*_-6?>]3F6@[%_2G"+"_YU1>\4[GH'<",>IUI/H&.R!YG56"
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M%Z.K794N%\.]/Z:>5[;=<4:_7Q[HBLUU @L D=+/'K<,1&P)W VW9.P/,<U
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M^7.(Q/]1]7VYQ7!WUI$1+>F0N5ZP &"Q_7''I[4IZ#W0/]SAH#<0<4Y.2RX
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M99=_[=PF!$\ 0W6(ED(R,U0E]6&JS\=,A!WD-](]B;I5(%G,5^H#'N#@]<9
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M*T_$W8@.CA[;V33HV?8EO J.#ZKH?0]VUI0U.M;TL^%-5M.!:ER!2-."Z$N
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M@\Q:DD$^ !%O&'F*R[ G>Y3V$IV]_.-]LD_G9B./2G9.?T#2QQ]@VXG+D)<
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MN K"2SYFS))T)QW=4AH#Q$ RBE_>I3&:5Z))1K#G*30"8HBZM#CB:IJ/1\.
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M@9)4O@FA+YS'7:MA^[Q;M)"PX'Y,_K\N0-,H6!?% Q^"@I3JL$O_NW#J!U!
M;'4^T5) A+@<U$G%2Z\U:B)QPLSOPRL;(HN13!Q)DVVCKLKD:0>0!$BZ,7L7
MO+7Z!NH" <V,] &G@N=BL;TY%-LY+ W^F#)F><JKE7I^8#9BJ;2 15D",./K
MNZRE_/";SCF-(ISP+0"/\:TS^Y&8H7,1"*BCH.MQ[O)2D-;Y-+P!GEI@XVOD
M>TWM/&ZWO3=!-Z_\1\KD'O( K <P!Z/Y+TVU)_2WA:O?#TS%5=*LR?AJE,E
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MS<HL<O-7G-G,BRI8:O\-?$MN+B 2D:0FFPV]M\\LP*KQ087A6'<5,P$S6:0
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M' 8M9QVJZ'$-1[@GQJ@X3J4S^L'!"2X8DT!]>13H2Q(73-4GU_LE0(= Y!C
M(5EB2W C%?#5\Y7R%,I\I&Z0]PTS81\"PCF*@7R(V"BT> B+SJ'3"]Q[/#?
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MP"8Y@;X+#Z#V2(R!0'2 VM)1!EP1P V"'=+'C;I0.^C21-/)7]"?NL&#(Q"
MF?!AMG27O@A07)<9I6*SV%*,DJ,-THOJC>'J078#5*VUT LP)\1<3)IY5)\G
M=(TT4T6;JJABQADV#DAQMIO;ULR8\5Y6D FU-V.KX%D7[]&B;';>N=4W3%D
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M*E*#TV*;R=L6'^GO"33&H=ASRDR(PH$X*ET41IZ\BT;H\(%D/@;:(D[-%"/
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M8.2<>%//FTZWTKRT>V7\D@+WMW4-HZ.W.D\?>Y.S_'29+=6_N.C3]E>]G=+
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M)9EZ^BG;7\^C_V":!\RA <T:Q-MM6_&Y.-BR;+PB]!4[G>4 L>N@"66$F$9
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M*ZGO92(G\&<-LG0:5VT)#SZF50&C7W2;T9_TF6 TR*',?H2<*&:=0HY/'I%
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M##T"0ERBHB!DJ30*F(B(*(A15%HARP9I(F8I(%%"HB"]@"X4MK @ M)))Y"
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M,DB3#-OZ1DO/,FG/FV%R'\@_AMP.):<1(]-#"WWNH52FT>L56T@<+%7U+OU
MW(0*T"H\/)3W9]YP8E3KF!WK](!-S8VNGN-W>=,_9XTNCDT-WXJC";EC-0-'
M?/\X1$>*TJ%2_D7Q5@E[SA/EBM,E+N $T"RTI7$ZYI/\D?>HV$V$\"7,\"28
M/8'4/A<VU )G8=1!(R[;-G%@_MM CMO0Y8%MC8T-#0-U5ZV\+4/9W3]#($P7
M,\ [YC(30Z$KF"OU!^&203"%J8'Z99KD*"\AZ8-[.Y0P.-U$K.+S'$ G/\D;
M'ST"6"4]%D0<G H+"RX-G.&>\_&^53J>U[SRATC@5S7G&2)8NJ,P([=_+33I
M)\8*#JAV.5Q-!(:D70Y'"H0'[$:]^^>(9P68^$+D$'VW<.T5O'; Z6=@K!^5
M.F03\'++S:@Q_P\<K\;=0=P CJ;J;*Y,QUBQX80\G\DO82*B.2-)L_P8-G*$
M.>$>>FLXA0@7X%/R,@NJV1/IR W3UV>-V/%8O[ 6C$0UY9>&+ ZUMZYF,L[=
MZOW%:WN[>N'?0KK(P/68;OP:<GN(4YSX!UZ%].E6^5ROH&Y].&_#>7FB2+&7
MD,1C72=DLY8]DY/*P$2#^ _9U_A310/1@::3G57FLBU_8+ORJO0&CS=BKJ&G
M0D0N3\,<8F2FQE([3/GTK8B[R^5W4(APHS\EWG9-C>$^DX(!<;[HD.^63(]1
MCO6^">G9'@]TKI$;\\(.(XHFR4*&!@] FYN$,[4 JR:4, VB#<!>FA,(QM;P
M.L?W#<_)D((E.A-$"U3"RCUJPW]RPW)Z8DP>??E=7OM=/>Q2HNANTN6C?ZI,
M(T"+<A$DA%8!X(.)>7!+-QL[JBI9#>:+W83V(O.::=1.4.UW)4PW&IFTW/S*
MZG20>+)]-NR*8G.8P^&6*+*F50WM/8[5\JK7-L"G?UN6RTOL%KC(P$U!M[KK
M$7'U^9-,K56'=G2OV*)5D0$S65FK&V<)XJ"Q7.SD_(10)5F 4 \'LUD.XP^$
MF TX]*801E_TF(I7XY!-A'\7-H/96)Y[LVPF+VI)WWZHX?9X(+OZ1R?H>(X_
M/,JDQ<PQH1R<!NLD62!;B!FQE$CDCTFFI/<.G R:\7S\^%KQD<? .%Z+$/+*
MJQK]:=F[WKI<NIG0?1(G);!2N?-LHX51SOO*0'+U9@3$#J)\VN,L)8^A)?5"
M(\4&8C%ZA.3.( 10Q^8DCNL!IC7/P# 1Q;]WSLE#G,T>\FGF[C*Z9^\0(XDW
MFT\7>?<?^OYLF]M)V%_)D@KY0Y(YY*0)"WCA/WEQ)#OESQD6(%/ $>T4<C1&
MP"5!<H9MK$I,]70O^-,9B$E98*:@=(%.(_1=V;$GN!:W-&W,ZG$>> V_4$ ^
MVL:D%7JD&U].AZ8\_PLV@:G/V$5N]R7SL\DJ-.2]F/&5X-@$9N2G(/E.=%8F
M28?:DB1E*6&:\Z3M8"YFD![W9(1P"UI.[JECIHV2@A-O><>8P,238 ^_7;"S
M&*X2]BE7H1$/)+?CN>D0\:<I82*F%$>$BCW^KNP">/' HTE6*FF[7_BR3_+"
MF(M[SH\(;6EGU0020?07XU-5D\U;(UQ8+5X@R^/C@MQO<B"D'U]FQPN&R<3R
M<NO+N0JXA?Q^X]99':(E($M5?\T_O!W<*6Z)-/0<=?8A/[Z6,;'O]7OR#9I,
MES1B:@U0[J#Y8O0(GEVX7^R31-<3!"($5Q/L:H3DC;AE3)*38RD;V<[+R/GX
MIF(V[^O7I-P+C9_?KZYY^;(EG=-2J!X:P[&YUBR)K51\8C;JDE:")6(5%AF!
M@A,FCH N?(0FT4W\!D!V4M80WDZR&'K 8N)[T;?&*G]"C/] 2'W_\)Q(>VQL
MJYUHMY9:S/T=*F C!-AXF8%87;$.VH#500!3II/+7THQI_6B+U)&<-U8(Z?(
M;2WYZ8YDQ$PAHEE<L_B %'&1,4#?&<G/V, =/SF,O#7\:X=]LKL\$O)U2@F[
MTI/%]8!(00B 9O<'FK/1GWJZN)1VCK;?3,R:P MXU9F&,0+EU:V:A>NK7S1I
MT3BI1(1>6T=N"F%W[C6O"DI/B$R[?X(C,S / B>EE\CMQ]'G$9_,!/.BX\PF
M>"=/SY=0UXTUUH\+[^Z8Q0GC,)V-!)U7X]AN9D)S9>G44)X\.1GOZS_##0_C
MGGC\E/LF=)?1ZF4/Q5JD^*(D%]IW$@272,4NT@<EK%FU0YT\0F:3@9.4=;.%
MEG00<Z$7KO9)YC;@Y%$+R0=!5XG@30W=9R+E-V"LDPQ098[% 9\)^6=RC-][
M\S X:FCO1A6)AP1J5 F7.*+&"1[70Y(LKT3SBWE4N\::F;SY+&((X +-C2L-
MK2 &P'7P/OUQCD!F<3.SA(O#WZVH!XR^?6ZJAR=<I>^\P#U*F;L_.NYAU4^Z
M JVR#$NS%QV;P,.@[YW1(7 3V1%Q;I8"1C0$=\8*T4GVA5OH@[1\S&H"8YI6
M8S3A F2^K,1<7T9E54[KL_PPZWTY>C6TMW;E)BW'KO] #R" 0"1H.9]%#IO/
M],$"KA30/":+#A? #< ?2Z< A @K=2=(NPN-P$@^?#48-G?9U :,+099G;E#
M-S[Z^TY%Q-IW8K2F:ZY5'[BWEX!YQ;W<7#N#CRQ7,,GM>Y2P2Y1/C@HUD70#
M\: \EQD\S]41(+J1J<O#+(H187("G>&$%%N^&M\J3NZL,RI/P$?0,-KDCMV"
M.LV9)0=$(I5P)JS0M.]CH(;YD:0QVP.G3P\$S9]Z"5-L(O.3L< 1S(BQ8AT.
MT)'<!WNDQTE#02AYH2TO@:*9S^)N!)2P5)1Q6-[AY:- =&[:=O&19M4,JE04
M+K(1'?IV]H5#(/OAGH#VKU9C;0)MQ)2+0D-7_I0<BM$'\R4_Y8_H >)D-IJJ
M.O=5Z@A26$/0W*"3A8$^IX>N+$3ELE'[/Z*Z^=(Q[X#\?,QZ</YP[QPQ0#7Y
MC^EJZK$(#?8C6BO.'G]--D]N-X+Z6")3G<RO0M0;B.K%:9@4BJ[,1.HJTQ9;
M?;\#^+@#(DZBM<((3#A) T[D"T$;CA$!YP5TCF\?M%YLK?Q.];#,T.DV-4IZ
M&U!E^5+0XN$G:%64HOD?F=S8=M-?Y7^@]I"Z;Y6SLE83?Y4_@30J.>4/KLS%
M4\6YCX@6(E+&$<-7%STT[#L+?Y5JV0=M%F,3%D7&_D!2V[/7_D-#;#KRZIVK
MUN4Y7U26%_^5 \6Z/"7L(ODO6\0(3_%:";NMA"TB&NI*+;\Q/_$4GFZ2&$A-
MH/EHN=M<A<JT^_\XP;;\PN,&2/CR/.:EG5%'&6BPAQVDB=4,\V<TEX^%8E51
MMK+C_1-]49MKJGCA7$H',YEDVT]'KWZ(GW2/EM;LSAO;]B(U:.WE!P>D DXG
M6I7H#R 34=MDJ"'5%*+61)QV-\29A_6[3_<;G.V-WG%7XO/F?/7(-+?TV;G#
M[4.6L\8!MY\:)%[?LX+[_T:F(5NAB&"N5\(N<$94)7-0">>3^:4(524L(G#-
M:"=9;<X6FV9JW5#? CX0(I+6,BSZ>*^:6JY,! &<%/K>RG,- =CQ.^4:SD4/
M=^?Y;M4,CE-7K)WF4U:2NB&"'FG>11D)D6B#^4*T">EU) $OO)$KK+)"=\:@
MS('.&[<0=S-I$<4X[N<];4T,DA%AR"_*Q  [8-[2VOJ"-K9M\/.2]FN%3NG?
M YNQFMQ^!LW_B@=W&LQ-2IT)=<+F!)E.*9@L#.DTCCO-5[P46*FPX36A+NW>
MWC?Z@\">=M2!OOSC?UAY";[_XFEH7=!G9O+%P@0KA89E/,1ZVDW0YSG@MIP,
MH:\2=AF^ A<Q03;T=ST_@4@G:T7_%/)2@\SZ1-O"YJBIBSNN4#/4W?HB@B]N
M[J?O%HC6]<W@%_+!VN],\D'$A[%YV:9Y:12A$>J!(K(40?K >VZ>Q RE<",%
M]MV<E/$5H+F DNP0TQEXT?T%Z -4L15;H6I-HU\3NW?Q.MW.#-CZ6>VRN=S8
M#+!YR5>LYDL9!@$UWZ@_%)_EK62^ ).&;7C4/,>4_BK;)[^_B+_'!$[70:W%
M/H%X38@>&7IK14)O(&X3NZ7_AK@ 9-+*?,]Y"MMB_!@OZX>Y5BM9WC1Z[X+(
M;EP)\QZ@MTZY$E<H86L& P*.00,O&\K&]%@;K75L5'9)?,YN";,*$XG7X(@T
MQ$6U%^(%]]^O]['"7QW6ZIK)IM'7G(U<'TS<*WD,\@19X':DS"22+#VIX)XZ
M-Z6$P1@V,MN+P$_AHP_)%3,M6(BE;" D"\;*XTN&J\D-HJNU=5\^TCT%[R\>
M%EO5/M*0U)>&CN^U]_(]FFOWX!PLCB-U)+?WH&DQ+#27)4#,U4'+NRZ_\T6>
MA6<XX9;7)/"QIJ$ V,RZ%70'D;)XE'K L1.UHY<8^0S,#,2PU&H^^W\*7ZY-
MKPXH6+>3=[*MF1!1FJ)PAK;Z%84Z+YJWE^EG28+_5+S1_S8IB05S\>>ENOYE
MCX5_G98\[:LAGC6M+,=^MJI+Z:7MC:W]?"YTU&D/5W?4S&+MWB.+TQ0 FS6*
MD81#Z>HC]9,!#'Q$1:'&$P;PN/!N+- H>W]1:)Y WRLT,?<$OC:GU5'E%I[[
MD4ZN CFR4S,@M"D=G28[5I6_<<%D \LCH*>R[ \[.R4,PE[[.]1^8')N"8KV
M(.1]OPP/YJ)*2HF68,BU\G&PG)UZ_H#LQA!I(YB4V]+_]*2*U=>Q3,HU/#D2
M![LI2WWPP.2IZV_P3YXQ"O5CXA )"O+A\XGT&0N<YHQD3O#A(JT:V4$Q@D59
MJW@79!3H<VR0>+'.2E$VO@$72L14XI8+[Y3/.*QY'%,SZY!4&A.S^A&MQ2%E
M]%3#;84KE]S.84(T]TX,8CW#@?09JFH/=<I=):P>S@Z,P?3+',5H5@NV,P+1
MV1?F+XN(*PGW)]4):RYZ >.T:--4O0_U\G\L6Z<M?_'NTK 3CI2EA4^0^=/D
M]'&8O(W,IT".ND4U4F/9T9=@N]1&MD7^U"E24)>"U93!!:(+DR> \=::Z7']
MIK[H# P+9=%KH^'NNW# A74KI\!DO,0ZNX@<'CYD=/;KZ)OJ$3H6(C=4#!N?
M@*"6SZ7:WV&&XD$'%2Q( S[,=J#@8M,BZ5ZD3"?K#*4;P2W42S@^2,6J3K^)
M$%MVM)@1TEDM&8EMB4^[N_."'D1)8H,'2=W7IS>K+A1!.W,(RFJVS!XPE^FF
M*]14^%EPQ1NHZV-$2,$\-Q.SDI#_"D%%LBDJR'323N+.7B)>C'3]6+-(B1_?
MZ9&8Q3*([UL^$&XXM'\I_*/;MV=WMT:0V[V8? %E$P0 6S2_Q-18GEVKA(7$
MF4\8L$S(_,M9$P>VCW9D";>!'.%\FL)JP-9J;T<A_*.U&>,%T$4I^GQN-,!J
MH#G(<##:,+7 ZDOFD68?F1>TS$RB32]*@]SNS.1_(B>2C,0;2H4\. @7Q,S]
M%(@,.I<YR25 3DW==!-Y(Q$I\?0Y!=#]F]H0R=_GMP3G1?QB^S[PBA_]0<58
MXD_*+ +<8=5&&Y:90.1XE=@C/S;V47H[8OUDQM5?TJ+3A"9HH3K+8=<S@7DB
M('9_<LSX?.^CVS8K%IKG_"#Y9J@86IZ7Z7J\8C[WD>F62#8VR!_0>!F\D'2!
M)[L:M:?7Z5B1Y[/1V6;%QI=B1OZ$AH]O<D"?D[M-Y).1&91INKL==[;1\ZI$
M*DCXGH\!=QETY7- 9&"Y3/LF2E^&S.*_8VZ(SC+ B+=]$?N!?]IZ(@7E*;*K
MOZ1??:F$K:W[9#Y@DQ^@HSZ%#<M\7[M5>IJSE83Y$B+3?Y\*3;J':'Z6N^_]
M0E/@\N#6^ZT,,^)!<Y5]@=W9M_?<K%.5URAA88A$'H!1PD!''XB]4I$BEVH,
M(.4WU0!W(NJ<8JWSJ\+];V24$T8%B SBMJ>X7/V6H(*;Y+CR43 M(,#J7-B-
MX5P[S9YMK])BDN=^P$@_99 ZCF<1P\ ("%%O0"24TH9>E)X,R0 ]Q#H=)./A
M:"4L9;EZW!*M%6&].+_A'*XVS\$?=Y(0[HCS27,,SI2ZM>8$Q]Q_;YCAC4U&
M7YD']ZM(LN3_8/)+F=1)F0Y/,#^7*%#"N*ILE'X?Q&LY(S$LQ:KTKAB$IF(S
M\8RX^0[1>&)CL?BM2]7[LC>"B)W1;>>O5LOL2\.X=$G3$&;#D]K<8.:O4>11
M1SY6Q(/VT(?TCF?"O"S"=II:@H>YI'P^'@[.>P-#18(V1-=PX5J@1I%<C2-I
M>IYQK9@Q-8D%MV8._5!T>[1]KC$9SP_;8W-QAGP[IZD9#=SL%AT=MAL:UL !
MSK4U1L*U9;B 4M $L-[ZLBGLU#T#2]W^PXV=7J<V-71MVIJY464*#UI N)F5
MI( ^4*JN0TPJ##-:KE!KENXEE$PD=Y*Y[HC5A&').7D%:A..L1,B[>D9]BY@
M;@48V>W@=I?H5C/CP*:DE#X'%EO#FNVYU+X OUG_.ZGB+2H2<]$DM O7Y W,
MRR ZF'E'"7N.E^DT^\K+27N(E^0%-O",!K\I!TSJ)!C(1ZY7M[)^BX=/+Z,3
MT8WSXP<L9A0C6\*(+N4N(1<W>1>/^]S_'"#[^WB]G/S63K%2"1OA@6Y*2("S
MW\K$T*Z7065^B.3@J_C$JS>7Z4QT4YK*.R'U83Z'1,\5 8Y=%$W%?MGV/EJ%
M+% 8,*])=%2,1+C*,()TYXFCOR5[]4?0MYV/$&0<LVFS]O3R=.DTLJLYT !;
ML2R',O,"^@,R12^/&B)B5I+;'='\(DI])[D!+S*_*9#R= C>&D9HG6FC6^TA
M)<Y"XSCCSD(C<6%I#<YN*>][1K2&(K%J>ODI-^)S^.'[W9.=$\N4NI_J?[.D
M6>S*10JXWY&_B=S8+0J1.I-&L1K46#]J+)P+E]P?MB5K$7CL9@E*E;"XUJ8-
MTZGEC\LFG#[V8JQ\"L&]12KXO>EWB_1]]W?4+2S\ER]E_C^,<5#>+#LFX&D0
MUP^$B+VKI)X@YO! ]'OXD1=@LG2+S':8M(L8 <;:E=[*D2BV TL),C-@= )^
M;SNU^<:/Q4 /%D7#Z71TZ8A3\][1T8#D%]BZJ2?P;R>D+E2@>:X5B/058U.8
M_&+R*M)>T*-3"6LR;93NPC$;EN8:Q8UGP$?B[ ZT/LF<F>J$%B*Y/:QEY"OT
M/90Q@,A$V84OF]^EWYR81:=GR]8-S$?+\>?$:VA%LMW2H%)!W3H<*)R8*&C*
MAO9=8-#%N8TV='*5'E5P*6K,"]X J9F/O3.^1US..N:$$]2$G.Z770N;X*63
MM'MEQX!F_H<B('RAN3..-"Q4S:0?*#MHNY\GL"N90&KI7%+"^FIT5SQX,G)N
MFKLAHSSP:-W-\T_#AGSV5-D\6[)K.MEN<X>'>UUCL7=-1#7_Z_-C=6_'T-V\
M9H-7\Z,4B1^X4UPE20?WBH<%:)%ML:)OV/P(0)EC5LATQ3YWYE$:H%N'PA)8
MZ"70%"C9R2:QKD]YIW88]Q&=8=PK8]^Q+LK;?A&/K;']*U%ZDOSV.)F?@Y!
M<QR]>(IH]P3>S_TO[O*@;LG+T<&0@)+T@.?-V[.X9 $VF;2;B,P/ZB-B(.)T
M8OG/6V'#"TAJAME9/YLXE^,,CRJMV!OU&[\/KOOLWF!6=8&Q$4#(-),5:FH
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M^S8H(7?([:T4 ,,#=Z)%:M'2XZ2/PQ33:M36(-"%Q5!OR1(P.R/@+)1)OCO
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M7]G<XM/6*].;X&20=@!9K+JU8T%N=R*K9_T;Z'9OMOBQM[$JZIY5=:+0LA4
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M<4-)<.3YLM#\77-6UK9U<$*:;>IO=TK;Z@?*HL)D2_BI'&8Z#S2O;9S@)%(
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MG1&[8;S;1"+_HNPZ[/B1,T9ZXT/2^]P30N;P6A2:059;@>6-N57B%*Z06EO
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MK 9:(CH &X^6\!N-F+I&[IK1G; ,Y/L*T) .X,%P'4[_-/.Z9+XELTN3*+_
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MO;!$["MIC$-+R;J8)F3:)Y>(]\79'2VPC7'6:KY%UD&\@YKKL"".$]]6$2Z
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MEBXR%U:@-A/>M5RC2H#E"0U\RCVJ_)AIK/%<#T+1,I"]#M,6G!IO7(Z\"#T
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MTI8=@#60<4<Z@^$ZHMZ'!,]6O%55X_QU;=,14;;![S.\\8_-_!JA(_R=\WH
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M5[[C>MY>XTQUJ V@<^?$$_[BIX2%32RM$UZQTMC$WUT24!3ML/CC@A18SS^
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MOEH[FHZFWK_SGL/$]$ O"AG"E",**[PSPO3E9QF>Y-'VB9"V.K]@/=8.//R
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MI^YX+Z&%NK_[P)D),G.@'4%982!3K*3^C,;2$XC[+2WXMCBH*WB"&\KN$DN
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M _8;$":"I]8((!=) (J!DJ=)8>C2S88<[$/10;"7@Y  'W>$K;2W.+>N>9\
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MR7LIQ.A:7 I<\230TSZN# YPH(IS3&H!;2_M_#UZ8AX,] R!,^_]WG<HAEU
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MK&,5V7E-$Q_TJ6/?8&W,^S6EN'('KC3^)-<X,S;$CBX[:Z*ZMZ%F\."CQP&
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MTTU'!L@'KKWXT?0B:JIY#!)5<:SZB(9/J\2OJ;MWG[6F2A?1?MZIPV:\^OD
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MJ,=Y.SO([0S%_8E<S'DR<4JK.N;[+ZX6;L\Z_/^6_/YO'G67!N2A-"0)(;@
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M&UQ<APQ3\GJ&EUI2V@]!< ?9)<0P; J,'Q98*\GP 629IU![($8)D!--<\%
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M#B%.!-NH$,?J\\N&N<$3-XLL<G)N/EI14CD_&]:X_3V5U;L'2NSZ8X&#'5/
M:.R!J)Z8?@1K^]N_GUY[GS7>_O\WZ&KH478[QW@6C03VT[",1'8L]#3FP]V
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M6!IIT_),^;&>+#_/5&Z,]]UYIW7$<;;5L.$;F2WY/%6MW_C^\U1E$$$7>-8
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MK'"0829.NH>=1C*D=,92;YR?Q0;6/E/U4\6:0?4!3Z$4W#ZH)NK\@M\7>4/
M80DG./N(5$/J]12;V-"8TS<X-==/?^I[?DKJN QKX-M6_TQM* 0 IY\]5SN
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M35BY%&-N&4PG\%>DE\O,E"U;U%#H-F_L;/*@S9RA7!5U78.@X$^I84:ERUF
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M_1B^X/H4H&X"9[1S4]N+JQYFS"_MU_I:E9HBKIG_S4YZ3N3KDORS4X2CB/D
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MZ_U<N-\B:RU"B"W6:30%AB$;#S7$C('W0; T+6IK;U:RH5#_R#'.1]PQ38P
MRYRKGHCQADH)S5I":%]VV?-ISJG9&9;C1\P)5.K\+PI[I=?8K6=*$BQ G6*I
M46H/[8'LZ!Z,-@9ALYK*U76GZ2L;H_2I)0N@D@J?F:4$I$#NP0;F>!9WB.FZ
M"V)!2*JQD,EXEQSZRB1K_Z*5[70?0@0BM*@&0*Y ;"@"^_^F<YHCNTZ,?]^
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M+3H?Z11:A/TT#-I-)0B1@^\.MSS&'F^1G*)?JO(L(_O-)2P49-SX:+*[BBC
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M&N76,-+"7PS@')/TFR9\Y1HS#S0<)NWU7V!#_'SA<(TOVZ.X6FG2]X])GG5
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M&S[ZB_$SR:3HT5@FQ:ZS\Z7)U=(//W]N.A-?CY\IMUWMM%7O?R$;"S^=CJA
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M06G]@I)&DFG]MI-4FFDGL#:BV5=-WME$5R3HB$9VC'VM&O!_@A*Q*Q5[UO7
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M(!>HL*G@><,(B!C*G+J]EW-Y'"(-$&Z'=<Y-L<3HT"A-0%>%TA=;4.GBUZ.
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M\P)ED=.$9@4B)+I3:L+ ]5 *=9W&F[2M?7/W&80M8.&<@?*Q/Q,T>^!RG2N
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M_8S->>%)1JN,:6Y 1LE7HF3._$7J7F?%CMXW@FKO/1I0OO)57Z/O[@9YA<U
MU=S>!:_#SI;XJ)+&YU0H<M+*-KIB-N5IEO+G*<^A3,B-?@/K@<?X1L6!E;@!
M6G"_QM=;H4H-0W=-4\*7WVS.:0\XNFO!K2KLO@0_'>N92 G=JQ82U[,(ZK::
M(DTRCD"3(=_!O?.:--_>0052F-%?5&RT-\"M'H.WH:C_!0Q[4N?KE@BG6C"J
M\V\KD$I?_ HO=K[LO>8[LDSXH*,>J,E9%?C/^X=UM6BO%$[2 8)HPQ?0J=B"
M:VJCK?3PQG?JC[]O'%-G&/H:I5$@ K#YM=G2[!<5\^OZJ4E>M7\/5+NLM<=L
M#14%^#X[%?;[X]<W&!LPV$A,XK6?]G$N]5)=TH"6(Q!_-,0O\)[4&70)Y@SS
MC=L1R,]&3#<6]B&)5]-%,^6B6%UZ9>0HF&/^5*N'64^G0_:H1^UV#$&(WT8^
M4--D,B.$=[&Y0/X0'*\U0A\6_];S5%OJBDN&_:AVE96A=]M#Q^=?O-[@5TXZ
MX>0U)E.41HNL:V6D$D(KG4+FC3Z*=N>#/Q2?&7,,#ZU)J)T0E$93LGGU_UUY
M-7Y0".:H7+Y-'.J$YRPIWZ5>-3TM:B'JZ"G*)2]?"MV3V:MVA+Z)BUUINOR&
M2]+#V7FNO$XX@QX%>(B\)=C28+_PS$,C4<;M#);A$8BLN/,D/)(;H<OZ9PLQ
M\!OWY\^H 4:3Q8\Y)O4'3Z>R*F8VH(&I=5B#AJ_K3O6>L^:&-9/)@X@@\0&^
MW*$#SH Y\R?U.ZJ_MA;;8G8D1\TN-J35%"=WWY,EQ_7<W1A2SK4M]LQR-=6U
M?-O+GV&QI=P<T(3S_33:0];@?U240)S.=]8J-FW63[=M=Q^ZG)GK#/>H\BB=
M%%E]G[BJ_W\-\7PS9EI=.90XN._XUECW\-TKFT5N(T(>>BZG&_,7PX.&HW^G
MK?2ZP<ZL@YLPGPH@]$N=S)10A*#-0P(?2WP>&47QJ5./58_\JV2065'DP;@)
M9&#KXE#PX,714_.&3>,J#(VEG(\C*EN!#B</S&1!YN=!9V5W08_-Z7\1"M5G
MP^A;S)A(+737]6-@Q1B) Z&']R*_&!GAQPUT#Y%(,.EI6#3K*DJ'QOTSA8(6
M9<A0C5+("!Y_>BXL0<UWO+E.8)VNV^X<%S+P+[EC6MM2^2/$(O87?=9/X(!]
MQ+LSY_JH[Z3P]0KS$OC8^B79>U=-=F9N[/O3%!W-V;I>:?D+*GO_#;I'R-N>
M7:&/4@FID(='H*]\>VE?<?1#UA?JPXS#AVMA^MQ]FW5U711U84L*.&;^].C2
M)$MJ;0FZ@S+F2:'[=$XT<YK%K[6$Z>C:<>=PL _2LF$I@X!Q8D,^[NSSOI]B
M=3R^X0\YV7+O*=^]\LU3 9Q->93YZ"O#"<R;6!?7-57@-TZ:*HZML2NX9'T;
M>TDV=;.A6=+(.X>B/%%C$0N6BJYSJI7FJ_ LT-=>F\A?'<\GGYU(3'J4C!7\
MD1XHLXF)7FC1W2109<CL\2R>R&\$2=8IAO!(,TP06+"DG@.V:>I=G:?&(A49
M!C2].))^<VV.>G+S_^+L/:.:VJ+VWW@L2#/2I<8"T@2D=W(4!0$! >DE(M*E
MB4B00%2D-T$!02 B36I 0A&0" D@TJ1724%!>D)S"RDW_N^X7^Y[WC'NN!]@
M,/:'S=YS/7/.Y[>2M5;417VO-=PL-C$LBM-Y+( K1^?ZTV_26>>:QC%_/(&Q
M?746#*4P>B$?XGLMSS#Z6Y4V*@ZU$*[T]+TJ\5"R<2<AJ9 /^$DY['&R_'QF
MT;MC*EH<83.EEGYZP1'0[2*R>U*&:M NCK[O+!MF';]LA+R/>ID_A@W*[1".
M'IE5BMF%QL/X.P0<_&;UL[,DL1BVI\5 $)73K&-2:5-IAZQTU!]=:5CN(U*6
M&_#.R7='V.U@/_RE74,KI@G;U-1$/P,T1)0S9K!LM$B*#9FMJQ_-S^UVLA'-
MY;]P7&/R<?D3];F3N%_1\F-HI6,UW M9%7_LV55N8@/'-H-V^[$Z/2N+T&Z$
M^F*9.RG-A!0>C[HA 1EL$>IQ@8))%)IN0M^' >\S%"9(Y-['P'_X%2X9GS0X
MVS/6NTAZ%L>F_77Q>8W]D<*>./_G9=M?,05*SAK$ 6PJ5<P,7\CKK>7R&]SE
M.*G+G1CGF1!GDMQ/5:^W@-=">B]-"D?I?+1U>I#R@-9I,IJJP^^G\[+77;ZK
M+ >O!,C&TWB*R<WQFP@E*N?^'_I3/=MWWV6Y_2NCQR#'-KD4M4TVI TN[]1X
M)U(E'W2>5VFM"DVQQZ<R0<<YZ"E8+Q//<2;(BP#(Q:_K4RU)66WZW<.?AQ.A
MC<V=D^.[AZ[=/^([#>11/=9?,N6V7LTMJ/2'2F<%\3\X#OI)8X'&L]P%FBY@
M3MZ*=].G5S%!WI8B"./1=F@)X$S"IBL^['_CJ\9M?*W!]2(39$_=+U ?'R2G
M6FS>X%ZO"I+"<+Z7-3+">"5A[1#'#SU\#0P JR!J,@YY:IGJC?ORT-79=L+@
M'-SC]NA/RIWXKOYP2+(ZIW]5EG^"VL;%M9OC[1,?E4*X[*JKO8*%F2 'V(WT
M8_#,4IW=T%,:GY?5ZE9+E!V1<0;23) ?R6/#T^*VG^7QSI;W=WVZ_/(K;W7;
MX.^455DMQ;S_R1%-8/.:M[_Z?+M=AS0_+(NW<:A&<BPC;#IS:^VMW49&*Z"5
MI);,&I=3&F+U3=[9=IT>LETU2IXIR:\J>G>FR.@>,' !1>-'$N% ^N$-H(TX
M_.32[AL-E#G02TZ'P)U)/6B2]O(+9\4&8E!JQNHC)_WU!RY&?5RST1\C6J78
M0P-.9QA&^SDC.TT@#/9&_IR_NWU70NJ8(!I_^K[CR#,(<)O!"F\T]PH,,_5,
M38;G2#/%J!Z27'N>.B 24!N 20<[->[75+K(]85POQ,,H1\!AGZ3>C?"*#M=
M$O(=]#?MAHL$=G@#3D<HF2&&N$&9+"HUC(+&(<S*G8 8G-L%2D[B_4G.'V/J
MY@;[O0X?KIQM;$MR$%F=Z%1.3]<+I8KNOZ,7S!E38H=[?[6SDVJN!-VCZ#?W
MH$_ _;LEU#Z-KDLVQ2VQ[_W!_(%B[HZY;7\%31MRF',\;5R;+-UM( Z)X<S
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M,FNPG\4Q.IN1X X9DT-KX*@1BBS15L(81W&C$1>*AHEFZ!,N:Q(\EL)KP3/
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M DYT4(*-?"/VW4MII$;EQ1. F3^T _3D>\3S%OT[D%MGT7535%$RC^KF"*$
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MR] IU $\DP_CC_[(VWNHX<\8.W0LI4Y3J-#"?8QN3+Q//! \T=#8#H]7$V,
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MF_=M]3NC4[5HN(@<KOQ5W025KKL)W2$T#Y?2@&P@DV];> J0&_G(0'T5;Q9
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MW$4Q"542XP>?I#EI*KL,LJX<YX74%<WQM/NI+IU(:=\Y>]>:F>K +]WP!$;
ML5>G?"VDC11&LW4LM&]C*ASN:KFE7<F?6XSJURJB*XOM^HL\"GMB*_&+ORS4
M&/Y2-.ZCOW!WTCG.1ZF4/R$G8EM:;N0:XF3P5]E*]+U&C:#&6Y#\'JF,F^";
M9!ANF?Q$D7G9".ESQ:7I$"CSP[;<@O?AZ*D#E+*)VDW8>_).4=<F; ^"2[I?
MM3(_L8?.1*>3Y--$ZJTU] $D]Q $@L4\"39N_U]Z.H:+VA/K>GV=R+U&\XX[
M)Q82>-UG'CK6MK7TXRXW]8>UO:)3@C9>B]3QU8(%<6&VWB*%4F2(GR9D-F$8
MYQW$+HJ,, !P$..]5K%Z(9XZ.B]F(<(Q_B>S)7*AY! !]5HTH*8U2+#C52>Y
M?:UJFZ0G<ISCZM)/ZF_Q[L('IOJV(KXXPA1<+OHY-30,*3M)J=?).TU&'I<.
M/;+E^]F_+6:VL2UU";L 7"=NKW +Z)GR?64^U$$0#O5;FD%[+)1^?!SL7>VT
MXNJSR \/]S$?C<T.]4[,(($4PC70O?OK@D;O$JF!6H>M7D34^(Q]14>[DXR0
MVY"3+_S%_H^/4!$-(AL"5Q>+@6[N:OKM)<X]4L()?&TGJ>8U^LV==P& &^\
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M.T;A3ZN]NW@)^XJE#KJ<2ZDX&/PJ*47Q+YAD3@KL)ST9N5ND)D3W$0Q*"+;
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M@^MPJ"8WD.KTTPB1ZW\)78:6D7M#_ T 3S' Z0<)$?SN!\@]!'1%L E-":=
ML(1LJ1-=7+@4-L?RX,#*AK(#_4W-WEE.5-+*>G1HZBM?>90@^O^,-[T6R431
MDY%[RB#*2W3["ZR:(J 9+[P+(G_;(HEV\F[HX:7&02.*E' O$)2DKU>'2S!5
M*H[&PMZ]!4:-/PI>#:)H'Y?DUE/^SZF?7VQ!YD:NV'WV^ZL!561^NB=/,\Z(
M#H.>0Y^XFS F^:$("<([NE.(6T&%-:5:KI^3V-.J60#4KK)W1:IBTW$$E(B/
M_$HMDPNAJ0VN6)R<51N?944($&]M%Z;+A;#>3=CUE\+=N'!@R/Z++L'BP)Q\
M@15K]0VJ2[6?4UC!/\[,1_=';M@ORHQ74D?]&EZ0PG6ZS;N^R:$]7?Z28TA[
M@-;;Y6RWR]H\LI+6>FLM[?+R/"_%4/(16P7V,NF%^U_N,)BV_>^$J&FU46!Y
M !_1B52C_1$,0 E#G<BZA\&:/,\DB?^KN6^/2BIM^Z:Q4C/#8Y2F9)96BDP'
M<\80*C,K,[*3J2EO!T,TY.TQDU$$LQ0/J9633C9*9FKE*1.RE" %=*83J:B)
MHPAT\$3NG8I[Y."',\_ZOF]]ZUG?6N_SQ[O>/ZX_69MUW]?U.^SKWM>=Z>DO
M64I? <0W7KYH3S%[,VDM#PCWVLF^&M8_S#]W+7K[]![SQ,^A,]'KC>1Y?7#U
M BA<8[M;2FG-RY)Q$)E<-\<LJ>.M(=PU%ALOQ&='+ +&K4:#O3FB"29MBT*U
M1RW8UUT[4?LULDE2(PD_N.YBPL8+A+CYA/X6K$)K5FH]= ^FX8L@IBAB/20"
M^MMXWS'#'@,S0GP*RU8; A 5"Q,1F6M240FM,X-N0.1 0>4#*O&(9NN6DU&-
MAW\GJ7_6'(A9]>8=G7,O!;=M>@X&K?,:OU%'T'J7H' *1OH480$5;=@N@2ZL
M!0N'ZI7(I52X$IZF1U K0T'QY7$>!L('\)D!T/-MF4J\%94INC (/7%KKLI)
M.-F-KHV\/>%B/NMK$]1B\Y^"51=\EY)L@G9GKPKRM[NZ5YFSXVB.S:+=AVR/
M+H+!-DP=,GY+>(K7%C%5MG.PLTGM_-D\0G G9S)8E3\'<RG5^#'Z',$)?5EO
M]U0-S";([_]$[^X;CC_:AJ\][N]_:'CX995;U=G-C]=NOKYSX966RJ =R&6&
M] ;PC+Y)=31TBP'ZRJ?XUM,^X1=E*Z+H)O,ES5M/;6BG+X9^O$O;"3HPLS%Q
M=[7+ 48&.I;-2"_RS\;L+!^1IC\GRC^@>J;'[V9^V%$29$CTO^']TX0T6+T/
MBM$$[1S*U!+F41@&4@3)Q$,]7#B('F((Q=8T)ZA8_KMGL:-F1^]%U?:V0<NF
MAA[GCGB5\Z%G3WHNYKN%$OP_W3XCL_I^JBX5N8AKI/&A>0"%K<CTQ.3/+#G2
MF*1H$W'"]T^$]<8'W':H]71($!:I[WX;]9Z#94PWC[A*IM]2@@K"5$<./W_&
M?7ZC_%9.XHN_8>/C',R>;CG"7Z6WCYF#+>4P[+2'H>1*ZM4/R54BW&*>$_6*
MG"*T7S&.5M6]L</E<-$78FI(APBZ.^/>]R_EW^5WN3;5L[X_N;=2\1M_Z!:_
M0=380KC*6%C-6ZV7)";GO;SM646YRK<:9Y!PF04R>ZZEG& QTI/HT0",[8$:
M'!]A0HP%V3KC@UT75])6Q?;OM]O&BCQ]H_I2ATKG=B_E!UR:;/X5 $7>FZJW
MU?ITGGFOM1V"+R/1EP.#!;F3/KS"^_WKV.CXN U;!D<1?G83AR6Q(5^G'78E
MW1E[OO;YLX(]$_,>4CL'ZYZ##?TJ,_5$2^-$?$XZ"TQ0UP-YPCS'Z!(+"9=H
M2.-%],[YK_<]@09A!]7>K^$]!G=O5+9TW-,/X.H=F >?Y,1.^;$#[/_\]/QY
M4VY(;>0E'>Q>"B97-A3<VH_.*B*TA<%-2:$)>1<9B\<B%M9+IL:V!ZRPWM$[
M378-E72K4&1%5L (Y6*8D^/=/YO2>U7+,U>G?C[+.&D 1+?7]"W:M<!$.SI=
M[PQ%*G((;1&.G5H_VT<&W/,')D1%_,N8G^1CK^U_0X]/,TP@\8Z2_E"@AQ/C
MTV02[[-9X?9S^KZA/TZ7^%$.&XIU"S?8('/*#(;S%% IX)MYHNWT7<?_,4Q8
M6<V(<O!5/,W6[-'NZ\3^2%4J!O/EOW.=[U$;%6A1$NHPSAKJ&=L%?"R0'LPF
MU_QQ,H3TM.C<S8*>X8N:2X1G>CC-HP'R-)3%;BCIE)*0*;,@7]QZVQDDM"&1
M,7QK^NIH^L6:#>2X-OK:$N6)[I+-_4XQ#T^(5EA6V"R(*/Z[)']""%F7"698
M]QQ3+D7NX'KD&3"1@W%5JKS_=*\>DL SN+95TK$BF\;@U[&QL>,*?D/*P(=
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M' !OE=G$B\U.0F['(98<G_HMW% _U@;OY3A(#?TVZ4>Q_$ "!T3$^!^NO$I
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M&BG:;M=%0$PU"53-" VRM"PF/TH=;%=228RD/(@:=&-GK0P6.B*:FSLQN)K
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MQD?8B%_RO)#B-N_0ZH?B6_81L9:VP/@HG0K"A_X.8&)3>2@RA"PU;/=>L=1
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M00O9R7'$H"(HVHORM:;H&>P%1"2ZG2)(!6 ;9Y\MY[?4[WKY;M#MI'^*S
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M NLLT?M7E -6I/S&PY]40.MC@2]SO\(CS6._J9#\>D.^!K8'O2+33QC,P*D
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MN$SEE:\&[XE[S%66)'TZO?%?+3\TC#<0)-W2FJD 5LC7'!0;23Q<NQ #G6?
M@&(H##ZS^,FFH 4?B%A;UVR4_ZO' C_ M#@OXL4]>VUAC YPO-/KH4X^US &
M)$A^X?1QI2,7:$N8"( 2*"R_#QZQ=GEBJFY$M2G!. @F&&"?M&3%7UZ?DRD<
M;HEY%R,_JRD:\5\J_I*XE*-G HSOL/2MT+R^.[7=IUC(JW3H&^)QP6'SI/98
M\PO&*MXN-4L@&<^1 A=8OKP^!395KOX!E_RZ/>:X5>,\C3V(;PHX'P;5Q28D
M^'DT?M.4+?-9%IJH$];3B[TWL7<-N?M7]9^=7[@W)UOML@N_YSPP&S-2O)QC
M+<*1H?'C2FSSRT]7_](9TJ&/41^IW!%;S,_*]VM9B&A9Z/0[\ML>?V4DDF$D
M4ILQ(=)B%&PH97\M#^-=M[<:[I6GE\;[RD0S0Z&ONG)$I.AC1%%,24.9-E<8
MSZZ">&*(]^VN0A#&*>!ZC-];_U8YMJ6\@)-'@,_Z7/V>V/=+V5^[Q+C#.CX7
M!"?-E)W>49T^[2[I0(B,%S8#Y\!#5,#%9H&#%.@'_<Z*,"M,S[NMZBA]@E_M
MXN("28SP#7>&DHP1,#'<]\"B4CU:F,'N.&83Y,9403_W&^C52:^\,*V-E?0]
M=K1\"FI!"!@-LL$R#*8ST"=CQ'O'^9*=0%?"5'ZTO7#N4D$N;E&N8\>FOO 8
MX6!Q!R%09M_B;%EE@S:.7F!5V.A@3A'G9%E75FUNYOED\V;Q];R5V.;7K'<5
M@$6VJVN6U:'L;OD(;FWN89R)RV17:'E8K#T6.!3 LM@]&Z,M'6:OWW-]HGZ-
M!8A_5/&(T(2SBY,O#?*H"?.R.2<7O%5_%2D?'#EW?>KJ9IS]@P=5F 5347[[
MIH)J*R/'&W5<=;Z2HI>/:HQ5\/Z!227D*#W?\'M;5GUZ7^4="68!H=D'MID1
M5@.FR\ZMUC7:7A9W@O"C1W>2"/UH^3UA3)WT@*-\;_I\;O]I:#\T>3Z[$\88
MUGKO#0IM-P2.M$X9CUS9L]T4*1+$61N)<((A@)DBA\.-[J9DW=DH8Z$?#M$P
MY^E*ZV)1/KB/G+>9K'&AH>OGX/7NN<&FF;S!"CZ)$6/IN>*7%2\3M%1%P9+(
M F>IR>S,'S5FMEEBF69COGE93LFF619Z#Q[3V!7@_Z0)*Y;D/."RYOAB!J#+
M,-("-"C/''E-B2L,&38EIN=H\/$&KJLV;GAKG>$#K+>0S*L>ZU3T$;S.[#,5
MV; MI0MW1J\+!K;.I@G]R?2S(0G(U81*X)Y_! /#W0B(X67)'"=Y.A+H6U?.
M#,D$\IP^HRN7H]>S=-/VO/V/:9)NK8N]]VG4O1JM;5,9A6Y8,H@S>#Q.Z!)L
MP"XG:$>C>V^I)8Z6^IF^O^.')7<Y5"LD&'ZKU9^5R# 4^F7=Q6ZLM,0_;C$5
ME1_?[.33?O "=3'$G'7)%\&N?6VIMR'J#UQ=70DAW3(5BG%!:XF)^M1J"Q'N
MB'NI0(#?'K:U\X0^[YG#L#Q8M9SVSV.^E<PB?@__3DU3ZXHJOL6+0?-ZE8:]
M#$=!U=28@G5T?I7I5R'RE?-\UN6XMI=J4_E9-UX[]'4;OTX13TP?PD@_0+Q7
M;*_T$%2S&?9P%K8MLGI1O<$?<EFD4&,N7A19=865'[[5>R?LB[7XG6Q-[9O,
M'Z'T!YXXP8I!MU1'>$,Z1&I -%.OY>4]"CW!A6O1[TJ'07^WV+[:0%#_X[V*
MY; 6S.2X$XY>.V2HE/[IDG'I9K5$O0S$/>D+6+]>JL2W@.N*%G]@JHP*)QOW
MXHWO]S0YX G%#))JR K>"DGCI^M5ZE]=VBYV,N9,9%^15>6Q]&^YWFUD7"_.
M\S++@P_3^#HIS290+2E)P;+&UM)7(57M*?+%-8YW4588& M!N+]C.+G+H\%'
MFQ>+2-A=FU)&7 *WXN<?9<+G[L#+VKIZNC($PJSH+@C=GE1G'^+[+KE"D2/Y
M8.UZ4[E'+7!W9SOB6QM<ZC-7QND($;-$NZ$B]=ERWI:)+N62LE?* ^\_V7CU
M=.:-&[_3YW!%Z78H9ZXRTPS)2;D9AC#';>RY>YW/K]C,_0L,8J$"O%@TC@ZZ
M^%:^=3Y"1NFLDG4LES2AJ[EN4NN1SUK>8V<2A 4%:Y71/N2J$*4;GP-M:L:_
MH_<GLQLL/R0[3VWJ-'^9F:R2MH17:!8L2HY?Z5>T5VNS*-_!".;*56<+>8:-
MLUN(?\J;N3R]/4V4U,TKTWHV>H=03 0/3$B%(5;2=^%A&8G-DGJS\=KR41'O
MH$N#K/F/AEA"T</]T3HFYN$J'UA?8;HCYM4.WP2+333?&JWLM":XE48)OD?V
M  E>.DB2.MKO_)0C(=1TTL^C">F![!H1L8U1R[8>$VF0:4WK'\O86L_^U:5P
M:H5V2],O#@#&'ZG:=#<E6IGF,B4'@3GBN'NMI<I:-B_K5ZMTW8Z[(&SCOS/4
MP]&,>Y2%_\I]B_ADTN?8!?,ZS2.(='_T3\&P'V<O;(@ZZV97Z4OE",EA2WE"
MODQWUQDI%3K6^4AE-.=V7NC+2^&Y@K7&?;=)BC.R'5(C3GL]7+ -ZA]B7BHU
MDQ6_8*"_I_[Y:4&UR2J3U-)1ZDQ^:*!')+-."%A:3\ETVH61@8&0M2K5'^_,
MWEN=S? GTK0\SZ<):>M3Q^^SG1?YMB%/4QU"!3""_%'GRXON:5\AU]$TD=X?
ML9Z#Z&SM(-1A@_I;>V3?XP*%$YOI"9[HMBZY;V=>>;,@.70:X#MK*-X%1"+"
M'_0]W1#9$]D0STR\'66#XZC\I0EC#6M8F4WNX?+)-*P9ZQC!F-ZY8!L.#16^
M\1P4UM=Y(V*4DP%K?B9MP_S1EGNU72F4^ :N5]?]H[D[J63MBBW3?3]3CW>!
MMJB,^NN%_%2 ?,UT#50:%A5E2'!:022=7G$43U$:*OB^5%[Q%IP7-581EMN7
MM\@H\JSC..YH](E\L-^#.;$\B0/9AT::B?M7Q1^.N9JB P1I*X/Y2Z7Q>)A
MB%7]EN/@YRTJ@(6B;,+DZ!B6H?O<#^WV\I9];S%AG4N:JZ?T"14PUR/=RNZF
M6[D(!BUP/W,SG=7"C#,1H,-"5Z:[Q#%UBBC[;\J=MLV(=^T,%RO$)%>RF<;
MX7YBHLV=K6$;,3I93YAK?)Y_6>5GEOU2K&EK(_G9(N;#P-KTHUD5>9DJE6RI
MU#(<KYWHB^'!IW8I8 .VI/YH(9!T5DW7N$RVII@?[Y!B07L.CV*I.;IW_4EY
M?HW9;!J0NU3&]:PYC$W2(D>8,7'S)6W?0L]Q09B>O9=>2(>ALJSA30\?H6$
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M2M46YL6[S@LD5=YAUW.80WO):;U%GG'HT*+I,ZTMK_P[ZB( TL^<M!B09Z6
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M_P?;^M6G6QMK1C7K_?6;;,[X3=?>/VKGW.>^&0C1T='-3.0<ZCQ"U5 P.YM
MDI4;5?K'VE$(8UQLC9S6\_(8X ^&+Z[,DRPZX$N:QP#O@HAC0,\2V1/DMD<
M$2^M_->D\:<I;0=/;G.1.0'8%;>465!BO-D1?)@$,SA,>']#FXEI8]9-3+16
M93C/DW:9;<S3@6Y;3#2+3^M!TG+_HH :$P52C@$C^XQQ$!5"<V 231V\6_,K
MZ)=[]#'@L]P?.!ZK?A">Q!#E_8<12YVGL3&I59Y11<,PBOC_4LPRR[,%AL$H
M=C";(>+/A/PE)N0WZ15PT@ZDE@EXL &->Y[!IG'.8&ORR#H:M%Y#_5OL=0QX
M%?(6_AUWZACPW&Z'280P_^U=(3*[$GQ7J7>S8_R_,,QIE E[C<_+&CI1G/5:
M_X;P8W:8?#8^#]YIP.2\R<QVFFX R<QN3QX#_O&I) W3>) ,-K-%L/:@_S1H
MJ;=!;RPL4MMA*=^SN\8OY?:KLXXI>)E:Z.FLR5<_ [_BQ$>SXQW2[5)!IZ2F
M*C8:W9[0#H-W+T%O#>8:V5]Z:F>;S^JTO,7#8,0?1G"VS). JZ;^35CF=-(N
MP(:0I$#_K4I2PX$Q'G;C5P<K_7V;\-GON B_X!_:P"6-*O4+ =J:V[G<Z*IU
MK_B0IG$_A??I>JS:_0+RH&K_'_X,-KVC:_#.FVU2 950;O+=!E?E$84/N3WS
M;&W6-> "+=+4M4KC&Q_GOOM$6/+^NR$";!I7^7'K@HO+G6>?[B)OY)!Z_3-Z
MQKN_VUQ=G^Q>_+D^FC*;77?P2#/,5WS]]C7?XN*I/0$[KF6'-H2V#MBJV_$8
M8-NM9UDIY_U'9\VJW*/2>E5&HM+8ZG?)+]V7?ZP3_L;=ETV^/^1<MOS/9NP.
MZ$$?Z']&P-_^CU?GG282M<_-^6$?GFEP#/AO6X8K_Y>GYW_W"%PV:P$!5[QM
M?R'-?LF*_Z>\Q"]ACQ'-Q*KEU7U:\9L]-\P^ZN\?V0_Q_\U95>6& QY%[@I2
ME]<8=Y?^9_C[N11FMV+7=8O^C/ZG_KCAR;V[^__Q3,G*(C2!F#WN6&"T&ZB?
MLY+'M<K<[L<QH!%^JR;T[X8-H_S_N-?^_6]A\2>4:AD2AVD?$J6E_^\3G6.E
MC@%^2*I,ZHLC76]_DM-"0<8Q@-V)DC#A="2)OSOJGFV'AUZI<(473?=53/^0
MZ/F&)O*7I*LWD,9CU*^KCI94ERK8E%Z8U0RJ5+27PW8J;FVF;P]+:0XK?P-^
M'OL:Y'S_&16B>D;NQ@3&T>TTD$-?O=RUW:!8!F_RZ^<6_X#QIALADM) 53V2
MA"B:\4(MR6>ONKG<"6":A?,Q\N*I2STBLFVQ,"=?J?NV/G$O/"!%;6."8CX/
MTQ,\GW*@R)SW1T"^&*I<7*-B3?5Z3OQGX-05)1?YO4&O;=]%LFJR98LA3XL<
M3CTYY(8E2';GD.$TS &>#/ATI[3+X[&_#SV;*8'>B8"H[4MZ]!+LPOL6IAJ0
M @57&OM7@(%L^T+D*(^'N<F4CU3,EP(?GIH:VPM35,L!I]PS$Y[J<0+HI00L
M1(6NBS/\6#NZURKGHF6"WWK_Z>/'FF@Y)RTM8Z\)H4@?)R\;T>@SHG=3I8OT
M[HW8V-P$V!GH:*ME-GM/.(U[DUZNEZ-:G8)T#D,,<#CYX:85XPO=%[I_7E(D
M9 'CP3:(2\,JL;\%FU=$,XNT=5B+BS^M*Q@-R=:N)&8R'M#?P1\I/<=^BH]_
M/]K!![D]KCK1<$\U37A#1J1H23CPEDA_<?.XQ_T?MYX%[H!SM"-@6?RTAD?_
M &U&](*,+',#,P(S9AM#8?'1GQ<^S:C*\[K%%K[L,D],D=<5R0-;1KL4_9OA
M'VXX9QF6F>O[\4.BK.G'_Y<AI?^\(0\_A_*0K^,BTEXR+D/<[I+A<2'V.7);
M0J[XK7UVF3 YT2%!T^2)@V?;2KZ13[_/$@8;?,!$A$W?HGKO,8 J:="K-)7=
M38COPU*ELM.T#0O=[)O'5$$QRFXF48J%/A?;=NS!2J%/&LD*,5XEHB/:AOZ5
M\_WB-;GLF5D\WHP7O]!@VWS)/XX!<&YQ#&M$S]JN+<SSFR=-(9/,+3,H8!0<
M\ ,>^4_.P@IIJN#DAXGKN(=KA \6B.(UDV_)R)[3FY,_^S8-F9S^#LFS;W#:
M/P8N]/0*5>_HYMIN0TI(D?? H6T"L=UQG,"Z-*H[-T#PJ_,P4US"32JW#Q,L
MP^JM7Q2^@#ML[,(ITTS1XT^3H:.?5FO;E;##X^%"51\<5-)>.9HTO3RR]?$X
M/3K8\\;Q?89EHUTJ]TMSCYPCTYM;3S_YR;C]S4+;>@SP OY(ZVOQWQP_BOK5
M,OX[-GU%6*Z3J<[<#Q.LO%-Z^H*3JW'%^]>02MQ(EVU8SIP3\CR8MTQ^._C+
MW/B"8(MY5=XOL&I5F7JXXG;ND<6&[^20V,K5&;U<4GZ$@Z=@_\/ ]8R4LZU)
MORQ_XFQ\R_"%^2/QRI\?%B1MJ!^V>X82 LK-&?%E56A.YY$VDZ*UCLLD2KD[
M^E=$3YY@'*(2'&8^MW88BQA@O=Q2U]H8%@=Y?)NMY8;PK<Y_.1R708;)11J]
MS](S'V<62==+#RC;62;9F:C@3=1RPF[I<9O_;^*3:<C_)*8>Z5 @[3%.TC,9
M%WWL.H28VEMOONY!MX@F.2YGQVF]X!15JGC6$$PT,=!K2X[_-$ES"O(-6!BZ
M:!F;OJK?,69EW?!&JC'UW@'.?34!+6CAK6Z9N2JW@T>=:1XKE_,>$\W]U%:\
MQ8^2S%CXNLLFX,K6H=D^(]WC>*%1U3'#FWM-_U#&-##9;R_1S_+@X501^8#!
M%KZ(.0/!.%*=CM1I:G]7!H=?S0&;?;6Z#X>JFUEB.LY1I2S\57G[NN'G4Y&8
MF=GUFGZ!UVL=0-)<I1^Y3]2LTF' PFFI'^L+I,KHEZADUW@C/Z%B%M\,&BQ2
M2,!4[<<39>?N&G0GD?_IJH3<HT^]]5)K.@8X+ <MIVF3^N)4@*>]-,/BM*^5
M3J\)BF0+I([VCI^4/+B":LF/'PZ(#+M\W=7EZZBS\X#QH%C>H]!V2)LJS^ =
M=GU#Q_V JY3]"H??TM],8U7VZ\"CIC)E+0B%(:4^<IY5P2/9EB0A*U;3K:XX
MKK'",_/WFG>.'*L'':QS369[KYHAHBZ2C@$,-C@YZ'.&PS1C''EB[R<I_:.+
MW1++9\R%.<BG0?W8GS\(F$28X/JAVKN*7Q$2T1FZA>'%5%2/>CF8.Z.SQ$QQ
M^@D=1N+L!IZ"6I(*TI8P\062HU"716'8A-:0F,M(M>W*P#;K!>=_NH;\ _@?
M-/*&6=P*\Y%\V!PM8_,:#C+ZFBP@@,A<=C"T_3?X<O)Y@S)5) EK3ZT_TH80
MS/@80R>%RFC&%7?44QB ]8MU(@!J1E"0=*K+'=S$=-;T9_CYDEVA_LF]6ZBU
MPY]?43V4B+4&/&,HWXC_J='!%3,6M^(BF2I5 \*'<ID6K@C"L^P:TQ&$9D#[
MO:,;4H*/I&UBSXX/"L3G)O.*JBSM5R@09 94BGA>Q3M$=LR'R]B$OF2\J422
M[6*U59?2.+WG+I)A"2A($BYB.:]!L"&E8EIB'+%5-6"3?F^&JSJ>ZY:VB7!/
M7;]P3UN-V:5 I4PH.U.C$B!/&XSEWFL<;Y-;0K*9^);2#*@.Q".#$5H4:<.U
M8%9*T"U!10N1N"VM^-"C=20D) 9\2$&HEJ)17RB- 8('$3N>;'6R&D-&^?8J
M1T9*AOH6/BUU1=*M*F,?"&!D65=P#7?FHK1-B86.38F @O4'_'K^DG2_%&_>
MXPP3X#N8#FFUUW^*#W>@!N/R/T][0$>(!05$?3B=:TOM)"D9)?,5*/""A0VZ
MW6(IU\J:?#577+1Z"KCPFZO77*A]6S*GL$&D+A,QXE9#2B45Z/!QDJ9:U<FS
M*7(9+Z[.*]KS_$G8V9JA4Z,O/QFS-VUA?)<Y.+Z>'TA]^;N%"N\Y!C#5Y&38
M60C*D=IW)#8%5G/,:@Y6!29@:Y?IW8)F.&1B?&1_6 7U(=C(D7:=^GK%T..E
MTZA)=ES(X'12+I;?JZ7G9V5H>R):V]&[,D7>BNK3JH\(]V6,C.8;?+ 9+Y1"
MA_"NND":JM"]]9K?$8Y-]G45[HA52X3*;\90Z$PYBFP^$1 [SK[3E72D;CA:
M%:R@.6_R,?F.#_B\N:GZC7^43:X_.)VN/_AE]9\ C1,W_UGE3&!H,F9:?#GO
M9^9+?G/;2[!><'.1$FZ9[@KZ*"+^J*DB4^!G\#PAMPO+VZ8>50K1"W$[1QTT
M1!Z)$<U>0$T\U5*6TN(=:Y+?!2N=_]5HR#&;U_@&60=NB<]4J#>1M0^1X]OQ
M$W/OF[Q>I&F5Z=W3%1 :D+5Q%[_; D;5FABJY3QQ2'4W#9X08I5N,94Q?49]
MVE B4C%1-Y&B^F5\[+6%'O?P6?-[EZ-O_7N>R8(#SXB]OO7SPF@;7P^0O<UJ
M$<L_3"ZB0,@<&!PR:85?='+OJ#7<3U<(ZHQ7$%Y)NTU-6QQTV/PQ5Z1=60S!
M&C1_&M_K5Y2(I.Y_>53;6'N0(^=H@])W_NYC,ZC1+W.[6,BDJUAX24-+<DE\
M?-1[U+!X?,8Q,+E00MJ4H[?D!KJ$M7<TN='.Q$6=#]* K( -@^K]8V'JP_"%
M]LB[[50G,JZ+=(7<V 7D<ND+*ON1_R*U?E$!_*"V@=SX4FF2+J=/YD#DQ_X\
MA+XVJ_**$,:W9[K9VBW;=1\#8G2%J04MDB4!4540X[X"SGQ,VPGRG2X^F5+(
MQN>6K"79X2)O#Q&M(66'!%^K+L*89EIL"%4D4CA2?^RI7[7ORAXP&EL_F4"[
M1LP76T!N>9Q+6QSF7S^XMN;&T:$"OJJ;2\(N"7]V..MH91@DU[DP_VIGNH]2
MM*BU\3:U^9)C"2/6YU1!;L"_85:<IFTNSJ+>%J8VSU*:35E]9!:7)9<=T\>;
MU&7'/N1F5)X9*-\3@ 6$G=75M4C17V*SKY3&HZ4>%]G(Z:> =7C0^E7H_LU5
MZ1&0'E,5WQTN_'^W6_7_=.RZ7?CV9.RG,^WCA[LL16>S:#MRHY5?]EG/-DX&
M7AS\MKK?!T0 K#!OM&6. 7P7*5U4)%%@F*""G#KZ/,=/!1=UPWQ\X/S06WAY
M:'C%AMI/,H6\V/X$?FZFS?-GX[SOY9DSF.J<N[&.X'-BL2)@SN( F?0[\Q]D
M=+3L5LQPG 2I3M!I70%J7^\A33 [N4.:%D(OA-V8I=V@>B[>Y9O3H*:@O.;/
MMQD60RX\E1^12A_4Q[<)@U%J]42M)G%\,(<B>[X1*2IKXJ9NKCC*LL"N6X-@
MGKDQS![3?[5";B[EZ?P%V1^)V2U&P"F')QYQE:'IJ0I&)K?N_3&]C-%;R;L1
MC;%4^;A'MO]ZP"?3>CM8^:FVM'NY@[_5D9OJX#7K=)/F!S,/\I:%8-&T6]3X
M!4RLZX4)[3 R9W=$6"Q4IG"ZOK>PTML2<?\YM-)8"S*^72^LO]:' *-^X'1F
MO\9?Z+9QR=ZM=<%2LX\\^4O)+J@$&"=LL(H\LX;DS/$<U96$/JN?$:\?AT:%
M@67@IZCG=G32IZC&)EF_G2;DBU-W#EQ&/'),E-D/6;K\A:#69-=<<CREI!7?
M=H>8K[;@1@-1;Y1\G82S=9R7#)MV5LP5SW"@3A-/<L1M] J2Q^&?/)(Q,=EW
MC9/VFP]?O,M_-_LN/^')$XEW;_.RGMP0S^@73S>3;/O28@]:U!CO055?<1A]
MOX?GH.WS-G8;2O#1SLQ=PR@^#7WD=+5=H]R\$_0GF$[X@9@_CV^3T7T+:>T'
MO_)5U[\1H992# DRQ.\!.=>R-!43BJ<-/$O!FAYUMJ&\:B/2UG%S<SS6MYZS
M-YQ-[WB,F--_HFEMX8QNF/9E_AI#I\<;YM"-K1J43X[BZ<;,4UOZR*G@#FZR
MZFILB%>]D',_:W=80_'K;-MNVJ^(K3?ZCC( +7$VHY9H5,Z'K.7;@2B-;QR]
MS[PM?((G]RNFT"+QLX>N* _TVL1A;&:"3LG,K3'2S-4_2V\B-7]6%IT]3+Z
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M4P0[_7?-TAP4!4,NN0VKT_@\&6QO*F!?.DXWT'-USZRG>)!WB8WQ/]LFM2W
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MG2$?9NVI:!N5Z7S)145> 545H&?TNEPE^)I"W?/0;#>2&9"0BJ?TF?V0A7-
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MYLQDSA]G]MYKK=_Z_?;99ZTLN;?%NDNSRQ"4S$Y B&N"YXB&SE<K@YE 99,
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M=.\E!QSAHE^S@3HS*$@O(62+&\:K]E;:[.*Z2+[:9A#CP4$3 9(47E#4?@A
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M')!2/U&HPS3!@GO03&E&<EVUP?.W*E^K5]DBS!FTRV]<J>^FZ.41_1 T5X$
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MA/IB'+X@+?J.ERK >,&TWA>/=#JR],V_YU,)6]/J#"P=N%%!]I,W' F(%*<
MN2.O3A@HN,$K(#F?:^Z$O9^!3DG&55FB23!,[9SJ!JW]8E6AX7]?GT_T VF.
MP#,L(9H\BT^:P4/#;^S0/>V89%J$&;/&@^;=Q>/=,<'F&FVV?QC)N?!L(A0L
M.KH1/$U5'?O8:L=X<.TB=1V2=@@@JK,N(-EBK@RY@W2@9Q'3MH@6<P@@J5P
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M07^IG@<%LYW$;R'=[/$C615E[I+A].EAA]RG%PUT"!MTM)VC8+BPEY@O MS
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ME0X5YY!ZK-FCU/OM:J@D=:,3)[@JHS+6++!8OR4YW9&97K,PS^\MJK,_F!5
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M+)IH]<+K[F.*AL *S&[*? ZV')Q361*Y0N_&A'8QZPQ.8>+H4<P4G#?NV9Q
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M[B-%BLT_+0F]BO37(P2;_ER]OLM1@U[9U\('2M_7EMSUD++INJ'R:YY7E^9
MKVU2&%V>;7SDR(G6-X-E/I7UF9Q-2[WT]D6;@XV$T[U+_WSXYWI^BPO];V9"
M<]"!NA8;E&# /8ED@X1Q7J817?1JZOAEA7(:>&&L[->[QA:J6^?PD45TU/B%
M&,6,CHFWSD!21_W#0?W6 DH@9EV6QL^/B3.DW4_PI/#SKJ0W=B>4W)2O:ZVY
M?[$!K'?9Z%R/'R* :^^\VB]*V*^I/^_FBL^(5"U??U166USV):761[YOM#+4
M_)\F_Y6BD+;ZG.S2OD)U'8#ND;YXJ=FPXZZR[N.Q=K,MF\ICZ#GKTGL$:?MM
MFSB?R_'R>35&PA/^"3)F;N=B-8/DTXWM$I46;3;-9*NY7W3'#OSJ5"E1,P6-
M>W%%49*$?KJ?HM*K*20A'X<IXV>OOPZ6K&0FS,0)BXZ/_W1[6?-TZ<'11*U3
MO[X=LT%2>2B#794A])= %&?9\+A%4GH^2)Y*F<:J4=.^>/+\96'<JC:NGO6-
M-30FJQ[@A3I7 S/1M(&D/8R\N,(&U>%[]B#>>+$9K#XU9RU\(>K9CG&44U-#
MX$T@C=(O-JUW=C1L3G1(#NQUUDPW87=JPM_:4,J,_.>Q0_;V]G]RE^79_RG.
M7?9:I>3,;W\-Q+V#&-DONM9RT?XNPC=7,G6B@PV"EW4=,!&VV(2M@4*/O2B1
M)3;(N623(<<&^5E.U9DV'/32H15WGV18?G\R]>U@B2[,\;!BL*[,J(!R'/_)
M'8T8?$UZGF["8_+-B=<KK5SSVGO8Z]2R'_OW:JN3+W""6F_ *JBBML5&XEZ3
M69;-VS?U^ ,^X,C!#88LDV @M0P6,3B%Z8#2<!%:;E^L4/W3*U/'B=QYK=3=
MF&V7M#B;+UKK>HU/"RQ'*U^G6P2AZGB@M<L9]8X9D*4M][8#".L+20+G"8VV
M9E@!0I2D-=X[C@UP(<#1UB5N\##V^@@JFT1WC/._XJMN86K7.(V$>78EEONL
M):EWS3C0J4:1LOP6DD3K,J?4RC-&+5/U#M:=1>7!\I(T*Z1/;'Y-U/A#_MBO
M V#Z58<0E:^,5S#A\MG1;L^5Y?..BI^C.XS<M^\Q"S6";1 A.JPP$=[/=2W?
M6[IR9D[/PMP,U>O&ZCH1FF*B6P5&FD(=?WA_C_2>+$C7<3 Q]OS+[@4<Q.H@
M4:W1X>#Z@;\?;-]@'0)Z\IUZ( FA_,A=JBM2URXVCIY@V!&<W.4%CL.>W_1%
M2M^?ZVM?7P_[7(*01'A(AX8Y#CH4./);CU2>L/(9&/BLN1-?H-0@T6[A-,#;
M;>%4G[02SW?MV"NRTN)#\<PKS0KGN/W+AS)SKG95K=ZO3Y5+S=^0D!LQ6<SH
MV?B*[L*=U*A+BH&_38_7VCCBUONX C-(]W4I#[GH%:CVUM4G<[?-)6L9M;TN
M2=_6F?K%X'D<5/13IS%S;J6^QH!0/O/G_'G I%OR1*)F^KB>?J <=7K6C+#R
M1"<] W:_[K4/_7OZAB%-(:JD UF.P;E6OY"+W34=5UO;X4'(!J3/<F>RXE:W
MV"!Z/C.J%A^;F3;?10K7S<GHX$^JIXKB[9!>&6UP834*<Q$#IS@D/!BJC<'T
M&>,ILY?O5^?Y:/"5!R IJDB'H:JGDE<^WE$_Y9JJ\C,O#E&GGIRHK/K>NZ):
MP"J?#<JH+LM,@_PSB+'2"J(%V<ER-PY4\6I)!KC_<@J9TES1=RF>*M+Q=;2<
MQV_-Q7[3'!18J9]3'&-),6Y0/W.\*F*<C)3IMPDL?X5N+SW++# .=QHP<;"+
MG>AR%QT]BI9/+_#^Q[T]W)=0C%BC!LT^15XQSWY_OV(M<TR3,K:HU*?>;9U<
M$Y\_<R\341L:>*5/,%51XL;#E'BRYJ)2K_>B4FWVO=P$S<P5CMVY?M;5H8;\
MU 8BR''=!%C20,%M $$+::=%,W1H)PQC%%Y.J<TCT/R8<K/ R)&NUM/->/42
M#-K^2?5[05-GLP>.2"-71=U'-N$U8P\R$3\Y_5_INP0S%[2Z9%FJD&487\1E
M_# U[XJ9N=#S;"\NHUGS2W$V\2ECFB/0^Z%AH?WX!H4T&M2Q&KA.*[]5#3C3
M]E!9:[H>C4%87IK#-3OUQQ4,59ITNY%HGNJ-XLW%ML8W(UB$UX.,P((;&;?>
M-C75,X\2EPR[YG@Y46BB)G$M20!FH6D-Y?V54^+L:N91^1.64Q&GE5[]VN?+
MG56+L0=>-W/G**+>LQF]36$KPV;K10?S=#5F&=:P%$B#W,<E3!'IA$Y>R/4,
M5P!.$_4_@##4B2>7WP9)%J43N(]'3E-.A(U5D,ARIK/J6D]U;(:ULN03*2NL
M[OY3QJ(Y3@/UDGK)88\K(QW]K.$B,-X&Q9,;-O'9!"OET7B"I:4U4S8*DT/Y
M#CWTLD]52-60/\;,Z(YT+<%!6:F]IJ%):4H$WM3/M5F&)W $$^0U'?'_JGOM
MR'$(ZA37Q<BXR< %UGN:2>>30-W9[4#M4##5,7R;<KQZD2B--#9MOD:6%K_P
M%;UC1DG;->T]XS"^>ZDF++;2OW2@SM2&(*:;)I=WLG*F<"W#\\=<C,^4:5^+
MCY./EI_(C]*A BZ[TJLH\>M7S5JK>KV342V"J$(D(Y29'RK"^NQ^,J,'+-S\
MI^9TT'<D/R\0 FW(<J#A$NHH?T]C'K>U2E:;U;GAG-[=3_+7=A@V]/#]C"L=
M]"1TZ(_"H^:%]1 T.+UU8AUK09N;PYW$RH]HG0R 'PK]G)X9'PCS^8SZ(^,6
M3;';(HOKWHB>"P7#W1/H2?[Z?72;G\_]>>.;%F3UN7'+^AC*_!F LK08V&,)
M@XAC[XR?\T,+6JC-\0,N158_G+ 2U$7+ER?749I='J@@BDOT0 W1M4>[(.<2
M#VGMX],C1!@=<2.7%Q9GVPD;Z=R.PI"#N_S3 GU2IC*+3OQ?;'T'5!/;MW>\
M%HI@I L(J(!T$ 3I1$6Z@'0!(2)2 B(U$%IRI4J7KK1(":$CO0A$NH#T)B E
M0:1# @*!%#Z\_^_[WGUOO;5FULR<:6?.V6>7^9V]MQ3D6,V_ZVGLK'&N7B8P
M'8WBGBV\*8&*@LREESF+=2@/3B0]*RHI*GD;_3::B8E5])8P?4GTQXMF@(M/
M  " B'->C9K''U!.Y+ZXQ\>D\])?AMA8/U?]-M-P? $SNQ@%8+&TZFG*@_EV
M+)L1+E6BUYK=RNX.J_[*!:7DV)1)>"K-/> :\"]Z5D [)AB1Z>9?]..Y8'G!
M7K7FPC%>[-"0D+[-\(IL1G#LM"1ZXL6/Y9N=W@CZCK?=(EMKWK*V)#_'IR>T
MJYVC+?;(X:UJFFAY@&MRK&Y#FN*SN/363WXEAJQ 7?1FC&)J2^0",3_1W&CS
M_+&1^,3F5!T3M'\%&2/1[0B=O"XG+V&ALO .S;TI,N",&B^KCT[)B-E#A"]>
M@0O"QS+JAN+P 3!9OO.0:3<T#+/<D^O*<Q3Y>S/%(WU6JO.RB+HUD=2M%.#@
M#M4V([.AYOMNOZ?>!#.M*Q5^<#@)Q^<ON;]1 \ @+6Q+-KQZ"BN?@_7 TW)B
MD1-DPV5&K^?P21R8S?7HQJ)KQM#'K?UGX 7MO:]CTD("&2=^G0L\(RV"N>MP
M+OQ0LEVN,Y=$@3F7>2)J3@MB9P>A[5!W=V<NN='GY-ON[^"49NYO,Y]L.69B
M'.GEIE?4+MT7?PTQ+'_C9?%60/$J3>X^0:'!7*T_)3B-1_98RG\B:1;ZJWQ8
ML.56$MI@-TEER!NY,:.F%=X/0;.6X!Q82UX(I!Y:Q D>WCB96\B)-^@3)@\3
M[+%IR01P^Q$OUX0D>@PJYOK9S;L#+O2I?V.!B>"8UN/&UZ7TK-_\4=*"S6%S
M>+-2!3K?9L/J\<\Y\#>@'#X3YUA9:;N!8(3SS[;GD>WP;EG,F[X>6-EAKC4-
M*S'0VQQF+S9)V6#+CUDNLT%VKUM42^<6YYY9=19FR^SL3K;8X$! V/F'4RU&
MR\'>>GAD1(NB@V>Q:_-.JS\[LA#B>Z^J=OS'LQ_?[G?TQ-I'WQ38K[_5$&UI
M:>^^PD*E/S.?+XHW44JA,5(7X4/W+'+HB6"LQ,-C8*_RVQT?S-L<U?E,UT'Y
M=NG9^8<+?'B>U33]P9V2D]2I9L['2K;14]MRNS7)1;^N^3OXQV:+-[,)60#?
M-RJVY'.8/3 P"CDB7'OU#-*AT,(F-AF40DCAWQ8V1;\]SI$=WML!1N. [OJ.
M;"*]0 L1,U:G'&RQKD&V;%)2;G2';L%*>*\!;[]TL06=33,T5P6TAMP^D]87
MW4>H++:NR/,8!T59][=@+K<I-U WF$E@#PJ*. 70HAV<"^)V6 ><EH%<EM(_
MVGC'PP_"4W$QJ@&;^AEB!9''%9/<76HWSX;<,H:%^+G+]C816;F!)R98$%,K
MP(-%L)+=+M^:X,)>(_F:KWM:[O9J&A4923'.V[RN=X**<S[5/G#*4[\2X<8_
M;JMR_+B<O[T(([C3-JVLXZGZHU?*XZBZSVO_;D0.-N$]134 %LOX*LFCLR,3
M19\8Y_*T45?._OV8\9&T;!7KKFX]YY!44O;M];$L&Z5BG,B$TQZ&!1:902B4
M?E'R0BBBP\X5?#EM+*6XC%&[L6[[X[;BB]1\$=-BPNULV6(%_D.Q0U-*GLFR
M>[C3:,OCYY^(Q4O?W;:#K-'\Y]@;'#?ZT+ !+1I&261IF;'@;PUC5YX7T\91
M>>Q@^Z;&DV9,M@U-%UP8+Q3M(_66]R+&1KY[X=J'E1J9"#>0Y?@O82CPRF;:
M&B%SD-\D7LZ2GUE+_*ZX5[NL8N8WRB11FA#8">)NN5@(6^T4F#M>*:O;IO<W
MMU'OH-ZL^Q:0$UJ$??*AK,+8.;=I;SG^A'9JY^*>@]6^M.R+Z2D1#6$=E'G&
M;)R%WT[E\8'QX#A5$Z5#EDZASD7>_>I(?*U;KL4=&6MORR7E7)94>9%<': O
MZ&RHGV5HEA<-&E[I ]U7%/I4P;_6T5C)05Q]C$^:F:&DG0)L"?=J5'QY.?&^
MH:[WT#@PBTL#)WO&ZV24E4"#G\PW=7V54KYD.[1Z8.FBCCL*,GV4=A#Q&3?,
M QN:QH+:05= \=1;BX]>2V4+N1I>ADGI+=@I+<8&W7]GHU7P_1AS2YQ]^B3Q
M84/:B<-\E6;R@=#A2TJ""C^>;I6 ?@OE)P@MPS]?1G1H$/C,:I_:C5\@V;H!
MOUC='?!MX\ ?? :*_N#^3+'5[@K1?_+ 6Z)JS'882#O9);\KZ6)Z:ZS4$G'W
M-;4_@:*2]-K:.(RR"D3P8[<<_8P,Y'/?Q)9;< IDI);]N$- =&=G9V$B:> 0
M14F+)5#-XA;H;'P71A+<#]%U-9-R\TI/#\ 7@UBB<:KJ';STS6[5G66PWGZ(
M["X;K.,';5+_!?E9PT@&8QN(WYZM2W.*$3R7"@@$ 'B_, !4 8 K$T:VMOPL
M)BP"OR;L62>5GC2C="7F>YC<9G<M=1H4!Q:R4+=G2.PV:4M[+2H>WY5TL]BR
M?AV46D$$-LRS*Q5K&P($=[HU100L%'&[[$2_+SG<DRW6N$&#1:T166M[;T2P
MQW> UZV&D#L,Z?+IQB^XK9\RZZRFA,?1,F@I$J1PE:%J+&NC&PL2$X+6,>O&
MPP_POU)?0T&L1*1)UG;=&!F4U[4NMS+Y+=S>LC#01NF2@WSZU-?VA#2BR1>U
M.T0D3D(*Y]?+>$_UUKA6H_4I(!)T,6PSN)"H:<# RT^8[.D*[;)52'SX53R)
MMM8=Z+1%1ZDF\#P$:YT_,[C9G3[H%G*(QOZP4]@K,W P9__5X? I SX6,-LF
M8Y3&<IYCT-:X7%R-@Z4W?M"!:U>\?]F0(U-7.@4KZ10^X#R!D;Q[M_A2:Y:$
MOQW>,\OS_;$0%U,X[0M/F /1'LMWE;C?8T2&$[,+GT&4WH[OU.Z&J0$F6%B"
ME/ Y*.YNM892ZZP"T%45"WMQS)Q,T+256C;"$UMYYX%[=5LZZD]4O;,E*\E0
M(,E?($='%2*6?*=W\IMK24V8\!A*]UK0;?942@203B]SQJZH6%[H6I,!2C?9
MJ_1MEVEY5*7B=+FQU]: UXFE+Z]I[MF151E!X9N-+=@]KL?,R,Q3+LLX.B7E
MID&V@O!8)W9]M/-)N!(KQ"2&NR08483ZOV&>-#>0X T1:R)B@6^JT8#POT=I
MHB,A#G<W:'8KQ\D0PP4PD6.OX)\@2[KPO5/ %TSJ^?B!4?A]3#>50$V)&J$@
M/J+ N+.GGP)T'ZW!,2-F4C54H5- ??(4/&;/'EQT@C#17NRDKE%K*R>"0<4%
M?ZKB@[#R6K"-V7\[/7,*N'P*F-/X-Z!LC/Z#:R8B8BCC%-'E0TS7*>"AP^$I
M8'NT]I"TNH;XS>6@VG9\PD>Y5!3,OX91^.LW OU;=J%W Y1LDIY/ >46'H*,
MR!DA]M6G "YR6'$@>N04<-/(]!_,_V,ZIA^4Q-1V0N7[-I'*'7Q !GTH%A:U
M5A__K=[[P[V2:!((+*;J&?!YMF&P^EMJZ&.)"W\0UB@QRC@1(6U0B)D'1>ZS
M;EQJ&R8BJ;.J_X"S,63P#G)=]Q\,6X,J=63X^R/_.-F(\I_/TC/Z!ZA%?7R'
M%EK@2]B3G?4*QA)/ ?SW%TX!PE3MP/\@RO;_V5Q0")[Z![M5\@[N)H,2"Q.:
M%_%\JP;NC9C(/5G P9I:Z+%IU#\P\/3'$^"*\3\/__LZA6;ZA.O#G^JP7?Z3
M(<[EY9_Y'$_48B:I1GQD!)YOTYQE)Z'W.*/RWP?G=O<2?KY16R,C/A1;YP6#
M/A8E_U.>VBPT?D)_UC7IR.F])*U1.&8*>7:?U.;CA#P*HAQT5OTE\%05@@&Q
MO?O-=3D=?<SR7YFB1I3DSQJ"H^@D857GS_-#N$'@49:)XC_$4E1B^H=*C%GA
M=$&G  &U,K. J@=@>^H\Y5+W' 5+$?7[!^=F\OU#L+K9)\#*W[(7SMHZ?4,M
M6OCCQW__2/V)G(LYC P]M*-D4&\&&1MQ;WYZBG@.4YM]Y2]O*SZ%RV&\Q5G=
M'J8[.JC,:LEW=(/VJT!"-&8I_A10$WS4B0DYJ>P]!5POF$8P8YRYTPF7-P(B
M7DZRM _[3',99?RLX0XG7/_:)NSGZ"01?,TMOJ)N?Y',EM 5@-X^3]*%?T-4
MR8=6Q.@5NZ:I"1'\__[@9H]\AG&U46(T.E_RR">0D7GYR0_L(\]-H[LZD?28
M-O@U_*_DI5, XQHORXA$VH Z?BBNT)E+-6/9K>)#@66GG3U@M@28ZG9!YUW)
ME1]+3FR34O-VN6P%FPV*1Z:XL<)6@5VI)C^08KN&)Y#WE\()LF6 J QD*)4R
MM#)4^B;24^_P-GK3XG+DX=-["XG>K^5?;WI%"U>8_'[^IZ42"*> A!9^/*;]
MY&PGR*_"DNC7D<,YOCIQD&U[?*CNYOHZ?,[E[Y<9$%JF=G?FEAKM_L1B>_#7
MQ>WY,QWM$3&3I+\QFQ "O^;"M=B)>'.XZ^G8#$V=^PX+[:W?T95;C%ZI?7<<
M\*K_O/6:F.PGT;>KC70^/%H%IX#VYQ@W1A/<4;?>\,SFEY,E/OHVSGEUCBC-
MS+O^:I($G' &H6+GQ3N)A73LVJ]0_?IJZ9+NDL[2VD&/I$=5< F+JM".HAXY
M%['!V2>&SA+C-21#A(1$,;D.EQYUK:63.QK[+9E%1<TR+ M/))O1[4U\\V1=
M&3!/<6G?U[JHJS/N&9,P];)P=5 K2?P/[TWN$]=C#CYCP\%]>=%B(R"&_X;9
MBQW>I=(-DJ3)/,0H/&AYM;>2FRS01"EH<<"/K?M4,I"O)%C8<$T;F8\]G]#_
M4:/)N[KMS?G2^76''L/5KOXT/Y./)OL-75*<U/X%?LI'ZCD77F;*!W<J@W-I
M!21#JE<J!"X1;+#?L7,2485>]ZV!^%DPYFYRI/V:W31J;&U.XA&5JK6:Z?M+
M5D^TWG92<8@IMF"]TK_"6JB_(*WZU]2A87K:"3@P6,. O5)=M'__L8%].G8Y
MLU&/)KSX8-H*YF\/1RGMU*E<Q\OGRFY,=8I;=W<".<Q&ZB-75]A(H03^0RZB
M*Y#,QH_M;:]D(()T:XB<R_K<G:< MD)\>-91I,8I((Q^=DQ/-:!')$-'LGR[
MPKWL=DLR=$Z4DAO]X]:G1Y])QO!.)'TMAB@LM36 W\>"0GW*E9>F>]9:1'#*
M2 88W+78QS)(.=_EWCMBU?;/#(A0"*.)3GT+IA':DG@XM/\H:J_7N(IU+GK2
MVQ@*K4NR:FR%2_!F.A^HTK><RS')3RA;X'(]UR4+\_((*VF:ZIHNUDR1-F7)
M:\('$6-5GOU<-E,:L>T_:L#&L9$&\<I+-%LU!&LJ?3"A%\N*N$3F]\;;8X=#
M@K3L"V#LWS<Z._>)D9T<LX(%S4ONVY!=H99FCOU+[VQB?+W*)#@@ZGL<VR "
M^- 3V<FK@N<( 2UEWSL%G%?1<,*YZ77.2O70J>CCUI?KJ3V3NSZG@-J9IRX+
MP+$RIV!;Y9<YW)ZE_<4L[^*\P]XK3!DGQ=K=^W'SWES(2NQAL_=G5^NB8C?4
MT"L+VH&+Z3COZ^;>:29H+;Z,E<8 3U3&5(XR2TI_EAB);F3 901E4%;2_J0X
MIC0RMBDY,\PT"R%75/EC<683Z[XUN80D"O$B2?IGHO509PP#,>0[!71T3:HH
M>A:> IQA,893E>*2*@Z2X<[KWOE/-R.4W6Z-E!4J_+;89[[-_$,3^!XI0;R]
MO 3:IB.YP8?;F,80+UOO+G'\#;5QE #V@.DK#Y!77?!$Y-!XG7+!!)2_:!U^
M;:(\WZ_!+%KA1M3+IV_N?NW?ZB@KV+!B62G\A0)Y38=7)*W^FCI1LW:IF/QM
M1M0MY,W1+G&<\>IQFM@K(:K\A<I0&LG--#,M,BM_2QT^"0O.RD)997EZE>1?
MPM(UL)X"SKYNW?T!48QT,<B#@L(X@[XW&% 293$1:C>(T#R;OGSR<[Q?=!WW
MYU\YC'<-)ZSPW^=GN,&,SQ[-ADG/=D/5&GA.>KT #<*<<.Y30(@C?!!,"^>'
MCR'YX+Q!3GCS&(+]HS-SE\>_=H!1>[[7WJ_4&<Z/?*R4^NE3L\[Y!?77YGP+
M!D6"QJ7\@,=ECYXY"='U)EW-C#'Z'$OEX-;I7APL;,YO1@,<+TOW?[H6-"#6
MW2OWS?MZ88Y,3*\Z,.*;3.&4,C J@O^B%G.V6&"JR)-2W9(I%I=OY+=Y;:<
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MV>$(\[>K2DFU>KTC,XL2F>U'B<QE9$U#\RUB4_)^@/?EL!@.Z\V&@*DW19"
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M0PP!)'6>C/PE97%R"C!Y>("H/)#]]S[+'P1Z<0*X"$83QY M&+S4BO9_BQ-
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MK&<6WT_W2AGN"?%PG]7F\D2PUO['_W):3O[SC@OWX)@\H6*3?XC%R/0??+Q
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M5>@9EUESM*M<?'ZAB_DG,.3HT$*ZUH(]O=Y/>L =ZJ;R>'3PPFB+,3\KU$'
M8E_J3.*<.Z-ZA8T%YLPN,!?"7N+2ON6(H&NY>S>X9C#]@S\"_75N!WIY,8P^
M:*#O16++W%LX7W) FT]4(<Q<56E@:^I>#I6;VY##!?I,&%=O,L8J#7R4/,LJ
M!DKEBEO?*DA"[D?R$1^(VBXJ8)4,?%HWWF=ER'N'U*V8 .9:EEM0$6Z#X"-)
MW8GI)0DVV]E?R@5.L4JR7CH7\/K<G9ZNWI??K]8UA]RO?N#M+EIKTGDK,E[#
MP2[17"S/*$5@66!9N![%>3O#U6=\4A:AJBL3AJ+K,<JRCLT_.].GK- O.2C[
M&U(P/GJF<FO?OW\CY-R%JP\X+_#2WL _N'X5QA\*?D'M0C0(=0]_U^LV[EL*
MA)$=\-;@B9<8PFJ[7E]:_UA@)EH]$(<XMQ'#,(A=9/L[S[+<J1XS>E";0%(M
M_]WD9*.[N%PBNJQFIJ#0X[,A:952F(DV%C,M2-:7/8C%+2N  IACZU0?(Q6_
M55^'7N\5[3;MP!6U"M+ 3!-F45:91Z)C&6,^O[*LIC63P8O K4Z211 ;I8)Z
MW3)(ERB-\YG\?>0-J8 AGCPM"[+&,KX05/?+@^6KLPQ*(A$N._PR6H*#X7T,
M4Q8-PF4#OX,1.97MP[&+[!@GT%MS!!OU(K%GM9U7H?:.%B*<!(YHL2^\?XP
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M!3CLSF&PP]T*<':712"9#S]G0'+JY .0C49V$B*HPC PV"%IMW<.%Z@9\X3
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MTXSOPF^:^E5J6%5*_2G!L7%M3<IP=TTB<'ZW)UZR4DRRN.LC+1OLLAS/ *"
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MM_6=-[0@W;>R[\689>I/F19^]8X'TH_<7*OC>R<J^1Q=KQV!.N! 32F?%3,
M1:;;9H1#&P=F_2$L9"9RIV]#?Y+@)6Q]PO::^Y47]L/108&!O]_.NNAR?UF<
M]PFJUB+GJUN4FV:JC+#>3U+7A?+>D5:$B*4QA7_=@Y8"KS0Z\^5":+%4LPI=
M;XQ"I.9#G!G'EZTH^C@H-Z3HQ08@0^!74VS7W\+>2I]9?GEWI*PN]PJ $I?/
M:%T+59B2*VY/& B_-'V0^_3)8P,XRJ2U=4(\L_0TM]ROW!"V:+F7I^[N0CJ4
M2U18F];)B?CEXF Z2UQ?J__/<-!8PW @^>-""U],24  84,O?&"[!76_$X4B
M5-+#_&WVXC7E:F&@OAP&(")4WU,EJQ/GY&9!)-?Z:$(%X\)*G49<;NT\$QC)
M+_JYXO7(0#Q95_P!9Q3$L&N0*%:B;G2_DN=<CZE29+I%)!Z;\;B@LK\L)[CL
M=;SD^S?_D<1@MW NEWX.=ZQ-GW'^:U9+-%0J%T<-OAA5M?@C;9Y2W1=<EEKM
MP9^9V;Y@XE/F\(WB9]N2\>:UY-+Z_H2#_275;WUI$L/\9KT^O-MPCAHZ^^;1
MW488^;A_$B:\K"M6DX27]%G'()H4F@KEY.767"1UWMX?KM &T)?IO6CN +/7
M8*()* [,K9PP).NM*7!\!^9HT?8Q:>[LQ'>2=XPK4I3;51RBVX9V*B4L6+WQ
MC3^*L*3E:(H0>\D]%.:&.WUJ"DJX2N%&4+D:*=NXXXBR\F\NI,/8@ZR&UQ=D
M];K^GFKZ-0E%;:>(L0#Q=LLBI2(?EZZ:YUO+*.>5&(KM;G"S:1^$CI5"H36[
M9+!]R:<7@2X9Q#&)$Y:<9CS.R9!DO*%U]3GSWC6[WRZ_?[)*#6@-%+"[PMY.
M6_@E9#K($YH+<>4$Q^.SH;ZT9&7TV2T&X/)NQ^D0EU4GO6.CB>]$LUB5V]"T
M8[.F-#)>X/M4![B(%^S+V:"IA[/_$%E]9OY '$UE<G=R89AH[]%8^2IR;J3W
M/B77J&E&><2,,_3^M'^2=LW>U?C'-QQ'5EKTTL0*1)[)N;8:E#X$O76,/X10
MI"")OY"QZ'J>';75/?:Q0_[#1)104!^VJ6Y/1.UH-D8!Q9:A][Q/5[#E?.JU
MP.+3UB?^YO[%0N5RZX'4\\3N@)\8,@ >XW%PWM!S>#9(I.7@RK%9=#A'/4DN
MJZALB"?F8I%JM=QR%&H5ZL<];(?HD/%[TC HV]_8$OJ\>MJW.+>I7'HB/4K-
MG$YH:OTG!V,2,.&)<:[*$^FU(H6:6.1+IW]::X6SK3X_LD\.T9<JRWJAQ^TI
MZ^QBRV:1DV$UVQ!1UEI^S(RV9E?JHHZ5J XD^*"<,3F8J)KR<!4=&VQ3'5;F
M!#KG8;X5+K#?M"Q#./H2_+/?A^U'8+6FC_CO*$.+>\\T+&0VP0G+Q'L0K,[*
M[$M-2Q*GXXP6$%9]CZB+GM=T+*:<Q)_J$B&9OG(3?'UK?H1V=4-[,O4*!OCV
MZ)7Q8!I7M(W!FC1WU\B?]UR;6.]WN,+YA#[X!<YC_8%P$-'!GJK9V=9D1]4&
MQ8AG]X\BG'\;532K.61<GL% =*'G9;/?G!*Y>[TX_(HV/H6[VQ>YV(\'<6A7
MP!#RV?VSU[>PI6KAHCPU>Q4*<8_C_;-MC%L?I^YQ6JN=4VI_%W%98]&HM,J(
MU3P>\;ET0<#O>7QZ2T>K=9/CW)Y_:(&$W.>&+S&R7WS?RH8K</8IJ%=&P$('
M\@55;?5/QL%N7H*N5#$ 3VW)RQUU:[*:8=G2\9'E?LN:+L<25 NBVLXV\9C\
M?J:.*B31"XD+1C4GX4:@8(>N5M*#H" ;AZ0#DRKW&S]F9FP^O+CI]#4PQJ8]
M5>QZ98K7JWZH)]F!\JXH?+2 GU:%K.L06SZO:8UW)19D>_K4.(_@UZ8=UM>_
MWEY*QMX-O#X7!Q674P[NFY3F7>C]^1+\=&,"_&34CWY._U@&2\?0U2DI*Z"3
M_7ACOJ8D6UQ6S)G.V@>4./\4=KG.S$7$0!2RU,'O&XJ*O-X4EP7[QTR319+*
M0O KHW(QX^>5= CK#MIMCPLV/@!FPU,F_L&J=J[2Y.4$^@XMFXNJ4$?.W[01
M/R;ZWBR\$WU9&^FX:BW6^CO9D_T:OM5I203S_'M:C'17O)F^'(]M[8%^2]Q*
M37.R@%!2\K6$<IU7Q'<$V:M?/NQ_$7TW@WB=MS7=+?XKZN7S6MO,85:M7^I5
M22CXB-F<&_D6I??X'T_Z-2(S*O*AZ,I^)V:]<Z_<OHE,"@BA 75UNSJ2!V8&
MEGZ:3:!:W:;6<Y[.R6E]B>SK^7L# 8OI5X@)EZ#<8C)/OE!E4F?3Y0))HGSC
MBR+/>OL1\?[">=EGKFG#>#MHP?K,WSHZ2MKGWKA)EK)#OJKMQ!S?HG_M^N.4
M7_RXN;QS7.1^(]21,D3R[(5PJFB$ZN =06R][BO+9V"O)[>U[104)K+P<D'W
M)FI&YO4 ^TBLA:.OZ!J$(N?3+6?<O<S7(4YZZV[HXD+R^31#@D7.$0IZ, -T
MH>8X%8."?9'O(WX5M<?WDDO98G=*LU3.?KS(_9MT,5OYA6/&H^P^Q$7'EKI)
M[P?M,OIAYN,YQ#N?GCGS:";S7$]^:)KEE/)%QCHRZR^8[)(=(@81W:E>#CE3
M\@K67&4R8->'X*UH[C*AO&( 3AW0BL,%Z.,.M@25VNX5YG:+N5E66+*UY_Y^
MNZV@"-\I83C3%XVQG#ZH[ "[N4!=.0;X]^U40M*]Q1.AJ0E5OX60.X.DJS_)
MWM-P#YAWJ*06WU.Z7"/1:;%ZZS !OUKCO*7H_J;CIOIDSM".;M_G\5L>I.&K
M"]O>_8&V!RKXPB0ZSY_*]-_T<=E]GU?;*!K'AJ' :2TNJFY+^QLV 5&MPM*6
M:-3FC,6C9+FKQ_<[/*-C]96W?3F4(^^^#,TD(5?J.H\UX=TWPK5"0236X5GG
MB[3R \_;6OO6\[3:]R:K H8'%]RO5Y7==C0*<?R.58UZ>\+\_%WLZVP%Y:W^
M:UD'"PNNB,,$U++[W5]*\BQ#%;3 KC-V;6]#T=&^ZHE0C9G$JH=^GUW5->=9
M- PMDHBP!55ITWPU@>,'\M=R\M_G4HM(@SLM)"7<X0Z-.$_.G*WK$)?H1<:W
M%6\*\[1@5!*VT5RZ@3-!LY^VCN[EZ*(0I<YZA<_8'+>RT\Z=EUE+O?+PH+!W
MG"(>1# A 3]U"9+PQL3J[LM+"O4WLZ.H2B3.04N8S\!-0KK>-=1'S &L2<B(
MQ9%B+]9@B];W]W>WN?1IMH..262RIE-O:/'"U^:D872>N$\7&NX2-V*QJECM
M"ZA/ZE<B$B_IAOB\IDN'#S%9DT4GYPJ\!QZ?,YO<=2I\"@[T=P(SF=9YJC7N
M>/NM/\V#R3$P^.9&?NO1/MM@*&JF@DP:%:_QQ7J.T>'??O&N.,(F$0[E$C<;
MXBLME-(B<B,?T69'ON2:65^KF]FXQAE%\5U/4$#>3._'P^ QBG/.D-A1D2R=
MZX/KL&#N^JF2MU,]CZ0PM=SF'9?Y2Z5ZFM9V%FU=]N$KX)T@4CHYAM+)9.2O
MA5D3>OG!R1VL.=VDN\XWIG</\I5,LN^@<^]-09U_FDZB*DM;DX_.R4U;?!WX
MHJ9<]?(#[L_%I+F?>+6==I*,)<669#-O%-&7\R3?M9I6?:?SXU33;7WCJ<M/
M4%T8G[H:_[GU*&J<SKF:VK6D;*_4RJMH"'PE%\P6"B&:_:G00^>#K=I"@_H+
MN"A0_#S4K"_!UT^Y0"3-<;YUA<1I%J1\.!#VZ)J)[NABWVR<V :!T_"ZFU8M
MWNSEX3+10B$:7.\V %7NK:!D]SC?GF*J<V"7ZJ, >M]7^;69 $>:A^O"OCT6
M!)Q_>C^LXH.AYKW4.NOF5+R@1Y>[_K>*GGVCF8R5]?SYN;G2CJ\?%B[H7,?U
MRPJ=]U*OLL]R-2U@K75X'DE\]\3UU4B]W0N+1%$O4[YU+L^I2KY]]8G:4I<G
M:%FJ-E,CEFBEH0K'ZFB"3MW@BC$PIA[F#.0=+1G!R]V'X2^<6==S]'SG;XF;
M*(MIC=4/.F]8IQ'B&/OXLXN8+Y43,@4?8  2C^ #"G-@.JM1 ?];M9==O&;E
M5 FB4)-(,0HUH<F'&V4=VU*7>[6//U=G6'TG,;9])5[8_L[J[V?5O5.5YF98
M,01?:9I-0X:H<@'2>M1M'9;GF[K&)RPA'6UBT>FE)2.?[X#:MDZRAG!&?U%\
MRXKZ\;&'55G&^!S!7=M/G$_&,(K+W(FE[S^S(<.-"HE_+Y\?88F&/U7@>RNH
M7;4=SD&<?) )33-^C]T*3GS#(NJI;(SL6],>CLM(C3[% *CH@WMJ=F!6NK*[
M@U%WS=/&=NX4OS16!/QE O>&$^\A7]E"3H ? Z./SM0_4F8 N"EMM]"Q6K*1
MIUF.S?J@(+*O5^C\8'3-@5BFF/CJN\<Z21\%[7Y7?/7M:LRP<(+R?%D>'J97
MMQXMO_[M],"'%S,HB7Z8\4^]74YZXYJUK_(2:Y*:7,9Z]72>K=UD!7U$BUX<
M+],'1OXK<0FZ ))LP  TZE,OF^' ?0&N'XA[A!,EFS<#6RL;>6OP81YJQ+*:
M;!:!>V]T<;>OK4,RWLA/_FU<+W'$C^Q&4N1](A$1W>C&EG[:;8>9PT\0#F_E
M^5H][CF%]#KCHM'R?MG5==W73C>/#+C8?YJ!'^3YX_C)'2D>'_+5F*Q4#LS%
MI'9&Y3=#U027,E[4"][*67NQ=JK)9^OCL/]V-2V#B-K^J95ZC[96W H^02D&
M"E! W70EU#Y]%#_.]D-++&)(O'@_H%-^UB)E^)'=6_*#I,@THY7OO^H:6G,:
MW7>;W)8PE:Q-.)O<]2@#O5*QY@P);DETCCMS1;4?_M=KO?]38UE=IG))T,\9
MKD"P20&0!#"+@"'%[5AWH#8HJ.)L4GEDN/0IB\<8S1!/=X'3TVL"IN_P!RV%
MY@TY2FZWY))+PGQ!^R$DED]:FA3]U4X_7% _Y)P'_20E!M?,8D6<09U--H0*
MY<O]JN4@7\OJ[1,6[E(T)-_VT6OKPF#M=F5+/YK<&2-C@0=ZR!2TY]ZWF)44
M0O[*-^IMDII!3F_?D28/A!A%U2<>IKJM*K L/9"\:LRV>3530?GPG6A(K?1O
M<=0[S8ESJ ++9[=#KSVJY><=6#.5R2H0D9!NLFA(?((\WI*2>8Y>LK0A/_=-
M:<C^OO "%PCIVRISR0J1;=<TSK$T7^M9Q4(N2BLZK]G4E,2]7I^S3IS.@T>Q
MRFS"L8WD.Y2Y8U[*/)U=(:'MD8<6WY3/6A,1W,_<AC JSVKL"3D/<7WW4B(R
M=JU%L?,P1H5O5P35X=: 0>7_PQ:24)@C@\D0?.$T5:0R:EH*4I;6;LXH$F]K
M<Z\5YY/@DQQ21ZZ=Q\A\N>$%]4(K]4QWXW_<,DVRFT--/DOK\+#,F>&^LG9.
MSNJMN2ZW1 '7MOM>$\%2?_; R=*2&8/%:6I4.FYK"9#DHT)4WR%A(?:-4').
M64JEXXT']LY_S\W+FI:6W%"U3E*-KQB^GY;AF)C>YCY7_GVDW (A_:;:R*_<
M)J_D9H#44,^S/(<,5S[=2CUS=V6,B=+1 Z8W> [OALP/',7$T 'AL[-D?OT4
M'_'FB2X0U2M9K(&([COWW?="<L+JXP>Z.#"_@;T<#IT'!&[7?/B,K0D>7<A*
MHIU[??;4)6W ZXO:+&^T!2_IZT VN#79'_0137/Q;P##?!.O6*1)0P)B]<8"
M )()9VF]P66#?"'KF%\E3#OZD(:D&I-65S;BM,Z'WIO>51F/19\P32BWAV5;
MB 0H\%).VD9O^K-M#]PP.$JN?R_ 7NYY5"77I,8!<7_E19CWS8X0BHPR"E#T
M%^%_CAB1U964=_"^D1;3@N NE=.XHR(UN&#JX3_U#X*7 ;" 6>-5);0*CSKS
MQ['K5A5&96R".^6));H*[L:7FKJNYH6M68L3_D&,=1:O%Q+DN,R=18YCS76Y
M3L3@?<Y3@IC4:"94"K\(-"(I1(?JE#N[\^^^JOTVO^5@BD0L?R+/-O-'12T\
MGU]T6'0<$E/24?9*3A[65Z$'PHF.*11QK6JFM'A*)VXY!0WP"4A0> EFISK*
M;40J*&^T15A2Y$C\8Q#"Z*U>MBK]F,N-B-JQ:IS 07X=NW\"19X^]A5+*Z'Q
MRZQ"_N2!6\:AL;UD#<IOHGY?3D!7$0-P3N)E0+Y^[ZA*AY^)"]/'7YC70N,2
M1J0$?1H_0AW-7@\;?^1[8BPP\CF:LIXFI94=]1,[=\W5Z,'H2KV*B+Z ]O8Y
MB[S6,*1,&SGC12M^.B\M4_6WF^@ZK%RDI, 5Y?(YZ]:%<S.?9AU,N1^U=J:G
M36-J1X;$=HL7/,1'3XTG@5?B0$1S.[C/\IR24?; S31CTD]FW!EZ@10X8W@W
M^V:[>+T6'VF8\]WC9I)6+EMO@)]OLV?*)?>;VP3%MXL,@*LG=8O)?1: R5JB
ME),,P&GAPI7F%K$/[G"^4!4\*+I+#@-=&P8)PD2MWE""]67-Q2/,IB1(Y^\%
MGN/SYI[Z"P$\DK;)>YB!&?9K.R!NZK/%1RJ^A=46L8X9(=3)B3)ZQ:]MC0JO
ME3T0R+4>W;_)[7MAA#LZCPB+ \?[%9<,63AMW+Q1MJ6%TOC&W'_[@]-_2@6<
M3S/ )1O^27&26IJF+V(NRO1R7V#6UJ??%@!.Y3  &N,4^10J%^< J&6#$ '<
M62-:_'0@L72/1RXI@BZ$GL1!.8SC+/'P_M8 $$7_%^B2=OE=PL62VV,M8D?
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M2,$OM>N+VSSLH\(Y7Y07Y=<]!>S$O$#8%'(N28V .-:!;9!?D<X?&N-LI@*
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M@:'PA/03 = R?;P)IZ&;\.- ?1N21/2%EC>C'TL0!:EAK)=T3N7\ _RB&\X
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MCB9@&TQ_YWJ*2E[@Y3AICW'1H=/?^U2:C%)?[C?:S,(]\_V<::D=/,=7%V#
M.PF]7>=)*'32(U+.]LW$G(%*Y9M1T\>;00Y*V M:;(ZO_&<FQX46TF2?UJ2>
M<1O_W&1IM5+[E !^B@HVL_V"6K8MPQ+J(W_N+#VOEG)YL@:1+D^S#A\![JU9
ME1@I$Z'24I)ZRE(*3]/J?G,&.#[WV4[!II/;2"""FB<Q6R^].T>M5^%<J!!1
MI? 5504'9MUVR"=GBUTV>M-?=<^[=N<>CZ<[O[V8XEW2H'=1Z"#T"S9<D]9
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MI"\3=1D =JWZXTLP,^/4!'0T%;(Z<JEO+=*V2WI:Q>[-ST,7GBC+5Y&?!$]
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M-_]ZYI'=:C6'YV%7FV+AGDJ8+3V=$]]QHV+K&>C"T#)MX)DMP8P[MAS4IFC
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ME8J;W\QV:*"_/[AP\BZQ.0%!\>L-MDZ.>_\C2_7(.[W4/6L":^=.OEP?6TN
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M:X#J>\E//QQA58^<*",G&]3CA6ZL8B>PGF.=MM'B%Q<K++<ZN(N_KDUCSG_
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MFY8MYYBEMRY@&)KPS<Z<ZD8JNOMUEJ/?6>H"KD+*N8O$CW!!Q-W#TO[,B4W
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M#OT^VF%BE5:R4(87FET4+3,KW>X0-):L[;^8_OZX];O%8U9E<D;$$6QY):5
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M,^ Y/;R$M<>CN" ^N7Y@Q!/D)([2\V4P 5(+Z4[</#Q  [?/G  **YC*M+/
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M+'-@BPHY OR>$TQ ^:BGNIT$B)6L:T._V@(<Z0L9U"O1PRQ9:GR><\[M #X
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M?]ZNWFD8ZY2_@O(SYAH\\BDQ6Z8O2&<8?:&T27W#)LL SKJE9(-S+*_#+;S
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M[-P/+&#!@$LQY'_3<&RS/Z^L/!9YF7((ZCZ2NR\>T"$QZHUNMSI^7#0E9/V
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M#>4&-NDW7/;5S0?4;1NF7"J-G##)OG@02P!XL@)-/ 3Y!DAU%4Z0#T$$*0X
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M*PDC&^3*WIE#D$__0]%M<JYI[D2BYDUY9XE'Z;?,_5__G I=O#C"D.[0FCO
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MF:/Y4XSR"9#XS-\UN:3L0Y HXLK'I@,Q< (:Z]%\Q':PLPAX]R@N(U>PF2,
M7(D.D!B:4XP9%O9;]TX237Y0'D*HO.MM,#CWQ,*B+6W7UI0/XY3?^.%KNL'K
M%RN/6N0+9U3J;%^=7>(5'4/U3U1\*^N:G,<HC9=OCS>ZE7-8\]<C*2$):PGP
MD2/QHP $4]L^$M>[8?&L,V.,T&4TWUQ" *S[]^1E\X"'+[=D[;J-VO_U_.+I
M]JE2K:8 ,T]<<K6H5,-]M@-UC[".LP;P1^IY>S"@ALC@!8(Q@ 324JXX:W7
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M84-)[DUR[B1:[?9H'$-$$, "%'3BJHB,TZBA/KFI,8C/3UA:G7_4=;/ZSOW
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MC=HV"D)DGH2T(B*S S-(&A00:$!F 2&B(@2$B( $"$FKS&.K#"U3E"F,1H2
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MMR3JC2, VV=!=>3\2BL".M7;K#6O[;Q[#C+8[,Z_WZZ?GJDK?[:EGP9C7]H
MCVVOAP,N#/QZ)/<2;Q^_WE(2.R&0G+0XS43(G.>>RSVP6K8/2$WCR<8$13T-
M-1,0F(J;JXU>1H*1UI2+X=&-JBO*AH>O(%;DS3<J?VA>/7O K8NI_?55.K'^
MYNTJ&T;(];H@L-,9Z2>KE'_*L[IVZ-KM[]GROA;#I21[>\1X??;@BF=OX-)-
M@S\FM75+?0>%2.=RJOO28$C@%4W6R:YA?6B:>UVM8[X'RO'5ZV $6IE#!'_E
M:EOBYUJH<6_R/,!$H)CE7&"I<IQ\#D15K<0'9-: /IT:+!1H5T[#M1HTPEQI
MF/._A47'^'LQ/Y!6'<5^?E\? /O7549X1Z[7!9<(/NY"H%%E4;L0F=@4;3PH
M] ;[[4%=H%@@MH^-XVP+!8:0)6'[R8J.\WRMQ8MR\7>;67R7"^R"!TQ_3</+
MT? V9$>T6?)FQU"3F?UD@'ETAK=@]-]_" OT3%QK;#=4!=?EIP^/."<WTB_)
MDW_%?XK1!&S-5<[_^:(-8+,GTQE\9<?.]$YSU7;+,L.;[>.+IWRR,=3CML9A
MKZ8']&N3NU@_EVG$!]'!>E)E4I%5#C++YQ5UK(NIUC+\_QQFZFYON\W,J WT
M,-E:TLDZOO4*@*>%A[I7PXIGF81,'K;)E,;_PJHJM?=O(S<(?I6'>-$!2\6A
M*%#L# *RN:1+X-=2YLN4R'B@_NWAWEMJDY@HMG)O@'++%.]Z=>^7GCX>.F#6
MC;9NP#=53WB=^<9L9F/M5>%[![K4=_C\4Q@;=?NA0AZHSNQ%?\3,$Y/FH8KN
MH]2]#81_J"(/$>EX&<I\K4"EZ5=*^E4*^Q+BGIRJ5B'#+IVD?V!9]20[-B?:
MW.GL%2"8ZL4FXQDN:5CEB18QIV#W\=XA08&AQX<R?^>5 Q%?6L@%>SV?$AMW
M(4A]4$=^+0H0X_"%C<8+1G$'.^6!3%M0G7L,B3TSQO-\MHH]/+JY(:N,D)I6
M3C#'B2Z-HE\*QCUR^JR'CKZ>V%QGI%V2T;2TL:@X0QT=9+_HGBQ3"3)-#JD/
M2^YCG8EC  JFC4?.5>M-G*S$4P(://,DUUR,!R-EFS[6,FNHAW_\1<Z<^LL+
M>K#$G9C:9U6%U$([CC?,U<D@G3X/S2[E@CJP>[N0<)0HFL7I!1N%DAO43NWF
M:\]_K1A*#.?*+>U"6BAIX>2378QWF'///M+1>Z')KK8Z:K08S:)5=S.M@6.O
M7I*-)7"8@2CX/#T;UKNSS9-F"40]RS&68%,Y3P1H)23(XI,%9\#4GB@0?AY$
M-CBQ9PZL8?SKP.H)W\4_FT:K3\^YU'8?*GC8'>2:+PMHK%< XX(#]EPWH6MG
M$=:EPP-_Y2YLX3\C:_*;>WQOW5F&2QCDIAX&)U5$^^U&>R?^?D/;<CQW(/O,
M>WJ?H7+]?7%J_Q\W+P08"PX&<G&"/J$B"EYKXUX5#%):Y7*!X1_==-)O#Y>;
MZ1A)MB"Y?J55<*23G855FF#Y\6/]QJ^.Q?R)6=:I#A-W.R(3=^R_TV5/KC9%
M,0C)*5#IK:*8EP2S.P-+@2N&UM4J$U^J#AKF>.2=^+0RXXE53&ALSK]^^Q^F
M";,JDYKH6Z4S9%T9909FA'HN>WN4K#AKSI=ZNQ5EF]GWE0'AE7%3ZXV,C9EB
MQD8???I\%Z[%F">#$"J]MCE\'<:634RW@,>PZ:PR$E!,I4,W=#"Q#!6C;[H^
M6Q[9T4[7?3, ]9>2VH:?2TNI9_<<]A5TDTTP*OP&7A 7@QU"'!9(">8"Y$$7
MMAUCJAOU&UC,)*[E0W-X=K$L"FPI7G:X/8H)DY[%J(PU/%\S7-?V;'XUOIDW
M@3**:_/U\]5$JJ4K@RG\<D,XJ!Z;%+-Q/T"-?W^>3WQ\B3W50X2B,YD9V ]L
M].GUX^S6>PW+2I7[ND^!R&=Q6Q4<<Q*:J)YQ<,]]PX)CPZO;P>MAPN'#@E$L
M.*@9N_::>ULP=!<O?0NCST8PB/<P^UAOI/N4=%.3#.ERR Y+$M.<(@O&A$=_
MCNTY/+=D5HVOFS9P,?RB;TB#0O/W$DO5;RH&&,..D )K'(JK"A=/E329WE1*
M.M>(N+;L7B9IZDH=D1Q@.3285LF]>;Z>N>?)_(LS_9U.:)IGY,\+C".606E$
M=5L\G%1[R/U+8UJR6*UGE;8-8:W5'F\O[#85K+) J.W9=TC$7D2RJAP-HSW_
M^7R/*OS#U:9) T7,V8:5^)$D@?)*&0P022/!H?XVX37+QF5_3.KH;?GHD#(=
M5>[LNWM]\M8MDNRK-CLA>U_A0;EA:*5%3@?X$,Z3[6?$9@K$_=$+@I.4Z_IB
MV#'!41I9[2/HYS>Q^<8,MN<31N?T<_RA(F5G?5*XXHW#,S[G=9Z6OH*?L1=V
MHCP_I5-6^%WXJ[ZX&D,CQ?(LDKZ/=+G3BHAQ9)-V(?=:5,[V&969 [#D;YO^
MU]W94ZGK/$1L8*U?F%GCIYEO3[>5)LM6HZ(,(OL\/7.EN4&87Q6T%3%Q$V1+
MWATP(4C8^&\D?A59*[1H*COZ G"BE+WJ!/K+Y\3$Z0Z>J @.BTJL]T6C;8[\
M_;9PREO4(=?T'8-Z,$"QS!.Q8O(Q,/#1UX_>BE\WF[Y7>>6<<([6]FA@LG\D
MZ7Q-KRP9"W7UK?P+B-8H6,A3-1>Q</IK\52OYGD5[WVB>?6!RS7>%:):CI('
M!U9,XG/S#?_[\GF:$\R3\NZW- !_;=?U_C5%C]YF4#*V-O:BZ=V%.RFU#)P\
MVMOMU6CG><:Z U04[?D'973+W-8Q4_F5YY/K97+>?_;L>^!/YTFK<1Z#O];K
M'^5G"N, Y>74^D/FZD;VC#R5?F]FL0>_!V,%IFJOS.FPZ6DM?,N$STH)=&G_
MEK:BI!E8FJYNS+IE0JW%K$&;W&AXZG&>BO!R_N,+!=HUE[]Q37;K+MP_!!]W
M<.O[(BL$8[X\?$0G*,L@0E>\)\D*[1^B$\V69L.*-M)TW!TF>A>*%@[O&%4=
M:--:ZYV]NF*1(+RJT_P4W$W]:3@3O_9:V'0;> [(M*%10G2UA1S:NY&#:#%?
M>H'>!%$>X_2+M.@W9B-_/OH^?JF 9?LHW&A@Q70SI&4\DO-.9V,A^?RPMG[/
M9.\"#?DU_VM&;[""A9?(F6AD7XY2OA+:,GY57E.S__&T9\!P45[UUR"Y+P/=
M+#;MQ;0_<B%:+9D:9-)@9*SG&6SV,8,4G'ZIG-V4F=3^IE'3[#'22N_FV$4!
M9C%S;5O>B-&6F5"<>?OG,/#;=VO8N>TD\;*?0S9VM$=QQQ\_LC<]7O;ED;UE
M=08? IXJSSBYC[MO%_+ C6<5>VYJO9;A+<5_\-<X]A!X?Z_]=^Q48RC6>/S;
MW4/S]E^6)N<"^QS6%L>Y4O^S[AJG)7P2P[R[Q;VINY ]0E E9F]SAL(# 1CS
M]]3Y<PJ#BC[ZC1;[JWL;!FNL>>DZ1:N];7(/7_3O.%6-L;+P*\_^9ZX%U) ?
MEF9:O!M']CHGJ5#*RI2RM/0]W<ZX#"_Q9Y,8)K>_7:X+^&:2+@P3[]REO:*W
ME]^=G!V8W+^R"T&LA(ZP<6]Q55X!Q"U!=<,N1(0GLN,]!+/_-148(;CHN63Y
MX*<W:X,G1Z=2#F^AIB54S@OM3(;^-EZO&/";;Z2D6<!A]RS@S!3 9J$*R'U;
MT+%_%\)9J(\-KPG91S7+[*\KUC54?X X7&KL&K(>_#!U36H39L6K_Z(_V\^)
M ?37';F&Z$&&_GU2ML8%H'*'<H^'8"@W8MX7[>]/P\) .E5@.-[R)B+A1@%S
MY*^)J@^4Y@CBT[:.@G=Z9%I!H2WLF#/O><NIGSFB)'MKF65FS4#EX@'G4_=K
M5>-,AL_DOE8F1P2$D(;D*A]?B2L]>.VVR<KAK*]F__HV)2&'/;YJ?@^0=,MZ
MRE\^7G(E[P9>AR@W_I/*DN^ES.#F[Q9SS;"#9&60^I3GS:_:A83JRX7-H%*Q
MQNAZ!CR5IRB$B60<M-.P$HS?Z+%4*V1,)='=/UC8UX>XKLI1/LY@GUG(%55N
MG[6I^>3;%;;O'8F!RZ2WH-88W,L\%7XI)828601?%Y_'SR"L@3","9B+9#?_
M";HRX?N%8/!VQK*"N&(I/6&@+W*.D]X08M:77.44&]9P)> Y(;SFDWKSC'K>
MS2_C8#,7+I@0JM.6W.E^%F_N,*C+IG)(_().G[H5@1*8& PX]@18@NX O'MF
MX>%3I$"=36X"] 6R&P\,B?MRI1PKU+H2H'];>,WLM9*[.JDT_V\\_  /PB\7
M& MH%'$X$C=33T6(8F61B.:%;*:3$(.Z8<DX24-ZUCXW )ZUZ?A9'@%L9%K^
M$:9Z$ S0=7I>6CN'G/%.7N,IWJX;[<)9OM$8N9%0W-T WR _G9H0*G\_3F0W
M/Y#UJ8[OQ% Y^4/+:*?>Y<"DTAQ]5ON'QF)5^DXWQQ$F .[M$"R:PB1>B,JH
MGKZ6'SRPBNLD;+UFMI?"@LJ]EN#S%?06XU[H-)71U@63Y&G3#/S-O8"V=3@[
MDY&;%C1E(*9_N N>A/&)JZ$VSLS,(B152GGO4(?;:.7O.96GLU3Z.E_WP.1P
MMQ"9E+;4=1&N!D\-K)K7?X 7MU3&' 7M 2E8NC$>:D!1!;>I15.9,3C%CT;I
ME>!UOXN=YLQP[1[<1P1@3)Z*<52F2U3C;T9?W("YO3'Z%6#W_\Y_(E##TA!0
M2W$T@M$XDMQ(@D,$8PA1LLYJ(W/(]\?%EL?=<X=>TS0FCXU7OQPCQ;9/JNA=
MES.Z0PU'F?\N-?<G1".!D;JVP=H0$<PA6BCKVO570*1 !7,%A+/]WI;)M+ZD
M?5L$+OC2J?RH_IF<-R>:J^RKK8*#".]$TJ-'"5>LZN:&HHY]UIF<K)<)-_((
MG:^]>J3D]LL^VQ3=7L\JY\HW];U!*YEY&HJV=SRP+Y;[0ETCW9WU+-XM^Y:=
MJ3:U/=-K=] ,= YVJ'*(Y(2)Y7"6':3<DOQ15PDG7PT^Z>IS<#B#4 2#!:(:
M (ZQN':/:X-^S21G"WL>WV*WML6U"MV%O%QX'%5^>81!%^6Y ()&ENO\2++@
M^(1!H]&,)WL.3QS$5:SX\G/R"L__E>+XZ@_[ZNQCJ&:L)*C&&0?C'X/-+/WU
MT_/$[+DC9##F^4I\?\KX_%2J0&$.U.A]5ST;.F,P)T7#G)H:8KXY,6-#&==?
MYWG,W'@YJTM:"YV2LD=!WRE1>-+!3(U<@83@$T+<PIWE(H$V]P/7N:Y#7!N,
M)(!(C4!A_K0PK@-C YH!Q-_?,/Z$*SY+V<IVSY&MKJM%_MEK*Y-25]1;"0OK
MD5LCW?6YL_V]9+L4@1G/E%\JD$>[_,66:"]?V2G\VU(3;&9.M@%J/=MFUY!*
M%I->17AJ;HK7+D1LLV;;J0[Q)()\=$A[_SA+4DV9U.G>9>89(#Y_[&M:": 5
M6?&^UE$\.?\DXUSE%99L&KKF>Z#NR7<V7OR!!SZ, KVSE4UA1UA'+(ZFW,Z/
M\/8R*;D0VHEHS@O4=+A/=<3+HX?UG/-7V@D_I[@&@FE$JP2)>PR]*!#=+[Q'
M;W9$*;N>(4-76 L$S>?Q*:I'$G(SS;SO=\82E\R@&3Q[EG9M((VWKX;_["C[
M:U_N4YLX BXX1).I79S?2?O6.([_@)M_1I'!*H?BF_5[Z*J"3\*!1:V+5&/N
M@H5LH:,2RLH@EV2SW*XI -'5CC58\?(U3IUZB]5@$]))<&7TCGZ*TD+[=23S
MR1;_1+?3^8MC&QO_BA5ZH%X(($* A//L";]6>_%\N%#>G<E-)[@W,(@):)F(
MV=@[]PG]P'E<%Q,%P'K*3K'YZR4=U<7ECK&1R+":Y?Y+S05C!]X/QH0\'I2;
M36UCGYTGK",8]?C4@+W XMHB5P(,<V#O_Y:+;!2,J4H5N$BB7_<709.JDX^1
MQP0B;=W$ S9L;H_ Y,5+FP(0$P*$4^Z1=*U(!\([+Q?=;J:LEJEIY?^%R3\D
MPS@2A+8M$0)$MT]\]83BI9*E@4K"NHK] /HF$.OA@;*_TU]0>FC8X#O8\?'C
MP&4+@T6W.[W>C_K;NZ:RT=TM@0I:H9)9D7+=L[.FOO4+V':N/WJ\?TYAPL+@
MQ:_*PA#<->A>^N4KY,=,8KH<7()GQ:2K@,F_P4+& D?)NBMD>?;0\\S*F?>%
M*:M6$QM;Z82BDRC=QL8O/B+=2G">3!LK1:C%?YL'<.L'"4@AN7OWY*;254CT
MO['Z(''>7Y$7,Q\&.[2L-.[GQ+7[" 9WM<Y\,2.DWNHTC:M8]2[2_:?8T7$U
MO9QK_\+F(3D59'%U!!\.<I$KN)8-*CX5L5<H]&$'T;/SK87L$J'L_<D*=^GR
MHOQ&\M>X,KZEB F:__<H& :X. $WL,<RU"*)(;N00+8707O9J/446&:"6BR;
M*5Q[P]433%%>$M88@'QWO IA;9E%3,>>Y%=T(H%KVV]_9$=UT<5X84*+ZC/R
M/3.'/C;H01J-Z0<#:]+7@UO::'"&))A</>OG9Z<6,G5L:[W15"C>@\^+I')R
M1=+JZN;K^J1WWART-W9?]=!R/H5.5F@[X(QN=\A$>E3LMW&PLT$11Y01CU?1
M\<X%9_((L@&=UVB:B;YOS.[4U)@Z3&B(HB_VO<S,-R.I!,O<[BA<;V/N0J:Y
M'"^PG7LA=V9['K;^F>%A*?+!4@&D4B?)!\!P:#)6$W.!,KJI?PAT9]Y'_[X+
M\6#34SH5&ALN@X\#IBS.UR#)FJ.Z9=]F?MCDS.POC=-/QK5!<RQ5L&.P9F,J
M2@G[F=*,6"<QB#/!EZ8L55<M8: UY8!!KCQ& <Q%,1+HRDL[;_+Q5)0T^L$E
MP)CZ4X=WC@A>X[I/E3>_SKW4_N&;F\J4>U6K*NE7<A3P =<*Q'-RP%I F4KY
M'7=C1(;GRN[O;H1U(<0$!U8Z"GM'4KZC1^9W(1D&T"/HZ\S<7OUUN"CFV&BG
M=Z)E$X/K(C&'CK5G6SXX/B>E'Q;+-!\L_S[$67RKGXIKF>*=P$K@A0C?SU7
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M'<M)!T<8<!@/GGN!1D3%F">*V8 )5>@ #ES*[\KRW</(CG3:6G6([MISTL6
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M63<II299JH/NGNR^QL/'3!E^2Y?] GQ=LCEM7FW:,@\_];S3"3U^8$6E68!
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MZEETW0YG5DCZ1YE#<N>,^RA290?EG4>C?U;>_[;:';"OK2/'O%@<NGZ7\SV
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ML6K3X/*:=JV2Y>2$>A#2O5Z&H(6=<"OYNO^ =S0E;DWCY.27[3=X/<)T7M9
MG<^_6C7J3])$G]ZQUX! 3(^SM7_@.;\*FJ<C$:W^GPN>L<,XT>#72/;,; "
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M@]JIOG304 +\C2*!#FJ%5*G\UU$<3W=Y"B6\S:2A#L*Z O10!X'C7Z@C4+(
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MJ>;1R^K=<>0:WUH9MGAE2'FI+90MPCVQ?O][V0/QI76K>$\_XU0>22$C??^
MD@)QA6MI/Y'B@0(*8CH6XQ/\9MLZQ6JZ4@XW)<^*#E@T+R+#$H5Y,27E'<,*
M9;AR[4ZY\'!]T]+Y*!ST_YX&N4Q<B*MG3EP@F"^01;9[$!%-W'TQ<*X-.@@$
M<1OTE.&U([MV3W'?96V/P='DF:8F]ZJDE_0_*GHX-S9-"GS(6VM4^) LF#!'
MVHJUV%4)*!,WZ=)3,OLJ:I:*"N16.C0+-T^J:5TW2VN>O#.0\PAUTDC1+,%B
MT,.R?-V8[2+2^A^G2LL3.17W/#H+GV0VUHM-QBOS\KJ*WGA?KC]\'0A!/X3.
MAF#[-D4HU\A])!U:H3R"B^Q/"B,'H:BWQNN9HS(0YV$N.*;MA*?S,NA//D>"
MHSI5JF/N5P1[FH3W92H:./.LSU\=%VP(GC6TE=\(K>,'&]+R 5$J&_DD@QW&
M$D026V4KYX+;1TCD1L8B1YV?7<M\GDPX'I6DYKD$Y9IUF_V>(6+6@$F]A6F8
M4[VIC[-_A=G<3L'-> O:O-IA@$]YJQ$5VK+^ARZ_$38GFTJH@K?;1#6!''MZ
MS*E7.D*>:%FNI&_Y?BX^M# ^L/_A]@RF6,U8_MK$E<C.G='E--$^ELAJ6AVI
MUK)<(:+8T$@\_D%S\>;W8N2R=:^CA%4F<.8'A7>==&A4(9WJ15&'>=9/*,2%
MWC@T%)_5\VJ]12(%'5::*"2TI@PXAX385[QZ]E"4T/O58GJ]BMTZ,[I;A=BE
MW96Y_LT-BUE!JR3833XC.3216EM;J(KMC4ZY9U4*).^F-;?710='5GGK_!HK
M'ORT C K[)&KO*0'1 N;$U\4QHJ"_F<%%4$'/=[^)H!EQB=C]Q LM^?9R9E%
ML_).[.34HKG>V9*\@;NO;=>GL.]4>E\+S>(]O+V\B\31+FTOCE3M:W.8Y)3U
MZ[/ZIDPJT#Q_[2GY2];]DW-OP^4@[V*&W,GH)"D[CJ(A3B]GT09WS??@-J/W
M0MQI/],*!,===T,):%(MK12Q^!:0'P=.P+\=7JPA,BW"=IG )Z@F&/Y0HU4]
M#*LIKS6W3MF3U]5U2+M(TV?O/):,)B7'];RE&I@ZW(5:T:.*73XQ[4?);=AS
M(GV(\VJ&Q614Y^R/EN\VZUF.G8;\/%?>-4>S*!1/2)XQ]'J2/,1SWMK=2J%=
M#"9"?D9$=K0@7\!%R-;ZQ*"(AN"WTO)XLW\$-,1T$U7Q*OBG/]:R$EH^T?*
M7C?IPK/KM0=^=Q+(7$O0&4Y2%T,]^P1WV9)K*!<W6IIZF,.:K$7,B(J=N4;"
M4SY2F^;7#3U+?UU+.*Q\TL65 #-\UX7T;)RZ9E=%HZ*XDEL0@3'01PF(EG0K
M -"#-#>M!A[L(:;.'X&U?IP7P9ZBJE5L< $:>C(1?;I9+GM34PC;@F- CSR2
MQC,&?0NM8:!N#J;%(+S2(2(<IG6=,9:>*_;*,&:<9W%3PU3#*5*?**&QS']9
M&[ZKS^"&0GF&.E-\91*&EQ^A,"8:H+!3 I<3-4X6G/RH,*+BCY2V[>DA(;)"
M%%:JDUH'_'-0-SNZ^-*6W)R?8&I7BR0&<C:SD78Y*66:E>8.$^6=' )3HJ*%
ML>&8_W9 Q/^H/$S1/>MG(!G#;BJ@)UE[_;UO;ZSMS^1O$;>UC[]]$V%Y+ 4D
MW'J4](I6"C\#_\K/@>" 08FY45%+&6(\=T:7 C\19:)=XM-O'%Z,8>/!ZVC?
M@_6&W4CDL'[&I<E-52:*X-DH3Q@ Q^2WEQ9V>Q.+C=L.@]159IJYMPL3EY=&
M7(-*O\F)YDE!NVO>E.0YEG.I*6-C]N:R*]R]KTX8?M>W:BK6#.24\V#'3+W_
M45C5UM)/,JA.*/JYNW5MT,]N;'!-L]$G;QJZ^9;?'NR34";<-C.]W'K-)C!0
M;+I;J=@XZTF$]L6D,O3C)+*X%RH2IDD'U>UOOGP/9MA9OL"XS#'!J?I/[@H^
MY\A6@/G/T+QAG@=(IZE[CV14&X8BDTJ8KUJWM;G'FSS\0_T,J@S5''T8-'".
M&]_78QQ_6+4>G(CI5&F8)E4G8'_HN%(<%/DO?[SWP>.PH7(SDZG$9L[6+<OE
M.^*1Q807[IS(++H&O<E"<&: [SW7+I4 N# YM=2N,#@3Y]3DP]ZR_#U%1WW2
MI4@,*J$Y-FOU.C2KXTH>"2*YGCJOQ_LXW\]RH%X,:7P^R] N$$H4^8E.4=<?
M^MW8M',=X/@JE^-R=C=AW;0'5]IO.1@<<O[[SN/<7TLJR=XSB?<YBN]JNZB8
MI'K$NW 8]I3&L KZ%O;Q>I3QNA6PL( L;EO^8VEYR](2) H"@9"FVG[Y!?^G
M9Q[\>^'B'G[3DEYC"7+0SGR95*VLB6A9=&YG%FA[%E[4B^>--1V+K?W0877R
M&,NFYTS%V^D XT:QE@83Z3274=_5TCTZJ"2\!I"..K;R0JW+#!- <S6:D ^U
M&Y@S&V_PY&F3L\"@KMI6R>SA-><-##8D2AW8,^;7I]SO9=TX)N]W/:^!^+6E
M86%SN2@X%>N:$'BZ6IUY@Y^-F)#?"8[F?K]<1$C#N'%7QA#0O2TYJU[%#17Z
M;)\/AS8KW&;M45&SP5?&I(I0#;:VEXK*K,RT),Y>T#716'-0[!YBTR&*="&B
MN46B RKX/'7;"-:Q[=,EZ]>D>HK[4M]YR-VV/<\EF'C['&_-=0.NX3['H7RH
MQ-<K4?X=SF(C+!D/ULTRKL;S.MLE>,#&"A([!MP[\V3.(Y6*97[@1"TJ(LLG
MQ"GZ<'7/3(ON$#7O,^^OS92<YW".1"DUFU9IHB0K%F5K(I#F)Z,#UOIWT.Y1
M**-$\815O4[D,!U$,!HYT-W?5*6#'B53U.B@]7)"0V@2-#7_ [(;$KUP'/W
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MS#!I\DL&-A:=#L3X!P6%4(([2H(]NYX_- S"@3D]=^%?T+4?ZT=;(27=W"L
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M%SX0AA $<"6;E;O9]UH<P!O3:QX^B$P>.=8KM(TIP=K+O V>FYW.-EWK.[9
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M,.AE,#0D-#HF-BX^(3$I(S,K.R?W[;N\XI+2LO**RJKJAL8F='-+:UM[7__
MX-#PIY'1Z9G9N?F%KXM+6-SFMZWOVS]V=@D_?_T^)IZ0_OS]%RXJP.5_A_[?
MQ,5\@>O2E2N7K]#^"Q?5I>!_36"^0GW['@V+IBFMLQ^KX/W(JVQ:;S[4]]+=
M>6"&9W?QGZ+G$)+#WB7\"]J_(?N/ 8OZ_X7LWX']W[B6 -<N4UULWF5F !!
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M@^$;WGC05Y)Y?]$U B2NDS\GET>&Z#;0GM(^5($+N^/S(J\PXR&/\L^*E5)
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M XYWC)L5I$IS=:;KCK!Q/G4I(W+->\S:@<&K:&Z;*+4PHA:I<7,];1V@QDJ
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MAN#"@9R#P4!P'G]BU2ZQFV_JRUB-=PM/>,&"R8^_]N";$\(?*D=8EFR+!\7
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M"'A:$2:P;Z4":U+%B=K3@952P*8CD6CS9E#BW5:7^KB)<-53'1+&YNP#W$.
M)#+<QT2_VV"SA[AY/,%=2K@B>Y$7$$SG@#Z)(#</'Z1!Q5'RP<>EQ\_>3%7$
MF@@S%'P+5)-C?9\W4SC4E#6;J4\/P?H,2AA): MGO.RP(KWU(WHG5 RR5UI6
M<4]*]KNT0BZ#Q*MB:V)0B>-;6<[OMU/[L)MO)UG5=!Q2"O[L844GF<7I48WE
MVS)(-;J+E"_A8XX3B")3$:*)(-+4*1"1 )%OB3I>YXT,\T!Y,2\CIT$@D/:'
MG8:S=Q^>A011/=#T%4KX5*K?]BODHB1&9FA7>!7)1E\0K$$X/E>7P+<0C^J6
ML=EKYM1@2*U%<7S>_;8VC)U_9<"@TOB5%Z-NDY#L*U@),SW+A#W$!V"W4X&>
MZTL>Q'1"_('8ID!T!/V\;P1KJM/C^/XEXY@@@T_( S+I]]<Z"#_EA'D@IP$Y
M?NE6 T>:PP:JM]VXERD10=_-'_&IB)\T3  -\=\]>POW5 \SG \ZBOYKT=S-
MVH!/:ZN-G:V5.N;MR/>Q/0X($WWMT+PLA1.L3K)GKS3KFW 0[;+PF;#4,1(W
MSZ@8GUW)"H$GS(+:=U'][PBT"<K/L;&HY &3O#*UYS66O?@#>RM.IJ0!MS^^
M=K]:L98P1DFA7]RN]EO9M3K22HYZLQVINL8GJH,8]%'L;P$>RH3CM2]DD5IH
M.63)J_<8<6U-N,2G1._]C\1RP^IS -@KU&>K;'!B_G;BG8PE;JDUL;N\B*U;
MO_.,#T3*O9W0G,EP=SY@GTK,4FY4)WL%=,:>\'YN_W,^A*/R^6!YWI(L^M3%
M^%9W9&R_8\@S_CO?7#<+>0V^D)TN-E5CYC>?B,%CF-BI-)F^*5X_2?0MN%L
M86[(,:\J(7S_?DF_L_J 7Y5J9UGXP,^YK7-  ]/P>N2-B-EU]/J 0 *"#<:\
M<<0%;<$Y(/J=:'>ZQ>99C>:/#V0>94P:M"3K-?O=;FO)M_B8-GTKAK9-]/TU
M7#WQWC=?V:S22IV7]A._9BO;0 :EX(X?R+#F9LQ\?^*OJYOXIGNV:4R,#]D'
MWW;66U1^G/6$>SQ[]\C*C3[(NU<5%U YRK8MGM9T6W2ZPNQP^,##+D3WLM +
MFM T!.(<X-A]]1P0E4(&$9SZX(O-IR9XXP2F&#2$DY39W\T,YQ&5.@=<;7Z#
MW'UI%5K^L>;GENO,D;#+(.YJ#2;8B]Q'HL(O;-2NM]#V3%*3J4DMFY,I13?Q
M)W$R%%&R/H&C:I,!=8-DV!E"G;<ZN@329,P#H1!@'G3!03#])QY9FRH1E4#E
MG='24EQ&OE5TAA>=8HAPEN^2:==RN%35[K;]LX;.([H,DQZS(2N4M429E>4#
M'AN5USD^B877@',OZN($N^7-8L5;4RPVJLP^&&JJ9&1]^W!:4?NO?/6>[(S'
M](1KG0.L@"R=SN]72?G:TP=R!AU=<C^:GR3Z!5=Z,PLT['Q[\.K-"F#:.0F1
MM8!ZI=?S+8\"6]X0V"<02BCTEH2%_G/ C6XA:&Y_;JA18[$C%*393,!.=6KB
M$'R.^7&8Z4#1?*/6C,V'C4G+3Q15#-L2M(GO)_S70F-.X11Z!.X$/[P_[(K-
M-V:&]XFNJ9,BL0(T]GMPKXR94T7M(M4=%.1[$:?>@%7YZ!I87X7#C;K@TD-E
MDW1U'K^LMFJ=ZT:F#49@?<+"FIYZ4S!H=3%@@]3!>Y8[&/(92!OUMUPO?5SV
M3[B:L+I1LS 73V:_BE)WJ)ZSUR2SH;Z\&W2T$(K6UDEO0OY]6E__C/;5/AL_
MDU!D@4>S]W=@)*:I+ILP-HSA[>0LA9J=/JHGW<41-B8,!CGS!@L/TCJJBO7N
MCBTM]H*OM?O;)92SW)T8V(>5J\9&Z)%IHGL03!CO1;3Q*P1_IR4!U4?A(]'A
M4&SD4,+!.2")=Z";<T'^L92DW=JZI@WR "E7G)>2</#4\3N.2?*1KY,W![;[
M,NS:68D\<'$8EWM@O9&^]&O0B0HFL#D!PND.&()Z[(RC76>=!@2<N^;FUW;W
M+! 6,37>][*BZ*C;./!K-,MB3_+_-K' YEB^6V3=%9V0%QOI4-+-L]Y*1L]/
M&Y;NA]S?'!]C31A;8Q"IL31!%5E,O'@7X9SM>L>)*L?YQ9LTP337Y*JHOC >
M:&<XNYV%>-6IO;J=7%E">9G(J?:I4L0,C]/!;<7!G"^=MZN@P08D6P*K*2GX
M#!5>8^=E BT_,;!?V0T-M)K/F?!P%V)Y5#]^<EW?8WR;O2=B"HY&#" B*?*-
M^(IHS#.FU'7^P+%4>CZ7O2$@TY?A]^"3^ZOVR\WI<JD?O+Q.7@]>"3:3+?PG
M"2=K<D,/!]_(Y;_>@9_<C]]8#;!NR0$RP[3G.K4W?2*^;RFL>07;Q;542=65
MO>P!_%RS"2\*[[5\L4&59N1Q,$9 #;47(3?. 5^W-Q1*A(#<&HJ^Z0-V@YER
MJ?A3;/W+:,>%P\W$[,BB$7FV(+!/WAJ7%?:9S_(CT8=[+%$I;E=;.$/TM$5K
M]'T&JVQM1Q?6M:?XD4^6'YP#3'^2U]G?N<C:UCU@BAF8SF&B?G41M7$/Z'YM
M^-=JL++K0#WL&E#Q?6TJ/OTY015")2K)\T#7]"52Q,*:  &1Z*/!"LW$IN5O
MG$$HS$/P&][-*NO$\D::ZQ7.#+;@=BBZ;7K^,>/L_3]IUT:O:ET/7]_4'3*^
M#*,F!:'(AJ38JKK"]YY^XL,LKQ?^#E4IP3]ZAFIC[CMZM2?K"BXM]37HXY2Y
M3:.8[8']ZJH;P?N]6$P<L'$B-QDFC^T*,&GD*.+Z$F2HI=2IMXE\EAT.,F^)
MT1$PZVSO?)O[]D!0H'%([RL7Q3GB*_"&AMJ/<T!3$7ISG2MB%,,:<0]&1Q(K
M<5R!J;360TBZW0)@%7*]FC7F!GKG4.[,A2]\W](G8FCY>4G+^.;V [>KTZEV
M$UIJ6<=9+EL>HN4EGJ,0:Y&R91BRBZ_645%]7 D>]V)ZW._%>./R=)]K/13&
M1E""8;CM"NKEO3=?O#.DLX@3N!P?;)I*[S_P<^I[-A>.SS,B-N(3$)U+ED?$
M=WK@E+K92)G8H)9HLB9GO"$F43Y?W6[3HFMP??F1 ;C")CS-4/D@0[4F)"9#
M8D6'SNPJT&EA:X',8@NS031JKQ2)XA4:L9&UT$D[@F\FSL'EZ3D 7V0++0Z1
M@:,#?VA,TB4;-S(/WV3E]J6>7J6ED7T+K$070H?8*[AJ=.YOZ1^"A(J0+34=
MC7..JTS>,7ZMXV-Q#<\CG.V@*>XRM#S'N[/]NG3*1J450D7\;)5:],Q^%=Q:
M!:YF]RQ=OI=7"":)UJ:7_'_L!:%R- 0I7Q'4W>SD9Z1P/&BHO>M[)A*F'V]F
MS$1*,X!.1N/F O=BFGU8+1:>[%''E?DI>T.?9G$H:MA3:[[TI%3L35<-F9KZ
MR)6B..93'1>,ZRJD!?BB!V<'3?M=/!=JHI \7.V!V]S&3'866#O9&K8C6G'+
MVTK-2-&.P0Y5-DLI ]./4[]/#T"6G<TS31/WIW'G !-,YSNI \E:I&#(85V=
MQ^O:%[U7[G4V?-IG9[9]^TIB6V;Q%[&)I'GZI"4E'QM7!@_QP#*Q.Y%,O'BR
MWWYL)+#/YX,]@D+"L&W\[BK(&*#WU9F^5OHB9RJ;&+9GLZ69?JEMA4W64_;B
MFQ\#[RD]YWMNR .M]4!#[=5VM:WJ*LO$ZPID)D1GS-+E,AK\DWQ_ZIW):[-9
M%&K^KVCLFXZ)][,U*O=I\XY^PU\:*GN;N0S@R:CT:C:L N?E%.0R>IT0.7,,
M A,:U!L=0".75H2>6SI\N$_'SAU5;U+Z*N ?@<$VTL$I$&;3=L$W$%#OWF[F
MW"$,WC1]69?X?HY" Q,A>5=!069ML\>8R#4JPC=K_JN$G#>XMM]_ E6-J0:Q
M!N'FCK,R$:L0^;H2YY)HWP,AB,"/]1B@2\?Z4@V%_O*I[@71USU]%+& H3[
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MKDWX_CJ7N;>"K$I@]3*\NU_NH!0Q//6/ (_QJ2XT=!V'&A3X.K/A%'6LUZU
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MZO!A%A,;/EVH"!!O*SU;VL?+3Z("/$_5YGR4GI%%\5=@I;^YJ(#XG5_G9-,
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M36Q-S](_DR<UHFY# HEQ)'JD#Y %Z)*6/$TD;,W:Z:]%_K6E=V/+X3KA&GJ
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M(I"6AU3 ZDC.62^P^(3\700ZM.-_>@*3CC=Z:Z+%^NKS_^C(_V>*51G$E?)
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M;Z/]'ZV+E&]GS^GB^CVL&>HR4&F]/[K,_'/D4 KL]Z$2_%7K4JB'<MX^DXU
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M5T@F'41DZC/*+<'%):[NF7>^C6?>[K=,_GR@Q3&M4[#URL8'FG?@\SQ(L//
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MA0U5#I\'O^>>F'[,AM7$/7VJD6T]Y-LA9&W$_:>=+,*(']):1F1CBC"D56'
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MP")?4K,38+]@.S1PJ4'K/^:SIXU<@#3\7'\#$UQ$(6%% <A9@[ @5 IEI-:
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M6RN:4M;1FX-A"2R?G5+9J"]0X?$@3IKM4@[0Q:)$)J9C[C]T$&C\\F>9?KD
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M=W#?@NVS(I"+KAE5TIG<$@;9JFPH3;.L!R:L>S^D#*H'#&[ $;"2V*KS:)A
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M)<I)"R:.@KM%3Y.G$XA MG59,<\"()F!@J'755B4:I0JO%V\4KM8!V7;DKD
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M\+>:%^ESM]$].#<@JIC0D_5D<2YSS[O8V>_=V-RW1.$XP'H3N-5B,*#R[H/
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M^.^1_/_ID#ZQ?CTUS25$>\@J_K:TS.=HBX;$LM/A'*>YV4,[XX\![L"YY8'
M1<?0F275KAH^ K2R>]><PM&C>-;KH+A*T_A".M(3^K-)H")PI98EH)ZE2,WU
MZ=!YJIT,T3R(H*S^-:^UVT1Q-^'^.[U;UADNXGA#Y?T[!8I$Z%PK]1E9:3K;
MZ0*-A>S2/=,H!JS;T.#H 9Y9M\LS/5G>ITK-3$XXL^P@I2M!++E]FWUE.-!I
M^I?AU;.&HMKE?$;U-ZW,HLP^Y<F\ IQZ=1908G9OP[+T;[E)L/AB0 :*(#&[
M+-AG=]/,L3 -^LI,E^_4OPYRK7TBQ]'K/=@A:PI=K+'&_O]CP:R!13F68P#[
M\R?SCW^#B3DPO6. 8C<HU)1F]^*Y[&K,,2#R<$@2I>A^=+6U?QUXZ*.-W53^
MP9!+_7??E?2[Z#]M7'^!9HBF=]R/Y+74X;L?V9 TDT3[SA#J&!;9?44DUK51
M Z<CM1?_LP;Y?9&P\V=[?1>VZJS#@,*.7N0> ^9;GS_[KQ)9?<AY(P8+^O >
M_"Z]XDC]$,;H@38@H\#N-?B+'"SVH1Q]Z7 =\B1#G(RH(;:*U9R(N5\W'CS6
MM.!HH$K ;_+7/!KEE8NWU=,LHA;]FU\&L0ANZ-P:).\2FQ+ /JB8 CG:)OKH
MR3CBYM$_E&- PI%JS7H!H."PQ[JE+A1YEZP?<21+I&UM*R6!-BWBGS^:#/*V
MFCR3<?:ONUL?@HG,G!9$KXQX#)PO)-=EG=%6>X&]$>J5.:7AY95_:293TCK(
M\W>34$!N_#-?E=1EZR\!!V/\/VIO)BM_M5JWZ"-Y?LO8" B#U!8)Q>?)3/Z
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M_ZF;: )SIK%G"P1M;PZTQ$E_7'ODSD8'/'V5&N*EF'N?[^$5JW$WY:?SU-$
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M>26LM*^_R0</NFSLG2CAG'UC\JGY'+;5H^UPF#4&K57;2PS'#PR^;M"F?5P
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M^R;O_9)<DB.2G<9#Y#,:WM(2&7NR<V.LJ5[+QNFGJ7>%_8/[05^Q"DZJ3"^
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M^?JI[@L\^CAC)"+;JG1=M()'@D>WIC*_V5B;%ZQ7_.-/[+\5Y?-!==,.\%_
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M-_TS:'?73UPS3$X+7.OUJMS\FX-WP!^;(;V\/1+^-O_>S=RQJ#RJ&3F\!.)
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M"_)\$Z9K&NZ8HO[$XKJO@,7]TP5V0G_;K76)Y*,QZ4%.6S=A-+:B]^/U +=
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M'#V+EQA(K2T-S5V8SBQ2"N%/^MS@8L1HWM5US(U[V=$KZF(ODQG5K6Y;<;X
M&$.XUI8ON+BFKQ(,#!P?S,U),Y^'W''\X_AXYE'(=1B*>:##V:]<I5=F03@H
M9PY7)LE6GGI>L?'TX57#=#[&U!)#J2*UI\2=FYN^P]\;L^:,AU<L_&Q^AP!3
M[WWV!:I.-#WI%[*HE.9(_-1NN?14._OV^#8YR2*_VVLZ3FG=A,4T5V'2>6<)
M.AUZ%LDEMT&YJ)(U8;F'NJU?*J:ISD@RR$?6SP.=;H<*;;T:,FU\J4LF*R4&
M?2N.[>_%_?;U!?!WX-<VFD%H$F:O.NS?,CG3-;LCY.N+<3(J'JDE>OS9")ML
M4*^Z4:ZDM/3PB.GF$A#1+B*4.J9F=.NS_^\5";[442_;@?ELR>E@[S$=4+M%
MG(8_QNN!@C/KM0?_GJ^^()KUF@$A\5I:WFP.M:_,4^_+%O:)Y?:JR%V>I99
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MA8+^^;Y,W0!H'*%@2=9- PDO-TE:#H=O@B+*87MTUW.)GKQ7'$V2J&LZ'2\
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M@<4_D;1<V>_X%^$PP2Z>OV3;RP0FGA--#]L&:Z":8F@AY-4%X$"\*W*VX0(
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MDSRK?@X> O9Y*C'6I# 4-WBX3+:4(.XIQM;N'D+]L<KWF>_+O#\7 'T.[@M
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M:*MK#2E":.OPR0O =5%\=N\8FI;0]R/27I)F2;7P?:5_&T_/<U<E_Q&FL<0
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M$P&B_DUUK?7>^"&.M]X__T*R[NOJ4[]SC 6Z0/\/]MXSJJFN;1>-CRA-1$%
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MSI8T/X@2*+K]WY-4$N7YO*)XQ83+*Q]^>5Z3*/[P"67)#3";VX$RI6'@V]W
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M"B?>+6^]GW-LBU/OE.J%8S*MW^=":DJ!%3V9'[WL<1D3" /UY\LK)2YG6>-
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MB@3&N!=0^V#Y44PSS/C_)@!02P,$%     @ ECIE7,)JP"*#5P( WG<" !$
M  !I;6<R,CDY-#(T,U\X+FIP9Z2[!U1361@&&"O21$2ZP$CO*%*D2$84$!A
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M/;W!H4BI+R._20P-%/!1%[3I[2_[HX'];:64N=FA6M?87*Y"'Y(;V,5;T92
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MXHM2])E.9X%2-K8;\^!W8NPT>1>N]; $LK4])3RAZW%N $[8(BX7G8HP"@M
MN! ?$LA#@.\AOF/D&+>L/ONQZEVF95=[P18TH#Q"*L+TMF8>7B 9R_]V3+6'
MY'KCL8)U_C===5_58J&0*OWOH5=33#_<E?!*NQ_/)&Q_M1:Z)/<\=R%4CEZI
M:5"#&7:AK<IJBLW:K1LS9AWUF(F&Z1"S] PF]2I9:VZC\0B3&&^I-QDSC(N
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M+24S%;-^AN65+C<_UMNT%Y#R'<LJ[,_&W-*S_W7T(9Z5[0Y"H<_V=_6GK>E
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M$[#'&(%JCV$(V'DTP6)_CKFJ9'H7\BHMN(MB,,?DYN\1#RA<_W1I858!Y/!
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MZ!"N<X#>[Z$?;NS0;F&S)U\6-YO5/JHJ8 7<?,,A51<JVS)&O_%F(?_;5,M
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MANLK' TGP6$P:AC'" CF'@]75,+V.NHO:HYODD3AM,OINJX^+*>6FAE(D,4
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M1WC(+- DPO%ZT3D>-E^:-AY82C/T 0W%]22ZA>^20C9#/W?[0/$]UE[.M!U
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MW^3G/OY'. H<)?/DNSCO^ VH4! 5QO$>L]S'LQJ/HXG!FZ=[)FQ9!==*Z<$
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M,&<N0Z",T>#8=",2[P'"D#:""9W-L!%(_FA0,C_#N?G6GSD^JM_>JZA(WX-
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M3I2QJ]=CQG7;395*W@(.1].60P -0A)4!^W,3?DK6AM(4,"J!]+EB$>\^'<
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M,V+/3->3JX[=+11E$N=?XJN&MT OQ#4$N])QA7I;H,*O6R _OU8.%+,%6H&
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MY@OG*@7?[^";;:]ZS@/UOWJI,!E2"#Y1(,&QP?,1[ TN[ V;%->@Y]P5N<X
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M9X=IL@),A_X]+A^04F#+N%LX7B)]YU&I0OBQL,K9>;M&W?,N&/M<-6;61@]
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M"$7^<09^/\;Y31JS^>%L&XG8!O@QVL!B: V*K\FHA2)G6SC*;O$BQ^&U [-
M!#YJE!',*F,+R9(;MQ](8OM@M?DPX %[CNE0EL5F]4"D5L*5Q&8CJ"'BDP 0
M2 !#I=")+,9&K!%8&MUZ&COBR4:D8H^@T^S'V\\) ?NQ%<L<L6-Z$HV@C$<V
M;,3!-V=&U_K,/4?"E13=WC:.KA5X]JQ>'#.:^J'26C=JM,A[H!=R*T2OS"V5
M.;Y"\T"M',Y6,"UZS KWORY:.I]W/Z4LB'82[X<L"S*SRBA[5CK?=,P&Z5\^
M/R[+H7FX3TZ=JY#IJ"YM</*:ZCQ0===2P3I5Y@P(DH00%V++%F@*R73$%P&/
MT"H,=[9+=GD2H<NL*85=SCI=5LU1A'/P/5S@++(:<SH:V<6>0BN'[)N/ #/[
MSM&=&P!\@%E@W1?**_W'%6D9)W")6Z!&F^6QZ >,U3V!GN#X?_<;O(\RD$03
MF!,4>"KQZ'ACVFIJ:U+G0%)>82D2FB%,Y$6#/"]"]Q,YA8VL@?V3U*OC$Y(_
M/!.?]Q95+W,;RP3?G<Y _DWJ7@6$K+GZU6=OC E[@VR^*@$4NP%:''VP]")1
M 8!P(@>$0]QEL ]S&DBK^0$YP =7?EDL5$FZPK[?P83O<I^/1"368G2,F3.+
M)]!1CAQ$<OBTZ;^D6D*]QK)3+=\9L&%N!G3_24H(AQ\*O,-W&.>+5?W BG(F
M**@=S $*8;O0U=RG^/;#%J*<O=R-[D*E(9'41BW^0=SN\JK^B=;,E-"JH'J;
MTN"<<Y#VA83Q[#*$T?*#\DF?TWWQ?URZLF@4W:SY7!L3,TR=F5R43NP.A^!_
MKSU^&'#NC-$VP)1W&CM%:DI:AM=B^\RV0 _UH(KT>64-!WLWCG4-5 D3"KBQ
M$Z,R<+,GT".N0!!S-R<<G])N7PW$,0)2U(8S"U@9>Z-@>X"\$$G/^2&OLQ5!
M;F\=UDQ2:J!0C.UF&BF I[@%^AOJ\,L2'$-F0C,E"B^'.35A/+ 7EA!B8<,B
MR'Q&9_4052U+;.Z^0CN_]]TV%%X=01Z/Y!*0R,K@)F79NE&06>7M3;?!!CU%
M\A_UQXS:?4&N"G))?%B9^X]6Y;123XI?Z;R"=2Y2)J>@+&C<=5ZIHR CX_G^
M*<^ILPJ6.R55G5Z^?&@<N.-G"+?LKZ0*&L<R6(J;Q<5$@KLS0F97<GG6?%,V
MI&<UQ5=A: VROY>YF(5C$O8 N4)TO#D>TM 7<G;(XK1R 9(%ED=_ZK5&F7MW
MM U5K2U[BD5%7]8AC=O]]])Q_]%T1+IFM-AS<4;VJY) O=>(A7E1T-#OYM::
MV@<2V<_%AO;W&FH^*+UELZL]:NY==HZ\RA.W*X<5Q[Y#]A./H:48Y9^K,985
M ^%,)4^K)"'F)=VZC;%B.6 ?[!O%V[+'<W(5G@[)DGMQ1JY__,LL9Q!>U%\3
MN08I CT^RA4..HMC1S"R1^V<F28I1MFP Q;P':1_!7O9CM5[DLBT\"Z5DS-J
MG.SV/_%#G^H_HSV</Q*A%6P> QP#/9@VA9<(,E#OJ,S&[4=3O-O>36#\F;:C
MXE^01+71F6C'M1S%X5$'6<(MQUX=\\#8GA?*P1SL($$Z;G?A"#>*'5;/KPS9
MS&6!TV@%B=MVVY9X#>Q$'_7H/$R5QAJ2X@[_YCXILIYM#^))HTVZ%E\I&?1
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M8 YP_Q=&-G;1%F6O0\&QG6&Q,YJ<@5@^K!SMQKR.AG>/1^1X)J5_9_LVJT+
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M\XI"#J82BB>=;HS<F7&9F382(554--\<'O37K>X2]AJ4?E\J/>\70ZL+64X
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M)S^F%2_\T61I;\2H?9+T%(4[^:?96[/-AUVEE9U610-!U?W'=1(F23+)A9
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MZ84"O-7T%^4Z75T+!N(G7(6<?<.\Q) /.V;3A08,*NPR6B^I\HJP<+J]D]D
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ME077+J1&7D@8_=,B[<@AI"H8RZ?%CYW*91#U.AQM$I?\+=K)9D!Z?MG7QNJ
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M4 KD=;+U2.Y1I<8>L34O3',9?6@H&,F1:_77*307T?O7?BE<L+!GS,G9XE=
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MC96.6*TO,-_CMC.$GI#MK'B.8.G-?J0&R/$;")5O!J>%G[#:BTB[ /"<@/#
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M">I[_QIDX\\M+&E$KE@/? JH8T%S=-NB*GE0%Z5;9\%."%"7Q;&@TM^'$08
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M@PN/I=E;_/E89S#NM-L;U(XUR WZ/90RR3,*&!B_(%+N1*>F#U?[N4B0I W
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M'CGD,+VS7R@UY1XHU9&R/Q'_/K"\957!KJ1+"X5U&<*KG83__7_-!OYO[<.
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MD]\?Q1>_TOT=+,JSL"_#"\2R!KO2!!9"B[2S@%\:\L0XA.))QX>(?#M;B;L
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M_(#=1_+AC$Y9HR52U@\Z/JD^5G7W+XXE$.P\_$L6K021N:4#WU+G''-:-+7
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M'Q?O)B"&&0C!2:$+(%DB+GS$VV&08%^$9_'VSJ 427X&JE!4YVUWR'Y9EI+
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M< JNXDZX!(15%6-52 HKOYGJPX%KL)K"05KN2?<)%W?/&;"KTJWK>66A[J\
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M4EK7))%%/LR>(,(>:O>D_Z]%!8^Y5?[C%]A(4[[I_?Y+E]-<Z*#RHUKWB1^
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MJ\MHQV']L/^+LO>.:K)[MT5C1:5)5UHL-*6I$%!*(B(@(" H78B*"B&&J+0
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MHP]$]'J>&#2"% /=/#%K> I8\A83G=)ZW!68L6)U=\[L_>*)R+:+Y"EA"DV
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MC*\HQBG+HC1X&WP7$$;K?V)D*)]8@O&G9-RA?NTW#,ELS"L,/&E3BG3[0;B
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M^NPMX]DODK3B_B%S D/3.O0PRZ1"-5I_/<WGJ5"XZL>9@U YK%Y\>INGR&"
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M?K?Q.L-E8X@'!%>7G[)H,K+^Z7M#*V<?GHKR\T0B6GNE@10J6W:NV6,'=(+
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MYZR 7J9L_W76W+, #E$$T]0MT"$]GG=BJ+)D<%\_Q2-"T*O"##)D_.1]-OW
M;?U+QS5J+63]@J]%$&M::D?>+@<*0Q>FM]JWIN6:#'LL"]_7-]:_3[X729_&
M9!5F'RT(3#MU\KZ%N5!1I##(]7]7;K]V0/^VT95S#_S?JM)Y LWYC]>WZK/(
MRSL@CA+V LN//(L^BH4/!Z E ;A]CN6X;IDN3/*KY>W2BY(]?FL3/S.EA\[M
MOUFG<R76Z"RQ>!T7IR@TCI4IPEZN9DF_RCLTKIMH'&S#DLY_V&B;J_>R]"))
M.C.MISP\?:FZ1[#B:<#Q0 &1<A/)75\&X88>O"&HU*A?3":SD#*M#HR6?_#A
M[H!V(?Z>%JW]2Z&<2NC0O(_2;V,/K!ZS9"M<O][D*.3PV<DC)@?09O1WE/[-
MVDQYT"H&/$:\['\6<;AODZ?^H98SXS7&4UG,$*O/(0D^;#W,7,D\O^N9P>3)
MOT"&_7$P6>XN)ITNK.HTHK6!EY[9Q_O$E.$/)%X2PW#RW@$YL^U$$-:0;])]
M&)2U V=_NNCT!W)TA._:&FTF&2;SE90<*(B/Q(M.7_LT2Q9 BGEPK5@*SX^>
MP1"[V,IOFU71YV9MBC&GK9/MO'HD\]22DJ/&N >931]APJC5VTQXS%O=D U+
MLZ[:<M[6#@@^7O7DQQJ<)5*H.4VJG#K;<W3#D%.V1^>E^ONYUC<BSFUY!YB9
ME*G]PQ3%0P.Z,R(^3O>HZL)ZNPX9#56'K*P4*U=I$U>*5-R;.)^\FYNRLMWC
MOS]/5"S_CW, KT6!"^X,@64D<YCM!J@61'3!I)M-F=?I_4D\W3@(6,$'JCMB
M=.0.,RB+YG%KP0TR,F9@6TKJ*?=UWKH1YY><VY"ED+3UC&0?XD-AD7D'.CE(
MWO@93#!C[AD9,4/-9#_?)D$27;CZWI48TUE\G$8S L<<$I;> ;EY.%,,9CIA
M<;*K3[FJS";3,8> ]RQRIZ:U2UU#2I^F.L5-NGX[_\)?=3D3^D%I-2V3$Z&M
MB67G7MS)>5$H67A*7R7-/OE#T:3O8/*X3JAZ1;T_QY2%[LS%=1JP"<S^V:O2
M!G.)NK_-,I.@Q^!=X]#=P,VAPS7=.-V[%O14V4XQQ%NL%,&F\>A>?TS"JG7M
M;RTH#F#\.=X+8]K"8QLS$Z G@$Q[ED4'\>@5;:4:)[@8]RY H0>2?!ZL>=V3
MF.HDQ"8_T*VPME8/%[WRK+O$QPU+NIJ1"<[%B41H\S6!%0Z9;*X=,U-#C(HX
MQ.O$U>Z/51LF0E5_'@SC-Q-^>VVMU WCWK75^CP?"QUM-@WH?;B5S.^*LXP<
MM96Y#)\()4U:JC-Z'/847KW:3HP,3F0(OMH03<#+:DM^HH-3R!+%=A)<J]&5
M(I)T364&,4(5+8RP1.58V\A=U MZYZICHNZATZO;DBAJ)_*"E3E7\ZC=A%I'
M+&?_JMUJ-GA?M_C)5<W$TA%NJ#$LE:-O<>S:5I,?Q'^!.?=QV))JK5'TU1,)
M#Y0=?-2#L/J5H2KA\)KISXT%PFE$0"V3*RG0.7T4F* 38PW@2U.S+M%=!";#
M>;L J[O5TMW>%)9EY0*DTV!+M9!U&4\5()O]J/.10 >1JF//7,DIJAOL?\/5
M'-64EH:])8/(=^!1Y-U8FQ"6[0^T%-=[.[^^]X2P3">\+K5K^P&P2>=5EW3T
MZOADFQ,#T:@B+)2)HQ9EA.%V<_4&L<HTP3N?DD]8GG!%+AU2/S2ZX)SF7Y,D
MHVGP\&;=_*7-[X1]!<ZCI!!;F\^/7TRF;YSCDH0SAE^KA5F]1/93Z2Q,?./[
M9E2$HPQ<PK5H#GJC\(#9I>1#OKI_[&^>G>HHJ.::T!7VM+NI5-#14LAL6$RS
M?K[+5]_0F3@CDS)7'ZI*:@DU/V/QVBC$PQR)5(!^IIZYF[>P@GD3OPNAY+AW
M?$XEGX/F6FT7:*.YQW= >W\!]J*=2+4?*7T<=AU 4JR?79T 4XI++C=_8/H5
MH^45];8+ZJV/8+M(PSRI+VVS.3GI0J&Q'=O*^BL=ZZ*D5AWL(\""8X01O0YD
ML8AT@9A6><Q)*Q\:WIVEE:]0X#'SU4_:0"OQ;NO]0KKHX84TXL0Z3N1G4'8,
MJ6)*JG[X@5:5@A?LN2QZ:9S(F\0?^<$?,0&. 6#*%@!P]/,GWC=O%WL#=K-X
M8?X$MN 9S#M7-^NG8= WW@]J;< G8MMYQX=WNWKP^>>0+U@QT$/V7D*W-1#4
M+S7/\9\=7U*FP00Q'#M@DW,)6.R UZ<N0PA3'M,_X5*M:E_FQUKE 4?VSXRC
MZ^@)#DWOE5P;6"# AP;VY@T-H>IA<0;-9OT)1L'$O]LR5P^!?HD^)8-XHKQ>
MO&C=3/3,7JQ  1;&],PQGF(-U\45IZTZCP6>RIYS9JG&UU?,^]63I3 5-YM#
MM /[)8#$:R,;4W?8%HTCZ)7[=S86U__O=<#[)!W$04I_@?:FV8+VI%D:@024
M\EZ ZM>\^<PP29;+4TZ?[6X31(H>YGHVUD7.>8ZAZ6'X_5B% 72<&<LN127Z
MN=9&9OP_/&FF0C-K@7<BRX$^QX%=2F'85X5UP*2,[K%R7$9:%7A]I.<N/[/#
M)^<CH-MO?C3$VC/'8]STTQ2L*3-"M_ZJQZ= CYG6M4& M>:3M%,Y_XRL0(P=
MCA>,O^>> SQF=T#/\H[:"6&@73ZW,A;"G=U&-^2R(-IBF(H.F2;W&RS]A,"*
MI&FD&Z_B7#P1O?(J_1F)E#+=)QCFT_CR_(!58-I+I_1H ?9UY^O$"7>7(6".
M99<A7TY(-+)Y,.20GSGR4D/2/495-\JY=+B.^=MKU#;T_%CWQ""E:9C">6!7
MER%A2--NM]E#4XD*N4WP@"_RE%C"K'%L"*,E9&BN4]&(=76@2-^-W1147BKR
M]]BX]5"EM(+VI>$3I*'U"F38%2F[<GLS_[['9:H7/GUV"$9M]PPJ%UA]4DJS
M5$IUB#YTWDV7"80^*C9_$7+[P-++253#Y(MBE>\7/GWH\[O^NOB4WF>U@J(O
M_WMV\M],AS'P@)K=DT!< JY:8-F2.6-2RP^C;S&,V>YD[%G"%XS3YWX'UK[O
M7=7%G^XW4/TR2S&4C[)!%4KM3BD>ZO8L?*SNMNU4R;O6$5K]^U?Z<\'<P[\^
M L[MN+IQ2K+[+(Z">^*IP]1/Y2F8T%/W_RD?,SK),>P)5*QG;@G;71J'3$FT
MS=2)+N\K!E)L3&UP0*;O8B4F''4B8<XFT>J5>_/BEL0.:)_$\)M1W&T\M=#N
M/4N?0A0P>\2$=X6P]#M[E3=68[)-S0A&@U\QPR:QEUG*?4WY1M5%,J&:&='E
MOK*D[,:(7)_-<>EO6!T^OIBRG&.Q%OSP'>H#/H2[:Q>5N ,Z"(MJ-O&G:4\X
MTU:[8#'^?:UJS,#ZJ1(2RXX"EFW6IZU*N $Q;'6GVJ$[3Q:DM\)+<L(+IVS0
MI?,DI^HG$53GSV0P[L'JDQU0+2P9*H,1I8]5TUO470%2)<(-'+.J"X]MU6/9
MQ>HV)8=UNHD^K3/$'\444JB*^6\ :+<+*S5^75MDOG:1Q$X.+/4]X!5';0OV
M%QAU_+W(04=TS_"I %+3FR:212.F\!0!-)/8#M5A>B=A VDV[C2]3 9,.AE'
MVP&E-E]@K H"G-G^#N5Q76%O6FQ'C^, D2NG51T&3N!"IV586N7SM/K1PICE
MC\;H6=5E(L<X8JCU I#(7*-I)P2&>W? A84[NTJHA&=8&UHON"-;&9_(M6%N
M<3IQHAM3_E>KAYI#:.I@!4"G4_%P,TLTQJ]>V&#&<]#O[;<7 @UI.)7MEW_#
M&BRXDK.1!W9 T;T<@Z2H/(NEY\QG8MT/,="7-%AM+%<\EK(#$H*@$PU4N_H5
M?N(46@47>?M&>:)85> ^3["5B>4=!2SIHJFMNMM%]<;Z=.VXMUSW4AL&4=J,
M)=@EYH*@LE,1LYPC1A=HO7JG N*)JX'J6:%X0+6[#1\#!I%]^H%3VA1P5*O(
M,%9@UAC,P'T,6]:GN%VE/F,[D;*[E\J8.==&M<1M;'_QEEJ^+PW=M)+]_MSC
M[V2Q,V_V;#@E](]"4-JFU?@;8_6:L"O#FI?J^PK+/=T1;+V%E>KC>2LK5U T
MT9-%OG>?FQJ6"]6"0G+ \3@1B'4/RO J\'0VU^):2Q9J:4D#ZYSO,>W1]WMB
M7WUE"S>]7V=V.44I^('\J?)KK]-?W%:5"JN7'JII:K+ZW./\[9[!^JD^W06G
MXH.?^\[D7C%_;/.+<.13R:IVH*OONEMNO:2]@^__JMN[L2%L83?T8&X$XKYH
M?*Y]5(BD3XT>D0X*8A%=53]\P-"B!8*?CUKX7Y11(^:AR0BPP(Q'KCHM)9Y.
M3MKJ6I,0C76[UL(<?9T3Z7V#]:,,FC7;I$:YV]KKM_#=T1U5\>&R+\-ZNZC9
M/V"U A/5#M[+U5V,6^\_Z-[-$J#O+?VX7\93>7QIV>AXD75RAV9L3/VPG-1$
MZ*3^E5TKH3N@>*PAS<8 Y=6QM9)*FSH]Y4H8J6^QZK>NB5/[-.,?IGLF*B61
M["\.VON7>OL.B%9PC.71A&M_"80SM!,=#.,J-WK"M %3*'CE;V$=8+SS$Z$M
M'"G[%P\=L[YZ6+>BX_3$_@;N!8X!]LQ@H#)K?VW) DS,R.GM745U(+=\"L-P
M33#ENH4B]WNH7K;GGO4QN)]UB#_7O"K#LLL+RD]$._ZQJW9T/'+HS2W0?WQN
M71/H$YY%IWH:7TE-X:G,SPBMQQ]JZ8[F";MD03*3_NKJVZ3K)VKZ5?V2V73H
M_[,K^U-"OLGD<6S/<T/X :X0/^ZT7%G<@D>CZD6E#)[J)S7;/0JA]Q_I,]?7
M 7(Z_!?<ZDP^Q_B@_%#+;2"ET^7EQG[_>H8$$&!OPI,4P8 E RZ/D:/?)Q7\
ME/6++;0(G%T$[\;"Q@/&6^TD$-4-9:6+>2<_U(TO#_WT=.]6J,IBOQ^R/N:I
M5ICG#7/DJ@SPCOULW-?/U8"#D8I&H^A5F]ZBQKEGS0HTN6WIP9,NL-J[=<RK
MXVXV7])<\EA^R:,=3=XN/:4>B6LPKJ0[W9NRNBNB9^9P0/]1H(<R+3O2[(HH
M1O".#@>B;*GC]N.KFD;6^9Y3)D5?:K>K?E>BCF70OU?2GFO2/=;.[?[ $6R+
M.,\,[L )(UK/,F7BUV%',,XN<;TE2)["""K00VM#*L'RVQ354L/\2I%3BD]6
MALL]IY0;EE(O@F\X0O,O^;VX<<^SV;@\WU;+GB!D^"R\IJ1H^90C!_5I[91^
MS[VU5XC;>(G[NB>3*PU&'G\EB;^ST^V\$7WZ59(Y4LC,;NGWG6+S@T,QHG:W
M"FT,KD=&E;YNS%8K>&]7^+]2]>42OMGWR%RLK]YAW#BR!T->OR"=J%_S/L?:
M:<ACTGI->_!F;W\R5N[NP686.@8%ZK/I:RF^N%_G=9;?\)&V_H$MV?;W0!,S
M;UAED8ZC]-PRR$F5!?SDO2[T9Y55G8T:YW^AWA;M8[-E1OYTI$<B)K8[+E^4
MY4@ ]UU9-U#OTL;YK$ZLV?9/ME[@'JL_>4$">X49*I;R0<#E;V[%JZ;M=[A[
MAD(Y_53]V<KW"M_XHN",8;!LOD#I_'3E;98XX.,4\:)D!Z3V>KBWIAS7\<^O
M+1RCZW;A#JCXAL7@B/.G3!@I=<G;YTHZ.PO0/RFB-P',6)"QK*Z>HRLN^%>W
M=O5AWF:19]_P6<"+DS FF2OW\.QS]I' [<LD3J'=8)7U7,. ?Y?.<Z=W+MT-
M$N+;:HXXSNU^K1,T *&QIIJXK-&_EVSPDZ.2 *3! 37B4N0Y3:B:KVQMD,=)
M&JE3T^*1X7L+$M/=?":X_(.G29^P=S\_6DMOYZ3SC/H[E^$<\@1X=ZNFY^IB
M<A-6)>OOO4F,U(C3&7OD=T _1,5;?&[ 7SL'W 4*8\:Y_;^\)S//M?7Q7K\L
M]E]I5)^MYK])&+"^P >5X'8R-=/Q:'M]YA*-=<J^1:]^)=.[;6XO(W\UB<R3
MFZ34*C3BEL8Y=Q8>=.R5_G.=?-SA"THBLBOL"0O/N6HV84/(^Z:Q&4_I3[]!
MON(W"+&Y'_QO:EHO+Q4;D-;9#W,W?X8S'(F:=UIK&ZM?__/.T]T.J>/>#ZEL
M[WPD87H\<H%ZI4JSY,"W3N/FZE[!Y;13XF9.8*'4261'L-$\N1JWG!I4F9P<
MR.PV'S)1]=,7MNA\^(+S=054)7*QK5,8SOX$="IFE7W]B7\7O P+#$839FZZ
M*=B"8QH]*FZ:(#7>"4;G=">'?*NK./)2<[FD4<WC5B0BLJO](]VOA?HH>#A'
M+#8:O]WBJ'OJ$=2*H>[4Z7BSLM[Z="]2I7$')+I/=QBNTIRPA?Z(%L!3O3R9
MZAB^%,:XVP%G::G2KO.IK&&&1*<B.9#A@;OZH77-O:LK1&A,3Z]A=6_-IP=.
M)RZ;Y/9$/.V6[91_I$6O+N@JGBH*+\TWGY>O;;HEW+?T3[=RO%(V[RA6FX/C
M?3G%N3*!O0N/CU EL\:(=&'#RV1F81E.U-= ;C$GD[;*/=$%KK4HM##^9VPL
MR/YCYEAF*OL]P>:B[APG;7@N>Z']\P_Z'M0C?P3*B-V;.[9F<\A20_BU?,?2
MX.LGCYO'"W._ Z\%V\/OU/F6USWXX'W*K5AM.-GI=QHZZ[.F)=9MNA>L2NN6
MNLNU%EKE:&M7/LV0D)^#(<V3C*MD9*Z+&8D[%)Y2FC?/=;&*"BHL>%9\U,.]
M($&]'7;U_/]1/DG7Q?U6-/+> 7EZ'MD!#2$7EG^"B/_L@ !U?%2K'$!D2P,D
M_0Y1$9?%S&SC_B=XVL9HW]-9840=.8Y*Z"#N1W@>M)[@J;A]Q1A:,H-JZ8FY
M<F; \Y"J'D0QF<+I%S/!G8WN0&W=AC^?8;KBJ'*>P"G.*3A@1XE0L/'E,#0G
M,>YN(\JL[O;4O6;YP![S$5UC+[HU9*:SUC^_!TJ>+:P X':M=8,0#E%T(;0W
MXST5J9S=<T3 D4]CDP>+F9M+@PR4S,UJ)B^===)NNX!WMI.5>(6IE3MKHTUS
M>LDRV] \AS[LBCU1#Z 1]VB/F("K=9'=[1/N)35;_VS-<97*\X[+OK;<2H6G
MXYGFVC)?,-UL_8Q%BIYE(59_D'>.>VT *@X@N'#F6C<5'QTA]V4&4?LS6Z2)
M 8MQ8D_+LT1J]RW_J @)##MG5VDAM=R25UGJ.ZY'II+(;P- SO343E$)8E0S
MCK^,J\;_R;L^R17=QC]XDQXTE!DZ_E%;QB?CJERM8(NY\ =&T"XB=8''UR6H
MJ7 L= ?$=)G3KJY/AK$/#WB!9IO@@"U"Z-8&I;A"_>EF>BC^1?;"1PK5Z^'#
M^M^L&R?&TROV[H#V4.@/K-J8/W )C[]OM=IDC3J$4J^UC;WPR"!.6YM5S)=-
M1K1'R%:SQCMA@"JJ3MJN! &OQ2_ILW(8@HC;J'^\NN!U^AW+)VFQL9"P5.63
M\+K_A[7W#FJJC?I%8T4$!)&.$)6F5)$J)7D1 0$Q(@("0E1JB! 1D @A49'>
M7D3@%02D=T(+("U *"(B2)4@)8E*AT0A;$D()^_WW;GWG&_N-^?<F?O'SF3V
M[-G96<]:O^?W>_9ZUIH%D)U$$?+G!>56$USXZ2RRN<?>+WS_/*"PEU-$W8R!
M$_1Z9X:46.*FH]JX:1CS'ETQY9]/!N;)=$-F.'TS >..\/Y!\A<5[!E.=%,C
MM#G$2FYJ-Z6DR/P#_JH\+/2G8NI5?%R:;W+:8';?[]0?@7[O"?6IJ*RPUNPW
M-E#WM!\-V7<F@VHD#/P;SJMJJ^C?7^Z=B)(\7VGDJS,LQ:M@J6.C,'B/Z]NG
M1OZ7S#1D>4N=045!F:/%@;2TY_R5A4(?._\V.2QT34YDA0I1=$,XAY!P,091
M[\-0Q4OID&,,UY^UI;/3;KX.C5+VU1$X2%Y88 EB*A2;AT,A?5)A.FF)>VD_
MQ@,:Q*:>C'U(/</S@2.^][:#!\.[]XXM7DU&X_LK*M@F#(N^[$ *C"1=_.4G
MG2<2XTZ+M['NGY<@5)VC6=-[,V+%;$*_K63\_15H[0V=2RR6?K/&OESR%9??
MBV)&1YM7-[8\FT0U[%T)Q //I@=*E"L==DV1XM'7:IN/Q9S(NU\B'>9J$N.%
M_%#L%?+@#@>$Z]+K$%L*P([*RC*>1"_X;&RR92@H$2=TA6TNTQDHH5<O4CQR
M+M*3(JK1#H;),5CH7A7G$OH&S0Z(I,@$7IU8Q^@LA!_J(;.Q,A/K,[T9;H(D
MDP 6EY%.3#A,W91J_YD5=GF*_=?D*T2,\/F@XHF-SZG>CP]:9%L-PW29Y%1*
M_%ROEOCC$"&!W?_9^+]A<2$YAA&D$#&W0W37C(3-[;!PB^MM3>T,FY+(@C&_
MC4JE*)4?S:TU1)=/-U82'\:?BAR,UN\-=14Y0,4=/ ?$%Z'%3>@E/>##RQSA
M9GIT5)L6954E&]J;GJ,4[V+@EBH0^6-NQ@_2V_!=V+F@7Z38*\6+]?'FXLQ_
MDZ=X*7B=QXQAGEB&#NL)M8]ZGX<4>_5UI<6\#"FZD5LZ?4-W"/D4:="FU76.
MSOB04&D0!PPO$#OQ$;I028Z1VS1;@VY,F(^ G$.+K79G:*)#;)S:C /!)"+_
MBN9PH7Z$KI8">W1./ITEZ>^!>!U]&4\(5A@'PSIL%%VNZ5@T-+L:A"UY-M=%
M_<D/0*K-MIUR&3)N"'R-R(]#>[RZ^.&5G!!I$1JU#Q* :*.M^SD:#'B,D3>=
MYC#:AJM>SIR*;9A5ZH:<'<-3_.1(8FZG"1'F[2T,XS4AE>IL9*"6F_.LF**'
M3=[K9X+%/EPF_:>"^3ZWIP75R>71R=V0BT#JPGI8]Y-+Z%18%@427X*.[L.>
M::MM:HXC=:<;.!3EHZ,NK&\/6?W\*#UP=LRCN3$.VJ":TBO2LP]2A]=^WP<U
M)L6S;NZ#4.@O.%]<5&9(?_+)F>5]D#CD'!!&*:Y2?[<SU:0U6(#,_(25IV/+
M"@0,;TQLW#)<?5D?Y0>U:&G7?=4KK'T)YPR6P&H"X 7'"$7&3H]AHM<827=J
MDBFNYZP4K3-\ZMN,9:#HI]6 @!( VW^S/:I/PD_IU0KGFMCHQ&W)'S;+K5S1
M(8"=E%4$ JC&6E18OR7[VOQ1(F*XP7<?=+"A'=PEM5%;@3%(O8)>;X#Q(D.Q
MT<6S*\F!#/&N6\Z8JRY9K<&Z4J\-.-G/_7SEHY<NM=G[ZAO9GU\HHXH&G[\2
M++SX]M6M-.4+7S(KE*TT3BKHTL#>,I??WMX'*=/NYFI\0D<H]#W0CY=,AZD$
MK4Z2*"70"DK9[?(EDO0_L%4@)"(O(?N:YZ.RZ)<JL%4=Z:R"XQ/GPYU8,(S8
M1(?QO]L,3OZ;K:L0;SII=)_"$H!,N4SX+;:,::@W5+E83^+JC6P0)0/(@& *
M7E3F0AN4.F.M:.EO9%RQ4F,B75]IPUB,X/!@)R#'@?EW[,>C$![.AQ9)AE(4
M!KX@& ,6Q/#24!)HAYEK7]I,*C'@3 W)8:H[O>7G,-4Q3GX,>WJ.W)C#$:(+
M$-)?&T'S+<M\1YV_K1"8N'4E1@MTFK6@EXS5+G[&44+Q(@Q<AZ*BU7XM-4Z%
M['*:"H$0RW!O^QR^Y_D^#LY1!&0XU<9IW5_ZVLAZL/0^J/X&LUN<,1^9V^#=
MD^A(J^2>&>Z90;VXA.XF4;A2(J0423QN%%*&CK[1X"=M#UA[4]HUG.F3M0A$
M-7!K'V1' %)PP3I150%&4TPI\ZRJ92V=),)W)\R?W7Q"6F-=8]-8<<O\5-DO
MBX1]T$*6K.:7ZBV\"$9@W.A0'C!&F>_?%,/  <NG-!M8KT%[252;6B$&.KXU
M'P$^?J95+"2T.)+^NSM'C2$8K^K8'2H?7PB@NCK4IZJ")(K#2NJQ^R F<A_T
M @WM2D12?M934< 5MED9X-@[3^C)_$GT)U<@0XG/H3[S0D/4EU_>Y2!]I"9I
M-Z>J_8/QXJ;\-?*9"2F# K.,QB8TG6W!G=W%@:J%<+NNDOYYT!:>!_V Q$P<
MQ7G!$UKFBFB\W@:PN*JVL[3A&(@A8X?TO;XF70U.X2+;(<KF,30)-HFYL@LI
M*I]&=^^#;-K'@L(V>5<$0I:@A_9!_L.R; \&E%1Q#7O"9Q<5P0YCF6"_0'FF
M>E1H**U;]5\XHA@H0[ '&D7.;HS630//$))C,H\FGLBK5)UJE-*+.M,:=PP5
M'/8&]XC_E\;!?5"7(5:1K0\,L P ?-?NYK,@Z$&V<@V].+%TN=&17/AD3IC>
M](P=PDCN>018='$.IY).+4FQ9?5&($H(LC*R):F>,F1*:=^(#JOTN>B[XU@;
MMY> _Q"?#%Q02E[#N-*MNSO. - \M!5<;"5'-Y=VA-TR'(NYG\>&T#F1+'M?
M8MW&<Z0G'NU-ZE(8W]Q>57&9A;FTC<E_40LVMK 9S6L,5V:N]I MEAS>,(9)
MN[G]4&'VL612AW;3E)'F0J)@WXZ;8BN]NM5O837+!FDW%31>1V#PMX0B8,;O
M1[ZGKH,?LG3&/DVFUUD'(X)%[LG.F&$5EHET1PF(G 7# @:84O "ON22**@/
M^!!&GPXI)6OTPF1<T!D45.(FYRP0.M6_N8 _B':&G5[9;>/BG OU'-GBI9].
MXF4,M!JP<PJ'>0ZM/9KBRDB1&>;+-L8^*(H-IB5/_[:FJQ>4H7=(N0(;;'#E
M$EQD3<=ZR/$6X$\\M>WZ0"/&N3C>?0',"S==B,+)(HA\& ]5CMQ==*CBE^]U
MLO)>32\/,<O]Q"V:TQ:;1X.F?_Z]\0I1J>:9-@/R_(Y^\W7A0+K\P@%R@[!V
MK+!^BER2SK&4_)=7S23LS6Z*VO\%.@\"73RJ\GW^ZV]FZC@4,1P=NIBH@SJQ
MC!5M'S6"%2UI+H?ZE^@6ILZL@/DATL >7F;C_@L/GPU,,.1MJ9SRR!V3R_?E
M-^*WB_[O&L"!5=1]$"\^SIVNA2X@5= 004Y&EN(162YC%G&>]#5'9,D@OI_R
M^[&.]Q=W8E!=JKV+Z8,,_\8A_3<O9)'V0#\]W@0EI?B>84?I2Y@_<6:LNN-L
M=04MF1\QM*#BZGYOU!_CHZ%S#1;Y;H(_=B];MUG5O7TNUPL1PL^YCK'9BR'Z
M<,/J16HOZSY:JQMWPLB"DBP(O.BG-J91!]C<T#VVV6OC/$@BUN$3L0>5UFI%
M[ "'%36M3HX:8R<F:!\4%P(Y\YYQF"-5]P;ULYV^_;E=(*WK3S)-D'T*17/L
MSXW9!Q'Z$S%.+#F,-OU)-N/$3K>N[,&1#C'L"$0<\ YDZ'61P7W$(Q@X(ZF>
M8=AG8-&=>Q)(=0:&:<,B0*@Q=LR.\=8@]P5;(Q\=9D._\48F=I)0%7I/L(T+
M5[6<,R,8)ZY&X3[(BQ?HK&[R7 H5?@))K"WI,[:[RCCZO,P)::!87^R&!MMF
MCMF.$EP-D%D"YMTKXDY^U>OJBDTYBD[G4EZ_P+;MQ4&_#T$]<EFZL&?$W7+V
M!?AS'-TN]VL&LX#K@B=GJ'-EM-R9"&K&"W_L$5R7,=N) HL#'^@01J,H1KC#
MD N^LL+TS1B4NM_VX) U90@?9Q^L=GS1AOZDO1SMC#MF4=%;(!,(&VUP231'
MWM[;^H_?PWGDS#,2_C.QPV[R/S,[#OUYO5>.6\@&$_I[YLD:-,%DMC2=/&A'
M;XHW0I:M[(KE*26VG7RPDQG>W7TVNW*3;8)Z^A#N#E;^>:P(3C6!UT/K]T%K
M60MX?K82X'J?X=(]!5%G#$>SY2BK?K?Z^SO.MC#F4BFS;A^[19K'MM04-SC[
MH.XGNJ'AG>C*&>O:L^[7F*[73\H24\" JA);QI-U%3L()2SVXK[N,.\#.G3N
MU0P,+Q#/]0UX,D0#37;)C9&:C[N1HU8=;+NPR6N$E1II *FACM3IOM>+.>W[
MI$X45ROT&W<-7+?X NH[3)YA/@2D65=6X'3;W$39TR-8 _8%ND:O(?0$QAB0
M9%U$6VU>:600HX,VA=1CR#\)]*:^S(3191O,I/!L'UTZZGFA_<WI,V"\;F/C
MI -]>MJE"X'PDS)%(9'\3YA,>M_!PIM=PH6VYG$'"P/*RY^!0+<_?8S[O%8>
MQZ>E>;S\G4>]9B?HA*4\Z++.GPJN#CP\6<,0XTKQ.[C&3;:(:7_*9]UO=_9!
MI)N^N!/:[TV^22AD=.$%V/KH0RJ7]%(?%UZ0MDJ[I;NU"2@XKNF<#A 482M,
M052&I8Z\VJ2%],XGY$K^:+FL.NI*8BCUSRG4Y#A)I*JTYW@L3=\$@9C$.'"3
M^)HW_185J1$/)\#7=N@[MYX]5T^FYL;/'1XE]'JIGC2/#JA6KQZ64Y'GRM91
M_:_/<W_@A3NX'OZ.\TE\<LZ[.PR<3&SP6RL?<G=G03A#N=+8L\Z^9B;=9'0/
M6L4*"*J0PY09+R94J<4'OSVO:EQR92\+]P _3;+)ZH6 N1;688N/-92V#2:+
MW&$; *B%5(3(PTJI\/"@+-X^F9OO7M%K,_P[/>2@FF@6YW@976P8C@-ACM4P
M!/OGI;&_)LF"H"7GGQ44 "_JY-X4Y2=M/4[P\[KJJ4I?(M]MC!?6S+!K^,O3
M!G&SRJGY2]&M"I?R1Z_76@?3##7T/%K?WOG6KS&8)TEC--\][;7.$XNW2F[(
M^#5FKR!^"W4U[\@%W5'+QI11'.DV9P8GI,W*(KZ$TV'&N$ZFQNED=RJ*O$@;
M)L%?B@5<*>?M(-)#NG\ FS2D3]Z1HO0QNYJ1#?Z :\5W8LVA6JMN\O^Q(08^
MIM/L#T5JO 0+!L7X;?+$&%FPU#$7FD:QDL#14?%7AF4$/!G'C!O'A+CCW;X*
MU X@Z2S*Z9#BH-1AXDB7&@]<-IJ%QHXEHD+P;.@7CBP0,&@C@CNML:&-XR$7
M1@=9(^ERG09IG%;J:E9PZEF.,C!GH^Y@OP^*536\;K\5S54=]U#'5NT0!L1U
M,(.G#]S@5E+X3^%8FQR>@'\)X5D2OM+JM\Z^3(=W6]^GZ#]<>\:'E*UK^7+D
M:N7AES1<^5A)M=+)&X*<\)N-BMS0[I0O-1VZT9+)L?!*5EN\T^;=FNJI7VD5
MYAYX?OSC)6!^7:/R2[JGV]0-0<&,&Y%F^3U=.G)_^O<:U#M :*TNK P]*9)E
MCO'?JX<HMQ/CQ/N@XE@Y8*;'39'^?'+;4ALX0Z"O^I[JHO2/:3?G3;J+84_4
MY]Y(\EE3PZNG>C #MN?I%J@7N(,<;8PG0RR58=4W[^0GWKTC]=;MV 1A4$:#
M!%$?+YC8>KHEWD+_I/<D8^YRZO6X^;OC.@(&NP(6U^J1?NI,ZO0=I3>[%[A\
M[@F@D ]4LYA/ 6NZ^((&"2S-&<4)&>DQH)8 #-R3#$9/4;P[-R/G!2!"2Y,<
M0R""JH:T #P?D*.(Y=?(DZGY:'?2I.6]ILS&"E1@*9R,D/+[K?=SBBU<0H-W
M:DRW]N;R=\AC9QMSZZ/7%FG)<<3Z5YQ1>'U(+_PH^PGCY2X\GB,)9-F.L96H
MX&A98\";%M]**V*[?OG<6NC[I%%6D,@0S8C1KFB=&GVE@A?T-=EK_OG43[6Z
M6/A%_ZV>@<"^^J"?E%L&YIJE13S''\<UM&?KZ_\>J/9^:OT[DRW9"\SI=2^^
MS]@E) ^466FK+#RHO7/'H=L^(;S=^1\]BY/\-Y33S,OM=N>4VU3"W1(\U]Y-
M&."^WL@J7B8;1^:D%=YQ6@YUR_83S8[*+G$Q]71W1QP\MD!H:&B\MM#8%*5S
M.T["_1KM+]';H".N^*'59."\0Q&-%8\4G+9F7MTKV0<A!)N4V_%)>+8(L1[?
MY1%GRLH:@,AQ1H31LON@.V/%?WE;#Q\$M/HJ%)H%^1^WU9BIN%!RV2*I-+\?
MG4 68Y7"LQ9/YVSH): -F??I0_V]Q 0MYQM6 R@<HY]F'ET"F)JVWY%XUT)O
MZI)4]RNQU4FOEGX8^UMZ _OI59QMG-6%?W,*7M59J@E;7TV/!7NQ'P"K=&]F
M&/TE!P(L,JP[<;P8Z<,#OA@SVC[HU#)$8LQ?P^,PJ>2.=;FK2V-1^=U[\7X:
M-ZRKKGQ/;&2.ZHDRU*;6LQF;M.\9F7IK&BPM).?<EW\L^*$-3>O6GE3<LWW0
M@3._F;1;](P('9MST"2B^/T7NEI7M.%'T:;=Y']NJK'#1&Z1M#N*Z-$<7AI+
MC:W $(WNX<L]ZCLOV7'QJ]64)CM@K\#(KAH3##3)K+8:SB(@RD!D<*7&2X@7
M2KF_<U)6?+3J[W_6'YY)_HYO*I7\TU7 Y?I&6_.QH3\RDHC^R?&R9_?J,/8^
MS(P6."E9&.' .;:79B1:YF)@(S/\DNAM++N[#_IK"G\F1?3<5(?&*OS4]CYH
MMJJ7L)%[]F3_KIJWMW>)$WEY-[R*$!D9V2#V1%?WD1F2>Q8IW.6'1/H=E-=E
M3M+S30\+Y9OQ7ZOMBXL#U?]W[5'_IT83)(#5@U6A]R6*Y5$$#[ABKHQ+,<XV
MCZIQ^=X^B-^X*B4.H3#N,6YD$8A\\.4O1K]T=]V?_J$3Y;:GD^IOCJMJ9TE7
MP>P[ZL>"9B046CK&-3;NU]?5-T;RI]YU=;UK],BE2_C"4X7TJXDB8EZ@4_ T
M7&/T>O4F/<N63NS$'6/#&,$9/6\VC([M@TX;R2T("J'CN]RD:]JNY"B,LW5D
MXEQ6.O1;FKY$;A=5[40?]'E"3ARJ%Q2*CTF0P_-$5L15W1!9+BO1[[N!^?@:
M5;'XVI.GT.Y5@D>)BL[AN>CHW$5]U2R-'JKFG;+[*^:15J_OFT[#)!ULZ^+R
MK C*=,R$PO''%<X)-5OA^6F(*[*_*NB+G./)@@D$7"R37-(5UBYH2=>+\]NJ
M.L>A]7-$">\9ZBF/6L)?VZ&?=#.O;;#]*N\B3WU\V+!YQ*3".KS8UPV</B<>
MMOT44KH/>HFC9JRK.J!DG%?W04>Q1ZY_&>0A-?O/7P>J& 8CEPVQ9U<R,2SV
M(8K*U\Y3:!6S]ZD]+83*8N,PYU$YK:51K +F$E"[H!'EIIM*K2)VP\G07IP(
M6XU10)**?K$]9,?$,L0B*"SBBQVHH)$T?:=/5H) 'XIM^6)T,@!Q)*<L/ _F
MC7Q:<8I"%*@NJ)SER4[>FO4,.;*77;1=K^7B-F,2XC]\.L70)%#8YI31K7+K
M4Q*SUA;G5&,>5Y=W/E_V"BI;\+:Z\U"O-EC.9SRU[(+YHT0(SELJ-2VWK;#"
M2O/5XU<)9PTP_7UT+T/)GM>:K^LQ/W[R\=E;%9^(-%*3"BYUJ(B]C6URY#5/
M3=-;*[$J/IIMU>!](^W")#Z61)T03GI.V1/L;E%_0R'R+TL]>?[.I_'1\JYY
M8J%3U_WBY4G=%6%I%T-#CZ1C9Q,M>*5 EJJ//UE.Y<?1_\TX\FMMW/9KGPEW
M@5Y/<#_6)Y1P_UBON6;<O[OQ??HT'?X36=+2GYN)W#K_7XLE_!^F(_VVXQRO
M9U#!SW+KODSH< >S!=H'CH(+M8458%2!?]_ "Z%A_6YZHP\Y8NA<4H=JQU0A
M1 H(1#RE9LT&]DHEQ19@].A^XR=[2Q"RNER*K9/HMB( Z7X\K_!O5P>V3M@"
M.!K<D$'BRJ@(['' KQ0PY.J'K!XI+C%1Z]#4J2Z@"8JR+W(9=8*1$SW#90JB
MA\;W=5Q@P&*AWC:.+J@H@_D8[6PTX,#9Y2T<TYZ]Q&(YSQ%#8@[?>V:1)RE+
M_)QB?UNHO)Q/2^@=R"G6R_W9I4\]Z4I<PZ3^=>(_=OH-)_]_:[:V,2SL0SY!
MS/<U<(S=\M/HD1+M.;(M(.=45SL>-/.AZHV_O;J?C@)2\HKU<:NHQ8>V'V+E
M#![.$;/F:WOGU[9I&EQ1T/ :(DS7(_5--0@F/EZ=DVT=6X-(S,X!WM<;Z>*D
M/1WQ:RC!5:F</$]AY-^^ZS*3\8>6&*Y9A09Q<*,1P7<X%/0HQ@:(8)UC/Z9'
M=^V#&@=HZ]Y=HZ3":42JME1.%4)@+VWR??[R:('<7JOCR,)X$,LG9:+:L]G%
M\YZ7),>.JYR@!Z"^KBAF-3T+<[Z1$=(=#N^2*L[SHPV#?3M.MF18T<W_T?[C
MZ#"*,2M$:DXC=K,Y>0(]#I,=HN.>22ZM\5EA44GG\UE7PD\X/HM24O^D,BA;
M\_GM7?O+NGD;Y<'A16:2@8_'D=/JUZQLRN2+UWG^6$@Q=# E\6@[C2*2CA::
M6EZ>+'K,;.)UA56'X,I7IQNY=<&/ LJVR3GD=N6 6\4_#(0>X\'KC7'L+D95
M1B]88%9&KH=(MX5*(]T4E0:3N^"\G,,8Y7&VJ]&GHV?BK]!_1E)MW*;_R7T5
M;K'6N/KWZ(VXP+M&N?7>ZV\8,O?#^9CY>X40:82>>I5B.T,.#H24K$9]^:#*
M!)_@R*"=39&/_SI[RHV1'=_;+*F*_0O_G76<#Q/,PSE^A\L/BNXOA(\-:5FP
M(5*?,K(Q_A8VF+TD1"SNL?=JP:7\^E;E<R\^K5TI+Y54_70-=&! _AF/,WW=
MFQD+(-PK7-$H4D9F4T^NF%,4RR(*(NFSDW.)V/@(.K'BN/N8JQ*-\W5O\$[I
M5.G<C/K6*;?^QV&3PSN0AV[Z*]X4J&?!.).X4W+<@(Q]'4(4*QK1SK:Z!?)*
M-?O2T+P^>NJ#D-&4A%U4RF>GA@8<H.B]MEB J/%A[F[VIX^J97@X.V/00&+Q
M\LJ; 5M$'E+J^ADQA:1QN_?_+"KFUG7AX\5MN2%W_ ?W#TX6PZ::H^"D#Q=K
M]T$U;S>TUU>W,:WB /QG6.G$/LAG4\;L?+0-'=ZI)AO8*(T_.6O" %-YFXSB
M7WYI:&TW[ I5(^&OMDX:V7S?2O_:X6 @0/=>^*Z!*,7<8S00Q8+C+SML& ['
MYZB-H8)<D$7WYK"Y"Z7SUG3SMR<[?=B)H %)>TB@013>D,"->7_.AYL);FRC
M*<(:+0R=2HWN%0@NZH=KKT NYF)I@]YE\ML_6ZS!@-+\FFM)#1KJ#8T^I;\/
M2L^,R@JNN(;NFE4L"T-O_GUY;BBG1#%#\0!ND'VW_>)K]YF*/NOA=Q-8I5?[
MH!0W,]B4<?\$<D)=MC 7WMAA47<7\P@X0@F[LZZ.56>?&U%3I=VY5X^311O>
MB"*?I\?SBQ')*:JV)<=K^R5NGSX"<CQ4SB'O@^K48UM9,&8*H//P]D(I8R>Z
M!+-[;!WO]03RL7!B3X]IM/>ZX?&);-9EMGC3_2_#I-SC0TK&N+" 8FLECO%4
M#F$>,7\(RX>0X P"9O1!F$IB\5AGCL3SC$.'D!9%%?R"5\YS=9&K9N!4NU1H
M^$0P7X#1[G=]'"OD8N_,/DBQ"XY'_:)+$X'S&6LPK];"O?RV(_IKJ@H3A$O[
MH T!0^L6==SL9PMCE=-<J+T&]; \)&-(%8S1&3EQX-\%BLTXYP^8MX? 7S$R
MFG_+OGMGY/AU,D>(GI-C4D,G1C^,^U4\9C;F%Y=[\W[C=:QHZVFA7DZY1$%G
MYR_:U<ZM/W_1R+F0 [A/$+5=VGE\U[W<GQH5C*M-0X^50]=/1X-M9]BWJ.=5
M]D$SZ;\@,LF<XP)TARW:%;KCNC3UK\#:+=ST,'4DZ3IX(?4V??*?Q)QW&Z"D
M;7>.M+]AKY+)7AKN86(@JTZC2VE4[1\/_C^[BS%!OPK^?OQ@(7CQ7,=\?@:A
MJZHF%;?]6^3'SB_;(L!EI.C%<!'[^HX F'5T(,]JQF\[X8G6<-#.C.G"'R)R
M/J%)U=%D+X++]5U-+W_=[1TF0?E[S!_Q95OTP<YYXW>+Y<82QBV8J7MXU%^<
M_KWG1G<BN[@6YA7LAT:&ZMOU'2Z^@/K(&%"6EKF,;_<IV4XPF#D0C:-6)*#V
M00H]7=C#;27:&;V]DI5AY?JJ+_A^K#].N)K!!2@1K/J_);KQY@^)[O.1+2;N
MOY*%L*-202R3?5!.M"D]>$>N^:^Y@AK=>PP+MDC8S0$H+]%C'W1"Q=MWG@T#
M4JCBR3E&PVO[()[E8W]DGESLTU?L6,M/KK)CZ9\^C;WS!BNJJ05_IIHJPD6(
MGC=[9M.#2@4 I2Y4 ).;QSB$X )FHJ5%%C7WZTXWI271L)LHWF86 (;.CQN9
M%<^\[Y?;.>/]PO@"E 0&SLN^Z_G&&>>J32.C:$!;</HGS2YXM7NP&F",TY*<
M3[T-VH0_L;5>384+G#ZW#WKO?&H?-/;W&]B9/"CUY^7U&^O>3]-E6;@1!8R!
M2Y!U5?(/:<[Q,9829XJ!CN\&B[,#J.O6S$AZ5 ;EVA;?I@@:U>7@)EI/%QB8
MK#[M!$<[6K03K9%J;GY7)FA372B"Z^NQC5DIOK_V01[_=HJ%WM\'D5N[X: 2
MN!@F%*AEZ9A1-43AJRTPD@"?*=US>YWP<C+=8=%E8JJ'[% 5DK\BU=:XL0^:
MMI4._]OTR-!$W;?/$[MAK"#<0"F;>Z\:\\A]4!DNNF+58+M\$5WFB7X(K2>9
M*6_?_URS535HKNTM;1L0=&ZF>BR@N$-DU&: &-F%#DRUI3V<TD6WS1469=RK
M/9Y0;^3A5>$EJOG5]S-Z-YCRS^1+]_3NFY%W;V?H.%UXWYU]GK30NY?4H3:\
M#SJK,3/&+/T'W-;R<)YO"Y-T2?0=@-..$Y0[N\-/?WS)WX(E@A3VYD))SUYM
ML&IR%D>].*W$8T=E+X-B:/QF\>5,DU&0!"LG[E<',7;9 ,G6OLC8!XTBY#8<
M^;^O6M[L&7>M\'I:A)UA/?2T7A\'7G)(LA+-KBVYZX*L![[O/V\W[Q6PD0CI
MU-;+\59^QJ!!;Q\)"8F%!__@%G*Y0[YXV-=-:R\_^.W>YCJ<K$+M'? /_/V0
MH>J*_JPY$B*);_8IVF8_F#EICXNZ2]RUB0+<H^?[7R^LX*;(6#*G8^+S/DB+
M$O!O4=.]='E#@N )S%^3+@G9[C18+VOA:S\_GF9OSN/S0>6K_4LNP@=@^\HU
M];J^HAR;QXW<::OTT'!:"#4V/HAS+C37#O[(UF**,;\E&??'L;QMU_H#= ++
MY8+Y. 7LXX_T6Z%^(<IJQ#<,#S#]!OYKTE$!KC*CT7<I_8SYF97,5/ 3Y-Z-
M[[4;@3F6VY?G&O<B<.Z&]GSB:\-T=.E2/:!EU0*.:8FZ%YKS?A7N_.46H[F_
M0T-X#SF!8STM1 =&Y]$]+FOC2&D+[G]N6GS6A=9NKN45+WSE#!$/57U8N(31
MH".P^Z"^7</+*Z%-@:[AN6M_Z.*PXZK8XQC%!MZ=J^ 3;#G9;][23Y8/20ST
M:8[O3N&_W&2(_F X5N[YVG >_X('3,"4/R[C^-0Z[?9!>+21$70KTX=:!9%B
M7ZXY\!!S8*'B3/N1DL@@E4>:8P>E#Q]ZM[SLTLB1'5'39+H*6C3.)(3G7J^+
MENC3_-'9W'=4<\E8Y4'<T&?44\O= >+X2N+QBZ,B"),GB?H6OZX]Z)<2*(V)
MTS]@?_M @COHP%AR$21.V>;*?U2T5Z[:SNXH\'Q:,EO17K5=U9O]T4*UYAIS
MQ];HE#+L4+^1^I?6(^F2<NF73/N65BH%X:N_3K5GO_+_/-"JN*LXZJ>RL;8^
MO88-6\JM%U]C>;.>H%/['.9YV'P\,>M8871(/[,ET\>!MC:G.]X60#64GA=U
M(0L% 3HS\6%W[ GGJV[]\$Q>YSWWK?[C?+[]KP9XK??:^M'"X'_:Y/#JE7[W
M:L.M.6+0GH@PA30":=9E>O QYH[GJU&5-[)!32F9"FFSW3^RH'9F4J:G'_4=
M2Y*_-B+F??;DE5+5'V]B;E[Z9'UJ0/X5$B_NIC.K)$58"3.X6,1:*OJ8)](^
MXU!1F#V3E/Z[(T?,+,-^,"\I\?I1I^>[DP8=>IQ3%59X0OJYPN*]EJ=8GOD2
MV6OFN+9 1X?B_->Y9B*.9S=/FR?O@^3Z$_9!JX,D\*Y-N&M[@!24G2RKQ1U*
M#7[<LL[VDRV0XT\-MN@<RX+>M&9/@\:&3O5HQ$ %_+ 2P" %'B<WQ>9AQ(&?
M/PHOIE&]7VY)FS'F>W@Q,K2=,:SLG=F5R=WA^%N#W5(;);IOBJUE(B-[AGY
MER<P<BPLQFB/@)7'J(]HP[_64U'/(;)(!CK.J4/1":BP&<MGZ"4:'=[UZ[F%
M#J.4)!$V>=E7Z<,DG)2 V;O6.H9%#.0TNF54(=G#=MF13[9 XBB4?<K4;13#
MG4KN JE60/M";A*LBFW#:&=6, 2YNF[]5 5VK$-F?/O!KH>>6 K&8@)SB#[D
MYQ\$G"4T-=-S,A;V#*U&&-(F"N,[35K$)1WL(US7A0Y)S"W A'4:,.S,E6G3
M8'B3<#(-^)- &4=KCGT/>(Y@&#HS2GJLLY:*)C'!%+S$<@NSJ=!7]A#CL.)
MF]K1%,&H+1:?B]-#"KTZACYPB),\PO.)@9V$\\KOE:D3/7@%$ZH@ZC-L_?=
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M>EV;1U<@8(9>;UB9QU3N308JKLVBR,?9LS]69Q\DY89VH3"CJ0)PVU&L+-J
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M'0T)I':3&]O] HWHT_(U,[Z:SC&5?\LK>S5?"NTG:1Q%#W>%>A5YTN#QLO(
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M5_\;YTO.;I"S0D[@@OPL(*P80^RT]4:THB&/IBV-4*,Z#0QO'^#(K$''Q=0
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MK7T#CD$F MIR/-L=I+87%'M!N!:/.D2;1^_6D&G="8>H#LU 8P-@IC16]U7
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M:"FV*6MT[.3EVAYI$9J7A#9$[2=X*/R0AC0D=OJM@]S +7SXM!) XE,2));
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MD9O# (^34+:0L1P2L;W9G_%1[4M1B;_*9)Z(;\]#3YU$A[*T:8G?&9Q+=0W
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M+P<0RV'LI7*@VIR^Y:)/ &FHO\81/'#C-I#1J7$;\&SH;WR>C+<?XZP?2GO
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M^"Y\;<;?VO&Y(JA",7CC[?B%/]QA_.$^X_>$A6"SK^TT;6"?A=\8I#GO%B(
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MBH''S;TR9Y&9 X?G/@OKV;B([_QDW@-+ ECVJ"O=)&QD&I,,)V*2#9A=\X=
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MIBLD],Y,Z(O0L2;_Z,>%V4:5C!(PY--<D7Y&CR?#DRU9X@VZ +L3'OPZE K
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M1+7NHD6*@_XKTR'-V, 2=U(UJ6-R8H/8K<DMUJ1A]ZX="+=Z)_OE@4$PA14
MU,ZWHJEH,0HR8UH>=M@_6,YLOB<PHG^A?5I+;_4NUL3KF&YJROS64HK!(>HC
MR90_;Z$+_C$_AKI0&.XO  S3<BJH#=>UV-Y78,0<F>P @H=Q01(96T#*Z&CJ
M4_NP1!B;#_'8EF'> I]\+VR?^V-"ON&)V%DNP"50.J)X$#ESZ>_<(XP/CV[R
MC4%6!92MO+#$L$G>TCXEWW*;(+>>'AZSX)3N\\<-?P31_!'ML_Q;N<&^%OH2
M^]2\;@<#FH3Y9BAWV<TO9E']UY'!."O99DV[MGRZE'=\:+WI2WJ(77'+^YWB
M#N5+ULN.*COL'LTW9S6F$<YEL1(? *3:8:):@=I7"I#\H#:9\/20G?OWJTN%
MK*-#Q0WEZF(/"H(G\BH]JEFY&2J8,[O_JV<,!:C:?*B0A(=A4HRY]YGJ\%G"
M!H%R&*>]C#C %F VH=.[Y#@8MF)1-X9]JJO\MQ]8,;ACZIN)CDU^<7VP:,6*
M+(H=X935?WI%#!JCB**I">@!%E<FAZT&W4GFJY,VGSCKN1+PW30>)!P=B2;P
ML^!&Q1J>7Y%WTS@8KE_3:_ZU=SIA+).-!WA6&XDT%<YJ'0N+#W^6#7&QDH)(
MNGB3<:TU(/IBWS3VLY/36%2\@5#WI+Z?QP^*TT1S>)[\4D]?3ZYZ6+#G";V\
M"VDB D:G[IF[_@<P\216M**S>I6??4H8EXXU3(\R<]QVX]1Q-9!$Q[;VR;6E
MOCZ@[OF\0HX]XSBVV"XB<"SR2\8%>O29-+*]FEZ8Z@T/7#%CB:]$*14'IQ7Y
M6:27K;#[12"@,AWAS-"J\S(8'&?KUMG$84*M9N]HSW0L3[Y^G902O;^F0G>B
MZ\N]S6*+W_?E0B"YMJ\@MVR5[T%6PK[A06\^@['C6/ADM#"%L'L1O])[FT&@
M+1(]!O?(ECB",=4E>-D5-<8CS9?304#^+7;:N,I=A<,)HS'EV@HQP]#T<DVP
M*O>O=U1U$2AQ(^5M_8BZ .A&(/U&"=,94-0I9)CC6S*3?F^W_&KZ=T'$^KPO
MOJ=^Y(D6^).9 4@7%E.241)-GT >A.:Z3 *6RZ7!Z%H_Y*)+VQ19A-H6'KX9
M57+AXT(G3AR[Q&36U^VXJ+>+/2']M&JQ:;9J7AE#)NL?W0*WU+]OO=B*?N'G
MK1_]LB!:<G)Z[4!K@^;"/_X''C'OWS@CD? S&NW%/09TI:!@=995H!-Q5SNE
M(Q.]97PML<X[Q$ G[]TY;&N*,&KX3$>NY-D+ SWM.F?8MQD]_?YB?9P6_%]-
M):,BR*OKBP,YC"&$N-/M)\MN(QA;ZF@JV8^26C-=6SA&<8_?O\I1MH[[5M;1
MDT/Q^N?,3I//;9>(M]L.\SS(VY*NW#L_=V9$\%=',XI-*<+FQ]F_,7+2M/3X
M'[4RHU()7*TN_,>MN8U#[YI#8\S%7WZLFFY9&TW3RP=*BTT]BHQU$5:"':J2
M60]^<YJ;&D!N4/'W$Y1"3ELQ2"E1>/&9H6^^EG$BOG2#I2S_X-W:GO.-W[??
MW6_;MN_IZ+YXY9K J=X(A"#[)NAQ)#(E0=4I,^%(Y[XN8D6&3]$LVS<RHAI^
M#:@?/+H0\^+OPZT^WB"-Z/Q01>!,\4INMD+$>/C:7,1G_;5=U.9/@>5N]0$4
ME/&S7T%K6J9_MRV4<HA[ZFF.(75I0%Z'RH.(.]YZLQ3L:JM1[)2Q%AC\)2Z,
M(K9BG/LNHHKF19_JS(EH#'UU5X@NPH.<@2ZF<G*AZ>C=Y%7WA%'TC]^Y0GR&
M.0&&\" -_IDV_Q-]+C'A](V/4,0OS/^U\[4C])^LXW^!)2+X^-^)YLQA^/CO
MBL,]+5QE_\:#C)_:8R7I?L]S288MR>)>@"6AUS#?8;O)(!=O$_8SDRL:_^L'
M$.!,STTHQX*-]G1:S&F 57?\PN%?M@B5R#K%@XR,HF<IJ% >Y',HWUC\C?X+
ML?-R@U]'LA&LEDO:*0CFQC<ATJ2+U87_:*N$+SA[IXGN.<//R(.YM@L0HS.
M(/HX#]()94M)\A4+</TL0*TG:),CF6Y@!573?@@MBC(!H,3YX[\.Y^_C@ 5
M$OB,-( 7R9H_ [8OPF11%HAL?S$06[W:CD("&L5WDJ9)W./ '0PUC))$5D[C
MGEPE+8=P4M[K2E8'E?SSZ>[=X<<%<*6X2-9+>BD)< (\F:J<S@[MN;#SX&-@
MCBM2Q+) ]Y_C'O)CWYQ G5_$"Z(.MH*6+ 12EY9<Q#YSYQT\T]033C=B>2#1
M_7Q_IA&IF8\(\X0+\Y$^K$(Z9/<OUS?5GR^'[GT[_J%M=/ZF@9,CMO!0*36M
M2;7N.:.A%1E\GA9TB8]O^<?H:].&LK9=/H5^^E*9!'_M;12\;+JF6N-RH\T!
M"X6UI^>F*C-;7*C+P\6]K<=F8ITS;U8^R%=SK\P<=H[^/C:(O@V3XL-DY,+2
M WU$FH+6A/G)E5WI;*TRL:^I!'P27-K<&$D.FMPZ$'YV9AEQD"N"5*?)#&3?
M47D60<MSKO@#J*L\]*B^]D/+TS>!M=[S_OUL&LJ#P[=YU_G:@:QGTAC0?C39
M@[68\VHCY6^D !77QPCRYI1QY=F& '2MG66!NL:IQ<DA87^ X4#$A/.X[P#B
M</3&[#8SCO&MG@8GG\09@8FTP(=YC!@'X(M,;.3]A1<,)T+XZ5TTIM#4B'6
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M+#TP;Q#=-CR0A@[ 9QJ.Q"]D7UJ/1%^K@#GB' H^Y/\5H@@&1-%/UU;,I,<
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MW206_<,_E"-/_E5GOO_([>0OR)]2N=_..4]OX_=&$5%?)R=_FQSA$#C2W&Q
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M3_J,^015%)2VB'#USFS^*1)%3PP ;X)\]A_8#F=OOW!!%3=U$0&8"]NYA*U
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MTH K)XP;R6GL(L2O>]/) MNW]_@6(RMZ"1/;J7+4[TAU1AXIT4"P9:7WV,N
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MAZ(B3=7/?7@C^#;M6%1$M4F)1_>TM5]DT36/.2XSP(*51.40N[D>U#R#7LI
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M8ULQ\8$"Q+<M_S^. ?K+(,3"?)< #<)B%4\7J 5OX=MR>K^VG0X("!C; $D
M5B9M'&C%BU'/[AE76^:.NEU>)3WA6ZRJD$;?.*'A.CCBT(X"KD2/U3/A2R"*
M(_^6)(Y6K0)^,,T35F#; =B%*)8B(<[X G9/ 6Y,6_E)!T%;[$UK<P:^-:;
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ME_H6PS0L89][;N#[GTV5%Y\DXU8\8^ND)*5JTDWD;,<"+-PPBF?3W*83_N#
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M8L8=G>?Z6.[\68T1"QEB[3KL*QVQ6M-K=A;(R.# "6!3=Y<*\&MO0YT:\Z6
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MR\>M[/*9!S;FTA5,8/#@;5.5F*J8(>!;?IW[=%W2@#$ZU=G]I46^0W658VI
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M[[4IXP][#H;0.IX6@>%2A:)'&"46'O!-AJ$ &'N5X]6'TX-LQ8<EF9!_LM@
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M]/+_^L_R?^(E^0;B)1IW>3]R-^22_F'$J%CR28.C!;#M-&0:,# AR"Q"[,3
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M)&]#;DL8)IQ943DUDTO?OA1,-YFDN23;$G$&\71]Z&X3)HH;*9T!!\A"2Z8
M>DRN2.NQCXTJ.3S)G&D^UKOHD^?@;C4"E<VZ/C3WJR7\^T*(PF15PDB]*[$_
MH.Y8YWRHZ]"^4\1N4>"5XGK7 ++?_OKP/SZ&$P[4$QIUD'BUPI$.;)2ZDHYG
MM6G^<X'Y9(O[MMI\=.?:"(;)#K.]"C<6$/6@&POGL$=^#65+BC*;23&X[]HY
M]EWEX'S@Y!>=^5M;-5SB$NSO-E3NS'OWPBJA I9+DL=98'W UJOB([C1@V@-
MZ;Y0B?7Z_5];OK/GE50+*[DLO-X[26C[>@4C[DC2@#F?0JA4'6#L2+23N">C
M!SA=Y7]V&1ZJ8)=AO=JAC*16[UKHFN6S$S3W^G]2"B3):8+1JVC K\6(3QX8
M+<&KT=6A;T+D\PTYR)2\O 0KE1IA&(+>^MP?):/9$B/0_12 +(#'I0I@VZ&6
M+S07L)DEFC%TEJEO06]FT#AM=WWXD"!I1?WX:T&G%@JM-DQ@!@> (<4(W=;?
M'>(=+85I$>1==<J!AWQ2F8+&^4MLJS\>UXQ3'"*VG)ER=:O9UN!\XA,F2],(
M'HLX9Z.GE]__23,^F-"&]PUML-6TTLQJ(DZ;P>N,!SX]9KVLWFIE@.TY;Y&1
M.OEU];,C/Y/X"&>)=8#P(/+D&/8H?]A.UMIP.^$5QW^!$;JQE(+.*TBVDT--
M=PP9<VW&;2ICV&(VA$JE%QJX<5'3&<XG;&Z%U-*?NN[HSD03:P[10>VKC$1&
M[DR4.3C#0JOA1DEJ\$N D!>WW$S!C: -J-5Z/I 'N*EO3@=4AFV7P4H'[V#)
ME60>L5A7B]$$P8*[I[%)@D@C0<DH\UG0LXE/ )?9^;H5ZU<S)&L1->A%IM@9
MN5P$=IP"-^3R)6K 3#^::EC^0!+=-;::@>G$JV-4!V"*"(MX2S*FV6O"I%0E
MS:<-A-,-ISJ7K'UMK)/79KT=3W5=\_899RFPHH$U2SXY-XV<]ZI#/J??/[4\
M@;]X>O^AK)"3FL%:2RA-[Y@+-\'MZ=$VEYJ>X%NB+:-3,;>906P7E:B=_^['
MO&(82R?87W$+IXWRG@O G3T0YN7W6X89[9(,*S@_JBG#;*HV_,WI^.!:U/>L
M0NE%FC98(:H'54N1\:2W=FR2NB2#+!,$U$P6X]J&W':X3NT;#"&R;8H1BWP[
M)$BY>A^49U\$<D0=UWGYTNT86']%S=9V4)5 /;3B@"R5[A[/\+J8'0%JY*6X
M3[4R$GZ=L1K@=G96:K-0JA)#Z!)0)BQ]*G:0[ &_2=]LR'7*]VW(:4@,0/=K
MG>M*;H_!BF)D')<@$P)(_BK'E(UP!DNI<:WQ/;8##.(H7U4=<]D7Z"+%\FX6
M>H>EZ"?HWZ=02PY/D;<\OCX0'-Q0E7#TS,U47']@HE]M@4CGUF5WRUH_!SYA
MX#006N[D4'[2HOY4:(UA #](.[U),+>M)"ITLF$^]-/:8[NFQY/@H4(O]8H/
MM]^-]&H2&HOZ_IR_UABL:ES\8.;+FN8_H;*\XQR@%^( Z=2<#<@8H)3H<OM1
M;]OG>?A^O(($(</?%%VL([!:@+.6P*'4:#!&H%WB\ R6*]W[VM8AJ<7MA\"M
M[%X23E[8CS -CZG#3+B!R0U%_!5GYH:<,VX(D$XCJ>=)8KAT8LX6:N/C<^RP
M@6#I'="9V4/.P2=Q2Z261#241%[Z4;-["AFGA'[3CB?@E1AQ=PW";.5"%FMV
M@,12^%&!:C%)#6O7^#8)9^+U=DW)8!_T5_S'MA8S1HM_R6872W8PZ\E+^_AH
MNY=VK(\[BP+3FV9"B@V4HV*"2@W+([RMMAA^CS^=IGA]R#<89A'P$=DTE7&I
MS3XANFJA9RWU4E;A*V \P#BJ6CN'[7,KK'FZ47''*PLS0>*?@$7HM?5W]QF.
M&W+G-^0*D7I6V$MB6]P(<E/PT<[I#;EXM";V.(FM2\Q'6$!DGN\47 ]H[FL6
M7/%_'J4-]?%5<W^-X3W*(VE"=,'/D6@\?U0>)9@&6K,%MR5VS5"P/X8668OE
M@_(GH%[ 4>0!$55(*PJ"Y$PANI3N (4)16Z0+_!#2&;C.9N"QG$V$$)X[&F9
MZ#RZ!*\IPTIL(,3GPS0PS?U1^\J$*H.L;F P#VL ;,B= B-Z2 3:;CY)\>0Y
MH#8GT&R"%=CT<(*27^^^[:9Q%!5#&U2I$)BB5#RAPALY2Z>-";D6@48%->A"
MIF<#3"W8-L_Y?NON_N8Z'\-QWUH_:EBYZ?*^R=BU<U%[;EJ>3G1_,Q[QQ!4>
MZ-E!UD=HJ[MK>I]N'!\<W"Q&1[F#0T)D+EU.<FA2:@S1A\*GTH<,XOH-]3O&
MX Z&UQWSJ:MJF%4V!W958GL__K^2.*.$[W>H*B@68O=$\FFO]Z?[M]_P,/(6
M][;\H\W#EZ U<!88%U' 5 :ZV/ P,%B\(<>K11K2O/BCA5R "!$BQCJ);SOZ
M-^3^D*B#JBS$WO4[N!UOW@\AKLOX##9(P6R9YU<42_<>38H!U0=TAP=+:-%U
M<PG)#1A3'R"%@KT(..8DP_W%:KAAQ.\0$=06N.=@KXCC5 MUWR$<(;( 59I%
M(< =Q388% NM3EW_'5U@>&02&R,<:M$[";'YQ-_Z&D,Q$P-ATI:ZI3"65'\B
MQ;[%Q-E _>1B:'AM23\?G(K>2AM2<M_9>&CZU'-^,S\*'W6H,"U][^.="<(@
MPWJ=:7)A8X6@V12E8+7%:-_'6W\V1:=F ),?/GI9#Y[^;/$.NC3%<LL[\[7*
MM+W98XI<\&J_3E8QL+8PWI)++F*Z/3*T.;1L(K_V[[]^Z],QV';@2*F"CB&+
M>"S>5*[L]5]) ,IWO9X6VXH;B#HP]9U85..0+?BQTB).QW#YML^1;=!06#>8
MF2/Y[2%N0H3?E/P!4/XK\10:L^E? $$65@5NT@2JMK4HI0[*#KSBAC9EZW[S
MOL0 5X7E-1TR5=5WG.Z$C83&0+PLWMF,&+1:)%8+4N&C\_!:M&!@9'%)H%4"
MX)E1<(3CM.0P7[Q^8$(P6B#!"[@&"SVVN7!CT-\=G&%V ER"M8,S6O&=:V-2
M3R_7OEURK#;HT6ZG,N;K%KB;8;6C$\CB)UR8W!]BH3&!#F/[O7K2;#&TVV<'
MH9MB,9[M6V_?$UU(AD=<P$[6.3WA-O*;)IMWOF[1O4W[6:JNXY=H$W).RU2>
M>:GK#*AI_G6<R:_22 RL/H1:8_#B!B@*TM=HU62I*<9P-*H3Z/U1",?S2PZ@
MU4+?AD0EE@ _!G%&$/YATJU3(8M.]PWDPR<E=I<;H8N"2RNK%'OGNTK/5IR]
MGU6&Z^&C*//=?%&!^-AZ\W-8&S+//7=9JB]]B6PC+:\*B$5Y/T0R=R_6A8I8
M##6Z11A$/ 4B63)EXX/;+-D+.K)2M"%T?S==<=KXV8058C?6#)#6"@PN1Q '
MPHCY>VLX2.5UE4V0Z)L@K@_VYH?0?04FC/3G,YB_Z [9V3U *HU2AH@"QC7.
MAAQ;7(#;_183_CS+N)M-V0+5'8>NDC'JSYWV_FQH%N"W8RX/BJ1[0'09[]FH
M?E)[>"*GNH8Q6_*R,1K,>#C!?BU*TK[]"/Y4: SOMF+.'^*\^5GVJ=<\X/F'
MV\5!NN4G^F^9'*HR=L+<GOZYIB^_1=7AYXANC3%_Z8F7RJVI1U,Z_0%M=T:,
M3)B\"QH+GM*9,C42;]_MPO]J]FO0?6 9T.(9@* 4L'$5D*T0E2.Y#+H(3?M+
M?I^)2,[DQ8Y>35_57>P.NN6+N>@=,SBG@["=2(_4^GK$+4G\WMT+^,X)JFUM
MF;X3G938\Z7<H'JZUC*JOL(X1>RVX#0S>"6%A[PFU<=Z@"L;<E<9CP40%51G
M-@.B07YWOX$[V^D/J2DP4" 0CVI+C@'=Q1GO4\+&=HQ($KA*$DUPVQ6MV9"Q
M\W ?>^<K/G-G_[&3*OA'1S_"*D-M8-<02VH.=MT5'Y6.;\CI2C+Y1!UH<6T-
MIKO$4*'!!'] ML#+9'Q@Y:!/+RU>IIZ8'A6HRI]:DR6YK]07*[1U:3]S68PJ
M^B9 J_$^[B5)%^$@V0Y5@"E])%U\BNULMQ_D"# '-PDWY 9DUS]( I9\UQ]T
MHG)ZT$7GTFWU)+Y3Z2I) [KN_:JY3C)]U@+/;$?IN_/_N*)Z$O0FYNWJ'C\W
M9=5SXU5,=LM*-++QPVU47!!I3P2J*NC%U_E; MZ27V,>V<6@Y-7BP:9O_J%G
M/OI.E>CPP6!_ _]%.]9$N=:MF$JWC+HH.S)JS\N$^9#%?^8,6YPT:]$J5EK^
M>1=Z%6O&=:JW186^=)")(<_OP1_)Q1)'!\**.9 I,GL,/05GCP,P(D);$KW^
M0&H%O13+V,L%1 EN4?C62?R9J^>PF_BJ!=TX$T,3*)A_E@9&KA+AWGS*WQP&
M\QE*=4/NS$(00G="8LU?R0SMFI2Z$ 1Q \GA/"YK-(>[E7X0>PJE*)%Y^6LW
M,4JBM/7K"+M$!!+4)DJ-0B2FP#OZ5A ]:!!\#"H1K'BQHO9!=_@,Q47Z[Y"P
M]FV2X;X9K%M*YUT5+\_)-6\4\V);G\G.<U1!C:8O12\F4(>?.+(C5_'F1_;.
MJ.T4\\F4RN+&3VMM#@\G&GT.4,ICGTCZR5.]-\T"./0CT;W/6CP&#GD$E1[<
M7]8<KO2">7O$JN&]Q:G*5L9CX'%C 2:Q_$JILU[V\]<_WY'#6E0_&Q9*CE?T
M=W/0 RC([.Q= 8P#$]WN7K_-B"-F_QJI+8@TPXWA=\ZP?R!U6[&_"4D%<XZ@
M#1%T&F7OQQZ'4FO?8MSFGW>/ K-\F=G1 43"@)H_T/+,!WM_(FI_Q"VOM6 &
M;"'3#;E^M#H6/R/Q:L2,,6+QRE"9H#O_O$,UFFFXO\+O"920\@A3^57(PAD\
M?4U=5V<]MJKX/1GO3AO/>';$SW1RQ6:9^H='W0?V&#EW"'Q+Z"[F7ZTM/QVW
MS>/H2%Y*]O#^VUDW9QGV@? &:G \0Q01%1D64;XTTQ^==6$J\?3^-U;:4XO]
M(3_?ENBJ8]O3;H4'FY!#S;Z9/:6LT!S,V9/%,45U174^&0_]ZXM:EI'J^'AT
M+E>)KB0)A,"'F&L3[*@_(.<ZC- ?3(.T?5]+7!_*G#GVR&4Q:@>$Z'.C)#0X
MEE@[M#@)F=[\=?> B;@N<)>N6YUQ;O]+H[7W,%_IFW'[WO#E8$Z*J*$Z1O;A
MN,3KKEO(Y/4NCB6I+7%?WY')[=RP2W37=Z?>O7,U8/VU-^WEU3,I\T@F^G>K
M=!AD0EBNX\&V8,H$6\I!6ZFB&J@M2D3M'!7\.L2L2;>+YZ1(K$CZ0V(/B=^,
MQ!*8%XP2:4F\*W:^W4!Y11$5IA654&G D)BHZO\DLA0DKO *;;\L$GNU&+83
M&0O3QG$ODN01>S%<=@\Z%[M?K ZI][5C+T%WA<1\G!X 6Y$7NT-BEE0;1+/"
M1]4P+VA97%6):1T4SHK:!+JU\%-4XH.0RNF'K5?VCM-^2TJ&3SO.]6+O^+>4
M]/E5>P@O_#,545AM\;CD\/0@/\J;4!6MF&'1?R@B" FOS:XM+/>@//(G^P0L
M] F2QKXU?JJ9WNDDN5F7Q_HXV7%[I#QTJKB]:E"]I#Z;8C%E?JJXF6\6>^B=
MCTGNH;T (X3U\D$DW!"F+G[OBDO%O41OICM!ID+3?)HOJ">H<HJM@LG:MQT;
M"YB,BMJAM[].S)^'NEE.TZ1&*$EH2!;8ELSM@-#R?3?.=:)WRB+)',W!*V -
M>)&Q#L[/VN!=4H-Q^Q+38FA8N.XL"%[Q H7\0?9H(7([3EDZ@F]/6?X&S I(
M^5\0,$DX./K\/7J ;@]U-$.@ $2T"?$$W=5LR:5,?HI,F:MN*;\/I9P %8#1
M KB_(-)SAI5UD7&Y82$KEG@'K>13+*@QJ5KP[Q?LO\UY_)$T9<8OO^3SKJP<
M?AS<7^_*,_)L:?BFK G'MG.:8:C?WKIK.DTV#4<O#N!#F-&/;SYXT'1Z,2;Q
MS\^O(TH5ZV$Q:)UED#;Y<7E:72=XTWJ=UZ+_@/2A+WJ4L3PO0);B]27[9?+T
M$X2_)#Z&Q;;1H4ED F765L H.@.6O">RCL3QE#-__&_-G>=74UO;[K&@($BD
M"08E-D2:;(5("T%10, D$IHB@8>-;)H0I6PBA&2+0.@\0B);I$@)(4!$!$1I
M44+9PJ:% -)):-)D12E+"?#B>_Z$<SZ<#^OCG&.LL>YU7]=OCCFNV^T8: \L
M.F<V#7 YUWO@G7J"E<?8WK*J#JU(N>^<OD629**%T+&((C@L16Z"*36JSY,A
M>>#52=V$7+EI@-R6"VJJI^Z(>77'3B@0[860%K(<,0(8G'3G;)E@&\!$CWS1
M'3"5"=:UA-?$A>[",%$;I/'=]_B[:0DOE+\BD/"*(R?V?O45F13>YHPAGM5?
MO/31^'6*6GO(_.9M1P:%=M-,UH/@?@Q*>Z^F:0O)%/@7TJ T/X^@LH$Z.MKA
M ;7BLS8WG<.!,M$$,Y)C25^V)NV4Q?2=<CG^0E_!L>UOADDOM%).([[GTUR[
MM0O0CHY^:P\FZM-1BE5ZKIC3%OMEK?6Y_[0_;5&XX69]XG/,]>O8?_\U+XFR
M%G-^MJN]+?SNX7U\@RC2)= $-5C%EA1=X4X/$N$'XSVX 6O^+,GR5\LA#1Z"
MGK7L"/3=$^%=PR?P-RXN!(TBGQ;?;E@]:M 9[!$ /A;D)G")^G6[ E+@#SNP
MJ[[!X&,@=]UWZ[E(%PCF=SV98B=.R)(,?.Q(/+:2<TL&\F1UC\A>J.(LI"2(
M?,OG,[/8DE52]@*((J$0Q-@-(J[R.V6K<)KK<[:8JP/(<V#NN@28#%N:YP<$
MNPLM&5.8S]?6[X/XS;/$LP/P+?-%ZWZRC^X>0FD+[&#Y%+ =U[4.-7:[2ZC[
ML/MF!:7ST("J/\=E@6<,08 /ZUGT]X]908/8##4E>]F4-HYNCE7TK63C=S^<
M.KYG#<K&;)2T4_UY[5^F"4MZZVETS4=IJ8BJ%T%M$4:UM.Q#RC=/W$1I#\IK
MBG@/;)2_'NO0<"X>D^"MAU1*S^DU"=*3U"WOG+L4E&A710XM[=39/OLB-W$X
MH^DZ2!;J*-F"Y")P?4J0W!;#'>%+KY0L#@XKUCQ>G5#N+FZ[7"K<J]CW"MYI
M>Z4O)+$T\LS5M-8-1U[9;+]^QUWV/^P$%TPS^_'/N0^M8+JP>\JYU7UH5YA^
MPCY,#)603XB4MPKJ[?CLE%\-PW_9N_43/\!;X-QB)GY[ 1C:[H5Z)^N*,'QO
MGDAR*G%%=1A4[;"JUP6<FUV<\B(?*>T*6/IZ/#@8MAD^3)0#.0%YA(I?-"Y&
M/ ;*\_&*HNN- (X25Z\!2'V<D*F>&-;BP&2J5;1T C?YNQQ/Q!?OMG?UZ#7=
M>%5E('N]@K]E.6([,)1'N<:%ZQ@[N1_LQ*:<BST7K>H1OL["2"T]&(K%T+0=
M+?.T[YVQ05C0YM(+CI\MJ7\54FH7J^.T?B'G,JJ59@/_K5]S1^R/8LM"9J2'
M<S/_X8\LX&%TX>N4>O[3V1^([)NNIZQ@,:TE_;^]YO"%\!VQW\^7)YMYP)3!
MNVWL/8/-.3+I4P%ODQ"10BF.'N@]U=:<C)F")8B."7:+)6?S0XXN,)LL],8-
MBKS+11: 'Z&4D]G*X*_(+S2:"DM=.4R4OT?)?"V.GA&K#WNSF*AX;6%MP:XN
M0UTGBRKO=RNI?XOFPLM)<UN#]A=W3Q6XL(PL@Q8X_:'SE@4)22^RU!46D-9<
MIJ;CR2V6IJ+G>;1<4IY3LN;KM =,M'Q2?L+Y_-?_3VYI&>+C<J614)$;T# 1
MA=06(0"#%HCX1 ?>=$<L&GF:8'M%6!.SXEWU7Y0_?/RQ &=FSWWE]98J&3"=
MV3M^3(S0_OK >]I6SO8>=8XD4E+]P^XJ2>!W'XMZML0@GQ$UR(]^*[A.O:K^
MEV4"XCP0[YER5=Y7;?_3@N71$JOR7@>&89/#E)%F,!-:653(4W.2/.] M9^A
MW3A//U8UHY"&NB,WI63(>YB8=<;0/$#=T+P 77CF7+ER9^&< C?=]KF)JCM]
MUZ_KYH%[.7S+1(#")ST%:FQJ^W2KNF-KW?]":## ?>B&WE!_U*ZE>@V$%J5#
M*/>_5F6'85X/5'4D1AH;E<']M5"6_8+ZM['WII!&HN-"]6;3,\XO^.YQC<>)
M&B!-D"O3 :PTLY405X&_B#>$)41--@Z+PS2-*_"TB8^ K]\M^D_VPT^] O&W
M!E=$GOS#2K=3(D9VQ"C#HHR F<B#%HKJFJ_09=F!CWC9%G<W*DHU>?W0[0&X
M48&C<SY-^KJ?AF6#5&\9P_J=@;7FH8L%RMPDA3/B:,U#F72X4V)1?D8E[5!%
MLI\\1?N+<[26'56S23XU260,[@$*^+F<W<Y)EM'''/0)3TG>-"60K_<@Y=U!
MR@UN:')$T\'K '7\("K8HC]0>_^P5=R:[F'<@HM;1=G\/DPM3P<>Z<)UVE3-
M"\:KX_! &[^:\62MF_(V%T*$^$_"Y',5:N(1$#S?] #L(!A3_S"R>($$-YZ+
M]>P;M.A/38+K>#KQ$%C\TBM(G&XURG+%:=-U8_"2[:B=B^"B89*CRUJ%8HD3
M,[X46_VH"U5;[8]V].OR]];@41DZ\'0\\YEJS'$UA*DVW+ W5BX;>MOK\ DH
M@6 <<@;M')3ZYLG#)[/U#G3O%9-OK$GW_4@&W]17=(+O/$ 4]RSV)1WH?\$9
MON9'DNJ#1VCA#!S[ZM5)]SL'*=JAIL:MK9Q;5;TSE34-;RJKJ]^GW-;A)U]<
M0<J*SO.(%Z<@^Q=@TB35"8*>X"B];%$5"23/18D,0OFIQ_VVSSP])Y0IG3J\
M-Q*^6B[OY[+:VW:A,I+EXC;FEW;:.E)[J<0JS^Z.#9;V@ZX1;&F7H1<HS'9T
M>Q@6WNK(99U=I3F4F'1J0%LO1D5%W7*8D>RSL]&4W_5W>89J7L?,J7,V<LE9
MOEVW4)8HLY/ RM(&(-4$DX'CG^3(@S#@2=..F$3U%[@6+HSO3B%!";J[F,&Z
MZV^R(U:]O(;?-U^K4Q,+5X:[[[J7JKQZ[FS*9L06TVLTN'S2[ E9@J18)@EP
M^,X<,D4R@+]ET.3T:=)L'\&S20K/QT$WL+PJLO2'1E7N*E^)LLJRNC.@NSH&
M_:TV-/EK*1/G,F)ANL9+^VFA&%3N$L34<"K5<'P8ZJ693BUYU_H@L7@D,/ W
MIJ%%^[)E<,*;=/09&^H9"7.:85-F6O09B=;?[)GH,M[I-#MLJ66R]=D,N(W#
M[,IYBU?!5P!R=+V&6=RK>AT^7H;@-]>R??*=T#LQ4/^P_,U>AM J :^]%++(
ME@,3 HP'AE'X9B474D;1YU%_XW37!;VA^8'+;T:KCCZ;AV41V.OWM[*1IWRV
MSP(KJ8U[B(K"-HK(:TH">8K -A>2F]A[P0PKH7LJJZHN0&:D3?5L'YQU:+W#
M51C3F.CM6_!1@,-*L?QT+@R,8%+6 DXF**Z7:"K,*1VS#$HJ0-/.?[)F0!W4
MS$-\6QBAZ"3@LR\WJLJW V)^RYI;-(6^Z&?W,#%ISJFPSYKI4 [M*<?:#% 7
MK>3CDN_4M1?Z#]@'.&9F/ 4-ULD@!)C["-VU!A3V_FW970%DQ[%"I72/$)$
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M&8A^&@/NOJ@9O.VKC=FTTJM;WQ%K8%=MI!X70I:6-\T(-1]^*G%@BB(IT$B
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MWS@^DK=;CT>/?M)K(UIMFI"ZQR\"*0W [A\ZL5L^!,8'DL;_GDUC)G-E19<
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MJP%E_Q\_L)VA_P%02P$"% ,4    " "6.F5< 9V>EC6)!  ?_S0 $0
M        @ $     8VQY;2TR,#(U,3(S,2YH=&U02P$"% ,4    " "6.F5<
M$<*?=1B  0#TSQ8 $0              @ %DB00 8VQY;2TR,#(U,3(S,2YX
M<V102P$"% ,4    " "6.F5<T3@8P-4"  #-!P  #P              @ &K
M"08 8VQY;2UE>#(Q7S$N:'1M4$L! A0#%     @ ECIE7%*3R@$#!   XQ
M  \              ( !K0P& &-L>6TM97@R,U\Q+FAT;5!+ 0(4 Q0    (
M )8Z95S4<1#PJ0D  *4]   /              "  =T0!@!C;'EM+65X,S%?
M,2YH=&U02P$"% ,4    " "6.F5<%L5HX)X)  "B/0  #P
M@ &S&@8 8VQY;2UE>#,Q7S(N:'1M4$L! A0#%     @ ECIE7)HQD(D[!P
M:"X   \              ( !?B0& &-L>6TM97@S,E\Q+FAT;5!+ 0(4 Q0
M   ( )8Z95RM3$QJ-0<  &4N   /              "  >8K!@!C;'EM+65X
M,S)?,BYH=&U02P$"% ,4    " "6.F5<'EO\]Z3] 0!\NP( $0
M    @ %(,P8 :6UG,C(Y.30R-#-?,"YJ<&=02P$"% ,4    " "6.F5<K6#N
MUII! P R?@, $0              @ $;,0@ :6UG,C(Y.30R-#-?,2YJ<&=0
M2P$"% ,4    " "6.F5<X-'BFSB*  #;B@  $@              @ 'D<@L
M:6UG,C(Y.30R-#-?,3 N9VEF4$L! A0#%     @ ECIE7&;7031A?P  XG\
M !$              ( !3/T+ &EM9S(R.3DT,C0S7S(N9VEF4$L! A0#%
M  @ ECIE7"F<T>?Z0 , *F$# !$              ( !W'P, &EM9S(R.3DT
M,C0S7S,N:G!G4$L! A0#%     @ ECIE7%Q+./B>QP( UVH# !$
M     ( !!;X/ &EM9S(R.3DT,C0S7S0N:G!G4$L! A0#%     @ ECIE7"@Q
M:MHQ(@( #40" !$              ( !TH42 &EM9S(R.3DT,C0S7S4N:G!G
M4$L! A0#%     @ ECIE7(9\Z"NMW0( R@H# !$              ( !,J@4
M &EM9S(R.3DT,C0S7S8N:G!G4$L! A0#%     @ ECIE7/#HA#FC"0( CSD"
M !$              ( !#H87 &EM9S(R.3DT,C0S7S<N:G!G4$L! A0#%
M  @ ECIE7,)JP"*#5P( WG<" !$              ( !X(\9 &EM9S(R.3DT
M,C0S7S@N:G!G4$L! A0#%     @ ECIE7 %6 OIQ'P$ Q38! !$
M     ( !DN<; &EM9S(R.3DT,C0S7SDN:G!G4$L%!@     3 !, H@0  #('
$'0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>clym-20251231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:clym="http://climbbio.com/20251231"
  xmlns:country="http://xbrl.sec.gov/country/2025"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="clym-20251231.xsd" xlink:type="simple"/>
    <context id="C_80658773-af42-4dbf-91d7-91c7e6c647c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_80b88047-d92c-4121-9779-7cec8fdafae6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_80f05462-1973-4d3e-8520-b5a9f59b1778">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">clym:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_816130b0-f672-44b1-b634-9034b70a760f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
        </entity>
        <period>
            <instant>2026-02-27</instant>
        </period>
    </context>
    <context id="C_81960adb-5d4d-4573-bc54-80d5eb37fb9c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">clym:StockBasedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_81a10eed-87b5-4e58-b248-df503d6194b9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">clym:TwoThousandTwentyFiveInducementPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_826ab126-2f0f-4ee0-80a3-17e4f28432a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">clym:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_84f00985-ac68-4cfe-8454-b7dc6d4cc926">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">clym:SeveranceAndBenefitsCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_8579d8f5-3430-4159-88d1-ebaf49448cd2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">clym:DevelopmentRegulatoryCommercialAndSalesMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">clym:CrhAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="C_871db5fb-78d1-4c8c-9435-954b2bb1e0b9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">clym:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_892c3e10-a60b-4010-9024-013505fca3fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_89c728ad-be3d-454b-8a42-c4b78f7c05f2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_89e402ec-8a69-4241-9a74-d42ab514978d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">clym:ManufacturingServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">clym:ProbiogenAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_8b239563-a96d-46e3-ad49-e8ca68499571">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_8c7ebad7-98a1-4e64-b935-7123699f4e44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_8d01d41c-acfb-4b36-86b4-52db5162e53b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">clym:DevelopmentRegulatoryAndCommercialMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">clym:AcelyrinAssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-11</instant>
        </period>
    </context>
    <context id="C_8df34eff-0fa0-4471-a95a-aa6f2075612e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_90041a5e-41bb-41f0-9714-a6b1a0938dd1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clym:BlackbirdClinicalAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">clym:AcquisitionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_9044897e-bda8-464c-bcb1-ec1f0a7b9592">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_905153fa-065a-4b24-a22c-0410b7b3bfda">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">clym:MilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">clym:ProbiogenAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_95114177-d276-4bf7-acfa-a07347587ae6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_98215062-e0fc-42fc-b9b2-81c479845247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">clym:DirectExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">clym:CLYM116Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_98544ab6-691e-467e-be62-d270667fdc07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9919181b-3aee-4458-b7d9-1a4a0eaa9fb2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_9b4e2e25-766b-4195-902e-5d8cc2e9e3df">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">clym:StockBasedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_9d3703f0-77df-42a1-9ca1-0e2e95db2565">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_9e183b21-7abc-4bbb-a514-9fac970fc0da">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_a1639fe2-538e-4c2e-8eb6-781b99e56320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">clym:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_a2afa2c5-af46-4829-87c9-63140a0edb2a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a81d855c-f7c2-4536-8f9e-51e73b2054d6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_a8e8a23d-3bb9-47c3-9f60-1878b2e54d8c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_a9351123-b279-44ed-b948-3c21858af6ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">clym:ManufacturingServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">clym:ProbiogenAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="C_a9d1e150-d582-4292-80b0-a0a5033ea1b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_aa482204-5cdf-42f9-b194-151104d06794">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_aad0ea95-775d-4c74-b575-deb8723088ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="C_adc4015d-fb3a-4ffb-9ada-76a96f681121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_afdf6eb5-5976-48c1-824a-42df181b79c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">clym:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-01-01</endDate>
        </period>
    </context>
    <context id="C_b0c73b5f-de7f-4ef4-87ec-0e261c6ff876">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_b2c1de80-7339-46dc-9101-dff3552ca399">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_b2cb9c72-8c63-4b1f-9bfe-c20a91b5c47f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">clym:RouAssetImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_b2cd3b34-df50-4fcb-a36c-6d0072bb1fba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">clym:FourZeroOneKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_b4452408-22d4-4ee5-aebd-bdfbc907dccc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_b4634d19-4dbe-4167-828d-3b0dea46ce12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">clym:UpfrontPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">clym:MabworksAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_b4947833-f3f8-4c09-9229-596d3c11ebb0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b551ae63-1f55-4c33-bec6-c98569fc1002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_b6de63ae-c1ba-465a-83f3-ca5197585acd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">clym:MilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">clym:CrhAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_b8dc21c9-0746-48db-ae13-fe4513f56fc2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">clym:AcquisitionAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-10</startDate>
            <endDate>2024-04-10</endDate>
        </period>
    </context>
    <context id="C_ba58008a-9a99-409a-9227-d0761c6dddab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_ba5d6e15-a48f-47c7-9a81-6786f5b4f65b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">clym:SeveranceAndBenefitsCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_bb651521-2c6d-4fbd-b7ad-6cfc21cd0b6a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">clym:FirstDayOfOfferingPeriodMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_bd13e69e-5c42-4043-b717-21b094f74c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">clym:DirectExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">clym:BudoprutugServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_bde3f747-62a1-4f1f-a73d-375dcd93e40c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_bed1b934-9767-4736-8d75-5898620908e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_c03b49f0-805e-4685-86c8-e850f4d0a421">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_c04dc289-c837-42ec-90ed-96b37ca44352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">clym:LastDayOfOfferingPeriodMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_c2a2497b-98c5-4d07-ac31-0ab57e9c6f6a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c4117672-57e4-4a80-95aa-824a99550138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-01-01</endDate>
        </period>
    </context>
    <context id="C_c6853a23-c64f-400c-a86c-924a3bb8491a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_c6ae4ef4-19bf-455d-8977-04567e0168e2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_c6e42dca-dd21-461f-8178-f4beb56519dc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_c751770e-5639-4fb1-ae0f-ff557e717b97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ca2a5c36-84bf-4318-8dcb-1ce0dfebe519">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">clym:AcquisitionAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-27</endDate>
        </period>
    </context>
    <context id="C_cb8006fb-9972-4de5-8228-dd0f468981f6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">clym:DevelopmentRegulatoryCommercialAndSalesMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">clym:CrhAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_ce134265-fb84-4e8d-9157-57ff9ef7e7ff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">clym:AfterFirstAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_d015dd5d-fe12-4337-9262-398335ac7a9b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_d4c5c2ea-4149-489e-bc3b-000c9f96aa69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_d868bdfb-8cf1-4ee9-b1bf-c44bf7490d1f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">clym:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_dacb7ce4-e0c8-40f2-abc8-8ae1a39abc75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_dcc85fc3-485a-42b9-b4a7-8f1dd16319b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">clym:AcquisitionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-27</startDate>
            <endDate>2024-06-27</endDate>
        </period>
    </context>
    <context id="C_dd8c59f4-3742-43b0-84bb-363445fa8ccb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">clym:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_ddbb4b04-852b-4f3b-aeb7-aa35ab1cf616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_deced632-72c6-45c5-a3ca-d77bd56f0dad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e08c8f3c-6d20-45a5-9fa5-1cb8ef652339">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e158c5d9-1a89-4e43-8ef0-1635b5f8acb7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clym:ExchangeAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">clym:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-11</instant>
        </period>
    </context>
    <context id="C_e15c6a9d-687e-42af-b12a-cad341bda1e1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">clym:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_e1c23734-80c9-41dd-8d11-0134db853cac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_e2570053-78b9-4413-a875-a4e14bf5d7a4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e3e5dc09-b6d0-4ff0-b26f-a809c7b2d2a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e56178b2-2c10-48d7-b80d-784d82a747b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_e5a79ba0-ff7c-4c63-a7dc-6397a5945808">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">clym:AdditionalOfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2026-12-31</endDate>
        </period>
    </context>
    <context id="C_e5b62da0-95aa-41be-88d8-378341822749">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_e8ccac22-cccd-4604-a52d-f88a9f26a088">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">clym:AcelyrinAssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_eae9b56b-e6e5-40e9-bbd0-fcdfa9342978">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">clym:TwoThousandTwentyFiveInducementPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="C_eb135969-7a37-4398-8643-db443b9da969">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">clym:AcquisitionAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-27</startDate>
            <endDate>2024-06-27</endDate>
        </period>
    </context>
    <context id="C_ecee46ed-d146-4031-b499-6e0840c72f93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_ef6867d1-f320-430c-a6a8-a7cce3a87985">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">clym:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f19e76bb-81d4-4bcc-92ba-46dff13be9f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f2839107-9d2e-4b8c-98bb-fb38fcdc5134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">clym:PensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_f3c7c70c-8584-4bd4-8cb7-4ec3bb217286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">clym:FourZeroOneKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_f497deb3-4bfb-4c8f-9883-3d0724584857">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">clym:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f4a412c4-4532-42cb-8fef-51e2df6f0cd9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_f71c8195-caff-4e2d-b7a5-aa6363cff720">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_f88dd6f3-ebdc-4647-b965-79b931a0dc44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_fab74366-ad6b-4993-b418-2c772c8de0bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">clym:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">clym:MabworksAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-08</instant>
        </period>
    </context>
    <context id="C_fad7a1ea-38aa-452c-960d-f95e7b53f110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_fe9354d0-7134-4802-ac6f-dbcfc70b829d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">clym:StephenThomasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_ffe66a6a-2737-4df5-8bd7-75a6156fd39c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">clym:DirectExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">clym:BudoprutugServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_015297a3-3968-4419-a989-c89674259ced">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">clym:UnallocatedExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">clym:PersonnelRelatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_0427b5f4-a659-4e63-a2a5-bbd14bc3d153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">clym:StephenThomasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_04dcce48-ee98-4468-a92e-30daf88a02ee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_06ef22a7-6f48-4029-8a4d-33c077e1cac9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">clym:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_077a91d2-792f-4523-9b7a-5cb3ca9f9427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_08d2f2e1-0339-4338-abfa-e32c391b4121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_09c5db3e-d09d-4b4f-b0d8-2f7673550209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_0b3af095-e13b-4823-afed-c09031e8be17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">clym:CommercialMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">clym:MabworksAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-08</instant>
        </period>
    </context>
    <context id="C_0d0169f6-b7e0-49bb-b22e-a0097bdb8aef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_0d43faf6-11a6-437b-94d9-14ad3457ce60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_0f8a9914-3000-454c-ab10-75100dc7832f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">clym:SalesMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">clym:ProbiogenAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="C_0fbedef7-74ba-4411-abad-f702157bda82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_116ecf73-7a8a-49b3-bad1-9ebacd1a92f4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_11bb4c97-86dc-433d-8f9f-b1671660f359">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_1209e286-0944-4ac4-896b-e702d0d7ea37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_122e88aa-833d-49ea-931c-cdd318154ed2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_12593a5c-196b-480a-886e-b17facf60df2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">clym:DevelopmentManufacturingAndCommercialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">clym:ProbiogenAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="C_12786af0-d6f4-4fe0-aebb-f1db256fd20d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-27</instant>
        </period>
    </context>
    <context id="C_12d2135a-b5b7-4af6-8957-a06f4411e554">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_130e2c73-2289-4af1-866f-b3e95291e78a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_132b3bc1-f201-4b4f-9cc1-62f73c6af233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">clym:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_135efb28-52e9-4b39-b859-c79c58e3ffaa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_143ed184-c01f-49b6-be44-844b0eccbf0d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">clym:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_1469ea52-2e42-41aa-be6d-28e711fcb465">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">clym:SharesConvertedUponAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_16927a58-af3a-42b4-98d5-64f89907d927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">clym:RouAssetImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_16c70f60-6525-47ed-a134-8055357fb60d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">clym:FourZeroOneKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_17e50103-a558-453b-9429-8e636ff6a3b8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
        </entity>
        <period>
            <instant>2024-06-27</instant>
        </period>
    </context>
    <context id="C_1898b0b8-f16b-4f56-9289-bef317318637">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clym:Pre-FundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_1b535855-abfa-4f1d-9fb5-d30b12645dea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">clym:StockBasedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_1bcd3bb5-c5b5-4602-ab79-6c587ad285a1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">clym:UnallocatedExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_1c1140e8-fbcf-4f4b-b119-b4e0831d7ee2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">clym:RouAssetImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_1cd90362-0202-4f43-82f2-856942e3293d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">clym:AcquisitionAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">clym:SharesConvertedUponAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-27</startDate>
            <endDate>2024-06-27</endDate>
        </period>
    </context>
    <context id="C_1f63916b-0391-41c4-8463-6860486b9487">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20e4b68b-286f-4226-a52b-f50692b883e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_21205dde-2f21-4a5b-878c-9c16723dcb5f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_229c18f8-1124-4b2d-9a29-665a8a728b8d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">clym:AcquisitionAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_239f2b84-9e87-4d24-8ef6-ec35e511039c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">clym:SalesMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">clym:ProbiogenAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_24b9841c-7af8-45b7-a8fd-326e3878b0f2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_259b8ff0-14b6-480a-93a7-28890d7655ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">clym:OptionToExtendMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">clym:AdditionalOfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2027-01-01</startDate>
            <endDate>2027-12-31</endDate>
        </period>
    </context>
    <context id="C_26331409-5c32-4037-8326-ec8e383f9fff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_2691b0a1-6374-46d9-a04c-367ba1059083">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">clym:UnallocatedExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_28105de5-c93d-4001-a309-95d3ba3b4731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">clym:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_2829c600-2470-432e-befb-c0c057ac53de">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">clym:MilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">clym:MabworksAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_29397fb4-e48e-4a21-bd44-1d67c539182e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">clym:AcquisitionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_2a071569-fdc7-4495-8732-ea28c8ae9688">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_2d40f93a-6e30-47ec-9b7b-b71b689a098a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-01</endDate>
        </period>
    </context>
    <context id="C_304c3dfd-55bb-45b2-a8b2-e1afe73e55f4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clym:ExchangeAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-11</startDate>
            <endDate>2025-12-11</endDate>
        </period>
    </context>
    <context id="C_3208a51a-315a-4c57-94b7-9a59ba63f36c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_3238fdb8-36cf-4c49-90ac-67c04b90e3fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_34d8c2a2-a75c-4398-b4d8-8fa4f3948fad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_3657c5eb-d257-42f6-9ce8-e538450d6c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_3764c6b2-4005-4af7-aa82-8f2372cb37f7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">clym:CompanyStockOwnedByRACapitalImmediatelyPriorToAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">clym:AcquisitionAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-27</instant>
        </period>
    </context>
    <context id="C_380311ae-d23a-413a-a7a8-c787758e7d24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_3831b4d7-2630-4d1c-a211-547ef8149bc9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_3883179f-cde0-439b-9eb8-f31242d68421">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_3893b746-214f-47a9-ab19-782719fe3a18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">clym:AcquisitionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-27</instant>
        </period>
    </context>
    <context id="C_389487f4-111c-4263-b8a6-56fb2d222f6d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">clym:MabworksAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-08</startDate>
            <endDate>2025-01-08</endDate>
        </period>
    </context>
    <context id="C_3a31c020-0ff0-49fa-b2ef-a1848d998afe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_3a734757-e1ee-40b3-8578-67d0507ee846">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clym:SeraServicesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">clym:AcquisitionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_3c01e103-0ded-4d1e-be15-85317f4afcac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">clym:DirectExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">clym:CLYM116Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_3cb182f5-fa8c-4e88-b58e-b8e49cc15ab2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">clym:FirstAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_3cce3a91-16bf-4fd1-a028-5515dbbca5c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_3d75d312-973d-41a8-a6dc-96c192554cdc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_3e184d6d-add2-4b8e-bb9b-90a0e05d219a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">clym:ExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-11</startDate>
            <endDate>2025-12-11</endDate>
        </period>
    </context>
    <context id="C_3f3384f6-f21d-457a-af6e-c427fa15b93a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_41711020-7e54-4cd4-9a26-fdac1e897d3f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">clym:SeveranceAndBenefitsCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_428a9132-cc2d-4fef-8e17-79b45da3689d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_43590eda-3065-4d1d-82a7-d6a196b38e75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_4886ee1e-e6b0-4ffe-a68d-f50c26f75b4c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_48b9f054-2754-412a-9e64-8ac7cd01dbef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">clym:DevelopmentManufacturingAndCommercialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">clym:ProbiogenAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_48e4ad5a-7bc4-467d-b65f-6be30cf02804">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">clym:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_4a576f93-6b66-4d5d-b1c0-bff422cdc503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_4b99e9a3-7e4b-4844-b231-419f9b1fc292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_4e50e1e3-bd9c-40de-bb68-3128ec238afe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_5003f42b-a928-4d3a-9175-c224ea1b673a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_50f9f95a-751c-4f2f-91d3-e149f6c84a6f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">clym:PerformanceBasedVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_51534b8e-0ca9-48c3-97a9-d9df1a0b13ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">clym:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-01</endDate>
        </period>
    </context>
    <context id="C_52e5d444-52de-4a17-998f-18fdef06290a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_54357343-07e1-4dfa-b18d-381a152a7bcd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_54db0f01-b239-4cf6-8fdb-eb4625a650a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_550b780f-159a-4ee0-bc82-3f2210b1684b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_5544a4ea-f6c3-43ec-b41e-4209eb125966">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">clym:TwoThousandTwentyFiveInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-30</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="C_55e0a766-eff7-448c-af18-1396354e6f58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">clym:DirectExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">clym:LegacyProgramExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_5917f89f-b247-498e-9e76-b710f5430033">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_59a3bf61-d6f4-4d70-be41-c0021e29d89c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_5aa3c816-c0b5-4d5f-9461-9b02539bee4b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">clym:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_5b33bfda-7940-4aa2-a368-a61504f508d9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_5ba093f0-d16e-4ef7-8562-6da6013de54a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">clym:DirectExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">clym:LegacyProgramExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_5c3cedbc-3847-4e15-a7c4-4fe16652631d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_5e29120a-ab8d-4722-9dfa-39d97775d181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">clym:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_5ebc4489-2c5c-40db-bf3d-8aa0443a01d9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_63169a3f-785d-4de2-b401-eff12e91f2ac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">clym:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_633a4534-233a-47cb-9dd5-77bb31081fad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_63ae5d9d-6a3f-4dea-8e44-bc65e7b9ac46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_64d950f8-dcf6-4e8a-9c63-e1b34b08c3d9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_6566157b-2549-4f25-ab16-6ff8b45c4d64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_66f073f4-73ec-4e49-b873-cf1990ed99bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_67a4d641-d6ae-4d5f-aded-eba6a55bcaed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_67fbe650-9798-4fbe-bbe0-3a6d9e4fd743">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">clym:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_691140a1-fa6d-479a-bd61-6df4cc2c5e1a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_692bb88f-3f78-4543-9ceb-82120ad5dcf9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_69a98cdd-d277-4823-8526-1135dd15782f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">clym:UnallocatedExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">clym:PersonnelRelatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_6a0b2fc4-e53f-4894-a5d0-249ab8cdaaa8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_6bb7bc11-3822-497f-a5fa-c0b7de9605dc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_6cab0607-2860-4e20-a77b-ee3751551c8f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_6fd1e7a7-23cc-4225-bfaa-c65b03df60f2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_745ac205-619f-4d46-a569-a29ce2487e40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_746a74d7-c8f6-4d27-bf0b-6d5329bfce92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_748a9a3a-36eb-4467-86a9-2986b4bca451">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_75ea6436-b4b6-4e75-8aec-a8b8c3cc4fd8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">clym:Pre-FundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_760e2bea-9b82-40c0-9ace-1bb642dcf176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_79c45355-4ab4-4e2a-a1e5-2f20b0546a60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_7a1a17c3-5482-4393-8497-495abe0d0025">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_7c0e8a73-22f5-429f-9ff0-a34f09540718">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001768446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <unit id="U_EUR">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="U_USDollarShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_Segments">
        <measure>clym:Segments</measure>
    </unit>
    <unit id="U_GBP">
        <measure>iso4217:GBP</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_16527e97-dc93-4ed0-ad7e-7b7abd3cd558">0001768446</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_9ec1bf85-71d7-40e2-a04b-50f075db7fba">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_800d4fd8-ba6d-4002-9a2a-dc9451e31b51">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      id="F_6e9c1843-16ca-4b62-af29-4ec50ad49bc2"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e"
      id="F_1a7d6320-c589-4343-9bdf-6398fa567414"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration
      contextRef="C_4e50e1e3-bd9c-40de-bb68-3128ec238afe"
      id="F_2a7e8018-774a-4c44-8376-7e8c696ec434">http://fasb.org/us-gaap/2025#PropertyPlantAndEquipmentUsefulLife</us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_0ecb2fd9-391a-4200-85ea-df3460e76587">2026-12-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:OpenTaxYear
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_1ed21085-1747-4238-9882-f67da405f9c3">2018 2019 2020 2121 2022 2323 2024 2025</us-gaap:OpenTaxYear>
    <us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_486ead36-778f-4db7-a0cb-c45b1a00e08c">http://fasb.org/srt/2025#ChiefExecutiveOfficerMember</us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration>
    <dei:DocumentType
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_10eece64-cd1c-4013-94b1-b41a014e5b84">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_7dbd6f5c-86bb-4ca8-8995-3f893f61a049">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_44e2b039-0d26-4057-be86-32b02b4b3f79">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_fb224c3b-778d-4671-a9de-f25bd79778fc">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_435dfeb5-072c-448a-89a7-b98d3b8113a4">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_56a8a397-d861-49e8-826e-3dde9bcea97f">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_3d40ffa5-0a1d-43d3-983f-b261c2d41f75">001-40708</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_35d405fb-18bf-421c-9ad7-0eb5428d70a0">CLIMB BIO, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_ad6f40f2-5ad8-48b4-ba30-5783a5ba1ce2">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_7032b58e-f697-4c8c-84c0-b4957f4e527d">83-2273741</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_07a96dfb-c7d2-446f-b9b4-d344de31dc53">20 William Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_824b0ea3-14ff-4e35-b445-d6b1d95c8aa0">Suite 145</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_87f6c35b-eebe-4123-9150-ff88bc08b9d7">Wellesley Hills</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_4c52b4dd-044e-4056-a1c4-fc89893e4a78">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_456101b3-5d43-42f6-b8f3-03e18ff3e06c">02481</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_7ea26bec-b6bb-442b-b651-3b6fed528085">866)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_3b38503e-6dc1-4050-a8f4-102fd4d0bec4">857-2596</dei:LocalPhoneNumber>
    <dei:SecurityExchangeName
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_a7d31672-a742-4821-b788-b236a2f6c3e9">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_d617300a-9ef1-4383-9508-6f661084e0d3">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_dff5db90-0489-4a10-ba7d-3aa624313a1d">CLYM</dei:TradingSymbol>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_8ede689b-bfb0-490e-b41e-7d795490dee4">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_9be300bc-01d8-478c-b549-dcfc08947069">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_efa9cf6c-d5fb-496c-8050-b6ed7d8bef3e">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_3c35842e-8eef-435d-a99d-e37b70abed86">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_b094bc2d-7e6f-4a16-9837-a80854e878c9">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_eabbb2ac-aaae-4edc-88cc-dffa2f259abf">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_11181031-2fc0-445a-8d38-e4accda33059">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_b5e7d694-e27d-41fa-a7a7-29a5c6024f1a">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_50a20db0-e5d4-417e-a41d-695d2766e91a">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_068c9a18-bb7f-4180-bde2-d78fdcfe3ce9">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_dc6465c3-4a78-42ca-90d8-298a9e8284f0">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_f71c8195-caff-4e2d-b7a5-aa6363cff720"
      decimals="-5"
      id="F_f0d4d97c-2268-4171-9e90-be164e2f1e39"
      unitRef="U_USD">44800000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_816130b0-f672-44b1-b634-9034b70a760f"
      decimals="INF"
      id="F_32e58395-7170-457e-826e-746460a32441"
      unitRef="U_shares">47767980</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_74bf168e-b18e-4320-895a-005ff5453989">&lt;p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Portions of the registrant&#x2019;s definitive proxy statement for its 2026 Annual Meeting of Stockholders, which the registrant intends to file pursuant to Regulation 14A with the Securities and Exchange Commission not later than 120 days after the registrant&#x2019;s fiscal year ended December 31, 2025, are incorporated by reference into Part III of this Annual Report on Form 10-K.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_951b4037-c06b-4a9a-a925-8c36e31f23da">&lt;p id="item_1c_cybersecurity" style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Item 1C. Cybersecurity.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Risk Management and Strategy&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have implemented and maintain various information security &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;processes&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; designed to identify, assess and manage material risks from cybersecurity threats to our critical computer networks, third-party hosted services, communications systems, and our critical data, including intellectual property, confidential information that is proprietary, strategic or competitive in nature, and data related to nonclinical studies and clinical trials involving certain of our product candidates (Information Systems and Data).&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We manage, identify and assess risks from cybersecurity threats by monitoring and evaluating our threat environment and risk profile using various methods including, for example: through the use of automated tools, including but not limited to tools for monitoring, remote wiping, threat detection, intrusion detection and prevention; conducting (&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;through third parties&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;) regular audits and threat assessments for internal and external threats; subscribing to reports and services that identify cybersecurity threats; analyzing reports of threats and actors; conducting vulnerability assessments to identify vulnerabilities; evaluating our and our industry&#x2019;s risk profile; and evaluating threats reported to us.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Depending on the environment, we implement and maintain various processes, standards and policies designed to manage and mitigate material risks from cybersecurity threats to our Information Systems and Data, including, for example: risk assessments, implementation of security standards and certifications, encryption of data in transit and at rest, network security controls, data segregation, access controls, systems monitoring, vendor risk management program, employee training and penetration testing.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As part of our cybersecurity risk management program, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;we maintain processes to assess and review the cybersecurity practices of third-party vendors and suppliers&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Prior to engaging key third-party vendors and suppliers, we conduct a security assessment and, as appropriate, include security requirements in contracts.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We, like other companies in our industry, face cybersecurity risks in connection with our business. However, to date, risks from cybersecurity threats have not &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;materially affected&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and are not reasonably likely to materially affect our business strategy, results of operations, and financial condition. For more information on our cybersecurity related risks, see &#x201c;Risk Factors&#x201d; under Part I, Item 1A of this Annual Report on Form 10-K.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Governance&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our board of directors considers cybersecurity risk management as part of its general oversight function. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The audit committee of our board of directors is responsible for overseeing our cybersecurity risk management processes, including oversight and mitigation of risks from cybersecurity threats.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our management team provides periodic updates to the audit committee regarding our cybersecurity program, including information about cyber risk management governance and status updates on various projects intended to enhance the overall cybersecurity posture of the Company. &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;chief financial officer&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, with the assistance of third-party technical advisors, leads the operational oversight of company-wide cybersecurity strategy, policy, standards and processes and works across relevant departments to assess and help the Company and our employees to address cybersecurity risks.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our third-party technical advisors include consultants with over 20 years of experience in IT leadership as well as subject matter experts in cybersecurity that have extensive experience managing cybersecurity programs.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_1d4c5332-e080-4f03-82ee-ef7a55195958">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have implemented and maintain various information security &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;processes&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; designed to identify, assess and manage material risks from cybersecurity threats to our critical computer networks, third-party hosted services, communications systems, and our critical data, including intellectual property, confidential information that is proprietary, strategic or competitive in nature, and data related to nonclinical studies and clinical trials involving certain of our product candidates (Information Systems and Data).&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_4db55927-ea6d-45ba-8ac9-173614ed438e">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_10259f2b-74a8-4d83-8a0e-12d5058acb59">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_af33229d-16c8-4f04-8fbd-6af584727b87">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_929f0df5-5f3b-4a90-b246-46c4d25defc3">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_33f2f5fb-abce-4537-bec6-2e62cc277008">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Governance&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our board of directors considers cybersecurity risk management as part of its general oversight function. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The audit committee of our board of directors is responsible for overseeing our cybersecurity risk management processes, including oversight and mitigation of risks from cybersecurity threats.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our management team provides periodic updates to the audit committee regarding our cybersecurity program, including information about cyber risk management governance and status updates on various projects intended to enhance the overall cybersecurity posture of the Company. &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;chief financial officer&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, with the assistance of third-party technical advisors, leads the operational oversight of company-wide cybersecurity strategy, policy, standards and processes and works across relevant departments to assess and help the Company and our employees to address cybersecurity risks.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our third-party technical advisors include consultants with over 20 years of experience in IT leadership as well as subject matter experts in cybersecurity that have extensive experience managing cybersecurity programs.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_0153025c-0570-41c1-98c6-13b070a9f6fb">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our board of directors considers cybersecurity risk management as part of its general oversight function. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The audit committee of our board of directors is responsible for overseeing our cybersecurity risk management processes, including oversight and mitigation of risks from cybersecurity threats.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_cf4867e2-2a87-47a2-8a8a-8414a0f929b8">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The audit committee of our board of directors is responsible for overseeing our cybersecurity risk management processes, including oversight and mitigation of risks from cybersecurity threats.&lt;/span&gt;</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_311f4785-0030-48b6-bb99-b3346b578755">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our management team provides periodic updates to the audit committee regarding our cybersecurity program, including information about cyber risk management governance and status updates on various projects intended to enhance the overall cybersecurity posture of the Company. &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;chief financial officer&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, with the assistance of third-party technical advisors, leads the operational oversight of company-wide cybersecurity strategy, policy, standards and processes and works across relevant departments to assess and help the Company and our employees to address cybersecurity risks.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our third-party technical advisors include consultants with over 20 years of experience in IT leadership as well as subject matter experts in cybersecurity that have extensive experience managing cybersecurity programs.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_4e26fa3e-d3ea-4955-b768-2be1407400fb">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our management team provides periodic updates to the audit committee regarding our cybersecurity program, including information about cyber risk management governance and status updates on various projects intended to enhance the overall cybersecurity posture of the Company. &lt;/span&gt;</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_f6890bce-59fd-4ab6-b81c-ab47d955175d">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;chief financial officer&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, with the assistance of third-party technical advisors, leads the operational oversight of company-wide cybersecurity strategy, policy, standards and processes and works across relevant departments to assess and help the Company and our employees to address cybersecurity risks.&lt;/span&gt;</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_289d3463-95dc-42fc-8c90-55300a8ab3e9">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_bd9b83e7-73b8-4e8a-b463-6880c426f868">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our third-party technical advisors include consultants with over 20 years of experience in IT leadership as well as subject matter experts in cybersecurity that have extensive experience managing cybersecurity programs.&lt;/span&gt;</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <dei:AuditorFirmId
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_1d565ce3-0d42-42d7-8d72-793d791c4792">238</dei:AuditorFirmId>
    <dei:AuditorOpinionTextBlock
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_a235792f-7105-4432-b178-af69a11e4bc0">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Opinion on the Financial Statements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have audited the accompanying consolidated balance sheets of Climb Bio, Inc. and its subsidiaries (the &#x201c;Company&#x201d;) as of December 31, 2025 and 2024, and the related consolidated statements of operations and comprehensive loss, of stockholders&#x2019; equity and of cash flows for the years then ended, including the related notes (collectively referred to as the &#x201c;consolidated financial statements&#x201d;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America.&lt;/span&gt;&lt;/p&gt;</dei:AuditorOpinionTextBlock>
    <dei:AuditorName
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_71a08637-cc59-4a86-b6e7-cba74f21b893">PricewaterhouseCoopers LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_9d311eb9-2d22-4a7f-9ece-531cb4e982f9">Seattle, Washington</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-3"
      id="F_51f2263d-068d-48e7-bcca-c81905f8fa6d"
      unitRef="U_USD">35685000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e"
      decimals="-3"
      id="F_b82cc5d1-c500-4400-b7c5-fb4ff384e920"
      unitRef="U_USD">87229000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-3"
      id="F_6dadc4b3-c8f1-4b28-ab1c-96e8c5755083"
      unitRef="U_USD">65395000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e"
      decimals="-3"
      id="F_c7e69392-5df4-461b-bfd5-1f93feecbca3"
      unitRef="U_USD">63690000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-3"
      id="F_b4b4b88a-d7d3-493c-870e-6ec3b8a65faf"
      unitRef="U_USD">4769000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e"
      decimals="-3"
      id="F_faf020b4-0623-4776-8a38-60fa47fe8a5b"
      unitRef="U_USD">3953000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-3"
      id="F_ca5a3b2a-90a7-4232-88d9-aa3eb8ec21df"
      unitRef="U_USD">105849000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e"
      decimals="-3"
      id="F_149401bb-7dff-4cab-b836-be11b8643cbf"
      unitRef="U_USD">154872000</us-gaap:AssetsCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-3"
      id="F_f344c39f-4ef1-4012-b4a7-addad690ff41"
      unitRef="U_USD">59572000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e"
      decimals="-3"
      id="F_8c49727a-5a78-4d5b-8d19-fd0654124eb1"
      unitRef="U_USD">61610000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-3"
      id="F_59fc71ae-2184-4b4d-b7e7-b38c12005a84"
      unitRef="U_USD">505000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e"
      decimals="-3"
      id="F_fff33242-a012-4b9f-b45b-3cbc19d1647b"
      unitRef="U_USD">490000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-3"
      id="F_f65553d1-e98e-44a6-a83e-a2adfe7ecbaa"
      unitRef="U_USD">288000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e"
      decimals="-3"
      id="F_a1c1c717-4f9e-4473-8c89-2eb9197776f6"
      unitRef="U_USD">199000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-3"
      id="F_f80d363f-f811-4717-b65d-bcd41c292897"
      unitRef="U_USD">1530000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e"
      decimals="-3"
      id="F_eedf356f-745d-48d8-ba92-3177cfff2da3"
      unitRef="U_USD">16000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-3"
      id="F_0ab70e26-218d-44d7-a120-4297113220cf"
      unitRef="U_USD">167744000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e"
      decimals="-3"
      id="F_a6e20038-4f3d-4866-aa1d-634de421bb92"
      unitRef="U_USD">217187000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-3"
      id="F_cdd9f1ee-2ea9-4094-b780-c71930734fb2"
      unitRef="U_USD">2269000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e"
      decimals="-3"
      id="F_4787c469-7be2-4dbf-beaf-375329eef263"
      unitRef="U_USD">705000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-3"
      id="F_e53613a2-9eda-4a1b-8bae-fc61f583b9dc"
      unitRef="U_USD">4459000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e"
      decimals="-3"
      id="F_a39a805a-bb9d-44c5-800e-e4acf6e513ad"
      unitRef="U_USD">4069000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-3"
      id="F_1ab88fea-7bdf-4a51-a40d-1d225f54ffe2"
      unitRef="U_USD">256000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e"
      decimals="-3"
      id="F_a68a18db-1d17-40bb-9deb-beb392cc79ea"
      unitRef="U_USD">157000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-3"
      id="F_14efe678-d23e-40ad-b73a-9aeb683b8cf4"
      unitRef="U_USD">6984000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e"
      decimals="-3"
      id="F_21855285-dfd2-4e98-a450-76886af681ee"
      unitRef="U_USD">4931000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-3"
      id="F_941e5c41-dd6f-4647-9459-b2a8cd91c92d"
      unitRef="U_USD">285000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e"
      decimals="-3"
      id="F_5461f45f-4c4a-4895-8c14-c48a1538c712"
      unitRef="U_USD">375000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-3"
      id="F_a3d80ea4-61eb-4c91-a626-a580a071cdc9"
      unitRef="U_USD">7269000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e"
      decimals="-3"
      id="F_34ed4006-8a82-46a3-b58c-03f37ae3c474"
      unitRef="U_USD">5306000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="4"
      id="F_c28957af-8b14-41e9-8d53-5c97b990ce36"
      unitRef="U_USDollarShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e"
      decimals="4"
      id="F_bb1e8afc-ec3d-4915-89c4-5f5755528622"
      unitRef="U_USDollarShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="INF"
      id="F_6f450f74-d0a0-46c6-b7d5-c8ec560e0f38"
      unitRef="U_shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e"
      decimals="INF"
      id="F_c55a433f-5c6b-47b4-bd51-633bd1165c40"
      unitRef="U_shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="0"
      id="F_4ac3c955-ae2f-4554-a18c-c8ee78b13f31"
      unitRef="U_shares">47766338</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="0"
      id="F_b43527f0-6ae1-4631-bc7e-7abd3f427299"
      unitRef="U_shares">47766338</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e"
      decimals="0"
      id="F_0ec880b2-7ee1-4550-802d-9faab7edbffe"
      unitRef="U_shares">67255434</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e"
      decimals="0"
      id="F_0d2e4576-8861-4b1e-b74f-83f591a24203"
      unitRef="U_shares">67255434</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-3"
      id="F_68216a99-5ceb-4cb0-a790-a06d1e2924ee"
      unitRef="U_USD">5000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e"
      decimals="-3"
      id="F_522e8012-f1e5-45e6-b87e-664c69e0ec07"
      unitRef="U_USD">7000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-3"
      id="F_7e10db51-295c-45f2-b1eb-ba13638e2663"
      unitRef="U_USD">449762000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e"
      decimals="-3"
      id="F_6717ea91-d192-4fd6-b8d0-c249dd4f4ae6"
      unitRef="U_USD">441727000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-3"
      id="F_06a20337-f033-4ad0-a6c3-b76664ec9dde"
      unitRef="U_USD">435000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e"
      decimals="-3"
      id="F_95eddd25-81bc-4d46-8fb8-2d37692a20b8"
      unitRef="U_USD">23000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-3"
      id="F_e4402734-63e5-4388-9955-bbf4d6c754b4"
      unitRef="U_USD">-289727000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e"
      decimals="-3"
      id="F_d7388c61-2f24-4f41-9dbc-3e34352c8ceb"
      unitRef="U_USD">-229876000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-3"
      id="F_aef6ba98-cf8e-42a3-af6f-ef28240fa22d"
      unitRef="U_USD">160475000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e"
      decimals="-3"
      id="F_a3295770-ad66-4e40-b00d-815508ca8170"
      unitRef="U_USD">211881000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-3"
      id="F_676cdfb9-bf88-4c6d-8e20-5e9575835576"
      unitRef="U_USD">167744000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e"
      decimals="-3"
      id="F_c5c7378b-7fdf-4cd3-9fa0-cb78ba5d0100"
      unitRef="U_USD">217187000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_04a6f76a-888c-449b-8e6c-670011026f45"
      unitRef="U_USD">46713000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_77069f6f-fff7-49e0-9623-102080a3e3ea"
      unitRef="U_USD">14336000</us-gaap:ResearchAndDevelopmentExpense>
    <clym:AcquiredInProcessResearchAndDevelopmentExpenses
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_30c66287-2250-43bf-8e2e-e07d2f820faf"
      unitRef="U_USD">0</clym:AcquiredInProcessResearchAndDevelopmentExpenses>
    <clym:AcquiredInProcessResearchAndDevelopmentExpenses
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_41668d27-f9d0-42bf-b234-530457929a53"
      unitRef="U_USD">51659000</clym:AcquiredInProcessResearchAndDevelopmentExpenses>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_82a679f8-81ed-4a70-a2cf-b10ad3d08496"
      unitRef="U_USD">21170000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_26b64c1c-ac60-4bde-921b-2d2d2db2e09b"
      unitRef="U_USD">16025000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_ce0d849e-161b-448d-975c-2a109ae26cb9"
      unitRef="U_USD">67883000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_e1ccf37d-6a1c-45d1-83c1-6c3efd687553"
      unitRef="U_USD">82020000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_28818bfd-69d5-4e45-b830-3f6a4fb1f232"
      unitRef="U_USD">-67883000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_b631ed8e-e7d2-41cf-bbfc-33b92bba7b6a"
      unitRef="U_USD">-82020000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_436b5892-9ced-4d44-ae00-a4b5fd372a28"
      unitRef="U_USD">8323000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_a7ccf149-7e5a-4ee7-aa60-c112c8c244e2"
      unitRef="U_USD">8132000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_81a15814-e08e-4474-9413-1fc45dba8c43"
      unitRef="U_USD">-291000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_49cff15f-7bc4-4e69-9a54-176e0862a708"
      unitRef="U_USD">-9000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_de6c206e-9f8a-4d70-bbee-26f95fd7d62f"
      unitRef="U_USD">8032000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_7ff7b890-cd4d-40b0-8918-63eef085ad10"
      unitRef="U_USD">8123000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_53acd088-5b29-4892-a229-8c406fd773b5"
      unitRef="U_USD">-59851000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_6cc374f0-dacc-40cf-9327-0a9d06260f71"
      unitRef="U_USD">-73897000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="2"
      id="F_0c51c63e-e2f9-414a-bc66-d9bf6e70bd39"
      unitRef="U_USDollarShare">-0.88</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="2"
      id="F_d3b6721b-2748-4f0b-9978-0c86fc7a4558"
      unitRef="U_USDollarShare">-0.88</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="2"
      id="F_af596a67-92fa-4276-a6d1-da7333f408fb"
      unitRef="U_USDollarShare">-1.53</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="2"
      id="F_944c0e0b-f9a5-4388-b8c2-01b7502d775c"
      unitRef="U_USDollarShare">-1.53</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="INF"
      id="F_1afddb10-4895-4c07-976b-771c453b0ea8"
      unitRef="U_shares">67812145</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="INF"
      id="F_4c3d007f-69e7-420a-891a-44a849d62f57"
      unitRef="U_shares">67812145</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="INF"
      id="F_8e6747fd-74dd-406a-9f7e-fe3b5854428a"
      unitRef="U_shares">48163301</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="INF"
      id="F_312707ad-8c98-455a-89f7-b529f84f99be"
      unitRef="U_shares">48163301</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_9caee71a-e34a-4afa-9066-1d01961fa4eb"
      unitRef="U_USD">-59851000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_836a3b72-c09c-41fb-812b-03896b6f3464"
      unitRef="U_USD">-73897000</us-gaap:NetIncomeLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_1ada2c2c-7411-4bfc-a0cb-035e208090e7"
      unitRef="U_USD">412000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_95d3837a-d13b-406d-bbf2-dcdd6203dded"
      unitRef="U_USD">25000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_2a6be381-5d0e-41f8-abfa-cb26166799f5"
      unitRef="U_USD">-59439000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_7abd867c-04fc-4ee9-84c2-80d5423867d3"
      unitRef="U_USD">-73872000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_6566157b-2549-4f25-ab16-6ff8b45c4d64"
      decimals="0"
      id="F_34bc079a-c41d-4d01-84b0-4fa74ae91ed7"
      unitRef="U_shares">27626435</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_6566157b-2549-4f25-ab16-6ff8b45c4d64"
      decimals="-3"
      id="F_385701dc-7b26-4002-b494-175aaa229bb9"
      unitRef="U_USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_7c0e8a73-22f5-429f-9ff0-a34f09540718"
      decimals="-3"
      id="F_ccd06060-2e82-41ef-8d9f-3df4da16f2a4"
      unitRef="U_USD">263577000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_98544ab6-691e-467e-be62-d270667fdc07"
      decimals="-3"
      id="F_8b0e44a6-7b27-444c-a908-4a827592204b"
      unitRef="U_USD">-2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_550b780f-159a-4ee0-bc82-3f2210b1684b"
      decimals="-3"
      id="F_58ae6ed4-83b1-41fa-a346-a0b21c5fa01b"
      unitRef="U_USD">-155979000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_c2a2497b-98c5-4d07-ac31-0ab57e9c6f6a"
      decimals="-3"
      id="F_589b134e-b133-4429-8076-1bf227512c0a"
      unitRef="U_USD">107599000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_11bb4c97-86dc-433d-8f9f-b1671660f359"
      decimals="0"
      id="F_c659bc0c-885b-4cad-8ee7-9b21bb070815"
      unitRef="U_shares">154599</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_11bb4c97-86dc-433d-8f9f-b1671660f359"
      decimals="0"
      id="F_a4451480-a335-4cd7-80f6-77c603379c99"
      unitRef="U_shares">2676071</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_a9d1e150-d582-4292-80b0-a0a5033ea1b3"
      decimals="-3"
      id="F_ae30ad78-f876-4a04-87df-d26c5ac56c7d"
      unitRef="U_USD">10979000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_08875668-1a8a-4d31-a522-4a0e2377e35b"
      unitRef="U_USD">10979000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NoninterestExpenseOfferingCost
      contextRef="C_e2570053-78b9-4413-a875-a4e14bf5d7a4"
      decimals="-3"
      id="F_474e390d-53c0-491e-b3cf-b30f6dce632a"
      unitRef="U_USD">250000</us-gaap:NoninterestExpenseOfferingCost>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_deced632-72c6-45c5-a3ca-d77bd56f0dad"
      decimals="0"
      id="F_dbd5febb-eced-4eec-8749-80547f054fe5"
      unitRef="U_shares">31238282</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_deced632-72c6-45c5-a3ca-d77bd56f0dad"
      decimals="-3"
      id="F_9fb42b38-49b4-4a60-aa7d-ef8751a9910e"
      unitRef="U_USD">3000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_79c45355-4ab4-4e2a-a1e5-2f20b0546a60"
      decimals="-3"
      id="F_beb767ef-07aa-419a-bac9-b9281f993086"
      unitRef="U_USD">119747000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_b0c73b5f-de7f-4ef4-87ec-0e261c6ff876"
      decimals="-3"
      id="F_d701a922-8624-4137-8d82-0c68f6dda858"
      unitRef="U_USD">119750000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_ddbb4b04-852b-4f3b-aeb7-aa35ab1cf616"
      decimals="0"
      id="F_e754d34a-1bac-45de-a879-01c4ae7421e0"
      unitRef="U_shares">5560047</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_ddbb4b04-852b-4f3b-aeb7-aa35ab1cf616"
      decimals="-3"
      id="F_9706074c-731e-438f-805e-136d4b1bc972"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_892c3e10-a60b-4010-9024-013505fca3fd"
      decimals="-3"
      id="F_21557e2d-07fd-45b4-bc8b-03618b13b13d"
      unitRef="U_USD">41867000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_21205dde-2f21-4a5b-878c-9c16723dcb5f"
      decimals="-3"
      id="F_ee59fb94-0b5c-4646-9bd8-2debf66f8b2a"
      unitRef="U_USD">41868000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_a9d1e150-d582-4292-80b0-a0a5033ea1b3"
      decimals="-3"
      id="F_3cb96f4c-4572-4faf-afba-17d49cc49811"
      unitRef="U_USD">5557000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_c7386794-6ae3-4e99-b985-9ac5c71bc6da"
      unitRef="U_USD">5557000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="C_b551ae63-1f55-4c33-bec6-c98569fc1002"
      decimals="-3"
      id="F_0b49b6ed-53ff-4f96-8dbd-6dcfb77ca244"
      unitRef="U_USD">25000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_c084f807-2a67-4c7c-b1b3-6b9320995a81"
      unitRef="U_USD">25000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_a8e8a23d-3bb9-47c3-9f60-1878b2e54d8c"
      decimals="-3"
      id="F_8e976280-a5a9-43be-907b-78343ade0401"
      unitRef="U_USD">-73897000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_0c2db32f-5d95-46c8-8c40-e342cb1df4b7"
      unitRef="U_USD">-73897000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_3657c5eb-d257-42f6-9ce8-e538450d6c16"
      decimals="0"
      id="F_430173ca-57da-4a57-8097-94a5792cd8a4"
      unitRef="U_shares">67255434</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_3657c5eb-d257-42f6-9ce8-e538450d6c16"
      decimals="-3"
      id="F_dbde915a-364f-4541-87c0-d974a0b61469"
      unitRef="U_USD">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0d0169f6-b7e0-49bb-b22e-a0097bdb8aef"
      decimals="-3"
      id="F_110ffec6-f986-4ca1-ac29-f591e9a9af59"
      unitRef="U_USD">441727000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_746a74d7-c8f6-4d27-bf0b-6d5329bfce92"
      decimals="-3"
      id="F_031afdb8-1a1d-4d5f-a7aa-6f7b1f280229"
      unitRef="U_USD">23000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_9d3703f0-77df-42a1-9ca1-0e2e95db2565"
      decimals="-3"
      id="F_8f99220d-3539-4bde-bf25-74e6ffcc939a"
      unitRef="U_USD">-229876000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e"
      decimals="-3"
      id="F_b6edee4a-94e4-4673-b0e5-837801536d6a"
      unitRef="U_USD">211881000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_e56178b2-2c10-48d7-b80d-784d82a747b6"
      decimals="0"
      id="F_5e85dde4-b13b-454b-812e-8e0f000a6bf2"
      unitRef="U_shares">929563</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_e56178b2-2c10-48d7-b80d-784d82a747b6"
      decimals="0"
      id="F_0938392c-3e27-4a68-84dc-90153457b6c0"
      unitRef="U_shares">21341</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_122e88aa-833d-49ea-931c-cdd318154ed2"
      decimals="-3"
      id="F_12cf910d-31cb-44ae-b465-d48249c31c75"
      unitRef="U_USD">65000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_d7ba0db2-ca86-47de-98b5-4190b2698722"
      unitRef="U_USD">65000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NoninterestExpenseOfferingCost
      contextRef="C_1f63916b-0391-41c4-8463-6860486b9487"
      decimals="-3"
      id="F_782f017a-f24d-4c71-93fc-fa8016154ff0"
      unitRef="U_USD">86000</us-gaap:NoninterestExpenseOfferingCost>
    <clym:SharesExchangedForPreFundedWarrants
      contextRef="C_e56178b2-2c10-48d7-b80d-784d82a747b6"
      decimals="0"
      id="F_0880d4b6-9286-4332-8c48-b4274dcd755b"
      unitRef="U_shares">-20440000</clym:SharesExchangedForPreFundedWarrants>
    <clym:SharesExchangedForPreFundedWarrantsValue
      contextRef="C_e56178b2-2c10-48d7-b80d-784d82a747b6"
      decimals="-3"
      id="F_27110df4-d4d3-4170-8bd7-1049000a00bd"
      unitRef="U_USD">-2000</clym:SharesExchangedForPreFundedWarrantsValue>
    <clym:SharesExchangedForPreFundedWarrantsValue
      contextRef="C_122e88aa-833d-49ea-931c-cdd318154ed2"
      decimals="-3"
      id="F_f6dcf7d4-7059-4543-be89-77af2b0bba86"
      unitRef="U_USD">-84000</clym:SharesExchangedForPreFundedWarrantsValue>
    <clym:SharesExchangedForPreFundedWarrantsValue
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_eca749e9-e0b1-4b0c-a283-4968b97813f3"
      unitRef="U_USD">-86000</clym:SharesExchangedForPreFundedWarrantsValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_122e88aa-833d-49ea-931c-cdd318154ed2"
      decimals="-3"
      id="F_560fc9ce-f323-42ac-9a3b-282664a376dc"
      unitRef="U_USD">8054000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_d84d89bc-ec64-4b89-94d1-982dfa1852f9"
      unitRef="U_USD">8054000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="C_3d75d312-973d-41a8-a6dc-96c192554cdc"
      decimals="-3"
      id="F_b5a2f52f-d215-4cc4-b35c-375a4b96071f"
      unitRef="U_USD">412000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_320c3172-c65b-45ea-b27f-c3077a20193b"
      unitRef="U_USD">412000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_26331409-5c32-4037-8326-ec8e383f9fff"
      decimals="-3"
      id="F_34128aa9-ff30-49c5-ae10-af39f62da0bc"
      unitRef="U_USD">-59851000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_fdee6bb1-3d7b-472b-bba4-417d7e08c1e6"
      unitRef="U_USD">-59851000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_d015dd5d-fe12-4337-9262-398335ac7a9b"
      decimals="0"
      id="F_ccace5e8-0bf9-4ef1-8034-f1c435a5f70d"
      unitRef="U_shares">47766338</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_d015dd5d-fe12-4337-9262-398335ac7a9b"
      decimals="-3"
      id="F_96903683-3697-487e-899b-1da630425b48"
      unitRef="U_USD">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4b99e9a3-7e4b-4844-b231-419f9b1fc292"
      decimals="-3"
      id="F_82f7bcc2-df97-4244-b978-b2e487af0c2f"
      unitRef="U_USD">449762000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_3a31c020-0ff0-49fa-b2ef-a1848d998afe"
      decimals="-3"
      id="F_0a85c465-2f24-4561-a9da-bb89e1064e1c"
      unitRef="U_USD">435000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_691140a1-fa6d-479a-bd61-6df4cc2c5e1a"
      decimals="-3"
      id="F_80b150ed-c8fc-446c-b35e-390887806c10"
      unitRef="U_USD">-289727000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-3"
      id="F_2ca4912e-76ec-49a7-a12e-94d57f6ed8c7"
      unitRef="U_USD">160475000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_2ae1fb87-4b35-42ff-b9ca-23f98a819dff"
      unitRef="U_USD">-59851000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_4aa1c278-a85e-4922-8291-ded715540642"
      unitRef="U_USD">-73897000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_cb954c51-5daa-45a9-864f-08391282ad0b"
      unitRef="U_USD">8054000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_f1e5b052-3da8-44a7-af64-07504ba6f8bf"
      unitRef="U_USD">5557000</us-gaap:ShareBasedCompensation>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_566598ea-05e0-4a36-a615-5f84201aac0e"
      unitRef="U_USD">201000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_7f693eef-e315-4b08-bf3f-e46717c2b3f6"
      unitRef="U_USD">220000</us-gaap:OperatingLeaseExpense>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_42c1a929-e90a-4de3-aadb-649eabf724c1"
      unitRef="U_USD">2274000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_ba9307a5-e819-4c37-a02d-25b7056442c9"
      unitRef="U_USD">757000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_4d597f09-531d-42ef-90e0-e1abbedeecfb"
      unitRef="U_USD">97000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_e42efcc2-e504-4237-989f-9c4f0f53d80f"
      unitRef="U_USD">0</us-gaap:DepreciationDepletionAndAmortization>
    <clym:AcquiredInProcessResearchAndDevelopmentExpenses
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_58084c58-9735-48bf-b4a7-314cc88ee120"
      unitRef="U_USD">0</clym:AcquiredInProcessResearchAndDevelopmentExpenses>
    <clym:AcquiredInProcessResearchAndDevelopmentExpenses
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_59a153bc-d1e7-4059-b8ad-7416650c7f88"
      unitRef="U_USD">51659000</clym:AcquiredInProcessResearchAndDevelopmentExpenses>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_34d634eb-6162-43e1-b63b-be3b64af6711"
      unitRef="U_USD">-18000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_87f49326-b4e5-42a3-affe-fc3618c1708f"
      unitRef="U_USD">42000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_b7679b56-e5bc-44f3-ae78-cfca01697f25"
      unitRef="U_USD">816000</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_28298fd0-9aff-4576-9d96-936305f282f6"
      unitRef="U_USD">-1942000</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_6a690678-3789-478f-8b35-22a4dbd5dc4b"
      unitRef="U_USD">1514000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_21b7e3e5-8d41-495b-94ff-24e2f2f6f34d"
      unitRef="U_USD">200000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_94f54e1e-93dd-4d28-bdfa-c97b7e100d94"
      unitRef="U_USD">1564000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_4d89dcff-fa63-47f5-b03d-3e50fa742d3c"
      unitRef="U_USD">-963000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <clym:IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedparties
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_2742d40f-1774-4618-8f4b-ee00418bac54"
      unitRef="U_USD">0</clym:IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedparties>
    <clym:IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedparties
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_4d97f86a-4734-4aaf-a1b0-730d37494845"
      unitRef="U_USD">-177000</clym:IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedparties>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_8a9c186e-0fcd-49d8-ac8e-e89121af1987"
      unitRef="U_USD">372000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_3f677223-6bee-4216-bb1b-90f4550364c9"
      unitRef="U_USD">1445000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_130251c1-235a-45da-abda-710e85d7aafa"
      unitRef="U_USD">-207000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_5b3fdea2-4e81-4131-989c-16dbfc3881bd"
      unitRef="U_USD">-327000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_aa4afab6-8f2f-43ec-94a5-2e709628580a"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_3bc10223-b848-473e-bbae-2f2853b73551"
      unitRef="U_USD">-22000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_3049cf3c-369d-43bc-a7cf-dbbb8d64191a"
      unitRef="U_USD">-54356000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_63e4fbeb-771c-4354-82b4-f103369b6a46"
      unitRef="U_USD">-15562000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_f869c928-7fd4-4b17-b0b2-d64824ecc8e0"
      unitRef="U_USD">186000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_cee6a6ad-608c-4c7f-ada0-92cfc47a9871"
      unitRef="U_USD">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_fd84721d-bcfc-4c9d-8416-655a633c348d"
      unitRef="U_USD">108078000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_209196d7-ba22-4fdb-b637-dabd65ebc78b"
      unitRef="U_USD">132197000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_8828a1e7-ab55-461e-aa53-b37ffaaf9575"
      unitRef="U_USD">111097000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_92c4a8aa-c797-4b1b-a6e1-5f3e6b49d74b"
      unitRef="U_USD">20750000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <clym:IssuanceOfPromissoryLoanInConnectionWithAssetsAcquisition
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_71bac7ee-a6cc-4e81-aad7-337637390aa6"
      unitRef="U_USD">0</clym:IssuanceOfPromissoryLoanInConnectionWithAssetsAcquisition>
    <clym:IssuanceOfPromissoryLoanInConnectionWithAssetsAcquisition
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_344f69a6-28b0-4b6c-b06d-78b7276ca9c3"
      unitRef="U_USD">5000000</clym:IssuanceOfPromissoryLoanInConnectionWithAssetsAcquisition>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_bc951d62-e62a-4085-903a-e878953dfaca"
      unitRef="U_USD">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_833810a5-e3d7-4be4-a882-e8510f5118cb"
      unitRef="U_USD">4645000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_8a369325-c2d8-473b-b73a-7f1f624c44ab"
      unitRef="U_USD">2833000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_0752913a-4a64-4b20-a07d-c9495987ade3"
      unitRef="U_USD">-121092000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_b5504c4c-5aaf-4784-9477-a7eaf30a3f63"
      unitRef="U_USD">65000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_51cd9221-7860-44db-8667-dcac668e46ff"
      unitRef="U_USD">10979000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_4218354e-7794-4b5a-b025-054fc0ee70c2"
      unitRef="U_USD">86000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_53fea17c-df60-4785-9143-78cf7a5214f0"
      unitRef="U_USD">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_eed0b69e-24af-4632-bb10-6e965c97a33b"
      unitRef="U_USD">0</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_a80e4ee1-4df5-4d29-9b14-d9b5dbe8801a"
      unitRef="U_USD">119750000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_43114343-2706-4f7d-b859-656ba953a8bd"
      unitRef="U_USD">-21000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_be40e8c8-abb2-4cfb-903c-261da82b124c"
      unitRef="U_USD">130729000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_f50cbe4a-4cfc-4a8a-9c80-b8dd8148ee62"
      unitRef="U_USD">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_37089460-1e15-4f65-82bd-37a3cb4597c0"
      unitRef="U_USD">42000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_0582bcee-764f-4ba5-8626-798339e6e0e5"
      unitRef="U_USD">-51544000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_6aaf865d-5315-400c-a97d-99feb7b7255a"
      unitRef="U_USD">-5883000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e"
      decimals="-3"
      id="F_85618ce4-3db9-4330-ab69-b71efe09dbd5"
      unitRef="U_USD">87229000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_c2a2497b-98c5-4d07-ac31-0ab57e9c6f6a"
      decimals="-3"
      id="F_0bdd4570-6efb-4b2f-99da-685101f98976"
      unitRef="U_USD">93112000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-3"
      id="F_8ba056aa-7675-4bb5-b4af-fd7b4b634dba"
      unitRef="U_USD">35685000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e"
      decimals="-3"
      id="F_dd91ca69-2050-457a-ad9b-04db031da80f"
      unitRef="U_USD">87229000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <clym:CommonStockIssuedInExchangeForIn-ProcessResearchAndDevelopmentAssets
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_c7c031dc-7ab3-457a-bb09-5959eed1b506"
      unitRef="U_USD">0</clym:CommonStockIssuedInExchangeForIn-ProcessResearchAndDevelopmentAssets>
    <clym:CommonStockIssuedInExchangeForIn-ProcessResearchAndDevelopmentAssets
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_d1f31b8c-8de8-40ab-b6a9-1b21ec30128a"
      unitRef="U_USD">41867000</clym:CommonStockIssuedInExchangeForIn-ProcessResearchAndDevelopmentAssets>
    <clym:AmountOfPromissoryLoanSettledInConnectionWithAnAssetAcquisition
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_5f062108-5619-4dc0-9da2-08e06517f54d"
      unitRef="U_USD">0</clym:AmountOfPromissoryLoanSettledInConnectionWithAnAssetAcquisition>
    <clym:AmountOfPromissoryLoanSettledInConnectionWithAnAssetAcquisition
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_754fb854-22d5-4e64-b8ff-8677067df23c"
      unitRef="U_USD">5036000</clym:AmountOfPromissoryLoanSettledInConnectionWithAnAssetAcquisition>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_b1b28963-ecc0-4130-928b-7f7960109f8d">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 1. Nature of Operations and Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Organization&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Climb Bio, Inc. (the Company), is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company&#x2019;s pipeline includes budoprutug and CLYM116. Budoprutug is an anti-CD19 monoclonal antibody designed to treat a broad range of B-cell mediated diseases. The Company is currently developing budoprutug for the treatment of primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus. CLYM116 is an anti-APRIL (A Proliferation-Inducing Ligand) monoclonal antibody currently being developed for the treatment of immunoglobulin A nephropathy. The Company was incorporated on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 18, 2018&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; in Delaware, and its corporate headquarters is in Massachusetts.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On June 27, 2024, the Company completed its acquisition of Tenet Medicines, Inc. (the Acquisition). In connection with the closing of the Acquisition, the Company issued and sold &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,238,282&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of its common stock at a price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.84&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share in a private placement to several accredited institutional investors (the Private Placement). The Company received aggregate gross proceeds from the Private Placement of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;120.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, before deducting offering costs of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million (see Note 3). &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On January 8, 2025, the Company entered into a technology transfer and exclusive license agreement (the Mabworks Agreement) with Beijing Mabworks Biotech Co., Ltd. (Mabworks), for rights to develop and commercialize CLYM116 for all indications worldwide outside of mainland China, Hong Kong, Macau, and Taiwan (Greater China) (see Note 8).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, reliance on single-source suppliers and manufacturers, availability of raw materials, patentability of the Company&#x2019;s product candidates and processes and clinical efficacy and safety of the Company&#x2019;s product candidates, compliance with government regulations and the need to obtain additional financing to fund operations. Budoprutug, CLYM116, or any product candidate the Company may develop will require significant additional research and development efforts, including extensive nonclinical studies, clinical trials, and regulatory approval, prior to commercialization. These efforts will require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance and reporting.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;There can be no assurance that any future research and development will be successfully completed, that adequate protection for the Company&#x2019;s intellectual property will be obtained or maintained, that any product candidate developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if any future product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales. The Company operates in an environment of rapid technological change and substantial competition from other pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and other third parties.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (U.S. GAAP). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Update (ASU) of the Financial Accounting Standards Board (FASB).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accompanying consolidated financial statements reflect the operations of the Company and its wholly owned subsidiaries. Intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Liquidity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Since inception, the Company has experienced recurring losses from operations and generated negative cash flows from operations. The Company has an accumulated deficit of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;289.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as of December 31, 2025 and expects to incur additional losses from operations in the future. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In March 2025, the Company entered into an Equity Distribution Agreement (the Distribution Agreement) with Oppenheimer &amp;amp; Co. Inc., as agent (Oppenheimer), pursuant to which the Company may offer and sell shares of its common stock from time to time through Oppenheimer having an aggregate offering price of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in an at the market offering. During the year ended December 31&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, 2025, the Company did not issue and sell any shares of its common stock pursuant to the Distribution Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company believes its available cash, cash equivalents and marketable securities of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;160.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as of December 31, 2025 will be sufficient to meet its projected operating requirements for at least the next twelve months from the filing date of these consolidated financial statements, and the Company anticipates that it will need to raise substantial financing in the future to fund its operations. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company may finance future cash needs through the sale of equity, debt financings or other capital sources, which could include income from collaborations, strategic partnerships or other strategic arrangements. There are no assurances that the Company will be able to raise sufficient amounts of funding in the future on acceptable terms, or at all.&lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <dei:EntityIncorporationDateOfIncorporation
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_9a0b9f1d-e148-4365-b54d-dd58fd2eaa26">2018-10-18</dei:EntityIncorporationDateOfIncorporation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_dcc85fc3-485a-42b9-b4a7-8f1dd16319b6"
      decimals="0"
      id="F_fcd6a570-80f8-4bad-9933-3a31a01a6c44"
      unitRef="U_shares">31238282</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_3893b746-214f-47a9-ab19-782719fe3a18"
      decimals="2"
      id="F_01453f02-8b66-42b3-84f6-ece155ec9a1e"
      unitRef="U_USDollarShare">3.84</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_dcc85fc3-485a-42b9-b4a7-8f1dd16319b6"
      decimals="-5"
      id="F_cf0eeff8-82d6-41d3-b567-961a7c9825bb"
      unitRef="U_USD">120000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:NoninterestExpenseOfferingCost
      contextRef="C_dcc85fc3-485a-42b9-b4a7-8f1dd16319b6"
      decimals="-5"
      id="F_8723a503-9252-401a-8769-f928a0c8bd87"
      unitRef="U_USD">300000</us-gaap:NoninterestExpenseOfferingCost>
    <us-gaap:RisksAndUncertaintiesInEntitysBusiness
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_7b6675d6-7c6f-4404-ae12-3f6f1341293d">Risks and UncertaintiesThe Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, reliance on single-source suppliers and manufacturers, availability of raw materials, patentability of the Company&#x2019;s product candidates and processes and clinical efficacy and safety of the Company&#x2019;s product candidates, compliance with government regulations and the need to obtain additional financing to fund operations. Budoprutug, CLYM116, or any product candidate the Company may develop will require significant additional research and development efforts, including extensive nonclinical studies, clinical trials, and regulatory approval, prior to commercialization. These efforts will require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance and reporting.There can be no assurance that any future research and development will be successfully completed, that adequate protection for the Company&#x2019;s intellectual property will be obtained or maintained, that any product candidate developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if any future product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales. The Company operates in an environment of rapid technological change and substantial competition from other pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and other third parties.</us-gaap:RisksAndUncertaintiesInEntitysBusiness>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_ebd27b73-a763-4d50-b08e-8cc1edc75823">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (U.S. GAAP). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Update (ASU) of the Financial Accounting Standards Board (FASB).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accompanying consolidated financial statements reflect the operations of the Company and its wholly owned subsidiaries. Intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_04df00cf-f147-4799-ab28-82c800221b1c">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (U.S. GAAP). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Update (ASU) of the Financial Accounting Standards Board (FASB).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accompanying consolidated financial statements reflect the operations of the Company and its wholly owned subsidiaries. Intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-5"
      id="F_f29225b9-4d1a-4225-969e-0a02942e67be"
      unitRef="U_USD">-289700000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <clym:AggregateGrossSalesProceedsUnderSalesAgreements
      contextRef="C_5e29120a-ab8d-4722-9dfa-39d97775d181"
      decimals="-5"
      id="F_86646a05-e1a4-4c79-9a59-2c35de076108"
      unitRef="U_USD">22400000</clym:AggregateGrossSalesProceedsUnderSalesAgreements>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-5"
      id="F_183414dc-c0f1-43bd-aa0b-510df55911ac"
      unitRef="U_USD">160700000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_61a5b8dc-7bad-4cda-9db2-df006e36f260">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 2. Summary of Significant Accounting Policies&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (JOBS Act). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued after the enactment of the JOBS Act until those standards apply to private companies. The Company has elected to avail itself of this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts and disclosures. Accordingly, actual results could differ from those estimates. Key management estimates include those related to the accrual of research and development expenses and the valuation of stock-based awards. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Foreign Currency&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s reporting currency is the U.S. dollar. The functional currency of the Company and its subsidiaries is the U.S. dollar. Monetary assets and liabilities resulting from transactions denominated in currencies other than the functional currency are remeasured in the functional currency at exchange rates prevailing at the balance sheet date, and income items and expenses are translated into U.S. dollars at the average exchange rate in effect during the period. Exchange gains and losses resulting from remeasurement and foreign currency transactions are included in the determination of net loss.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segment Information&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. Significantly all of the Company&#x2019;s tangible assets are held in the United States.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Concentration of Credit Risk &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;and Significant Suppliers and Manufacturers&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company maintains its cash and cash equivalents at accredited financial institutions that may, at times, exceed federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company&#x2019;s investments in money market funds and marketable securities are held in segregated accounts at a third-party custodian. The Company has established guidelines relative to credit ratings and maturities intended to safeguard principal balances and maintain liquidity.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is dependent on third-party suppliers and manufacturers for material used in its nonclinical and clinical development activities. In particular, the Company relies and expects to continue to rely on single-source suppliers and manufacturers to supply it with certain critical materials related to the Company&#x2019;s product candidates. The Company&#x2019;s development efforts could be adversely affected if a supplier or manufacturer is unable to successfully carry out its contractual obligations or meet expected deadlines. If a supplier or manufacturer needs to be replaced, the Company may not be able to complete its product development on its anticipated timelines and may incur additional expenses as a result.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company considers all highly liquid investments with maturities of three months or less from the purchase date to be cash equivalents.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company classifies its marketable securities as available-for-sale. Marketable securities with remaining maturities of less than one year from the balance sheet date are classified as short-term marketable securities. Marketable securities with remaining maturities of greater than one year from the balance sheet date are classified as long-term marketable securities. The Company reports available-for-sale investments at fair value as of each balance sheet date and records unrealized gains or losses as a component of stockholders&#x2019; equity in accumulated other comprehensive income (loss). Realized gains and losses of securities sold are determined on a specific identification basis and included in other income (expense) within the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;When the fair value is below the amortized cost of a marketable security, the Company estimates the portion of the unrealized loss that relates to credit&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The credit-related impairment amount is recorded in other income (expense) in the consolidated statements of operations and comprehensive loss. Credit losses are recognized through the use of an allowance for credit losses account in the consolidated balance sheet and subsequent improvements in expected credit losses are recorded as a reversal of an amount in the allowance account. If the Company intends to sell the security or it is more likely than not that the Company will be required to sell the security prior to recovery of its amortized cost basis, then the allowance for the credit loss, if any, is written-off and the excess of the amortized cost basis of the asset over its fair value is recognized in other income (expense) in the consolidated statements of operations and comprehensive loss. There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; credit losses recorded during the years ended December 31, 2025 and 2024.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 1&#x2014;Quoted prices in active markets for identical assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 2&#x2014;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 3&#x2014;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s cash equivalents and marketable securities are carried at fair value, determined according to the fair value hierarchy (see Note 4). The carrying values of the Company&#x2019;s accounts payable and accrued expenses approximate their fair values due to the short-term nature of these liabilities.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Comprehensive loss includes net loss as well as other changes in stockholders&#x2019; equity that result from transactions and economic events other than those with stockholders. The Company&#x2019;s only element of other comprehensive income (loss) is unrealized gains and losses on available-for-sale marketable securities.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Asset Acquisitions&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In determining whether an acquisition of assets and related liabilities should be accounted for as a business combination or asset acquisition, the Company first determines whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets. If this is the case, the single identifiable asset or the group of similar assets is not deemed to be a business and the acquisition is accounted for as an asset acquisition. If this is not the case, the Company then further evaluates whether the acquisition includes, at a minimum, an input and a substantive process that together significantly contribute to the ability to create outputs. If so, the Company concludes that the acquisition is a business and accounts for it as a business combination.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the asset or group of assets, which includes transaction costs, allocated on a relative fair value basis. Goodwill is not recognized in asset acquisitions. In an asset acquisition, the cost allocated to acquire in-process research and development (IPR&amp;amp;D) with no alternative future use is charged to expense at the acquisition date.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:0.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;margin-right:0.13%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful life of each asset.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
         &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
          &lt;tr style="visibility:collapse;"&gt;
           &lt;td style="width:59.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:2.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:37.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated Useful Life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
           &lt;td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
           &lt;td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_2a7e8018-774a-4c44-8376-7e8c696ec434;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shorter of remaining life of lease or useful life&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
         &lt;/table&gt;&lt;/div&gt;&lt;p style="margin-left:0.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;When an item is sold or retired, the costs and related accumulated depreciation are eliminated, and the resulting gain or loss, if any, is credited or charged to operating loss in the consolidated statements of operations and comprehensive loss. Repairs and maintenance costs are expensed as incurred.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for leases under ASC Topic 842, Leases (&#x201c;ASC 842&#x201d;). In accordance with ASC 842, the Company accounts for a contract as a lease when it has the right to control the asset for a period of time while obtaining substantially all of the asset&#x2019;s economic benefits. The Company determines if an arrangement is a lease or contains an embedded lease at inception. For arrangements that meet the definition of a lease, the Company determines the initial classification and measurement of its right-of-use asset and lease liability at the lease commencement date and thereafter if modified. The lease term includes any renewal options that the Company is reasonably assured to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its estimated secured incremental borrowing rate for that lease term. The Company&#x2019;s policy is to not record leases with an original term of 12 months or less on its consolidated balance sheets and recognizes those lease payments in the income statement on a straight-line basis over the lease term. The Company&#x2019;s existing lease is for office space.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In addition to rent, leases may require the Company to pay additional costs, such as utilities, maintenance and other operating costs, which are generally referred to as non-lease components. The Company has elected to not separate lease and non-lease components. Only the fixed costs for lease components and their associated non-lease components are accounted for as a single lease component and recognized as part of a right-of-use asset and lease liability. Rent expense for operating leases is recognized on a straight-line basis over the reasonably assured lease term based on the total lease payments and is included in operating expense in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Long-lived assets consist of property and equipment and right-of-use assets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company reviews the recoverability of its long-lived assets, including the related useful lives, whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset might not be recoverable, based on undiscounted cash flows. If such assets are considered to be impaired, an impairment loss is recognized and is measured as the amount by which the carrying amount of the assets exceed their estimated fair value, which is measured based on the projected discounted future net cash flows arising from the assets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and development expenses consist of costs incurred in performing research and development activities, including salaries and bonuses, stock-based compensation, employee benefits, termination benefits, facilities costs and depreciation, and external costs of vendors engaged to conduct research, nonclinical and clinical development activities as well as the cost of acquiring and licensing technology.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Upfront payments and milestone payments made for the licensing of technology are expensed as research and development over the period to which they relate. Costs for research and development activities are expensed in the period in which they are incurred. Payments for such activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid expense or accrued research and development expense. Determining the prepaid and accrued balances at the end of any reporting period incorporate certain judgments and estimates by management that are based on information available to the Company including information provided by vendors regarding the progress to completion of specific tasks or costs incurred.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Patent costs&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;All patent-related costs incurred in connection with filing and prosecuting patent applications are recorded as general and administrative expenses as incurred.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company measures its stock options with service-based vesting or performance-based vesting granted to employees, non-employee directors, consultants and independent advisors based on the estimated fair value on the date of grant using the Black-Scholes option-pricing model. The Company measures compensation expense for restricted common stock units based on the fair value on the date of grant using the market value of the Company&#x2019;s common stock. Compensation expense for the awards is recognized over the requisite service period for employees and directors and as services are delivered for consultants and independent advisors, both of which are generally the vesting period of the respective award. The Company uses the straight-line method to record the expense of awards with only service-based vesting conditions. The Company uses the graded-vesting method to record the expense of awards with both service-based and performance-based vesting conditions, commencing once achievement of the performance condition becomes probable. The Company accounts for forfeitures of share-based awards as they occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company classifies stock-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#x2019;s payroll costs are classified or in which the award recipient&#x2019;s service payments are classified.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#x2019;s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to the provision for income taxes. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. Any resulting unrecognized tax benefits are recorded within the provision for income taxes.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic net loss per share attributable to common stockholders is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net loss per share attributable to common stockholders is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, adjusted for potential dilutive common shares.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In periods in which the Company reported a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company reported a net loss attributable to common stockholders for the years ended December 31, 2025 and 2024.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently Issued Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU No. 2023-09 (ASU 2023-09), &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which requires, among other things, the following for public business entities: (i) enhanced disclosures of specific categories of reconciling items included in the rate reconciliation, as well as additional information for any of these items meeting certain qualitative and quantitative thresholds; (ii) disclosure of the nature, effect and underlying causes of each individual reconciling item disclosed in the rate reconciliation and the judgment used in categorizing them if not otherwise evident; and (iii) enhanced disclosures for income taxes paid, which includes federal, state, and foreign taxes, as well as for individual jurisdictions over a certain quantitative threshold. The amendments in ASU 2023-09 eliminate the requirement to disclose the nature and estimate of the range of the reasonably possible change in unrecognized tax benefits for the 12 months after the balance sheet date. The effective date of this update for non-public companies is for fiscal years beginning after December 15, 2025; early adoption is permitted. The Company expects ASU 2023-09 to require additional disclosures in the notes to its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU 2024-03 (ASU 2024-03), &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Disaggregation of Income Statement Expenses&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which requires additional disclosures about specific types of expenses included in the expense captions presented on the face of the income statement, as well as disclosures about selling expenses. The provisions of ASU 2024-03 are effective for public business entities for fiscal years beginning after December 15, 2026, and interim periods beginning after December 15, 2027. Early adoption is permitted. The guidance is to be applied prospectively, with the option for retrospective application. The Company is currently evaluating the impact of ASU 2024-03 on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_4767f4c7-8c5a-4435-b294-ec0dfb63869d">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts and disclosures. Accordingly, actual results could differ from those estimates. Key management estimates include those related to the accrual of research and development expenses and the valuation of stock-based awards. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_b29127bc-265e-46d6-af1f-1628f2c14c69">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Foreign Currency&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s reporting currency is the U.S. dollar. The functional currency of the Company and its subsidiaries is the U.S. dollar. Monetary assets and liabilities resulting from transactions denominated in currencies other than the functional currency are remeasured in the functional currency at exchange rates prevailing at the balance sheet date, and income items and expenses are translated into U.S. dollars at the average exchange rate in effect during the period. Exchange gains and losses resulting from remeasurement and foreign currency transactions are included in the determination of net loss.&lt;/span&gt;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_a2997997-3826-402a-90e0-20098e5cb9e0">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segment Information&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. Significantly all of the Company&#x2019;s tangible assets are held in the United States.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_22b3023b-1ff8-4f4e-90c6-a4d7bbfe4ec1">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Concentration of Credit Risk &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;and Significant Suppliers and Manufacturers&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company maintains its cash and cash equivalents at accredited financial institutions that may, at times, exceed federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company&#x2019;s investments in money market funds and marketable securities are held in segregated accounts at a third-party custodian. The Company has established guidelines relative to credit ratings and maturities intended to safeguard principal balances and maintain liquidity.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is dependent on third-party suppliers and manufacturers for material used in its nonclinical and clinical development activities. In particular, the Company relies and expects to continue to rely on single-source suppliers and manufacturers to supply it with certain critical materials related to the Company&#x2019;s product candidates. The Company&#x2019;s development efforts could be adversely affected if a supplier or manufacturer is unable to successfully carry out its contractual obligations or meet expected deadlines. If a supplier or manufacturer needs to be replaced, the Company may not be able to complete its product development on its anticipated timelines and may incur additional expenses as a result.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_c41b61e3-e05c-4918-b04e-a58f82e99a2c">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company considers all highly liquid investments with maturities of three months or less from the purchase date to be cash equivalents.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_79364581-83be-42a3-b4e4-833e40d8f5bf">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company classifies its marketable securities as available-for-sale. Marketable securities with remaining maturities of less than one year from the balance sheet date are classified as short-term marketable securities. Marketable securities with remaining maturities of greater than one year from the balance sheet date are classified as long-term marketable securities. The Company reports available-for-sale investments at fair value as of each balance sheet date and records unrealized gains or losses as a component of stockholders&#x2019; equity in accumulated other comprehensive income (loss). Realized gains and losses of securities sold are determined on a specific identification basis and included in other income (expense) within the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;When the fair value is below the amortized cost of a marketable security, the Company estimates the portion of the unrealized loss that relates to credit&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The credit-related impairment amount is recorded in other income (expense) in the consolidated statements of operations and comprehensive loss. Credit losses are recognized through the use of an allowance for credit losses account in the consolidated balance sheet and subsequent improvements in expected credit losses are recorded as a reversal of an amount in the allowance account. If the Company intends to sell the security or it is more likely than not that the Company will be required to sell the security prior to recovery of its amortized cost basis, then the allowance for the credit loss, if any, is written-off and the excess of the amortized cost basis of the asset over its fair value is recognized in other income (expense) in the consolidated statements of operations and comprehensive loss. There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; credit losses recorded during the years ended December 31, 2025 and 2024.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_4169682a-fd33-4098-a5b5-50e2033e49bd"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_ff6d0913-6a7f-49bc-ba47-010e9cb99563"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_867fde65-3b04-48de-b010-7b03b0f9da6b">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 1&#x2014;Quoted prices in active markets for identical assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 2&#x2014;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 3&#x2014;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s cash equivalents and marketable securities are carried at fair value, determined according to the fair value hierarchy (see Note 4). The carrying values of the Company&#x2019;s accounts payable and accrued expenses approximate their fair values due to the short-term nature of these liabilities.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_dbd03d7c-1015-48e6-86d2-d16820a44d4b">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Comprehensive loss includes net loss as well as other changes in stockholders&#x2019; equity that result from transactions and economic events other than those with stockholders. The Company&#x2019;s only element of other comprehensive income (loss) is unrealized gains and losses on available-for-sale marketable securities.&lt;/span&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_1a621bb2-6c46-431b-be45-7e84ae7de60e">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Asset Acquisitions&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In determining whether an acquisition of assets and related liabilities should be accounted for as a business combination or asset acquisition, the Company first determines whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets. If this is the case, the single identifiable asset or the group of similar assets is not deemed to be a business and the acquisition is accounted for as an asset acquisition. If this is not the case, the Company then further evaluates whether the acquisition includes, at a minimum, an input and a substantive process that together significantly contribute to the ability to create outputs. If so, the Company concludes that the acquisition is a business and accounts for it as a business combination.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the asset or group of assets, which includes transaction costs, allocated on a relative fair value basis. Goodwill is not recognized in asset acquisitions. In an asset acquisition, the cost allocated to acquire in-process research and development (IPR&amp;amp;D) with no alternative future use is charged to expense at the acquisition date.&lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_4a6a3a84-9ecd-4b8c-81b4-65706a640219">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:0.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;margin-right:0.13%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful life of each asset.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
         &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
          &lt;tr style="visibility:collapse;"&gt;
           &lt;td style="width:59.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:2.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:37.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated Useful Life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
           &lt;td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
           &lt;td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_2a7e8018-774a-4c44-8376-7e8c696ec434;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shorter of remaining life of lease or useful life&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
         &lt;/table&gt;&lt;/div&gt;&lt;p style="margin-left:0.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;When an item is sold or retired, the costs and related accumulated depreciation are eliminated, and the resulting gain or loss, if any, is credited or charged to operating loss in the consolidated statements of operations and comprehensive loss. Repairs and maintenance costs are expensed as incurred.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <clym:ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_125c0bb5-20da-499c-af55-d842b9505db5">&lt;p style="margin-left:0.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;margin-right:0.13%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful life of each asset.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
         &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
          &lt;tr style="visibility:collapse;"&gt;
           &lt;td style="width:59.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:2.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:37.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated Useful Life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
           &lt;td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
           &lt;td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_2a7e8018-774a-4c44-8376-7e8c696ec434;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shorter of remaining life of lease or useful life&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
         &lt;/table&gt;</clym:ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_bed1b934-9767-4736-8d75-5898620908e6"
      id="F_b304f535-cc08-4941-ac41-e489df697109">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_ccf85e97-d2a4-44c9-9970-5ac6117c345c">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for leases under ASC Topic 842, Leases (&#x201c;ASC 842&#x201d;). In accordance with ASC 842, the Company accounts for a contract as a lease when it has the right to control the asset for a period of time while obtaining substantially all of the asset&#x2019;s economic benefits. The Company determines if an arrangement is a lease or contains an embedded lease at inception. For arrangements that meet the definition of a lease, the Company determines the initial classification and measurement of its right-of-use asset and lease liability at the lease commencement date and thereafter if modified. The lease term includes any renewal options that the Company is reasonably assured to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its estimated secured incremental borrowing rate for that lease term. The Company&#x2019;s policy is to not record leases with an original term of 12 months or less on its consolidated balance sheets and recognizes those lease payments in the income statement on a straight-line basis over the lease term. The Company&#x2019;s existing lease is for office space.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In addition to rent, leases may require the Company to pay additional costs, such as utilities, maintenance and other operating costs, which are generally referred to as non-lease components. The Company has elected to not separate lease and non-lease components. Only the fixed costs for lease components and their associated non-lease components are accounted for as a single lease component and recognized as part of a right-of-use asset and lease liability. Rent expense for operating leases is recognized on a straight-line basis over the reasonably assured lease term based on the total lease payments and is included in operating expense in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_4a4a957f-3324-479c-8031-2d00d53ac131">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Long-lived assets consist of property and equipment and right-of-use assets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company reviews the recoverability of its long-lived assets, including the related useful lives, whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset might not be recoverable, based on undiscounted cash flows. If such assets are considered to be impaired, an impairment loss is recognized and is measured as the amount by which the carrying amount of the assets exceed their estimated fair value, which is measured based on the projected discounted future net cash flows arising from the assets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_64974de4-11fe-41df-9473-697355ad1103">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and development expenses consist of costs incurred in performing research and development activities, including salaries and bonuses, stock-based compensation, employee benefits, termination benefits, facilities costs and depreciation, and external costs of vendors engaged to conduct research, nonclinical and clinical development activities as well as the cost of acquiring and licensing technology.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Upfront payments and milestone payments made for the licensing of technology are expensed as research and development over the period to which they relate. Costs for research and development activities are expensed in the period in which they are incurred. Payments for such activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid expense or accrued research and development expense. Determining the prepaid and accrued balances at the end of any reporting period incorporate certain judgments and estimates by management that are based on information available to the Company including information provided by vendors regarding the progress to completion of specific tasks or costs incurred.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_931bce22-7936-4e94-ba53-95c61bc7ad25">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Patent costs&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;All patent-related costs incurred in connection with filing and prosecuting patent applications are recorded as general and administrative expenses as incurred.&lt;/span&gt;&lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_f679130f-2c86-40cc-95b2-55d114362bef">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company measures its stock options with service-based vesting or performance-based vesting granted to employees, non-employee directors, consultants and independent advisors based on the estimated fair value on the date of grant using the Black-Scholes option-pricing model. The Company measures compensation expense for restricted common stock units based on the fair value on the date of grant using the market value of the Company&#x2019;s common stock. Compensation expense for the awards is recognized over the requisite service period for employees and directors and as services are delivered for consultants and independent advisors, both of which are generally the vesting period of the respective award. The Company uses the straight-line method to record the expense of awards with only service-based vesting conditions. The Company uses the graded-vesting method to record the expense of awards with both service-based and performance-based vesting conditions, commencing once achievement of the performance condition becomes probable. The Company accounts for forfeitures of share-based awards as they occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company classifies stock-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#x2019;s payroll costs are classified or in which the award recipient&#x2019;s service payments are classified.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_3e4b7d0a-f826-42cd-b149-1d52c9f68147">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#x2019;s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to the provision for income taxes. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. Any resulting unrecognized tax benefits are recorded within the provision for income taxes.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_e63d0b4e-54b1-42e4-a0de-5a07ab6f3a6b">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic net loss per share attributable to common stockholders is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net loss per share attributable to common stockholders is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, adjusted for potential dilutive common shares.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In periods in which the Company reported a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company reported a net loss attributable to common stockholders for the years ended December 31, 2025 and 2024.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_6c2c8aff-9e3a-49bd-80b6-287c4dbfc1d0">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently Issued Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU No. 2023-09 (ASU 2023-09), &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which requires, among other things, the following for public business entities: (i) enhanced disclosures of specific categories of reconciling items included in the rate reconciliation, as well as additional information for any of these items meeting certain qualitative and quantitative thresholds; (ii) disclosure of the nature, effect and underlying causes of each individual reconciling item disclosed in the rate reconciliation and the judgment used in categorizing them if not otherwise evident; and (iii) enhanced disclosures for income taxes paid, which includes federal, state, and foreign taxes, as well as for individual jurisdictions over a certain quantitative threshold. The amendments in ASU 2023-09 eliminate the requirement to disclose the nature and estimate of the range of the reasonably possible change in unrecognized tax benefits for the 12 months after the balance sheet date. The effective date of this update for non-public companies is for fiscal years beginning after December 15, 2025; early adoption is permitted. The Company expects ASU 2023-09 to require additional disclosures in the notes to its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU 2024-03 (ASU 2024-03), &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Disaggregation of Income Statement Expenses&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which requires additional disclosures about specific types of expenses included in the expense captions presented on the face of the income statement, as well as disclosures about selling expenses. The provisions of ASU 2024-03 are effective for public business entities for fiscal years beginning after December 15, 2026, and interim periods beginning after December 15, 2027. Early adoption is permitted. The guidance is to be applied prospectively, with the option for retrospective application. The Company is currently evaluating the impact of ASU 2024-03 on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:AssetAcquisitionTextBlock
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_b860f17f-94d0-498d-9aa9-c04465d8d3ee">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 3. Asset Acquisition and Private Placement with a Related Party&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Background&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company entered into (i) an Agreement and Plan of Merger and Reorganization, dated as of April 10, 2024 (the Acquisition Agreement), by and among the Company, Tango Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (Transitory Subsidiary), Tenet Medicines, Inc. (Tenet), a Delaware corporation, and, solely in his capacity as Tenet equityholder representative, Stephen Thomas, providing for the acquisition of Tenet by the Company through the merger of Transitory Subsidiary into Tenet, with Tenet surviving as a wholly owned subsidiary of the Company, (ii) a Securities Purchase Agreement, dated as of April 10, 2024 (the Securities Purchase Agreement), by and among the Company and several accredited institutional investors (the PIPE Investors) including funds affiliated with RA Capital Management, L.P. (RA Capital Management), pursuant to which the Company agreed to issue and sell to the PIPE Investors in the Private Placement an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,238,282&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shar&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;es (the PIPE Shares) of the Company&#x2019;s common stock, and (iii) a registration rights agreement with the PIPE Investors, pursuant to which the Company agreed to register for resale the PIPE Shares.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On June 27, 2024, the Company completed its acquisition of Tenet in accordance with the terms of the Acquisition Agreement. Tenet was a private, development stage biotechnology company that was majority-owned by funds affiliated with RA Capital Management prior to the closing of the Acquisition. Immediately prior to the closing of the Acquisition and Private Placement, RA Capital Management beneficially owned approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the Company&#x2019;s outstanding common stock. The Private Placement closed immediately following the closing of the Acquisition. The Company received aggregate gross proceeds from the Private Placement of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;120.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, before deducting offering costs of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. The offering costs were recorded as a reduction of additional paid-in capital generated in connection with the Private Placement.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At the effective time of the Acquisition, by virtue of the Acquisition and without any action on the part of the holders of common stock of Tenet, (i) all issued and outstanding shares of the common stock of Tenet and (ii) all securities convertible into shares of common stock of Tenet were converted into the right to receive, in the aggregate, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,560,047&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Acquisition Accounting&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounted for the Acquisition as an asset acquisition and accordingly, total consideration of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;52.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, comprised of the fair value of common stock issued of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, settlement of pre-existing loan of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and transaction costs of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, was allocated to the assets acquired and liabilities assumed on a relative fair value basis. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table sets forth the allocation of the purchase consideration (in thousands):&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:86.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.76%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Assets acquired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;In-process research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;51,659&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;Prepaid expenses and other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total assets acquired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;54,724&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Liabilities assumed&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;Accounts payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,603&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;Accounts payable, related party&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;101&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;192&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;Accrued expenses, related party&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total liabilities assumed&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,972&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net assets acquired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;52,752&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The value of the IPR&amp;amp;D was expensed in the consolidated statements of operations and comprehensive loss, as the IPR&amp;amp;D was determined to have no future alternative use.&lt;/span&gt;&lt;/p&gt;</us-gaap:AssetAcquisitionTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_b8dc21c9-0746-48db-ae13-fe4513f56fc2"
      decimals="INF"
      id="F_85fb5591-611c-407f-ae21-6a0670b98f08"
      unitRef="U_shares">31238282</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="C_3764c6b2-4005-4af7-aa82-8f2372cb37f7"
      decimals="3"
      id="F_49355560-fb4a-4b8f-bd3a-1ccafbc1827e"
      unitRef="U_pure">0.439</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_ca2a5c36-84bf-4318-8dcb-1ce0dfebe519"
      decimals="-5"
      id="F_807bab24-a6f3-4b8a-8cd5-d3be7d52fefa"
      unitRef="U_USD">120000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:NoninterestExpenseOfferingCost
      contextRef="C_eb135969-7a37-4398-8643-db443b9da969"
      decimals="-5"
      id="F_e72c7268-79aa-4a64-b538-2d9bce873984"
      unitRef="U_USD">300000</us-gaap:NoninterestExpenseOfferingCost>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_1cd90362-0202-4f43-82f2-856942e3293d"
      decimals="INF"
      id="F_a367c2f6-5902-4697-b5ee-2f76fb3754e9"
      unitRef="U_shares">5560047</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="C_1469ea52-2e42-41aa-be6d-28e711fcb465"
      decimals="-5"
      id="F_e04a09ee-2f1e-4712-9786-68148451fb29"
      unitRef="U_USD">52800000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_229c18f8-1124-4b2d-9a29-665a8a728b8d"
      decimals="-5"
      id="F_ae0c75ac-3ef0-4504-b464-ce708469db9f"
      unitRef="U_USD">41900000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <clym:BusinessCombinationConsiderationTransferredSettlementOfPreExistingLoan
      contextRef="C_29397fb4-e48e-4a21-bd44-1d67c539182e"
      decimals="-5"
      id="F_b49c576e-5ebd-4add-83c2-a778caf1d814"
      unitRef="U_USD">5000000</clym:BusinessCombinationConsiderationTransferredSettlementOfPreExistingLoan>
    <us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost
      contextRef="C_29397fb4-e48e-4a21-bd44-1d67c539182e"
      decimals="-5"
      id="F_6c009d9e-f8fa-458a-89c3-4299f88b27c7"
      unitRef="U_USD">5800000</us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_7d842f40-c630-4d6b-a67c-15a38cd3b450">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table sets forth the allocation of the purchase consideration (in thousands):&lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:86.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.76%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Assets acquired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;In-process research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;51,659&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;Prepaid expenses and other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total assets acquired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;54,724&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Liabilities assumed&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;Accounts payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,603&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;Accounts payable, related party&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;101&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;192&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;Accrued expenses, related party&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total liabilities assumed&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,972&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net assets acquired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;52,752&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <clym:AmountOfIn-ProcessResearchAndDevelopmentAssetsAcquired
      contextRef="C_17e50103-a558-453b-9429-8e636ff6a3b8"
      decimals="-3"
      id="F_c68e14bd-d73e-4d52-96bb-243964ae3bb8"
      unitRef="U_USD">51659000</clym:AmountOfIn-ProcessResearchAndDevelopmentAssetsAcquired>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="C_17e50103-a558-453b-9429-8e636ff6a3b8"
      decimals="-3"
      id="F_ebf8de66-ba05-4190-8615-04a2fb2c46b6"
      unitRef="U_USD">1204000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="C_17e50103-a558-453b-9429-8e636ff6a3b8"
      decimals="-3"
      id="F_481ca79c-eb2c-48f0-a490-de3cb756fb42"
      unitRef="U_USD">1861000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets
      contextRef="C_17e50103-a558-453b-9429-8e636ff6a3b8"
      decimals="-3"
      id="F_75865d90-d224-4325-b0b1-81b6ac092b99"
      unitRef="U_USD">54724000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="C_17e50103-a558-453b-9429-8e636ff6a3b8"
      decimals="-3"
      id="F_2ddda152-0aa5-416a-af84-ebd6802a163a"
      unitRef="U_USD">1603000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="C_12786af0-d6f4-4fe0-aebb-f1db256fd20d"
      decimals="-3"
      id="F_181dfea8-b977-4ad5-818d-3257faf0f62c"
      unitRef="U_USD">101000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther
      contextRef="C_17e50103-a558-453b-9429-8e636ff6a3b8"
      decimals="-3"
      id="F_a135e603-7a1a-4507-8ba3-480440230016"
      unitRef="U_USD">192000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther
      contextRef="C_12786af0-d6f4-4fe0-aebb-f1db256fd20d"
      decimals="-3"
      id="F_d4a2cb7b-1c66-4f83-bce5-e833efe6ad4d"
      unitRef="U_USD">76000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities
      contextRef="C_17e50103-a558-453b-9429-8e636ff6a3b8"
      decimals="-3"
      id="F_698f1613-87e8-42ea-a412-9cc7da8aadc0"
      unitRef="U_USD">1972000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="C_17e50103-a558-453b-9429-8e636ff6a3b8"
      decimals="-3"
      id="F_434cefe6-6388-4c53-a4db-dd77d1781c95"
      unitRef="U_USD">52752000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_d8455684-7e36-40a5-b00e-847ae5386931">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 4. Marketable Securities and Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Marketable securities consisted of available-for-sale securities as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:52.899%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.879%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:7.897%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.879%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:7.897%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.879%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:7.897%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.879%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:7.897%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2005;&#x2005;&#x2005;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gain&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Short-term marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,874&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,976&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,419&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total short-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65,170&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65,395&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Long-term marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,341&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,518&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,054&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government agency debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total long-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59,362&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59,572&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:52.899%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.879%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:7.897%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.879%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:7.897%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.879%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:7.897%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.879%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:7.897%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2005;&#x2005;&#x2005;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gain&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Short-term marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,519&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,130&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,153&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total short-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,649&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,690&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Long-term marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,982&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,955&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,146&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,154&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government agency debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,501&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total long-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61,628&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;58&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61,610&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025, the Company&#x2019;s long-term marketable securities have contractual maturity dates between one and two years.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following tables present information about the Company&#x2019;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:54.489%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:7.439%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:7.439%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:7.439%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:7.439%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements at December 31, 2025 Using:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,320&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,320&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,473&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,473&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government agency debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:25pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:4.627%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,473&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;124,967&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;74,793&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;160,287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:54.489%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:7.439%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:7.439%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:7.439%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:7.439%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements at December 31, 2024 Using:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85,612&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85,612&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;54,307&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;54,307&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government agency debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,501&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,501&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:25pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:4.627%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;54,307&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;70,993&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;125,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;139,919&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;70,993&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;210,912&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents and U.S. Treasury securities were valued by the Company based on quoted market prices for identical securities, which represent a Level 1 measurement within the fair value hierarchy. Corporate bonds and agency securities were valued by the Company using quoted prices in active markets for similar securities, which represent a Level 2 measurement within the fair value hierarchy. There were no transfers into or out of Level 3 for any of the periods presented.&lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_732e261e-b827-4b77-82a7-c912e418aeb6">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Marketable securities consisted of available-for-sale securities as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:52.899%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.879%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:7.897%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.879%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:7.897%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.879%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:7.897%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.879%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:7.897%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2005;&#x2005;&#x2005;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gain&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Short-term marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,874&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,976&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,419&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total short-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65,170&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65,395&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Long-term marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,341&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,518&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,054&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government agency debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total long-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59,362&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59,572&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:52.899%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.879%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:7.897%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.879%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:7.897%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.879%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:7.897%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.879%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:7.897%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2005;&#x2005;&#x2005;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gain&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Short-term marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,519&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,130&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,153&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total short-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,649&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,690&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Long-term marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,982&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,955&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,146&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,154&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government agency debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,501&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total long-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61,628&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;58&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61,610&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="C_bde3f747-62a1-4f1f-a73d-375dcd93e40c"
      decimals="-3"
      id="F_9b1c7a43-1fa4-416b-8421-7ef3c836ddf7"
      unitRef="U_USD">31874000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_143ed184-c01f-49b6-be44-844b0eccbf0d"
      decimals="-3"
      id="F_13a33ac4-c398-43c2-bf6b-37c270b5c296"
      unitRef="U_USD">102000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_143ed184-c01f-49b6-be44-844b0eccbf0d"
      decimals="-3"
      id="F_a73e8dac-bc18-4580-8db2-05177ac03f3d"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_bde3f747-62a1-4f1f-a73d-375dcd93e40c"
      decimals="-3"
      id="F_905229e0-5041-4049-bf94-a73cbbad12a5"
      unitRef="U_USD">31976000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="C_5c3cedbc-3847-4e15-a7c4-4fe16652631d"
      decimals="-3"
      id="F_3e0fc09a-0754-4b71-ac4c-bb6a9d614076"
      unitRef="U_USD">33296000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_5aa3c816-c0b5-4d5f-9461-9b02539bee4b"
      decimals="-3"
      id="F_f2f6bfeb-84bd-4163-bcc0-1e165f1752b7"
      unitRef="U_USD">123000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_5aa3c816-c0b5-4d5f-9461-9b02539bee4b"
      decimals="-3"
      id="F_bed62545-c9fa-4041-8234-cfd3b6de524d"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_5c3cedbc-3847-4e15-a7c4-4fe16652631d"
      decimals="-3"
      id="F_790b7ca0-c9e3-4499-9c08-d7ffc9d0a56a"
      unitRef="U_USD">33419000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-3"
      id="F_db8bc8ca-6d3c-4227-a6ed-198c4eddba3c"
      unitRef="U_USD">65170000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_a1639fe2-538e-4c2e-8eb6-781b99e56320"
      decimals="-3"
      id="F_ed5d2a51-a457-42bc-9bd1-ef8439d589cc"
      unitRef="U_USD">225000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_a1639fe2-538e-4c2e-8eb6-781b99e56320"
      decimals="-3"
      id="F_01f360a7-1886-416e-9b93-a06b712fcb34"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-3"
      id="F_2fb7d47a-5a57-4d59-b5a8-18b3353ce602"
      unitRef="U_USD">65395000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="C_bde3f747-62a1-4f1f-a73d-375dcd93e40c"
      decimals="-3"
      id="F_fe9fae4a-01e9-40a0-a27c-456590e41864"
      unitRef="U_USD">50341000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_826ab126-2f0f-4ee0-80a3-17e4f28432a5"
      decimals="-3"
      id="F_3353bc0b-3ae3-46bd-b056-4f0682e6de3b"
      unitRef="U_USD">177000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_826ab126-2f0f-4ee0-80a3-17e4f28432a5"
      decimals="-3"
      id="F_47aa720e-aeb6-4306-94d3-b051f97ed80d"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="C_bde3f747-62a1-4f1f-a73d-375dcd93e40c"
      decimals="-3"
      id="F_aa04a99a-dfaf-41ba-9894-210dedf7f68b"
      unitRef="U_USD">50518000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="C_5c3cedbc-3847-4e15-a7c4-4fe16652631d"
      decimals="-3"
      id="F_041b7eb9-a6d2-448f-b545-2e8417d70fdc"
      unitRef="U_USD">6022000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_28105de5-c93d-4001-a309-95d3ba3b4731"
      decimals="-3"
      id="F_231b1f8c-15de-4ffe-a923-cf17c44645ee"
      unitRef="U_USD">32000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_28105de5-c93d-4001-a309-95d3ba3b4731"
      decimals="-3"
      id="F_ca09e2bc-1d54-40dd-85dd-f1dd84cb34e4"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="C_5c3cedbc-3847-4e15-a7c4-4fe16652631d"
      decimals="-3"
      id="F_ef26cba2-3ca1-4fe2-b453-2b0098d27466"
      unitRef="U_USD">6054000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="C_4886ee1e-e6b0-4ffe-a68d-f50c26f75b4c"
      decimals="-3"
      id="F_c09dd7fd-b403-4fad-bc5f-3b6b5b22d839"
      unitRef="U_USD">2999000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_e15c6a9d-687e-42af-b12a-cad341bda1e1"
      decimals="-3"
      id="F_9fbdf008-f25e-4296-a50c-71b659658e9d"
      unitRef="U_USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_e15c6a9d-687e-42af-b12a-cad341bda1e1"
      decimals="-3"
      id="F_daa5959d-33f3-4832-b9e6-b4bf26db7bfa"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="C_4886ee1e-e6b0-4ffe-a68d-f50c26f75b4c"
      decimals="-3"
      id="F_671b18c0-fc8b-49c3-9baa-78969575d41b"
      unitRef="U_USD">3000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-3"
      id="F_99e4e196-3c45-42ef-bd00-f0b57481091a"
      unitRef="U_USD">59362000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_d868bdfb-8cf1-4ee9-b1bf-c44bf7490d1f"
      decimals="-3"
      id="F_5dae0fd1-569d-40d1-9775-926334736489"
      unitRef="U_USD">210000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_d868bdfb-8cf1-4ee9-b1bf-c44bf7490d1f"
      decimals="-3"
      id="F_2dae41c0-9ac5-415c-8327-68097dfbf72b"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-3"
      id="F_c48336b2-92f8-44a6-a3fe-3701ae968b9f"
      unitRef="U_USD">59572000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="C_0fbedef7-74ba-4411-abad-f702157bda82"
      decimals="-3"
      id="F_91332e08-b44f-429f-9b9c-ac9199a63f15"
      unitRef="U_USD">33519000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_06ef22a7-6f48-4029-8a4d-33c077e1cac9"
      decimals="-3"
      id="F_515d984c-8ac1-4a29-a80a-5185cd3759ce"
      unitRef="U_USD">23000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_06ef22a7-6f48-4029-8a4d-33c077e1cac9"
      decimals="-3"
      id="F_f40a54ef-2aa8-4bba-b6df-533a641fcd27"
      unitRef="U_USD">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_0fbedef7-74ba-4411-abad-f702157bda82"
      decimals="-3"
      id="F_e219bddd-e3a4-4956-8284-d26d6c94c765"
      unitRef="U_USD">33537000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="C_748a9a3a-36eb-4467-86a9-2986b4bca451"
      decimals="-3"
      id="F_e6155b72-6664-40c8-a006-77173f59cdfd"
      unitRef="U_USD">30130000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_48e4ad5a-7bc4-467d-b65f-6be30cf02804"
      decimals="-3"
      id="F_621cd7d3-433c-4643-8bd0-6410dccffaca"
      unitRef="U_USD">27000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_48e4ad5a-7bc4-467d-b65f-6be30cf02804"
      decimals="-3"
      id="F_b464bf80-8197-45b8-8e71-fbc969e4330c"
      unitRef="U_USD">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_748a9a3a-36eb-4467-86a9-2986b4bca451"
      decimals="-3"
      id="F_b91956a4-4235-40f7-97ca-1726f4c09424"
      unitRef="U_USD">30153000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e"
      decimals="-3"
      id="F_2b695f1a-0c2c-427a-9537-ca68c17b09fd"
      unitRef="U_USD">63649000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_67fbe650-9798-4fbe-bbe0-3a6d9e4fd743"
      decimals="-3"
      id="F_b661143f-1770-435b-839d-023181db6eba"
      unitRef="U_USD">50000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_67fbe650-9798-4fbe-bbe0-3a6d9e4fd743"
      decimals="-3"
      id="F_1d1d7c4d-359a-460d-b94d-93f82bc11f0d"
      unitRef="U_USD">9000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e"
      decimals="-3"
      id="F_e1adc5fe-f1a9-4772-8cfc-dc4e092d69c4"
      unitRef="U_USD">63690000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="C_0fbedef7-74ba-4411-abad-f702157bda82"
      decimals="-3"
      id="F_c30f6490-184a-4a4e-8edd-68c65dc56ee4"
      unitRef="U_USD">33982000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_ef6867d1-f320-430c-a6a8-a7cce3a87985"
      decimals="-3"
      id="F_6f2c8ed1-195f-42ac-936b-298ddba8ecd2"
      unitRef="U_USD">16000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_ef6867d1-f320-430c-a6a8-a7cce3a87985"
      decimals="-3"
      id="F_a1b20950-7f63-40a0-8fe1-3f6a86c5555d"
      unitRef="U_USD">43000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="C_0fbedef7-74ba-4411-abad-f702157bda82"
      decimals="-3"
      id="F_9a745896-b2bb-4dc7-9342-237b4a0ccaef"
      unitRef="U_USD">33955000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="C_748a9a3a-36eb-4467-86a9-2986b4bca451"
      decimals="-3"
      id="F_9249bd4b-add4-4c1a-82b3-4d9157e0f618"
      unitRef="U_USD">24146000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_871db5fb-78d1-4c8c-9435-954b2bb1e0b9"
      decimals="-3"
      id="F_b29ffb6a-bf48-4613-9c79-3875a7daf89d"
      unitRef="U_USD">23000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_871db5fb-78d1-4c8c-9435-954b2bb1e0b9"
      decimals="-3"
      id="F_a383c7f0-dd68-4af0-b27b-870c3c73a630"
      unitRef="U_USD">15000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="C_748a9a3a-36eb-4467-86a9-2986b4bca451"
      decimals="-3"
      id="F_71abf1ca-805b-4f81-97c4-3f6842c5a4e5"
      unitRef="U_USD">24154000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="C_9919181b-3aee-4458-b7d9-1a4a0eaa9fb2"
      decimals="-3"
      id="F_4034eb95-6c15-41fe-8261-ae475db315dc"
      unitRef="U_USD">3500000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_f497deb3-4bfb-4c8f-9883-3d0724584857"
      decimals="-3"
      id="F_19f0c08d-3ce8-4a8e-96b5-5bac73ce7dcd"
      unitRef="U_USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_f497deb3-4bfb-4c8f-9883-3d0724584857"
      decimals="-3"
      id="F_08e5c6ab-81be-457b-8c5d-0b8274424c98"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="C_9919181b-3aee-4458-b7d9-1a4a0eaa9fb2"
      decimals="-3"
      id="F_e1533c39-c409-4b0c-8fc5-f640d74cd51e"
      unitRef="U_USD">3501000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e"
      decimals="-3"
      id="F_c4dc5eee-5aaa-4249-b2dd-2c8eabfaf2fd"
      unitRef="U_USD">61628000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_132b3bc1-f201-4b4f-9cc1-62f73c6af233"
      decimals="-3"
      id="F_85949dd1-b818-4f2c-867f-db7a6465729e"
      unitRef="U_USD">40000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_132b3bc1-f201-4b4f-9cc1-62f73c6af233"
      decimals="-3"
      id="F_cbec59fd-fc8d-4400-8f8c-56710b103685"
      unitRef="U_USD">58000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e"
      decimals="-3"
      id="F_9a1c1fe2-46cb-41c9-89bf-93de11abd87b"
      unitRef="U_USD">61610000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_4e580162-3b87-4332-9d56-8c12c97cd090">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following tables present information about the Company&#x2019;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:54.489%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:7.439%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:7.439%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:7.439%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:7.439%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements at December 31, 2025 Using:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,320&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,320&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,473&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,473&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government agency debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:25pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:4.627%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,473&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;124,967&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;74,793&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;160,287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:54.489%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:7.439%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:7.439%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:7.439%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:7.439%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements at December 31, 2024 Using:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85,612&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85,612&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;54,307&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;54,307&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government agency debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,501&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,501&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:25pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:4.627%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;54,307&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;70,993&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;125,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;139,919&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;70,993&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;210,912&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_130e2c73-2289-4af1-866f-b3e95291e78a"
      decimals="-3"
      id="F_953499e4-e867-4b0c-9c80-44b46528abad"
      unitRef="U_USD">35320000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_3831b4d7-2630-4d1c-a211-547ef8149bc9"
      decimals="-3"
      id="F_e572db33-30d1-4f4c-b75a-f82c7eab5f2a"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_f88dd6f3-ebdc-4647-b965-79b931a0dc44"
      decimals="-3"
      id="F_ba687cea-57c1-44d5-9cff-70c5c6cead33"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_dacb7ce4-e0c8-40f2-abc8-8ae1a39abc75"
      decimals="-3"
      id="F_4ce1eb4f-4129-44a3-9257-edda83a588d4"
      unitRef="U_USD">35320000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_adc4015d-fb3a-4ffb-9ada-76a96f681121"
      decimals="-3"
      id="F_29d95fb5-50c0-4c71-9840-41a2577a3f1e"
      unitRef="U_USD">39473000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_ecee46ed-d146-4031-b499-6e0840c72f93"
      decimals="-3"
      id="F_85286bf9-692d-4391-b17c-d7eacbce9cfa"
      unitRef="U_USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_ba58008a-9a99-409a-9227-d0761c6dddab"
      decimals="-3"
      id="F_ca33b190-5219-4877-b421-96fcc957212a"
      unitRef="U_USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_d4c5c2ea-4149-489e-bc3b-000c9f96aa69"
      decimals="-3"
      id="F_8e25f12e-ab24-4903-b9ba-8fdc55f2ca91"
      unitRef="U_USD">39473000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_8df34eff-0fa0-4471-a95a-aa6f2075612e"
      decimals="-3"
      id="F_fecdf1e1-0a08-4369-b876-3b6ce09b8de0"
      unitRef="U_USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_633a4534-233a-47cb-9dd5-77bb31081fad"
      decimals="-3"
      id="F_120106c0-6035-4942-8c0a-3c54ad4c37cc"
      unitRef="U_USD">82494000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_aa482204-5cdf-42f9-b194-151104d06794"
      decimals="-3"
      id="F_5e37f14c-5b66-4018-8730-a74271402ee8"
      unitRef="U_USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_89c728ad-be3d-454b-8a42-c4b78f7c05f2"
      decimals="-3"
      id="F_95d40231-78ab-4b85-a544-905a3ea24aa6"
      unitRef="U_USD">82494000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_95114177-d276-4bf7-acfa-a07347587ae6"
      decimals="-3"
      id="F_1a3904dd-2695-4586-9105-ec2f4dc39158"
      unitRef="U_USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_3883179f-cde0-439b-9eb8-f31242d68421"
      decimals="-3"
      id="F_c29c0415-3752-4c3a-87f9-2e49fb4cef59"
      unitRef="U_USD">3000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_c6853a23-c64f-400c-a86c-924a3bb8491a"
      decimals="-3"
      id="F_dd42f94c-01a1-4979-bfcc-4ac8e06b9bd0"
      unitRef="U_USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_2a071569-fdc7-4495-8732-ea28c8ae9688"
      decimals="-3"
      id="F_d9d28c9d-3cb0-455d-98f0-55fc1020f692"
      unitRef="U_USD">3000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_1209e286-0944-4ac4-896b-e702d0d7ea37"
      decimals="-3"
      id="F_66ff2d25-380b-446d-90d7-7c050e64c2d5"
      unitRef="U_USD">39473000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_12d2135a-b5b7-4af6-8957-a06f4411e554"
      decimals="-3"
      id="F_327dff62-0537-45be-8848-def9ce99e2ad"
      unitRef="U_USD">85494000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_692bb88f-3f78-4543-9ceb-82120ad5dcf9"
      decimals="-3"
      id="F_c6dd68ce-522b-4dfe-a6ff-1b0e4d28670c"
      unitRef="U_USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_428a9132-cc2d-4fef-8e17-79b45da3689d"
      decimals="-3"
      id="F_619b1e9f-fd3e-4a59-94ea-03c8d87dc625"
      unitRef="U_USD">124967000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_1209e286-0944-4ac4-896b-e702d0d7ea37"
      decimals="-3"
      id="F_88310803-14b9-4aeb-98fb-e297f83b60a9"
      unitRef="U_USD">74793000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_12d2135a-b5b7-4af6-8957-a06f4411e554"
      decimals="-3"
      id="F_21ddc7f3-cb50-4146-aed3-8d19b6c19317"
      unitRef="U_USD">85494000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_692bb88f-3f78-4543-9ceb-82120ad5dcf9"
      decimals="-3"
      id="F_453814bd-698f-4527-8383-af09855b0db6"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_428a9132-cc2d-4fef-8e17-79b45da3689d"
      decimals="-3"
      id="F_2fd2fb17-9ce3-46ef-9b14-a1fcbfb530e9"
      unitRef="U_USD">160287000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_380311ae-d23a-413a-a7a8-c787758e7d24"
      decimals="-3"
      id="F_9d09ecc2-68a4-4785-a456-413d92a3cce2"
      unitRef="U_USD">85612000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_e3e5dc09-b6d0-4ff0-b26f-a809c7b2d2a9"
      decimals="-3"
      id="F_6e404996-be60-41ea-a814-9b68f56b6e9d"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_52e5d444-52de-4a17-998f-18fdef06290a"
      decimals="-3"
      id="F_21762bec-2764-4ccb-ba3d-bce1b5e9df94"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_64d950f8-dcf6-4e8a-9c63-e1b34b08c3d9"
      decimals="-3"
      id="F_c08b220c-9a7a-4140-acd9-171d00e5180d"
      unitRef="U_USD">85612000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_8b239563-a96d-46e3-ad49-e8ca68499571"
      decimals="-3"
      id="F_221989e7-2340-4a0e-b59b-da10567d3f9f"
      unitRef="U_USD">54307000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_f19e76bb-81d4-4bcc-92ba-46dff13be9f8"
      decimals="-3"
      id="F_ee4dc145-ae69-46b4-b86b-00808409a190"
      unitRef="U_USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_54db0f01-b239-4cf6-8fdb-eb4625a650a6"
      decimals="-3"
      id="F_1eb16434-6870-4f2d-8182-537f8769803f"
      unitRef="U_USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_077a91d2-792f-4523-9b7a-5cb3ca9f9427"
      decimals="-3"
      id="F_d3ab650b-cdf6-487b-abd4-6898189452c8"
      unitRef="U_USD">54307000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_63ae5d9d-6a3f-4dea-8e44-bc65e7b9ac46"
      decimals="-3"
      id="F_3c92014c-fdda-4aea-9750-27ffd87b58f4"
      unitRef="U_USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_3208a51a-315a-4c57-94b7-9a59ba63f36c"
      decimals="-3"
      id="F_277193a8-f234-4d3d-98e3-74a8e918b721"
      unitRef="U_USD">67492000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0d43faf6-11a6-437b-94d9-14ad3457ce60"
      decimals="-3"
      id="F_5450693b-bf74-4704-bf73-7b2dd988ebd3"
      unitRef="U_USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_66f073f4-73ec-4e49-b873-cf1990ed99bd"
      decimals="-3"
      id="F_7e8c26d0-248c-4071-b1d8-2e1bb7649877"
      unitRef="U_USD">67492000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_54357343-07e1-4dfa-b18d-381a152a7bcd"
      decimals="-3"
      id="F_80058bfb-d630-4492-b738-f185a9e157db"
      unitRef="U_USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_a2afa2c5-af46-4829-87c9-63140a0edb2a"
      decimals="-3"
      id="F_d4eeb717-a649-4de0-bf42-0a2f44bb0f94"
      unitRef="U_USD">3501000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_b4947833-f3f8-4c09-9229-596d3c11ebb0"
      decimals="-3"
      id="F_6c7dc2f1-845d-4d98-af77-a0422f24bb70"
      unitRef="U_USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_760e2bea-9b82-40c0-9ace-1bb642dcf176"
      decimals="-3"
      id="F_24d97697-2456-4ee9-8dd5-63bb2a5a8e27"
      unitRef="U_USD">3501000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_43590eda-3065-4d1d-82a7-d6a196b38e75"
      decimals="-3"
      id="F_34d9aafd-8e49-416e-b86b-72c582aafe38"
      unitRef="U_USD">54307000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_6bb7bc11-3822-497f-a5fa-c0b7de9605dc"
      decimals="-3"
      id="F_5f07f0b6-bb4b-4dd4-b0a0-5762aaeb5f51"
      unitRef="U_USD">70993000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_3cce3a91-16bf-4fd1-a028-5515dbbca5c5"
      decimals="-3"
      id="F_ffcbe584-6bc2-482d-855c-6118d2246aca"
      unitRef="U_USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_9044897e-bda8-464c-bcb1-ec1f0a7b9592"
      decimals="-3"
      id="F_074c5659-a1a7-4ab7-8cc4-08458e045805"
      unitRef="U_USD">125300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_43590eda-3065-4d1d-82a7-d6a196b38e75"
      decimals="-3"
      id="F_23e64e80-0f4f-4ce7-9392-4028b11c584e"
      unitRef="U_USD">139919000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_6bb7bc11-3822-497f-a5fa-c0b7de9605dc"
      decimals="-3"
      id="F_cc6c61ad-68bc-4903-a799-4f8eed05a7a1"
      unitRef="U_USD">70993000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_3cce3a91-16bf-4fd1-a028-5515dbbca5c5"
      decimals="-3"
      id="F_4a2dea16-0656-4e32-8471-7bf4cdf827bd"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_9044897e-bda8-464c-bcb1-ec1f0a7b9592"
      decimals="-3"
      id="F_e42fa104-5d94-41f4-a944-f45932345046"
      unitRef="U_USD">210912000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_07b873a9-ee82-4914-b1da-f1e37be1530e">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 5. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued Expenses and Other Current Liabilities&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses and other current liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:72.446%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.598%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.598%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued payroll and related expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,891&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,997&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued external research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,816&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,237&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;693&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;746&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other accrued expenses and current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;89&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,459&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,069&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_42eac4e7-9974-47f8-9ebe-dff8958ecf4d">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses and other current liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:72.446%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.598%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.598%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued payroll and related expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,891&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,997&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued external research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,816&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,237&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;693&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;746&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other accrued expenses and current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;89&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,459&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,069&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-3"
      id="F_a38d8ad8-b4c8-44b1-9810-5ae2beaa1afa"
      unitRef="U_USD">1891000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e"
      decimals="-3"
      id="F_04005647-47f0-4be8-a5eb-70ae9b320869"
      unitRef="U_USD">1997000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <clym:AccruedExternalResearchAndDevelopmentsExpense
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-3"
      id="F_04498369-6d54-49c8-88fa-ea6f61ee9d1a"
      unitRef="U_USD">1816000</clym:AccruedExternalResearchAndDevelopmentsExpense>
    <clym:AccruedExternalResearchAndDevelopmentsExpense
      contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e"
      decimals="-3"
      id="F_5f2ebf08-27ef-4cc1-adb5-d2675dc4087e"
      unitRef="U_USD">1237000</clym:AccruedExternalResearchAndDevelopmentsExpense>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-3"
      id="F_f82693fb-07de-4e18-98d2-7c0540cf14f0"
      unitRef="U_USD">693000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e"
      decimals="-3"
      id="F_0ec02959-0f2d-44c0-a391-f773f67f53e5"
      unitRef="U_USD">746000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-3"
      id="F_f51c9a20-202b-430f-924b-c0438f7acbaa"
      unitRef="U_USD">59000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e"
      decimals="-3"
      id="F_83cd1de7-344e-4bc5-97f1-9399c1c96f4a"
      unitRef="U_USD">89000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-3"
      id="F_fce186d4-56ba-4395-85b5-0f701c8b573b"
      unitRef="U_USD">4459000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e"
      decimals="-3"
      id="F_7b76cb74-be08-4b8c-a382-07a8dc52d65a"
      unitRef="U_USD">4069000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_20e4391c-64a3-4c5d-a59c-bca6810e300a">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 6. Related Party Transactions&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Equity&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On December 11, 2025, the Company entered into an exchange agreement (the Exchange Agreement) with RA Capital Management and an entity affiliated with RA Capital Management (the Exchanging Holder), pursuant to which the Exchanging Holder exchanged an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,440,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock, beneficially owned by the Exchanging Holder for a pre-funded warrant to purchase the same number of shares of the Company&#x2019;s common stock (subject to adjustment in the event of stock splits, recapitalizations and other similar events affecting the Company&#x2019;s common stock), with an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share. The pre-funded warrant is exercisable at any time and does not expire.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Exchanging Holder is not entitled to exercise any portion of the pre-funded warrant if, upon giving effect or immediately prior to such exercise, such exercise would result in the aggregate number of shares of common stock beneficially owned by RA Capital Management, the Exchanging Holder, and their respective affiliates, collectively, to exceed &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the number of shares of common stock issued and outstanding immediately after giving effect to such exercise, as such percentage ownership is determined in accordance with the terms of the pre-funded warrant. The Exchanging Holder may increase or decrease such percentage to any other percentage not in excess of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%; provided that any such increase will not be effective until the 61st day after notice from the Exchanging Holder is delivered to the Company. In addition, following the date of the Exchange Agreement, RA Capital Management may exchange additional shares of common stock beneficially owned by it or its affiliates for pre-funded warrants, subject to certain terms and conditions, including the Company&#x2019;s written consent.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company determined that the pre-funded warrant did not meet the classification of a liability under ASC 480, Distinguishing Liabilities from Equity. The Company concluded that the pre-funded warrant should be classified as equity based on an analysis performed under ASC 815-40, Contracts in an Entity's Own Equity. The Exchange Agreement did not have any cash impact, and the shares of common stock exchanged for the pre-funded warrant were retired.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In June 2024, the Company issued shares to RA Capital Management and affiliates in connection with the Acquisition and Private Placement (see Note 3).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Service Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As a result of the Acquisition, the following legacy Tenet agreements effectively became agreements of the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Tenet was a party to a service agreement with Sera Services, Inc. (Sera Services), a wholly-owned subsidiary of Sera Medicines, LLC (Sera Medicines) to provide research and other services to the Company. Sera Medicines is an entity controlled by RA Capital Management, and Dr. Stephen Thomas, a current board member of the Company, owns a minority ownership in and is also a board member of Sera Medicines. No services were provided under the Sera Services Agreement for the year ended December 31, 2025 and, in March 2026, the Company terminated the agreement. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company paid $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to Sera Services for services provided under the Sera Services Agreement for the year ended December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Tenet was a party to a service agreement with Blackbird Clinical, Inc. (Blackbird), an entity controlled by RA Capital Management. Under the terms of the service agreement, Blackbird provided consulting services to Tenet in connection with its clinical trials. For the year ended December 31, 2024, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the Company paid approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to Blackbird under the Blackbird Service Agreement.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; In October 2024, the Company terminated the Blackbird Service Agreement.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <clym:SharesExchangedForPreFundedWarrants
      contextRef="C_304c3dfd-55bb-45b2-a8b2-e1afe73e55f4"
      decimals="0"
      id="F_107652de-a59f-40d0-86f9-8d6607dfc51e"
      unitRef="U_shares">20440000</clym:SharesExchangedForPreFundedWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_e158c5d9-1a89-4e43-8ef0-1635b5f8acb7"
      decimals="4"
      id="F_d1769cf0-328b-4c31-ad76-f999b9087bd6"
      unitRef="U_USDollarShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <clym:AggregateBeneficialOwnershipExchangingStockholders
      contextRef="C_3e184d6d-add2-4b8e-bb9b-90a0e05d219a"
      decimals="3"
      id="F_de6680c4-418f-4d0c-87c9-ec695919989f"
      unitRef="U_pure">0.33</clym:AggregateBeneficialOwnershipExchangingStockholders>
    <clym:AggregateBeneficialOwnershipExchangingStockholders
      contextRef="C_3e184d6d-add2-4b8e-bb9b-90a0e05d219a"
      decimals="3"
      id="F_38abaeb3-d746-431f-914a-ed1649f06604"
      unitRef="U_pure">0.33</clym:AggregateBeneficialOwnershipExchangingStockholders>
    <us-gaap:OtherExpenses
      contextRef="C_3a734757-e1ee-40b3-8578-67d0507ee846"
      decimals="-5"
      id="F_2dbe45d6-6e95-42a0-b2f2-9765c79bb616"
      unitRef="U_USD">100000</us-gaap:OtherExpenses>
    <us-gaap:OtherExpenses
      contextRef="C_90041a5e-41bb-41f0-9714-a6b1a0938dd1"
      decimals="-5"
      id="F_9eb5bed0-5293-41b7-a0b0-b7b21dd079c9"
      unitRef="U_USD">100000</us-gaap:OtherExpenses>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_3a7d71d7-54f1-4375-92cb-a37a2d7bd28d">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 7. Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company leases office space under a non-cancelable operating lease in Wellesley, Massachusetts under a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;-month lease agreement that expires in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_0ecb2fd9-391a-4200-85ea-df3460e76587;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 2026&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The lease contains rent escalation clauses and an option to extend the term of the lease for an additional 12-month period at a market rate determined according to the lease. At the lease&#x2019;s inception and as of December 31, 2025, the Company expects to exercise its &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;option to extend&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; the lease, and therefore the period covered by this option is included in the lease term.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In April 2025, the Company amended the lease to add space to the existing lease for additional fixed payments totaling $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million through 2026 with an option to extend the lease through 2027 for additional fixed payments of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. As the Company expects to exercise its option to extend the lease, the extension period is included in the lease term. Accordingly, the Company recorded an increase to operating lease right-of-use assets and operating lease liabilities of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company previously leased office space in Bellevue, Washington, which expired in January 2025, and Cambridge, U.K., which expired in June 2024.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The components of lease expense were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:70.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;243&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Short-term lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Variable lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;259&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;329&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Supplemental disclosure of cash flow information related to leases was as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:70.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash paid for amounts included in the measurement of operating &lt;br/&gt;&#160;&#160;&#160;&#160;&#160;lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;256&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;350&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;Operating lease liabilities arising from obtaining right-of-use&lt;br/&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;216&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;510&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The weighted-average remaining lease term and discount rate were as follows:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:70.148%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.301%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.625%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.301%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.625%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average remaining lease term - operating lease (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average discount rate - operating lease&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025, the annual future minimum lease payments due under the Company&#x2019;s non-cancelable operating lease was as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:82.44%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;"&gt;Year ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;293&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;298&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;Total undiscounted lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;591&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;541&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Total operating lease liabilities in the table above are classified on the consolidated balance sheet as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:82.44%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Included in the consolidated balance sheet (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;256&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease liability, net of current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;285&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;541&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      id="F_b8f23b79-109a-475b-88f4-8837a8a1b530">P24M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_108e52b3-ce58-4d4c-bba6-49da2ab04414">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:LeaseCost
      contextRef="C_e5a79ba0-ff7c-4c63-a7dc-6397a5945808"
      decimals="-5"
      id="F_3cfe4bb5-803a-42bd-b9bf-ad981cf9979f"
      unitRef="U_USD">200000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_259b8ff0-14b6-480a-93a7-28890d7655ca"
      decimals="-5"
      id="F_8e940a34-bb26-4df9-9449-ba674cfc74e8"
      unitRef="U_USD">100000</us-gaap:LeaseCost>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_aad0ea95-775d-4c74-b575-deb8723088ed"
      decimals="-5"
      id="F_aa3e3926-e4b3-4204-b33a-8f8c86697328"
      unitRef="U_USD">200000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <clym:IncreaseDecreaseInOperatingLeaseAssets
      contextRef="C_aad0ea95-775d-4c74-b575-deb8723088ed"
      decimals="-5"
      id="F_9ac13657-5bb4-4402-b20f-b4e94cdb9e80"
      unitRef="U_USD">200000</clym:IncreaseDecreaseInOperatingLeaseAssets>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_18c590ae-3b8f-4aa9-9aaf-70aedf942318">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The components of lease expense were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:70.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;243&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Short-term lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Variable lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;259&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;329&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The weighted-average remaining lease term and discount rate were as follows:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:70.148%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.301%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.625%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.301%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.625%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average remaining lease term - operating lease (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average discount rate - operating lease&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_79d2e938-caa6-4afc-9a37-b1ae9540ee35"
      unitRef="U_USD">250000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_45cde996-e02d-4f60-a536-ba0866080707"
      unitRef="U_USD">243000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_cbc0cea8-d500-4d85-942b-9552ac361a19"
      unitRef="U_USD">0</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_387abdae-9d3c-4c5a-9fa4-55027518ba3a"
      unitRef="U_USD">0</us-gaap:ShortTermLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_ba4b57fc-b96d-41f3-89fa-0e7bfc7c21f7"
      unitRef="U_USD">9000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_53194cb0-eddb-486c-b548-dea1919a0cdb"
      unitRef="U_USD">86000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_4d9d96b9-2a82-4e45-9bfe-5e4479e2ad5c"
      unitRef="U_USD">259000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_d30509f5-796a-4b4e-b80e-f8cbf9912777"
      unitRef="U_USD">329000</us-gaap:LeaseCost>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_db9b9a44-8db6-4de5-8ed1-b47b4672c0ee">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Supplemental disclosure of cash flow information related to leases was as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:70.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash paid for amounts included in the measurement of operating &lt;br/&gt;&#160;&#160;&#160;&#160;&#160;lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;256&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;350&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;Operating lease liabilities arising from obtaining right-of-use&lt;br/&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;216&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;510&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_c720d6c4-57ba-47f1-a078-21455f160867"
      unitRef="U_USD">256000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_28c58b18-cd45-403e-b654-c6b3a7914718"
      unitRef="U_USD">350000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_d4de41d3-677b-4ed7-9429-d4fc8d765189"
      unitRef="U_USD">216000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_0032c46b-1484-4be8-bf1c-15c52f84db2f"
      unitRef="U_USD">510000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      id="F_295dec30-1447-4651-bf8c-2bc2b0a540e7">P2Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e"
      id="F_e702d343-a929-46a4-99c1-d585ce60cf7b">P2Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="3"
      id="F_7cba45b4-b9f5-421d-956a-e2ff136e5373"
      unitRef="U_pure">0.085</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e"
      decimals="3"
      id="F_4bbc8940-6ea1-477a-9a2f-217c0c5ee230"
      unitRef="U_pure">0.085</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_ec605b1b-dd0d-4953-861c-95536b1c5063">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025, the annual future minimum lease payments due under the Company&#x2019;s non-cancelable operating lease was as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:82.44%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;"&gt;Year ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;293&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;298&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;Total undiscounted lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;591&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;541&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-3"
      id="F_28f5fe80-251f-4695-ab72-811695892ee7"
      unitRef="U_USD">293000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-3"
      id="F_f34c2d68-534d-4756-b8a6-5b024ff3c0e0"
      unitRef="U_USD">298000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-3"
      id="F_544b81e5-2e02-4847-8e7f-dd414e2fa157"
      unitRef="U_USD">591000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-3"
      id="F_88348a85-4e74-4843-831c-22d2e44412f6"
      unitRef="U_USD">50000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-3"
      id="F_4af9ecce-b9bd-45f6-9a6f-c430f6385247"
      unitRef="U_USD">541000</us-gaap:OperatingLeaseLiability>
    <clym:ScheduleOfBalanceSheetSupplementalDisclosuresTableTextBlock
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_f0c1071f-b94b-4fcd-9eb5-dd7cbff507b3">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Total operating lease liabilities in the table above are classified on the consolidated balance sheet as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:82.44%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Included in the consolidated balance sheet (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;256&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease liability, net of current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;285&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;541&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</clym:ScheduleOfBalanceSheetSupplementalDisclosuresTableTextBlock>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-3"
      id="F_2b99ab56-6ba6-4161-b9fd-051af272cd8c"
      unitRef="U_USD">256000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-3"
      id="F_38ebd449-d9d8-44ad-9ac2-e8b920a03048"
      unitRef="U_USD">285000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-3"
      id="F_64b80591-845a-40de-a9b6-3b1e0b58625a"
      unitRef="U_USD">541000</us-gaap:OperatingLeaseLiability>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_c7967904-01ce-4c02-95c2-72f75d4c598e">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 8. Commitments and Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s commitments under its leases are described in Note 7.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;License Agreements (Budoprutug)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As a result of the Acquisition, the following legacy Tenet agreements effectively became agreements of the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Acelyrin Asset Purchase Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On January 11, 2024, Tenet entered into an asset purchase agreement (the Asset Purchase Agreement) with Acelyrin, Inc. (Acelyrin) and WH2, LLC, which was subsequently transferred to the Company by operation of law upon the closing of the Acquisition, providing for the acquisition of certain assets of Acelyrin related to budoprutug (the Transferred Assets), including certain assigned contracts. Under these assigned contracts, the Company (i) received worldwide licenses (with the right to sublicense) to certain patents, know-how and other intellectual property rights to develop, manufacture, use and commercialize budoprutug for any non-oncology indication, and (ii) assumed certain liabilities of Acelyrin arising from (1) governmental authority action or notification relating to budoprutug, (2) contracts assigned to the Company pursuant to the Asset Purchase Agreement and (3) the Company&#x2019;s ownership, lease or operation of the Transferred Assets. The Asset Purchase Agreement includes customary representations, warranties and covenants, as well as standard mutual indemnities, including those covering losses arising from any material breach of the Asset Purchase Agreement.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the Asset Purchase Agreement, the Company also acquired the rights and obligations, including financial obligations, under a license agreement with Cancer Research Technology Limited (CRH), which Tenet subsequently amended and restated in the CRH Agreement (as defined below) and a cell line development, manufacturing services and license agreement with ProBioGen AG (ProBioGen).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the Asset Purchase Agreement with respect to any &#x201c;Product&#x201d;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (as such term is defined in the Asset Purchase Agreement), the Company is obligated to (i) make total payments of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;157.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to Acelyrin upon the achievement of various development, regulatory and commercial milestones, (ii) pay royalties in the single-digit percentages, subject to specified reductions, to Acelyrin on worldwide net sales in a given calendar year, and (iii) make non-refundable and non-creditable payments to Acelyrin on sublicense income with rates ranging from the low single digit to mid teen percent depending on the stage of development of the most advanced Product at the time of such sublicense.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The royalty term continues for each Product on a country-by-country and Product-by-Product basis beginning on the first commercial sale of such Product and ending on the latest of (a) the date when such Product is no longer covered by a valid claim of a royalty-bearing patent (as such term is defined in the Asset Purchase Agreement) in such country, (b) the expiration of any regulatory exclusivity period for such Product in such country, and (c) the twelfth anniversary of the first commercial sale of such Product in such country.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is obligated to use commercially reasonable efforts to commercialize at least one Product in the U.S., to the extent a Product exists under the Asset Purchase Agreement, and to achieve specified development, regulatory and commercial milestones for such Product set forth in the Asset Purchase Agreement.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;To the extent a Product exists under the Asset Purchase Agreement, if Acelyrin asserts that the Company has failed to meet a specified diligence obligation under the Asset Purchase Agreement within specified time periods, and such failure is finally determined through a dispute resolution process, Acelyrin may elect, in lieu of a claim for damages, to repurchase the Transferred Assets at the then-fair market value of such Transferred Assets, as Acelyrin&#x2019;s sole and exclusive remedy for such breach.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;If, within a specified period following the top line data readout from the first Phase 2 clinical trial of a Product, the Company receives a bona fide offer or proposal from a third party to sell, transfer or otherwise divest all or substantially all of the rights to the Transferred Assets or Products, or grant an exclusive license or exclusive sublicense to such third party to develop and commercialize Products under specified terms, then prior to entering into any discussions or negotiations with any third party in relation to such a transaction, the Company shall provide written notice to Acelyrin of such intent or receipt of proposal. Acelyrin shall have the right to negotiate with the Company the terms for a definitive agreement with respect to such sale, transfer or grant of the rights to Products for a specified period of time. If Acelyrin does not exercise its right to negotiate or the parties are unable to agree on the terms of a definitive agreement, the Company shall have the right to negotiate or enter into an agreement with a third party with respect to such transaction, subject to specified conditions.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company may not sell, assign or transfer all or substantially all of the rights to develop or commercialize a Product unless, as a condition to such sale, assignment or transfer, the purchaser, assignee or transferee (as applicable) assumes in writing all of our obligations as set forth in the Asset Purchase Agreement with respect to the applicable Products.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company records expense related to milestone payments when achievement of the milestone is assessed as probable. As of December 31, 2025, the Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t recorded expense related to milestone payments under the Asset Purchase Agreement. On December 31, 2025, the Company filed a complaint in Delaware Superior Court against Alumis Inc. and its wholly owned subsidiary, Acelyrin, relating to a dispute concerning the Asset Purchase Agreement as further described below.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;CRH Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In connection with the Asset Purchase Agreement, in January 2024 Tenet was assigned a license agreement with CRH and, in connection with such assignment, Tenet entered into an amended and restated license agreement with CRH (the CRH Agreement) which was subsequently transferred to the Company by operation of law upon the closing of the Acquisition. The CRH Agreement granted the Company a worldwide exclusive license (other than specified patent rights and materials, which are licensed to the Company on a non-exclusive basis) under certain know-how, patents and materials, or the licensed rights, to research, develop, test, manufacture or sell certain licensed products related to budoprutug, for all therapeutic uses except for oncology indications. The Company is permitted to grant a sublicense under these licenses with CRH&#x2019;s prior written consent. CRH retains, on behalf of itself and the charitable company Cancer Research U.K., a worldwide, fully paid-up, perpetual and irrevocable right in the licensed rights and in certain intellectual property owned or controlled by the Company that is necessary to exploit the licensed products and used, conceived or generated in the course of exercising the license or exploiting any licensed product, or product-specific foreground intellectual property, for the purpose of non-commercial, non-clinical scientific research.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is obligated to use commercially reasonable efforts to perform all activities set forth in a mutually agreed-upon development plan within the timelines set forth therein. The Company is also obligated to develop at least one licensed product in an autoimmune indication and to pursue worldwide regulatory authorization for licensed products. The Company must use commercially reasonable efforts to commercialize each licensed product throughout each of the specified major markets as soon as practicable following receipt of regulatory authorization for such product in such market. Additionally, the Company must use commercially reasonable efforts to make the licensed product available through the U.K. and negotiate with relevant regulatory authorities to make each licensed product available through the National Health Service in England and Wales within a specified time of the licensed product being made available elsewhere in the territory. If the Company fails to meet one or more of these diligence obligations, and such failure is not remedied within the specified cure period, CRH shall have the right to terminate the CRH Agreement with respect to the relevant licensed product.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is obligated to pay CRH a mid-five figure digit fee on each anniversary of the effective date. The Company is obligated to pay up to an aggregate of &#xa3;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;106.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million (&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;143.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as of December 31, 2025) upon the achievement of specified development, regulatory, commercial and sales milestone events, including: (i) payments of up to mid-six figure digits in pounds sterling for certain development milestones, (ii) payments of up to low-eight figures in pounds sterling per indication (for up to three indications) for certain regulatory and commercial milestones and (iii) payments up to mid-eight figures in pounds sterling for certain sales milestones. The Company is also obligated to pay tiered royalties ranging from a rate in the mid-single digit to high-single digit percentage on net sales. The royalty term continues for each licensed product on a country-by-country basis beginning on the first commercial sale of such licensed product and ending on the latest of (a) the date when such licensed product is no longer covered by a valid claim of a licensed patent in such country, (b) the expiration of the exclusivity period for such licensed product in such country, and (c) the tenth anniversary of the first commercial sale of such licensed product in such country. The Company is also responsible for a sublicensing revenue payment ranging from a rate in the mid-single digit to mid-double digits for any sublicense revenue.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The CRH Agreement shall remain in effect in each country in the territory until the expiry of our obligation to pay royalties in such country. Either party may terminate the CRH Agreement if the other party is in material breach that has not been remedied within the specified cure period or if the other party becomes insolvent. CRH also has the right to terminate the CRH Agreement if the Company or one of its sublicensees or affiliates challenges a licensed patent, or if the Company is acquired by a tobacco company.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company records expense related to milestone payments when achievement of the milestone is assessed as probable. During the year ended December 31, 2025, the Company recorded $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of research and development expense related to the milestones.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;ProBioGen Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the Asset Purchase Agreement, Tenet was assigned a cell line development, manufacturing services and license agreement (the ProBioGen Agreement) originally entered into by ValenzaBio, Inc. and ProBioGen in February 2021, which was subsequently transferred to the Company by operation of law upon the closing of the Acquisition. The ProBioGen Agreement granted the Company a non-exclusive license under certain know-how, patents and materials, to use cell lines in which ProBioGen&#x2019;s proprietary technology is applied, to research, develop, manufacture, use, sell, offer to sell, import or export budoprutug. This license includes a non-exclusive sublicense by ProBioGen of certain third-party patent rights, limited to the use of budoprutug.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is obligated to (i) make payments of up to &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million (&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as of December 31, 2025) upon the achievement of certain development, manufacturing and commercial milestones, including the start of a Phase 2 clinical trial for budoprutug, and (ii) make milestone payments of up to &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million (&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as of December 31, 2025) upon the achievement of certain sales milestones. If the Company elects to contract ProBioGen to perform certain manufacturing services for budoprutug, the milestone payments would be reduced by &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million (&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as of December 31, 2025).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The ProBioGen Agreement will remain in effect until the services are completed for the service-related component and until the payment obligations expire in connection with the commercial license component. Both parties have the right to terminate the ProBioGen Agreement if the other party becomes insolvent, or materially breaches the ProBioGen Agreement and fails to remedy such default within the specified cure period.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company records expense related to milestone payments when achievement of the milestone is assessed as probable. During the year ended December 31, 2025, the Company recorded $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of research and development expense related to the milestones.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;License Agreement (CLYM116)&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On January 8, 2025, the Company entered into the Mabworks Agreement, pursuant to which Mabworks granted to the Company (i) an exclusive (even as to Mabworks and its affiliates), sublicensable right and license under certain patent rights and related know-how (the Licensed Intellectual Property) to develop, manufacture and commercialize Mabworks&#x2019; proprietary antibodies associated with Mabworks&#x2019; proprietary antibody program, identified as MIL116 (the Licensed Compounds or CLYM116) and products containing the Licensed Compounds (Licensed Products) outside of Greater China (the Licensed Territory), (ii) a non-exclusive, sublicensable right and license under the Licensed Intellectual Property to manufacture the Licensed Compounds and Licensed Products in Greater China and (iii) a non-exclusive, sublicensable right and license under the Licensed Intellectual Property to develop the Licensed Compounds and Licensed Products in the Greater China in connection with certain global clinical studies (as described below).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the terms of the Mabworks Agreement, the Company paid to Mabworks a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million upfront payment, and the Company is obligated to pay a total of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million upon the achievement of certain development and regulatory milestones pertaining to the first indication for a Licensed Product, additional lower amounts upon the achievement of certain development and regulatory milestones pertaining to up to two additional indications for a Licensed Product and a total of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;832.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;upon the achievement of certain commercial milestones for all Licensed Products. In addition, the Company is obligated to pay Mabworks tiered royalties in the low-to mid-single-digit percentages on aggregate annual net sales of all Licensed Products in the Licensed Territory. The Company is obligated to pay royalties on a Licensed Product-by-Licensed Product and country-by-country basis from the date of the first commercial sale in such country until the latest of: (i) the expiration of the last valid claim on the Licensed Intellectual Property covering the composition of matter of the Licensed Compound in such Licensed Product in such country; and (ii) ten years following the first commercial sale of such Licensed Product in such country (each, a Royalty Term). The royalty rate is subject to reduction on a Licensed Product-by-Licensed Product and country-by-country basis under certain circumstances. In the event that the Company grants sublicenses under the&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Licensed &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Intellectual Property, the Company will be obligated to pay Mabworks a percentage, in the mid-single-digits to low-double-digits, of certain consideration received under such sublicenses.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company agreed to use commercially reasonable efforts to develop, obtain regulatory approval for and commercialize a Licensed Product in the U.S. The Company has also granted Mabworks a right of first refusal to develop and commercialize in Greater China any product the Company controls that contains an antibody directed to tumor necrosis factor ligand superfamily member 13 (APRIL). Mabworks has agreed not to exploit in the Licensed Territory any product that is directed to APRIL during the term of the Mabworks Agreement. The Mabworks Agreement also contains a mechanism for the parties to collaborate on global clinical studies in the future, where the Company has a right to perform clinical studies in Greater China with Mabworks&#x2019; approval in the event that Mabworks elects not to participate in such global clinical studies. Unless earlier terminated, the Mabworks Agreement will expire on the expiration of the last to expire Royalty Term. Either party may terminate the Mabworks Agreement for the other party&#x2019;s material breach, following a customary notice and cure period, or insolvency. Additionally, the Company may terminate the Mabworks Agreement for any reason upon 60 days written notice to Mabworks.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recorded the upfront payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as research and development expenses in the first quarter of 2025 in the consolidated statements of operations and comprehensive loss. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company records expense related to milestone payments when achievement of the milestone is assessed as probable. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the year ended December 31, 2025, the Company recorded $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of research and development expense related to a milestone.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Legal Proceedings&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of its business activities. The Company records accruals for estimated losses when available information indicates a loss is probable and reasonably estimable. Significant judgment is required to determine both probability and the estimated amount. The Company expenses the costs related to its legal proceedings as they are incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On December 31, 2025, the Company filed a complaint in Delaware Superior Court against Alumis Inc. and its wholly owned subsidiary, Acelyrin, relating to a dispute concerning the Asset Purchase Agreement seeking a declaratory judgment that the Company&#x2019;s budoprutug drug candidate is not a Product under the Asset Purchase Agreement, and that the Company does not owe a milestone payment sought by Alumis in connection with its development of budoprutug. This matter is currently pending. The Company is unable to predict the timeline for resolution or the outcome of this matter.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of the date of these consolidated financial statements, the Company is not party to any other material legal matters or claims.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Indemnification&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless, and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third-party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In addition, the Company has entered into indemnification agreements with members of its board of directors and executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. To date, the Company has not incurred any material costs as a result of such indemnification provisions. The Company is not currently aware of any indemnification claims and has not accrued any liabilities related to such obligations in its consolidated financial statements as of December 31, 2025.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <clym:MilestonePayments
      contextRef="C_8d01d41c-acfb-4b36-86b4-52db5162e53b"
      decimals="-5"
      id="F_43dcb77c-83a2-4c31-b7bb-e77860e26816"
      unitRef="U_USD">157500000</clym:MilestonePayments>
    <clym:MilestonePaymentsDue
      contextRef="C_e8ccac22-cccd-4604-a52d-f88a9f26a088"
      decimals="-6"
      id="F_6d147578-7c1d-42fd-a95d-97b6e8b26fe9"
      unitRef="U_USD">0</clym:MilestonePaymentsDue>
    <clym:MilestonePayments
      contextRef="C_8579d8f5-3430-4159-88d1-ebaf49448cd2"
      decimals="-5"
      id="F_f12e4b05-0da9-4939-a4a6-0695e3beebf7"
      unitRef="U_GBP">106800000</clym:MilestonePayments>
    <clym:MilestonePayments
      contextRef="C_cb8006fb-9972-4de5-8228-dd0f468981f6"
      decimals="-5"
      id="F_970f43bd-b8ab-4d8d-8882-ee14a59af9d6"
      unitRef="U_USD">143600000</clym:MilestonePayments>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_b6de63ae-c1ba-465a-83f3-ca5197585acd"
      decimals="-5"
      id="F_906714ee-998e-4ab7-a07f-be8584893ab6"
      unitRef="U_USD">1000000</us-gaap:ResearchAndDevelopmentExpense>
    <clym:MilestonePayments
      contextRef="C_12593a5c-196b-480a-886e-b17facf60df2"
      decimals="-5"
      id="F_6110c710-070a-4893-a4d7-7d1c9a0c6d44"
      unitRef="U_EUR">10000000</clym:MilestonePayments>
    <clym:MilestonePayments
      contextRef="C_48b9f054-2754-412a-9e64-8ac7cd01dbef"
      decimals="-5"
      id="F_dcba2d54-cdea-4cd5-a1c5-1045f1efa320"
      unitRef="U_USD">11700000</clym:MilestonePayments>
    <clym:MilestonePayments
      contextRef="C_0f8a9914-3000-454c-ab10-75100dc7832f"
      decimals="-5"
      id="F_02030359-058c-4734-9c82-fb5b2777ffbf"
      unitRef="U_EUR">7000000</clym:MilestonePayments>
    <clym:MilestonePayments
      contextRef="C_239f2b84-9e87-4d24-8ef6-ec35e511039c"
      decimals="-5"
      id="F_d0d0587a-126c-44b8-8a2b-b0d04d06e923"
      unitRef="U_USD">8200000</clym:MilestonePayments>
    <clym:MilestonePaymentAmountReduced
      contextRef="C_a9351123-b279-44ed-b948-3c21858af6ed"
      decimals="-5"
      id="F_a20fe0a2-5a34-44f1-9b3b-5a5f599185a1"
      unitRef="U_EUR">1100000</clym:MilestonePaymentAmountReduced>
    <clym:MilestonePaymentAmountReduced
      contextRef="C_89e402ec-8a69-4241-9a74-d42ab514978d"
      decimals="-5"
      id="F_00f16c15-3b61-4e0d-8b76-6156771060b2"
      unitRef="U_USD">1200000</clym:MilestonePaymentAmountReduced>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_905153fa-065a-4b24-a22c-0410b7b3bfda"
      decimals="-5"
      id="F_4415056f-318f-4a18-93ba-022aab48ff1b"
      unitRef="U_USD">2700000</us-gaap:ResearchAndDevelopmentExpense>
    <clym:UpfrontPaymentPaid
      contextRef="C_389487f4-111c-4263-b8a6-56fb2d222f6d"
      decimals="-5"
      id="F_b19fa417-f0f4-497f-9cab-f3601af7390d"
      unitRef="U_USD">9000000</clym:UpfrontPaymentPaid>
    <clym:MilestonePayments
      contextRef="C_fab74366-ad6b-4993-b418-2c772c8de0bd"
      decimals="-5"
      id="F_da9a3821-9cac-4feb-b59b-647a51432981"
      unitRef="U_USD">30000000</clym:MilestonePayments>
    <clym:MilestonePayments
      contextRef="C_0b3af095-e13b-4823-afed-c09031e8be17"
      decimals="-5"
      id="F_4f42e340-e701-4d48-a3c7-4e003b4d8dcd"
      unitRef="U_USD">832000000</clym:MilestonePayments>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_b4634d19-4dbe-4167-828d-3b0dea46ce12"
      decimals="-5"
      id="F_dbdc4004-67fd-430f-9771-8fed660bd907"
      unitRef="U_USD">9000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_2829c600-2470-432e-befb-c0c057ac53de"
      decimals="-5"
      id="F_76d4eef5-4e07-428d-a19e-e0e1488632ad"
      unitRef="U_USD">1000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_aa6cc44a-ed90-4167-91d0-4fca494c2e0f">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 9.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;2019 and 2021 Equity Incentive Plans&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has outstanding awards under its 2019 Equity Incentive Plan (the 2019 Plan), but is no longer granting awards under this plan. The Company&#x2019;s 2021 Equity Incentive Plan (the 2021 Plan and, together with the 2019 Plan, the Plans) provides for the grant of incentive stock options, non-statutory stock options, restricted stock awards, restricted stock units (RSUs), stock appreciation rights and other stock-based awards to the Company&#x2019;s employees, officers, directors and consultants. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Any shares that are returned under the 2019 Plan as a result of cancellation or forfeiture become available for grant under the 2021 Plan. Further, the number of shares of common stock reserved for issuance under the 2021 Plan automatically increases on January 1 of each year continuing through and including January 1, 2031, by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;of the total number of shares of common stock outstanding on December 31 of the immediately preceding calendar year, or a lesser number of shares&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;determined &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;by the Company&#x2019;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;s board of directors. The number of authorized shares reserved for issuance under the 2021 Plan was increased by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,362,771&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares effective as of January 1, 2025 in accordance with the provisions of the 2021 Plan described above. As of December 31, 2025, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,124,834&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares remained available for future grant under the 2021 Plan. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The number of shares reserved for issuance under the 2021 Plan was increased by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,388,316&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares effective January 1, 2026.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the terms of the 2021 Plan, options are granted at an exercise price no less than fair value of the Company&#x2019;s common stock on the grant date, except in certain cases related to significant corporate transactions. Options expire no later than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; from the date of the grant.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;2025 Inducement Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In March 2025, the Company&#x2019;s board of directors adopted the 2025 Inducement Plan (the Inducement Plan), pursuant to which the Company may grant nonstatutory stock options, stock appreciation rights, restricted stock awards, RSUs and other stock-based awards with respect to an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,250,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of its common stock. Awards under the Inducement Plan may only be granted to new employees who were not previously an employee or director of the Company or are commencing employment with the Company following a bona fide period of non-employment, in either case, as an inducement material to the individual&#x2019;s entering into employment with the Company in accordance with the requirements of Nasdaq Stock Market Rule 5635(c)(4). On September 30, 2025, the Company&#x2019;s board of directors approved an amendment to the Inducement Plan to increase the number of shares of common stock authorized for issuance under the Inducement Plan by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;750,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares remained available for issuance under the Inducement Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s 2021 Employee Stock Purchase Plan (the ESPP) allows employees, including executive officers, to contribute up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of their earnings, subject to certain limitations, for the purchase of the Company&#x2019;s common stock at a price per share equal to the lower of (a) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the fair market value of a share of common stock on the first day of the offering period, or (b) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the fair market value of a share of common stock on the last day of the offering period. The number of shares of common stock reserved for issuance under the ESPP automatically increases on January 1 of each calendar year through and including January 1, 2031, by the lesser of (1) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the total number of shares of the Company&#x2019;s common stock outstanding on December 31 of the preceding calendar year or (2) a number of shares determined by the Company&#x2019;s board of directors. Shares subject to purchase rights granted under the ESPP that terminate without having been exercised in full will not reduce the number of shares available for issuance under the ESPP. The number of authorized shares reserved for issuance under the ESPP was increased by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;672,554&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares effective as of January 1, 2025 in accordance with the provisions of the ESPP described above. The first offering period began on December 16, 2025 and will end on June 15, 2026. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares had been granted or purchased under the ESPP and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,736,779&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares remained available for issuance under the ESPP. The number of shares reserved for issuance under the ESPP was increased by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;477,663&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares effective January 1, 2026. &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock Option Valuation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair value of stock option grants is estimated on the date of grant using the Black Scholes option pricing model. Volatility is estimated based on the historical and implied volatilities of comparable publicly traded companies as the Company does not have sufficient history of trading in its common stock. The expected term of the Company&#x2019;s stock options has been determined utilizing the &#x201c;simplified&#x201d; method for awards that qualify as &#x201c;plain-vanilla&#x201d; options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The relevant data used to determine the fair value of the stock option grants during the years ended December 31, 2025 and 2024 is as follows, presented on a weighted-average basis:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:62.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;103.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;104.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock Option Activity&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Outstanding stock options consist of option grants with service-based vesting conditions, typically &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% on the first anniversary of the grant date with the remainder vesting monthly over the following &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The activity for stock options is as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:47.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.06%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.54%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.06%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.54%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Exercise&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Contractual&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Intrinsic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,817,751&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.87&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,766,696&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.77&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,341&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,135,329&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding as of December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,427,777&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.81&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.05&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,727&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested and expected to vest as of December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,427,777&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.81&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.05&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,727&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options exercisable as of December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;631,921&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.00&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;331&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The aggregate intrinsic value disclosed in the above table is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#x2019;s common stock for those stock options that had strike prices lower than the fair value of the Company&#x2019;s common stock. The aggregate intrinsic value of options exercised during the years ended December 31, 2025 and 2024 was less than $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The weighted-average grant date fair value of stock options granted duri&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ng the years ended December 31, 2025 and 2024 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.45&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.56&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has outstanding RSUs with service-based vesting conditions and RSUs with performance-based vesting conditions. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The activity for RSUs is as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:63.113%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.921%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.223%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:3.381%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.362%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,228,876&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,084&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;929,563&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;92,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested at December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;207,897&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The total fair value of restricted stock vested during the years ended December 31, 2025 and 2024 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table sets forth stock-based compensation expense included in the Company&#x2019;s consolidated statements of operations and comprehensive loss (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:62.695%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.079%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.574%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.079%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.574%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,503&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,032&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,551&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,525&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,054&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation expense for the year ended December 31, 2025 included &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million related to performance-based RSUs that vested in the third quarter of 2025 upon achievement of the performance conditions. As of December 31, 2025, ther&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;e was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million o&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;f total unrecognized compensation cost related to unvested awards expected to vest, which is expected to be recognized over a weighted average period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.9&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <clym:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage
      contextRef="C_dd8c59f4-3742-43b0-84bb-363445fa8ccb"
      decimals="2"
      id="F_2521cad1-6b64-44e0-9997-00e9d41c75fa"
      unitRef="U_pure">0.05</clym:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_51534b8e-0ca9-48c3-97a9-d9df1a0b13ca"
      decimals="0"
      id="F_854da3b9-0ed8-4cce-8099-cbd8650aa061"
      unitRef="U_shares">3362771</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_63169a3f-785d-4de2-b401-eff12e91f2ac"
      decimals="0"
      id="F_5a3e51ca-1dee-4e35-b2bc-bfab1c0bb454"
      unitRef="U_shares">3124834</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_afdf6eb5-5976-48c1-824a-42df181b79c2"
      decimals="0"
      id="F_ac8a538f-501c-4711-a776-8fa11d5cde1f"
      unitRef="U_shares">2388316</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
      contextRef="C_80f05462-1973-4d3e-8520-b5a9f59b1778"
      id="F_f27c828b-f32a-4a56-9c6f-7a7183208868">Under the terms of the 2021 Plan, options are granted at an exercise price no less than fair value of the Company&#x2019;s common stock on the grant date, except in certain cases related to significant corporate transactions. Options expire no later than ten years from the date of the grant.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_80f05462-1973-4d3e-8520-b5a9f59b1778"
      id="F_1b870876-909a-4f68-b3a7-b47a7c512cca">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_81a10eed-87b5-4e58-b248-df503d6194b9"
      decimals="0"
      id="F_9a5e1e47-95fa-432d-aac0-334082b2b88f"
      unitRef="U_shares">1250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_5544a4ea-f6c3-43ec-b41e-4209eb125966"
      decimals="0"
      id="F_9d963852-80e4-4906-9c19-7eb711b5c517"
      unitRef="U_shares">750000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_eae9b56b-e6e5-40e9-bbd0-fcdfa9342978"
      decimals="0"
      id="F_b6138a3d-4406-41f8-900c-7d8a858c8e17"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
      contextRef="C_b4452408-22d4-4ee5-aebd-bdfbc907dccc"
      id="F_d5e20941-5ac1-41e5-a3e3-edfe40fb77cd">The Company&#x2019;s 2021 Employee Stock Purchase Plan (the ESPP) allows employees, including executive officers, to contribute up to 15% of their earnings, subject to certain limitations, for the purchase of the Company&#x2019;s common stock at a price per share equal to the lower of (a) 85% of the fair market value of a share of common stock on the first day of the offering period, or (b) 85% of the fair market value of a share of common stock on the last day of the offering period. The number of shares of common stock reserved for issuance under the ESPP automatically increases on January 1 of each calendar year through and including January 1, 2031, by the lesser of (1) 1% of the total number of shares of the Company&#x2019;s common stock outstanding on December 31 of the preceding calendar year or (2) a number of shares determined by the Company&#x2019;s board of directors. Shares subject to purchase rights granted under the ESPP that terminate without having been exercised in full will not reduce the number of shares available for issuance under the ESPP. The number of authorized shares reserved for issuance under the ESPP was increased by 672,554 shares effective as of January 1, 2025 in accordance with the provisions of the ESPP described above. The first offering period began on December 16, 2025 and will end on June 15, 2026. As of December 31, 2025, no shares had been granted or purchased under the ESPP and 1,736,779 shares remained available for issuance under the ESPP. The number of shares reserved for issuance under the ESPP was increased by 477,663 shares effective January 1, 2026. </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <clym:ShareBasedCompensationArrangementBySharebasedPaymentAwardContributionPercentMaximum
      contextRef="C_b4452408-22d4-4ee5-aebd-bdfbc907dccc"
      decimals="2"
      id="F_de762d4d-8b90-42b8-884e-477602c3c9d6"
      unitRef="U_pure">0.15</clym:ShareBasedCompensationArrangementBySharebasedPaymentAwardContributionPercentMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_bb651521-2c6d-4fbd-b7ad-6cfc21cd0b6a"
      decimals="2"
      id="F_d1776689-8dcb-4fbb-8e4c-5ffcfaf3cf0f"
      unitRef="U_pure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_c04dc289-c837-42ec-90ed-96b37ca44352"
      decimals="2"
      id="F_4cf2f240-8631-4fce-b974-e13ec13aa19b"
      unitRef="U_pure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <clym:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage
      contextRef="C_e5b62da0-95aa-41be-88d8-378341822749"
      decimals="2"
      id="F_039875fe-0117-4a52-8266-7ef5e60bac85"
      unitRef="U_pure">0.01</clym:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_2d40f93a-6e30-47ec-9b7b-b71b689a098a"
      decimals="0"
      id="F_ec69507c-7427-4397-95c2-1ea63ee0a3aa"
      unitRef="U_shares">672554</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_b4452408-22d4-4ee5-aebd-bdfbc907dccc"
      decimals="0"
      id="F_4833f7dd-4da9-4ca1-b887-2fd229db3377"
      unitRef="U_shares">0</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_9e183b21-7abc-4bbb-a514-9fac970fc0da"
      decimals="0"
      id="F_3d4527ad-9288-4bcf-b5ac-717f058e8e3c"
      unitRef="U_shares">1736779</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_c4117672-57e4-4a80-95aa-824a99550138"
      decimals="0"
      id="F_913ca7b3-c7d8-402f-96d9-61155e2f514e"
      unitRef="U_shares">477663</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_8e3a3426-2e2a-40f8-91b9-59e42baa5264">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The relevant data used to determine the fair value of the stock option grants during the years ended December 31, 2025 and 2024 is as follows, presented on a weighted-average basis:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:62.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;103.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;104.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_64fe7ee2-9412-49eb-816d-c3a0fbdc1b98">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      id="F_dab6b8ec-093c-4ed5-9ba0-95b0a556637c">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="3"
      id="F_d1654264-8855-484a-9e72-287fa6b44358"
      unitRef="U_pure">1.036</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="3"
      id="F_cc81edf7-c112-4170-acf1-00cfa8651b0b"
      unitRef="U_pure">1.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="3"
      id="F_d0f4d85a-5fd0-4c9c-8bbe-874ac0e107ea"
      unitRef="U_pure">0.043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="3"
      id="F_aaec020d-0291-4dde-b399-cf02bc5a6906"
      unitRef="U_pure">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="2"
      id="F_2a402cea-6dfb-481f-9152-8576899d4822"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="2"
      id="F_01453d6b-54a3-4ba9-89cd-b9c7cb262a78"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_3cb182f5-fa8c-4e88-b58e-b8e49cc15ab2"
      decimals="2"
      id="F_90bb676a-096d-4e7e-9453-3281ca521281"
      unitRef="U_pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_ce134265-fb84-4e8d-9157-57ff9ef7e7ff"
      id="F_10b474f8-6e20-4faf-9aaa-6346163a17ca">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_58397267-7a57-4d34-ac33-4ab0dfa46aad">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The activity for stock options is as follows:&lt;/span&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:47.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.06%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.54%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.06%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.54%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Exercise&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Contractual&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Intrinsic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,817,751&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.87&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,766,696&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.77&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,341&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,135,329&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding as of December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,427,777&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.81&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.05&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,727&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested and expected to vest as of December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,427,777&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.81&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.05&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,727&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options exercisable as of December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;631,921&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.00&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;331&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e"
      decimals="0"
      id="F_2f5099d2-650f-4896-9f0b-a1b9d78e49e5"
      unitRef="U_shares">2817751</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e"
      decimals="2"
      id="F_ccccb1a8-7a9d-44f8-b33e-25a35b6c39f2"
      unitRef="U_USDollarShare">6.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      id="F_df637f64-9fdc-4360-a654-1ad5c8a2cab4">P6Y10M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e"
      decimals="-3"
      id="F_ede2223d-88bc-4823-94d0-6b8648c6f713"
      unitRef="U_USD">19000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="0"
      id="F_ee3d5f18-b284-458f-b5ad-6be5bbb1feb7"
      unitRef="U_shares">5766696</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="2"
      id="F_325f785f-7b9b-45fd-add2-56379ffd4828"
      unitRef="U_USDollarShare">1.77</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="0"
      id="F_4b95ae85-6b74-461a-ae99-071f86646f58"
      unitRef="U_shares">21341</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="2"
      id="F_56e02f30-099c-4aa8-9551-e1375c0e86e3"
      unitRef="U_USDollarShare">3.04</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="0"
      id="F_712c54ca-9366-4d27-aa71-b9f0d47c31f2"
      unitRef="U_shares">2135329</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="2"
      id="F_f8f4519e-b8c5-468b-bcbd-18537c77cae3"
      unitRef="U_USDollarShare">4.85</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="0"
      id="F_0fb390d3-7212-41c3-af7c-52e2315cb553"
      unitRef="U_shares">6427777</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="2"
      id="F_efbc238b-d121-4def-ba9a-45e395bfae24"
      unitRef="U_USDollarShare">2.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_a0d249ff-be56-4802-8086-6dcf5b449963">P9Y18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-3"
      id="F_56433c85-5f4d-432f-be26-9552191905df"
      unitRef="U_USD">11727000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="0"
      id="F_98b4e16a-4cdf-4adf-9c44-844a63fd30a0"
      unitRef="U_shares">6427777</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="2"
      id="F_f096ad19-9d08-4845-8957-ad0c935d9057"
      unitRef="U_USDollarShare">2.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_c29f5747-c497-470c-a9a1-030a6993a5ca">P9Y18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-3"
      id="F_bdade66e-d720-4b0f-9fc0-ff054d3836af"
      unitRef="U_USD">11727000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="0"
      id="F_46ac30a2-92a1-48be-80a1-81659df548d2"
      unitRef="U_shares">631921</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="2"
      id="F_bef84822-c428-405d-bd08-13ea2ed16d8f"
      unitRef="U_USDollarShare">6.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_e10c7de5-7aef-4142-94ff-8cb645bc799e">P8Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-3"
      id="F_94631471-18dc-40e8-91e0-dd21486aec79"
      unitRef="U_USD">331000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_08d2f2e1-0339-4338-abfa-e32c391b4121"
      decimals="-5"
      id="F_771783ce-8f87-4740-9d37-226f18509995"
      unitRef="U_USD">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-5"
      id="F_172332b9-9ab3-4508-8e62-b5152aa8aea9"
      unitRef="U_USD">6400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_3238fdb8-36cf-4c49-90ac-67c04b90e3fc"
      decimals="2"
      id="F_94a6cd6c-c10a-4f01-941c-b0fadd972aee"
      unitRef="U_USDollarShare">1.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_5917f89f-b247-498e-9e76-b710f5430033"
      decimals="2"
      id="F_33edeede-2c1f-41d4-aa53-0cbeb4e8a686"
      unitRef="U_USDollarShare">5.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_32d53db6-0f3f-497e-984f-c2e4c64d70c4">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The activity for RSUs is as follows:&lt;/span&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:63.113%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.921%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.223%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:3.381%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.362%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,228,876&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,084&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;929,563&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;92,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested at December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;207,897&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The total fair value of restricted stock vested during the years ended December 31, 2025 and 2024 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_c751770e-5639-4fb1-ae0f-ff557e717b97"
      decimals="0"
      id="F_ceecbfd6-afe4-4d73-9598-81049673d7a7"
      unitRef="U_shares">1228876</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_c751770e-5639-4fb1-ae0f-ff557e717b97"
      decimals="2"
      id="F_0e01f465-fc02-4ebb-b960-1fe8c2bb4a65"
      unitRef="U_USDollarShare">7.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_116ecf73-7a8a-49b3-bad1-9ebacd1a92f4"
      decimals="0"
      id="F_4c746e17-f00a-4211-9ecc-3fecc35ec61c"
      unitRef="U_shares">1084</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_116ecf73-7a8a-49b3-bad1-9ebacd1a92f4"
      decimals="2"
      id="F_20d9ed9f-94a8-4cb4-87da-a4558c616172"
      unitRef="U_USDollarShare">4.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_116ecf73-7a8a-49b3-bad1-9ebacd1a92f4"
      decimals="0"
      id="F_35618a88-81cf-459e-9e3b-b27c83227de5"
      unitRef="U_shares">929563</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_116ecf73-7a8a-49b3-bad1-9ebacd1a92f4"
      decimals="2"
      id="F_bf16fc93-22f2-4a35-9a1a-f8619f813d04"
      unitRef="U_USDollarShare">7.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_116ecf73-7a8a-49b3-bad1-9ebacd1a92f4"
      decimals="0"
      id="F_103706d0-0354-4510-9873-95c7c2d30ad7"
      unitRef="U_shares">92500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_116ecf73-7a8a-49b3-bad1-9ebacd1a92f4"
      decimals="2"
      id="F_8dc9f114-5147-41cd-a22d-e6a7ceea47e7"
      unitRef="U_USDollarShare">5.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_6fd1e7a7-23cc-4225-bfaa-c65b03df60f2"
      decimals="0"
      id="F_a76dea78-c527-4609-992e-119e645e3ee1"
      unitRef="U_shares">207897</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_6fd1e7a7-23cc-4225-bfaa-c65b03df60f2"
      decimals="2"
      id="F_91d53013-ba7d-43d7-b312-c023d8e80ed4"
      unitRef="U_USDollarShare">7.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="C_116ecf73-7a8a-49b3-bad1-9ebacd1a92f4"
      decimals="-5"
      id="F_45d4b64d-5db6-4a7e-943a-8c26a508b1dc"
      unitRef="U_USD">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="C_59a3bf61-d6f4-4d70-be41-c0021e29d89c"
      decimals="-5"
      id="F_50df4759-e38b-4125-b738-f4a9cb47fa5d"
      unitRef="U_USD">900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_6c535a04-879a-4cf0-af92-a204155ba1e7">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table sets forth stock-based compensation expense included in the Company&#x2019;s consolidated statements of operations and comprehensive loss (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:62.695%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.079%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.574%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.079%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.574%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,503&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,032&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,551&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,525&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,054&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_c6ae4ef4-19bf-455d-8977-04567e0168e2"
      decimals="-3"
      id="F_15d21222-ca11-4a8b-9b2c-3880bd62574d"
      unitRef="U_USD">3503000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_09c5db3e-d09d-4b4f-b0d8-2f7673550209"
      decimals="-3"
      id="F_0044e2bf-4a80-4fb2-9a37-27c2be963634"
      unitRef="U_USD">3032000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_745ac205-619f-4d46-a569-a29ce2487e40"
      decimals="-3"
      id="F_61a09209-a220-48c9-abc0-73a1df09fe5b"
      unitRef="U_USD">4551000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_04dcce48-ee98-4468-a92e-30daf88a02ee"
      decimals="-3"
      id="F_cb1f9da8-0654-4360-8049-92cd713dc7a5"
      unitRef="U_USD">2525000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_9dd935c5-c6bc-44fa-ad29-d58c12f1c37a"
      unitRef="U_USD">8054000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_2279123b-6121-4010-8834-62cc8c403ddd"
      unitRef="U_USD">5557000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_50f9f95a-751c-4f2f-91d3-e149f6c84a6f"
      decimals="-5"
      id="F_594a4cc8-3a68-4ca0-9bdb-c46676308fd3"
      unitRef="U_USD">3000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-5"
      id="F_0ef82f55-ad6e-4ed3-9faf-0c8ee2e4f4e9"
      unitRef="U_USD">11700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_0e3ba689-87d3-421c-b1ba-ee52f99a5947">P2Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_719952dc-e5b0-427d-b94f-999a8cfe3fc4">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 10. Net Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic and diluted net loss per share are computed using the weighted-average number of shares of common stock outstanding for the period. The Company issued a pre-funded warrant in December 2025 (see Note 6). The shares of common stock underlying the pre-funded warrant are included in the calculation of basic and diluted net loss per share because they are considered shares issuable for little or no consideration under ASC 260, Earnings Per Share. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table shows the computation of basic and diluted net loss per share (in thousands, except share and per share data):&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:64.307%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.077%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:3.439%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.077%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59,851&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;73,897&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Weighted-average common shares outstanding, basic &lt;br/&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66,692,145&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48,163,301&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Weighted-average common shares outstanding under the &lt;br/&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;pre-funded warrant, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,120,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;Weighted-average common shares outstanding, basic &lt;br/&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67,812,145&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48,163,301&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.88&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share for the periods presented because their effect would have been anti-dilutive:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:64.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.64%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.54%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.54%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,427,777&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,817,751&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;207,897&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,228,876&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares of common stock issuable under &lt;br/&gt;&#160;&#160;&#160;the ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,944&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total potentially dilutive shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,659,618&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,046,627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_a1b7f1b8-661b-4624-a008-3b8d47d21c67">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table shows the computation of basic and diluted net loss per share (in thousands, except share and per share data):&lt;/span&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:64.307%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.077%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:3.439%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.077%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59,851&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;73,897&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Weighted-average common shares outstanding, basic &lt;br/&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66,692,145&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48,163,301&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Weighted-average common shares outstanding under the &lt;br/&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;pre-funded warrant, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,120,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;Weighted-average common shares outstanding, basic &lt;br/&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67,812,145&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48,163,301&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.88&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_1a295b97-616f-446d-acf7-04d0cdd60029"
      unitRef="U_USD">-59851000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_b04f0d9c-ffdb-4533-81fe-a6fa645d7467"
      unitRef="U_USD">-73897000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_1f63916b-0391-41c4-8463-6860486b9487"
      decimals="0"
      id="F_774da70a-2bab-4b25-bc4e-02026f8a0788"
      unitRef="U_shares">66692145</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_1f63916b-0391-41c4-8463-6860486b9487"
      decimals="0"
      id="F_0bfc3655-21f9-4e20-a75a-513fdb53daca"
      unitRef="U_shares">66692145</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_5003f42b-a928-4d3a-9175-c224ea1b673a"
      decimals="0"
      id="F_8b1f7462-d08f-4485-a94e-01ab75f8dea9"
      unitRef="U_shares">48163301</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_5003f42b-a928-4d3a-9175-c224ea1b673a"
      decimals="0"
      id="F_00e62e53-78bc-4ee6-a0e0-74566d2b3a06"
      unitRef="U_shares">48163301</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_75ea6436-b4b6-4e75-8aec-a8b8c3cc4fd8"
      decimals="0"
      id="F_bef674c8-6f93-48ae-9130-d8428a6f9738"
      unitRef="U_shares">1120000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_75ea6436-b4b6-4e75-8aec-a8b8c3cc4fd8"
      decimals="0"
      id="F_e3feb66f-5faa-4b3b-96b8-44485f714c06"
      unitRef="U_shares">1120000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_1898b0b8-f16b-4f56-9289-bef317318637"
      decimals="0"
      id="F_2b0793b8-1ae0-4f31-a6e1-3c8c6161b7aa"
      unitRef="U_shares">0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_1898b0b8-f16b-4f56-9289-bef317318637"
      decimals="0"
      id="F_4f3023b9-c401-4766-8279-56071e80a0eb"
      unitRef="U_shares">0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="0"
      id="F_3ee73dfd-9c0e-4e04-86a3-a05e1a019781"
      unitRef="U_shares">67812145</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="0"
      id="F_e71305ab-a318-4988-b7c0-c0bb90016bf6"
      unitRef="U_shares">67812145</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="0"
      id="F_e163f944-a653-45a4-ac31-0941248f6872"
      unitRef="U_shares">48163301</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="0"
      id="F_2722d890-30b9-4f14-8364-6da006b30b13"
      unitRef="U_shares">48163301</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="2"
      id="F_b822fa94-8185-477e-b7f0-bc49e0c97f37"
      unitRef="U_USDollarShare">-0.88</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="2"
      id="F_9391023b-535a-4347-a5f1-e7ab6e8fc06a"
      unitRef="U_USDollarShare">-0.88</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="2"
      id="F_f66f1bad-a777-4985-ae60-8a872030bd8a"
      unitRef="U_USDollarShare">-1.53</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="2"
      id="F_3fb49075-f4f1-4497-9fba-77727b7f28df"
      unitRef="U_USDollarShare">-1.53</us-gaap:EarningsPerShareBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_0f6b4784-2a8d-45ce-a4fa-b06d473bd4a4">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share for the periods presented because their effect would have been anti-dilutive:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:64.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.64%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.54%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.54%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,427,777&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,817,751&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;207,897&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,228,876&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares of common stock issuable under &lt;br/&gt;&#160;&#160;&#160;the ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,944&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total potentially dilutive shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,659,618&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,046,627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_6cab0607-2860-4e20-a77b-ee3751551c8f"
      decimals="0"
      id="F_df18a44f-b260-498f-af00-36b69c360e5e"
      unitRef="U_shares">6427777</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20e4b68b-286f-4226-a52b-f50692b883e7"
      decimals="0"
      id="F_67d2c71a-74eb-48aa-bf53-a0e2c9eab3e6"
      unitRef="U_shares">2817751</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_a81d855c-f7c2-4536-8f9e-51e73b2054d6"
      decimals="0"
      id="F_44faf04f-8c93-465c-b59d-46f6c9db3418"
      unitRef="U_shares">207897</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_fad7a1ea-38aa-452c-960d-f95e7b53f110"
      decimals="0"
      id="F_f287ae7a-8b1c-4df9-92f7-e357c1cc2c16"
      unitRef="U_shares">1228876</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_24b9841c-7af8-45b7-a8fd-326e3878b0f2"
      decimals="0"
      id="F_156499b4-b851-4045-a00a-9d7ee981eead"
      unitRef="U_shares">23944</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_5ebc4489-2c5c-40db-bf3d-8aa0443a01d9"
      decimals="0"
      id="F_c799d860-ad07-4a31-b867-ef1f3fa9f09e"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="0"
      id="F_20c9a028-e50d-4f52-a73c-3e099cfe3418"
      unitRef="U_shares">6659618</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="0"
      id="F_32236d6b-6c55-42cf-bda5-fb5796a78fef"
      unitRef="U_shares">4046627</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_22dfc61c-332b-47ef-86ab-538f3b803dfa">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 11. Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The components of net loss before tax provision from income taxes are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:64.387%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.537%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.44%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.537%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;United States&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59,579&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67,137&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;United Kingdom&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,760&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59,851&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;73,897&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents a reconciliation of the Company&#x2019;s expected tax computed at the U.S. statutory federal income tax rate to the total provision for income taxes (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:62.873%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.163%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.163%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;word-break:break-word;"&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. federal taxes at statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,569&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,518&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;State taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;word-break:break-word;"&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Acquired in-process research and development, related party&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,698&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Effect of cross-border transfers&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,303&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;word-break:break-word;"&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Non-deductible officer compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;293&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;575&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Foreign rate differential&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;237&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;211&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;word-break:break-word;"&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;588&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;403&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;word-break:break-word;"&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Other expenses, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;228&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,284&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,076&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;word-break:break-word;"&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Effective income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The significant components of the Company&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2019;s deferred tax assets and liabilities are presented below (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:64.387%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.537%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.44%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.537%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Net operating losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,202&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,725&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,447&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,946&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,824&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,388&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Stock compensation expense, including 162m limitations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;432&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Research credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;702&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Accrued compensation and benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;332&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;303&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;113&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;121&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Other expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,459&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,630&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,368&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;91&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;138&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Operating lease, right-of-use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;106&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;112&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Other assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;91&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;138&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net deferred tax assets and liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025, the Company had federal net operating loss carryforwards of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, which may be available to offset future taxable income and do not expire but are limited in their usage to an annual deduction equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of annual taxable income. As of December 31, 2025, the Company had state net operating loss carryforwards of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, which may be available to offset future taxable income and expire at various dates beginning in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2038&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. As of December 31, 2025, the Company also had U.S. federal and state research and development tax credit carryforwards of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, which may be available to offset future tax liabilities and expire at various dates beginning in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2039&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. As of December 31, 2025, the Company had foreign net operating loss carryforwards of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, which may be available to offset future taxable income and do not expire.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Utilization of the U.S. federal and state net operating loss carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Sections 382 and 383 of the Internal Revenue Code of 1986, and corresponding provisions of state law, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income or tax liabilities. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50% over a three-year period. The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception due to the significant complexity and cost associated with such a study. If the Company has experienced a change of control, as defined by Section 382, at any time since inception, utilization of the net operating loss carryforwards or research and development tax credit carryforwards would be subject to an annual limitation under Section 382, which is determined by first multiplying the value of the Company&#x2019;s stock at the time of the ownership change by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before utilization. Further, until a study is completed by the Company and any limitation is known, no amounts are being presented as an uncertain tax position.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As required by ASC 740, management of the Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets, which are comprised principally of net operating loss carryforwards. Management has determined that it is more likely than not that the Company will not recognize the benefits of its deferred tax assets and, as a result, a valuation allowance has been recorded.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The changes in the valuation allowance were as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:64.387%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.537%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.44%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.537%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Valuation allowance as of beginning of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,856&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Net increases recorded to income tax provision&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,876&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,636&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Valuation allowance as of end of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,368&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The increase in the valuation allowance for deferred tax assets during the year ended December 31, 2025 related primarily to an increase in net operating losses. The increase in the valuation allowance for deferred tax assets during the year ended December 31, 2024 related primarily to increases in net operating losses and capitalized research and development costs.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company assesses the uncertainty in its income tax positions to determine whether a tax position of the Company is more likely than not to be sustained upon examination, including resolution of any related appeals of litigation processes, based on the technical merits of the position. For tax positions meeting the more-likely-than-not threshold, the tax amount recognized in the consolidated financial statements is reduced by the largest benefit that has a greater than fifty percent likelihood of being realized upon the ultimate settlement with the relevant taxing authority. No reserve for uncertain tax positions or related interest and penalties has been recorded at December 31, 2025 and 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is subject to taxation in the U.S. (federal and various states) and the U.K. Currently, no historical years are under examination. The Company&#x2019;s tax years starting in December 31, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_1ed21085-1747-4238-9882-f67da405f9c3;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2018&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; are open and subject to examination by the U.S. (federal and various states) and the U.K. taxing authorities due to the carryforward of utilized net operating losses and research and development credits.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_1e936b18-88db-4ecb-b6ea-5260408c8baf">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The components of net loss before tax provision from income taxes are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:64.387%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.537%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.44%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.537%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;United States&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59,579&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67,137&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;United Kingdom&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,760&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59,851&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;73,897&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_8c7ebad7-98a1-4e64-b935-7123699f4e44"
      decimals="-3"
      id="F_1f0d49f7-8bcf-45a7-9765-e95e9b87034b"
      unitRef="U_USD">-59579000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_b2c1de80-7339-46dc-9101-dff3552ca399"
      decimals="-3"
      id="F_43c800ee-9882-4504-80c7-b973b5938c44"
      unitRef="U_USD">-67137000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_f4a412c4-4532-42cb-8fef-51e2df6f0cd9"
      decimals="-3"
      id="F_5861d254-0a64-43ea-8c51-1a9c02bedfff"
      unitRef="U_USD">-272000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_e08c8f3c-6d20-45a5-9fa5-1cb8ef652339"
      decimals="-3"
      id="F_b1e8d059-6846-4d08-87c3-1eb68ba42ff8"
      unitRef="U_USD">-6760000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_2b8c6456-a7af-499b-a67f-94c6f6218f5f"
      unitRef="U_USD">-59851000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_7ebd5882-51e6-4b56-b3a3-a69738814e8a"
      unitRef="U_USD">-73897000</us-gaap:NetIncomeLoss>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_c38cf024-166b-40d7-baca-551d2f24dc18">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents a reconciliation of the Company&#x2019;s expected tax computed at the U.S. statutory federal income tax rate to the total provision for income taxes (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:62.873%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.163%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.163%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;word-break:break-word;"&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. federal taxes at statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,569&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,518&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;State taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;word-break:break-word;"&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Acquired in-process research and development, related party&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,698&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Effect of cross-border transfers&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,303&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;word-break:break-word;"&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Non-deductible officer compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;293&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;575&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Foreign rate differential&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;237&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;211&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;word-break:break-word;"&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;588&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;403&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;word-break:break-word;"&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Other expenses, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;228&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,284&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,076&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;word-break:break-word;"&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Effective income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_6496c156-6d7f-4cac-acf8-492addc7ac6c"
      unitRef="U_USD">-12569000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_3458ce1a-938a-4aa1-a12b-df321807b2f9"
      unitRef="U_USD">-15518000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_9e921f07-b419-4783-827d-3e900ca98faf"
      unitRef="U_USD">0</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_61aaa363-cf07-4171-81a9-1bfab0314e80"
      unitRef="U_USD">1000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <clym:EffectiveIncomeTaxRateReconciliationAcquiredIn-ProcessResearchDevelopmentRelatedParty
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_fea8bf26-08bc-4339-8805-db388514be3b"
      unitRef="U_USD">0</clym:EffectiveIncomeTaxRateReconciliationAcquiredIn-ProcessResearchDevelopmentRelatedParty>
    <clym:EffectiveIncomeTaxRateReconciliationAcquiredIn-ProcessResearchDevelopmentRelatedParty
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_4eedbf5f-62df-4449-8782-6ef303f9f5ee"
      unitRef="U_USD">7698000</clym:EffectiveIncomeTaxRateReconciliationAcquiredIn-ProcessResearchDevelopmentRelatedParty>
    <us-gaap:EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_d5f8edfe-b5fe-48a5-836b-da58d3ff3f59"
      unitRef="U_USD">1303000</us-gaap:EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_bddd55fc-8278-447c-823a-a06c1d9721e6"
      unitRef="U_USD">0</us-gaap:EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount>
    <clym:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficerCompensationAmount
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_84cf958d-cbe8-4428-9d03-e7d9aba23912"
      unitRef="U_USD">293000</clym:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficerCompensationAmount>
    <clym:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficerCompensationAmount
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_d7b110d2-70a8-4179-ac19-32a993e97e30"
      unitRef="U_USD">575000</clym:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficerCompensationAmount>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_3753548e-800b-4695-ad6f-d7f709713d62"
      unitRef="U_USD">237000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_3a2034c8-740c-4553-a6c4-4200b0060a7c"
      unitRef="U_USD">-211000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_6b0b8c6c-9ea9-477f-960a-5a35b027e37c"
      unitRef="U_USD">83000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_3a312c08-519f-4dfa-a55e-f9ad03472682"
      unitRef="U_USD">588000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_7ee8ceba-82af-49dd-b494-3c6a3f86aa45"
      unitRef="U_USD">403000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_d0e049bf-8357-4ca4-b0a2-2f2b52eb95ef"
      unitRef="U_USD">86000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_303b333b-f3e2-497e-b3e5-2e49723afded"
      unitRef="U_USD">-228000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_2fcac2c2-a189-4b8c-a941-afacfc0dc913"
      unitRef="U_USD">-123000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_082c70b4-9d4b-4256-8f60-993c77819468"
      unitRef="U_USD">11284000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_efd91126-7155-4293-8969-0259954d70b9"
      unitRef="U_USD">7076000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_7113d9c0-d909-42b2-afb2-af146035662c"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_ad7fa3f1-91c7-423b-b052-71469a7554ca"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_4bd413ab-8b09-4ed8-a0df-3fe2f45d695f">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The significant components of the Company&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2019;s deferred tax assets and liabilities are presented below (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:64.387%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.537%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.44%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.537%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Net operating losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,202&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,725&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,447&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,946&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,824&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,388&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Stock compensation expense, including 162m limitations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;432&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Research credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;702&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Accrued compensation and benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;332&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;303&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;113&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;121&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Other expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,459&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,630&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,368&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;91&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;138&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Operating lease, right-of-use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;106&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;112&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Other assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;91&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;138&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net deferred tax assets and liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-3"
      id="F_6f546f73-4a5a-4e60-897a-6fc1e9ffbb39"
      unitRef="U_USD">28202000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e"
      decimals="-3"
      id="F_05f6b5cb-c48e-474c-9bc4-0616cc40442b"
      unitRef="U_USD">22725000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-3"
      id="F_2c3a9b55-7dbb-44ee-b250-07b47cecfa86"
      unitRef="U_USD">4447000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e"
      decimals="-3"
      id="F_3882855e-05c9-4405-b50d-cbd7133bcfd5"
      unitRef="U_USD">1946000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <clym:DeferredTaxAssetsResearchAndDevelopmentExpenses
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-3"
      id="F_ab445d5b-477f-4977-8a7c-6ddc6bd47366"
      unitRef="U_USD">3824000</clym:DeferredTaxAssetsResearchAndDevelopmentExpenses>
    <clym:DeferredTaxAssetsResearchAndDevelopmentExpenses
      contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e"
      decimals="-3"
      id="F_624da2bd-cd0e-4112-bb0c-d705654a5d2c"
      unitRef="U_USD">2388000</clym:DeferredTaxAssetsResearchAndDevelopmentExpenses>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-3"
      id="F_86e7f677-9c62-4901-a810-35bbcf74b480"
      unitRef="U_USD">1400000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e"
      decimals="-3"
      id="F_f18470e5-6c9a-4585-85b4-3c0e22b8c95e"
      unitRef="U_USD">432000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-3"
      id="F_4fe6cac6-593c-4f35-ac5a-a1780a905307"
      unitRef="U_USD">1104000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e"
      decimals="-3"
      id="F_4f862819-842a-4799-a573-84c66471572e"
      unitRef="U_USD">702000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-3"
      id="F_20269d61-1b1b-45f3-86ba-f3d5e7a16526"
      unitRef="U_USD">332000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
      contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e"
      decimals="-3"
      id="F_eee8c3f2-1561-42d5-ab38-d44ef9675b89"
      unitRef="U_USD">303000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
    <clym:DefferedTaxAssetOperatingLeaseLiability
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-3"
      id="F_d35dfcd7-3928-4840-ae94-174ac6f1152a"
      unitRef="U_USD">113000</clym:DefferedTaxAssetOperatingLeaseLiability>
    <clym:DefferedTaxAssetOperatingLeaseLiability
      contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e"
      decimals="-3"
      id="F_5feae16d-9b6b-4e65-aa4b-8f93a157c1bd"
      unitRef="U_USD">121000</clym:DefferedTaxAssetOperatingLeaseLiability>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-3"
      id="F_c568f1c5-f9c2-4457-878d-740e18075747"
      unitRef="U_USD">37000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e"
      decimals="-3"
      id="F_d8eafc40-fba7-425a-b7ae-1f98327452da"
      unitRef="U_USD">13000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-3"
      id="F_590bca23-6948-4344-b591-61cb9b9cc8f1"
      unitRef="U_USD">39459000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e"
      decimals="-3"
      id="F_1cf5e71f-379b-4b40-8a79-183d18188f56"
      unitRef="U_USD">28630000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-3"
      id="F_acfcf692-d544-4911-8c7f-8a96f248791a"
      unitRef="U_USD">39368000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e"
      decimals="-3"
      id="F_3f41c214-26b6-4725-81e5-fd790b656ae6"
      unitRef="U_USD">28492000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-3"
      id="F_7584b400-86ac-468e-acbd-1b0339406d34"
      unitRef="U_USD">91000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e"
      decimals="-3"
      id="F_4fa156de-ee7c-4530-ac49-3d423152695c"
      unitRef="U_USD">138000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-3"
      id="F_e4c9ad75-79e5-4935-aa72-91af9f62dd07"
      unitRef="U_USD">106000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e"
      decimals="-3"
      id="F_3c37fff6-5745-4e55-b1d0-296dce81df38"
      unitRef="U_USD">112000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-3"
      id="F_2ed4f26a-c708-41b6-8419-c4c86cafe40b"
      unitRef="U_USD">-15000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e"
      decimals="-3"
      id="F_b42b515d-e5ed-43ec-b2d2-08001cfb812f"
      unitRef="U_USD">26000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-3"
      id="F_cb45dcf6-93a0-41f8-915d-d217230f2dbe"
      unitRef="U_USD">91000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e"
      decimals="-3"
      id="F_4a7fb641-3033-43fb-8467-a158d38cb7ac"
      unitRef="U_USD">138000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-3"
      id="F_3e9d0946-2899-4cd1-8a96-46fadb3cf962"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e"
      decimals="-3"
      id="F_c9983bb0-7061-4d24-88a7-9e884fa71763"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_7a1a17c3-5482-4393-8497-495abe0d0025"
      decimals="-5"
      id="F_320a0205-d790-4776-8fa5-20d14f084873"
      unitRef="U_USD">55800000</us-gaap:OperatingLossCarryforwards>
    <clym:PercentageOfAnnualDeductionOfTaxableIncome
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="2"
      id="F_518ac01c-80ea-4052-b834-b179500d229a"
      unitRef="U_pure">0.80</clym:PercentageOfAnnualDeductionOfTaxableIncome>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_6a0b2fc4-e53f-4894-a5d0-249ab8cdaaa8"
      decimals="-5"
      id="F_c44ee1b4-44bd-4e65-93d6-d8d76d2cf503"
      unitRef="U_USD">9500000</us-gaap:OperatingLossCarryforwards>
    <clym:OperatingLossCarryforwardsExpirationStartYear
      contextRef="C_5b33bfda-7940-4aa2-a368-a61504f508d9"
      id="F_29698cea-5fba-4346-955f-9e8c8373199e">2038</clym:OperatingLossCarryforwardsExpirationStartYear>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_7a1a17c3-5482-4393-8497-495abe0d0025"
      decimals="-5"
      id="F_5588120b-1bff-463e-9723-ee0340a6fd64"
      unitRef="U_USD">1000000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_6a0b2fc4-e53f-4894-a5d0-249ab8cdaaa8"
      decimals="-5"
      id="F_88bfd315-1868-4870-85af-90d857a0f5e0"
      unitRef="U_USD">100000</us-gaap:TaxCreditCarryforwardAmount>
    <clym:TaxCreditCarryforwardExpirationYearStart
      contextRef="C_34d8c2a2-a75c-4398-b4d8-8fa4f3948fad"
      id="F_e11a8fa3-ef34-484d-bdc9-02309cd431eb">2039</clym:TaxCreditCarryforwardExpirationYearStart>
    <clym:TaxCreditCarryforwardExpirationYearStart
      contextRef="C_5b33bfda-7940-4aa2-a368-a61504f508d9"
      id="F_538dd92f-deee-4db8-a502-f02cb65bfdcf">2039</clym:TaxCreditCarryforwardExpirationYearStart>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_67a4d641-d6ae-4d5f-aded-eba6a55bcaed"
      decimals="-5"
      id="F_4aa4cf05-37b7-40d7-bc79-3ab6dd892ca7"
      unitRef="U_USD">63200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:SummaryOfValuationAllowanceTextBlock
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_74c4e846-0db5-4911-9767-bacaca98a890">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The changes in the valuation allowance were as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:64.387%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.537%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.44%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.537%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Valuation allowance as of beginning of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,856&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Net increases recorded to income tax provision&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,876&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,636&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Valuation allowance as of end of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,368&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e"
      decimals="-3"
      id="F_8ba55bcc-4e9f-410c-bd2e-0df5bdfd3cb0"
      unitRef="U_USD">28492000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_c2a2497b-98c5-4d07-ac31-0ab57e9c6f6a"
      decimals="-3"
      id="F_f8ed12ee-7f82-4712-9da9-4d09f8cdf309"
      unitRef="U_USD">20856000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="-3"
      id="F_8b75d969-6236-4999-a53e-45ffbe834e16"
      unitRef="U_USD">10876000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_78f971fb-c1c2-4044-a0b8-daca9df11ad5"
      unitRef="U_USD">7636000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_135efb28-52e9-4b39-b859-c79c58e3ffaa"
      decimals="-3"
      id="F_53e066a5-c197-4fb7-aaf5-68f81297b1f7"
      unitRef="U_USD">39368000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_faa5264a-05a4-41f5-96b4-ebbd6e86ca9e"
      decimals="-3"
      id="F_7ae15b51-2d39-4e96-a947-82c149051c4d"
      unitRef="U_USD">28492000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DefinedBenefitPlanTextBlock
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_12070e85-cfef-4b9d-a6e0-c7c924bf0f57">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 12. Defined Contribution Plans&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.204%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has a 401(k) defined contribution plan. Participation in the plan is available to substantially all U.S.-based employees. Company contributions are discretionary but the Company has an employer matching program pursuant to which the Company makes matching contributions of up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of each participating employee&#x2019;s eligible compensation. For the years ended December 31, 2025 and 2024, total expense recognized from the 401(k) matching contributions was approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.269%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Prior to the Company's restructuring in 2024 (see Note 13), the Company had a workplace pension contribution scheme for U.K.-based employees. For the year ended December 31, 2024, the Company made contributions to the pension scheme of approximatel&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;y $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:DefinedBenefitPlanTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="C_b2cd3b34-df50-4fcb-a36c-6d0072bb1fba"
      decimals="INF"
      id="F_d82c937f-337c-4559-a179-871988d8efd9"
      unitRef="U_pure">0.04</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="C_f3c7c70c-8584-4bd4-8cb7-4ec3bb217286"
      decimals="-5"
      id="F_69598e2e-e790-4f53-b6b4-7d4d8b7aa678"
      unitRef="U_USD">200000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="C_16c70f60-6525-47ed-a134-8055357fb60d"
      decimals="-5"
      id="F_34acecd6-d161-4034-b8cf-8b78a95c61c9"
      unitRef="U_USD">100000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="C_f2839107-9d2e-4b8c-98bb-fb38fcdc5134"
      decimals="-5"
      id="F_71690030-c5e7-4f34-8f15-44cc6eb40075"
      unitRef="U_USD">100000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_003dd8b6-3364-4af2-8afd-e8fd1830f102">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 13. Restructuring Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In 2024, the Company shifted its focus from developing therapeutics for neuronal excitability disorders to immune-mediated diseases. In connection with this shift, the Company ceased its operations in the U.K. and separated from seven U.K. employees in 2024. The costs associated with this headcount reduction were fully recognized and all of the related payments were made by December 31, 2024. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A summary of the restructuring costs recorded in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2024 were as follows (in thousands):&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:34.227%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.683%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.683%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:16.203%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:16.203%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="11" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;ROU Asset &lt;br/&gt;Impairment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Severance and  &lt;br/&gt;Benefit Costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Stock-based&lt;br/&gt;Compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;br/&gt;Restructuring&lt;br/&gt;Cost Recorded&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,778&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;944&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;475&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;161&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;636&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total restructuring costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,253&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,358&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_f9db8da0-0f52-43f9-9118-31fce5f59c89">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A summary of the restructuring costs recorded in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2024 were as follows (in thousands):&lt;/span&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:34.227%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.683%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.683%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:16.203%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:16.203%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="11" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;ROU Asset &lt;br/&gt;Impairment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Severance and  &lt;br/&gt;Benefit Costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Stock-based&lt;br/&gt;Compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;br/&gt;Restructuring&lt;br/&gt;Cost Recorded&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,778&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;944&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;475&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;161&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;636&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total restructuring costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,253&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,358&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:RestructuringCosts
      contextRef="C_16927a58-af3a-42b4-98d5-64f89907d927"
      decimals="-3"
      id="F_3a0c6461-51dc-4f2b-8bbb-70dfb084781c"
      unitRef="U_USD">0</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts
      contextRef="C_41711020-7e54-4cd4-9a26-fdac1e897d3f"
      decimals="-3"
      id="F_08fece21-4867-4a8e-8537-9d4d0aa073cd"
      unitRef="U_USD">1778000</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts
      contextRef="C_81960adb-5d4d-4573-bc54-80d5eb37fb9c"
      decimals="-3"
      id="F_d4b60a36-955a-4ff0-afc8-4f6feec1a0b1"
      unitRef="U_USD">944000</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts
      contextRef="C_c6e42dca-dd21-461f-8178-f4beb56519dc"
      decimals="-3"
      id="F_158d404a-d690-476f-8a47-246051833651"
      unitRef="U_USD">2722000</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts
      contextRef="C_b2cb9c72-8c63-4b1f-9bfe-c20a91b5c47f"
      decimals="-3"
      id="F_7397d018-3da8-4e3c-a998-c8090ddcaf03"
      unitRef="U_USD">0</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts
      contextRef="C_84f00985-ac68-4cfe-8454-b7dc6d4cc926"
      decimals="-3"
      id="F_f6219282-9a75-4ecc-9710-8ba809a1e065"
      unitRef="U_USD">475000</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts
      contextRef="C_1b535855-abfa-4f1d-9fb5-d30b12645dea"
      decimals="-3"
      id="F_6eac4d9f-514d-4f56-8848-121b574cd20f"
      unitRef="U_USD">161000</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts
      contextRef="C_3f3384f6-f21d-457a-af6e-c427fa15b93a"
      decimals="-3"
      id="F_1e37745e-775c-4b6e-9676-abfd839d4cf6"
      unitRef="U_USD">636000</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts
      contextRef="C_1c1140e8-fbcf-4f4b-b119-b4e0831d7ee2"
      decimals="-3"
      id="F_53bb6ebf-7b15-4de3-b446-23ece973f101"
      unitRef="U_USD">0</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts
      contextRef="C_ba5d6e15-a48f-47c7-9a81-6786f5b4f65b"
      decimals="-3"
      id="F_7a983f76-b3d9-4662-93f8-9dd0be53ff6d"
      unitRef="U_USD">2253000</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts
      contextRef="C_9b4e2e25-766b-4195-902e-5d8cc2e9e3df"
      decimals="-3"
      id="F_f52bd53b-6975-401b-a506-abf44df3943d"
      unitRef="U_USD">1105000</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts
      contextRef="C_80658773-af42-4dbf-91d7-91c7e6c647c7"
      decimals="-3"
      id="F_d6747052-7602-4ad0-8d92-3e06c497c58c"
      unitRef="U_USD">3358000</us-gaap:RestructuringCosts>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_6e40277a-e980-4a7c-9871-fa2610669eb8">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 14. Segments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker (the CODM). The Company views its operations and manages its business as &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; operating and reportable segment, focused on developing therapeutics for patients with immune-mediated diseases. The Company&#x2019;s CODM is its &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_486ead36-778f-4db7-a0cb-c45b1a00e08c;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;chief executive officer&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Segment profit or loss is measured as net loss presented in the consolidated statements of operations and comprehensive loss. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the purpose of evaluating segment performance and allocating resources, the CODM reviews the Company&#x2019;s financial information on a consolidated basis together with certain operating metrics and evaluates net loss against comparable prior periods and the Company&#x2019;s annual operating plan. The measure of segment assets is reported on the consolidated balance sheets as total consolidated assets.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In addition to the significant expense categories included within net loss presented on the consolidated statements of operations and comprehensive loss, the following table sets forth disaggregated research and development expenses (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:65.513%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.323%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.323%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Direct research and development expenses:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Budoprutug&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,045&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,982&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;CLYM116&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,964&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Legacy programs&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;107&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;201&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unallocated research and development expenses:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Personnel-related (including stock-based compensation)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,232&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,990&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,365&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,713&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,336&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:3.35pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.695pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Includes the upfront payment and the associated direct transaction costs incurred in connection with the Mabworks Agreement for the year ended December 31, 2025.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.695pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Includes direct expenses related to the Company's legacy product candidates ETX-123 and ETX-155.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="0"
      id="F_58d19a22-2920-4eb0-8e07-88c1a4b0a3d4"
      unitRef="U_Segments">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      decimals="0"
      id="F_5d64bf2b-c07f-468a-86bf-88892f99d6aa"
      unitRef="U_Segments">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_bfadf5b5-7780-4978-a038-1b86677710a6">For the purpose of evaluating segment performance and allocating resources, the CODM reviews the Company&#x2019;s financial information on a consolidated basis together with certain operating metrics and evaluates net loss against comparable prior periods and the Company&#x2019;s annual operating plan. The measure of segment assets is reported on the consolidated balance sheets as total consolidated assets.</us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_fc9e4f23-fd4b-445d-b9d4-3ec9694a2841">&lt;p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In addition to the significant expense categories included within net loss presented on the consolidated statements of operations and comprehensive loss, the following table sets forth disaggregated research and development expenses (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:65.513%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.323%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.323%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Direct research and development expenses:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Budoprutug&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,045&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,982&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;CLYM116&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,964&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Legacy programs&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;107&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;201&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unallocated research and development expenses:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Personnel-related (including stock-based compensation)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,232&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,990&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,365&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,713&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,336&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:3.35pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.695pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Includes the upfront payment and the associated direct transaction costs incurred in connection with the Mabworks Agreement for the year ended December 31, 2025.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.695pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Includes direct expenses related to the Company's legacy product candidates ETX-123 and ETX-155.&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_bd13e69e-5c42-4043-b717-21b094f74c19"
      decimals="-3"
      id="F_c74170fd-3bd4-4971-96df-7637f43ffde3"
      unitRef="U_USD">25045000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_ffe66a6a-2737-4df5-8bd7-75a6156fd39c"
      decimals="-3"
      id="F_4df717d8-b998-4bbd-a5f1-6baa25240a10"
      unitRef="U_USD">5982000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_3c01e103-0ded-4d1e-be15-85317f4afcac"
      decimals="-3"
      id="F_94a611c6-fe60-4f7e-aa05-ab8af00ceabb"
      unitRef="U_USD">11964000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_98215062-e0fc-42fc-b9b2-81c479845247"
      decimals="-3"
      id="F_24849bd4-af46-419c-b5d3-444ee75bc1f2"
      unitRef="U_USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_5ba093f0-d16e-4ef7-8562-6da6013de54a"
      decimals="-3"
      id="F_f1bda04b-4315-43f6-8d54-43a89d4c656b"
      unitRef="U_USD">107000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_55e0a766-eff7-448c-af18-1396354e6f58"
      decimals="-3"
      id="F_ee2ef0ab-8059-46e1-9500-b4698a700b23"
      unitRef="U_USD">201000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_015297a3-3968-4419-a989-c89674259ced"
      decimals="-3"
      id="F_c4676f52-fbe7-429e-b682-43cc4d33963c"
      unitRef="U_USD">8232000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_69a98cdd-d277-4823-8526-1135dd15782f"
      decimals="-3"
      id="F_bdd3ae9b-f90b-4024-bb41-e0493a39459f"
      unitRef="U_USD">7990000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_2691b0a1-6374-46d9-a04c-367ba1059083"
      decimals="-3"
      id="F_e5d859c9-8cf4-4473-a17c-d70fb4cafa68"
      unitRef="U_USD">1365000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_1bcd3bb5-c5b5-4602-ab79-6c587ad285a1"
      decimals="-3"
      id="F_3c21b10f-0bbb-431b-87fa-e93d46147752"
      unitRef="U_USD">163000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_4a576f93-6b66-4d5d-b1c0-bff422cdc503"
      decimals="-3"
      id="F_007de669-c2ce-472c-a43f-a2b4964398e1"
      unitRef="U_USD">46713000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_c03b49f0-805e-4685-86c8-e850f4d0a421"
      decimals="-3"
      id="F_1eccdaa6-834b-43e2-ab9c-6f6ca189bdbc"
      unitRef="U_USD">14336000</us-gaap:ResearchAndDevelopmentExpense>
    <ecd:MtrlTermsOfTrdArrTextBlock
      contextRef="C_e1c23734-80c9-41dd-8d11-0134db853cac"
      id="F_2388707b-e38e-4873-9c23-e668a6f44228">&lt;p id="item_9b_other_information" style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;It&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;em 9B. Other Information.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Director and Officer Trading Arrangements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The adoption or termination of contracts, instructions or written plans for the purchase or sale of our securities by our Section 16 officers and directors for the three months ended December 31, 2025, each of which is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act (&#x201c;Rule 10b5-1 Plan&#x201d;), were as follows:&lt;/span&gt;&lt;/p&gt;
     &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
      &lt;tr style="visibility:collapse;"&gt;
       &lt;td style="width:17.163%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;td style="width:15.743%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;td style="width:22.545%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;td style="width:11.262%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;td style="width:18.044%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;td style="width:13.243%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
       &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Name (Title)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Action taken&lt;br/&gt;(Date of Action)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Type of Trading Arrangement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Nature of Trading&lt;br/&gt;Arrangement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Duration of Trading&lt;br/&gt;Arrangement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate Number&lt;br/&gt;of Securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
       &lt;td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:pre-wrap;border-left:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stephen Thomas&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&lt;br/&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Director&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;Adoption&lt;br/&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;October 14, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Rule 10b5-1&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&#160;trading arrangement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Sale&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;Until &lt;/span&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;August 8, 2026&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;, or, if earlier, upon the completed sale of the maximum shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;150,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;/tr&gt;
     &lt;/table&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrIndName
      contextRef="C_0427b5f4-a659-4e63-a2a5-bbd14bc3d153"
      id="F_53cc9270-628c-4b53-a31b-fb446aa777b0">Stephen Thomas</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle
      contextRef="C_0427b5f4-a659-4e63-a2a5-bbd14bc3d153"
      id="F_42b3774f-fdd1-45a5-9abf-4770f3abd48c">Director</ecd:TrdArrIndTitle>
    <ecd:TrdArrAdoptionDate
      contextRef="C_0427b5f4-a659-4e63-a2a5-bbd14bc3d153"
      id="F_e4eb3626-1974-415c-9eea-f2de931d15a7">October 14, 2025</ecd:TrdArrAdoptionDate>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_0427b5f4-a659-4e63-a2a5-bbd14bc3d153"
      id="F_cdbfcd16-675d-4137-a2cf-356edf3cdbaf">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrExpirationDate
      contextRef="C_0427b5f4-a659-4e63-a2a5-bbd14bc3d153"
      id="F_fde9c606-9a03-4338-88e7-de9ae92bc860">August 8, 2026</ecd:TrdArrExpirationDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="C_fe9354d0-7134-4802-ac6f-dbcfc70b829d"
      decimals="0"
      id="F_ca756d78-b9a9-4cbf-b784-56c42e01ae77"
      unitRef="U_shares">150000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag
      contextRef="C_80b88047-d92c-4121-9779-7cec8fdafae6"
      id="F_b9765c03-962d-4edc-8847-a5ed7f0c57de">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#F_24849bd4-af46-419c-b5d3-444ee75bc1f2"
          xlink:label="F_24849bd4-af46-419c-b5d3-444ee75bc1f2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_94a611c6-fe60-4f7e-aa05-ab8af00ceabb"
          xlink:label="F_94a611c6-fe60-4f7e-aa05-ab8af00ceabb"
          xlink:type="locator"/>
        <link:footnote id="FNT_12707c51-ddf2-4b1d-9b50-539eb84344b9" xlink:label="FNT_12707c51-ddf2-4b1d-9b50-539eb84344b9" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes the upfront payment and the associated direct transaction costs incurred in connection with the Mabworks Agreement for the year ended December 31, 2025.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_24849bd4-af46-419c-b5d3-444ee75bc1f2"
          xlink:to="FNT_12707c51-ddf2-4b1d-9b50-539eb84344b9"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_94a611c6-fe60-4f7e-aa05-ab8af00ceabb"
          xlink:to="FNT_12707c51-ddf2-4b1d-9b50-539eb84344b9"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_f1bda04b-4315-43f6-8d54-43a89d4c656b"
          xlink:label="F_f1bda04b-4315-43f6-8d54-43a89d4c656b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_ee2ef0ab-8059-46e1-9500-b4698a700b23"
          xlink:label="F_ee2ef0ab-8059-46e1-9500-b4698a700b23"
          xlink:type="locator"/>
        <link:footnote id="FNT_c66c06d3-a16d-45aa-bd91-9bfdc6bbe5d7" xlink:label="FNT_c66c06d3-a16d-45aa-bd91-9bfdc6bbe5d7" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes direct expenses related to the Company's legacy product candidates ETX-123 and ETX-155.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_f1bda04b-4315-43f6-8d54-43a89d4c656b"
          xlink:to="FNT_c66c06d3-a16d-45aa-bd91-9bfdc6bbe5d7"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_ee2ef0ab-8059-46e1-9500-b4698a700b23"
          xlink:to="FNT_c66c06d3-a16d-45aa-bd91-9bfdc6bbe5d7"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
